Generic Name Other	Designation	Generic Name	GSRS PREFERRED NAME	Trade Name	Designation Date	Orphan Drug Status	FDA Approval Status	Approved Indication	Marketing Approval Date	Exclusivity End Date	Contact Company	Contact City	Contact State	Contact Zip	Contact Country	match_type	bdnum	bdnum__1	UNII	Rancho Drug Name	Rancho Drug UNII	Rancho Drug Source	Rancho Drug Status	Rancho Drug Comment	GARD Disease Title	GARD Disease ID	Rancho Disease Comment	Rancho Disease Status
(+)-DIHYDROTETRABENAZINE	Treatment pediatric patients with Tourette's syndrome	(+)-a-dihydrotetrabenazine	NBI-98782	n/a	3/30/17	Designated			N/A	N/A	"Adeptio Pharmaceuticals, Ltd"	London			United Kingdom	EXACT	0111781AB	(+)-DIHYDROTETRABENAZINE	IFRYDMLSGE						Tourette syndrome	7783	done	
"(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate"	Treatment of soft tissue sarcoma	"(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate"	EVOFOSFAMIDE	n/a	3/9/12	Designated			N/A	N/A	"Threshold Pharmaceuticals, Inc."	South San Francisco	California	94080	USA	EXACT	0310474AA	"(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate"	8A9RZ3HN8W						Soft tissue sarcoma	4898	done	
"(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide"	Treatment of C3 glomerulopathy (C3G)	"(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide"	ACH-4471	n/a	12/14/17	Designated			N/A	N/A	"Achillion Pharmaceuticals, Inc"	300 George Street	New Haven	6511	USA	EXACT	0113191AB	"(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide"	JM8C1SFX0U								MISSING	
"(3S)-3-(4-trifluoromethoxybenzyloxy)-6-nitro-2H-3,4-dihydroimidazo(2,1-b)oxazine"	Treatment of tuberculosis	"(3S)-3-(4-trifluoromethoxybenzyloxy)-6-nitro-2H-3,4-dihydroimidazo[2,1-b]oxazine"	PRETOMANID	n/a	7/5/07	Designated			N/A	N/A	Global Alliance for TB Drug Development	New York	New York	10005	USA	EXACT	0736743AA	"(3S)-3-(4-trifluoromethoxybenzyloxy)-6-nitro-2H-3,4-dihydroimidazo(2,1-b)oxazine"	2XOI31YC4N						Tuberculosis	7827	done	
"(6R,S)5,10-methylene-tetrahydrofolic acid"	For use in combination with 5-fluorouracil for the treatment of patients with pancreatic cancer	"(6R,S)5,10-methylene-tetrahydrofolic acid"	"METHYLENETETRAHYDROFOLIC ACID, L-(+)-"	Cofactor	8/13/04	Designated			N/A	N/A	"Adventrx Pharmaceuticals, Inc."	San Diego	California	92121	USA	EXACT	0802517AA	"(6R,S)5,10-methylene-tetrahydrofolic acid"	Z8R4A37V9Q						Pancreatic cancer	9364	done	Not a rare disease
"(R)-2-(5-CYANO-2-(6-(METHOXYCARBONYL)-7-METHYL-3-OXO-8-(3-(TRIFLUOROMETHYL)PHENYL)-2,3,5,8-TETRAHYDRO-(1,2,4)TRIAZOLO(4,3-A)PYRIMIDIN-5-YL)PHENYL)-N,N,N-TRIMETHYLETHANAMINIUM METHANESULFONATE"	Treatment of cystic fibrosis	"(R)-2-(5-cyano-2-(6-(methoxycarbonyl)-7-methyl-3-oxo-8-(3-(trifluoromethyl)phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidin-5-yl)phenyl)-N,N,N-trimethylethanaminium methanesulfonate dehydrate"	"(R)-2-(5-CYANO-2-(6-(METHOXYCARBONYL)-7-METHYL-3-OXO-8-(3-(TRIFLUOROMETHYL)PHENYL)-2,3,5,8-TETRAHYDRO-(1,2,4)TRIAZOLO(4,3-A)PYRIMIDIN-5-YL)PHENYL)-N,N,N-TRIMETHYLETHANAMINIUM METHANESULFONATE"	n/a	1/25/17	Designated			N/A	N/A	Chiesi Farmaceutici S.p.A.	Parma			Italy	EXACT	1801010AA	"(R)-2-(5-CYANO-2-(6-(METHOXYCARBONYL)-7-METHYL-3-OXO-8-(3-(TRIFLUOROMETHYL)PHENYL)-2,3,5,8-TETRAHYDRO-(1,2,4)TRIAZOLO(4,3-A)PYRIMIDIN-5-YL)PHENYL)-N,N,N-TRIMETHYLETHANAMINIUM METHANESULFONATE"	Q0656F336Y						Cystic fibrosis	6233	done	
"(RS)-baclofen, naltrexone and D-sorbitol"	Treatment of Charcot-Marie-Tooth disease type 1A	"(RS)-baclofen, naltrexone and D-sorbitol"	NALTREXONE	n/a	3/17/14	Designated			N/A	N/A	Pharnext SA				France	exact	0057249AA	naltrexone	5S6W795CQM						Charcot-Marie-Tooth disease	6034	done	
"(S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)-imidazo(1,5-a)pyrazin-1-yl)-N-(pyridin-2-yl)-benzamide"	Treatment of Waldenstrom macroglobulinemia.	"(S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)-imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)-benzamide"	ACALABRUTINIB	n/a	10/22/15	Designated			N/A	N/A	Acerta Pharma BV				Netherlands	EXACT	1102961AA	ACALABRUTINIB	I42748ELQW						Waldenstrom macroglobulinemia	7872	done	
(met5)-enkephalin	Treatment of pancreatic cancer	[met5]-enkephalin	METENKEFALIN	Opioid Growth Factor	1/24/13	Designated			N/A	N/A	"TNI BioTech, Inc."	Bethesda	Maryland	20817	USA	EXACT	0128574AA	(met5)-enkephalin	9JEZ9OD3AS						Pancreatic cancer	9364	done	Not a rare disease
.ALPHA.-MELANOTROPIN	Prevention and treatment of intrinsic acute renal failure due to ischemia.	Alpha-melanocyte stimulating hormone	.ALPHA.-MELANOTROPIN	n/a	8/19/97	Designated			N/A	N/A	"National Institute of Diabetes, and Digestive and Kidney Diseases"	Bethesda	Maryland	20892	USA	EXACT	0052186AA	.ALPHA.-MELANOTROPIN	OVF025LA77								MISSING	
.ALPHA.1-PROTEINASE INHIBITOR HUMAN	Prevention of graft-versus-host disease (GVHD)	human Alpha1-Proteinase inhibitor	.ALPHA.1-PROTEINASE INHIBITOR HUMAN	n/a	7/30/18	Designated			N/A	N/A	CSL Behring LLC	1020 First Ave.	Pennsylvania	19406	USA	EXACT	0163520AA	.ALPHA.1-PROTEINASE INHIBITOR HUMAN	F43I396OIS						Chronic graft versus host disease	10964	approximate	type of GVHD (acute or chronic) is not specified
.ALPHA.1-PROTEINASE INHIBITOR HUMAN	Prevention of graft-versus-host disease (GVHD)	human Alpha1-Proteinase inhibitor	.ALPHA.1-PROTEINASE INHIBITOR HUMAN	n/a	7/30/18	Designated			N/A	N/A	CSL Behring LLC	1020 First Ave.	Pennsylvania	19406	USA	EXACT	0163520AA	.ALPHA.1-PROTEINASE INHIBITOR HUMAN	F43I396OIS						Acute graft versus host disease	6544	approximate	type of GVHD (acute or chronic) is not specified
.ALPHA.1-PROTEINASE INHIBITOR HUMAN	Treatment of emphysema secondary to congenital alpha1-antitrypsin deficiency.	alpha1 proteinase inhibitor (human)	.ALPHA.1-PROTEINASE INHIBITOR HUMAN	n/a	1/29/10	Designated			N/A	N/A	"Grifols Therapeutics, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0163520AA	.ALPHA.1-PROTEINASE INHIBITOR HUMAN	F43I396OIS						Alpha-1 antitrypsin deficiency	5784	done	
.Alpha.-1-acid glycoprotein	Treatment of tricyclic antidepressant poisoning	Alpha-1-acid glycoprotein	ALPHA-1-ACID GLYCOPROTEIN	n/a	3/17/04	Designated/Withdrawn			N/A	N/A	Bio Products Laboratory				United Kingdom	EXACT	1721999AA	.Alpha.-1-acid glycoprotein	31V857ZRPY								MISSING	not a disease
.Alpha.-tocopherol quinone	Treatment of inherited mitochondrial respiratory chain diseases	Alpha-tocopherol quinone	.ALPHA.-TOCOPHEROL QUINONE	n/a	3/28/06	Designated			N/A	N/A	Penwest Pharmaceuticals Company	Danbury	Connecticut	6810	USA	EXACT	1576336AA	.Alpha.-tocopherol quinone	5W7XN0VOX8						Mitochondrial complex I deficiency	3908	approximate	
.Alpha.-tocopherol quinone	Treatment of inherited mitochondrial respiratory chain diseases	Alpha-tocopherol quinone	.ALPHA.-TOCOPHEROL QUINONE	n/a	3/28/06	Designated			N/A	N/A	Penwest Pharmaceuticals Company	Danbury	Connecticut	6810	USA	EXACT	1576336AA	.Alpha.-tocopherol quinone	5W7XN0VOX8						Mitochondrial complex II deficiency	5053	approximate	
.Alpha.-tocopherol quinone	Treatment of inherited mitochondrial respiratory chain diseases	Alpha-tocopherol quinone	.ALPHA.-TOCOPHEROL QUINONE	n/a	3/28/06	Designated			N/A	N/A	Penwest Pharmaceuticals Company	Danbury	Connecticut	6810	USA	EXACT	1576336AA	.Alpha.-tocopherol quinone	5W7XN0VOX8						Mitochondrial complex III deficiency	8295	approximate	
.Alpha.-tocopherol quinone	Treatment of inherited mitochondrial respiratory chain diseases	Alpha-tocopherol quinone	.ALPHA.-TOCOPHEROL QUINONE	n/a	3/28/06	Designated			N/A	N/A	Penwest Pharmaceuticals Company	Danbury	Connecticut	6810	USA	EXACT	1576336AA	.Alpha.-tocopherol quinone	5W7XN0VOX8						Cytochrome c oxidase deficiency	48	approximate	
.Alpha.-tocopherol quinone	Treatment of inherited mitochondrial respiratory chain diseases	Alpha-tocopherol quinone	.ALPHA.-TOCOPHEROL QUINONE	n/a	3/28/06	Designated			N/A	N/A	Penwest Pharmaceuticals Company	Danbury	Connecticut	6810	USA	EXACT	1576336AA	.Alpha.-tocopherol quinone	5W7XN0VOX8						Mitochondrial complex V deficiency	1459	approximate	
"1,2:5,6-dianhydrogalactitol"	Treatment of medulloblastoma.	"1,2:5,6-dianhydrogalactitol"	DIANHYDROGALACTITOL	n/a	3/10/16	Designated			N/A	N/A	"DelMar Pharmaceuticals, Inc."	Menlo Park	California	94025	USA	EXACT	0061712AA	"1,2:5,6-dianhydrogalactitol"	4S465RYF7M						Medulloblastoma	7005	done	
"1,2:5,6-dianhydrogalactitol"	Treatment of ovarian cancer.	"1,2:5,6-dianhydrogalactitol"	DIANHYDROGALACTITOL	n/a	4/19/16	Designated			N/A	N/A	"DelMar Pharmaceuticals, Inc. (Clinical Operations)"	Menlo Park	California	94025	USA	EXACT	0061712AA	"1,2:5,6-dianhydrogalactitol"	4S465RYF7M						Ovarian cancer	7295	done	
"1-(2,8-Dimethyl-1-thia-3,8-diazaspiro(4.5)dec-3-yl)-3-(1H-indol-3-yl)propan-1-one"	Treatment of frontotemporal dementia.	"1-(2,8-Dimethyl-1-thia-3,8-diazaspiro[4.5]dec-3-yl)-3-(1H-indol-3-yl)propan-1-one"	AF-710B	n/a	4/6/16	Designated			N/A	N/A	Anavex Life Sciences Corp.	New York	New York	10019	USA	EXACT	1576610AA	"1-(2,8-Dimethyl-1-thia-3,8-diazaspiro(4.5)dec-3-yl)-3-(1H-indol-3-yl)propan-1-one"	AAE07Z061B						Frontotemporal dementia	8436	done	
"1-118-signal regulatory protein alpha (human) fusion protein with immunoglobulin G1 (human Fc fragment), dimer"	Treatment of Cutaneous T-Cell Lymphoma	"1-118-signal regulatory protein alpha (human) fusion protein with immunoglobulin G1 (human Fc fragment), dimer"	PROTEIN	n/a	3/8/18	Designated			N/A	N/A	Trillium Therapeutics Inc.	2488 Dunwin Drive			Canada	LONGEST CONTAINS	0087274AA	protein					PROBLEM	can't find	Cutaneous T-cell lymphoma	6226	done	
10 synthetic peptides targeting 5 tumor asociated antigens	Treatment of non-small cell lung cancer in patients expressing HLA-A2	10 synthetic peptides targeting 5 tumor asociated antigens	ALLERGENIC EXTRACTS	n/a	1/23/13	Designated			N/A	N/A	Orphan Synergy Europe Pharma (OSE Pharma)	Paris			France	LONGEST CONTAINS	0123397AA	antigens					PROBLEM	can't find	"Non-small cell lung cancer, childhood"	9343	approximate	
12-A-p21 RAS(5-21). 12-C-p21 RAS(5-21). 12-D-p21 RAS(5-21). 12-Rp21 RAS(5-21). 12-S-p21 RAS(5-21). 12-V-p21 RAS(5-21). 13-D-p21 RAS(5-21)	Treatment of pancreatic cancer	12-A-p21 RAS(5-21). 12-C-p21 RAS(5-21). 12-D-p21 RAS(5-21). 12-Rp21 RAS(5-21). 12-S-p21 RAS(5-21). 12-V-p21 RAS(5-21). 13-D-p21 RAS(5-21)		n/a	6/7/11	Designated			N/A	N/A	Oncos Therapeutics	Helsinki			Finland								PROBLEM	can't find	Pancreatic cancer	9364	done	Not a rare disease
14-amino acid peptide derived from wound growth factor	Treatment of delayed graft function in renal transplant recipients	14-amino acid peptide derived from wound growth factor	NX-001	n/a	8/16/10	Designated/Withdrawn			N/A	N/A	NephRx Corporation	Kalamazoo	Michigan	49008	USA	EXACT	0800737AA	NX-001	2NIW95147T								MISSING	
16 base single stranded PNA oligonucleotide–7 aminoacids peptide	Treatment of neuroblastoma	16 base single stranded PNA oligonucleotide–7 aminoacids peptide		n/a	10/25/17	Designated			N/A	N/A	BIOGENERA SpA	"46 Via Marconi, Porretta Terme (BO)"			Italy					16-base single-stranded PNA oligonucleotide linked to a 7-aminoacid peptide for the treatment of neuroblastoma	NA	https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu309692	PROBLEM		Neuroblastoma	7185	done	
16 base single stranded peptide nucleic acid oligonucleotide – 7 aminoacids peptide	Treatment of Small Cell Lung Cancer	16 base single stranded peptide nucleic acid oligonucleotide – 7 aminoacids peptide		n/a	2/22/18	Designated			N/A	N/A	BIOGENERA SpA	46 Via Marconi	Porretta Terme (BO)		Italy					16-base single-stranded peptide nucleic acid oligonucleotide linked to a 7 amino acid peptide	NA	https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3161690	PROBLEM	absent from GINAS	Small cell lung cancer	9344	done	
"16-HYDROXY-9Z,12Z,14E-OCTADECATRIENOIC ACID"	Prophylactic treatment of sickle cell disease.	"Synthetic derivative of 16-hydroxy-9Z, 12Z, 14E-octadecatrienoic acid"	"16-HYDROXY-9Z,12Z,14E-OCTADECATRIENOIC ACID"	Drepanol	10/24/91	Designated			N/A	N/A	"Omex International, Inc."	Houston	Texas	77036	USA	EXACT	0112170AB	"16-HYDROXY-9Z,12Z,14E-OCTADECATRIENOIC ACID"					PROBLEM	can't find	Sickle cell anemia	8614	done	Type of sickle cell disease is unspecified
"16-HYDROXY-9Z,12Z,14E-OCTADECATRIENOIC ACID"	Prophylactic treatment of sickle cell disease.	"Synthetic derivative of 16-hydroxy-9Z, 12Z, 14E-octadecatrienoic acid"	"16-HYDROXY-9Z,12Z,14E-OCTADECATRIENOIC ACID"	Drepanol	10/24/91	Designated			N/A	N/A	"Omex International, Inc."	Houston	Texas	77036	USA	EXACT	0112170AB	"16-HYDROXY-9Z,12Z,14E-OCTADECATRIENOIC ACID"					PROBLEM	can't find	Hemoglobin SE disease	12088	done	Type of sickle cell disease is unspecified
"16-HYDROXY-9Z,12Z,14E-OCTADECATRIENOIC ACID"	Prophylactic treatment of sickle cell disease.	"Synthetic derivative of 16-hydroxy-9Z, 12Z, 14E-octadecatrienoic acid"	"16-HYDROXY-9Z,12Z,14E-OCTADECATRIENOIC ACID"	Drepanol	10/24/91	Designated			N/A	N/A	"Omex International, Inc."	Houston	Texas	77036	USA	EXACT	0112170AB	"16-HYDROXY-9Z,12Z,14E-OCTADECATRIENOIC ACID"					PROBLEM	can't find	Sickle delta beta thalassemia	10819	done	Type of sickle cell disease is unspecified
"16-HYDROXY-9Z,12Z,14E-OCTADECATRIENOIC ACID"	Prophylactic treatment of sickle cell disease.	"Synthetic derivative of 16-hydroxy-9Z, 12Z, 14E-octadecatrienoic acid"	"16-HYDROXY-9Z,12Z,14E-OCTADECATRIENOIC ACID"	Drepanol	10/24/91	Designated			N/A	N/A	"Omex International, Inc."	Houston	Texas	77036	USA	EXACT	0112170AB	"16-HYDROXY-9Z,12Z,14E-OCTADECATRIENOIC ACID"					PROBLEM	can't find	Sickle cell - hemoglobin D disease	12458	done	Type of sickle cell disease is unspecified
"16-HYDROXY-9Z,12Z,14E-OCTADECATRIENOIC ACID"	Prophylactic treatment of sickle cell disease.	"Synthetic derivative of 16-hydroxy-9Z, 12Z, 14E-octadecatrienoic acid"	"16-HYDROXY-9Z,12Z,14E-OCTADECATRIENOIC ACID"	Drepanol	10/24/91	Designated			N/A	N/A	"Omex International, Inc."	Houston	Texas	77036	USA	EXACT	0112170AB	"16-HYDROXY-9Z,12Z,14E-OCTADECATRIENOIC ACID"					PROBLEM	can't find	Sickle beta thalassemia	10333	done	Type of sickle cell disease is unspecified
"16-HYDROXY-9Z,12Z,14E-OCTADECATRIENOIC ACID"	Prophylactic treatment of sickle cell disease.	"Synthetic derivative of 16-hydroxy-9Z, 12Z, 14E-octadecatrienoic acid"	"16-HYDROXY-9Z,12Z,14E-OCTADECATRIENOIC ACID"	Drepanol	10/24/91	Designated			N/A	N/A	"Omex International, Inc."	Houston	Texas	77036	USA	EXACT	0112170AB	"16-HYDROXY-9Z,12Z,14E-OCTADECATRIENOIC ACID"					PROBLEM	can't find	Hemoglobin SC disease	6584	done	Type of sickle cell disease is unspecified
"2',3',5'-tri-o-acetyluridine"	Treatment of mitochondrial disease	"2',3',5'-tri-o-acetyluridine"	URIDINE TRIACETATE	n/a	1/13/03	Designated/Withdrawn			N/A	N/A	Repligen Corporation	Waltham	Massachusetts	2453	USA	EXACT	0179760AA	"2',3',5'-tri-o-acetyluridine"	2WP61F175M								MISSING	mitchondrial disease not specified
2'-3'-dideoxyadenosine	Treatment of aquired immunodeficiency syndrome.	2'-3'-dideoxyadenosine	DIDEOXYADENOSINE	n/a	7/21/87	Designated/Withdrawn			N/A	N/A	"National Cancer Institute, Dct"	Bethesda	Maryland	20892	USA	EXACT	0163428AA	2'-3'-dideoxyadenosine	4Q86AH641A						Congenital human immunodeficiency virus	10328	approximate	"aquired, not congenital immunodeficiency"
2'-deoxycytidine	As a host-protective agent in the treatment of acute myelogenous leukemia.	2'-deoxycytidine	DEOXYCYTIDINE	n/a	9/9/96	Designated			N/A	N/A	"Grant, Steven M.D."	Richmond	Virginia	23298	USA	EXACT	0031958AA	2'-deoxycytidine	0W860991D6						Acute myeloid leukemia	12757	done	
"2-(2-chlorophenyl)-4-(3-(dimethylamino)phenyl)-5-methyl-1H-pyrazolo(4,3-C)pyridine-3,6(2H,5H)-dione"	Treatment of idiopathic pulmonary fibrosis.	"2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione"	GKT-137831	n/a	9/21/10	Designated			N/A	N/A	GenKyoTex S.A.	Geneva			Switzerland	EXACT	0711295AA	"2-(2-chlorophenyl)-4-(3-(dimethylamino)phenyl)-5-methyl-1H-pyrazolo(4,3-C)pyridine-3,6(2H,5H)-dione"	45II35329V						Idiopathic pulmonary fibrosis	8609	done	
2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	Treatment of congenital ichthyosis	2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	ADX-102	n/a	4/17/17	Designated			N/A	N/A	Aldeyra Therapeutics	Lexington	Massachusetts	2421	USA	EXACT	0377140AA	2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	F0GIZ22IJH						CHILD syndrome	6039	approximate	
2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	Treatment of congenital ichthyosis	2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	ADX-102	n/a	4/17/17	Designated			N/A	N/A	Aldeyra Therapeutics	Lexington	Massachusetts	2421	USA	EXACT	0377140AA	2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	F0GIZ22IJH						X-linked ichthyosis	7904	approximate	
2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	Treatment of congenital ichthyosis	2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	ADX-102	n/a	4/17/17	Designated			N/A	N/A	Aldeyra Therapeutics	Lexington	Massachusetts	2421	USA	EXACT	0377140AA	2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	F0GIZ22IJH						KID syndrome	3113	approximate	
2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	Treatment of congenital ichthyosis	2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	ADX-102	n/a	4/17/17	Designated			N/A	N/A	Aldeyra Therapeutics	Lexington	Massachusetts	2421	USA	EXACT	0377140AA	2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	F0GIZ22IJH						Harlequin ichthyosis	6568	approximate	
2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	Treatment of congenital ichthyosis	2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	ADX-102	n/a	4/17/17	Designated			N/A	N/A	Aldeyra Therapeutics	Lexington	Massachusetts	2421	USA	EXACT	0377140AA	2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	F0GIZ22IJH						Lamellar ichthyosis	10803	approximate	
2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	Treatment of congenital ichthyosis	2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	ADX-102	n/a	4/17/17	Designated			N/A	N/A	Aldeyra Therapeutics	Lexington	Massachusetts	2421	USA	EXACT	0377140AA	2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	F0GIZ22IJH						Netherton syndrome	7182	approximate	
2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	Treatment of congenital ichthyosis	2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	ADX-102	n/a	4/17/17	Designated			N/A	N/A	Aldeyra Therapeutics	Lexington	Massachusetts	2421	USA	EXACT	0377140AA	2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	F0GIZ22IJH						Sjogren-Larsson syndrome	7654	approximate	
2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	Treatment of congenital ichthyosis	2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	ADX-102	n/a	4/17/17	Designated			N/A	N/A	Aldeyra Therapeutics	Lexington	Massachusetts	2421	USA	EXACT	0377140AA	2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	F0GIZ22IJH						Trichothiodystrophy	12109	approximate	
2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	Treatment of congenital ichthyosis	2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	ADX-102	n/a	4/17/17	Designated			N/A	N/A	Aldeyra Therapeutics	Lexington	Massachusetts	2421	USA	EXACT	0377140AA	2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol	F0GIZ22IJH						Chanarin-Dorfman syndrome	3979	approximate	
"2-(4-CHLORO-2-METHOXYPHENYL)-2-((3-METHOXY-5-(METHYLSULFONYL)PHENYL)AMINO)-1-(5-(TRIFLUOROMETHOXY)-1H-INDOL-3-YL)ETHANONE, (S)-"	Treatment of dengue virus infection		"2-(4-CHLORO-2-METHOXYPHENYL)-2-((3-METHOXY-5-(METHYLSULFONYL)PHENYL)AMINO)-1-(5-(TRIFLUOROMETHOXY)-1H-INDOL-3-YL)ETHANONE, (S)-"	n/a	12/26/17	Designated			N/A	N/A	"Janssen Research & Development, LLC"	125 Trenton-Harbourton Road	Titusville	8560	USA	EXACT	0114043AB	"2-(4-CHLORO-2-METHOXYPHENYL)-2-((3-METHOXY-5-(METHYLSULFONYL)PHENYL)AMINO)-1-(5-(TRIFLUOROMETHOXY)-1H-INDOL-3-YL)ETHANONE, (S)-"	5EJO0RJF9O						Dengue fever	6254	done	
"2-O, 3-O, desulfated heparin"	Treatment of acute myeloid leukemia	"2-O, 3-O, desulfated heparin"	HEPARIN	n/a	12/21/17	Designated			N/A	N/A	"Cantex Pharmaceuticals, Inc."	1792 Bell Tower Lane	Weston	33326	USA	LONGEST CONTAINS	0118230AA	heparin	T2410KM04A						Acute myeloid leukemia	12757	done	
2-iminobiotin	Treatment of perinatal asphyxia.	2-iminobiotin	2-IMINOBIOTIN	n/a	2/24/09	Designated			N/A	N/A	Neurophyxia B.V.				Netherlands	EXACT	0808435AA	2-iminobiotin	HXH71NRQ5C								MISSING	Not a disease
20% Lipid emulsion solution	Treatment of local anesthetic systemic toxicity	20% Lipid emulsion solution		Lipidrescue	6/8/17	Designated			N/A	N/A	ResQ Pharma	Lincoln	Nebraska	68502	USA					Lipidrescue Therapy	NA	https://lipidrescue.com/pipeline | https://adisinsight.springer.com/drugs/800045422	PROBLEM	absent from GINAS			MISSING	not a disease
225Ac-lintuzumab	Treatment of acute myelogenous leukemia	225Ac-lintuzumab	LINTUZUMAB ACTINIUM AC-225	n/a	11/25/14	Designated			N/A	N/A	"Actinium Pharmaceuticals, Inc."	Edison	New Jersey	8837	USA	EXACT	1802762AA	225Ac-lintuzumab	V860J30J9N						Acute myeloid leukemia	12757	done	
"24,25-DIHYDROXYVITAMIN D3"	Treatment of uremic osteodystrophy.	"24,25 dihydroxycholecalciferol"	24-HYDROXYCALCIDIOL	n/a	2/27/87	Designated			N/A	N/A	Lemmon Company	Kulpsville	Pennsylvania	19443	USA	EXACT	0794821AA	"24,25-DIHYDROXYVITAMIN D3"	0AXX2V8L5Z								MISSING	Not a rare disease
"2S,4R ketoconazole"	Treatment of endogenous Cushing's syndrome	"2S,4R ketoconazole"	LEVOKETOCONAZOLE	n/a	3/9/12	Designated			N/A	N/A	Cortendo AB (HQ address)				Sweden	EXACT	0740454AA	"2S,4R ketoconazole"	2DJ8R0NT7K						Cushing's syndrome	6224	done	
2’-O-(2-methoxyethyl) modified antisense oligonucleotide targeting exon 13 in the USH2A gene	Treatment of retinitis pigmentosa	2’-O-(2-methoxyethyl) modified antisense oligonucleotide targeting exon 13 in the USH2A gene		n/a	11/20/17	Designated			N/A	N/A	ProQR Therapeutics IV B.V.	9 Zernikedreef			Netherlands					QR 421a	NA	https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3181973 | https://adisinsight.springer.com/drugs/800041596	PROBLEM	absent from GINAS	Retinitis pigmentosa	5694	done	
"3,4 diaminopyridine"	Treatment of Lambert-Eaton myasthenic syndrome	"3,4 diaminopyridine and choline bitartrate"	AMIFAMPRIDINE	n/a	4/30/10	Designated			N/A	N/A	MS Therapeutics Limited				United Kingdom	EXACT	0144445AA	"3,4 diaminopyridine"	RU4S6E2G0J						Lambert Eaton myasthenic syndrome	6851	done	
"3,4 diaminopyridine and choline bitartrate"	Treatment of Lambert-Eaton myasthenic syndrome	"3,4 diaminopyridine and choline bitartrate"	CHOLINE BITARTRATE	n/a	4/30/10	Designated			N/A	N/A	MS Therapeutics Limited				United Kingdom	EXACT	0015021AA	choline bitartrate	6K2W7T9V6Y						Lambert Eaton myasthenic syndrome	6851	done	
"3,4-diaminopyridine"	Treatment of Lambert-Eaton myasthenic syndrome.	"3,4-diaminopyridine"	AMIFAMPRIDINE	n/a	12/18/90	Designated			N/A	N/A	Jacobus Pharmaceutical Company	Princeton	New Jersey	8540	USA	EXACT	0144445AA	"3,4-diaminopyridine"	RU4S6E2G0J						Lambert Eaton myasthenic syndrome	6851	done	
"3,4-diaminopyridine"	Treatment of congenital myasthenic syndrome (CMS)	"3,4-diaminopyridine"	AMIFAMPRIDINE	n/a	3/30/17	Designated			N/A	N/A	"Jacobus Pharmaceutical Co., Inc."	Princeton	New Jersey	8540	USA	EXACT	0144445AA	"3,4-diaminopyridine"	RU4S6E2G0J						Congenital myasthenic syndrome	11902	done	
"3,5-diiodothyropropionic acid"	Treatment of Allan-Herndon-Dudley syndrome	"3,5-diiodothyropropionic acid"	"3,5-DIIODOTHYROPROPIONIC ACID"	n/a	5/14/13	Designated			N/A	N/A	Zarion Pharmaceuticals P/L	Victoria			Australia	EXACT	0256859AA	"3,5-diiodothyropropionic acid"	1HTO2X0SJ9						Allan-Herndon-Dudley syndrome	5617	done	
"3-(4-(1,5-NAPTHRYDINE)IMIDAZOLE(1,2-A)PYRIDINE-7-(1-PHENYL-4-(1-(4-METHYL PIPERAZINE)))"	Treatment of fibrodysplasia ossificans progressiva.	"3-(4-(1,5-NAPTHRYDINE)IMIDAZOLE(1,2-A)PYRIDINE-7-(1-PHENYL-4-(1-(4-METHYL PIPERAZINE)))"	"3-(4-(1,5-NAPTHRYDINE)IMIDAZOLE(1,2-A)PYRIDINE-7-(1-PHENYL-4-(1-(4-METHYL PIPERAZINE)))"	EXACT	1802660AA	Designated	1G7DB33DC7		N/A	N/A	"La Jolla Pharmaceutical Company, Inc."	San Diego	California	92121	USA	EXACT	1802660AA	"3-(4-(1,5-NAPTHRYDINE)IMIDAZOLE(1,2-A)PYRIDINE-7-(1-PHENYL-4-(1-(4-METHYL PIPERAZINE)))"	1G7DB33DC7						Fibrodysplasia ossificans progressiva	6445	done	
"3-(4-(8-FLUOROQUINOLINE)IMIDAZOLE(1,2-A)PYRIDINE-7-(1-PHENYL-4-(1-(4-METHYL PIPERAZINE)"	Treatment of fibrodysplasia ossificans progressiva.	"3-(4-(8-fluoroquinoline)-Imidazole[1,2-a]pyridine-7-(1-phenyl-4-(1-(4-methyl piperazine)"	"3-(4-(8-FLUOROQUINOLINE)IMIDAZOLE(1,2-A)PYRIDINE-7-(1-PHENYL-4-(1-(4-METHYL PIPERAZINE)"	n/a	7/14/15	Designated			N/A	N/A	"La Jolla Pharmaceutical Company, Inc."	San Diego	California	92121	USA	EXACT	1802659AA	"3-(4-(8-FLUOROQUINOLINE)IMIDAZOLE(1,2-A)PYRIDINE-7-(1-PHENYL-4-(1-(4-METHYL PIPERAZINE)"	0PD95Q5DD1						Fibrodysplasia ossificans progressiva	6445	done	
"3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride"	Treatment of hepatocellular carcinoma (HCC)	"3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride"	AVADOMIDE HYDROCHLORIDE	n/a	7/3/17	Designated			N/A	N/A	Celgene Corporation	Summit	New Jersey	7901	USA	EXACT	0926830AA	"3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride"	6CX4AEX3KR						Childhood hepatocellular carcinoma	9331	approximate	
"3-[2-(1-methylpyrrolidin-2-yl) ethyl]-6-(2-pyrrolidin-1yl) ethyl-9-benzyloxycarbonyl-12-diethyl-4,7-dioxo-3,6,9,12-tetraazadodecancarboxamide"	Treatment of anterior ischemic optic neuropathy (AION)	"3-[2-(1-methylpyrrolidin-2-yl) ethyl]-6-(2-pyrrolidin-1yl) ethyl-9-benzyloxycarbonyl-12-diethyl-4,7-dioxo-3,6,9,12-tetraazadodecancarboxamide"		n/a	12/26/17	Designated			N/A	N/A	Neurizon Pharma	15 Paul-Ehrlich-Straße	Tübingen		Germany					"3-[2-(1-methylpyrrolidin-2-yl) ethyl]-6-(2-pyrrolidin-1yl) ethyl-9-benzyloxycarbonyl-12-diethyl-4,7-dioxo-3,6,9,12-tetraazadodecancarboxamide"	NA	http://5.102.145.157/checkorphan/treatment/7331f75319d4a37af7b9977e2fa5342c/	PROBLEM	absent from GINAS	Anterior ischemic optic neuropathy	9790	done	
3-bromopyruvate	Treatment of pancreatic cancer	3-bromopyruvate	BROMOPYRUVATE	n/a	4/29/14	Designated			N/A	N/A	"PreScience Labs, LLC"	Potomac	Maryland	20854	USA	EXACT	0548458AA	3-bromopyruvate	63JMV04GRK						Pancreatic cancer	9364	done	Not a rare disease
3g10	Prevention of arteriovenous fistula or arteriovenous graft failure in patients with end stage renal disease receiving hemodialysis or preparing for hemodialysis	Human monoclonal antibody against phosphorylcholine		n/a	6/15/17	Designated			N/A	N/A	"Athera Biotechnologies, AB"	Norrmalm			Sweden	EXACT							PROBLEM	can't find			MISSING	incorrect spelling
4''-(P-FLUOROBENZYL)TYLOSIN A	Treatment of onchocerciasis	4”-(p-fluorobenzyl)tylosin A	4''-(P-FLUOROBENZYL)TYLOSIN A	n/a	6/8/17	Designated			N/A	N/A	AbbVie Inc.	North Chicago	Illinois	60044	USA	EXACT	0111826AB	4''-(P-FLUOROBENZYL)TYLOSIN A	HXL1F57P8O						Onchocerciasis	7252	done	
4'-THIO-FAC	Treatment of cholangiocarcinoma	"4-amino-1-[(2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl] pyrimidin-2(1H)-one"	4-AMINO-1-(2-DEOXY-2-FLUORO-4-THIO-.BETA.-D-ARABINOFURANOSYL)-2(1H)-PYRIMIDINONE	n/a	8/1/18	Designated			N/A	N/A	"FUJIFILM Pharmaceutical U.S.A., Inc."	1 Broadway	Massachusetts	2142	USA	EXACT	1193233AA	4'-THIO-FAC	R5B1HX1HUY						Intrahepatic cholangiocarcinoma	6042	done	
"4,5,6,7-tetrachloro-2',4',5',7'-tetraiodofluorescein disodium salt"	Treatment of hepatocellular carcinoma.	"4,5,6,7-tetrachloro-2',4',5',7'-tetraiodofluorescein disodium salt"	"DISODIUM 4,5,6,7-TETRACHLORO-2',4',5',7'-TETRAIODOFLUORESCEIN"	n/a	4/18/11	Designated			N/A	N/A	"Provectus Pharmaceuticals, Inc."	Knoxville	Tennessee	37931	USA	EXACT	1718612AA	"4,5,6,7-tetrachloro-2',4',5',7'-tetraiodofluorescein disodium salt"	U1PBKAJVAD						Childhood hepatocellular carcinoma	9331	approximate	
"4,5-dibromorhodamine 123"	Treatment of chronic myelogenous leukemia	"4,5-dibromorhodamine 123"	TH-9402	Theralux Irradiation Device	4/10/03	Designated/Withdrawn			N/A	N/A	"Kiadis Pharma Canada, Inc."				Canada	EXACT	0736583AA	"4,5-dibromorhodamine 123"	RVY229824B						Chronic myeloid leukemia	6105	done	
"4-((2E)-1-Oxo-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-propen-1-yl)-1-piperazinecarboxamide"	Treatment of retinitis pigmentosa	"4-[(2E)-1-Oxo-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-propen-1-yl]-1-piperazinecarboxamide"	"4-((2E)-1-OXO-3-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2-PROPEN-1-YL)-1-PIPERAZINECARBOXAMIDE"	n/a	2/8/16	Designated			N/A	N/A	"Shire HGT, Inc."	Lexington	Massachusetts	2421	USA	EXACT	1576347AA	"4-((2E)-1-Oxo-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-propen-1-yl)-1-piperazinecarboxamide"	BC9KBY85WY						Retinitis pigmentosa	5694	done	
"4-(4-((((3-(1,1-dimethylethyl)-1-(6-quinolinyl)-1H-pyrazol-5-yl)amino)carbonyl)-amino)-3-fluorophenoxyl)-N-methyl-2-pyridinecarboxamide, p-toluenesulfonate salt"	Treatment of Philadelphia chromosome positive chronic myeloid leukemia	"4-[4-[[[[3-(1,1-dimethylethyl)-1-(6-quinolinyl)-1H-pyrazol-5-yl]amino]carbonyl]-amino]-3-fluorophenoxyl]-N-methyl-2-pyridinecarboxamide, p-toluenesulfonate salt"	REBASTINIB TOSYLATE	n/a	9/3/09	Designated			N/A	N/A	"Deciphera Pharmaceuticals, LLC"	Lawrence	Kansas	66044	USA	EXACT	0711137AA	"4-(4-((((3-(1,1-dimethylethyl)-1-(6-quinolinyl)-1H-pyrazol-5-yl)amino)carbonyl)-amino)-3-fluorophenoxyl)-N-methyl-2-pyridinecarboxamide, p-toluenesulfonate salt"	042A5NJE6B						Chronic myeloid leukemia	6105	done	
"4-[(7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl]benzoic acid, hemifumarate"	Treatment of Ryanodine receptor type 1-related myopathies	"4-[(7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl]benzoic acid, hemifumarate"	BENZOIC ACID	n/a	8/17/18	Designated			N/A	N/A	"ARMGO Pharma, Inc."	777 Old Saw Mill River Road	New York	10591	USA	LONGEST CONTAINS	0011461AA	benzoic acid	8SKN0B0MIM						Myopathy congenital	5898	approximate	
4-aminosalicylic acid	Treatment of acute flares in pediatric patients with ileo-cecal Crohn's disease	4-aminosalicylic acid	AMINOSALICYLIC ACID	Paser Granules	4/26/06	Designated			N/A	N/A	"Jacobus Pharmaceutical Co., Inc."	Princeton	New Jersey	8540	USA	EXACT	0011438AA	4-aminosalicylic acid	5B2658E0N2						Pediatric Crohn's disease	9856	done	
4-aminosalicylic acid	Treatment of mild to moderate ulcerative colitis in patients intolerant to sulfasalazine.	4-aminosalicylic acid	AMINOSALICYLIC ACID	"Pamisyl (P-D), Rezipas (Squibb)"	12/13/89	Designated			N/A	N/A	"Beeken, Warren M.D."	Burlington	Vermont	5405	USA	EXACT	0011438AA	4-aminosalicylic acid	5B2658E0N2						Pediatric ulcerative colitis	9857	approximate	
"4-cholest-en-3-one, oxime"	Treatment of amyotrophic lateral sclerosis	"4-cholest-en-3-one, oxime"	OLESOXIME	n/a	12/1/05	Designated/Withdrawn			N/A	N/A	Trophos SA				France	EXACT	0340045AA	"4-cholest-en-3-one, oxime"	A6778U5IFY						Amyotrophic lateral sclerosis	5786	done	
4”-(p-fluorobenzyl)tylosin A	Treatment of lymphatic filariasis	4”-(p-fluorobenzyl)tylosin A	TYLOSIN	n/a	6/6/17	Designated			N/A	N/A	AbbVie Inc.	North Chicago	Illinois	60044	USA	EXACT	0111826AB	tylosin A	YEF4JXN031						Lymphatic filariasis	3321	done	
5'-GCCATGGTTTTTTCTCAGG-3'	Prophylaxis following documented or suspected exposure to marburg virus	5'-GCCATGGTTTTTTCTCAGG-3'		n/a	10/31/12	Designated			N/A	N/A	"Sarepta Therapeutics, Inc."	Cambridge	Massachusetts	2142	USA								PROBLEM	can't find	Marburg hemorrhagic fever	9444	done	
"5,6-dihydro-5-azacytidine"	Treatment of malignant mesothelioma.	"5,6-dihydro-5-azacytidine"	"5,6-DIHYDRO-5-AZACYTIDINE"	n/a	5/11/92	Designated			N/A	N/A	"ILEX Oncology, Inc."	San Antonio	Texas	78229	USA	EXACT	0549939AA	"5,6-dihydro-5-azacytidine"	0627D8VG1C						Malignant mesothelioma	7026	done	
"5-((4-(6-chlorothieno(2,3-d)pyrimidine-4-ylamino)piperidin-1-yl)methyl)-2-fluorobenzonitrile monofumurate"	Treatment of pulmonary arterial hypertension	"5-((4-(6-chlorothieno[2,3-d]pyrimidine-4-ylamino)piperidin-1-yl)methyl)-2-fluorobenzonitrile monofumurate"	PRX-08066	n/a	10/21/10	Designated/Withdrawn			N/A	N/A	"Forest Laboratories, Inc."	Jersey City	New Jersey	7311	USA	EXACT	0737360AA	"5-((4-(6-chlorothieno(2,3-d)pyrimidine-4-ylamino)piperidin-1-yl)methyl)-2-fluorobenzonitrile monofumurate"	92E9B7675Y						Autoimmune pulmonary alveolar proteinosis	7499	done	
"5-(1-(2,6-Dichlorobenzyl)-piperidin-4-yl)methoxyquinazoline-2,4-diamine"	Treatment of spinal muscular atrophy	"5-[1-(2,6-Dichlorobenzyl)-piperidin-4-yl]methoxyquinazoline-2,4-diamine"	D-157495	n/a	8/25/09	Designated			N/A	N/A	CureSMA	Elk Grove Village	Illinois	60007	USA	EXACT	0659858AA	"5-(1-(2,6-Dichlorobenzyl)-piperidin-4-yl)methoxyquinazoline-2,4-diamine"	KSV93L7URW						Congenital benign spinal muscular atrophy dominant	1474	approximate	
"5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride"	Treatment of progressive supranuclear palsy.	"5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride"	MCD-386CR	n/a	4/18/11	Designated			N/A	N/A	"Mithridion, Inc."	Madison	Wisconsin	53711	USA	EXACT	0645669AA	"5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride"	6P87MRR8OA						Progressive supranuclear palsy	7471	done	
5-aminosalicylic acid	Treatment of ulcerative colitis in pediatric patients (revised indication 10/21/2010).	mesalamine; 5-aminosalicylic acid	MESALAMINE	Lialda	2/27/08	Designated			N/A	N/A	Shire	Wayne	Pennsylvania	19087	USA	EXACT	0127719AA	5-aminosalicylic acid	4Q81I59GXC						Pediatric ulcerative colitis	9857	done	
5-aza-2'-deoxycytidine	Treatment of acute leukemia.	5-aza-2'-deoxycytidine	DECITABINE	n/a	8/3/87	Designated			N/A	N/A	"SuperGen, Inc."	Dublin	California	94568	USA	EXACT	0171244AA	5-aza-2'-deoxycytidine	776B62CQ27						Acute leukemia of ambiguous lineage	8638	done	
5-aza-2'-deoxycytidine	Treatment of thalassemia	"5-aza-2'-dexocytidine combined with 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one"	DECITABINE	n/a	2/16/17	Designated			N/A	N/A	EpiDestiny Inc.	Solon	Ohio	44139	USA	EXACT	0171244AA	5-aza-2'-deoxycytidine	776B62CQ27						Thalassemia	7756	done	
5-hydroxymethyl-2-furfuraldehyde	Treatment of sickle cell disease	5-hydroxymethyl-2-furfuraldehyde	5-(HYDROXYMETHYL)-2-FURALDEHYDE	n/a	5/26/06	Designated			N/A	N/A	"Baxalta US, Inc."	Westlake Village	California	91362	USA	EXACT	0409574AA	5-hydroxymethyl-2-furfuraldehyde	70ETD81LF0						Sickle cell anemia	8614	done	Type of sickle cell disease is not specified
5-hydroxymethyl-2-furfuraldehyde	Treatment of sickle cell disease	5-hydroxymethyl-2-furfuraldehyde	5-(HYDROXYMETHYL)-2-FURALDEHYDE	n/a	5/26/06	Designated			N/A	N/A	"Baxalta US, Inc."	Westlake Village	California	91362	USA	EXACT	0409574AA	5-hydroxymethyl-2-furfuraldehyde	70ETD81LF0						Hemoglobin SE disease	12088	done	Type of sickle cell disease is not specified
5-hydroxymethyl-2-furfuraldehyde	Treatment of sickle cell disease	5-hydroxymethyl-2-furfuraldehyde	5-(HYDROXYMETHYL)-2-FURALDEHYDE	n/a	5/26/06	Designated			N/A	N/A	"Baxalta US, Inc."	Westlake Village	California	91362	USA	EXACT	0409574AA	5-hydroxymethyl-2-furfuraldehyde	70ETD81LF0						Sickle delta beta thalassemia	10819	done	Type of sickle cell disease is not specified
5-hydroxymethyl-2-furfuraldehyde	Treatment of sickle cell disease	5-hydroxymethyl-2-furfuraldehyde	5-(HYDROXYMETHYL)-2-FURALDEHYDE	n/a	5/26/06	Designated			N/A	N/A	"Baxalta US, Inc."	Westlake Village	California	91362	USA	EXACT	0409574AA	5-hydroxymethyl-2-furfuraldehyde	70ETD81LF0						Sickle cell - hemoglobin D disease	12458	done	Type of sickle cell disease is not specified
5-hydroxymethyl-2-furfuraldehyde	Treatment of sickle cell disease	5-hydroxymethyl-2-furfuraldehyde	5-(HYDROXYMETHYL)-2-FURALDEHYDE	n/a	5/26/06	Designated			N/A	N/A	"Baxalta US, Inc."	Westlake Village	California	91362	USA	EXACT	0409574AA	5-hydroxymethyl-2-furfuraldehyde	70ETD81LF0						Sickle beta thalassemia	10333	done	Type of sickle cell disease is not specified
5-hydroxymethyl-2-furfuraldehyde	Treatment of sickle cell disease	5-hydroxymethyl-2-furfuraldehyde	5-(HYDROXYMETHYL)-2-FURALDEHYDE	n/a	5/26/06	Designated			N/A	N/A	"Baxalta US, Inc."	Westlake Village	California	91362	USA	EXACT	0409574AA	5-hydroxymethyl-2-furfuraldehyde	70ETD81LF0						Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
"6,8-bis(benzylthio)octanoic acid"	Treatment of Burkitt’s Lymphoma (BL)	"6,8-bis(benzylthio)octanoic acid"	CPI-613	n/a	1/25/18	Designated			N/A	N/A	"Rafael Pharmaceuticals, Inc."	1 Duncan Drive	Cranbury Township	8512	USA	EXACT	0298840AA	"6,8-bis(benzylthio)octanoic acid"	E76113IR49						Burkitt lymphoma	5973	done	
"6,8-bis(benzylthio)octanoic acid"	Treatment of Peripheral T-cell Lymphoma (PTCL)	"6,8-bis(benzylthio)octanoic acid"	CPI-613	n/a	2/28/18	Designated			N/A	N/A	"Rafael Pharmaceuticals, Inc."	1 Duncan Drive	Cranbury Township	8512	USA	EXACT	0298840AA	"6,8-bis(benzylthio)octanoic acid"	E76113IR49						Peripheral T-cell lymphoma	7368	done	
"6,8-bis-benzylsulfanyl-octanoic acid"	Treatment of acute myeloid leukemia.	"6,8-bis-benzylsulfanyl-octanoic acid"	CPI-613	n/a	8/22/11	Designated			N/A	N/A	"Cornerstone Pharmaceuticals, Inc."	Stony Brook	New Mexico	11790	USA	EXACT	0298840AA	CPI-613	E76113IR49						Acute myeloid leukemia	12757	done	
"6,8-bis-benzylsulfanyl-octanoic acid"	Treatment of myelodysplastic syndrome	"6,8-bis-benzylsulfanyl-octanoic acid"	CPI-613	n/a	9/26/13	Designated			N/A	N/A	"Cornerstone Pharmaceuticals, Inc."	Stony Brook	New Mexico	11790	USA	EXACT	0298840AA	CPI-613	E76113IR49						Myelodysplastic syndromes	7132	done	
"6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-bensoxazin-4-one"	Treatment of Netherton syndrome	"6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-bensoxazin-4-one"	"6-ETHOXY-7-METHOXY-2-(2-METHYLSULFANYLPHENYL)-3,1-BENSOXAZIN-4-ONE"	n/a	6/18/15	Designated			N/A	N/A	Sixera Pharma AB				Sweden	EXACT	1576950AA	"6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-bensoxazin-4-one"	BDQ30W2KTS						Netherton syndrome	7182	done	
6-hydroxymethylacylfulvene	Treatment of histologically confirmed advanced or metastatic pancreatic cancer.	6-hydroxymethylacylfulvene	IROFULVEN	n/a	4/6/99	Designated/Withdrawn			N/A	N/A	"Eisai, Inc."	Woodcliff Lake	New Jersey	7677	USA	EXACT	0209234AA	6-hydroxymethylacylfulvene	6B799IH05A						Pancreatic cancer	9364	done	Not a rare disease
7-ETHYL-10-HYDROXYCAMPTOTHECIN	Treatment of small cell lung cancer.	7-ethyl-10-hydroxycamptothecin (EHC)	7-ETHYL-10-HYDROXYCAMPTOTHECIN	n/a	4/13/16	Designated			N/A	N/A	"Nippon Kayaku Co., Ltd."	Chiyoda			Japan	EXACT	0245807AA	7-ETHYL-10-HYDROXYCAMPTOTHECIN	0H43101T0J						Small cell lung cancer	9344	done	
"8-CYCLOPENTYL-1,3-DIPROPYLXANTHINE"	Treatment of cystic fibrosis.	"8 Cyclopentyl 1,3-dipropylxanthine"	"8-CYCLOPENTYL-1,3-DIPROPYLXANTHINE"	n/a	3/24/97	Designated/Withdrawn			N/A	N/A	"SciClone Pharmaceuticals, Inc."	San Mateo	California	94404	USA	EXACT	0183142AA	"8-CYCLOPENTYL-1,3-DIPROPYLXANTHINE"	9PTP4FOI9E						Cystic fibrosis	6233	done	
8-methoxsalen	For use in conjunction with the UVAR photopheresis to treat diffuse systemic sclerosis.	8-methoxsalen	METHOXSALEN	Uvadex	6/22/93	Designated			N/A	N/A	"Therakos, Inc."	Exton	Pennsylvania	19341	USA	EXACT	0023836AA	methoxsalen	U4VJ29L7BQ						Systemic scleroderma	9748	done	Not a rare disease
"9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER"	Treatment of PLA2G6-associated neurodegeneration	"9-cis,12-cis-11,11-D2-linoleic acid ethyl ester"	"9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER"	n/a	10/24/17	Designated			N/A	N/A	"Retrotope, Inc."	Los Altos	California	94022	USA	EXACT	1149173AA	"9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER"	24B102R86P						NBIA/DYT/PARK-PLA2G6	12568	done	
9-ING-41	Treatment of Neuroblastoma	"3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5 f]indol-7-yl)-pyrrole-2,5-dione"	9-ING-41	n/a	8/18/17	Designated			N/A	N/A	Actuate Therapeutics	Fort Worth	Texas	76107	USA	EXACT	1576369AA	9-ING-41	ND1SOF0DLU						Neuroblastoma	7185	done	
9-ING-41	Treatment of glioblastoma	"3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-pyrrole-2,5-dione"	9-ING-41	n/a	3/29/16	Designated			N/A	N/A	Actuate Therapeutics	Fort Worth	Texas	76107	USA	EXACT	1576369AA	9-ING-41	ND1SOF0DLU						Glioblastoma	2491	done	
9-cis-retinoic acid	Prevention of retinal detachment due to proliferative vitreoretinopathy.	9-cis-retinoic acid	ALITRETINOIN	n/a	1/2/97	Designated/Withdrawn			N/A	N/A	"Allergan, Inc."	Irvine	California	92623	USA	EXACT	0184576AA	9-cis-retinoic acid	1UA8E65KDZ								MISSING	
9-nitro-20-(S)-camptothecin	Treatment of pancreatic cancer.	9-nitro-20-(S)-camptothecin	RUBITECAN	n/a	9/16/96	Designated			N/A	N/A	"SuperGen, Inc."	San Ramon	California	94583	USA	EXACT	0187597AA	9-nitro-20-(S)-camptothecin	H19C446XXB						Pancreatic cancer	9364	done	Not a rare disease
9-nitro-20-(S)-camptothecin	Treatment of pediatric HIV infection/AIDS	9-nitro-20-(S)-camptothecin	RUBITECAN	Camvirex	5/15/01	Designated			N/A	N/A	"NovoMed Pharmaceuticals, Inc."	Germantown	Maryland	20875	USA	EXACT	0187597AA	9-nitro-20-(S)-camptothecin	H19C446XXB						Congenital human immunodeficiency virus	10328	approximate	
"A replication-incompetent, non-integrating Herpes simplex type 1 (HSV-1) vector expressing the human transglutaminase-1 (TGM-1) enzyme"	Treatment of TGM-1-deficient autosomal recessive congenital ichthyosis (ARCI)	"A replication-incompetent, non-integrating Herpes simplex type 1 (HSV-1) vector expressing the human transglutaminase-1 (TGM-1) enzyme"	HERPES	n/a	8/7/18	Designated			N/A	N/A	"Krystal Biotech, Inc."	2100 Wharton Street	Pennsylvania	15203	USA	LONGEST CONTAINS	0354825AA	Herpes	22G38P19RL	HUMAN HERPESVIRUS 1	22G38P19RL	https://ginas.ncats.nih.gov/ginas/app/substance/af9f2dbe	approximate		X-linked ichthyosis	7904	done	
A-4250	Treatment of progressive familial intrahepatic cholestatis	"(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid"	A-4250	n/a	10/31/12	Designated			N/A	N/A	Albireo AB				USA	EXACT	1301333AA	A-4250	2W150K0UUC						Progressive familial intrahepatic cholestasis 1	9802	done	
A-4250	Treatment of progressive familial intrahepatic cholestatis	"(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid"	A-4250	n/a	10/31/12	Designated			N/A	N/A	Albireo AB				USA	EXACT	1301333AA	A-4250	2W150K0UUC						Progressive familial intrahepatic cholestasis 2	1288	done	
A-4250	Treatment of progressive familial intrahepatic cholestatis	"(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid"	A-4250	n/a	10/31/12	Designated			N/A	N/A	Albireo AB				USA	EXACT	1301333AA	A-4250	2W150K0UUC						Progressive familial intrahepatic cholestasis 3	1289	done	
A-4250	Treatment of progressive familial intrahepatic cholestatis	"(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid"	A-4250	n/a	10/31/12	Designated			N/A	N/A	Albireo AB				USA	EXACT	1301333AA	A-4250	2W150K0UUC						"Cholestasis, progressive familial intrahepatic 4"	9803	done	
AAV-G6Pase vector	Treatment of glycogen storage disease type Ia	AAV-G6Pase vector		n/a	3/11/13	Designated			N/A	N/A	"GlyGenix Therapeutics, Inc."	Woodbridge	Connecticut	6443	USA								PROBLEM	can't find	Glycogen storage disease type 1A	7864	done	
AB-​22	Treatment of Idiopathic pulmonary fibrosis (IPF)	"N-(2-chloro-6-propoxypyridin-4-yl)-2-(2-hydroxyethyl)-2-(4-isopropyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)hydrazinecarboxamide"		n/a	5/23/18	Designated			N/A	N/A	"Arroyo Biosciences, LLC"	1812 Pelling Court		20905	USA	EXACT			R228S06SOH		R228S06SOH		PROBLEM	can't find	Idiopathic pulmonary fibrosis	8609	done	
ABBV-257	Treatment of pediatric patients 0 to	human recombinant dual-variable domain immunoglobulin G1 monoclonal antibody that selectively neutralizes tumor necrosis factor-alpha and interkeukin-17A	ABBV-257	n/a	2/4/16	Designated			N/A	N/A	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0928245AA	ABBV-257	MA59O0RPES								PROBLEM	it looks like the designation phrase is incomplete
ABC-294640	Treatment of pancreatic cancer.	4-pyridinylmethyl 3(4-chlorophenyl)adamantine carboxamide	ABC-294640	n/a	11/2/10	Designated			N/A	N/A	Apogee Biotechnology Corporation	Hummelstown	Pennsylvania	17036	USA	EXACT	0547864AA	ABC-294640	DRG21OQ517						Pancreatic cancer	9364	done	Not a rare disease
ABCA4 DNA nanoparticles	Treatment of Stargardt Macular Degeneration	ABCA4 DNA nanoparticles		n/a	10/28/15	Designated			N/A	N/A	"Copernicus Therapeutics, Inc."	Cleveland	Ohio	44106	USA								PROBLEM	can't find	Stargardt disease	181	done	
ABT-308	Treatment of eosinophilic esophagitis	recombinant humanized anti-interleukin 13 (IL-13) monoclonal antibody	ABT-308	n/a	2/11/15	Designated			N/A	N/A	"Receptos Services, LLC"	San Diego	California	92121	USA	EXACT	0353059AA	ABT-308	O8R9U9ZUVN						Eosinophilic enteropathy	9142	done	
ACALABRUTINIB	Treatment of mantle cell lymphoma.	"(S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)-imidazo[1,5-a]pyrazine-1-yl)-N-(pyridine-2-yl)-benzamide"	ACALABRUTINIB	n/a	9/21/15	Designated			N/A	N/A	Acerta Pharma BV				Netherlands	EXACT	1102961AA	ACALABRUTINIB	I42748ELQW						Mantle cell lymphoma	6969	done	
ACH-4471	Treatment of paroxysmal nocturnal hemoglobinuria	"(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide"	ACH-4471	n/a	11/2/17	Designated			N/A	N/A	"Achillion Pharmaceuticals, Inc"	300 George Street	Connecticut	6511	USA	EXACT	0113191AB	ACH-4471	JM8C1SFX0U						Paroxysmal nocturnal hemoglobinuria	7337	done	
ACLERASTIDE	Treatment of dermal injury due to nuclear/radiation incident	NorLeu3-Angiotensin(1-7) [NorLeu3-A(1-7)]	ACLERASTIDE	n/a	1/31/14	Designated			N/A	N/A	"US Biotest, Inc."	San Luis Obispo	California	93401	USA	EXACT	0296617AA	ACLERASTIDE	YYD6UT8T47								MISSING	
ACT-001 FUMARATE	Treatment of glioblastoma multiforme	"(3R,3aS,9R,9aS,9bS)-3-((dimethylamino)methyl)-9-hydroxy-6,9-dimethyl-3,3a,4,5,7,8,9,9a-octahydroazuleno[4,5-b]furan-2(9bH)-one fumarate"	ACT-001 FUMARATE	n/a	11/8/17	Designated			N/A	N/A	Accendatech USA Incorporated	3730 Kirby Drive	Texas	77098	USA	EXACT	0113583AB	ACT-001 FUMARATE	KM6239D2QV						Glioblastoma	2491	done	
ADH-1	"For use in conjunction with melphalen for the treatment of malignant melanoma, AJCC stages IIB, IIC, III and IV"	Cys-His-Ala-Val-Cys	ADH-1	n/a	2/14/08	Designated			N/A	N/A	"Adherex Technologies, Inc."	Durham	North Carolina	27703	USA	EXACT	0758714AA	ADH-1	B058ME29VU								MISSING	
AEM-28	Treatment of homozygous familial hypercholesterolemia	apolipoprotein E mimetic peptide	AEM-28	n/a	12/3/12	Designated			N/A	N/A	"LipimetiX Development, LLC"	Natick	Massachusetts	1760	USA	EXACT	1297887AA	AEM-28	V9526P2UXZ						Familial hypercholesterolemia	10416	done	Not a rare disease
AEOL-10150	Treatment of Amyotrophic Lateral Sclerosis	"[5,10,15,20-tetrakis(1,3-diethylimidazolium-2-yl)porphyrinato] manganese(III)pentachloride"	AEOL-10150	n/a	11/4/03	Designated			N/A	N/A	"Aeolus Pharmaceuticals, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0251489AA	AEOL-10150	KPKO7W46E8						Amyotrophic lateral sclerosis	5786	done	
AG-10	Treatment of transthyretin amyloidosis	"3-(3-(3,5-Dimethyl-1H-pyrazol-4- yl)propoxy)-4-fluorobenzoic acid"	AG-10	n/a	10/2/18	Designated			N/A	N/A	"Eidos Therapeutics, Inc."	101 Montgomery Street	California	94104	USA	EXACT	0113137AB	AG-10	T12B44A1OE						Familial transthyretin amyloidosis	656	done	
AGKISTRODON PISCIVORUS IMMUNE FAB ANTIVENIN (OVINE)	Treatment of envenomations inflicted by North American crotalid snakes.	"Antivenin, crotalidae polyvalent immune Fab (ovine)"	AGKISTRODON PISCIVORUS IMMUNE FAB ANTIVENIN (OVINE)	Crofab	1/12/94	Designated/Approved	Approved for Orphan Indication	Treatment of minimal and moderate North American Crotalidae envenomation	10/2/00	10/2/07	"Protherics, Inc."	Nashville	Tennessee	37212	USA	EXACT	0696640AA	AGKISTRODON PISCIVORUS IMMUNE FAB ANTIVENIN (OVINE)	IA6O0K772M								MISSING	not a disease
AI-RSA	Treatment of autoimmune uveitis.	AI-RSA		n/a	10/8/92	Designated/Withdrawn			N/A	N/A	"AutoImmune, Inc."	Lexington	Massachusetts	2173	USA					AI-RSA	NA	doi: 10.1016/S1542-0124(12)70105-2	PROBLEM	absent from GINAS	Panuveitis	8577	approximate	
AJOENE	Treatment of Pseudomonas aeruginosa pulmonary infections in cystic fibrosis patients	"(E, Z)-4,5,9-trithiadodeca-1, 6, 11-triene 9-oxide (Ajoene)"	AJOENE	n/a	4/21/16	Designated			N/A	N/A	Neem Biotech Ltd.	Blaenau Gwent			United Kingdom	EXACT	0420508AA	AJOENE	99A0041VG8						Pneumonia caused by Pseudomonas aeruginosa infection	13613	approximate	
ALISERTIB SODIUM ANHYDROUS	Treatment of ovarian cancer	"sodium 4-{ [9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-d] [2] benzazepin-2-yl]-2-methoxybenzoate"	ALISERTIB SODIUM ANHYDROUS	n/a	4/3/09	Designated/Withdrawn			N/A	N/A	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0702487AA	ALISERTIB SODIUM ANHYDROUS	23KN826MQ4						Ovarian cancer	7295	done	
ALLN-177	Treatment of pediatric hyperoxaluria	Bacillus subtilis oxalate decarboxylase	RELOXALIASE	n/a	2/29/16	Designated			N/A	N/A	Allena Pharmaceuticals	Newton	Massachusetts	2462	USA	EXACT	1802488AA	ALLN-177	48OB405WWC								MISSING	
ALLN-177	Treatment of primary hyperoxaluria	Bacillus subtilis oxalate decarboxylase	RELOXALIASE	n/a	6/12/17	Designated			N/A	N/A	"Allena Pharmaceuticals, Inc."	Newton	Massachusetts	2462	USA	EXACT	1802488AA	ALLN-177	48OB405WWC						Primary hyperoxaluria type 1	2835	done	
ALLN-177	Treatment of primary hyperoxaluria	Bacillus subtilis oxalate decarboxylase	RELOXALIASE	n/a	6/12/17	Designated			N/A	N/A	"Allena Pharmaceuticals, Inc."	Newton	Massachusetts	2462	USA	EXACT	1802488AA	ALLN-177	48OB405WWC						Primary hyperoxaluria type 2	2836	done	
ALLN-177	Treatment of primary hyperoxaluria	Bacillus subtilis oxalate decarboxylase	RELOXALIASE	n/a	6/12/17	Designated			N/A	N/A	"Allena Pharmaceuticals, Inc."	Newton	Massachusetts	2462	USA	EXACT	1802488AA	ALLN-177	48OB405WWC						Primary hyperoxaluria type 3	10738	done	
ALPROLIX	Control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease)	"Coagulation factor IX (recombinant), Fc fusion protein"	EFTRENONACOG ALFA	Alprolix	10/30/08	Designated/Approved	Approved for Orphan Indication	"Adults and children with Hemophilia B for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes."	3/28/14	3/28/21	Biogen Idec Inc.	Cambridge	Massachusetts	2142	USA	EXACT	0784349AA	ALPROLIX	02E00T2QDE						Hemophilia B	8732	done	
AM-0010	Treatment of pancreatic cancer	Pegylated recombinant human interleukin-10	PEGILODECAKIN	n/a	7/18/16	Designated			N/A	N/A	"ARMO BioSciences, Inc."	Redwood City	California	94063	USA	EXACT	1800222AA	AM-0010	5Z9850I25F						Pancreatic cancer	9364	done	Not a rare disease
AM-111	Treatment of acute sensorineural hearing loss	(UDU-stereoisomer of c-UJUun UNU-terminal UkUnhibitor)	XG-102 C-TERMINAL ACID	n/a	3/28/06	Designated			N/A	N/A	"Auris Medical, Inc."	Chicago	Illinois	60611	USA	EXACT	0739322AA	AM-111	FU288768DP						Sudden sensorineural hearing loss	12927	done	
AMG-714	Treatment of refractory celiac disease.	human immunoglobulin (IgG1K) monoclonal antibody that binds to interleukin 15	AMG-714	n/a	4/10/18	Designated			N/A	N/A	Amgen Inc.	1 Amgen Center Drive		91320	USA	EXACT	0740807AA	AMG-714	EJ48MR05C3						Celiac disease	11998	done	
AML-2-23	For the exogenous depletion of CD14 and CD15 positive acute myeloid leukemic bone marrow cells from patients undergoing bone marrow transplantation.	Monoclonal antibodies PM-81 and AML-2-23		n/a	3/12/90	Designated/Withdrawn			N/A	N/A	"Medarex, Inc."	Bloomsbury	New Jersey	8804	USA	EXACT							PROBLEM	can't find			MISSING	not a disease
AMUVATINIB	"Treatment, in combination with radiotherapy and temozolomide chemotherapy, of patients with glioblastoma multiforme."	"4-[1]benzofuro[3,2-d]pyrimidin-4-yl-N-(1,3-benzodioxol-5-ylmethyl)piperazine-1-carbothioamide"	AMUVATINIB	n/a	7/30/08	Designated			N/A	N/A	"SuperGen, Inc."	Dublin	California	94568	USA	EXACT	0304392AA	AMUVATINIB	SO9S6QZB4R						Glioblastoma	2491	done	
AMY-101	Treatment of paroxysmal nocturnal hemoglobinuria (PNH)	"S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)"	AMY-101	n/a	10/9/14	Designated			N/A	N/A	Amyndas Pharmaceuticals	Glyfada			Greece	EXACT	1802864AA	AMY-101	4Z4DFR9BX7						Paroxysmal nocturnal hemoglobinuria	7337	done	
ANAVEX-2-73	Treatment of Rett Syndrome.	"(2,2-diphenyl-tetrahydro-furan-3-yl-methyl)-dimethylamine hydrochloride"	ANAVEX-2-73	n/a	5/18/16	Designated			N/A	N/A	Anavex Life Sciences Corporation	New York	New York	10019	USA	EXACT	0918718AA	ANAVEX-2-73	1M49V1PBPL						Rett syndrome	5696	done	
ANAVEX-2-73	Treatment of infantile spasms	"tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride"	ANAVEX-2-73	n/a	6/20/16	Designated			N/A	N/A	Anavex Life Sciences Corp.	New York	New York	10019	USA	EXACT	0918718AA	ANAVEX-2-73	1M49V1PBPL						West syndrome	7887	done	
ANFIBATIDE	Treatment of thrombotic thrombocytopenic purpura.	anfibatide	ANFIBATIDE	n/a	3/10/16	Designated			N/A	N/A	Lee's Pharmaceutical (Hong Kong) Limited				China	EXACT	1576325AA	ANFIBATIDE	DCG29J773G						"Thrombotic thrombocytopenic purpura, acquired"	4607	approximate	
ANFIBATIDE	Treatment of thrombotic thrombocytopenic purpura.	anfibatide	ANFIBATIDE	n/a	3/10/16	Designated			N/A	N/A	Lee's Pharmaceutical (Hong Kong) Limited				China	EXACT	1576325AA	ANFIBATIDE	DCG29J773G						Congenital thrombotic thrombocytopenic purpura	9430	approximate	
ANG-1005	Treatment of breast cancer patients with brain metastases	[Î±â¿¿N-(2â¿¿succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[Îµâ¿¿N-(2â¿¿succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[Îµâ¿¿N-(2â¿¿succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr	PACLITAXEL TREVATIDE	n/a	4/15/15	Designated			N/A	N/A	"Angiochem, Inc."				Canada	EXACT	0632133AA	ANG-1005	8P77G99D3P						Familial breast cancer	10415	approximate	
ANTRIL	Prevention and treatment of graft versus host disease in transplant recipients.	"Interleukin-1 receptor antagonist, human recombinant"	ANAKINRA	Antril	10/16/92	Designated			N/A	N/A	Swedish Orphan Biovitrum AB (publ) (SOBI)	Stockholm			Sweden	EXACT	0242524AA	ANTRIL	9013DUQ28K						Chronic graft versus host disease	10964	approximate	type of GVHD (acute or chronic) is not specified
ANTRIL	Prevention and treatment of graft versus host disease in transplant recipients.	"Interleukin-1 receptor antagonist, human recombinant"	ANAKINRA	Antril	10/16/92	Designated			N/A	N/A	Swedish Orphan Biovitrum AB (publ) (SOBI)	Stockholm			Sweden	EXACT	0242524AA	ANTRIL	9013DUQ28K						Acute graft versus host disease	6544	approximate	type of GVHD (acute or chronic) is not specified
ANTRIL	Treatment of juvenile rheumatoid arthritis.	"Interleukin-1 receptor antagonist, human recombinant"	ANAKINRA	Antril	9/23/91	Designated			N/A	N/A	Swedish Orphan Biovitrum AB (publ) (SOBI)	Stockholm			Sweden	EXACT	0242524AA	ANTRIL	9013DUQ28K						Juvenile idiopathic arthritis	3067	done	Not a rare disease
AP-1903	Treatment of acute graft-versus-host disease in patients undergoing bone marrow transplantation.	Dimerizing drug that binds to mutated Fas protein/drug-binding domain fusion protein (FKBP)	RIMIDUCID	n/a	11/24/99	Designated			N/A	N/A	"Bellicum Pharmaceuticals, Inc."	Houston	Texas	77030	USA	EXACT	0738921AA	AP-1903	H564L1W5J2						Acute graft versus host disease	6544	done	
AP-301	Treatment of high altitude pulmonary edema	synthetic peptide; cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-ALA-Lys-Pro-Trp-Tyr-Cys	SOLNATIDE	n/a	1/16/13	Designated			N/A	N/A	Apeptico Forschung und Entwicklung GmbH	Vienna			Austria	EXACT	0766778AA	AP-301	17ZS80333G						Acute mountain sickness	5730	approximate	
APTO-253	Treatment of acute myeloid leukemia	"2-(5-fluoro-2-methyl-1H-indol-3-yl)-1H-imidazo[4,5-f][1,10] phenanthroline"	APTO-253	n/a	6/1/15	Designated			N/A	N/A	"Aptose Biosciences, Inc."	"Mississauga, Ontario L4V"			Canada	EXACT	0547717AA	APTO-253	WB59MRW00U						Acute myeloid leukemia	12757	done	
APX-001	"Treatment of invasive rare mold infections caused by scedosporium spp., fusarium spp., and mucorales fungi (including mucor spp., and rhizopus spp.)"	2-amino-3-[3-[[4-(2-pyridyloxymethyl)phenyl]methyl]isoxazol-5-yl]pyridin-1-ium-1-yl]methyl hydrogen phosphate	APX-001	n/a	11/2/16	Designated			N/A	N/A	"Amplyx Pharmaceuticals, Inc."	San Diego	California	92130	USA	EXACT	1718429AA	APX-001	1XQ871489P								PROBLEM	
AQ-13 FREE BASE	Treatment of malaria.	"N'-(7-Chloroquinolin-4-yl)-N,N-diethyl-propane-1,3-diamine"	AQ-13 FREE BASE	n/a	10/29/15	Designated			N/A	N/A	"Donald J. Krogstad, MD"	New Orleans	Louisiana	70112	USA	EXACT	0807669AA	AQ-13 FREE BASE	4K7VT5621X						Malaria	6961	done	
AR-101	Treatment of hospital acquired pneumonia caused by serotype 011 positive Pseudomonas aeruginosa	Human monoclonal antibody directed against serotype 011 Pseudomonas aeruginosa	PANOBACUMAB	Aerumab 11	9/18/06	Designated			N/A	N/A	Kenta Biotech Limited				Switzerland	EXACT	0432473AA	AR-101	62B4OXU259						Pneumonia caused by Pseudomonas aeruginosa infection	13613	approximate	
AR-101	Treatment of pneumonia caused by serotype O1 positive Pseudomonas aeruginosa	human monoclonal antibody directed against serotype O1 Pseudomonas aeruginosa	PANOBACUMAB	n/a	1/6/10	Designated			N/A	N/A	Kenta Biotech Limited				Switzerland	EXACT	0432473AA	AR-101	62B4OXU259						Pneumonia caused by Pseudomonas aeruginosa infection	13613	done	
ARA-290	Prevention of delayed graft function following renal transplant	L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	CIBINETIDE	n/a	9/18/09	Designated			N/A	N/A	"Araim Pharmaceuticals, Inc."	Ossining	New York	10562	USA	EXACT	0693812AA	ARA-290	9W5677JKDA								MISSING	
ARCHEXIN	Treatment of pancreatic cancer	20-mer oligonucleotide complementary to Akt mRNA	ARCHEXIN	n/a	12/8/04	Designated			N/A	N/A	Rexahn Corporation	Rockville	Maryland	20850	USA	EXACT	0252631AA	ARCHEXIN	4TEW51C830						Pancreatic cancer	9364	done	Not a rare disease
ARM-210 HEMIFUMARATE	Treatment of patients with Duchenne Muscular Dystrophy.	"4-[(7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl]benzoic acid, hemifumarate"	ARM-210 HEMIFUMARATE	n/a	11/18/15	Designated			N/A	N/A	"ARMGO Pharma, Inc."	Tarrytown	New York	10591	USA	EXACT	1674802AA	ARM-210 HEMIFUMARATE	ZHR6WM1ADJ						Duchenne muscular dystrophy	6291	done	
AROPLATIN	Treatment of malignant mesothelioma.	"Liposomal-cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane-Pt (II)"	AROPLATIN	Aroplatin	9/1/99	Designated/Withdrawn			N/A	N/A	Antigenics Incorporated	Lexington	Massachusetts	2421	USA	EXACT	0230808AA	AROPLATIN	J7M4Z2D183						Malignant mesothelioma	7026	done	
ARQ-092	Treatment of Proteus Syndrome.	"3-{3-[4-(1-aminocyclobutyl)phenyl]-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl}cpyridin-2-amine bis-mesylate"	ARQ-092	n/a	11/9/15	Designated			N/A	N/A	"ArQule, Inc."	Burlington	Massachusetts	1803	USA	EXACT	0708770AA	ARQ-092	T1DQI1B52Y						Proteus syndrome	7475	done	
ARRY-797	"Treatment of dilated cardiomyopathy, including dilated cardiomyopathy secondary to lamin A/C gene mutations"	p38 mitogen-activated kinase inhibitor	ARRY-1797	n/a	5/27/14	Designated			N/A	N/A	"Array BioPharma, Inc."	Boulder	Colorado	80301	USA	EXACT	0304358AA	ARRY-797	4JG61K4659						Dilated cardiomyopathy	221	done	
AS-013	Treatment of Fontaine Stage IV chronic critical limb ischemia.	Prostaglandin E1 enol ester (AS-013)	ECRAPROST	Circulase	6/12/98	Designated			N/A	N/A	"LTT Baio-Pharma Co., Ltd"				Japan	EXACT	0222139AA	AS-013	Q2XM6VR8DO								MISSING	
AS101	Treatment of acquired immunodeficiency syndrome.	"Ammonium trichloro [dioxoethylene-O,O') tellurium (IV)"	AMMONIUM TRICHLOROTELLURATE	n/a	11/9/87	Designated/Withdrawn			N/A	N/A	"NPDC-AS101, Inc."	New Brunswick	New Jersey	8901	USA	EXACT	0161046AA	AS101	708681952A						Congenital human immunodeficiency virus	10328	approximate	
ASC-JM-17	Treatment of spinal and bulbar muscular atrophy	"1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione or [(1E, 4Z,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one]"	ASC-JM-17	n/a	2/17/16	Designated			N/A	N/A	Allianz Pharmascience Ltd.	Silver Spring	Maryland	20910	USA	EXACT	1577088AA	ASC-JM-17	5VLL140BN9						Congenital benign spinal muscular atrophy dominant	1474	approximate	
ASLAN-003	Treatment of acute myeloid leukemia	"2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)nicotinic acid"	ASLAN-003	n/a	8/16/18	Designated			N/A	N/A	"ASLAN Pharmaceuticals Pte, Ltd."	83 Clemenceau Avenue			Singapore	EXACT	0117178AB	ASLAN-003		ASLAN003	NA	http://aslanpharma.com/drug/aslan003/	PROBLEM	absent from GINAS	Acute myeloid leukemia	12757	done	
ATI-355	Treatment of acute spinal cord injury	anti human Nogo-A human monoclonal antibody	ATI-355	n/a	10/20/08	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0349473AA	ATI-355	MVU4UCZ5LA								MISSING	
ATIPRIMOD DIMALEATE	Treatment of carcinoid tumors	"2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5] decane dimaleate"	ATIPRIMOD DIMALEATE	Atiprimod	9/18/06	Designated			N/A	N/A	"Callisto Pharmaceuticals, Inc."	New York	New York	10170	USA	EXACT	0216206AA	ATIPRIMOD DIMALEATE	YNU265SSR3						Carcinoid tumor	9316	done	
ATR-101	Treatment of congenital adrenal hyperplasia	"N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt"	ATR-101	n/a	8/17/17	Designated			N/A	N/A	"Millendo Therapeutics, Inc."	Ann Arbor	Michigan	48104	USA	EXACT	0740410AA	ATR-101	VK9OS8R205						Congenital adrenal hyperplasia	1467	done	
ATR-101 HYDROCHLORIDE	Treatment of adrenocortical carcinoma	"(N-[2,6-bis(1-methylethyl)-pheyl-N'-[[1-4-dimethyl-amino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt"	PD-132301 HYDROCHLORIDE	n/a	3/9/12	Designated			N/A	N/A	"Atterocor, Inc."	Ann Arbor	Michigan	48104	USA	EXACT	0740421AA	atr-101	TK694ZFS57						Adrenocortical carcinoma	558	done	
AUT-00206	Treatment of fragile X syndrome	"5,5-dimethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione"	AUT-00206	n/a	6/12/17	Designated			N/A	N/A	Autifony Therapeutics Limited				United Kingdom	EXACT	0111874AB	AUT-00206	46P8AHZ243						Fragile X syndrome	6464	done	
AVA-4746 sodium	For mobilization of hematopoietic stem cells	"(3S)-3-[({1-(2-Chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3yl}amino)carbonyl]amino-3-(4-methylphenyl)propanoic acid monosodium salt"	AVA-4746 SODIUM	n/a	4/25/16	Designated			N/A	N/A	"Aviara Pharmaceuticals, Inc/"	Houston	Texas	77027	USA	EXACT	1577179AA	AVA-4746 sodium	TGC4U44G07								MISSING	not a disease
AVADOMIDE HYDROCHLORIDE	Treatment of follicular lymphoma	"3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl) piperidine-2,6-dione hydrochloride"	AVADOMIDE HYDROCHLORIDE	n/a	3/12/18	Designated			N/A	N/A	Celgene Corporation	86 Morris Avenue		7901	USA	EXACT	0926830AA	AVADOMIDE HYDROCHLORIDE	6CX4AEX3KR						Follicular lymphoma	2356	done	
AVI-7537	Prophylaxis for patients following documented or suspected exposure to ebolavirus	5'-GCCATGGTTTTTTCTCAGG-3'	AVI-7537	n/a	10/31/12	Designated			N/A	N/A	"Sarepta Therapeutics, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	1803107AA	AVI-7537	0P93LDFNTU						Ebola virus disease	2035	done	
AXITINIB	"Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer."	N-Methyl-2-[3-[((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]benzamide	AXITINIB	Axitinib	5/4/07	Designated/Withdrawn			N/A	N/A	"Pfizer, Inc."	San Diego	California	92121	USA	EXACT	0242897AA	AXITINIB	C9LVQ0YUXG						"Thyroid cancer, follicular"	5206	done	
AXITINIB	"Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer."	N-Methyl-2-[3-[((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]benzamide	AXITINIB	Axitinib	5/4/07	Designated/Withdrawn			N/A	N/A	"Pfizer, Inc."	San Diego	California	92121	USA	EXACT	0242897AA	AXITINIB	C9LVQ0YUXG						"Thyroid cancer, medullary"	7004	done	
AXITINIB	"Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer."	N-Methyl-2-[3-[((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]benzamide	AXITINIB	Axitinib	5/4/07	Designated/Withdrawn			N/A	N/A	"Pfizer, Inc."	San Diego	California	92121	USA	EXACT	0242897AA	AXITINIB	C9LVQ0YUXG						Anaplastic thyroid cancer	664	done	
AXITINIB	"Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer."	N-Methyl-2-[3-[((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]benzamide	AXITINIB	Axitinib	5/4/07	Designated/Withdrawn			N/A	N/A	"Pfizer, Inc."	San Diego	California	92121	USA	EXACT	0242897AA	AXITINIB	C9LVQ0YUXG						Papillary thyroid carcinoma	12027	done	
Acetylcysteine	Intravenous treatment of patients presenting with moderate to severe acetaminophen overdose.	Acetylcysteine	ACETYLCYSTEINE	Mucomyst/Mucomyst 10 Iv	8/13/87	Designated			N/A	N/A	Bristol-Myers Squibb Company	Princeton	New Jersey	8543	USA	EXACT	0029969AA	Acetylcysteine	WYQ7N0BPYC								MISSING	not a disease
Aclerastide	Treatment of leakage from the surgical site following penetrating keratoplasty	NorLeu3-Angiontensin(1-7)) [NorLeu3-A(1-7)]	ACLERASTIDE	n/a	12/31/13	Designated			N/A	N/A	"US Biotest, Inc."	San Luis Obispo	California	93401	USA	EXACT	0296617AA	Aclerastide	YYD6UT8T47								MISSING	not a disease
Adeno-Associated Viral Vector Expressing Low-Density Lipoprotein Receptor	Treatment of homozygous familial hypercholesterolemia	Adeno-Associated Viral Vector Expressing Low-Density Lipoprotein Receptor		n/a	1/31/12	Designated			N/A	N/A	ReGenX Biosciences LLC	Washington	District of Columbia	20006	USA								PROBLEM	can't find	Familial hypercholesterolemia	10416	done	Not a rare disease
Adeno-Associated Viral Vector encoding C1 Esterase Inhibitor	Treatment of Angioedema due to C1-Inhibitor Deficiency	Adeno-Associated Viral Vector encoding C1 Esterase Inhibitor	CONESTAT ALFA	n/a	8/22/18	Designated			N/A	N/A	"Adverum Biotechnologies, Inc."	1035 O'Brien Drive	California	94025	USA	LONGEST CONTAINS	0432166AA	C1 Esterase Inhibitor	5QS67N4551								MISSING	
Adeno-associated vector expressing the human lipoprotein lipase protein	Treatment of lipoprotein lipase deficiency	Adeno-associated vector expressing the human lipoprotein lipase protein	PROTEIN	n/a	5/21/07	Designated			N/A	N/A	uniQure B.V.	Amsterdam			Netherlands	LONGEST CONTAINS	0087274AA	protein					PROBLEM	can't find	Familial lipoprotein lipase deficiency	12241	approximate	
Adeno-associated vector expressing the human lipoprotein lipase protein	Treatment of lipoprotein lipase deficiency	Adeno-associated vector expressing the human lipoprotein lipase protein	PROTEIN	n/a	5/21/07	Designated			N/A	N/A	uniQure B.V.	Amsterdam			Netherlands	LONGEST CONTAINS	0087274AA	protein					PROBLEM	can't find	Lipase deficiency combined	10244	approximate	
Adeno-associated viral vector expressing human acid alpha glucosidase gene	Treatment of Pompe disease	Adeno-associated viral vector expressing human acid alpha glucosidase gene		n/a	3/20/07	Designated			N/A	N/A	"Audentes Therapeutics, Inc."	San Francisco	California	94104	USA								PROBLEM	can't find	Glycogen storage disease type 2	5714	done	
Adeno-associated viral vector serotype 5 containing human ABCA4 gene	Treatment of Stargardt's disease.	Adeno-associated viral vector serotype 5 containing human ABCA4 gene		n/a	9/30/08	Designated/Withdrawn			N/A	N/A	Fondazione Telethon				Italy								PROBLEM	can't find	Stargardt disease	181	done	
Adenosine	For use in conjunction with BCNU in the treatment of brain tumors.	Adenosine	ADENOSINE	n/a	8/1/89	Designated/Withdrawn			N/A	N/A	"Medco Research, Inc."	Los Angeles	California	90048	USA	EXACT	0009869AA	Adenosine	K72T3FS567								MISSING	not a disease
Adenoviral vector expressing Herpes simplex virus thymidine kinase gene	Treatment of malignant brain tumors	Adenoviral vector expressing Herpes simplex virus thymidine kinase gene	THYMIDINE	n/a	6/17/05	Designated			N/A	N/A	"Advantagene, Inc."	Waban	Massachusetts	2468	USA	LONGEST CONTAINS	0007669AA	thymidine	VC2W18DGKR						Gliomatosis cerebri	6514	approximate	
Adenoviral vector expressing Herpes simplex virus thymidine kinase gene	Treatment of malignant brain tumors	Adenoviral vector expressing Herpes simplex virus thymidine kinase gene	THYMIDINE	n/a	6/17/05	Designated			N/A	N/A	"Advantagene, Inc."	Waban	Massachusetts	2468	USA	LONGEST CONTAINS	0007669AA	thymidine	VC2W18DGKR						Brain stem cancer	8244	approximate	
"Adenovirus serotype-5 (Ad5) vector that contains a modified non-oncogenic fused early 6 (E6) and early 7 (E7) gene of the human papillomavirus (HPV); (Ad5 (E1-, E2b-)-E6/E7)"	Treatment of human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC)	"Adenovirus serotype-5 (Ad5) vector that contains a modified non-oncogenic fused early 6 (E6) and early 7 (E7) gene of the human papillomavirus (HPV); (Ad5 [E1-, E2b-]-E6/E7)"	HUMAN PAPILLOMAVIRUS	n/a	9/4/14	Designated			N/A	N/A	Etubics Corporation	Seattle	Washington	98119	USA	LONGEST CONTAINS	0316892AA	human papillomavirus	23CVL7WF4J						Squamous cell carcinoma of the head and neck	8503	done	Not a rare disease
Aerosolized pooled immune globulin	Treatment of respiratory syncytial virus lower respiratory tract disease.	Aerosolized pooled immune globulin	IMMUNE GLOBULIN NOS	n/a	1/3/89	Designated/Withdrawn			N/A	N/A	"Pediatric Pharmaceuticals, Inc."	Westfield	New Jersey	7090	USA	LONGEST CONTAINS	0006531AA	immune globulin	66Y330CJHS	HUMAN IMMUNE GLOBULIN G	66Y330CJHS	https://ginas.ncats.nih.gov/ginas/app/substance/c6126a46	done				MISSING	
Agalsidase alfa	Treatment of Pompe disease	recombinant human acid a-glucosidase co-administered with N-butyl-deoxynojirimycin (reconbinant human acid a-glucosidase/miglustat)	AGALSIDASE ALFA	n/a	9/13/17	Designated			N/A	N/A	"Amicus Therapeutics, Inc."	Cranbury Township	New Jersey	8512	USA	EXACT	0302125AA	Agalsidase alfa	2HLC17MX9G						Glycogen storage disease type 2	5714	done	
Albendazole	"Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis."	Albendazole	ALBENDAZOLE	Albenza	1/18/96	Designated/Approved	Approved for Orphan Indication	"Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium."	6/11/96	6/11/03	Amedra Pharmaceuticals LLC	Horsham	Pennsylvania	19044	USA	EXACT	0121142AA	Albendazole	F4216019LN						Status epilepticus	10191	done	
Albuterol	Prevention of paralysis due to spinal cord injury	Albuterol	ALBUTEROL	n/a	3/12/02	Designated			N/A	N/A	"MotoGen, Inc."	Mount Kisco	New York	10549	USA	EXACT	0064437AA	Albuterol	QF8SVZ843E								MISSING	
Aldesleukin	For the treatment non-Hodgkin's lymphoma.	Aldesleukin	ALDESLEUKIN	Proleukin	11/24/98	Designated			N/A	N/A	"Prometheus Laboratories, Inc."	San Diego	California	92121	USA	EXACT	0181566AA	Aldesleukin	M89N0Q7EQR						B-cell lymphoma	5877	approximate	
Aldesleukin	Treatment of acute myelogenous leukemia.	Aldesleukin	ALDESLEUKIN	Proleukin	7/31/98	Designated/Withdrawn			N/A	N/A	Chiron Corporation	Emeryville	California	94608	USA	EXACT	0181566AA	Aldesleukin	M89N0Q7EQR						Acute myeloid leukemia	12757	done	
Alefacept	For use as prophylaxis of rejection in patients receiving allogenic solid organ transplants.	Alefacept	ALEFACEPT	Amevive	12/19/07	Designated/Withdrawn			N/A	N/A	"Astellas Pharma Global Development, Inc."	Deerfield	Illinois	60015	USA	EXACT	0247381AA	Alefacept	ELK3V90G6C								MISSING	"not a disease, a procedure"
Alfentanil	Management of postherpetic neuralgia	Alfentanil	ALFENTANIL	n/a	7/8/05	Designated			N/A	N/A	"Cinergen, LLC"	Blue Bell	Pennsylvania	19422	USA	EXACT	0160963AA	Alfentanil	1N74HM2BS7						Herpes zoster oticus	7525	approximate	postherpetic neuralgia is a complication of varicella-zoster virus infection
Alfentanil	Treatment of painful HIV-associated neuropathy	Alfentanil	ALFENTANIL	n/a	8/9/05	Designated			N/A	N/A	"Cinergen, LLC"	Blue Bell	Pennsylvania	19422	USA	EXACT	0160963AA	Alfentanil	1N74HM2BS7								MISSING	
Alfimeprase	Treatment of peripheral arterial occlusion (PAO)	Novel Acting Thrombolytic (NAT)	ALFIMEPRASE	n/a	1/26/01	Designated/Withdrawn			N/A	N/A	"Nuvelo, Inc. Inc."	San Carlos	California	94070	USA	EXACT	0263229AA	Alfimeprase	GPN9HBH1HS								MISSING	symptom
Alglucerase injection	For replacement therapy in patients with Gaucher's disease type I.	Alglucerase injection	ALGLUCERASE	Ceredase	3/11/85	Designated/Approved	Approved for Orphan Indication	"Long-term enzyme replacement therapy for children, adolescents and adult patients with a confirmed diagnosis of Type I Gaucher disease who exhibit signs and symptoms that are severe enough to result in one or more of the following conditions: a) moderate-to-severe anemia; b) thrombocytopenia with bleeding tendency; c) bone disease; d) significant hepatomegaly or splenomegaly."	4/5/91	4/5/98	Genzyme Corporation	Cambridge	Massachusetts	2139	USA	EXACT	0064868AA	Alglucerase	27T56C7KK0						Gaucher disease type 1	2441	done	
Alglucerase injection	Replacement therapy in patients with Type II and III Gaucher's disease.	Alglucerase injection	ALGLUCERASE	Ceredase	7/21/95	Designated			N/A	N/A	Genzyme Corporation	Cambridge	Massachusetts	2139	USA	EXACT	0064868AA	Alglucerase	27T56C7KK0						Gaucher disease type 1	2441	done	
Alglucerase injection	Replacement therapy in patients with Type II and III Gaucher's disease.	Alglucerase injection	ALGLUCERASE	Ceredase	7/21/95	Designated			N/A	N/A	Genzyme Corporation	Cambridge	Massachusetts	2139	USA	EXACT	0064868AA	Alglucerase	27T56C7KK0						Gaucher disease type 2	2442	done	
Alglucerase injection	Replacement therapy in patients with Type II and III Gaucher's disease.	Alglucerase injection	ALGLUCERASE	Ceredase	7/21/95	Designated			N/A	N/A	Genzyme Corporation	Cambridge	Massachusetts	2139	USA	EXACT	0064868AA	Alglucerase	27T56C7KK0						Gaucher disease type 3	2443	done	
"Allogeneic T-cells cultured with anti-CD3 and IL-2; transduced with retroviral vector (SFCMM-3), expressing herpes simplex 1 virus-thymidine kinase (HSV-TK) and truncated low affinity nerve growth factor receptor; selected with anti-low affinity nerve gro"	Immunotherapy for acceleration of T-cell reconstitution in patients undergoing allogeneic hematopoietic stem cell transplantation	"Allogeneic T-cells cultured with anti-CD3 and IL-2; transduced with retroviral vector (SFCMM-3), expressing herpes simplex 1 virus-thymidine kinase (HSV-TK) and truncated low affinity nerve growth factor receptor; selected with anti-low affinity nerve gro"	NERVE GROWTH FACTOR	n/a	1/28/05	Designated			N/A	N/A	MolMed S.p.A.	Milan			Italy	LONGEST CONTAINS	0358612AA	nerve growth factor	V7FWP1D62O								MISSING	"not a disease, a procedure"
Allogeneic cytomegalovirus cytotoxic T lymphocytes	Treatment of cytomegalovirus viremia and disease in immunocompromised patients	Allogeneic cytomegalovirus cytotoxic T lymphocytes	HUMAN HERPESVIRUS 5	n/a	8/31/17	Designated			N/A	N/A	"Atara Biotherapeutics, Inc."	Westlake Village	California	91361	USA	LONGEST CONTAINS	0354529AA	cytomegalovirus	7COI029E6K								MISSING	
Allogeneic human aortic endothelial cells cultured in a porcine gelatin matrix	Prevention of arteriovenous fistula or arteriovenous graft failure in patients with end satge renal disease receiving hemodialysis or preparing for hemodialysis	Allogeneic human aortic endothelial cells cultured in a porcine gelatin matrix	"GELATIN, UNSPECIFIED"	Vascugel (R)	4/3/09	Designated			N/A	N/A	Shire	Lexington	Massachusetts	2421	USA	LONGEST CONTAINS	0004739AA	gelatin	2G86QN327L								MISSING	incorrect spelling
Allogeneic human retinal pigment epithelial cells on gelatin microcarriers	Treatment of Hoehn and Yahr stage 3 and 4 Parkinson's disease.	Allogeneic human retinal pigment epithelial cells on gelatin microcarriers	"RETINAL, ALL-TRANS"	Spheramine	7/18/97	Designated/Withdrawn			N/A	N/A	"Bayer Healthcare Pharmaceuticals, Inc."	Whippany	New Jersey	7981	USA	LONGEST CONTAINS	0018746AA	retinal	RR725D715M						Parkinson disease	10251	done	
Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture	Treatment of pancreatic cancer	Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture	BLOOD	Cytoimplant	6/13/97	Designated			N/A	N/A	"Applied Immunotherapeutics, LLC"	Santa Fe Springs	California	90670	USA	LONGEST CONTAINS	0098420AA	blood	43MX67MYM9						Pancreatic cancer	9364	done	Not a rare disease
Allogeneic umbilical cord blood (UCB) cell therapy product consisting of two cell fractions (CD34 enriched and CD34 depleted) derived from the same UCB unit	For the enhancement of cell engraftment in patients receiving hematopoietic stem cell transplantation (HSCT)	Allogeneic umbilical cord blood (UCB) cell therapy product consisting of two cell fractions (CD34 enriched and CD34 depleted) derived from the same UCB unit	CORD BLOOD	n/a	4/11/18	Designated			N/A	N/A	Magenta Therapeutics	50 Hampshire Street		2139	USA	LONGEST CONTAINS	0854240AA	umbilical cord blood	PVH8394DLN								MISSING	
"Allogeneic, ex vivo expanded, umbilical cord blood-derived, hematopoietic CD34+ progenitor cells and Allogeneic, non-expanded, umbilical cord blood-derived, hematopoietic mature myeloid and lymphoid cells (Non-cultured fraction)"	Treatment in hematopoietic stem cell transplantation	"Allogeneic, ex vivo expanded, umbilical cord blood-derived, hematopoietic CD34+ progenitor cells and Allogeneic, non-expanded, umbilical cord blood-derived, hematopoietic mature myeloid and lymphoid cells (Non-cultured fraction)"	CORD BLOOD	n/a	5/23/18	Designated			N/A	N/A	Gamida Cell Ltd.	P. O. Box 34670			Israel	LONGEST CONTAINS	0854240AA	umbilical cord blood	PVH8394DLN								MISSING	procedure
Allopurinol sodium	Ex-vivo preservation of cadaveric kidneys for transplantation	Allopurinol sodium	ALLOPURINOL SODIUM	n/a	11/9/87	Designated/Withdrawn			N/A	N/A	Burroughs Wellcome Company	Research Triangle Pk	North Carolina	27709	USA	EXACT	0058662AA	Allopurinol sodium	428673RC2Z								MISSING	Not a rare disease
Allopurinol sodium	"Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy."	Allopurinol sodium	ALLOPURINOL SODIUM	Aloprim For Injection	10/16/92	Designated/Approved	Approved for Orphan Indication	"Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy."	5/17/96	5/17/03	"Catalytica Pharmaceuticals, Inc"	Greenville	North Carolina	27835	USA	EXACT	0058662AA	Allopurinol sodium	428673RC2Z								MISSING	Not a rare disease
Alpha-1-acid glycoprotein	Treatment of cocaine overdose	Alpha-1-acid glycoprotein	ALPHA-1-ACID GLYCOPROTEIN	n/a	3/5/04	Designated/Withdrawn			N/A	N/A	Bio Products Laboratory				United Kingdom	EXACT	1721999AA	Alpha-1-acid glycoprotein	31V857ZRPY								MISSING	Not a rare disease
Alpha-1-antitrypsin	As supplementation therapy for alpha-1-antitrypsin deficiency in the ZZ phenotype population.	Alpha-1-antitrypsin (recombinant DNA Origin)	.ALPHA.1-PROTEINASE INHIBITOR HUMAN	n/a	1/1/84	Designated/Withdrawn			N/A	N/A	Chiron Corporation	Emeryville	California	94608	USA	EXACT	0163520AA	Alpha-1-antitrypsin	F43I396OIS						Alpha-1 antitrypsin deficiency	5784	done	
Alpha-galactosidase A	Treatment of Fabry's disease.	Alpha-galactosidase A	AGALSIDASE ALFA	Fabrase	7/20/90	Designated			N/A	N/A	"Desnick, Robert J. M.D."	New York	New York	10029	USA	EXACT	0302125AA	Alpha-galactosidase A	2HLC17MX9G						Fabry disease	6400	done	
Alpha-galactosidase A	Treatment of alpha-galactosidase A deficiency (Fabry's disease).	Alpha-galactosidase A	AGALSIDASE ALFA	Cc-Galactosidase	6/17/91	Designated			N/A	N/A	"David Calhoun, Ph.D."	New York	New York	10031	USA	EXACT	0302125AA	Alpha-galactosidase A	2HLC17MX9G						Fabry disease	6400	done	
Alpha1-Proteinase Inhibitor (Human)	Inhalation therapy for the treatment of congential deficiency of alpha1-proteinase inhibitor.	Alpha1-Proteinase Inhibitor (Human)	.ALPHA.1-PROTEINASE INHIBITOR (HUMAN)	n/a	12/22/04	Designated			N/A	N/A	Kamada Ltd.	Ness Ziona			Israel	EXACT	0334770AA	Alpha1-Proteinase Inhibitor (Human)	F43I396OIS								MISSING	not a disease
Alpha1-antitrypsin	Treatment of bronchiectasis	Alpha1-antitrypsin(human)	.ALPHA.1-PROTEINASE INHIBITOR (HUMAN)	n/a	4/3/08	Designated			N/A	N/A	Kamada Ltd.	Ness Ziona			Israel	EXACT	0334770AA	Alpha1-antitrypsin	F43I396OIS								MISSING	symptom of several conditions
Alpha1-proteinase inhibitor (human)	For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.	Alpha1-proteinase inhibitor (human)	.ALPHA.1-PROTEINASE INHIBITOR (HUMAN)	Prolastin	12/7/84	Designated/Approved	Approved for Orphan Indication	For chronic replacement therapy of individuals having congenital deficiency of alpha1- proteinase inhibitor with clinically demonstrable panacinar emphysema.	12/2/87	12/2/94	Bayer Corporation	New Haven	Connecticut	6516	USA	EXACT	0334770AA	Alpha1-proteinase inhibitor (human)	F43I396OIS						Alpha-1 antitrypsin deficiency	5784	done	
Alpha1-proteinase inhibitor (human)	For slowing the progression of emphysema in alpha1-antitrypsin deficient patients.	Alpha1-proteinase inhibitor (human)	.ALPHA.1-PROTEINASE INHIBITOR (HUMAN)	n/a	11/24/99	Designated/Withdrawn			N/A	N/A	CSL Behring L.L.C.	King of Prussia	Pennsylvania	19406	USA	EXACT	0334770AA	Alpha1-proteinase inhibitor (human)	F43I396OIS						Alpha-1 antitrypsin deficiency	5784	done	
Alprostadil	"Treatment of severe peripheral arterial occlusive disease (critical limb ischemia) in patients where other procedures, grafts or angioplasty, are not indicated."	Alprostadil	ALPROSTADIL	n/a	10/20/93	Designated/Withdrawn			N/A	N/A	"Schwarz Pharma, Inc."	Milwaukee	Wisconsin	53201	USA	EXACT	0030864AA	Alprostadil	F5TD010360								MISSING	Not a rare disease
Amantadine HCl	Treatment of levodopa-induced dyskinesia	Amantadine HCl	AMANTADINE HYDROCHLORIDE	n/a	7/20/15	Designated			N/A	N/A	Osmotica Pharmaceutical Corporation	Wilmington	North Carolina	28403	USA	EXACT	0030604AA	Amantadine HCl	M6Q1EO9TD0						Drug induced dyskinesia	8236	done	Not a rare disease
Amantadine hydrochloride	Treatment of levodopa-induced dyskinesia	Amantadine hydrochloride	AMANTADINE HYDROCHLORIDE	Nurelin	4/9/15	Designated			N/A	N/A	"Adamas Pharmaceuticals, Inc."	Emeryville	California	94608	USA	EXACT	0030604AA	Amantadine hydrochloride	M6Q1EO9TD0						Drug induced dyskinesia	8236	done	Not a rare disease
Amatuximab	Treatment of pancreatic cancer	Chimeric monoclonal antibody to mesothelin	AMATUXIMAB	n/a	10/31/06	Designated			N/A	N/A	"Morphotek, Inc."	Exton	Pennsylvania	19341	USA	EXACT	0583288AA	Amatuximab	6HP0354G04						Pancreatic cancer	9364	done	Not a rare disease
Amifostine	For the reduction of the incidence and severity of toxicities associated with cisplatin administration.	Amifostine	AMIFOSTINE	Ethyol	11/24/98	Designated			N/A	N/A	Clinigen Group plc				United Kingdom	EXACT	0102409AA	Amifostine	M487QF2F4V								MISSING	
Amifostine	Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.	Amifostine	AMIFOSTINE	Ethyol	5/12/98	Designated/Approved	Approved for Orphan Indication	"Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands."	6/24/99	6/24/06	"Medimmune Oncology, Inc."	West Conshohocken	Pennsylvania	19428	USA	EXACT	0102409AA	Amifostine	M487QF2F4V								MISSING	"Xerostomia is not a disease, but it may be a symptom of various medical conditions"
Aminocaproic acid	For the topical treatment of traumatic hyphema of the eye.	Aminocaproic acid	AMINOCAPROIC ACID	Caprogel	1/6/95	Designated			N/A	N/A	Eastern Virginia Medical School	Norfolk	Virginia	23502	USA	EXACT	0010435AA	Aminocaproic acid	U6F3787206								MISSING	
Aminosalicylate sodium	Treatment of Crohn's disease.	Aminosalicylate sodium	AMINOSALICYLATE SODIUM	n/a	4/6/93	Designated/Withdrawn			N/A	N/A	"Syncom Pharmaceuticals, Inc."	Florham Park	New Jersey	7932	USA	EXACT	0045578AA	Aminosalicylate sodium	S38B9W6AXW						Crohn's disease	10232	done	Not a rare disease
Amiodarone	Treatment of incessant ventricular tachycardia.	Amiodarone	AMIODARONE	Amio-Aqueous	8/17/93	Designated			N/A	N/A	"Academic Pharmaceuticals, Inc."	Lake Bluff	Illinois	60044	USA	EXACT	0130643AA	Amiodarone	N3RQ532IUT						Bidirectional tachycardia	878	approximate	
Amiodarone HCl	For the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation.	Amiodarone HCl	AMIODARONE HYDROCHLORIDE	Cordarone	3/16/94	Designated/Approved	Approved for Orphan Indication	For initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy.	8/3/95	8/3/02	Wyeth-Ayerst Laboratories	Philadelphia	Pennsylvania	19101	USA	EXACT	0037912AA	Amiodarone HCl	976728SY6Z						Bidirectional tachycardia	878	approximate	
Amiodarone HCl	For the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation.	Amiodarone HCl	AMIODARONE HYDROCHLORIDE	Cordarone	3/16/94	Designated/Approved	Approved for Orphan Indication	For initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy.	8/3/95	8/3/02	Wyeth-Ayerst Laboratories	Philadelphia	Pennsylvania	19101	USA	EXACT	0037912AA	Amiodarone HCl	976728SY6Z						Familial ventricular tachycardia	2263	approximate	
Ammonium tetrathiomolybdate	Treatment of Wilson's disease.	Ammonium tetrathiomolybdate	TIOMOLIBDATE DIAMMONIUM	Coprexa	1/31/94	Designated			N/A	N/A	"Pipex Pharmaceuticals, Inc."	Ann Arbor	Michigan	48108	USA	EXACT	0161820AA	Ammonium tetrathiomolybdate	4V6I63LW1E						Wilson disease	7893	done	
Amphotericin B inhalation powder	"Prevention of pulmonary fungal infections in patients at risk for aspergillosis due to immunosuppressive therapy including those receiving organ or stem cell transplants, or treated with chemotherapy or radiation for hematologic malignancies"	Amphotericin B inhalation powder	AMPHOTERICIN B	n/a	12/15/05	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	San Carlos	California	94070	USA	EXACT	0035881AA	Amphotericin B	7XU7A7DROE						Aspergillus niger infection	9716	done	
Amphotericin B lipid complex	Treatment of invasive fungal infections.	Amphotericin B lipid complex	AMPHOTERICIN B	Abelcet	12/5/91	Designated/Approved	Approved for Orphan Indication	Treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy.	10/18/96	10/18/03	"Liposome Company, Inc."	Princeton	New Jersey	8540	USA	EXACT	0035881AA	Amphotericin B lipid complex	7XU7A7DROE						Aspergillosis	5856	approximate	
Amphotericin B lipid complex	Treatment of invasive fungal infections.	Amphotericin B lipid complex	AMPHOTERICIN B	Abelcet	12/5/91	Designated/Approved	Approved for Orphan Indication	Treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy.	10/18/96	10/18/03	"Liposome Company, Inc."	Princeton	New Jersey	8540	USA	EXACT	0035881AA	Amphotericin B lipid complex	7XU7A7DROE						Systemic candidiasis	1076	approximate	
Amphotericin B lipid complex	Treatment of invasive protothecosis.	Amphotericin B lipid complex	AMPHOTERICIN B	Abelcet	8/21/96	Designated/Withdrawn			N/A	N/A	"The Liposome Company, Inc."	Princeton	New Jersey	8540	USA	EXACT	0035881AA	Amphotericin B lipid complex	7XU7A7DROE								PROBLEM	Human protothecosis is a rare infection but it's absent in GARD
Amsacrine	Treatment of acute adult leukemia.	Amsacrine	AMSACRINE	Amsidyl	12/7/84	Designated/Withdrawn			N/A	N/A	Warner-Lambert Company	Ann Arbor	Michigan	48106	USA	EXACT	0115946AA	Amsacrine	00DPD30SOY						Acute leukemia of ambiguous lineage	8638	done	
Amyl nitrite	Treatment of cyanide poisoning	"Amyl nitrite, sodium nitrite, sodium thiosulfate"	AMYL NITRITE	Cyanide Antidote Kit	12/18/06	Designated			N/A	N/A	"Akorn, Inc."	Buffalo Grove	Illinois	60089	USA	EXACT	0017765AA	Amyl nitrite	22T8Z09XAK								MISSING	Not a disease
"Amyl nitrite, sodium nitrite, sodium thiosulfate"	Treatment of cyanide poisoning	"Amyl nitrite, sodium nitrite, sodium thiosulfate"	SODIUM THIOSULFATE	Cyanide Antidote Kit	12/18/06	Designated			N/A	N/A	"Akorn, Inc."	Buffalo Grove	Illinois	60089	USA	EXACT	0053225AA	sodium thiosulfate	HX1032V43M								MISSING	Not a disease
Anagrelide	Treatment of thrombocytosis in chronic myelogenous leukemia.	Anagrelide	ANAGRELIDE	Agrylin	7/14/86	Designated			N/A	N/A	Roberts Pharmaceutical Corp.	Eatontown	New Jersey	7724	USA	EXACT	0225956AA	Anagrelide	K9X45X0051						Chronic myeloid leukemia	6105	done	
Ananain	For the enzymatic debridement of severe burns.	"Ananain, comosain"	ANANAIN	Vianain	1/21/92	Designated			N/A	N/A	Genzyme Corporation	Cambridge	Massachusetts	2139	USA	EXACT	0641554AA	Ananain	K0H66D72UT								MISSING	
"Ananain, comosain"	For the enzymatic debridement of severe burns.	"Ananain, comosain"	COMOSAIN	Vianain	1/21/92	Designated			N/A	N/A	Genzyme Corporation	Cambridge	Massachusetts	2139	USA	LONGEST CONTAINS	0641565AA	comosain	55MVW171WS								MISSING	
Anaritide acetate	Improvement of early renal allograft function following renal transplantation.	Anaritide acetate	ANARITIDE ACETATE	Auriculin	4/10/92	Designated/Withdrawn			N/A	N/A	"Scios, Inc."	Mountain View	California	94043	USA	EXACT	0153491AA	Anaritide acetate	EGV6V52K6N								MISSING	"not a disease, a procedure"
Anaritide acetate	Treatment of patients with acute renal failure.	Anaritide acetate	ANARITIDE ACETATE	Auriculin	8/27/92	Designated/Withdrawn			N/A	N/A	"Scios, Inc."	Mountain View	California	94043	USA	EXACT	0153491AA	Anaritide acetate	EGV6V52K6N								MISSING	
Anatibant	Treatment of patients having experienced a severe traumatic brain injury (Glasgow Coma Scale 3 to 8) in order to decrease early mortality and improve long-term functional and neurological outcome	Anatibant	ANATIBANT	n/a	4/15/05	Designated			N/A	N/A	"Xytis, Inc."	San Mateo	California	94402	USA	EXACT	0320274AA	Anatibant	CLO4JRD21F								MISSING	
Ancestim	For use in combination with filgrastim to decrease the number of phereses required to collect peripheral blood progenitor cells capable of providing rapid multi-lineage hematopoietic reconstitution following myelosuppressive or myeloablative therapy.	Ancestim	ANCESTIM	Stemgen	7/5/95	Designated/Withdrawn			N/A	N/A	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0323875AA	Ancestim	PYB4Q6JG41								MISSING	"not a disease, a procedure"
Ancrod	To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.	Ancrod	ANCROD	Viprinex	10/20/89	Designated			N/A	N/A	Knoll Pharmaceutical Company	Mt. Olive	New Jersey	7828	USA	EXACT	0172316AA	Ancrod	EL55307L15								MISSING	preparation for procedure
Angiotensin 1-7	Treatment of neutropenia associated with autologous bone marrow transplantation.	Angiotensin 1-7	ANGIOTENSIN 1-7	n/a	2/16/00	Designated			N/A	N/A	Maret Pharmaceuticals	Newport Beach	California	92660	USA	EXACT	0232428AA	Angiotensin 1-7	IJ3FUK8MOF								MISSING	
Anti pan T lymphocyte monoclonal antibody	1. For ex-vivo treatment to eliminate mature T cells from potential bone marrow grafts 2. For in-vivo treatment of bone marrow recipients to prevent graft rejection and graft versus host disease.	Anti pan T lymphocyte monoclonal antibody		Anti-T Lymphocyte Immunotoxin Xmmly-H65-Rta	1/29/86	Designated/Withdrawn			N/A	N/A	Xoma Corporation	Berkeley	California	94710	USA								PROBLEM	can't find			MISSING	Not a rare disease
Anti-CD55 ADCC Enhanced Antibody (PAT-SC1)	Treatment of patients with CD55 (sc-1) positive gastric tumors	SC-1 monoclonal antibody	COMPLEMENT DECAY-ACCELERATING FACTOR	n/a	11/12/03	Designated			N/A	N/A	Patrys Limited				Australia	LONGEST CONTAINS	1803367AA	CD55	MGD8SRO8MO								MISSING	not a disease
Anti-CEA Sheep-human chimeric monoclonal antibody labeled w/iodine-131 (KAb201)	Treatment of pancreatic cancer	Anti-CEA Sheep-human chimeric monoclonal antibody labeled w/iodine-131 (KAb201)		n/a	5/21/03	Designated/Withdrawn			N/A	N/A	Avaant Pharmaceuticals India Ltd.				India					XR 303	NA	https://adisinsight.springer.com/drugs/800009269	PROBLEM	absent from GINAS	Pancreatic cancer	9364	done	Not a rare disease
Anti-T cell receptor murine monoclonal antibody	Prophylaxis of acute rejection of solid organ transplantation	Anti-T cell receptor murine monoclonal antibody		n/a	4/3/09	Designated			N/A	N/A	"Tolera Therapeutics, Inc."	Kalamazoo	Michigan	49008	USA								PROBLEM	can't find			MISSING	
Anti-cytomegalovirus monoclonal antibodies	1. Treatment of human cytomegalovirus infection in bone marrow and organ transplant patients 2. Prevention of human cytomegalovirus infection in bone marrow and organ transplant patients	Anti-cytomegalovirus monoclonal antibodies	HUMAN HERPESVIRUS 5	n/a	5/2/90	Designated/Withdrawn			N/A	N/A	Biomedical Research Institute	St. Paul	Minnesota	55102	USA	LONGEST CONTAINS	0354529AA	cytomegalovirus	7COI029E6K								MISSING	Not a rare disease
Anti-cytomegalovirus monoclonal antibodies	1. Treatment of human cytomegalovirus infection in patients diagnosed with AIDS 2. Prevention of human cytomegalovirus infection in patients diagnosed with AIDS	Anti-cytomegalovirus monoclonal antibodies	HUMAN HERPESVIRUS 5	n/a	5/3/90	Designated/Withdrawn			N/A	N/A	Biomedical Research Institute	St. Paul	Minnesota	55102	USA	LONGEST CONTAINS	0354529AA	cytomegalovirus	7COI029E6K								MISSING	Not a rare disease
Anti-von Willebrand Aptamer	Treatment of thrombotic thrombocytopenic purpura	Anti-von Willebrand Aptamer		n/a	4/9/08	Designated/Withdrawn			N/A	N/A	Archemix Corporation	Cambridge	Massachusetts	2142	USA				DT0445S65M	EGAPTIVON PEGOL	DT0445S65M	https://www.ncbi.nlm.nih.gov/pubmed/19538431 | https://ginas.ncats.nih.gov/ginas/app/substance/3e0a67f0	done		"Thrombotic thrombocytopenic purpura, acquired"	4607	approximate	
Anti-von Willebrand Aptamer	Treatment of thrombotic thrombocytopenic purpura	Anti-von Willebrand Aptamer		n/a	4/9/08	Designated/Withdrawn			N/A	N/A	Archemix Corporation	Cambridge	Massachusetts	2142	USA				DT0445S65M	EGAPTIVON PEGOL	DT0445S65M	https://www.ncbi.nlm.nih.gov/pubmed/19538431 | https://ginas.ncats.nih.gov/ginas/app/substance/3e0a67f0	done		Congenital thrombotic thrombocytopenic purpura	9430	approximate	
Antiepilepsirine	Treatment of drug resistant generalized tonic-clonic epilepsy in children and adults.	Antiepilepsirine	ILEPCIMIDE	n/a	3/23/89	Designated			N/A	N/A	Children's Hospital	Columbus	Ohio	43205	USA	EXACT	0172587AA	Antiepilepsirine	5ML58O200F						Epilepsy with myoclonic-atonic seizures	2169	approximate	
Antihemophilic factor (human)	Treatment of von Willebrand's disease	Antihemophilic factor (human)	ANTIHEMOPHILIC FACTOR (HUMAN)	Alphanate	1/5/96	Designated/Approved	Approved for Orphan Indication	For surgical and/or invasive procedures in patients with von Willebrand Disease (VWD) in whom desmopressin is either ineffective or contraindicated. It is not indicated for patients with severe VWD (Type 3) undergoing major surgery	1/31/07	1/31/14	Grifols Biologicals Inc.	Los Angeles	California	90032	USA	EXACT	0324743AA	Antihemophilic factor (human)	839MOZ74GK						Von Willebrand disease	7867	done	
Antihemophilic factor (recombinant)	For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).	Antihemophilic factor (recombinant)	"ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT"	"Refacto, Xyntha"	2/8/96	Designated/Approved	Approved for Orphan Indication		3/6/00	N/A	"Wyeth Pharmaceuticals, Inc."	Philadelphia	Pennsylvania	19101	USA	EXACT	0182832AA	Antihemophilic factor (recombinant)	P89DR4NY54						Hemophilia A	6591	done	
"Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized"	Treatment of patients with von Willebrand's disease	"Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized"	"ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX (HUMAN), DRIED, PASTEURIZED"	Humate-P	10/16/92	Designated/Approved	Approved for Orphan Indication	"(1) In adult patients for treatment and prevention of bleeding in hemophilia A (classic hemophilia) and (2) in adult and pediatric patients for treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease, and in mild and moderate von Willebrand disease where use of desmopressin is known or suspected to be inadequate."	4/1/99	4/1/06	CSL Behring	King Of Prussia	Pennsylvania	19406	USA	EXACT	0329328AA	"Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized"	5T6B772R4Q						Von Willebrand disease	7867	done	
Antipyrine Test	For use as an index of hepatic drug-metabolizing capacity.	Antipyrine Test	ANTIPYRINE	n/a	2/21/85	Designated/Withdrawn			N/A	N/A	"Upsher-Smith Laboratories, Inc"	Minneapolis	Minnesota	55447	USA	EXACT	0010559AA	Antipyrine	T3CHA1B51H								MISSING	not a disease
Antithrombin III	For prophylaxis and treatment of thromboembolic episodes in patients with genetic AT-III deficiency.	Antithrombin III (human) concentrate IV	ANTITHROMBIN III HUMAN	Kybernin P	7/2/85	Designated/Withdrawn			N/A	N/A	CSL Behring	King of Prussia	Pennsylvania	19406	USA	EXACT	0172032AA	Antithrombin III	T0LTO7L82X								MISSING	Not a rare disease
Antithrombin III (human)	For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.	Antithrombin III (human)	ANTITHROMBIN III HUMAN	Thrombate Iii	11/26/84	Designated/Approved	Approved for Orphan Indication		12/30/91	12/30/98	Bayer Corporation	New Haven	Connecticut	6516	USA	EXACT	0172032AA	Antithrombin III (human)	T0LTO7L82X						Hereditary antithrombin deficiency	6148	done	
Antithrombin III (human)	For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.	Antithrombin III (human)	ANTITHROMBIN III HUMAN	Atnativ	2/8/85	Designated/Approved	Approved for Orphan Indication		12/13/89	12/13/96	Pharmacia & Upjohn AB				Sweden	EXACT	0172032AA	Antithrombin III (human)	T0LTO7L82X						Hereditary antithrombin deficiency	6148	done	
Antithrombin III human	Preventing or arresting episodes of thrombosis in patients with congenital AT-III deficiency and/or to prevent the occurrence of thrombosis in patients with AT-III deficiency who have undergone trauma or who are about to undergo surgery or parturition.	Antithrombin III human	ANTITHROMBIN III HUMAN	Antithrombin Iii Human	1/2/86	Designated			N/A	N/A	American National Red Cross	Bethesda	Maryland	20814	USA	EXACT	0172032AA	Antithrombin III human	T0LTO7L82X						Hereditary antithrombin deficiency	6148	done	
Antithrombin alfa	Treatment of antithrombin III dependent heparin resistance requiring anticoagulation.	Recombinant human antithrombin III	ANTITHROMBIN ALFA	n/a	4/6/00	Designated			N/A	N/A	AT III LLC	Framingham	Massachusetts	1701	USA	EXACT	0310463AA	Antithrombin alfa	AWV6I5L6H2								MISSING	
Apomorphine	For use as rescue treatment for early morning motor dysfunction in late-stage Parkinson's disease.	Apomorphine	APOMORPHINE	n/a	10/20/97	Designated/Withdrawn			N/A	N/A	Scherer DDS	Wiltshire			United Kingdom	EXACT	0009654AA	Apomorphine	N21FAR7B4S						Parkinson disease	10251	done	Not a rare disease
Apomorphine	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	Apomorphine	APOMORPHINE	n/a	7/17/95	Designated			N/A	N/A	"Pentech Pharmaceuticals, Inc."	Buffalo Grove	Illinois	60089	USA	EXACT	0009654AA	Apomorphine	N21FAR7B4S						Parkinson disease	10251	done	not a rare disease
Apomorphine HCl	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	Apomorphine HCl	APOMORPHINE HYDROCHLORIDE	Apokyn	4/22/93	Designated/Approved	Approved for Orphan Indication	"For the acute, intermittent treatment of hypomobility, ""off"" episodes (""end-of-dose-wearing-off"" and unpredictable :on/off"" episodes) associated with advanced Parkinson's disease"	4/20/04	4/20/11	"US WorldMeds, LLC"	Louisville	Kentucky	40207	USA	EXACT	0044962AA	Apomorphine HCl	F39049Y068						Parkinson disease	10251	done	not a rare disease
Apomorphine hydrochloride	For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous)	Apomorphine hydrochloride	APOMORPHINE HYDROCHLORIDE	n/a	5/23/06	Designated			N/A	N/A	"NeuroHealing Pharmaceuticals, Inc."	Newton	Massachusetts	2135	USA	EXACT	0044962AA	Apomorphine hydrochloride	F39049Y068								MISSING	
Aprotinin	"For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary coronary artery bypass graft surgery where the risk of bleeding is especially high (impaired hemostasis) or where transfusion is unavailable or unacceptable."	Aprotinin	APROTININ	Trasylol	11/17/93	Designated/Approved	Approved for Orphan Indication		12/29/93	12/29/00	Bayer Corporation	West Haven	Connecticut	6516	USA	EXACT	0054057AA	Aprotinin	04XPW8C0FL								MISSING	
Arcitumomab	"Diagnosis and localization of primary, residual, recurrent and metastatic medullary thyroid carcinoma."	Arcitumomab	ARCITUMOMAB	99m Tc-Labeled Cea-Scan	5/10/96	Designated/Withdrawn			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA	EXACT	0220280AA	Arcitumomab	79T6JRG308						"Thyroid cancer, medullary"	7004	done	
Arenegyr	Treatment of malignant pleural mesothelioma	Arenegyr		n/a	8/22/08	Designated			N/A	N/A	MolMed S.p.A.	Milan			Italy					ARENEGYR	NA	https://www.molmed.com/sites/default/files/uploads/press-releases/1375-molmed_presents_arenegyr_key_preliminary_results_of_phase_ii_trials_in_mesothelioma_and_colorectal_cancer_at_asco/1375_1337758068.pdf	done		Malignant mesothelioma	7026	approximate	
Aspirin (162mg)	Treatment of multiple sclerosis in patients who experience dimethyl fumarate flushing	Fixed combination of dimethyl fumarate and aspirin (162mg)	ASPIRIN	n/a	9/27/18	Designated			N/A	N/A	Vitalis LLC	93 4th Avenue	New York	10003	USA	EXACT	0007647AA	Aspirin	R16CO5Y76E						Multiple sclerosis	10255	done	
Atezolizumab	"Treatment of patients with stage IIb, IIc, III, and IV melanoma"	Atezolizumab	ATEZOLIZUMAB	Tecentriq® +Cotellic®	2/13/17	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	1113913AA	Atezolizumab	52CMI0WC3Y								MISSING	the term is too general
Atezolizumab	Treatment of small cell lung cancer (SCLC)	Atezolizumab	ATEZOLIZUMAB	n/a	10/13/16	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	1113913AA	Atezolizumab	52CMI0WC3Y						Small cell lung cancer	9344	done	
Atg-Fresenius	Prevention of graft versus host disease (GVHD)	"anti-T-lymphocyte immune globulin, rabbit"	LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN	Atg-Fresenius(R)	3/26/10	Designated			N/A	N/A	"Neovii Biotech NA, Inc."	Lexington	Massachusetts	2420	USA	EXACT	0233385AA	Atg Fresenius	D7RD81HE4W						Chronic graft versus host disease	10964	approximate	type of GVHD (acute or chronic) is not specified
Atg-Fresenius	Prevention of graft versus host disease (GVHD)	"anti-T-lymphocyte immune globulin, rabbit"	LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN	Atg-Fresenius(R)	3/26/10	Designated			N/A	N/A	"Neovii Biotech NA, Inc."	Lexington	Massachusetts	2420	USA	EXACT	0233385AA	Atg Fresenius	D7RD81HE4W						Acute graft versus host disease	6544	approximate	type of GVHD (acute or chronic) is not specified
Atiprimod	Treatment of mulitple myeloma and associated bone resorption	"2-(3-diethylaminopropyl)-8,8-dipropyl-2-azaspiro [4,5] decan dimaleate"	ATIPRIMOD	Atiprimod	12/2/03	Designated			N/A	N/A	"Callisto Pharmaceuticals, Inc."	Somerset	New Jersey	8873	USA	EXACT	0320412AA	Atiprimod	MG7D3QD743						Multiple myeloma	7108	done	
Atomoxetine hydrochloride	Treatment of Tourette's Syndrome	Atomoxetine hydrochloride	ATOMOXETINE HYDROCHLORIDE	Strattera	8/26/03	Designated/Withdrawn			N/A	N/A	Eli Lilly & Company	Indianapolis	Indiana	46285	USA	EXACT	0120569AA	Atomoxetine hydrochloride	57WVB6I2W0						Tourette syndrome	7783	done	
Atovaquone	"Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3."	Atovaquone	ATOVAQUONE	Mepron	8/14/91	Designated/Approved	Approved for Orphan Indication	Prevention of PCP in patients who are intolerant to trimethoprim-sulfamethoxazole.	1/5/99	1/5/06	Glaxo Wellcome Research and Development	Research Triangle Park	North Carolina	27709	USA	EXACT	0170694AA	Atovaquone	Y883P1Z2LT						Pneumocystic carinii pneumonia	7409	done	
Atovaquone	Primary prophylaxis of HIV-infected persons at high risk for developing Toxoplasma gondii encephalitis.	Atovaquone	ATOVAQUONE	Mepron	3/16/93	Designated/Withdrawn			N/A	N/A	"GlaxoSmithKline, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0170694AA	Atovaquone	Y883P1Z2LT						Congenital human immunodeficiency virus	10328	approximate	
Atovaquone	Treatment and suppression of Toxoplasma gondii encephalitis.	Atovaquone	ATOVAQUONE	Mepron	3/16/93	Designated/Withdrawn			N/A	N/A	"GlaxoSmithKline, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0170694AA	Atovaquone	Y883P1Z2LT								MISSING	Not a rare disease
Atovaquone	Treatment of AIDS associated Pneumocystis Carinii Pneumonia.	Atovaquone	ATOVAQUONE	Mepron	9/10/90	Designated/Approved	Approved for Orphan Indication	For the acute oral treatment of mild to moderate Pneumocystis carinii pneumonia in patients who are intolerant to trimethoprim-sulfamethoxazole.	11/25/92	11/25/99	Glaxo Wellcome Inc.	Research Triangle Park	North Carolina	27709	USA	EXACT	0170694AA	Atovaquone	Y883P1Z2LT						Pneumocystic carinii pneumonia	7409	done	
Atryn	"Treatment of congenital antithrombin deficiency to prevent the occurrence of serious, potentially life-threatening venous thromboembolisms which may develop as a result of surgical or obstetrical procedures"	recombinant human antithrombin	ANTITHROMBIN ALFA	Atryn	12/7/07	Designated/Approved	Approved for Orphan Indication	"Prevention of peri-operative and peri-partum thromboembolic events, in hereditary antithrombin deficient patients."	2/6/09	2/6/16	"GTC Biotherapeutics, Inc."	Framingham	Massachusetts	1702	USA	EXACT	0310463AA	Atryn	AWV6I5L6H2						Hereditary antithrombin deficiency	6148	done	
Attenuated autologous cancer cells and granulocyte macrophage colony stimulating factor in combination with activated autologous blood derived T-cells	Treatment of primary central nervous system malignancies	Attenuated autologous cancer cells and granulocyte macrophage colony stimulating factor in combination with activated autologous blood derived T-cells	HUMAN BLOOD AUTOLOGOUS	n/a	4/27/07	Designated			N/A	N/A	"TVAX Biomedical, LLC"	Lenexa	Kansas	66214	USA	LONGEST CONTAINS	0263694AA	autologous blood	EQ6UHPL10W						Primary central nervous system lymphoma	9318	approximate	central nervous system malignancy not specified
Autologous Engineered Skin Substitute	Treatment of hospitalized patients with deep partial and full thickness burns requiring grafting.	Autologous Engineered Skin Substitute	SKIN	Permaderm	6/1/12	Designated			N/A	N/A	"Amarantus BioScience Holdings, Inc."	San Francisco	California	94111	USA	LONGEST CONTAINS	0226926AA	Skin	0EE2343509	HUMAN SKIN	0EE2343509	https://ginas.ncats.nih.gov/ginas/app/substances?page=3&facet=Substance%20Class%2FstructurallyDiverse&q=SKIN	approximate	mapping is approximate			MISSING	not a disease
Autologous cultured endothelial cells on a donor human corneal disk	"Treatment of Fuch's dystrophy, pseudophakic bullous keratopathy, and bullous keratopathy"	Autologous cultured endothelial cells on a donor human corneal disk		n/a	6/1/07	Designated			N/A	N/A	"Cellular Bioengineering, Inc."	Honolulu	Hawaii	96826	USA								PROBLEM	can't find	Fuchs endothelial corneal dystrophy	10018	approximate	
Autologous dendritic cells ex vivo incubated with zebularine and factor VIII	Treatment to reduce factor VIII neutralizing antibodies (inhibitors)	Autologous dendritic cells ex vivo incubated with zebularine and factor VIII	ANTIHEMOPHILIC FACTOR NOS	n/a	9/24/18	Designated			N/A	N/A	Idogen AB	2 Scheelevägen			Sweden	LONGEST CONTAINS	0101768AA	factor VIII	7A9Y5SX0GY | P89DR4NY54	"4-DEOXYURIDINE | ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT | IN-3012"	7A9Y5SX0GY | P89DR4NY54	https://ginas.ncats.nih.gov/ginas/app/substance/a4159581 | https://ginas.ncats.nih.gov/ginas/app/substance/ccc29bb8 | https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3161813	approximate		Hemophilia A	6591	approximate	
Autologous dendritic cells pulsed with autologous antigens from primay malignant brain tumor cells	Treatment of primary brain malignant cancer	Autologous dendritic cells pulsed with autologous antigens from primay malignant brain tumor cells	ALLERGENIC EXTRACTS	Dcvax-Brain	11/29/02	Designated			N/A	N/A	"Northwest Biotherapeutics, Inc."	Bothell	Washington	98021	USA	LONGEST CONTAINS	0123397AA	antigens		DCVax-L	NA	https://adisinsight.springer.com/drugs/800017222	PROBLEM	absent from GINAS	"Brain tumor, adult"	9307	approximate	
Autologous olfactory neural progenitors	"Treatment of spinal cord injury patients with ASIA Impairment grades A, B, or C"	Autologous olfactory neural progenitors		Rhinocytes	2/1/08	Designated			N/A	N/A	"RhinoCyte, Inc."	Louisville	Kentucky	40202	USA								PROBLEM	can't find			MISSING	Not a rare disease
Autologous or allogeneic limbal epithelial stem cells expanded ex vivo on human amniotic membrane	Treatment of ocular surface diseases that are characterized by total limbal stem cell deficiency	Autologous or allogeneic limbal epithelial stem cells expanded ex vivo on human amniotic membrane	HUMAN AMNIOTIC MEMBRANE	n/a	7/14/05	Designated			N/A	N/A	"TissueTech, Inc."	Miami	Florida	33173	USA	LONGEST CONTAINS	0806166AA	human amniotic membrane	T9O10FB50M						Superior limbic keratoconjunctivitis	10940	approximate	
Autologous stromal vascular cell fraction from adipose tissue (central facitily processed)	Treatment of impaired hand function due to systemic sclerosis	Autologous stromal vascular cell fraction from adipose tissue (central facitily processed)		Eccs-50	11/9/16	Designated			N/A	N/A	"Cytori Therapuetics, Inc."	San Diego	California	92121	USA				9DRI670EXJ | 15A1NQ39W2	HUMAN ADIPOSE TISSUE DERIVED CELL | HUMAN AUTOLOGOUS ADIPOSE TISSUE	9DRI670EXJ | 15A1NQ39W2	https://ginas.ncats.nih.gov/ginas/app/substance/ac1f6e34 | https://ginas.ncats.nih.gov/ginas/app/substance/2aadefea	done				MISSING	
Avacopan	Treatment of C3 glomerulopathy	Avacopan	AVACOPAN	n/a	3/20/17	Designated			N/A	N/A	"ChemoCentryx, Inc."	Mountain View	California	94043	USA	EXACT	1083336AA	Avacopan	O880NM097T								MISSING	
Avatrombopag maleate	Treatment of idiopathic thrombocytopenic purpura	"1-(3-chloro-5-{[4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-l-yl)-1,3-thiazol-2-yl]carbamoyl}- 2-pyridyl) piperidine-4-caboxylic acid Monomaleate"	AVATROMBOPAG MALEATE	n/a	9/1/11	Designated			N/A	N/A	"Eisai, Inc."	Woodcliff Lake	New Jersey	7677	USA	EXACT	0268520AA	Avatrombopag maleate	GDW7M2P1IS						Idiopathic thrombocytopenic purpura	5194	done	
Avonex	Treatment of primary brain tumors.	Interferon beta (recombinant human)	INTERFERON BETA-1A	Avonex	1/13/93	Designated/Withdrawn			N/A	N/A	"Biogen Idec, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0215689AA	Avonex	XRO4566Q4R						"Brain tumor, adult"	9307	approximate	
Azathioprine	Treatment of oral manifestations of graft-versus-host disease.	Azathioprine	AZATHIOPRINE	Imuran	9/14/99	Designated			N/A	N/A	"Oral Solutions, Inc."	New York	New York	10019	USA	EXACT	0025832AA	Azathioprine	MRK240IY2L						Acute graft versus host disease 	6552	approximate	
Azathioprine	Treatment of oral manifestations of graft-versus-host disease.	Azathioprine	AZATHIOPRINE	Imuran	9/14/99	Designated			N/A	N/A	"Oral Solutions, Inc."	New York	New York	10019	USA	EXACT	0025832AA	Azathioprine	MRK240IY2L						 Chronic graft versus host disease	10964	approximate	
B-TRISACCHARIDE	"For use in ABO-incompatible solid organ transplantation, including kidney, heart, liver and pancreas."	Trisaccharides A and B	B-TRISACCHARIDE	Biosynject	4/20/87	Designated			N/A	N/A	"Chembiomed, Ltd."				Canada	EXACT	0790670AA	B-TRISACCHARIDE	2P888H42QS								MISSING	"not a disease, a procedure"
B-TRISACCHARIDE	Prevention of ABO medical hemolytic reactions arising from ABO-incompatible bone marrow transplantation.	Trisaccharides A and B	B-TRISACCHARIDE	Biosynject	4/15/88	Designated			N/A	N/A	"Chembiomed, Ltd."				Canada	EXACT	0790670AA	B-TRISACCHARIDE	2P888H42QS								MISSING	
B-TRISACCHARIDE	Treatment of moderate to severe clinical forms of hemolytic disease of the newborn arising from placental transfer of antibodies against blood group substances A and B.	Trisaccharides A and B	B-TRISACCHARIDE	Biosynject	4/12/87	Designated			N/A	N/A	"Chembiomed, Ltd."				Canada	EXACT	0790670AA	B-TRISACCHARIDE	2P888H42QS								MISSING	
B-TRISACCHARIDE	"Treatment of moderate to very severe clinical forms of transfusion reactions arising from ABO incompatible transfusions of blood, blood products, and blood derivatives."	Trisaccharides A and B	B-TRISACCHARIDE	n/a	8/3/87	Designated/Withdrawn			N/A	N/A	"Chembiomed, Ltd."				Canada	EXACT	0790670AA	B-TRISACCHARIDE	2P888H42QS								MISSING	Not a disease
BACLOFEN	Treatment of Charcot-Marie-Tooth disease type 1A	"(RS)-baclofen, naltrexone and D-sorbitol"	BACLOFEN	n/a	3/17/14	Designated			N/A	N/A	Pharnext SA				France	EXACT	0032804AA	BACLOFEN	H789N3FKE8						Charcot-Marie-Tooth disease	6034	done	
BCX-7353	Treatment of C1-inhibitor-dependent angioedema (including prevention and treatment of attacks)	(+)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride	BCX-7353	n/a	11/1/17	Designated			N/A	N/A	"BioCryst Pharmaceuticals, Inc."	4505 Emperor Blvd	North Carolina	27703	USA	EXACT	0111978AB	BCX-7353	88SH1NBL2B								MISSING	
BECLOMETHASONE DIPROPIONATE	Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster	"beclomethasone 17,21-dipropionate"	BECLOMETHASONE DIPROPIONATE	n/a	11/19/12	Designated			N/A	N/A	"Soligenix, Inc"	Princeton	New Jersey	8540	USA	EXACT	0043798AA	BECLOMETHASONE DIPROPIONATE	5B307S63B2								MISSING	
BERUBICIN HYDROCHLORIDE	Treatment of malignant gliomas	"5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(phenylmethyl)-a-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S,10S)- (9CI)"	BERUBICIN HYDROCHLORIDE	n/a	10/11/06	Designated/Withdrawn			N/A	N/A	"Reata Pharmaceuticals, Inc."	Dallas	Texas	75207	USA	EXACT	0252982AA	BERUBICIN HYDROCHLORIDE	7BA3X03948						Gliomatosis cerebri 	6514	approximate	
BERUBICIN HYDROCHLORIDE	Treatment of malignant gliomas	"5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(phenylmethyl)-a-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S,10S)- (9CI)"	BERUBICIN HYDROCHLORIDE	n/a	10/11/06	Designated/Withdrawn			N/A	N/A	"Reata Pharmaceuticals, Inc."	Dallas	Texas	75207	USA	EXACT	0252982AA	BERUBICIN HYDROCHLORIDE	7BA3X03948						 Childhood brain stem glioma 	9306	approximate	
BERUBICIN HYDROCHLORIDE	Treatment of malignant gliomas	"5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(phenylmethyl)-a-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S,10S)- (9CI)"	BERUBICIN HYDROCHLORIDE	n/a	10/11/06	Designated/Withdrawn			N/A	N/A	"Reata Pharmaceuticals, Inc."	Dallas	Texas	75207	USA	EXACT	0252982AA	BERUBICIN HYDROCHLORIDE	7BA3X03948						 Glioma	6513	approximate	
BGB-3111	Treatment of Waldenstrom's macroglobulinemia	"(S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide"	BGB-3111	n/a	6/29/16	Designated			N/A	N/A	"BeiGene USA, Inc."	Fort Lee	New Jersey	7024	USA	EXACT	1143619AA	BGB-3111	AG9MHG098Z						Waldenstrom macroglobulinemia	7872	done	
BGB-3111	Treatment of chronic lymphocytic leukemia.	"(S)-7-(1acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide"	BGB-3111	n/a	7/20/16	Designated			N/A	N/A	"BeiGene USA, Inc."	Fort Lee	New Jersey	7024	USA	EXACT	1143619AA	BGB-3111	AG9MHG098Z						Chronic lymphocytic leukemia	6104	done	
BGB-3111	Treatment of mantle cell lymphoma.	"(S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydroprazolo[1,5-a]pyrimidine-3-carboxamide"	BGB-3111	n/a	6/23/16	Designated			N/A	N/A	"BeiGene USA, Inc."	Fort Lee	New Jersey	7024	USA	EXACT	1143619AA	BGB-3111	AG9MHG098Z						Mantle cell lymphoma	6969	done	
BI-836826	Treatment of chronic lymphocytic leukemia (CLL).	"mouse-human chimeric antibody of the IgG1 isotype, directed against human CD37"	BI-836826	n/a	3/24/15	Designated			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc."	Ridgefield	Connecticut	6877	USA	EXACT	0110874AB	BI-836826	LB090AB8DB						Chronic lymphocytic leukemia	6104	done	
BIMIRALISIB	Treatment of primary central nervous system lymphoma.	"5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)-pyridin-2-amine"	BIMIRALISIB	n/a	11/21/16	Designated			N/A	N/A	PIQUR Therapeutics AG				Switzerland	EXACT	1106225AA	BIMIRALISIB	6Z3QHB00LB						Primary central nervous system lymphoma	9318	done	
BIRABRESIB DIHYDRATE	Treatment of acute myeloid leukemia	"2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thienol[3,2,-f]-[1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)-acetamide dihydrate"	BIRABRESIB DIHYDRATE	n/a	7/16/14	Designated			N/A	N/A	OncoEthix SA				Switzerland	EXACT	0796065AA	BIRABRESIB DIHYDRATE	4Q356KA5V2						Acute myeloid leukemia	12757	done	
BIS(CHOLINE)TETRATHIOMOLYBDATE	Treatment of Wilson's disease.	choline tetrathiomolybdate	BIS(CHOLINE)TETRATHIOMOLYBDATE	n/a	8/25/11	Designated			N/A	N/A	Wilson Therapeutics AB				USA	EXACT	0251763AA	BIS(CHOLINE)TETRATHIOMOLYBDATE	FD57A79R4P						Wilson disease	7893	done	
BL-8040	For use to mobilize hematopoietic stem cells (HSCs) from the marrow to peripheral blood for collection for autologous or allogeneic transplantation	"N-(4-Fluoro-benzoyl)-L-arginyl-L-arginyl-[L-3-(naphthyl-alanyl]-L-cysteinyl-L-tyrosyl-L-citrullinyl-L-lysyl-D-lysyl-L-prolyl-L-trosyl-L-arginyl-L-citrullinyl-L-cysteinyl-L-aginine amide, cyclic (4-13)-disulfide"	BL-8040	n/a	7/6/12	Designated			N/A	N/A	"BioLineRx, Ltd."	Modi'in			Israel	EXACT	1154194AA	BL-8040	DA9G065962								MISSING	"not a disease, a procedure"
BLU-667	"Treatment of rearranged during transfection (RET)-rearranged non-small cell lung cancer (NSCLC), JAK1/2-positive NSCLC, or TRKC-positive NSCLC."	small Molecule rearranged during transfection (RET) Inhibitor	BLU-667	n/a	4/11/18	Designated			N/A	N/A	Blueprint Medicines Corporation	45 Sidney Street		2139	USA	EXACT	1794532AA	BLU-667	1WPE73O1WV						"Non-small cell lung cancer, childhood"	934	approximate	
BLU-9931	Treatment of hepatocellular cancer (HCC).	small molecule FGFR4 inhibitor	BLU-9931	n/a	9/14/15	Designated			N/A	N/A	Blueprint Medicines Corporation	Cambridge	Massachusetts	2139	USA	EXACT	1718236AA	BLU-9931	FQK825B5DX						Childhood hepatocellular carcinoma	9331	approximate	
BLZ-100	Diagnostic for the management of malignant brain tumors	chlorotoxin conjugated to indocyanine green dye	BLZ-100	n/a	6/23/15	Designated			N/A	N/A	"Blaze Bioscience, Inc."	Seattle	Washington	98109	USA	EXACT	1090319AA	BLZ-100	35VUL88S9Z						Glioma	6513	approximate	
BN-82451	Treatment of Huntington's disease.	"phenol, 4-[2-(aminomethyl)-4-thiazolyl]-2,6-bis (1,1-dimethyethyl) monohydrochloride"	BN-82451	n/a	3/16/15	Designated			N/A	N/A	"Ipsen Biopharmaceuticals, Inc."	Basking Ridge	New Jersey	7920	USA	EXACT	0832053AA	BN-82451	531B661QBY						Huntington disease	6677	done	
BPR-0L075	Treatment of cholangiocarcinoma	"6-methoxy-3-(3',4',5'-trimethoxybenzoyl) indole"	BPR-0L075	n/a	5/11/16	Designated			N/A	N/A	SynCore Biotechnology Co. Ltd.				Taiwan	EXACT	0684855AA	BPR-0L075	W918223VQ6						Intrahepatic cholangiocarcinoma	6042	done	
BRENTUXIMAB	Treatment of CD30 positive T-cell lymphomas	Chimeric monoclonal antibody to CD30 (anti-CD30 antibody)	BRENTUXIMAB	n/a	2/18/04	Designated/Withdrawn			N/A	N/A	"Seattle Genetics, Inc."	Bothell	Washington	98021	USA	EXACT	0267685AA	BRENTUXIMAB	C67ORA155P						Adult T-cell leukemia/lymphoma	13103	done	
BTZ-043	Treatment of Tuberculosis (TB)	"2-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-trifluoromethyl-4H-1,3-benzothiazin-4-one"	BTZ-043	n/a	3/15/18	Designated			N/A	N/A	Klinikum der Universität München	15 Marchioninistr.			Germany	EXACT	0811847AA	BTZ-043	G55ZH52P57						Tuberculosis	7827	done	
BUTHIONINE SULFOXIMINE	Use as a modulator of chemotherapy for the treatment of pediatric patients with primary malignant brain tumors	Buthionine sulfoxamine	BUTHIONINE SULFOXIMINE	n/a	10/5/05	Designated			N/A	N/A	USC-CHLA Institute for Pediatric Clinical Research	Los Angeles	California	90027	USA	EXACT	0791208AA	BUTHIONINE SULFOXIMINE	LW4108Q0BV						"Brain tumor, adult"	9307	approximate	brain tumor not specified
Bacitracin	Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.	Bacitracin	BACITRACIN	Altracin	3/13/84	Designated			N/A	N/A	"A. L. Laboratories, Inc."	Fort Lee	New Jersey	7024	USA	EXACT	0036384AA	Bacitracin	58H6RWO52I						Necrotizing enterocolitis	9767	approximate	
Baclofen	Treatment of spasticity associated with cerebral palsy.	Baclofen	BACLOFEN	Lioresal Intrathecal	9/26/94	Designated			N/A	N/A	"Medtronic, Inc."	Minneapolis	Minnesota	55440	USA	EXACT	0032804AA	Baclofen	H789N3FKE8						Cerebral palsy	10450	done	
Bafetinib	Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia.	"N-[3-(4',5'-bipyrimidin-2-ylamino)-4-methylphenyl]-4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl}-3-(trifluoromethyl)benzamide"	BAFETINIB	n/a	12/27/06	Designated			N/A	N/A	CytRx Corporation	San Diego	California	92109	USA	EXACT	0323148AA	Bafetinib	NVW4Z03I9B						Chronic myeloid leukemia	6105	done	
Balsalazide disodium	Treatment of pediatric patients with ulcerative colitis	Balsalazide disodium	BALSALAZIDE DISODIUM	Colazal	8/12/05	Designated/Approved	Approved for Orphan Indication	Treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Safety and Effectiveness of Colazal beyond 8 weeks in children (ages 5-17) and 12 weeks in adults have not been established.	12/20/06	12/20/13	"Salix Pharmaceuticals, Inc."	Bridgewater	New Jersey	8807	USA	EXACT	0178461AA	Balsalazide disodium	1XL6BJI034						Pediatric ulcerative colitis	9857	done	
Bardoxolone	Treatment of pancreatic cancer	Bardoxolone	BARDOXOLONE	n/a	8/6/08	Designated			N/A	N/A	"Reata Pharmaceuticals, Inc."	Irving	Texas	75063	USA	EXACT	0268439AA	Bardoxolone	7HT68L8941						Pancreatic cancer	9364	done	Not a rare disease
Basiliximab	Prophylaxis of solid organ rejection.	Basiliximab	BASILIXIMAB	Simulect	12/12/97	Designated/Approved	Approved for Orphan Indication	Prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.	5/12/98	5/12/05	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0229027AA	Basiliximab	9927MT646M								MISSING	
Beclomethasone dipropionate	For oral administration in the treatment of intestinal graft-versus-host disease.	Beclomethasone dipropionate	BECLOMETHASONE DIPROPIONATE	n/a	3/27/98	Designated			N/A	N/A	"Soligenix, Inc."	Princeton	New Jersey	8540	USA	EXACT	0043798AA	Beclomethasone dipropionate	5B307S63B2						Chronic graft versus host disease 	10964	approximate	
Beclomethasone dipropionate	For oral administration in the treatment of intestinal graft-versus-host disease.	Beclomethasone dipropionate	BECLOMETHASONE DIPROPIONATE	n/a	3/27/98	Designated			N/A	N/A	"Soligenix, Inc."	Princeton	New Jersey	8540	USA	EXACT	0043798AA	Beclomethasone dipropionate	5B307S63B2						 Acute graft versus host disease	6544	approximate	
Begedina	Treatment of graft versus host disease	murine monoclonal antibody against CD26		Begedina	2/18/11	Designated			N/A	N/A	Adienne S.A.				Switzerland				360N6PY2A1	BEGELOMAB	360N6PY2A1	https://www.ema.europa.eu/documents/medicine-qa/questions-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_en.pdf https://ginas.ncats.nih.gov/ginas/app/substance/aeaa1314	done		Chronic graft versus host disease 	10964	approximate	
Begedina	Treatment of graft versus host disease	murine monoclonal antibody against CD26		Begedina	2/18/11	Designated			N/A	N/A	Adienne S.A.				Switzerland				360N6PY2A1	BEGELOMAB	360N6PY2A1	https://www.ema.europa.eu/documents/medicine-qa/questions-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_en.pdf https://ginas.ncats.nih.gov/ginas/app/substance/aeaa1314	done		 Acute graft versus host disease	6544	approximate	
Benzoate	"For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency."	Benzoate and phenylacetate	BENZOIC ACID	Ucephan	1/21/86	Designated/Approved	Approved for Orphan Indication		12/23/87	12/23/94	ImmunexImmunex	Irvine	California	92623	USA	EXACT	0011461AA	Benzoate	8SKN0B0MIM						Carbamoyl phosphate synthetase 1 deficiency 	7269	done	
Benzoate	"For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency."	Benzoate and phenylacetate	BENZOIC ACID	Ucephan	1/21/86	Designated/Approved	Approved for Orphan Indication		12/23/87	12/23/94	ImmunexImmunex	Irvine	California	92623	USA	EXACT	0011461AA	Benzoate	8SKN0B0MIM						 Ornithine transcarbamylase deficiency 	8391	done	
Benzoate	"For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency."	Benzoate and phenylacetate	BENZOIC ACID	Ucephan	1/21/86	Designated/Approved	Approved for Orphan Indication		12/23/87	12/23/94	ImmunexImmunex	Irvine	California	92623	USA	EXACT	0011461AA	Benzoate	8SKN0B0MIM						 Citrullinemia type I	6114	done	
Benzophenone-3	For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy	"Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide"	OXYBENZONE	Total Block Vl Spf 75	8/13/01	Designated			N/A	N/A	Fallien Cosmeceuticals Ltd.	King of Prussia	Pennsylvania	19406	USA	EXACT	0021001AA	Benzophenone-3	95OOS7VE0Y								MISSING	
"Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide"	For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy	"Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide"	OCTINOXATE	Total Block Vl Spf 75	8/13/01	Designated			N/A	N/A	Fallien Cosmeceuticals Ltd.	King of Prussia	Pennsylvania	19406	USA	exact	0156263AA	octylmethoxycinnamate	4Y5P7MUD51								MISSING	
Benzydamine hydrochloride	Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.	Benzydamine hydrochloride	BENZYDAMINE HYDROCHLORIDE	Tantum	5/18/98	Designated			N/A	N/A	"Angelini Pharmaceuticals, Inc."	River Edge	New Jersey	7661	USA	EXACT	0021158AA	Benzydamine hydrochloride	K2GI407R4Q								MISSING	prevention of drug-induced side-effects
Benzylpenicillin	Assessing the risk of administrating penicillin when it is the preferred drug of choice in adult patients who have previously received penicillin and have a history of clinical sensitivity.	"Benzylpenicillin, benzylpenicilloic, benzylpenilloic acid"	PENICILLIN G	Pre-Pen/Mdm	9/28/87	Designated			N/A	N/A	AllerQuest LLC	West Hanford	Connecticut	6119	USA	EXACT	0010662AA	Benzylpenicillin	Q42T66VG0C								MISSING	
Beractant	"Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis."	Beractant	BERACTANT	Survanta Intratracheal Suspension	12/20/93	Designated			N/A	N/A	Ross Laboratories	Columbus	Ohio	43215	USA	EXACT	0171164AA	Beractant	S866O45PIG						Meconium aspiration syndrome 	10494	done	
Beractant	"Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis."	Beractant	BERACTANT	Survanta Intratracheal Suspension	12/20/93	Designated			N/A	N/A	Ross Laboratories	Columbus	Ohio	43215	USA	EXACT	0171164AA	Beractant	S866O45PIG						 Alveolar capillary dysplasia	8644	done	
Beractant	Treatment of neonatal respiratory distress syndrome	Beractant	BERACTANT	Survanta Intratracheal Suspension	2/5/86	Designated/Approved	Approved for Orphan Indication	Prevention of RDS (hyaline membrane disease) in premature infants less than 1250 grams birthweight or with evidence of surfactant deficiency	7/2/91	7/2/98	Ross Laboratories	Columbus	Ohio	43215	USA	EXACT	0171164AA	Beractant	S866O45PIG						"Respiratory distress syndrome, infant"	112	done	
Beractant	Treatment of neonatal respiratory distress syndrome	Beractant	BERACTANT	Survanta Intratracheal Suspension	2/5/86	Designated/Approved	Approved for Orphan Indication	"Treatment of (""rescue"") of premature infants with RDS confirmed by x-ray and requiring mechanical ventilation"	7/1/91	7/1/98	Ross Laboratories	Columbus	Ohio	43215	USA	EXACT	0171164AA	Beractant	S866O45PIG						"Respiratory distress syndrome, infant"	112	done	
Beraprost	"Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV)."	Beraprost	BERAPROST	n/a	4/29/99	Designated			N/A	N/A	"LungRx, Inc."	Silver Spring	Maryland	20910	USA	EXACT	0304665AA	Beraprost	35E3NJJ4O6						Autoimmune pulmonary alveolar proteinosis	7499	done	
Bethanidine sulfate	Prevention of recurrence of primary ventricular fibrillation.	Bethanidine sulfate	BETHANIDINE SULFATE	n/a	11/24/89	Designated/Withdrawn			N/A	N/A	"Medco Research, Inc."	Los Angeles	California	90048	USA	EXACT	0018440AA	Bethanidine sulfate	J4THI5N7O2						"Ventricular fibrillation, idiopathic"	5474	approximate	
Bethanidine sulfate	Treatment of primary ventricular fibrillation.	Bethanidine sulfate	BETHANIDINE SULFATE	n/a	9/20/88	Designated/Withdrawn			N/A	N/A	"Medco Research, Inc."	Los Angeles	California	90048	USA	EXACT	0018440AA	Bethanidine sulfate	J4THI5N7O2						"Ventricular fibrillation, idiopathic"	5474	done	
Bio-engineered oral mucosal tissue	For use as a graft for restoring a cornea-like epithelial phenotype to substitute for the normal corneal epithelium that is lost in patients due to total limbal stem cell deficiency	Bio-engineered oral mucosal tissue		n/a	4/27/06	Designated			N/A	N/A	"TissueTech, Inc."	Miami	Florida	33173	USA								PROBLEM	can't find	Superior limbic keratoconjunctivitis	10940	approximate	
Bioartificial liver system utilizing xenogenic hepatocytes in a hollow fiber bioreactor cartridge (BAL)	Treatment of patients with acute liver failure presenting with encephalopathy deteriorating beyond Parson's grade 2	Bioartificial liver system utilizing xenogenic hepatocytes in a hollow fiber bioreactor cartridge (BAL)	LIVER	n/a	2/11/02	Designated			N/A	N/A	"Excorp Medical, Inc."	Oakdale	Minnesota	55128	USA	LONGEST CONTAINS	0152749AA	liver					PROBLEM	can't find			MISSING	
Bleomycin	Treatment of pancreatic cancer.	Bleomycin	BLEOMYCIN	Blenoxane	2/9/99	Designated			N/A	N/A	"Genetronics, Inc."	San Diego	California	92121	USA	EXACT	0054217AA	Bleomycin	40S1VHN69B						Pancreatic cancer	9364	done	Not a rare disease
Bleomycin	Treatment of pancreatic cancer.	Bleomycin	BLEOMYCIN	n/a	12/20/10	Designated			N/A	N/A	CIRJ Company Ltd.	Pasadena	California	91004	USA	EXACT	0054217AA	Bleomycin	40S1VHN69B						Pancreatic cancer	9364	done	Not a rare disease
Bleomycin sulfate	Treatment of malignant pleural effusion.	Bleomycin sulfate	BLEOMYCIN SULFATE	Blenoxane	9/17/93	Designated/Approved	Approved for Orphan Indication	Treatment of malignant pleural effusion.	2/20/96	2/20/03	Bristol-Myers Squibb Pharmaceutical Research Institute	Princeton	New Jersey	8543	USA	EXACT	0052415AA	Bleomycin sulfate	7DP3NTV15T								MISSING	not a disease
Bone marrow-derived mononuclear cells	Treatment of thromboangiitis obliterans (Buerger's disease)	Bone marrow-derived mononuclear cells	BONE MARROW	n/a	5/17/10	Designated			N/A	N/A	t2cure GmbH				Germany	LONGEST CONTAINS	0100072AA	Bone marrow					PROBLEM	can't find	Buerger disease	5969	done	
Botulinum toxin type A	Treatment of dynamic muscle contracture in pediatric cerebral palsy patients.	Botulinum toxin type A	BOTULINUM TOXIN TYPE A	Botox	12/6/91	Designated			N/A	N/A	"Allergan, Inc."	Irvine	California	92623	USA	EXACT	0171595AA	Botulinum toxin type A	E211KPY694						Cerebral palsy	10450	done	
Botulinum toxin type A	Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.	Botulinum toxin type A	BOTULINUM TOXIN TYPE A	Dysport	10/20/99	Designated/Approved	Approved for Orphan Indication	Treatment of lower limb spasticity in pediatric cerebral patients 2 years of age and older	7/29/16	7/29/23	Ipsen Limited	Berkshire SL6 4UH			United Kingdom	EXACT	0171595AA	Botulinum toxin type A	E211KPY694						Cerebral palsy	10450	done	
Botulinum toxin type A	Treatment of strabismus and blepharospasms	Botulinum toxin type A	BOTULINUM TOXIN TYPE A	Botox	3/22/84	Designated/Approved	Approved for Orphan Indication	Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above)	12/29/89	12/29/96	"Allergan, Inc."	Irvine	California	92713	USA	EXACT	0171595AA	Botulinum toxin type A	E211KPY694								MISSING	
Botulinum toxin type A	Treatment of strabismus and blepharospasms	Botulinum toxin type A	BOTULINUM TOXIN TYPE A	Botox	3/22/84	Designated/Approved	Approved for Orphan Indication	Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above)	12/30/89	12/30/96	"Allergan, Inc."	Irvine	California	92713	USA	EXACT	0171595AA	Botulinum toxin type A	E211KPY694								MISSING	
Botulinum toxin type A	Treatment of synkinetic closure of the eyelid associated with VII cranial nerve aberrant regeneration.	Botulinum toxin type A	BOTULINUM TOXIN TYPE A	n/a	9/15/92	Designated			N/A	N/A	"Botulinum Toxin Research Associates, Inc."	Quincy	Massachusetts	2169	USA	EXACT	0171595AA	Botulinum toxin type A	E211KPY694								MISSING	
Bovine colostrum	Treatment of AIDS-related diarrhea.	Bovine colostrum	BOS TAURUS COLOSTRUM	n/a	11/19/90	Designated			N/A	N/A	"Hastings, Donald DVM"	Bismarck	North Dakota	58501	USA	EXACT	0630193AA	Bovine colostrum	S256WJ3OFQ						Congenital human immunodeficiency virus	10328	approximate	
"Bovine immunoglobulin concentrate, Cryptosporidium parvum"	Treatment and symptomatic relief of Cryptosporidium parvum infection of the gastrointestinal tract in immunocompromised patients.	"Bovine immunoglobulin concentrate, Cryptosporidium parvum"	CRYPTOSPORIDIUM PARVUM	Sporidin-G	3/1/94	Designated			N/A	N/A	"GalaGen, Inc."	Arden Hills	Minnesota	55126	USA	LONGEST CONTAINS	0446491AA	Cryptosporidium parvum	TGR919EN5P						Cryptosporidiosis	6219	approximate	
Brentuximab vedotin	Treatment of primary cutaneous CD30-positive T-cell lymphoproliferative disorders	Brentuximab vedotin	BRENTUXIMAB VEDOTIN	Adcetris	9/7/16	Designated			N/A	N/A	"Seattle Genetics, Inc."	Bothell	Washington	98021	USA	EXACT	0297767AA	Brentuximab vedotin	7XL5ISS668						Anaplastic large cell lymphoma	3112	approximate	"Not specified. The spectrum of CD30+ cutaneous lymphoproliferative disorders includes lymphomatoid papulosis (LyP), cutaneous anaplastic large-cell lymphoma (CALCL), and borderline cases that represent the second most common types of CTCL after mycosis fungoides (MF) and comprise approximately 25% of all CTCL"
Brilliant Blue G	"To selectively stain the thickened internal limiting membrane, which has formed onto the inner side of the retina in vitreo-retinal disorders"	Brilliant Blue G	BRILLIANT BLUE G	Dorc Ilm-Blue	7/31/12	Designated			N/A	N/A	Dutch Opthalmic Research Center	Zuidland			Netherlands	EXACT	0797751AA	Brilliant Blue G	M1ZRX790SI								MISSING	procedure
Brivaracetam	Treatment of symtomatic myoclonus	Brivaracetam	BRIVARACETAM	n/a	10/5/05	Designated			N/A	N/A	"UCB Pharma, Inc."	Smyra	Georgia	30080	USA	EXACT	0251887AA	Brivaracetam	U863JGG2IA								MISSING	
Brivudin	Adjunct treatment of pancreatic cancer	Brivudin	BRIVUDINE	n/a	11/15/07	Designated/Withdrawn			N/A	N/A	"SciClone Pharmaceuticals, Inc."	San Mateo	California	94404	USA	EXACT	0301699AA	Brivudin	2M3055079H						Pancreatic cancer	9364	done	
Bromhexine	Treatment of mild to moderate keratoconjunctivitis sicca in patients with Sjogren's syndrome.	Bromhexine	BROMHEXINE	Bisolvon	5/15/89	Designated/Withdrawn			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc."	Ridgefield	Connecticut	6877	USA	EXACT	0100629AA	Bromhexine	Q1J152VB1P						Sjogren syndrome	10252	done	
Broxuridine	Radiation sensitizer in the treatment of primary brain tumors.	Broxuridine	BROXURIDINE	Broxine/Neomark	9/18/95	Designated			N/A	N/A	"NeoPharm, Inc."	Lake Forest	Illinois	60045	USA	EXACT	0010071AA	Broxuridine	G34N38R2N1						"Brain tumor, adult"	9307	approximate	brain tumor not specified
Bruton’s agammaglobulinemia tyrosine kinase (BTK) inhibitor	Treatment of immune thrombocytopenic purpura (ITP)	Bruton’s agammaglobulinemia tyrosine kinase (BTK) inhibitor	TYROSINE-PROTEIN KINASE BTK	n/a	10/15/18	Designated			N/A	N/A	Principia Biopharma Inc.	400 East Jamie Court	California	94080	USA	LONGEST CONTAINS	1564256AA	agammaglobulinemia tyrosine kinase	SBH6S6T2J2						Idiopathic thrombocytopenic purpura	5194	approximate	
Buffered intrathecal electrolyte/dextrose injection	For use as a diluent in the intrathecal administration of methotrexate and cytarabine for the prevention or treatment meningeal leukemia and lymphocytic lymphoma	Buffered intrathecal electrolyte/dextrose injection		Elliotts B Solution	8/24/94	Designated/Approved	Approved for Orphan Indication	For the intrathecal administration of methotrexate and cytarabine for the prevention or treatment of meningeal leukemia and lymphocytic lymphoma.	9/27/96	9/27/03	"Lukare Medical, LLC"	Scotch Plains	New Jersey	7076	USA					Elliotts B® Solution	NA	https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b1e83fb1-7f51-41b7-a1eb-495414bbf1f2	PROBLEM	can't find	Acute lymphoblastic leukemia	522	approximate	
Buprenorphine hydrochloride	Treatment of opiate addiction in opiate users.	Buprenorphine hydrochloride	BUPRENORPHINE HYDROCHLORIDE	Subutex	6/15/94	Designated/Approved	Approved for Orphan Indication	Treatment of opioid dependence in patients 16 years of age or older	10/8/02	10/8/09	"Reckitt Benckiser Pharmaceuticals, Inc."	Richmond	Virginia	23235	USA	EXACT	0065974AA	Buprenorphine hydrochloride	56W8MW3EN1								MISSING	
Busulfan	As preparative therapy in the treatment of malignancies with bone marrow transplantation.	Busulfan	BUSULFAN	Busulfex	7/28/94	Designated/Approved	Approved for Orphan Indication	For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia.	2/4/99	2/4/06	Otsuka Pharmaceutical Company				Japan	EXACT	0008946AA	Busulfan	G1LN9045DK								MISSING	
Busulfan	For use as preparative therapy for malignancies treated with bone marrow transplantation.	Busulfan	BUSULFAN	Spartaject	4/21/94	Designated			N/A	N/A	"Sparta Pharmaceuticals, Inc."	Horsham	Pennsylvania	19044	USA	EXACT	0008946AA	Busulfan	G1LN9045DK								MISSING	not a disease
Busulfan	Intrathecal therapy for neoplastic meningitis	Busulfan	BUSULFAN	Spartajet-Busulfan	3/5/01	Designated/Withdrawn			N/A	N/A	"SuperGen, Inc."	Dublin	California	94568	USA	EXACT	0008946AA	Busulfan	G1LN9045DK								MISSING	
Busulfan	Treatment of primary brain malignancies.	Busulfan	BUSULFAN	Spartaject	7/7/97	Designated			N/A	N/A	"SuperGen, Inc."	San Ramon	California	94583	USA	EXACT	0008946AA	Busulfan	G1LN9045DK						"Brain tumor, adult"	9307	approximate	
Butyrylcholinesterase	For the reduction and clearance of toxic blood levels of cocaine encountered during a drug overdose.	Butyrylcholinesterase		n/a	3/25/92	Designated			N/A	N/A	Shire Laboratories Inc.	Rockville	Maryland	20850	USA								PROBLEM	can't find			MISSING	
Butyrylcholinesterase	Treatment of post-surgical apnea.	Butyrylcholinesterase		n/a	9/30/92	Designated			N/A	N/A	Shire Laboratories Inc.	Rockville	Maryland	20850	USA								PROBLEM	can't find			MISSING	surgery complication
C1 esterase inhibitor (Human)	Treatment of acute antibody mediated rejection following kidney transplantation	C1 esterase inhibitor (Human)	C1 ESTERASE INHIBITOR (HUMAN)	Cinryze	11/30/16	Designated			N/A	N/A	"Shire ViroPharma, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0335717AA	C1 esterase inhibitor (Human)	6KIC4BB60G						Acute graft versus host disease	6544	approximate	
C1 esterase inhibitor (human)	Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.	C1 esterase inhibitor (human)	C1 ESTERASE INHIBITOR (HUMAN)	n/a	8/21/96	Designated			N/A	N/A	Alpha Therapeutic Corporation	Los Angeles	California	90032	USA	EXACT	0335717AA	C1 esterase inhibitor (human)	6KIC4BB60G						Hereditary angioedema 	5979	done	
C1 esterase inhibitor (human)	Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.	C1 esterase inhibitor (human)	C1 ESTERASE INHIBITOR (HUMAN)	n/a	8/21/96	Designated			N/A	N/A	Alpha Therapeutic Corporation	Los Angeles	California	90032	USA	EXACT	0335717AA	C1 esterase inhibitor (human)	6KIC4BB60G						 Acquired angioedema	8605	done	
C1 esterase inhibitor (human)	Treatment of angioedema	C1 esterase inhibitor (human)	C1 ESTERASE INHIBITOR (HUMAN)	Cinryze(R)	7/16/04	Designated/Approved	Approved for Orphan Indication	Routine prophylaxis against angioedema attacks in patients with Hereditary Angioedema (HAE)	10/10/08	10/10/15	Shire	Lexington	Massachusetts	2421	USA	EXACT	0335717AA	C1 esterase inhibitor (human)	6KIC4BB60G						Hereditary angioedema	5979	done	
C1 esterase inhibitor (human)	Treatment of angioedema	C1 esterase inhibitor (human)	C1 ESTERASE INHIBITOR (HUMAN)	Cinryze(R)	7/16/04	Designated/Approved	Approved for Orphan Indication	Routine prophylaxis against angioedema attacks in patients with Hereditary Angioedema (HAE)	10/10/08	10/10/15	Shire	Lexington	Massachusetts	2421	USA	EXACT	0335717AA	C1 esterase inhibitor (human)	6KIC4BB60G						Acquired angioedema	8605	done	
C1-inhibitor	"Prevention of acute attacks of angioedema, including short-term prophylaxis for patients requiring dental or other surgical procedures."	C1-inhibitor	C1 ESTERASE INHIBITOR (HUMAN)	"C1-Inhibitor (Human) Vapor Heated, Immuno"	8/30/90	Designated/Withdrawn			N/A	N/A	Baxter Healthcare Corp.	Westlake Village	California	91362	USA	EXACT	0335717AA	C1 inhibitor	6KIC4BB60G						Acquired angioedema	8605	done	
C1-inhibitor	Treatment of acute attacks of angioedema.	C1-inhibitor	C1 ESTERASE INHIBITOR (HUMAN)	"C1-Inhibitor (Human) Vapor Heated, Immuno"	8/30/90	Designated/Withdrawn			N/A	N/A	Baxter Healthcare Corp.	Westlake Village	California	91362	USA	EXACT	0335717AA	C1 inhibitor	6KIC4BB60G						Acquired angioedema	8605	done	
C1-inhibitor	Treatment of acute attacks of angioedema.	C1-inhibitor	C1 ESTERASE INHIBITOR (HUMAN)	"C1-Inhibitor (Human) Vapor Heated, Immuno"	8/30/90	Designated/Withdrawn			N/A	N/A	Baxter Healthcare Corp.	Westlake Village	California	91362	USA	EXACT	0335717AA	C1 inhibitor	6KIC4BB60G						Hereditary angioedema	5979	done	
C20-D3-retinyl acetate	Treatment of Stargardt's disease	C20-D3-retinyl acetate	VITAMIN A ACETATE C20-D3	n/a	9/16/10	Designated			N/A	N/A	"Alkeus pharmaceuticals, Inc."	Cambridge	Massachusetts	2140	USA	EXACT	1804417AA	C20-D3-retinyl acetate	JN7W3M3OI7						Stargardt disease	181	done	
CAEL-101	For use as a radioimmaging agent in amyloidosis	monoclonal antibody 11-1F4		n/a	12/7/09	Designated			N/A	N/A	"Alan Solomon, M.D."	Knoxville	Tennessee	37920	USA					CAEL-101	NA	https://adisinsight.springer.com/drugs/800048692	PROBLEM	can't find	Hereditary amyloidosis	6611	approximate	
CANOCTAKIN	Prevention of delayed graft function after solid organ transplantation	glycafilin	CANOCTAKIN	n/a	8/22/08	Designated			N/A	N/A	ProtAffin Biotechnologie AG				Austria	EXACT	0925257AA	CANOCTAKIN	MU4128F2CO								MISSING	
CANTUZUMAB MERTANSINE	For pancreatic cancer	N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-Maystansine-Conjugated Humanized C242 Monoclonal Antibody	CANTUZUMAB MERTANSINE	n/a	12/7/00	Designated			N/A	N/A	SmithKline Beecham Pharmaceuticals	Collegeville	Pennsylvania	19426	USA	EXACT	0232962AA	CANTUZUMAB MERTANSINE	7Z7EUX7R6M						Pancreatic cancer	9364	done	
CATRIDECACOG	Treatment of congenital FXIII deficiency	"Factor XIII [A2] homodimer, recombinant DNA origin"	CATRIDECACOG	n/a	5/21/03	Designated			N/A	N/A	"Novo Nordisk Pharmaceuticals, INc."	Princeton	New Jersey	8540	USA	EXACT	0679458AA	CATRIDECACOG	NU23Q531G1						Factor XIII deficiency	10766	done	
CATRIDECACOG	Treatment of congenital factor XIII deficiency.	"Factor XIII, recombinant"	CATRIDECACOG	n/a	4/22/93	Designated/Withdrawn			N/A	N/A	"Zymogenetics, Inc."	Seattle	Washington	98105	USA	EXACT	0679458AA	CATRIDECACOG	NU23Q531G1						Hereditary antithrombin deficiency	6148	done	
CB-5083	Treatment of multiple myeloma	"1-(4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide"	CB-5083	n/a	7/8/15	Designated			N/A	N/A	"Cleave Biosciences, Inc."	Burlingame	California	94010	USA	EXACT	1069836AA	CB-5083	591IV6UL6J						Multiple myeloma	7108	done	
CBP-501 ACETATE	For use in combination with cisplatin and pemetrexed for the treatment of patients with mesothelioma	H-(D)p-Benzoylphenylalanyl-(D)seryl-(D)tryptophanyl-(D)seryl-(D)pentafluorophenylalanyl-(D)cyclohexylalanyl-(D)arginyl-(D)arginyl-(D)arginyl-(D)glutaminyl-(D)arginyl-(D)arginine acetate salt	CBP-501 ACETATE	n/a	12/22/11	Designated			N/A	N/A	"CanBas Company, Ltd."	"Numazu City, Shizuoka"			Japan	EXACT	0252222AA	CBP-501 ACETATE	8HSP55450P						Malignant mesothelioma	7026	done	
CC-122 HYDROCHLORIDE	Treatment of diffuse large B-cell lymphoma	"3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride"	CC-122 HYDROCHLORIDE	n/a	9/19/16	Designated			N/A	N/A	Celgene Corporation	Berkeley Heights	New Jersey	7922	USA	EXACT	0926830AA	CC-122 HYDROCHLORIDE	6CX4AEX3KR						Diffuse Large B-Cell Lymphoma	3178	done	
CCX-140B	Treatment of focal segmental glomerulosclerosis	"4-Chloro-N-[5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidin-4-ylcarbonyl)-3-pyridinyl]-3-(trifluoromethyl)benzenesulfonamide, sodium salt"	CCX-140 SODIUM SALT	n/a	9/12/18	Designated			N/A	N/A	"ChemoCentryx, Inc."	850 Maude Avenue	California	94043	USA	EXACT	0812793AA	CCX-140 SODIUM SALT	X39CM70JTQ						Focal segmental glomerulosclerosis	6517	done	
CCX-168	"Treatment of anti-neutrophil cytoplasmic autoantibodies associated vasculitides (granulomatosis with polyangiitis or Wegener's granulomatosis), microscopic polyangiitis, and Churg-Strauss syndrome."	antagonist of the complement 5a receptor	CCX-168	n/a	6/2/14	Designated			N/A	N/A	"ChemoCentryx, Inc."	Mountain View	California	94043	USA	EXACT	1083336AA	CCX-168	O880NM097T						Granulomatosis with polyangiitis	7880	done	
CCX-168	"Treatment of anti-neutrophil cytoplasmic autoantibodies associated vasculitides (granulomatosis with polyangiitis or Wegener's granulomatosis), microscopic polyangiitis, and Churg-Strauss syndrome."	antagonist of the complement 5a receptor	CCX-168	n/a	6/2/14	Designated			N/A	N/A	"ChemoCentryx, Inc."	Mountain View	California	94043	USA	EXACT	1083336AA	CCX-168	O880NM097T						Microscopic polyangiitis	3652	done	
CCX-168	"Treatment of anti-neutrophil cytoplasmic autoantibodies associated vasculitides (granulomatosis with polyangiitis or Wegener's granulomatosis), microscopic polyangiitis, and Churg-Strauss syndrome."	antagonist of the complement 5a receptor	CCX-168	n/a	6/2/14	Designated			N/A	N/A	"ChemoCentryx, Inc."	Mountain View	California	94043	USA	EXACT	1083336AA	CCX-168	O880NM097T						Eosinophilic granulomatosis with polyangiitis	6111	done	
CD4 human truncated 369 AA polypeptide	Treatment of acquired immunodeficiency syndrome.	CD4 human truncated 369 AA polypeptide		Soluble T4	11/21/89	Designated/Withdrawn			N/A	N/A	SmithKline Beecham	King Of Prussia	Pennsylvania	19406	USA								PROBLEM	can't find	Congenital human immunodeficiency virus	10328	approximate	
CD4-mediated activated regulatory T cells	Treatment of graft-versus-host disease	CD4-mediated activated regulatory T cells		Atreg	11/27/17	Designated			N/A	N/A	Universitatsmedizin der Johannes Gutenberg-Universitat Mainz	1 Langenbeckstraße	Mainz		Germany				J56RKY13OV	HUMAN THYMOCYTE	J56RKY13OV	https://ginas.ncats.nih.gov/ginas/app/substance/9784a943	approximate		Chronic graft versus host disease 	10964	approximate	
CD4-mediated activated regulatory T cells	Treatment of graft-versus-host disease	CD4-mediated activated regulatory T cells		Atreg	11/27/17	Designated			N/A	N/A	Universitatsmedizin der Johannes Gutenberg-Universitat Mainz	1 Langenbeckstraße	Mainz		Germany				J56RKY13OV	HUMAN THYMOCYTE	J56RKY13OV	https://ginas.ncats.nih.gov/ginas/app/substance/9784a943	approximate		 Acute graft versus host disease	6544	approximate	
CD40/CD80/CD86 modified autologous dendritic cell therapy	Treatment Type 1 diabetes mellitus patients with residual beta cell function	CD40/CD80/CD86 modified autologous dendritic cell therapy		n/a	12/20/13	Designated			N/A	N/A	"DiaVacs, Inc."	Edgewater	New Jersey	7020	USA								PROBLEM	"procedure, not a drug"	Diabetes mellitus type 1	10268	done	
CD5-T lymphocyte immunotoxin	Treatment of graft versus host disease and/or rejection in patients who have received bone marrow transplants.	CD5-T lymphocyte immunotoxin		Xomazyme-H65	8/27/87	Designated/Withdrawn			N/A	N/A	Xoma Corporation	Berkeley	California	94710	USA				2C1ZT922TD	ZOLIMOMAB ARITOX	2C1ZT922TD	https://ginas.ncats.nih.gov/ginas/app/substance/78de6344	approximate		Chronic graft versus host disease 	10964	approximate	
CD5-T lymphocyte immunotoxin	Treatment of graft versus host disease and/or rejection in patients who have received bone marrow transplants.	CD5-T lymphocyte immunotoxin		Xomazyme-H65	8/27/87	Designated/Withdrawn			N/A	N/A	Xoma Corporation	Berkeley	California	94710	USA				2C1ZT922TD	ZOLIMOMAB ARITOX	2C1ZT922TD	https://ginas.ncats.nih.gov/ginas/app/substance/78de6344	approximate		 Acute graft versus host disease	6544	approximate	
CDP-571	Treatment of Crohn's disease.	Genetically engineered human recombinant IgG4 monoclonal antibody directed against human TNF alpha	SENLIZUMAB	n/a	12/11/97	Designated			N/A	N/A	Celltech Chiroscience Limited				United Kingdom	EXACT	0297972AA	CDP-571	1V3N66A87N						Crohn's disease	10232	done	Not a rare disease
CDX-1135	Prevention of post-cardiopulmonary bypass syndrome in children undergoing cardiopulmonary bypass.	Soluble complement receptor type 1	CDX-1135	n/a	3/6/00	Designated			N/A	N/A	"Avant Immunotherapeutics, Inc."	Needham	Massachusetts	2494	USA	EXACT	0260719AA	CDX-1135	2RF4H67MOG								MISSING	prevention of surgical complications
CENISERTIB BENZOATE	Treatment of acute myeloid leukemia	"(1S, 2S, 3R, 4R)-3-(5-Fluoro-2-(3-methyl-4-(4-methylpiperazin-1-yl)-phenylamino)-pyrimidin-4-ylamino)bicycle[2.2.1]hept-5-ene-2-carboxamide benzoate"	CENISERTIB BENZOATE	n/a	1/19/10	Designated/Withdrawn			N/A	N/A	"EMD Serono, Inc."	Rockland	Massachusetts	2370	USA	EXACT	0737315AA	CENISERTIB BENZOATE	S68QU67MAZ						Acute myeloid leukemia	12757	done	
CETYL MYRISTOLEATE	Treatment of juvenile rheumatoid arthritis joint and related tissue inflammation in the pediatric population	Kre-Celazine	CETYL MYRISTOLEATE	n/a	4/1/13	Designated			N/A	N/A	All American Pharmaceutical & Natural Foods Corpor	Billings	Montana	59105	USA	EXACT	0349995AA	CETYL MYRISTOLEATE	87P8K33Q5X						Juvenile idiopathic arthritis	3067	done	Not a rare disease
CETYL OLEATE	Treatment of juvenile rheumatoid arthritis joint and related tissue inflammation in the pediatric population	Kre-Celazine	CETYL OLEATE	n/a	4/1/13	Designated			N/A	N/A	All American Pharmaceutical & Natural Foods Corpor	Billings	Montana	59105	USA	EXACT	0380541AA	CETYL OLEATE	78K2L26L8N						Juvenile idiopathic arthritis	3067	done	Not a rare disease
CETYL PALMITOLEATE	Treatment of juvenile rheumatoid arthritis joint and related tissue inflammation in the pediatric population	Kre-Celazine	CETYL PALMITOLEATE	n/a	4/1/13	Designated			N/A	N/A	All American Pharmaceutical & Natural Foods Corpor	Billings	Montana	59105	USA	EXACT	0380676AA	CETYL PALMITOLEATE	962I97113K						Juvenile idiopathic arthritis	3067	done	Not a rare disease
CG-026806	Treatment of acute myeloid leukemia (AML)	"1-{3-fluoro-4-[7-(5-methyl-lH-imidazol-2-yl)- 1-oxo-2,3-dihydro-lH-isoindo 1-4-yl]-phenyl}-3-(3-trifluoromethyl-phenyl)-urea"	CG-026806	n/a	12/22/17	Designated			N/A	N/A	"Aptose Biosciences, Inc."	12770 High Bluff Drive	San Diego	92130	USA	EXACT	0114040AB	CG-026806	7W3FGR71NN						Acute myeloid leukemia	12757	done	
CHOLERA ENTEROTOXIN SUBUNIT B	Treatment of ulcerative colitis in pediatric patients	cholera toxin B subunit	CHOLERA ENTEROTOXIN SUBUNIT B	n/a	11/16/17	Designated			N/A	N/A	Aliment Wellness LLC	9462 Brownsboro Road	Kentucky	40241	USA	EXACT	0709455AA	CHOLERA ENTEROTOXIN SUBUNIT B	1FKD81GIZJ						Pediatric ulcerative colitis	9857	done	
CIBINETIDE	Treatment to increase survival and improve functioning of pancreatic islets following transplantation	L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	CIBINETIDE	n/a	6/13/16	Designated			N/A	N/A	"Araim Pharmaceuticals, Inc."	Tarrytown	New York	10591	USA	EXACT	0693812AA	CIBINETIDE	9W5677JKDA								MISSING	procedure
CILOFEXOR TROMETHAMINE	Treatment of Primary Sclerosing Cholangitis (PSC)	"2-[3-(2-chloro-4-{[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy}phenyl)-3-hydroxyazetidin-1-yl]pyridine-4-carboxylic acid—2-amino-2-(hydroxymethyl)propane-1,3-diol (1/1)"	GS-9674 TROMETHAMINE	n/a	10/25/18	Designated			N/A	N/A	"Gilead Sciences, Inc."	333 Lakeside Drive	California	94404	USA	EXACT	1240115AA	CILOFEXOR TROMETHAMINE	Z7AR0KNS4A						Primary sclerosing cholangitis	1280	done	
CLODRONATE DISODIUM TETRAHYDRATE	Treatment of increased bone resorption due to malignancy.	Disodium clodronate tetrahydrate	CLODRONATE DISODIUM	Bonefos	3/5/90	Designated			N/A	N/A	"Anthra Pharmaceuticals, Inc."	Princeton	New Jersey	8540	USA	EXACT	0060924AA	CLODRONATE DISODIUM TETRAHYDRATE	N030400H8J								MISSING	
CLT-28643	Prevention of scarring post ab externo glaucoma surgery	4-(4-Methoxy-phenylamino)-6-methylcarbamyl-quinoline-3-carboxylic acid	QUINOLINE	n/a	3/24/15	Designated			N/A	N/A	Clanotech AB				Sweden	EXACT	1576358AA	quinoline	E66400VT9R								MISSING	prevention of surgical complications
CM-101	Treatment of systemic sclerosis	monoclonal antibody targeting eotaxin-2	CM-101	n/a	1/6/15	Designated			N/A	N/A	"ChemomAb, Ltd."	Tel Aviv			Israel	EXACT	0110872AB	CM-101					PROBLEM	can't find	Systemic scleroderma	9748	done	
CN-105	Treatment of intracerebral hemorrhage	pentapeptide with sequence Ac-VSRRR-NH2	CN-105	n/a	1/13/15	Designated			N/A	N/A	"CereNOva, LLC"	Raleigh	North Carolina	27613	USA	EXACT	1125253AA	CN-105	W525NLS74J								MISSING	
CNTO-148	"Treatment of uveitis of the posterior segment of non-infectious etiology, and uveitis of the anterior segment of non-infectious etiology and refractory to conventional therapy"	Human Anti-tumor Necrosis factor alpha monoclonal antibody	GOLIMUMAB	n/a	1/16/03	Designated/Withdrawn			N/A	N/A	"Centocor, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	0265463AA	CNTO-148	91X1KLU43E						Panuveitis	8577	approximate	
COAGULATION FACTOR IX HUMAN	Reversal of anticoagulation therapy in patients needing treatment of serious or life threatening bleeding and/or needing urgent surgery or invasive procedures	Human prothrombin complex concentrate	COAGULATION FACTOR IX HUMAN	Octaplex	2/1/08	Designated			N/A	N/A	"Octapharma USA, Inc."	Hoboken	New Jersey	7030	USA	EXACT	0324969AA	COAGULATION FACTOR IX HUMAN	6U90Y1795T								MISSING	treatment of drug-induced side-effects
COAGULATION FACTOR IX HUMAN	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	prothrombin complex concentrate (human)	COAGULATION FACTOR IX HUMAN	Kcentra	12/27/12	Designated/Approved	Approved for Orphan Indication	"Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy (VKA, e.g., warfarin) in adult patients with the need for urgent surgery/invasive procedure."	12/13/13	12/13/20	CSL Behring	King of Prussia	Pennsylvania	19406	USA	EXACT	0324969AA	COAGULATION FACTOR IX HUMAN	6U90Y1795T								MISSING	not a disease
COAGULATION FACTOR IX HUMAN	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	prothrombin complex concentrate (human)	COAGULATION FACTOR IX HUMAN	Kcentra	12/27/12	Designated/Approved	Approved for Orphan Indication	"Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding."	4/29/13	4/29/20	CSL Behring	King of Prussia	Pennsylvania	19406	USA	EXACT	0324969AA	COAGULATION FACTOR IX HUMAN	6U90Y1795T								MISSING	not a disease
COAGULATION FACTOR VII HUMAN	Reversal of anticoagulation therapy in patients needing treatment of serious or life threatening bleeding and/or needing urgent surgery or invasive procedures	Human prothrombin complex concentrate	COAGULATION FACTOR VII HUMAN	Octaplex	2/1/08	Designated			N/A	N/A	"Octapharma USA, Inc."	Hoboken	New Jersey	7030	USA	EXACT	0324970AA	COAGULATION FACTOR VII HUMAN	4156XVB4QD								MISSING	treatment of drug-induced side-effects
COAGULATION FACTOR VII HUMAN	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	prothrombin complex concentrate (human)	COAGULATION FACTOR VII HUMAN	Kcentra	12/27/12	Designated/Approved	Approved for Orphan Indication	"Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding."	4/29/13	4/29/20	CSL Behring	King of Prussia	Pennsylvania	19406	USA	EXACT	0324970AA	COAGULATION FACTOR VII HUMAN	4156XVB4QD								MISSING	not a disease
COAGULATION FACTOR VII HUMAN	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	prothrombin complex concentrate (human)	COAGULATION FACTOR VII HUMAN	Kcentra	12/27/12	Designated/Approved	Approved for Orphan Indication	"Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy (VKA, e.g., warfarin) in adult patients with the need for urgent surgery/invasive procedure."	12/13/13	12/13/20	CSL Behring	King of Prussia	Pennsylvania	19406	USA	EXACT	0324970AA	COAGULATION FACTOR VII HUMAN	4156XVB4QD								MISSING	not a disease
COAGULATION FACTOR X HUMAN	Reversal of anticoagulation therapy in patients needing treatment of serious or life threatening bleeding and/or needing urgent surgery or invasive procedures	Human prothrombin complex concentrate	COAGULATION FACTOR X HUMAN	Octaplex	2/1/08	Designated			N/A	N/A	"Octapharma USA, Inc."	Hoboken	New Jersey	7030	USA	EXACT	0324947AA	COAGULATION FACTOR X HUMAN	0P94UQE6SY								MISSING	treatment of drug-induced side-effects
COAGULATION FACTOR X HUMAN	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	prothrombin complex concentrate (human)	COAGULATION FACTOR X HUMAN	Kcentra	12/27/12	Designated/Approved	Approved for Orphan Indication	"Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy (VKA, e.g., warfarin) in adult patients with the need for urgent surgery/invasive procedure."	12/13/13	12/13/20	CSL Behring	King of Prussia	Pennsylvania	19406	USA	EXACT	0324947AA	COAGULATION FACTOR X HUMAN	0P94UQE6SY								MISSING	not a disease
COAGULATION FACTOR X HUMAN	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	prothrombin complex concentrate (human)	COAGULATION FACTOR X HUMAN	Kcentra	12/27/12	Designated/Approved	Approved for Orphan Indication	"Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding."	4/29/13	4/29/20	CSL Behring	King of Prussia	Pennsylvania	19406	USA	EXACT	0324947AA	COAGULATION FACTOR X HUMAN	0P94UQE6SY								MISSING	not a disease
CPG-52852	Treatment of stages IIB-IV melanoma	"N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide"	CPG-52852	n/a	8/13/04	Designated/Withdrawn			N/A	N/A	"Pfizer, Inc."	New London	Connecticut	6320	USA	EXACT	0249309AA	CPG-52852	6PJC3KPK6S						"Melanoma, familial"	3460	approximate	
CPI-613	Treatment of pancreatic cancer	"6,8-bis-benzylsulfanyl-octanoic acid"	CPI-613	n/a	2/6/06	Designated			N/A	N/A	"Cornerstone Pharmaceuticals, Inc."	Stony Brook	New York	11790	USA	EXACT	0298840AA	CPI-613	E76113IR49						Pancreatic cancer	9364	done	Not a rare disease
CPP-115	Treatment of infantile spasms.	"(1S,3S)-3-amino-4-(difluoromethylene)cyclopentanecarboxylic acid hydrochloride, (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride"	CPP-115	n/a	9/15/10	Designated			N/A	N/A	"Catalyst Pharmaceuticals, Inc."	Coral Gables	Florida	33134	USA	EXACT	0737337AA	CPP-115	0285I2MVUA						West syndrome	7887	done	
CROTALUS ADAMANTEUS IMMUNE FAB ANTIVENIN (OVINE)	Treatment of envenomations inflicted by North American crotalid snakes.	"Antivenin, crotalidae polyvalent immune Fab (ovine)"	CROTALUS ADAMANTEUS IMMUNE FAB ANTIVENIN (OVINE)	Crofab	1/12/94	Designated/Approved	Approved for Orphan Indication	Treatment of minimal and moderate North American Crotalidae envenomation	10/2/00	10/2/07	"Protherics, Inc."	Nashville	Tennessee	37212	USA	EXACT	0696628AA	CROTALUS ADAMANTEUS IMMUNE FAB ANTIVENIN (OVINE)	A4229A7019								MISSING	not a disease
CROTALUS ATROX IMMUNE FAB ANTIVENIN (OVINE)	Treatment of envenomations inflicted by North American crotalid snakes.	"Antivenin, crotalidae polyvalent immune Fab (ovine)"	CROTALUS ATROX IMMUNE FAB ANTIVENIN (OVINE)	Crofab	1/12/94	Designated/Approved	Approved for Orphan Indication	Treatment of minimal and moderate North American Crotalidae envenomation	10/2/00	10/2/07	"Protherics, Inc."	Nashville	Tennessee	37212	USA	EXACT	0696606AA	CROTALUS ATROX IMMUNE FAB ANTIVENIN (OVINE)	RBR61YAJ4V								MISSING	not a disease
CROTALUS SCUTULATUS IMMUNE FAB ANTIVENIN (OVINE)	Treatment of envenomations inflicted by North American crotalid snakes.	"Antivenin, crotalidae polyvalent immune Fab (ovine)"	CROTALUS SCUTULATUS IMMUNE FAB ANTIVENIN (OVINE)	Crofab	1/12/94	Designated/Approved	Approved for Orphan Indication	Treatment of minimal and moderate North American Crotalidae envenomation	10/2/00	10/2/07	"Protherics, Inc."	Nashville	Tennessee	37212	USA	EXACT	0696639AA	CROTALUS SCUTULATUS IMMUNE FAB ANTIVENIN (OVINE)	7WZ1744G86								MISSING	not a disease
CT-179 DIMESYLATE	Treatment of glioma	"1-{2-[3-(3,4-Dichlorophenyl)ureido]-6-methyl-pyrimidin-4-yl}-amino-3(dimethylamino)propane Di methansulfonate"	CT-179 DIMESYLATE	n/a	8/2/17	Designated			N/A	N/A	"Curtana Pharmaceuticals, Inc."	Austin	Texas	78754	USA	EXACT	0112689AB	CT-179 DIMESYLATE	FG4454219O						Glioma	6513	done	
CT-2584 MESYLATE	Treatment of hormone refractory prostate carcinoma.	"1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine hydrogen methanesulfonate"	CT-2584 MESYLATE	n/a	1/18/00	Designated/Withdrawn			N/A	N/A	"Cell Therapeutics, Inc."	Seattle	Washington	98119	USA	EXACT	0211803AA	CT-2584 MESYLATE	6YX1G1VY8K						Familial prostate cancer	4520	approximate	
CTS-1027	Prophylaxis of organ rejection in patients receiving allogeneic liver transplants	4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]-methyl] tetrahydro-N-hydroxy-2H-pyran-4-carboxamide	CTS-1027	n/a	6/18/08	Designated/Withdrawn			N/A	N/A	"Conatus Pharmaceuticals, Inc."	San Diego	California	92121	USA	EXACT	0222048AA	CTS-1027	2QD3F58224								MISSING	
CY-1503	Treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.	"Pentasaccharide ethyl glycoside consisting of one alpha-D-sialylosyl residue as a sodium salt, two beta-D-galactopyranosyl residues, one 2-acetamido-beta-D-glucopyranosyl unit, and one alpha-L-fucopyranosyl unit"	CYLEXIN	Cylexin	7/18/97	Designated			N/A	N/A	Cytel Corporation	San Diego	California	92121	USA	EXACT	0184930AA	CY-1503	WLZ3BA9R26								MISSING	
Caffeine	Treatment of apnea of prematurity.	Caffeine	CAFFEINE	Cafcit	9/20/88	Designated/Approved	Approved for Orphan Indication	Short term treatment of apnea of prematurity in infants between 28 and less than 33 weeks gestational age.	9/21/99	9/21/06	"O.P.R. Development, L.P."	Lawrence	Kansas	66047	USA	EXACT	0009676AA	Caffeine	3G6A5W338E						Infantile apnea	6779	done	
Calcitonin salmon nasal spray	Treatment of symptomatic Paget's disease (osteitis deformans).	Calcitonin salmon nasal spray	CALCITONIN SALMON	Miacalcin Nasal Spray	10/29/90	Designated/Withdrawn			N/A	N/A	Sandoz Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0079754AA	Calcitonin salmon	7SFC6U2VI5						Paget disease of bone 	8615	done	not a rare disease
Calcitonin salmon nasal spray	Treatment of symptomatic Paget's disease (osteitis deformans).	Calcitonin salmon nasal spray	CALCITONIN SALMON	Miacalcin Nasal Spray	10/29/90	Designated/Withdrawn			N/A	N/A	Sandoz Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0079754AA	Calcitonin salmon	7SFC6U2VI5						" Paget disease of bone, familial"	4191	done	not a rare disease
Calcitonin-human for injection	Treatment of symptomatic Paget's disease (osteitis deformans).	Calcitonin-human for injection	CALCITONIN HUMAN	Cibacalcin	1/20/87	Designated/Approved	Approved for Orphan Indication		10/31/86	10/31/93	Novartis Pharmaceutical Corporation	East Hanover	New Jersey	7936	USA	EXACT	0125202AA	Calcitonin human	I0IO929019						Paget disease of bone 	8615	done	not a rare disease
Calcitonin-human for injection	Treatment of symptomatic Paget's disease (osteitis deformans).	Calcitonin-human for injection	CALCITONIN HUMAN	Cibacalcin	1/20/87	Designated/Approved	Approved for Orphan Indication		10/31/86	10/31/93	Novartis Pharmaceutical Corporation	East Hanover	New Jersey	7936	USA	EXACT	0125202AA	Calcitonin human	I0IO929019						" Paget disease of bone, familial"	4191	done	not a rare disease
Calcium acetate	Treatment of hyperphosphatemia in end stage renal disease.	Calcium acetate	CALCIUM ACETATE	n/a	6/27/89	Designated			N/A	N/A	Pharmedic Company	Lake Forest	Illinois	60045	USA	EXACT	0010902AA	Calcium acetate	Y882YXF34X								MISSING	
Calcium acetate	Treatment of hyperphosphatemia in end stage renal failure.	Calcium acetate	CALCIUM ACETATE	Phos-Lo	12/22/88	Designated/Approved	Approved for Orphan Indication		12/10/90	12/10/97	Fresenius Medical Care North America	Waltham	Massachusetts	2451	USA	EXACT	0010902AA	Calcium acetate	Y882YXF34X								MISSING	
Calcium carbonate	Treatment of hyperphosphatemia in patients with end stage renal disease.	Calcium carbonate	CALCIUM CARBONATE	R & D Calcium Carbonate/600	6/6/90	Designated			N/A	N/A	"R & D Laboratories, Inc."	Marina Del Rey	California	90292	USA	EXACT	0125600AA	Calcium carbonate	H0G9379FGK								MISSING	
Calcium gluconate	For use as a wash for hydrofluoric acid spills on human skin.	Calcium gluconate	CALCIUM GLUCONATE	Calgonate	11/20/97	Designated			N/A	N/A	Calgonate Corp.	Highland Beach	Florida	33487	USA	EXACT	0023869AA	Calcium gluconate	SQE6VB453K								MISSING	not a disease
Calcium gluconate gel	For use in the emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Calcium gluconate gel	CALCIUM GLUCONATE	H-F Gel	5/21/91	Designated			N/A	N/A	Calgonate Corporation	Highland Beach	Florida	33487	USA	EXACT	0023869AA	Calcium gluconate	SQE6VB453K								MISSING	not a disease
Calcium gluconate gel 2.5%	Emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Calcium gluconate gel 2.5%	CALCIUM GLUCONATE	n/a	9/10/90	Designated			N/A	N/A	"Paddock Laboratories, Inc."	Minneapolis	Minnesota	55427	USA	EXACT	0023869AA	Calcium gluconate	SQE6VB453K								MISSING	Not a rare disease
Caplacizumab	Treatment of thrombotic thrombocytopenic purpura	Caplacizumab	CAPLACIZUMAB	n/a	4/14/09	Designated			N/A	N/A	Ablynx NV	Zwijnaarde			Belgium	EXACT	0698293AA	Caplacizumab	2R27AB6766						"Thrombotic thrombocytopenic purpura, acquired "	4607	approximate	
Caplacizumab	Treatment of thrombotic thrombocytopenic purpura	Caplacizumab	CAPLACIZUMAB	n/a	4/14/09	Designated			N/A	N/A	Ablynx NV	Zwijnaarde			Belgium	EXACT	0698293AA	Caplacizumab	2R27AB6766						 Congenital thrombotic thrombocytopenic purpura	9430	approximate	
Capsaicin	Treatment of intermetatarsal neuroma (Morton's Neuroma) that does not respond to conservative treatment and requires either neurectomy or neurolysis	Capsaicin	CAPSAICIN	n/a	9/29/06	Designated			N/A	N/A	Centrexion Corporation	Baltimore	Maryland	21202	USA	EXACT	0025490AA	Capsaicin	S07O44R1ZM								MISSING	
Capsaicin	Treatment of postherpetic neuralgia.	Capsaicin	CAPSAICIN	n/a	8/3/05	Designated			N/A	N/A	"TheraQuest Biosciences, LLC"	Blue Bell	Pennsylvania	19422	USA	EXACT	0025490AA	Capsaicin	S07O44R1ZM								MISSING	Not a rare disease; symptom
Carbovir	Treatment of persons with AIDS and in patients with symptomatic HIV infection and a CD4 count less than 200/mm3.	Carbovir	CARBOVIR	n/a	12/13/89	Designated/Withdrawn			N/A	N/A	Glaxo Wellcome Inc.	Research Triangle Park	North Carolina	27709	USA	EXACT	0791195AA	Carbovir	05469V2RW8						Congenital human immunodeficiency virus	10328	approximate	
Carmustine	Treatment of intracranial malignancies.	Carmustine	CARMUSTINE	n/a	7/3/00	Designated			N/A	N/A	"Direct Therapeutics, Inc."	Redwood	California	94063	USA	EXACT	0023596AA	Carmustine	U68WG3173Y								MISSING	
Cascara sagrada fluid extract	Treatment of oral drug overdosage to speed lower bowel evacuation.	Cascara sagrada fluid extract	CASCARA SAGRADA BARK	n/a	3/21/89	Designated			N/A	N/A	Intramed Corporation	Augusta	Georgia	30907	USA	EXACT	0146474AA	Cascara sagrada	4VBP01X99F								MISSING	
CaspaCIDe System (combination product) consisting of allogeneic T Cell genetically modified to contain an inducible caspase 9 gene and Rimiducid	Replacement T-cell therapy for the treatment of immunodeficiency and graft versus host disease after allogeneic hematopoietic stem cell transplant	CaspaCIDe System (combination product) consisting of allogeneic T Cell genetically modified to contain an inducible caspase 9 gene and Rimiducid	RIMIDUCID	n/a	2/18/16	Designated			N/A	N/A	"Bellicum Pharmaceuticals, Inc."	Houston	Texas	77030	USA	EXACT	0738921AA	Rimiducid	H564L1W5J2						Chronic graft versus host disease 	10964	approximate	secondary condition
CaspaCIDe System (combination product) consisting of allogeneic T Cell genetically modified to contain an inducible caspase 9 gene and Rimiducid	Replacement T-cell therapy for the treatment of immunodeficiency and graft versus host disease after allogeneic hematopoietic stem cell transplant	CaspaCIDe System (combination product) consisting of allogeneic T Cell genetically modified to contain an inducible caspase 9 gene and Rimiducid	RIMIDUCID	n/a	2/18/16	Designated			N/A	N/A	"Bellicum Pharmaceuticals, Inc."	Houston	Texas	77030	USA	EXACT	0738921AA	Rimiducid	H564L1W5J2						 Acute graft versus host disease	6544	approximate	secondary condition
Celecoxib oral liquid suspension	Treatment of pediatric juvenile idiopathic arthritis	Celecoxib oral liquid suspension	CELECOXIB	Nu-Celecoxib	1/5/17	Designated			N/A	N/A	"NuBioPharma, LLC"	Sanford	North Carolina	27330	USA	EXACT	0208935AA	Celecoxib	JCX84Q7J1L						Juvenile idiopathic arthritis	3067	done	
Cells produced using the AastromReplicelle System and SC-I Therapy Kit	For use in patients receiving high dose chemotherapy who are unable to generate an acceptable dose of peripheral blood stem cells and who have a sufficient bone marrow aspirate without morphological evidence of tumor	Cells produced using the AastromReplicelle System and SC-I Therapy Kit		n/a	7/10/02	Designated			N/A	N/A	Aastrom Biosciences Incorporated	Ann Arbor	Michigan	48106	USA								PROBLEM	can't find			MISSING	not a disease
Centovir	Treatment of cytomegalovirus infections in allogenic bone marrow transplant patients.	Human IgM monoclonal antibody (C-58) To CMV		Centovir	8/7/89	Designated/Withdrawn			N/A	N/A	"Centocor, Inc."	Malvern	Pennsylvania	19355	USA				0102XFH2B9	HUMAN CYTOMEGALOVIRUS IMMUNE GLOBULIN	0102XFH2B9	https://ginas.ncats.nih.gov/ginas/app/substance/84293bbb	done				MISSING	
Cetiedil citrate injection	Treatment of sickle cell disease crisis.	Cetiedil citrate injection	CETIEDIL CITRATE	n/a	12/22/88	Designated/Withdrawn			N/A	N/A	"Baker Cummins Pharmaceuticals, Inc."					EXACT	0321391AA	Cetiedil citrate	IE65P4OE02						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
Cetiedil citrate injection	Treatment of sickle cell disease crisis.	Cetiedil citrate injection	CETIEDIL CITRATE	n/a	12/22/88	Designated/Withdrawn			N/A	N/A	"Baker Cummins Pharmaceuticals, Inc."					EXACT	0321391AA	Cetiedil citrate	IE65P4OE02						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
Cetiedil citrate injection	Treatment of sickle cell disease crisis.	Cetiedil citrate injection	CETIEDIL CITRATE	n/a	12/22/88	Designated/Withdrawn			N/A	N/A	"Baker Cummins Pharmaceuticals, Inc."					EXACT	0321391AA	Cetiedil citrate	IE65P4OE02						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
Cetiedil citrate injection	Treatment of sickle cell disease crisis.	Cetiedil citrate injection	CETIEDIL CITRATE	n/a	12/22/88	Designated/Withdrawn			N/A	N/A	"Baker Cummins Pharmaceuticals, Inc."					EXACT	0321391AA	Cetiedil citrate	IE65P4OE02						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
Cetiedil citrate injection	Treatment of sickle cell disease crisis.	Cetiedil citrate injection	CETIEDIL CITRATE	n/a	12/22/88	Designated/Withdrawn			N/A	N/A	"Baker Cummins Pharmaceuticals, Inc."					EXACT	0321391AA	Cetiedil citrate	IE65P4OE02						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
Cetiedil citrate injection	Treatment of sickle cell disease crisis.	Cetiedil citrate injection	CETIEDIL CITRATE	n/a	12/22/88	Designated/Withdrawn			N/A	N/A	"Baker Cummins Pharmaceuticals, Inc."					EXACT	0321391AA	Cetiedil citrate	IE65P4OE02						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
"Chimeric monoclonal antibodies, c-alphaStx2"	For treatment of shiga-toxin producing bacterial infection	"Chimeric monoclonal antibodies, c-alphaStx2"		n/a	10/4/05	Designated			N/A	N/A	"Thallion Pharmaceuticals, Inc."				Canada								PROBLEM	can't find			MISSING	not a disease
Chlorhexidine gluconate mouthrinse	For use in the amelioration of oral mucositis associated with cytoreductive therapy used in conditioning patients for bone marrow transplantation therapy.	Chlorhexidine gluconate mouthrinse	CHLORHEXIDINE GLUCONATE	Peridex	8/18/86	Designated			N/A	N/A	Procter & Gamble Company	Cincinnati	Ohio	45241	USA	EXACT	0058775AA	Chlorhexidine gluconate	MOR84MUD8E								MISSING	not a disease
Choline chloride	Prevention and/or treatment of choline deficiency in patients on long-term parenteral nutrition	Choline chloride	CHOLINE CHLORIDE	Intrachol	7/20/06	Designated			N/A	N/A	"Alan L. Buchman, MD, MSPH"	Glencoe	Illinois	60022	USA	EXACT	0011610AA	Choline chloride	45I14D8O27								MISSING	
Choline chloride	"Treatment of choline deficiency, specifically the choline deficiency, hepatic steatosis, and cholestasis, associated with long-term parenteral nutrition."	Choline chloride	CHOLINE CHLORIDE	Intrachol	2/10/94	Designated			N/A	N/A	"Alan L. Buchman, MD, MSPH"	Glencoe	Illinois	60022	USA	EXACT	0011610AA	Choline chloride	45I14D8O27								MISSING	Not a rare disease
Chondrocyte-alginate gel suspension	For use in correcting vesicoureteral reflux in the pediatric population.	Chondrocyte-alginate gel suspension	ALGINIC ACID	n/a	12/1/97	Designated			N/A	N/A	"Curis, Inc."	Cambridge	Massachusetts	2138	USA	LONGEST CONTAINS	0052313AA	alginate	8C3Z4148WZ								MISSING	not a disease
Chondroitinase	Treatment of patients undergoing vitrectomy.	Chondroitinase	ELOSULFASE ALFA	n/a	2/9/95	Designated/Withdrawn			N/A	N/A	"Bausch & Lomb Pharmaceuticals, Inc."	Tampa	Florida	33637	USA	EXACT	0786301AA	Chondroitinase	ODJ69JZG85								MISSING	"not a disease, a procedure"
Chymotrypsinogen	Treatment of pancreatic cancer	Trypsinogen/Chymotrypsinogen		n/a	6/19/17	Designated			N/A	N/A	Propanc Pty Ltd.	Camberwell			Australia				JZ7EJ8JU4B	TRYPSIN-1 | Chymotrypsinogen/trypsinogen	JZ7EJ8JU4B	https://ginas.ncats.nih.gov/ginas/app/substance/f7cb59ca | https://adisinsight.springer.com/drugs/800049438	approximate	Trypsinogen  is the precursor form or zymogen of trypsin- no entry for Trypsinogen in GINAS	Pancreatic cancer	9364	done	Not a rare disease
"Ciliary neurotrophic factor, recombinant human"	"Treatment of motor neuron disease (including amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and primary lateral sclerosis)."	"Ciliary neurotrophic factor, recombinant human"	"HUMAN CILIARY NEUROTROPHIC FACTOR, RECOMBINANT (E. COLI)"	n/a	5/8/92	Designated/Withdrawn			N/A	N/A	Syntex-Synergen Neuroscience	Boulder	Colorado	80301	USA	EXACT	0113784AB	"Ciliary neurotrophic factor, recombinant human"	CR102F038W	CILIARY NEUROTROPHIC FACTOR	CR102F038W	https://ginas.ncats.nih.gov/ginas/app/substances?q=Ciliary%20neurotrophic%20factor	done		Amyotrophic lateral sclerosis 	5786	done	
"Ciliary neurotrophic factor, recombinant human"	"Treatment of motor neuron disease (including amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and primary lateral sclerosis)."	"Ciliary neurotrophic factor, recombinant human"	"HUMAN CILIARY NEUROTROPHIC FACTOR, RECOMBINANT (E. COLI)"	n/a	5/8/92	Designated/Withdrawn			N/A	N/A	Syntex-Synergen Neuroscience	Boulder	Colorado	80301	USA	EXACT	0113784AB	"Ciliary neurotrophic factor, recombinant human"	CR102F038W	CILIARY NEUROTROPHIC FACTOR	CR102F038W	https://ginas.ncats.nih.gov/ginas/app/substances?q=Ciliary%20neurotrophic%20factor	done		 Progressive bulbar palsy 	10928	done	
"Ciliary neurotrophic factor, recombinant human"	"Treatment of motor neuron disease (including amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and primary lateral sclerosis)."	"Ciliary neurotrophic factor, recombinant human"	"HUMAN CILIARY NEUROTROPHIC FACTOR, RECOMBINANT (E. COLI)"	n/a	5/8/92	Designated/Withdrawn			N/A	N/A	Syntex-Synergen Neuroscience	Boulder	Colorado	80301	USA	EXACT	0113784AB	"Ciliary neurotrophic factor, recombinant human"	CR102F038W	CILIARY NEUROTROPHIC FACTOR	CR102F038W	https://ginas.ncats.nih.gov/ginas/app/substances?q=Ciliary%20neurotrophic%20factor	done		 Primary lateral sclerosis	10684	done	
"Ciliary neurotrophic factor, recombinant human"	Treatment of spinal muscular atrophies.	"Ciliary neurotrophic factor, recombinant human"	"HUMAN CILIARY NEUROTROPHIC FACTOR, RECOMBINANT (E. COLI)"	n/a	4/2/92	Designated/Withdrawn			N/A	N/A	Syntex-Synergen Neuroscience	Boulder	Colorado	80301	USA	EXACT	0113784AB	"Ciliary neurotrophic factor, recombinant human"	CR102F038W	CILIARY NEUROTROPHIC FACTOR	CR102F038W	https://ginas.ncats.nih.gov/ginas/app/substances?q=Ciliary%20neurotrophic%20factor	done		Congenital benign spinal muscular atrophy dominant	1474	approximate	
Cisplatin	Treatment of mesothelioma	Cisplatin loaded hyaluronate film for implant	CISPLATIN	Hyalcis	5/2/17	Designated			N/A	N/A	PlumeStars s.r.l.				Italy	EXACT	0056633AA	Cisplatin	Q20Q21Q62J						Malignant mesothelioma	7026	done	
Cisplatin ChemoThin Wafer	"Treatment of anatomically accessible oral cancers (lip, tongue, gum, floor of mouth, salivary gland, and other oral cavity)"	Cisplatin ChemoThin Wafer	CISPLATIN	n/a	11/3/15	Designated			N/A	N/A	Privo Technologies	Cambridge	Massachusetts	2141	USA	EXACT	0056633AA	Cisplatin	Q20Q21Q62J						Oral cancer	9360	done	
Citric acid	Treatment of renal and bladder calculi of the apatite or struvite variety.	"Citric acid, glucono-delta-lactone and magnesium carbonate"	MAGNESIUM CARBONATE	Renacidin Irrigation	8/28/89	Designated/Approved	Approved for Orphan Indication		10/2/90	10/2/97	"United-Guardian, Inc."	Smithtown	New York	11787	USA	EXACT	0028397AA	magnesium carbonate	0E53J927NA								MISSING	
"Citric acid, glucono-delta-lactone and magnesium carbonate"	Treatment of renal and bladder calculi of the apatite or struvite variety.	"Citric acid, glucono-delta-lactone and magnesium carbonate"	MAGNESIUM CARBONATE	Renacidin Irrigation	8/28/89	Designated/Approved	Approved for Orphan Indication		10/2/90	10/2/97	"United-Guardian, Inc."	Smithtown	New York	11787	USA	EXACT	0028397AA	magnesium carbonate	0E53J927NA								MISSING	
Civacir	Prophylaxis of hepatitis C infection in liver transplant recipients.	Hepatitis C virus immune globulin (human)	HEPATITIS C IMMUNE GLOBULIN (HUMAN)	Civacir(Tm)	11/14/02	Designated			N/A	N/A	Biotest Pharmaceuticals Corporation	Boca Raton	Florida	33487	USA	EXACT	1198238AA	Civacir	U5V5MUD1KD								MISSING	Not a rare disease
Cladribine	Treatment of non-Hodgkin's lymphoma.	Cladribine	CLADRIBINE	Leustatin Injection	4/19/93	Designated/Withdrawn			N/A	N/A	"Janssen Research & Development, LLC"	Raritan	New Jersey	8869	USA	EXACT	0092944AA	Cladribine	47M74X9YT5						B-cell lymphoma	5877	approximate	
Cladribine	Treatment of the chronic progressive form of multiple sclerosis.	Cladribine	CLADRIBINE	Mylinax	4/19/94	Designated			N/A	N/A	"Johnson & Johnson Pharmaceutical R & D, LLC"	Raritan	New Jersey	8869	USA	EXACT	0092944AA	Cladribine	47M74X9YT5						Multiple sclerosis	10255	done	not a rare disease
Claudiximab	Treatment of gastric cancer	chimeric monoclonal antibody to claudin 18 splice variant 2	ZOLBETUXIMAB	n/a	11/20/12	Designated			N/A	N/A	GANYMED Pharmaceuticals AG				Germany	EXACT	0741899AA	Claudiximab	TF5MPQ8WGY						Stomach cancer	7704	done	
Clazosentan	Treatment of cerebral vasospasm following subarachnoid hemorrhage	Clazosentan	CLAZOSENTAN	Erajet	2/16/06	Designated			N/A	N/A	Actelion Pharmaceuticals Ltd.				Switzerland	EXACT	0318309AA	Clazosentan	3DRR0X4728								MISSING	Not a rare disease
Clenbuterol	Treatment of Pompe disease (glycogen storage disease type II)	Clenbuterol	CLENBUTEROL	n/a	1/9/17	Designated			N/A	N/A	"Dwight D. Koeberl, MD, PhD"	Durham	North Carolina	27710	USA	EXACT	0074497AA	Clenbuterol	XTZ6AXU7KN						Glycogen storage disease type 2	5714	done	
Clindamycin	Prevention of Pneumocystis carinii pneumonia in AIDS patients.	Clindamycin	CLINDAMYCIN	Cleocin	10/28/88	Designated			N/A	N/A	Pfizer Inc.	New York	New York	10017	USA	EXACT	0058764AA	Clindamycin	3U02EL437C						Pneumocystic carinii pneumonia	7409	done	
Clindamycin	Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.	Clindamycin	CLINDAMYCIN	Cleocin	10/28/88	Designated			N/A	N/A	Pharmacia & Upjohn	Kalamazoo	Michigan	49001	USA	EXACT	0058764AA	Clindamycin	3U02EL437C						Pneumocystic carinii pneumonia	7409	done	
Clindamycin hydrochloride	Treatment of sarcoidosis	Clindamycin hydrochloride	CLINDAMYCIN HYDROCHLORIDE	n/a	8/9/06	Designated			N/A	N/A	Autoimmunity Research Foundation	Thousand Oaks	California	91360	USA	EXACT	0059529AA	Clindamycin hydrochloride	T20OQ1YN1W						Sarcoidosis	7607	done	
Clofazimine	"Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum."	Clofazimine	CLOFAZIMINE	Lamprene	6/11/84	Designated/Approved	Approved for Orphan Indication		12/15/86	12/15/93	Novartis Pharmaceutical Corporation	East Hanover	New Jersey	7936	USA	EXACT	0038186AA	Clofazimine	D959AE5USF						Hansen's disease	6886	done	
Clonazepam	Treatment of hyperekplexia (startle disease).	Clonazepam	CLONAZEPAM	Klonopin	8/4/94	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	Nutley	New Jersey	7110	USA	EXACT	0037229AA	Clonazepam	5PE9FDE8GB						Hereditary hyperekplexia	3129	done	
Clonazepam Intranasal Spray	Treatment of recurrent acute repetitive seizures	Clonazepam Intranasal Spray	CLONAZEPAM	n/a	12/19/07	Designated			N/A	N/A	"Jazz Pharmaceuticals, Inc."	Palo Alto	California	94304	USA	EXACT	0037229AA	Clonazepam	5PE9FDE8GB								MISSING	
Clonidine	"For continous epidural administration as adjunctive therapy with intraspinal opiates for the treatment of pain in cancer patients tolerant to, or unresponsive to, intraspinal opiates."	Clonidine	CLONIDINE	Duraclon	1/24/89	Designated/Approved	Approved for Orphan Indication	In combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone.	10/2/96	10/2/03	"Roxane Laboratories, Inc."	Columbus	Ohio	43216	USA	EXACT	0100630AA	Clonidine	MN3L5RMN02								MISSING	Not a rare disease
Clotrimazole	Topical treatment of children and adults with pouchitis	Clotrimazole	CLOTRIMAZOLE	n/a	6/14/05	Designated			N/A	N/A	"AesRx, LLC"	Newton	Massachusetts	2466	USA	EXACT	0062373AA	Clotrimazole	G07GZ97H65								MISSING	Not a rare disease
Clotrimazole	Treatment of sickle cell disease.	Clotrimazole	CLOTRIMAZOLE	n/a	4/24/95	Designated			N/A	N/A	"Brugnara, Carlo M.D."	Boston	Massachusetts	2115	USA	EXACT	0062373AA	Clotrimazole	G07GZ97H65						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
Clotrimazole	Treatment of sickle cell disease.	Clotrimazole	CLOTRIMAZOLE	n/a	4/24/95	Designated			N/A	N/A	"Brugnara, Carlo M.D."	Boston	Massachusetts	2115	USA	EXACT	0062373AA	Clotrimazole	G07GZ97H65						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
Clotrimazole	Treatment of sickle cell disease.	Clotrimazole	CLOTRIMAZOLE	n/a	4/24/95	Designated			N/A	N/A	"Brugnara, Carlo M.D."	Boston	Massachusetts	2115	USA	EXACT	0062373AA	Clotrimazole	G07GZ97H65						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
Clotrimazole	Treatment of sickle cell disease.	Clotrimazole	CLOTRIMAZOLE	n/a	4/24/95	Designated			N/A	N/A	"Brugnara, Carlo M.D."	Boston	Massachusetts	2115	USA	EXACT	0062373AA	Clotrimazole	G07GZ97H65						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
Clotrimazole	Treatment of sickle cell disease.	Clotrimazole	CLOTRIMAZOLE	n/a	4/24/95	Designated			N/A	N/A	"Brugnara, Carlo M.D."	Boston	Massachusetts	2115	USA	EXACT	0062373AA	Clotrimazole	G07GZ97H65						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
Clotrimazole	Treatment of sickle cell disease.	Clotrimazole	CLOTRIMAZOLE	n/a	4/24/95	Designated			N/A	N/A	"Brugnara, Carlo M.D."	Boston	Massachusetts	2115	USA	EXACT	0062373AA	Clotrimazole	G07GZ97H65						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
Coagulation Factor IX (human)	"For use as replacement therapy in patients with hemophilia B for the prevention and control of bleeding episodes, and during surgery to correct defective hemostasis."	Coagulation Factor IX (human)	COAGULATION FACTOR IX (HUMAN)	Alphanine	7/5/90	Designated/Approved	Approved for Orphan Indication		12/31/90	12/31/97	Alpha Therapeutic Corporation	Los Angeles	California	90032	USA	EXACT	0174834AA	Coagulation Factor IX (human)	6U90Y1795T						Hemophilia B	8732	done	
Coagulation Factor VIIa (Recombinant)	Treatment of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Coagulation Factor VIIa (Recombinant)	COAGULATION FACTOR VIIA (RECOMBINANT)	Novoseven	7/16/04	Designated/Approved	Approved for Orphan Indication	Treatment of bleeding episodes in surgical interventions or invasive procedures in patients with acquired hemophilia	10/13/06	10/13/13	"Novo Nordisk, Inc."	Princeton	New Jersey	8540	USA	EXACT	0324765AA	Coagulation Factor VIIa (Recombinant)	AC71R787OV						Hemophilia A 	6591	approximate	
Coagulation Factor VIIa (Recombinant)	Treatment of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Coagulation Factor VIIa (Recombinant)	COAGULATION FACTOR VIIA (RECOMBINANT)	Novoseven	7/16/04	Designated/Approved	Approved for Orphan Indication	Treatment of bleeding episodes in surgical interventions or invasive procedures in patients with acquired hemophilia	10/13/06	10/13/13	"Novo Nordisk, Inc."	Princeton	New Jersey	8540	USA	EXACT	0324765AA	Coagulation Factor VIIa (Recombinant)	AC71R787OV						 Hemophilia B	8732	approximate	
Coagulation Factor VIIa (Recombinant)	Treatment of bleeding in patients experiencing intracranial hemorrhage.	Coagulation Factor VIIa (Recombinant)	COAGULATION FACTOR VIIA (RECOMBINANT)	Novoseven	10/3/06	Designated/Withdrawn			N/A	N/A	"Novo Nordisk, Inc."	Plainsboro	New Jersey	8536	USA	EXACT	0324765AA	Coagulation Factor VIIa (Recombinant)	AC71R787OV								MISSING	Not a rare disease
Coagulation factor VIIa (recombinant)	Prevention of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Coagulation factor VIIa (recombinant)	COAGULATION FACTOR VIIA (RECOMBINANT)	Novoseven	7/21/04	Designated/Approved	Approved for Orphan Indication	Prevention of bleeding in surgical interventions or invasive procedures in patients with acquired hemophilia	10/13/06	10/13/13	"Novo Nordisk, Inc."	Princeton	New Jersey	8540	USA	EXACT	0324765AA	Coagulation factor VIIa (recombinant)	AC71R787OV						Acquired hemophilia A	6405	approximate	aquired hemophilia B
Coagulation factor VIIa (recombinant)	Prevention of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Coagulation factor VIIa (recombinant)	COAGULATION FACTOR VIIA (RECOMBINANT)	Novoseven	7/21/04	Designated/Approved	Approved for Orphan Indication	Prevention of bleeding in surgical interventions or invasive procedures in patients with acquired hemophilia	10/13/06	10/13/13	"Novo Nordisk, Inc."	Princeton	New Jersey	8540	USA	EXACT	0324765AA	Coagulation factor VIIa (recombinant)	AC71R787OV						Hemophilia B	8732	approximate	aquired hemophilia B
Coagulation factor VIIa (recombinant)	"Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors"	Coagulation factor VIIa (recombinant)	COAGULATION FACTOR VIIA (RECOMBINANT)	Novoseven	6/18/04	Designated/Approved	Approved for Orphan Indication	Prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX	8/12/05	8/12/12	"Novo Nordisk, Inc."	Princeton	New Jersey	8540	USA	EXACT	0324765AA	Coagulation factor VIIa (recombinant)	AC71R787OV						Hemophilia A	6591	done	
Coagulation factor VIIa (recombinant)	"Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors"	Coagulation factor VIIa (recombinant)	COAGULATION FACTOR VIIA (RECOMBINANT)	Novoseven	6/18/04	Designated/Approved	Approved for Orphan Indication	Prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX	8/12/05	8/12/12	"Novo Nordisk, Inc."	Princeton	New Jersey	8540	USA	EXACT	0324765AA	Coagulation factor VIIa (recombinant)	AC71R787OV						Hemophilia B	8732	done	
Colchicine	For arresting the progression of neurologic disability caused by chronic progressive multiple sclerosis.	Colchicine	COLCHICINE	n/a	12/9/85	Designated/Withdrawn			N/A	N/A	Pharmacontrol Corporation	Englewood Cliffs	New Jersey	7632	USA	EXACT	0011314AA	Colchicine	SML2Y3J35T						Multiple sclerosis	10255	done	
Colchicine	Treatment of Behcet's Syndrome	Colchicine	COLCHICINE	n/a	9/25/07	Designated			N/A	N/A	"AR Scientific, Inc."	Philadelphia	Pennsylvania	19124	USA	EXACT	0011314AA	Colchicine	SML2Y3J35T						Behçet disease	848	done	
"Colfosceril palmitate, cetyl alcohol, tyloxapol"	"1. Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less 2. prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32 weeks gestation or less and in the treatment of established HMO at all gestational ages."	"Colfosceril palmitate, cetyl alcohol, tyloxapol"	COLFOSCERIL PALMITATE	Exosurf Neonatal For Intratracheal Suspension	10/20/89	Designated/Approved	Approved for Orphan Indication	"Prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32 weeks gestation or less and in the treatment of established HMO at all gestational ages"	8/2/90	8/2/97	Glaxo Wellcome Inc.	Research Triangle Park	North Carolina	27709	USA	EXACT	0120003AA	Colfosceril palmitate	319X2NFW0A						"Respiratory distress syndrome, infant"	112	done	
"Colfosceril palmitate, cetyl alcohol, tyloxapol"	Treatment of adult respiratory distress syndrome.	"Colfosceril palmitate, cetyl alcohol, tyloxapol"	COLFOSCERIL PALMITATE	Exosurf	1/11/93	Designated/Withdrawn			N/A	N/A	GlaxoSmithKline	Research Triangle Park	North Carolina	27709	USA	EXACT	0120003AA	Colfosceril palmitate	319X2NFW0A						Acute respiratory distress syndrome	5698	done	
"Combination of an inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium)"	Treatment of hepatocellular carcinoma	"Combination of an inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium)"	RABIES VIRUS	n/a	10/13/16	Designated			N/A	N/A	"Yisheng US Biopharma, Inc."	Gaithersburg	Maryland	20878	USA	LONGEST CONTAINS	0317044AA	rabies virus	I0V66KI1LD						Childhood hepatocellular carcinoma	9331	approximate	
Combretastatin A-4 Phosphate	"Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer"	Combretastatin A4 Phosphate	FOSBRETABULIN	n/a	7/23/03	Designated			N/A	N/A	"Mateon Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	0322623AA	Combretastatin A-4 Phosphate	I5590ES2QZ						Anaplastic thyroid cancer	664	done	
Contulakin-G	Intrathecal treatment of neuropathic pain associated with spinal cord injury	Contulakin-G	CONTULAKIN-G	n/a	7/7/05	Designated			N/A	N/A	"Cognetix, Inc."	Salt Lake City	Utah	84108	USA	EXACT	0739048AA	Contulakin-G	G040R0738T								MISSING	not a disease
Cordycepin	Treatment of TdT-positive acute lymphocytic leukemia	Cordycepin	CORDYCEPIN	n/a	7/5/07	Designated			N/A	N/A	"OncoVista, Inc."	San Antonio	Texas	78245	USA	EXACT	0137315AA	Cordycepin	GZ8VF4M2J8						Acute lymphoblastic leukemia	522	done	
Corticorelin	Treatment of peritumoral brain edema.	"Corticotropin-releasing factor, human"	CORTICORELIN	Xerecept	4/6/98	Designated			N/A	N/A	"Neurobiological Technologies, Inc."	Richmond	California	94804	USA	EXACT	0121675AA	Corticorelin	305OE8862Y								MISSING	symptom
Corticorelin ovine triflutate	For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushings syndrome.	Corticorelin ovine triflutate	CORTICORELIN OVINE TRIFLUTATE	Acthrel	11/24/89	Designated/Approved	Approved for Orphan Indication	To differentiate between pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome.	5/23/96	5/23/03	"Ferring Laboratories, Inc."	Suffern	New York	10901	USA	EXACT	0214631AA	Corticorelin ovine triflutate	56X54T817Q						Cushing's syndrome	6224	approximate	
Coxsackievirus A21	"Treatment of stage II (T4), stage III, and stage IV melanoma"	Coxsackievirus A21	COXSACKIEVIRUS A21	Cavatak	12/15/05	Designated			N/A	N/A	Viralytics Limited				Australia	EXACT	1266893AA	Coxsackievirus A21	4B57CWT710						"Melanoma, familial"	3460	approximate	
Crizanlizumab	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	humanized IgG2 antibody	CRIZANLIZUMAB	n/a	7/22/08	Designated			N/A	N/A	Selexys Pharmaceuticals Corp.	Oklahoma	Oklahoma	73104	USA	EXACT	1310334AA	Crizanlizumab	L7451S9126						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
Crizanlizumab	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	humanized IgG2 antibody	CRIZANLIZUMAB	n/a	7/22/08	Designated			N/A	N/A	Selexys Pharmaceuticals Corp.	Oklahoma	Oklahoma	73104	USA	EXACT	1310334AA	Crizanlizumab	L7451S9126						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
Crizanlizumab	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	humanized IgG2 antibody	CRIZANLIZUMAB	n/a	7/22/08	Designated			N/A	N/A	Selexys Pharmaceuticals Corp.	Oklahoma	Oklahoma	73104	USA	EXACT	1310334AA	Crizanlizumab	L7451S9126						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
Crizanlizumab	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	humanized IgG2 antibody	CRIZANLIZUMAB	n/a	7/22/08	Designated			N/A	N/A	Selexys Pharmaceuticals Corp.	Oklahoma	Oklahoma	73104	USA	EXACT	1310334AA	Crizanlizumab	L7451S9126						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
Crizanlizumab	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	humanized IgG2 antibody	CRIZANLIZUMAB	n/a	7/22/08	Designated			N/A	N/A	Selexys Pharmaceuticals Corp.	Oklahoma	Oklahoma	73104	USA	EXACT	1310334AA	Crizanlizumab	L7451S9126						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
Crizanlizumab	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	humanized IgG2 antibody	CRIZANLIZUMAB	n/a	7/22/08	Designated			N/A	N/A	Selexys Pharmaceuticals Corp.	Oklahoma	Oklahoma	73104	USA	EXACT	1310334AA	Crizanlizumab	L7451S9126						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
Cryptosporidium hyperimmune bovine colostrum IgG concentrate	Treatment of diarrhea in AIDS patients caused by infection with Cryptosporidium parvum.	Cryptosporidium hyperimmune bovine colostrum IgG concentrate	BOS TAURUS COLOSTRUM	n/a	12/30/91	Designated			N/A	N/A	ImmuCell Corporation	Portland	Maine	4103	USA	LONGEST CONTAINS	0630193AA	bovine colostrum	S256WJ3OFQ						Cryptosporidiosis	6219	done	
"Cyclo (((E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl)-L-2-aminobytyrl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl)"	"Treatment and chronic control of non-infectious posterior, intermediate and pan-uveitis"	"Cyclo {{(E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl}-L-2-aminobytyrl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl}"	VOCLOSPORIN	n/a	12/20/06	Designated			N/A	N/A	"Lux Biosciences, Inc."	Jersey City	New Jersey	7302	USA	EXACT	0242115AA	"Cyclo (((E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl)-L-2-aminobytyrl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl)"	2PN063X6B1						Posterior uveitis 	4457	done	
"Cyclo (((E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl)-L-2-aminobytyrl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl)"	"Treatment and chronic control of non-infectious posterior, intermediate and pan-uveitis"	"Cyclo {{(E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl}-L-2-aminobytyrl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl}"	VOCLOSPORIN	n/a	12/20/06	Designated			N/A	N/A	"Lux Biosciences, Inc."	Jersey City	New Jersey	7302	USA	EXACT	0242115AA	"Cyclo (((E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl)-L-2-aminobytyrl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl)"	2PN063X6B1						 Pars planitis 	7339	done	
"Cyclo (((E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl)-L-2-aminobytyrl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl)"	"Treatment and chronic control of non-infectious posterior, intermediate and pan-uveitis"	"Cyclo {{(E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl}-L-2-aminobytyrl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl}"	VOCLOSPORIN	n/a	12/20/06	Designated			N/A	N/A	"Lux Biosciences, Inc."	Jersey City	New Jersey	7302	USA	EXACT	0242115AA	"Cyclo (((E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl)-L-2-aminobytyrl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl)"	2PN063X6B1						 Panuveitis	8577	done	
Cyclosporine	Prophylaxis of organ rejection in patients receiving allogeneic lung transplant	Cyclosporine	CYCLOSPORINE	n/a	11/25/03	Designated			N/A	N/A	"APT Pharmaceuticals, Inc."	Burlingame	California	94010	USA	EXACT	0066808AA	Cyclosporine	83HN0GTJ6D								MISSING	
Cyclosporine	Treatment of acute rejection in patients requiring allogenic lung transplants	Cyclosporine	CYCLOSPORINE	Pluminiq	11/25/03	Designated			N/A	N/A	"APT Pharmaceuticals, Inc."	Burlingame	California	94010	USA	EXACT	0066808AA	Cyclosporine	83HN0GTJ6D						Acute graft versus host disease	6544	approximate	
Cyclosporine 2% ophthalmic ointment	Treatment of patients at high risk of graft rejection following penetrating keratoplasty	Cyclosporine 2% ophthalmic ointment	CYCLOSPORINE	n/a	8/1/91	Designated			N/A	N/A	"Allergan, Inc."	Irvine	California	92612	USA	EXACT	0066808AA	Cyclosporine	83HN0GTJ6D						Acute graft versus host disease	6544	approximate	
Cyclosporine A implant	For the prevention of acute rejection in cornea transplant patients	Cyclosporine A implant	CYCLOSPORINE	n/a	1/8/07	Designated/Withdrawn			N/A	N/A	"Lux Biosciences, Inc."	Jersey City	New Jersey	7302	USA	EXACT	0066808AA	Cyclosporine A	83HN0GTJ6D						Acute graft versus host disease	6544	approximate	
Cyclosporine in combination with omega-3 polyunsaturated fatty acids	Prevention of solid organ graft rejection.	Cyclosporine in combination with omega-3 polyunsaturated fatty acids	CYCLOSPORINE	n/a	12/6/00	Designated			N/A	N/A	RTP Pharma Corporation	Durham	North Carolina	27713	USA	EXACT	0066808AA	Cyclosporine	83HN0GTJ6D								MISSING	
Cyclosporine ophthalmic	Treatment of severe keratoconjunctivitis sicca associated with Sjogren's syndrome.	Cyclosporine ophthalmic	CYCLOSPORINE	Optimmune	11/9/88	Designated			N/A	N/A	University Of Georgia	Athens	Georgia	30602	USA	EXACT	0066808AA	Cyclosporine	83HN0GTJ6D						Keratoconjunctivitis sicca	8444	done	
Cyproterone acetate	Treatment of severe hirsutism.	Cyproterone acetate	CYPROTERONE ACETATE	Androcur	10/26/84	Designated/Withdrawn			N/A	N/A	"Berlex Laboratories, Inc."	Wayne	New Jersey	7470	USA	EXACT	0025569AA	Cyproterone acetate	4KM2BN5JHF								MISSING	symptom of several conditions
Cytarabine liposomal	Treatment of neoplastic meningitis.	Cytarabine liposomal	CYTARABINE	Depocyt	6/2/93	Designated/Approved	Approved for Orphan Indication	Intrathecal treatment of lymphomatous meningitis.	4/1/99	4/1/06	"Pacira Pharmaceuticals, Inc."	San Diego	California	92121	USA	EXACT	0023052AA	Cytarabine	04079A1RDZ								MISSING	secondary to cancer
Cytomegalovirus DNA Vaccine w/Copolymer/Benzalkonium Chloride	"For use in prevention of clinically significant CMV viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant and solid organ transplant populations"	Cytomegalovirus DNA Vaccine w/Copolymer/Benzalkonium Chloride	HUMAN HERPESVIRUS 5	n/a	9/23/06	Designated			N/A	N/A	Vical Inc.	San Diego	California	92121	USA	LONGEST CONTAINS	0354529AA	Cytomegalovirus	7COI029E6K								MISSING	not a disease
Cytomegalovirus DNA vaccine with plasmids expressing pp65 and gB genes	"Prevention of clinically significant cytomegalovirus (CMV) viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant and solid transplant populations"	Cytomegalovirus DNA vaccine with plasmids expressing pp65 and gB genes	HUMAN HERPESVIRUS 5	n/a	6/3/05	Designated			N/A	N/A	"Astellas Pharma Global Development, Inc."	Northbrook	Illinois	60062	USA	LONGEST CONTAINS	0354529AA	Cytomegalovirus	7COI029E6K								MISSING	
Cytomegalovirus immune globulin (human)	Prevention or attenuation of primary cytomegalovirus disease in immunosuppressed recipients of organ transplants.	Cytomegalovirus immune globulin (human)	HUMAN CYTOMEGALOVIRUS IMMUNE GLOBULIN	Cytogam	8/3/87	Designated/Approved	Approved for Orphan Indication	"#1) Attenuation of primary CMV disease associated with kidney transplant recipients who are seronegative for CMV and who receive a kidney from a CMV seropositve donor; #2) Prophylaxis of CMV disease associated transplantation of kidney (all other), lung, liver, pancreas and heart."	12/4/98	12/4/05	CSL Behring LLC	King of Prussia	Pennsylvania	19406	USA	EXACT	0157619AA	Cytomegalovirus immune globulin (human)	129L90A25N								MISSING	primary condition complication; not a rare disease
Cytomegalovirus immune globulin intravenous (human)	For use in conjunction with ganciclovir sodium for the treatment of cytomegalovirus pneumonia in bone marrow transplant patients.	Cytomegalovirus immune globulin intravenous (human)	HUMAN CYTOMEGALOVIRUS IMMUNE GLOBULIN	n/a	1/28/91	Designated			N/A	N/A	Bayer Corporation	New Haven	Connecticut	6516	USA	EXACT	0157619AA	Cytomegalovirus immune globulin intravenous (human)	129L90A25N								MISSING	
D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-Nh2 (disulfide bridge: 2-6) acetate	"Treatment of melanoma, stages IIb through IV"	D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-Nh2 (disulfide bridge: 2-6) acetate	D-PHE-CYS-TYR-D-TRP-LYS-CYS-THR-NH2 (DISULFIDE BRIDGE: 2-6) ACETATE	n/a	3/19/09	Designated/Withdrawn			N/A	N/A	"Thallion Pharmaceuticals, Inc."				Canada	EXACT	1798329AA	D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-Nh2 (disulfide bridge: 2-6) acetate	QRJ8C05E9C						"Melanoma, familial"	3460	approximate	melanoma type not specified
D-sorbitol	Treatment of Charcot-Marie-Tooth disease type 1A	"(RS)-baclofen, naltrexone and D-sorbitol"	SORBITOL	n/a	3/17/14	Designated			N/A	N/A	Pharnext SA				France	EXACT	0007614AA	D-sorbitol	506T60A25R						Charcot-Marie-Tooth disease	6034	done	
DDP-225 FREE BASE ANHYDROUS	Treatment of Chronic Functional Vomiting to include functional vomiting and cyclic vomiting syndrome.	4-(2-fluorophenyl)-6-methyl-2-(1-piperzinyl)	DDP-225 FREE BASE ANHYDROUS	n/a	10/11/06	Designated			N/A	N/A	"Dynogen Pharmaceuticals, Inc."	Waltham	Massachusetts	2451	USA	EXACT	0711217AA	DDP-225 FREE BASE ANHYDROUS	CU79LWT2HF						Cyclic vomiting syndrome	6230	done	Not a rare disease
DEAE-rebeccamycin	Treatment of bile duct tumors	DEAE-rebeccamycin	BECATECARIN	n/a	3/1/04	Designated			N/A	N/A	Helsinn Healthcare SA				Switzerland	EXACT	0190090AA	DEAE-rebeccamycin	A60X6MBU6G						Bile duct cancer	9304	done	
DEFACTINIB HYDROCHLORIDE	Treatment of mesothelioma	N-methyl-4-({4-[({3-methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride	DEFACTINIB HYDROCHLORIDE	n/a	7/18/13	Designated			N/A	N/A	"Verastem, Inc."	Needham	Massachusetts	2494	USA	EXACT	0705362AA	DEFACTINIB HYDROCHLORIDE	L2S469LM49						Malignant mesothelioma	7026	done	
DELPAZOLID	Treatment of tuberculosis	"(R)-3-[3-Fluoro-4-(1+A4263:A4292-methyl-1,4,5,6-tetrahydro-1,2,4-triazin-4-yl)phenyl]-5(R)-(hydroxymethyl)oxazolidin-2-one"	DELPAZOLID	n/a	7/19/17	Designated			N/A	N/A	"LegoChem Biosciences, Inc."	Daejeon			"Korea, Republic of"	EXACT	1123779AA	DELPAZOLID	43EP6XV33E						Tuberculosis	7827	done	
DENUFOSOL TETRASODIUM	For the treatment of cystic fibrosis	"p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium salt"	DENUFOSOL TETRASODIUM	n/a	3/7/01	Designated/Withdrawn			N/A	N/A	"Inspire Pharmaceuticals, Inc."	Durham	North Carolina	27703	USA	EXACT	0238846AA	DENUFOSOL TETRASODIUM	82M942WZ4A						Cystic fibrosis	6233	done	Not a rare disease
DEOXYCYTIDINE 5'-MONOPHOSPHATE	Treatment of thymidine kinase 2 deficiency.	deoxythymidine monophosphate and deoxycytidine monophosphate	DEOXYCYTIDINE 5'-MONOPHOSPHATE	n/a	7/7/16	Designated			N/A	N/A	Columbia University Medical Center	New York	New York	10032	USA	EXACT	0894746AA	DEOXYCYTIDINE 5'-MONOPHOSPHATE	W7A9174XQL								MISSING	
DHA-paclitaxel	Treatment of pancreatic cancer	DHA-paclitaxel	PACLITAXEL DOCOSAHEXAENOIC ACID	Taxoprexin	9/25/01	Designated/Withdrawn			N/A	N/A	"Luitpold Pharmaceuticals, Inc."	Shirley	New York	11976	USA	EXACT	0232440AA	DHA-paclitaxel	OJE5810C4F						Pancreatic cancer	9364	done	Not a rare disease
DIANHYDROGALACTITOL	Treatment of malignant gliomas	"1,2:5,6-Dianhdrogalactitol, NSC-132313"	DIANHYDROGALACTITOL	n/a	1/31/12	Designated			N/A	N/A	"DelMar Pharmaceuticals, Inc."	Menlo Park	California	94025	USA	EXACT	0061712AA	DIANHYDROGALACTITOL	4S465RYF7M						Gliomatosis cerebri 	6514	approximate	
DIANHYDROGALACTITOL	Treatment of malignant gliomas	"1,2:5,6-Dianhdrogalactitol, NSC-132313"	DIANHYDROGALACTITOL	n/a	1/31/12	Designated			N/A	N/A	"DelMar Pharmaceuticals, Inc."	Menlo Park	California	94025	USA	EXACT	0061712AA	DIANHYDROGALACTITOL	4S465RYF7M						 Childhood brain stem glioma 	9306	approximate	
DIANHYDROGALACTITOL	Treatment of malignant gliomas	"1,2:5,6-Dianhdrogalactitol, NSC-132313"	DIANHYDROGALACTITOL	n/a	1/31/12	Designated			N/A	N/A	"DelMar Pharmaceuticals, Inc."	Menlo Park	California	94025	USA	EXACT	0061712AA	DIANHYDROGALACTITOL	4S465RYF7M						 Glioma	6513	approximate	
DIAZEPINOMICIN	Treatment of malignant glioma.	"4,6,8-trihydroxy-10-(3,7,11-trimethyldodeca-2,6,10-trienyl)-5,10-dihydrodibenzo b,e][1,4]diazepin-11-one"	DIAZEPINOMICIN	n/a	4/27/09	Designated/Withdrawn			N/A	N/A	"Thallion Pharmaceuticals, Inc."				Canada	EXACT	0736889AA	DIAZEPINOMICIN	YPH994Y0RF						Gliomatosis cerebri 	6514	approximate	
DIAZEPINOMICIN	Treatment of malignant glioma.	"4,6,8-trihydroxy-10-(3,7,11-trimethyldodeca-2,6,10-trienyl)-5,10-dihydrodibenzo b,e][1,4]diazepin-11-one"	DIAZEPINOMICIN	n/a	4/27/09	Designated/Withdrawn			N/A	N/A	"Thallion Pharmaceuticals, Inc."				Canada	EXACT	0736889AA	DIAZEPINOMICIN	YPH994Y0RF						 Childhood brain stem glioma 	9306	approximate	
DIAZEPINOMICIN	Treatment of malignant glioma.	"4,6,8-trihydroxy-10-(3,7,11-trimethyldodeca-2,6,10-trienyl)-5,10-dihydrodibenzo b,e][1,4]diazepin-11-one"	DIAZEPINOMICIN	n/a	4/27/09	Designated/Withdrawn			N/A	N/A	"Thallion Pharmaceuticals, Inc."				Canada	EXACT	0736889AA	DIAZEPINOMICIN	YPH994Y0RF						 Glioma	6513	approximate	
DIPALMITOYL N-ACETYL-B-D-GLUCOSAMINYL-(1-4)-N-ACETYLMURAMYL-ALANYL-D-ISOGLUTAMINYL-ALANYL-GLYCEROL	Treatment of Ewing's sarcoma.	Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala -gylcerolidpalmitoyl	DISACCHARIDE TRIPEPTIDE GLYCEROL DIPALMITOYL	Immther	6/10/98	Designated			N/A	N/A	Endorex Corp.	Lake Bluff	Illinois	60044	USA	EXACT	0237070AA	DIPALMITOYL N-ACETYL-B-D-GLUCOSAMINYL-(1-4)-N-ACETYLMURAMYL-ALANYL-D-ISOGLUTAMINYL-ALANYL-GLYCEROL	6PHSP9EORV						Ewing's family of tumors	9323	approximate	
DIQUAFOSOL TETRASODIUM	Treatment of cystic fibrosis.	"P1, P4-Di(uridine 5'-tetraphosphate), tetrasodium salt"	DIQUAFOSOL TETRASODIUM	n/a	10/27/98	Designated/Withdrawn			N/A	N/A	"Inspire Pharmaceuticals, Inc."	Durham	North Carolina	27703	USA	EXACT	0296708AA	DIQUAFOSOL TETRASODIUM	X8T9SBH9LL						Cystic fibrosis	6233	done	
DISITERTIDE	Treatment of systemic sclerosis	Peptide 144 TGF beta-1 inhibitor	DISITERTIDE	n/a	4/27/06	Designated			N/A	N/A	"Digna Biotech, S.L."	Madrid			Spain	EXACT	0679798AA	DISITERTIDE	3N988KP8HD						Systemic scleroderma	9748	done	
DNA Plasmid Vector encoding IL-12 (pUMVC3-hIL-12-NGVL331)	"Treatment of Stage IIB, IIc, III, and IV melanoma (which includes use in combination with pembrolizumab)"	DNA Plasmid Vector encoding IL-12 (pUMVC3-hIL-12-NGVL331)		n/a	6/6/17	Designated			N/A	N/A	OncoSec Medical Incorporated	San Diego	California	92121	USA				7B590791ER	INTERLEUKIN-12 HUMAN	7B590791ER	https://ginas.ncats.nih.gov/ginas/app/substance/236023ed	approximate	GINAS has entry only for IL-12 protein	"Melanoma, familial"	3460	approximate	melanoma type is not specified
"DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the nastive eIF5A mRNA, and PEI (polyethyleneimine)"	Treatment of diffuse large B cell lymphoma	"DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the nastive eIF5A mRNA, and PEI (polyethyleneimine)"	PROTEIN	n/a	7/24/12	Designated			N/A	N/A	"Senesco Technologies, Inc."	Bridgewater	New Jersey	8807	USA	LONGEST CONTAINS	0087274AA	protein					PROBLEM	can't find	Diffuse Large B-Cell Lymphoma	3178	done	
"DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the native eIF5A mRNA, and PEI (polyethyleneimine)"	Treatment of mantle cell lymphoma	"DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the native eIF5A mRNA, and PEI (polyethyleneimine)"	PROTEIN	n/a	7/24/12	Designated			N/A	N/A	"Senesco Technologies, Inc."	Bridgewater	New Jersey	8807	USA	LONGEST CONTAINS	0087274AA	protein					PROBLEM	can't find	Mantle cell lymphoma	6969	done	
"DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2"	Treatment of renal cell carcinoma.	"DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2"		Leuvectin	4/28/00	Designated			N/A	N/A	Vical Incorporated	San Diego	California	92121	USA					Leuvectin	NA	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/il-2-plasmid-dna-lipid-complex	PROBLEM	absent from GINAS	Renal cell carcinoma	13215	done	
DOCONEXENT	Treatment of retinitis pigmentosa	"all-cis-docosa-4,7,10,13,16,19-hexaenoic acid"	DOCONEXENT	Retriacyl	5/21/14	Designated			N/A	N/A	"Natac Pharma, S.L."	Madrid			Spain	EXACT	0145960AA	DOCONEXENT	ZAD9OKH9JC						Retinitis pigmentosa	5694	done	
DS-3032 TOSYLATE MONOHYDRATE	Treatment of liposarcoma	"(3'R,4'S,5'R)-N-[(3R,6S)-6-Carbamoyltetrahydro-2H-pyran-3-yl]-6''-chloro-4'-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2''-oxo-1'',2''-dihydrodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indole]-5'-carboxamide mono(4-methylbenzenesulfonate) monohydrate"	MILADEMETAN TOSYLATE MONOHYDRATE	n/a	2/13/17	Designated			N/A	N/A	"Daiichi Sankyo, Inc."	Edison	New Jersey	8837	USA	EXACT	1800971AA	DS-3032 TOSYLATE MONOHYDRATE	4Y0K58UFU2						Liposarcoma	6913	done	
DSM-265	Treatment of malaria	"2-(1,1-difluoroethyl)-5-methyl-N-[4-(pentafluoro-¿{6}-sulfanyl)phenyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine"	DSM-265	n/a	8/18/17	Designated			N/A	N/A	"Paul Maher, MD"	Bethesda	Maryland	20814	USA	EXACT	1210588AA	DSM-265	0Q42P4YI6B						Malaria	6961	done	
DUR-928 SODIUM	Treatment of primary sclerosing cholangitis (PSC)	"5-cholesten-3ß, 25-diol 3-sulfate sodium salt (25HC3S)"	DUR-928 SODIUM	n/a	7/6/17	Designated			N/A	N/A	DURECT Corporation	Cupertino	California	95014	USA	EXACT	1800562AA	DUR-928 SODIUM	71A5JOPBE8						Primary sclerosing cholangitis	1280	done	
Daclizumab	Prevention of acute renal allograft rejection.	Daclizumab	DACLIZUMAB	Zenapax	3/5/93	Designated/Approved	Approved for Orphan Indication	"Prophylaxis of acute organ rejection in patients receiving renal transplants, to be used as a part of an immunosuppressive regimen that includes cyclosporine and corticosteroids."	12/10/97	12/10/04	"Hoffmann-La Roche, Inc."	Nutley	New Jersey	7110	USA	EXACT	0226744AA	Daclizumab	CUJ2MVI71Y						Acute graft versus host disease	6544	approximate	
Dapsone	Prophylaxis of toxoplasmosis in severely immunocompromised patients with CD4 counts below 100.	Dapsone	DAPSONE	n/a	11/7/94	Designated			N/A	N/A	"Jacobus Pharmaceutical Company, Inc."	Princeton	New Jersey	8540	USA	EXACT	0013978AA	Dapsone	8W5C518302								MISSING	secondary condition
Dapsone USP	For the combination treatment of Pneumocystis carinii pneumonia in conjunction with trimethoprim.	Dapsone USP	DAPSONE	Dapsone	1/8/92	Designated			N/A	N/A	Jacobus Pharmaceutical Company	Princeton	New Jersey	8540	USA	EXACT	0013978AA	Dapsone	8W5C518302						Pneumocystic carinii pneumonia	7409	done	
Dapsone USP	Prophylaxis for Pneumocystis carinii pneumonia.	Dapsone USP	DAPSONE	Dapsone	12/24/91	Designated			N/A	N/A	Jacobus Pharmaceutical Company	Princeton	New Jersey	8540	USA	EXACT	0013978AA	Dapsone	8W5C518302						Pneumocystic carinii pneumonia	7409	done	
Dasatinib	Treatment of chronic myelogenous leukemia	Dasatinib	DASATINIB	Sprycel	11/28/05	Designated/Approved	Approved for Orphan Indication	Treatment of adults with chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib	6/28/06	6/28/13	Bristol-Myers Squibb Company	Wallingford	Connecticut	6492	USA	EXACT	0258560AA	Dasatinib	RBZ1571X5H						Chronic myeloid leukemia	6105	done	
Debio-1143	Treatment of ovarian cancer	"(5S,8S, 10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5] diazocine-8-carboxyamide"	AT-406	n/a	4/14/16	Designated			N/A	N/A	DebioPharm International SA	Lausanne			Switzerland	EXACT	0793680AA	Debio-1143	N65WC8PXDD						Ovarian cancer	7295	done	
Dectrekumab	Treatment of eosinophilic esophagitis	human monoclonal antibody againt human interleukin 13 (IL-13)	DECTREKUMAB	n/a	10/15/13	Designated			N/A	N/A	Novartis Pharmaceuticals Corporaton	East Hanover	New Jersey	7936	USA	EXACT	0698180AA	Dectrekumab	764HZ2554D						Eosinophilic enteropathy	9142	done	
Deferasirox	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Deferasirox	DEFERASIROX	Exjade	11/21/02	Designated/Approved	Approved for Orphan Indication	Treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age or older	11/2/05	11/2/12	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0232860AA	Deferasirox	V8G4MOF2V9								MISSING	secondary condition
Deferitrin	Treatment of iron overload	Deferitrin	DEFERITRIN	n/a	4/14/04	Designated/Withdrawn			N/A	N/A	Genzyme Corporation	Waltham	Massachusetts	2451	USA	EXACT	0243389AA	Deferitrin	T69Y9LDN44								MISSING	not a disease
Defibrotide	Treatment of thrombotic thrombocytopenic purpura.	Defibrotide	DEFIBROTIDE SODIUM	n/a	7/5/85	Designated			N/A	N/A	Crinos International	"Villa Guardia, Italy"		22079	USA	EXACT	0645487AA	Defibrotide	L7CHH2B2J0						"Thrombotic thrombocytopenic purpura, acquired "	4607	approximate	
Defibrotide	Treatment of thrombotic thrombocytopenic purpura.	Defibrotide	DEFIBROTIDE SODIUM	n/a	7/5/85	Designated			N/A	N/A	Crinos International	"Villa Guardia, Italy"		22079	USA	EXACT	0645487AA	Defibrotide	L7CHH2B2J0						 Congenital thrombotic thrombocytopenic purpura	9430	approximate	
Dehydroepiandrosterone	Treatment of systemic lupus erythematosus (SLE) and the reduction in the use of steroids in steroid-dependent SLE patients.	Dehydroepiandrosterone	PRASTERONE	n/a	7/13/94	Designated/Withdrawn			N/A	N/A	GlaxoSmithKline	Research Triangle Park	North Carolina	27709	USA	EXACT	0008468AA	Dehydroepiandrosterone	459AG36T1B						Lupus	10253	done	"a rare disease according to Orphanet, but not according to GARD"
Dehydroepiandrosterone (DHEA)	Replacement therapy in individuals with adrenal insufficiency	Dehydroepiandrosterone (DHEA)	PRASTERONE	Fidelin	8/19/03	Designated			N/A	N/A	"Paladin Labs, Inc."	Quebec H4P 2T4			Canada	EXACT	0008468AA	Dehydroepiandrosterone	459AG36T1B						Secondary adrenal insufficiency	12735	approximate	
Dehydroepiandrosterone sulfate sodium	Treatment of serious burns requiring hospitalization.	Dehydroepiandrosterone sulfate sodium	PRASTERONE SODIUM SULFATE ANHYDROUS	n/a	1/29/97	Designated			N/A	N/A	"Pharmadigm, Inc."	Salt Lake City	Utah	84109	USA	EXACT	0068280AA	PRASTERONE SODIUM SULFATE ANHYDROUS	B9840IHU4T								MISSING	Not a disease
Delamanid	Treatment of pulmonary tuberculosis.	"(R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole"	DELAMANID	n/a	7/12/07	Designated			N/A	N/A	"Otsuka Pharmaceutical Company, Ltd"	Rockville	Maryland	20850	USA	EXACT	0382809AA	Delamanid	8OOT6M1PC7						Tuberculosis	7827	done	
Dexrazoxane	For the prevention of cardiomyopathy associated with doxorubicin administration.	Dexrazoxane	DEXRAZOXANE	Zinecard	12/17/91	Designated/Approved	Approved for Orphan Indication	Cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative dose of 300mg/m2.	5/26/95	5/26/02	Pharmacia & Upjohn	Kalamazoo	Michigan	49001	USA	EXACT	0062919AA	Dexrazoxane	048L81261F								MISSING	not a disease
Dextran	Treatment of acute iron poisoning.	Dextran and deferoxamine	DEXTRAN	Bio-Rescue	3/8/91	Designated			N/A	N/A	"Biomedical Frontiers, Inc."	Minneapolis	Minnesota	55414	USA	EXACT	0005856AA	Dextran	7SA290YK68 | P8272ET3N5 | E8A73H7RG1 | 42N66Q2197 | 7C8S056150 | 05Q25F6XJ3 | PD6VU01UVN | 21C3YS80Q6 | B854H05S7D | 41Z0077J45 | 65DL069QBP | V7031C06AY | 95HR524N2M | 85AMG1WQ9L | AIW09WL51K | 01W9V5H5WO | 928L14E681 | JY83SHX053 | I8LHQ0D645 | ZNJ8R24I7Z | NXV22KT7NQ | K3R6ZDH4DU | 7SA290YK68 | EW7Q6SVD0D	DEXTRAN 70/75 | DEXTRAN 6 | DEXTRAN 3.5 | DEXTRAN 20 | DEXTRAN 10 | DEXTRAN 110 | DEXTRAN 25 | DEXTRAN 150 | DEXTRAN 500 | DEXTRAN 250 | DEXTRAN 2000 | DEXTRAN 1.5 | IRON DEXTRAN | DIETHYLAMINOETHYL-DEXTRAN HYDROCHLORIDE | DEXTRAN SULFATE SODIUM (MW 54000) | DEXTRAN SULFATE SODIUM (MW 520000) | DEXTRAN 5 | DEXTRAN 75 | DEXTRAN 1 | DEXTRAN 60 | DEXTRAN SULFATE SODIUM (MW 9500) | DEXTRAN 40 | DEXTRAN 70 | DEXTRAN 750	7SA290YK68 | P8272ET3N5 | E8A73H7RG1 | 42N66Q2197 | 7C8S056150 | 05Q25F6XJ3 | PD6VU01UVN | 21C3YS80Q6 | B854H05S7D | 41Z0077J45 | 65DL069QBP | V7031C06AY | 95HR524N2M | 85AMG1WQ9L | AIW09WL51K | 01W9V5H5WO | 928L14E681 | JY83SHX053 | I8LHQ0D645 | ZNJ8R24I7Z | NXV22KT7NQ | K3R6ZDH4DU | 7SA290YK68 | EW7Q6SVD0D	https://ginas.ncats.nih.gov/ginas/app/substances?q=root_Display%5C%20Name:dextran	done		Heavy metal poisoning	6577	approximate	
Dextran 70	Treatment of recurrent corneal erosion unresponsive to conventional therapy.	Dextran 70	DEXTRAN 70	Dehydrex	3/5/90	Designated			N/A	N/A	"Holles Laboratories, Inc."	Cohasset	Massachusetts	2025	USA	EXACT	0098759AA	Dextran 70	7SA290YK68								MISSING	
Dextran and deferoxamine	Treatment of acute iron poisoning.	Dextran and deferoxamine	DEFEROXAMINE	Bio-Rescue	3/8/91	Designated			N/A	N/A	"Biomedical Frontiers, Inc."	Minneapolis	Minnesota	55414	USA	EXACT	0012204AA	deferoxamine	J06Y7MXW4D						Heavy metal poisoning	6577	approximate	
"Dextran sulfate (inhaled, aerosolized)"	For use as an adjunct to the treatment of cystic fibrosis.	"Dextran sulfate (inhaled, aerosolized)"	DEXTRAN	Uendex	10/5/90	Designated			N/A	N/A	"Kennedy & Hoidal, M.D.'s"	Salt Lake City	Utah	84132	USA	LONGEST CONTAINS	0005856AA	Dextran	7SA290YK68 | P8272ET3N5 | E8A73H7RG1 | 42N66Q2197 | 7C8S056150 | 05Q25F6XJ3 | PD6VU01UVN | 21C3YS80Q6 | B854H05S7D | 41Z0077J45 | 65DL069QBP | V7031C06AY | 95HR524N2M | 85AMG1WQ9L | AIW09WL51K | 01W9V5H5WO | 928L14E681 | JY83SHX053 | I8LHQ0D645 | ZNJ8R24I7Z | NXV22KT7NQ | K3R6ZDH4DU | 7SA290YK68 | EW7Q6SVD0D	DEXTRAN 70/75 | DEXTRAN 6 | DEXTRAN 3.5 | DEXTRAN 20 | DEXTRAN 10 | DEXTRAN 110 | DEXTRAN 25 | DEXTRAN 150 | DEXTRAN 500 | DEXTRAN 250 | DEXTRAN 2000 | DEXTRAN 1.5 | IRON DEXTRAN | DIETHYLAMINOETHYL-DEXTRAN HYDROCHLORIDE | DEXTRAN SULFATE SODIUM (MW 54000) | DEXTRAN SULFATE SODIUM (MW 520000) | DEXTRAN 5 | DEXTRAN 75 | DEXTRAN 1 | DEXTRAN 60 | DEXTRAN SULFATE SODIUM (MW 9500) | DEXTRAN 40 | DEXTRAN 70 | DEXTRAN 750	7SA290YK68 | P8272ET3N5 | E8A73H7RG1 | 42N66Q2197 | 7C8S056150 | 05Q25F6XJ3 | PD6VU01UVN | 21C3YS80Q6 | B854H05S7D | 41Z0077J45 | 65DL069QBP | V7031C06AY | 95HR524N2M | 85AMG1WQ9L | AIW09WL51K | 01W9V5H5WO | 928L14E681 | JY83SHX053 | I8LHQ0D645 | ZNJ8R24I7Z | NXV22KT7NQ | K3R6ZDH4DU | 7SA290YK68 | EW7Q6SVD0D	https://ginas.ncats.nih.gov/ginas/app/substances?q=root_Display%5C%20Name:dextran	done		Cystic fibrosis	6233	done	Not a rare disease
Dextran sulfate sodium	Treatment of aquired immunodeficiency syndrome.	Dextran sulfate sodium	DEXTRAN SULFATE SODIUM	n/a	11/19/87	Designated			N/A	N/A	"Ueno Fine Chemicals Industry, Ltd."	Osaka 541			Japan	EXACT	0006882AA	Dextran sulfate sodium	NXV22KT7NQ | 01W9V5H5WO | AIW09WL51K	DEXTRAN SULFATE SODIUM (MW 9500) | DEXTRAN SULFATE SODIUM (MW 520000) | DEXTRAN SULFATE SODIUM (MW 54000)	NXV22KT7NQ | 01W9V5H5WO | AIW09WL51K	https://ginas.ncats.nih.gov/ginas/app/substances?q=root_Display%5C%20Name:%22dextran%20sulfate%20sodium%22	done		Congenital human immunodeficiency virus	10328	approximate	"aquired, not congenital immunodeficiency"
Dezapelisib	Treatment of Hodgkin lymphoma	"(S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one"	DEZAPELISIB	n/a	4/29/15	Designated			N/A	N/A	Incyte Corporation	Wilmington	Delaware	19803	USA	EXACT	0897121AA	Dezapelisib	2K59L7G59M						Hodgkin lymphoma	2714	done	
Dianeal peritoneal dialysis solution with 1.1% amino acids	For use as a nutritional supplement for the treatment of malnourishment in patients undergoing continuous ambulatory peritoneal dialysis.	Dianeal peritoneal dialysis solution with 1.1% amino acids	AMINO ACIDS	Nutrineal (Peritoneal Dialysis Solution With 1.1% Amino Acid	6/11/92	Designated			N/A	N/A	Baxter Healthcare Corporation	McGaw Park	Illinois	60085	USA	LONGEST CONTAINS	0069750AA	amino acids	0O72R8RF8A								MISSING	not a disease
Diazepam buccal soluble film	"Treatment of selected, refractory patients with epilepsy who are on stable regimens of antiepileptic drugs (AED) and who require intermittent use of diazepam to control bouts of increased seizure activity (acute repetitive seizures)"	Diazepam buccal soluble film	DIAZEPAM	n/a	11/10/16	Designated			N/A	N/A	"MonoSol Rx, LLC"	Warren	New Jersey	7059	USA	EXACT	0025752AA	Diazepam	Q3JTX2Q7TU						Status epilepticus	10191	done	
Diazepam viscous solution for rectal administration	"For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity."	Diazepam viscous solution for rectal administration	DIAZEPAM	n/a	2/25/92	Designated/Approved	Approved for Orphan Indication		7/29/97	7/29/04	Valeant Pharmaceuticals	Costa Mesa	California	92626	USA	EXACT	0025752AA	Diazepam	Q3JTX2Q7TU						Familial focal epilepsy with variable foci	13295	approximate	
Dideoxyinosine	Treatment of acquired immunodeficiency syndrome.	Dideoxyinosine	DIDANOSINE	n/a	6/22/88	Designated/Withdrawn			N/A	N/A	Bristol-Myers Squibb	Evansville	Indiana	47721	USA	EXACT	0167135AA	Dideoxyinosine	K3GDH6OH08						Congenital human immunodeficiency virus	10328	approximate	
Diethyldithiocarbamate	Treatment of AIDS.	Diethyldithiocarbamate	DITIOCARB	Imuthiol	4/3/86	Designated			N/A	N/A	Connaught Laboratories	Swiftwater	Pennsylvania	18370	USA	EXACT	0330892AA	Diethyldithiocarbamate	99Z2744345						Congenital human immunodeficiency virus	10328	approximate	
Diethylenetriaminepentaacetic acid (DTPA)	"Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination."	Diethylenetriaminepentaacetic acid (DTPA)	PENTETIC ACID	n/a	4/28/04	Designated/Approved	Approved for Orphan Indication	"Treatment of internal contamination with plutonium, americium or curium"	8/11/04	8/11/11	Hameln Pharmaceuticals gmbh	Hameln			Germany	EXACT	0011596AA	Diethylenetriaminepentaacetic acid	7A314HQM0I								MISSING	not a disease
Digoxin immune FAB (Ovine)	Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.	Digoxin immune FAB (Ovine)	DIGOXIN IMMUNE FAB (OVINE)	Digibind	11/1/84	Designated/Approved	Approved for Orphan Indication		4/22/86	4/22/93	Glaxo Wellcome Inc.	Research Triangle Park	North Carolina	27709	USA	EXACT	0324629AA	Digoxin immune FAB (Ovine)	YB12NQZ1YN								MISSING	drug-induced complication
Digoxin immune fab(ovine)	"Treatment of life-threatening acute cardiac glycoside intoxication manifested by conduction disorders, ectopic ventricular activity and (in some cases) hyperkalemia."	Digoxin immune fab(ovine)	OVINE DIGOXIN IMMUNE FAB	Digidote	3/11/85	Designated			N/A	N/A	Boehringer Mannheim Corp.	Rockville	Maryland	20850	USA	EXACT	0322930AA	Digoxin immune fab(ovine)	YB12NQZ1YN								MISSING	not a disease
Dihydrotestosterone	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Dihydrotestosterone	STANOLONE	Androgel -Dht	2/5/96	Designated			N/A	N/A	"Besins Internaitonal, US Inc."	Herndon	Virginia	20170	USA	EXACT	0027429AA	Dihydrotestosterone	08J2K08A3Y						Congenital human immunodeficiency virus	10328	approximate	
Dilanubicel	Reduction of morbidity and mortality associated with hematopoietic stem cell transplantation	Dilanubicel	DILANUBICEL	n/a	7/9/18	Designated			N/A	N/A	"Nohla Therapeutics, Inc."	1616 Fairview Avenue East	Washington	98102	USA	EXACT	0113533AB	Dilanubicel	XU53VK93MC	HUMAN CORD BLOOD HEMATOPOIETIC PROGENITOR CELL	XU53VK93MC	https://ginas.ncats.nih.gov/ginas/app/substance/7a1426ae | https://nohlatherapeutics.com/our-products/	approximate	"An ex vivo expanded hematopoietic stem and progenitor cell therapy derived from umbilical cord blood, designated dilanubicel (NLA 101)"			MISSING	procedure
Dimethyl sulfoxide	Treatment of cutaneous manifestations of scleroderma.	Dimethyl sulfoxide	DIMETHYL SULFOXIDE	n/a	6/6/86	Designated/Withdrawn			N/A	N/A	Research Industries Corp.					EXACT	0011676AA	Dimethyl sulfoxide	YOW8V9698H						Scleroderma	10308	done	
Dimethyl sulfoxide	"Treatment of increased intracranial pressure in patients with severe, closed-head injury, also known as traumatic brain coma, for whom no other effective treatment is available."	Dimethyl sulfoxide	DIMETHYL SULFOXIDE	n/a	11/22/94	Designated			N/A	N/A	"Abela Pharmaceuticals, Inc."	Lake Forest	California	92630	USA	EXACT	0011676AA	Dimethyl sulfoxide	YOW8V9698H								MISSING	
Dimethylsulfoxide	Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.	Dimethylsulfoxide	DIMETHYL SULFOXIDE	n/a	4/15/97	Designated			N/A	N/A	"Cancer Technologies, Inc."	Tucson	Arizona	85710	USA	EXACT	0011676AA	Dimethylsulfoxide	YOW8V9698H								MISSING	treatment of drug-induced side-effects
Dimethylsulfoxide	Treatment of palmar-plantar erythrodysethesia syndrome.	Dimethylsulfoxide	DIMETHYL SULFOXIDE	n/a	4/6/98	Designated			N/A	N/A	"Cancer Technologies, Inc."	Tucson	Arizona	85710	USA	EXACT	0011676AA	Dimethylsulfoxide	YOW8V9698H								MISSING	
Dipalmitoylphosphatidylcholine	Prevention and treatment of neonatal respiratory distress syndrome.	Dipalmitoylphosphatidylcholine /phosphatidylglycerol	COLFOSCERIL PALMITATE	Alec	7/28/88	Designated			N/A	N/A	"Forum Products, Inc."	Southampton	New York	11968	USA	EXACT	0120003AA	Dipalmitoylphosphatidylcholine	319X2NFW0A						"Respiratory distress syndrome, infant"	112	done	
Dipalmitoylphosphatidylglycerol	Prevention and treatment of neonatal respiratory distress syndrome.	Dipalmitoylphosphatidylcholine /phosphatidylglycerol	"DIPALMITOYLPHOSPHATIDYLGLYCEROL, DL-"	Alec	7/28/88	Designated			N/A	N/A	"Forum Products, Inc."	Southampton	New York	11968	USA	EXACT	0380289AA	Dipalmitoylphosphatidylglycerol	VA9U6BR3SB						"Respiratory distress syndrome, infant"	112	done	
Disodium clodronate	Treatment of hypercalcemia of malignancy.	Disodium clodronate	CLODRONATE DISODIUM	n/a	6/16/93	Designated			N/A	N/A	"Discovery Experimental & Development, Inc."	Wesley Chapel	Florida	33543	USA	EXACT	0060924AA	Disodium clodronate	N030400H8J								MISSING	
Double-stranded DNA plasmid carrying the gene for the diphtheria toxin A (DT-A) chain	Treatment of pancreatic cancer	Double-stranded DNA plasmid carrying the gene for the diphtheria toxin A (DT-A) chain	DIPHTHERIA TOXIN	n/a	8/6/10	Designated			N/A	N/A	BioCancell Therapeutics Israel Ltd.	Jerusalem			Israel	LONGEST CONTAINS	1183820AA	diphtheria toxin					PROBLEM	can't find	Pancreatic cancer	9364	done	Not a rare disease
Dronabinol	For the stimulation of appetite and prevention of weight loss in patients with a confirmed diagnosis of AIDS.	Dronabinol	DRONABINOL	Marinol	1/15/91	Designated/Approved	Approved for Orphan Indication	Treatment of anorexia associated with weight loss in patients with AIDS.	12/22/92	12/22/99	"Unimed Pharmaceuticals, Inc."	Marietta	Georgia	30062	USA	EXACT	0045169AA	Dronabinol	7J8897W37S						Congenital human immunodeficiency virus	10328	approximate	
"Dual antibody including HBV-Ab 17, libivirumab, and HBV-Ab 19, exbivirumab"	For the prevention of hepatitis B virus (HBV) reinfection in patients who have received a liver transplantation	"Dual antibody including HBV-Ab 17, libivirumab, and HBV-Ab 19, exbivirumab"	LIBIVIRUMAB	Hepex-B	7/15/03	Designated/Withdrawn			N/A	N/A	Cubist Pharmaceuticals	Lexington	Massachusetts	2421	USA	EXACT	1085070AA	libivirumab	J1R33H8X7A								MISSING	
EDASALONEXENT	Treatment of Duchenne muscular dystrophy	"N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)ethyl)-2-hydroxybenzamide"	EDASALONEXENT	n/a	11/17/14	Designated			N/A	N/A	"Catabasis Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0709104AA	EDASALONEXENT	AF3Z6434KS						Duchenne muscular dystrophy	6291	done	
EDOTREOTIDE GALLIUM GA-68	Diagnostic for the clinical management of neuroendocrine tumors	"Gallium [Ga-68]-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic(2-7)disulfide"	EDOTREOTIDE GALLIUM GA-68	Netspot	12/31/13	Designated/Approved	Approved for Orphan Indication	"For use after radiolabeling with Ga 68, with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients."	6/1/16	6/1/23	"Advanced Accelerator Applications, USA"	New York	New York	10118	USA	EXACT	1117799AA	EDOTREOTIDE GALLIUM GA-68	Y68179SY2L						Neuroendocrine tumor	13445	done	
EDRECOLOMAB	Treatment of pancreatic cancer.	Monoclonal antibody 17-1a	EDRECOLOMAB	Panorex	4/4/88	Designated/Withdrawn			N/A	N/A	"Centocor, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	0297916AA	EDRECOLOMAB	0KYI9U9FSJ						Pancreatic cancer	9364	done	Not a rare disease
EHP-101	Treatment of systemic scleroderma (SSc)	"(1'R,6'R)-3-(Benzylamine)-6-hydroxy-3'-methyl-4-pentyl-6'-(prop-1-en-2-yl)-[1,1'-bi(cyclohexane)]-2',3,6-triene-2,5-dione"	EHP-101	n/a	7/6/17	Designated			N/A	N/A	Emerald Health Pharmaceuticals Inc.	San Diego	California	92121	USA	EXACT	0112106AB	EHP-101	KTJCIKNF3F						Systemic scleroderma	9748	done	
EHP-102	Treatment of Huntington’s Disease (HD)	"2-(3,7-Dimethyl-octa-2, 6-dienyl)—6-ethylamino-3-hydroxy-5-pentyl-[1,4]benzoquinone"	EHP-102	n/a	2/1/18	Designated			N/A	N/A	Emerald Health Pharmaceuticals Inc.	5820 Nancy Ridge Drive	San Diego	92121	USA	EXACT	0114256AB	EHP-102	FDH1SMY691						Huntington disease	6677	done	
ELECLAZINE	Treatment of congenital long QT syndrome	"4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one"	ELECLAZINE	n/a	5/4/15	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0805185AA	ELECLAZINE	PUY08529FK						Long QT syndrome 1 	3284	approximate	
ELECLAZINE	Treatment of congenital long QT syndrome	"4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one"	ELECLAZINE	n/a	5/4/15	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0805185AA	ELECLAZINE	PUY08529FK						 Long QT syndrome 2 	3285	approximate	
ELECLAZINE	Treatment of congenital long QT syndrome	"4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one"	ELECLAZINE	n/a	5/4/15	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0805185AA	ELECLAZINE	PUY08529FK						 Long QT syndrome 3 	3286	approximate	
ELECLAZINE	Treatment of congenital long QT syndrome	"4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one"	ELECLAZINE	n/a	5/4/15	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0805185AA	ELECLAZINE	PUY08529FK						 Long QT syndrome 4 	10432	approximate	
ELECLAZINE	Treatment of congenital long QT syndrome	"4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one"	ELECLAZINE	n/a	5/4/15	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0805185AA	ELECLAZINE	PUY08529FK						 Long QT syndrome 5 	10433	approximate	
ELECLAZINE	Treatment of congenital long QT syndrome	"4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one"	ELECLAZINE	n/a	5/4/15	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0805185AA	ELECLAZINE	PUY08529FK						 Long QT syndrome 6 	10434	approximate	
ELECLAZINE	Treatment of congenital long QT syndrome	"4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one"	ELECLAZINE	n/a	5/4/15	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0805185AA	ELECLAZINE	PUY08529FK						 Andersen-Tawil syndrome	9453	approximate	
ELECLAZINE	Treatment of congenital long QT syndrome	"4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one"	ELECLAZINE	n/a	5/4/15	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0805185AA	ELECLAZINE	PUY08529FK						 Timothy syndrome 	9294	approximate	
ELECLAZINE	Treatment of congenital long QT syndrome	"4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one"	ELECLAZINE	n/a	5/4/15	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0805185AA	ELECLAZINE	PUY08529FK						 Long QT syndrome 9 	10435	approximate	
ELECLAZINE	Treatment of congenital long QT syndrome	"4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one"	ELECLAZINE	n/a	5/4/15	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0805185AA	ELECLAZINE	PUY08529FK						 Long QT syndrome 10 	10436	approximate	
ELECLAZINE	Treatment of congenital long QT syndrome	"4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one"	ELECLAZINE	n/a	5/4/15	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0805185AA	ELECLAZINE	PUY08529FK						 Long QT syndrome 11	10437	approximate	
EMERAMIDE	Treatment of mercury toxicity	"N,N'-bis(2-mercaptoethyl)isophthalamide (NBMI)"	EMERAMIDE	n/a	4/6/12	Designated			N/A	N/A	CTI Science Limited	Dublin 2			Ireland	EXACT	1120247AA	EMERAMIDE	4U7K5X4ANS						Mercury poisoning	7021	done	
ENTOLIMOD	Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster	FliC Flagellin Deletion Variant TLR5 Agonist	ENTOLIMOD	n/a	11/23/10	Designated			N/A	N/A	"Cleveland BioLabs, Inc."	Buffalo	New York	14203	USA	EXACT	0786345AA	ENTOLIMOD	R1UQ6D1ECM								MISSING	
ENTOSPLETINIB DIMESYLATE	Treatment of chronic lymphocytic leukemia	"6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo-[1,2-alpha]pyrazin-8-amine bis-methanesulfonate"	ENTOSPLETINIB DIMESYLATE	n/a	4/14/14	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	1137173AA	ENTOSPLETINIB DIMESYLATE	4N0Q3I064C						Chronic lymphocytic leukemia	6104	done	
EP-217609	Prevention of ischemia reperfusion injury associated wth solid organ transplantation	"Methyl O-4-O-[2-[2-[2-[2-[[N-[(1R)-1-[[4-(aminoiminomethyl)phenyl] methyl]-2-oxo-2-(1-piperidinyl)ethyl]-N2-[(4-methoxy-2,3,6- trimethylphenyl)sulfonyl]-L-α-asparaginyl-4-aminobutanoyl-N6-[5- [(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1- oxopentyl]-L-lysyl]amino]ethoxy]ethoxy]ethoxy]ethyl]-2,3-di-O-methyl6-O-sulfo-α-D-glucopyranosyl-(1->4)-O-2,3-di-O-methyl-β-Dglucopyranuronosyl-(1->4)-O-2,3,6-tri-O-sulfo-α-D-glucopyranosyl- (1->4)-O-2,3-di-O-methyl-α-L-idopyranuronosyl-(1->4)-3-O-methyl-α-Dglucopyranoside 2,6-bis(hydrogen sulfate) octasodium salt"	EP-217609	n/a	4/18/11	Designated			N/A	N/A	Endotis Pharma				France	EXACT	0778369AA	EP-217609	R6464792NG								MISSING	Not a rare disease
EPI-589	Treatment of amyotrophic lateral sclerosis	"(R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl) butanamide"	EPI-589	n/a	7/27/17	Designated			N/A	N/A	BioElectron Technology Corporation	Mountain View	California	94043	USA	EXACT	1144270AA	EPI-589	I4ZSB1Q2DU						Amyotrophic lateral sclerosis	5786	done	
EW-7197	Treatment of hepatocellular carcinoma	"N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline"	EW-7197	n/a	6/14/17	Designated			N/A	N/A	"MedPacto, Inc."	Suwon			"Korea, Republic of"	EXACT	0936298AA	EW-7197	6T4O391P5Y						Childhood hepatocellular carcinoma	9331	approximate	
EXENDIN (9-39) AMIDE	Treatment of hyperinsulinemic hypoglycemia	Exendin 9-39 (Competitive antagonist of glucagon-like peptide-1)	EXENDIN (9-39) AMIDE	n/a	12/8/16	Designated			N/A	N/A	"Eiger BioPharmaceuticals, Inc."	Palo Alto	California	94306	USA	EXACT	0380610AA	EXENDIN (9-39) AMIDE	5313W10MYT						Exercise-induced hyperinsulinemic hypoglycemia 	9932	approximate	
EXENDIN (9-39) AMIDE	Treatment of hyperinsulinemic hypoglycemia	Exendin 9-39 (Competitive antagonist of glucagon-like peptide-1)	EXENDIN (9-39) AMIDE	n/a	12/8/16	Designated			N/A	N/A	"Eiger BioPharmaceuticals, Inc."	Palo Alto	California	94306	USA	EXACT	0380610AA	EXENDIN (9-39) AMIDE	5313W10MYT						 Congenital hyperinsulinism	3947	approximate	
"Echinocandin B,1-((4R,5R)-4-hydroxy-N2-((4’’-(pentyloxy)(1,1’:4’,1’’-terphenyl)-4-yl)carbonyl)-5-(2-(trimethylammonio)ethoxy)-L-ornithine)-4-((4S)-4-hydroxy-4-(4-hydroxyphenyl)-L-allothreonine)"	Treatment of candidemia and invasive candidiasis infections caused by susceptible Candida spp.	"Echinocandin B,1-[(4R,5R)-4-hydroxy-N2-[[4’’-(pentyloxy)[1,1’:4’,1’’-terphenyl]-4-yl]carbonyl]-5-[2-(trimethylammonio)ethoxy]-L-ornithine]-4-[(4S)-4-hydroxy-4-(4-hydroxyphenyl)-L-allothreonine]"	ECHINOCANDIN B	n/a	2/8/16	Designated			N/A	N/A	"Cidara Therapeutics, Inc."	San Diego	California	92121	USA	EXACT	0850635AA	Echinocandin B	CNW0ZW8ZTQ						Systemic candidiasis	1076	approximate	
Edotreotide	Treatment of somatostatin receptor-positive neuroendocrine gastroenteropancreatic tumors	Edotreotide	EDOTREOTIDE	Onalta(Tm)	7/28/05	Designated			N/A	N/A	"Molecular Insight Pharmaceuticals, Inc. (Progenics Subsidiary)"	Tarrytown	New York	10591	USA	EXACT	0308781AA	Edotreotide	U194AS08HZ						Gastro-enteropancreatic neuroendocrine tumor	2437	done	
Efdispo	Treatment of Ewings Sarcoma.	Efdispo (tm)		Efdispo (Tm)	1/15/13	Designated			N/A	N/A	"TDP Biotherapeutics, Inc."	Gaithersburg	Maryland	20878	USA								PROBLEM	"drug name is YK-4-279, can't find it"	Ewing's family of tumors	9323	approximate	
Eflornithine HCl	Treatment of Pneumocystis carinii pneumonia in AIDS patients.	Eflornithine HCl	EFLORNITHINE HYDROCHLORIDE	Ornidyl	4/18/86	Designated/Withdrawn			N/A	N/A	"Marion Merrell Dow, Inc."	Kansas City	Missouri	64134	USA	EXACT	0118774AA	Eflornithine HCl	4NH22NDW9H						Pneumocystic carinii pneumonia	7409	done	
Eflornithine HCl	Treatment of Trypanosoma brucei gambiense infection (sleeping sickness).	Eflornithine HCl	EFLORNITHINE HYDROCHLORIDE	Ornidyl	4/23/86	Designated/Approved	Approved for Orphan Indication		11/28/90	11/28/97	Hoechst Marion Roussel	Kansas City	Missouri	64134	USA	EXACT	0118774AA	Eflornithine HCl	4NH22NDW9H						"Trypanosomiasis, Human East-African"	7826	done	
Elcatonin	Intrathecal treatment of intractable pain.	Elcatonin	ELCATONIN	n/a	9/25/95	Designated			N/A	N/A	"Innapharma, Inc."	Upper Saddle River	New Jersey	7458	USA	EXACT	0465021AA	Elcatonin	W0CMS474JK								MISSING	not a disease
Eloctate	Treatment of hemophilia A	"antihemophilic factor (recombinant), Fc fusion protein"	EFMOROCTOCOG ALFA	Eloctate	11/23/10	Designated/Approved	Approved for Orphan Indication	"Treatment of adults and children with Hemophilia A (congenital Factor VIII deficiency) for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes."	6/6/14	6/6/21	Biogen Idec Inc.	Cambridge	Massachusetts	2142	USA	EXACT	0791979AA	Eloctate	7PCM518YLR						Hemophilia A	6591	done	
Enadoline hydrochloride	Treatment of severe head injury.	Enadoline hydrochloride	ENADOLINE HYDROCHLORIDE	n/a	1/28/97	Designated			N/A	N/A	Warner-Lambert Company	Ann Arbor	Michigan	48105	USA	EXACT	0171233AA	Enadoline hydrochloride	086I9HO04E								MISSING	Not a disease
Enasidenib	Treatment of acute myelogenous leukemia	isocitrate dehydrogenase 2-mutant inhibitor	ENASIDENIB	n/a	6/12/14	Designated			N/A	N/A	Celgene Corporation	Overland Park	Kansas	66210	USA	EXACT	1148147AA	Enasidenib	3T1SS4E7AG						Acute myeloid leukemia	12757	done	
Encapsulated porcine islet preparation	Treatment of type I diabetic patients who are already on immunosuppression.	Encapsulated porcine islet preparation		Betarx	7/5/95	Designated			N/A	N/A	VivoRx	Santa Monica	California	90404	USA					Encapsulated porcine islet preparation	NA	https://books.google.ru/books?id=dff0-gJVk4cC&pg=PA166&lpg=PA166&dq=%22Encapsulated+porcine+islet+preparation%22&source=bl&ots=I953Hd707t&sig=ACfU3U09LVnvNWaoqJ11ZmpHrGFwK--peQ&hl=ru&sa=X&ved=2ahUKEwjglIGAup3gAhXFWywKHUvyDHgQ6AEwCXoECAEQAQ#v=onepage&q=%22Encapsulated%20porcine%20islet%20preparation%22&f=false	PROBLEM	can't find	Diabetes mellitus type 1	10268	done	not a rare disease
Epidermal growth factor (human)	For promotion of cutaneous wound healing in extreme burn treatment protocols.	Epidermal growth factor (human)	NEPIDERMIN	n/a	3/6/85	Designated/Withdrawn			N/A	N/A	"Ethicon, Inc."	Somerville	New Jersey	8876	USA	EXACT	0006804AA	Epidermal growth factor (human)	TZK30RF92W								MISSING	not a disease
Epirubicin	Treatment of breast cancer.	Epirubicin	EPIRUBICIN	Ellence	9/14/99	Designated/Approved	Approved for Orphan Indication	Component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.	9/15/99	9/15/06	Pharmacia & Upjohn Company	Kalamazoo	Michigan	49001	USA	EXACT	0147615AA	Epirubicin	3Z8479ZZ5X						Familial breast cancer	10415	approximate	
Epoetin alfa	Treatment of anemia associated with HIV infection or HIV treatment.	Epoetin alfa	EPOETIN ALFA	Epogen	7/1/91	Designated/Approved	Approved for Orphan Indication	Treatment of AZT-induced anemia in HIV infected patients.	12/31/90	12/31/97	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0172770AA	Epoetin alfa	64FS3BFH5W						Congenital human immunodeficiency virus	10328	approximate	any immunodeficiency
Epoetin alfa	Treatment of anemia associated with end stage renal disease.	Epoetin alfa	EPOETIN ALFA	Epogen	4/10/86	Designated/Approved	Approved for Orphan Indication		6/1/89	6/1/96	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0172770AA	Epoetin alfa	64FS3BFH5W								MISSING	
Epoetin alpha	Treatment of HIV associated anemia related to HIV infection or HIV treatment.	Epoetin alpha	EPOETIN ALFA	Procrit	3/7/89	Designated			N/A	N/A	R. W. Johnson Pharmaceutical Research Institute	Raritan	New Jersey	8869	USA	EXACT	0172770AA	Epoetin alpha	64FS3BFH5W								MISSING	
Epoetin alpha	Treatment of anemia associated with end stage renal disease.	Epoetin alpha	EPOETIN ALFA	Procrit	8/27/87	Designated			N/A	N/A	R. W. Johnson Pharmaceutical Research Institute	Raritan	New Jersey	8869	USA	EXACT	0172770AA	Epoetin alpha	64FS3BFH5W								MISSING	
Epoetin alpha	Treatment of anemia of prematurity in preterm infants.	Epoetin alpha	EPOETIN ALFA	Procrit	7/21/88	Designated/Withdrawn			N/A	N/A	"Janssen Research & Development, LLC"	Spring House	Pennsylvania	19477	USA	EXACT	0172770AA	Epoetin alpha	64FS3BFH5W								MISSING	
Epoetin beta	Treatment of anemia associated with end stage renal disease.	Epoetin beta	EPOETIN BETA	Marogen	10/22/87	Designated			N/A	N/A	"Chugai-USA, Inc."	Waukegan	Illinois	60087	USA	EXACT	0280999AA	Epoetin beta	64FS3BFH5W								MISSING	
Epoprostenol	Replacement of heparin in patients requiring hemodialysis and who are at increased risk of hemorrhage.	Epoprostenol	EPOPROSTENOL	Cycloprostin	10/29/84	Designated/Withdrawn			N/A	N/A	Upjohn Company	Kalamazoo	Michigan	49001	USA	EXACT	0216660AA	Epoprostenol	DCR9Z582X0								MISSING	
Epoprostenol	Replacement of heparin in patients requiring hemodialysis and who are at risk of hemmorrage	Epoprostenol	EPOPROSTENOL	Flolan	3/29/84	Designated/Withdrawn			N/A	N/A	Glaxo Wellcome Inc.	Research Triangle Park	North Carolina	27709	USA	EXACT	0216660AA	Epoprostenol	DCR9Z582X0								MISSING	
Epoprostenol	Treatment of primary pulmonary hypertension.	Epoprostenol	EPOPROSTENOL	Flolan	9/25/85	Designated/Approved	Approved for Orphan Indication	Long-term intravenous treatment of primary pulmonary hypertension in NYHA Class III and Class IV patients.	9/20/95	9/20/02	Glaxo Wellcome Inc.	Research Triangle Park	North Carolina	27709	USA	EXACT	0216660AA	Epoprostenol	DCR9Z582X0						Pulmonary arterial hypertension	7501	done	
Eprodisate	Treatment of secondary amyloidosis	Eprodisate	EPRODISATE	Kiacta(Tm)	4/6/99	Designated			N/A	N/A	"C. T. Development America, Inc."	New York	New York	10022	USA	EXACT	0309206AA	Eprodisate	6QFP76V7S7						Amyloidosis AA	10560	done	
Epstein Barr Virus specific cytotoxic T lymphocytes	Prevention and treatment of EBV-post transplant lymphoproliferative disease after hematopoietic stem cell transplant or solid organ transplant.	Epstein Barr Virus specific cytotoxic T lymphocytes	LYMPHOCYTES	n/a	12/27/06	Designated/Withdrawn			N/A	N/A	Center for Cell and Gene Therapy	Houston	Texas	77030	USA	LONGEST CONTAINS	0263092AA	lymphocytes	2A26YW7PNX	HUMAN HERPESVIRUS 4	2A26YW7PNX	https://ginas.ncats.nih.gov/ginas/app/substance/99009f5e	approximate		Post-transplant lymphoproliferative disease	9553	done	
Erwinase	Treatment of acute lymphocytic leukemia.	Erwinia L-asparaginase	ASPARAGINASE ERWINIA CHRYSANTHEMI	Erwinase	7/30/86	Designated/Approved	Approved for Orphan Indication	Treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.	11/18/11	11/18/18	"Jazz Pharmaceuticals, Inc."	Palo Alto	California	94304	USA	EXACT	0260322AA	Erwinase	D733ET3F9O						Acute lymphoblastic leukemia	522	done	
"Erythropoietin (human, recombinant)"	Treatment of anemia associated with end stage renal disease.	"Erythropoietin (human, recombinant)"	ERYTHROPOIETIN	n/a	11/19/87	Designated/Withdrawn			N/A	N/A	Organon Teknika Corporation					EXACT	0115195AA	"Erythropoietin (human, recombinant)"	64FS3BFH5W								MISSING	
Erythropoietin (recombinant human)	Treatment of anemia associated with end stage renal disease.	Erythropoietin (recombinant human)	ERYTHROPOIETIN	n/a	8/19/87	Designated			N/A	N/A	McDonnell Douglas Corp	St. Louis	Missouri	63166	USA	EXACT	0115195AA	Erythropoietin (recombinant human)	64FS3BFH5W								MISSING	
Ethanol gel	Treatment of congenital venous malformations	Ethanol gel	ALCOHOL	n/a	3/29/06	Designated/Withdrawn			N/A	N/A	Orfagen				France	EXACT	0098679AA	Ethanol	3K9958V90M						CLOVES syndrome	10939	done	
Ethanolamine oleate	"Treatment of patients with esophageal varices that have recently bled, to prevent rebleeding."	Ethanolamine oleate	ETHANOLAMINE OLEATE	Ethamolin	3/22/84	Designated/Approved	Approved for Orphan Indication		12/22/88	12/22/95	QOL Medical	Vero Beach	Florida	32963	USA	EXACT	0123342AA	Ethanolamine oleate	U4RY8MRX7C						Esophageal varices	6384	done	not a rare disease
"Ethinyl Estradiol, USP"	Treatment of Turner's syndrome.	"Ethinyl Estradiol, USP"	ETHINYL ESTRADIOL	n/a	6/22/88	Designated/Withdrawn			N/A	N/A	Bio-Technology General Corp.	Iselin	New Jersey	8830	USA	EXACT	0009507AA	Ethinyl Estradiol	423D2T571U						Turner syndrome	7831	done	
"Ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate"	Treatment of Crohn's disease.	"Ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate"	TAK-603	n/a	5/13/98	Designated/Withdrawn			N/A	N/A	Tap Holdings Inc.	Deerfield	Illinois	60015	USA	EXACT	0216217AA	"Ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate"	W6RZK26FCB						Crohn's disease	10232	done	Not a rare disease
Etidronate disodium	Prevention of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition.	Etidronate disodium	ETIDRONATE DISODIUM	Didronel Iv Infusion	5/2/91	Designated/Withdrawn			N/A	N/A	"MGI Pharma, Inc."	Bloomington	Minnesota	55438	USA	EXACT	0047892AA	Etidronate disodium	M16PXG993G								MISSING	
Etidronate disodium	Treatment of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition.	Etidronate disodium	ETIDRONATE DISODIUM	Didronel Iv Infusion	5/2/91	Designated/Withdrawn			N/A	N/A	"MGI Pharma, Inc."	Bloomington	Minnesota	55438	USA	EXACT	0047892AA	Etidronate disodium	M16PXG993G								MISSING	
Etidronate disodium	Treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.	Etidronate disodium	ETIDRONATE DISODIUM	Didronel	3/21/86	Designated/Approved	Approved for Orphan Indication		4/21/87	4/21/94	"MGI Pharma, Inc."	Bloomington	Minnesota	55437	USA	EXACT	0047892AA	Etidronate disodium	M16PXG993G								MISSING	
"Eubacterial Spores, Purified Suspension, Encapsulated"	Treatment of pediatric ulcerative colitis	"Eubacterial Spores, Purified Suspension, Encapsulated"		n/a	11/27/17	Designated			N/A	N/A	"Seres Therapeutics, Inc."	200 Sidney Street	Cambridge	2139	USA					SER-109	NA	https://adisinsight.springer.com/drugs/800040880 | https://www.serestherapeutics.com/pipeline/ser-109	PROBLEM	absent from GINAS	Pediatric ulcerative colitis	9857	done	
Evofosfamide	Treatment of pancreatic cancer	"(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-broethyl) diamidophosphate"	EVOFOSFAMIDE	n/a	6/5/13	Designated			N/A	N/A	EMD Serono	Rockland	Massachusetts	2370	USA	EXACT	0310474AA	Evofosfamide	8A9RZ3HN8W						Pancreatic cancer	9364	done	Not a rare disease
Exemestane	Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.	Exemestane	EXEMESTANE	Aromasin	9/19/91	Designated/Approved	Approved for Orphan Indication	Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.	10/21/99	10/21/06	Pharmacia & Upjohn	Kalamazoo	Michigan	49001	USA	EXACT	0174469AA	Exemestane	NY22HMQ4BX						Metaplastic carcinoma of the breast	10804	approximate	
"Extract of sea cucumber, sea sponge, shark fin, sea urchin, and sargassum grass"	Treatment of multiple myeloma	"Extract of sea cucumber, sea sponge, shark fin, sea urchin, and sargassum grass"	"SEA CUCUMBER, UNSPECIFIED"	n/a	5/14/12	Designated			N/A	N/A	Unicorn Pacific Corporation	Port Vila			Vanuatu	LONGEST CONTAINS	0377457AA	sea cucumber	LUE8BK8H5Q						Multiple myeloma	7108	done	
FB-825	Treatment of hyperimmunoglobulin E syndrome (HIES)	Recombinant humanized immunoglobulin gamma 1 monoclonal antibody (mAb) directed against the CemX segment of human membrane-bound immunoglobulin E (mIgE)	FB-825	n/a	9/28/17	Designated			N/A	N/A	"Fountain Biopharma, Inc."	Nangang District			Taiwan	EXACT	0114136AB	FB-825	YO4XL7781V						Hyper IgE syndrome	10956	done	
FG-3019	Treatment of idiopathic pulmonary fibrosis	"human recombinant DNA-derived, IgG1 kappa monoclonal anti-body to connective growth factor"	PAMREVLUMAB	n/a	7/6/12	Designated			N/A	N/A	"FibroGen, Inc."	San Francisco	California	94158	USA	EXACT	0267458AA	FG-3019	QS5F6VTS0O						Idiopathic pulmonary fibrosis	8609	done	
FLINDOKALNER	Treatment of Fragile X Syndrome.	"(3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one"	FLINDOKALNER	n/a	12/9/15	Designated			N/A	N/A	Centre National de la Recherche Scientifique (CNRS)	Paris			France	EXACT	0221396AA	FLINDOKALNER	J57O328W4W						Fragile X syndrome	6464	done	
FLUORODOPA F-18	A diagnostic for management of patients with Lesch-Nyhan syndrome	"6-fluoro-(18F)-L-3,4-dihydroxyphenylalanine"	FLUORODOPA F-18	n/a	9/7/16	Designated			N/A	N/A	"Advanced Imaging Projects, LLC"	Lake Worth	Florida	33467	USA	EXACT	0173568AA	FLUORODOPA F-18	2C598205QX						Lesch Nyhan syndrome	7226	done	
FLUORODOPA F-18	Diagnostic agent for the management of patients with aromatic L-amino acid decarboxylase deficiency (AADC).	"L-3,4-Dihydroxy-6-[18F]fluorophenylalanine"	FLUORODOPA F-18	n/a	5/31/17	Designated			N/A	N/A	"Advanced Imaging Projects, LLC"	Lake Worth	Florida	33467	USA	EXACT	0173568AA	FLUORODOPA F-18	2C598205QX						Aromatic L-amino acid decarboxylase deficiency	770	done	
FORODESINE HYDROCHLORIDE	Treatment of T-cell non-Hodgkin's lymphoma	"(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride"	FORODESINE HYDROCHLORIDE	n/a	1/29/04	Designated			N/A	N/A	Mundipharma Research Limited	England			United Kingdom	EXACT	0241736AA	FORODESINE HYDROCHLORIDE	6SN82Y9U73						Adult T-cell leukemia/lymphoma	13103	approximate	
FORODESINE HYDROCHLORIDE	Treatment of acute lymphoblastic leukemia	"(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride"	FORODESINE HYDROCHLORIDE	n/a	8/13/04	Designated			N/A	N/A	Mundipharma Research Limited	England			United Kingdom	EXACT	0241736AA	FORODESINE HYDROCHLORIDE	6SN82Y9U73						Acute lymphoblastic leukemia	522	done	
FORODESINE HYDROCHLORIDE	"Treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia"	"(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride"	FORODESINE HYDROCHLORIDE	n/a	8/10/04	Designated			N/A	N/A	Mundipharma Research Ltd.				United Kingdom	EXACT	0241736AA	FORODESINE HYDROCHLORIDE	6SN82Y9U73						Chronic lymphocytic leukemia 	6104	done	
FORODESINE HYDROCHLORIDE	"Treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia"	"(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride"	FORODESINE HYDROCHLORIDE	n/a	8/10/04	Designated			N/A	N/A	Mundipharma Research Ltd.				United Kingdom	EXACT	0241736AA	FORODESINE HYDROCHLORIDE	6SN82Y9U73						 Adult T-cell leukemia/lymphoma 	13103	done	
FORODESINE HYDROCHLORIDE	"Treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia"	"(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride"	FORODESINE HYDROCHLORIDE	n/a	8/10/04	Designated			N/A	N/A	Mundipharma Research Ltd.				United Kingdom	EXACT	0241736AA	FORODESINE HYDROCHLORIDE	6SN82Y9U73						" Leukemia, T-cell, chronic "	8224	done	
FORODESINE HYDROCHLORIDE	"Treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia"	"(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride"	FORODESINE HYDROCHLORIDE	n/a	8/10/04	Designated			N/A	N/A	Mundipharma Research Ltd.				United Kingdom	EXACT	0241736AA	FORODESINE HYDROCHLORIDE	6SN82Y9U73						 Hairy cell leukemia	6560	done	
FPA-144	Treatment of gastric cancer including cancer of the gastroesophageal junction.	"recombinant, glycoenfineered humanized IgG1 kappa monoclonal antibody directed against Fibroblast Growth Factor Receptor 2b"	BEMARITUZUMAB	n/a	6/29/16	Designated			N/A	N/A	"Five Prime Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	1112794AA	FPA-144	RJW23BQ0KW						Stomach cancer	7704	done	
FUNAPIDE	Treatment of erythromelalgia	"1'-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3-f][1,3]benzodioxole-7,3'-indol]-2'(1'H)-one"	FUNAPIDE	n/a	11/19/12	Designated			N/A	N/A	Teva Pharmaceuticals	Frazer	Pennsylvania	19355	USA	EXACT	0340012AA	FUNAPIDE	A5595LHJ2L						Erythromelalgia	6377	done	
Fabrazyme	Treatment of Fabry's disease.	Ceramide trihexosidase/alpha-galactosidase A	AGALSIDASE BETA	Fabrazyme	1/19/88	Designated/Approved	Approved for Orphan Indication	For use in patients with Fabry disease to reduce globotriaosylceramide (GL-3) deposition in capillary endothelium of the kidney and certain other cell types	4/24/03	4/24/10	Genzyme Corporation	Cambridge	Massachusetts	2139	USA	EXACT	0248215AA	Fabrazyme	RZD65TSM9U						Fabry disease	6400	done	
Facilitated DNA Plasmid Vaccine	Treatment of cutaneous T cell lymphoma.	Facilitated DNA Plasmid Vaccine		n/a	3/8/95	Designated			N/A	N/A	Wyeth-Lederle Vaccines and Pediatrics	West Henrietta	New York	14586	USA								PROBLEM	can't find	Cutaneous T-cell lymphoma	6226	done	
Fampridine	"Treatment of chronic, incomplete spinal cord injury."	Fampridine	DALFAMPRIDINE	Neurelan	6/2/97	Designated			N/A	N/A	"Acorda Therapeutics, Inc."	Hawthorne	New York	10532	USA	EXACT	0121335AA	Fampridine	BH3B64OKL9								MISSING	Not a disease
Fibrin-based agent containing a N-terminally modified parathyroid hormone fragment TGplPTH1-34	Treatment of solitary (unicameral) bone cysts	Fibrin-based agent containing a N-terminally modified parathyroid hormone fragment TGplPTH1-34	PARATHYROID HORMONE	n/a	2/1/07	Designated			N/A	N/A	Kuros Biosurgery AG	Zurich			Switzerland	LONGEST CONTAINS	0005312AA	parathyroid hormone	N19A0T0E5J								MISSING	Not a rare disease
Fibrinogen (human)	For the control of bleeding and prophylactic treatment of patients deficient in fibrinogen.	Fibrinogen (human)	FIBRINOGEN HUMAN	n/a	8/23/95	Designated			N/A	N/A	Alpha Therapeutic Corporation	Los Angeles	California	90032	USA	EXACT	0323977AA	Fibrinogen (human)	N94833051K						"Fibrinogen deficiency, congenital"	2320	approximate	
Fibronectin Peptide	"Prevention of burn injury progression of acute, deep dermal burns in hospitalized patients."	Fibronectin Peptide	FIBRONECTIN	n/a	6/29/11	Designated			N/A	N/A	"NeoMatrix Therapeutics, Inc."	Stony Brook	New York	11790	USA	LONGEST CONTAINS	0136889AA	Fibronectin	AC6UDA2MFC	FIBRONECTIN TETRAPEPTIDE	AC6UDA2MFC	https://ginas.ncats.nih.gov/ginas/app/substances?q=FIBRONECTIN%20TETRAPEPTIDE	done				MISSING	
Filgrastim	For use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy.	Filgrastim	"FILGRASTIM, LICENSE HOLDER UNSPECIFIED"	Neupogen	7/17/95	Designated/Approved	Approved for Orphan Indication	For use in the mobilization of hematopoietic progenitor cells into the peripheral blood collection by leukapheresis.	12/28/95	12/28/02	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0174823AA	Filgrastim	PVI5M0M1GW								MISSING	not a disease
Filgrastim	"Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia."	Filgrastim	"FILGRASTIM, LICENSE HOLDER UNSPECIFIED"	Neupogen	11/7/96	Designated/Approved	Approved for Orphan Indication	"Reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with acute myeloid leukemia."	4/2/98	4/2/05	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0174823AA	Filgrastim	PVI5M0M1GW						Acute myeloid leukemia	12757	done	
Filgrastim	Treatment of neutropenia associated with bone marrow transplants.	Filgrastim	"FILGRASTIM, LICENSE HOLDER UNSPECIFIED"	Neupogen	10/1/90	Designated/Approved	Approved for Orphan Indication	Reduce the duration of neutropenia and neutropenia sequelae in patients with non-myeloid malignancies undergoing ablative chemotherapy followed by BMT.	6/15/94	6/15/01	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0174823AA	Filgrastim	PVI5M0M1GW								MISSING	
Filgrastim	"Treatment of patients with AIDS who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir"	Filgrastim	"FILGRASTIM, LICENSE HOLDER UNSPECIFIED"	Neupogen	9/3/91	Designated/Withdrawn			N/A	N/A	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0174823AA	Filgrastim	PVI5M0M1GW						Cytomegalovirus retinitis	9531	done	not a rare disease
Filgrastim	Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).	Filgrastim	"FILGRASTIM, LICENSE HOLDER UNSPECIFIED"	Neupogen	11/7/90	Designated/Approved	Approved for Orphan Indication	Treatment of patients with severe chronic neutropenia.	12/19/94	12/19/01	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0174823AA	Filgrastim	PVI5M0M1GW								MISSING	
Fixed combination of dimethyl fumarate and aspirin (162mg)	Treatment of multiple sclerosis in patients who experience dimethyl fumarate flushing	Fixed combination of dimethyl fumarate and aspirin (162mg)	DIMETHYL FUMARATE	n/a	9/27/18	Designated			N/A	N/A	Vitalis LLC	93 4th Avenue	New York	10003	USA	EXACT	0306796AA	dimethyl fumarate	FO2303MNI2						Multiple sclerosis	10255	done	
Fk778	"Prevention of acute rejection following kidney, heart, and liver transplantation"	(2Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethly)phenyl]-2-hepten-6-ynamide	MANITIMUS	Fk778	1/10/05	Designated			N/A	N/A	"Fujisawa Healthcare, Inc."	Deerfield	Illinois	60015	USA	EXACT	0334554AA	Fk778	4B135RK2KL						Acute graft versus host disease	6544	approximate	
"Floxuridine, FUDR"	Intraperitoneal treatment of gastric cancer.	"Floxuridine, FUDR"	FLOXURIDINE	n/a	12/22/04	Designated			N/A	N/A	"Franco Muggia, M.D."	New York	New York	10016	USA	EXACT	0007670AA	Floxuridine	039LU44I5M						Stomach cancer	7704	done	
Fludarabine phosphate	Treatment and management of patients with non-Hodgkins lymphoma.	Fludarabine phosphate	FLUDARABINE PHOSPHATE	Fludara	4/18/89	Designated			N/A	N/A	"Berlex Laboratories, Inc."	Richmond	California	94804	USA	EXACT	0127479AA	Fludarabine phosphate	1X9VK9O1SC						Diffuse Large B-Cell Lymphoma	3178	approximate	There are several types of non-Hodgkins lymphoma - type not specified here
Fludarabine phosphate	"Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL."	Fludarabine phosphate	FLUDARABINE PHOSPHATE	Fludara	4/18/89	Designated/Approved	Approved for Orphan Indication		4/18/91	4/18/98	"Berlex Laboratories, Inc."	Richmond	California	94804	USA	EXACT	0127479AA	Fludarabine phosphate	1X9VK9O1SC						Chronic lymphocytic leukemia	6104	done	
Flumecinol	Treatment of hyperbilirubinemia in newborn infants unresponsive to phototherapy.	Flumecinol	FLUMECINOL	Zixoryn	1/15/85	Designated/Withdrawn			N/A	N/A	"Farmacon, Inc."	Westport	Connecticut	6880	USA	EXACT	0136516AA	Flumecinol	JB0YA8LDOW						Hyperbilirubinemia transient familial neonatal	2791	approximate	
Fluocinolone	Treatment uveitis involving the posterior segment of the eye.	Fluocinolone	FLUOCINOLONE	Retisert	7/31/00	Designated/Approved	Approved for Orphan Indication	Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye	4/8/05	4/8/12	"Bausch & Lomb Pharmaceuticals, Inc."	Tampa	Florida	33637	USA	EXACT	0101348AA	Fluocinolone	CT1IX58L9S						Posterior uveitis	4457	done	
Fluorouracil	"For use in combination with interferon alpha-2a, recombinant, for the treatment of advanced colorectal carcinoma."	Fluorouracil	FLUOROURACIL	n/a	4/18/90	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	Nutley	New Jersey	7110	USA	EXACT	0007772AA	Fluorouracil	U3P01618RT						Familial colorectal cancer	8533	done	
Fluorouracil	"For use in combination with interferon alpha-2a, recombinant, for the treatment of esophageal carcinoma."	Fluorouracil	FLUOROURACIL	n/a	10/27/89	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	Nutley	New Jersey	7110	USA	EXACT	0007772AA	Fluorouracil	U3P01618RT						Esophageal cancer	6383	done	
Fluoxetine	Treatment of autism.	Fluoxetine	FLUOXETINE	Prozac	4/30/99	Designated			N/A	N/A	"Neuropharm, Ltd."				United Kingdom	EXACT	0164636AA	Fluoxetine	01K63SUP8D						Autism spectrum disorder	10248	done	
Fluoxetine	Treatment of body dysmorphic disorder in children and adolescents	Fluoxetine	FLUOXETINE	Prozac	4/14/04	Designated			N/A	N/A	"Hollander, Eric MD"	New York	New York	10029	USA	EXACT	0164636AA	Fluoxetine	01K63SUP8D								MISSING	
"Follitropin alfa, recombinant"	"For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism. AMENDED indication 6/27/00: For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure."	"Follitropin alfa, recombinant"	FOLLITROPIN ALFA	Gonal-F	12/21/98	Designated/Approved	Approved for Orphan Indication	For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.	5/24/00	5/24/07	"EMD Serono, Inc."	Rockland	Massachusetts	2370	USA	EXACT	0223029AA	Follitropin alfa	076WHW89TW						"Hypogonadism, isolated, hypogonadotropic "	2897	approximate	
"Follitropin alfa, recombinant"	"For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism. AMENDED indication 6/27/00: For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure."	"Follitropin alfa, recombinant"	FOLLITROPIN ALFA	Gonal-F	12/21/98	Designated/Approved	Approved for Orphan Indication	For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.	5/24/00	5/24/07	"EMD Serono, Inc."	Rockland	Massachusetts	2370	USA	EXACT	0223029AA	Follitropin alfa	076WHW89TW						 Hypothalamic dysfunction	2932	approximate	
Fomepizole	Treatment of methanol or ethylene glycol poisoning.	Fomepizole	FOMEPIZOLE	Antizole	12/22/88	Designated/Approved	Approved for Orphan Indication	"As an antidote to ethylene glycol (antifreeze) poisoning, or for use in suspected ethylene glycol ingestion."	12/4/97	12/4/04	Jazz Pharmaceuticals	Palo Alto	California	94304	USA	EXACT	0155679AA	Fomepizole	83LCM6L2BY								MISSING	Not a disease
Fomepizole	Treatment of methanol or ethylene glycol poisoning.	Fomepizole	FOMEPIZOLE	Antizole	12/22/88	Designated/Approved	Approved for Orphan Indication	"Use for suspected or confirmed methanol poisoning, either alone or in combination with hemodialysis"	12/8/00	12/8/07	Jazz Pharmaceuticals	Palo Alto	California	94304	USA	EXACT	0155679AA	Fomepizole	83LCM6L2BY								MISSING	Not a disease
Fresolimumab	Treatment of idiopathic pulmonary fibrosis	"human anti-transforming growth factor-B1,2,3"	FRESOLIMUMAB	n/a	7/9/04	Designated/Withdrawn			N/A	N/A	Genzyme Corporation	Cambridge	Massachusetts	2142	USA	EXACT	0266319AA	Fresolimumab	375142VBIA						Idiopathic pulmonary fibrosis	8609	done	
Fresolimumab	Treatment of systemic sclerosis	human anti-transforming growth factor beta 1 monoclonal antibody	FRESOLIMUMAB	n/a	1/11/02	Designated/Withdrawn			N/A	N/A	Genzyme Corporation	Cambridge	Massachusetts	2139	USA	EXACT	0266319AA	Fresolimumab	375142VBIA						Systemic scleroderma	9748	done	
Fructose	To decrease intracranial hypertension and/or alleviate cerebral edema in patients who may benefit from osmotherapy.	Glyceol	FRUCTOSE	n/a	2/22/90	Designated/Withdrawn			N/A	N/A	"Chugai Pharmaceutical Co., Ltd."					EXACT	0049934AA	Fructose	6YSS42VSEV								MISSING	symptom; procedure
"Fructose-1,6-diphosphate"	Treatment of painful vaso-occlusive episodes associated with sickle cell disease.	"Fructose-1,6-diphosphate"	FOSFRUCTOSE	Cordox	5/29/98	Designated/Withdrawn			N/A	N/A	"Questcor Pharmaceuticals, Inc."	Union City	California	94587	USA	EXACT	0184292AA	"Fructose-1,6-diphosphate"	M7522JYX1H						Sickle cell anemia	8614	done	
Full Phosphorothioate Antisense Oligonucleotide against EWS-Fli-1 nanoparticles	Treatment of Ewing's sarcoma	Full Phosphorothioate Antisense Oligonucleotide against EWS-Fli-1 nanoparticles		n/a	9/22/08	Designated			N/A	N/A	The Cure Our Children Foundation	Pacific Palisades	California	90272	USA								PROBLEM	can't find	Ewing's family of tumors	9323	approximate	
G17DT Immunogen	Treatment of gastric cancer	G17DT Immunogen		Gastrimmune(Tm)	7/18/02	Designated			N/A	N/A	"Cancer Advances, Inc."	Durham	North Carolina	27713	USA					G17DT	NA	https://adisinsight.springer.com/drugs/800005017 | https://www.drugbank.ca/drugs/DB04914	PROBLEM	absent from GINAS	Stomach cancer	7704	done	
GABOXADOL	Treatment of Angelman syndrome.	"4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol"	GABOXADOL	n/a	9/6/16	Designated			N/A	N/A	Ovid Therapeutics	New York	New York	10036	USA	EXACT	0306876AA	GABOXADOL	K1M5RVL18S						Angelman syndrome	5810	done	
GALSULFASE	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	"N-acetylgalactosamine-4-sulfatase, recombinant human"	GALSULFASE	Naglazyme	2/17/99	Designated/Approved	Approved for Orphan Indication	For patients with mucopolysaccharidosis VI. Galsulfase has been shown to improve walking and stair-climbing capacity.	5/31/05	5/31/12	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA	EXACT	0263661AA	GALSULFASE	59UA429E5G						Mucopolysaccharidosis type VI	7095	done	
GBT-440	Treatment of sickle cell disease (SCD).	2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl) methoxy)benzaldehyde	GBT-440	n/a	12/29/15	Designated			N/A	N/A	"Global Blood Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	1108389AA	GBT-440	3ZO554A4Q8						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
GBT-440	Treatment of sickle cell disease (SCD).	2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl) methoxy)benzaldehyde	GBT-440	n/a	12/29/15	Designated			N/A	N/A	"Global Blood Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	1108389AA	GBT-440	3ZO554A4Q8						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
GBT-440	Treatment of sickle cell disease (SCD).	2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl) methoxy)benzaldehyde	GBT-440	n/a	12/29/15	Designated			N/A	N/A	"Global Blood Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	1108389AA	GBT-440	3ZO554A4Q8						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
GBT-440	Treatment of sickle cell disease (SCD).	2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl) methoxy)benzaldehyde	GBT-440	n/a	12/29/15	Designated			N/A	N/A	"Global Blood Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	1108389AA	GBT-440	3ZO554A4Q8						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
GBT-440	Treatment of sickle cell disease (SCD).	2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl) methoxy)benzaldehyde	GBT-440	n/a	12/29/15	Designated			N/A	N/A	"Global Blood Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	1108389AA	GBT-440	3ZO554A4Q8						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
GBT-440	Treatment of sickle cell disease (SCD).	2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl) methoxy)benzaldehyde	GBT-440	n/a	12/29/15	Designated			N/A	N/A	"Global Blood Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	1108389AA	GBT-440	3ZO554A4Q8						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
GC-1102	Prevention of hepatitis B recurrence following liver transplantation	hepatitis B virus neutralizing human monoclonal antibody		Hepabig Gene	5/6/13	Designated			N/A	N/A	Green Cross Corp.				"Korea, Republic of"	EXACT			XII270YC6M	HEPATITIS B IMMUNE GLOBULIN	XII270YC6M	https://ginas.ncats.nih.gov/ginas/app/substance/dc532395	done				MISSING	Not a rare disease
GDC-0084	Treatment of glioblastoma multiforme (GBM)	"5-(6,6-dimethyl-4-morpholino-8,9-dihydro-6H-[1,4]oxazino[3,4-e]purin-2-yl)pyrimidin-2-amine"	GDC-0084	n/a	2/21/18	Designated			N/A	N/A	Kazia Therapeutics Limited	20 George Street	Hornsby		Australia	EXACT	0706514AA	GDC-0084	P5DKZ70636						Glioblastoma	2491	done	
GDP-fucose	To improve homing to bone (treatment of myeloablation) in patients receiving hematopoietic stem cell transplantation.	FTV1+GDP-fucose	GUANOSINE 5'-DIPHOSPHO-.BETA.-L-FUCOSE	n/a	3/18/11	Designated			N/A	N/A	"America Stem Cell, Inc."	Helotes	Texas	78023	USA	EXACT	0808377AA	GDP-fucose	SM108QK2IH								MISSING	
GDP-fucose	To increase the activity of regulatory T-cells (Tregs) used in the prevention of graft versus host disease in patients undergoing hematopoietic stem cell transplantation	recombinant human fucosyltransferase VI [ FTVI ] + GDP-fucose	GUANOSINE 5'-DIPHOSPHO-.BETA.-L-FUCOSE	n/a	1/27/15	Designated			N/A	N/A	"TargaZyme, Inc."	Carlsbad	California	92011	USA	EXACT	0808377AA	GDP-fucose	SM108QK2IH						Chronic graft versus host disease 	10964	approximate	
GDP-fucose	To increase the activity of regulatory T-cells (Tregs) used in the prevention of graft versus host disease in patients undergoing hematopoietic stem cell transplantation	recombinant human fucosyltransferase VI [ FTVI ] + GDP-fucose	GUANOSINE 5'-DIPHOSPHO-.BETA.-L-FUCOSE	n/a	1/27/15	Designated			N/A	N/A	"TargaZyme, Inc."	Carlsbad	California	92011	USA	EXACT	0808377AA	GDP-fucose	SM108QK2IH						 Acute graft versus host disease	6544	approximate	
GEMCITABINE ELAIDATE	Treatment of pancreatic cancer	"5'-O-(trans-9""-octadecenoyl)-1-beta-D-2'deoxy-2',2'-difluorocytidine"	GEMCITABINE ELAIDATE	n/a	12/7/09	Designated/Withdrawn			N/A	N/A	"Clovis Oncology, Inc."	Boulder	Colorado	80301	USA	EXACT	0699036AA	GEMCITABINE ELAIDATE	231C73W7LG						Pancreatic cancer	9364	done	Not a rare disease
GENISTEIN	Prevention of acute radiation syndrome	"5,7-dihydroxy-3-(4-hydroxyphenyl)-chromen-4-one"	GENISTEIN	n/a	6/18/07	Designated			N/A	N/A	Humanetics Corporation	Eden Prairie	Minnesota	55416	USA	EXACT	0216944AA	GENISTEIN	DH2M523P0H								MISSING	
GIMATECAN	Treatment malignant glioma	"(4S)-4-ethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1-H-pyrano[3?,4?:6,7]-indolizino-[1,2-b]-quinoline-11-carbaldehyde O-(tert-butyl)-(E)-oxime"	BUSULFAN	Gimatecan	11/29/02	Designated/Withdrawn			N/A	N/A	"Sigma-Tau Research, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0241894AA	GIMATECAN	G1LN9045DK						Glioma	6513	done	
GKT-137831	Treatment of systemic sclerosis.	"(2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1h-pyrazolo [4,3-c] pyridine-3,6(2h,5h)-dione)"	GKT-137831	n/a	10/14/15	Designated			N/A	N/A	Genkyotex Innovation SAS	Archamps			France	EXACT	0711295AA	GKT-137831	45II35329V						Systemic scleroderma	9748	done	
GLPG-1690	Treatment of idiopathic pulmonary fibrosis.	"2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-piperazin-1-yl)-8-methylimidazo[1,2-a]pyridin-3-yl)-(methyl)amino)-4-(4-fluorophenyl)-thiazole-5-carbonitrile"	GLPG-1690	n/a	6/8/17	Designated			N/A	N/A	Galapagos NV	Mechelen			Belgium	EXACT	1569660AA	GLPG-1690	I02418V13W						Idiopathic pulmonary fibrosis	8609	done	
GLUTAMATE DECARBOXYLASE 2	Treatment of Type I diabetes with residual beta cell function	Recombinant human glutamic acid decarboxylase 65KDa isoform	GLUTAMATE DECARBOXYLASE 2	n/a	3/22/10	Designated			N/A	N/A	Diamyd Therapeutics AB				Sweden	EXACT	1321251AA	GLUTAMATE DECARBOXYLASE 2	I7YY5T4995						Diabetes mellitus type 1	10268	done	
GLUTATHIONE	Treatment of AIDS-associated cachexia.	Reduced L-glutathione	GLUTATHIONE	Cachexon	2/14/94	Designated			N/A	N/A	Telluride Pharmaceutical Corporation	Hillsborough	New Jersey	8876	USA	EXACT	0012135AA	GLUTATHIONE	GAN16C9B8O						Congenital human immunodeficiency virus	10328	approximate	
GNE Lipoplex	Treatment of hereditary inclusion body myopathy-2	GNE Lipoplex		n/a	11/13/08	Designated			N/A	N/A	"Gradalis, Inc."	Carrollton	Texas	75006	USA								PROBLEM	can't find	Inclusion body myopathy 2	9493	done	
GNE plasmid(H001)	Treatment of hereditary inclusion body myopathy type 2	GNE plasmid(H001)		n/a	3/26/10	Designated			N/A	N/A	HIBM Research Group	Reseda	California	91335	USA								PROBLEM	can't find	Inclusion body myopathy 2	9493	done	
GS-5734	Treatment of Ebola virus disease	"2-Ethylbutyl (2S)-2-{[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate"	GS-5734	n/a	9/18/15	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	1180592AA	GS-5734	3QKI37EEHE						Ebola virus disease	2035	done	
GS-5745	Treatment of gastric cancer	recombinant humanized anti-matrix metalloprotein 9 (MMP9) monoclonal antibody IgG4	ANDECALIXIMAB	n/a	7/16/15	Designated			N/A	N/A	"Gilead Sciences, Inc."	Seattle	Washington	98102	USA	EXACT	1264319AA	GS-5745	571045EIM4						Stomach cancer	7704	done	
Gallium nitrate injection	Treatment of hypercalcemia of malignancy.	Gallium nitrate injection	GALLIUM NITRATE	Ganite	12/5/88	Designated/Approved/Withdrawn			N/A	1/17/98	Solopak Pharmaceutical Co.	Elk Grove Village	Illinois	60007	USA	EXACT	0074884AA	Gallium nitrate	VRA0C6810N								MISSING	
Gamma hydroxybutyrate	"Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations and automatic behavior."	Gamma hydroxybutyrate	4-HYDROXYBUTANOIC ACID	n/a	12/3/87	Designated			N/A	N/A	"Biocraft Laboratories, Inc."	Fair Lawn	New Jersey	7410	USA	EXACT	0029663AA	Gamma hydroxybutyrate	30IW36W5B2						Narcolepsy	7162	done	
Gamma-hydroxybutyric acid	"Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations, and automatic behavior."	Gamma-hydroxybutyric acid	4-HYDROXYBUTANOIC ACID	n/a	1/22/85	Designated/Withdrawn			N/A	N/A	Sigma Chemical Company					EXACT	0029663AA	Gamma-hydroxybutyric acid	30IW36W5B2						Narcolepsy	7162	done	
Gammalinolenic acid	Treatment of juvenile rheumatoid arthritis.	Gammalinolenic acid	GAMOLENIC ACID	n/a	7/27/94	Designated			N/A	N/A	"Zurier, Robert B. M.D."	Worcester	Massachusetts	1655	USA	EXACT	0157891AA	Gammalinolenic acid	78YC2MAX4O						Juvenile idiopathic arthritis	3067	done	Not a rare disease
Gancyclovir	Treatment of severe human cytomegalovirus infections in specific immunosuppressed patient populations.	Gancyclovir	GANCICLOVIR	n/a	6/7/85	Designated/Withdrawn			N/A	N/A	Burroughs Wellcome Company	Research Triangle Park	North Carolina	27709	USA	EXACT	0138738AA	Gancyclovir	P9G3CKZ4P5								MISSING	Not a rare disease; secondary condition
Gastrin 17C Diphtheria Toxoid Immunogen	Treatment of pancreatic cancer	Gastrin 17C Diphtheria Toxoid Immunogen	DIPHTHERIA TOXOID	n/a	7/7/09	Designated			N/A	N/A	Astrimmune Ltd.	Mansfield			United Kingdom	LONGEST CONTAINS	0122236AA	Diphtheria Toxoid	IRH51QN26H						Pancreatic cancer	9364	done	Not a rare disease
Gavilimomab	Acute graft-versus-host disease (aGVHD)	Gavilimomab	GAVILIMOMAB	n/a	11/20/00	Designated/Withdrawn			N/A	N/A	Amgen	Thousand Oaks	California	91320	USA	EXACT	0260275AA	Gavilimomab	TCR92293RC						Acute graft versus host disease	6544	done	
Geneticin	Treatment of amoebiasis.	Geneticin	GENETICIN	n/a	6/6/05	Designated			N/A	N/A	"ProcesScience, Inc (PSI)"	Fayetteville	New York	13066	USA	EXACT	0736334AA	Geneticin	A08F5XTI6G						Amebiasis	652	done	
Gentamicin impregnated PMMA beads on surgical wire	"Treatment of chronic osteomyelitis of post-traumatic, postoperative, or hematogenous origin."	Gentamicin impregnated PMMA beads on surgical wire	GENTAMICIN	Septopal	1/31/91	Designated			N/A	N/A	"Lipha Pharmaceuticals, Inc."	New York	New York	10019	USA	EXACT	0036055AA	Gentamicin	T6Z9V48IKG						Osteomyelitis	7286	done	
Gentamicin liposome injection	Treatment of disseminated Mycobacterium avium-intracellulare infection.	Gentamicin liposome injection	GENTAMICIN	Maitec	7/10/90	Designated			N/A	N/A	"Liposome Company, Inc."	Princeton	New Jersey	8540	USA	EXACT	0036055AA	Gentamicin	T6Z9V48IKG						Mycobacterium Avium Complex infections	7123	done	
Glatiramer acetate	Treatment of multiple sclerosis.	Glatiramer acetate	GLATIRAMER ACETATE	Copaxone	11/9/87	Designated/Approved	Approved for Orphan Indication	For reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis.	12/20/96	12/20/03	Teva Pharmaceuticals USA	Kulpsville	Pennsylvania	19443	USA	EXACT	0218484AA	Glatiramer acetate	5M691HL4BO						Multiple sclerosis	10255	done	
Glatiramer acetate for injection	Treatment of primary-progressive multiple sclerosis	Glatiramer acetate for injection	GLATIRAMER ACETATE	Copaxone	6/5/01	Designated			N/A	N/A	Teva Pharmaceuticals USA	North Wales	Pennsylvania	19454	USA	EXACT	0218484AA	Glatiramer acetate	5M691HL4BO						Multiple sclerosis	10255	approximate	
Glyburide	Treatment of severe cerebral edema in patients with acute ischemic stroke	Glyburide	GLYBURIDE	Cirara	1/12/17	Designated			N/A	N/A	"Remedy Pharmaceuticals, Inc."	New York	New York	10279	USA	EXACT	0053601AA	Glyburide	SX6K58TVWC								MISSING	Not a rare disease
Gonadorelin acetate	For induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion.	Gonadorelin acetate	GONADORELIN ACETATE	Lutrepulse	4/22/87	Designated/Approved	Approved for Orphan Indication		10/10/89	10/10/96	"Ferring Laboratories, Inc."	Suffern	New York	10901	USA	EXACT	0067969AA	Gonadorelin acetate	2RG1XQ1NYJ						Hypothalamic dysfunction	2932	approximate	
Gossypol	Treatment of cancer of the adrenal cortex.	Gossypol	GOSSYPOL	n/a	10/22/90	Designated			N/A	N/A	"Reidenberg, Marcus M. M.D."	New York	New York	10021	USA	EXACT	0392712AA	Gossypol	KAV15B369O						Adrenocortical carcinoma	558	done	
Granexin® gel (aCTI peptide)	Treatment of cutaneous radiation injury due to radiation disaster	Granexin® gel (aCTI peptide)		n/a	8/3/17	Designated			N/A	N/A	"FirstString Research, Inc."	Mount Pleasant	South Carolina	29464	USA	EXACT	0117185AB			ACT-1	NA	https://adisinsight.springer.com/drugs/800027772	PROBLEM	absent from GINAS			MISSING	Not a disease
Group B streptococcus immune globulin	Treatment of neonates for disseminated group B streptococcal infection.	Group B streptococcus immune globulin	IMMUNE GLOBULIN NOS	n/a	5/8/90	Designated/Withdrawn			N/A	N/A	"North American Biologicals, Inc."	Rockville	Maryland	20852	USA	LONGEST CONTAINS	0006531AA	immune globulin					PROBLEM	can't find	Group B strep disease in newborns	9786	done	
Guanethidine monosulfate	Treatment of moderate to severe reflex sympathetic dystrophy and causalgia.	Guanethidine monosulfate	GUANETHIDINE MONOSULFATE	Ismelin	1/6/86	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0030477AA	Guanethidine monosulfate	5UBY8Y002G						Complex regional pain syndrome	4647	done	
Gusperimus	Treatment of acute renal graft rejection episodes.	Gusperimus	GUSPERIMUS	Spanidin	6/27/96	Designated/Withdrawn			N/A	N/A	Bristol-Myers Squibb Pharmaceutical Research Institute	Wallingford	Connecticut	6492	USA	EXACT	0358929AA	Gusperimus	UJ0ZJ76DO9						Acute graft versus host disease	6544	approximate	
H3B-6527	Treatment of hepatocellular carcinoma (HCC)	"(N-{2-[(6-{[(2,6-Dichloro-3,5-dimethoxyphenyl)carbamoyl](methyl)amino}pyrimidin-4- yl)amino]-5-(4-ethylpiperazin-1-yl)phenyl}prop-2-enamide)"	H3B-6527	n/a	9/7/17	Designated			N/A	N/A	"H3 Biomedicine Inc., a US Research Subsidiary of Eisai Co., Ltd."	Cambridge	Massachusetts	2139	USA	EXACT	1278848AA	H3B-6527	4HTE364XIK						Childhood hepatocellular carcinoma	9331	approximate	
H3B-8800	Treatment of acute myeloid leukemia (AML)	"(2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl]oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate"	H3B-8800	n/a	6/21/17	Designated			N/A	N/A	"H3 Biomedicine Inc. (US Research Subsidiary of Eisai Co., Ltd.)"	Cambridge	Massachusetts	2139	USA	EXACT	1297763AA	H3B-8800	90YLS47BRX						Acute myeloid leukemia	12757	done	
H3B-8800	Treatment of chronic myelomonocytic leukemia (CMML)	"(2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl]oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate"	H3B-8800	n/a	6/22/17	Designated			N/A	N/A	"H3 Biomedicine Inc. (US Research Subsidiary of Eisai Co., Ltd.)"	Cambridge	Massachusetts	2139	USA	EXACT	1297763AA	H3B-8800	90YLS47BRX						Chronic myelomonocytic leukemia	8225	done	
HEC-68498 SODIUM	Treatment of idiopathic pulmonary fibrosis (IPF)	"soidum (5-(3-cyanopyrazolo[1,5-a]pyridin-5-yl)-2-methoxypyridin-3-yl)((2,4-difluorophenyl)sulfonyl)amide"	HEC-68498 SODIUM	n/a	7/9/18	Designated			N/A	N/A	"Sunshine Lake Pharma Co., Ltd"	Northern Industry Road #1			China	EXACT	0114833AB	HEC-68498 SODIUM	8PL809KPW4						Idiopathic pulmonary fibrosis	8609	done	
HILTONOL	Treatment for orthopox virus infections	polyinosinic-polycytidilic acid (Poly-ICLC)	HILTONOL	Hiltonol	11/19/02	Designated			N/A	N/A	Oncovir	Washington	District of Columbia	20008	USA	EXACT	0777651AA	HILTONOL					PROBLEM	can't find	Smallpox	7444	approximate	
HIV neutralizing antibodies	Treatment of acquired immunodeficiency syndrome.	HIV neutralizing antibodies		Immupath	3/24/92	Designated/Withdrawn			N/A	N/A	Hemacare Corporation	Sherman Oaks	California	91403	USA								PROBLEM	can't find	Congenital human immunodeficiency virus	10328	approximate	
HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex	"Treatment of invasive and metastatic melanoma (Stages II, III, and IV)."	HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex		Allovectin-7	9/30/99	Designated			N/A	N/A	Vical Incorporated	San Diego	California	92121	USA					Allovectin-7		https://www.semanticscholar.org/topic/Allovectin-7/1355981	PROBLEM	absent from GINAS	"Melanoma, familial"	3460	approximate	
HM-30181	Treatment of angiosarcoma	Oraxol	HM-30181	n/a	4/16/18	Designated			N/A	N/A	"Athenex, Inc. dba Kinex Pharmaceuticals, Inc."	1001 Main Street	Suite 600	14203	USA	EXACT	0843243AA	HM-30181	K4I4I996O4						Angiosarcoma of the liver	5813	approximate	localization of angiosarcoma is not specified
HM-43239 MONOHYDRATE	Treatment of Acute Myeloid Leukemia	"5-Chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazine-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine·monohydrate"	HM-43239 MONOHYDRATE	n/a	10/25/18	Designated			N/A	N/A	"Hanmi Pharmaceutical Company, Ltd."	"14, Wiryeseong-daero"			"Korea, Republic of"	EXACT	0115284AB	HM-43239 MONOHYDRATE	1YT25M37WR						Acute myeloid leukemia	12757	done	
HPV16 E6/E7 synthetic long peptides vaccine	Treatment of epithelial neoplasias of the vulva positive for human papilloma virus type 16.	HPV16 E6/E7 synthetic long peptides vaccine		n/a	9/1/11	Designated			N/A	N/A	ISA Therapeutics BV				Netherlands					synthetic long HPV16 E6/E7 peptides vaccine ISA101b	NA	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/793552	PROBLEM		Vulvar cancer	9349	done	
HTD-1801	Treatment of primary sclerosing cholangitis	"9,10-dimethoxy-5,6-dihydro-[1,3] dioxolo[4,5-g]isoquinolino[3,2-alpha]isoquinolin-7-ium(R)-4-((3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyhexadecahydro-1H-cyclopentane"	HTD-1801	n/a	8/29/16	Designated			N/A	N/A	HighTide Biopharma Pty. Ltd.	Mount Waverley			Australia	EXACT	0117117AB	HTD-1801					PROBLEM	can't find	Primary sclerosing cholangitis	1280	done	
HU5F9-G4	Treatment of acute myeloid (myelogenous) leukemia.	humanized monoclonal antibody of the IgG4 kappa isotype targeting CD47	HU5F9-G4	n/a	8/20/15	Designated			N/A	N/A	"Forty Seven, Inc."	Menlo Park	California	94025	USA	EXACT	1085752AA	HU5F9-G4	90YIEHRFJ9						Acute myeloid leukemia	12757	done	
HUMAN C1-ESTERASE INHIBITOR	Prevention and/or treatment of acute attacks of hereditary angioedema.	"C1-esterase-inhibitor, human, pasteurized"	HUMAN C1-ESTERASE INHIBITOR	Berinert	10/16/92	Designated/Approved	Approved for Orphan Indication	Treatment of acute attacks of hereditary angioedema.	10/8/09	10/8/16	CSL Behring LLC	King of Prussia	Pennsylvania	19406	USA	EXACT	0322941AA	HUMAN C1-ESTERASE INHIBITOR	6KIC4BB60G						Hereditary angioedema	5979	done	
HUMAN C1-ESTERASE INHIBITOR	Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	C1-esterase inhibitor (recombinant)	HUMAN C1-ESTERASE INHIBITOR	Ruconest	2/23/99	Designated/Approved	Approved for Orphan Indication	Treatment of acute attacks of hereditary angioedema (HAE) in adult and adolescent patients.	7/16/14	7/16/21	"Santarus, Inc."	Raleigh	North Carolina	27615	USA	EXACT	0322941AA	HUMAN C1-ESTERASE INHIBITOR	6KIC4BB60G						Hereditary angioedema 	5979	done	
HUMAN C1-ESTERASE INHIBITOR	Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	C1-esterase inhibitor (recombinant)	HUMAN C1-ESTERASE INHIBITOR	Ruconest	2/23/99	Designated/Approved	Approved for Orphan Indication	Treatment of acute attacks of hereditary angioedema (HAE) in adult and adolescent patients.	7/16/14	7/16/21	"Santarus, Inc."	Raleigh	North Carolina	27615	USA	EXACT	0322941AA	HUMAN C1-ESTERASE INHIBITOR	6KIC4BB60G						 Acquired angioedema	8605	done	
HUMAN C1-ESTERASE INHIBITOR	Treatment of antibody mediated rejection (AMR) of solid organ transplants	"C1 esterase inhibitor, human"	HUMAN C1-ESTERASE INHIBITOR	n/a	4/5/18	Designated			N/A	N/A	CSL Behring	1020 First Avenue	PO Box 61501	19406	USA	EXACT	0322941AA	HUMAN C1-ESTERASE INHIBITOR	6KIC4BB60G						Acute graft versus host disease	6544	done	
HUMAN IMMUNOGLOBULIN G	Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)	"Immune Globulin Subcutaneous (Human), 20% Liquid"	HUMAN IMMUNOGLOBULIN G	Hizentra	8/18/14	Designated			N/A	N/A	CSL Behring	King of Prussia	Pennsylvania	19406	USA	EXACT	0201570AA	HUMAN IMMUNOGLOBULIN G	66Y330CJHS						Chronic inflammatory demyelinating polyneuropathy	6102	done	
HUMAN IMMUNOGLOBULIN G	Treatment of patients with primary immune deficiency (PID) that are intolerant to immune globulin intravenous (IGIV) due to severe adverse events or poor venous access	Immune Globulin Subcutaneous (Human)	HUMAN IMMUNOGLOBULIN G	Vivaglobin P (Proposed)	9/22/04	Designated/Withdrawn			N/A	N/A	CSL Behring	King of Prussia	Pennsylvania	19406	USA	EXACT	0201570AA	HUMAN IMMUNOGLOBULIN G	66Y330CJHS								MISSING	
HUMAN T-CELL RECEPTOR (BV13S1)PEPTIDE	Treatment of Pediatric Multiple Sclerosis	"T cell receptor (TCR) peptide (BV5S2, BV6S5, BV13S1) vaccine"	IR-401	Neurovax	2/6/14	Designated			N/A	N/A	"Immune Response BioPharma, Inc."	New York		10001	USA	EXACT	0264335AA	HUMAN T-CELL RECEPTOR (BV13S1)PEPTIDE	VYD9GJM8HP						Pediatric multiple sclerosis	10443	done	
HUMAN T-CELL RECEPTOR (BV5S2)PEPTIDE	Treatment of Pediatric Multiple Sclerosis	"T cell receptor (TCR) peptide (BV5S2, BV6S5, BV13S1) vaccine"	IR-901	Neurovax	2/6/14	Designated			N/A	N/A	"Immune Response BioPharma, Inc."	New York		10001	USA	EXACT	0264313AA	HUMAN T-CELL RECEPTOR (BV5S2)PEPTIDE	VS2A96444Q						Pediatric multiple sclerosis	10443	done	
Halofuginone	Treatment of systemic sclerosis.	Halofuginone	HALOFUGINONE	Stenorol	2/7/00	Designated			N/A	N/A	Collgard Biopharmaceuticals Ltd.				Israel	EXACT	0239918AA	Halofuginone	L31MM1385E						Systemic scleroderma	9748	done	
Hanferon	Treatment of Behcet's disease	Hanferon	PEGINTERFERON ALFA-2A	Hanferon	3/9/12	Designated			N/A	N/A	"HanAll BioPharma Co., Ltd."	Seoul			"Korea, Republic of"	EXACT	0246593AA	Hanferon	Q46947FE7K						Behçet disease	848	done	
Heat Shock Protein (hsp60) antigen	For use in type 1 diabetic mellitus patients with residual beta-cell function	Heat Shock Protein (hsp60) antigen	PROTEIN	Diapep277	5/21/12	Designated/Withdrawn			N/A	N/A	"AndromedA Biotech, LTD"	Yavne 81227			Israel	LONGEST CONTAINS	0087274AA	Protein					PROBLEM	can't find	Diabetes mellitus type 1	10268	done	Not a rare disease
Hemin	"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria."	Hemin	HEMIN	Panhematin	3/16/84	Designated/Approved	Approved for Orphan Indication		7/20/83	7/20/90	Abbott Laboratories	Abbott Park	Illinois	60064	USA	EXACT	0135171AA	Hemin	743LRP9S7N						Acute intermittent porphyria	5732	done	
Hemoximer (pyridoxalated hemoglobin polyoxyethylene)	Treatment of cardiogenic shock	Hemoximer (pyridoxalated hemoglobin polyoxyethylene)	"POLYETHYLENE GLYCOL, UNSPECIFIED"	n/a	12/18/07	Designated			N/A	N/A	"Apex Bioscience, Inc."	Chapel Hill	North Carolina	27514	USA	LONGEST CONTAINS	0137031AA	polyoxyethylene	3WJQ0SDW1A								MISSING	Not a rare disease
Heparin-binding epidermal growth factor-like growth factor	"Prevention and treatment of necrotizing enterocolitis (NEC) in preterm infants with birth weight less than 1,500 grams"	Heparin-binding epidermal growth factor-like growth factor	NEPIDERMIN	n/a	9/18/06	Designated			N/A	N/A	"Trillium Therapeutics, Inc."				Canada	LONGEST CONTAINS	0006804AA	epidermal growth factor	TZK30RF92W						Necrotizing enterocolitis	9767	done	
Hepatitis B immune globulin intravenous (human)	Prophylaxis against hepatitis B virus reinfection in liver transplant patients.	Hepatitis B immune globulin intravenous (human)	HEPATITIS B IMMUNE GLOBULIN INTRAVENOUS (HUMAN)	Nabi-Hb	3/8/95	Designated			N/A	N/A	Biotest Pharmaceuticals Corporation	Boca Raton	Florida	33487	USA	EXACT	0324652AA	Hepatitis B immune globulin intravenous (human)	XII270YC6M								MISSING	Not a rare disease
Herpes simplex virus gene	Treatment of primary and metastatic brain tumors.	Herpes simplex virus gene	HERPES	n/a	10/16/92	Designated			N/A	N/A	"Genetic Therapy, Inc."	Gaithersburg	Maryland	20878	USA	LONGEST CONTAINS	0354825AA	Herpes					PROBLEM	can't find	"Brain tumor, adult"	9307	approximate	
Histrelin	"Treatment of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria."	Histrelin	HISTRELIN	n/a	5/3/91	Designated			N/A	N/A	"Anderson, Karl E., M.D."	Galveston	Texas	77550	USA	EXACT	0135864AA	Histrelin	H50H3S3W74						Porphyria	10353	done	
Histrelin	"Treatment of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria."	Histrelin	HISTRELIN	n/a	5/3/91	Designated			N/A	N/A	"Anderson, Karl E., M.D."	Galveston	Texas	77550	USA	EXACT	0135864AA	Histrelin	H50H3S3W74						Hereditary coproporphyria	6619	done	
Histrelin	"Treatment of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria."	Histrelin	HISTRELIN	n/a	5/3/91	Designated			N/A	N/A	"Anderson, Karl E., M.D."	Galveston	Texas	77550	USA	EXACT	0135864AA	Histrelin	H50H3S3W74						Variegate porphyria	7848	done	
"Human Allogeneic HLA-matched, Umbilical Cord Blood Hematopoietic Progenitor Cells Ex Vivo Expanded on Allogeneic Mesenchymal Precursor Cells"	Treatment of insufficient hematopoietic stem cell production in patients with hematologic malignancies who have failed treatment with conventional chemotherapy.	"Human Allogeneic HLA-matched, Umbilical Cord Blood Hematopoietic Progenitor Cells Ex Vivo Expanded on Allogeneic Mesenchymal Precursor Cells"	HUMAN CORD BLOOD HEMATOPOIETIC PROGENITOR CELL	n/a	9/12/08	Designated			N/A	N/A	"Mesoblast, Inc."	New York	New York	10016	USA	LONGEST CONTAINS	0489101AA	Cord Blood Hematopoietic Progenitor Cells	XU53VK93MC								MISSING	
Human Hemin	Prevention of ischemia reperfusion injury in patients undergoing solid organ transplantation	Human Hemin	HEME	n/a	8/6/13	Designated			N/A	N/A	Borders Technology Management Ltd	Scotland			United Kingdom	EXACT	0183608AA	Human Hemin	42VZT0U6YR								MISSING	Not a rare disease
Human IgM monoclonal antibody (C-58) To CMV	Prophylaxis of cytomegalovirus infections in bone marrow transplant patients.	Human IgM monoclonal antibody (C-58) To CMV	HUMAN IMMUNOGLOBULIN M	Centovir	8/7/89	Designated/Withdrawn			N/A	N/A	"Centocor, Inc."	Malvern	Pennsylvania	19355	USA	LONGEST CONTAINS	0324061AA	Human IgM	Z033I8A98M								MISSING	Not a rare disease
Human T-lymphotropic virus type III Gp160 antigens	Treatment of AIDS.	Human T-lymphotropic virus type III Gp160 antigens	ALLERGENIC EXTRACTS	Vaxsyn Hiv-1	11/20/89	Designated			N/A	N/A	"MicroGeneSys, Inc."	Meriden	Connecticut	6450	USA	LONGEST CONTAINS	0123397AA	antigens					PROBLEM	can't find	Congenital human immunodeficiency virus	10328	approximate	
"Human acid precursor alpha-glucosidase, recombinant"	Treatment of glycogen storage disease type II.	"Human acid precursor alpha-glucosidase, recombinant"		n/a	9/10/96	Designated/Withdrawn			N/A	N/A	Pharming/Genzyme LLC	Framingham	Massachusetts	1701	USA				DTI67O9503	ALGLUCOSIDASE ALFA	DTI67O9503	https://ginas.ncats.nih.gov/ginas/app/substances?q=RHGAA	approximate		Glycogen storage disease type 2	5714	done	
"Human alpha 2,6 sialyltransferase adenoviral gene therapy"	"Treatment of patients with invasive (malignant) brain and central nervous system tumors lacking alpha 2,6 sialyltransferase."	"Human alpha 2,6 sialyltransferase adenoviral gene therapy"		n/a	4/4/05	Designated			N/A	N/A	Falk Center for Molecular Therapeutics	Evanston	Illinois	60201	USA						NA		PROBLEM	"approach, not a drug"			MISSING	
Human autologous bone-forming cell derived from bone marrow stem cells	Treatment of osteonecrosis	Human autologous bone-forming cell derived from bone marrow stem cells	BONE MARROW	n/a	3/24/08	Designated			N/A	N/A	Bone Therapeutics S.A.	Gosselies			Belgium	LONGEST CONTAINS	0100072AA	bone marrow					PROBLEM	can't find			MISSING	
Human immune globulin	Treatment of post-polio syndrome	Human immune globulin	IMMUNE GLOBULIN NOS	Flebogamma(R) 5% Dif	3/29/06	Designated			N/A	N/A	"Instituto Grifols, S.A."	Barcelona			Spain	EXACT	0006531AA	immune globulin	66Y330CJHS	HUMAN IMMUNE GLOBULIN G	66Y330CJHS	https://ginas.ncats.nih.gov/ginas/app/substance/c6126a46	done		Post Polio syndrome	4454	done	
Human immunodeficiency virus immune globulin	Treatment of AIDS.	Human immunodeficiency virus immune globulin	IMMUNE GLOBULIN NOS	n/a	11/21/89	Designated/Withdrawn			N/A	N/A	NABI	Boca Raton	Florida	33487	USA	LONGEST CONTAINS	0006531AA	immune globulin					PROBLEM	can't find	Congenital human immunodeficiency virus	10328	approximate	
Human immunodeficiency virus immune globulin	Treatment of HIV-infected pediatric patients.	Human immunodeficiency virus immune globulin	IMMUNE GLOBULIN NOS	Hivig	1/4/95	Designated/Withdrawn			N/A	N/A	NABI	Boca Raton	Florida	33487	USA	LONGEST CONTAINS	0006531AA	immune globulin					PROBLEM	can't find			MISSING	Not a rare disease
Human immunodeficiency virus immune globulin	Treatment of HIV-infected pregnant women and infants of HIV-infected mothers.	Human immunodeficiency virus immune globulin	IMMUNE GLOBULIN NOS	n/a	3/25/92	Designated/Withdrawn			N/A	N/A	NABI	Boca Raton	Florida	33487	USA	LONGEST CONTAINS	0006531AA	immune globulin					PROBLEM	can't find			MISSING	Not a rare disease
Human telomerase reverse transcriptase peptide vaccine	Treatment of pancreatic cancer	Human telomerase reverse transcriptase peptide vaccine		n/a	7/20/06	Designated			N/A	N/A	GemVax A/S				Norway					telomerase: 540-548 peptide vaccine	NA	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/telomerase-540-548-peptide-vaccine	PROBLEM		Pancreatic cancer	9364	done	Not a rare disease
Human wilms tumor protein 1 peptides	treatment of mesothelioma.	Human wilms tumor protein 1 peptides	PROTEIN	n/a	2/23/16	Designated			N/A	N/A	SELLAS Life Sciences Group	Zug			Switzerland	LONGEST CONTAINS	0087274AA	protein		WT1 126-134 peptide vaccine	NA	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/wt1-126-134-peptide-vaccine	PROBLEM	absent from GINAS	Malignant mesothelioma	7026	done	
"Humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s"	Treatment of immune thrombocytopenia	"Humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s"		n/a	3/28/18	Designated			N/A	N/A	Bioverativ USA Inc.	225 2nd Avenue		2451	USA				GNWE7KJ995	SUTIMLIMAB	GNWE7KJ995	https://ginas.ncats.nih.gov/ginas/app/substance/66f9b5f1 | https://adisinsight.springer.com/drugs/800043955	done		Immune thrombocytopenia	6768	done	
HydroxYPropyl-Beta-Cyclodextrin	"Treatment of Niemann Pick Disease, Type C"	Hydroxy-Propyl-Beta-Cyclodextrin	BETADEX	Trappsol	5/17/10	Designated			N/A	N/A	"Sphingo Biotech, LLC"	Alachua	Florida	32615	USA	LONGEST CONTAINS	0086884AA	Beta Cyclodextrin	JV039JZZ3A						Niemann-Pick disease type C1 	7207	done	
HydroxYPropyl-Beta-Cyclodextrin	"Treatment of Niemann Pick Disease, Type C"	Hydroxy-Propyl-Beta-Cyclodextrin	BETADEX	Trappsol	5/17/10	Designated			N/A	N/A	"Sphingo Biotech, LLC"	Alachua	Florida	32615	USA	LONGEST CONTAINS	0086884AA	Beta Cyclodextrin	JV039JZZ3A						 Niemann-Pick disease type C2	3992	done	
Hydroxocobalamin	Treatment of acute cyanide poisoning	Hydroxocobalamin	HYDROXOCOBALAMIN	n/a	9/22/00	Designated			N/A	N/A	Jazz Pharmaceuticals	Palo Alto	California	94304	USA	EXACT	0055050AA	Hydroxocobalamin	Q40X8H422O								MISSING	
Hydroxocobalamin	Treatment of acute cyanide poisoning	Hydroxocobalamin	HYDROXOCOBALAMIN	Cyanokit	11/25/03	Designated/Approved	Approved for Orphan Indication	Treatment on known or suspected cyanide poisoning	12/15/06	12/15/13	"SERB, S.A."	Brussels			Belgium	EXACT	0055050AA	Hydroxocobalamin	Q40X8H422O								MISSING	
Hydroxycobalamin	Treatment of severe acute cyanide poisoning.	Hydroxycobalamin/sodium thiosulfate	HYDROXOCOBALAMIN	n/a	10/4/85	Designated/Withdrawn			N/A	N/A	"Hall, Alan H., M.D."	Elk Mountain	Wyoming	82324	USA	EXACT	0055050AA	Hydroxycobalamin	Q40X8H422O								MISSING	Not a disease
Hydroxyprogesterone caproate	Prevention of preterm birth in women with a singleton pregnancy	17-a-hydroxyprogesterone caporate (oral formulation)	HYDROXYPROGESTERONE CAPROATE	n/a	6/1/15	Designated			N/A	N/A	"Lipocine, Inc."	Salt Lake City	Utah	84108	USA	EXACT	0030160AA	Hydroxyprogesterone caproate	276F2O42F5								MISSING	
ICA-17043	Treatment of sickle cell disease.	Bis(4-fluorophenyl)phenylacetamide	SENICAPOC	n/a	3/2/00	Designated			N/A	N/A	ICAgen Inc.	Durham	North Carolina	27709	USA	EXACT	0235698AA	ICA-17043	TS6G201A6Q						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
ICA-17043	Treatment of sickle cell disease.	Bis(4-fluorophenyl)phenylacetamide	SENICAPOC	n/a	3/2/00	Designated			N/A	N/A	ICAgen Inc.	Durham	North Carolina	27709	USA	EXACT	0235698AA	ICA-17043	TS6G201A6Q						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
ICA-17043	Treatment of sickle cell disease.	Bis(4-fluorophenyl)phenylacetamide	SENICAPOC	n/a	3/2/00	Designated			N/A	N/A	ICAgen Inc.	Durham	North Carolina	27709	USA	EXACT	0235698AA	ICA-17043	TS6G201A6Q						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
ICA-17043	Treatment of sickle cell disease.	Bis(4-fluorophenyl)phenylacetamide	SENICAPOC	n/a	3/2/00	Designated			N/A	N/A	ICAgen Inc.	Durham	North Carolina	27709	USA	EXACT	0235698AA	ICA-17043	TS6G201A6Q						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
ICA-17043	Treatment of sickle cell disease.	Bis(4-fluorophenyl)phenylacetamide	SENICAPOC	n/a	3/2/00	Designated			N/A	N/A	ICAgen Inc.	Durham	North Carolina	27709	USA	EXACT	0235698AA	ICA-17043	TS6G201A6Q						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
ICA-17043	Treatment of sickle cell disease.	Bis(4-fluorophenyl)phenylacetamide	SENICAPOC	n/a	3/2/00	Designated			N/A	N/A	ICAgen Inc.	Durham	North Carolina	27709	USA	EXACT	0235698AA	ICA-17043	TS6G201A6Q						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
"ICG140:CD19-CD123 cCAR T-cells, a chimeric antigen receptor (CAR) on the surface of T-cells directed against the target proteins CD19 and CD 123"	Treatment of acute lymphoblastic leukemia		PROTEINS	n/a	12/26/17	Designated			N/A	N/A	iCell Gene Therapeutics	25 Health Sciences Drive	Stony Brook	11793	USA	LONGEST CONTAINS	0634640AA	proteins	Q6C9WHR03O	TISAGENLECLEUCEL	Q6C9WHR03O	https://ginas.ncats.nih.gov/ginas/app/substance/9186d841	approximate		Acute lymphoblastic leukemia	522	done	
IDASANUTLIN	Treatment of Acute Myeloid Leukemia	"4-{[(2R,3S,4R,5S)-4-(4-Chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid"	IDASANUTLIN	n/a	5/19/14	Designated			N/A	N/A	Roche Genentech	New York	New York	10016	USA	EXACT	0927402AA	IDASANUTLIN	QSQ883V35U						Acute myeloid leukemia	12757	done	
IDN-7314	Treatment of primary sclerosing cholangitis (PSC)	"(S)-3-((S)-2-(2,6-difluorophenyl)amino)-2-oxoacetamido)propanamido-4-oxo-5-(2,3,4,6-tetrafluorophenoxy)pentanoic acid"	IDN-7314	n/a	6/21/17	Designated			N/A	N/A	Conatus Pharmaceuticals	San Diego	California	92127	USA	EXACT	0111923AB	IDN-7314	WLA1SUY9N8						Primary sclerosing cholangitis	1280	done	
ILORASERTIB	Treatment of acute myelogenous leukemia	"1-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridine-3-yl}phenyl)-3-(3-fluorophenyl)urea)"	ILORASERTIB	n/a	7/28/11	Designated/Withdrawn			N/A	N/A	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0700776AA	ILORASERTIB	6L5D03D975						Acute myeloid leukemia	12757	done	
IMG-7289 DITOSYLATE	Treatment of acute myeloid leukemia (AML)	"N-[(2S)-5-{[(2S)-2-(4-fluorophenyl)cyclopropyl]amino}-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide bis-tosylate salt"	IMG-7289 DITOSYLATE	n/a	2/7/17	Designated			N/A	N/A	"Imago BioSciences, Inc."	San Carlos	California	94070	USA	EXACT	1801123AA	IMG-7289 DITOSYLATE	2PYF2U9JNF						Acute myeloid leukemia	12757	done	
IMG-7289 DITOSYLATE	Treatment of myelofibrosis	"N-[(2S)-5-{[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino}-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide, bis-tosylate salt"	IMG-7289 DITOSYLATE	n/a	6/26/17	Designated			N/A	N/A	"Imago BioSciences, Inc."	San Carlos	California	94070	USA	EXACT	1801123AA	IMG-7289 DITOSYLATE	2PYF2U9JNF						Myelofibrosis	8618	done	
IMGN-901	Treatment of small cell lung cancer.	Maytansinoid DM-1 Conjugated Humanized Monoclonal Antibody N901	LORVOTUZUMAB MERTANSINE	n/a	8/17/10	Designated/Withdrawn			N/A	N/A	"ImmunoGen, Inc."	Waltham	Massachusetts	2451	USA	EXACT	0432575AA	IMGN-901	0IVD6ASY0W						Small cell lung cancer	9344	done	
IMLIFIDASE	Prevention of antibody mediated organ rejection in solid organ transplant patients.	immunoglobulin G degrading enzyme of Streptococcus pyogenes	IMLIFIDASE	n/a	9/10/15	Designated			N/A	N/A	Hansa Medical AB				Sweden	EXACT	1269201AA	IMLIFIDASE	UVJ7NL8S2P						Acute graft versus host disease	6544	approximate	
IMM-101	Treatment of pancreatic cancer	heat killed whole cell mycobacterium obuense	IMM-101	n/a	9/23/14	Designated			N/A	N/A	Immodulon Therapeutics Limited				United Kingdom	EXACT	0787166AA	IMM-101	IZT740JY57						Pancreatic cancer	9364	done	Not a rare disease
IMO-2125	Treatment of melanoma stages IIb-IV.	"two identical 11-mer oligodeoxynucleotide phosphorothioate sequences linked together at their 3'-ends by glycerol-1,3-diphosphorothioate linkages"	TILSOTOLIMOD SODIUM	n/a	6/21/17	Designated			N/A	N/A	"Idera Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0114019AB	IMO-2125	I6CNU8SY0F						"Melanoma, familial"	3460	approximate	melanoma type not specified
IMO-8400	Treatment of Waldenstrom's macroglobulinemia	"antagonist of the endosomal Toll-like receptors (TLRs) 7, 8, and 9"	BAZLITORAN	n/a	12/23/14	Designated			N/A	N/A	"Idera Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	1153271AA	IMO-8400	2U46M95B5M						Waldenstrom macroglobulinemia	7872	done	
IMR-687	Treatment of sickle cell disease (SCD)	"6-[(3S,4S-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imadazo[1,5-a]pyrazin-8-one"	IMR-687	n/a	1/31/17	Designated			N/A	N/A	Imara Inc.	Cambridge	Massachusetts	2139	USA	EXACT	1570429AA	IMR-687	W248Y1AKOR						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
IMR-687	Treatment of sickle cell disease (SCD)	"6-[(3S,4S-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imadazo[1,5-a]pyrazin-8-one"	IMR-687	n/a	1/31/17	Designated			N/A	N/A	Imara Inc.	Cambridge	Massachusetts	2139	USA	EXACT	1570429AA	IMR-687	W248Y1AKOR						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
IMR-687	Treatment of sickle cell disease (SCD)	"6-[(3S,4S-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imadazo[1,5-a]pyrazin-8-one"	IMR-687	n/a	1/31/17	Designated			N/A	N/A	Imara Inc.	Cambridge	Massachusetts	2139	USA	EXACT	1570429AA	IMR-687	W248Y1AKOR						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
IMR-687	Treatment of sickle cell disease (SCD)	"6-[(3S,4S-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imadazo[1,5-a]pyrazin-8-one"	IMR-687	n/a	1/31/17	Designated			N/A	N/A	Imara Inc.	Cambridge	Massachusetts	2139	USA	EXACT	1570429AA	IMR-687	W248Y1AKOR						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
IMR-687	Treatment of sickle cell disease (SCD)	"6-[(3S,4S-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imadazo[1,5-a]pyrazin-8-one"	IMR-687	n/a	1/31/17	Designated			N/A	N/A	Imara Inc.	Cambridge	Massachusetts	2139	USA	EXACT	1570429AA	IMR-687	W248Y1AKOR						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
IMR-687	Treatment of sickle cell disease (SCD)	"6-[(3S,4S-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imadazo[1,5-a]pyrazin-8-one"	IMR-687	n/a	1/31/17	Designated			N/A	N/A	Imara Inc.	Cambridge	Massachusetts	2139	USA	EXACT	1570429AA	IMR-687	W248Y1AKOR						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
INO-1001	Prevention of post-operative complications of aortic anuerysm surgical repair	"(9-[N-(3-morpholinopropyl)-sulfonyl]-5,6-dihydro-5-oxo-11-H-indeno [1,2-c] isoquinoline methanesulfonic acid"	INO-1001	n/a	12/8/04	Designated			N/A	N/A	Inotek Pharmaceuticals Corporation	Beverly	Massachusetts	1915	USA	EXACT	0252175AA	INO-1001	55E08EN074								MISSING	prevention of surgical complications
INO-4995	Treatment of cystic fibrosis	"2-0-Butyryl-1-0-octyl-myo-inositol 3,4,5,6-tetrakisphosphate"	INO-4995	n/a	8/15/03	Designated			N/A	N/A	"Inologic, Inc."	Seattle	Washington	98119	USA	EXACT	0759411AA	INO-4995	3LM5SX2N4X						Cystic fibrosis	6233	done	
INTERFERON BETA-1B	Treatment of acquired immunodeficiency syndrome.	"Interferon beta, recombinant human"	INTERFERON BETA-1B	Betaseron	11/15/88	Designated/Withdrawn			N/A	N/A	"Berlex Laboratories, Inc."	Alameda	California	94501	USA	EXACT	0215690AA	INTERFERON BETA-1B	TTD90R31WZ						Congenital human immunodeficiency virus	10328	approximate	
INTERLEUKIN-1.ALPHA.	For hematopoietic potentiation in aplastic anemia.	"Interleukin-1 alpha, human recombinant"	INTERLEUKIN-1.ALPHA.	n/a	6/17/91	Designated/Withdrawn			N/A	N/A	Immunex Corporation	Seattle	Washington	98101	USA	EXACT	0260639AA	INTERLEUKIN-1.ALPHA.	8666ZWZ3E1						Aplastic anemia	5836	done	
IOFLUBENZAMIDE I-131	"Treatment of metastatic melanoma, stages IIB, IIC, III and IV"	[131I]-N-(2-(diethylamino) ethyl-4-(4 flurobenzamido)-5-(iodo)-2-methoxybenzamide	IOFLUBENZAMIDE I-131	n/a	9/17/08	Designated			N/A	N/A	"Molecular Insight Pharmaceuticals, Inc. (Progenics Subsidiary)"	Tarrytown	New York	10591	USA	EXACT	0460822AA	IOFLUBENZAMIDE I-131	65O1D58Z6V						"Melanoma, familial"	3460	approximate	melanoma type not specified
IR-208	Treatment of Pediatric Multiple Sclerosis	"T cell receptor (TCR) peptide (BV5S2, BV6S5, BV13S1) vaccine"	IR-208	Neurovax	2/6/14	Designated			N/A	N/A	"Immune Response BioPharma, Inc."	New York		10001	USA	EXACT	1259387AA	IR-208	6532E45BS6						Pediatric multiple sclerosis	10443	done	
ITACITINIB ADIPATE	Treatment of pancreatic cancer	"2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-l-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-yl)azetidin-3-yl)acetonitrile adipate"	ITACITINIB ADIPATE	n/a	1/26/15	Designated			N/A	N/A	Incyte Corporation	Wilmington	Delaware	19803	USA	EXACT	0565695AA	ITACITINIB ADIPATE	XZG407XE0Y						Pancreatic cancer	9364	done	Not a rare disease
IVA-337	Treatment of systemic sclerosis	1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid	IVA-337	n/a	3/31/15	Designated			N/A	N/A	Inventiva Pharma				France	EXACT	1338472AA	IVA-337	28Q8AG0PYL						Systemic scleroderma	9748	done	
IVIG	Infection prophylaxis in pediatric patients affected with the human immunodeficiency virus.	"Immune globulin intravenous, human"	HUMAN IMMUNOGLOBULIN G	Gamimune N	2/18/93	Designated/Approved	Approved for Orphan Indication	"For prophylaxis of children with clinical or immunologic evidence of human immunodeficiency virus to decrease the frequency of serious and minor bacterial infections and the frequency of hospitalization, and to increase the time free of serious bacterial infections."	12/27/93	12/27/00	Bayer Corporation	New Haven	Connecticut	6516	USA	EXACT	0201570AA	IVIG	66Y330CJHS						Congenital human immunodeficiency virus	10328	approximate	
IVIG	Treatment for Guillain Barre Syndrome	Immune Globulin Intravenous (human)	IMMUNE GLOBULIN INTRAVENOUS (HUMAN)	Carimune Nf	5/4/04	Designated			N/A	N/A	ZLB Bioplasma AG				Switzerland	EXACT	0233705AA	Immune Globulin Intravenous (human)	66Y330CJHS						Guillain-Barre syndrome	6554	done	
IVIG	Treatment of juvenile rheumatoid arthritis.	Immune globulin intravenous (human)	IMMUNE GLOBULIN INTRAVENOUS (HUMAN)	"Iveegam, Immuno"	12/16/92	Designated/Withdrawn			N/A	N/A	Immuno Clinical Research Corp.	New York	New York	10022	USA	EXACT	0233705AA	Immune globulin intravenous (human)	66Y330CJHS						Juvenile idiopathic arthritis	3067	done	Not a rare disease
IVIG	Treatment of patients with acute myocarditis.	Immune globulin intravenous (human)	IMMUNE GLOBULIN INTRAVENOUS (HUMAN)	"Immune Globulin Intravenous (Human) Immuno, Iveegam"	11/22/93	Designated/Withdrawn			N/A	N/A	Immuno Clinical Research Corp.	New York	New York	10022	USA	EXACT	0233705AA	Immune globulin intravenous (human)	66Y330CJHS								MISSING	
IVIG	Treatment of polymyositis/dermatomyositis.	Immune globulin intravenous (human)	IMMUNE GLOBULIN INTRAVENOUS (HUMAN)	"Iveegam, Immuno"	10/13/92	Designated/Withdrawn			N/A	N/A	Immuno Clinical Research Corp.	New York	New York	10022	USA	EXACT	0233705AA	Immune globulin intravenous (human)	66Y330CJHS						Polymyositis	7425	done	
Ibalizumab	For use in post-exposure prophylaxis for occupational exposure to human immunodeficiency virus.	"5a8, monoclonal antibody to CD4"	IBALIZUMAB	n/a	12/20/93	Designated/Withdrawn			N/A	N/A	"Biogen, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0304938AA	Ibalizumab	LT369U66CE						Congenital human immunodeficiency virus	10328	approximate	
Icodextrin	Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.	Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution	ICODEXTRIN	Extraneal (With 7.5% Icodextrin) Peritoneal Dialysis Solutio	7/18/97	Designated/Approved	Approved for Orphan Indication	For use as a single daily exchange for the long (8-16 hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of chronic renal failure.	12/20/02	12/20/09	Baxter Healthcare Corporation	McGaw Park	Illinois	60085	USA	EXACT	0217367AA	Icodextrin	2NX48Z0A9G								MISSING	too general term
Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution	Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.	Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution	ELECTROLYTES NOS	Extraneal (With 7.5% Icodextrin) Peritoneal Dialysis Solutio	7/18/97	Designated/Approved	Approved for Orphan Indication	For use as a single daily exchange for the long (8-16 hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of chronic renal failure.	12/20/02	12/20/09	Baxter Healthcare Corporation	McGaw Park	Illinois	60085	USA	LONGEST CONTAINS	0704405AA	Electrolytes	2NX48Z0A9G	ICODEXTRIN	2NX48Z0A9G	https://ginas.ncats.nih.gov/ginas/app/substance/82158b80	done				MISSING	too general term
Idarubicin	Treatment of chronic myelogenous leukemia.	Idarubicin	IDARUBICIN	Idamycin	12/2/92	Designated/Withdrawn			N/A	N/A	Pharmacia & Upjohn	Kalamazoo	Michigan	49001	USA	EXACT	0270655AA	Idarubicin	ZRP63D75JW						Chronic myeloid leukemia	6105	done	
Idarubicin HCl for injection	"Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia."	Idarubicin HCl for injection	IDARUBICIN HYDROCHLORIDE	Idamycin	7/25/88	Designated/Approved	Approved for Orphan Indication		9/27/90	9/27/97	"Adria Laboratories, Inc."	Columbus	Ohio	43216	USA	EXACT	0116574AA	Idarubicin HCl	5VV3MDU5IE						Acute myeloid leukemia	12757	done	
Idoxuridine	Treatment of nonparenchymatous sarcomas.	Idoxuridine	IDOXURIDINE	n/a	4/8/96	Designated			N/A	N/A	"NeoPharm, Inc."	Lake Forest	Illinois	60045	USA	EXACT	0008662AA	Idoxuridine	LGP81V5245						Soft tissue sarcoma	4898	approximate	
Ilomastat	Treatment of corneal ulcers.	Matrix metalloproteinase inhibitor	ILOMASTAT	Galardin	12/5/91	Designated			N/A	N/A	"Glycomed, Inc"	Alameda	California	94501	USA	EXACT	0180392AA	Ilomastat	I0403ML141								MISSING	
Iloprost solution for infusion	Treatment of Raynaud's phenomenon secondary to systemic sclerosis.	Iloprost solution for infusion	ILOPROST	n/a	9/21/89	Designated/Withdrawn			N/A	N/A	"Berlex Laboratories, Inc."	Wayne	New Jersey	7470	USA	EXACT	0128096AA	Iloprost	JED5K35YGL						Systemic scleroderma	9748	done	
Iloprost solution for infusion	Treatment of heparin-associated thrombocytopenia.	Iloprost solution for infusion	ILOPROST	n/a	5/14/90	Designated/Withdrawn			N/A	N/A	"Berlex Laboratories, Inc."	Wayne	New Jersey	7470	USA	EXACT	0128096AA	Iloprost	JED5K35YGL						Heparin-induced thrombocytopenia	2650	done	
Imatinib	Treatment of chronic myelogenous leukemia	Imatinib	IMATINIB	Gleevec	1/31/01	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy"	5/10/01	5/10/08	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0240153AA	Imatinib	BKJ8M8G5HI						Chronic myeloid leukemia	6105	done	
Imciromab pentetate	Detecting early necrosis as an indication of rejection of orthotopic cardiac transplants.	Imciromab pentetate	IMCIROMAB PENTETATE	Myoscint	1/25/89	Designated			N/A	N/A	"Centocor, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	0218633AA	Imciromab pentetate	3U979E1001								MISSING	
Imiglucerase	"Replacement therapy in patients with types I, II, and III Gaucher's disease."	Imiglucerase	IMIGLUCERASE	Cerezyme	11/5/91	Designated/Approved	Approved for Orphan Indication	Enzyme replacement therapy in patients with type I Gaucher's disease.	5/23/94	5/23/01	Genzyme Corporation	Cambridge	Massachusetts	2139	USA	EXACT	0192698AA	Imiglucerase	Q6U6J48BWY						Gaucher disease type 1 	2441	done	
Imiglucerase	"Replacement therapy in patients with types I, II, and III Gaucher's disease."	Imiglucerase	IMIGLUCERASE	Cerezyme	11/5/91	Designated/Approved	Approved for Orphan Indication	Enzyme replacement therapy in patients with type I Gaucher's disease.	5/23/94	5/23/01	Genzyme Corporation	Cambridge	Massachusetts	2139	USA	EXACT	0192698AA	Imiglucerase	Q6U6J48BWY						 Gaucher disease type 2 	2442	done	
Imiglucerase	"Replacement therapy in patients with types I, II, and III Gaucher's disease."	Imiglucerase	IMIGLUCERASE	Cerezyme	11/5/91	Designated/Approved	Approved for Orphan Indication	Enzyme replacement therapy in patients with type I Gaucher's disease.	5/23/94	5/23/01	Genzyme Corporation	Cambridge	Massachusetts	2139	USA	EXACT	0192698AA	Imiglucerase	Q6U6J48BWY						 Gaucher disease type 3	2443	done	
Imlifidase	Treatment of anti-glomerular basement membrane (anti-GBM) disease	Imlifidase	IMLIFIDASE	n/a	7/3/18	Designated			N/A	N/A	Hansa Medical AB	"Scheelevägen 22, P. O. Box 785"			Sweden	EXACT	1269201AA	Imlifidase	UVJ7NL8S2P						Goodpasture syndrome	2551	done	
Immortalized human liver cells found in the extracorporeal liver assist device	Treatment of fulminant hepatic failure (acute liver failure)	Immortalized human liver cells found in the extracorporeal liver assist device	HUMAN LIVER	Elad	7/16/04	Designated			N/A	N/A	"Vital Therapies, Inc."	San Diego	California	92128	USA	LONGEST CONTAINS	1309279AA	human liver	JFENOMOVE6								MISSING	Not a rare disease
Implitapide	Treatment of homozygous familial hypercholesterolemia	Implitapide	IMPLITAPIDE	n/a	8/13/04	Designated/Withdrawn			N/A	N/A	Medical Research Laboratories International	Highland Heights	Kentucky	41076	USA	EXACT	0296300AA	Implitapide	Q70OH404HR						Familial hypercholesterolemia	10416	done	Not a rare disease
Implitapide	Treatment of patients with Fredrickson type I or V hyperlipoproteinemia	Implitapide	IMPLITAPIDE	n/a	8/19/04	Designated/Withdrawn			N/A	N/A	Medical Research Laboratories International	Highland Heights	Kentucky	41076	USA	EXACT	0296300AA	Implitapide	Q70OH404HR						Hyperlipoproteinemia type 5	6704	done	
"Imported fire ant venom, allergenic extract"	"For skin testing of victims of fire ant stings to confirm fire ant sensitivity and if positive, for use as immunotherapy for the prevention of IgE-mediated anaphylactic reactions."	"Imported fire ant venom, allergenic extract"	DINOTEFURAN	n/a	5/12/92	Designated			N/A	N/A	"ALK Laboratories, Inc."	Wallingford	Connecticut	6492	USA	LONGEST CONTAINS	0784316AA	venom	1W509710WF								MISSING	not a disease
"Inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium)"	Prevention of rabies virus infection including post-exposure prophylaxis (PEP) for rabies	"Inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium)"	RABIES VIRUS	n/a	12/29/16	Designated			N/A	N/A	"Yisheng US Biopharma, Inc."	Gaithersburg	Maryland	20878	USA	LONGEST CONTAINS	0317044AA	rabies virus	I0V66KI1LD						Rabies	7516	done	
"Inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Polyinosinic-polycyidylic acid, kanamycin and calcium)"	Treatment of Pancreatic Cancer	"Inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Polyinosinic-polycyidylic acid, kanamycin and calcium)"	RABIES VIRUS	n/a	2/15/18	Designated			N/A	N/A	"Yisheng US Biopharma, Inc."	11 Firstfield Road	Gaithersburg		USA	LONGEST CONTAINS	0317044AA	rabies virus	I0V66KI1LD						Pancreatic cancer	9364	done	
Indusatumab vedotin	Treatment of gastric cancer	antibody drug conjugate consisting of fully human anti-guanylyl cyclase C monoclonal antibody linked to the cytotoxic drug monomethyl auristatin E	INDUSATUMAB VEDOTIN	n/a	7/21/14	Designated/Withdrawn			N/A	N/A	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	1198307AA	Indusatumab vedotin	3F0FR4W3H8						Stomach cancer	7704	done	
Indusatumab vedotin	Treatment of pancreatic cancer.	monomethyl auristatin E conjugated to a monoclonal antibody which targets guanylyl cyclase C	INDUSATUMAB VEDOTIN	n/a	7/29/14	Designated/Withdrawn			N/A	N/A	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	1198307AA	Indusatumab vedotin	3F0FR4W3H8						Pancreatic cancer	9364	done	Not a rare disease
Inebilizumab	Treatment of systemic sclerosis	human IgG1k monoclonal antibody	INEBILIZUMAB	n/a	10/16/13	Designated			N/A	N/A	MedImmune	Gaithersburg	Maryland	20878	USA	EXACT	0810173AA	Inebilizumab	74T7185BMM						Systemic scleroderma	9748	done	
Infliximab	Treatment of chronic sarcoidosis	Infliximab	"INFLIXIMAB, LICENSE HOLDER UNSPECIFIED"	Remicade	5/21/03	Designated			N/A	N/A	"Centocor, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	0233716AA	Infliximab	B72HH48FLU						Sarcoidosis	7607	done	
Infliximab	Treatment of pediatric (0 to 16 years of age) Crohn's Disease	Infliximab	"INFLIXIMAB, LICENSE HOLDER UNSPECIFIED"	Remicade	11/12/03	Designated/Approved	Approved for Orphan Indication	For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy	5/19/06	5/19/13	"Centocor, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	0233716AA	Infliximab	B72HH48FLU						Pediatric Crohn's disease	9856	done	
Interferon alfa-2a	Treatment of chronic myelogenous leukemia.	Interferon alfa-2a	INTERFERON ALFA-2A	Roferon A	6/6/89	Designated/Approved	Approved for Orphan Indication	Treatment of chronic myelogenous leukemia.	10/19/95	10/19/02	"Hoffmann-La Roche, Inc."	Nutley	New Jersey	7110	USA	EXACT	0158269AA	Interferon alfa-2a	47RRR83SK7						Chronic myeloid leukemia	6105	done	
Interferon alfa-2a (recombinant)	For the concomitant administration with fluorouracil for the treatment of advanced colorectal cancer.	Interferon alfa-2a (recombinant)	INTERFERON ALFA-2A	Roferon-A	5/14/90	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	Nutley	New Jersey	7110	USA	EXACT	0158269AA	Interferon alfa-2a (recombinant)	47RRR83SK7						Familial colorectal cancer 	8533	approximate	
Interferon alfa-2a (recombinant)	For the concomitant administration with fluorouracil for the treatment of advanced colorectal cancer.	Interferon alfa-2a (recombinant)	INTERFERON ALFA-2A	Roferon-A	5/14/90	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	Nutley	New Jersey	7110	USA	EXACT	0158269AA	Interferon alfa-2a (recombinant)	47RRR83SK7						" Colorectal cancer, childhood"	9320	approximate	
Interferon alfa-2b (recombinant)	Treatment of chronic delta hepatitis.	Interferon alfa-2b (recombinant)	INTERFERON ALFA-2B	Intron A	5/4/90	Designated/Withdrawn			N/A	N/A	Schering Corporation	Kenilworth	New Jersey	7033	USA	EXACT	0160601AA	Interferon alfa-2b (recombinant)	43K1W2T1M6						Hepatitis D	13659	done	
Interferon alfa-2b (recombinant)	Treatment of chronic myelogenous leukemia.	Interferon alfa-2b (recombinant)	INTERFERON ALFA-2B	Intron A	6/22/87	Designated/Withdrawn			N/A	N/A	Schering Corporation	Kenilworth	New Jersey	7033	USA	EXACT	0160601AA	Interferon alfa-2b (recombinant)	43K1W2T1M6						Chronic myeloid leukemia	6105	done	
Interferon alfa-2b (recombinant)	Treatment of laryngeal (respiratory) papillomatosis.	Interferon alfa-2b (recombinant)	INTERFERON ALFA-2B	Intron A	8/17/88	Designated/Withdrawn			N/A	N/A	Schering Corporation	Kenilworth	New Jersey	7033	USA	EXACT	0160601AA	Interferon alfa-2b (recombinant)	43K1W2T1M6						Laryngeal papillomatosis	6864	done	
Interferon alfa-2b (recombinant)	Treatment of primary malignant brain tumors.	Interferon alfa-2b (recombinant)	INTERFERON ALFA-2B	Intron A	5/13/88	Designated/Withdrawn			N/A	N/A	Schering Corporation	Kenilworth	New Jersey	7033	USA	EXACT	0160601AA	Interferon alfa-2b (recombinant)	43K1W2T1M6						"Brain tumor, adult"	9307	approximate	brain tumor not specified
Interferon beta-1a	Treatment of multiple sclerosis.	Interferon beta-1a	INTERFERON BETA-1A	Avonex	12/16/91	Designated/Approved	Approved for Orphan Indication	Treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations.	5/17/96	5/17/03	"Biogen, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0215689AA	Interferon beta-1a	XRO4566Q4R						Multiple sclerosis	10255	done	
Interferon beta-1a	Treatment of patients with secondary progressive multiple sclerosis.	Interferon beta-1a	INTERFERON BETA-1A	Rebif	3/11/96	Designated			N/A	N/A	"EMD Serono, Inc."	Rockland	Massachusetts	2370	USA	EXACT	0215689AA	Interferon beta-1a	XRO4566Q4R						Multiple sclerosis	10255	done	Not a rare disease
Interferon beta-1a (recombinant human)	"Treatment of acute non-A, non-B hepatitis."	Interferon beta-1a (recombinant human)	INTERFERON BETA-1A	n/a	7/24/92	Designated			N/A	N/A	"Biogen, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0215689AA	Interferon beta-1a (recombinant human)	XRO4566Q4R						Non-A-E hepatitis	8687	done	
Interferon beta-1a (recombinant human)	Treatment of pulmonary fibrosis.	Interferon beta-1a (recombinant human)	INTERFERON BETA-1A	Avonex	1/7/99	Designated/Withdrawn			N/A	N/A	"Biogen Idec, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0215689AA	Interferon beta-1a (recombinant human)	XRO4566Q4R						Idiopathic pulmonary fibrosis	8609	done	
Interferon beta-1a (recombinant)	Treatment of symptomatic patients with AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.	Interferon beta-1a (recombinant)	INTERFERON BETA-1A	Rebif	12/2/92	Designated			N/A	N/A	"EMD Serono, Inc."	Roackland	Massachusetts	2370	USA	EXACT	0215689AA	Interferon beta 1a	XRO4566Q4R						Congenital human immunodeficiency virus	10328	approximate	
Interferon beta-1b	Treatment of multiple sclerosis.	Interferon beta-1b	INTERFERON BETA-1B	Betaseron	11/17/88	Designated/Approved	Approved for Orphan Indication	In ambulatory patients with relapsing-remitting multiple sclerosis to reduce the frequency of clinical exacerbations.	7/23/93	7/23/00	Chiron Corp. & Berlex Laboratories	Emeryville	California	94608	USA	EXACT	0215690AA	Interferon beta-1b	TTD90R31WZ						Multiple sclerosis	10255	done	
Interferon gamma-1b	"Delaying time to disease progression in patients with severe, malignant osteopetrosis."	Interferon gamma-1b	INTERFERON GAMMA-1B	Actimmune	9/30/96	Designated/Approved	Approved for Orphan Indication	"Delaying time to disease progression in patients with severe, malignant osteopetrosis."	2/10/00	2/10/07	Horizon Pharma Ireland Limited	Dublin 4			Ireland	EXACT	0174812AA	Interferon gamma-1b	21K6M2I7AG						Osteopetrosis	4155	done	
"Interleukin-1 alpha, human recombinant"	For the promotion of early engraftment in bone marrow transplantation.	"Interleukin-1 alpha, human recombinant"	INTERLEUKIN-1.ALPHA.	n/a	6/17/91	Designated/Withdrawn			N/A	N/A	Immunex Corporation	Seattle	Washington	98101	USA	EXACT	0260639AA	INTERLEUKIN-1.ALPHA.	8666ZWZ3E1								MISSING	
"Interleukin-3, human, recombinant"	For sequential administration with sargramostim to accelerate neutrophil and platelet recovery in patients undergoing autologous bone marrow transplantation for the treatment of Hodgkin's disease or non-Hodgkin's lymphoma.	"Interleukin-3, human, recombinant"	MUPLESTIM	n/a	9/30/93	Designated/Withdrawn			N/A	N/A	Sandoz Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0259836AA	HUMAN INTERLEUKIN-3 (NONGLYCOSYLATED)	A802907MI4						B-cell lymphoma	5877	approximate	
Intetumumab	Treatment of patients with angiosarcoma	Human anti-integrin receptor av monoclonal antibody	INTETUMUMAB	n/a	5/5/05	Designated/Withdrawn			N/A	N/A	"Janssen Research & Development, LLC"	Raritan	New Jersey	8869	USA	EXACT	0267356AA	Intetumumab	GQE1BJE2NI						Angiosarcoma of the breast 	9974	approximate	
Intetumumab	Treatment of patients with angiosarcoma	Human anti-integrin receptor av monoclonal antibody	INTETUMUMAB	n/a	5/5/05	Designated/Withdrawn			N/A	N/A	"Janssen Research & Development, LLC"	Raritan	New Jersey	8869	USA	EXACT	0267356AA	Intetumumab	GQE1BJE2NI						 Angiosarcoma of the scalp 	5814	approximate	
Intetumumab	Treatment of patients with angiosarcoma	Human anti-integrin receptor av monoclonal antibody	INTETUMUMAB	n/a	5/5/05	Designated/Withdrawn			N/A	N/A	"Janssen Research & Development, LLC"	Raritan	New Jersey	8869	USA	EXACT	0267356AA	Intetumumab	GQE1BJE2NI						 Angiosarcoma of the liver	5813	approximate	
Intetumumab	"Treatment of patients with high-risk stage II, stage III, and stage IV malignant melanoma"	human anti-integrin receptor avb3/avb5 monoclonal antibody	INTETUMUMAB	n/a	12/1/04	Designated/Withdrawn			N/A	N/A	"Janssen Research & Development, LLC"	Raritan	New Jersey	8869	USA	EXACT	0267356AA	Intetumumab	GQE1BJE2NI						Primary malignant melanoma of the cervix 	9664	approximate	
Intetumumab	"Treatment of patients with high-risk stage II, stage III, and stage IV malignant melanoma"	human anti-integrin receptor avb3/avb5 monoclonal antibody	INTETUMUMAB	n/a	12/1/04	Designated/Withdrawn			N/A	N/A	"Janssen Research & Development, LLC"	Raritan	New Jersey	8869	USA	EXACT	0267356AA	Intetumumab	GQE1BJE2NI						 Primary malignant melanoma of the conjunctiva 	10410	approximate	
Intetumumab	"Treatment of patients with high-risk stage II, stage III, and stage IV malignant melanoma"	human anti-integrin receptor avb3/avb5 monoclonal antibody	INTETUMUMAB	n/a	12/1/04	Designated/Withdrawn			N/A	N/A	"Janssen Research & Development, LLC"	Raritan	New Jersey	8869	USA	EXACT	0267356AA	Intetumumab	GQE1BJE2NI						" Malignant melanoma, childhood"	91	approximate	
Intraoral fluoride releasing system	Prevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer	Intraoral fluoride releasing system	FLUORIDE ION	Ifrs	7/31/01	Designated			N/A	N/A	"Digestive Care, Inc."	Bethlehem	Pennsylvania	18017	USA	EXACT	0057421AA	fluoride	Q80VPU408O						Head and neck cancer	12425	approximate	Not a rare disease; specific condition due to treatment of a disease
Iobenguane Sulfate I-123	"For scintigraphic detection, localization and staging of neuroblastoma."	Iobenguane Sulfate I-123	IOBENGUANE SULFATE I-123	Omaclear	10/17/05	Designated			N/A	N/A	"Brogan Pharmaceuticals, LLC"	Schererville	Indiana	46375	USA	EXACT	0094202AA	Iobenguane Sulfate I-123	23X1185WBO						Neuroblastoma	7185	done	
Iodine I 123 murine monoclonal antibody to hCG	Detection of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Iodine I 123 murine monoclonal antibody to hCG	IODINE	n/a	11/7/88	Designated			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA	LONGEST CONTAINS	0049183AA	Iodine	9679TC07X4						Gestational trophoblastic tumor	6498	approximate	
Iodine I 131 bis(indium-diethylenetriaminepentaacetic acid)tyrosyllysine/hMN-14 x m734 F(ab')2 bispecific monoclonal antibody	Treatment of small-cell lung cancer.	Iodine I 131 bis(indium-diethylenetriaminepentaacetic acid)tyrosyllysine/hMN-14 x m734 F(ab')2 bispecific monoclonal antibody	PENTETIC ACID	Pentacea	2/22/00	Designated			N/A	N/A	"IBC Pharmaceuticals, L.L.C."	Morris Plains	New Jersey	7950	USA	LONGEST CONTAINS	0011596AA	diethylenetriaminepentaacetic acid	7A314HQM0I						Small cell lung cancer	9344	done	
Iodine I 131 murine monoclonal antibody IgG2a to B cell	Treatment of B-cell leukemia and B-cell lymphoma.	Iodine I 131 murine monoclonal antibody IgG2a to B cell	IODINE	"Immurait, Ll-2-I-131"	9/18/89	Designated/Withdrawn			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA	LONGEST CONTAINS	0049183AA	Iodine	9679TC07X4						"Leukemia, B-cell, chronic "	8227	done	
Iodine I 131 murine monoclonal antibody IgG2a to B cell	Treatment of B-cell leukemia and B-cell lymphoma.	Iodine I 131 murine monoclonal antibody IgG2a to B cell	IODINE	"Immurait, Ll-2-I-131"	9/18/89	Designated/Withdrawn			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA	LONGEST CONTAINS	0049183AA	Iodine	9679TC07X4						 B-cell lymphoma	5877	done	
Iodine I 131 murine monoclonal antibody to hCG	Treatment of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Iodine I 131 murine monoclonal antibody to hCG	IODINE	n/a	11/7/88	Designated/Withdrawn			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA	LONGEST CONTAINS	0049183AA	Iodine	9679TC07X4								MISSING	not a disease
Ipatasertib	For the treatment of gastric cancer including cancer of the gastro-esophageal junction.	Ipatasertib	IPATASERTIB	n/a	4/30/14	Designated/Withdrawn			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0706490AA	Ipatasertib	524Y3IB4HQ						Stomach cancer	7704	done	
Iratumumab	Treatment of Hodgkin's disease	Human anti-CD30 monoclonal antibody	IRATUMUMAB	n/a	9/27/04	Designated			N/A	N/A	"Bristol-Myers Squibb, Inc."	Bloomsbury	New Jersey	8804	USA	EXACT	0256199AA	Iratumumab	AYH22O1B1U						Hodgkin lymphoma	2714	done	
"Isoindolin-1,3-DiThione"	Treatment of Frontotemporal dementia	"Isoindolin-1,3-Di Thione"	"ISOINDOLIN-1,3-DITHIONE"	n/a	11/21/16	Designated			N/A	N/A	"P2D, Inc."	Cincinnati	Ohio	45242	USA	EXACT	1800391AA	"Isoindolin-1,3-DiThione"	7R978066MK						Frontotemporal dementia	8436	done	
Itraconazole suspension	Topical treatment of fungal otitis externa (otomycosis)	Itraconazole suspension	ITRACONAZOLE	n/a	10/30/08	Designated			N/A	N/A	"Fairfield Clinical Trials, LLC"	Weston	Connecticut	6883	USA	EXACT	0130278AA	Itraconazole	304NUG5GF4								MISSING	Not a rare disease
JBT-101	Treatment of cystic fibrosis.	"(6aR, 10aR)-3-(1’,1’-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid"	AJULEMIC ACID	n/a	10/13/15	Designated			N/A	N/A	"Corbus Pharmaceuticals, Inc."	Norwood	Massachusetts	2062	USA	EXACT	0856735AA	JBT-101	OGN7X90BT8						Cystic fibrosis	6233	done	
JBT-101	Treatment of systemic sclerosis	"(6aR, 10aR)-3-(1â¿¿,1â¿¿-dimethylheptyl)-Î¿8-tetrahydro-cannabinol-9-carboxylic acid"	AJULEMIC ACID	n/a	6/10/15	Designated			N/A	N/A	"Corbus Pharmaceuticals, Inc."	Norwood	Massachusetts	2062	USA	EXACT	0856735AA	JBT-101	OGN7X90BT9						Systemic scleroderma	9748	done	
JS-K	Treatment of multiple myeloma	"O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1yl]diazen-1-ium-1,2-diolate"	JS-K	n/a	12/13/13	Designated			N/A	N/A	"JSK Therapeutics, Inc."	Salt Lake City	Utah	84158	USA	EXACT	0761193AA	JS-K	80P1Q21652						Multiple myeloma	7108	done	
"Japanese encephalitis vaccine (live, attenuated)"	Prevention of Japanese encephalitis.	"Japanese encephalitis vaccine (live, attenuated)"		n/a	5/19/99	Designated			N/A	N/A	"Glovax Co., Ltd."								DZ854I04ZE	JAPANESE ENCEPHALITIS VIRUS STRAIN SA 14-14-2 ANTIGEN (FORMALDEHYDE INACTIVATED)	DZ854I04ZE	https://ginas.ncats.nih.gov/ginas/app/substances?q=JAPANESE%20ENCEPHALITIS%20VIRUS%20STRAIN%20SA%2014-14-2%20ANTIGEN%20(FORMALDEHYDE%20INACTIVATED)	done		Japanese encephalitis	6797	done	
"Japanese encephalitis vaccine, inactivated, adsorbed"	Prevention of Japanese encephalitis virus in pediatric patients.	"Japanese encephalitis vaccine, inactivated, adsorbed"		Ixiaro	9/25/12	Designated/Approved	Approved for Orphan Indication	"To extend the age range to include infants, children, and adolescents 2 months to less than 17 years of age for active immunization for the prevention of disease caused by Japanese encephalitis virus."	5/17/13	5/17/20	Intercell AG	Vienna			Austria				2V2JJ0S00T	JAPANESE ENCEPHALITIS VIRUS VACCINE INACTIVATED	2V2JJ0S00T	https://ginas.ncats.nih.gov/ginas/app/substance/c9badd4a	done		Japanese encephalitis	6797	done	
KAF-156 DIPHOSPHATE	Treatment of malaria.	"2-amino-1-[2-(4-fluoro-phenyl)-3-(4-fluoro-phenyl)amino)-8,8-dimethyl-5,6-dihydro-imidazo[1,2-a]pyrazin-7(8H)-yl)-ethanone diphosphate"	KAF-156 DIPHOSPHATE	n/a	5/11/17	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0111776AB	KAF-156 DIPHOSPHATE	R3ZA37PM4S						Malaria	6961	done	
KAR-5585	Treatment of pulmonary arterial hypertension (PAH).	"(S)-8-{2-Amino-6-[1-(5-chloro-biphenyl-2-yl)-(R)-2,2,2-trifluoro-ethoxy]-pyrimidin-4-yl}-2,8-diaza-spiro[4.5]decane-3-carboxylic acid ethyl ester"	KAR-5585	n/a	10/6/15	Designated			N/A	N/A	"KAROS Pharmaceuticals, Inc."	New Haven	Connecticut	6511	USA	EXACT	1200460AA	KAR-5585	507FY6OL37						Autoimmune pulmonary alveolar proteinosis	7499	done	
KD-025	Treatment of graft versus host disease (GVHD)	(2-(3-(4-(1H-indazol-5-ylamino)quinazolin-2-yl)phenoxy)-N-isopropylacetamide-methane sulfonic acid salt)	KD-025	n/a	10/5/17	Designated			N/A	N/A	"Kadmon Corporation, LLC"	New York	New York	10016	USA	EXACT	0540192AA	KD-025	6MX7XE1M0U						Chronic graft versus host disease 	10964	approximate	
KD-025	Treatment of graft versus host disease (GVHD)	(2-(3-(4-(1H-indazol-5-ylamino)quinazolin-2-yl)phenoxy)-N-isopropylacetamide-methane sulfonic acid salt)	KD-025	n/a	10/5/17	Designated			N/A	N/A	"Kadmon Corporation, LLC"	New York	New York	10016	USA	EXACT	0540192AA	KD-025	6MX7XE1M0U						 Acute graft versus host disease	6544	approximate	
KH-176 HYDROCHLORIDE	Treatment of inherited mitochondrial respiratory chain diseases	"(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride"	KH-176 HYDROCHLORIDE	n/a	11/17/14	Designated			N/A	N/A	Khondrion BV				Netherlands	EXACT	1339044AA	KH-176 HYDROCHLORIDE	858M8246UL						Mitochondrial complex I deficiency 	3908	approximate	
KH-176 HYDROCHLORIDE	Treatment of inherited mitochondrial respiratory chain diseases	"(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride"	KH-176 HYDROCHLORIDE	n/a	11/17/14	Designated			N/A	N/A	Khondrion BV				Netherlands	EXACT	1339044AA	KH-176 HYDROCHLORIDE	858M8246UL						 Mitochondrial complex II deficiency 	5053	approximate	
KH-176 HYDROCHLORIDE	Treatment of inherited mitochondrial respiratory chain diseases	"(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride"	KH-176 HYDROCHLORIDE	n/a	11/17/14	Designated			N/A	N/A	Khondrion BV				Netherlands	EXACT	1339044AA	KH-176 HYDROCHLORIDE	858M8246UL						 Mitochondrial complex III deficiency 	8295	approximate	
KH-176 HYDROCHLORIDE	Treatment of inherited mitochondrial respiratory chain diseases	"(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride"	KH-176 HYDROCHLORIDE	n/a	11/17/14	Designated			N/A	N/A	Khondrion BV				Netherlands	EXACT	1339044AA	KH-176 HYDROCHLORIDE	858M8246UL						 Cytochrome c oxidase deficiency 	48	approximate	
KH-176 HYDROCHLORIDE	Treatment of inherited mitochondrial respiratory chain diseases	"(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride"	KH-176 HYDROCHLORIDE	n/a	11/17/14	Designated			N/A	N/A	Khondrion BV				Netherlands	EXACT	1339044AA	KH-176 HYDROCHLORIDE	858M8246UL						 Mitochondrial complex V deficiency	1459	approximate	
KL-1333	Treatment of inherited mitochondrial respiratory chain disease	"2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione"	KL-1333	n/a	4/16/18	Designated			N/A	N/A	NeuroVive Pharmaceutical AB	Medicon Village			Sweden	EXACT	0115042AB	KL-1333	NA2ZOL5UGM						Mitochondrial complex I deficiency 	3908	approximate	
KL-1333	Treatment of inherited mitochondrial respiratory chain disease	"2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione"	KL-1333	n/a	4/16/18	Designated			N/A	N/A	NeuroVive Pharmaceutical AB	Medicon Village			Sweden	EXACT	0115042AB	KL-1333	NA2ZOL5UGM						 Mitochondrial complex II deficiency 	5053	approximate	
KL-1333	Treatment of inherited mitochondrial respiratory chain disease	"2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione"	KL-1333	n/a	4/16/18	Designated			N/A	N/A	NeuroVive Pharmaceutical AB	Medicon Village			Sweden	EXACT	0115042AB	KL-1333	NA2ZOL5UGM						 Mitochondrial complex III deficiency 	8295	approximate	
KL-1333	Treatment of inherited mitochondrial respiratory chain disease	"2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione"	KL-1333	n/a	4/16/18	Designated			N/A	N/A	NeuroVive Pharmaceutical AB	Medicon Village			Sweden	EXACT	0115042AB	KL-1333	NA2ZOL5UGM						 Cytochrome c oxidase deficiency 	48	approximate	
KL-1333	Treatment of inherited mitochondrial respiratory chain disease	"2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione"	KL-1333	n/a	4/16/18	Designated			N/A	N/A	NeuroVive Pharmaceutical AB	Medicon Village			Sweden	EXACT	0115042AB	KL-1333	NA2ZOL5UGM						 Mitochondrial complex V deficiency	1459	approximate	
KP-1339	Treatment of pancreatic cancer	sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)]	IT-139	n/a	6/8/17	Designated			N/A	N/A	"Intezyne Technologies, Inc."	Tampa	Florida	33612	USA	EXACT	1308867AA	KP-1339	7OSJ9KS483						Pancreatic cancer	9364	done	Not a rare disease
KRN-5500	"Parenteral treatment of painful, chronic, chemotherapy-induced peripheral neuropathy that is refractory to conventional analgesics"	"(6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl] amino-L-glyceroB-L-manno-heptopyranosyl]amino-9H-purine)"	KRN-5500	n/a	2/21/14	Designated			N/A	N/A	"DARA BioSciences, Inc."	Raleigh	North Carolina	27615	USA	EXACT	0217243AA	KRN-5500	8VH13L5K20								MISSING	
KRP-203	Prevention of graft versus host disease.	"2-amino-2-[2-[2-chloro-4-[[3-(phenylmethoxy) phenyl] thio]phenyl]ethyl]1,3-propanediol hydrochloride"	KRP-203	n/a	10/6/15	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0831152AA	KRP-203	3YH0N35CE3						Chronic graft versus host disease	10964	approximate	type of GVHD (acute or chronic) is not specified
KRP-203	Prevention of graft versus host disease.	"2-amino-2-[2-[2-chloro-4-[[3-(phenylmethoxy) phenyl] thio]phenyl]ethyl]1,3-propanediol hydrochloride"	KRP-203	n/a	10/6/15	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0831152AA	KRP-203	3YH0N35CE3						Acute graft versus host disease	6544	approximate	type of GVHD (acute or chronic) is not specified
Ketoconazole	For use with cyclosporine A to diminish the nephrotoxicity induced by cyclosporine in organ transplantation.	Ketoconazole	KETOCONAZOLE	Nizoral	3/27/91	Designated/Withdrawn			N/A	N/A	Pharmedic Company	Lake Forest	Illinois	60045	USA	EXACT	0067209AA	Ketoconazole	R9400W927I								MISSING	not a disease
L-2-oxothiazolidine-4-carboxylic acid	Treatment of adult respiratory distress syndrome.	L-2-oxothiazolidine-4-carboxylic acid	OXOTHIAZOLIDINECARBOXYLIC ACID	Procysteine	6/14/94	Designated			N/A	N/A	"Transcend Therapeutics, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0694417AA	L-2-oxothiazolidine-4-carboxylic acid	X7063P804E						Acute respiratory distress syndrome	5698	done	
L-alanine	Use as a targeted contrast agent for diagnostic MRI for the detection and localization of focal liver lesions in patients where use of gadolinium based contrast agents may be medically inadvisable or where gadolinium based contrast agents cannot be administered	manganese (II) chloride tetrahydrate (with L-alanine and vitamin D3 as promoters of absorption)	ALANINE	n/a	9/26/13	Designated			N/A	N/A	CMC Contrast AB				Denmark	EXACT	0009041AA	L-alanine	OF5P57N2ZX								MISSING	
"L-amino acids, vitamins and minerals combined with omega-3 fatty acids"	Treatment of patients with pediatric Crohn's disease	"L-amino acids, vitamins and minerals combined with omega-3 fatty acids"	OMEGA-3 ACIDS	n/a	1/12/11	Designated			N/A	N/A	"Immunopath Profile, Inc."	Naples	Florida	34110	USA	LONGEST CONTAINS	0362765AA	omega 3 fatty acids	71M78END5S						Crohn's disease	10232	done	Not a rare disease
L-asparaginase encapsulated in red blood cells	Treatment of pancreatic cancer.	L-asparaginase encapsulated in red blood cells	HUMAN RED BLOOD CELL	Graspa	7/6/12	Designated			N/A	N/A	ERYTECH Pharma	lyon			France	EXACT	0233896AA	red blood cells	2K524Y8G0J						Pancreatic cancer	9364	done	Not a rare disease
L-baclofen	Treatment of intractable spasticity in children with cerebral palsy.	L-baclofen	"BACLOFEN, (S)-"	Neuralgon	1/30/92	Designated			N/A	N/A	Osmotica Pharmaceutical Corp.	Wilmington	North Carolina	28405	USA	EXACT	0133971AA	L-baclofen	3OHN4989XM						Cerebral palsy	10450	done	Not a rare disease
L-baclofen	Treatment of spasticity associated with spinal cord injury or multiple sclerosis.	L-baclofen	"BACLOFEN, (S)-"	n/a	12/17/91	Designated			N/A	N/A	Osmotica Pharmaceutical Corp.	Wilmington	North Carolina	28405	USA	EXACT	0133971AA	L-baclofen	3OHN4989XM						Multiple sclerosis	10255	done	
L-citrulline	Prevention of clinical sequelae of acute lung injury induced by cardiopulmonary bypass in pediatric patients	L-citrulline	CITRULLINE	n/a	1/9/17	Designated			N/A	N/A	"Asklepion Pharmaceuticals, LLC"	Baltimore	Maryland	21202	USA	EXACT	0124856AA	L-citrulline	29VT07BGDA						Acute respiratory distress syndrome	5698	done	
L-cycloserine	Treatment of Gaucher's disease.	L-cycloserine	LEVCYCLOSERINE	n/a	8/1/89	Designated			N/A	N/A	"Lev, Meir M.D."	New York	New York	10031	USA	EXACT	0319426AA	L-cycloserine	AK7DRB7FMO						Gaucher disease	8233	done	
L-glutamine	Treatment of sickle cell disease	L-glutamine	GLUTAMINE	n/a	8/1/01	Designated			N/A	N/A	"Emmaus Medical, Inc."	Torrance	California	90503	USA	EXACT	0009165AA	L-glutamine	0RH81L854J						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
L-glutamine	Treatment of sickle cell disease	L-glutamine	GLUTAMINE	n/a	8/1/01	Designated			N/A	N/A	"Emmaus Medical, Inc."	Torrance	California	90503	USA	EXACT	0009165AA	L-glutamine	0RH81L854J						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
L-glutamine	Treatment of sickle cell disease	L-glutamine	GLUTAMINE	n/a	8/1/01	Designated			N/A	N/A	"Emmaus Medical, Inc."	Torrance	California	90503	USA	EXACT	0009165AA	L-glutamine	0RH81L854J						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
L-glutamine	Treatment of sickle cell disease	L-glutamine	GLUTAMINE	n/a	8/1/01	Designated			N/A	N/A	"Emmaus Medical, Inc."	Torrance	California	90503	USA	EXACT	0009165AA	L-glutamine	0RH81L854J						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
L-glutamine	Treatment of sickle cell disease	L-glutamine	GLUTAMINE	n/a	8/1/01	Designated			N/A	N/A	"Emmaus Medical, Inc."	Torrance	California	90503	USA	EXACT	0009165AA	L-glutamine	0RH81L854J						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
L-glutamine	Treatment of sickle cell disease	L-glutamine	GLUTAMINE	n/a	8/1/01	Designated			N/A	N/A	"Emmaus Medical, Inc."	Torrance	California	90503	USA	EXACT	0009165AA	L-glutamine	0RH81L854J						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	Treatment of neuropathic pain in patients with sarcoidosis.	L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	CIBINETIDE	n/a	9/13/11	Designated			N/A	N/A	"Araim Pharmaceuticals, Inc."	Ossining	New York	10562	USA	EXACT	0693812AA	ARA-290	9W5677JKDA						Sarcoidosis	7607	done	Not a rare disease
L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	Treatment of sarcoidosis.	L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	CIBINETIDE	n/a	6/13/16	Designated			N/A	N/A	"Araim Pharmaceuticals, Inc."	Tarrytown	New York	10591	USA	EXACT	0693812AA	ARA-290	9W5677JKDA						Sarcoidosis	7607	done	
L. reuteri	"Prevention of necrotizing enterocolitis in preterm infants with birth weight less than or equal to 1,500 grams"	L. reuteri	LACTOBACILLUS REUTERI	n/a	8/1/13	Designated			N/A	N/A	Infant Bacterial Therapeutics	Stockholm			Sweden	EXACT	0734827AA	L. reuteri	9913I24QEE						Necrotizing enterocolitis	9767	done	
LANSOPRAZOLE	Treatment of hepatocellular carcinoma.	"2-[(3-methyl-4-(2,2,2-trifluoroethoxy) pyridin-2-yl)methylsulfinyl] -1H-benzoimidazole"	LANSOPRAZOLE	Prevonco (Tm)	8/27/08	Designated			N/A	N/A	"BioQuant, Inc."	San Diego	California	92121	USA	EXACT	0163199AA	LANSOPRAZOLE	0K5C5T2QPG						Childhood hepatocellular carcinoma	9331	approximate	
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN	Prophylaxis of acute allograft rejection in adult recipients in solid organ transplantation	"anti-T-lymphocyte immune globulin, rabbit"	LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN	n/a	9/12/08	Designated			N/A	N/A	"Neovii Biotech NA, Inc."	Lexington	Massachusetts	2420	USA	EXACT	0233385AA	LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN	D7RD81HE4W								MISSING	
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN	"Treatment of allograft rejection, including solid organ (kidney, liver, heart, lung, and pancreas) and bone marrow transplantation."	Anti-thymocyte serum	LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN	Nashville Rabbit Anti-Thymocyte Serum	6/2/93	Designated			N/A	N/A	Applied Medical Research	Nashville	Tennessee	37203	USA	EXACT	0233385AA	LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN	D7RD81HE4W						Acute graft versus host disease	6544	done	
LAROTRECTINIB SULFATE	Treatment of soft tissue sarcoma.	"(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate"	LAROTRECTINIB SULFATE	n/a	8/31/15	Designated			N/A	N/A	"Loxo Oncology, Inc."	Stamford	Connecticut	6901	USA	EXACT	0934634AA	LAROTRECTINIB SULFATE	RDF76R62ID						Soft tissue sarcoma	4898	done	
LAS-191954	Treatment of epidermolysis bullosa acquisita	"(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile"	LAS-191954	n/a	1/5/17	Designated			N/A	N/A	"Almirall, S.A."	Barcelona			Spain	EXACT	1793813AA	LAS-191954	1MK0TQ597B						Epidermolysis bullosa acquisita	6360	done	
LAS-191954	Treatment of pemphigus vulgaris	"(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile"	LAS-191954	n/a	1/26/15	Designated			N/A	N/A	Almirall S.A.	Barcelona			Spain	EXACT	1793813AA	LAS-191954	1MK0TQ597B						Pemphigus vulgaris	7355	done	
LBS-008	Treatment of Stargardt disease	"1-(3-{4-[3,4-difluoro-2-(trifluoromethyl)phenyl]piperidine-1-carbonyl}-1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridin-6-yl)ethan-1-one"	LBS-008	n/a	9/19/17	Designated			N/A	N/A	"Lin BioScience, LLC"	San Diego	California	92121	USA	EXACT	0112622AB	LBS-008	63WI9S8P1M						Stargardt disease	181	done	
LCL-161	Treatment of multiple myeloma	"(2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide"	LCL-161	n/a	6/28/17	Designated			N/A	N/A	"Paul Maher, MD"	Bethesda	Maryland	20814	USA	EXACT	0922861AA	LCL-161	6TNS415Y3P						Multiple myeloma	7108	done	
LDN-193189 MONOHYDROCHLORIDE	Treatment of fibrodysplasia ossificans progressiva	"4-(6-(4-(piperazin-1-yl)phenyl-pyrazolo[1,5-a]pyrimidin-3-yl)quinoline hydrochloride"	LDN-193189 MONOHYDROCHLORIDE	n/a	4/15/13	Designated			N/A	N/A	"La Jolla Pharmaceutical Company, Inc."	San Diego	California	92121	USA	EXACT	0822037AA	LDN-193189 MONOHYDROCHLORIDE	PLH51K438W						Fibrodysplasia ossificans progressiva	6445	done	
LIPROTAMASE AMYLASE	Treatment of pancreatic insufficiency	"lipase, amylase, and protease"	LIPROTAMASE AMYLASE	Theraclec-Total	1/23/02	Designated/Withdrawn by OPD			N/A	N/A	Altus Biologics Inc.	Cambridge	Massachusetts	2139	USA	EXACT	0052131AA	LIPROTAMASE AMYLASE	I909J9CFAT								MISSING	
LIPROTAMASE LIPASE	Treatment of pancreatic insufficiency	"lipase, amylase, and protease"	LIPROTAMASE LIPASE	Theraclec-Total	1/23/02	Designated/Withdrawn by OPD			N/A	N/A	Altus Biologics Inc.	Cambridge	Massachusetts	2139	USA	EXACT	1307740AA	LIPROTAMASE LIPASE	9VP88M3N3O								MISSING	
LIPROTAMASE PROTEASE	Treatment of pancreatic insufficiency	"lipase, amylase, and protease"	LIPROTAMASE PROTEASE	Theraclec-Total	1/23/02	Designated/Withdrawn by OPD			N/A	N/A	Altus Biologics Inc.	Cambridge	Massachusetts	2139	USA	EXACT	1307795AA	LIPROTAMASE PROTEASE	6435YY37C0								MISSING	
LM-CD45	Prevention of acute graft rejection of human organ transplants.	Anti-CD45 monoclonal antibodies	RECEPTOR-TYPE TYROSINE-PROTEIN PHOSPHATASE C	n/a	9/10/90	Designated/Withdrawn			N/A	N/A	Baxter Healthcare Corporation	Mcgaw Park	Illinois	60085	USA	LONGEST CONTAINS	1315566AA	CD45	FOR10CZY15						Acute graft versus host disease	6544	approximate	
"LOAd703, a modified adenovirus 5/35 containing a CMV promoter-driven transgene cassette with the human transgenes for a membrane-bound CD40 ligand (TMZ-CD40L) and full length 4-1BBL"	Treatment of pancreatic cancer	"LOAd703, a modified adenovirus 5/35 containing a CMV promoter-driven transgene cassette with the human transgenes for a membrane-bound CD40 ligand (TMZ-CD40L) and full length 4-1BBL"	CMV PROMOTER	n/a	5/4/15	Designated			N/A	N/A	Lokon Pharma AB				Sweden	LONGEST CONTAINS	0110845AB	CMV promoter					PROBLEM	can't find	Pancreatic cancer	9364	done	Not a rare disease
LORLATINIB	Treatment of anaplastic lymphoma kinase (ALK)-positive or ROS1-positive non-small cell lung cancer	"(10R)-7-amino-12-fluoro-2,10,16-trimethyl-15 oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile"	LORLATINIB	n/a	6/23/15	Designated			N/A	N/A	"Pfizer, Inc."	New York	New York	10017	USA	EXACT	1137822AA	LORLATINIB	OSP71S83EU						"Non-small cell lung cancer, childhood"	9343	approximate	
LOXO-195	Treatment of solid tumors with neurotrophic tyrosine receptor kinase (NTRK)-fusion proteins	"(13E,14E,22R,6R)-35-fluoro-6-methyl-7-aza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one"	LOXO-195	n/a	9/24/18	Designated			N/A	N/A	"Loxo Oncology, Inc."	"701 Gateway Blvd, Suite 420"	California	94080	USA	EXACT	1570430AA	LOXO-195	0J45910S3X								MISSING	tumor types not specified
LOXO-292	Treatment of pancreatic cancer.	"6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile"	LOXO-292	n/a	10/10/18	Designated			N/A	N/A	"Loxo Oncology, Inc."	"701 Gateway Blvd, Suite 420"	California	94080	USA	EXACT	1805830AA	LOXO-292	CEGM9YBNGD						Pancreatic cancer	9364	done	Not a rare disease
LY-156735	Treatment of circadian rhythm sleep disorders in blind people with no light perception	(R)-N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide	LY-156735	n/a	10/3/01	Designated			N/A	N/A	"Phase 2 Discovery, Inc."	Cincinnati	Ohio	45219	USA	EXACT	0214222AA	LY-156735	3ZX95B1ZWK						Non 24 hour sleep wake disorder	10949	done	
LY-156735	Treatment of neuroleptic-induced tardive dyskinesia in schizophrenia patients	(R)-N-[2-(6-Chloro-methoxy-1H-indol-3yl)propyl]acetamide	LY-156735	n/a	7/3/03	Designated			N/A	N/A	"Phase 2 Discovery, Inc."	Cincinnati	Ohio	45219	USA	EXACT	0214222AA	LY-156735	3ZX95B1ZWK						Tardive dyskinesia	7732	done	Not a rare disease
LY2784544	"Treatment of myeloproliferative disorders (polycythemia vera, essential throbocythemia, and myelofibrosis)"	Adenosine triphosphate type 1 competitive inhibitor of JAK2 V617F tyrosine kinase	GANDOTINIB	n/a	3/3/11	Designated			N/A	N/A	Eli Lilly and Company	Indianapolis	Indiana	46285	USA	EXACT	0763075AA	LY2784544	ANC71R916O						Polycythemia vera 	7422	done	
LY2784544	"Treatment of myeloproliferative disorders (polycythemia vera, essential throbocythemia, and myelofibrosis)"	Adenosine triphosphate type 1 competitive inhibitor of JAK2 V617F tyrosine kinase	GANDOTINIB	n/a	3/3/11	Designated			N/A	N/A	Eli Lilly and Company	Indianapolis	Indiana	46285	USA	EXACT	0763075AA	LY2784544	ANC71R916O						 Essential thrombocythemia 	6594	done	
LY2784544	"Treatment of myeloproliferative disorders (polycythemia vera, essential throbocythemia, and myelofibrosis)"	Adenosine triphosphate type 1 competitive inhibitor of JAK2 V617F tyrosine kinase	GANDOTINIB	n/a	3/3/11	Designated			N/A	N/A	Eli Lilly and Company	Indianapolis	Indiana	46285	USA	EXACT	0763075AA	LY2784544	ANC71R916O						 Myelofibrosis	8618	done	
Labetuzumab	Treatment of small cell lung cancer	MN14 monoclonal antibody to carcinoembryonic antigen	LABETUZUMAB	Cea-Cide	9/18/98	Designated			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA	EXACT	0298135AA	Labetuzumab	EFE6X5M3UY						Small cell lung cancer	9344	done	
Lactic acid	"Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients."	Lactic acid	"LACTIC ACID, UNSPECIFIED FORM"	Aphthaid	6/29/99	Designated			N/A	N/A	"Frontier Pharmaceutical, Inc."	Farmingdale	New York	11735	USA	EXACT	0001536AA	Lactic acid	33X04XA5AT						Aphthous stomatitis	5834	done	
Lactobacilli	Treatment of active chronic pouchitis	"lactic acid bacteria (Lactobacilli, Bifidobacteria, and Steptococci)"		n/a	1/15/02	Designated			N/A	N/A	"VSL Pharmaceuticals, Inc."	Gaithersburg	Maryland	20877	USA								PROBLEM	can't find			MISSING	
Lactobin	Treatment of AIDS-associated diarrhea unresponsive to initial antidiarrheal therapy.	Lactobin	BOS TAURUS COLOSTRUM IMMUNOGLOBULINS	Lactobin	9/12/90	Designated/Withdrawn			N/A	N/A	"Roxane Laboratories, Inc."	Columbus	Ohio	43216	USA	EXACT	1722265AA	Lactobin	EP5SDKM7A0						Congenital human immunodeficiency virus	10328	approximate	
Lanreotide	Treatment for acromegly	Lanreotide	LANREOTIDE	Somatuline Depot	9/11/00	Designated/Approved	Approved for Orphan Indication	Long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy	8/30/07	8/30/14	"IPSEN, Inc."	Milford	Massachusetts	1757	USA	EXACT	0310792AA	Lanreotide	0G3DE8943Y						Acromegaly	5725	done	
Laromustine	Treatment of acute myelogenous leukemia	Laromustine	LAROMUSTINE	Cloretazine	3/27/14	Designated			N/A	N/A	"Nanotherapeutics, Inc."	Alachua	Florida	32615	USA	EXACT	0252620AA	Laromustine	14J2G0U3NQ						Acute myeloid leukemia	12757	done	
Lead-212 DOTAMTATE	Treatment of neuroendocrine tumors	Lead-212 DOTAMTATE		Alphamedix™	10/11/18	Designated			N/A	N/A	"RadioMedix, Inc."	9701 Richmond Avenue	Texas	77042	USA	EXACT	0117207AB			Alphamedix	NA	http://www.checkorphan.org/treatments/cb4c844c8f8aa9b1d7681553a38103e4	PROBLEM	absent from GINAS	Neuroendocrine tumor	13445	done	
Leflunomide	Prevention of acute and chronic rejection in patients who have received solid organ transplants.	Leflunomide	LEFLUNOMIDE	n/a	10/18/96	Designated			N/A	N/A	"Williams, MD, James W."	Chicago	Illinois	60612	USA	EXACT	0170683AA	Leflunomide	G162GK9U4W						Chronic graft versus host disease	10964	approximate	type of GVHD (acute or chronic) is not specified
Leflunomide	Prevention of acute and chronic rejection in patients who have received solid organ transplants.	Leflunomide	LEFLUNOMIDE	n/a	10/18/96	Designated			N/A	N/A	"Williams, MD, James W."	Chicago	Illinois	60612	USA	EXACT	0170683AA	Leflunomide	G162GK9U4W						Acute graft versus host disease	6544	approximate	type of GVHD (acute or chronic) is not specified
Lepirudin	Treatment of heparin-associated thrombocytopenia type II.	Lepirudin	LEPIRUDIN	Refluden	2/13/97	Designated/Approved	Approved for Orphan Indication	For anticoagulation in patients with heparin-induced thrombocytopenia and associated thromboembolic disease in order to prevent further thromboembolic complications.	3/6/98	3/6/05	Hoechst Marion Roussel	Marburg			Germany	EXACT	0190670AA	Lepirudin	Y43GF64R34						Heparin-induced thrombocytopenia	2650	done	
Leu-Lys-Gly-Gln-Leu-Arg-Cys-Ile	Treatment of pancreatic cancer	Leu-Lys-Gly-Gln-Leu-Arg-Cys-Ile	BLISIBIMOD	n/a	8/7/17	Designated			N/A	N/A	"Kalos Therapeutics, Inc."	San Diego	California	92122	USA	EXACT	0267505AA	blisibimod	114VP6C6ES						Pancreatic cancer	9364	done	Not a rare disease
Leucomax	Treatment of neutropenia associated with bone marrow transplants.	Granulocyte macrophage-colony stimulating factor	MOLGRAMOSTIM	Leucomax	12/12/89	Designated/Withdrawn			N/A	N/A	Schering Corporation	Kenilworth	New Jersey	7033	USA	EXACT	0259541AA	Leucomax	B321AL142J								MISSING	
Leucomax	Treatment of severe thermal injuries in patients with greater than 40% full or partial thickness burns.	Granulocyte macrophage-colony stimulating factor	MOLGRAMOSTIM	Leucomax	6/6/89	Designated/Withdrawn			N/A	N/A	Schering Corporation	Kenilworth	New Jersey	7033	USA	EXACT	0259541AA	Leucomax	B321AL142J								MISSING	Not a disease
Leucovorin	For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.	Leucovorin	LEUCOVORIN	Leucovorin Calcium	12/8/86	Designated/Approved	Approved for Orphan Indication	For use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.	12/12/91	12/12/98	Immunex Corporation	Seattle	Washington	98101	USA	EXACT	0009665AA	Leucovorin	Q573I9DVLP						"Colorectal cancer, childhood"	9320	approximate	
Leucovorin calcium	For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.	Leucovorin calcium	LEUCOVORIN CALCIUM	Wellcovorin	6/23/88	Designated/Withdrawn			N/A	N/A	Glaxo Wellcome Research and Development	Research Triangle Park	North Carolina	27709	USA	EXACT	0036986AA	Leucovorin calcium	RPR1R4C0P4						"Colorectal cancer, childhood"	9320	approximate	
Leupeptin	For use as an adjunct to microsurgical peripheral nerve repair.	Leupeptin	LEUPEPTIN	n/a	9/18/90	Designated			N/A	N/A	"Neuromuscular Adjuncts, Inc."	Stony Brook	New York	11794	USA	EXACT	0123217AA	Leupeptin	J97339NR3V								MISSING	"not a disease, a procedure"
Levocarnitine	Treatment of genetic carnitine deficiency.	Levocarnitine	LEVOCARNITINE	Carnitor	2/28/84	Designated/Approved	Approved for Orphan Indication		4/10/86	4/10/93	"Sigma-Tau Pharmaceuticals, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0086908AA	Levocarnitine	0G389FZZ9M						Primary carnitine deficiency	5104	done	not a rare disease
Levocarnitine	Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.	Levocarnitine	LEVOCARNITINE	Carnitor	11/24/86	Designated/Withdrawn			N/A	N/A	"Sigma-Tau Pharmaceuticals, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0086908AA	Levocarnitine	0G389FZZ9M						Primary carnitine deficiency	5104	approximate	
Levocarnitine	Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.	Levocarnitine	LEVOCARNITINE	Carnitor	9/6/88	Designated/Approved	Approved for Orphan Indication	Prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis.	12/15/99	12/15/06	"Sigma-Tau Pharmaceuticals, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0086908AA	Levocarnitine	0G389FZZ9M						Primary carnitine deficiency	5104	approximate	
Levocarnitine	Treatment of pediatric cardiomyopathy.	Levocarnitine	LEVOCARNITINE	Carnitor	11/22/93	Designated			N/A	N/A	"Sigma-Tau Pharmaceuticals, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0086908AA	Levocarnitine	0G389FZZ9M								MISSING	
Levocarnitine	Treatment of primary and secondary carnitine deficiency of genetic origin.	Levocarnitine	LEVOCARNITINE	Carnitor	7/26/84	Designated/Approved	Approved for Orphan Indication	Treatment of primary systemic carnitine deficiency. (approved 12/27/85) Treatment of secondary carnitine deficiency. (approved 12/16/92)	12/16/92	12/16/99	"Sigma-Tau Pharmaceuticals, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0086908AA	Levocarnitine	0G389FZZ9M						Primary carnitine deficiency	5104	done	
Levocarnitine	Treatment of zidovudine-induced mitochondrial myopathy.	Levocarnitine	LEVOCARNITINE	Carnitor	4/7/97	Designated			N/A	N/A	"Sigma-Tau Pharmaceuticals, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0086908AA	Levocarnitine	0G389FZZ9M								MISSING	secondary condition; drug-induced
Levodopa	Treatment of late stage Parkinson's disease	Levodopa and carbidopa	LEVODOPA	Duodopa	1/18/00	Designated/Approved	Approved for Orphan Indication	Treatment of motor flucuations in patients with advanced Parkinson's disease	1/9/15	1/9/22	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0010264AA	Levodopa	46627O600J						Parkinson disease	10251	done	Not a rare disease
Levodopa and carbidopa	Treatment of late stage Parkinson's disease	Levodopa and carbidopa	CARBIDOPA	Duodopa	1/18/00	Designated/Approved	Approved for Orphan Indication	Treatment of motor flucuations in patients with advanced Parkinson's disease	1/9/15	1/9/22	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0065065AA	carbidopa	MNX7R8C5VO						Parkinson disease	10251	done	Not a rare disease
Levomethadyl acetate hydrochloride	Treatment of heroin addicts suitable for maintenance on opiate agonists.	Levomethadyl acetate hydrochloride	LEVOMETHADYL ACETATE HYDROCHLORIDE	Orlaam	1/24/85	Designated/Approved	Approved for Orphan Indication	For the management of opiate dependence.	7/9/93	7/9/00	Biodevelopment Corporation	McLean	Virginia	22102	USA	EXACT	0065054AA	Levomethadyl acetate hydrochloride	B54CW5KG52								MISSING	not a disease
Lidocaine patch 5%	"For relief of allodynia (painful hypersensitivity), and chronic pain in postherpetic neuralgia."	Lidocaine patch 5%	LIDOCAINE	Lidoderm Patch	10/24/95	Designated/Approved	Approved for Orphan Indication		3/19/99	3/19/06	"Teikoku Pharma USA, Inc."	Campbell	California	95008	USA	EXACT	0021807AA	Lidocaine	98PI200987								MISSING	
Linifanib	Treatment of acute myelogenous leukemia	N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea	LINIFANIB	n/a	10/23/07	Designated/Withdrawn			N/A	N/A	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0253098AA	Linifanib	CO93X137CW						Acute myeloid leukemia	12757	done	
Liothyronine sodium injection	Treatment of myxedema coma/precoma.	Liothyronine sodium injection	LIOTHYRONINE SODIUM	Triostat	7/30/90	Designated/Approved	Approved for Orphan Indication	Treatment of myxedema coma/precoma.	12/31/91	12/31/98	SmithKline Beecham Pharmaceuticals	Philadelphia	Pennsylvania	19101	USA	EXACT	0008811AA	Liothyronine sodium	GCA9VV7D2N								MISSING	
Liposomal Glutathione	Support of glutathione deficiency in individuals with inborn errors of metabolism of glutathione (IEMG)	Liposomal Glutathione	GLUTATHIONE	n/a	4/30/10	Designated			N/A	N/A	"Your Energy Systems, LLC"	Palo Alto	California	94301	USA	EXACT	0012135AA	Glutathione	GAN16C9B8O						Glutathione synthetase deficiency	10047	approximate	
Liposomal amphotericin B	Treatment of cryptococcal meningitis.	Liposomal amphotericin B	AMPHOTERICIN B	Ambisome	12/10/96	Designated/Approved	Approved for Orphan Indication	Treatment of disseminated cryptococcosis including meningitis.	8/11/97	8/11/04	"Fujisawa USA, Inc."	Deerfield	Illinois	60015	USA	EXACT	0035881AA	amphotericin B	7XU7A7DROE								MISSING	
Liposomal amphotericin B	Treatment of histoplasmosis.	Liposomal amphotericin B	AMPHOTERICIN B	Ambisome	12/10/96	Designated			N/A	N/A	"Fujisawa USA, Inc."	Deerfield	Illinois	60015	USA	EXACT	0035881AA	amphotericin B	7XU7A7DROE								MISSING	
Liposomal ciprofloxacin for inhalation	Management of bronchiectasis	Liposomal ciprofloxacin for inhalation	CIPROFLOXACIN	n/a	12/27/06	Designated			N/A	N/A	Aradigm Corporation	Hayward	California	94545	USA	EXACT	0140727AA	ciprofloxacin	5E8K9I0O4U								MISSING	
Liposomal cyclosporin A	For aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow transplantation.	Liposomal cyclosporin A	CYCLOSPORINE	Cyclospire	4/30/98	Designated			N/A	N/A	"Vernon Knight, M.D."	Houston	Texas	77030	USA	EXACT	0066808AA	cyclosporin A	83HN0GTJ6D								MISSING	
Liposomal nystatin	Treatment of invasive fungal infections.	Liposomal nystatin	NYSTATIN	Nyotran	6/13/00	Designated			N/A	N/A	The University of Texas	Houston	Texas	77030	USA	EXACT	0035961AA	nystatin	BDF1O1C72E						Aspergillosis 	5856	approximate	
Liposomal nystatin	Treatment of invasive fungal infections.	Liposomal nystatin	NYSTATIN	Nyotran	6/13/00	Designated			N/A	N/A	The University of Texas	Houston	Texas	77030	USA	EXACT	0035961AA	nystatin	BDF1O1C72E						 Systemic candidiasis	1076	approximate	
Liposomal α-galactosylceramide	Prevention of graft-versus-host disease	Liposomal α-galactosylceramide		Lip. Alpha Galactosylceramide	9/28/12	Designated			N/A	N/A	REGiMMUNE Corporation	Mountain View	California	94043	USA					Liposomal α-galactosylceramide			PROBLEM	can't find	Chronic graft versus host disease	10964	approximate	type of GVHD (acute or chronic) is not specified
Liposomal α-galactosylceramide	Prevention of graft-versus-host disease	Liposomal α-galactosylceramide		Lip. Alpha Galactosylceramide	9/28/12	Designated			N/A	N/A	REGiMMUNE Corporation	Mountain View	California	94043	USA					Liposomal α-galactosylceramide			PROBLEM	can't find	Acute graft versus host disease	6544	approximate	type of GVHD (acute or chronic) is not specified
Liposome encapsulated recombinant interleukin-2	Treatment of cancers of the kidney and renal pelvis	Liposome encapsulated recombinant interleukin-2	LIPOSOME	n/a	6/20/94	Designated			N/A	N/A	"Oncothyreon Canada, Inc."				Canada	LONGEST CONTAINS	0266671AA	Liposome		Interleukin-2 liposomal	NA	https://adisinsight.springer.com/drugs/800007372	PROBLEM	can't find	"Kidney cancer, childhood "	9340	approximate	
Liposome encapsulated recombinant interleukin-2	Treatment of cancers of the kidney and renal pelvis	Liposome encapsulated recombinant interleukin-2	LIPOSOME	n/a	6/20/94	Designated			N/A	N/A	"Oncothyreon Canada, Inc."				Canada	LONGEST CONTAINS	0266671AA	Liposome		Interleukin-2 liposomal	NA	https://adisinsight.springer.com/drugs/800007372	PROBLEM	can't find	 Transitional cell cancer of the renal pelvis and ureter	9376	approximate	
Lonafarnib	Treatment of Hepatitis Delta Virus (HDV)infection	Lonafarnib	LONAFARNIB	n/a	11/19/13	Designated			N/A	N/A	"Eiger Biopharmaceuticals, Inc."	San Carlos	California	94070	USA	EXACT	0223494AA	Lonafarnib	IOW153004F						Hepatitis D	13659	done	
Lucinactant	Treatment of cystic fibrosis.	Lucinactant	LUCINACTANT	"Surfaxin(R), Aerosurf(R)"	10/21/10	Designated			N/A	N/A	"Windtree Therapeutics, Inc."	Warrington	Pennsylvania	18976	USA	EXACT	0727402AA	Lucinactant					PROBLEM	can't find	Cystic fibrosis	6233	done	
Lucinactant	Treatment of respiratory distress syndrome in premature infants.	Lucinactant	LUCINACTANT	Surfaxin	10/18/95	Designated			N/A	N/A	"Windtree Therapeutics, Inc."	Warrington	Pennsylvania	18976	USA	EXACT	0727402AA	Lucinactant					PROBLEM	can't find	"Respiratory distress syndrome, infant"	112	approximate	
Lumacaftor	Treatment of cystic fibrosis	"3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxyl-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid"	LUMACAFTOR	n/a	3/2/10	Designated			N/A	N/A	Vertex Pharmaceuticals Inc.	Cambridge	Massachusetts	2139	USA	EXACT	0633114AA	Lumacaftor	EGP8L81APK						Cystic fibrosis	6233	done	
Lumiliximab	Treatment of chronic lymphocytic leukemia	"anti-CD23 IgG1, kappa monoclonal antibody"	GOMILIXIMAB	n/a	2/12/03	Designated/Withdrawn			N/A	N/A	"Biogen IDEC, Inc."	San Diego	California	92122	USA	EXACT	0298102AA	Lumiliximab	8Z13S29R5A						Chronic lymphocytic leukemia	6104	done	
Luveris	For use in association with recombinant human follicle stimulating hormone for the treatment of women with chronic anovulation due to hypogonadotropic hypogonadism.	Recombinant human luteinizing hormone	LUTROPIN ALFA	Luveris	10/7/94	Designated/Approved	Approved for Orphan Indication	"Luveris (lutropin alfa for injection), concomitantly administered with Gonal-f (follitropin alfa for injection), is indicated for stimulation of follicular development in infertile hypogonadotropic hypogonadal women with profound LH deficiency (LH (less than) 1.2 IU/L)."	10/8/04	10/8/11	"EMD Serono, Inc."	Rockland	Massachusetts	2370	USA	EXACT	0252017AA	Luveris	3JGY52XJNA						"Hypogonadism, isolated, hypogonadotropic"	2897	done	
Lysine acetylsalicylate injectable	Treatment of pain and fever secondary to sickle cell disease crisis.	Lysine acetylsalicylate injectable	ASPIRIN LYSINE	n/a	8/1/89	Designated/Withdrawn			N/A	N/A	G.D. Searle & Company	Skokie	Illinois	60077	USA	EXACT	0128143AA	Lysine acetylsalicylate	XAN4V337CI						Sickle cell anemia	8614	approximate	
MA09-hRPE cells	Treatment of Stargardt's macular dystrophy	MA09-hRPE cells		n/a	2/2/10	Designated			N/A	N/A	Astellas Pharma Global Development Inc.	Northbrook	Illinois	60062	USA								PROBLEM	can't find	Stargardt disease	181	done	
MANF	Treatment of retinal artery occlusion.	"mesencephalic, astrocyte-derived neurotrophic factor"	MANF	n/a	9/10/15	Designated			N/A	N/A	"Amarantus BioScience Holdings, Inc."	San Francisco	California	94111	USA	EXACT	0110776AB	MANF	5R3OV3AM5M								MISSING	
MANF	Treatment of retinitis pigmentosa	"human recombinant mesencephalic, astrocyte derived neurotrophic factor"	MANF	n/a	12/22/14	Designated			N/A	N/A	"Amarantus BioScience Holdings, Inc."	San Francisco	California	94111	USA	EXACT	0110776AB	MANF	5R3OV3AM5M						Retinitis pigmentosa	5694	done	
MANGANESE CHLORIDE	Use as a targeted contrast agent for diagnostic MRI for the detection and localization of focal liver lesions in patients where use of gadolinium based contrast agents may be medically inadvisable or where gadolinium based contrast agents cannot be administered	manganese (II) chloride tetrahydrate (with L-alanine and vitamin D3 as promoters of absorption)	MANGANESE CHLORIDE	n/a	9/26/13	Designated			N/A	N/A	CMC Contrast AB				Denmark	EXACT	0050997AA	MANGANESE CHLORIDE	QQE170PANO								MISSING	
MARALIXIBAT CHLORIDE	Treatment of alagille syndrome	"(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride"	MARALIXIBAT CHLORIDE	n/a	9/4/13	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0232326AA	MARALIXIBAT CHLORIDE	V78M04F0XC						Alagille syndrome	804	done	
MARALIXIBAT CHLORIDE	Treatment of primary biliary cirrhosis	"(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride"	MARALIXIBAT CHLORIDE	n/a	9/4/13	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0232326AA	MARALIXIBAT CHLORIDE	V78M04F0XC						Primary biliary cholangitis	7459	done	
MARALIXIBAT CHLORIDE	Treatment of primary sclerosing cholangitis	"(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride"	MARALIXIBAT CHLORIDE	n/a	9/4/13	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	Lexington	California	2421	USA	EXACT	0232326AA	MARALIXIBAT CHLORIDE	V78M04F0XC						Primary sclerosing cholangitis	1280	done	
MAVOGLURANT	Treatment of Fragile X syndrome	"(-)-(3aR,4S,7aR)-4-Hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester"	MAVOGLURANT	n/a	10/12/11	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0568354AA	MAVOGLURANT	GT0I9SV4F6						Fragile X syndrome	6464	done	
MAVORIXAFOR	"Treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome"	"N1-(1H-benzimidazol-2-ylmethyl)-N1-((S)-5,6,7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine"	MAVORIXAFOR	n/a	10/10/18	Designated			N/A	N/A	"X4 Pharmaceuticals, Inc."	1 Broadway	Massachusetts	2142	USA	EXACT	0248602AA	MAVORIXAFOR	0G9LGB5O2W						WHIM syndrome	9297	done	
MAX-40279 HEMIFUMARATE	Treatment of acute myeloid leukemia	"7-(4-fluoro-2-methoxyphenyl)-6-methyl-N-(1-(piperidin-4-yl)-1H-pyrazol-4-yl) thieno [3,2-d]pyrimidin-2-amine semi-fumarate"	MAX-40279 HEMIFUMARATE	n/a	3/26/18	Designated			N/A	N/A	"MaxiNovel Pharmaceutical Co.,Ltd"	Building A4-1005	181 Science Boulevard		China	EXACT	0115047AB	MAX-40279 HEMIFUMARATE	JU19P2M2KM						Acute myeloid leukemia	12757	done	
MB-07133	Treatment of hepatocellular carcinoma.	"4-Amino-1-[5-O-[(2R, 4S)-2-oxido-4-(4-pyridinyl)-1, 3, 2-dioxaphosphorinan-2-yl]-b-D-arabinofuranosyl]-2(1H)-pyrimidinone"	MB-07133	n/a	8/22/07	Designated			N/A	N/A	"Ligand Pharmaceuticals, Inc."	LaJolla	California	92037	USA	EXACT	0248179AA	MB-07133	BNL5ERR07R						Childhood hepatocellular carcinoma	9331	approximate	
MBL-HCV1	Prevention of Hepatitis C recurrence in patients receiving liver transplantation	monoclonal antibody directed at hepatitis C virus E2 glycoprotein	MBL-HCV1	n/a	11/4/13	Designated			N/A	N/A	MassBiologics-University of MA Medical School	Boston	Massachusetts	2126	USA	EXACT	0341071AA	MBL-HCV1					PROBLEM	can't find			MISSING	Not a rare disease
MCMV3068A	Prevention of maternal-fetal transmission of congenital CMV in pregnant women who acquire CMV infection during pregnancy	MCMV5322A/MCMV3068A	MCMV-3068A	n/a	11/22/11	Designated/Withdrawn			N/A	N/A	Genentech	South San Francisco	California	94080	USA	EXACT	0882542AA	MCMV3068A	I4SA959J1V						Congenital cytomegalovirus	1480	done	
MCMV5322A	Prevention of maternal-fetal transmission of congenital CMV in pregnant women who acquire CMV infection during pregnancy	MCMV5322A/MCMV3068A	MCMV-5322A	n/a	11/22/11	Designated/Withdrawn			N/A	N/A	Genentech	South San Francisco	California	94080	USA	EXACT	0882553AA	MCMV5322A	WEN12F23SC						Congenital cytomegalovirus	1480	done	
MDX-11	Adjunctive treatment of acute myelogenous leukemia.	Monoclonal antibody PM-81	MDX-11	n/a	6/27/91	Designated/Withdrawn			N/A	N/A	"Medarex, Inc."	Bloomsbury	New Jersey	8804	USA	EXACT	0259767AA	MDX-11					PROBLEM	can't find	Acute myeloid leukemia	12757	done	
MDX-11	For the exogenous depletion of CD14 and CD15 positive acute myeloid leukemic bone marrow cells from patients undergoing bone marrow transplantation.	Monoclonal antibodies PM-81 and AML-2-23	MDX-11	n/a	3/12/90	Designated/Withdrawn			N/A	N/A	"Medarex, Inc."	Bloomsbury	New Jersey	8804	USA	EXACT	0259767AA	MDX-11					PROBLEM	can't find			MISSING	not a disease
MECASERMIN	Treatment of short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines.	Recombinant human insulin-like growth factor-I	MECASERMIN	Pv802	2/16/00	Designated			N/A	N/A	GroPep Pty Ltd.				Australia	EXACT	0167215AA	MECASERMIN	7GR9I2683O						Short bowel syndrome	1502	done	
MEDI-551	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders	"humanized affinity-optimized, afucosylated immunoglobulin G1 kappa monoclonal antibody against CD19"	INEBILIZUMAB	n/a	2/10/16	Designated			N/A	N/A	"MedImmune, LLC"	Gaithersburg	Maryland	20878	USA	EXACT	0810173AA	MEDI-551	74T7185BMM						Neuromyelitis optica 	6267	done	
MEDI-551	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders	"humanized affinity-optimized, afucosylated immunoglobulin G1 kappa monoclonal antibody against CD19"	INEBILIZUMAB	n/a	2/10/16	Designated			N/A	N/A	"MedImmune, LLC"	Gaithersburg	Maryland	20878	USA	EXACT	0810173AA	MEDI-551	74T7185BMM						 Neuromyelitis optica spectrum disorder	9414	done	
MEDI-6012	Treatment of LCAT deficiency syndromes	recombinant human lecithin:cholesterol acyltransferase (rhLCAT)	RECOMBINANT HUMAN LECITHIN:CHOLESTEROL ACYLTRANSFERASE	n/a	9/2/10	Designated			N/A	N/A	"AlphaCore Pharma, LLC"	Ann Arbor	Michigan	48103	USA	EXACT	1217330AA	MEDI-6012	XBA7E67HMJ						Familial LCAT deficiency	4011	done	
METENKEFALIN	Treatment of pancreatic cancer.	met-enkephalin; Met-N	METENKEFALIN	n/a	2/18/11	Designated			N/A	N/A	"NBI Pharmaceuticals, Inc."	Bozeman	Montana	59715	USA	EXACT	0128574AA	METENKEFALIN	9JEZ9OD3AS						Pancreatic cancer	9364	done	Not a rare disease
METHIONINE C-11	Diagnostic agent for the Clinical Management of Medulloblastoma	"2-Amino-4-[11C]methylsulfanyl-butanoic acid, l-[S methyl[11C]methionine"	METHIONINE C-11	n/a	1/17/17	Designated			N/A	N/A	"Advanced Imaging Projects, LLC"	Lake Worth	Florida	33467	USA	EXACT	0154803AA	METHIONINE C-11	ED857BWP29						Medulloblastoma	7005	done	
MGd-006	Treatment of acute myeloid leukemia (AML)	CD123 x CD3 dual affinity re-targeting (DART®) protein	MGD-006	n/a	12/22/16	Designated			N/A	N/A	"MacroGenics, Inc."	Rockville	Maryland	20850	USA	EXACT	0914705AA	MGd-006	0AHT0IC02G						Acute myeloid leukemia	12757	done	
MIRIKIZUMAB	Treatment of ulcerative colitis in pediatric patients	humanized immunoglobulin G4-variant monoclonal antibody directed against the p19 subunit of interleukin (IL)-23	MIRIKIZUMAB	n/a	6/15/17	Designated			N/A	N/A	Eli Lilly & Company	Indianapolis	Indiana	46285	USA	EXACT	1800186AA	MIRIKIZUMAB	Z7HVY03PHP						Pediatric ulcerative colitis	9857	done	
MK-2206	Treatment of ovarian cancer.	"8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naph-thyrin-3(2H)-one mono-hydrochloride"	MK-2206	n/a	9/3/09	Designated			N/A	N/A	Merck Sharp & Dohme Corp.	North Wales	Pennsylvania	19454	USA	EXACT	0540136AA	MK-2206	4HA45S22ZZ						Ovarian cancer	7295	done	
MLN4924-Inhibitor of Nedd8-activating enzyme (NAE)	Treatment of acute myelogenous leukemia.	MLN4924-Inhibitor of Nedd8-activating enzyme (NAE)	PEVONEDISTAT	n/a	2/4/11	Designated			N/A	N/A	Millennium Pharmaceuticals	Cambridge	Massachusetts	2139	USA	EXACT	0645341AA	MLN4924	S3AZD8D215						Acute myeloid leukemia	12757	done	
MM-141	Treatment of pancreatic cancer	"human trtravalent, bi-specific monoclonal antibody that binds and co-inhibits two growth factor receptors; insulin-like growth factor receptor 1 (IGF-1R) and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (ErbB3)"	ISTIRATUMAB	n/a	10/22/14	Designated			N/A	N/A	"Merrimack Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	1311893AA	MM-141	XLR461MD3M						Pancreatic cancer	9364	done	Not a rare disease
MN14 monoclonal antibody to carcinoembryonic antigen	Treatment of pancreatic cancer.	MN14 monoclonal antibody to carcinoembryonic antigen	LABETUZUMAB	Cea-Cide	11/24/98	Designated			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA	EXACT	0298135AA	Labetuzumab	EFE6X5M3UY						Pancreatic cancer	9364	done	Not a rare disease
MNI-958 F-18	A diagnostic for the management of progressive supranuclear palsy	"1-(fluoro-18F)-3-((2-((1E,3E)-4-(6-(methylamino)pyridin-3-yl)buta-1,3-dien-1-yl)benzo[d]thiazol-6-yl)oxy)propan-2-ol"	MNI-958 F-18	n/a	11/1/17	Designated			N/A	N/A	Aprinoia Therapeutics	"17F, No. 3 Yuanqu Street"			Taiwan	EXACT	1576869AA	MNI-958 F-18	51M993JIQ4						Supranuclear ocular palsy	8403	done	
"MOAB, 81C6, MURINE, IODINE-I-131 RADIOLABELED, TO HUMAN GLIOMA"	Treatment of primary malignant brain tumors	Anti-tenascin 81C6 monoclonal antibody labeled w/ I 131	IODINE I-131 MONOCLONAL ANTIBODY 81C6	Neuradiab	10/4/05	Designated			N/A	N/A	"Bradmer Pharmaceuticals, Inc."	Louisville	Kentucky	40223	USA	EXACT	1305197AA	"MOAB, 81C6, MURINE, IODINE-I-131 RADIOLABELED, TO HUMAN GLIOMA"					PROBLEM	can't find	"Brain tumor, adult"	9307	approximate	brain tumor not specified
MOCETINOSTAT DIHYDROBROMIDE	Treatment of Hodgkin's lymphoma	N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide	MOCETINOSTAT DIHYDROBROMIDE	n/a	8/8/07	Designated			N/A	N/A	"Mirati Therapeutics, Inc."	San Diego	California	92121	USA	EXACT	0323104AA	MOCETINOSTAT DIHYDROBROMIDE	4V9P667Y2G						Hodgkin lymphoma	2714	done	
MORAb-066	Treatment of pancreatic cancer.	humanized monoclonal antibody to tissue factor	MORAB-066	n/a	4/26/11	Designated			N/A	N/A	"Morphotek, Inc."	Exton	Pennsylvania	19341	USA	EXACT	0791797AA	MORAb-066	5B3XF8CY3G						Pancreatic cancer	9364	done	Not a rare disease
MOTESANIB DIPHOSPHATE	Treatment of gastrointestinal stromal tumors	"N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide, phosphate (1:2)"	MOTESANIB DIPHOSPHATE	n/a	1/13/05	Designated/Withdrawn			N/A	N/A	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0302750AA	MOTESANIB DIPHOSPHATE	T6Q3060U91								MISSING	not a disease
"MV-NB-02, its bivalent ganglioside vaccine consisting of GD2-lactone and GD3-lactone each covalently conjugated to keyhole hemocyanin"	Treatment of Neuroblastoma	"MV-NB-02, its bivalent ganglioside vaccine consisting of GD2-lactone and GD3-lactone each covalently conjugated to keyhole hemocyanin"		n/a	9/23/14	Designated			N/A	N/A	"MabVax Therapeutics, Inc."	San Diego	California	92121	USA								PROBLEM	can't find	Neuroblastoma	7185	done	
MYK-461	Treatment of symptomatic obstructive hypertrophic cardiomyopathy	"6-{[(1S)-1-phenylethyl]amino}-3-(propan-2-yl)-1,2,3,4 tetrahydropyrimidine-2,4-dione"	MYK-461	n/a	4/27/16	Designated			N/A	N/A	"MyoKardia, Inc."	South San Francisco	California	94080	USA	EXACT	1114303AA	MYK-461	QX45B99R3J						Familial hypertrophic cardiomyopathy	7229	done	
MYRCLUDEX B	Treatment of hepatitis D virus infection.	"Synthetic 47 amino acid-long N-terminally myristoylated, HBV-L-protein derived lipopeptide"	MYRCLUDEX B	n/a	3/31/15	Designated			N/A	N/A	MYR GmbH				Germany	EXACT	1310390AA	MYRCLUDEX B	JA8K50N04H						Hepatitis D	13659	done	
Macitentan	Treatment of Fontan-Palliated patients	Macitentan	MACITENTAN	n/a	6/6/17	Designated			N/A	N/A	"Actelion Clinical Research, Inc."	Cherry Hill	New Jersey	8002	USA	EXACT	0339333AA	Macitentan	Z9K9Y9WMVL						Tricuspid atresia	5274	approximate	
Mafenide acetate solution	For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.	Mafenide acetate solution	MAFENIDE ACETATE	Sulfamylon Solution	7/18/90	Designated/Approved	Approved for Orphan Indication		6/5/98	6/5/05	"Mylan Laboratories, Inc."	Morgantown	West Virginia	26504	USA	EXACT	0054739AA	Mafenide acetate	RQ6LP6Z0WY								MISSING	bacterial infection is a too general term
Mafosfamide	Treatment of neoplastic meningitis	Mafosfamide	MAFOSFAMIDE	n/a	1/21/03	Designated			N/A	N/A	Baxter Healthcare Corporation	Round Lake	Illinois	60073	USA	EXACT	0275116AA	Mafosfamide	5970HH9923								MISSING	secondary to cancer
Manganese superoxide dismutase mimetic	Prevention of radiation- or chemotherapy-induced oral mucositis in cancer patients	Manganese superoxide dismutase mimetic	SUPEROXIDE DISMUTASE (SACCHAROMYCES CEREVISIAE)	n/a	2/27/08	Designated			N/A	N/A	"Galera Therapeutics, LLC"	St. Louis	Missouri	63108	USA	LONGEST CONTAINS	1103588AA	superoxide dismutase	W2T4YRA9AD								MISSING	prevention of drug-induced side-effects
Marijuana	Treatment of HIV-associated wasting syndrome.	Marijuana	CANNABIS SATIVA SUBSP. INDICA TOP	n/a	5/25/99	Designated			N/A	N/A	"Multidisciplinary Association for Psychedelic Studies, Inc."	Belmont	Massachusetts	2478	USA	EXACT	0000282AA	Marijuana	FTS5RM302N								MISSING	
Mecamylamine	Treatment of Tourette's syndrome.	Mecamylamine	MECAMYLAMINE	Inversine	10/14/98	Designated			N/A	N/A	"Targacept, Inc."	Winston-Salem	North Carolina	27101	USA	EXACT	0010457AA	Mecamylamine	6EE945D3OK						Tourette syndrome	7783	done	
Medroxyprogesterone acetate	Treatment of immune thrombocytopenic purpura.	Medroxyprogesterone acetate	MEDROXYPROGESTERONE ACETATE	Hematrol	2/22/01	Designated			N/A	N/A	"ZaBeCor Pharmaceutical Company, LLC"	Philadelphia	Pennsylvania	19119	USA	EXACT	0012340AA	Medroxyprogesterone acetate	C2QI4IOI2G						Idiopathic thrombocytopenic purpura	5194	approximate	
Megestrol acetate	"Treatment of patients with anorexia, cachexia, or significant weight loss (=/>10% of baseline body weight) and confirmed diagnosis of AIDS."	Megestrol acetate	MEGESTROL ACETATE	Megace	4/13/88	Designated/Approved	Approved for Orphan Indication	"Treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immune deficiency syndrome."	9/10/93	9/10/00	Bristol-Myers Squibb Pharmaceutical Research Institute	Evansville	Indiana	47721	USA	EXACT	0029709AA	Megestrol acetate	TJ2M0FR8ES								MISSING	
Melanoma peptide vaccine	"Treatment of HLA-A2+ patients with stage IIB, IIC, III, and IV malignant melanoma"	Melanoma peptide vaccine		n/a	3/29/05	Designated			N/A	N/A	Bristol-Myers Squibb Research Inst	Wallingford	Connecticut	6492	USA								PROBLEM	can't find	"Melanoma, familial"	3460	approximate	
Melatonin	Treatment of circadian rhythm sleep disorders in blind people with no light perception.	Melatonin	MELATONIN	n/a	11/15/93	Designated			N/A	N/A	"Sack, Robert, M.D."	Portland	Oregon	97201	USA	EXACT	0012657AA	Melatonin	JL5DK93RCL						Non 24 hour sleep wake disorder	10949	done	
Melatonin	Treatment of non-24-hour sleep-wake disorder in blind individuals without light perception	Melatonin	MELATONIN	Circadin	7/9/04	Designated			N/A	N/A	"Neurim Pharmaceuticals, Ltd."	Tel-Aviv			Israel	EXACT	0012657AA	Melatonin	JL5DK93RCL						Non 24 hour sleep wake disorder	10949	done	
Menadione Sodium Bisulfite	For the treatment of autosomal dominant polycystic kidney disease	Menadione Sodium Bisulfite	MENADIONE SODIUM BISULFITE	n/a	5/14/14	Designated			N/A	N/A	IC-MedTech Corporation	El Cajon	California	92021	USA	EXACT	0020815AA	Menadione Sodium Bisulfite	6XF3C2HK77						Polycystic kidney disease	7419	done	Not a rare disease
Meropenem	"Management of acute pulmonary exacerbations, in cystic fibrosis patients, due to respiratory tract infection with susceptible organisms."	Meropenem	MEROPENEM	Merrem Iv	4/27/00	Designated/Withdrawn			N/A	N/A	AstraZeneca Pharmaceuticals	Wilmington	Delaware	19850	USA	EXACT	0183562AA	Meropenem	FV9J3JU8B1						Cystic fibrosis	6233	done	Not a rare disease
Mesna	For use as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.	Mesna	MESNA	Mesnex	11/14/85	Designated/Approved	Approved for Orphan Indication		12/30/88	12/30/95	Degussa Corporation	Ridgefield Park	New Jersey	7660	USA	EXACT	0059187AA	Mesna	NR7O1405Q9								MISSING	
Mesna	Inhibition of the urotoxic effects induced by oxazaphosphorine compounds such as cyclophosphamide.	Mesna	MESNA	n/a	12/16/87	Designated/Withdrawn			N/A	N/A	"Asta Medica , Inc."	Tewksbury	Massachusetts	1876	USA	EXACT	0059187AA	Mesna	NR7O1405Q9								MISSING	not a disease
Methionine/L-methionine	Treatment of AIDS myelopathy.	Methionine/L-methionine	METHIONINE	n/a	8/21/96	Designated			N/A	N/A	"Genopia USA, Inc."	New York	New York	10038	USA	EXACT	0011096AA	methionine	AE28F7PNPL						Congenital human immunodeficiency virus	10328	approximate	
Methoxsalen	For use in conjunction with the UVAR photopheresis system to treat graft versus host disease.	Methoxsalen	METHOXSALEN	Uvadex	10/14/98	Designated			N/A	N/A	"Therakos, Inc."	Raritan	New Jersey	8869	USA	EXACT	0023836AA	Methoxsalen	U4VJ29L7BQ						Chronic graft versus host disease 	10964	done	Not a rare disease
Methoxsalen	For use in conjunction with the UVAR photopheresis system to treat graft versus host disease.	Methoxsalen	METHOXSALEN	Uvadex	10/14/98	Designated			N/A	N/A	"Therakos, Inc."	Raritan	New Jersey	8869	USA	EXACT	0023836AA	Methoxsalen	U4VJ29L7BQ						 Acute graft versus host disease	6544	done	Not a rare disease
Methylnaltrexone	Treatment of chronic opioid-induced constipation unresponsive to conventional therapy.	Methylnaltrexone	METHYLNALTREXONE	Relistor	6/17/96	Designated/Withdrawn by OPD			N/A	N/A	"Progenics Pharmaceuticals, Inc."	Tarrytown	New York	10591	USA	EXACT	0307131AA	Methylnaltrexone	0RK7M7IABE								MISSING	
Metronidazole	Treatment of perioral dermatitis.	Metronidazole	METRONIDAZOLE	Metrogel	10/24/91	Designated			N/A	N/A	"Galderma Laboratories, Inc."	Fort Worth	Texas	76163	USA	EXACT	0025810AA	Metronidazole	140QMO216E								MISSING	symptom
Metronidazole (topical)	Treatment of acne rosacea.	Metronidazole (topical)	METRONIDAZOLE	Metrogel	10/22/87	Designated/Approved	Approved for Orphan Indication		11/22/88	11/22/95	"Galderma Laboratories, Inc."	Fort Worth	Texas	76163	USA	EXACT	0025810AA	Metronidazole	140QMO216E								MISSING	Not a rare disease
Metronidazole (topical)	"Treatment of grade III and IV, anaerobically infected, decubitus ulcers."	Metronidazole (topical)	METRONIDAZOLE	Flagyl	11/24/87	Designated/Withdrawn			N/A	N/A	Searle	Skokie	Illinois	60077	USA	EXACT	0025810AA	Metronidazole	140QMO216E								MISSING	
Metronidazole 10% ointment	Topical treatment of active perianal Crohn's disease	Metronidazole 10% ointment	METRONIDAZOLE	n/a	11/8/07	Designated			N/A	N/A	SLA Pharma (UK) Ltd	Watford WD25 7SA			United Kingdom	EXACT	0025810AA	Metronidazole	140QMO216E						Crohn's disease	10232	done	
Microbubble contrast agent	Intraoperative aid in the identification and localization of intracranial tumors.	Microbubble contrast agent		Filmix Neurosonographic Contrast Agent	11/16/90	Designated			N/A	N/A	"Cav-Con, Inc."	Farmington	Connecticut	6032	USA								PROBLEM	can't find			MISSING	not a disease
Microvesiculated modified glycosylated tissue factor	"Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in hemophiliac patients"	Microvesiculated modified glycosylated tissue factor	THROMBOPLASTIN	n/a	1/25/07	Designated			N/A	N/A	Thrombotargets Corp.	Durham	North Carolina	27713	USA	LONGEST CONTAINS	0005163AA	tissue factor	1U5PI2DLU1						Hemophilia	10418	done	
Microvesiculated modified glycosylated tissue factor	"Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in patients with von Willebrand disease."	Microvesiculated modified glycosylated tissue factor	THROMBOPLASTIN	n/a	10/11/07	Designated			N/A	N/A	Thrombotargets Corp.	Durham	North Carolina	27713	USA	LONGEST CONTAINS	0005163AA	tissue factor	1U5PI2DLU1						Von Willebrand disease	7867	done	Not a rare disease
Midodrine HCl	Treatment of patients with symptomatic orthostatic hypotension.	Midodrine HCl	MIDODRINE HYDROCHLORIDE	Amatine	6/21/85	Designated/Approved	Approved for Orphan Indication	Treatment of symptomatic orthostatic hypotension.	9/6/96	9/6/03	Shire	Wayne	Pennsylvania	19087	USA	EXACT	0134203AA	Midodrine HCl	59JV96YTXV						Primary orthostatic hypotension	12959	approximate	
Miglustat	Treatment of Fabry's disease.	"1,5-(Butylimino)-1,5 dideoxy,D-glucitol"	MIGLUSTAT	n/a	5/12/98	Designated			N/A	N/A	Oxford GlycoSciences	United Kingdom			United Kingdom	EXACT	0169288AA	Miglustat	ADN3S497AZ						Fabry disease	6400	done	
Minnelide	Treatment of gastric cancer.	C21H27O10P	MINNELIDE	Minnelide	3/30/15	Designated			N/A	N/A	"Minneamrita Therapeutics, LLC"	Rock Island	Illinois	61201	USA	EXACT	0901133AA	Minnelide	1CIV2UMO40						Stomach cancer	7704	done	
Minnelide	Treatment of pancreatic cancer	Minnelide	MINNELIDE	Minnelide (Tm)	2/18/13	Designated			N/A	N/A	"Minneamrita Therapeutics, LLC"	Rock Island	Illinois	61201	USA	EXACT	0901133AA	Minnelide	1CIV2UMO40						Pancreatic cancer	9364	done	Not a rare disease
Minocycline HCl	Treatment of chronic malignant pleural effusion.	Minocycline HCl	MINOCYCLINE HYDROCHLORIDE	Minocin Intravenous	6/19/92	Designated/Withdrawn			N/A	N/A	Lederle Laboratories Division	Pearl River	New York	10965	USA	EXACT	0055232AA	Minocycline HCl	0020414E5U								MISSING	Not a rare disease
Minocycline hydrochloride	Treatment of sarcoidosis	Minocycline hydrochloride	MINOCYCLINE HYDROCHLORIDE	n/a	3/28/06	Designated			N/A	N/A	Autoimmunity Research Foundation	Thousand Oaks	California	91360	USA	EXACT	0055232AA	Minocycline hydrochloride	0020414E5U						Sarcoidosis	7607	done	
Mitoguazone	"Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma."	Mitoguazone	MITOGUAZONE	Apep	3/18/94	Designated			N/A	N/A	"ILEX Oncology, Inc."	San Antonio	Texas	78229	USA	EXACT	0358645AA	Mitoguazone	OD5Q0L447W						Diffuse Large B-Cell Lymphoma	3178	done	
Mitolactol	As adjuvant therapy in the treatment of primary brain tumors.	Mitolactol	MITOLACTOL	n/a	7/12/95	Designated			N/A	N/A	"Targent, Inc."	Princeton	New Jersey	8540	USA	EXACT	0053714AA	Mitolactol	LJ2P1SIK8Y						"Brain tumor, adult"	9307	approximate	
Mitomycin-C	Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.	Mitomycin-C	MITOMYCIN	n/a	8/20/93	Designated			N/A	N/A	IOP Inc.	Costa Mesa	California	92626	USA	EXACT	0132865AA	Mitomycin-C	50SG953SK6								MISSING	
Mitoxantrone	Treatment of hormone refractory prostate cancer.	Mitoxantrone	MITOXANTRONE	Novantrone	8/21/96	Designated/Approved	Approved for Orphan Indication	In combination with corticosteroids as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer.	11/13/96	11/13/03	Serono	Rockland	Massachusetts	2370	USA	EXACT	0156423AA	Mitoxantrone	BZ114NVM5P						Familial prostate cancer	4520	approximate	
Mitoxantrone	Treatment of progressive-relapsing multiple sclerosis.	Mitoxantrone	MITOXANTRONE	Novantrone	8/13/99	Designated/Approved	Approved for Orphan Indication	"Reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly adnormal between relapses)."	10/13/00	10/13/07	"Serono, Inc."	Rockland	Massachusetts	2370	USA	EXACT	0156423AA	Mitoxantrone	BZ114NVM5P						Multiple sclerosis	10255	approximate	
Mitoxantrone	Treatment of secondary-progressive multiple sclerosis.	Mitoxantrone	MITOXANTRONE	Novantrone	8/13/99	Designated/Approved	Approved for Orphan Indication	"Reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly adnormal between relapses)."	10/13/00	10/13/07	"Serono, Inc."	Rockland	Massachusetts	2370	USA	EXACT	0156423AA	Mitoxantrone	BZ114NVM5P						Multiple sclerosis	10255	done	
Mitoxantrone HCl	"Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia."	Mitoxantrone HCl	MITOXANTRONE HYDROCHLORIDE	Novantrone	7/13/87	Designated/Approved	Approved for Orphan Indication		12/23/87	12/23/94	Lederle Laboratories	Pearl River	New York	10965	USA	EXACT	0092546AA	Mitoxantrone HCl	U6USW86RD0						Acute myeloid leukemia	12757	done	
Molgramostim	"Treatment of AIDS patients with neutropenia due to the disease, AZTor ganciclovir."	Molgramostim	MOLGRAMOSTIM	Leucomax	1/24/89	Designated/Withdrawn			N/A	N/A	Schering Corporation	Kenilworth	New Jersey	7033	USA	EXACT	0259541AA	Molgramostim	B321AL142J						Congenital human immunodeficiency virus	10328	approximate	
Monoclonal antibody to cytomegalovirus (human)	Prophylaxis of cytomegalovirus disease in patients undergoing solid organ transplantation.	Monoclonal antibody to cytomegalovirus (human)	HUMAN HERPESVIRUS 5	n/a	9/13/91	Designated/Withdrawn			N/A	N/A	"Protein Design Labs, Inc."	Mountain View	California	94043	USA	LONGEST CONTAINS	0354529AA	cytomegalovirus	7COI029E6K								MISSING	Not a rare disease
Monoclonal antiendotoxin antibody XMMEn-0e5	Treatment of patients with gram-negative sepsis which has progressed to shock.	Monoclonal antiendotoxin antibody XMMEn-0e5		n/a	11/4/85	Designated/Withdrawn			N/A	N/A	"Pfizer, Inc."	New York	New York	10017	USA				908FWN27WK	NEBACUMAB	908FWN27WK	https://ginas.ncats.nih.gov/ginas/app/substance/ef374430	done				MISSING	
Monolaurin	Treatment of congenital primary ichthyosis.	Monolaurin	GLYCERYL LAURATE	Glylorin	4/29/93	Designated			N/A	N/A	Glaxo Wellcome Inc.	Research Triangle Park	North Carolina	27709	USA	EXACT	0034559AA	Monolaurin	Y98611C087						Lamellar ichthyosis	10803	approximate	
Monooctanoin	For dissolution of cholesterol gallstones retained in the common bile duct.	Monooctanoin	MONOCTANOIN	Moctanin	5/30/84	Designated/Approved	Approved for Orphan Indication		10/31/85	10/31/92	"Ethitek Pharmaceuticals, Inc."	Skokie	Illinois	60077	USA	EXACT	0122032AA	Monooctanoin	VFU0OU98LO								MISSING	
"Monovalent replication-incompetent adenovirus serotype 26 (Ad26) vaccine, AD26.ZEBOV in combination with multivalent replication-defective Modified Vaccinia Ankara (MVA)-Bavarian Nordic (BN) vaccine, MVA-mBN226B"	Pre-exposure prophylaxis of Ebola virus disease	"Monovalent replication-incompetent adenovirus serotype 26 (Ad26) vaccine, AD26.ZEBOV in combination with multivalent replication-defective Modified Vaccinia Ankara (MVA)-Bavarian Nordic (BN) vaccine, MVA-mBN226B"	MODIFIED VACCINIA ANKARA	n/a	1/11/17	Designated			N/A	N/A	Crucell Holland B.V.	Leiden			Netherlands	LONGEST CONTAINS	0862602AA	Modified Vaccinia Ankara	TU8J357395						Ebola virus disease	2035	done	
Morphine sulfate concentrate (preservative free)	For use in microinfusion devices for intraspinal administration in the treatment of intractable chronic pain.	Morphine sulfate concentrate (preservative free)	MORPHINE SULFATE	Infumorph	7/12/90	Designated/Approved	Approved for Orphan Indication	For intrathecal or epidural infusion in the treatment of tractable chronic pain. It was developed for use in continuous microinfusion devices and may require dilution before use as directed.	7/19/91	7/19/98	"Elkins-Sinn, Inc."	Cherry Hill	New Jersey	8003	USA	EXACT	0046173AA	Morphine sulfate	X3P646A2J0								MISSING	not a disease
Motolimod	Treatment of ovarian cancer	"{2-amino-8-[4-(pyrrolidinylcarbonyl)phenyl](3H-benzo[f]azepin-4-yl)}-N,N-dipropycarboxamide"	MOTOLIMOD	n/a	4/10/14	Designated			N/A	N/A	"VentiRx Pharmaceuticals, Inc."	Seattle	Washington	98101	USA	EXACT	0778074AA	Motolimod	WP6PY72ZH3						Ovarian cancer	7295	done	
Multi-vitamin infusion (neonatal formula)	For establishment and maintenance of total parenteral nutrition in very low birth weight infants.	Multi-vitamin infusion (neonatal formula)		n/a	12/12/89	Designated			N/A	N/A	"Astra Pharmaceuticals, L.P."	Wayne	Pennsylvania	19087	USA								PROBLEM	can't find			MISSING	
Multistem(r)	Prophylaxis of graft vs host disease	Multistem(r)		n/a	9/15/10	Designated			N/A	N/A	"Athersys, Inc."	Cleveland	Ohio	44115	USA								PROBLEM	can't find	Chronic graft versus host disease 	10964	done	
Multistem(r)	Prophylaxis of graft vs host disease	Multistem(r)		n/a	9/15/10	Designated			N/A	N/A	"Athersys, Inc."	Cleveland	Ohio	44115	USA								PROBLEM	can't find	 Acute graft versus host disease	6544	done	
Muparfostat	"Treatment of high-risk Stage II, Stage III, and Stage IV melanoma"	mannopentaose phosphate sulfate	MUPARFOSTAT	n/a	4/27/04	Designated			N/A	N/A	Medigen Biotechnology Corp.					EXACT	0891930AA	Muparfostat	P2BKS6T40H								MISSING	too general term
Murine MAb (Lym-1) and Iodine 131-I radiolabeled murine MAb (Lym-1) to human B-cell lymphoma	Treatment of B-cell non-Hodgkin's lymphoma.	Murine MAb (Lym-1) and Iodine 131-I radiolabeled murine MAb (Lym-1) to human B-cell lymphoma	IODINE I-131	Oncolym	11/27/98	Designated			N/A	N/A	"Peregrine Pharmaceuticals, Inc."	Tustin	California	92780	USA	LONGEST CONTAINS	0052880AA	Iodine 131	I5X6L61HUT						B-cell lymphoma	5877	done	
"Murine MAb to polymorphic epithelial mucin, human milk fat globule 1"	Adjuvant treatment of ovarian cancer.	"Murine MAb to polymorphic epithelial mucin, human milk fat globule 1"	MUCIN-1	Theragyn	3/22/99	Designated			N/A	N/A	Antisoma plc	London W5 3QR			United Kingdom	LONGEST CONTAINS	1804553AA	polymorphic epithelial mucin	I903D7RK7W						Ovarian cancer	7295	done	
Mx-dnG1 or Rexin-G retroviral vector	Treatment of pancreatic cancer	Mx-dnG1 or Rexin-G retroviral vector		Rexin-G	8/15/03	Designated			N/A	N/A	Epeius Biotechnologies Corporation	Glendale	California	91203	USA					Rexin-G	NA	https://adisinsight.springer.com/drugs/800019593	PROBLEM	absent from GINAS	Pancreatic cancer	9364	done	Not a rare disease
Mycobacterium avium sensitin RS-10	For use in the diagnosis of invasive Mycobacterium avium disease in immunocompetent individuals.	Mycobacterium avium sensitin RS-10	MYCOBACTERIUM AVIUM	n/a	10/11/95	Designated			N/A	N/A	Statens Seruminstitut				Sweden	LONGEST CONTAINS	0434720AA	Mycobacterium avium	67P4WI780Z						Mycobacterium Avium Complex infections	7123	approximate	Not a rare disease
Myelin	Treatment of multiple sclerosis.	Myelin		n/a	6/27/91	Designated/Withdrawn			N/A	N/A	"AutoImmune, Inc."	Lexington	Massachusetts	2173	USA								PROBLEM	can't find	Multiple sclerosis	10255	done	
"N-(3-(2-(2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)quinazolin-8-yl)phenyl)acrylamide"	Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)	"N-(3-(2-(2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)quinazolin-8-yl)phenyl)acrylamide"	CK-101	n/a	9/5/17	Designated			N/A	N/A	"Checkpoint Therapeutics, Inc."	New York	New York	10014	USA	EXACT	1340789AA	"N-(3-(2-(2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)quinazolin-8-yl)phenyl)acrylamide"	708TLB8J3Y						"Non-small cell lung cancer, childhood"	9343	approximate	
"N-(4-(4-amino-2-ethyl-lH-imidazo(4,5-c)quinolin-1-yl)butyl)methanesulfonamide"	Treatment of cutaneous T-cell lymphoma	"N-[4-(4-amino-2-ethyl-lH-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide"	CPG-52852	n/a	3/24/06	Designated/Withdrawn			N/A	N/A	"Pfizer, Inc."	New London	Connecticut	6320	USA	EXACT	0249309AA	CPG-52852	6PJC3KPK6S						Cutaneous T-cell lymphoma	6226	done	
"N-(4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl)-N'-(3,5-bis(trifluoromethyl)phenyl)urea"	Treatment of sickle cell disease	"N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]urea"	NS-3728	n/a	5/13/02	Designated/Withdrawn			N/A	N/A	NeuroSearch A/S				Denmark	EXACT	0243936AA	"N-(4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl)-N'-(3,5-bis(trifluoromethyl)phenyl)urea"	943YH53W21						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
"N-(4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl)-N'-(3,5-bis(trifluoromethyl)phenyl)urea"	Treatment of sickle cell disease	"N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]urea"	NS-3728	n/a	5/13/02	Designated/Withdrawn			N/A	N/A	NeuroSearch A/S				Denmark	EXACT	0243936AA	"N-(4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl)-N'-(3,5-bis(trifluoromethyl)phenyl)urea"	943YH53W21						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
"N-(4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl)-N'-(3,5-bis(trifluoromethyl)phenyl)urea"	Treatment of sickle cell disease	"N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]urea"	NS-3728	n/a	5/13/02	Designated/Withdrawn			N/A	N/A	NeuroSearch A/S				Denmark	EXACT	0243936AA	"N-(4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl)-N'-(3,5-bis(trifluoromethyl)phenyl)urea"	943YH53W21						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
"N-(4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl)-N'-(3,5-bis(trifluoromethyl)phenyl)urea"	Treatment of sickle cell disease	"N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]urea"	NS-3728	n/a	5/13/02	Designated/Withdrawn			N/A	N/A	NeuroSearch A/S				Denmark	EXACT	0243936AA	"N-(4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl)-N'-(3,5-bis(trifluoromethyl)phenyl)urea"	943YH53W21						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
"N-(4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl)-N'-(3,5-bis(trifluoromethyl)phenyl)urea"	Treatment of sickle cell disease	"N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]urea"	NS-3728	n/a	5/13/02	Designated/Withdrawn			N/A	N/A	NeuroSearch A/S				Denmark	EXACT	0243936AA	"N-(4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl)-N'-(3,5-bis(trifluoromethyl)phenyl)urea"	943YH53W21						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
"N-(4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl)-N'-(3,5-bis(trifluoromethyl)phenyl)urea"	Treatment of sickle cell disease	"N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]urea"	NS-3728	n/a	5/13/02	Designated/Withdrawn			N/A	N/A	NeuroSearch A/S				Denmark	EXACT	0243936AA	"N-(4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl)-N'-(3,5-bis(trifluoromethyl)phenyl)urea"	943YH53W21						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
"N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide"	"Treatment of TrkA-positive, TrkB-positive, TrkC-positive ROS1-positive or ALK-positive non-small cell lung cancer"	"N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide"	ENTRECTINIB	n/a	2/3/15	Designated			N/A	N/A	"Ignyta, Inc."	San Diego	California	92121	USA	EXACT	0933608AA	"N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide"	L5ORF0AN1I						"Non-small cell lung cancer, childhood"	9343	approximate	
"N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide"	"Treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive, or ALK-positive colorectal cancer"	"N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide"	ENTRECTINIB	n/a	2/12/15	Designated			N/A	N/A	"Ignyta, Inc."	San Diego	California	92121	USA	EXACT	0933608AA	"N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide"	L5ORF0AN1I						"Non-small cell lung cancer, childhood"	9343	approximate	
N-Acetylmannosamine (ManNAc)	Treatment of hereditary inclusion body myopathy type 2	N-Acetylmannosamine (ManNAc)	N-ACETYLMANNOSAMINE	n/a	4/5/10	Designated			N/A	N/A	"Escala Therapeutics, Inc."	New York	New York	10019	USA	EXACT	0803587AA	ManNAc	X80PR7P73R						Inclusion body myopathy 2	9493	done	
N-acetyl-DL-leucine	"Treatment of Niemann-Pick disease, type C"	N-acetyl-DL-leucine	ACETYLLEUCINE	n/a	2/22/18	Designated			N/A	N/A	IntraBio Inc.	270 Devon Road	Tenafly		USA	EXACT	0301019AA	N-acetyl-DL-leucine	K76S41V71X						Niemann-Pick disease type C1 	7207	done	
N-acetyl-DL-leucine	"Treatment of Niemann-Pick disease, type C"	N-acetyl-DL-leucine	ACETYLLEUCINE	n/a	2/22/18	Designated			N/A	N/A	IntraBio Inc.	270 Devon Road	Tenafly		USA	EXACT	0301019AA	N-acetyl-DL-leucine	K76S41V71X						 Niemann-Pick disease type C2	3992	done	
N-acetyl-procainamide	Prevention of life-threatening ventricular arrhythmias in patients with documented procainamide-induced lupus.	N-acetyl-procainamide	ACECAINIDE	n/a	12/10/96	Designated			N/A	N/A	NAPA of the Bahamas	Dubuque	Iowa	52002	USA	EXACT	0064211AA	N-acetyl-procainamide	910Q707V6F								MISSING	drug-induced condition
N-acetylcysteine	Prevention of ototoxicity caused by platinum-based chemotherapeutic agents used to treat pediatric cancers	N-acetylcysteine	ACETYLCYSTEINE	n/a	7/19/12	Designated			N/A	N/A	"Edward A. Neuwelt, MD"	Portland	Oregon	97239	USA	EXACT	0029969AA	N-acetylcysteine	WYQ7N0BPYC								MISSING	prevention of drug-induced side-effects
N-acetylcysteine	Prevention of platinum-induced toxicities in pediatric patients (0 through 16 years of age).	N-acetylcysteine and sodium thiosulfate	ACETYLCYSTEINE	n/a	8/31/15	Designated			N/A	N/A	"Edward A. Neuwelt, MD"	Portland	Oregon	97239	USA	EXACT	0029969AA	N-acetylcysteine	WYQ7N0BPYC								MISSING	prevention of drug-induced side-effects
N-acetylcysteine	Treatment of acute liver failure	N-acetylcysteine	ACETYLCYSTEINE	n/a	9/9/02	Designated			N/A	N/A	"Cumberland Pharmaceuticals, Inc."	Nashville	Tennessee	37203	USA	EXACT	0029969AA	N-acetylcysteine	WYQ7N0BPYC						Transient infantile liver failure	10593	approximate	
N-acetylcysteine	Treatment of apnea of prematurity	N-acetylcysteine	ACETYLCYSTEINE	"Acetadote(C), Mucomist(C)"	10/21/10	Designated/Withdrawn			N/A	N/A	Galleon Pharmaceuticals	Horsham	Pennsylvania	19044	USA	EXACT	0029969AA	N-acetylcysteine	WYQ7N0BPYC						Infantile apnea	6779	done	
N-acetylcysteine	Treatment of pediatric patients with ulcerative colitis (inclusive through age 16 years)	mesalamine and N-acetycysteine	ACETYLCYSTEINE	n/a	9/10/09	Designated			N/A	N/A	"Altheus Therapeutics, Inc."	Oklahoma City	Oklahoma	73104	USA	EXACT	0029969AA	N-acetylcysteine	WYQ7N0BPYC						Pediatric ulcerative colitis	9857	done	
N-acetylcysteine and sodium thiosulfate	Prevention of platinum-induced toxicities in pediatric patients (0 through 16 years of age).	N-acetylcysteine and sodium thiosulfate	SODIUM THIOSULFATE	n/a	8/31/15	Designated			N/A	N/A	"Edward A. Neuwelt, MD"	Portland	Oregon	97239	USA	EXACT	0053225AA	sodium thiosulfate	HX1032V43M								MISSING	prevention of drug-induced side-effects
N-acetylprocainamide	To lower the defibrillation energy requirement sufficiently to allow automatic implantable cardioverter defibrillator therapy in those patients who could otherwise not use the device.	N-acetylprocainamide	ACECAINIDE	Napa	3/23/90	Designated/Withdrawn			N/A	N/A	"Medco Research, Inc."	Los Angeles	California	90048	USA	EXACT	0064211AA	N-acetylprocainamide	910Q707V6F								MISSING	
NA-1	Treatment of acute ischemic stroke patients presenting within 3 hours of symptom onset	H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-Glu- Ser-Asp-Val-OH	NA-1	n/a	4/11/14	Designated			N/A	N/A	"NoNO, Inc."	Toronto			Canada	EXACT	0355475AA	NA-1	D45TI2TWMA								MISSING	NRD
NA-1	Treatment of subarachnoid hemorrhage	H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-alys-aleu-Ser-Ser-Ile-Glu-Ser-Asp-Val-OH	NA-1	n/a	5/14/13	Designated			N/A	N/A	"NoNO, Inc."	Ontario			Canada	EXACT	0355475AA	NA-1	D45TI2TWMA								MISSING	
NAVITOCLAX DIHYDROCHLORIDE	Treatment of chronic lymphocytic leukemia	"(R)-4-(3-morpholin-4-yl-l-phenylsulfanylmenthyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-enylmethyl]-piperazin-l-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride"	NAVITOCLAX DIHYDROCHLORIDE	n/a	12/19/07	Designated/Withdrawn			N/A	N/A	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0555895AA	NAVITOCLAX DIHYDROCHLORIDE	W8FZ00AY2S						Chronic lymphocytic leukemia	6104	done	
NAVITOCLAX DIHYDROCHLORIDE	Treatment of multiple myeloma	"(R)-4-(3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enylmethyl]-piperazin-1-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride"	NAVITOCLAX DIHYDROCHLORIDE	n/a	5/5/08	Designated/Withdrawn			N/A	N/A	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0555895AA	NAVITOCLAX DIHYDROCHLORIDE	W8FZ00AY2S						Multiple myeloma	7108	done	
NAVITOCLAX DIHYDROCHLORIDE	Treatment of small cell lung cancer.	"(R)-4-(3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enylmethyl]-piperazin-1-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride"	NAVITOCLAX DIHYDROCHLORIDE	n/a	12/19/07	Designated			N/A	N/A	"AbbVie, Inc"	North Chicago	Illinois	60064	USA	EXACT	0555895AA	NAVITOCLAX DIHYDROCHLORIDE	W8FZ00AY2S						Small cell lung cancer	9344	done	
NAVURIDINE	Treatment of acquired immunodeficiency syndrome.	"3'-azido-2',3'dideoxyuridine"	NAVURIDINE	Azdu	11/20/89	Designated/Withdrawn			N/A	N/A	"Berlex Laboratories, Inc."	Alameda	California	94501	USA	EXACT	0169686AA	NAVURIDINE	PS28W65479						Congenital human immunodeficiency virus	10328	approximate	
NB-124 SULFATE	Treatment of Rett syndrome	"6'-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)- paromamine sulfate"	NB-124 SULFATE	n/a	11/3/16	Designated			N/A	N/A	"Eloxx Pharmaceuticals, Ltd."	Ness Ziona			Israel	EXACT	1801145AA	NB-124 SULFATE	DZ671709NT						Rett syndrome	5696	done	
NB-124 SULFATE	Treatment of mucopolysaccharidosis type 1 (MPS I)	"6-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)- paromamine sulfate"	ELX-02 SULFATE	n/a	10/18/16	Designated			N/A	N/A	"Eloxx Pharmaceuticals, Ltd."	Ness Ziona			Israel	EXACT	1801145AA	NB-124 SULFATE	DZ671709NT						Mucopolysaccharidosis type I	10335	done	
NB-124 sulfate	Treatment of Cystinosis	"6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate"	NB-124 SULFATE	n/a	4/26/18	Designated			N/A	N/A	"ELOXX Pharmaceuticals, Inc."	"950 Winter Street, North"		2451	USA	EXACT	1801145AA	NB-124 sulfate	DZ671709NT						Cystinosis	6236	done	
NEO-212	Treatment of intracranially located metastases from breast cancer	(s)-perillyl alcohol temozolomide carbamate	NEO-212	n/a	2/28/17	Designated			N/A	N/A	"NeOnc Technologies, Inc."	Los Angeles	California	90069	USA	EXACT	1802206AA	NEO-212	237TB781D9						Familial breast cancer	10415	approximate	Not a rare disease
NEROFE	Treatment of acute myelogenous leukemia	D-peptide	NEROFE	Nerofe	2/4/11	Designated			N/A	N/A	"Immune System Key, Ltd"	Jerusalem 91233			Israel	EXACT	1337899AA	NEROFE	SR717JCM7M						Acute myeloid leukemia	12757	done	
NGM-282	Treatment of primary biliary cirrhosis	Engineered variant of recombinant human fibroblast growth factor 19	NGM-282	n/a	2/6/14	Designated			N/A	N/A	"NGM Biopharmaceuticals, Inc."	South San Francisco	California	94080	USA	EXACT	1077390AA	NGM-282	IK9NYN31ZM						Primary biliary cholangitis	7459	done	
NM-404 I-131	Treatment of Ewing’s Sarcoma	18-(p-[131I]-iodophenyl)octadecyl phosphocholine	NM-404 I-131	n/a	7/3/18	Designated			N/A	N/A	"Cellectar Biosciences, Inc."	3301 Agriculture Drive	Wisconsin	53716	USA	EXACT	1079705AA	NM-404 I-131	R048696O9L						Ewing's family of tumors	9323	approximate	
NMS-P937	Treatment of Acute Myeloid Leukemia	"1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy) phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide fumarate salt"	NMS-P937	n/a	9/28/17	Designated			N/A	N/A	"Trovagene, Inc."	San Diego	California	92121	USA	EXACT	0341399AA	NMS-P937	67RM91WDHQ						Acute myeloid leukemia	12757	done	
NNC0114-0006	Treatment of Type I Diabetes Mellitus with residual beta cell function.	anti-interleukin 21 (NNC0114-0006) in combination with liraglutide	NNC0114-0006	n/a	1/12/17	Designated			N/A	N/A	"Novo Nordisk, Inc."		New Jersey	8536	USA	EXACT	1194623AA	NNC0114-0006	L1SQ55DADE						Diabetes mellitus type 1	10268	done	
NP-118809	Management of postherpetic neuralgia	"1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one"	Z-160	n/a	9/26/13	Designated/Withdrawn			N/A	N/A	Zalicus Pharmaceuticals Ltd.	Cambridge	Massachusetts	2142	USA	EXACT	0256508AA	NP-118809	TX3R141LEP						Herpes zoster oticus	7525	approximate	postherpetic neuralgia is a complication of varicella-zoster virus infection
NP-59	For use in adrenal cortical imaging.	Iodine 131 6B-iodomethyl-19-norcholesterol	NORCHOLESTENOL IODOMETHYL I-131	n/a	8/1/84	Designated			N/A	N/A	"David E. Kuhl, M.D."	Ann Arbor	Michigan	48109	USA	EXACT	0080411AA	NP-59	HFE9M7UF0L								MISSING	"not a disease, a procedure"
NP-6A4	Treatment of pediatric cardiomyopathy	Angiotensin II type 2 receptor agonist		n/a	7/3/17	Designated			N/A	N/A	"Novopyxis, Inc."	Cambridge	Massachusetts	2142	USA	EXACT							PROBLEM	can't find			MISSING	
NRC-AN-019	Treatment of Glioma	"(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamideNRC-AN-019"	NRC-AN-019	n/a	3/18/11	Designated			N/A	N/A	NATCO Pharma Limited	Hyderbad 500033			India	EXACT	0710883AA	NRC-AN-019	K6W49JL148						Glioma	6513	done	
NRC-AN-019	Treatment of chronic myelogenous leukemia.	"(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide"	NRC-AN-019	n/a	3/18/11	Designated			N/A	N/A	NATCO Pharma Limited	Hyderbad 500033			India	EXACT	0710883AA	NRC-AN-019	K6W49JL148						Chronic myeloid leukemia	6105	done	
NRC-AN-019	Treatment of pancreatic cancer	"(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide"	NRC-AN-019	n/a	3/18/11	Designated			N/A	N/A	NATCO Pharma Limited	Hyderabad 500033			India	EXACT	0710883AA	NRC-AN-019	K6W49JL148						Pancreatic cancer	9364	done	Not a rare disease
NSC-203800	Treatment of gliomas	"antineoplaston A10, antineoplaston AS2-1"	PHENYLACETYLGLUTAMINE	n/a	11/21/08	Designated			N/A	N/A	"Burzynski Research Institute, Inc."	Houston	Texas	77055	USA	EXACT	0478579AA	NSC-203800	92358I79RG						Glioma	6513	done	
NTP-42	Treatment of pulmonary arterial hypertension	"N-(tert-butylcarbamoyl)-5-cyano-2-((4'-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)oxy)benzenesulfonamide"	NTP-42	n/a	3/1/18	Designated			N/A	N/A	ATXA Therapeutics Limited	75 Avoca Avenue	Blackrock		Ireland	EXACT	0114497AB	NTP-42	2057H3EG0S						Autoimmune pulmonary alveolar proteinosis	7499	done	
NX-001	Prevention of delayed graft function in renal transplant recipients	14-amino acid peptide derived from wound growth factor	NX-001	n/a	8/5/10	Designated/Withdrawn			N/A	N/A	NephRx Corporation	Kalamazoo	Michigan	49008	USA	EXACT	0800737AA	NX-001	2NIW95147T								MISSING	
Naltrexone HCl	For blockade of the pharmacological effects of exogenously administered opioids as an adjunct to the maintenance of the opioid-free state in detoxified formerly opioid-dependent individuals.	Naltrexone HCl	NALTREXONE HYDROCHLORIDE	Trexan	3/11/85	Designated/Approved	Approved for Orphan Indication		11/30/84	11/30/91	DuPont Pharmaceuticals	Wilmington	Delaware	19898	USA	EXACT	0067936AA	Naltrexone HCl	Z6375YW9SF								MISSING	Not a rare disease
Nanoparticle suspension containing biosynthetic codon-optimized human ornithine transcarbamylase messenger RNA	Treatment of ornithine transcarbamylase (OTC) deficiency	Nanoparticle suspension containing biosynthetic codon-optimized human ornithine transcarbamylase messenger RNA	ORNITHINE	n/a	3/28/18	Designated			N/A	N/A	"Translate Bio, Inc."	200 Sidney Street		2139	USA	LONGEST CONTAINS	0012168AA	ornithine	E524N2IXA3						Ornithine transcarbamylase deficiency	8391	done	
Natural human lymphoblastoid interferon-alpha	Treatment of Behcet's disease	Natural human lymphoblastoid interferon-alpha	"INTERFERON ALFA, ORAL"	n/a	1/18/00	Designated			N/A	N/A	"Amarillo Biosciences, Inc."	Amarillo	Texas	79110	USA	LONGEST CONTAINS	0259530AA	interferon alpha		MOR-22	NA	https://adisinsight.springer.com/drugs/800008731	PROBLEM	absent from GINAS	Behçet disease	848	done	
Natural human lymphoblastoid interferon-alpha	Treatment of papillomavirus warts in the oral cavity of HIV positive patients.	Natural human lymphoblastoid interferon-alpha	"INTERFERON ALFA, ORAL"	n/a	8/10/00	Designated			N/A	N/A	"Amarillo Biosciences, Inc."	Amarillo	Texas	79110	USA	LONGEST CONTAINS	0259530AA	interferon alpha		MOR-22	NA	https://adisinsight.springer.com/drugs/800008731	PROBLEM	absent from GINAS			MISSING	
Nebacumab	Treatment of patients with gram-negative bacteremia which has progressed to endotoxin shock.	Nebacumab	NEBACUMAB	Centoxin	10/1/86	Designated			N/A	N/A	"Centocor, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	0801014AA	Nebacumab	908FWN27WK								MISSING	
Netazepide	Treatment of gastric carcinoids	"R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1 H -1,4-benzodiazepine -3-yl]-3-(3-methylaminophenyl)urea"	NETAZEPIDE	n/a	9/10/09	Designated			N/A	N/A	Trio Medicines Ltd.				United Kingdom	EXACT	0338432AA	Netazepide	HOU4I0G29C								MISSING	
Neuprex	Treatment of severe meningococcal disease.	Recombinant bactericidal/permeability-increasing protein	OPEBACAN	Neuprex	6/22/98	Designated/Withdrawn			N/A	N/A	Xoma (US) LLC	Berkeley	California	94710	USA	EXACT	0755522AA	Neuprex	4X9EPQ6FMA						Meningococcal infection	9547	done	
NiCord (cord blood-derived exvivo expanded CD34+ cells and the non-expanded cell fraction of the same cord blood unit)	Treatment of chronic myelogenous leukemia (CML)	NiCord (cord blood-derived exvivo expanded CD34+ cells and the non-expanded cell fraction of the same cord blood unit)	CORD BLOOD	n/a	11/9/16	Designated			N/A	N/A	Gamida Cell Ltd.	Jerusalem			Israel	LONGEST CONTAINS	0854240AA	cord blood	PVH8394DLN						Chronic myeloid leukemia	6105	done	
Nifedipine	Treatment of interstitial cystitis.	Nifedipine	NIFEDIPINE	n/a	6/13/91	Designated			N/A	N/A	"Fleischmann, Jonathan M.D."	Cleveland	Ohio	44109	USA	EXACT	0059610AA	Nifedipine	I9ZF7L6G2L						Interstitial cystitis	6787	done	Not a rare disease
Nintedanib	Treatment of mesothelioma	Nintedanib	NINTEDANIB	n/a	12/12/16	Designated			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc."	Ridgefield	Connecticut	6877	USA	EXACT	0359900AA	Nintedanib	G6HRD2P839						Malignant mesothelioma	7026	done	
Nitric oxide	Diagnosis of sarcoidosis	Nitric oxide	NITRIC OXIDE	n/a	2/16/05	Designated			N/A	N/A	SensorMedics Corporation	Yorba Linda	California	92887	USA	EXACT	0176341AA	Nitric oxide	31C4KY9ESH						Sarcoidosis	7607	done	
Nitric oxide	To reduce the risk of chronic lung disease in premature neonates	Nitric oxide	NITRIC OXIDE	Inomax	9/27/04	Designated			N/A	N/A	INO Therapeutics	Hampton	New Jersey	8827	USA	EXACT	0176341AA	Nitric oxide	31C4KY9ESH								MISSING	chronic lung disease - too general
Nitric oxide	Treatment of persistent pulmonary hypertension in the newborn.	Nitric oxide	NITRIC OXIDE	Inomax	6/22/93	Designated/Approved	Approved for Orphan Indication	"In conjunction with ventilatory support and other appropriate agents, in the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation."	12/23/99	12/23/06	"INO Therapeutics, Inc."	Hampton	New Jersey	8827	USA	EXACT	0176341AA	Nitric oxide	31C4KY9ESH						Pulmonary arterial hypertension	7501	approximate	
Nitroprusside	Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.	Nitroprusside	NITROPRUSSIDE	n/a	2/21/01	Designated			N/A	N/A	"Thomas, MD, Jeffrey Evan"	Philadelphia	Pennsylvania	19107	USA	EXACT	0294962AA	Nitroprusside	169D1260KM								MISSING	Not a rare disease
Nivolumab and Ipilimumab	Treatment of gastric cancer and gastric-esophageal junction cancer.	Nivolumab and Ipilimumab	IPILIMUMAB	n/a	12/20/16	Designated			N/A	N/A	Bristol-Myers Squibb Co.	Wallingford	Connecticut	6492	USA	EXACT	0265452AA	Ipilimumab	6T8C155666						Stomach cancer	7704	done	
Non-replicating recombinant adeno-associated viral vector expressing the human acid alpha-glucosidase gene	Treatment of Pompe disease	Non-replicating recombinant adeno-associated viral vector expressing the human acid alpha-glucosidase gene		n/a	1/11/17	Designated			N/A	N/A	Duke University Medical Center	Durham	North Carolina	27710	USA				B769I4XPY3	ADENO-ASSOCIATED VIRUS | AAV2/8-LSPhGAA	B769I4XPY3	https://ginas.ncats.nih.gov/ginas/app/substance/1b238f0c | https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3182007	PROBLEM	absent from GINAS	Glycogen storage disease type 2	5714	done	
Nucleic acid aptamer binding to tumor cell nucleolin	Treatment of pancreatic cancer	Nucleic acid aptamer binding to tumor cell nucleolin		n/a	8/17/04	Designated			N/A	N/A	Antisoma Research Ltd.				United Kingdom				Z03K553649	AS-1411	Z03K553649	https://ginas.ncats.nih.gov/ginas/app/substances?q=AS-1411	done		Pancreatic cancer	9364	done	Not a rare disease
"O,O'-Bis({4-[3,5-diiodo-4-(1-methylene-1,2,3-triazol-4-ylmethoxy)phenoxy]-3,5-diiodophenyl}acetic acid)polyethylene glycol"	Treatment of pancreatic cancer	"O,O'-Bis({4-[3,5-diiodo-4-(1-methylene-1,2,3-triazol-4-ylmethoxy)phenoxy]-3,5-diiodophenyl}acetic acid)polyethylene glycol"	"POLYETHYLENE GLYCOL, UNSPECIFIED"	n/a	8/18/17	Designated			N/A	N/A	"NanoPharmaceuticals, LLC"	Rensselaer	New York	12144	USA	LONGEST CONTAINS	0137031AA	polyethylene glycol	3WJQ0SDW1A						Pancreatic cancer	9364	done	Not a rare disease
"O2-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate"	Treatment of acute myeloid leukemia	"O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate"	JS-K	n/a	3/16/12	Designated			N/A	N/A	"JSK Therapeutics, Inc."	Salt Lake City	Utah	84158	USA	EXACT	0761193AA	"O2-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate"	80P1Q21652						Acute myeloid leukemia	12757	done	
OBI-3424	Treatment of Acute Lymphoblastic Leukemia	"3-[5-[(1R)-1-[bis(aziridin-1-yl(phosphoryloxy]ethyl]-2-nitrophenoxy]-N,N-dimethylbenzamide"	OBI-3424	n/a	9/17/18	Designated			N/A	N/A	"OBI Pharma USA, Inc."	"6020 Cornerstone Court W, Suite 200"	California	92121	USA	EXACT	0116369AB	OBI-3424	X6SH5T8H76						Acute lymphoblastic leukemia	522	done	
OBI-3424	Treatment of hepatocellular carcinoma	"3-[5-[(1R)-1-[bis(aziridin-1-yl(phosphoryloxy]ethyl]-2-nitrophenoxy]-N,N-dimethylbenzamide"	OBI-3424	n/a	7/3/18	Designated			N/A	N/A	"OBI Pharma USA, Inc."	"6020 Cornerstone Court W, Suite 200"	California	92121	USA	EXACT	0116369AB	OBI-3424	X6SH5T8H76						Childhood hepatocellular carcinoma	9331	approximate	
OMS-721	Prevention (inhibition) of complement-mediated thrombotic microangiopathy	Human monoclonal antibody inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2)	OMS-721	n/a	12/16/13	Designated			N/A	N/A	Omeros Corporation	Seattle	Washington	98119	USA	EXACT	0935466AA	OMS-721	FT24ZQQ5RP						Atypical hemolytic uremic syndrome	8702	done	
OMS-721	Treatment of immunoglobulin A nephropathy (IgAN)	human monoclonal antibody inhibitor of mannan-binding lectin-associated serine protease-2	OMS-721	n/a	8/3/17	Designated			N/A	N/A	Omeros Corporation	Seattle	Washington	98119	USA	EXACT	0935466AA	OMS-721	FT24ZQQ5RP						IgA nephropathy	863	done	
ONC-201	Treatment of malignant glioma	"7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one"	ONC-201	n/a	6/4/18	Designated			N/A	N/A	"Oncoceutics, Inc."	3624 Market Street	Suite 5E	19104	USA	EXACT	0928041AA	ONC-201	9U35A31JAI						Gliomatosis cerebri 	6514	approximate	
ONC-201	Treatment of malignant glioma	"7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one"	ONC-201	n/a	6/4/18	Designated			N/A	N/A	"Oncoceutics, Inc."	3624 Market Street	Suite 5E	19104	USA	EXACT	0928041AA	ONC-201	9U35A31JAI						 Childhood brain stem glioma 	9306	approximate	
ONC-201	Treatment of malignant glioma	"7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one"	ONC-201	n/a	6/4/18	Designated			N/A	N/A	"Oncoceutics, Inc."	3624 Market Street	Suite 5E	19104	USA	EXACT	0928041AA	ONC-201	9U35A31JAI						 Glioma	6513	approximate	
ONC-201	Treatment of mantle cell lymphoma (MCL)	"7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one-2HCL"	ONC-201	n/a	2/7/17	Designated			N/A	N/A	"Oncoceutics, Inc."	Philadelphia	Pennsylvania	19104	USA	EXACT	0928041AA	ONC-201	9U35A31JAI						Mantle cell lymphoma	6969	done	
ONC-201 DIHYDROCHLORIDE	Treatment of glioblastoma.	"7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one*2HCl"	ONC-201 DIHYDROCHLORIDE	n/a	6/23/16	Designated			N/A	N/A	"Oncoceutics, Inc."	Philadelphia	Pennsylvania	19104	USA	EXACT	0928052AA	ONC-201 DIHYDROCHLORIDE	53VG71J90J						Glioblastoma	2491	done	
ONL-1204	Treatment of retinal detachment	His-His- Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr-NH2	ONL-1204	n/a	1/13/16	Designated			N/A	N/A	"ONL Therapeutics, Inc"	Ann Arbor	Michigan	48109	USA	EXACT	1571740AA	ONL-1204	XNA75YDV3F						Knobloch syndrome	380	approximate	
ONO-7579 TOSYLATE	Treatment of tropomyosin receptor kinase (Trk) gene fusion-positive cancer	N-{2-[4-(2-Amino-5-chloropyridin-3-yl)phenoxy]pyrimidin-5-yl}-N'-[2-(methanesulfonyl)-5-(trifluoromethyl)phenyl]urea mono-4-toluenesulfonate	ONO-7579 TOSYLATE	n/a	9/13/17	Designated			N/A	N/A	Ono Pharmaceuticals Co. Ltd.	Chuo-ku			Japan	EXACT	1797268AA	ONO-7579 TOSYLATE	1C01KML96K								MISSING	
OPC-167832	Treatment of active tuberculosis	"5-{[(3R,4R)-1-(4-chloro-2,6-difluorophenyl)-3,4-dihydroxypiperidin-4-yl]methoxy}-8-fluoro-3,4-dihydroquinolin-2(1H)-one"	OPC-167832	n/a	12/5/16	Designated			N/A	N/A	"Otsuka Pharmaceutical Company, Ltd"	Rockville	Maryland	20850	USA	EXACT	1565044AA	OPC-167832	1PQN78P4S3						Tuberculosis	7827	done	
OPN-305	Prevention of ischemia/reperfusion injury associated with solid organ tranplantation	humanized IgG4 monoclonal antibody	OPN-305	n/a	12/12/11	Designated			N/A	N/A	Opsona Theraeputics	Dublin 8			Ireland	EXACT	0787575AA	OPN-305	P45C2W27DU								MISSING	Not a rare disease
OTILIMAB	"Treatment of pigmented villonodular synovitis, including giant cell tumor of the tendon sheath"	recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor	OTILIMAB	n/a	8/19/14	Designated			N/A	N/A	Novartis Pharmaceuticals Corp	East Hanover	New Jersey	7936	USA	EXACT	0112972AB	OTILIMAB	Y8127R3VCH						Pigmented villonodular synovitis	7396	done	
OZ-439 mesylate	"Treatment of malaria caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, or Plasmodium malariae"	"cis-adamantane-2-spiro-3'-8'-[4'-[2'-(4'-morpholinyl)ethoxy]phenyl]-1',2,'4'-trioxaspiro[4.5] decane mesylate"	ARTEFENOMEL MESYLATE	n/a	1/19/10	Designated			N/A	N/A	Medicines for Malaria Venture (MMV)	CH-1215 Geneva 15			Switzerland	EXACT	0739377AA	OZ-439 mesylate	PXW0Q9H3IJ						Malaria	6961	done	
Odevixibat	Treatment of Alagille syndrome	"(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid"	ODEVIXIBAT	n/a	10/15/18	Designated			N/A	N/A	"Albireo AB c/o Albireo Pharma, Inc."	10 Post Office Square	Massachusetts	2109	USA	EXACT	1301333AA	Odevixibat	2W150K0UUC						Alagille syndrome	804	done	
Ofloxacin	Treatment of bacterial corneal ulcers.	Ofloxacin	OFLOXACIN	Ocuflox Ophthalmic Solution	4/18/91	Designated/Approved	Approved for Orphan Indication	Treatment of bacterial corneal ulcers.	5/22/96	5/22/03	"Allergan, Inc."	Irvine	California	92713	USA	EXACT	0127231AA	Ofloxacin	A4P49JAZ9H								MISSING	Not a rare disease
Ombitasvir /Paritaprevir/Ritonavir	Treatment of pediatric patients with chronic hepatitis C virus infection	Ombitasvir/Paritaprevir/Ritonavir	OMBITASVIR	Technivie® Tablets	2/24/16	Designated			N/A	N/A	AbbVie Inc.	North Chicago	Illinois	60064	USA	EXACT	0871250AA	Ombitasvir	2302768XJ8								MISSING	Not a rare disease
Ombitasvir/ Paritaprevir /Ritonavir	Treatment of pediatric patients with chronic hepatitis C virus infection	Ombitasvir/Paritaprevir/Ritonavir	PARITAPREVIR	Technivie® Tablets	2/24/16	Designated			N/A	N/A	AbbVie Inc.	North Chicago	Illinois	60064	USA	EXACT	0343259AA	Paritaprevir	OU2YM37K86								MISSING	Not a rare disease
Ombitasvir/Paritaprevir/ Ritonavir	Treatment of pediatric patients with chronic hepatitis C virus infection	Ombitasvir/Paritaprevir/Ritonavir	RITONAVIR	Technivie® Tablets	2/24/16	Designated			N/A	N/A	AbbVie Inc.	North Chicago	Illinois	60064	USA	EXACT	0184929AA	Ritonavir	O3J8G9O825								MISSING	Not a rare disease
Omega-3 (n-3) polyunsaturated fatty acid with all double bonds in the cis configuration	Prevention of organ graft rejection.	Omega-3 (n-3) polyunsaturated fatty acid with all double bonds in the cis configuration		n/a	11/22/95	Designated			N/A	N/A	Research Triangle Pharmaceuticals	Durham	North Carolina	27713	USA				AAN7QOV9EA	ICOSAPENT	AAN7QOV9EA	https://ginas.ncats.nih.gov/ginas/app/substances?q=ALL-CIS-FATTY%20ACID%2020:5%20OMEGA-3	done				MISSING	
Omegaven emulsion	Treatment of parenteral nutrition-associated liver disease	Omegaven emulsion	FISH OIL	Omegaven	2/27/08	Designated			N/A	N/A	Fresenius Kabi Deutschland GmbH				Germany	EXACT	0168105AA	Omegaven	XGF7L72M0F								MISSING	
"One, two, three, or four antisense oligonucleotides of Phosphorodiamidate morpholino oligomer combination that skips exons 4, 5, 6, and 7 of the gamma sarcoglycan (SGCG) gene"	"Treatment of limb-girdle muscular dystrophy type 2C that have mutations or deletions in exons 4, 5, 6, or 7of gamma sarcoglycan gene"	"One, two, three, or four antisense oligonucleotides of Phosphorodiamidate morpholino oligomer combination that skips exons 4, 5, 6, and 7 of the gamma sarcoglycan (SGCG) gene"	MORPHOLINO SUGAR FRAGMENT	n/a	7/18/17	Designated			N/A	N/A	Kurt+Peter Foundation	Menlo Park	California	94025	USA	LONGEST CONTAINS	1797166AA	morpholino			NA		PROBLEM	can't find	"Limb-girdle muscular dystrophy, type 2C"	2429	done	
Oprelvekin	Prevention of severe chemotherapy-induced thrombocytopenia.	Oprelvekin	OPRELVEKIN	Neumega	12/17/96	Designated/Approved	Approved for Orphan Indication		11/25/97	11/25/04	"Genetics Institute, Inc."	Cambridge	Massachusetts	2140	USA	EXACT	0218359AA	Oprelvekin	HM5641GA6F						Acquired amegakaryocytic thrombocytopenia	9596	done	
Orgotein for injection	"Treatment of familial amyotrophic lateral sclerosis associated with a mutation of the gene (on chromosome 21q) for copper, zinc superoxide dismutase."	Orgotein for injection	ORGOTEIN	n/a	12/22/94	Designated/Withdrawn			N/A	N/A	"Oxis International, Inc."	Portland	Oregon	97217	USA	EXACT	0052379AA	Orgotein	PKE82W49V1						Amyotrophic lateral sclerosis	5786	done	
Oxalobacter formigenes	Treatment of primary hyperoxaluria	Oxalobacter formigenes	OXALOBACTER FORMIGENES	n/a	3/29/06	Designated			N/A	N/A	"OxThera, Inc."	Alachua	Florida	32615	USA	EXACT	0736527AA	Oxalobacter formigenes	330ZY4KI6F						Primary hyperoxaluria type 1 	2835	done	
Oxalobacter formigenes	Treatment of primary hyperoxaluria	Oxalobacter formigenes	OXALOBACTER FORMIGENES	n/a	3/29/06	Designated			N/A	N/A	"OxThera, Inc."	Alachua	Florida	32615	USA	EXACT	0736527AA	Oxalobacter formigenes	330ZY4KI6F						 Primary hyperoxaluria type 2 	2836	done	
Oxalobacter formigenes	Treatment of primary hyperoxaluria	Oxalobacter formigenes	OXALOBACTER FORMIGENES	n/a	3/29/06	Designated			N/A	N/A	"OxThera, Inc."	Alachua	Florida	32615	USA	EXACT	0736527AA	Oxalobacter formigenes	330ZY4KI6F						 Primary hyperoxaluria type 3	10738	done	
Oxandrolone	Adjunctive therapy for AIDS patients suffering from HIV-wasting syndrome.	Oxandrolone	OXANDROLONE	Oxandrin	9/6/91	Designated			N/A	N/A	Bio-Technology General Corp.	Iselin	New Jersey	8830	USA	EXACT	0008435AA	Oxandrolone	7H6TM3CT4L								MISSING	
Oxandrolone	Treatment of constitutional delay of growth and puberty.	Oxandrolone	OXANDROLONE	n/a	10/5/90	Designated/Withdrawn			N/A	N/A	Bio-Technology General Corp.	Iselin	New Jersey	8830	USA	EXACT	0008435AA	Oxandrolone	7H6TM3CT4L								MISSING	
Oxandrolone	Treatment of moderate/severe acute alcoholic hepatitis in the presence of moderate protein calorie malnutrition.	Oxandrolone	OXANDROLONE	Hepandrin	3/18/94	Designated/Withdrawn			N/A	N/A	Bio-Technology General Corp.	Iselin	New Jersey	8830	USA	EXACT	0008435AA	Oxandrolone	7H6TM3CT4L								MISSING	Not a rare disease
Oxandrolone	Treatment of short stature associated with Turner's syndrome.	Oxandrolone	OXANDROLONE	Oxandrin	7/5/90	Designated/Withdrawn			N/A	N/A	Bio-Technology General Corp.	Iselin	New Jersey	8830	USA	EXACT	0008435AA	Oxandrolone	7H6TM3CT4L						Turner syndrome	7831	done	
Oxsodrol	Prevention of reperfusion injury to donor organ tissue.	Superoxide dismutase (recombinant human)		Oxsodrol	5/17/88	Designated/Withdrawn			N/A	N/A	Bio-Technology General Corp.	Iselin	New Jersey	8830	USA				WEW0I84437	EXTRACELLULAR SUPEROXIDE DISMUTASE (CU-ZN) HUMAN	WEW0I84437	https://ginas.ncats.nih.gov/ginas/app/substance/b2a51460	done				MISSING	
Oxymorphone	For relief of severe intractable pain in narcotic-tolerant patients.	Oxymorphone	OXYMORPHONE	Numorphan H.P.	3/19/85	Designated			N/A	N/A	DuPont Merck Pharmaceutical Company	Wilmington	Delaware	19880	USA	EXACT	0013161AA	Oxymorphone	9VXA968E0C								MISSING	not a disease
Oxypurinol	Treatment of hyperuricemia in patients intolerant to allopurinol.	Oxypurinol	OXYPURINOL	n/a	11/9/98	Designated			N/A	N/A	Cardiome Pharma Corp.				Canada	EXACT	0039225AA	Oxypurinol	G97OZE5068								MISSING	
P-2045 Re-188	Treatment of pancreatic cancer.	Re188 P2045 somatostatin peptide analogue	P-2045 RE-188	n/a	6/19/14	Designated			N/A	N/A	"Andarix Pharmaceuticals, Inc."	Somerville	Massachusetts	2144	USA	EXACT	0238857AA	P-2045 Re-188	2H4MY43GJD						Pancreatic cancer	9364	done	Not a rare disease
P-2045 Re-188	Treatment of small cell lung cancer	Re188 P2045 somatostatin analog	P-2045 RE-188	n/a	2/6/14	Designated			N/A	N/A	Andarix Pharmaceuticals	Somerville	Massachusetts	2144	USA	EXACT	0238857AA	P-2045 Re-188	2H4MY43GJD						Small cell lung cancer	9344	done	
P-2745	Treatment of chronic myeloid leukemia	"4-[2-(3-Propyl-[1,2,4]0xadiazol-5-yl)-vinyl]-benzene-1,2-diol"	"4-(2-(3-PROPYL-(1,2,4)OXADIAZOL-5-YL)-VINYL)-BENZENE-1,2-DIOL"	n/a	10/4/11	Designated			N/A	N/A	Piramal Enterprises Limited	Mumbai			India	EXACT	0740476AA	P-2745	ZGL5E40F57						Chronic myeloid leukemia	6105	done	
PBI-4050 SODIUM SALT	Treatment of Alström syndrome	3-pentylbenzeneacetic acid sodium salt	PBI-4050 SODIUM SALT	n/a	2/28/17	Designated			N/A	N/A	"ProMetic BioTherapeutics, Inc"	Rockville	Maryland	20850	USA	EXACT	1576621AA	PBI-4050 SODIUM SALT	R05571KE07						Alström syndrome	5787	done	
PBT-1033 HYDROCHLORIDE	Treatment of Huntington's disease	"5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline hydrochloride"	PBT-1033 HYDROCHLORIDE	n/a	9/4/14	Designated			N/A	N/A	Prana Biotechnology Limited	Victoria 3052			Australia	EXACT	1656048AA	PBT-1033 HYDROCHLORIDE	24Z79C941B						Huntington disease	6677	done	
PD-0325901	Treatment of Neurofibromatosis type I	"N-[(2R)-2,3 dihydroxypropoxyl]-3,4 difluro-2 -[(2-fluoro-4-iodophenyl)amino] benzamide"	PD-0325901	n/a	10/30/18	Designated			N/A	N/A	"SpringWorks Subsidiary 3, PBC (Spring Works)"	"575 5th Avenue, 16th Floor"	New York	10017	USA	EXACT	0743146AA	PD-0325901	86K0J5AK6M						Neurofibromatosis type 1	7866	done	
PD-132301 HYDROCHLORIDE	For the treatment of Cushing's Syndrome	"N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt"	PD-132301 HYDROCHLORIDE	n/a	1/7/15	Designated			N/A	N/A	"Millendo Therapeutics, Inc."	"Ann Arbor,"	Michigan	48104	USA	EXACT	0740421AA	PD-132301 HYDROCHLORIDE	TK694ZFS57						Cushing's syndrome	6224	done	
PEG-3350	For use in cleansing of the colon in preparation for colonoscopy in children and adolescents	"sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride"	POLYETHYLENE GLYCOL 3350	Suclear	9/4/13	Designated			N/A	N/A	"Braintree Laboratories, Inc."	Braintree	Massachusetts	2185	USA	EXACT	0117635AA	PEG 3350	G2M7P15E5P								MISSING	"not a disease, a procedure"
"PEG-b-PLA micelles containing (1) paclitaxel, (2) sirolimus (rapamycin) and (3) tanespimycin (17-AAG)(also known as: triolimus)"	Treatment of angiosarcoma	"PEG-b-PLA micelles containing (1) paclitaxel, (2) sirolimus (rapamycin) and (3) tanespimycin (17-AAG)(also known as: triolimus)"	TANESPIMYCIN	n/a	4/2/15	Designated			N/A	N/A	"Co-D Therapeutics, Inc."	Madison	Wisconsin	53718	USA	LONGEST CONTAINS	0230819AA	tanespimycin	4GY0AVT3L4						Angiosarcoma of the liver	5813	approximate	localization of angiosarcoma is not specified
PEG-glucocerebrosidase	For use as chronic enzyme replacement therapy in patients with Gaucher's disease who are deficient in glucocerebrosidase.	PEG-glucocerebrosidase		Lysodase	12/9/92	Designated			N/A	N/A	"National Institute of Mental Health, NIH"	Bethesda	Maryland	20892	USA					PEG glucocerebrosidase	NA	https://adisinsight.springer.com/drugs/800003631	PROBLEM		Gaucher disease	8233	done	
PEGASEMP™(doxorubicin hydrochloride in a lipid-based pegylated nanoparticle modified with a 31 aminoacid peptide targeting nucleolin)	Treatment of Mesothelioma	PEGASEMP™(doxorubicin hydrochloride in a lipid-based pegylated nanoparticle modified with a 31 aminoacid peptide targeting nucleolin)	DOXORUBICIN HYDROCHLORIDE	n/a	3/15/18	Designated			N/A	N/A	"TREAT U, S.A."	Parque Industrial de Taveiro	Lote 44		Portugal	EXACT	0063014AA	doxorubicin hydrochloride	82F2G7BL4E						Malignant mesothelioma	7026	done	
PEXIDARTINIB HYDROCHLORIDE	Treatment of pigmented villonodular synovitis/giant cell tumor of the tendon sheath	"[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride salt"	PEXIDARTINIB HYDROCHLORIDE	n/a	2/14/14	Designated			N/A	N/A	"Daiichi Sankyo, Inc."	Edison	New Jersey	8837	USA	EXACT	0341048AA	PEXIDARTINIB HYDROCHLORIDE	YS6WAI3XN7						Pigmented villonodular synovitis	7396	done	
PF-04136309	Treatment of pancreatic cancer	antagonist of chemokine Ligand-2	PF-04136309	n/a	7/3/17	Designated			N/A	N/A	"Pfizer, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0300221AA	PF-04136309	3M2595V4KT						Pancreatic cancer	9364	done	Not a rare disease
PF-04447943	Treatment of sickle cell disease	"6-((3S,4S)-4-Methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl-1-(tetrahydro-pyran-4-yl)-1,5-dihydro-pryazolo[3,4-d]pyrimidin-4-one"	PF-04447943	n/a	9/4/14	Designated			N/A	N/A	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	0570967AA	PF-04447943	7N969W8Y4O						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
PF-04447943	Treatment of sickle cell disease	"6-((3S,4S)-4-Methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl-1-(tetrahydro-pyran-4-yl)-1,5-dihydro-pryazolo[3,4-d]pyrimidin-4-one"	PF-04447943	n/a	9/4/14	Designated			N/A	N/A	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	0570967AA	PF-04447943	7N969W8Y4O						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
PF-04447943	Treatment of sickle cell disease	"6-((3S,4S)-4-Methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl-1-(tetrahydro-pyran-4-yl)-1,5-dihydro-pryazolo[3,4-d]pyrimidin-4-one"	PF-04447943	n/a	9/4/14	Designated			N/A	N/A	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	0570967AA	PF-04447943	7N969W8Y4O						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
PF-04447943	Treatment of sickle cell disease	"6-((3S,4S)-4-Methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl-1-(tetrahydro-pyran-4-yl)-1,5-dihydro-pryazolo[3,4-d]pyrimidin-4-one"	PF-04447943	n/a	9/4/14	Designated			N/A	N/A	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	0570967AA	PF-04447943	7N969W8Y4O						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
PF-04447943	Treatment of sickle cell disease	"6-((3S,4S)-4-Methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl-1-(tetrahydro-pyran-4-yl)-1,5-dihydro-pryazolo[3,4-d]pyrimidin-4-one"	PF-04447943	n/a	9/4/14	Designated			N/A	N/A	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	0570967AA	PF-04447943	7N969W8Y4O						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
PF-04447943	Treatment of sickle cell disease	"6-((3S,4S)-4-Methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl-1-(tetrahydro-pyran-4-yl)-1,5-dihydro-pryazolo[3,4-d]pyrimidin-4-one"	PF-04447943	n/a	9/4/14	Designated			N/A	N/A	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	0570967AA	PF-04447943	7N969W8Y4O						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
PF-05230907	Treatment of intracerebral hemorrhage	recombinant activated Factor X variant		n/a	3/3/15	Designated			N/A	N/A	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA				0P94UQE6SY	COAGULATION FACTOR X HUMAN	0P94UQE6SY	https://ginas.ncats.nih.gov/ginas/app/substances?q=factor%20X	done	PF-05230907 is a mutant of Factor Xa			MISSING	
PF-06741086	"Treatment of hemophilia A and hemophilia B patients with or without inhibitors, which includes routine prophylaxis to prevent or reduce the frequency of bleeding in hemophilia A and hemophilia B patients."	human monoclonal antibody directed against tissue factor pathway inhibitor	MARSTACIMAB	n/a	5/18/16	Designated			N/A	N/A	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	0112525AB	PF-06741086	0UB3OA67O7						Hemophilia A 	6591	done	
PF-06741086	"Treatment of hemophilia A and hemophilia B patients with or without inhibitors, which includes routine prophylaxis to prevent or reduce the frequency of bleeding in hemophilia A and hemophilia B patients."	human monoclonal antibody directed against tissue factor pathway inhibitor	MARSTACIMAB	n/a	5/18/16	Designated			N/A	N/A	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	0112525AB	PF-06741086	0UB3OA67O7						 Hemophilia B	8732	done	
PGC-C12E-terlipressin	Treatment of ascites due to all etiologies except for cancer	PGC-C12E-terlipressin	TERLIPRESSIN	n/a	12/27/12	Designated			N/A	N/A	PharmaIN Corporation	Bothell	Washington	98011	USA	LONGEST CONTAINS	0056111AA	terlipressin	7Z5X49W53P								MISSING	
PHOSPHOPANTOTHENIC ACID	Treatment of pantothenate kinase associated neurodegeneration (PKAN).	pantothenate phosphate	PHOSPHOPANTOTHENIC ACID	n/a	5/4/15	Designated			N/A	N/A	"Retrophin, Inc."	New York	New York	10017	USA	EXACT	0933357AA	PHOSPHOPANTOTHENIC ACID	1SCE5NG3E8						Pantothenate kinase-associated neurodegeneration	6564	done	
PHOTOBAC	Treatment of glioma	3-(1’-butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-N-butylimide methyl ester	BACTERIOPURPURINIMIDE-METHYL ESTER	Photobac	12/6/17	Designated			N/A	N/A	"Photolitec, LLC"	6220 Creekhaven Drive	East Amherst	14051	USA	EXACT	0113754AB	PHOTOBAC					PROBLEM	can't find	Glioma	6513	done	
PIMASERTIB HYDROCHLORIDE	Treatment of acute myeloid leukemia (AML).	"N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino] isonicotinamide hydrochloride"	PIMASERTIB HYDROCHLORIDE	n/a	1/12/11	Designated			N/A	N/A	"EMD Serono, Inc."	Rockland	Massachusetts	2370	USA	EXACT	0736890AA	PIMASERTIB HYDROCHLORIDE	6GS1ULF5HV						Acute myeloid leukemia	12757	done	
PIMASERTIB HYDROCHLORIDE	Treatment of pancreatic cancer	"N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino] isonicotinamide hydrochloride"	PIMASERTIB HYDROCHLORIDE	n/a	1/29/10	Designated			N/A	N/A	"EMD Serono, Inc."	Rockland	Massachusetts	2370	USA	EXACT	0736890AA	PIMASERTIB HYDROCHLORIDE	6GS1ULF5HV						Pancreatic cancer	9364	done	Not a rare disease
PK-10571	Treatment of pulmonary arterial hypertension	"(S)-3-((3-(1-((6-((3,4-dimethoxyphenyl)pryazin-2-yl)amino)ethyl)phenyl)carbamoyl)-5-methylpridin-1-ium"	PK-10571	n/a	11/17/14	Designated			N/A	N/A	"Pulmokine, Inc."	Rensselaer	New York	12144	USA	EXACT	1793506AA	PK-10571	3P63ZTE3OY						Autoimmune pulmonary alveolar proteinosis	7499	done	
PM-81	For the exogenous depletion of CD14 and CD15 positive acute myeloid leukemic bone marrow cells from patients undergoing bone marrow transplantation.	Monoclonal antibodies PM-81 and AML-2-23		n/a	3/12/90	Designated/Withdrawn			N/A	N/A	"Medarex, Inc."	Bloomsbury	New Jersey	8804	USA	EXACT							PROBLEM	can't find			MISSING	not a disease
POCAPAVIR	Treatment of poliovirus infection.	"1-[(2-Chloro-4-methoxyphenoxy)methyl]-4-[(2,6-dichlorophenoxy) methyl]benzene"	POCAPAVIR	n/a	1/9/12	Designated			N/A	N/A	"ViroDefense, Inc."	Rockville	Maryland	20850	USA	EXACT	0710941AA	POCAPAVIR	4ILA3VOV97						Poliomyelitis	7413	approximate	
PR-1	Treatment of acute myelogenous leukemia	Nine amino acid polypeptide derived from proteinase 3	PR1 LEUKEMIA PEPTIDE VACCINE	n/a	9/3/04	Designated			N/A	N/A	The Vaccine Company	Carmel	California	93921	USA	EXACT	1801894AA	PR-1	54XUF2TZ7G						Acute myeloid leukemia	12757	done	
PR-1	Treatment of chronic myelogenous leukemia.	Nine amino acid polypeptide derived from proteinase 3	PR1 LEUKEMIA PEPTIDE VACCINE	n/a	9/3/04	Designated			N/A	N/A	The Vaccine Company	Carmel	California	93921	USA	EXACT	1801894AA	PR-1	54XUF2TZ7G						Chronic myeloid leukemia	6105	done	
PRASTERONE SODIUM SULFATE ANHYDROUS	To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.	Dehydroepiandrosterone sulfate sodium	PRASTERONE SODIUM SULFATE ANHYDROUS	n/a	1/28/97	Designated			N/A	N/A	"Pharmadigm, Inc."	Salt Lake City	Utah	84109	USA	EXACT	0068280AA	PRASTERONE SODIUM SULFATE ANHYDROUS	B9840IHU4T								MISSING	
PREIMPLANTATION FACTOR	Prevention of graft versus host disease	synthetic preImplantation factor	PIF-1	Spif	5/8/18	Designated			N/A	N/A	"BioIncept, LLC"	140 East 40th Street	Suite 11E	10016	USA	EXACT	1305255AA	PREIMPLANTATION FACTOR	3K6A6FJ98O						Chronic graft versus host disease	10964	approximate	type of GVHD (acute or chronic) is not specified
PREIMPLANTATION FACTOR	Prevention of graft versus host disease	synthetic preImplantation factor	PIF-1	Spif	5/8/18	Designated			N/A	N/A	"BioIncept, LLC"	140 East 40th Street	Suite 11E	10016	USA	EXACT	1305255AA	PREIMPLANTATION FACTOR	3K6A6FJ98O						Acute graft versus host disease	6544	approximate	type of GVHD (acute or chronic) is not specified
PREXASERTIB MESYLATE MONOHYDRATE	Treatment of anal cancer	"2-Pyrazinecarbonitrile, 5-[[5-2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino] monomesylate monohydrate"	PREXASERTIB MESYLATE MONOHYDRATE	n/a	4/9/15	Designated			N/A	N/A	Eli Lilly and Company	Indianapolis	Indiana	46285	USA	EXACT	0898760AA	PREXASERTIB MESYLATE MONOHYDRATE	S4D3L195S4						Anal cancer	9300	done	
PRO-140	Prevention of graft versus host disease	humanized monoclonal antibody to CCR5	LERONLIMAB	n/a	10/4/17	Designated			N/A	N/A	"CytoDyn, Inc."	Vancouver	Washington	98660	USA	EXACT	0266751AA	PRO-140	Y1J4NP8FF0						Chronic graft versus host disease	10964	approximate	type of GVHD (acute or chronic) is not specified
PRO-140	Prevention of graft versus host disease	humanized monoclonal antibody to CCR5	LERONLIMAB	n/a	10/4/17	Designated			N/A	N/A	"CytoDyn, Inc."	Vancouver	Washington	98660	USA	EXACT	0266751AA	PRO-140	Y1J4NP8FF0						Acute graft versus host disease	6544	approximate	type of GVHD (acute or chronic) is not specified
PROTHROMBIN	Reversal of anticoagulation therapy in patients needing treatment of serious or life threatening bleeding and/or needing urgent surgery or invasive procedures	Human prothrombin complex concentrate	PROTHROMBIN	Octaplex	2/1/08	Designated			N/A	N/A	"Octapharma USA, Inc."	Hoboken	New Jersey	7030	USA	EXACT	0324903AA	PROTHROMBIN	8FB1K07F16								MISSING	treatment of drug-induced side-effects
PROTHROMBIN	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	prothrombin complex concentrate (human)	PROTHROMBIN	Kcentra	12/27/12	Designated/Approved	Approved for Orphan Indication	"Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy (VKA, e.g., warfarin) in adult patients with the need for urgent surgery/invasive procedure."	12/13/13	12/13/20	CSL Behring	King of Prussia	Pennsylvania	19406	USA	EXACT	0324903AA	PROTHROMBIN	8FB1K07F16								MISSING	not a disease
PRX-102	Treatment of Fabry's disease	a-Galactosidase A	PEGUNIGALSIDASE ALFA	Plant-Produced Human A-Glactosidase A	1/21/03	Designated			N/A	N/A	"iBio, Inc."	Newark	Delaware	19711	USA	EXACT	1336341AA	PRX-102	8M7V7Q6537						Fabry disease	6400	done	
PT-112	Treatment of thymoma and thymic carcinoma	"(1R,2R)-1,2-cyclohexane-diaminepyrophosphato-platinum(II)"	"CYCLOHEXANEDIAMINE PYROPHOSPHATOPLATINUM(II), (1R,2R)-"	n/a	10/25/18	Designated			N/A	N/A	Phosplatin Therapeutics LLC	1350 6th Avenue	New York	10019	USA	EXACT	0811541AA	PT-112	F5I3T42BXC						"Thymoma, childhood"	7767	approximate	
PTG-300	Treatment of ß-thalassemia	hepcidin mimetic peptide		n/a	3/1/18	Designated			N/A	N/A	Protagonist Therapeutics	521 Cottonwood Drive	Milpitas	95035	USA					PTG-300	NA	https://adisinsight.springer.com/drugs/800049673 | https://www.protagonist-inc.com/pipeline/#product-candidates	PROBLEM	absent from GINAS	Beta-thalassemia	871	done	
PTI-110	Treatment of AL Amyloidosis	"N-(3,4-dihydroxyphenyl)-3,4-dihydroxybenzamide"	PTI-110	n/a	10/15/14	Designated			N/A	N/A	"ProteoTech, Inc."	Kirkland	Washington	98034	USA	EXACT	1577146AA	PTI-110	YI3H6V056C						AL amyloidosis	5797	done	
PTI-428	Treatment of cystic fibrosis	"N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)cyclobutyl)-3-phenylisoxazole-5-carboxamide"	PTI-428	n/a	3/7/18	Designated			N/A	N/A	"Proteostasis Therapeutics, Inc."	200 Technology Square	Massachusetts		USA	EXACT	0115043AB	PTI-428	T2U4ZA62U4						Cystic fibrosis	6233	done	
PU-H71	Treatment of Myelofibrosis	"8-(6-iodobenzo[1,3]dioxol-5-ylsufanyl)-9-(3-isopropylamino propyl)adenine dihydrochloride"	PU-H71	n/a	5/16/18	Designated			N/A	N/A	"Samus Therapeutics, Inc."	10 South Main Street		1983	USA	EXACT	0540341AA	PU-H71	06IVK87M04						Myelofibrosis	8618	done	
PYRIDOXAL PHOSPHATE	Treatment of seizures associated with pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency	pyridoxal-5’ phosphate monohydrate (P5P)	PYRIDOXAL PHOSPHATE	n/a	1/4/17	Designated			N/A	N/A	Medicure International Inc.	Winnipeg	Manitoba		Canada	EXACT	0322270AA	PYRIDOXAL PHOSPHATE	5V5IOJ8338						Pyridoxal 5'-phosphate-dependent epilepsy	10730	done	
Pafuramidine maleate	Treatment of human African trypanosomiasis (sleeping sickness)	Pafuramidine maleate	PAFURAMIDINE MALEATE	n/a	8/31/07	Designated			N/A	N/A	"Immtech Pharmaceuticals, Inc."	Vernon Hills	Illinois	60061	USA	EXACT	0251650AA	Pafuramidine maleate	K27F04K3A9						"Trypanosomiasis, Human West-African "	7826	done	
Pafuramidine maleate	Treatment of human African trypanosomiasis (sleeping sickness)	Pafuramidine maleate	PAFURAMIDINE MALEATE	n/a	8/31/07	Designated			N/A	N/A	"Immtech Pharmaceuticals, Inc."	Vernon Hills	Illinois	60061	USA	EXACT	0251650AA	Pafuramidine maleate	K27F04K3A9						" Trypanosomiasis, Human East-African"	8540	done	
Pamrevlumab	Treatment of pancreatic cancer	Pamrevlumab	PAMREVLUMAB	n/a	6/19/17	Designated			N/A	N/A	"FibroGen, Inc."	San Francisco	California	94158	USA	EXACT	0267458AA	Pamrevlumab	QS5F6VTS0O						Pancreatic cancer	9364	done	Not a rare disease
Papain	Treatment of multiple myeloma.	"Papain, trypsin, and chymotrypsin"	PAPAIN	Wobe-Mugos	12/21/98	Designated			N/A	N/A	"Marlyn Nutraceuticals, Inc."	Scottsdale	Arizona	85254	USA	EXACT	0004999AA	Papain	A236A06Y32						Multiple myeloma	7108	done	
"Papain, trypsin, and chymotrypsin"	Treatment of multiple myeloma.	"Papain, trypsin, and chymotrypsin"	CHYMOTRYPSIN	Wobe-Mugos	12/21/98	Designated			N/A	N/A	"Marlyn Nutraceuticals, Inc."	Scottsdale	Arizona	85254	USA	EXACT	0005743AA	chymotrypsin	BVS505O332						Multiple myeloma	7108	done	
Papaverine topical gel	Treatment of sexual dysfunction in spinal cord injury patients.	Papaverine topical gel	PAPAVERINE	n/a	2/6/92	Designated/Withdrawn by OPD			N/A	N/A	Pharmedic Company	Wheeling	Illinois	60090	USA	EXACT	0009916AA	Papaverine	DAA13NKG2Q								MISSING	Not a rare disease
Pasireotide	"Treatment of patients with functional gastroenteropancreatic (GEP) neuroendocrine tumors (specifically, carcinoid, insulinoma, gastrinoma, somastatinoma, GRFoma, VIPoma and glucagonoma."	Multi-ligand somatostatin analog	PASIREOTIDE	n/a	7/27/04	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0269534AA	Pasireotide	98H1T17066								MISSING	
Pegadricase	Prophylaxis of hyperuricemia in cancer patients prone to develop tumor lysis syndrome during chemotherapy.	Polyethylene glycol-modified uricase	PEGADRICASE	Zurase	9/14/99	Designated			N/A	N/A	"EnzymeRx, LLC"	Paramus	New Jersey	7652	USA	EXACT	0909240AA	Pegadricase	50XB37EKN8								MISSING	prevention of drug-induced side-effects
Pegadricase	Treatment of hyperuricemia in patients with gout refractory to conventional therapy or in whom conventional therapy is contraindicated	Polyethylene glycol-modified uricase	PEGADRICASE	n/a	6/6/05	Designated			N/A	N/A	"EnzymeRx, LLC"	Paramus	New Jersey	7652	USA	EXACT	0909240AA	Pegadricase	50XB37EKN8								MISSING	
Pegadricase	Treatment of tumor lysis syndrome in cancer patients undergoing chemotherapy.	Polyethylene glycol-modified uricase	PEGADRICASE	Zurase	12/21/98	Designated			N/A	N/A	"EnzymeRx, LLC"	Paramus	New Jersey	7652	USA	EXACT	0909240AA	Pegadricase	50XB37EKN8								MISSING	
Pegaspargase	Treatment of acute lymphocytic leukemia.	Pegaspargase	PEGASPARGASE	Oncaspar	10/20/89	Designated/Approved	Approved for Orphan Indication	Combination chemotherapy for the treatment of patients with acute lymphoblastic leukemia who are hypersensitive to native forms of L-asparaginase.	2/1/94	2/1/01	"Baxalta US, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0187848AA	Pegaspargase	7D96IR0PPM						Acute lymphoblastic leukemia	522	done	
Pegfilgrastim	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	Pegfilgrastim	PEGFILGRASTIM	Neulasta	11/20/13	Designated/Approved	Approved for Orphan Indication	To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome)	11/13/15	TBD	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0243287AA	Pegfilgrastim	3A58010674								MISSING	"not a disease, a process"
Peginterferon alfa-2a	Treatment of chronic myelogenous leukemia.	Peginterferon alfa-2a	PEGINTERFERON ALFA-2A	Pegasys	9/30/99	Designated			N/A	N/A	Hoffman-La Roche Inc.	Nutley	New Jersey	7110	USA	EXACT	0246593AA	Peginterferon alfa-2a	Q46947FE7K						Chronic myeloid leukemia	6105	done	
Pegylated recombinant human megakaryocyte growth and development factor	For reducing the period of thrombocytopenia in patients undergoing hematopoietic stem cell transplantation.	Pegylated recombinant human megakaryocyte growth and development factor		Megagen	10/20/97	Designated/Withdrawn			N/A	N/A	"Amgen, Inc."	Thousand Oaks	California	91320	USA					PEG-rHuMGDF	NA	https://www.ncbi.nlm.nih.gov/pubmed/12225796	PROBLEM	absent from GINAS			MISSING	Not a rare disease
Pegzilarginase	Treatment of arginase I deficiency (hyperargininemia).	pegylated human recombinant arginase I	PEGZILARGINASE	n/a	3/16/15	Designated			N/A	N/A	"AERase, Inc."	Austin	Texas	78701	USA	EXACT	0112460AB	Pegzilarginase	4YV4KW88GD						Arginase deficiency	5840	done	
Pembrolizumab	Treatment of Small Cell Lung Cancer excluding those that have been identified as having a biomarker referred to as microsatellite instability-high (MSI-H) or mismatched repair deficient (dMMR)	Pembrolizumab	PEMBROLIZUMAB	Keytruda	10/3/17	Designated			N/A	N/A	"Merck, Sharp, & Dohme, a subsidiary of Merck & Co., Inc."	Whitehouse Station	New Jersey	8889	USA	EXACT	0809245AA	Pembrolizumab	DPT0O3T46P						Small cell lung cancer	9344	done	
Pentamidine isethionate	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.	Pentamidine isethionate	PENTAMIDINE ISETHIONATE	Nebupent	1/12/88	Designated/Approved	Approved for Orphan Indication		6/15/89	6/15/96	"Fujisawa USA, Inc."	Deerfield	Illinois	60015	USA	EXACT	0022219AA	Pentamidine isethionate	V2P3K60DA2						Pneumocystic carinii pneumonia	7409	done	
Pentamidine isethionate	Treatment of Pneumocystis carinii pneumonia.	Pentamidine isethionate	PENTAMIDINE ISETHIONATE	Pentam 300	2/28/84	Designated/Approved	Approved for Orphan Indication		10/16/84	10/16/91	"Fujisawa USA, Inc."	Deerfield	Illinois	60015	USA	EXACT	0022219AA	Pentamidine isethionate	V2P3K60DA2						Pneumocystic carinii pneumonia	7409	done	
Pentamidine isethionate	Treatment of Pneumocystis carinii pneumonia.	Pentamidine isethionate	PENTAMIDINE ISETHIONATE	n/a	10/29/84	Designated			N/A	N/A	Aventis Behring L.L.C.	King of Prussia	Pennsylvania	19406	USA	EXACT	0022219AA	Pentamidine isethionate	V2P3K60DA2						Pneumocystic carinii pneumonia	7409	done	
Pentamidine isethionate (inhalation)	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease	Pentamidine isethionate (inhalation)	PENTAMIDINE ISETHIONATE	Pneumopent	10/5/87	Designated			N/A	N/A	Fisons Corporation	Rochester	New York	14603	USA	EXACT	0022219AA	Pentamidine isethionate	V2P3K60DA2						Pneumocystic carinii pneumonia	7409	done	
Pentastarch	As an adjunct in leukapheresis to improve the harvesting and increase the yield of leukocytes by centrifugal means.	Pentastarch	PENTASTARCH	Pentaspan	8/28/85	Designated/Approved	Approved for Orphan Indication		5/19/87	5/19/94	DuPont Pharmaceuticals	Wilmington	Delaware	19898	USA	EXACT	0164556AA	Pentastarch	MOQ3RNM0SV								MISSING	
Pentetic acid	"Treatment of known or suspected cases of internal contamination with plutonium, americium, or curium"	NanoDTPA(tm)	PENTETIC ACID	n/a	6/17/11	Designated			N/A	N/A	"Nanotherapeutics, Inc."	Alachua	Florida	32615	USA	EXACT	0011596AA	Pentetic acid	7A314HQM0I								MISSING	not a disease
Pentosan polysulfate sodium	Treatment of interstitial cystitis.	Pentosan polysulfate sodium	PENTOSAN POLYSULFATE SODIUM	Elmiron	8/7/85	Designated/Approved	Approved for Orphan Indication	Relief of bladder pain or discomfort associated with interstitial cystitis.	9/26/96	9/26/03	Alza Corporation	Palo Alto	California	94303	USA	EXACT	0033545AA	Pentosan polysulfate sodium	914032762Y						Interstitial cystitis	6787	done	Not a rare disease
Perflubron	Treatment of acute respiratory distress disease (ARDS) in adults	Perflubron	PERFLUBRON	Liquivent(Tm)	4/26/01	Designated			N/A	N/A	PFC Development/New Alliance Pharmaceutical	Sherman Oaks	California	91403	USA	EXACT	0068699AA	Perflubron	Q1D0Q7R4D9						Acute respiratory distress syndrome	5698	done	
Perflubron	Treatment of respiratory distress syndrome (RDS)	perfluorooctyl-bromide (PFOB)	PERFLUBRON	n/a	3/22/18	Designated			N/A	N/A	Children’s Hospital of Philadelphia	Clinical Research Support	"Colket Translational Research Building, 11th Floor, Room 11101"	19104	USA	EXACT	0068699AA	Perflubron	Q1D0Q7R4D9						"Respiratory distress syndrome, infant "	112	approximate	
Perflubron	Treatment of respiratory distress syndrome (RDS)	perfluorooctyl-bromide (PFOB)	PERFLUBRON	n/a	3/22/18	Designated			N/A	N/A	Children’s Hospital of Philadelphia	Clinical Research Support	"Colket Translational Research Building, 11th Floor, Room 11101"	19104	USA	EXACT	0068699AA	Perflubron	Q1D0Q7R4D9						 Acute respiratory distress syndrome	5698	approximate	
Perfosfamide	"For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia."	Perfosfamide	PERFOSFAMIDE	Pergamid	12/4/89	Designated/Withdrawn			N/A	N/A	"Scios Nova, Inc."	Mountain View	California	94043	USA	EXACT	0124607AA	Perfosfamide	U880A4FUDA						Acute myeloid leukemia	12757	done	
Pergolide	Treatment of Tourette's syndrome.	Pergolide	PERGOLIDE	Permax	11/20/97	Designated/Withdrawn			N/A	N/A	"Sallee, Floyd R. M.D., Ph.D."	Cincinnati	Ohio	45229	USA	EXACT	0185079AA	Pergolide	24MJ822NZ9						Tourette syndrome	7783	done	
Phenobarbital sodium	Treatment of neonatal seizures	Phenobarbital sodium	PHENOBARBITAL SODIUM	n/a	3/28/18	Designated			N/A	N/A	Genus Lifesciences	514 North 12th Street		18102	USA	EXACT	0009358AA	Phenobarbital sodium	SW9M9BB5K3						Seizures benign familial neonatal recessive form	4789	approximate	
Phenoxodiol	Treatment of Stage IIB through Stage IV malignant melanoma	"(+/-)-cis-3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2H-cromen-7-ol"	IDRONOXIL	n/a	2/1/08	Designated/Withdrawn			N/A	N/A	"Marshall Edwards, Inc."	San Diego	California	92130	USA	EXACT	0239032AA	Phenoxodiol	995FT1W541						"Melanoma, familial"	3460	approximate	melanoma type is not specified
Phenoxodiol	Treatment of cholangiocarcinoma	"(+/-)-cis-3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2H-cromen-7-ol"	IDRONOXIL	n/a	1/10/08	Designated/Withdrawn			N/A	N/A	"Marshall Edwards, Inc."	San Diego	California	92130	USA	EXACT	0239032AA	Phenoxodiol	995FT1W541						Intrahepatic cholangiocarcinoma	6042	done	
Phenoxodiol	Treatment of pancreatic cancer	"(+/-)-cis-3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2H-cromen-7-ol"	IDRONOXIL	n/a	1/10/08	Designated/Withdrawn			N/A	N/A	"Marshall Edwards, Inc."	San Diego	California	92130	USA	EXACT	0239032AA	Phenoxodiol	995FT1W541						Pancreatic cancer	9364	done	Not a rare disease
Phenylacetate	"For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma."	Phenylacetate	PHENYL ACETATE	n/a	3/6/98	Designated			N/A	N/A	"Elan Drug Delivery, Inc."	Gainesville	Georgia	30504	USA	EXACT	0019512AA	Phenylacetate	355G9R500Y						Glioma	6513	approximate	
Phenylalanine ammonia-lyase	Treatment of hyperphenylalaninemia	Phenylalanine ammonia-lyase	PHENYLALANINE	Phenylase. Ravpal-Peg	3/8/95	Designated			N/A	N/A	BioMarin Pharmaceutical	Novato	California	94949	USA	LONGEST CONTAINS	0011132AA	Phenylalanine	47E5O17Y3R						Maternal hyperphenylalaninemia 	3413	approximate	
Phenylalanine ammonia-lyase	Treatment of hyperphenylalaninemia	Phenylalanine ammonia-lyase	PHENYLALANINE	Phenylase. Ravpal-Peg	3/8/95	Designated			N/A	N/A	BioMarin Pharmaceutical	Novato	California	94949	USA	LONGEST CONTAINS	0011132AA	Phenylalanine	47E5O17Y3R						 6-pyruvoyl-tetrahydropterin synthase deficiency 	5682	approximate	
Phenylalanine ammonia-lyase	Treatment of hyperphenylalaninemia	Phenylalanine ammonia-lyase	PHENYLALANINE	Phenylase. Ravpal-Peg	3/8/95	Designated			N/A	N/A	BioMarin Pharmaceutical	Novato	California	94949	USA	LONGEST CONTAINS	0011132AA	Phenylalanine	47E5O17Y3R						 GTP cyclohydrolase I deficiency 	2844	approximate	
Phenylalanine ammonia-lyase	Treatment of hyperphenylalaninemia	Phenylalanine ammonia-lyase	PHENYLALANINE	Phenylase. Ravpal-Peg	3/8/95	Designated			N/A	N/A	BioMarin Pharmaceutical	Novato	California	94949	USA	LONGEST CONTAINS	0011132AA	Phenylalanine	47E5O17Y3R						 Dihydropteridine reductase deficiency 	4319	approximate	
Phenylalanine ammonia-lyase	Treatment of hyperphenylalaninemia	Phenylalanine ammonia-lyase	PHENYLALANINE	Phenylase. Ravpal-Peg	3/8/95	Designated			N/A	N/A	BioMarin Pharmaceutical	Novato	California	94949	USA	LONGEST CONTAINS	0011132AA	Phenylalanine	47E5O17Y3R						 Hyperphenylalaninemia due to dehydratase deficiency	2843	approximate	
Picoplatin	Treatment of small cell lung cancer	Picoplatin	PICOPLATIN	n/a	11/2/05	Designated			N/A	N/A	Poniard Pharmaceuticals	Seattle	Washington	98119	USA	EXACT	0239021AA	Picoplatin	B5TAN0L720						Small cell lung cancer	9344	done	
Pilocarpine	Treatment of xerostomia induced by radiation therapy for head and neck cancer.	Pilocarpine	PILOCARPINE	Salagen	9/24/90	Designated/Approved	Approved for Orphan Indication	Treatment of symptoms of xerostomia from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck.	3/22/94	3/22/01	"MGI Pharma, Inc."	Bloomington	Minnesota	55437	USA	EXACT	0015554AA	Pilocarpine	01MI4Q9DI3								MISSING	secondary condition; therapy-induced
Pilocarpine HCl	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	Pilocarpine HCl	PILOCARPINE HYDROCHLORIDE	Salagen	2/28/92	Designated/Approved	Approved for Orphan Indication	Treatment of dry mouth in patients with Sjogren's syndrome.	2/11/98	2/11/05	"MGI Pharma, Inc."	Bloomington	Minnesota	55437	USA	EXACT	0008720AA	Pilocarpine HCl	0WW6D218XJ						Sjogren syndrome	10252	done	
Piracetam	Treatment of myoclonus.	Piracetam	PIRACETAM	Nootropil	10/2/87	Designated/Withdrawn			N/A	N/A	"UCB Pharma, Inc."	Smyrna	Georgia	30080	USA	EXACT	0048862AA	Piracetam	ZH516LNZ10						Myoclonus epilepsy	7142	done	
Piritrexim isethionate	"Treatment of infections caused by Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium-intracellulare."	Piritrexim isethionate	PIRITREXIM ISETHIONATE	n/a	6/13/88	Designated/Withdrawn			N/A	N/A	Burroughs Wellcome Company	Research Triangle Park	North Carolina	27709	USA	EXACT	0124743AA	Piritrexim isethionate	V77I71FH72						Pneumocystic carinii pneumonia 	7409	approximate	
Piritrexim isethionate	"Treatment of infections caused by Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium-intracellulare."	Piritrexim isethionate	PIRITREXIM ISETHIONATE	n/a	6/13/88	Designated/Withdrawn			N/A	N/A	Burroughs Wellcome Company	Research Triangle Park	North Carolina	27709	USA	EXACT	0124743AA	Piritrexim isethionate	V77I71FH72						 Mycobacterium Avium Complex infections	7123	approximate	
Poloxamer 188	Treatment of severe burns requiring hospitalization.	Poloxamer 188	POLOXAMER 188	Florcor	2/22/90	Designated			N/A	N/A	CytRx Corporation	Norcross	Georgia	30092	USA	EXACT	0006826AA	Poloxamer 188	LQA7B6G8JG								MISSING	Not a disease
Poloxamer 188	Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.	Poloxamer 188	POLOXAMER 188	n/a	8/5/97	Designated			N/A	N/A	CytRx Corporation	Norcross	Georgia	30092	USA	EXACT	0006826AA	Poloxamer 188	LQA7B6G8JG								MISSING	Not a rare disease
Poloxamer 331	Initial therapy of toxoplasmosis in patients with AIDS.	Poloxamer 331	POLOXAMER 331	Protox	3/21/91	Designated			N/A	N/A	CytRx Corporation	Norcross	Georgia	30092	USA	EXACT	0155613AA	Poloxamer 331	IS93EQR73R						Congenital human immunodeficiency virus	10328	approximate	
Poly-ICLC	Treatment of primary brain tumors.	Poly-ICLC	HILTONOL	Hiltonol	3/17/97	Designated			N/A	N/A	Oncovir	Washington	District of Columbia	20008	USA	EXACT	0777651AA	Poly-ICLC					PROBLEM	can't find	"Brain tumor, adult"	9307	approximate	
Poly-Iclc	"Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses"	polyinosinic-polycytidilic acid	HILTONOL	Poly-Iclc	3/3/03	Designated			N/A	N/A	Oncovir	Washington	District of Columbia	20008	USA	EXACT	0777651AA	Poly-Iclc					PROBLEM	can't find	West nile virus 	9238	done	
Poly-Iclc	"Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses"	polyinosinic-polycytidilic acid	HILTONOL	Poly-Iclc	3/3/03	Designated			N/A	N/A	Oncovir	Washington	District of Columbia	20008	USA	EXACT	0777651AA	Poly-Iclc					PROBLEM	can't find	 Japanese encephalitis 	6797	done	
Poly-Iclc	"Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses"	polyinosinic-polycytidilic acid	HILTONOL	Poly-Iclc	3/3/03	Designated			N/A	N/A	Oncovir	Washington	District of Columbia	20008	USA	EXACT	0777651AA	Poly-Iclc					PROBLEM	can't find	 Dengue fever 	6254	done	
Poly-Iclc	"Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses"	polyinosinic-polycytidilic acid	HILTONOL	Poly-Iclc	3/3/03	Designated			N/A	N/A	Oncovir	Washington	District of Columbia	20008	USA	EXACT	0777651AA	Poly-Iclc					PROBLEM	can't find	 Yellow fever	7914	done	
Polyribonucleotide; Polyribo-inosinic/-cyclidylic/-uridylic acid	Treatment of AIDS	Polyribonucleotide; Polyribo-inosinic/-cyclidylic/-uridylic acid		Ampligen	7/19/88	Designated			N/A	N/A	"Hemispherx Biopharma, Inc."	Philadelphia	Pennsylvania	19103	USA				94325AJ25N	RINTATOLIMOD	94325AJ25N	https://ginas.ncats.nih.gov/ginas/app/substance/53db11e4	approximate		Congenital human immunodeficiency virus	10328	approximate	
"Polyvalent, shed-antigen melanoma vaccine"	Treatment of stage IIb to stage IV melanoma	"Polyvalent, shed-antigen melanoma vaccine"		n/a	6/9/06	Designated			N/A	N/A	Polynoma LLC	San Diego	California	92130	USA								PROBLEM	can't find	"Melanoma, familial"	3460	approximate	
Porcine Sertoli cells aseptically prepared for intracerebral co-implantation with fetal neural tissue	Treatment of Hoehn and Yahr stage four and five Parkinson's disease.	Porcine Sertoli cells aseptically prepared for intracerebral co-implantation with fetal neural tissue		N-Graft	6/24/97	Designated			N/A	N/A	"Titan Pharmaceuticals, Inc."	Somerville	New Jersey	8876	USA					N-Graft	NA	https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=104697	PROBLEM	absent from GINAS	Parkinson disease	10251	done	
Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation		Neurocell-Pd	12/17/96	Designated			N/A	N/A	Diacrin/Genzyme LLC	Cambridge	Massachusetts	2129	USA								PROBLEM	can't find	Parkinson disease	10251	done	
Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared for intracerebral implantation.	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared for intracerebral implantation.		Neurocell-Pd	12/17/96	Designated			N/A	N/A	Diacrin/Genzyme LLC	Cambridge	Massachusetts	2139	USA								PROBLEM	can't find	Parkinson disease	10251	done	
Porfiromycin	Treatment of cervical cancer.	Porfiromycin	PORFIROMYCIN	Promycin	3/13/97	Designated			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc."	Ridgefield	Connecticut	6877	USA	EXACT	0031061AA	Porfiromycin	H1WK901OA6						Glassy cell carcinoma of the cervix	8437	approximate	
Porfiromycin	Treatment of head and neck cancer.	Porfiromycin	PORFIROMYCIN	Promycin	9/19/95	Designated			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc."	Ridgefield	Connecticut	6877	USA	EXACT	0031061AA	Porfiromycin	H1WK901OA6						Head and neck cancer	12425	done	not a rare disease
Potassium Iodide	For use as a thyroid blocking agent in pediatric patients exposed to radiactive iodine	Potassium Iodide Oral Solution	POTASSIUM IODIDE	Thyroshield	11/17/04	Designated/Approved	Approved for Orphan Indication	For use as a thyroid blocking agent in pediatric patients exposed to radiactive iodine	1/12/05	N/A	"Fleming & Company, Pharmaceuticals"	Fenton	Missouri	63026	USA	EXACT	0050033AA	Potassium Iodide	1C4QK22F9J								MISSING	not a disease
Potassium citrate	1. Prevention of calcium renal stones in patients with hypocitraturia 2. For avoidance of the complication of calcium stone formation in patients with uric lithiasis.	Potassium citrate	POTASSIUM CITRATE	Urocit-K	11/1/84	Designated/Approved	Approved for Orphan Indication	Prevention of recurring calcium conating stines associated with a deficiency in the urine.	8/7/85	8/7/92	University of Texas Health Science Center at Dallas	Dallas	Texas	75235	USA	EXACT	0045761AA	Potassium citrate	EE90ONI6FF								MISSING	Not a rare disease
Potassium citrate	Prevention of uric acid nephrolithiasis.	Potassium citrate	POTASSIUM CITRATE	Urocit-K	11/1/84	Designated/Approved	Approved for Orphan Indication		8/30/85	8/30/92	University of Texas Health Science Center at Dallas	Dallas	Texas	75235	USA	EXACT	0045761AA	Potassium citrate	EE90ONI6FF						Renal hypouricemia	9496	approximate	
Potassium citrate and citric acid	For the dissolution and control of uric acid and cysteine calculi in the urinary tract.	Potassium citrate and citric acid	POTASSIUM CITRATE	n/a	2/14/86	Designated/Withdrawn			N/A	N/A	Willen Drug Company					EXACT	0045761AA	Potassium citrate	EE90ONI6FF								MISSING	not a disease
"Powdered extracts of the herbs Scutellaria baicalensis Geori, Glycyrrhiza uralensis Fisch, Paeonia lactiflora Pall, and Ziziphus jujuba Mill"	Treatment of hepatocellular carcinoma	"Powdered extracts of the herbs Scutellaria baicalensis Geori, Glycyrrhiza uralensis Fisch, Paeonia lactiflora Pall, and Ziziphus jujuba Mill"	SCUTELLARIA BAICALENSIS ROOT	n/a	3/22/18	Designated			N/A	N/A	Yiviva Inc.	"447 Broadway, 2FL"		10013	USA	LONGEST CONTAINS	0367204AA	Scutellaria baicalensis	7J95K7ID2S						Childhood hepatocellular carcinoma	9331	approximate	
Pr-122 (redox-phenytoin)	"For the emergency rescue treatment of status epilepticus, grand mal type."	Pr-122 (redox-phenytoin)	PHENYTOIN	n/a	7/5/90	Designated/Withdrawn			N/A	N/A	Pharmos	Alachua	Florida	32615	USA	EXACT	0009381AA	phenytoin	6158TKW0C5						Status epilepticus	10191	approximate	
Pradigastat	"Treatment of hypertriglyceridemia in te setting of Type I hyperlipoproteinemia, also known as Familial Chylomicronemia Syndrome"	selective deacylglycerol acyltransferase 1 inhibitor	PRADIGASTAT	n/a	3/28/11	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0648362AA	Pradigastat	2U23G6VNUZ						Familial lipoprotein lipase deficiency	12241	done	
Pramiracetam Sulfate	For the management of cognitive dysfunction and enhancement of antidepressant activity associated with electroconvulsive therapy.	Pramiracetam Sulfate	PRAMIRACETAM SULFATE	n/a	11/4/91	Designated/Withdrawn			N/A	N/A	"Cambridge Neuroscience, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0115800AA	Pramiracetam Sulfate	OP7O7MNS9P								MISSING	not a disease
Prednimustine	Treatment of malignant non-Hodgkin's lymphomas.	Prednimustine	PREDNIMUSTINE	Sterecyt	6/17/85	Designated/Withdrawn			N/A	N/A	Pharmacia Inc.	Columbus	Ohio	43216	USA	EXACT	0063741AA	Prednimustine	9403SIO2S8						B-cell lymphoma	5877	approximate	
Priliximab	Treatment of multiple sclerosis.	Chimeric M-T412 (human-murine) IgG monoclonal anti-CD4	PRILIXIMAB	n/a	6/5/91	Designated/Withdrawn			N/A	N/A	"Centocor, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	1093170AA	Priliximab					PROBLEM	can't find	Multiple sclerosis	10255	done	
Primaquine phosphate	For use in combination with clindamycin hydrochloride in the treatment of Pneumocystis carinii pneumonia associated with AIDS.	Primaquine phosphate	PRIMAQUINE PHOSPHATE	n/a	7/23/93	Designated			N/A	N/A	"Sanofi Winthrop, Inc."	New York	New York	10016	USA	EXACT	0011074AA	Primaquine phosphate	H0982HF78B						Pneumocystic carinii pneumonia	7409	done	
ProTmune (ex vivo Programmed Mobilized Peripheral Blood)	Prevention of graft-versus-host disease in patients undergoing allogenic hematopoietic cell transplantation	ProTmune (ex vivo Programmed Mobilized Peripheral Blood)	BLOOD	n/a	9/19/16	Designated			N/A	N/A	Fate Therapeutics	San Diego	California	92121	USA	LONGEST CONTAINS	0098420AA	Blood	43MX67MYM9						Chronic graft versus host disease	10964	approximate	type of GVHD (acute or chronic) is not specified
ProTmune (ex vivo Programmed Mobilized Peripheral Blood)	Prevention of graft-versus-host disease in patients undergoing allogenic hematopoietic cell transplantation	ProTmune (ex vivo Programmed Mobilized Peripheral Blood)	BLOOD	n/a	9/19/16	Designated			N/A	N/A	Fate Therapeutics	San Diego	California	92121	USA	LONGEST CONTAINS	0098420AA	Blood	43MX67MYM9						Acute graft versus host disease	6544	approximate	type of GVHD (acute or chronic) is not specified
Prostaglandin E1 in lipid emulsion	Treatment of ischemic ulceration of the lower limbs due to peripheral arterial disease.	Prostaglandin E1 in lipid emulsion	ALPROSTADIL	Lipo-Pge1	9/10/96	Designated/Withdrawn			N/A	N/A	Alpha Therapeutic Corporation	Los Angeles	California	90032	USA	EXACT	0030864AA	Prostaglandin E1	F5TD010360								MISSING	
Protein C	Reversal of anticoagulation therapy in patients needing treatment of serious or life threatening bleeding and/or needing urgent surgery or invasive procedures	Human prothrombin complex concentrate	PROTEIN C	Octaplex	2/1/08	Designated			N/A	N/A	"Octapharma USA, Inc."	Hoboken	New Jersey	7030	USA	EXACT	0340501AA	Protein C	3Z6S89TXPW								MISSING	treatment of drug-induced side-effects
Protein C	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	prothrombin complex concentrate (human)	PROTEIN C	Kcentra	12/27/12	Designated/Approved	Approved for Orphan Indication	"Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy (VKA, e.g., warfarin) in adult patients with the need for urgent surgery/invasive procedure."	12/13/13	12/13/20	CSL Behring	King of Prussia	Pennsylvania	19406	USA	EXACT	0340501AA	Protein C	3Z6S89TXPW								MISSING	not a disease
Protein C	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	prothrombin complex concentrate (human)	PROTEIN C	Kcentra	12/27/12	Designated/Approved	Approved for Orphan Indication	"Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding."	4/29/13	4/29/20	CSL Behring	King of Prussia	Pennsylvania	19406	USA	EXACT	0340501AA	Protein C	3Z6S89TXPW								MISSING	not a disease
Protein C concentrate	"For replacement therapy in congenital protein C deficiency for the prevention and treatment of thrombosis, pulmonary emboli, and purpura fulminans."	Protein C concentrate	PROTEIN C	Ceprotin	6/23/92	Designated/Approved	Approved for Orphan Indication	Prevention and treatment of venous thrombosis and purpura fulminans	3/30/07	3/30/14	"Baxalta US, Inc."	West Lake Village	California	91362	USA	EXACT	0340501AA	Protein C	3Z6S89TXPW						Autosomal recessive protein C deficiency	13041	approximate	
Protein C concentrate	For replacement therapy in patients with congenital or acquired protein C deficiency for the prevention and treatment of warfarin-induced skin necrosis during oral anticoagulation.	Protein C concentrate	PROTEIN C	"Protein C Concentrate (Human) Vapor Heated, Immuno"	6/19/92	Designated			N/A	N/A	Immuno Clinical Research Corp.	New York	New York	10022	USA	EXACT	0340501AA	Protein C	3Z6S89TXPW						Autosomal recessive protein C deficiency	13041	approximate	
Protein C concentrate	For use in the prevention and treatment of purpura fulminans in meningococcemia.	Protein C concentrate	PROTEIN C	"Protein C Concentrate (Human) Vapor Heated, Immuno"	4/22/93	Designated/Withdrawn			N/A	N/A	Immuno Clinical Research Corp.	New York	New York	10022	USA	EXACT	0340501AA	Protein C	3Z6S89TXPW						Meningococcemia	3472	done	
Protein S Human	Reversal of anticoagulation therapy in patients needing treatment of serious or life threatening bleeding and/or needing urgent surgery or invasive procedures	Human prothrombin complex concentrate	PROTEIN S HUMAN	Octaplex	2/1/08	Designated			N/A	N/A	"Octapharma USA, Inc."	Hoboken	New Jersey	7030	USA	EXACT	0695545AA	Protein S Human	90J3F6N5FN								MISSING	treatment of drug-induced side-effects
Protein S Human	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	prothrombin complex concentrate (human)	PROTEIN S HUMAN	Kcentra	12/27/12	Designated/Approved	Approved for Orphan Indication	"Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy (VKA, e.g., warfarin) in adult patients with the need for urgent surgery/invasive procedure."	12/13/13	12/13/20	CSL Behring	King of Prussia	Pennsylvania	19406	USA	EXACT	0695545AA	Protein S Human	90J3F6N5FN								MISSING	not a disease
Protein S Human	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	prothrombin complex concentrate (human)	PROTEIN S HUMAN	Kcentra	12/27/12	Designated/Approved	Approved for Orphan Indication	"Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding."	4/29/13	4/29/20	CSL Behring	King of Prussia	Pennsylvania	19406	USA	EXACT	0695545AA	Protein S Human	90J3F6N5FN								MISSING	not a disease
Protirelin	Prevention of infant respiratory distress syndrome associated with prematurity.	Protirelin	PROTIRELIN	n/a	8/24/93	Designated/Withdrawn			N/A	N/A	"UCB Pharma, Inc."	Smyrna	Georgia	30080	USA	EXACT	0062486AA	Protirelin	5Y5F15120W						"Respiratory distress syndrome, infant"	112	done	
Prussian blue	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	iron(III)-hexacyanoferrate(II)	FERRIC FERROCYANIDE	Radiogardase	5/1/03	Designated/Approved	Approved for Orphan Indication	Treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination	10/2/03	10/2/10	"Heyl Chemisch-Pharmzeutische Fabrik GMBH & Co, KG"				Germany	EXACT	0055709AA	Prussian blue	TLE294X33A								MISSING	not a disease
Pulmonary surfactant replacement	Prevention and treatment of infant respiratory distress syndrome.	Pulmonary surfactant replacement		n/a	12/5/88	Designated/Withdrawn			N/A	N/A	"Scios Nova, Inc."	Mountain View	California	94043	USA								PROBLEM	not a drug	"Respiratory distress syndrome, infant"	112	done	
"Pulmonary surfactant replacement, porcine"	For the treatment and prevention of respiratory distress syndrome in premature infants.	"Pulmonary surfactant replacement, porcine"		Curosurf	8/2/93	Designated/Approved	Approved for Orphan Indication	Treatment (rescue) of respiratory distress syndrome in premature infants.	11/18/99	N/A	"Chiesi USA, Inc."	Cary	North Carolina	27518	USA				KE3U2023NP	PORACTANT ALFA	KE3U2023NP	https://ginas.ncats.nih.gov/ginas/app/substances?q=CUROSURF	done		"Respiratory distress syndrome, infant"	112	done	
Purified type II collagen	Treatment of juvenile rheumatoid arthritis.	Purified type II collagen	COLLAGEN	Colloral	2/9/95	Designated			N/A	N/A	"AutoImmune, Inc."	Lexington	Massachusetts	2421	USA	LONGEST CONTAINS	0006462AA	collagen	76TK29UQEZ | NBU8H1YFTO	BOVINE TYPE II COLLAGEN (TRACHEAL CARTILAGE) | BOVINE TYPE II COLLAGEN (NASAL SEPTUM)	76TK29UQEZ | NBU8H1YFTO	https://ginas.ncats.nih.gov/ginas/app/substances?q=root_Display%5C%20Name:%22type%20ii%20collagen%22	approximate		Juvenile idiopathic arthritis	3067	done	Not a rare disease
Pyruvate	Treatment of interstitial lung disease.	Pyruvate	PYRUVIC ACID	n/a	2/21/01	Designated			N/A	N/A	"Cellular Sciences, Inc"	Flemington	New Jersey	8822	USA	EXACT	0020291AA	Pyruvate	8558G7RUTR						Interstitial lung disease	13336	done	Not a rare disease
Quinacrine hydrochloride	For prevention of recurrence of pneumothorax in patients at high risk of recurrence.	Quinacrine hydrochloride	QUINACRINE HYDROCHLORIDE	n/a	10/17/84	Designated/Withdrawn			N/A	N/A	"Lyphomed, Inc."					EXACT	0011905AA	Quinacrine hydrochloride	G6242H2NAA						Primary spontaneous pneumothorax	4997	done	
R-AZASETRON BESYLATE	Prevention of platinum-induced ototoxicity in pediatric patients	(R)-Azasetron besylate	R-AZASETRON BESYLATE	n/a	8/16/17	Designated			N/A	N/A	Sensorion SA	Montpellier			France	EXACT	0112152AB	R-AZASETRON BESYLATE	UXP39EQ477								MISSING	prevention of drug-induced side-effects
RAPASTINEL	Treatment of neuropathic pain associated with spinal cord injury	L-threonyl-L-prolyl-L-prolyl-L-threonine	RAPASTINEL	n/a	4/26/05	Designated			N/A	N/A	"Nyxis Neurotherapies, Inc."	Evanston	Illinois	60201	USA	EXACT	0738932AA	RAPASTINEL	6A1X56B95E								MISSING	
RAXATRIGINE HYDROCHLORIDE	Treatment of erythromelalgia	"(5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, hydrochloride"	RAXATRIGINE HYDROCHLORIDE	n/a	1/30/17	Designated			N/A	N/A	Convergence Pharmaceuticals (Biogen Subsidiary)	Cambridge	Massachusetts	2142	USA	EXACT	0565708AA	RAXATRIGINE HYDROCHLORIDE	7L3OLR4M8T						Erythromelalgia	6377	done	
RAXATRIGINE HYDROCHLORIDE	Treatment of trigeminal neuralgia	"(5R)-5-(4-{[2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, hydrochloride"	RAXATRIGINE HYDROCHLORIDE	n/a	7/24/13	Designated			N/A	N/A	Convergence Pharmaceuticals Ltd.				United Kingdom	EXACT	0565708AA	RAXATRIGINE HYDROCHLORIDE	7L3OLR4M8T						Trigeminal neuralgia	7805	done	
REGN-3470	Treatment of ebola virus infection	"three human IgG1 mAbs (REGN3470, REGN3471, and REGN3479) directed against different epitopes on Ebola virus glycoprotein"	REGN-3470	n/a	7/14/16	Designated			N/A	N/A	"Regeneron Pharmaceuticals, Inc."	Tarrytown	New York	10591	USA	EXACT	1211967AA	REGN-3470	FJZ07Q63VY						Ebola virus disease	2035	done	
REGN-3471	Treatment of ebola virus infection	"three human IgG1 mAbs (REGN3470, REGN3471, and REGN3479) directed against different epitopes on Ebola virus glycoprotein"	REGN-3471	n/a	7/14/16	Designated			N/A	N/A	"Regeneron Pharmaceuticals, Inc."	Tarrytown	New York	10591	USA	EXACT	1211978AA	REGN-3471	UY9LQ8P6HW						Ebola virus disease	2035	done	
REGN-3479	Treatment of ebola virus infection	"three human IgG1 mAbs (REGN3470, REGN3471, and REGN3479) directed against different epitopes on Ebola virus glycoprotein"	REGN-3479	n/a	7/14/16	Designated			N/A	N/A	"Regeneron Pharmaceuticals, Inc."	Tarrytown	New York	10591	USA	EXACT	1211989AA	REGN-3479	KOP95331M4						Ebola virus disease	2035	done	
RELTECIMOD	Treatment of necrotizing soft tissue infections (NSTI)	synthetic peptide H-D-Ala-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-D-Ala-OH	RELTECIMOD	n/a	10/12/11	Designated			N/A	N/A	"Atox Bio, Inc."	Ness Ziona			Israel	EXACT	1311257AA	RELTECIMOD	U00J02UY29								MISSING	Not a rare disease; infections not specified
REMUNE HIV 1	Treatment of pediatric HIV/AIDS (age through 16 years)	REMUNE HIV 1		n/a	2/14/14	Designated			N/A	N/A	"Immune Response BioPharma, Inc."	Atlantic City	New Jersey	8401	USA								PROBLEM	can't find	Congenital human immunodeficiency virus	10328	approximate	
RESVERATROL	Treatment of MELAS syndrome	"5-[(E)-2-(4-hydroxyphenyl)-ethenyl] benzene-1,3 diol"	RESVERATROL	Resveratrol	3/13/08	Designated			N/A	N/A	"Sirtris Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0237978AA	RESVERATROL	Q369O8926L						Mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes	7009	done	
RGG-853	Treatment of ovarian cancer.	"RGG0853, E1A lipid complex"		n/a	9/15/95	Designated/Withdrawn			N/A	N/A	Targeted Genetics Corporation	Seattle	Washington	98101	USA					"RGG0853, E1A lipid complex"	NA	https://adisinsight.springer.com/drugs/800009406	PROBLEM	can't find	Ovarian cancer	7295	done	
RGX-104	Treatment of glioblastoma multiforme.	"2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid"	RGX-104	n/a	6/16/15	Designated			N/A	N/A	"Rgenix, Inc."	New York	New York	10065	USA	EXACT	1576778AA	RGX-104	Q26B92650V						Glioblastoma	2491	done	
RGX-104	Treatment of malignant melanoma stages IIB to IV.	"2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid"	RGX-104	n/a	6/23/15	Designated			N/A	N/A	"Rgenix, Inc."	New York	New York	10065	USA	EXACT	1576778AA	RGX-104	Q26B92650V						"Melanoma, familial"	3460	approximate	
RGX-104	Treatment of ovarian cancer.	"2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid"	RGX-104	n/a	6/16/15	Designated			N/A	N/A	"Rgenix, Inc."	New York	New York	10065	USA	EXACT	1576778AA	RGX-104	Q26B92650V						Ovarian cancer	7295	done	
RIVIPANSEL	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	"(1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O-(sodium(2S)-3-cyclohexyl-propanoate-"	RIVIPANSEL	n/a	2/17/09	Designated			N/A	N/A	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	0828013AA	RIVIPANSEL	4B115V09LB						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
RIVIPANSEL	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	"(1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O-(sodium(2S)-3-cyclohexyl-propanoate-"	RIVIPANSEL	n/a	2/17/09	Designated			N/A	N/A	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	0828013AA	RIVIPANSEL	4B115V09LB						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
RIVIPANSEL	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	"(1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O-(sodium(2S)-3-cyclohexyl-propanoate-"	RIVIPANSEL	n/a	2/17/09	Designated			N/A	N/A	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	0828013AA	RIVIPANSEL	4B115V09LB						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
RIVIPANSEL	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	"(1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O-(sodium(2S)-3-cyclohexyl-propanoate-"	RIVIPANSEL	n/a	2/17/09	Designated			N/A	N/A	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	0828013AA	RIVIPANSEL	4B115V09LB						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
RIVIPANSEL	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	"(1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O-(sodium(2S)-3-cyclohexyl-propanoate-"	RIVIPANSEL	n/a	2/17/09	Designated			N/A	N/A	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	0828013AA	RIVIPANSEL	4B115V09LB						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
RIVIPANSEL	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	"(1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O-(sodium(2S)-3-cyclohexyl-propanoate-"	RIVIPANSEL	n/a	2/17/09	Designated			N/A	N/A	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	0828013AA	RIVIPANSEL	4B115V09LB						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
RO-6958688	Treatment of pancreatic cancer	humanized immunoglobulin G1 (IgG1) T-cell bispecific (TCB) antibody targeting carcinoembryonic antigen (CEA) and CD3 epsilon chain (CD3e) on T-cells	"POLYETHYLENE GLYCOL, UNSPECIFIED"	n/a	7/27/17	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0113055AB	polyethylene glycol	3WJQ0SDW1A						Pancreatic cancer	9364	done	Not a rare disease
RP-5063 hydrochloride	Treatment of Idiopathic Pulmonary Fibrosis	"6-(4-(4-(2,3-Dicholorophenyl) piperazin-1-yl) butoxy)-2H-benzo [b] [1,4] oxazin-3(4H)-one hydrochloride"	"6-(4-(4-(2,3-DICHLOROPHENYL)-PIPERAZIN-1-YL)-BUTOXY)-2H-BENZO(B)(1,4)OXAZIN-3(4H)-ONE HYDROCHLORIDE"	n/a	4/4/18	Designated			N/A	N/A	"Reviva Pharmaceuticals, Inc."	"1250 Oakmead Parkway, Suite 210"		94085	USA	EXACT	1800357AA	RP-5063 hydrochloride	I440YY0HX0						Idiopathic pulmonary fibrosis	8609	done	
RP-5063 hydrochloride	Treatment of pulmonary arterial hypertension (WHO Group 1)	"6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo[b][1,4]oxazin-3(4H)-one hydrochloride"	"6-(4-(4-(2,3-DICHLOROPHENYL)-PIPERAZIN-1-YL)-BUTOXY)-2H-BENZO(B)(1,4)OXAZIN-3(4H)-ONE HYDROCHLORIDE"	n/a	11/9/16	Designated			N/A	N/A	"Reviva Pharmaceuticals, Inc."	Santa Clara	California	95054	USA	EXACT	1800357AA	RP-5063 hydrochloride	I440YY0HX0						Autoimmune pulmonary alveolar proteinosis	7499	done	
RRX-001	Treatment of neuroendocrine tumors	"N-(bromoacetyl)-3,3-dinitroazetidine"	RRX-001	n/a	6/15/17	Designated			N/A	N/A	"EpicentRx, Inc."	San Diego	California	92121	USA	EXACT	0832199AA	RRX-001	7RPW6SU9SC						Neuroendocrine tumor	13445	done	
RRX-001	Treatment of small cell lung cancer	"N-(bromoacetyl)-3,3-dinitroazetidine"	RRX-001	n/a	6/15/17	Designated			N/A	N/A	"EpicentRx, Inc."	San Diego	California	92121	USA	EXACT	0832199AA	RRX-001	7RPW6SU9SC						Small cell lung cancer	9344	done	
RT-001	Treatment of Friedreich's Ataxia	"9-cis, 12-cis-11,11-d2-linoleic acid ethyl ester"	RT-001	n/a	5/23/16	Designated			N/A	N/A	"Retroitope, Inc."	Los Altos	California	94022	USA	EXACT	1149173AA	RT-001	24B102R86P						Friedreich ataxia	6468	done	
RTL-1000	Treatment of multiple sclerosis patients who are both HLA-DR2 positive and autoreactive to myelin oligodendrocyte glycoprotein residues 35-55	Recombinant T-cell receptor ligand	RTL-1000	n/a	5/2/03	Designated			N/A	N/A	"Artielle ImmunoTherapeutics, Inc."	"Tigard,"	Oregon	97223	USA	EXACT	1802477AA	RTL-1000	8D7IFF667N						Multiple sclerosis	10255	done	
RVT-801	Treatment of Faber disease	recombinant human acid ceramidase	ACID CERAMIDASE	Plexcerase(Tm)	12/24/13	Designated			N/A	N/A	Enzyvant Sciences Ltd.	Hamilton HM11			Bermuda	EXACT	1321808AA	RVT-801	QK6ZKF2EPJ						Farber's disease	6426	done	Faber disease or Farber disease?
Rabbit anti-human thymocyte globulin (rATG)	Induction treatment to prevent rejection and to minimize maintenance immunosupression in pediatric liver transplant recipients	Rabbit anti-human thymocyte globulin (rATG)	LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN	Thymoglobulin	9/26/06	Designated			N/A	N/A	Children's Hospital of Pittsburgh	Pittsburgh	Pennsylvania	15213	USA	EXACT	0233385AA	Rabbit anti-human thymocyte globulin (rATG)	D7RD81HE4W								MISSING	"not a disease, a procedure"
Recombinant Epstein-Barr virus gp350 glycoprotein vaccine	Prevention of post-transplantation lymphoproliferative disorders in pediatric recipients of solid-organ transplantation	Recombinant Epstein-Barr virus gp350 glycoprotein vaccine		n/a	8/18/05	Designated			N/A	N/A	Henogen S.A.				Belgium								PROBLEM	can't find	Post-transplant lymphoproliferative disease	9553	done	
Recombinant Human Interleukin-21 (rIL-21)	"Treatment of stage II (T4), III or IV malignant melanoma."	Recombinant Human Interleukin-21 (rIL-21)	DENENICOKIN	n/a	10/4/05	Designated			N/A	N/A	"Zymo Genetics, Inc"	Seattle	Washington	98102	USA	EXACT	0267027AA	Recombinant Human Interleukin 21	A4LY1V9F0H						"Melanoma, familial"	3460	approximate	
Recombinant P-Selectin glycoprotein ligand	Prevention of delayed graft function in renal transplant patients	Recombinant P-Selectin glycoprotein ligand		n/a	3/29/06	Designated			N/A	N/A	"Y's Therapeutics, Inc."	San Bruno	California	94066	USA								PROBLEM	can't find			MISSING	
Recombinant P-selectin glycoprotein ligand-immunoglobulin Ig	Prevention of ischemia reperfusion injury in all solid organ transplants	Recombinant P-selectin glycoprotein ligand-immunoglobulin Ig		n/a	7/26/07	Designated			N/A	N/A	"Y's Therapeutics, Inc."	Redwood City	California	94061	USA								PROBLEM	can't find			MISSING	Not a rare disease
"Recombinant adeno-associated viral vector, AAV2 serotype 6 (rAAv2/6), expressing human factor 8 (hf8) cDNA"	Treatment of hemophilia A	"Recombinant adeno-associated viral vector, AAV2 serotype 6 (rAAv2/6), expressing human factor 8 (hf8) cDNA"	AAV-2	n/a	5/3/17	Designated			N/A	N/A	"Sangamo Therapeutics, Inc."	Richmond	California	94804	USA	LONGEST CONTAINS	0112841AB	AAV2	YA02LE18L3						Hemophilia A	6591	done	
Recombinant adeno-associated virus (serotype 2) (rAAV2) gene transfer agent expressing RPE65	Treatment of Leber's congential amaurosis	Recombinant adeno-associated virus (serotype 2) (rAAV2) gene transfer agent expressing RPE65	RETINOID ISOMEROHYDROLASE	n/a	5/11/09	Designated			N/A	N/A	AmpliPhi Biosciences Corporation	Seattle	Washington	98111	USA	LONGEST CONTAINS	0116711AB	RPE65	CH2LY7Q64L						Leber congenital amaurosis	634	done	
Recombinant adenovirus carrying the cDNA coding sequence for the human interferon gamma gene	"Treatment of basal cell carcinomas in individuals with basal cell nevus syndrome (BCNS), also known as Gorlin syndrome"	Recombinant adenovirus carrying the cDNA coding sequence for the human interferon gamma gene	INTERFERON GAMMA	n/a	7/19/17	Designated			N/A	N/A	Ascend Biopharmaceuticals Ltd	South Melbourne			Australia	LONGEST CONTAINS	0214573AA	interferon gamma	P050J5FWC5						Nevoid basal cell carcinoma syndrome	7166	done	
Recombinant coagulation factor VIIa	Treatment of diffuse alveolar hemorrhage	Recombinant coagulation factor VIIa	COAGULATION FACTOR VIIA RECOMBINANT HUMAN	n/a	4/26/06	Designated			N/A	N/A	Savara Inc.	Austin	Texas	78746	USA	EXACT	0280922AA	Recombinant coagulation factor VIIa	AC71R787OV						Idiopathic pulmonary hemosiderosis	6763	approximate	
Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs	"Prevention of thrombotic thrombocytopenic purpura including its congential, acquired idiopathic and secondary forms."	Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs		n/a	7/29/08	Designated			N/A	N/A	Baxalta US Inc.	Westlake Village	California	91362	USA								PROBLEM	can't find	"Thrombotic thrombocytopenic purpura, acquired "	4607	done	
Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs	"Prevention of thrombotic thrombocytopenic purpura including its congential, acquired idiopathic and secondary forms."	Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs		n/a	7/29/08	Designated			N/A	N/A	Baxalta US Inc.	Westlake Village	California	91362	USA								PROBLEM	can't find	 Congenital thrombotic thrombocytopenic purpura 	9430	done	
Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs	"Prevention of thrombotic thrombocytopenic purpura including its congential, acquired idiopathic and secondary forms."	Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs		n/a	7/29/08	Designated			N/A	N/A	Baxalta US Inc.	Westlake Village	California	91362	USA								PROBLEM	can't find	 Idiopathic thrombocytopenic purpura	5194	done	
Recombinant human C1 inhibitor	Prevention and/or treatment of delayed graft function after solid organ transplantation	Recombinant human C1 inhibitor	CONESTAT ALFA	n/a	6/9/06	Designated			N/A	N/A	Pharming Group N.V.				Netherlands	EXACT	0432166AA	Recombinant human C1 inhibitor	5QS67N4551								MISSING	
Recombinant human C1 inhibitor	Treatment of capillary leakage syndrome	Recombinant human C1 inhibitor	CONESTAT ALFA	n/a	6/9/06	Designated			N/A	N/A	Pharming Technologies B.V.				Netherlands	EXACT	0432166AA	Recombinant human C1 inhibitor	5QS67N4551						Systemic capillary leak syndrome	1084	done	
Recombinant human C1-esterase inhibitor	Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Recombinant human C1-esterase inhibitor	"HUMAN C1-ESTERASE INHIBITOR, RECOMBINANT"	n/a	2/23/99	Designated			N/A	N/A	Pharming Group N.V.				Netherlands	EXACT	0759193AA	Recombinant human C1-esterase inhibitor	RB0RV8I60K						Hereditary angioedema 	5979	done	
Recombinant human C1-esterase inhibitor	Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Recombinant human C1-esterase inhibitor	"HUMAN C1-ESTERASE INHIBITOR, RECOMBINANT"	n/a	2/23/99	Designated			N/A	N/A	Pharming Group N.V.				Netherlands	EXACT	0759193AA	Recombinant human C1-esterase inhibitor	RB0RV8I60K						 Acquired angioedema	8605	done	
Recombinant human CD4 immunoglobulin G	Treatment of AIDS resulting from infection with HIV-1.	Recombinant human CD4 immunoglobulin G		n/a	8/30/90	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA				LT369U66CE	IBALIZUMAB	LT369U66CE	"https://ginas.ncats.nih.gov/ginas/app/substances?q=IMMUNOGLOBULIN%20G4,%20ANTI-(HUMAN%20CD4%20(ANTIGEN))%20(HUMAN-MOUSE%20MONOCLONAL%205A8%20.GAMMA.4-CHAIN),%20DISULPHIDE%20WITH%20HUMAN-MOUSE%20MONOCLONAL%205A8%20.KAPPA.-CHAIN,%20DIMER"	done		Congenital human immunodeficiency virus	10328	approximate	
Recombinant human acid alpha-glucosidase; alglucosidase alfa	Treatment of glycogen storage disease type II.	Recombinant human acid alpha-glucosidase; alglucosidase alfa	ALGLUCOSIDASE ALFA	1. Myozyme 2. Lumizyme	8/19/97	Designated/Approved	Approved for Orphan Indication	"Myozyme for use in patients with Pompe disease (GAA deficiency). Alglucosidase alfa has been shown to improve ventilator-free survival in patients with infantile onset Pompe disease as compared to an untreated historical control, whereas use of Alphaglucosidase in patients with other forms of Pompe disease has not been adequately studied to assure safety and efficacy."	4/28/06	4/28/13	Genzyme Corporation	Cambridge	Massachusetts	2142	USA	EXACT	0262873AA	alglucosidase alfa	DTI67O9503						Glycogen storage disease type 2	5714	done	
Recombinant human acid alpha-glucosidase; alglucosidase alfa	Treatment of glycogen storage disease type II.	Recombinant human acid alpha-glucosidase; alglucosidase alfa	ALGLUCOSIDASE ALFA	1. Myozyme 2. Lumizyme	8/19/97	Designated/Approved	Approved for Orphan Indication	(Lumizyme) Patients with Pompe disease (acid alpha-glucosidase (GAA deficiency)).	8/1/14	8/1/21	Genzyme Corporation	Cambridge	Massachusetts	2142	USA	EXACT	0262873AA	alglucosidase alfa	DTI67O9503						Glycogen storage disease type 2	5714	done	
Recombinant human fibrinogen	Treatment of bleeding in patients deficient in fibrinogen	Recombinant human fibrinogen	FIBRINOGEN HUMAN	n/a	10/4/07	Designated			N/A	N/A	Pharming Technologies B.V.				Netherlands	LONGEST CONTAINS	0323977AA	human fibrinogen	N94833051K						"Fibrinogen deficiency, congenital"	2320	approximate	
Recombinant human gelsolin	Treatment of acute and chronic respiratory symptoms of bronchiectasis.	Recombinant human gelsolin	GELSOLIN	n/a	3/6/95	Designated			N/A	N/A	"BioAgeis, Therapeutics, Inc."	Morristown	New Jersey	7960	USA	EXACT	1577442AA	Recombinant human gelsolin	JBT6SFF5BV								MISSING	
Recombinant human granulocyte colony stimulating factor	Prevention of implantation failure and unexplained recurrent miscarriage	Recombinant human granulocyte colony stimulating factor		n/a	7/24/06	Designated/Withdrawn			N/A	N/A	"Nora Therapeutics, Inc."	Palo Alto	California	94301	USA				A418D0W758	GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR HUMAN (NON-GLYCOSYLATED)	A418D0W758	https://ginas.ncats.nih.gov/ginas/app/substance/c2bb993d	approximate				MISSING	
Recombinant human insulin receptor monoclonal antibody-N-heparan sulfamidase fusion protein	"Treatment of Mucopolysaccharidosis Type IIIA, Sanfilippo A Syndrome"	Recombinant human insulin receptor monoclonal antibody-N-heparan sulfamidase fusion protein	INSULIN RECEPTOR	n/a	7/12/18	Designated			N/A	N/A	"ArmaGen, Inc."	"26679 Agoura Road, Suite #100"	California	91302	USA	LONGEST CONTAINS	1337275AA	insulin receptor	4CH8636GFF						Mucopolysaccharidosis type IIIA	7071	done	
Recombinant human microplasmin	Treatment of peripheral arterial occlusion	Recombinant human microplasmin	OCRIPLASMIN	n/a	1/23/06	Designated			N/A	N/A	ThromboGenics Ltd	Dublin			Ireland	EXACT	0345562AA	Recombinant human microplasmin	7V6HE3DM5A								MISSING	symptom
Recombinant human nerve growth factor	Treatment of HIV-associated sensory neuropathy.	Recombinant human nerve growth factor	RHNGF	n/a	4/16/99	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	1106214AA	Recombinant human nerve growth factor	Y8JXJ39EE9								MISSING	
Recombinant human thrombopoietin	For use in accelerating platelet recovery in patients undergoing hematopoietic stem cell transplantation.	Recombinant human thrombopoietin	THROMBOPOIETIN	n/a	9/29/97	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	LONGEST CONTAINS	0255254AA	thrombopoietin	5651J3R2JF								MISSING	"not a disease, a procedure"
Recombinant humanized IgG1 anti-HER2 monoclonal antibody conjugated to Duostatin-5	Treatment of gastric cancer.	Recombinant humanized IgG1 anti-HER2 monoclonal antibody conjugated to Duostatin-5	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2	n/a	6/7/18	Designated			N/A	N/A	"Klus Pharma, Inc."	8 Clarke Drive	Suite 4	8512	USA	LONGEST CONTAINS	1336761AA	HER2	7J9Y28299R						Stomach cancer	7704	done	
Recombinant methionyl human stem cell factor	Treatment of primary bone marrow failure.	Recombinant methionyl human stem cell factor	STEM CELL FACTOR	n/a	11/22/95	Designated/Withdrawn			N/A	N/A	"Amgen, Inc."	Thousand Oaks	California	91320	USA	LONGEST CONTAINS	0259450AA	stem cell factor	PYB4Q6JG41	ANCESTIM	PYB4Q6JG41	https://ginas.ncats.nih.gov/ginas/app/substances?q=ANCESTIM	done		Inherited bone marrow failure syndromes	9853	approximate	
Recombinant retroviral vector - glucocerebrosidase	"For use as enzyme replacement therapy for patients with types I, II, or III Gaucher disease."	Recombinant retroviral vector - glucocerebrosidase		n/a	11/15/93	Designated			N/A	N/A	"Genetic Therapy, Inc."	Gaithersburg	Maryland	20878	USA					MFG-GC	NA	https://www.jstor.org/stable/pdf/2360701.pdf?seq=1#page_scan_tab_contents	PROBLEM	can't find	Gaucher disease type 1	2441	done	
Recombinant retroviral vector - glucocerebrosidase	"For use as enzyme replacement therapy for patients with types I, II, or III Gaucher disease."	Recombinant retroviral vector - glucocerebrosidase		n/a	11/15/93	Designated			N/A	N/A	"Genetic Therapy, Inc."	Gaithersburg	Maryland	20878	USA					MFG-GC	NA	https://www.jstor.org/stable/pdf/2360701.pdf?seq=1#page_scan_tab_contents	PROBLEM	can't find	 Gaucher disease type 2	2442	done	
Recombinant soluble human CD4	Treatment of acquired immunodeficiency syndrome.	Recombinant soluble human CD4		Receptin	11/20/89	Designated/Withdrawn			N/A	N/A	"Biogen, Inc."	Cambridge	Massachusetts	2142	USA								PROBLEM	can't find	Congenital human immunodeficiency virus	10328	approximate	
Recombinant soluble human CD4 (rCD4)	Treatment of AIDS in patients infected with HIV virus.	Recombinant soluble human CD4 (rCD4)		n/a	3/23/89	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA								PROBLEM	can't find	Congenital human immunodeficiency virus	10328	approximate	
Recombinant urate oxidase	Prophylaxis of chemotherapy-induced hyperuricemia.	Recombinant urate oxidase	RASBURICASE	n/a	10/11/00	Designated			N/A	N/A	Sanofi-Synthelabo Research	Malvern	Pennsylvania	19355	USA	EXACT	0178278AA	urate oxidase	08GY9K1EUO								MISSING	prevention of drug-induced side-effects
Recombinant vaccinia (human papillomavirus)	Treatment of cervical cancer.	Recombinant vaccinia (human papillomavirus)	HUMAN PAPILLOMAVIRUS	Ta-Hpv	8/24/94	Designated/Withdrawn			N/A	N/A	Xenova Research Limited				USA	LONGEST CONTAINS	0316892AA	human papillomavirus	23CVL7WF4J						Glassy cell carcinoma of the cervix	8437	approximate	
Remitogen	For use in the treatment of 1D10+ B cell non-Hodgkin's lymphoma	"Hu1D10, humanized monoclonal antibody"	APOLIZUMAB	Remitogen	11/28/01	Designated			N/A	N/A	"PDL BioPharma, Inc."	Fremont	California	94555	USA	EXACT	0298022AA	Remitogen	G88KCP51RE						"Non-Hodgkin lymphoma, during pregnancy "	9347	approximate	
Remitogen	For use in the treatment of 1D10+ B cell non-Hodgkin's lymphoma	"Hu1D10, humanized monoclonal antibody"	APOLIZUMAB	Remitogen	11/28/01	Designated			N/A	N/A	"PDL BioPharma, Inc."	Fremont	California	94555	USA	EXACT	0298022AA	Remitogen	G88KCP51RE						" Non-Hodgkin lymphoma, childhood"	9346	approximate	
Replication defective recombinant adenovirus serotype 5 vector carrying the p53 gene in its E1 deleted region	Treatment of head and neck cancer	Replication defective recombinant adenovirus serotype 5 vector carrying the p53 gene in its E1 deleted region		Advexin	1/27/03	Designated			N/A	N/A	"Introgen Therapeutics, Inc."	Houston	Texas	77030	USA					Advexin	NA	https://adisinsight.springer.com/drugs/800004882 | https://www.drugbank.ca/drugs/DB05322	PROBLEM	absent from GINAS	Head and neck cancer	12425	done	not a rare disease
Replication-incompetent GM-CSF-expressing gene-modified allogeneic pancreatic cancer cell lines	Treatment of pancreatic cancer.	Replication-incompetent GM-CSF-expressing gene-modified allogeneic pancreatic cancer cell lines		Gvax Pancreas	3/1/10	Designated			N/A	N/A	"Aduro BioTech, Inc."	Berkeley	California	94710	USA								PROBLEM	can't find	Pancreatic cancer	9364	done	Not a rare disease
Respigam	Prophylaxis of respiratory syncytial virus lower respiratory tract infections in infants and young children at high risk of RSV disease.	Respiratory syncytial virus immune globulin (Human)	RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN)	Respigam	9/27/90	Designated/Approved	Approved for Orphan Indication	For the prevention of serious lower respiratory tract infections caused by RSV in children less than 24 months of age with bronchopulmonary dysplasia or a history of prematurity (less than or equal to 35 weeks gestation).	1/18/96	1/18/03	MedImmune & Massachussetts Public Health Biologics Labs.	Gaithersburg	Maryland	20878	USA	EXACT	0218531AA	Respigam	78I1W13C3D								MISSING	
Respigam	Treatment of respiratory syncytial virus lower respiratory tract infections in hospitalized infants and young children.	Respiratory Syncytial Virus Immune Globulin (human)	RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN)	Hypermune Rsv	9/27/90	Designated			N/A	N/A	"MedImmune, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0218531AA	Respigam	78I1W13C3D								MISSING	
"Retroviral vector, R-GC and GC gene 1750"	Treatment of Gaucher disease.	"Retroviral vector, R-GC and GC gene 1750"		n/a	5/6/97	Designated/Withdrawn			N/A	N/A	Genzyme Corporation	Cambridge	Massachusetts	1701	USA					"Retroviral vector, R-GC and GC gene 1750"	NA	http://www.checkorphan.org/treatments/b89932f160e785cf44d7ee2341a559e7	PROBLEM	absent from GINAS	Gaucher disease	8233	done	
Reveglucosidase alfa	Treatment of Pompe disease.	recombinant glycosylated independent lysosomal targeting (GILT) tagged human acid alpha glucosidase	REVEGLUCOSIDASE ALFA	n/a	8/20/10	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA	EXACT	0816546AA	Reveglucosidase alfa	E86R97M8XQ						Glycogen storage disease type 2	5714	done	
Reviparin sodium	Long-term treatment of acute deep vein trombosis with or without pulmonary embolism in pregnant patients	Reviparin sodium	REVIPARIN SODIUM	Clivarine	6/18/01	Designated			N/A	N/A	Abbott	Abbott Park	Illinois	60064	USA	EXACT	0230944AA	Reviparin sodium	5XQ9UBJ16W								MISSING	
Reviparin sodium	Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients	Reviparin sodium	REVIPARIN SODIUM	Clivarine	6/18/01	Designated			N/A	N/A	Abbott	Abbott Park	Illinois	60064	USA	EXACT	0230944AA	Reviparin sodium	5XQ9UBJ16W								MISSING	
Ricin (blocked) conjugated murine MCA (anti-my9)	For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia.	Ricin (blocked) conjugated murine MCA (anti-my9)	RICIN	n/a	2/1/90	Designated/Withdrawn			N/A	N/A	"ImmunoGen, Inc."	Waltham	Massachusetts	2451	USA	LONGEST CONTAINS	0811450AA	Ricin	U6E7R9OE4R						Acute myeloid leukemia	12757	done	
Ricin (blocked) conjugated murine MCA (anti-my9)	"Treatment of myeloid leukemia, including AML, and blast crisis of CML."	Ricin (blocked) conjugated murine MCA (anti-my9)	RICIN	n/a	8/3/89	Designated/Withdrawn			N/A	N/A	"ImmunoGen, Inc."	Waltham	Massachusetts	2451	USA	LONGEST CONTAINS	0811450AA	Ricin	U6E7R9OE4R						Myeloid leukemia 	8226	done	
Ricin (blocked) conjugated murine MCA (anti-my9)	"Treatment of myeloid leukemia, including AML, and blast crisis of CML."	Ricin (blocked) conjugated murine MCA (anti-my9)	RICIN	n/a	8/3/89	Designated/Withdrawn			N/A	N/A	"ImmunoGen, Inc."	Waltham	Massachusetts	2451	USA	LONGEST CONTAINS	0811450AA	Ricin	U6E7R9OE4R						 Acute myeloid leukemia 	12757	done	
Ricin (blocked) conjugated murine MCA (anti-my9)	"Treatment of myeloid leukemia, including AML, and blast crisis of CML."	Ricin (blocked) conjugated murine MCA (anti-my9)	RICIN	n/a	8/3/89	Designated/Withdrawn			N/A	N/A	"ImmunoGen, Inc."	Waltham	Massachusetts	2451	USA	LONGEST CONTAINS	0811450AA	Ricin	U6E7R9OE4R						 Chronic myeloid leukemia	6105	done	
Ricin (blocked) conjugated murine MCA (n901)	Treatment of small cell lung cancer	Ricin (blocked) conjugated murine MCA (n901)	RICIN	n/a	1/25/91	Designated/Withdrawn			N/A	N/A	"ImmunoGen, Inc."	Waltham	Massachusetts	2451	USA	LONGEST CONTAINS	0811450AA	Ricin	U6E7R9OE4R						Small cell lung cancer	9344	done	
Ricin (blocked) conjugated murine mca (anti-b4)	For the ex-vivo purging of leukemic cells from the bone marrow of non-T cell acute lymphocytic leukemia patients who are in complete remission.	Ricin (blocked) conjugated murine mca (anti-b4)	RICIN	n/a	1/24/91	Designated/Withdrawn			N/A	N/A	"ImmunoGen, Inc."	Waltham	Massachusetts	2451	USA	LONGEST CONTAINS	0811450AA	Ricin	U6E7R9OE4R						Acute leukemia of ambiguous lineage	8638	approximate	
Ricin (blocked) conjugated murine monoclonal antibody (CD6)	"Treatment of cutaneous T-cell lymphomas, acute T-cell leukemia-lymphoma, and related mature T-cell malignancies."	Ricin (blocked) conjugated murine monoclonal antibody (CD6)	RICIN	n/a	9/6/94	Designated/Withdrawn			N/A	N/A	"ImmunoGen, Inc."	Waltham	Massachusetts	2451	USA	LONGEST CONTAINS	0811450AA	Ricin	U6E7R9OE4R						Cutaneous T-cell lymphoma 	6226	done	
Ricin (blocked) conjugated murine monoclonal antibody (CD6)	"Treatment of cutaneous T-cell lymphomas, acute T-cell leukemia-lymphoma, and related mature T-cell malignancies."	Ricin (blocked) conjugated murine monoclonal antibody (CD6)	RICIN	n/a	9/6/94	Designated/Withdrawn			N/A	N/A	"ImmunoGen, Inc."	Waltham	Massachusetts	2451	USA	LONGEST CONTAINS	0811450AA	Ricin	U6E7R9OE4R						 Adult T-cell leukemia/lymphoma	13103	done	
Rifampin	For the short-course treatment of tuberculosis.	"Rifampin, isoniazid, pyrazinamide"	RIFAMPIN	Rifater	9/12/85	Designated/Approved	Approved for Orphan Indication	Short-course treatment of tuberculosis.	5/31/94	5/31/01	Hoechst Marion Roussel	Kansas City	Missouri	64134	USA	EXACT	0054966AA	Rifampin	VJT6J7R4TR						Tuberculosis	7827	done	
"Rifampin , isoniazid, pyrazinamide"	For the short-course treatment of tuberculosis.	"Rifampin, isoniazid, pyrazinamide"	PYRAZINAMIDE	Rifater	9/12/85	Designated/Approved	Approved for Orphan Indication	Short-course treatment of tuberculosis.	5/31/94	5/31/01	Hoechst Marion Roussel	Kansas City	Missouri	64134	USA	EXACT	0016499AA	pyrazinamide	2KNI5N06TI						Tuberculosis	7827	done	
Ritonavir powder for oral suspension	Use with other antiretroviral agents for the treatment of pediatric HIV-1 infection	Ritonavir powder for oral suspension	RITONAVIR	Norvir Powder For Oral Suspension	1/11/17	Designated			N/A	N/A	AbbVie Inc.	North Chicago	Illinois	60044	USA	EXACT	0184929AA	Ritonavir	O3J8G9O825						Congenital human immunodeficiency virus	10328	approximate	
Roquinimex	To prolong time to relapse in leukemia patients who have undergone autologous bone marrow transplantation.	Roquinimex	ROQUINIMEX	Linomide	7/1/93	Designated/Withdrawn			N/A	N/A	Pharmacia & Upjohn	Kalamazoo	Michigan	49001	USA	EXACT	0174196AA	Roquinimex	372T2944C0						Unclassified acute myeloid leukemia	12760	approximate	leukemia - too general
Roseburia hominis	Treatment of ulcerative colitis in pediatric patients age 0 through 16 years	Roseburia hominis	ROSEBURIA HOMINIS	Rosburix	8/4/14	Designated			N/A	N/A	4D Pharma Research Ltd				United Kingdom	EXACT	1802999AA	Roseburia hominis	M881HBT4WO						Pediatric ulcerative colitis	9857	done	
Rozanolixizumab	Treatment of immune thrombocytopenic purpura (ITP)	Rozanolixizumab	ROZANOLIXIZUMAB	n/a	4/30/18	Designated			N/A	N/A	"UCB, Inc."	1950 Lake Park Drive Building 2100		30080	USA	EXACT	1310527AA	Rozanolixizumab	P7186074QC						Idiopathic thrombocytopenic purpura	5194	approximate	
Ruplizumab	Prevention of rejection of pancreatic islet cell transplants.	Recombinant humanized MAb 5c8	RUPLIZUMAB	n/a	3/22/99	Designated			N/A	N/A	"Biogen, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	1090342AA	Ruplizumab	562JQF15GN								MISSING	
Ruplizumab	Prevention of rejection of solid organ transplants.	Recombinant humanized MAb 5c8	RUPLIZUMAB	n/a	3/22/99	Designated			N/A	N/A	"Biogen, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	1090342AA	Ruplizumab	562JQF15GN								MISSING	
Ruplizumab	Treatment of immune thrombocytopenic purpura.	Recombinant humanized monclonal antibody 5c8	RUPLIZUMAB	n/a	2/3/98	Designated			N/A	N/A	"Biogen, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	1090342AA	Ruplizumab	562JQF15GN						Idiopathic thrombocytopenic purpura	5194	approximate	
Ruplizumab	Treatment of systemic lupus erythematosus.	Recombinant humanized monoclonal antibody 5c8	RUPLIZUMAB	n/a	2/18/98	Designated			N/A	N/A	"Biogen, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	1090342AA	Ruplizumab	562JQF15GN						Lupus	10253	done	"a rare disease according to Orphanet, but not according to GARD"
"S-(2,3-bispalmitoyloxy-(2R)-propyl)-cysteinly-GNNDESNISFKEK"	Treatment of pancreatic cancer	"S-[2,3-bispalmitoyloxy-(2R)-propyl]-cysteinly-GNNDESNISFKEK"	MALP-2	n/a	10/20/09	Designated			N/A	N/A	MBiotec GmBH				Germany	EXACT	1803969AA	"S-(2,3-bispalmitoyloxy-(2R)-propyl)-cysteinly-GNNDESNISFKEK"	DZX5IUA94D						Pancreatic cancer	9364	done	Not a rare disease
S-59 treated FFP (plasma treated with amotosalen hydrochloride & ultraviolet A light	Treatment of thrombotic thrombocytopenic purpura	S-59 treated FFP (plasma treated with amotosalen hydrochloride & ultraviolet A light	AMOTOSALEN HYDROCHLORIDE	Intercept Blood System For	2/14/11	Designated			N/A	N/A	Cerus Corporation	Concord	California	94520	USA	LONGEST CONTAINS	0302670AA	amotosalen hydrochloride	67B255SI5F						"Thrombotic thrombocytopenic purpura, acquired "	4607	approximate	
S-59 treated FFP (plasma treated with amotosalen hydrochloride & ultraviolet A light	Treatment of thrombotic thrombocytopenic purpura	S-59 treated FFP (plasma treated with amotosalen hydrochloride & ultraviolet A light	AMOTOSALEN HYDROCHLORIDE	Intercept Blood System For	2/14/11	Designated			N/A	N/A	Cerus Corporation	Concord	California	94520	USA	LONGEST CONTAINS	0302670AA	amotosalen hydrochloride	67B255SI5F						 Congenital thrombotic thrombocytopenic purpura	9430	approximate	
S-ETHYLISOTHIURONIUM DIETHYL PHOSPHATE	"Treatment of symptomatic intradialytic hypotension, including symptomatic hypotension in the immediate post-dialytic period."	S-ethylisothiourea diethylphosphate	S-ETHYLISOTHIURONIUM DIETHYL PHOSPHATE	n/a	8/29/16	Designated			N/A	N/A	"TrioxBio, Inc."	Wilmington	Delaware	19801	USA	EXACT	0837707AA	S-ETHYLISOTHIURONIUM DIETHYL PHOSPHATE	CTD25O6OBI								MISSING	
S-adenosylmethionine	Treatment of AIDS-myelopathy.	S-adenosylmethionine	ADEMETIONINE	n/a	4/30/98	Designated			N/A	N/A	"Genopia USA, Inc."	New York	New York	10038	USA	EXACT	0126443AA	S-adenosylmethionine	7LP2MPO46S						Congenital human immunodeficiency virus	10328	approximate	
SAR-100842+Q2922	Treatment of patients with systemic sclerosis	2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indian-2-carboxylic acid	SAR-100842	n/a	5/14/13	Designated			N/A	N/A	"Sanofi U. S., Inc."	Bridgewater	New Jersey	8807	USA	EXACT	1126494AA	SAR-100842	Y76WZ464EY	SAR-100842	Y76WZ464EY	https://ginas.ncats.nih.gov/ginas/app/substance/cc54c426	done		Systemic scleroderma	9748	done	
SARUPLASE	Treatment of empyema (pleural)	single chain urokinase plasminogen activator	SARUPLASE	n/a	9/11/14	Designated			N/A	N/A	"Lung Therapeutics, Inc."	Austin	Texas	78715	USA	EXACT	1079114AA	SARUPLASE	U5NH2JV64T								MISSING	symptom due to different causes
SATOREOTIDE TRIZOXETAN GALLIUM GA-68	Management of gastroenteropancreatic neuroendocrine tumors.	"68Ga-OPS202, small somatostatin analog labeled with 68Gallium"	SATOREOTIDE TRIZOXETAN GALLIUM GA-68	n/a	9/24/14	Designated			N/A	N/A	"Ipsen Biosciences, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0113078AB	SATOREOTIDE TRIZOXETAN GALLIUM GA-68	ZP2ODR0UR3						Gastro-enteropancreatic neuroendocrine tumor	2437	done	
SBP-101	Treatment of pancreatic cancer	"N1,N14,-diethyl-3,12,-dihydroxyhomospermine"	SBP-101	n/a	8/7/14	Designated			N/A	N/A	"Sun BioPharma, Inc."	Ponte Vedra Beach	Florida	32082	USA	EXACT	1150045AA	SBP-101	775S1NC70I						Pancreatic cancer	9364	done	Not a rare disease
SBT-100	Treatment of pancreatic cancer	anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single domain antibody		n/a	8/29/16	Designated			N/A	N/A	"Singh Biotechnology, LLC"	Lutz	Florida	33558	USA	EXACT							PROBLEM	can't find	Pancreatic cancer	9364	done	Not a rare disease
SC-41930	Prevention of serious adverse events associated with vascular leak syndrome caused by Interleukin-2 therapy	"(+/-)-7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid"	SC-41930	n/a	3/31/03	Designated/Withdrawn			N/A	N/A	"Intarcia Therapeutics, Inc."	Hayward	California	94545	USA	EXACT	0170092AA	SC-41930	EVH7O0422T								MISSING	prevention of drug-induced side-effects
SCY-078	"Treatment of invasive Candida infections, including candidemia"	"enfumafungin derivative B-(1,3)-D-glucan synthestis inhibitor"	MK-3118	n/a	5/10/16	Designated			N/A	N/A	"SCYNEXIS, Inc."	Jersey City	New Jersey	7302	USA	EXACT	0823574AA	SCY-078	A92JFM5XNU						Systemic candidiasis	1076	approximate	
SELADELPAR LYSINE DIHYDRATE	Treatment of homozygous familial hypercholesterolemia (HoFH)	2-[4-[[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate	SELADELPAR LYSINE DIHYDRATE	n/a	3/18/15	Designated			N/A	N/A	"CymaBay Therapeutics, Inc."	Newark	California	94560	USA	EXACT	1194054AA	SELADELPAR LYSINE DIHYDRATE	N1429130KR						Familial hypercholesterolemia	10416	done	Not a rare disease
SELADELPAR LYSINE DIHYDRATE	Treatment of patients with Frederickson Type I or V hyperlipoproteinemia	2-[4-[[(2-R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate	SELADELPAR LYSINE DIHYDRATE	n/a	4/15/15	Designated			N/A	N/A	"CymaBay Therapeutics, Inc."	Newark	California	94560	USA	EXACT	1194054AA	SELADELPAR LYSINE DIHYDRATE	N1429130KR						Hyperlipoproteinemia type 5	6704	done	
SF-RI-1 bovine surfactant for inhalation	Treatment of respiratory distress syndrome (RDS)	SF-RI-1 bovine surfactant for inhalation		Aerofact™	1/23/18	Designated			N/A	N/A	Aerogen Pharma Corporation	1660 South Amphlett Boulevard	San Mateo	94402	USA				Q4K217VGA9	CALFACTANT	Q4K217VGA9	https://ginas.ncats.nih.gov/ginas/app/substance/8998d3a4	done		"Respiratory distress syndrome, infant "	112	approximate	
SF-RI-1 bovine surfactant for inhalation	Treatment of respiratory distress syndrome (RDS)	SF-RI-1 bovine surfactant for inhalation		Aerofact™	1/23/18	Designated			N/A	N/A	Aerogen Pharma Corporation	1660 South Amphlett Boulevard	San Mateo	94402	USA				Q4K217VGA9	CALFACTANT	Q4K217VGA9	https://ginas.ncats.nih.gov/ginas/app/substance/8998d3a4	done		 Acute respiratory distress syndrome	5698	approximate	
SF1126	Treatment of chronic lymphocytic leukemia (CLL)	"Phosphatidylinositol 3-Kinase ""PI3K"" Inhibitor"	SF-1126 CHLORIDE HYDROCHLORIDE	n/a	11/2/10	Designated			N/A	N/A	Semafore Pharmaceuticals	Westfield	Indiana	46074	USA	EXACT	0310714AA	SF1126	63WQ37Y7BL						Chronic lymphocytic leukemia	6104	done	
SHP-602	Treatment of chronic iron overload in patients with transfusion-dependent anemias	"(S)-4,5-dihydro-2[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiaxolecarboxylic acid"	SHP-602	n/a	2/4/09	Designated			N/A	N/A	"Ferrokin BioSciences, Inc."	San Carlos	California	94070	USA	EXACT	1577102AA	SHP-602	9X1ZQD68K7								MISSING	secondary condition
SHP-610	For treatment of Sanfilippo Syndrome (MPS IIIA)	sulfamidase	N-SULFOGLUCOSAMINE SULFOHYDROLASE RECOMBINANT	n/a	5/22/08	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0760112AA	SHP-610	X0MD128U01						Mucopolysaccharidosis type IIIA	7071	done	
SHP-647	Treatment of pediatric patients with Ulcerative Colitis (UC)	human IgG2 anti-monoclonal antibody directed against mucosal addressin cell adhesion molecule (MAdCAM)	ONTAMALIMAB	n/a	11/16/17	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc. (Shire)"	300 Shire Way	Massachusetts	2421	USA	EXACT	0924232AA	SHP-647	6LGI7RV4PB						Pediatric ulcerative colitis	9857	done	
SHP-655	"Treatment of thrombotic thrombocytopenic purpura including its congential, acquired idiopathic, and secondary forms."	Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs	APADAMTASE ALFA	n/a	7/29/08	Designated			N/A	N/A	Baxalta US Inc.	Westlake Village	California	91362	USA	EXACT	1323597AA	SHP-655	U5SFU33XUX						"Thrombotic thrombocytopenic purpura, acquired "	4607	approximate	
SHP-655	"Treatment of thrombotic thrombocytopenic purpura including its congential, acquired idiopathic, and secondary forms."	Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs	APADAMTASE ALFA	n/a	7/29/08	Designated			N/A	N/A	Baxalta US Inc.	Westlake Village	California	91362	USA	EXACT	1323597AA	SHP-655	U5SFU33XUX						 Congenital thrombotic thrombocytopenic purpura	9430	approximate	
SILIBININ DIHEMISUCCINATE DISODIUM	Prevention of recurrent hepatitis C in liver transplant patients	"Silibinin-C-2',3-dihydrogensuccinate, disodium salt"	SILIBININ DIHEMISUCCINATE DISODIUM	Legalon Sil	2/17/12	Designated			N/A	N/A	Meda AB	Solna			Sweden	EXACT	0808468AA	SILIBININ DIHEMISUCCINATE DISODIUM	57LSQ377IE								MISSING	Not a rare disease
SILIBININ DIHEMISUCCINATE DISODIUM	"Treatment of amatoxin poisoning, which includes the prevention and treatment of amatoxin induced hepatic failure"	"silibinin-C-2',3-dihydrogensuccinate, disodium salt"	SILIBININ DIHEMISUCCINATE DISODIUM	Legalon(R) Sil	9/11/14	Designated			N/A	N/A	"Meda Pharmaceuticals, Inc."	Somerset	New Jersey	8873	USA	EXACT	0808468AA	SILIBININ DIHEMISUCCINATE DISODIUM	57LSQ377IE								MISSING	
SILIBININ DIHEMISUCCINATE DISODIUM	Treatment of hepatic intoxication by Amanita phalloides (mushroom poisoning).	Disodium silibinin dihemisuccinate	SILIBININ DIHEMISUCCINATE DISODIUM	Legalon	7/10/86	Designated/Withdrawn			N/A	N/A	Pharmaquest Corporation	San Rafael	California	94903	USA	EXACT	0808468AA	SILIBININ DIHEMISUCCINATE DISODIUM	57LSQ377IE								MISSING	
SKF-110679	For the long term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	His-D-Trp-Ala-Trp-D-Phe-Lys NH2	GROWTH HORMONE RELEASING HEXAPEPTIDE	n/a	5/23/90	Designated/Withdrawn			N/A	N/A	SmithKline Beecham Pharmaceuticals	Philadelphia	Pennsylvania	19101	USA	EXACT	0177388AA	SKF-110679	4H7N4I6X6A						Growth hormone deficiency	6552	done	
SNX-5422 MESYLATE	Treatment of neuroendocrine tumors (NETs).	"trans-4-({2-(aminocarbonyl)-5-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]phenyl}amino)cyclohexyl glycinate mesylate"	SNX-5422 MESYLATE	n/a	5/23/18	Designated			N/A	N/A	Esanex Inc.	115 West Washington Street	South Tower Suite 1680	46240	USA	EXACT	0709579AA	SNX-5422 MESYLATE	K3BO8V06RM						Neuroendocrine tumor	13445	done	
SOR-C13	Treatment of pancreatic cancer.	Peptide consisting of L-amino acids with the sequence H-lys-glu-phe-leu-his-pro-ser-lys-val-asp-leu-pro-arg-OH	SOR-C13	n/a	6/29/16	Designated			N/A	N/A	"Soricimed Biopharma, Inc."	Moncton	New Brunswick		Canada	EXACT	1311984AA	SOR-C13	C79B5A73C4						Pancreatic cancer	9364	done	Not a rare disease
SP-2577 MESYLATE	Treatment of Ewing's sarcoma.	(E)-N’-(1-(5-Chloro-2-hydroxy phenyl)Ethylidene)-3-((4-Methyl Piperazin-1-yl) Sulfonyl) Benzohydrazide Mesylate	SP-2577 MESYLATE	n/a	1/12/17	Designated			N/A	N/A	Salarius Pharmaceuticals	Houston	Texas	77021	USA	EXACT	1281169AA	SP-2577 MESYLATE	BD6N473ZLF						Ewing's family of tumors	9323	approximate	
STX-100	Treatment of fibrosis-associated chronic allograft nephropathy in kidney transplant patients.	humanized monocloncal antibody against human integrin alphaVbeta6	STX-100	n/a	6/18/08	Designated			N/A	N/A	"Stromedix, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0313677AA	STX-100	JD43Y6YF3N								MISSING	
SUSOCTOCOG ALFA	Treatment and prevention of episodic bleeding in patients with inhibitor antibodies to human coagulation factor VIII	"antihemophilic factor (recombinant), porcine sequence"	SUSOCTOCOG ALFA	Obizur	3/16/04	Designated/Approved	Approved for Orphan Indication	Treatment of bleeding episodes in adults with acquired hemophilia A.	10/23/14	10/23/21	"Baxalta US, Inc."	Westlake Village	California	91362	USA	EXACT	0913553AA	SUSOCTOCOG ALFA	6892UQT2GK						Hemophilia A	6591	approximate	
SUTEZOLID	Treatment of tuberculosis.	"N-{[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide"	SUTEZOLID	n/a	2/4/11	Designated			N/A	N/A	"Sequella, Inc."	Rockville	Maryland	20820	USA	EXACT	0570752AA	SUTEZOLID	3A71182L8P						Tuberculosis	7827	done	
SYD-003	Treatment of pancreatic cancer	"[5-Amino-1-(4-fluoro-phenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxy-propoxy)-phenyl]-methanone"	SYD-003	n/a	10/20/14	Designated			N/A	N/A	Synovo GmbH				Germany	EXACT	1576881AA	SYD-003	TE3ESF890C						Pancreatic cancer	9364	done	Not a rare disease
"Sar9, Met(O2)11-Substance P"	Treatment of idiopathic pulmonary fibrosis	"Sar9, Met(O2)11-Substance P"	"SUBSTANCE P, 9-(N-METHYLGLYCINE)-11-((2S)-2-AMINO-4-(METHYLSULFONYL)BUTANAMIDE)-"	Homspera	3/16/11	Designated			N/A	N/A	"ImmuneRegen BioSciences, Inc."	Scottsdale	Arizona	85258	USA	EXACT	0803601AA	"Sar9, Met(O2)11-Substance P"	8V0QAFPRXV						Idiopathic pulmonary fibrosis	8609	done	
Sargramostim	To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.	Sargramostim	SARGRAMOSTIM	Leukine	3/6/95	Designated/Approved	Approved for Orphan Indication	Following induction chemotherapy in older adult patients with acute myelogenous leukemia to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death.	9/15/95	9/15/02	Immunex Corporation	Seattle	Washington	98101	USA	EXACT	0168536AA	Sargramostim	5TAA004E22						Acute myeloid leukemia	12757	done	
Sargramostim	"Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment."	Sargramostim	SARGRAMOSTIM	Leukine	5/3/90	Designated/Approved	Approved for Orphan Indication		3/5/91	3/5/98	Immunex Corporation	Seattle	Washington	98101	USA	EXACT	0168536AA	Sargramostim	5TAA004E22								MISSING	
Save3D Zoom	Treatment of Kaposi's sarcoma.	"3-(3,5-dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one"	SEMAXANIB	n/a	9/11/98	Designated			N/A	N/A	"Sugen, Inc."	South San Francisco	California	94080	USA	EXACT	0221807AA	semaxanib	71IA9S35AJ						Kaposi sarcoma	6814	done	
Selegiline HCl	"As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism."	Selegiline HCl	SELEGILINE HYDROCHLORIDE	Eldepryl	11/7/84	Designated/Approved	Approved for Orphan Indication		6/5/89	6/5/96	"Somerset Pharmaceuticals, Inc."	Denville	New Jersey	7834	USA	EXACT	0137702AA	Selegiline HCl	6W731X367Q						Parkinson disease	10251	done	
Selinexor	Treatment of acute myeloid leukemia	"Selinexor; (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide"	SELINEXOR	n/a	5/14/14	Designated			N/A	N/A	"Karyopharm Therapeutics, Inc."	Natick	Massachusetts	1760	USA	EXACT	0899718AA	Selinexor	31TZ62FO8F						Acute myeloid leukemia	12757	done	
Selinexor	Treatment of diffuse large B-cell lymphoma	"(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide"	Selinexor	n/a	5/14/14	Designated			N/A	N/A	"Karyopharm Therapeutics, Inc."	Natick	Massachusetts	1760	USA	EXACT	0899718AA	Selinexor	31TZ62FO8F						Diffuse Large B-Cell Lymphoma	3178	done	
Selonsertib	Treatment pulmonary arterial hypertension	"5-(4-Cyclopropyl-1H-imidazol-l-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide"	SELONSERTIB	n/a	1/15/15	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	1077527AA	Selonsertib	NS3988A2TC						Pulmonary arterial hypertension	7501	done	
Sermorelin acetate	Adjunct to gonadotropin therapy in the induction of ovulation in women with anovulatory or oligo-ovulatory infertility who fail to ovulate in response to adequate treatment with clomiphene citrate alone and gonadotropin therapy alone.	Sermorelin acetate	SERMORELIN ACETATE	Geref	2/13/90	Designated/Withdrawn			N/A	N/A	"EMD Serono, Inc."	Rockland	Massachusetts	2370	USA	EXACT	0165253AA	Sermorelin acetate	00IBG87IQW								MISSING	Not a rare disease
Sermorelin acetate	Treatment of AIDS-associated catabolism/weight loss.	Sermorelin acetate	SERMORELIN ACETATE	Geref	12/5/91	Designated/Withdrawn			N/A	N/A	"EMD Serono, Inc."	Rockland	Massachusetts	2370	USA	EXACT	0165253AA	Sermorelin acetate	00IBG87IQW								MISSING	
Serratia marcescens extract (polyribosomes)	Treatment of primary brain malignancies.	Serratia marcescens extract (polyribosomes)	SERRATIA MARCESCENS	Imuvert	9/7/88	Designated			N/A	N/A	"Cell Technology, Inc."	Boulder	Colorado	80306	USA	LONGEST CONTAINS	0340910AA	Serratia marcescens	FB3Y68CF2Y						"Brain tumor, adult"	9307	approximate	
Short chain fatty acid enema	Treatment of chronic radiation proctitis.	Short chain fatty acid enema		Colomed	8/19/97	Designated			N/A	N/A	"Richard I. Breuer, M.D."	Evanston	Illinois	60201	USA					Short Chain Fatty Acid Enema	NA	https://www.woodlandhillspharmacy.com/compounds/gastroenterology/short-chain-fatty-acid-enema/	PROBLEM	absent from GINAS			MISSING	Not a rare disease
Short chain fatty acid solution	Treatment of the active phase of ulcerative colitis with involvement restricted to the left side of the colon.	Short chain fatty acid solution		Colomed	5/29/90	Designated			N/A	N/A	Richard I. Breuer	Evanston	Illinois	60201	USA								PROBLEM	can't find	Pediatric ulcerative colitis	9857	approximate	
Silver sulfadiazine and cerium nitrate	Treatment of patients with severe dermal burns	Silver sulfadiazine and cerium nitrate	SILVER SULFADIAZINE	Flammacerium	11/17/99	Designated			N/A	N/A	Alliance Pharmaceuticals Ltd	"Wiltshire, SN15 2BB"			United Kingdom	EXACT	0060071AA	Silver sulfadiazine	W46JY43EJR								MISSING	not a disease
Simtuzumab	Treatment of myelofibrosis.	"Recombinant humanized anti-LOXL2 monoclonal antibody, IgG4(S241P)"	SIMTUZUMAB	n/a	6/1/11	Designated/Withdrawn			N/A	N/A	"Gilead Sciences, Inc."	Seattle	Washington	98102	USA	EXACT	0762403AA	Simtuzumab	11Z5AIU653						Myelofibrosis	8618	done	
Simtuzumab	Treatment of pancreatic cancer.	"recombinant humanized anti-LOXL2 monoclonal antibody, IgG4(S241P)"	SIMTUZUMAB	n/a	5/17/11	Designated/Withdrawn			N/A	N/A	"Gilead Sciences, Inc."	Seattle	Washington	98102	USA	EXACT	0762403AA	Simtuzumab	11Z5AIU653						Pancreatic cancer	9364	done	Not a rare disease
Siplizumab	"For the induction of donor-specific immunologic unresponsiveness resulting in prophylaxis of organ rejection without the need for chronic immunosuppressive therapy, in patients receiving allogeneic renal transplants."	Humanized anti-human CD2 MAb	SIPLIZUMAB	Medi-507	9/17/98	Designated/Withdrawn			N/A	N/A	"Biotransplant, Inc."	Charlestown	Massachusetts	2129	USA	EXACT	0298124AA	Siplizumab	KUW1QG1ZM3								MISSING	not a disease
Siplizumab	Prevention of solid organ transplant rejection	Siplizumab	SIPLIZUMAB	Vicalex	2/15/18	Designated			N/A	N/A	ITB-MED AB	15 Västra Trädgårdsgatan	Norrmalm		Sweden	EXACT	0298124AA	Siplizumab	KUW1QG1ZM3								MISSING	
Siplizumab	Treatment of graft-versus-host disease.	Humanized anti-CD2 monoclonal antibody	SIPLIZUMAB	n/a	11/13/98	Designated/Withdrawn			N/A	N/A	"MedImmune, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0298124AA	Siplizumab	KUW1QG1ZM3						Chronic graft versus host disease 	10964	approximate	
Siplizumab	Treatment of graft-versus-host disease.	Humanized anti-CD2 monoclonal antibody	SIPLIZUMAB	n/a	11/13/98	Designated/Withdrawn			N/A	N/A	"MedImmune, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0298124AA	Siplizumab	KUW1QG1ZM3						 Acute graft versus host disease	6544	approximate	
Sodium ascorbate	Treatment of autosomal dominant polycystic kidney disease	sodium ascorbate and menadione sodium bisulfite	SODIUM ASCORBATE	Apatone	4/15/13	Designated			N/A	N/A	IC-MedTech Corporation	El Cajon	California	92021	USA	EXACT	0021363AA	Sodium ascorbate	S033EH8359						Autosomal dominant polycystic kidney disease	10413	done	
Sodium ascorbate	Treatment of noninfected painful total joint without mechanical complication	sodium ascorbate and menadione sodium bisulfite	SODIUM ASCORBATE	Apatone	4/9/15	Designated			N/A	N/A	IC-MedTech Corporation	El Cajon	California	92021	USA	EXACT	0021363AA	Sodium ascorbate	S033EH8359								MISSING	
Sodium dichloroacetate	Treatment of congenital lactic acidosis	Sodium dichloroacetate	SODIUM DICHLOROACETATE	n/a	6/11/90	Designated			N/A	N/A	"Stacpoole, Peter W. M.D., Ph.D."	Gainesville	Florida	32610	USA	EXACT	0079492AA	Sodium dichloroacetate	42932X67B5						Lactic acidosis congenital infantile	3163	done	
Sodium dichloroacetate	Treatment of congenital lactic acidosis.	Sodium dichloroacetate	SODIUM DICHLOROACETATE	n/a	12/31/97	Designated/Withdrawn			N/A	N/A	"Questcor Pharmaceuticals, Inc."	Union City	California	94587	USA	EXACT	0079492AA	Sodium dichloroacetate	42932X67B5						Lactic acidosis congenital infantile	3163	done	
Sodium dichloroacetate	Treatment of homozygous familial hypercholesterolemia.	Sodium dichloroacetate	SODIUM DICHLOROACETATE	n/a	6/11/90	Designated			N/A	N/A	"Stacpoole, Peter W. M.D., Ph.D."	Gainesville	Florida	32610	USA	EXACT	0079492AA	Sodium dichloroacetate	42932X67B5						Familial hypercholesterolemia	10416	done	Not a rare disease
Sodium dichloroacetate	Treatment of severe head injury.	Sodium dichloroacetate	SODIUM DICHLOROACETATE	Ceresine	6/14/99	Designated/Withdrawn			N/A	N/A	"Questcor Pharmaceuticals, Inc."	Union City	California	94587	USA	EXACT	0079492AA	Sodium dichloroacetate	42932X67B5								MISSING	Not a disease
Sodium nitrite	Prevention of vasospasm associated with subarachnoid hemorrhage	Sodium nitrite	SODIUM NITRITE	n/a	1/17/07	Designated			N/A	N/A	Hope Pharmaceuticals	Scottsdale	Arizona	85260	USA	EXACT	0049581AA	Sodium nitrite	M0KG633D4F								MISSING	
Sodium nitrite	Treatment of cyanide poisoning	Sodium nitrite	SODIUM NITRITE	n/a	4/18/07	Designated			N/A	N/A	Hope Pharmaceuticals	Scottsdale	Arizona	85260	USA	EXACT	0049581AA	Sodium nitrite	M0KG633D4F								MISSING	Not a disease
Sodium nitrite	Treatment of vaso-occlusive crisis associated with sickle cell disease	Sodium nitrite	SODIUM NITRITE	n/a	4/2/07	Designated			N/A	N/A	Hope Pharmaceuticals	Scottsdale	Arizona	85260	USA	EXACT	0049581AA	Sodium nitrite	M0KG633D4F						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
Sodium nitrite	Treatment of vaso-occlusive crisis associated with sickle cell disease	Sodium nitrite	SODIUM NITRITE	n/a	4/2/07	Designated			N/A	N/A	Hope Pharmaceuticals	Scottsdale	Arizona	85260	USA	EXACT	0049581AA	Sodium nitrite	M0KG633D4F						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
Sodium nitrite	Treatment of vaso-occlusive crisis associated with sickle cell disease	Sodium nitrite	SODIUM NITRITE	n/a	4/2/07	Designated			N/A	N/A	Hope Pharmaceuticals	Scottsdale	Arizona	85260	USA	EXACT	0049581AA	Sodium nitrite	M0KG633D4F						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
Sodium nitrite	Treatment of vaso-occlusive crisis associated with sickle cell disease	Sodium nitrite	SODIUM NITRITE	n/a	4/2/07	Designated			N/A	N/A	Hope Pharmaceuticals	Scottsdale	Arizona	85260	USA	EXACT	0049581AA	Sodium nitrite	M0KG633D4F						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
Sodium nitrite	Treatment of vaso-occlusive crisis associated with sickle cell disease	Sodium nitrite	SODIUM NITRITE	n/a	4/2/07	Designated			N/A	N/A	Hope Pharmaceuticals	Scottsdale	Arizona	85260	USA	EXACT	0049581AA	Sodium nitrite	M0KG633D4F						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
Sodium nitrite	Treatment of vaso-occlusive crisis associated with sickle cell disease	Sodium nitrite	SODIUM NITRITE	n/a	4/2/07	Designated			N/A	N/A	Hope Pharmaceuticals	Scottsdale	Arizona	85260	USA	EXACT	0049581AA	Sodium nitrite	M0KG633D4F						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
Sodium nitrite /sodium thiosulfate	Treatment of cyanide poisoning	Sodium nitrite/sodium thiosulfate	SODIUM NITRITE	Cyanide Antidote Package	3/23/07	Designated			N/A	N/A	"Keystone Pharmaceuticals, Inc."	Laguna Hills	California	92653	USA	EXACT	0049581AA	Sodium nitrite	M0KG633D4F								MISSING	Not a disease
Sodium nitrite /sodium thiosulfate	Treatment of cyanide poisoning	Sodium nitrite/sodium thiosulfate	SODIUM THIOSULFATE	Cyanide Antidote Package	3/23/07	Designated			N/A	N/A	"Keystone Pharmaceuticals, Inc."	Laguna Hills	California	92653	USA	EXACT	0053225AA	sodium thiosulfate	HX1032V43M								MISSING	Not a disease
Sodium phenylbutyrate	"For use as an adjuct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma."	Sodium phenylbutyrate	SODIUM PHENYLBUTYRATE	n/a	4/24/98	Designated			N/A	N/A	"Elan Drug Delivery, Inc."	Gainesville	Georgia	30504	USA	EXACT	0180767AA	Sodium phenylbutyrate	NT6K61736T						Glioma	6513	approximate	
Sodium thiosulfate	Prevention of platinum-induced ototoxicity in pediatric patients	Sodium thiosulfate	SODIUM THIOSULFATE	n/a	3/17/04	Designated			N/A	N/A	"Fennec Pharmaceuticals, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0053225AA	Sodium thiosulfate	HX1032V43M								MISSING	prevention of drug-induced side-effects
"Sodium thiosulfate , sodium nitrite, amyl nitrite"	Treatment of cyanide poisoning	"Sodium thiosulfate, sodium nitrite, amyl nitrite"	SODIUM THIOSULFATE	Cyanide Antidote Package	6/16/06	Designated			N/A	N/A	"Keystone Pharmaceuticals, Inc."	Laguna Hills	California	92653	USA	EXACT	0053225AA	Sodium thiosulfate	HX1032V43M								MISSING	Not a disease
Sodium thiosulfate and sodium nitrite	Treatment of cyanide poisoning	Sodium thiosulfate and sodium nitrite	SODIUM THIOSULFATE	n/a	12/18/06	Designated			N/A	N/A	"Akorn, Inc."	Buffalo Grove	Illinois	60089	USA	EXACT	0053225AA	Sodium thiosulfate	HX1032V43M								MISSING	Not a disease
Solasonine	"Treaatment of high risk stage II, stage III and stage IV melanoma"	Solasonine and solamargine	SOLASONINE	Coramsine	2/6/06	Designated			N/A	N/A	Solbec Pharmaceuticals Limited				Australia	EXACT	0789935AA	Solasonine	TR60638HXL						"Melanoma, familial"	3460	approximate	
Solasonine and solamargine	"Treaatment of high risk stage II, stage III and stage IV melanoma"	Solasonine and solamargine	SOLAMARGINE	Coramsine	2/6/06	Designated			N/A	N/A	Solbec Pharmaceuticals Limited				Australia	EXACT	0791219AA	solamargine	8KG991E7BN						"Melanoma, familial"	3460	approximate	
Solnatide	Prevention of ischemia reperfusion injury in the lung during lung tranplantation	17 amino acid peptide	SOLNATIDE	n/a	1/29/10	Designated			N/A	N/A	Apeptico Forschung und Entwicklung GmbH	Vienna			Austria	EXACT	0766778AA	Solnatide	17ZS80333G								MISSING	Not a rare disease
Somatostatin	"Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas."	Somatostatin	SOMATOSTATIN	Zecnil	6/20/88	Designated			N/A	N/A	"Ferring Laboratories, Inc."	Suffern	New York	10901	USA	EXACT	0078740AA	Somatostatin	6E20216Q0L								MISSING	
Somatrem for injection	"1. Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion (prevalence 15,000) 2. Treatment of short stature associated with Turner's syndrome (prevalence 8000)."	Somatrem for injection	SOMATREM	Protropin	12/9/85	Designated/Approved	Approved for Orphan Indication		10/17/85	10/17/92	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0127242AA	Somatrem	CU8D464EDW						Turner syndrome 	7831	done	
Somatrem for injection	"1. Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion (prevalence 15,000) 2. Treatment of short stature associated with Turner's syndrome (prevalence 8000)."	Somatrem for injection	SOMATREM	Protropin	12/9/85	Designated/Approved	Approved for Orphan Indication		10/17/85	10/17/92	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0127242AA	Somatrem	CU8D464EDW						 Growth hormone deficiency	6552	done	
Somatropin	"Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization procedures."	Somatropin	SOMATROPIN	Norditropin	9/1/87	Designated/Withdrawn			N/A	N/A	Novo Nordisk Pharmaceuticals	Princeton	New Jersey	8540	USA	EXACT	0054682AA	Somatropin	NQX9KB6PCL						"Hypogonadism, isolated, hypogonadotropic"	2897	approximate	
Somatropin	For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Somatropin	SOMATROPIN	Nutropin	3/6/87	Designated/Approved	Approved for Orphan Indication		10/17/85	10/17/92	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0054682AA	Somatropin	NQX9KB6PCL								MISSING	not a disease
Somatropin	Treatment of cachexia associated with AIDS.	Somatropin	SOMATROPIN	Biotropin	2/12/93	Designated/Withdrawn			N/A	N/A	Bio-Technology General Corp.	Iselin	New Jersey	8830	USA	EXACT	0054682AA	Somatropin	NQX9KB6PCL						Congenital human immunodeficiency virus	10328	approximate	
Somatropin	Treatment of short stature in pediatric patients with short stature homeobox-containing gene (SHOX) deficiency	Somatropin	SOMATROPIN	Humatrope	12/15/05	Designated/Approved	Approved for Orphan Indication	Treatment of short stature or growth failure in children with SHOX (short stature homeobox-containing gene) deficiency whose epiphyses are not closed	11/1/06	11/1/13	Eli Lilly and Company	Indianapolis	Indiana	46285	USA	EXACT	0054682AA	Somatropin	NQX9KB6PCL						Langer mesomelic dysplasia	3553	approximate	
Somatropin (r-DNA) for injection	Treatment of children with AIDS-associated failure-to-thrive including AIDS-associated wasting.	Somatropin (r-DNA) for injection	SOMATROPIN	Serostim	3/26/96	Designated			N/A	N/A	"EMD Serono, Inc."	Roackland	Massachusetts	2370	USA	EXACT	0054682AA	Somatropin	NQX9KB6PCL						Congenital human immunodeficiency virus	10328	approximate	
Somatropin (rDNA origin)	Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Somatropin (rDNA origin)	SOMATROPIN	Nutropin Depot	10/28/99	Designated/Approved	Approved for Orphan Indication	Long-term treatment of growth failure due to a lack of adequate endogenous growth hormone secetion for once- or twice-a-month administration.	12/22/99	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0054682AA	Somatropin (rDNA origin)	NQX9KB6PCL								MISSING	
Somatropin (rDNA origin) injection	1. Treatment of growth failure in children due to inadequate growth hormone secretion 2. Treatment of short stature associated with Turner's syndrome	Somatropin (rDNA origin) injection	SOMATROPIN	Norditropin	7/10/87	Designated/Approved	Approved for Orphan Indication	Long-term treatment of children who have growth failure due to inadequate secretion of endogenous growth hormone.	6/20/00	N/A	Novo Nordisk Pharmaceuticals	Princeton	New Jersey	8540	USA	EXACT	0054682AA	Somatropin	NQX9KB6PCL						Turner syndrome 	7831	done	
Somatropin (rDNA origin) injection	1. Treatment of growth failure in children due to inadequate growth hormone secretion 2. Treatment of short stature associated with Turner's syndrome	Somatropin (rDNA origin) injection	SOMATROPIN	Norditropin	7/10/87	Designated/Approved	Approved for Orphan Indication	Long-term treatment of children who have growth failure due to inadequate secretion of endogenous growth hormone.	6/20/00	N/A	Novo Nordisk Pharmaceuticals	Princeton	New Jersey	8540	USA	EXACT	0054682AA	Somatropin	NQX9KB6PCL						 Growth hormone deficiency	6552	done	
Somatropin (rDNA)	For the enhancement of nitrogen retention in hospitalized patients suffering from severe burns.	Somatropin (rDNA)	SOMATROPIN	Saizen	5/3/89	Designated			N/A	N/A	"EMD Serono, Inc."	Rockland	Massachusetts	2370	USA	EXACT	0054682AA	Somatropin	NQX9KB6PCL								MISSING	
Somatropin for injection	For the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.	Somatropin for injection	SOMATROPIN	Humatrope	6/12/86	Designated/Approved	Approved for Orphan Indication		3/8/87	3/8/94	Eli Lilly and Company	Indianapolis	Indiana	46285	USA	EXACT	0054682AA	Somatropin for injection	NQX9KB6PCL						Growth hormone deficiency	6552	approximate	
Somatropin for injection	Treatment of AIDS-associated catabolism/weight loss.	Somatropin for injection	SOMATROPIN	Serostim	11/15/91	Designated/Approved	Approved for Orphan Indication	Treatment of AIDS wasting or cachexia.	8/23/96	8/23/03	"EMD Serono, Inc."	Roackland	Massachusetts	2370	USA	EXACT	0054682AA	Somatropin for injection	NQX9KB6PCL								MISSING	
Somatropin for injection	Treatment of growth retardation associated with chronic renal failure.	Somatropin for injection	SOMATROPIN	Nutropin	8/4/89	Designated/Approved	Approved for Orphan Indication	Treatment of children with growth failure associated with chronic renal insufficency.	11/17/93	11/17/00	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0054682AA	Somatropin for injection	NQX9KB6PCL								MISSING	
Somatropin for injection	Treatment of short stature associated with Turner's syndrome.	Somatropin for injection	SOMATROPIN	Nutropin	3/23/89	Designated/Approved	Approved for Orphan Indication	Treatment of growth failure associated with Turner syndrome.	12/30/96	12/30/03	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0054682AA	Somatropin for injection	NQX9KB6PCL						Turner syndrome	7831	done	
Sorivudine	Treatment of herpes zoster (shingles) in immunocompromised patients	Sorivudine	SORIVUDINE	Bravavir	11/9/95	Designated/Withdrawn			N/A	N/A	Bristol-Myers Squibb	Wallingford	Connecticut	6492	USA	EXACT	0169506AA	Sorivudine	C7VOZ162LV								MISSING	
Sotalol HCl	1. Treatment of life-threatening ventricular tachyarrhythmias 2. Prevention of life treatening ventricular tachyarrhythmias	Sotalol HCl	SOTALOL HYDROCHLORIDE	Betapace	9/23/88	Designated/Approved	Approved for Orphan Indication	Treatment of life-threatening ventricular tachyarrhythmias	10/30/92	10/30/99	"Berlex Laboratories, Inc."	Wayne	New Jersey	7470	USA	EXACT	0032042AA	Sotalol HCl	HEC37C70XX						Bidirectional tachycardia	878	done	
Staphylococcal immunoglobulin (human)	Reduction (prevention) of nosocomial bacteremia caused by staphylococci in very low birth weight infants.	Staphylococcal immunoglobulin (human)	INH-A21	Veronate	6/13/01	Designated/Withdrawn			N/A	N/A	"Inhibitex, Inc."	Alpharetta	Georgia	30004	USA	EXACT	0803645AA	Staphylococcal immunoglobulin (human)	9LKK68BOP0								MISSING	Not a rare disease
Staphylococcus aureus Immune Globulin (Human)	Prophylaxis against Staphylococcus aureus infections in low birth weight neonates	Staphylococcus aureus Immune Globulin (Human)	HUMAN STAPHYLOCOCCUS AUREUS IMMUNE GLOBULIN	Altastaph	1/29/04	Designated			N/A	N/A	Biotest Pharmaceuticals Corporation	Boca Raton	Florida	33487	USA	EXACT	1803914AA	Staphylococcus aureus Immune Globulin (Human)	SX5Y4A7UBI								MISSING	Not a rare disease
Stem and progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood	For use as hematopoietic support in patients with relapsed or refractory hematologic malignancies who are receiving high-dose therapy	Stem and progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood	CORD BLOOD	Stemex	3/4/05	Designated/Withdrawn			N/A	N/A	Gamida Cell Ltd - Teva Joint Venture	Jerusalem			Israel	LONGEST CONTAINS	0854240AA	umbilical cord blood	PVH8394DLN								MISSING	
Steptococci	Treatment of active chronic pouchitis	"lactic acid bacteria (Lactobacilli, Bifidobacteria, and Steptococci)"		n/a	1/15/02	Designated			N/A	N/A	"VSL Pharmaceuticals, Inc."	Gaithersburg	Maryland	20877	USA								PROBLEM	can't find			MISSING	
"Sterile Bicarbonate Infusate, Hemofiltration, Hemodiafiltration, and Hemopdialysis Solution"	For use as a replacement solution in adults and children during Continous Renal Replacement Therapy	"Sterile Bicarbonate Infusate, Hemofiltration, Hemodiafiltration, and Hemopdialysis Solution"	BICARBONATE ION	Accusol	5/29/09	Designated			N/A	N/A	"Nikkiso America, Inc."	San Diego	California	92121	USA	LONGEST CONTAINS	0012328AA	Bicarbonate	HN1ZRA3Q20								MISSING	not a disease
Sterile talc	Treatment of malignant pleural effusion.	Sterile talc	TALC	Steritalc	12/8/97	Designated			N/A	N/A	Novatech SA				France	EXACT	0056224AA	talc	7SEV7J4R1U								MISSING	not a disease
Sterile talc	Treatment of pneumothorax.	Sterile talc	TALC	Steritalc	12/8/97	Designated			N/A	N/A	Novatech SA				France	EXACT	0056224AA	talc	7SEV7J4R1U						Primary spontaneous pneumothorax	4997	done	
Sterile talc powder	Treatment of malignant pleural effusion.	Sterile talc powder	TALC	Sclerosol Intrapleural Aerosol	9/18/95	Designated/Approved	Approved for Orphan Indication	Prevention of recurrence of malignant pleural effusions in symptomatic patients.	12/24/97	12/24/04	Bryan Corporation	Woburn	Massachusetts	1801	USA	EXACT	0056224AA	talc powder	7SEV7J4R1U								MISSING	not a disease
Succimer	Treatment of lead poisoning in children.	Succimer	SUCCIMER	Chemet Capsules	5/9/84	Designated/Approved	Approved for Orphan Indication		1/30/91	1/30/98	Bock Pharmacal Company	Saint Louis	Missouri	63141	USA	EXACT	0068928AA	Succimer	DX1U2629QE								MISSING	not a disease
Succimer	Treatment of mercury intoxication.	Succimer	SUCCIMER	Chemet	3/22/91	Designated			N/A	N/A	"Sanofi Winthrop, Inc."	New York	New York	10016	USA	EXACT	0068928AA	Succimer	DX1U2629QE						Mercury poisoning	7021	done	
Sucralfate	Treatment of oral mucositis and stomatitis following radiation therapy for head and neck cancer.	Sucralfate	SUCRALFATE	n/a	7/15/93	Designated/Withdrawn			N/A	N/A	"Fuisz Technologies, Ltd."	Chantilly	Virginia	20151	USA	EXACT	0066580AA	Sucralfate	XX73205DH5								MISSING	
Sucralfate suspension	Treatment of oral complications of chemotherapy in bone marrow transplant patients.	Sucralfate suspension	SUCRALFATE	n/a	3/12/90	Designated			N/A	N/A	"Darby Pharmaceuticals, Inc."	Rockville Centre	New York	11570	USA	EXACT	0066580AA	Sucralfate	XX73205DH5								MISSING	
Sulfadiazine	For use in combination with pyrimethamine for the treatment of Toxoplasma gondii encephalitis in patients with and without AIDS.	Sulfadiazine	SULFADIAZINE	n/a	3/14/94	Designated/Approved	Approved for Orphan Indication	"Toxoplasmosis, as adjunctive with pyrimethamine"	7/29/94	7/29/01	"Eon Labs Manufacturing, Inc."	Laurelton	New York	11413	USA	EXACT	0011825AA	Sulfadiazine	0N7609K889								MISSING	
Superoxide dismutase (human)	"For protection of donor organ tissue from damage or injury mediated by oxygen-derived free radicals that are generated during the necessary periods of ischemia (hypoxia, anoxia), and especially reperfusion, associated with the operative procedure."	Superoxide dismutase (human)	LEDISMASE	n/a	3/6/85	Designated			N/A	N/A	Pharmacia-Chiron Partnership	Emeryville	California	94608	USA	EXACT	0156467AA	Superoxide dismutase (human)	0786H5RV0T								MISSING	
Suramin	Treatment of hormone-refractory prostate cancer.	Suramin	SURAMIN	Metaret	5/6/97	Designated			N/A	N/A	Warner-Lambert Company	Ann Arbor	Michigan	48105	USA	EXACT	0145686AA	Suramin	6032D45BEM						Familial prostate cancer	4520	approximate	
Surfactant (human) (amniotic fluid derived)	Prevention and treatment of neonatal respiratory distress syndrome.	Surfactant (human) (amniotic fluid derived)	AMNIOTIC FLUID (BOVINE)	Human Surf	3/25/87	Designated/Withdrawn			N/A	N/A	"Merritt, T. Allen M.D."	Sacramento	California	95817	USA	LONGEST CONTAINS	0203418AA	amniotic fluid	P06X62O7E9						"Respiratory distress syndrome, infant"	112	done	
Synsorb Pk	Treatment of verocytotoxogenic E. coli infections.	Synsorb Pk	SYNSORB PK	n/a	7/17/95	Designated			N/A	N/A	Synsorb Biotech Inc.				Canada	EXACT	0212066AA	Synsorb Pk					PROBLEM	can't find			MISSING	Not a rare disease
Synthetic double-stranded siRNA oligonucleotide against caspase 2 mRNA	Treatment of ischemic optic neuropathy	Synthetic double-stranded siRNA oligonucleotide against caspase 2 mRNA		n/a	9/25/12	Designated			N/A	N/A	"Quark Pharmaceuticals, Inc."	Fremont	California	94555	USA								PROBLEM	can't find	Anterior ischemic optic neuropathy	9790	done	
Synthetic human secretin	For use in conjunction with diagnostic procedures (excluding ERCP) for pancreatic disorders to increase pancreatic fluid secretion	Synthetic human secretin	SECRETIN HUMAN	n/a	9/18/06	Designated			N/A	N/A	"Innovate Biopharmaceuticals, Inc."	Raleigh	North Carolina	27615	USA	EXACT	0234559AA	Synthetic human secretin	A0426J905J								MISSING	"not a disease, a procedure"
Synthetic human secretin	"For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion."	Synthetic human secretin	SECRETIN HUMAN	n/a	3/7/00	Designated			N/A	N/A	"ChiRhoClin, Inc."	Silver Spring	Maryland	20905	USA	EXACT	0234559AA	Synthetic human secretin	A0426J905J								MISSING	"not a disease, a procedure"
Synthetic human secretin	For use in the evaluation of exocrine pancreas function.	Synthetic human secretin	SECRETIN HUMAN	n/a	6/16/99	Designated			N/A	N/A	"ChiRhoClin, Inc."	Silver Spring	Maryland	20905	USA	EXACT	0234559AA	Synthetic human secretin	A0426J905J								MISSING	"not a disease, a procedure"
Synthetic porcine secretin	"For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion."	Synthetic porcine secretin	SECRETIN PORCINE	Secreflo	3/7/00	Designated/Approved	Approved for Orphan Indication	"Use in secretin stimulation testing for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction"	4/4/02	4/4/09	"ChiRhoClin, Inc."	Silver Spring	Maryland	20905	USA	EXACT	0223132AA	Synthetic porcine secretin	D0L9J6I13I								MISSING	"not a disease, a procedure"
Synthetic porcine secretin	For use in the evaluation of exocrine pancreas function.	Synthetic porcine secretin	SECRETIN PORCINE	Secreflo	6/18/99	Designated/Approved	Approved for Orphan Indication	For use in secretin stimulation testing for: Stimulation of pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangio-pancreatography (ERCP)	11/1/02	11/1/09	"ChiRhoClin, Inc."	Silver Spring	Maryland	20905	USA	EXACT	0223132AA	Synthetic porcine secretin	D0L9J6I13I								MISSING	"not a disease, a procedure"
"T4 endonuclease V, liposome encapsulated"	To prevent cutaneous neoplasms and other skin abnormalities in xeroderma pigmentosum.	"T4 endonuclease V, liposome encapsulated"	LIPOSOME	n/a	6/27/89	Designated			N/A	N/A	AGI Dermatics	Freeport	New York	11520	USA	LONGEST CONTAINS	0266671AA	liposome					PROBLEM	can't find	Xeroderma pigmentosum	7910	done	
TAK-659	Treatment of acute myeloid leukemia (AML)	"6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one monocitrate"	TAK-659	n/a	10/3/17	Designated			N/A	N/A	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0893072AA	TAK-659	6ZJ8V3Q0H1						Acute myeloid leukemia	12757	done	
TAK-659	Treatment of diffuse large B-cell lymphoma	"6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridine-3-one monocitrate"	TAK-659	n/a	2/14/17	Designated			N/A	N/A	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0893072AA	TAK-659	6ZJ8V3Q0H1						Diffuse Large B-Cell Lymphoma	3178	done	
TAK-925	Treatment of narcolepsy	"methyl (2R,3S)-3-[(methylsulfonyl)amino]-2-{[(cis-4-phenylcyclohexyl)oxy]methyl}piperidine-1-carboxylate"	TAK-925	n/a	12/19/17	Designated			N/A	N/A	"Takeda Development Center Americas, Inc."	Takeda Parkway	Deerfield	60015	USA	EXACT	0114122AB	TAK-925	1QMD83K4YN						Narcolepsy	7162	done	
TANZISERTIB	Treatment of idiopathic pulmonary fibrosis	"4-[[9-(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol"	TANZISERTIB	n/a	9/23/11	Designated			N/A	N/A	Celgene Corporation	Warren	New Jersey	7059	USA	EXACT	0357608AA	TANZISERTIB	M5O06306UO						Idiopathic pulmonary fibrosis	8609	done	
TAS-120	Treatment of cholangiocarcinoma (CCA)	"1-[(3S)-[4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one"	FGFR-â€‹IN-â€‹1	n/a	5/23/18	Designated			N/A	N/A	"Taiho Oncology, Inc."	101 Carnegie Center Drive	Suite 101	8540	USA	EXACT	0922474AA	TAS-120	4B93MGE4AL						Intrahepatic cholangiocarcinoma	6042	done	
TECHNETIUM TC-99M SULFUR COLLOID	For localization of sentinel lymph nodes in patients with melanoma.	"Technetium Tc99m sulfur colloid injection, lyophilized"	TECHNETIUM TC-99M SULFUR COLLOID	Technetium Tc99m Sulfur Colloi	3/17/09	Designated/Approved	Approved for Orphan Indication	Localization of lymph nodes draining a primary tumor in patients with melanoma when used with a hand-held gamma counter	8/13/12	8/13/19	"Pharmalucence, Inc."	Bedford	Massachusetts	1730	USA	EXACT	0075138AA	TECHNETIUM TC-99M SULFUR COLLOID	556Q0P6PB1								MISSING	Not a rare disease
TEMPOL	Treatment of cerebral cavernous malformation.	"4-Hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl"	TEMPOL	n/a	9/29/15	Designated			N/A	N/A	"REcursion Pharmaceuticals, LLC"	Salt Lake City	Utah	84108	USA	EXACT	0109502AA	TEMPOL	U78ZX2F65X						Cerebral cavernous malformation	1204	done	
TEN-010	Treatment of nuclear protein in testis (NUT) midline carcinoma.	"2-[(4S)-6-(4-chlorophenyl)-1,7,8-trimethylthiophenol[3,2-f]1,2,4-triazolo[4,3-a]1,4-diazepin-4-yl]-N-[3-(4-methylpiperazinyl)propyl]acetamide"	"JQ-35, (S)-"	n/a	9/29/15	Designated			N/A	N/A	"Genentech, Inc (a Roche Group Member)"	South San Francisco	California	94080	USA	EXACT	1343120AA	TEN-010	TA3QN7788D								PROBLEM	
TETRAHYDROURIDINE	Treatment of thalassemia	"5-aza-2'-dexocytidine combined with 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one"	TETRAHYDROURIDINE	n/a	2/16/17	Designated			N/A	N/A	EpiDestiny Inc.	Solon	Ohio	44139	USA	EXACT	0058957AA	TETRAHYDROURIDINE	0NIZ8H6OL8						Thalassemia	7756	done	
TEZACAFTOR	Treatment of cystic fibrosis	"(R)-1-(2,2-difluorobenzo [d][1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide"	TEZACAFTOR	n/a	4/24/14	Designated			N/A	N/A	Vertex Pharmaceuticals Inc.	Boston	Massachusetts	2210	USA	EXACT	1139328AA	TEZACAFTOR	8RW88Y506K						Cystic fibrosis	6233	done	
TH-9402 FREE BASE	For immune reconstitution and prevention of graft versus host disease following allogeneic hematopoietic stem cell transplantation.	"4,5 dibromorhodamine methyl ester"	TH-9402 FREE BASE	Theralux Photodynamic Therapy	10/23/07	Designated			N/A	N/A	Kiadis Pharma Netherlands B.V.				Netherlands	EXACT	0807454AA	TH-9402 FREE BASE	934QHK1OOK						Chronic graft versus host disease 	10964	approximate	
TH-9402 FREE BASE	For immune reconstitution and prevention of graft versus host disease following allogeneic hematopoietic stem cell transplantation.	"4,5 dibromorhodamine methyl ester"	TH-9402 FREE BASE	Theralux Photodynamic Therapy	10/23/07	Designated			N/A	N/A	Kiadis Pharma Netherlands B.V.				Netherlands	EXACT	0807454AA	TH-9402 FREE BASE	934QHK1OOK						 Acute graft versus host disease	6544	approximate	
TH-9402 FREE BASE	Treatment of diffuse large B-cell lymphoma	"4, 5 dibromorhodamine methyl ester"	TH-9402 FREE BASE	Theralux Photodynamic Therapy	10/30/08	Designated			N/A	N/A	"Kiadis Pharma Canada, Inc."				Canada	EXACT	0807454AA	TH-9402 FREE BASE	934QHK1OOK						Diffuse Large B-Cell Lymphoma	3178	done	
TH-9402 FREE BASE	Treatment of follicular lymphoma	"4, 5 dibromorhodamine methyl ester"	TH-9402 FREE BASE	Theralux Photodynamic Therapy	10/30/08	Designated			N/A	N/A	"Kiadis Pharma Canada, Inc."				Canada	EXACT	0807454AA	TH-9402 FREE BASE	934QHK1OOK						Follicular lymphoma	2356	done	
"THIOMAB antibody drug conjugate comprised of humanized IgG1 anti-C-type lectin-like molecule-1 monoclonal antibody and DNA alkylating cross-linking agent pyrrolo [2,1-c][1,4] benzodiazepine dimer"	Treatment of acute myeloid leukemia	"THIOMAB antibody drug conjugate comprised of humanized IgG1 anti-C-type lectin-like molecule-1 monoclonal antibody and DNA alkylating cross-linking agent pyrrolo [2,1-c][1,4] benzodiazepine dimer"	BENZODIAZEPINE	n/a	10/24/17	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	LONGEST CONTAINS	0511740AA	benzodiazepine	M0Q7802G2B						Acute myeloid leukemia	12757	done	
TIDEGLUSIB	Treatment of progressive supranuclear palsy	"4-benzyl-2-(a-naphtyl)-1,2,4-thiadiazolidine-3,5-dione"	TIDEGLUSIB	n/a	10/13/09	Designated/Withdrawn			N/A	N/A	"NOSCIRA, S.A."	Madrid			Spain	EXACT	0362094AA	TIDEGLUSIB	Q747Y6TT42						Progressive supranuclear palsy	7471	done	
TIPRELESTAT	Prevention of inflammatory complications of transthoracic esophagectomy	recombinant elafin	TIPRELESTAT	n/a	3/18/13	Designated			N/A	N/A	Proteo Biotech AG				Germany	EXACT	0795799AA	TIPRELESTAT	78I8295690								MISSING	
TIRABRUTINIB HYDROCHLORIDE	Treatment of chronic lymphocytic leukemia.	"6-Amino-9-[(3R)-1-(but-2-ynoyl)pyrrolidin-3-yl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one monohydrochloride"	TIRABRUTINIB HYDROCHLORIDE	n/a	6/5/17	Designated			N/A	N/A	"Gilead Sciences, Inc."	Seattle	Washington	98102	USA	EXACT	1136692AA	TIRABRUTINIB HYDROCHLORIDE	U374135N48						Chronic lymphocytic leukemia	6104	done	
TIRATRICOL	"Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid gland."	"3,5,3'-triiodothyroacetate"	TIRATRICOL	n/a	9/20/00	Designated			N/A	N/A	"Elliot Danforth, Jr., M.D."	Underhill	Vermont	5489	USA	EXACT	0007783AA	TIRATRICOL	29OQ9EU4R1						Papillary thyroid carcinoma 	12027	done	
TIRATRICOL	"Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid gland."	"3,5,3'-triiodothyroacetate"	TIRATRICOL	n/a	9/20/00	Designated			N/A	N/A	"Elliot Danforth, Jr., M.D."	Underhill	Vermont	5489	USA	EXACT	0007783AA	TIRATRICOL	29OQ9EU4R1						" Thyroid cancer, follicular"	5206	done	
TNT-009	Treatment of autoimmune hemolytic anemia (AIHA)	"humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s (C1s)"	SUTIMLIMAB	n/a	7/27/16	Designated			N/A	N/A	"True North Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	1799617AA	TNT-009	GNWE7KJ995						Autoimmune hemolytic anemia	5870	done	
TNT-009	Treatment of bullous pemphigoid (BP).	"humanized IgG4 Monoclonal Antibody against total complement component 1, subcomponent s (C1s)"	TNT-009	n/a	8/17/17	Designated			N/A	N/A	"True North Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	1799617AA	TNT-009	GNWE7KJ995						Bullous pemphigoid	5972	done	
TOL-101	Treatment of patients 16 years of age and younger with immune-mediated T1DM and preserved pancreatic beta cell function	"anti-TCR murine monoclonal antibody (MAb, type IgM)"	TOL-101	n/a	6/7/10	Designated			N/A	N/A	"Tolera Therapeutics, Inc."	Kalamazoo	Michigan	49001	USA	EXACT	0113923AB	TOL-101	28X0AGG6P8						Diabetes mellitus type 1	10268	done	Not a rare disease
TOL-101	Treatment of pediatric multiple sclerosis in patients less than or equal to 16 years of age	"anti-TCR murine monoclonal antibody (MAB, type IgM)"	TOL-101	n/a	1/12/11	Designated			N/A	N/A	"Tolera Therapeutics, Inc."	Kalamazoo	Michigan	49008	USA	EXACT	0113923AB	TOL-101	28X0AGG6P8						Pediatric multiple sclerosis	10443	done	
TP-10	Prevention or reduction of adult respiratory distress syndrome.	Soluble recombinant human complement receptor type 1	CDX-1135	n/a	11/21/94	Designated			N/A	N/A	"T Cell Sciences, Inc."	Needham Heights	Massachusetts	2194	USA	EXACT	0260719AA	TP-10	2RF4H67MOG						Acute respiratory distress syndrome	5698	done	
TPX-0005	Treatment of non-small cell lung adenocarcinomas with adenocarcinoma histology	"(7S,13R)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one"	TPX-0005	n/a	6/22/17	Designated			N/A	N/A	"TP Therapeutics, Inc."	San Diego	California	92121	USA	EXACT	1574261AA	TPX-0005	08O3FQ4UNP						Lung adenocarcinoma	5742	done	
TR2-A	Treatment of gastric neuroendocrine tumors (gastric NETs).	"(R)-1-[1-(4-Acetoxy-3,3-dimethyl-2-oxo-butyl)-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-(3-methylamino-phenyl)-urea"	CECLAZEPIDE	n/a	5/12/16	Designated			N/A	N/A	Trio Medicines Ltd.				United Kingdom	EXACT	1718623AA	TR2-A	99B5ZR9276								MISSING	not a disease
TRALESINIDASE ALFA	"Treatment of mucopolysaccharidosis III Type B (MPS IIIB, Sanfilippo Syndrome Type B)"	chimeric fusion protein of recombinant human alpha-N-acetylglucosaminidase and human insulin-like growth factor 2	TRALESINIDASE ALFA	n/a	11/25/14	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA	EXACT	0112449AB	TRALESINIDASE ALFA	AA60A4ST8X						Mucopolysaccharidosis type IIIB	7072	done	
TRANSCROCETINATE SODIUM	Treatment of brain metastasis	trans sodium crocetinate	TRANSCROCETINATE SODIUM	n/a	12/3/12	Designated			N/A	N/A	"Diffusion Pharmaceuticals, LLC"	Charlottesville	Virginia	22902	USA	EXACT	0931737AA	TRANSCROCETINATE SODIUM	YP57637WMX								MISSING	Not a rare disease; symptom of many types of cancer
TV-1360	Treatment of pancreatic cancer.	"4-amino-1-[(1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl) cyclopent-2-en-1-yl] pyrimidin-2-one"	FLUOROCYCLOPENTENYLCYTOSINE	n/a	9/23/14	Designated			N/A	N/A	"Rexahn Pharmaceuticals, Inc."	Rockville	Maryland	20850	USA	EXACT	1302029AA	FLUOROCYCLOPENTENYLCYTOSINE	0Z4A82I0JO						Pancreatic cancer	9364	done	Not a rare disease
TZ-101	To improve homing to bone (treatment of myeloablation) in patients receiving hematopoietic stem cell transplantation.	FTV1+GDP-fucose	TZ-101	n/a	3/18/11	Designated			N/A	N/A	"America Stem Cell, Inc."	Helotes	Texas	78023	USA	EXACT	1803378AA	TZ-101	K2X1EE8C73								MISSING	
TZ-101	To increase the activity of regulatory T-cells (Tregs) used in the prevention of graft versus host disease in patients undergoing hematopoietic stem cell transplantation	recombinant human fucosyltransferase VI [ FTVI ] + GDP-fucose	TZ-101	n/a	1/27/15	Designated			N/A	N/A	"TargaZyme, Inc."	Carlsbad	California	92011	USA	EXACT	1803378AA	TZ-101	K2X1EE8C73						Chronic graft versus host disease 	10964	approximate	
TZ-101	To increase the activity of regulatory T-cells (Tregs) used in the prevention of graft versus host disease in patients undergoing hematopoietic stem cell transplantation	recombinant human fucosyltransferase VI [ FTVI ] + GDP-fucose	TZ-101	n/a	1/27/15	Designated			N/A	N/A	"TargaZyme, Inc."	Carlsbad	California	92011	USA	EXACT	1803378AA	TZ-101	K2X1EE8C73						 Acute graft versus host disease	6544	approximate	
Tacrolimus	Prophylaxis of graft-versus-host-disease.	Tacrolimus	TACROLIMUS	Prograf	4/6/98	Designated			N/A	N/A	"Fujisawa USA, Inc."	Deerfield	Illinois	60015	USA	EXACT	0168956AA	Tacrolimus	WM0HAQ4WNM						Chronic graft versus host disease 	10964	done	
Tacrolimus	Prophylaxis of graft-versus-host-disease.	Tacrolimus	TACROLIMUS	Prograf	4/6/98	Designated			N/A	N/A	"Fujisawa USA, Inc."	Deerfield	Illinois	60015	USA	EXACT	0168956AA	Tacrolimus	WM0HAQ4WNM						 Acute graft versus host disease	6544	done	
Tacrolimus	Prophylaxis of organ rejection in patients receiving heart transplants.	Tacrolimus	TACROLIMUS	Prograf	6/6/05	Designated/Approved	Approved for Orphan Indication	Prophylaxis of organ rejection in patients receiving allogenic heart transplants.	3/29/06	3/29/13	"Astellas Pharma US, Inc."	Deerfield	Illinois	60015	USA	EXACT	0168956AA	Tacrolimus	WM0HAQ4WNM								MISSING	
Tacrolimus granules for oral suspension	"Prevention of rejection in kidney, liver or heart transplant in pediatric patients."	Tacrolimus granules for oral suspension	TACROLIMUS	n/a	10/4/16	Designated			N/A	N/A	"Astellas Pharma Global Development, Inc."	Northbrook	Illinois	60062	USA	EXACT	0168956AA	Tacrolimus	WM0HAQ4WNM								MISSING	
Talabostat	Treatment of pancreatic cancer	Talabostat	TALABOSTAT	n/a	3/16/17	Designated			N/A	N/A	BioXcel Corporation	Branford	Connecticut	6405	USA	EXACT	0307562AA	Talabostat	KZ1O2SH88Z						Pancreatic cancer	9364	done	Not a rare disease
Talactoferrin alfa	Treatment of stage III/IV non-small cell lung cancer	Talactoferrin alfa	TALACTOFERRIN ALFA	n/a	8/8/07	Designated/Withdrawn			N/A	N/A	"Agennix, Inc."	Houston	Texas	77046	USA	EXACT	0314363AA	Talactoferrin alfa	7A055A9QRR						"Non-small cell lung cancer, childhood"	9343	approximate	
Taliglucerase alfa	Treatment of Gaucher's disease	Taliglucerase alfa	TALIGLUCERASE ALFA	Elelyso For Injection	9/3/09	Designated/Approved	Approved for Orphan Indication	Use as long-term enzyme replacement therapy in patients with Type 1 Gaucher disease	5/1/12	N/A	"Pfizer, Inc."	New York	New York	10017	USA	EXACT	0349724AA	Taliglucerase alfa	0R4NLX88O4						Gaucher disease	8233	done	
Tanespimycin	Treatment of chronic myelogenous leukemia	17-allylamino-17-demethoxygeldanamycin (17-AGG)	TANESPIMYCIN	n/a	9/3/04	Designated			N/A	N/A	Bristol-Myers Squibb Company	Wallingford	Connecticut	6492	USA	EXACT	0230819AA	Tanespimycin	4GY0AVT3L4						Chronic myeloid leukemia	6105	done	
Targeted Gastrin 17 Complexed Peptide	Treatment of pancreatic cancer	Targeted Gastrin 17 Complexed Peptide	GASTRIN HUMAN	n/a	5/14/14	Designated			N/A	N/A	Tyg Oncology Ltd				United Kingdom	LONGEST CONTAINS	0005389AA	Gastrin	M2ZSG4KZO6						Pancreatic cancer	9364	done	Not a rare disease
Taxol	Treatment of angiosarcoma	Oraxol	PACLITAXEL	n/a	4/16/18	Designated			N/A	N/A	"Athenex, Inc. dba Kinex Pharmaceuticals, Inc."	1001 Main Street	Suite 600	14203	USA	EXACT	0132127AA	Taxol	P88XT4IS4D						Angiosarcoma of the liver	5813	approximate	localization of angiosarcoma is not specified
Tazemetostat	Treatment of mesothelioma	Tazemetostat	TAZEMETOSTAT	n/a	9/28/17	Designated			N/A	N/A	Epizyme Inc.	Cambridge	Massachusetts	2139	USA	EXACT	1120394AA	Tazemetostat	Q40W93WPE1						Malignant mesothelioma	7026	done	
Technetium Tc99m anti-melanoma murine monoclonal antibody	"For use in detecting, by imaging, metastases of malignant melanoma."	Technetium Tc99m anti-melanoma murine monoclonal antibody		Oncotrac Melanoma Imaging Kit	6/2/87	Designated/Withdrawn			N/A	N/A	NeoRx Corporation	Seattle	Washington	98119	USA								PROBLEM	can't find			MISSING	
Technetium Tc99m murine monoclonal antibody (IgG2a) to B cell	"Diagnostic imaging in the evaluation of the extent of disease in patients with histologically confirmed diagnosis of non-Hodgkin's B-cell lymphoma, acute B-cell lymphoblastic leukemia (in children and adults), and chronic B-cell lymphocytic leukemia."	Technetium Tc99m murine monoclonal antibody (IgG2a) to B cell		Lymphoscan	4/7/92	Designated			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA					Bectumomab	NA	https://www.drugbank.ca/drugs/DB04962	PROBLEM	absent from GINAS	B-cell lymphoma 	5877	done	
Technetium Tc99m murine monoclonal antibody (IgG2a) to B cell	"Diagnostic imaging in the evaluation of the extent of disease in patients with histologically confirmed diagnosis of non-Hodgkin's B-cell lymphoma, acute B-cell lymphoblastic leukemia (in children and adults), and chronic B-cell lymphocytic leukemia."	Technetium Tc99m murine monoclonal antibody (IgG2a) to B cell		Lymphoscan	4/7/92	Designated			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA					Bectumomab	NA	https://www.drugbank.ca/drugs/DB04962	PROBLEM	absent from GINAS	 Acute lymphoblastic leukemia 	522	done	
Technetium Tc99m murine monoclonal antibody (IgG2a) to B cell	"Diagnostic imaging in the evaluation of the extent of disease in patients with histologically confirmed diagnosis of non-Hodgkin's B-cell lymphoma, acute B-cell lymphoblastic leukemia (in children and adults), and chronic B-cell lymphocytic leukemia."	Technetium Tc99m murine monoclonal antibody (IgG2a) to B cell		Lymphoscan	4/7/92	Designated			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA					Bectumomab	NA	https://www.drugbank.ca/drugs/DB04962	PROBLEM	absent from GINAS	 Chronic lymphocytic leukemia	6104	done	
Technetium Tc99m murine monoclonal antibody to hCG	Detection of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Technetium Tc99m murine monoclonal antibody to hCG		"Immuraid, Hcg-Tc-99m"	8/7/89	Designated/Withdrawn			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA								PROBLEM	can't find	Gestational trophoblastic tumor	6498	approximate	
Technetium Tc99m murine monoclonal antibody to human AFP	Detection of alpha-fetoprotein producing germ cell tumors.	Technetium Tc99m murine monoclonal antibody to human AFP		Afp-Scan	8/1/89	Designated/Withdrawn			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA								PROBLEM	can't find			MISSING	
Technetium Tc99m murine monoclonal antibody to human alpha-fetoprotein	Detection of hepatocellular carcinoma and hepatoblastoma.	Technetium Tc99m murine monoclonal antibody to human alpha-fetoprotein		"Immuraid, Afp-Scan"	8/1/89	Designated/Withdrawn			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA								PROBLEM	can't find	Hepatoblastoma	2657	done	
Technetium Tc99m rh-Annexin V	"Diagnosis or assessment of rejection status in heart, heart-lung, single lung, or bilateral lung transplants."	Technetium Tc99m rh-Annexin V		Apomate	11/3/00	Designated			N/A	N/A	Theseus Imaging Corporation	Cambridge	Massachusetts	2138	USA					Tc-99m-annexin V-128	NA	https://adisinsight.springer.com/drugs/800040921	PROBLEM	absent from GINAS			MISSING	
Tegafur	Treatment of gastric cancer	Tegafur/gimeracil/oteracil	TEGAFUR	n/a	7/20/06	Designated			N/A	N/A	"Taiho Pharma USA, Inc."	Princeton	New Jersey	8540	USA	EXACT	0058695AA	Tegafur	1548R74NSZ						Stomach cancer	7704	done	
Temoporfin	"Palliative treatment of recurrent, refractory or second primary squamous cell carcinomas of the head and neck in patients considered to be incurable with surgery or radiotherapy."	Temoporfin	TEMOPORFIN	Foscan	10/28/99	Designated			N/A	N/A	Biolitec Pharma Ireland Ltd.				Ireland	EXACT	0183653AA	Temoporfin	FU21S769PF						Squamous cell carcinoma of the head and neck	8503	done	not a rare disease
Teniposide	Treatment of refractory childhood acute lymphocytic leukemia.	Teniposide	TENIPOSIDE	Vumon For Injection	11/1/84	Designated/Approved	Approved for Orphan Indication	Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents.	7/14/92	7/14/99	Bristol-Myers Squibb Pharmaceutical Research Institute	Wallingford	Connecticut	6492	USA	EXACT	0063832AA	Teniposide	957E6438QA						Childhood acute lymphoblastic leukemia	9240	done	
Teriparatide	Treatment of idiopathic osteoporosis.	Teriparatide	TERIPARATIDE	Parathar	10/28/99	Designated			N/A	N/A	"Biomeasure, Inc."	Milford	Massachusetts	1757	USA	EXACT	0249503AA	Teriparatide	10T9CSU89I						Juvenile osteoporosis	6760	approximate	
Testosterone	For use as physiologic testosterone replacement in androgen deficient HIV+ patients with an associated weight loss.	Testosterone	TESTOSTERONE	Theraderm Testosterone Transdermal System	9/22/97	Designated			N/A	N/A	Watson Laboratories	Salt Lake City	Utah	84108	USA	EXACT	0009734AA	Testosterone	3XMK78S47O						Congenital human immunodeficiency virus	10328	approximate	
Testosterone	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Testosterone	TESTOSTERONE	Androgel	2/5/96	Designated/Withdrawn			N/A	N/A	"Unimed Pharmaceuticals, Inc."	Marietta	Georgia	30062	USA	EXACT	0009734AA	Testosterone	3XMK78S47O						Congenital human immunodeficiency virus	10328	approximate	
Testosterone propionate ointment 2%	Treatment of vulvar dystrophies.	Testosterone propionate ointment 2%	TESTOSTERONE PROPIONATE	n/a	7/31/91	Designated			N/A	N/A	"Star Pharmaceuticals, Inc."	Pompano Beach	Florida	33064	USA	EXACT	0009585AA	Testosterone propionate	WI93Z9138A								MISSING	Not a rare disease
Testosterone sublingual	Treatment of constitutional delay of growth and puberty in boys.	Testosterone sublingual	TESTOSTERONE	n/a	1/16/91	Designated/Withdrawn			N/A	N/A	Bio-Technology General Corp.	Iselin	New Jersey	8830	USA	EXACT	0009734AA	Testosterone	3XMK78S47O								MISSING	
Tetrabenazine	Treatment of moderate/severe tardive dyskinesia.	Tetrabenazine	TETRABENAZINE	n/a	5/12/98	Designated			N/A	N/A	"Prestwick Pharmaceuticals, Inc."	Washington	District of Columbia	20006	USA	EXACT	0009825AA	Tetrabenazine	Z9O08YRN8O						Tardive dyskinesia	7732	done	
Tetraiodothyroacetic acid	Suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.	Tetraiodothyroacetic acid	"3,3',5,5'-TETRAIODOTHYROACETIC ACID"	n/a	5/1/00	Designated			N/A	N/A	"Danforth, Jr., MD, Elliot"	Underhill	Vermont	5489	USA	EXACT	0497176AA	Tetraiodothyroacetic acid	PA7UX1FFYQ						Papillary thyroid carcinoma 	12027	done	
Tetraiodothyroacetic acid	Suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.	Tetraiodothyroacetic acid	"3,3',5,5'-TETRAIODOTHYROACETIC ACID"	n/a	5/1/00	Designated			N/A	N/A	"Danforth, Jr., MD, Elliot"	Underhill	Vermont	5489	USA	EXACT	0497176AA	Tetraiodothyroacetic acid	PA7UX1FFYQ						 Hurthle cell thyroid cancer 	9428	done	
Tetraiodothyroacetic acid	Suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.	Tetraiodothyroacetic acid	"3,3',5,5'-TETRAIODOTHYROACETIC ACID"	n/a	5/1/00	Designated			N/A	N/A	"Danforth, Jr., MD, Elliot"	Underhill	Vermont	5489	USA	EXACT	0497176AA	Tetraiodothyroacetic acid	PA7UX1FFYQ						" Thyroid cancer, follicular"	5206	done	
Thalidomide	Prevention of graft versus host disease.	Thalidomide	THALIDOMIDE	n/a	3/5/90	Designated			N/A	N/A	Andrulis Research Corporation	Beltsville	Maryland	20705	USA	EXACT	0007409AA	Thalidomide	4Z8R6ORS6L						Chronic graft versus host disease	10964	approximate	type of GVHD (acute or chronic) is not specified
Thalidomide	Prevention of graft versus host disease.	Thalidomide	THALIDOMIDE	n/a	3/5/90	Designated			N/A	N/A	Andrulis Research Corporation	Beltsville	Maryland	20705	USA	EXACT	0007409AA	Thalidomide	4Z8R6ORS6L						Acute graft versus host disease	6544	approximate	type of GVHD (acute or chronic) is not specified
Thalidomide	Treatment and maintenance of reactional lepromatous leprosy.	Thalidomide	THALIDOMIDE	n/a	11/15/88	Designated			N/A	N/A	"Pediatric Pharmaceuticals, Inc."	Westfield	New Jersey	7090	USA	EXACT	0007409AA	Thalidomide	4Z8R6ORS6L						Hansen's disease	6886	done	
Thalidomide	"Treatment and prevention of recurrent aphthous ulcers in severely, terminally immunocompromised patients."	Thalidomide	THALIDOMIDE	n/a	5/15/95	Designated			N/A	N/A	Andrulis Research Corporation	Beltsville	Maryland	20705	USA	EXACT	0007409AA	Thalidomide	4Z8R6ORS6L								MISSING	Not a rare disease; secondary condition
Thalidomide	Treatment of Crohn's disease.	Thalidomide	THALIDOMIDE	Thalomid	4/6/99	Designated			N/A	N/A	Celgene Corporation	Warren				EXACT	0007409AA	Thalidomide	4Z8R6ORS6L						Crohn's disease	10232	done	Not a rare disease
Thalidomide	Treatment of HIV-associated wasting syndrome.	Thalidomide	THALIDOMIDE	Synovir	3/11/96	Designated			N/A	N/A	Celgene Corporation	Warren				EXACT	0007409AA	Thalidomide	4Z8R6ORS6L								MISSING	
Thalidomide	Treatment of erythema nodosum leprosum.	Thalidomide	THALIDOMIDE	Thalomid	7/26/95	Designated/Approved	Approved for Orphan Indication	Acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) and as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrences.	7/16/98	7/16/05	Celgene Corporation	Summit	New Jersey	7901	USA	EXACT	0007409AA	Thalidomide	4Z8R6ORS6L						Hansen's disease	6886	done	
Thalidomide	Treatment of graft versus host disease.	Thalidomide	THALIDOMIDE	n/a	3/5/90	Designated			N/A	N/A	Andrulis Research Corporation	Beltsville	Maryland	20705	USA	EXACT	0007409AA	Thalidomide	4Z8R6ORS6L						Chronic graft versus host disease 	10964	approximate	
Thalidomide	Treatment of graft versus host disease.	Thalidomide	THALIDOMIDE	n/a	3/5/90	Designated			N/A	N/A	Andrulis Research Corporation	Beltsville	Maryland	20705	USA	EXACT	0007409AA	Thalidomide	4Z8R6ORS6L						 Acute graft versus host disease	6544	approximate	
Thalidomide	Treatment of primary brain malignancies.	Thalidomide	THALIDOMIDE	n/a	2/27/98	Designated			N/A	N/A	Celgene Corporation	Warren				EXACT	0007409AA	Thalidomide	4Z8R6ORS6L						"Brain tumor, adult"	9307	approximate	
Thalidomide	"Treatment of severe recurrent aphthous stomatitis in severely, terminally immunocompromised patients."	Thalidomide	THALIDOMIDE	n/a	5/1/95	Designated			N/A	N/A	Celgene Corporation	Warren				EXACT	0007409AA	Thalidomide	4Z8R6ORS6L						Aphthous stomatitis	5834	done	
Thawed donor matched banked umbilical cord blood enriched by cell sorting to produce a subpopulation expressing high levels of intracellular aldehyde dehydrogenase	To improve patient outcomes by decreasing time to platlet and neutrophil engraftment in patients with inherited metabolic diseases (IMD) undergoing umbilical cord blood transplantation.	Thawed donor matched banked umbilical cord blood enriched by cell sorting to produce a subpopulation expressing high levels of intracellular aldehyde dehydrogenase	CORD BLOOD	n/a	10/23/08	Designated			N/A	N/A	"Aldagen, Inc."	Durham	North Carolina	27713	USA	LONGEST CONTAINS	0854240AA	umbilical cord blood	PVH8394DLN								MISSING	metabolic diseases - too general
Thiotepa	Conditioning treatment prior to hematopoietic stem cell transplantation	Thiotepa	THIOTEPA	Tepadina	4/2/07	Designated			N/A	N/A	Adienne S.A.				Switzerland	EXACT	0008139AA	Thiotepa	905Z5W3GKH								MISSING	
Thymoxamine HCl	Reversal of phenylephrine-induced mydriasis in patients who have narrow anterior angles and are at risk of developing an acute attack of angle-closure glaucoma following mydriasis.	Thymoxamine HCl	MOXISYLYTE HYDROCHLORIDE	n/a	11/16/87	Designated/Withdrawn			N/A	N/A	Iolab Pharmaceuticals	Claremont	California	94608	USA	EXACT	0032111AA	Thymoxamine HCl	WK2KZM9V6X								MISSING	treatment of drug-induced side-effects
Thyrotropin alfa	"Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid"	Thyrotropin alfa	THYROTROPIN ALFA	Thyrogen	8/3/01	Designated/Approved	Approved for Orphan Indication	For use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of metastatic thyroid cancer	12/14/07	12/14/14	Genzyme Corporation	Cambridge	Massachusetts	2139	USA	EXACT	0172703AA	Thyrotropin alfa	AVX3D5A4LM						Papillary thyroid carcinoma 	12027	done	
Thyrotropin alfa	"Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid"	Thyrotropin alfa	THYROTROPIN ALFA	Thyrogen	8/3/01	Designated/Approved	Approved for Orphan Indication	For use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of metastatic thyroid cancer	12/14/07	12/14/14	Genzyme Corporation	Cambridge	Massachusetts	2139	USA	EXACT	0172703AA	Thyrotropin alfa	AVX3D5A4LM						" Thyroid cancer, follicular"	5206	done	
Thyrotropin alpha	As an adjunct in the diagnosis of thyroid cancer.	Thyrotropin alpha	THYROTROPIN	Thyrogen	2/24/92	Designated/Approved	Approved for Orphan Indication	As an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with thyroid cancer.	11/30/98	11/30/05	Genzyme Corporation	Cambridge	Massachusetts	2139	USA	EXACT	0005367AA	Thyrotropin	02KSI6Z9AK						Papillary thyroid carcinoma 	12027	approximate	
Thyrotropin alpha	As an adjunct in the diagnosis of thyroid cancer.	Thyrotropin alpha	THYROTROPIN	Thyrogen	2/24/92	Designated/Approved	Approved for Orphan Indication	As an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with thyroid cancer.	11/30/98	11/30/05	Genzyme Corporation	Cambridge	Massachusetts	2139	USA	EXACT	0005367AA	Thyrotropin	02KSI6Z9AK						" Thyroid cancer, follicular "	5206	approximate	
Thyrotropin alpha	As an adjunct in the diagnosis of thyroid cancer.	Thyrotropin alpha	THYROTROPIN	Thyrogen	2/24/92	Designated/Approved	Approved for Orphan Indication	As an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with thyroid cancer.	11/30/98	11/30/05	Genzyme Corporation	Cambridge	Massachusetts	2139	USA	EXACT	0005367AA	Thyrotropin	02KSI6Z9AK						" Thyroid cancer, medullary "	7004	approximate	
Thyrotropin alpha	As an adjunct in the diagnosis of thyroid cancer.	Thyrotropin alpha	THYROTROPIN	Thyrogen	2/24/92	Designated/Approved	Approved for Orphan Indication	As an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with thyroid cancer.	11/30/98	11/30/05	Genzyme Corporation	Cambridge	Massachusetts	2139	USA	EXACT	0005367AA	Thyrotropin	02KSI6Z9AK						  Anaplastic thyroid cancer	664	approximate	
Tiapride	Treatment of Tourette's syndrome.	Tiapride	TIAPRIDE	n/a	4/21/98	Designated/Withdrawn			N/A	N/A	"Sanofi-Synthelabo, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	0120058AA	Tiapride	LAH70H9JPH						Tourette syndrome	7783	done	
Tiazofurin (2-Beta-D-ribofuranosyl-4-thiazolecarboxamide)	Chronic myelogenous leukemia (CML)	Tiazofurin (2-Beta-D-ribofuranosyl-4-thiazolecarboxamide)	TIAZOFURIN	n/a	12/27/00	Designated			N/A	N/A	Valeant Pharmaceuticals North America	Costa Mesa	California	92626	USA	EXACT	0127753AA	Tiazofurin	ULJ82834RE						Chronic myeloid leukemia	6105	done	
Tilarginine acetate	Treatment of cardiogenic shock	Tilarginine acetate	TILARGININE ACETATE	n/a	4/11/05	Designated			N/A	N/A	"Arginox Pharmceuticals, Inc."	Menlo Park	California	94025	USA	EXACT	0178245AA	Tilarginine acetate	2FL3530AF2								MISSING	Not a rare disease
Tiratricol	For use in combination with levo-thyroxine to suppress thyroid stimulating hormone in patients with well-differentiated thyroid cancer who are intolerant to adequate doses of levo-thyroxine alone.	Tiratricol	TIRATRICOL	Triacana	8/13/91	Designated			N/A	N/A	Laphal Laboratoires				France	EXACT	0007783AA	Tiratricol	29OQ9EU4R1						"Thyroid cancer, medullary "	7004	approximate	
Tiratricol	For use in combination with levo-thyroxine to suppress thyroid stimulating hormone in patients with well-differentiated thyroid cancer who are intolerant to adequate doses of levo-thyroxine alone.	Tiratricol	TIRATRICOL	Triacana	8/13/91	Designated			N/A	N/A	Laphal Laboratoires				France	EXACT	0007783AA	Tiratricol	29OQ9EU4R1						" Thyroid cancer, follicular "	5206	approximate	
Tiratricol	For use in combination with levo-thyroxine to suppress thyroid stimulating hormone in patients with well-differentiated thyroid cancer who are intolerant to adequate doses of levo-thyroxine alone.	Tiratricol	TIRATRICOL	Triacana	8/13/91	Designated			N/A	N/A	Laphal Laboratoires				France	EXACT	0007783AA	Tiratricol	29OQ9EU4R1						 Papillary thyroid carcinoma 	12027	approximate	
Tiratricol	For use in combination with levo-thyroxine to suppress thyroid stimulating hormone in patients with well-differentiated thyroid cancer who are intolerant to adequate doses of levo-thyroxine alone.	Tiratricol	TIRATRICOL	Triacana	8/13/91	Designated			N/A	N/A	Laphal Laboratoires				France	EXACT	0007783AA	Tiratricol	29OQ9EU4R1						 Anaplastic thyroid cancer	664	approximate	
Tissue Plasminogen activator	Treatment of acute ischemic stroke (AIS) in children age 16 years and younger.	Tissue Plasminogen activator	ALTEPLASE	n/a	4/18/11	Designated			N/A	N/A	"Catherine Amlie-Lefond, MD"	Seattle	Washington	98105	USA	EXACT	0162447AA	Tissue Plasminogen activator	1RXS4UE564						Neonatal stroke	10444	approximate	not only neonatal
Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system	Treatment of osteonecrosis.	Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system	"BONE MARROW, AUTOLOGOUS"	n/a	3/13/06	Designated			N/A	N/A	"Aastrom Biosciences, Inc."	Ann Arbor	Michigan	48105	USA	LONGEST CONTAINS	0260924AA	autologous bone marrow					PROBLEM	can't find			MISSING	
Titanium dioxide and bisoctrizole	"For the secondary prevention (prevention of lesional induction) of disorders with UV-A and visible light-induced photosensitivity, specifically Actinic prurigo, Hydroa vacciniforme, Solar urticara (SU), Chronic Actinic Dermatitis (CAD), the cutaneous prophyrias, Smith-Lemli-Optiz Syndrome, and Hartnup's Disease."	Titanium dioxide and bisoctrizole	TITANIUM DIOXIDE	n/a	5/25/05	Designated/Withdrawn			N/A	N/A	Orfagen				France	EXACT	0033807AA	Titanium dioxide	15FIX9V2JP						Hartnup disease 	5683	done	
Titanium dioxide and bisoctrizole	"For the secondary prevention (prevention of lesional induction) of disorders with UV-A and visible light-induced photosensitivity, specifically Actinic prurigo, Hydroa vacciniforme, Solar urticara (SU), Chronic Actinic Dermatitis (CAD), the cutaneous prophyrias, Smith-Lemli-Optiz Syndrome, and Hartnup's Disease."	Titanium dioxide and bisoctrizole	TITANIUM DIOXIDE	n/a	5/25/05	Designated/Withdrawn			N/A	N/A	Orfagen				France	EXACT	0033807AA	Titanium dioxide	15FIX9V2JP						 Hydroa vacciniforme 	9654	done	
Titanium dioxide and bisoctrizole	"For the secondary prevention (prevention of lesional induction) of disorders with UV-A and visible light-induced photosensitivity, specifically Actinic prurigo, Hydroa vacciniforme, Solar urticara (SU), Chronic Actinic Dermatitis (CAD), the cutaneous prophyrias, Smith-Lemli-Optiz Syndrome, and Hartnup's Disease."	Titanium dioxide and bisoctrizole	TITANIUM DIOXIDE	n/a	5/25/05	Designated/Withdrawn			N/A	N/A	Orfagen				France	EXACT	0033807AA	Titanium dioxide	15FIX9V2JP						 Smith-Lemli-Opitz syndrome	6569	done	
Tizanidine HCl	Treatment of spasticity associated with multiple sclerosis and spinal cord injury.	Tizanidine HCl	TIZANIDINE HYDROCHLORIDE	Zanaflex	1/31/94	Designated			N/A	N/A	"Athena Neurosciences, Inc."	South San Francisco	California	94080	USA	EXACT	0090879AA	Tizanidine HCl	B53E3NMY5C						Multiple sclerosis	10255	done	
Tobramycin	Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.	Tobramycin	TOBRAMYCIN	Tobi	6/18/99	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0064233AA	Tobramycin	VZ8RRZ51VK						Pneumonia caused by Pseudomonas aeruginosa infection	13613	approximate	
Tocophersolan oral solution (vitamin E-tpgs)	Treatment of vitamin E deficiency resulting from malabsorption due to prolonged cholestatic hepatobiliary disease.	Tocophersolan oral solution (vitamin E-tpgs)	TOCOPHERSOLAN	n/a	4/15/88	Designated/Withdrawn			N/A	N/A	Sterling Winthrop	Malvern	Pennsylvania	19355	USA	EXACT	0143511AA	vitamin E tpgs	O03S90U1F2								MISSING	Not a rare disease
Tolcapone	Treatment of transthyretin amyloidosis	Tolcapone	TOLCAPONE	n/a	12/24/13	Designated			N/A	N/A	SOM Innovation Biotech SL (SOM Biotech)	Barcelona			Spain	EXACT	0173773AA	Tolcapone	CIF6334OLY						Familial transthyretin amyloidosis	656	done	
Toralizumab	Treatment of systemic lupus erythematosus.	Humanized MAb (IDEC-131) to CD40L	TORALIZUMAB	n/a	2/9/99	Designated/Withdrawn			N/A	N/A	Biogen IdecInc.	San Diego	California	92121	USA	EXACT	0255016AA	Toralizumab	KX44A9HM0B						Lupus	10253	done	"a rare disease according to Orphanet, but not according to GARD"
Tramadol hydrochloride	Management of postherpetic neuralgia	Tramadol hydrochloride	TRAMADOL HYDROCHLORIDE	n/a	4/26/05	Designated			N/A	N/A	"TheraQuest Biosciences, LLC"	Blue Bell	Pennsylvania	19422	USA	EXACT	0060548AA	Tramadol hydrochloride	9N7R477WCK						Herpes zoster oticus	7525	approximate	postherpetic neuralgia is a complication of varicella-zoster virus infection
Tramadol hydrochloride	Treatment of painful HIV-associated neuropathy	Tramadol hydrochloride	TRAMADOL HYDROCHLORIDE	n/a	1/28/05	Designated			N/A	N/A	"TheraQuest Biosciences, LLC"	Blue Bell	Pennsylvania	19422	USA	EXACT	0060548AA	Tramadol hydrochloride	9N7R477WCK								MISSING	
Transforming growth factor-beta 2	Treatment of full thickness macular holes.	Transforming growth factor-beta 2	CETERMIN	n/a	12/18/92	Designated			N/A	N/A	"Celtrix Pharmaceuticals, Inc."	Santa Clara	California	95054	USA	EXACT	0679549AA	Transforming growth factor-beta 2	693Y43MXY4								MISSING	symptom
Transgenic human alpha 1 antitrypsin	Treatment of emphysema secondary to alpha 1 antitrypsin deficiency.	Transgenic human alpha 1 antitrypsin		n/a	5/19/99	Designated			N/A	N/A	PPL Therapeutics (Scotland) Limited				United Kingdom				F43I396OIS	.ALPHA.1-PROTEINASE INHIBITOR HUMAN	F43I396OIS	https://ginas.ncats.nih.gov/ginas/app/substances?q=ALPHA%201-ANTITRYPSIN	approximate		Alpha-1 antitrypsin deficiency	5784	done	
Tretinoin	Treatment of T-cell non-Hodgkin's lymphoma	Tretinoin	TRETINOIN	Atra-Iv	4/11/03	Designated			N/A	N/A	"Antigenics, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0024180AA	Tretinoin	5688UTC01R								MISSING	T-cell non-Hodgkin's lymphoma type not specified
Tretinoin	Treatment of acute and chronic leukemia.	Tretinoin	TRETINOIN	Atra-Iv	1/14/93	Designated			N/A	N/A	"Antigenics, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0024180AA	Tretinoin	5688UTC01R						Acute leukemia of ambiguous lineage	8638	approximate	chronic leukemia of undetermined origin
Tretinoin	Treatment of acute and chronic leukemia.	Tretinoin	TRETINOIN	Atra-Iv	1/14/93	Designated			N/A	N/A	"Antigenics, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0024180AA	Tretinoin	5688UTC01R						Chronic myeloid leukemia	6105	approximate	chronic leukemia of undetermined origin
Tretinoin	Treatment of squamous metaplasia of the ocular surface epithelia (conjunctiva and/or cornea) with mucous deficiency and keratinization.	Tretinoin	TRETINOIN	n/a	4/15/85	Designated			N/A	N/A	"Hannan Ophthalmic Marketing Services, Inc"	Marshfield	Massachusetts	2050	USA	EXACT	0024180AA	Tretinoin	5688UTC01R								MISSING	
Triapine	Treatment of stage 1B to IV cervical cancer	3-aminopyridine-2-carboxaldehyde thiosemicarbazone	TRIAPINE	Triapine	11/8/17	Designated			N/A	N/A	"National Cancer Institute, Div of Cancer Treatment & Diagnosis (DCTD)"	9609 Medical Center Drive	Maryland	20850	USA	EXACT	0224511AA	Triapine	U4XIL4091C						Glassy cell carcinoma of the cervix	8437	approximate	type of cervical cancer not specified
Trientine HCl	"Treatment of patients with Wilson's disease who are intolerant, or inadequately responsive to penicillamine."	Trientine HCl	TRIENTINE HYDROCHLORIDE	Syprine	12/24/84	Designated/Approved	Approved for Orphan Indication		11/8/85	11/8/92	Merck Sharp & Dohme Research	West Point	Pennsylvania	19486	USA	EXACT	0064993AA	Trientine HCl	HC3NX54582						Wilson disease	7893	done	
Triheptanoin	Treatment of fatty acid disorders	Triheptanoin	TRIHEPTANOIN	Triheptanoim-Sasol Special Oil	5/26/06	Designated			N/A	N/A	Baylor Research Institute	Dallas	Texas	75226	USA	EXACT	0236011AA	Triheptanoin	2P6O7CFW5K								MISSING	fatty acid disorders not specified
Triheptanoin	Treatment of glycogen storage disorder II (Pompe disease)	Triheptanoin	TRIHEPTANOIN	Triheptanoin-Sasol Special Oil	2/1/08	Designated			N/A	N/A	Baylor Research Institute	Dallas	Texas	75204	USA	EXACT	0236011AA	Triheptanoin	2P6O7CFW5K						Glycogen storage disease type 2	5714	done	
Trimetazidine	Treatment of acute-on-chronic liver failure	Trimetazidine	TRIMETAZIDINE	n/a	3/15/18	Designated			N/A	N/A	"Martin Pharmaceuticals, Inc."	233 Broadway	Suite 1750	10279	USA	EXACT	0043196AA	Trimetazidine	N9A0A0R9S8						Transient infantile liver failure	10593	approximate	
Trimetrexate glucuronate	Treatment of Pneumocystis carinii pneumonia in AIDS patients.	Trimetrexate glucuronate	TRIMETREXATE GLUCURONATE	Neutrexin	5/15/86	Designated/Approved	Approved for Orphan Indication	"Concurrent leucovorin administration as an alternative therapy for the treatment of moderate to severe PCP in immunocompromised patients who are intolerant of, or are refractory to, trimethoprim sulfamethoxazole."	12/17/93	12/17/00	"Medimmune Oncology, Inc."	West Conshohocken	Pennsylvania	19428	USA	EXACT	0133664AA	Trimetrexate glucuronate	L137U4A79K						Pneumocystic carinii pneumonia	7409	done	
Trisaccharide A	"For use in ABO-incompatible solid organ transplantation, including kidney, heart, liver and pancreas."	Trisaccharides A and B	A-TRISACCHARIDE	Biosynject	4/20/87	Designated			N/A	N/A	"Chembiomed, Ltd."				Canada	EXACT	0790681AA	Trisaccharide A	P104QT2V1B								MISSING	"not a disease, a procedure"
Trisaccharide A	Prevention of ABO medical hemolytic reactions arising from ABO-incompatible bone marrow transplantation.	Trisaccharides A and B	A-TRISACCHARIDE	Biosynject	4/15/88	Designated			N/A	N/A	"Chembiomed, Ltd."				Canada	EXACT	0790681AA	Trisaccharide A	P104QT2V1B								MISSING	
Trisaccharide A	Treatment of moderate to severe clinical forms of hemolytic disease of the newborn arising from placental transfer of antibodies against blood group substances A and B.	Trisaccharides A and B	A-TRISACCHARIDE	Biosynject	4/12/87	Designated			N/A	N/A	"Chembiomed, Ltd."				Canada	EXACT	0790681AA	Trisaccharide A	P104QT2V1B								MISSING	
Trisaccharide A	"Treatment of moderate to very severe clinical forms of transfusion reactions arising from ABO incompatible transfusions of blood, blood products, and blood derivatives."	Trisaccharides A and B	A-TRISACCHARIDE	n/a	8/3/87	Designated/Withdrawn			N/A	N/A	"Chembiomed, Ltd."				Canada	EXACT	0790681AA	Trisaccharide A	P104QT2V1B								MISSING	Not a disease
Trisodium citrate concentration	For use in leukapheresis procedures.	Trisodium citrate concentration	"SODIUM CITRATE, UNSPECIFIED FORM"	Hemocitrate	6/15/95	Designated			N/A	N/A	"Hemotec Medical Products, Inc."	Johnston	Rhode Island	2919	USA	EXACT	0045921AA	Trisodium citrate	1Q73Q2JULR								MISSING	not a disease
Trisodium zinc Diethylenetriaminepentaacetate	"Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rate of elimination."	Trisodium zinc Diethylenetriaminepentaacetate	PENTETATE ZINC TRISODIUM	n/a	2/27/04	Designated			N/A	N/A	CustomCare Pharmacy	Tampa	Florida	33634	USA	EXACT	0091485AA	Trisodium zinc Diethylenetriaminepentaacetate	NXU65IC8PG								MISSING	not a disease
Troleandomycin	Treatment of severe steroid-requiring asthma.	Troleandomycin	TROLEANDOMYCIN	n/a	9/21/89	Designated/Withdrawn			N/A	N/A	"Szefler, Stanley M. M.D."	Denver	Colorado	80206	USA	EXACT	0039656AA	Troleandomycin	C4DZ64560D						Asthma	10246	done	
Trypan blue	Selectively staining epiretinal membranes during ophthalmic surgical vitrectomy procedures	Trypan blue	TRYPAN BLUE	Membraneblue	8/2/06	Designated/Approved	Approved for Orphan Indication	"For use as an aid in ophthalmic surgery by staining the epiretinal membranes during ophthalmic surgical vitrectomy procedures, facilitating removal of the tissue"	2/20/09	2/20/16	Dutch Ophthalmic Research Center Int'l BV				Netherlands	EXACT	0248737AA	Trypan blue	I2ZWO3LS3M								MISSING	procedure
Trypsinogen	Treatment of pancreatic cancer	Trypsinogen/Chymotrypsinogen		n/a	6/19/17	Designated			N/A	N/A	Propanc Pty Ltd.	Camberwell			Australia				JZ7EJ8JU4B	TRYPSIN-1 | Chymotrypsinogen/trypsinogen	JZ7EJ8JU4B	https://ginas.ncats.nih.gov/ginas/app/substance/f7cb59ca | https://adisinsight.springer.com/drugs/800049438	approximate	Trypsinogen  is the precursor form or zymogen of trypsin- no entry for Trypsinogen in GINAS	Pancreatic cancer	9364	done	Not a rare disease
Tumor necrosis factor-binding protein 1	Treatment of symptomatic patients with AIDS including all patients with CD4 counts less than 200 cells per mm3.	Tumor necrosis factor-binding protein 1	PROTEIN	n/a	1/6/93	Designated			N/A	N/A	"EMD Serono, Inc."	Roackland	Massachusetts	2370	USA	LONGEST CONTAINS	0087274AA	protein	1IEO802L3J	ONERCEPT	1IEO802L3J	https://ginas.ncats.nih.gov/ginas/app/substances?q=R-HTBP-1	done		Congenital human immunodeficiency virus	10328	approximate	
Tumor necrosis factor-binding protein II	Treatment of symptomatic patients with the AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.	Tumor necrosis factor-binding protein II	PROTEIN	n/a	1/6/93	Designated			N/A	N/A	"EMD Serono, Inc."	Roackland	Massachusetts	2370	USA	LONGEST CONTAINS	0087274AA	protein	1IEO802L3J	ONERCEPT	1IEO802L3J	https://ginas.ncats.nih.gov/ginas/app/substances?q=R-HTBP-1	done		Congenital human immunodeficiency virus	10328	approximate	
Tuvirumab	Prophylaxis of hepatitis B reinfection in patients undergoing liver transplantation secondary to end-stage chronic hepatitis B infection.	Monoclonal antibody to hepatitis B virus (human)	TUVIRUMAB	n/a	6/17/91	Designated/Withdrawn			N/A	N/A	"Protein Design Labs, Inc."	Fremont	California	94555	USA	EXACT	1091710AA	Tuvirumab	31Z0AB5WNC								MISSING	Not a rare disease
Type 1 native bovine skin collagen	Treatment of diffuse systemic sclerosis	Type 1 native bovine skin collagen	BOS TAURUS SKIN	n/a	2/1/08	Designated			N/A	N/A	"arGentis Pharmaceuticals, LLC"	Memphis	Tennessee	38139	USA	LONGEST CONTAINS	0327457AA	bovine skin	7J12CD6O9L						Diffuse cutaneous systemic sclerosis	9751	done	
U-0126	Treatment of subarachnoid hemorrhage (SAH)	"1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene"	U-0126	n/a	8/3/17	Designated			N/A	N/A	Edvince AB	Lund			Sweden	EXACT	0942278AA	U-0126	8027P94HLL								MISSING	
UKRAIN	Treatment of pancreatic cancer	"5,5',5""-[Phosphinothioylidyne-tris(imino-2,1-ethanediyl)]tris[5-methylchelidoninium]trihydroide hexahydrochloride"	UKRAIN	n/a	8/20/03	Designated			N/A	N/A	Now Pharm AG					EXACT	0738783AA	UKRAIN	6251Q9UK1S						Pancreatic cancer	9364	done	Not a rare disease
UPADACITINIB	Treatment of Pediatric Crohn's disease	"(3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate"	UPADACITINIB	n/a	6/15/17	Designated			N/A	N/A	AbbVie	North Chicago	Illinois	60044	USA	EXACT	0847847AA	UPADACITINIB	4RA0KN46E0						Pediatric Crohn's disease	9856	done	
UPADACITINIB TARTRATE	Treatment of pediatric (aged 0 through 16 years) juvenile idiopathic arthritis (JIA) ILAR categories excluding systemic JIA	"(3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (2R,3R)-2,3-dihydroxybutanedioate"	UPADACITINIB TARTRATE	n/a	9/18/15	Designated			N/A	N/A	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0848168AA	UPADACITINIB TARTRATE	7KCW9IQM02						Juvenile idiopathic arthritis	3067	done	
USL-311	Treatment of glioblastoma multiforme (GBM).	"6-{4-[l-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide"	USL-311	n/a	2/11/16	Designated			N/A	N/A	"Upsher-Smith Laboratories, Inc."	Maple Grove	Minnesota	55369	USA	EXACT	1251123AA	USL-311	2BTG5MX2Q2						Glioblastoma	2491	done	
"Ubiquinol, coenzyme Q10, ubiquinone"	Treatment of pediatric congestive heart failure	"Ubiquinol, coenzyme Q10, ubiquinone"	UBIDECARENONE	Ubi-Q-Nol	4/12/04	Designated			N/A	N/A	"Gel-Tec, Division of Tishcon Corporation"	Westbury	New York	11590	USA	EXACT	0024282AA	coenzyme Q10	EJ27X76M46								MISSING	
Ubiquinone	Treatment of mitochondrial cytopathies.	Ubiquinone	UBIDECARENONE	Ubi-Q-Gel	12/14/99	Designated			N/A	N/A	"Gel-Tec, Division of Tishcon Corp."	Westbury	New York	11590	USA	EXACT	0024282AA	Ubiquinone	EJ27X76M46								MISSING	mitchondrial disease not specified
Urofollitropin	For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.	Urofollitropin	UROFOLLITROPIN	Metrodin	11/25/87	Designated/Approved	Approved for Orphan Indication		9/18/86	9/18/93	"EMD Serono, Inc."	Roackland	Massachusetts	2370	USA	EXACT	0142392AA	Urofollitropin	W9BB98U6HP						Polycystic ovarian syndrome	7421	done	
Urofollitropin	"For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism."	Urofollitropin	UROFOLLITROPIN	Fertinex	12/5/97	Designated/Withdrawn			N/A	N/A	"EMD Serono, Inc."	Rockland	Massachusetts	2370	USA	EXACT	0142392AA	Urofollitropin	W9BB98U6HP						"Hypogonadism, isolated, hypogonadotropic "	2897	approximate	
Urofollitropin	"For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism."	Urofollitropin	UROFOLLITROPIN	Fertinex	12/5/97	Designated/Withdrawn			N/A	N/A	"EMD Serono, Inc."	Rockland	Massachusetts	2370	USA	EXACT	0142392AA	Urofollitropin	W9BB98U6HP						 Hypothalamic dysfunction	2932	approximate	
Urogastrone	For acceleration of corneal epithelial regeneration and healing of stromal incisions from corneal transplant surgery.	Urogastrone	NEPIDERMIN	n/a	11/1/84	Designated			N/A	N/A	Chiron Vision	Claremont	California	91711	USA	EXACT	0006804AA	Urogastrone	TZK30RF92W								MISSING	Not a rare disease
Ursodeoxycholic acid	"Treatment of Niemann-Pick disease, type C"	Ursodeoxycholic acid	URSODIOL	n/a	4/26/18	Designated			N/A	N/A	IntraBio Inc.	270 Devon Road		7670	USA	EXACT	0020519AA	Ursodeoxycholic acid	724L30Y2QR						Niemann-Pick disease type C1 	7207	done	
Ursodeoxycholic acid	"Treatment of Niemann-Pick disease, type C"	Ursodeoxycholic acid	URSODIOL	n/a	4/26/18	Designated			N/A	N/A	IntraBio Inc.	270 Devon Road		7670	USA	EXACT	0020519AA	Ursodeoxycholic acid	724L30Y2QR						 Niemann-Pick disease type C2	3992	done	
Ursodiol	Management of the clinical signs and symptoms associated with primary biliary cirrhosis.	Ursodiol	URSODIOL	Actigall	2/19/91	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0020519AA	Ursodiol	724L30Y2QR						Primary biliary cholangitis	7459	done	
Ursodiol	Treatment of patients with primary biliary cirrhosis	Ursodiol	URSODIOL	Urso 250	6/20/91	Designated/Approved	Approved for Orphan Indication		12/10/97	12/10/04	"Aptalis Pharma US, Inc."	Bridgewater	New Jersey	8807	USA	EXACT	0020519AA	Ursodiol	724L30Y2QR						Primary biliary cholangitis	7459	done	
VALINE-VALINE-GANCICLOVIR	Treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HSV1 and HSV2.	valine-valine-ganciclovir	VALINE-VALINE-GANCICLOVIR	n/a	5/21/07	Designated			N/A	N/A	"Verenta Pharmaceuticals, Inc."	Leawood	Kansas	66211	USA	EXACT	1570667AA	VALINE-VALINE-GANCICLOVIR	ZW811N4EW6								MISSING	Not a rare disease
VELAFERMIN	Treatment of radiation induced oral mucositis	recombinant human fibroblast growth factor-20	VELAFERMIN	n/a	1/29/04	Designated/Withdrawn			N/A	N/A	CuraGen Corporation	Branford	Connecticut	6405	USA	EXACT	0265474AA	VELAFERMIN	6Z25C35927								MISSING	
VELDOREOTIDE ACETATE	Treatment of acromegaly	"cyclo(-y-aminobutyryl-L-phenylalanyl-L-tryptophanyl-D-tryptophanyl-L-lysyl-L-threonly-L-phenylalanyl-N-3-carboxypropyl)-glycine amide, acetate salt"	VELDOREOTIDE ACETATE	n/a	6/24/13	Designated			N/A	N/A	Aspireo Pharmaceuticals Limited	Ra'annana			Israel	EXACT	1803027AA	VELDOREOTIDE ACETATE	9F2286627L						Acromegaly	5725	done	
VENETOCLAX	Treatment of diffuse large B-cell lymphoma.	"4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide"	VENETOCLAX	n/a	3/27/14	Designated			N/A	N/A	AbbVie	North Chicago	Illinois	60064	USA	EXACT	0790283AA	VENETOCLAX	N54AIC43PW						Diffuse Large B-Cell Lymphoma	3178	done	
VENGLUSTAT	Treatment of Fabry's disease	"(3S)-1-azabicylo[2.2.2]oct-3yl {2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate"	VENGLUSTAT	n/a	8/26/14	Designated			N/A	N/A	Genzyme Corporation	Cambridge	Massachusetts	1242	USA	EXACT	1120270AA	VENGLUSTAT	BLP1XA3FZA						Fabry disease	6400	done	
VENGLUSTAT	Treatment of Gaucher disease	"(3S)-1-azabicyclo[2.2.2]oct-3-yl {2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate"	VENGLUSTAT	n/a	9/11/14	Designated			N/A	N/A	Genzyme	Cambridge	Massachusetts	2142	USA	EXACT	1120270AA	VENGLUSTAT	BLP1XA3FZA						Gaucher disease	8233	done	
VERUCERFONT	Treatment of congenital adrenal hyperplasia (CAH)	"2,5-dimethyl-3-[2-methyl-4-(methyloxy)phenyl]-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-"	VERUCERFONT	n/a	1/15/15	Designated			N/A	N/A	"Neurocrine Biosciences, Inc."	San Diego	California	92130	USA	EXACT	0304610AA	VERUCERFONT	X60608B091						Congenital adrenal hyperplasia	1467	done	
VESTRONIDASE ALFA	"Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)"	recombinant human beta-glucuronidase	VESTRONIDASE ALFA	n/a	2/16/12	Designated			N/A	N/A	"Ultragenyx Pharmaceutical, Inc."	Novato	California	94949	USA	EXACT	1217738AA	VESTRONIDASE ALFA	7XZ4062R17						Mucopolysaccharidosis type VII	7096	done	
VK-0214	Treatment of X-linked adrenoleukodystrophy.	"Propanoic acid, 2,2-dimethyl-,1,1'-[[[[4-[[4-hydroxy-3-(phenylmethyl)phenyl]methyl]-3,5-dimethylphenoxy]methyl]phosphinylidene]bis(oxymethylene)] ester"	VK-0214	n/a	12/5/16	Designated			N/A	N/A	"Viking Therapeutics, Inc."	San Diego	California	92130	USA	EXACT	1800324AA	VK-0214	BYT6883X9X						X-linked adrenoleukodystrophy	5758	done	
VLX-1570	Treatment of multiple myeloma	"(3E,5E)-3,5-bis[(4-fluoro-3-nitrophenyl)methylidene]-1-(prop-2-enoyl)azepan-4-0ne"	VLX-1570	n/a	4/30/14	Designated			N/A	N/A	VivoLux AB				Sweden	EXACT	1101059AA	VLX-1570	K6067N5M6N						Multiple myeloma	7108	done	
VMD-928	Treatment of pancreatic cancer	"4-{[4-Amino-3-(4-cyclohexylpiperazin-1-yl)-9,10-dioxo-9,10-dihydroanthracen-1-yl]amino}benzoic acid"	VMD-928	n/a	4/11/18	Designated			N/A	N/A	"VM Oncology, LLC"	45535 Northport Loop East		94538	USA	EXACT	0114418AB	VMD-928	1JT6DVS51P						Pancreatic cancer	9364	done	Not a rare disease
VONVENDI	Treatment of von Willebrand disease.	recombinant von Willebrand factor (rhVWF)	VONICOG ALFA	n/a	11/23/10	Designated/Approved	Approved for Orphan Indication	Indicated for on-demand treatment and control of bleeding episodes in adults diagnosed with von Willebrand disease (VWD)	12/8/15	12/8/22	"Baxalta US, Inc."	Westlake Village	California	91362	USA	EXACT	1081352AA	VONVENDI	5PKM8P0G5I						Von Willebrand disease	7867	done	
VT-1129	Treatment of cryptococcal meningitis	selective inhibitor of fungal lanosterol demethylase	VT-1129	n/a	8/19/14	Designated			N/A	N/A	"Viamet Pharmaceuticals, Inc."	Durham	North Carolina	27703	USA	EXACT	1195728AA	VT-1129	7WJ1XH4Z6A								MISSING	
VT-270	"Treatment of Niemann Pick disease, type C."	2-hydroxypropyl-B-cyclodextrin	HYDROXYPROPYL BETADEX (0.6 HYDROXYPROPYL RESIDUES PER GLUCOSE)	Kleptose	2/18/13	Designated			N/A	N/A	"Vtesse, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	1029987AA	VT-270	8W6Q67R6NX						Niemann-Pick disease type C1 	7207	done	
VT-270	"Treatment of Niemann Pick disease, type C."	2-hydroxypropyl-B-cyclodextrin	HYDROXYPROPYL BETADEX (0.6 HYDROXYPROPYL RESIDUES PER GLUCOSE)	Kleptose	2/18/13	Designated			N/A	N/A	"Vtesse, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	1029987AA	VT-270	8W6Q67R6NX						 Niemann-Pick disease type C2	3992	done	
VX-210	Treatment of acute spinal cord injury	recombinant deriative of C3 transferase	PRACONASE	Cethrin	11/18/05	Designated			N/A	N/A	"Vertex Pharmaceuticals, Inc."	Boston	Massachusetts	2210	USA	EXACT	1803118AA	VX-210	B36V5S1RFJ								MISSING	
VX-445	Treatment of Cystic Fibrosis	"N-(1,3-dimethyl-1H-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide/tezacaftor/ivacaftor"	VX-445	n/a	8/29/18	Designated			N/A	N/A	Vertex Pharmaceuticals Inc.	50 Northern Avenue	Massachusetts	2210	USA	EXACT	1797279AA	VX-445	RRN67GMB0V						Cystic fibrosis	6233	done	
VX-659 POTASSIUM	Treatment of Cystic Fibrosis	"potassium (benzenesulfonyl)({[6-(3-{2-[1-(trifluoromethyl)cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridin-3-yl]carbonyl})azanide/tezacaftor/ivacaftor"	VX-659 POTASSIUM	n/a	5/23/18	Designated			N/A	N/A	Vertex Pharmaceuticals Inc.	50 Northern Avenue		2210	USA	EXACT	0115469AB	VX-659 POTASSIUM	VY7D8MTV72						Cystic fibrosis	6233	done	
Vaccinia Immune Globulin (Human) Intravenous	Treatment of complications of vaccinia vaccination	Vaccinia Immune Globulin (Human) Intravenous	HUMAN VACCINIA VIRUS IMMUNE GLOBULIN	Cnj-016	6/18/04	Designated/Approved	Approved for Orphan Indication	"treatment and/or modification of the following conditions, which are complications resulting from smallpox vaccination: Eczema vaccinatum Progressive vaccinia Severe generalized vaccinia Vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions Aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in cases of isolated keratitis), mouth, or other areas where vaccinia infection would constitute a special hazard."	5/2/05	N/A	Cangene Corporation	"Winnipeg, ManitobaR3T 5Y3"			Canada	LONGEST CONTAINS	0322907AA	Vaccinia Immune Globulin	7UB4J759TD								MISSING	
Valine	Treatment of hyperphenylalaninemia	"Valine, isoleucine and leucine"	VALINE	Vil	1/5/96	Designated			N/A	N/A	Leas Research Products	North Haven	Connecticut	6473	USA	EXACT	0012464AA	Valine	HG18B9YRS7						Maternal hyperphenylalaninemia 	3413	approximate	
Valine	Treatment of hyperphenylalaninemia	"Valine, isoleucine and leucine"	VALINE	Vil	1/5/96	Designated			N/A	N/A	Leas Research Products	North Haven	Connecticut	6473	USA	EXACT	0012464AA	Valine	HG18B9YRS7						 6-pyruvoyl-tetrahydropterin synthase deficiency 	5682	approximate	
Valine	Treatment of hyperphenylalaninemia	"Valine, isoleucine and leucine"	VALINE	Vil	1/5/96	Designated			N/A	N/A	Leas Research Products	North Haven	Connecticut	6473	USA	EXACT	0012464AA	Valine	HG18B9YRS7						 GTP cyclohydrolase I deficiency 	2844	approximate	
Valine	Treatment of hyperphenylalaninemia	"Valine, isoleucine and leucine"	VALINE	Vil	1/5/96	Designated			N/A	N/A	Leas Research Products	North Haven	Connecticut	6473	USA	EXACT	0012464AA	Valine	HG18B9YRS7						 Dihydropteridine reductase deficiency 	4319	approximate	
Valine	Treatment of hyperphenylalaninemia	"Valine, isoleucine and leucine"	VALINE	Vil	1/5/96	Designated			N/A	N/A	Leas Research Products	North Haven	Connecticut	6473	USA	EXACT	0012464AA	Valine	HG18B9YRS7						 Hyperphenylalaninemia due to dehydratase deficiency	2843	approximate	
"Valine, isoleucine and leucine"	Treatment of hyperphenylalaninemia	"Valine, isoleucine and leucine"	ISOLEUCINE	Vil	1/5/96	Designated			N/A	N/A	Leas Research Products	North Haven	Connecticut	6473	USA	EXACT	0012668AA	isoleucine	04Y7590D77						Maternal hyperphenylalaninemia 	3413	approximate	
"Valine, isoleucine and leucine"	Treatment of hyperphenylalaninemia	"Valine, isoleucine and leucine"	ISOLEUCINE	Vil	1/5/96	Designated			N/A	N/A	Leas Research Products	North Haven	Connecticut	6473	USA	EXACT	0012668AA	isoleucine	04Y7590D77						 6-pyruvoyl-tetrahydropterin synthase deficiency 	5682	approximate	
"Valine, isoleucine and leucine"	Treatment of hyperphenylalaninemia	"Valine, isoleucine and leucine"	ISOLEUCINE	Vil	1/5/96	Designated			N/A	N/A	Leas Research Products	North Haven	Connecticut	6473	USA	EXACT	0012668AA	isoleucine	04Y7590D77						 GTP cyclohydrolase I deficiency 	2844	approximate	
"Valine, isoleucine and leucine"	Treatment of hyperphenylalaninemia	"Valine, isoleucine and leucine"	ISOLEUCINE	Vil	1/5/96	Designated			N/A	N/A	Leas Research Products	North Haven	Connecticut	6473	USA	EXACT	0012668AA	isoleucine	04Y7590D77						 Dihydropteridine reductase deficiency 	4319	approximate	
"Valine, isoleucine and leucine"	Treatment of hyperphenylalaninemia	"Valine, isoleucine and leucine"	ISOLEUCINE	Vil	1/5/96	Designated			N/A	N/A	Leas Research Products	North Haven	Connecticut	6473	USA	EXACT	0012668AA	isoleucine	04Y7590D77						 Hyperphenylalaninemia due to dehydratase deficiency	2843	approximate	
"Valproic acid, sodium"	Treatment of familial adenomatous polyposis	"Valproic acid, sodium"	VALPROATE SODIUM	Peac(R)	6/24/05	Designated/Withdrawn			N/A	N/A	Topotarget A/S	Copenhagen			Denmark	EXACT	0032542AA	"Valproic acid, sodium"	5VOM6GYJ0D						Familial adenomatous polyposis	6408	done	
Varicella Zoster Immune Globulin (Human)	"Passive immunization for the treatment of exposed, susceptible individuals who are at risk of complications from varicella"	Varicella Zoster Immune Globulin (Human)	HUMAN VARICELLA-ZOSTER IMMUNE GLOBULIN	Varizig	11/7/06	Designated/Approved	Approved for Orphan Indication	Post exposure prophylaxis of varicella in high risk individuals to reduce the severity of varicella	12/20/12	12/20/19	"Cangene bioPharma, Inc."	Manitoba R3T5Y3			Canada	EXACT	0127844AA	Varicella Zoster Immune Globulin (Human)	33T61IWL27						Herpes zoster oticus	7525	approximate	
Vasoactive intestinal polypeptide	Treatment of acute esophageal food impaction.	Vasoactive intestinal polypeptide	VASOACTIVE INTESTINAL PEPTIDE	n/a	6/23/93	Designated			N/A	N/A	Research Triangle Pharmaceuticals	Durham	North Carolina	27713	USA	EXACT	0094735AA	Vasoactive intestinal polypeptide	6J2WVD66KR								MISSING	
Vasomera	"Treatment of cardiomyopathy associated with dystrophinopathies; Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy BMD), and X-linked dilated cardiomyopathy (XL-dCMP)."	Vasomera	PB-1046	n/a	11/19/15	Designated			N/A	N/A	"PhaseBio Pharmaceuticals, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	1267045AA	Vasomera	200AW54D93						Duchenne muscular dystrophy 	6291	done	
Vasomera	"Treatment of cardiomyopathy associated with dystrophinopathies; Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy BMD), and X-linked dilated cardiomyopathy (XL-dCMP)."	Vasomera	PB-1046	n/a	11/19/15	Designated			N/A	N/A	"PhaseBio Pharmaceuticals, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	1267045AA	Vasomera	200AW54D93						 Becker muscular dystrophy 	5900	done	
Vasomera	"Treatment of cardiomyopathy associated with dystrophinopathies; Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy BMD), and X-linked dilated cardiomyopathy (XL-dCMP)."	Vasomera	PB-1046	n/a	11/19/15	Designated			N/A	N/A	"PhaseBio Pharmaceuticals, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	1267045AA	Vasomera	200AW54D93						 Dilated cardiomyopathy	221	done	
Vedolizumab	Treatment of graft versus host disease	Vedolizumab	VEDOLIZUMAB	n/a	3/21/17	Designated			N/A	N/A	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0263741AA	Vedolizumab	9RV78Q2002						Chronic graft versus host disease 	10964	approximate	
Vedolizumab	Treatment of graft versus host disease	Vedolizumab	VEDOLIZUMAB	n/a	3/21/17	Designated			N/A	N/A	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0263741AA	Vedolizumab	9RV78Q2002						 Acute graft versus host disease	6544	approximate	
Vibrilase	"Debridement of severe, deep dermal burns in hospitalized patients"	vibriolysin		Vibrilase	6/16/06	Designated			N/A	N/A	BioMarin Pharmaceutical Inc.	Novato	California	94949	USA					Vibriolysin	NA	https://adisinsight.springer.com/drugs/800015283 |  https://www.ncbi.nlm.nih.gov/pubmed/8245109	done				MISSING	
Vibrio alginolyticus collagenase	Treatment of advanced Dupuytren's disease (Dupuytren's contracture)	Vibrio alginolyticus collagenase	MICROBIAL COLLAGENASE	n/a	10/12/16	Designated			N/A	N/A	Fidia Farmaceutici S.p.A.	Abano Terme PD			Italy	EXACT	0110875AB	Vibrio alginolyticus collagenase	FY14NZH2SF						Familial Dupuytren contracture	12165	done	Not a rare disease
Virulizin	Treatment of pancreatic cancer.	Virulizin	BOS TAURUS BILE IMMUNOMODULATOR	Virulizin	2/1/01	Designated			N/A	N/A	"ZOR Pharmaceuticals, LLC"	Wilmington	North Carolina	28403	USA	EXACT	0733391AA	Virulizin	E5SF1Z7U1S						Pancreatic cancer	9364	done	Not a rare disease
Wellferon	Treatment of human papillomavirus in patients with severe resistant/recurrent respiratory (laryngeal) papillomatosis.	Interferon alfa-nl	INTERFERON ALFA-N1	Wellferon	10/16/87	Designated/Withdrawn			N/A	N/A	Glaxo Wellcome Inc.	Research Triangle Park	North Carolina	27709	USA	EXACT	0233727AA	Wellferon	41697D4Z5C						Recurrent respiratory papillomatosis 	111	done	
Wellferon	Treatment of human papillomavirus in patients with severe resistant/recurrent respiratory (laryngeal) papillomatosis.	Interferon alfa-nl	INTERFERON ALFA-N1	Wellferon	10/16/87	Designated/Withdrawn			N/A	N/A	Glaxo Wellcome Inc.	Research Triangle Park	North Carolina	27709	USA	EXACT	0233727AA	Wellferon	41697D4Z5C						 Laryngeal papillomatosis	6864	done	
Wharton's jelly mesenchymal stem cells	Treatment of graft-versus-host disease	Wharton's jelly mesenchymal stem cells	MESENCHYMAL STEM CELLS	n/a	9/27/16	Designated			N/A	N/A	Midwest Stem Cell Therapy Center	Kansas City	Kansas	66160	USA	LONGEST CONTAINS	1339839AA	mesenchymal stem cells	3FXW1IW7WT	WHARTON JELLY DERIVED MESENCHYMAL STEM CELL	3FXW1IW7WT	https://ginas.ncats.nih.gov/ginas/app/substance/7d6e7c6d | https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3171943 | https://adisinsight.springer.com/drugs/800052517	done		Chronic graft versus host disease 	10964	approximate	
Wharton's jelly mesenchymal stem cells	Treatment of graft-versus-host disease	Wharton's jelly mesenchymal stem cells	MESENCHYMAL STEM CELLS	n/a	9/27/16	Designated			N/A	N/A	Midwest Stem Cell Therapy Center	Kansas City	Kansas	66160	USA	LONGEST CONTAINS	1339839AA	mesenchymal stem cells	3FXW1IW7WT	WHARTON JELLY DERIVED MESENCHYMAL STEM CELL	3FXW1IW7WT	https://ginas.ncats.nih.gov/ginas/app/substance/7d6e7c6d | https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3171943 | https://adisinsight.springer.com/drugs/800052517	done		 Acute graft versus host disease	6544	approximate	
Wilate	Treatment of von Willebrand disease except for surgical and/or invasive procedures in patients with von Willebrand disease in whom desmopressin is either ineffective or contraindicated	Human plasma coagulation Factor VIII and human plasma von Willebrand Factor	VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN)	Wilate	4/18/07	Designated/Approved	Approved for Orphan Indication	Treatment of spontaneous or trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD) as well as patients with mild or moderate VWD in whom the use of desmopressin is known or suspected to be ineffective or contraindicated	12/4/09	N/A	"Octapharma USA, Inc."	Hoboken	New Jersey	7030	USA	EXACT	0364318AA	Wilate	5T6B772R4Q						Von Willebrand disease	7867	done	
Winrho	Treatment of immune thrombocytopenic purpura.	Rho (D) immune globulin intravenous (human)	HUMAN RHO(D) IMMUNE GLOBULIN	Winrho Sd	11/9/93	Designated/Approved	Approved for Orphan Indication	Treatment of adults and children with chronic and acute immune thrombocytopenic purpura.	3/24/95	3/24/02	"Rh Pharmaceuticals, Inc."				Canada	EXACT	0322894AA	Winrho	48W7181FLP						Idiopathic thrombocytopenic purpura	5194	approximate	
XMAB5871	Treatment of immunoglobulin G4-related disease	"humanized anti-CD19, Fc engineered, monoclonal antibody with enhanced binding to FcyRIIb"	XMAB-5871	Xmab(R)5871	5/9/17	Designated			N/A	N/A	"Xencor, Inc."	Monrovia	California	91016	USA	EXACT	1216804AA	XMAB5871	IGUVWLGHST						IgG4-related disease	12521	done	
Xenogeneic hepatocytes	Treatment of severe liver failure.	Xenogeneic hepatocytes		Hepatassist Liver Assist System	11/27/98	Designated			N/A	N/A	"Circe Biomedical, Inc."	Lexington	Massachusetts	2421	USA								PROBLEM	can't find			MISSING	Not a rare disease
YTTRIUM Y-90 CLIVATUZUMAB TETRAXETAN	Treatment of pancreatic cancer	90Y-hPAMA4	YTTRIUM Y-90 CLIVATUZUMAB TETRAXETAN	Pan-Cide	1/29/04	Designated			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA	EXACT	0343851AA	YTTRIUM Y-90 CLIVATUZUMAB TETRAXETAN	2L271110ED						Pancreatic cancer	9364	done	Not a rare disease
Yersinia pestis plague recombinant antigen (rF1V; F1 capsular protein fused to V antigen; E. coli) vaccine with aluminum hydroxide	Prevention of plague (Yersinia pestis)	Yersinia pestis plague recombinant antigen (rF1V; F1 capsular protein fused to V antigen; E. coli) vaccine with aluminum hydroxide	ALUMINUM HYDROXIDE	n/a	11/30/16	Designated			N/A	N/A	"DynPort Vaccine Company, LLC, a CSRA Comapny"	Frederick	Maryland	21702	USA	LONGEST CONTAINS	0033614AA	aluminum hydroxide	5QB0T2IUN0						Bubonic plague	183	done	
Yttrium (90Y) antiferritin polyclonal antibodies	Treatment of Hodgkin's disease.	Yttrium (90Y) antiferritin polyclonal antibodies	YTTRIUM	Ferritarg P	9/18/06	Designated			N/A	N/A	"Alissa Pharma, LLC"	Englewood	New Jersey	7631	USA	LONGEST CONTAINS	0514954AA	Yttrium	58784XQC3Y						Hodgkin lymphoma	2714	done	
"ZOLEDRONATE D,L-LYSINE MONOHYDRATE"	Treatment of complex regional pain syndrome (CRPS)	"zoledronate D,L-lysine monohydrate (ZLM)"	"ZOLEDRONATE D,L-LYSINE MONOHYDRATE"	n/a	4/15/15	Designated			N/A	N/A	Thar Pharmaceuticals	Pittsburgh	Pennsylvania	15238	USA	EXACT	1577099AA	"ZOLEDRONATE D,L-LYSINE MONOHYDRATE"	IL1N7FSO1U						Complex regional pain syndrome	4647	done	
ZURETINOL ACETATE	Treatment of Leber congential amaurosis (LCA) due to inherited mutations in RPE65 (encoding the protein retinal pigment epithelial protein 65) or LRAT (encoding the enzyme lecithin:retinol acyltransferase)genes.	"(2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenyl acetate 9-cis-retinyl acetate (API)"	ZURETINOL ACETATE	n/a	12/2/10	Designated			N/A	N/A	"QLT, Inc."	V5T 4T5			Canada	EXACT	0728303AA	ZURETINOL ACETATE	2K3YP54BYU						Leber congenital amaurosis	634	done	
ZURETINOL ACETATE	Treatment of retinitis pigmentosa	"(2E, 4E, 6Z, 8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-l-yl) nona-2,4,6,8-tetraen-l-yl acetate"	ZURETINOL ACETATE	n/a	12/2/10	Designated			N/A	N/A	QLT Inc.				Canada	EXACT	0728303AA	ZURETINOL ACETATE	2K3YP54BYU						Retinitis pigmentosa	5694	done	
Zalcitabine	Treatment of AIDS.	Zalcitabine	ZALCITABINE	n/a	12/9/86	Designated			N/A	N/A	"National Cancer Institute, DCT"	Bethesda	Maryland	20892	USA	EXACT	0158145AA	Zalcitabine	6L3XT8CB3I						Congenital human immunodeficiency virus	10328	approximate	
Zalcitabine	Treatment of AIDS.	Zalcitabine	ZALCITABINE	Hivid	6/28/88	Designated/Approved	Approved for Orphan Indication	Combination therapy with zidovudine is indicated for the treatment of adult patients with advanced HIV infection (CD4 count < 300) who have demonstrated malignant clinical or immunologic deterioration.	6/19/92	6/19/99	"Hoffmann-La Roche, Inc."	Nutley	New Jersey	7110	USA	EXACT	0158145AA	Zalcitabine	6L3XT8CB3I						Congenital human immunodeficiency virus	10328	approximate	
Zenapax	Prevention of acute graft-vs-host disease following bone marrow transplantation.	Humanized anti-tac	DACLIZUMAB	Zenapax	3/5/93	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	Nutley	New Jersey	7110	USA	EXACT	0226744AA	Zenapax	CUJ2MVI71Y						Acute graft versus host disease	6544	done	
Zinc acetate	Treatment of Wilson's disease.	Zinc acetate	ZINC ACETATE	Galzin	11/6/85	Designated/Approved	Approved for Orphan Indication	For maintenance treatment of patients with Wilson's disease who have been initially treated with a chelating agent.	1/28/97	1/28/04	Lemmon Company	Kulpsville	Pennsylvania	19443	USA	EXACT	0029107AA	Zinc acetate	FM5526K07A						Wilson disease	7893	done	
Zoledronate	Treatment of tumor induced hypercalcemia.	Zoledronate	ZOLEDRONIC ACID ANHYDROUS	"Zometa, Zabel"	8/18/00	Designated/Approved	Approved for Orphan Indication	Treatment of hypercalcemia of malignancy.	8/20/01	8/20/08	Novartis Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0271987AA	Zoledronate	70HZ18PH24								MISSING	
"[4-(4-{1-[2-(2-{2-[2-(2-{2-[2-(4-guanidinomethyl-phenoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethyl]-1H-[1,2,3]triazol-4-ylmethoxy}-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]-acetic acid"	Treatment of neuroblastoma	"[4-(4-{1-[2-(2-{2-[2-(2-{2-[2-(4-guanidinomethyl-phenoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethyl]-1H-[1,2,3]triazol-4-ylmethoxy}-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]-acetic acid"	"(4-(4-(1-(2-(2-(2-(2-(2-(2-(2-(4-GUANIDINOMETHYL-PHENOXY)-ETHOXY)-ETHOXY)-ETHOXY)-ETHOXY)-ETHOXY)-ETHOXY)-ETHYL)-1H-(1,2,3)TRIAZOL-4-YLMETHOXY)-3,5-DIIODO-PHENOXY)-3,5-DIIODO-PHENYL)-ACETIC ACID"	n/a	10/17/18	Designated			N/A	N/A	"NanoPharmaceuticals, LLC"	1 Discovery Place	New York	12144	USA	EXACT	0117194AB	"(4-(4-(1-(2-(2-(2-(2-(2-(2-(2-(4-GUANIDINOMETHYL-PHENOXY)-ETHOXY)-ETHOXY)-ETHOXY)-ETHOXY)-ETHOXY)-ETHOXY)-ETHYL)-1H-(1,2,3)TRIAZOL-4-YLMETHOXY)-3,5-DIIODO-PHENOXY)-3,5-DIIODO-PHENYL)-ACETIC ACID"		"[4-(4-{1-[2-(2-{2-[2-(2-{2-[2-(4-guanidinomethyl-phenoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethyl]-1H-[1,2,3]triazol-4-ylmethoxy}-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]-acetic acid"	NA	http://www.checkorphan.org/treatments/4990e96a4acf42a3fae70f4a86283a5a	PROBLEM	can't find	Neuroblastoma	7185	done	
a-4250	Treatment of primary biliary cirrhosis	"(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid"	A-4250	n/a	10/31/12	Designated			N/A	N/A	Albireo AB				Sweden	EXACT	1301333AA	a-4250	2W150K0UUC						Primary biliary cholangitis	7459	done	
"aadeno-associated viral vector, serotype 2, containing the human choroideremia gene encoding human Rab escort protein 1"	Treatment of choroideremia due to mutations in the human choroideremia gene (CHM)	"aadeno-associated viral vector, serotype 2, containing the human choroideremia gene encoding human Rab escort protein 1"	PROTEIN	n/a	9/12/13	Designated			N/A	N/A	"Sparks Therapeutics, Inc."	Philadelphia	Pennsylvania	19104	USA	LONGEST CONTAINS	0087274AA	protein					PROBLEM	can't find	Choroideremia	6061	done	
aag-1	Treatment of glioma.	"N-(4-Methoxyphenyl)-N,2,6-trimethylfuro[2,3-d] pyrimidin-4-amine"	AAG-1	n/a	2/18/16	Designated			N/A	N/A	"Flag Therapeutics, Inc."	Raleigh	North Carolina	27617	USA	EXACT	1577168AA	aag-1	LB2951OCS5						Glioma	6513	done	
abatacept	Prevention of Graft versus Host Disease	abatacept	ABATACEPT	Orencia	12/26/17	Designated			N/A	N/A	Bristol-Myers Squibb Co.	P.O Box 4000	Princeton	8543	USA	EXACT	0258173AA	abatacept	7D0YB67S97						Chronic graft versus host disease	10964	approximate	type of GVHD (acute or chronic) is not specified
abatacept	Prevention of Graft versus Host Disease	abatacept	ABATACEPT	Orencia	12/26/17	Designated			N/A	N/A	Bristol-Myers Squibb Co.	P.O Box 4000	Princeton	8543	USA	EXACT	0258173AA	abatacept	7D0YB67S97						Acute graft versus host disease	6544	approximate	type of GVHD (acute or chronic) is not specified
abatacept	Treatment of type 1 diabetes mellitus patients with residual beta cell function	abatacept	ABATACEPT	Orencia	5/30/13	Designated			N/A	N/A	Orban Biotech LLC	Brookline	Massachusetts	2446	USA	EXACT	0258173AA	abatacept	7D0YB67S97						Diabetes mellitus type 1	10268	done	not a rare disease
aceneuramic acid	Treatment of hereditary inclusion body myopathy	aceneuramic acid	ACENEURAMIC ACID	n/a	9/23/11	Designated			N/A	N/A	"Ultragenyx Pharmaceutical, Inc."	Novato	California	94949	USA	EXACT	0300981AA	aceneuramic acid	GZP2782OP0						Inclusion body myopathy 2	9493	done	
acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-cysteinyl-D-glutaminyl-D-cysteinyl-D-arginyl-D-arginyl-D-lysyl-Dasparaginylamide disulfide	Treatment of pancreatic cancer.	acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-cysteinyl-D-glutaminyl-D-cysteinyl-D-arginyl-D-arginyl-D-lysyl-Dasparaginylamide disulfide	GO-203-2C	n/a	2/18/11	Designated/Withdrawn			N/A	N/A	"Genus Oncology, LLC"	Chicago	Illinois	60614	USA	EXACT	0761739AA	acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-cysteinyl-D-glutaminyl-D-cysteinyl-D-arginyl-D-arginyl-D-lysyl-Dasparaginylamide disulfide	5YSY733NA3						Pancreatic cancer	9364	done	Not a rare disease
acetylcysteine	For the intravenous treatment of moderate to severe acetaminophen overdose	acetylcysteine	ACETYLCYSTEINE	Acetadote	10/19/01	Designated/Approved	Approved for Orphan Indication	"For the use of Acetadote(registered TM) Injection, administered intravenously within 8 to 10 hours after ingestion of a potentially heptotoxic quantity of acetaminophen, to prevent or lessen hepatic injur"	1/23/04	1/23/11	"Cumberland Pharmaceuticals, Inc."	Nashville	Tennessee	37203	USA	EXACT	0029969AA	acetylcysteine	WYQ7N0BPYC								MISSING	not a disease
acetylcysteine	Preventing hepatic injury from acetaminophin overdose	acetylcysteine effervescent tablets for oral solution	ACETYLCYSTEINE	Cetylev	2/24/15	Designated/Approved	Approved for Orphan Indication	Indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion	1/29/16	N/A	"Arbor Pharmaceuticals, Inc."	Atlanta	Georgia	30328	USA	EXACT	0029969AA	acetylcysteine	WYQ7N0BPYC								MISSING	
acyclovir	Treatment of acute herpetic keratitis caused by Herpes Simplex Virus type 1 and 2	acyclovir	ACYCLOVIR	n/a	12/13/10	Designated			N/A	N/A	Fera Pharmaceuticals	Locust Valley	New York	11560	USA	EXACT	0066773AA	acyclovir	X4HES1O11F						Vernal keratitis	10531	approximate	
acyclovir	Treatment of herpetic keratitis	acyclovir	ACYCLOVIR	n/a	9/16/10	Designated/Withdrawn			N/A	N/A	GlaxoSmithKline	Philadelphia	Pennsylvania	19101	USA	EXACT	0066773AA	acyclovir	X4HES1O11F								MISSING	
acyclovir	Treatment of herpetic keratitis.	acyclovir	ACYCLOVIR	n/a	5/3/16	Designated			N/A	N/A	Cumulus Pharmaceuticals LLC	Cheyenne	Wyoming	82001	USA	EXACT	0066773AA	acyclovir	X4HES1O11F								MISSING	
adalimumab	Treatment of Behcet's disease	adalimumab	"ADALIMUMAB, LICENSE HOLDER UNSPECIFIED"	n/a	7/10/14	Designated			N/A	N/A	Mucora				Israel	EXACT	0247176AA	adalimumab	FYS6T7F842						Behçet disease	848	done	
adalimumab	Treatment of juvenile rheumatoid arthritis	adalimumab	"ADALIMUMAB, LICENSE HOLDER UNSPECIFIED"	Humira	3/21/05	Designated/Approved	Approved for Orphan Indication	Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years to 4 years of age.	9/30/14	9/30/21	AbbVie Inc.	North Chicago	Illinois	60064	USA	EXACT	0247176AA	adalimumab	FYS6T7F842						Juvenile idiopathic arthritis	3067	done	Not a rare disease
adalimumab	Treatment of juvenile rheumatoid arthritis	adalimumab	"ADALIMUMAB, LICENSE HOLDER UNSPECIFIED"	Humira	3/21/05	Designated/Approved	Approved for Orphan Indication	Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older.	2/21/08	2/21/15	AbbVie Inc.	North Chicago	Illinois	60064	USA	EXACT	0247176AA	adalimumab	FYS6T7F842						Juvenile idiopathic arthritis	3067	done	Not a rare disease
adalimumab	Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)	adalimumab	"ADALIMUMAB, LICENSE HOLDER UNSPECIFIED"	Humira	5/13/15	Designated/Approved	Approved for Orphan Indication	Treatment of moderate to severe hidradenitis suppurativa	9/9/15	9/9/22	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0247176AA	adalimumab	FYS6T7F842						Hidradenitis suppurativa	6658	done	
adalimumab	"Treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis"	adalimumab	"ADALIMUMAB, LICENSE HOLDER UNSPECIFIED"	Humira	5/13/14	Designated/Approved	Approved for Orphan Indication	"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients"	6/30/16	6/30/23	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0247176AA	adalimumab	FYS6T7F842						Panuveitis 	8577	approximate	
adalimumab	"Treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis"	adalimumab	"ADALIMUMAB, LICENSE HOLDER UNSPECIFIED"	Humira	5/13/14	Designated/Approved	Approved for Orphan Indication	"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients"	6/30/16	6/30/23	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0247176AA	adalimumab	FYS6T7F842						 Anterior uveitis 	10941	approximate	
adalimumab	"Treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis"	adalimumab	"ADALIMUMAB, LICENSE HOLDER UNSPECIFIED"	Humira	5/13/14	Designated/Approved	Approved for Orphan Indication	"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients"	6/30/16	6/30/23	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0247176AA	adalimumab	FYS6T7F842						 Posterior uveitis	4457	approximate	
adalimumab	Treatment of pediatric patients with ulcerative colitis	adalimumab	"ADALIMUMAB, LICENSE HOLDER UNSPECIFIED"	Humira	5/11/11	Designated			N/A	N/A	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0247176AA	adalimumab	FYS6T7F842						Pediatric ulcerative colitis	9857	done	
adegramotide	Treatment of brain cancer	nelatimotide and adegramotide (DSP-7888 dosing emulsion)	ADEGRAPEPIMUT-S	n/a	9/18/17	Designated			N/A	N/A	"Boston Biomedical, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	1310016AA	adegramotide	4XQ7W02EQ0						Anaplastic oligoastrocytoma	10637	approximate	brain cancer not specified
adeno-associated viral vector expressing the human vascular endothelial growth factor gene	"Treatment of critical limb ischemia in no-option patients where other procedures, grafts, or angioplasty are not indicated"	adeno-associated viral vector expressing the human vascular endothelial growth factor gene	VASCULAR ENDOTHELIAL GROWTH FACTOR	n/a	12/31/15	Designated			N/A	N/A	"Integene International Holding, LLC"	Miami	Florida	33136	USA	LONGEST CONTAINS	0261609AA	vascular endothelial growth factor	NZN256ZSV8								MISSING	
adeno-associated viral vector serotype Anc80 containing the truncated human ATP7B gene under the control of the human alpha-1 antitrypsin promoter	Treatment of Wilson's disease (WD)	adeno-associated viral vector serotype Anc80 containing the truncated human ATP7B gene under the control of the human alpha-1 antitrypsin promoter		n/a	9/7/17	Designated			N/A	N/A	Vivet Therapeutics SAS	Paris			France					VTX-801	NA	https://adisinsight.springer.com/drugs/800050389 | https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3171898	PROBLEM	absent from GINAS	Wilson disease	7893	done	
adeno-associated virus type 8 delivering a vector genome with human retinoschisin promoter (RS/IRBP) and the human retinoschisin cDNA (hRS)	Treatment of X-linked retinoschisis	adeno-associated virus type 8 delivering a vector genome with human retinoschisin promoter (RS/IRBP) and the human retinoschisin cDNA (hRS)		n/a	11/16/15	Designated			N/A	N/A	"Paul A. Sievig, MD, PhD, National Eye Institute, NIH"	Bethesda	Maryland	20892	USA								PROBLEM	can't find	Juvenile retinoschisis	4690	done	
adenoviral vector expressing the E.coli purine nucleoside phosphorylase gene and fludarabine	"Intratumoral treatment of anatomically accessible oral and pharyngeal cancers (lip, tongue, gum, floor of mouth, salivary gland, and other oral cavity)"	adenoviral vector expressing the E.coli purine nucleoside phosphorylase gene and fludarabine	PURINE NUCLEOSIDE PHOSPHORYLASE	n/a	6/8/15	Designated			N/A	N/A	"PNP Therapeutics, Inc."	Birmingham	Alabama	35203	USA	LONGEST CONTAINS	1309542AA	purine nucleoside phosphorylase	3WH6OPR0RH						Nasopharyngeal carcinoma 	7163	approximate	
adenoviral vector expressing the E.coli purine nucleoside phosphorylase gene and fludarabine	"Intratumoral treatment of anatomically accessible oral and pharyngeal cancers (lip, tongue, gum, floor of mouth, salivary gland, and other oral cavity)"	adenoviral vector expressing the E.coli purine nucleoside phosphorylase gene and fludarabine	PURINE NUCLEOSIDE PHOSPHORYLASE	n/a	6/8/15	Designated			N/A	N/A	"PNP Therapeutics, Inc."	Birmingham	Alabama	35203	USA	LONGEST CONTAINS	1309542AA	purine nucleoside phosphorylase	3WH6OPR0RH						" Oropharyngeal cancer, adult "	9358	approximate	
adenoviral vector expressing the E.coli purine nucleoside phosphorylase gene and fludarabine	"Intratumoral treatment of anatomically accessible oral and pharyngeal cancers (lip, tongue, gum, floor of mouth, salivary gland, and other oral cavity)"	adenoviral vector expressing the E.coli purine nucleoside phosphorylase gene and fludarabine	PURINE NUCLEOSIDE PHOSPHORYLASE	n/a	6/8/15	Designated			N/A	N/A	"PNP Therapeutics, Inc."	Birmingham	Alabama	35203	USA	LONGEST CONTAINS	1309542AA	purine nucleoside phosphorylase	3WH6OPR0RH						" Oropharyngeal cancer, childhood"	9359	approximate	
adenovirus associated viral vector serotype 8 containing the human AIPL1 gene	"Treatment of inherited retinal dystrophy due to defects in AIPL1 gene, including Leber congenital amaurosis, retinitis pigmentosa, and cone-rod dystrophy"	adenovirus associated viral vector serotype 8 containing the human AIPL1 gene		n/a	2/1/18	Designated			N/A	N/A	MeiraGTx UK II Ltd	92 Britannia Walk	London		United Kingdom					adenovirus associated viral vector serotype 8 containing the human AIPL1 gene	NA	https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3171950	PROBLEM	absent from GINAS	Leber congenital amaurosis 	634	done	
adenovirus associated viral vector serotype 8 containing the human AIPL1 gene	"Treatment of inherited retinal dystrophy due to defects in AIPL1 gene, including Leber congenital amaurosis, retinitis pigmentosa, and cone-rod dystrophy"	adenovirus associated viral vector serotype 8 containing the human AIPL1 gene		n/a	2/1/18	Designated			N/A	N/A	MeiraGTx UK II Ltd	92 Britannia Walk	London		United Kingdom					adenovirus associated viral vector serotype 8 containing the human AIPL1 gene	NA	https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3171950	PROBLEM	absent from GINAS	 Retinitis pigmentosa 	5694	done	
adenovirus associated viral vector serotype 8 containing the human AIPL1 gene	"Treatment of inherited retinal dystrophy due to defects in AIPL1 gene, including Leber congenital amaurosis, retinitis pigmentosa, and cone-rod dystrophy"	adenovirus associated viral vector serotype 8 containing the human AIPL1 gene		n/a	2/1/18	Designated			N/A	N/A	MeiraGTx UK II Ltd	92 Britannia Walk	London		United Kingdom					adenovirus associated viral vector serotype 8 containing the human AIPL1 gene	NA	https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3171950	PROBLEM	absent from GINAS	 Cone-rod dystrophy	10790	done	
adenovirus associated viral vector serotype 8 containing the human CNGB3 gene	Treatment of achromatopsia due to mutations in the CNGB3 gene.	adenovirus associated viral vector serotype 8 containing the human CNGB3 gene		n/a	3/10/16	Designated			N/A	N/A	MeiraGTx Limited	New York	New York	10016	USA				B769I4XPY3	ADENO-ASSOCIATED VIRUS | Adenovirus associated viral vector serotype 8 containing the human CNGB3 gene | A002 - MeiraGTx | AAV-CNGB3 | AAV2/8-hCARp.hCNGB3	B769I4XPY3	https://ginas.ncats.nih.gov/ginas/app/substance/1b238f0c | https://www.ema.europa.eu/documents/orphan-designation/eu/3/15/1578-public-summary-opinion-orphan-designation-adenovirus-associated-viral-vector-serotype-8_en.pdf | https://adisinsight.springer.com/drugs/800048920	approximate		Achromatopsia 3	9650	done	
adenovirus associated viral vector serotype 8 containing the human Cyclic Nucleotide Gated Channel Alpha 3 subunit (CNGA3) gene	Treatment of achromatopsia due to CNGA3 gene mutations.	adenovirus associated viral vector serotype 8 containing the human Cyclic Nucleotide Gated Channel Alpha 3 subunit (CNGA3) gene		n/a	8/7/18	Designated			N/A	N/A	MeiraGTx UK II Ltd	92 Britannia Walk			United Kingdom					adenovirus associated viral vector serotype 2/8 containing the human CNGA3 gene	NA	https://www.ema.europa.eu/documents/orphan-designation/eu/3/18/2042-public-summary-opinion-orphan-designation-adenovirus-associated-viral-vector-serotype-2/8-containing-human-cnga3-gene-treatment-achromatopsia_en.pdf	PROBLEM	absent from GINAS	Achromatopsia 2	9649	done	
"adenovirus delta 24-RGD, an oncolytic adenovirus genetically modified for treatment of glioma"	Treatment of glioma	"adenovirus delta 24-RGD, an oncolytic adenovirus genetically modified for treatment of glioma"		n/a	10/1/14	Designated			N/A	N/A	"DNAtrix, Inc."	San Diego	California	92121	USA								PROBLEM	can't find	Glioma	6513	done	
adenovirus vaccine encoding reduced expression in immortalized cell protein	Treatment of mesothelioma	adenovirus vaccine encoding reduced expression in immortalized cell protein	ADENOVIRUS VACCINE	n/a	7/14/15	Designated			N/A	N/A	MTG Biotherapeutics	San Diego	California	92127	USA	LONGEST CONTAINS	0099365AA	adenovirus vaccine					PROBLEM	the drug name is probably incorrect	Malignant mesothelioma	7026	done	
adenovirus-associated viral vector serotype 5 containing the human RLBP1 gene	Treatment of retinitis punctata albescens due to RLBP1 gene mutation	adenovirus-associated viral vector serotype 5 containing the human RLBP1 gene		n/a	6/12/17	Designated			N/A	N/A	"HORAMA, SAS"	Paris			France				B769I4XPY3	ADENO-ASSOCIATED VIRUS | HORA-RLBP1	B769I4XPY3	https://ginas.ncats.nih.gov/ginas/app/substance/1b238f0c | https://adisinsight.springer.com/drugs/800050335 | https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3161741	PROBLEM	absent from GINAS			MISSING	
adult adherent bone marrow-derived multipotent stem cells	"Treatment of MPS-1, including Hurler syndrome"	adult adherent bone marrow-derived multipotent stem cells	BONE MARROW	Multistem	7/6/12	Designated			N/A	N/A	"Athersys, Inc."	Cleveland	Ohio	44115	USA	LONGEST CONTAINS	0100072AA	bone marrow					PROBLEM	can't find	Mucopolysaccharidosis type I	10335	done	
aerosolized beractant	Treatment of respiratory distress syndrome	aerosolized beractant	BERACTANT	n/a	3/11/13	Designated			N/A	N/A	"Beena G. Sood, MD, MS"	Detroit	Michigan	48201	USA	EXACT	0171164AA	beractant	S866O45PIG						"Respiratory distress syndrome, infant "	112	approximate	
aerosolized beractant	Treatment of respiratory distress syndrome	aerosolized beractant	BERACTANT	n/a	3/11/13	Designated			N/A	N/A	"Beena G. Sood, MD, MS"	Detroit	Michigan	48201	USA	EXACT	0171164AA	beractant	S866O45PIG						 Acute respiratory distress syndrome	5698	approximate	
afamelanotide	Treatment of solar urticaria	afamelanotide	AFAMELANOTIDE	n/a	12/11/09	Designated			N/A	N/A	"Clinuvel, Inc."	Blue Bell	Pennsylvania	19422	USA	EXACT	0253281AA	afamelanotide	QW68W3J66U								MISSING	
afatinib	Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).	afatinib	AFATINIB	Gilotrif	12/3/12	Designated/Approved	Approved for Orphan Indication	First-line treatment of patients with metastatic non-small cell lung cancer (NSCLS) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.	7/12/13	7/12/20	"Boehringer Ingelheim Pharmaceuticals, Inc."	Ridgefield	Connecticut	6877	USA	EXACT	0361966AA	afatinib	41UD74L59M						"Non-small cell lung cancer, childhood"	9343	approximate	
afatinib	Treatment of malignant brain and central nervous system tumors	afatinib	AFATINIB	Gilotrif(R)	6/4/14	Designated			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc."	Ridgefield	Connecticut	6877	USA	EXACT	0361966AA	afatinib	41UD74L59M						Gliomatosis cerebri 	6514	approximate	
afatinib	Treatment of malignant brain and central nervous system tumors	afatinib	AFATINIB	Gilotrif(R)	6/4/14	Designated			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc."	Ridgefield	Connecticut	6877	USA	EXACT	0361966AA	afatinib	41UD74L59M						 Brain stem cancer	8244	approximate	
afatinib	Treatment of non-small cell lung cancer with squamous histology.	afatinib	AFATINIB	Gilotrif(R)	8/3/15	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with metastatic, squamous, non-small cell lung cancer progressing after platinum-based chemotherapy"	4/15/16	4/15/23	"Boehringer Ingelheim Pharmaceuticals, Inc."	Ridgefield	Connecticut	6877	USA	EXACT	0361966AA	afatinib	41UD74L59M						"Non-small cell lung cancer, childhood"	9343	approximate	
aganirsen	Prevention of corneal graft rejection.	aganirsen	AGANIRSEN	n/a	11/7/16	Designated			N/A	N/A	Gene Signal International SA	Lausanne			Switzerland	EXACT	0338227AA	aganirsen	0N3FY8225K								MISSING	
ak-001	Treatment of eosinophilic gastritis	humanized non-fucosylated anti-siglec-8 monoclonal antibody (IgG1)	AK-001	n/a	2/1/18	Designated			N/A	N/A	"Allakos, Inc."	75 Shoreway Road	San Carlos	94070	USA	EXACT	1182463AA	ak-001	3RKV24P7EP						Eosinophilic enteropathy	9142	done	
ak-002	Treatment of eosinophilic gastroenteritis	humanized non-fucosylated Anti-Siglec-8 Monoclonal Antibody (IgG1)	AK-002	n/a	2/1/18	Designated			N/A	N/A	"Allakos, Inc."	75 Shoreway Road	San Carlos	94070	USA	EXACT	0113573AB	ak-002	SWS48LJU3T						Eosinophilic enteropathy	9142	done	
alanyl-glutamine dipeptide	Prevention of complications associated with peritoneal dialysis (PD) treatment in end stage renal disease (ESRD)	alanyl-glutamine dipeptide	ALANYL GLUTAMINE	Pd-Protectm	11/6/17	Designated			N/A	N/A	Zytoprotec GmbH	28/2 Mariannengasse			Austria	EXACT	0179919AA	alanyl glutamine	U5JDO2770Z								MISSING	
aldoxorubicin	Treatment of small cell lung cancer	aldoxorubicin	ALDOXORUBICIN	n/a	9/24/14	Designated			N/A	N/A	CytRx Corporation	Los Angeles	California	90049	USA	EXACT	0738294AA	aldoxorubicin	C28MV4IM0B						Small cell lung cancer	9344	done	
alectinib	Treatment of ALK-positive non-small cell lung cancer	alectinib	ALECTINIB	Alecensa	1/27/15	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), who have progressed on or are intolerant to crizotinib"	12/11/15	12/11/22	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0786572AA	alectinib	LIJ4CT1Z3Y						"Non-small cell lung cancer, childhood"	9343	approximate	
alfimeprase	Treatment of ST-elevation myocardial infarcted patients who are undergoing primary percutaneous coronary intervention	alfimeprase	ALFIMEPRASE	n/a	9/20/12	Designated			N/A	N/A	"Niche Therapeutics, LLC"	Ann Arbor	Michigan	48104	USA	EXACT	0263229AA	alfimeprase	GPN9HBH1HS								MISSING	Not a rare disease
algenpantucel-L	Treatment of pancreatic cancer.	algenpantucel-L		Hyperacute(R)-Pancreatic Cance	10/21/10	Designated			N/A	N/A	NewLink Genetics Corporation	Ames	Iowa	50010	USA					algenpantucel-L	NA	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/algenpantucel-l	done		Pancreatic cancer	9364	done	Not a rare disease
alglucosidase alfa	Treatment of glycogen storage disease type II.	Recombinant human acid alpha-glucosidase; alglucosidase alfa	ALGLUCOSIDASE ALFA	1. Myozyme 2. Lumizyme	8/19/97	Designated/Approved	Approved for Orphan Indication	"Lumizyme for patients 8 years and older with late (non-infantile) onset Pompe disease (GAA deficiency) who do not have evidence of cardiac hypertrophy. The safety and efficacy of Lumizyme (alglucosidase alfa) have not been evaluated in controlled clinical trials in infantile-onset patients, or in late (non-infantile) onset patients less than 8 years of age"	5/24/10	5/24/17	Genzyme Corporation	Cambridge	Massachusetts	2142	USA	EXACT	0262873AA	alglucosidase alfa	DTI67O9503						Glycogen storage disease type 2	5714	done	
alicaforsen	Treatment of pouchitis.	alicaforsen	ALICAFORSEN	n/a	6/24/08	Designated			N/A	N/A	Atlantic Healthcare Limited				United Kingdom	EXACT	0634413AA	alicaforsen	J8435V445B								MISSING	surgery complication
alirocumab	Treatment of homozygous familial hypercholesterolemia	alirocumab	ALIROCUMAB	n/a	6/15/17	Designated			N/A	N/A	"Sanofi-Aventis US, LLC"	Bridgewater	New Jersey	8807	USA	EXACT	0762298AA	alirocumab	PP0SHH6V16						Familial hypercholesterolemia	10416	done	Not a rare disease
alisertib	Treatment of small cell lung cancer	alisertib	ALISERTIB	n/a	7/12/13	Designated			N/A	N/A	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0383482AA	alisertib	T66ES73M18						Small cell lung cancer	9344	done	
allogeneic Epstein-Barr virus cytotoxic T lymphocytes	Treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disorders.	allogeneic Epstein-Barr virus cytotoxic T lymphocytes	LYMPHOCYTES	n/a	2/4/16	Designated			N/A	N/A	"ATARA Biotherapeutics, Inc."	Westlake Village	California	91361	USA	LONGEST CONTAINS	0263092AA	lymphocytes					PROBLEM	can't find			MISSING	
allogeneic Fecal Microbiota	Treatment of Graft-Versus-Host Disease	allogeneic Fecal Microbiota	FECAL MICROBIOTA	n/a	2/28/18	Designated			N/A	N/A	MaaT Pharma	317 Avenue Jean Jaurès	Lyon-7E-Arrondissement		France	LONGEST CONTAINS	0934338AA	Fecal Microbiota	Q805XO2F7C						Chronic graft versus host disease 	10964	done	
allogeneic Fecal Microbiota	Treatment of Graft-Versus-Host Disease	allogeneic Fecal Microbiota	FECAL MICROBIOTA	n/a	2/28/18	Designated			N/A	N/A	MaaT Pharma	317 Avenue Jean Jaurès	Lyon-7E-Arrondissement		France	LONGEST CONTAINS	0934338AA	Fecal Microbiota	Q805XO2F7C						 Acute graft versus host disease	6544	done	
allogeneic T Cell genetically modified to contain an inducible caspase 9 gene	Replacement T-cell therapy for the treatment of immunodeficiency and graft versus host disease after allogeneic hematopoietic stem cell transplant	CaspaCIDe System (combination product) consisting of allogeneic T Cell genetically modified to contain an inducible caspase 9 gene and Rimiducid		n/a	2/18/16	Designated			N/A	N/A	"Bellicum Pharmaceuticals, Inc."	Houston	Texas	77030	USA				J56RKY13OV | 8C251D28Q5 | H564L1W5J2	HUMAN THYMOCYTE | CASPASE-9 | RIMIDUCID	J56RKY13OV | 8C251D28Q5 | H564L1W5J2	https://ginas.ncats.nih.gov/ginas/app/substances?q=HUMAN%20T-CELLS | https://ginas.ncats.nih.gov/ginas/app/substances?q=CASPASE-9 | https://ginas.ncats.nih.gov/ginas/app/substances?q=Rimiducid	approximate	complex combination product; caspase-9 gene (not protein) introduced in T cells	Chronic graft versus host disease 	10964	approximate	secondary condition
allogeneic T Cell genetically modified to contain an inducible caspase 9 gene	Replacement T-cell therapy for the treatment of immunodeficiency and graft versus host disease after allogeneic hematopoietic stem cell transplant	CaspaCIDe System (combination product) consisting of allogeneic T Cell genetically modified to contain an inducible caspase 9 gene and Rimiducid		n/a	2/18/16	Designated			N/A	N/A	"Bellicum Pharmaceuticals, Inc."	Houston	Texas	77030	USA				J56RKY13OV | 8C251D28Q5 | H564L1W5J2	HUMAN THYMOCYTE | CASPASE-9 | RIMIDUCID	J56RKY13OV | 8C251D28Q5 | H564L1W5J2	https://ginas.ncats.nih.gov/ginas/app/substances?q=HUMAN%20T-CELLS | https://ginas.ncats.nih.gov/ginas/app/substances?q=CASPASE-9 | https://ginas.ncats.nih.gov/ginas/app/substances?q=Rimiducid	approximate	complex combination product; caspase-9 gene (not protein) introduced in T cells	 Acute graft versus host disease	6544	approximate	secondary condition
"allogeneic cord blood cells, ex vivo modulated with 16,16 dimethyl prostaglandin E2 (dmPGE2)"	"Enhancement of stem cell engraftment through ex vivo treatment of human allogeneic hematopoietic stem cells (treatment of neuropenia, thrombocytopenia, lymphopenia, and anemia)."	"allogeneic cord blood cells, ex vivo modulated with 16,16 dimethyl prostaglandin E2 (dmPGE2)"	DINOPROSTONE	n/a	12/2/10	Designated			N/A	N/A	"Fate Therapeutics, Inc."	San Diego	California	92121	USA	LONGEST CONTAINS	0025241AA	prostaglandin E2	K7Q1JQR04M								MISSING	
allogeneic ex-vivo expanded placental adherent stromal cells	Treatment of thromboangiitis obliterans (Buerger's disease)	allogeneic ex-vivo expanded placental adherent stromal cells		n/a	8/22/11	Designated			N/A	N/A	"Pluristem Therapeutics, Inc."	Haifa			Israel								PROBLEM	can't find	Buerger disease	5969	done	
allogeneic hematopoietic stem cell	"Prevention (reduction) of transplant related mortality (TRM, which is caused by graft versus host disease and/or infections) following mismatched (haploidentical) allogeneic hematopoietic stem cell transplantation."	allogeneic hematopoietic stem cell		Atir	2/2/10	Designated			N/A	N/A	Kiadis Pharma Netherlands B.V.				Netherlands								PROBLEM	can't find			MISSING	
allogeneic human islets of Langerhans	Treatment of Brittle Type 1 Diabetes	allogeneic human islets of Langerhans		n/a	2/1/17	Designated			N/A	N/A	University of Illinois	Chicago	Illinois	60612	USA				O27XRL3W27	HUMAN PANCREATIC ISLET CELL	O27XRL3W27	https://ginas.ncats.nih.gov/ginas/app/substance/b0e9f6bf	approximate		Brittle diabetes	11900	done	
allogenic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor	Treatment of macular telangiectasia type 2 (MacTel)	allogenic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor	"RETINAL, ALL-TRANS"	n/a	7/24/12	Designated			N/A	N/A	"Neurotech USA, Inc."	Lincoln	Rhode Island	2865	USA	LONGEST CONTAINS	0018746AA	retinal	RR725D715M						Macular telangiectasia type 2	10690	done	Not a rare disease
allopregnanolone	"Treatment of Neimann-Pick disease, type C"	allopregnanolone	ALLOPREGNANOLONE	n/a	7/12/13	Designated			N/A	N/A	"La Jolla Pharmaceutical Company, Inc."	San Diego	California	92122	USA	EXACT	0920434AA	allopregnanolone	S39XZ5QV8Y						Niemann-Pick disease type C1 	7207	done	
allopregnanolone	"Treatment of Neimann-Pick disease, type C"	allopregnanolone	ALLOPREGNANOLONE	n/a	7/12/13	Designated			N/A	N/A	"La Jolla Pharmaceutical Company, Inc."	San Diego	California	92122	USA	EXACT	0920434AA	allopregnanolone	S39XZ5QV8Y						 Niemann-Pick disease type C2	3992	done	
alpha-1 proteinase inhibitor (human)	Prevention of graft versus host disease	alpha-1 proteinase inhibitor (human)	.ALPHA.1-PROTEINASE INHIBITOR HUMAN	Glassia	7/31/17	Designated			N/A	N/A	Kamada Ltd.	Ness Ziona			Israel	EXACT	0163520AA	alpha-1 proteinase inhibitor (human)	F43I396OIS						Chronic graft versus host disease	10964	approximate	type of GVHD (acute or chronic) is not specified
alpha-1 proteinase inhibitor (human)	Prevention of graft versus host disease	alpha-1 proteinase inhibitor (human)	.ALPHA.1-PROTEINASE INHIBITOR HUMAN	Glassia	7/31/17	Designated			N/A	N/A	Kamada Ltd.	Ness Ziona			Israel	EXACT	0163520AA	alpha-1 proteinase inhibitor (human)	F43I396OIS						Acute graft versus host disease	6544	approximate	type of GVHD (acute or chronic) is not specified
alpha-1 proteinase inhibitor (human)	Treatment of graft versus host disease	alpha-1 proteinase inhibitor (human)	.ALPHA.1-PROTEINASE INHIBITOR HUMAN	Glassia	10/23/14	Designated			N/A	N/A	Kamada Ltd.	Ness-Ziona			Israel	EXACT	0163520AA	alpha-1 proteinase inhibitor (human)	F43I396OIS						Chronic graft versus host disease 	10964	approximate	
alpha-1 proteinase inhibitor (human)	Treatment of graft versus host disease	alpha-1 proteinase inhibitor (human)	.ALPHA.1-PROTEINASE INHIBITOR HUMAN	Glassia	10/23/14	Designated			N/A	N/A	Kamada Ltd.	Ness-Ziona			Israel	EXACT	0163520AA	alpha-1 proteinase inhibitor (human)	F43I396OIS						 Acute graft versus host disease	6544	approximate	
alpha-1 proteinase inhibitor (human)	Treatment of patients with recent onset (	alpha-1 proteinase inhibitor (human)	.ALPHA.1-PROTEINASE INHIBITOR HUMAN	Glassia	7/28/11	Designated			N/A	N/A	"Kamada, Ltd."				Israel	EXACT	0163520AA	alpha-1 proteinase inhibitor (human)	F43I396OIS								PROBLEM	it looks like the designation phrase is incomplete
alpha-tocotrienol quinone	Treatment of inherited mitochondrial respiratory chain diseases.	alpha-tocotrienol quinone	VATIQUINONE	n/a	10/21/10	Designated			N/A	N/A	"Edison pharmaceuticals, Inc."	Mountain View	California	94043	USA	EXACT	0739468AA	alpha-tocotrienol quinone	6O85FK9I0X						Mitochondrial complex I deficiency 	3908	approximate	
alpha-tocotrienol quinone	Treatment of inherited mitochondrial respiratory chain diseases.	alpha-tocotrienol quinone	VATIQUINONE	n/a	10/21/10	Designated			N/A	N/A	"Edison pharmaceuticals, Inc."	Mountain View	California	94043	USA	EXACT	0739468AA	alpha-tocotrienol quinone	6O85FK9I0X						 Mitochondrial complex II deficiency 	5053	approximate	
alpha-tocotrienol quinone	Treatment of inherited mitochondrial respiratory chain diseases.	alpha-tocotrienol quinone	VATIQUINONE	n/a	10/21/10	Designated			N/A	N/A	"Edison pharmaceuticals, Inc."	Mountain View	California	94043	USA	EXACT	0739468AA	alpha-tocotrienol quinone	6O85FK9I0X						 Mitochondrial complex III deficiency 	8295	approximate	
alpha-tocotrienol quinone	Treatment of inherited mitochondrial respiratory chain diseases.	alpha-tocotrienol quinone	VATIQUINONE	n/a	10/21/10	Designated			N/A	N/A	"Edison pharmaceuticals, Inc."	Mountain View	California	94043	USA	EXACT	0739468AA	alpha-tocotrienol quinone	6O85FK9I0X						 Cytochrome c oxidase deficiency 	48	approximate	
alpha-tocotrienol quinone	Treatment of inherited mitochondrial respiratory chain diseases.	alpha-tocotrienol quinone	VATIQUINONE	n/a	10/21/10	Designated			N/A	N/A	"Edison pharmaceuticals, Inc."	Mountain View	California	94043	USA	EXACT	0739468AA	alpha-tocotrienol quinone	6O85FK9I0X						 Mitochondrial complex V deficiency	1459	approximate	
alpha1-proteinase inhibitor (human)	Treatment of Type 1 diabetes mellitus patients with residual beta-cell function.	alpha1-proteinase inhibitor (human)	.ALPHA.1-PROTEINASE INHIBITOR (HUMAN)	Prolastin(R)-C	3/3/15	Designated			N/A	N/A	"Grifols Therapeutics, Inc."	Clayton	North Carolina	27520	USA	EXACT	0334770AA	alpha1-proteinase inhibitor (human)	F43I396OIS						Diabetes mellitus type 1	10268	done	
alteplase	Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage	alteplase	ALTEPLASE	Activase	1/27/03	Designated			N/A	N/A	"Daniel F. Hanley, MD"	Baltimore	Maryland	21287	USA	EXACT	0162447AA	alteplase	1RXS4UE564								MISSING	not a disease
amatuximab	Treatment of mesothelioma	amatuximab	AMATUXIMAB	n/a	9/28/12	Designated			N/A	N/A	"Morphotek, Inc."	Exton	Pennsylvania	19341	USA	EXACT	0583288AA	amatuximab	6HP0354G04						Malignant mesothelioma	7026	done	
amelubant	Management of cystic fibrosis	"carbamic acid, [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methyl-ethyl]phenoxy]methyl]phenyl]methoxy]-phenyl]iminomethyl]-,ethyl ester"	AMELUBANT	n/a	1/15/02	Designated/Withdrawn			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc"	Ridgefield	Connecticut	6877	USA	EXACT	0232064AA	amelubant	E0018IF0K4						Cystic fibrosis	6233	done	Not a rare disease
aminolevulinic acid hydrochloride	Treatment of esophageal dysplasia	aminolevulinic acid hydrochloride	AMINOLEVULINIC ACID HYDROCHLORIDE	Levulan	3/20/07	Designated			N/A	N/A	"DUSA Pharmaceuticals, Inc."	Wilmington	Massachusetts	1887	USA	EXACT	0092615AA	aminolevulinic acid hydrochloride	V35KBM8JGR								MISSING	Not a rare disease
amitriptyline	Treatment of postherpetic neuralgia	amitriptyline and ketamine	AMITRIPTYLINE	Amiket(Tm)	1/19/10	Designated			N/A	N/A	"Immune Pharmaceuicals, Inc."	New York	New York	10016	USA	EXACT	0007476AA	amitriptyline	1806D8D52K								MISSING	Not a rare disease; symptom
ammonium 21-tungsto-9-antimoniate	Treatment of acquired immunodeficiency syndrome.	ammonium 21-tungsto-9-antimoniate	HPA-23	n/a	7/17/85	Designated/Withdrawn			N/A	N/A	Rhone-Poulenc Rorer Pharm.	Collegeville	Pennsylvania	19426	USA	EXACT	0152103AA	ammonium 21-tungsto-9-antimoniate	J08H62IZC9						Congenital human immunodeficiency virus	10328	approximate	
ampligen	Treatment of chronic fatigue syndrome	Poly I: poly C12U	RINTATOLIMOD	Ampligen	12/9/93	Designated			N/A	N/A	"Hemispherx Biopharma, Inc."	Philadelphia	Pennsylvania	19103	USA	EXACT	0182025AA	ampligen	94325AJ25N						Chronic fatigue syndrome	7121	done	
ampligen	"Treatment of invasive metastatic melanoma (stage IIb, III, IV)."	Poly I: poly C12U	RINTATOLIMOD	Ampligen	12/9/93	Designated			N/A	N/A	"Hemispherx Biopharma, Inc."	Philadelphia	Pennsylvania	19103	USA	EXACT	0182025AA	ampligen	94325AJ25N						"Melanoma, familial"	3460	approximate	
amrubicin	Treatment of small cell lung cancer	amrubicin	AMRUBICIN	n/a	3/10/08	Designated/Withdrawn			N/A	N/A	Celgene Corporation	Overland Park	Kansas	66210	USA	EXACT	0269363AA	amrubicin	93N13LB4Z2						Small cell lung cancer	9344	done	
amy-101	Treatment of C3 glomerulopathy.	"S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide"	AMY-101	n/a	11/16/15	Designated			N/A	N/A	Amyndas Pharmaceuticals	Glyfada			Greece	EXACT	1802864AA	amy-101	4Z4DFR9BX7								MISSING	
amyl nitrite	Treatment of cyanide poisoning	"Sodium thiosulfate, sodium nitrite, amyl nitrite"	AMYL NITRITE	Cyanide Antidote Package	6/16/06	Designated			N/A	N/A	"Keystone Pharmaceuticals, Inc."	Laguna Hills	California	92653	USA	EXACT	0017765AA	amyl nitrite	22T8Z09XAK								MISSING	Not a disease
amylopectin	Treatment of glycogen storage disease types Ia and Ib	amylopectin	AMYLOPECTIN	n/a	3/24/15	Designated			N/A	N/A	"Michael K. Davis, MD, MBA"	Gainesville	Florida	32608	USA	EXACT	0068417AA	amylopectin	4XO4QFV777						Glycogen storage disease type 1A 	7864	done	
amylopectin	Treatment of glycogen storage disease types Ia and Ib	amylopectin	AMYLOPECTIN	n/a	3/24/15	Designated			N/A	N/A	"Michael K. Davis, MD, MBA"	Gainesville	Florida	32608	USA	EXACT	0068417AA	amylopectin	4XO4QFV777						 Glycogen storage disease type 1B	2515	done	
andexanet alfa	For reversing the anticoagulant effect of direct or indirect factor Xa inhibitors in patients experiencing a serious uncontrolled bleeding event or who require urgent or emergent surgery	andexanet alfa	ANDEXANET ALFA	n/a	2/23/15	Designated			N/A	N/A	Portola Pharmaceuticals	South San Francisco	California	94080	USA	EXACT	0925893AA	andexanet alfa	BI009E452R								MISSING	not a disease
angiotensin (1-7)	Treatment of patients requiring stem cell transplantation to accelerate the mobilization of hematopoietic stem cells (CD34+) from the bone marrow to the peripheral blood when combined with a granulocyte colony-stimulating factor	angiotensin (1-7)	ANGIOTENSIN 1-7	n/a	8/30/13	Designated			N/A	N/A	"US Biotest, Inc."	San Luis Obispo	California	93401	USA	EXACT	0232428AA	Angiotensin 1-7	IJ3FUK8MOF								MISSING	not a disease
angiotensin 1-7	"To accelerate engraftment of hematopoietic cells (treatment of neutropenia, thrombocytopenia, lymphoma, and aneima)in hematopoietic stem cell transplants."	angiotensin 1-7	ANGIOTENSIN 1-7	n/a	6/17/10	Designated			N/A	N/A	"US Biotest, Inc."	San Luis Obispo	California	93401	USA	EXACT	0232428AA	angiotensin 1-7	IJ3FUK8MOF								MISSING	
angiotensin 1-7	Treatment of sarcoma.	angiotensin 1-7	ANGIOTENSIN 1-7	n/a	1/29/10	Designated			N/A	N/A	"W. Jeffrey Petty, MD"	Winston-Salem	North Carolina	27157	USA	EXACT	0232428AA	angiotensin 1-7	IJ3FUK8MOF						Soft tissue sarcoma	4898	approximate	sarcoma type not specified
anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein and anti-CD7 mAb (WT1)-ricin A chain fusion protein	Treatment of graft versus host disease	anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein and anti-CD7 mAb (WT1)-ricin A chain fusion protein	PROTEIN	n/a	9/13/13	Designated			N/A	N/A	Xenikos BV	NIJMEGEN			Netherlands	LONGEST CONTAINS	0087274AA	protein					PROBLEM	can't find	Chronic graft versus host disease 	10964	approximate	
anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein and anti-CD7 mAb (WT1)-ricin A chain fusion protein	Treatment of graft versus host disease	anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein and anti-CD7 mAb (WT1)-ricin A chain fusion protein	PROTEIN	n/a	9/13/13	Designated			N/A	N/A	Xenikos BV	NIJMEGEN			Netherlands	LONGEST CONTAINS	0087274AA	protein					PROBLEM	can't find	 Acute graft versus host disease	6544	approximate	
anti-human epidermal growth factor receptor 2 (HER2) antibody drug conjugate	Treatment of gastric cancer including cancer of gastroesophageal junction	anti-human epidermal growth factor receptor 2 (HER2) antibody drug conjugate	EPIDERMAL GROWTH FACTOR RECEPTOR	n/a	2/1/18	Designated			N/A	N/A	"CSPC Dophen Corporation, subsidiary within CSPC Pharmaceutical Group"	4070 Truxel Road	Sacramento	95834	USA	LONGEST CONTAINS	1309962AA	epidermal growth factor receptor	RO03J093CP						Stomach cancer	7704	done	
anti-interferon-gamma Fab from goats	For the treatment of immunologic corneal allograft rejection	anti-interferon-gamma Fab from goats	INTERFERON GAMMA	n/a	11/18/03	Designated			N/A	N/A	"Advanced Biotherapy, Inc."	Woodland Hills	California	91367	USA	LONGEST CONTAINS	0214573AA	interferon gamma	P050J5FWC5						Acute graft versus host disease 	6552	approximate	
anti-interferon-gamma Fab from goats	For the treatment of immunologic corneal allograft rejection	anti-interferon-gamma Fab from goats	INTERFERON GAMMA	n/a	11/18/03	Designated			N/A	N/A	"Advanced Biotherapy, Inc."	Woodland Hills	California	91367	USA	LONGEST CONTAINS	0214573AA	interferon gamma	P050J5FWC5						 Chronic graft versus host disease	10964	approximate	
anti-sense oligonucleotide consisting of 2'-O-Me RNA with a phosphorothioate backbone	Treatment of cystic fibrosis	anti-sense oligonucleotide consisting of 2'-O-Me RNA with a phosphorothioate backbone		n/a	9/23/13	Designated			N/A	N/A	ProQR Therapeutics III B.V.				Netherlands				V30WFP6S2Y	Eluforsen	V30WFP6S2Y	https://www.sciencedirect.com/science/article/pii/S1569199318309147 | https://chem.nlm.nih.gov/chemidplus/rn/2101868-82-8	done	incorrect drug name [fixed -- IG]	Cystic fibrosis	6233	done	
anti-thymocyte globulin (rabbit)	Prophylaxis of acute organ rejection in patients receiving renal transplants	anti-thymocyte globulin [rabbit]	LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN	Thymoglobulin	5/25/10	Designated			N/A	N/A	Genzyme Corporation	Cambridge	Massachusetts	2142	USA	EXACT	0233385AA	anti-thymocyte globulin (rabbit)	D7RD81HE4W								MISSING	
antibody drug conjugate of metal-binding motif-introduced trastuzumab antibody variant and monomethyl auristatin E	Treatment of Gastric Cancer	antibody drug conjugate of metal-binding motif-introduced trastuzumab antibody variant and monomethyl auristatin E	MONOMETHYL AURISTATIN E	n/a	7/30/18	Designated			N/A	N/A	"Alteogen, Inc."	62 Yuseong-daero 1628beon-gil			"Korea, Republic of"	LONGEST CONTAINS	0297756AA	monomethyl auristatin E	V7I58RC5EJ						Stomach cancer	7704	done	
antibody drug conjugate targeting dipeptidase 3 (DPEP3)	"Treatment of DPEP3-positive ovarian, fallopian tube, and primary peritoneal cancers"	antibody drug conjugate targeting dipeptidase 3 (DPEP3)		n/a	1/8/18	Designated			N/A	N/A	"AbbVie Stemcentrx, LLC"	1 North Waukegan Road	Chicago	60064	USA					antibody drug conjugate targeting dipeptidase 3 (DPEP3)	NA	https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=555816	PROBLEM	absent from GINAS; withdrawn	Ovarian cancer 	7295	done	
antibody drug conjugate targeting dipeptidase 3 (DPEP3)	"Treatment of DPEP3-positive ovarian, fallopian tube, and primary peritoneal cancers"	antibody drug conjugate targeting dipeptidase 3 (DPEP3)		n/a	1/8/18	Designated			N/A	N/A	"AbbVie Stemcentrx, LLC"	1 North Waukegan Road	Chicago	60064	USA					antibody drug conjugate targeting dipeptidase 3 (DPEP3)	NA	https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=555816	PROBLEM	absent from GINAS; withdrawn	 Fallopian tube cancer	9162	done	
antimesothelin-ADC (antibody drug conjugate)	Treatment of mesothelioma	antimesothelin-ADC (antibody drug conjugate)		n/a	7/5/12	Designated			N/A	N/A	"Bayer HealthCare Pharmaceuticals, Inc."	Pine Brook	New Jersey	7058	USA								PROBLEM	can't find	Malignant mesothelioma	7026	done	
antineoplaston A10	Treatment of gliomas	"antineoplaston A10, antineoplaston AS2-1"	ANTINEOPLASTON A10	n/a	11/21/08	Designated			N/A	N/A	"Burzynski Research Institute, Inc."	Houston	Texas	77055	USA	EXACT	0129599AA	antineoplaston A10	16VY3TM7ZO						Glioma	6513	done	
antinuclear antibody conjugated liposomal doxorubicin	Treatment of Ewing's sarcoma.	antinuclear antibody conjugated liposomal doxorubicin	DOXORUBICIN	n/a	2/3/15	Designated			N/A	N/A	"NanoSmart Pharmaceuticals, Inc."	Laguna Hills	California	92653	USA	LONGEST CONTAINS	0061074AA	doxorubicin	80168379AG						Ewing's family of tumors	9323	approximate	
antisense oligonucleotide complementary to the exonic splicer enhancer sequence at intron 26 of the centrosomal protein 290 pre-mRNA	Treatment of Leber's congenital amaurosis.	antisense oligonucleotide complementary to the exonic splicer enhancer sequence at intron 26 of the centrosomal protein 290 pre-mRNA	PROTEIN	n/a	5/25/16	Designated			N/A	N/A	ProQR Therapeutics IV B.V.	Leiden			Netherlands	LONGEST CONTAINS	0087274AA	protein		QR-110 | Sepofarsen	NA	https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3161641 | https://adisinsight.springer.com/drugs/800049805	PROBLEM	absent from GINAS	Leber congenital amaurosis	634	done	
antisense oligonucleotide targeted to human transthyretin (TTR) mRNA	Treatment of familial amyloid polyneuropathy	antisense oligonucleotide targeted to human transthyretin (TTR) mRNA	TRANSTHYRETIN	n/a	7/24/12	Designated			N/A	N/A	"Isis Pharmaceuticals, Inc."	Carlsbad	California	92010	USA	LONGEST CONTAINS	0113161AB	transthyretin	2COU0B578R						Familial transthyretin amyloidosis	656	done	
antroquinonol	Treatment of pancreatic cancer	antroquinonol	ANTROQUINONOL	n/a	1/21/15	Designated			N/A	N/A	Golden Biotechnology Corp.				Taiwan	EXACT	1216428AA	antroquinonol	AX9P92T7JZ						Pancreatic cancer	9364	done	Not a rare disease
apatinib mesylate	Treatment of gastric cancer	apatinib mesylate	APATINIB MESYLATE	n/a	6/15/17	Designated			N/A	N/A	"LSK BioPartners, Inc."	Salt Lake City	Utah	84111	USA	EXACT	0755840AA	apatinib mesylate	TK02X14ASJ						Stomach cancer	7704	done	
apd-811	Treatment of pulmonary arterial hypertension	"2-{[(1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexy]methoxy} acetic acid"	RALINEPAG	n/a	8/28/14	Designated			N/A	N/A	"Arena Pharmaceuticals, Inc."	San Diego	California	92121	USA	EXACT	1076182AA	apd-811	CQY12ZJN6E						Autoimmune pulmonary alveolar proteinosis	7499	done	
aphidicolin	Treatment of Ebola virus infection	aphidicolin	APHIDICOLIN	n/a	4/20/16	Designated			N/A	N/A	Biospherics.net LLC	Nicholasville	Kentucky	40356	USA	EXACT	0841214AA	aphidicolin	192TJ6PP19						Ebola virus disease	2035	done	
apolipoprotein E mimetic peptide (AEM-28(R)-14)	Treatment of homozygous familial hypercholesterolemia (HoFH)	apolipoprotein E mimetic peptide (AEM-28(R)-14)	SELETALISIB	n/a	8/7/17	Designated			N/A	N/A	"LipimetiX Development, LLC"	Natick	Massachusetts	1760	USA	EXACT	1120383AA	seletalisib	64CW205BDD						Familial hypercholesterolemia	10416	done	Not a rare disease
apolipotrotein C-III antisense oligonucleotide	treatment of familial chylomicronemia syndrome	"volanesorsen sodium, apolipotrotein C-III antisense oligonucleotide"		n/a	6/23/15	Designated			N/A	N/A	"Ionis Pharmaceuticals, Inc."	Carlsbad	California	92010	USA				6JON30SLDT	VOLANESORSEN SODIUM	6JON30SLDT	https://ginas.ncats.nih.gov/ginas/app/substances?q=VOLANESORSEN%20SODIUM	done				MISSING	"The term familial chylomicronemia is sometimes used synonymously with familial lipoprotein lipase deficiency. However, there are different causes of familial chylomicronemia."
apremilast	Treatment of Behcet's disease	apremilast	APREMILAST	n/a	1/17/13	Designated			N/A	N/A	Celgene Corporation	Summit	New Jersey	7901	USA	EXACT	0253123AA	apremilast	UP7QBP99PN						Behçet disease	848	done	
apremilast	Treatment of pediatric patients with ulcerative colitis	apremilast	APREMILAST	Otezla®	1/17/18	Designated			N/A	N/A	Celgene Corporation	86 Morris Avenue	Summit	7901	USA	EXACT	0253123AA	apremilast	UP7QBP99PN						Pediatric ulcerative colitis	9857	done	
arimoclomol citrate	"Treatment of Neimann-Pick disease, type C"	arimoclomol citrate	ARIMOCLOMOL CITRATE	n/a	1/13/15	Designated			N/A	N/A	Orphazyme ApS				Denmark	EXACT	0909320AA	arimoclomol citrate	Q85FFY6179						Niemann-Pick disease type C1 	7207	done	
arimoclomol citrate	"Treatment of Neimann-Pick disease, type C"	arimoclomol citrate	ARIMOCLOMOL CITRATE	n/a	1/13/15	Designated			N/A	N/A	Orphazyme ApS				Denmark	EXACT	0909320AA	arimoclomol citrate	Q85FFY6179						 Niemann-Pick disease type C2	3992	done	
aripiprazole	Treatment of Tourette's syndrome	aripiprazole	ARIPIPRAZOLE	Abilify	1/25/06	Designated/Approved	Approved for Orphan Indication	Treatment of pediatric patients with Tourette's	12/12/14	12/12/21	Otsuka Pharmaceutical Development	Princeton	New Jersey	8540	USA	EXACT	0183200AA	aripiprazole	82VFR53I78						Tourette syndrome	7783	done	
arq-087 dihydrochloride	Treatment of cholangiocarcinoma.	"(R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride"	DERAZANTINIB DIHYDROCHLORIDE	n/a	11/19/15	Designated			N/A	N/A	"ArQule, Inc."	Burlington	Massachusetts	1803	USA	EXACT	1193073AA	arq-087 dihydrochloride	U6B7J0L31Q						Intrahepatic cholangiocarcinoma	6042	done	
arsenic	"Treatment of acute myelocytic leukemia subtypes M0, M1, M2, M4, M5, M6 and M7"	arsenic	ARSENIC	Trisenox	11/2/01	Designated			N/A	N/A	"Teva Branded Pharmaceutical Products R&D, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0048180AA	arsenic	N712M78A8G						Unclassified acute myeloid leukemia	12760	approximate	
arsenic trioxide	Treatment of Graft-versus-host disease	arsenic trioxide	ARSENIC TRIOXIDE	Arscimed	7/30/18	Designated			N/A	N/A	Medsenic	204 avenue de Colmar			France	EXACT	0034720AA	arsenic trioxide	S7V92P67HO						Chronic graft versus host disease 	10964	done	
arsenic trioxide	Treatment of Graft-versus-host disease	arsenic trioxide	ARSENIC TRIOXIDE	Arscimed	7/30/18	Designated			N/A	N/A	Medsenic	204 avenue de Colmar			France	EXACT	0034720AA	arsenic trioxide	S7V92P67HO						 Acute graft versus host disease	6544	done	
arsenic trioxide	Treatment of liver cancer	arsenic trioxide	ARSENIC TRIOXIDE	Trisenox	6/13/03	Designated			N/A	N/A	"Teva Branded Pharmaceutical Products R&D, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0034720AA	arsenic trioxide	S7V92P67HO						Primary liver cancer	6608	approximate	
artemether	For the treatment of infections due to Plasmodium falciparum or mixed infections including P. falciparum.	artemether/lumefantrine	ARTEMETHER	Coartem	8/31/07	Designated/Approved	Approved for Orphan Indication	"Treatment of malaria in patients of 5 kg bodyweight or above with acute, uncomplicated malaria due to Plasmodium falciparum or mixed infections including P. falciparum"	4/7/09	4/7/16	Novartis Pharmaceuticals	East Hanover	New Jersey	7936	USA	EXACT	0303311AA	artemether	C7D6T3H22J						Malaria	6961	done	
artesunate	Treatment of malaria	fixed dose combination of pyronaridine tetraphosphate and artesunate	ARTESUNATE	Pyramax®	9/27/18	Designated			N/A	N/A	"Shin Poong Pharmaceutical Co., Ltd."	"161 Yoksam-Ro, Gangnam-Gu"			"Korea, Republic of"	EXACT	0237285AA	artesunate	60W3249T9M						Malaria	6961	done	
asciminib	Treatment of chronic myelogenous leukemia	asciminib	ASCIMINIB	n/a	2/27/17	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	1290159AA	asciminib	L1F3R18W77						Chronic myeloid leukemia	6105	done	
astuprotimut-R	Treatment of MAGE-A3 positive non-small cell lung cancer	astuprotimut-R	ASTUPROTIMUT-R	n/a	5/29/09	Designated			N/A	N/A	"GlaxoSmithKline Biologicals, S.A."				Belgium	EXACT	0335375AA	astuprotimut-R	50I23C5UOR						"Non-small cell lung cancer, childhood"	9343	approximate	
atezolizumab	"Treatment of Stage llb, llc, lll and IV melanoma"	atezolizumab	ATEZOLIZUMAB	Tecentriq(Tm)	2/13/17	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	1113913AA	atezolizumab	52CMI0WC3Y						"Melanoma, familial"	3460	approximate	melanoma type is not specified
autologous CD34+ bone marrow derived stem cells transduced with a self-inactivating gammaretroviral vector encoding the human IL2RG (yc)	Treatment of severe combined immune deficiency-X1	autologous CD34+ bone marrow derived stem cells transduced with a self-inactivating gammaretroviral vector encoding the human IL2RG (yc)	BONE MARROW	n/a	1/15/15	Designated			N/A	N/A	Boston Children's Hospital	Boston	Massachusetts	2115	USA	LONGEST CONTAINS	0100072AA	bone marrow					PROBLEM	can't find	X-linked severe combined immunodeficiency	5618	done	
autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene	For the treatment of Sickle Cell Disease	autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene	STEM CELLS	n/a	2/26/14	Designated			N/A	N/A	bluebird bio Inc.	Cambridge	Massachusetts	2139	USA	LONGEST CONTAINS	0264620AA	stem cells					PROBLEM	can't find	Sickle cell anemia	8614	done	
autologous CD4+CD25hiFoxP3+regulatory T cells	Prevention of graft rejection following solid organ transplantation	autologous CD4+CD25hiFoxP3+regulatory T cells		n/a	11/19/13	Designated			N/A	N/A	iREG Medical AB	Uppsala			Sweden								PROBLEM	can't find	Chronic graft versus host disease	10964	approximate	type of GVHD (acute or chronic) is not specified
autologous CD4+CD25hiFoxP3+regulatory T cells	Prevention of graft rejection following solid organ transplantation	autologous CD4+CD25hiFoxP3+regulatory T cells		n/a	11/19/13	Designated			N/A	N/A	iREG Medical AB	Uppsala			Sweden								PROBLEM	can't find	Acute graft versus host disease	6544	approximate	type of GVHD (acute or chronic) is not specified
autologous Cytokine-Induced Killer Cells (Cytokine-induced Killer Cells plus Cytotoxic T Lymphocytes)	Treatment of Pancreatic Cancer.	autologous Cytokine-Induced Killer Cells (Cytokine-induced Killer Cells plus Cytotoxic T Lymphocytes)	LYMPHOCYTES	n/a	9/10/18	Designated			N/A	N/A	Green Cross Cell Corporation	"4, 6th floor, SJ Technovile 278"			"Korea, Republic of"	LONGEST CONTAINS	0263092AA	Lymphocytes	J56RKY13OV	HUMAN THYMOCYTE | Immuncell-Lc	J56RKY13OV	https://ginas.ncats.nih.gov/ginas/app/substance/9784a943 | http://www.checkorphan.org/treatments/b4fa10fd74b433e67f5ee2ecf3a4303b	approximate		Pancreatic cancer	9364	done	
autologous Epstein-Barr specific T-cells	Treatment of post-transplant lymphoproliferative disorder	autologous Epstein-Barr specific T-cells		n/a	5/31/17	Designated			N/A	N/A	"Cell Medica, Inc."	Houston	Texas	77054	USA				F9670LP52I	BALTALEUCEL-T	F9670LP52I	https://ginas.ncats.nih.gov/ginas/app/substance/1bff87af	done		Post-transplant lymphoproliferative disease	9553	done	
autologous T lymphocyte enriched population cultured in the rpesence of phosphatidylinositol 3-kinase inhibitor (bb007) that contains cells transduced with an anti-human B cell maturation antigen (BCMA02) chimeric antigen receptor (CAR) lentiviral vector encoding a CAR that targets human BCMA	Treatment of multiple myeloma	autologous T lymphocyte enriched population cultured in the rpesence of phosphatidylinositol 3-kinase inhibitor (bb007) that contains cells transduced with an anti-human B cell maturation antigen (BCMA02) chimeric antigen receptor (CAR) lentiviral vector encoding a CAR that targets human BCMA	PHOSPHATIDYLINOSITOL	n/a	10/5/17	Designated			N/A	N/A	"bluebird bio, Inc."	Cambridge	Massachusetts	2142	USA	LONGEST CONTAINS	0144649AA	phosphatidylinositol	J56RKY13OV	HUMAN THYMOCYTE	J56RKY13OV	https://ginas.ncats.nih.gov/ginas/app/substance/9784a943	PROBLEM	absent from GINAS	Multiple myeloma	7108	done	
autologous adipose tissue derived mesenchymal stem cells	Treatment of Buerger's disease (thromboangiitis obliterans).	autologous adipose tissue derived mesenchymal stem cells	MESENCHYMAL STEM CELLS	n/a	5/4/16	Designated			N/A	N/A	Biostar Stem Cell Research Institute	Seoul			"Korea, Republic of"	LONGEST CONTAINS	1339839AA	mesenchymal stem cells	9DRI670EXJ | 15A1NQ39W2	HUMAN ADIPOSE TISSUE DERIVED CELL | HUMAN AUTOLOGOUS ADIPOSE TISSUE	9DRI670EXJ | 15A1NQ39W2	https://ginas.ncats.nih.gov/ginas/app/substance/ac1f6e34 | https://ginas.ncats.nih.gov/ginas/app/substance/2aadefea	approximate		Buerger disease	5969	done	
"autologous bone marrow CD34+ cells transduced ex vivo with a self activating HIV-1 -based lentiviral vector, EFS-ADA"	Treatment of adenosine deaminase deficient severe combined immunodeficiency	"autologous bone marrow CD34+ cells transduced ex vivo with a self activating HIV-1 -based lentiviral vector, EFS-ADA"	"BONE MARROW, AUTOLOGOUS"	n/a	10/21/14	Designated			N/A	N/A	"Donald B. Kohn, MD - Professor, UC-UCLA"	Los Angeles	California	90095	USA	LONGEST CONTAINS	0260924AA	autologous bone marrow					PROBLEM	can't find	Adenosine deaminase deficiency	5748	done	
autologous ex vivo expanded polyclonal CD4+CD25+CD1271o/-FOXP3+ Regulatory T cells	Treatment of type 1 diabetes mellitus with residual beta cell function	autologous ex vivo expanded polyclonal CD4+CD25+CD1271o/-FOXP3+ Regulatory T cells		n/a	5/10/16	Designated			N/A	N/A	Caladrius Biosciences	Irvine	California	92612	USA				J56RKY13OV	HUMAN THYMOCYTE	J56RKY13OV	https://ginas.ncats.nih.gov/ginas/app/substances?q=HUMAN%20T-CELLS	approximate		Diabetes mellitus type 1	10268	done	not a rare disease
autologous human adipose perivascular stromal cells genetically modified to secrete soluble Tumor Necrosis Factor-related Apoptosis-inducing Ligand (sTRAIL)	Treatment of Pancreatic Cancer	autologous human adipose perivascular stromal cells genetically modified to secrete soluble Tumor Necrosis Factor-related Apoptosis-inducing Ligand (sTRAIL)	HUMAN ADIPOSE	n/a	5/22/18	Designated			N/A	N/A	Rigenerand Srl	"4, Via Maestri del Lavoro"			Italy	LONGEST CONTAINS	0762629AA	human adipose	LOS728452T						Pancreatic cancer	9364	done	
"autologous lymphocytes depleted ex vivo of immunoreactive T cells using 4,5"	Treatment of chronic graft versus host disease	"autologous lymphocytes depleted ex vivo of immunoreactive T cells using 4,5"	LYMPHOCYTES	Theralux Photodynamic Therapy	4/3/08	Designated			N/A	N/A	"Kiadis Pharma Canada, Inc."				Canada	LONGEST CONTAINS	0263092AA	lymphocytes					PROBLEM	can't find	Chronic graft versus host disease	10964	done	
autologous mononuclear cells derived from umbilical cord blood	Treatment of severe pediatric congenital heart disease	autologous mononuclear cells derived from umbilical cord blood	CORD BLOOD	n/a	7/13/17	Designated			N/A	N/A	"Timothy Nelson, MD, PhD"	Rochester	Minnesota	55902	USA	LONGEST CONTAINS	0854240AA	umbilical cord blood	PVH8394DLN								MISSING	congenital heart disease not specified
autologous neo-uninary conduit	Treatment of bladder dysfunction requiring incontinent urinary diversion.	autologous neo-uninary conduit		n/a	6/7/11	Designated			N/A	N/A	"Tengion, Inc."	East Norriton	Pennsylvania	19403	USA								PROBLEM	can't find			MISSING	
autologous osteogenic cells cultured from adipose tissue derived stem cells embedded in extracellular matrix with demineralized bone matrix.	Treatment of congenital pseudarthrosis of the tibia	autologous osteogenic cells cultured from adipose tissue derived stem cells embedded in extracellular matrix with demineralized bone matrix.	STEM CELLS	n/a	6/30/16	Designated			N/A	N/A	Novadip Biosciences	Mont-Saint-Guibert			Belgium	LONGEST CONTAINS	0264620AA	stem cells	9DRI670EXJ | FS47DYA83E	HUMAN ADIPOSE TISSUE DERIVED CELL | HUMAN DEMINERALIZED BONE MATRIX	9DRI670EXJ | FS47DYA83E	https://ginas.ncats.nih.gov/ginas/app/substance/ac1f6e34 | https://ginas.ncats.nih.gov/ginas/app/substance/3afa8baf	approximate				MISSING	
"autologous tumor cells fused with polyethylene glycol to human allogeneic FO-1, DNA plasmid transfected tumor cell line"	Treatment of glioblastoma	"autologous tumor cells fused with polyethylene glycol to human allogeneic FO-1, DNA plasmid transfected tumor cell line"	"POLYETHYLENE GLYCOL, UNSPECIFIED"	n/a	5/6/15	Designated			N/A	N/A	"Sebastiano Gattoni-Celli, MD"	Charleston	South Carolina	29403	USA	LONGEST CONTAINS	0137031AA	polyethylene glycol	3WJQ0SDW1A						Glioblastoma	2491	done	
autologous tumor infiltrating lymphocytes (TIL)	Treatment of cervical cancer with a tumor size greater than 2 cm. in diameter	autologous tumor infiltrating lymphocytes (TIL)	LYMPHOCYTES	n/a	4/30/18	Designated			N/A	N/A	"Iovance Biotherapeutics, Inc."	999 Skyway Road	Suite 150	94070	USA	LONGEST CONTAINS	0263092AA	lymphocytes					PROBLEM	can't find	Glassy cell carcinoma of the cervix	8437	approximate	type of cervical cancer not specified
autologous umbilical cord blood	Treatment of pediatric (0-16 yrs old inclusive) cerebral palsy due to acquired brain injury	autologous umbilical cord blood	CORD BLOOD	n/a	7/24/12	Designated			N/A	N/A	Duke University	Durham	North Carolina	27710	USA	LONGEST CONTAINS	0854240AA	umbilical cord blood	PVH8394DLN						Cerebral palsy	10450	approximate	
avelumab	Treatment of gastric cancer (GC) including cancer of the gastroesophageal junction (GEJ)	avelumab	AVELUMAB	Bavencio	10/11/17	Designated			N/A	N/A	"EMD Serono Research & Development Institute, Inc."	Billerica	Massachusetts	1821	USA	EXACT	0935433AA	avelumab	KXG2PJ551I						Stomach cancer	7704	done	
avobenzone	For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy	"Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide"	AVOBENZONE	Total Block Vl Spf 75	8/13/01	Designated			N/A	N/A	Fallien Cosmeceuticals Ltd.	King of Prussia	Pennsylvania	19406	USA	EXACT	0128461AA	avobenzone	G63QQF2NOX								MISSING	
axitinib	Treatment of pancreatic cancer	axitinib	AXITINIB	n/a	5/31/07	Designated/Withdrawn			N/A	N/A	"Pfizer, Inc."	San Diego	California	92121	USA	EXACT	0242897AA	axitinib	C9LVQ0YUXG						Pancreatic cancer	9364	done	Not a rare disease
aztreonam	Improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.	aztreonam	AZTREONAM	n/a	5/15/09	Designated/Withdrawn			N/A	N/A	"Gilead Sciences, Inc."	Seattle	Washington	98121	USA	EXACT	0116723AA	aztreonam	G2B4VE5GH8								MISSING	
baclofen	Treatment of dystonia	baclofen	BACLOFEN	n/a	12/2/03	Designated			N/A	N/A	Medtronic Neurological	Minneapolis	Minnesota	55432	USA	EXACT	0032804AA	baclofen	H789N3FKE8						Cervical dystonia	10668	approximate	
baclofen	"Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy)."	baclofen	BACLOFEN	Lioresal Intrathecal	11/10/87	Designated/Approved	Approved for Orphan Indication	Management of severe spasticity of spinal cord origin in patients who are unresponsive to oral baclofen therapy or experience intolerable CNS side effects at effective doses.	6/25/92	6/25/99	"Medtronic, Inc."	Minneapolis	Minnesota	55432	USA	EXACT	0032804AA	baclofen	H789N3FKE8						Transverse myelitis	7796	approximate	
baclofen	Treatment of intractable spasticity due to multiple sclerosis or spinal cord injury.	baclofen	BACLOFEN	n/a	12/16/91	Designated			N/A	N/A	"Metacel Pharmaceuticals, LLC"	Winder	Georgia	30680	USA	EXACT	0032804AA	baclofen	H789N3FKE8						Multiple sclerosis	10255	done	Not a rare disease
bacterium Bacteroides thetaiotaomicron	Treatment of active Crohn's disease in the pediatric population	bacterium Bacteroides thetaiotaomicron		n/a	9/26/13	Designated			N/A	N/A	4D Pharma Research Ltd				United Kingdom				6237OJ3T5Q	BACTEROIDES FRAGILIS	6237OJ3T5Q	https://ginas.ncats.nih.gov/ginas/app/substance/f4e5a8d2	done		Crohn's disease	10232	done	Not a rare disease
baricitinib	Treatment of pediatric systemic lupus erythematosus	baricitinib	BARICITINIB	Olumiant	11/2/17	Designated			N/A	N/A	Eli Lilly and Company	Lilly Corporate Center	Indiana	46285	USA	EXACT	0701133AA	baricitinib	ISP4442I3Y						Lupus	10253	done	
bb-3	To improve renal function and prevent delayed graft function following renal transplantation	refanalin	BB-3	n/a	5/25/10	Designated			N/A	N/A	Angion Biomedica Corporation	Garden City	New York	11530	USA	EXACT	0541957AA	bb-3	GG91UXK2M5								MISSING	
becaplermin	Treatment of osteonecrosis of the jaws	Recombinant human platelet derived growth factor BB	BECAPLERMIN	n/a	2/1/07	Designated			N/A	N/A	"Luitpold Pharmaceuticals, Inc."	Norristown	Pennsylvania	19403	USA	EXACT	0226755AA	becaplermin	1B56C968OA								MISSING	
beclomethasone	Treatment of pediatriac patients with ulcerative colitis	beclomethasone	BECLOMETHASONE	n/a	3/4/09	Designated			N/A	N/A	"Aptalis Pharma US, Inc."	Bridgewater	New Jersey	8807	USA	EXACT	0137291AA	beclomethasone	KGZ1SLC28Z						Pediatric ulcerative colitis	9857	done	not a rare disease
"beclomethasone 17,21-dipropionate"	Prevention of gastrointestinal graft-versus-host disease	"beclomethasone 17,21-dipropionate"	BECLOMETHASONE DIPROPIONATE	Bec	8/28/01	Designated			N/A	N/A	"Soligenix, Inc."	Princeton	New Jersey	8540	USA	EXACT	0043798AA	BECLOMETHASONE DIPROPIONATE	5B307S63B2						Chronic graft versus host disease	10964	approximate	type of GVHD (acute or chronic) is not specified
"beclomethasone 17,21-dipropionate"	Prevention of gastrointestinal graft-versus-host disease	"beclomethasone 17,21-dipropionate"	BECLOMETHASONE DIPROPIONATE	Bec	8/28/01	Designated			N/A	N/A	"Soligenix, Inc."	Princeton	New Jersey	8540	USA	EXACT	0043798AA	BECLOMETHASONE DIPROPIONATE	5B307S63B2						Acute graft versus host disease	6544	approximate	type of GVHD (acute or chronic) is not specified
"beclomethasone 17,21-dipropionate"	Treatment of gastrointestinal symptoms with chronic graft versed host disease in patients undergoing allogenic hematopoietic cell transplantation	"beclomethasone 17,21-dipropionate"	BECLOMETHASONE DIPROPIONATE	Orbec(R)	7/24/09	Designated			N/A	N/A	"Soligenix, Inc."	Princeton	New Jersey	8540	USA	EXACT	0043798AA	BECLOMETHASONE DIPROPIONATE	5B307S63B2						Chronic graft versus host disease	10964	done	not a rare disease
"beclomethasone 17,21-diproprionate"	Treatment of pediatric patients with Crohn disease.	"beclomethasone 17,21-diproprionate"	BECLOMETHASONE DIPROPIONATE	n/a	12/18/07	Designated			N/A	N/A	"Soligenix, Inc."	Princeton	New Jersey	8540	USA	EXACT	0043798AA	"beclomethasone 17,21-diproprionate"	5B307S63B2						Pediatric Crohn's disease	9856	done	
bedaquiline	Treatment of active tuberculosis	"bedaquiline; (1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol"	BEDAQUILINE	Sirturo	1/10/05	Designated/Approved	Approved for Orphan Indication	Part of combination therapy in adults (greater than or equal to 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB).	12/28/12	12/28/19	"Janssen Research & Development, LLC"	Raritan	New Jersey	8869	USA	EXACT	0338421AA	bedaquiline	78846I289Y						Tuberculosis	7827	done	
belatacept	Prophylaxis of organ rejection in renal allograft recipients	belatacept	BELATACEPT	Nulojix	2/20/08	Designated/Approved	Approved for Orphan Indication	Prophylaxis of organ rejection in adult patients receiving kidney transplants	6/15/11	6/15/18	Bristol-Myers Squibb Company	Princeton	New Jersey	8543	USA	EXACT	0297950AA	belatacept	E3B2GI648A								MISSING	
bendamustine for 50ml admixture	"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)"	bendamustine for 50ml admixture	BENDAMUSTINE	Bendeka	7/2/14	Designated/Approved	Approved for Orphan Indication	Treatment of patients with CLL and treatment of patients with indolent B-cell NHL	12/7/15	N/A	"Eagle Pharmaceuticals, Inc."	Woodcliff Lake	New Jersey	7677	USA	EXACT	0304245AA	bendamustine	9266D9P3PQ						Waldenstrom macroglobulinemia 	7872	done	
bendamustine for 50ml admixture	"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)"	bendamustine for 50ml admixture	BENDAMUSTINE	Bendeka	7/2/14	Designated/Approved	Approved for Orphan Indication	Treatment of patients with CLL and treatment of patients with indolent B-cell NHL	12/7/15	N/A	"Eagle Pharmaceuticals, Inc."	Woodcliff Lake	New Jersey	7677	USA	EXACT	0304245AA	bendamustine	9266D9P3PQ						 Marginal zone lymphoma 	13237	done	
bendamustine for 50ml admixture	"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)"	bendamustine for 50ml admixture	BENDAMUSTINE	Bendeka	7/2/14	Designated/Approved	Approved for Orphan Indication	Treatment of patients with CLL and treatment of patients with indolent B-cell NHL	12/7/15	N/A	"Eagle Pharmaceuticals, Inc."	Woodcliff Lake	New Jersey	7677	USA	EXACT	0304245AA	bendamustine	9266D9P3PQ						  B-cell lymphoma 	5877	done	
bendamustine for 50ml admixture	"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)"	bendamustine for 50ml admixture	BENDAMUSTINE	Bendeka	7/2/14	Designated/Approved	Approved for Orphan Indication	Treatment of patients with CLL and treatment of patients with indolent B-cell NHL	12/7/15	N/A	"Eagle Pharmaceuticals, Inc."	Woodcliff Lake	New Jersey	7677	USA	EXACT	0304245AA	bendamustine	9266D9P3PQ						 Follicular lymphoma	2356	done	
bendamustine hydrochloride	"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)"	bendamustine hydrochloride	BENDAMUSTINE HYDROCHLORIDE	Treanda	11/26/13	Designated/Approved	Approved for Orphan Indication	Treatment of Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.	10/31/08	10/31/15	"Cephalon, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0249241AA	bendamustine hydrochloride	981Y8SX18M						Waldenstrom macroglobulinemia 	7872	done	
bendamustine hydrochloride	"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)"	bendamustine hydrochloride	BENDAMUSTINE HYDROCHLORIDE	Treanda	11/26/13	Designated/Approved	Approved for Orphan Indication	Treatment of Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.	10/31/08	10/31/15	"Cephalon, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0249241AA	bendamustine hydrochloride	981Y8SX18M						 Marginal zone lymphoma 	13237	done	
bendamustine hydrochloride	"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)"	bendamustine hydrochloride	BENDAMUSTINE HYDROCHLORIDE	Treanda	11/26/13	Designated/Approved	Approved for Orphan Indication	Treatment of Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.	10/31/08	10/31/15	"Cephalon, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0249241AA	bendamustine hydrochloride	981Y8SX18M						  B-cell lymphoma 	5877	done	
bendamustine hydrochloride	"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)"	bendamustine hydrochloride	BENDAMUSTINE HYDROCHLORIDE	Treanda	11/26/13	Designated/Approved	Approved for Orphan Indication	Treatment of Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.	10/31/08	10/31/15	"Cephalon, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0249241AA	bendamustine hydrochloride	981Y8SX18M						 Follicular lymphoma	2356	done	
benznidazole	Treatment of Chagas disease	benznidazole	BENZNIDAZOLE	n/a	4/14/14	Designated			N/A	N/A	"Chemo Research, S.L."	Madrid			Spain	EXACT	0161740AA	benznidazole	YC42NRJ1ZD						Chagas disease	6030	done	Not a rare disease
benzoate	Treatment of pediatric schizophrenia	benzoate	BENZOIC ACID	Naben	7/6/12	Designated			N/A	N/A	SyneuRx International (Taiwan) Corp.	Pasadena	California	91106	USA	EXACT	0011461AA	benzoate	8SKN0B0MIM						Childhood-Onset Schizophrenia	4766	done	
benzoate /phenylacetate	Treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.	benzoate/phenylacetate	BENZOIC ACID	Ammonul	11/22/93	Designated/Approved	Approved for Orphan Indication	Adjunctive therapy in the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.	2/17/05	2/17/12	Medicis Pharmaceutical Corp.	Scottsdale	Arizona	85258	USA	EXACT	0011461AA	benzoate	8SKN0B0MIM						Urea cycle disorders	7837	approximate	
benzoate/ phenylacetate	Treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.	benzoate/phenylacetate	PHENYL ACETATE	Ammonul	11/22/93	Designated/Approved	Approved for Orphan Indication	Adjunctive therapy in the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.	2/17/05	2/17/12	Medicis Pharmaceutical Corp.	Scottsdale	Arizona	85258	USA	EXACT	0019512AA	phenylacetate	355G9R500Y						Urea cycle disorders	7837	approximate	
benzylpenilloic acid	Assessing the risk of administrating penicillin when it is the preferred drug of choice in adult patients who have previously received penicillin and have a history of clinical sensitivity.	"Benzylpenicillin, benzylpenicilloic, benzylpenilloic acid"	PENILLOIC ACID	Pre-Pen/Mdm	9/28/87	Designated			N/A	N/A	AllerQuest LLC	West Hanford	Connecticut	6119	USA	EXACT	0962061AA	benzylpenilloic acid	F93JSF8762								MISSING	
bevacizumab	Treatment of Coat's disease	bevacizumab	BEVACIZUMAB	n/a	3/10/16	Designated			N/A	N/A	"MicroSert, Ltd."	Nesher			Israel	EXACT	0244257AA	bevacizumab	2S9ZZM9Q9V						Coats disease	6121	done	
bevacizumab	Treatment of mesothelioma	bevacizumab	BEVACIZUMAB	Avastin	1/27/16	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0244257AA	bevacizumab	2S9ZZM9Q9V						Malignant mesothelioma	7026	done	
bevacizumab	Treatment of pancreatic cancer	bevacizumab	BEVACIZUMAB	Avastin	10/20/04	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0244257AA	bevacizumab	2S9ZZM9Q9V						Pancreatic cancer	9364	done	Not a rare disease
bi-shRNA furin and GMCSF Autologous Tumor Cell Vaccine	Treatment of Ewing's sarcoma	bi-shRNA furin and GMCSF Autologous Tumor Cell Vaccine	FURIN	Fang	10/22/14	Designated			N/A	N/A	"Gradalis, Inc."	Carrollton	Texas	75006	USA	LONGEST CONTAINS	1315748AA	furin					PROBLEM	can't find	Ewing's family of tumors	9323	approximate	
bictegravir	Treatment of Human Immunodeficiency Virus type 1 infection in pediatric patients	bictegravir/emtricitabine/tenofovir disoproxil fumarate	BICTEGRAVIR	n/a	5/17/17	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	1066940AA	bictegravir	8GB79LOJ07								MISSING	
"bilayer, engineered collagen hydrogel-based skin graft composed of autologous keratinocytes and fibroblasts"	Treatment of partial deep dermal and full thickness burn wounds	"bilayer, engineered collagen hydrogel-based skin graft composed of autologous keratinocytes and fibroblasts"	COLLAGEN	Primeskin	9/6/16	Designated			N/A	N/A	University Children's Hospital Zurich	Zürich			Switzerland	LONGEST CONTAINS	0006462AA	collagen	PT3TGI7OIP | 022461SR75 | 0EE2343509	HUMAN TYPE I COLLAGEN (SKIN) | AZFICEL-T | HUMAN SKIN | Primeskin	PT3TGI7OIP | 022461SR75 | 0EE2343509	https://ginas.ncats.nih.gov/ginas/app/substance/e7a8c464 | https://ginas.ncats.nih.gov/ginas/app/substance/7fd93703 | https://ginas.ncats.nih.gov/ginas/app/substance/9a9259c1 | https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=532816	approximate				MISSING	
biocarbonate infusate	Use in the management of patients undergoing continuous renal replacement therapy with hemofiltration	biocarbonate infusate		Normocarb Hf	8/9/05	Designated/Approved	Approved for Orphan Indication	Use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace water and to correct electrolytes and acid-base imbalances in adults and children	7/26/06	7/26/13	"Dialysis Solutions, Inc."				Canada					bicarbonate infusate	NA	https://www.ncbi.nlm.nih.gov/pubmed/1579193	done				MISSING	procedure
bisoctrizole	"For the secondary prevention (prevention of lesional induction) of disorders with UV-A and visible light-induced photosensitivity, specifically Actinic prurigo, Hydroa vacciniforme, Solar urticara (SU), Chronic Actinic Dermatitis (CAD), the cutaneous prophyrias, Smith-Lemli-Optiz Syndrome, and Hartnup's Disease."	Titanium dioxide and bisoctrizole	BISOCTRIZOLE	n/a	5/25/05	Designated/Withdrawn			N/A	N/A	Orfagen				France	EXACT	0254579AA	bisoctrizole	8NT850T0YS						Hartnup disease 	5683	done	
bisoctrizole	"For the secondary prevention (prevention of lesional induction) of disorders with UV-A and visible light-induced photosensitivity, specifically Actinic prurigo, Hydroa vacciniforme, Solar urticara (SU), Chronic Actinic Dermatitis (CAD), the cutaneous prophyrias, Smith-Lemli-Optiz Syndrome, and Hartnup's Disease."	Titanium dioxide and bisoctrizole	BISOCTRIZOLE	n/a	5/25/05	Designated/Withdrawn			N/A	N/A	Orfagen				France	EXACT	0254579AA	bisoctrizole	8NT850T0YS						 Hydroa vacciniforme 	9654	done	
bisoctrizole	"For the secondary prevention (prevention of lesional induction) of disorders with UV-A and visible light-induced photosensitivity, specifically Actinic prurigo, Hydroa vacciniforme, Solar urticara (SU), Chronic Actinic Dermatitis (CAD), the cutaneous prophyrias, Smith-Lemli-Optiz Syndrome, and Hartnup's Disease."	Titanium dioxide and bisoctrizole	BISOCTRIZOLE	n/a	5/25/05	Designated/Withdrawn			N/A	N/A	Orfagen				France	EXACT	0254579AA	bisoctrizole	8NT850T0YS						 Smith-Lemli-Opitz syndrome	6569	done	
bitopertin	Treatment of ß-thalassemia	bitopertin	BITOPERTIN	n/a	8/16/17	Designated			N/A	N/A	Hoffmann-La Roche Inc.	South San Francisco	California	94080	USA	EXACT	0459825AA	bitopertin	Q8L6AN59YY						Beta-thalassemia	871	done	
blinatumomab	Treatment of acute lymphocytic leukemia	blinatumomab	BLINATUMOMAB	Blincyto	5/16/08	Designated/Approved	Approved for Orphan Indication	Treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).	12/3/14	12/3/21	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0322758AA	blinatumomab	4FR53SIF3A						Acute lymphoblastic leukemia	522	done	
blinatumomab	"Treatment of indolent B-cell lymphoma, excluding CLL and NHL with CNS involvement"	blinatumomab	BLINATUMOMAB	n/a	2/6/06	Designated			N/A	N/A	"Amgen, Inc."	Thousand Oaks	California			EXACT	0322758AA	blinatumomab	4FR53SIF3A						Indolent B cell lymphoma	10482	done	
blinatumomab	Treatment of prolymphocytic leukemia	blinatumomab	BLINATUMOMAB	n/a	5/16/08	Designated			N/A	N/A	"Amgen, Inc."	Thousand Oaks	California			EXACT	0322758AA	blinatumomab	4FR53SIF3A						B cell prolymphocytic leukemia	8223	done	
blisibimod	Treatment of patients with immunoglobulin A nephropathy	blisibimod	BLISIBIMOD	n/a	8/7/17	Designated			N/A	N/A	"Anthera Pharmaceuticals, Inc."	Hayward	California	94545	USA	EXACT	0267505AA	blisibimod	114VP6C6ES								MISSING	
bosentan	Reduction of the number (treatment) of new digital ulcers in patients with systemic sclerosis	bosentan	BOSENTAN	Tracleer(R)	6/7/10	Designated/Withdrawn			N/A	N/A	Actelion Ltd.				Switzerland	EXACT	0186663AA	bosentan	Q326023R30						Systemic scleroderma	9748	done	
bosutinib	Treatment of chronic myelogenous leukemia	bosutinib	BOSUTINIB	Bosulf	2/24/09	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy"	9/4/12	9/4/19	"Wyeth Pharmaceuticals, Inc."	Groton	Connecticut	6340	USA	EXACT	0306694AA	bosutinib	5018V4AEZ0						Chronic myeloid leukemia	6105	done	
"botulism antitoxin heptavalent (A, B, C, D, E, F, G) (Equine)"	Treatment of botulism.	"botulism antitoxin heptavalent (A, B, C, D, E, F, G) (Equine)"	BOTULISM ANTITOXIN	n/a	6/29/11	Designated/Approved	Approved for Orphan Indication	"Treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients"	3/22/13	3/22/20	Cangene Corporation				Canada	LONGEST CONTAINS	0099025AA	botulism antitoxin	RJN8G983LQ | T95649SUV7 | LE3J6I6DXP | X5I2P7E9TY | 30Y9N0SEBE | 943578J0XG	EQUINE BOTULINUM NEUROTOXIN F IMMUNE FAB2 | EQUINE BOTULINUM NEUROTOXIN E IMMUNE FAB2 | EQUINE BOTULINUM NEUROTOXIN A IMMUNE FAB2 | EQUINE BOTULINUM NEUROTOXIN C IMMUNE FAB2 | EQUINE BOTULINUM NEUROTOXIN D IMMUNE FAB2 | EQUINE BOTULINUM NEUROTOXIN G IMMUNE FAB2	RJN8G983LQ | T95649SUV7 | LE3J6I6DXP | X5I2P7E9TY | 30Y9N0SEBE | 943578J0XG	https://ginas.ncats.nih.gov/ginas/app/substances?q=EQUINE%20BOTULISM%20ANTITOXIN%20F%20(FAB2) |  https://ginas.ncats.nih.gov/ginas/app/substances?q=EQUINE%20BOTULINUM%20NEUROTOXIN%20E%20IMMUNE%20FAB2 | https://ginas.ncats.nih.gov/ginas/app/substance/a8473499 | https://ginas.ncats.nih.gov/ginas/app/substance/68868371 | https://ginas.ncats.nih.gov/ginas/app/substance/ab37108a | https://ginas.ncats.nih.gov/ginas/app/substance/0410ffbc	done		Botulism	943	done	
bovine lactoferrin	Prevention of late-onset sepsis in very low birth weight infants	bovine lactoferrin	"LACTOFERRIN, BOVINE"	n/a	2/19/15	Designated			N/A	N/A	"Metrodora Therapeutics, LLC"	Brooklyn	New York	11210	USA	EXACT	0187393AA	bovine lactoferrin	KG21X1090A								MISSING	
brentuximab vedotin	Treatment of Hodgkin's lymphoma	brentuximab vedotin	BRENTUXIMAB VEDOTIN	Adcetris	1/30/07	Designated/Approved	Approved for Orphan Indication	Treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT).	8/17/15	8/17/22	"Seattle Genetics, Inc."	Bothell	Washington	98021	USA	EXACT	0297767AA	brentuximab vedotin	7XL5ISS668						Hodgkin lymphoma	2714	done	
brentuximab vedotin	Treatment of Hodgkin's lymphoma	brentuximab vedotin	BRENTUXIMAB VEDOTIN	Adcetris	1/30/07	Designated/Approved	Approved for Orphan Indication	The treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates	8/19/11	8/19/18	"Seattle Genetics, Inc."	Bothell	Washington	98021	USA	EXACT	0297767AA	brentuximab vedotin	7XL5ISS668						Hodgkin lymphoma	2714	done	
brentuximab vedotin	"Treatment of patients with peripheral T-cell lymphoma, not otherwise specified"	brentuximab vedotin	BRENTUXIMAB VEDOTIN	Adcetris	4/15/13	Designated			N/A	N/A	"Seattle Genetics, Inc."	Bothell	Washington	98021	USA	EXACT	0297767AA	brentuximab vedotin	7XL5ISS668						Adult T-cell leukemia/lymphoma	13103	done	
brigatinib	"Treatment of anaplastic lymphoma kinase-positive (ALK+), c-ros 1 oncogene positive (ROS1+), or epidermal growth factor receptor positive (EGFR+) non-small cell lung cancer (NSCLC)."	brigatinib	BRIGATINIB	n/a	4/28/16	Designated			N/A	N/A	"ARIAD Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	1113593AA	brigatinib	HYW8DB273J						"Non-small cell lung cancer, childhood"	9343	approximate	
brilliant blue G	For use in ophthalmic surgery to aid in the removal of the inner limiting membrane of the eye.	brilliant blue G	BRILLIANT BLUE G	Brilliant Peel	12/16/09	Designated			N/A	N/A	Fluron GmbH - Subsidiary of Geuder AG				Germany	EXACT	0797751AA	brilliant blue G	M1ZRX790SI								MISSING	not a disease
brimonidine	Treatment of ocular graft versus host disease	brimonidine	BRIMONIDINE	n/a	8/3/17	Designated			N/A	N/A	"Ocugen, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	0277236AA	brimonidine	E6GNX3HHTE						Acute graft versus host disease 	6552	approximate	
brimonidine	Treatment of ocular graft versus host disease	brimonidine	BRIMONIDINE	n/a	8/3/17	Designated			N/A	N/A	"Ocugen, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	0277236AA	brimonidine	E6GNX3HHTE						 Chronic graft versus host disease	10964	approximate	
budesonide	To slow the progression of immunoglobulin A nephropathy & delay kidney failure in patients affected by the disease.	budesonide	BUDESONIDE	Nefecon	5/17/10	Designated			N/A	N/A	Pharmalink AB	Stockholm			Sweden	EXACT	0115888AA	budesonide	Q3OKS62Q6X						IgA nephropathy	863	done	
budesonide	Treat of ulcerative colitis in pediatric patients aged 0 through 16 years.	budesonide	BUDESONIDE	Uceris	5/6/13	Designated			N/A	N/A	"Santarus, Inc."	San Diego	California	92130	USA	EXACT	0115888AA	budesonide	Q3OKS62Q6X						Pediatric ulcerative colitis	9857	done	
budesonide	Treatment of eosinophilic esophagitis	budesonide	BUDESONIDE	n/a	5/8/18	Designated			N/A	N/A	"Salix Pharmaceuticals, Inc., division of Valeant Pharmaceuticals North America"	400 Somerset Corporate Boulevard		8807	USA	EXACT	0115888AA	budesonide	Q3OKS62Q6X						Eosinophilic enteropathy	9142	done	
budesonide	Treatment of patients with eosinophilic esophagitis	budesonide	BUDESONIDE	n/a	12/20/06	Designated			N/A	N/A	Shire ViroPharma Incorporated	Lexington	Massachusetts	2421	USA	EXACT	0115888AA	budesonide	Q3OKS62Q6X						Eosinophilic enteropathy	9142	done	
bupivacaine	Relief of persistent pain associated with postherpetic neuralgia	bupivacaine	BUPIVACAINE	Transdur	6/18/08	Designated			N/A	N/A	"Impax Laboratories, Inc."	Hayward	California	94544	USA	EXACT	0038619AA	bupivacaine	Y8335394RO								MISSING	symptom of several conditions
bupivacaine hydrochloride	treatment of pain associated with postherpetic neuralgia.	bupivacaine hydrochloride	BUPIVACAINE HYDROCHLORIDE	n/a	5/31/16	Designated			N/A	N/A	"Grace Therapeutics, LLC"	North Brunswick Township	New Jersey	8902	USA	EXACT	0058708AA	bupivacaine hydrochloride	7TQO7W3VT8								MISSING	Not a rare disease
buprenorphine in combination with naloxone	Treatment of opiate addiction in opiate users	buprenorphine in combination with naloxone	BUPRENORPHINE	Suboxone	10/27/94	Designated/Approved	Approved for Orphan Indication	Treatment of opioid dependence in patients 16 years of age or older	10/8/02	10/8/09	"Reckitt Benckiser Pharmaceuticals, Inc."	Richmond	Virginia	23235	USA	EXACT	0157517AA	buprenorphine	40D3SCR4GZ								MISSING	
busulfan	Preparative therapy for pediatric patients undergoing bone marrow transplantation	busulfan	BUSULFAN	Partaject	11/25/02	Designated			N/A	N/A	"SuperGen, Inc."	Dublin	California	94568	USA	EXACT	0008946AA	busulfan	G1LN9045DK								MISSING	
c-myb antisense oligodeoxynucleotide	Treatment of chronic myelogenous leukemia	c-myb antisense oligodeoxynucleotide		n/a	2/22/05	Designated/Withdrawn			N/A	N/A	"Genta, Inc."	Berkeley Heights	New Jersey	7922	USA					G4460	NA	https://adisinsight.springer.com/drugs/800007895	PROBLEM	absent from GINAS	Chronic myeloid leukemia	6105	done	
cabozantinib	"Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer."	cabozantinib	CABOZANTINIB	Cometriq	11/29/10	Designated/Approved	Approved for Orphan Indication	"Treatment of progressive, metastatic medullary thyroid cancer (MTC)."	11/29/12	11/29/19	"Exelixis, Inc."	South San Francisco	California	94083	USA	EXACT	0580949AA	cabozantinib	1C39JW444G						"Thyroid cancer, follicular "	5206	done	
cabozantinib	"Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer."	cabozantinib	CABOZANTINIB	Cometriq	11/29/10	Designated/Approved	Approved for Orphan Indication	"Treatment of progressive, metastatic medullary thyroid cancer (MTC)."	11/29/12	11/29/19	"Exelixis, Inc."	South San Francisco	California	94083	USA	EXACT	0580949AA	cabozantinib	1C39JW444G						" Thyroid cancer, medullary "	7004	done	
cabozantinib	"Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer."	cabozantinib	CABOZANTINIB	Cometriq	11/29/10	Designated/Approved	Approved for Orphan Indication	"Treatment of progressive, metastatic medullary thyroid cancer (MTC)."	11/29/12	11/29/19	"Exelixis, Inc."	South San Francisco	California	94083	USA	EXACT	0580949AA	cabozantinib	1C39JW444G						 Anaplastic thyroid cancer 	664	done	
cabozantinib	"Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer."	cabozantinib	CABOZANTINIB	Cometriq	11/29/10	Designated/Approved	Approved for Orphan Indication	"Treatment of progressive, metastatic medullary thyroid cancer (MTC)."	11/29/12	11/29/19	"Exelixis, Inc."	South San Francisco	California	94083	USA	EXACT	0580949AA	cabozantinib	1C39JW444G						 Papillary thyroid carcinoma	12027	done	
cadazolid	Treatment of clostridium difficile infection in pediatric patients	cadazolid	CADAZOLID	n/a	8/8/17	Designated			N/A	N/A	Actelion Pharmaceuticals Ltd.	Allschwil			Switzerland	EXACT	0568025AA	cadazolid	2OEA2UN10Y						Clostridium septicum infection	11969	done	
caffeine	Treatment of seizure prolongation in patients undergoing electroconvulsive therapy	caffeine and sodium benzoate	CAFFEINE	n/a	8/22/12	Designated			N/A	N/A	"Luitpold Pharmaceuticals, Inc."	Norristown	Pennsylvania	19403	USA	EXACT	0009676AA	caffeine	3G6A5W338E						Status epilepticus	10191	approximate	
caffeine and sodium benzoate	Treatment of seizure prolongation in patients undergoing electroconvulsive therapy	caffeine and sodium benzoate	SODIUM BENZOATE	n/a	8/22/12	Designated			N/A	N/A	"Luitpold Pharmaceuticals, Inc."	Norristown	Pennsylvania	19403	USA	EXACT	0027849AA	sodium benzoate	OJ245FE5EU						Status epilepticus	10191	approximate	
calcium benzoate and risperidone	Treatment of pediatric patients with schizophrenia	calcium benzoate and risperidone	CALCIUM BENZOATE	n/a	12/20/10	Designated			N/A	N/A	"University of California, Los Angeles"	Torrance	California	90509	USA	EXACT	0141866AA	calcium benzoate	3QDE968MKD						Childhood-Onset Schizophrenia	4766	done	
calfactant	Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.	calfactant	CALFACTANT	Infasurf	6/7/85	Designated/Approved	Approved for Orphan Indication	Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.	7/1/98	N/A	"ONY, Inc."	Amherst	New York	14228	USA	EXACT	0153071AA	calfactant	Q4K217VGA9						"Respiratory distress syndrome, infant"	112	approximate	
camostat	Treatment of chronic pancreatitis	camostat	CAMOSTAT	n/a	5/18/11	Designated			N/A	N/A	NIXS Corporation	Tokyo			Japan	EXACT	0301735AA	camostat	0FD207WKDU						"Pancreatitis, pediatric "	10269	approximate	
camostat	Treatment of chronic pancreatitis	camostat	CAMOSTAT	n/a	5/18/11	Designated			N/A	N/A	NIXS Corporation	Tokyo			Japan	EXACT	0301735AA	camostat	0FD207WKDU						 Hereditary pancreatitis	6632	approximate	
canakinumab	Treatment of hyperimmunoglobulinemia D and periodic fever syndrome	canakinumab	CANAKINUMAB	Ilaris	12/5/13	Designated/Approved	Approved for Orphan Indication	Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients	9/23/16	9/23/23	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0323159AA	canakinumab	37CQ2C7X93						Hyper-IgD syndrome	2788	done	
canakinumab	Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.	canakinumab	CANAKINUMAB	Ilaris	9/30/08	Designated/Approved	Approved for Orphan Indication	Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 through 16 years.	5/9/13	5/9/20	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0323159AA	canakinumab	37CQ2C7X93								MISSING	
cannabidiol	Prevention of Graft versus Host Disease (GVHD).	cannabidiol	CANNABIDIOL	n/a	7/14/15	Designated			N/A	N/A	Talent biotechs Ltd.				Israel	EXACT	0027441AA	cannabidiol	19GBJ60SN5						Chronic graft versus host disease	10964	approximate	type of GVHD (acute or chronic) is not specified
cannabidiol	Prevention of Graft versus Host Disease (GVHD).	cannabidiol	CANNABIDIOL	n/a	7/14/15	Designated			N/A	N/A	Talent biotechs Ltd.				Israel	EXACT	0027441AA	cannabidiol	19GBJ60SN5						Acute graft versus host disease	6544	approximate	type of GVHD (acute or chronic) is not specified
cannabidiol	Treatment of Graft versus Host Disease	cannabidiol	CANNABIDIOL	n/a	11/29/16	Designated			N/A	N/A	Talent biotechs Ltd.	Bnei Brak			Israel	EXACT	0027441AA	cannabidiol	19GBJ60SN5						Chronic graft versus host disease 	10964	done	
cannabidiol	Treatment of Graft versus Host Disease	cannabidiol	CANNABIDIOL	n/a	11/29/16	Designated			N/A	N/A	Talent biotechs Ltd.	Bnei Brak			Israel	EXACT	0027441AA	cannabidiol	19GBJ60SN5						 Acute graft versus host disease	6544	done	
cannabidiol	Treatment of neonatal hypoxic ischemic encephalopathy	cannabidiol	CANNABIDIOL	n/a	4/22/15	Designated			N/A	N/A	GW Pharma Ltd.	Research Triangle Park	North Carolina	27709	USA	EXACT	0027441AA	cannabidiol	19GBJ60SN5								MISSING	Not a rare disease
cannabidiol	Treatment of pediatric schizophrenia (pediatrics is defined as 0 through 16 years of age)	cannabidiol	CANNABIDIOL	n/a	11/17/14	Designated			N/A	N/A	"Insys Development Company, Inc."	Chandler	Arizona	85286	USA	EXACT	0027441AA	cannabidiol	19GBJ60SN5						Childhood-Onset Schizophrenia	4766	done	
cantharidin	"Treatment of perforating diseases, including Kyrle's disease, reactive perforating collangenosis, perforating folliculitis and elastosis perforans serpiginosa"	cantharidin	CANTHARIDIN	n/a	7/24/12	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0129293AA	cantharidin	IGL471WQ8P						Kyrle disease 	9738	done	
cantharidin	"Treatment of perforating diseases, including Kyrle's disease, reactive perforating collangenosis, perforating folliculitis and elastosis perforans serpiginosa"	cantharidin	CANTHARIDIN	n/a	7/24/12	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0129293AA	cantharidin	IGL471WQ8P						 Familial reactive perforating collagenosis 	13331	done	
cantharidin	"Treatment of perforating diseases, including Kyrle's disease, reactive perforating collangenosis, perforating folliculitis and elastosis perforans serpiginosa"	cantharidin	CANTHARIDIN	n/a	7/24/12	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0129293AA	cantharidin	IGL471WQ8P						 Elastosis perforans serpiginosa	10103	done	
caprine hyperimmune serum against HIV lysate	Treatment of systemic sclerosis	caprine hyperimmune serum against HIV lysate		n/a	2/14/14	Designated			N/A	N/A	Daval International Limited	East Sussex			United Kingdom								PROBLEM	can't find	Systemic scleroderma	9748	done	
capsaicin	Management of neuropathic pain in patients with postherpetic neuralgia	capsaicin	CAPSAICIN	Qutenza	5/22/09	Designated/Approved	Approved for Orphan Indication	Management of neuropathic pain associated with postherpetic neuralgia	11/16/09	11/16/16	"Acorda Therapeutics, Inc."	Ardsley	New York	10502	USA	EXACT	0025490AA	capsaicin	S07O44R1ZM						Herpes zoster oticus	7525	approximate	postherpetic neuralgia is a complication of varicella-zoster virus infection
capsaicin	Treatment of painful HIV-associated neuropathy	capsaicin	CAPSAICIN	Qutenza	5/2/03	Designated			N/A	N/A	"Acorda Therapeutics, Inc."	Ardsley	New York	10502	USA	EXACT	0025490AA	capsaicin	S07O44R1ZM								MISSING	
carbamazepine	"For the emergency rescue treatment of status epilepticus, grand mal type."	Pr-320 (molecusol-carbamazepine)	CARBAMAZEPINE	n/a	7/20/90	Designated/Withdrawn			N/A	N/A	Pharmos	Alachua	Florida	32615	USA	EXACT	0023803AA	carbamazepine	33CM23913M						Status epilepticus	10191	approximate	
carbon monoxide	For use in the reduction of the incidence and severity of delayed graft function in patients undergoing solid organ transplanation.	carbon monoxide	CARBON MONOXIDE	Covox	6/24/08	Designated/Withdrawn			N/A	N/A	INO Therapeutics	Hampton	New Jersey	8827	USA	EXACT	0084899AA	carbon monoxide	7U1EE4V452								MISSING	not a disease
carbon monoxide	Treatment of sickle cell disease	carbon monoxide	CARBON MONOXIDE	n/a	9/28/12	Designated			N/A	N/A	"Hillhurst Biopharmaceuticals, Inc."	Montrose	California	91020	USA	EXACT	0084899AA	carbon monoxide	7U1EE4V452						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
carbon monoxide	Treatment of sickle cell disease	carbon monoxide	CARBON MONOXIDE	n/a	9/28/12	Designated			N/A	N/A	"Hillhurst Biopharmaceuticals, Inc."	Montrose	California	91020	USA	EXACT	0084899AA	carbon monoxide	7U1EE4V452						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
carbon monoxide	Treatment of sickle cell disease	carbon monoxide	CARBON MONOXIDE	n/a	9/28/12	Designated			N/A	N/A	"Hillhurst Biopharmaceuticals, Inc."	Montrose	California	91020	USA	EXACT	0084899AA	carbon monoxide	7U1EE4V452						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
carbon monoxide	Treatment of sickle cell disease	carbon monoxide	CARBON MONOXIDE	n/a	9/28/12	Designated			N/A	N/A	"Hillhurst Biopharmaceuticals, Inc."	Montrose	California	91020	USA	EXACT	0084899AA	carbon monoxide	7U1EE4V452						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
carbon monoxide	Treatment of sickle cell disease	carbon monoxide	CARBON MONOXIDE	n/a	9/28/12	Designated			N/A	N/A	"Hillhurst Biopharmaceuticals, Inc."	Montrose	California	91020	USA	EXACT	0084899AA	carbon monoxide	7U1EE4V452						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
carbon monoxide	Treatment of sickle cell disease	carbon monoxide	CARBON MONOXIDE	n/a	9/28/12	Designated			N/A	N/A	"Hillhurst Biopharmaceuticals, Inc."	Montrose	California	91020	USA	EXACT	0084899AA	carbon monoxide	7U1EE4V452						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
carboxyamidotriazole orotate	Treatment of malignant glioma	carboxyamidotriazole orotate	CARBOXYAMIDOTRIAZOLE OROTATE	Pravitinib™	5/10/18	Designated			N/A	N/A	"Tactical Therapeutics, Inc."	"48 Wall Street, 12th Floor"		10005	USA	EXACT	0698077AA	carboxyamidotriazole orotate	776C212QQH						Gliomatosis cerebri 	6514	approximate	
carboxyamidotriazole orotate	Treatment of malignant glioma	carboxyamidotriazole orotate	CARBOXYAMIDOTRIAZOLE OROTATE	Pravitinib™	5/10/18	Designated			N/A	N/A	"Tactical Therapeutics, Inc."	"48 Wall Street, 12th Floor"		10005	USA	EXACT	0698077AA	carboxyamidotriazole orotate	776C212QQH						 Childhood brain stem glioma 	9306	approximate	
carboxyamidotriazole orotate	Treatment of malignant glioma	carboxyamidotriazole orotate	CARBOXYAMIDOTRIAZOLE OROTATE	Pravitinib™	5/10/18	Designated			N/A	N/A	"Tactical Therapeutics, Inc."	"48 Wall Street, 12th Floor"		10005	USA	EXACT	0698077AA	carboxyamidotriazole orotate	776C212QQH						 Glioma	6513	approximate	
cardiotrophin-1	Prevention of ischemia-reperfusion injury in kidney transplant recipients	cardiotrophin-1	CARDIOTROPHIN 1	n/a	10/16/14	Designated			N/A	N/A	"Digna Biotech, S.L."				Spain	EXACT	0809825AA	cardiotrophin 1	AJ7U77BR8I								MISSING	Not a rare disease
cardiotrophin-1	To protect the liver from ischemia-reperfusion injury inherent to the procedure of transplantation.	cardiotrophin-1	CARDIOTROPHIN 1	n/a	6/24/08	Designated			N/A	N/A	"Digna Biotech, S.L."				Spain	EXACT	0809825AA	cardiotrophin 1	AJ7U77BR8I								MISSING	Not a rare disease;condition secondary to surgical procedure
cardiotrophin-1	Treatment of acute liver failure	cardiotrophin-1	CARDIOTROPHIN 1	n/a	9/13/11	Designated			N/A	N/A	Digna Biotech S.L.				Spain	EXACT	0809825AA	cardiotrophin 1	AJ7U77BR8I						Transient infantile liver failure	10593	approximate	
carglumic acid	Treatment of N-acetylglutamate synthetase deficiency.	carglumic acid	CARGLUMIC ACID	Carbaglu	1/20/98	Designated/Approved	Approved for Orphan Indication	As an adjunctive therapy for the treatment of acute hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS) and as manitenance therapy for chronic hyperammonemia due to NAGS deficiency	3/18/10	3/18/17	Orphan Europe SARL	92800 Puteaux			France	EXACT	0311864AA	carglumic acid	5L0HB4V1EW						N-acetylglutamate synthase deficiency	7158	done	
carlumab	Treatment of pancreatic cancer	carlumab	CARLUMAB	n/a	10/24/06	Designated			N/A	N/A	"Centocor, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	0583222AA	carlumab	6TC1BB2EV9						Pancreatic cancer	9364	done	Not a rare disease
carmustine	Conditioning treatment prior to hematopoietic progenitor cell transplantation	carmustine	CARMUSTINE	n/a	10/11/17	Designated			N/A	N/A	ADIENNE S.A.				Switzerland	EXACT	0023596AA	carmustine	U68WG3173Y								MISSING	
catumaxomab	Treatment of gastric cancer	catumaxomab	CATUMAXOMAB	n/a	7/1/09	Designated			N/A	N/A	"Neoviibiotech North America, Inc."	Waltham	Massachusetts	2451	USA	EXACT	0268304AA	catumaxomab	M2HPV837HO						Stomach cancer	7704	done	
celiprolol	Treatment of Ehlers-Danlos syndrome	celiprolol	CELIPROLOL	n/a	1/5/15	Designated			N/A	N/A	"Acer Therapeutics, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0321335AA	celiprolol	DRB57K47QC						Ehlers-Danlos syndromes	6322	done	
cell based therapeutic composed of allogeneic donor apoptotic cells	Prevention of graft versus host disease	cell based therapeutic composed of allogeneic donor apoptotic cells		Apocell	3/18/13	Designated			N/A	N/A	Enlivex Therapeutics Ltd.	Jerusalem			Israel								PROBLEM	can't find	Chronic graft versus host disease	10964	approximate	type of GVHD (acute or chronic) is not specified
cell based therapeutic composed of allogeneic donor apoptotic cells	Prevention of graft versus host disease	cell based therapeutic composed of allogeneic donor apoptotic cells		Apocell	3/18/13	Designated			N/A	N/A	Enlivex Therapeutics Ltd.	Jerusalem			Israel								PROBLEM	can't find	Acute graft versus host disease	6544	approximate	type of GVHD (acute or chronic) is not specified
cellspan esophageal implant	"Restore the structure and function of the esophagus subsequent to esophageal damage due to cancer, injury, or congenital abnormality"	cellspan esophageal implant		n/a	11/29/16	Designated			N/A	N/A	"Biostage, Inc."	Holliston	Massachusetts	1746	USA					Oesophageal stem cell implant	NA	https://adisinsight.springer.com/drugs/800050101	PROBLEM	absent from GINAS			MISSING	procedure
ceramide	Treatment of liver cancer	ceramide	CERAMIDE	n/a	8/8/16	Designated			N/A	N/A	"Keystone Nano, Inc."	State College	Pennsylvania	16801	USA	EXACT	1162169AA	ceramide	038753E78J | NQ0RNU9701 | BM601292L2 | CR0J8RN66K | 88KCS7120E | L4421JO9Q2 | 9O83X0C77V | 717F57PF9J | HE904A332Q | 7848GX36YB | 4370DF050B | C04977SRJ5 | 5THT33P7X7	"N-HEXANOYLSPHINGOSINE | TRIHYDROXYPALMITAMIDOHYDROXYPROPYL MYRISTYL ETHER | HYDROXYETHYL ETHYLENE DIPALMITAMIDE | 3-DEHYDROXY CERAMIDE 1 | CERAMIDE 9 | CERAMIDE 8 | CERAMIDE 7 | CERAMIDE 6 II, L- |  CERAMIDE 6 II, D- |  CERAMIDE 5 | CERAMIDE NP | CERAMIDE NG | CERAMIDE 1"	038753E78J | NQ0RNU9701 | BM601292L2 | CR0J8RN66K | 88KCS7120E | L4421JO9Q2 | 9O83X0C77V | 717F57PF9J | HE904A332Q | 7848GX36YB | 4370DF050B | C04977SRJ5 | 5THT33P7X7	https://ginas.ncats.nih.gov/ginas/app/substance/394203d0 | https://ginas.ncats.nih.gov/ginas/app/substance/954be543 | https://ginas.ncats.nih.gov/ginas/app/substance/d26807b7 | https://ginas.ncats.nih.gov/ginas/app/substance/7eb4190d | https://ginas.ncats.nih.gov/ginas/app/substance/4cc4e8e6 | https://ginas.ncats.nih.gov/ginas/app/substance/a850166b | https://ginas.ncats.nih.gov/ginas/app/substance/df219024 | https://ginas.ncats.nih.gov/ginas/app/substance/86049b5a | https://ginas.ncats.nih.gov/ginas/app/substance/ff5bc281 | https://ginas.ncats.nih.gov/ginas/app/substance/7327b072 | https://ginas.ncats.nih.gov/ginas/app/substance/aca882f1 | https://ginas.ncats.nih.gov/ginas/app/substance/78b33645	done		Primary liver cancer	6608	approximate	
cerebrolysin	"Treatment of frontotemporal dementia, including all subvariants"	cerebrolysin	CEREBROLYSIN	n/a	4/5/16	Designated			N/A	N/A	EVER Neuro Pharma GmbH				Austria	EXACT	0227543AA	cerebrolysin	37KZM6S21G						Frontotemporal dementia	8436	done	
ceritinib	Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive	ceritinib	CERITINIB	Zykadia	9/27/13	Designated/Approved	Approved for Orphan Indication	Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.	4/29/14	4/29/21	Novartis Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0814777AA	ceritinib	K418KG2GET						"Non-small cell lung cancer, childhood"	9343	approximate	
cerium nitrate	Treatment of patients with severe dermal burns	Silver sulfadiazine and cerium nitrate	CERIC AMMONIUM NITRATE	Flammacerium	11/17/99	Designated			N/A	N/A	Alliance Pharmaceuticals Ltd	"Wiltshire, SN15 2BB"			United Kingdom	EXACT	0553479AA	cerium nitrate	U99S55ED6B								MISSING	not a disease
cethromycin	Prophylactic treatment of plague due to Yersinia pestis	cethromycin	CETHROMYCIN	Restanza(Tm)	9/9/09	Designated			N/A	N/A	"Advanced Life Sciences, Inc."	Woodridge	Illinois	60517	USA	EXACT	0230580AA	cethromycin	J0086219X6						Bubonic plague	183	done	
cetuximab	Treatment of pancreatic cancer	cetuximab	CETUXIMAB	Erbitux	6/15/07	Designated/Withdrawn			N/A	N/A	ImClone Systems Incorporated	Branchburg	New Jersey	8876	USA	EXACT	0250033AA	cetuximab	PQX0D8J21J						Pancreatic cancer	9364	done	Not a rare disease
cetuximab	Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor	cetuximab	CETUXIMAB	Erbitux	7/3/00	Designated/Approved	Approved for Orphan Indication	"For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed"	3/1/06	3/1/13	ImClone Systems Incorporated	Branchburg	New Jersey	8876	USA	EXACT	0250033AA	cetuximab	PQX0D8J21J						Squamous cell carcinoma of the head and neck	8503	done	
cetyl alcohol	"1. Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less 2. prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32 weeks gestation or less and in the treatment of established HMO at all gestational ages."	"Colfosceril palmitate, cetyl alcohol, tyloxapol"	CETYL ALCOHOL	Exosurf Neonatal For Intratracheal Suspension	10/20/89	Designated/Approved	Approved for Orphan Indication	"Prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32 weeks gestation or less and in the treatment of established HMO at all gestational ages"	8/2/90	8/2/97	Glaxo Wellcome Inc.	Research Triangle Park	North Carolina	27709	USA	EXACT	0019750AA	cetyl alcohol	936JST6JCN						"Respiratory distress syndrome, infant"	112	done	
cetyl alcohol	Treatment of adult respiratory distress syndrome.	"Colfosceril palmitate, cetyl alcohol, tyloxapol"	CETYL ALCOHOL	Exosurf	1/11/93	Designated/Withdrawn			N/A	N/A	GlaxoSmithKline	Research Triangle Park	North Carolina	27709	USA	EXACT	0019750AA	cetyl alcohol	936JST6JCN						Acute respiratory distress syndrome	5698	done	
chenodiol	"For patients with radiolucent stones in well opacifying gallbladders, in whom elective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age"	chenodiol	CHENODIOL	Chenix	9/21/84	Designated/Approved	Approved for Orphan Indication		7/28/83	7/28/90	Solvay	Marietta	Georgia	30062	USA	EXACT	0026175AA	chenodiol	0GEI24LG0J								MISSING	
chimeric monoclonal antibody against claudin-18 splice variant 2	Treatment of pancreatic cancer	chimeric monoclonal antibody against claudin-18 splice variant 2		n/a	9/26/13	Designated			N/A	N/A	Ganymed Pharmaceuticals AG				Germany								PROBLEM	can't find	Pancreatic cancer	9364	done	Not a rare disease
chlorobutanol /propylene glycol/hydrochloric acid	Treatment of patulous eustachian tube	chlorobutanol/propylene glycol/hydrochloric acid	CHLOROBUTANOL	Patul-End	2/18/97	Designated			N/A	N/A	Ear Foundation	Santa Barbara	California	93105	USA	EXACT	0009303AA	chlorobutanol	HM4YQM8WRC								MISSING	not a disease
chlorobutanol/ propylene glycol	Treatment of patulous eustachian tube	chlorobutanol/propylene glycol/hydrochloric acid	PROPYLENE GLYCOL	Patul-End	2/18/97	Designated			N/A	N/A	Ear Foundation	Santa Barbara	California	93105	USA	EXACT	0009461AA	propylene glycol	6DC9Q167V3								MISSING	not a disease
chloropyramine	Treatment of pancreatic cancer	chloropyramine	CHLOROPYRAMINE	n/a	10/22/10	Designated			N/A	N/A	"CurFAKtor Pharmaceuticals, LLC"	Orchard Park	New York	14127	USA	EXACT	0312516AA	chloropyramine	2K3L8O9SOV						Pancreatic cancer	9364	done	Not a rare disease
chlorotoxin	"Treatment of stage IIb, IIc, III & IV melanoma"	chlorotoxin	CHLOROTOXIN	n/a	12/2/08	Designated			N/A	N/A	"Morphotek, Inc."	Exon	Pennsylvania	19341	USA	EXACT	0736732AA	chlorotoxin	06UV5RFW57						"Melanoma, familial"	3460	approximate	
"cholest-4-en-3-one, oxime"	Treatment of spinal muscular atrophy.	"cholest-4-en-3-one, oxime"	OLESOXIME	n/a	2/17/09	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0340045AA	"cholest-4-en-3-one, oxime"	A6778U5IFY						Congenital benign spinal muscular atrophy dominant	1474	approximate	
cholic acid	Treatment of inborn errors of cholesterol and bile acid synthesis and metabolism	cholic acid	CHOLIC ACID	Cholbam	7/18/03	Designated/Approved	Approved for Orphan Indication	Treatment of bile acid synthesis disorders due to single enzyme defects	3/17/15	3/17/22	"Retrophin, Inc."	New York	New York	10017	USA	EXACT	0014164AA	cholic acid	G1JO7801AE						"Congenital bile acid synthesis defect, type 1 "	9813	done	
cholic acid	Treatment of inborn errors of cholesterol and bile acid synthesis and metabolism	cholic acid	CHOLIC ACID	Cholbam	7/18/03	Designated/Approved	Approved for Orphan Indication	Treatment of bile acid synthesis disorders due to single enzyme defects	3/17/15	3/17/22	"Retrophin, Inc."	New York	New York	10017	USA	EXACT	0014164AA	cholic acid	G1JO7801AE						" Congenital bile acid synthesis defect, type 2"	10045	done	
chromium histidinate	Treatment of pediatic polycystic ovary syndrome (0 through 16 years of age)	chromium picolinate and chromium histidinate	CHROMIUM HISTIDINATE	n/a	12/22/14	Designated			N/A	N/A	"JDS Therapeutics, LLC"	Purchase	New York	10577	USA	EXACT	1576643AA	chromium histidinate	1BY3EP7D99						Polycystic ovarian syndrome	7421	done	not a rare disease
chromium picolinate and chromium histidinate	Treatment of pediatic polycystic ovary syndrome (0 through 16 years of age)	chromium picolinate and chromium histidinate	CHROMIUM PICOLINATE	n/a	12/22/14	Designated			N/A	N/A	"JDS Therapeutics, LLC"	Purchase	New York	10577	USA	EXACT	0211847AA	chromium picolinate	S71T8B8Z6P						Polycystic ovarian syndrome	7421	done	not a rare disease
cinacalcet	"Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery"	cinacalcet	CINACALCET	Sensipar	4/30/10	Designated/Approved	Approved for Orphan Indication	Treatment of severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy	2/25/11	2/25/18	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0282031AA	cinacalcet	UAZ6V7728S						Neonatal severe hyperparathyroidism	2838	approximate	
cinacalcet	"Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery"	cinacalcet	CINACALCET	Sensipar	4/30/10	Designated/Approved	Approved for Orphan Indication	"Treatment of hypercalcemia in adult patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy."	11/21/14	11/21/21	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0282031AA	cinacalcet	UAZ6V7728S						Neonatal severe hyperparathyroidism	2838	approximate	
cinacalcet	Treatment of secondary hyperparathyroidism (HPT) in pediatric patients with chronic kidney disease receiving dialysis	cinacalcet	CINACALCET	Sensipar	9/7/16	Designated			N/A	N/A	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0282031AA	cinacalcet	UAZ6V7728S								MISSING	secondary condition
ciprofloxacin	The management of bronchiectasis	ciprofloxacin	CIPROFLOXACIN	n/a	6/1/11	Designated			N/A	N/A	Aradigm Corporation	Hayward	California	94545	USA	EXACT	0140727AA	ciprofloxacin	5E8K9I0O4U								MISSING	"Not a rare disease, a symptom"
citric acid	For the dissolution and control of uric acid and cysteine calculi in the urinary tract.	Potassium citrate and citric acid	CITRIC ACID MONOHYDRATE	n/a	2/14/86	Designated/Withdrawn			N/A	N/A	Willen Drug Company					EXACT	0045147AA	citric acid	2968PHW8QP								MISSING	not a disease
citric acid monohydrate	Treatment of acute-on-chronic liver failure	citric acid monohydrate	CITRIC ACID MONOHYDRATE	n/a	6/21/17	Designated			N/A	N/A	Versantis AG	Zürich			Switzerland	EXACT	0045147AA	citric acid monohydrate	2968PHW8QP						Transient infantile liver failure	10593	approximate	
civamide	Treatment of postherpetic neuralgia of the trigeminal nerve	civamide	ZUCAPSAICIN	Zucapsaicin	12/9/02	Designated			N/A	N/A	"Winston Laboratories, Inc."	Vernon Hills	Illinois	60061	USA	EXACT	0183493AA	civamide	15OX67P384								MISSING	Not a rare disease; symptom
civamide	Treatment of postherpetic neuralgia.	civamide	ZUCAPSAICIN	n/a	2/17/09	Designated			N/A	N/A	"Winston Laboratories, Inc."	Vernon Hills	Illinois	60061	USA	EXACT	0183493AA	civamide	15OX67P384								MISSING	Not a rare disease; symptom
clarithromycin	Treatment of pediatric Crohn's disease.	"clarithromycin, rifabutin, clofazimine"	CLARITHROMYCIN	n/a	4/26/11	Designated			N/A	N/A	RedHill Biopharma Ltd.				Israel	EXACT	0152090AA	clarithromycin	H1250JIK0A						Pediatric Crohn's disease	9856	done	
clenbuterol	Adjunctive therapy with enzyme replacement therapy in the treatment of Pompe disease	clenbuterol	CLENBUTEROL	"Spiropent, Ventipulmin"	10/27/14	Designated			N/A	N/A	Duke University Medical Center	Durham	North Carolina	27710	USA	EXACT	0074497AA	clenbuterol	XTZ6AXU7KN						Glycogen storage disease type 2	5714	done	
clervonafusp alfa	Treatment of Pompe Disease	clervonafusp alfa		n/a	10/4/18	Designated			N/A	N/A	"Valerion Therapeutics, LLC"	100 Main Street	Massachusetts	1742	USA					clervonafusp alfa	NA	http://www.checkorphan.org/treatments/d74a8bcca70d361986725a5a004efc4a	PROBLEM	absent from GINAS	Glycogen storage disease type 2	5714	done	
clofarabine	Treatment of acute myelogenous leukemia	clofarabine	CLOFARABINE	Clofarex	3/14/02	Designated			N/A	N/A	"Genzyme Corp (Ilex Products, Inc.)"	San Antonio	Texas	78229	USA	EXACT	0183813AA	clofarabine	762RDY0Y2H						Acute myeloid leukemia	12757	done	
clofazimine	Treatment of Pulmonary Nontuberculous Mycobacterial Infections	clofazimine	CLOFAZIMINE	n/a	8/17/18	Designated			N/A	N/A	"Qrumpharma, Inc."	215 Decatur St.	Pennsylvania	18901	USA	EXACT	0038186AA	clofazimine	D959AE5USF						Nontuberculous mycobacterial lung disease	12829	done	
clofazimine	Treatment of pediatric Crohn's disease.	"clarithromycin, rifabutin, clofazimine"	CLOFAZIMINE	n/a	4/26/11	Designated			N/A	N/A	RedHill Biopharma Ltd.				Israel	EXACT	0038186AA	clofazimine	D959AE5USF						Pediatric Crohn's disease	9856	done	
clonidine	Treatment of postherpetic neuralgia	naltrexone/clonidine combination	CLONIDINE	n/a	4/14/14	Designated			N/A	N/A	Allodynic Therapeutics LLC	North Miami	Florida	33181	USA	EXACT	0100630AA	clonidine	MN3L5RMN02								MISSING	Not a rare disease; symptom
clotrimazole otic solution	Treatment of fungal otitis externa (otomycosis).	clotrimazole otic solution	CLOTRIMAZOLE	n/a	5/10/16	Designated			N/A	N/A	Laboratorios SALVAT S.A.	Barcelona			Spain	EXACT	0062373AA	clotrimazole	G07GZ97H65								MISSING	Not a rare disease
cobicistat	Treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients	cobicistat	COBICISTAT	Tybost®	6/15/17	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0383448AA	cobicistat	LW2E03M5PG						Congenital human immunodeficiency virus	10328	approximate	
cobimetinib	"Treatment of stage IIb, IIc, III, and IV melanoma with BRAFV600 mutation"	cobimetinib	COBIMETINIB	n/a	1/31/14	Designated/Approved	Approved for Orphan Indication	"For the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation, in combination with vemurafenib. COTELLIC is not indicated for treatment of patients with wild-type BRAF melanoma"	11/10/15	11/10/22	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0631550AA	cobimetinib	ER29L26N1X						"Melanoma, familial"	3460	approximate	
cobitolimod	Treatment of ulcerative colitis in pediatric patients	cobitolimod	COBITOLIMOD	n/a	8/8/17	Designated			N/A	N/A	InDex Pharmaceuticals AB	Hagalund			Sweden	EXACT	1197644AA	cobitolimod	328101264R						Pediatric ulcerative colitis	9857	done	
collagenase clostridium histolyticum	Treatment of Peyronie's disease.	collagenase clostridium histolyticum	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	Xiaflex	3/12/96	Designated/Approved	Approved for Orphan Indication	Treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.	12/6/13	12/6/20	"Auxilium Pharmaceuticals, Inc."	Chesterbrook	Pennsylvania	19087	USA	EXACT	0091623AA	collagenase clostridium histolyticum	9X7O8V25IT						Peyronie disease	7379	done	
collagenase clostridium histolyticum	Treatment of advanced (involutional or residual stage) Dupuytren's disease.	collagenase clostridium histolyticum	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	Xiaflex	5/23/96	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with Dupuytren's contracture with a palpable cord	2/2/10	2/2/17	"Auxilium Pharmaceuticals, Inc."	Malvern	Pennsylvania	19335	USA	EXACT	0091623AA	collagenase clostridium histolyticum	9X7O8V25IT						Familial Dupuytren contracture	12165	done	Not a rare disease
combretastatin A1 diphosphate	Treatment of acute myelogenous leukemia	combretastatin A 1 diphosphate	OXI-4503	n/a	11/19/12	Designated			N/A	N/A	"Mateon Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	0550505AA	combretastatin A1 diphosphate	JH6Z94GLUD						Acute myeloid leukemia	12757	done	
conjugate of human transferrin and a mutant diphtheria toxin (CRM 107)	Treatment of malignant tumors of the central nervous system	conjugate of human transferrin and a mutant diphtheria toxin (CRM 107)	DIPHTHERIA TOXIN	Transmid	12/3/01	Designated			N/A	N/A	Xenova Biomedix Limited				United Kingdom	LONGEST CONTAINS	1183820AA	diphtheria toxin	P4JG5VY10R	TRANSFERRIN ALDIFITOX	P4JG5VY10R	https://ginas.ncats.nih.gov/ginas/app/substances?q=CRM107	done		Brain stem cancer 	8244	approximate	
conjugate of human transferrin and a mutant diphtheria toxin (CRM 107)	Treatment of malignant tumors of the central nervous system	conjugate of human transferrin and a mutant diphtheria toxin (CRM 107)	DIPHTHERIA TOXIN	Transmid	12/3/01	Designated			N/A	N/A	Xenova Biomedix Limited				United Kingdom	LONGEST CONTAINS	1183820AA	diphtheria toxin	P4JG5VY10R	TRANSFERRIN ALDIFITOX	P4JG5VY10R	https://ginas.ncats.nih.gov/ginas/app/substances?q=CRM107	done		 Gliomatosis cerebri 	6514	approximate	
conjugate of human transferrin and a mutant diphtheria toxin (CRM 107)	Treatment of malignant tumors of the central nervous system	conjugate of human transferrin and a mutant diphtheria toxin (CRM 107)	DIPHTHERIA TOXIN	Transmid	12/3/01	Designated			N/A	N/A	Xenova Biomedix Limited				United Kingdom	LONGEST CONTAINS	1183820AA	diphtheria toxin	P4JG5VY10R	TRANSFERRIN ALDIFITOX	P4JG5VY10R	https://ginas.ncats.nih.gov/ginas/app/substances?q=CRM107	done		 Brain stem cancer	8244	approximate	
corifungin	Treatment of amebic meningoencephalitis.	corifungin	CORIFUNGIN	n/a	8/22/11	Designated			N/A	N/A	Ctr for Discovery & Innovation in Parasitic Diseas	San Francisco	California	94158	USA	EXACT	0807998AA	corifungin	L26BTK4791						Primary amebic meningoencephalitis	9554	done	
creatine monohydrate	Treatment of juvenile rheumatoid arthritis joint and related tissue inflammation in the pediatric population	Kre-Celazine	CREATINE MONOHYDRATE	n/a	4/1/13	Designated			N/A	N/A	All American Pharmaceutical & Natural Foods Corpor	Billings	Montana	59105	USA	EXACT	0248533AA	creatine monohydrate	9603LN7R2Q						Juvenile idiopathic arthritis	3067	done	Not a rare disease
crenolanib	Treatment of acute myelogenous leukemia	crenolanib	CRENOLANIB	n/a	10/31/12	Designated			N/A	N/A	"AROG Pharmaceuticals, LLC"	Dallas	Texas	75251	USA	EXACT	0632973AA	crenolanib	LQF7I567TQ						Acute myeloid leukemia	12757	done	
cridanimod	Treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy.	cridanimod	CRIDANIMOD	n/a	1/12/11	Designated			N/A	N/A	Kevelt Ltd.	Tallinn			Estonia	EXACT	0316063AA	cridanimod	X91E9EME19						Adenosquamous carcinoma of the endometrium	13107	approximate	
crizotinib	"Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer"	crizotinib	CRIZOTINIB	Xalkori	9/13/10	Designated/Approved	Approved for Orphan Indication	Treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDAapproved test	8/26/11	8/26/18	"Pfizer, Inc."	San Diego	California	92121	USA	EXACT	0274862AA	crizotinib	53AH36668S						"Non-small cell lung cancer, childhood"	9343	approximate	
crs-207	Treatment of mesothelioma.	Live-attenuated Listeria monocytogenes actA/inlB/human mesothelin (hMeso) Strain hMeso38	CRS-207	Not Determined	3/24/15	Designated			N/A	N/A	"Aduro BioTech, Inc."	Berkeley	California	94710	USA	EXACT	1206106AA	crs-207	JJX4JHS4PO						Malignant mesothelioma	7026	done	
cultured skin substitute (CSS)	Treatment of burns requiring skin grafting.	cultured skin substitute (CSS)	SKIN	Novaderm	8/22/16	Designated			N/A	N/A	Regenicin Inc.	Little Falls	New Jersey	7424	USA	LONGEST CONTAINS	0226926AA	skin	0EE2343509	HUMAN SKIN	0EE2343509	https://ginas.ncats.nih.gov/ginas/app/substance/9a9259c1	done				MISSING	Not a rare disease
"cultured, partially T-Cell depleted, allogenic thymic tissue for transplantation"	As a therapy for primary immune deficiency resulting from athymia associated with complete DiGeorge Syndrome	"cultured, partially T-Cell depleted, allogenic thymic tissue for transplantation"		n/a	8/15/03	Designated			N/A	N/A	Duke University Medical Center	Durham	North Carolina	27710	USA								PROBLEM	can't find	22q11.2 deletion syndrome	10299	done	
cyclocreatine	Treatment of creatine transporter deficiency	cyclocreatine	CYCLOCREATINE	n/a	6/18/12	Designated			N/A	N/A	Lumos Pharma	Austin	Texas	78756	USA	EXACT	0183766AA	cyclocreatine	6732XGX1RK						X-linked creatine deficiency	1608	done	
cyclocreatine phosphate	Prevention of ischemic injury to enhance cardiac graft recovery and survival in heart transplantation.	cyclocreatine phosphate	CYCLOCREATINE	Nourexal	1/17/18	Designated			N/A	N/A	"Nour Heart Therapeutics, LLC"	"121 Locust Street, SW"	Vienna	22180	USA	EXACT	0114123AB	cyclocreatine	6732XGX1RK								MISSING	Not a rare disease
cyclophosphamide	Prevention of graft versus host disease following allogeneic hematopoietic stem cell transplant	cyclophosphamide	CYCLOPHOSPHAMIDE	Cyrevia(Tm)	6/17/11	Designated			N/A	N/A	"Accentia Biopharmaceuticals, Inc."	Tampa	Florida	33606	USA	EXACT	0045692AA	cyclophosphamide	8N3DW7272P						Chronic graft versus host disease	10964	approximate	type of GVHD (acute or chronic) is not specified
cyclophosphamide	Prevention of graft versus host disease following allogeneic hematopoietic stem cell transplant	cyclophosphamide	CYCLOPHOSPHAMIDE	Cyrevia(Tm)	6/17/11	Designated			N/A	N/A	"Accentia Biopharmaceuticals, Inc."	Tampa	Florida	33606	USA	EXACT	0045692AA	cyclophosphamide	8N3DW7272P						Acute graft versus host disease	6544	approximate	type of GVHD (acute or chronic) is not specified
cyclophosphamide	Treatment of systemic sclerosis.	cyclophosphamide	CYCLOPHOSPHAMIDE	Cyrevia(Tm)	6/7/11	Designated			N/A	N/A	"Accentia Biopharmaceuticals, Inc."	Tampa	Florida	33606	USA	EXACT	0045692AA	cyclophosphamide	8N3DW7272P						Systemic scleroderma	9748	done	
cyclosporine	Prophylaxis of graft-versus-host disease	cyclosporine	CYCLOSPORINE	n/a	2/17/09	Designated			N/A	N/A	Sigmoid Pharma Limited				Ireland	EXACT	0066808AA	cyclosporine	83HN0GTJ6D						Chronic graft versus host disease 	10964	done	
cyclosporine	Prophylaxis of graft-versus-host disease	cyclosporine	CYCLOSPORINE	n/a	2/17/09	Designated			N/A	N/A	Sigmoid Pharma Limited				Ireland	EXACT	0066808AA	cyclosporine	83HN0GTJ6D						 Acute graft versus host disease	6544	done	
cyclosporine	Treatment of graft-versus-host disease	cyclosporine	CYCLOSPORINE	n/a	2/17/09	Designated			N/A	N/A	Sigmoid Pharma Limited				Ireland	EXACT	0066808AA	cyclosporine	83HN0GTJ6D						Chronic graft versus host disease 	10964	approximate	
cyclosporine	Treatment of graft-versus-host disease	cyclosporine	CYCLOSPORINE	n/a	2/17/09	Designated			N/A	N/A	Sigmoid Pharma Limited				Ireland	EXACT	0066808AA	cyclosporine	83HN0GTJ6D						 Acute graft versus host disease	6544	approximate	
cyclosporine 2% ophthalmic ointment	"For use in corneal melting syndromes of known or presumed immunologic etiopathogenesis, including Mooren's ulcer"	cyclosporine 2% ophthalmic ointment	CYCLOSPORINE	n/a	8/1/91	Designated			N/A	N/A	"Allergan, Inc."	Irvine	California	92612	USA	EXACT	0066808AA	cyclosporine	83HN0GTJ6D								MISSING	not a disease
cyclosporine A	Prevention of corneal graft rejection	cyclosporine A	CYCLOSPORINE	n/a	9/30/08	Designated			N/A	N/A	Santen SAS				France	EXACT	0066808AA	cyclosporine A	83HN0GTJ6D								MISSING	
cyclosporine A	Treatment of herpes simplex virus stromal keratitis	cyclosporine A	CYCLOSPORINE	Nova22007	4/9/08	Designated			N/A	N/A	Santen SAS				France	EXACT	0066808AA	cyclosporine A	83HN0GTJ6D								MISSING	
cyclosporine; ciclosporin	Treatment of moderate to severe traumatic brain injury.	cyclosporine; ciclosporin	CYCLOSPORINE	Neurostat(R)/Ciclomulsion(R)	11/23/10	Designated			N/A	N/A	NeuroVive Pharmaceutical AB	Lund			Sweden	EXACT	0066808AA	ciclosporin	83HN0GTJ6D								MISSING	Not a rare disease
cysteamine	Treatment of neuronal ceroid lipofuscinoses (Batten disease)	cysteamine	CYSTEAMINE	n/a	8/6/08	Designated			N/A	N/A	"Raptor Pharmaceuticals, Inc."	Novato	California	94949	USA	EXACT	0010377AA	cysteamine	5UX2SD1KE2						Neuronal ceroid lipofuscinosis	10739	done	
cysteamine	Treatment of pancreatic cancer	cysteamine	CYSTEAMINE	n/a	9/11/13	Designated			N/A	N/A	"Raptor Pharmaceuticals, Inc."	Novato	California	94949	USA	EXACT	0010377AA	cysteamine	5UX2SD1KE2						Pancreatic cancer	9364	done	Not a rare disease
cytochrome C	Treatment of mitochondrial disorders	"cytochrome C, flavin mononucleotide and thiamin diphosphate"	CYTOCHROME C	n/a	6/17/11	Designated			N/A	N/A	"NBI Pharmaceuticals, Inc."	Bozeman	Montana	59715	USA	EXACT	0006473AA	cytochrome C					PROBLEM	can't find			MISSING	mitchondrial disease not specified
cytochrome P450 isoform 2B1 gene transfected human embryonic kidney 293 cells encapsulated in polymeric cellulose sulphate	Treatment of pancreatic cancer in combination with ifosfamide	cytochrome P450 isoform 2B1 gene transfected human embryonic kidney 293 cells encapsulated in polymeric cellulose sulphate	CELLULOSE	n/a	12/17/14	Designated			N/A	N/A	"PharmaCyte Biotech, Inc."	Laguna Hills	California	92652	USA	LONGEST CONTAINS	0100685AA	cellulose	SMD1X3XO9M						Pancreatic cancer	9364	done	Not a rare disease
cytomegalovirus specific cytotoxic T lymphocytes	Treatment of cytomegalovirus infection in severely immunocompromised patients	cytomegalovirus specific cytotoxic T lymphocytes	HUMAN HERPESVIRUS 5	n/a	1/5/17	Designated			N/A	N/A	"ViraCyte, LLC"	New Brighton	Minnesota	55112	USA	LONGEST CONTAINS	0354529AA	cytomegalovirus	7COI029E6K								MISSING	
d-methadone	Treatment of postherpetic neuralgia	d-methadone	DEXTROMETHADONE	n/a	6/2/16	Designated			N/A	N/A	"Relmada Therapeutics, Inc."	New York	New York	10016	USA	EXACT	1124352AA	d-methadone	S95RZH8AMH								MISSING	Not a rare disease; symptom
"d6-tetrabenazine, deutetrabenazine"	Treatment of Huntington's Disease	"d6-tetrabenazine, deutetrabenazine"	DEUTETRABENAZINE	n/a	11/5/14	Designated			N/A	N/A	"Teva Pharmaceuticals, Inc."	La Jolla	California	92037	USA	EXACT	0934827AA	deutetrabenazine	P341G6W9NB						Huntington disease	6677	done	
dabrafenib	Treatment of patients with BRAF mutation positive non-small cell lung cancer	dabrafenib	DABRAFENIB	Tafinler	10/20/14	Designated			N/A	N/A	Novartis Pharmaceuticals Corp	East Hanover	New Jersey	7936	USA	EXACT	0632984AA	dabrafenib	QGP4HA4G1B						"Non-small cell lung cancer, childhood"	9343	approximate	
dabrafenib and trametinib	Treatment of patients with BRAF mutation positive non-small cell lung cancer.	dabrafenib and trametinib	DABRAFENIB	n/a	10/29/15	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0632984AA	dabrafenib	QGP4HA4G1B						"Non-small cell lung cancer, childhood"	9343	approximate	
dacomitinib	"Treatment of non-small cell lung cancer with EGFR, HER2, HER4, or DDR2 mutations."	dacomitinib	DACOMITINIB	n/a	3/3/15	Designated			N/A	N/A	"Pfizer, Inc."	New York	New York	10017	USA	EXACT	0258924AA	dacomitinib	5092U85G58						"Non-small cell lung cancer, childhood"	9343	approximate	
dalfampridine	Relief of symptoms of multiple sclerosis	dalfampridine	DALFAMPRIDINE	Ampyra	6/2/87	Designated/Approved	Approved for Orphan Indication	Treatment to improve walking in patients with multiple sclerosis	1/22/10	1/22/17	Acorda Therapeutics	Hawthorne	New York	10532	USA	EXACT	0121335AA	dalfampridine	BH3B64OKL9						Multiple sclerosis	10255	done	
dantrolene sodium	Treatment of heat stroke	dantrolene sodium	DANTROLENE SODIUM	n/a	9/25/12	Designated			N/A	N/A	"Eagle Pharmaceuticals, Inc."	Woodcliff Lake	New Jersey	7677	USA	EXACT	0056122AA	dantrolene sodium	287M0347EV								MISSING	
daratumumab	Treatment of systemic amyloid light-chain (AL) amyloidosis	daratumumab	DARATUMUMAB	n/a	9/5/17	Designated			N/A	N/A	"Janssen Research & Development, LLC"	Raritan	New Jersey	8869	USA	EXACT	0432519AA	daratumumab	4Z63YK6E0E						AL amyloidosis	5797	done	
davunetide	Treatment of Activity-Dependent Neuroprotective Protein (ADNP) Syndrome	davunetide	DAVUNETIDE	n/a	2/22/18	Designated			N/A	N/A	Coronis Neurosciences Ltd.	5 Golda Me'ir Street Lev-Hanevet Building	Ness Ziona		Israel	EXACT	0257647AA	davunetide	GF00K3IIWE						ADNP syndrome	12931	done	
debrase	"Debridement of acute, deep dermal burns in hospitalized patients"	debrase	STEM BROMELAIN	Debridase	8/20/03	Designated			N/A	N/A	"MediWound, Ltd."				Israel	EXACT	0349984AA	debrase	ZLM4P8929R								MISSING	
decitabine	Treatment of chronic myelogenous leukemia.	decitabine	DECITABINE	n/a	3/8/99	Designated/Withdrawn			N/A	N/A	Otsuka Pharmaceutical Development &	Princeton	New Jersey	8540	USA	EXACT	0171244AA	decitabine	776B62CQ27						Chronic myeloid leukemia	6105	done	
decitabine and tetrahydrouridine	Treatment of sickle cell disease	decitabine and tetrahydrouridine	DECITABINE	n/a	9/19/16	Designated			N/A	N/A	EpiDestiny Inc.	Solon	Ohio	44139	USA	EXACT	0171244AA	decitabine	776B62CQ27						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
decitabine and tetrahydrouridine	Treatment of sickle cell disease	decitabine and tetrahydrouridine	DECITABINE	n/a	9/19/16	Designated			N/A	N/A	EpiDestiny Inc.	Solon	Ohio	44139	USA	EXACT	0171244AA	decitabine	776B62CQ27						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
decitabine and tetrahydrouridine	Treatment of sickle cell disease	decitabine and tetrahydrouridine	DECITABINE	n/a	9/19/16	Designated			N/A	N/A	EpiDestiny Inc.	Solon	Ohio	44139	USA	EXACT	0171244AA	decitabine	776B62CQ27						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
decitabine and tetrahydrouridine	Treatment of sickle cell disease	decitabine and tetrahydrouridine	DECITABINE	n/a	9/19/16	Designated			N/A	N/A	EpiDestiny Inc.	Solon	Ohio	44139	USA	EXACT	0171244AA	decitabine	776B62CQ27						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
decitabine and tetrahydrouridine	Treatment of sickle cell disease	decitabine and tetrahydrouridine	DECITABINE	n/a	9/19/16	Designated			N/A	N/A	EpiDestiny Inc.	Solon	Ohio	44139	USA	EXACT	0171244AA	decitabine	776B62CQ27						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
decitabine and tetrahydrouridine	Treatment of sickle cell disease	decitabine and tetrahydrouridine	DECITABINE	n/a	9/19/16	Designated			N/A	N/A	EpiDestiny Inc.	Solon	Ohio	44139	USA	EXACT	0171244AA	decitabine	776B62CQ27						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
decitabine and tetrahydrouridine	Treatment of sickle cell disease	decitabine and tetrahydrouridine	TETRAHYDROURIDINE	n/a	9/19/16	Designated			N/A	N/A	EpiDestiny Inc.	Solon	Ohio	44139	USA	EXACT	0058957AA	tetrahydrouridine	0NIZ8H6OL8						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
decitabine and tetrahydrouridine	Treatment of sickle cell disease	decitabine and tetrahydrouridine	TETRAHYDROURIDINE	n/a	9/19/16	Designated			N/A	N/A	EpiDestiny Inc.	Solon	Ohio	44139	USA	EXACT	0058957AA	tetrahydrouridine	0NIZ8H6OL8						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
decitabine and tetrahydrouridine	Treatment of sickle cell disease	decitabine and tetrahydrouridine	TETRAHYDROURIDINE	n/a	9/19/16	Designated			N/A	N/A	EpiDestiny Inc.	Solon	Ohio	44139	USA	EXACT	0058957AA	tetrahydrouridine	0NIZ8H6OL8						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
decitabine and tetrahydrouridine	Treatment of sickle cell disease	decitabine and tetrahydrouridine	TETRAHYDROURIDINE	n/a	9/19/16	Designated			N/A	N/A	EpiDestiny Inc.	Solon	Ohio	44139	USA	EXACT	0058957AA	tetrahydrouridine	0NIZ8H6OL8						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
decitabine and tetrahydrouridine	Treatment of sickle cell disease	decitabine and tetrahydrouridine	TETRAHYDROURIDINE	n/a	9/19/16	Designated			N/A	N/A	EpiDestiny Inc.	Solon	Ohio	44139	USA	EXACT	0058957AA	tetrahydrouridine	0NIZ8H6OL8						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
decitabine and tetrahydrouridine	Treatment of sickle cell disease	decitabine and tetrahydrouridine	TETRAHYDROURIDINE	n/a	9/19/16	Designated			N/A	N/A	EpiDestiny Inc.	Solon	Ohio	44139	USA	EXACT	0058957AA	tetrahydrouridine	0NIZ8H6OL8						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
deferiprone	Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy	deferiprone	DEFERIPRONE	Ferriprox	12/12/01	Designated/Approved	Approved for Orphan Indication	Treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate	10/14/11	10/14/18	"ApoPharma, Inc. A Division of"				Canada	EXACT	0179680AA	deferiprone	2BTY8KH53L								MISSING	
deferoxamine starch conjugate	Treatment of acute iron poisoning	deferoxamine starch conjugate	DEFEROXAMINE	n/a	1/28/05	Designated			N/A	N/A	"Biomedical Frontiers, Inc."	Minneapolis	Minnesota	55414	USA	LONGEST CONTAINS	0012204AA	deferoxamine	J06Y7MXW4D						Heavy metal poisoning	6577	approximate	
deflazacort	Treatment of pediatric (0 through 16 years of age) juvenile idiopathis arthritis (JIA) International League of Associations for Rheumatology (ILAR) categories excluding systemic JIA.	deflazacort	DEFLAZACORT	n/a	10/22/15	Designated			N/A	N/A	"Marathon Pharmaceuticals, LLC"	Northbrook	Illinois	60062	USA	EXACT	0084537AA	deflazacort	KR5YZ6AE4B						Juvenile idiopathic arthritis	3067	done	
dehydrated alcohol	Treatment of hypertrophic obstructive cardiomyopathy	dehydrated alcohol	"ALCOHOL, DEHYDRATED"	Ablysinol	9/11/13	Designated			N/A	N/A	"Belcher Pharmaceuticals, LLC"	Largo	Florida	33777	USA	EXACT	0011187AA	dehydrated alcohol	3K9958V90M						Familial hypertrophic cardiomyopathy	7229	approximate	
demcizumab	Treatment of pancreatic cancer	demcizumab	DEMCIZUMAB	n/a	4/30/14	Designated			N/A	N/A	"OncoMed Pharmaceuticals, Inc."	Redwood City	California	94063	USA	EXACT	0762287AA	demcizumab	SF168W7FW0						Pancreatic cancer	9364	done	Not a rare disease
"dendritic cells pulsed with synthetic peptides derived from antigens MAGE1, HER-2, AIM-2,TRP-2, gp100 and interleukin-13 receptor alpha"	Treatment of glioblastoma or brain stem glioma	"dendritic cells pulsed with synthetic peptides derived from antigens MAGE1, HER-2, AIM-2,TRP-2, gp100 and interleukin-13 receptor alpha"	ALLERGENIC EXTRACTS	n/a	6/7/10	Designated			N/A	N/A	ImmunoCellular Therapeutics Ltd.	Woodland Hills	California	91367	USA	LONGEST CONTAINS	0123397AA	antigens				https://www.ema.europa.eu/documents/orphan-designation/eu/3/14/1247-public-summary-opinion-orphan-designation-autologous-dendritic-cells-pulsed-tumour-antigen_en.pdf	PROBLEM	can't find	Glioblastoma	2491	done	
"dendritic-cell targeting, lentiviral vector encoding the NY-ESO-1 gene"	Treatment of soft tissue sarcoma.	"dendritic-cell targeting, lentiviral vector encoding the NY-ESO-1 gene"		n/a	1/6/16	Designated			N/A	N/A	Immune Design Corp.	Seattle	Washington	98102	USA								PROBLEM	can't find	Soft tissue sarcoma	4898	done	
denosumab	Treatment of hypercalcemia in malignancy	denosumab	DENOSUMAB	Xgeva	9/11/13	Designated/Approved	Approved for Orphan Indication	To treat hypercalcemia of malignancy refractory to biphosphonate therapy.	12/5/14	12/5/21	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0297949AA	denosumab	4EQZ6YO2HI								MISSING	
deoxythymidine monophosphate	Treatment of thymidine kinase 2 deficiency.	deoxythymidine monophosphate and deoxycytidine monophosphate	THYMIDINE 5'-MONOPHOSPHATE	n/a	7/7/16	Designated			N/A	N/A	Columbia University Medical Center	New York	New York	10032	USA	EXACT	0894735AA	deoxythymidine monophosphate	43W3021X6C								MISSING	
deutetrabenazine	Treatment of Tourette syndrome in the pediatric population (defined as 0 through 16 years of age)	deutetrabenazine	DEUTETRABENAZINE	n/a	1/13/15	Designated			N/A	N/A	TEVA Pharmaceuticals	LaJolla	California	92037	USA	EXACT	0934827AA	deutetrabenazine	P341G6W9NB						Tourette syndrome	7783	done	
dexamethasone intravitreal implant	"Treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate, posterior, and panuveitis"	dexamethasone intravitreal implant	DEXAMETHASONE	Ozurdex	9/11/98	Designated/Approved	Approved for Orphan Indication	For treatment of non-infectious uveitis affecting the posterior segment of the eye	9/24/10	9/24/17	Allergan	Irvine	California	92623	USA	EXACT	0007192AA	dexamethasone	7S5I7G3JQL						Panuveitis 	8577	approximate	
dexamethasone intravitreal implant	"Treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate, posterior, and panuveitis"	dexamethasone intravitreal implant	DEXAMETHASONE	Ozurdex	9/11/98	Designated/Approved	Approved for Orphan Indication	For treatment of non-infectious uveitis affecting the posterior segment of the eye	9/24/10	9/24/17	Allergan	Irvine	California	92623	USA	EXACT	0007192AA	dexamethasone	7S5I7G3JQL						 Posterior uveitis	4457	approximate	
dexamethasone phosphate	Treatment of corneal graft rejection.	dexamethasone phosphate	DEXAMETHASONE PHOSPHATE	n/a	12/2/08	Designated			N/A	N/A	"EyeGate Pharmaceuticals, Inc."	Waltham	Massachusetts	2453	USA	EXACT	0024511AA	dexamethasone phosphate	2BP70L44PR								MISSING	
dexamethasone sodium phosphate encapsulated in autologous erythrocytes	Treatment of ataxia-telangiectasia	dexamethasone sodium phosphate encapsulated in autologous erythrocytes	DEXAMETHASONE SODIUM PHOSPHATE	n/a	7/24/12	Designated			N/A	N/A	EryDel S.p.A.				Italy	EXACT	0038993AA	dexamethasone sodium phosphate	AI9376Y64P						Ataxia telangiectasia	12971	done	
dexanabinol	For the attenuation or amelioration of the long-term neurological sequelae associated with moderate and severe traumatic brain injury	dexanabinol	DEXANABINOL	n/a	8/11/04	Designated			N/A	N/A	Pharmos Corporation	Iselin	New Jersey	8830	USA	EXACT	0225456AA	dexanabinol	R6VT8U5372								MISSING	
dexrazoxane	Treatment of anthracycline extravasation during chemotherapy	dexrazoxane	DEXRAZOXANE	Totect(R)	3/25/04	Designated/Approved	Approved for Orphan Indication	Treatment of extravasation resulting from IV anthracycline chemotherapy	9/6/07	9/6/14	Clinigen Healthcare Ltd.	Staffordshire			United Kingdom	EXACT	0062919AA	dexrazoxane	048L81261F								MISSING	
dexrazoxane hydrochloride	Prevention of cardiomyopathy for chilren and adolescents 0 through 16 years of age treated with anthracyclines	dexrazoxane hydrochloride	DEXRAZOXANE HYDROCHLORIDE	n/a	8/19/14	Designated			N/A	N/A	"Satiscor, LLC"	Boston	Massachusetts	2127	USA	EXACT	0200453AA	dexrazoxane hydrochloride	5346058Q7S						Cardiomyopathy due to anthracyclines	1107	done	
dezamizumab	dezamizumab	recombinant monoclonal antibody to human serum amyloid P component	DEZAMIZUMAB	EXACT	1310323AA	DEZAMIZUMAB	6U3F28IT58		N/A	N/A	"Glaxo Group Limited, England d/b/a GlaxoSmithKline"				United Kingdom	EXACT	1310323AA	dezamizumab	6U3F28IT58								PROBLEM	no disease indicated
diannexin	Prevention of ischemia-reperfusion injury in solid organ transplants	diannexin	DIANEXIN	n/a	10/28/09	Designated			N/A	N/A	"Astellas Pharma Global Development, Inc."	Deerfield	Illinois	60015	USA	EXACT	0684140AA	diannexin	S5HS95L6CN								MISSING	Not a rare disease
diazepam (intranasal)	Management of acute repetitive seizures.	diazepam (intranasal)	DIAZEPAM	n/a	11/16/15	Designated			N/A	N/A	"Neurelis Pharmaceuticals, Inc."	Encinitas	California	92024	USA	EXACT	0025752AA	diazepam	Q3JTX2Q7TU								MISSING	
diazepam (intranasal)	Management of patients with acute repetitive seizures	diazepam (intranasal)	DIAZEPAM	n/a	7/31/12	Designated			N/A	N/A	"Acorda Therapeutics, Inc."	Ardsley	New York	10502	USA	EXACT	0025752AA	diazepam	Q3JTX2Q7TU						Status epilepticus	10191	approximate	ARS is a symptom of treatment-resistant epilepsy
diazepam auto-injector	"Management of selected, refractory patients with epilepsy on stable regimens of antiepileptic drugs, who require intermittent use of diazepam to control bouts of increased seizure activity"	diazepam auto-injector	DIAZEPAM	n/a	5/30/13	Designated			N/A	N/A	Meridian Medical Technologies-a Pfizer subsidiary	Groton	Connecticut	6340	USA	EXACT	0025752AA	diazepam	Q3JTX2Q7TU						Status epilepticus	10191	done	
diazepam subcutaneous injection	Treatment of acute repetitive seizures.	diazepam subcutaneous injection	DIAZEPAM	Diazepen(Tm)	5/26/16	Designated			N/A	N/A	"Xeris Pharmaceuticals, Inc."	Austin	Texas	78705	USA	EXACT	0025752AA	diazepam	Q3JTX2Q7TU						Status epilepticus	10191	approximate	
dichlorphenamide	Treatment of primary periodic paralyses	dichlorphenamide	DICHLORPHENAMIDE	n/a	9/2/10	Designated/Approved	Approved for Orphan Indication	"Treatment of primary hyperkalemic periodic paralysis, primary hypokalemic period paralysis, and related variants"	8/7/15	8/7/22	Taro Pharmaceuticals	Hawthorne	New York	10532	USA	EXACT	0019227AA	dichlorphenamide	VVJ6673MHY						Familial periodic paralysis	6422	approximate	
diethylenetriaminepentaacetate (DPTA)	"For treatment of patients with known or suspected internal contamination with plutonium, americium or curium to increase the rates of elimination."	diethylenetriaminepentaacetate (DPTA)	PENTETIC ACID	n/a	4/14/04	Designated			N/A	N/A	CIS-US	Bedford	Massachusetts	1730	USA	EXACT	0011596AA	diethylenetriaminepentaacetate	7A314HQM0I								MISSING	not a disease
dihydroartemisinin and piperaquine	"Treatment of uncomplicated malaria caused by ""Plasmodium falciparum,"" Plasmodium vivax,"" Plasmodium malariae,"" or ""Plasmodium ovale."""	dihydroartemisinin and piperaquine	ARTENIMOL	Eurartesim	1/8/07	Designated			N/A	N/A	"Sigma-Tau Pharmaceuticals, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0303333AA	dihydroartemisinin	6A9O50735X						Malaria	6961	done	
diosmin	Treatment of systemic sclerosis	diosmin	DIOSMIN	n/a	5/15/18	Designated			N/A	N/A	"Primus Pharmaceuticals, Inc."	7373 North Scottsdale Road	Suite B-200	85253	USA	EXACT	0256871AA	diosmin	7QM776WJ5N						Systemic scleroderma	9748	done	
dipraglurant	Treatment of levodopa-induced dyskinesias	dipraglurant	DIPRAGLURANT	n/a	12/29/15	Designated			N/A	N/A	Addex Pharma SA	Geneva			Switzerland	EXACT	0360554AA	dipraglurant	CV8JZR21A1						Drug induced dyskinesia	8236	done	Not a rare disease
"disulfide-stabilized single-chain variable region fragment of the anti-EGFR wild type/EGFRvIII dual specificity monoclonal antibody with variable fragments fused to a truncated version of the Pseudomonas exotoxin A, PE38, and KDEL"	Treatment of glioma.	"disulfide-stabilized single-chain variable region fragment of the anti-EGFR wild type/EGFRvIII dual specificity monoclonal antibody with variable fragments fused to a truncated version of the Pseudomonas exotoxin A, PE38, and KDEL"	DISULFIDE	n/a	9/19/16	Designated			N/A	N/A	"Darell D. Bigner, MD, PhD"	Durham	North Carolina	27710	USA	LONGEST CONTAINS	0524969AA	disulfide	KD33TF3UJR						Glioma	6513	done	
docetaxel encapsulated in an albumin-stabilized liposome	Treatment of small cell lung cancer (SCLC)	docetaxel encapsulated in an albumin-stabilized liposome	DOCETAXEL	n/a	9/12/18	Designated			N/A	N/A	"Cytori Therapeutics, Inc."	3020 Callan Road	California	92121	USA	EXACT	0214802AA	docetaxel	15H5577CQD						Small cell lung cancer	9344	done	
docosahexaenoic acid	Treatment of sickle cell disease	docosahexaenoic acid	DOCONEXENT	n/a	4/27/15	Designated			N/A	N/A	"Sancilio & Company, Inc."	Riviera Beach	Florida	33404	USA	EXACT	0145960AA	docosahexaenoic acid	ZAD9OKH9JC						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
docosahexaenoic acid	Treatment of sickle cell disease	docosahexaenoic acid	DOCONEXENT	n/a	4/27/15	Designated			N/A	N/A	"Sancilio & Company, Inc."	Riviera Beach	Florida	33404	USA	EXACT	0145960AA	docosahexaenoic acid	ZAD9OKH9JC						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
docosahexaenoic acid	Treatment of sickle cell disease	docosahexaenoic acid	DOCONEXENT	n/a	4/27/15	Designated			N/A	N/A	"Sancilio & Company, Inc."	Riviera Beach	Florida	33404	USA	EXACT	0145960AA	docosahexaenoic acid	ZAD9OKH9JC						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
docosahexaenoic acid	Treatment of sickle cell disease	docosahexaenoic acid	DOCONEXENT	n/a	4/27/15	Designated			N/A	N/A	"Sancilio & Company, Inc."	Riviera Beach	Florida	33404	USA	EXACT	0145960AA	docosahexaenoic acid	ZAD9OKH9JC						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
docosahexaenoic acid	Treatment of sickle cell disease	docosahexaenoic acid	DOCONEXENT	n/a	4/27/15	Designated			N/A	N/A	"Sancilio & Company, Inc."	Riviera Beach	Florida	33404	USA	EXACT	0145960AA	docosahexaenoic acid	ZAD9OKH9JC						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
docosahexaenoic acid	Treatment of sickle cell disease	docosahexaenoic acid	DOCONEXENT	n/a	4/27/15	Designated			N/A	N/A	"Sancilio & Company, Inc."	Riviera Beach	Florida	33404	USA	EXACT	0145960AA	docosahexaenoic acid	ZAD9OKH9JC						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
"docosahexaenoic acid, DHA"	Treatment of primary sclerosing cholangitis	"docosahexaenoic acid, DHA"	DOCONEXENT	n/a	12/17/14	Designated			N/A	N/A	"Sancilio and Company, Inc."	Riviera Beach	Florida	33404	USA	EXACT	0145960AA	docosahexaenoic acid	ZAD9OKH9JC						Primary sclerosing cholangitis	1280	done	
docosahexanoic acid-paclitaxel	Treatment of hormone-refractory prostate cancer.	docosahexanoic acid-paclitaxel	DOCONEXENT	Taxoprexin	3/5/01	Designated/Withdrawn			N/A	N/A	"Luitpold Pharmaceuticals, Inc."	Shirley	New York	11976	USA	EXACT	0145960AA	docosahexanoic acid	ZAD9OKH9JC						Familial prostate cancer	4520	approximate	
dodecafluoropentane emulsion	Treatment of sickle cell disease	dodecafluoropentane emulsion	PERFLENAPENT	n/a	2/11/16	Designated			N/A	N/A	NuvOx Pharma	Tucson	Arizona	85719	USA	EXACT	0183915AA	dodecafluoropentane	483AU1Y5CZ						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
dodecafluoropentane emulsion	Treatment of sickle cell disease	dodecafluoropentane emulsion	PERFLENAPENT	n/a	2/11/16	Designated			N/A	N/A	NuvOx Pharma	Tucson	Arizona	85719	USA	EXACT	0183915AA	dodecafluoropentane	483AU1Y5CZ						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
dodecafluoropentane emulsion	Treatment of sickle cell disease	dodecafluoropentane emulsion	PERFLENAPENT	n/a	2/11/16	Designated			N/A	N/A	NuvOx Pharma	Tucson	Arizona	85719	USA	EXACT	0183915AA	dodecafluoropentane	483AU1Y5CZ						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
dodecafluoropentane emulsion	Treatment of sickle cell disease	dodecafluoropentane emulsion	PERFLENAPENT	n/a	2/11/16	Designated			N/A	N/A	NuvOx Pharma	Tucson	Arizona	85719	USA	EXACT	0183915AA	dodecafluoropentane	483AU1Y5CZ						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
dodecafluoropentane emulsion	Treatment of sickle cell disease	dodecafluoropentane emulsion	PERFLENAPENT	n/a	2/11/16	Designated			N/A	N/A	NuvOx Pharma	Tucson	Arizona	85719	USA	EXACT	0183915AA	dodecafluoropentane	483AU1Y5CZ						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
dodecafluoropentane emulsion	Treatment of sickle cell disease	dodecafluoropentane emulsion	PERFLENAPENT	n/a	2/11/16	Designated			N/A	N/A	NuvOx Pharma	Tucson	Arizona	85719	USA	EXACT	0183915AA	dodecafluoropentane	483AU1Y5CZ						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
domperidone	"Treatment of hypoprolactinemia in breastfeeding mothers, and in some hypoprolactinemic conditions following the use of cabergoline or bromocriptine in mothers who wish to initiate or return to breastfeeding"	domperidone	DOMPERIDONE	n/a	9/2/11	Designated			N/A	N/A	"Thomas W. Hale, RPh, PhD"	Amarillo	Texas	79106	USA	EXACT	0066604AA	domperidone	5587267Z69								MISSING	
dopamine hydrochloride	Prevention of intraventricular hemorrhage in hypotensive premature neonates	dopamine hydrochloride	DOPAMINE HYDROCHLORIDE	n/a	10/24/17	Designated			N/A	N/A	"Brepco Biopharma, Ltd."	Bethlehem	Pennsylvania	18015	USA	EXACT	0010822AA	dopamine hydrochloride	7L3E358N9L								MISSING	
dornase alfa	Prevention of graft-vs-host disease	recombinant human deoxyribonuclease I (DNase I)	DORNASE ALFA	n/a	8/18/14	Designated			N/A	N/A	SciVac Ltd.				Israel	EXACT	0226175AA	dornase alfa	953A26OA1Y						Chronic graft versus host disease	10964	approximate	type of GVHD (acute or chronic) is not specified
dornase alfa	Prevention of graft-vs-host disease	recombinant human deoxyribonuclease I (DNase I)	DORNASE ALFA	n/a	8/18/14	Designated			N/A	N/A	SciVac Ltd.				Israel	EXACT	0226175AA	dornase alfa	953A26OA1Y						Acute graft versus host disease	6544	approximate	type of GVHD (acute or chronic) is not specified
dornase alfa	Treatment of graft-vs-host disease	recombinant human deoxyribonuclease I	DORNASE ALFA	n/a	8/18/14	Designated			N/A	N/A	SciVac Ltd.				Israel	EXACT	0226175AA	dornase alfa	953A26OA1Y						Chronic graft versus host disease 	10964	approximate	
dornase alfa	Treatment of graft-vs-host disease	recombinant human deoxyribonuclease I	DORNASE ALFA	n/a	8/18/14	Designated			N/A	N/A	SciVac Ltd.				Israel	EXACT	0226175AA	dornase alfa	953A26OA1Y						 Acute graft versus host disease	6544	approximate	
double stranded RNA which targets the mutated KRAS oncogene	Treatment of pancreatic cancer	double stranded RNA which targets the mutated KRAS oncogene	GTPASE KRAS	n/a	1/26/15	Designated			N/A	N/A	Silenseed Ltd				Israel	LONGEST CONTAINS	1336681AA	KRAS	Q250P2D9Y8						Pancreatic cancer	9364	done	Not a rare disease
doxofylline	Treatment of bronchiectasis	doxofylline	DOXOFYLLINE	n/a	2/14/14	Designated			N/A	N/A	"Alitair Pharmaceuticals, Inc."	Morristown	New Jersey	7960	USA	EXACT	0162867AA	doxofylline	MPM23GMO7Z								MISSING	symptom of several conditions
doxorubicin with pluronics F-127 and L-61	Treatment of gastric cancer	doxorubicin with pluronics F-127 and L-61	DOXORUBICIN	n/a	2/20/08	Designated			N/A	N/A	"Supratek Pharma, Inc."	Quebec H4P 2R2			Canada	EXACT	0061074AA	doxorubicin	80168379AG						Stomach cancer	7704	done	
droxidopa	"Treatment of neurogenic symptomatic orthostatic hypotension in patients with primary autonomic failure, dopamine-beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy."	droxidopa	DROXIDOPA	Northera	1/17/07	Designated/Approved	Approved for Orphan Indication	"Treatment of orthostatic dizziness, lightheadedness, or the ""feeling that you are about to black out"" in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy."	2/18/14	2/18/21	Lundbeck LLC	Deerfield	Illinois	60015	USA	EXACT	0295921AA	droxidopa	J7A92W69L7						Pure autonomic failure 	10428	approximate	
droxidopa	"Treatment of neurogenic symptomatic orthostatic hypotension in patients with primary autonomic failure, dopamine-beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy."	droxidopa	DROXIDOPA	Northera	1/17/07	Designated/Approved	Approved for Orphan Indication	"Treatment of orthostatic dizziness, lightheadedness, or the ""feeling that you are about to black out"" in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy."	2/18/14	2/18/21	Lundbeck LLC	Deerfield	Illinois	60015	USA	EXACT	0295921AA	droxidopa	J7A92W69L7						 Dopamine beta hydroxylase deficiency 	1903	approximate	
droxidopa	"Treatment of neurogenic symptomatic orthostatic hypotension in patients with primary autonomic failure, dopamine-beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy."	droxidopa	DROXIDOPA	Northera	1/17/07	Designated/Approved	Approved for Orphan Indication	"Treatment of orthostatic dizziness, lightheadedness, or the ""feeling that you are about to black out"" in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy."	2/18/14	2/18/21	Lundbeck LLC	Deerfield	Illinois	60015	USA	EXACT	0295921AA	droxidopa	J7A92W69L7						 Hereditary sensory and autonomic neuropathy	12688	approximate	
dupilumab	Treatment of eosinophilic esophagitis	dupilumab	DUPILUMAB	n/a	9/5/17	Designated			N/A	N/A	"Regneron Pharmaceuticals, Inc."	Tarrytown	New York	10591	USA	EXACT	0762572AA	dupilumab	420K487FSG						Eosinophilic enteropathy	9142	done	
duvoglustat hydrochloride	Treatment of Pompe disease	duvoglustat hydrochloride	DUVOGLUSTAT HYDROCHLORIDE	n/a	6/18/07	Designated			N/A	N/A	"Amicus Therapeutics, Inc"	Cranbury	New Jersey	8512	USA	EXACT	0338125AA	duvoglustat hydrochloride	0RN23C42QR						Glycogen storage disease type 2	5714	done	
ecallantide	Treatment of angioedema	ecallantide	ECALLANTIDE	Kalbitor	2/4/03	Designated/Approved	Approved for Orphan Indication	Treatment of acute attacks of hereditary angioedema in patients 16 years of age and older	12/1/09	12/1/16	Dyax Corp.	Burlington	Massachusetts	1803	USA	EXACT	0298851AA	ecallantide	5Q6TZN2HNM						Hereditary angioedema	5979	done	
ecallantide	Treatment of angioedema	ecallantide	ECALLANTIDE	Kalbitor	2/4/03	Designated/Approved	Approved for Orphan Indication	Treatment of acute attacks of hereditary angioedema in patients 16 years of age and older	12/1/09	12/1/16	Dyax Corp.	Burlington	Massachusetts	1803	USA	EXACT	0298851AA	ecallantide	5Q6TZN2HNM						Acquired angioedema	8605	done	
ecallantide	Treatment of angioedema	ecallantide	ECALLANTIDE	Kalbitor	2/4/03	Designated/Approved	Approved for Orphan Indication	Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older	3/28/14	3/28/21	Dyax Corp.	Burlington	Massachusetts	1803	USA	EXACT	0298851AA	ecallantide	5Q6TZN2HNM						Hereditary angioedema	5979	done	
ecallantide	Treatment of angioedema	ecallantide	ECALLANTIDE	Kalbitor	2/4/03	Designated/Approved	Approved for Orphan Indication	Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older	3/28/14	3/28/21	Dyax Corp.	Burlington	Massachusetts	1803	USA	EXACT	0298851AA	ecallantide	5Q6TZN2HNM						Acquired angioedema	8605	done	
echinomycin	Treatment of graft-versus-host disease (GVHD)	echinomycin	ECHINOMYCIN	n/a	1/5/17	Designated			N/A	N/A	"OncoImmune, Inc."	Washington	District of Columbia	20002	USA	EXACT	0121448AA	echinomycin	TG824J6RQT						Chronic graft versus host disease 	10964	approximate	
echinomycin	Treatment of graft-versus-host disease (GVHD)	echinomycin	ECHINOMYCIN	n/a	1/5/17	Designated			N/A	N/A	"OncoImmune, Inc."	Washington	District of Columbia	20002	USA	EXACT	0121448AA	echinomycin	TG824J6RQT						 Acute graft versus host disease	6544	approximate	
echothiophate iodide	Treatment of Stargardt's disease	echothiophate iodide	ECHOTHIOPHATE IODIDE	n/a	6/2/14	Designated			N/A	N/A	"Makindus, Inc."	Doylestown	Pennsylvania	18902	USA	EXACT	0027032AA	echothiophate iodide	BA9QH3P00T						Stargardt disease	181	done	
ecopipam hydrochloride	Symptomatic treatment of self injurious behaviors in patients with Lesch-Nyhan disease.	ecopipam hydrochloride	ECOPIPAM HYDROCHLORIDE	n/a	7/21/09	Designated			N/A	N/A	"Psyadon Pharmaceuticals, Inc."	Germantown	Maryland	20876	USA	EXACT	0171960AA	ecopipam hydrochloride	5X1J3190JI						Lesch Nyhan syndrome	7226	done	
ecopipam hydrochloride	Treatment of Tourette's syndrome in children 0-16 years old.	ecopipam hydrochloride	ECOPIPAM HYDROCHLORIDE	n/a	9/29/10	Designated			N/A	N/A	"Psyadon Pharmaceuticals, Inc."	Germantown	Maryland	20876	USA	EXACT	0171960AA	ecopipam hydrochloride	5X1J3190JI						Tourette syndrome	7783	done	
eculizumab	Prevention of delayed graft function after renal transplantation	eculizumab	ECULIZUMAB	Soliris	1/10/14	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	Cheshire	Connecticut	6410	USA	EXACT	0298000AA	eculizumab	A3ULP0F556								MISSING	
eculizumab	Treatment of idiopathic membranous glomerular nephropathy	eculizumab	ECULIZUMAB	n/a	3/5/01	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	Cheshire	Connecticut	6410	USA	EXACT	0298000AA	eculizumab	A3ULP0F556						Membranous nephropathy	9180	done	
efaproxiral	Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancer	efaproxiral	EFAPROXIRAL	n/a	7/28/04	Designated			N/A	N/A	"Allos Therapeutics, Inc."	Westminster	Colorado	80020	USA	EXACT	0306901AA	efaproxiral	J81E81G364								MISSING	
eflornithine	Treatment of pancreatic cancer.	eflornithine	EFLORNITHINE	n/a	12/14/16	Designated			N/A	N/A	"Cancer Prevention Pharmaceutical, Inc."	Tucson	Arizona	85718	USA	EXACT	0311422AA	eflornithine	ZQN1G5V6SR						Pancreatic cancer	9364	done	Not a rare disease
eflornithine + sulindac	Treatment of pancreatic cancer	eflornithine + sulindac	EFLORNITHINE	n/a	1/8/18	Designated			N/A	N/A	"Cancer Prevention Pharmaceutical, Inc."	1760 East River Road	Tucson	85718	USA	EXACT	0311422AA	eflornithine	ZQN1G5V6SR						Pancreatic cancer	9364	done	Not a rare disease
eflornithine HCL	Treatment of gastric cancer	eflornithine HCL	EFLORNITHINE HYDROCHLORIDE	n/a	4/7/15	Designated			N/A	N/A	"Cancer Prevention Pharmaceuticals, Inc."	Tucson	Arizona	85718	USA	EXACT	0118774AA	eflornithine HCL	4NH22NDW9H						Stomach cancer	7704	done	
eft-508	Treatment of diffuse large B-cell lymphoma	"6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-2'H-spiro[cyclohexane-1,3'-imidazo[1,5a]pyridine]-1',5'-dione hydrochloride"	EFT-508	n/a	2/23/17	Designated			N/A	N/A	eFFECTOR Therapeutics	San Diego	California	92121	USA	EXACT	1200891AA	eft-508	U2H19X4WBV						Diffuse Large B-Cell Lymphoma	3178	done	
elamipretide	Treatment of Barth syndrome	elamipretide	ELAMIPRETIDE	Bendavia™	3/22/18	Designated			N/A	N/A	Stealth BioTherapeutics	275 Grove Street	Suite 3-107	2466	USA	EXACT	1115146AA	elamipretide	87GWG91S09						Barth syndrome	5890	done	
elamipretide	Treatment of Leber’s Hereditary Optic Neuropathy	elamipretide	ELAMIPRETIDE	Ocuvia™	4/2/18	Designated			N/A	N/A	Stealth BioTherapeutics Inc.	275 Grove Street 3-107		2466	USA	EXACT	1115146AA	elamipretide	87GWG91S09						Leber hereditary optic neuropathy	6870	done	
elamipretide	Treatment of primary mitochondrial myopathy	elamipretide	ELAMIPRETIDE	Bendavia	9/5/17	Designated			N/A	N/A	Stealth BioTherapeutics	Newton	Massachusetts	2466	USA	EXACT	1115146AA	elamipretide	87GWG91S09						Myopathy mitochondrial cataract	3888	approximate	
elapegademase	Treatment of systemic sclerosis	monomethoxypolyethylene glycol recombinant adenosine deaminase	ELAPEGADEMASE	n/a	6/15/17	Designated			N/A	N/A	"Leadiant Biosciences, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	1311246AA	elapegademase	9R3D3Y0UHS						Systemic scleroderma	9748	done	
eltoprazine Hydrochloride	Treatment of levodopa-induced dyskinesia associated with Parkinson's disease.	eltoprazine HCl	ELTOPRAZINE HYDROCHLORIDE	n/a	2/8/16	Designated			N/A	N/A	"Amarantus BioScience Holdings, Inc."	San Francisco	California	94111	USA	EXACT	0161999AA	eltoprazine Hydrochloride	5275JY4PKD						Drug induced dyskinesia	8236	done	Not a rare disease
eltrombopag	Treatment of idiopathic thrombocytopenia purpura	eltrombopag	ELTROMBOPAG	Promacta	5/5/08	Designated/Approved	Approved for Orphan Indication	"Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy"	11/20/08	11/20/15	Novartis Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0305511AA	eltrombopag	S56D65XJ9G						Idiopathic thrombocytopenic purpura	5194	done	
emodepside	"Treatment of onchocerhiasis (""river blindness"") caused by the filarial nematode onchocerca volvulus"	emodepside	EMODEPSIDE	n/a	9/13/16	Designated			N/A	N/A	"Bayer HealthCare Pharmaceuticals, Inc."	Whippany	New Jersey	7981	USA	EXACT	0342029AA	emodepside	YZ647Y5GC9						Onchocerciasis	7252	done	
emricasan	Treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end stage liver disease	emricasan	EMRICASAN	n/a	11/20/13	Designated			N/A	N/A	Conatus Pharmaceuticals Inc.	San diego	California	92121	USA	EXACT	0238891AA	emricasan	P0GMS9N47Q								MISSING	
emricasan	Treatment of patients undergoing solid organ transplantation.	"(3S)-3-[(2S)-2-({N-[2-tert-butyl)phenyl]carbamoyl}carbonylamino) propanoylamino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy) pentanoic acid"	EMRICASAN	n/a	8/19/03	Designated			N/A	N/A	Pfizer Global Research and Development	New London	Connecticut	6320	USA	EXACT	0238891AA	emricasan	P0GMS9N47Q								MISSING	"not a disease, a procedure"
emtricitabine	Treatment of HIV-1 infection in pediatric patients under 12 years of age	emtricitabine and tenofovir alafenamide combination	EMTRICITABINE	Descovy(R)	6/6/17	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0184985AA	emtricitabine	G70B4ETF4S								MISSING	Not a rare disease
emtricitabine	Treatment of Human Immunodeficiency Virus type 1 infection in pediatric patients	bictegravir/emtricitabine/tenofovir disoproxil fumarate	EMTRICITABINE	n/a	5/17/17	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0184985AA	emtricitabine	G70B4ETF4S								MISSING	
enalapril maleate (powder for oral solution)	Treatment of hypertension in pediatric patients	enalapril maleate (powder for oral solution)	ENALAPRIL MALEATE	Epaned	1/30/13	Designated/Withdrawn by OPD		"Treatment of hypertension in adults and children older than one month, to lower blood pressure."	N/A	N/A	"Silvergate Pharmaceuticals, Inc."	Dublin	Ohio	43017	USA	EXACT	0121006AA	enalapril maleate	9O25354EPJ						Pediatric hypertension	11921	done	
encapsulated spores from fecal microbiota	Treatment of recurrent Clostridium difficile infection (CDI)	encapsulated spores from fecal microbiota	FECAL MICROBIOTA	n/a	8/19/15	Designated			N/A	N/A	"Seres Health, Inc."	Cambridge	Massachusetts	2142	USA	LONGEST CONTAINS	0934338AA	fecal microbiota	Q805XO2F7C						Clostridium septicum infection	11969	approximate	
encochleated amikacin	Treatment of non-tuberculous mycobacteria (NTM) infections	encochleated amikacin	AMIKACIN	n/a	3/3/16	Designated			N/A	N/A	"Aquarius Biotechnologies, Inc."	Bedminster Township	New Jersey	7921	USA	EXACT	0122203AA	amikacin	84319SGC3C						Nontuberculous mycobacterial lung disease	12829	approximate	
enisoprost	1. For use with cyclosporine in organ transplant recipients to reduce acute transplant rejection 2. For use in organ transplant patients to diminish the nephrotoxicity induced by cyclosporine.	enisoprost	ENISOPROST	n/a	10/20/89	Designated/Withdrawn			N/A	N/A	G.D. Searle & Company	Skokie	Illinois	60077	USA	EXACT	0133675AA	enisoprost	J85F4K48Q1								MISSING	Not a rare disease
ensituximab	Treatment of pancreatic cancer.	ensituximab	ENSITUXIMAB	n/a	10/21/10	Designated			N/A	N/A	"Neogenix Oncology, Inc."	Rockville	Maryland	20850	USA	EXACT	0432586AA	ensituximab	F988K568V2						Pancreatic cancer	9364	done	Not a rare disease
entospletinib	Prevention of chronic graft-versus-host disease	entospletinib	ENTOSPLETINIB	n/a	8/10/17	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0928507AA	entospletinib	6I3O3W6O3B						Chronic graft versus host disease	10964	done	
entrectinib	Treatment of NTRK fusion-positive solid tumors	entrectinib	ENTRECTINIB	n/a	7/5/17	Designated			N/A	N/A	"Ignyta, Inc."	San Diego	California	92121	USA	EXACT	0933608AA	entrectinib	L5ORF0AN1I								MISSING	
entrectinib	Treatment of neuroblastoma	"entrectinib;N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide"	ENTRECTINIB	n/a	12/22/14	Designated			N/A	N/A	"Ignyta, Inc."	San Diego	California	92121	USA	EXACT	0933608AA	entrectinib	L5ORF0AN1I						Neuroblastoma	7185	done	
epoprostenol	Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.	epoprostenol	EPOPROSTENOL	Flolan	3/22/99	Designated/Approved	Approved for Orphan Indication	treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases.	4/14/00	4/14/07	GlaxoSmithKline	King of Prussia	Pennsylvania	19406	USA	EXACT	0216660AA	epoprostenol	DCR9Z582X0								MISSING	Not a rare disease
epratuzumab	Treatment of non-Hodgkin's lymphoma	epratuzumab	EPRATUZUMAB	Lymphocide	7/13/98	Designated			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA	EXACT	0281049AA	epratuzumab	3062P60MH9						B-cell lymphoma	5877	approximate	
eptifibatide and iloprost	Treatment of purpura fulminans	eptifibatide and iloprost	EPTIFIBATIDE	n/a	4/20/12	Designated			N/A	N/A	Thrombologic				Denmark	EXACT	0173524AA	eptifibatide	NA8320J834						Protein C deficiency	4521	done	
erdosteine	Treatment of bronchiectasis.	erdosteine	ERDOSTEINE	n/a	12/20/13	Designated			N/A	N/A	"Alitair Pharmaceuticals, Inc."	Morristown	New Jersey	7960	USA	EXACT	0269170AA	erdosteine	76J0853EKA								MISSING	symptom of several conditions
etanercept	Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.	etanercept	"ETANERCEPT, LICENSE HOLDER UNSPECIFIED"	Enbrel	10/27/98	Designated/Approved	Approved for Orphan Indication	Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older	5/27/99	5/27/06	Immunex Corporation	Thousand Oaks	California	91320	USA	EXACT	0233556AA	etanercept	OP401G7OJC						Polyarticular onset juvenile idiopathic arthritis	10967	done	
etaracizumab	"For the treatment of of stage IIb, stage IIc, stage III and stage IV melanoma"	etaracizumab	ETARACIZUMAB	Abegrin	4/14/04	Designated/Withdrawn			N/A	N/A	"MedImmune, LLC"	Gaithersburg	Maryland	20878	USA	EXACT	0432611AA	etaracizumab	41W9MFI160						"Melanoma, familial"	3460	approximate	
etelcalcetide	Treatment of pediatric hyperparathyroidism	etelcalcetide	ETELCALCETIDE	n/a	5/31/17	Designated			N/A	N/A	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0625138AA	etelcalcetide	60ME133FJB								MISSING	
etodolac	Treatment of pancreatic cancer.	propranolol and etodolac	ETODOLAC	n/a	4/27/15	Designated			N/A	N/A	"Vicus Therapeutics, LLC"	Morristown	New Jersey	7960	USA	EXACT	0065327AA	etodolac	2M36281008						Pancreatic cancer	9364	done	Not a rare disease
etrolizumab	Treatment of pediatric patients with ulcerative colitis	etrolizumab	ETROLIZUMAB	n/a	8/22/16	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0574094AA	etrolizumab	I2A72G2V3J						Pediatric ulcerative colitis	9857	done	
everolimus	Treatment of gastric cancer	everolimus	EVEROLIMUS	Afinitor	5/24/11	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0218031AA	everolimus	9HW64Q8G6G						Stomach cancer	7704	done	
everolimus	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	everolimus	EVEROLIMUS	Afinitor	6/8/09	Designated/Approved	Approved for Orphan Indication	Treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical resection	10/29/10	10/29/17	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0218031AA	everolimus	9HW64Q8G6G						Tuberous sclerosis 	7830	done	
everolimus	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	everolimus	EVEROLIMUS	Afinitor	6/8/09	Designated/Approved	Approved for Orphan Indication	Treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical resection	10/29/10	10/29/17	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0218031AA	everolimus	9HW64Q8G6G						 Subependymal giant cell astrocytoma 	10632	done	
everolimus	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	everolimus	EVEROLIMUS	Afinitor	6/8/09	Designated/Approved	Approved for Orphan Indication	Treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical resection	10/29/10	10/29/17	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0218031AA	everolimus	9HW64Q8G6G						 Lymphangioleiomyomatosis	3319	done	
everolimus	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	everolimus	EVEROLIMUS	Afinitor	6/8/09	Designated/Approved	Approved for Orphan Indication	Treatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery.	4/26/12	4/26/19	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0218031AA	everolimus	9HW64Q8G6G						Tuberous sclerosis 	7830	done	
everolimus	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	everolimus	EVEROLIMUS	Afinitor	6/8/09	Designated/Approved	Approved for Orphan Indication	Treatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery.	4/26/12	4/26/19	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0218031AA	everolimus	9HW64Q8G6G						 Subependymal giant cell astrocytoma 	10632	done	
everolimus	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	everolimus	EVEROLIMUS	Afinitor	6/8/09	Designated/Approved	Approved for Orphan Indication	Treatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery.	4/26/12	4/26/19	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0218031AA	everolimus	9HW64Q8G6G						 Lymphangioleiomyomatosis	3319	done	
evinacumab	Treat of homozygous familial hypercholesterolemia.	evinacumab	EVINACUMAB	n/a	2/8/16	Designated			N/A	N/A	"Regeneron Pharmaceuticals, Inc."	Tarrytown	New York	10591	USA	EXACT	1076091AA	evinacumab	T8B2ORP1DW						Familial hypercholesterolemia	10416	done	
evolocumab	Treatment of homozygous familial hypercholesterolemia	evolocumab	EVOLOCUMAB	Repatha	9/12/13	Designated/Approved	Approved for Orphan Indication	"As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C."	8/27/15	8/27/22	Amgen Inc.	Thousand Oaks	California	91320	USA	EXACT	0703128AA	evolocumab	LKC0U3A8NJ						Familial hypercholesterolemia	10416	done	Not a rare disease
ex vivo cultured human mesenchymal stromal cells	Prevention of graft rejection following solid organ transplantation	ex vivo cultured human mesenchymal stromal cells		n/a	5/8/14	Designated			N/A	N/A	iCell Science AB				Sweden				3FXW1IW7WT	UMBILICAL CORD MESENCHYMAL STROMAL CELLS	3FXW1IW7WT	https://ginas.ncats.nih.gov/ginas/app/substances?q=mesenchymal&facet=Substance%20Class%2FstructurallyDiverse&page=1	done		Chronic graft versus host disease	10964	approximate	type of GVHD (acute or chronic) is not specified
ex vivo cultured human mesenchymal stromal cells	Prevention of graft rejection following solid organ transplantation	ex vivo cultured human mesenchymal stromal cells		n/a	5/8/14	Designated			N/A	N/A	iCell Science AB				Sweden				3FXW1IW7WT	UMBILICAL CORD MESENCHYMAL STROMAL CELLS	3FXW1IW7WT	https://ginas.ncats.nih.gov/ginas/app/substances?q=mesenchymal&facet=Substance%20Class%2FstructurallyDiverse&page=1	done		Acute graft versus host disease	6544	approximate	type of GVHD (acute or chronic) is not specified
ex vivo expanded autologous human corneal epithelial cells containing stem cells	Treatment of limbal stem cell deficiency	ex vivo expanded autologous human corneal epithelial cells containing stem cells	STEM CELLS	Holoclar®	4/26/18	Designated			N/A	N/A	"Chiesi USA, Inc."	1255 Crescent Green	Suite 250	27518	USA	LONGEST CONTAINS	0264620AA	stem cells					PROBLEM	can't find			PROBLEM	rare condition but absent in GARD
ex-vivo cultered adult human mesenchymal stem cells	Treatment of Type 1 diabetes patients with residual beta cell function	ex-vivo cultered adult human mesenchymal stem cells	MESENCHYMAL STEM CELLS	Prochymal(R)	4/30/10	Designated			N/A	N/A	"Mesoblast, Inc."	New York	New York	10017	USA	LONGEST CONTAINS	1339839AA	mesenchymal stem cells		Prochymal	NA	https://www.ncbi.nlm.nih.gov/pubmed/20457269	done		Diabetes mellitus type 1	10268	done	
ex-vivo expanded placental adherent stromal cells	"Treatment of graft failure and incomplete hematopoietic recovery, following hematopoietic cell transplantation (HCT)"	ex-vivo expanded placental adherent stromal cells		n/a	9/24/18	Designated			N/A	N/A	"Pluristem Therapeutics, Inc"	MATAM Advanced Technology Park			Israel				DPX6XLD4X1	EMIPLACEL	DPX6XLD4X1	https://fdasis.nlm.nih.gov/srs/auto/startswith/emiplacel	done				MISSING	not a disease
exbivirumab	For the prevention of hepatitis B virus (HBV) reinfection in patients who have received a liver transplantation	"Dual antibody including HBV-Ab 17, libivirumab, and HBV-Ab 19, exbivirumab"	EXBIVIRUMAB	Hepex-B	7/15/03	Designated/Withdrawn			N/A	N/A	Cubist Pharmaceuticals	Lexington	Massachusetts	2421	USA	EXACT	0279834AA	exbivirumab	5Q374M1S1P								MISSING	
exendin-(9-39)	Treatment of congential hyperinsulinenic hypoglycemia and other causes of hyperinsulinemic hypoglycemia in adults and children	exendin-(9-39)	EXENDIN (9-39) AMIDE	n/a	6/1/11	Designated			N/A	N/A	The Children's Hospital of Philadelphia	Philadelphia	Pennsylvania	19104	USA	EXACT	0380610AA	exendin-(9-39)	5313W10MYT						Congenital hyperinsulinism	3947	done	
expanded human allogeneic mesenchymal adult stem cells extracted from adipose tissue	Treatment of fistulizing Crohn's disease	expanded human allogeneic mesenchymal adult stem cells extracted from adipose tissue	STEM CELLS	n/a	10/18/17	Designated			N/A	N/A	TiGenix S.A.U.	Leuven			Belgium	LONGEST CONTAINS	0264620AA	stem cells	9DRI670EXJ	HUMAN ADIPOSE TISSUE DERIVED CELL	9DRI670EXJ	https://ginas.ncats.nih.gov/ginas/app/substance/ac1f6e34	approximate		Crohn's disease	10232	done	
extract of sorghum bicolor extract	Treatment of sickle cell disease	extract of sorghum bicolor extract	SORGHUM	n/a	11/19/12	Designated			N/A	N/A	"Invenux, LLC"	Windsor	Colorado	80550	USA	EXACT	0711079AA	sorghum	CUL9PN8ELJ						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
extract of sorghum bicolor extract	Treatment of sickle cell disease	extract of sorghum bicolor extract	SORGHUM	n/a	11/19/12	Designated			N/A	N/A	"Invenux, LLC"	Windsor	Colorado	80550	USA	EXACT	0711079AA	sorghum	CUL9PN8ELJ						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
extract of sorghum bicolor extract	Treatment of sickle cell disease	extract of sorghum bicolor extract	SORGHUM	n/a	11/19/12	Designated			N/A	N/A	"Invenux, LLC"	Windsor	Colorado	80550	USA	EXACT	0711079AA	sorghum	CUL9PN8ELJ						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
extract of sorghum bicolor extract	Treatment of sickle cell disease	extract of sorghum bicolor extract	SORGHUM	n/a	11/19/12	Designated			N/A	N/A	"Invenux, LLC"	Windsor	Colorado	80550	USA	EXACT	0711079AA	sorghum	CUL9PN8ELJ						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
extract of sorghum bicolor extract	Treatment of sickle cell disease	extract of sorghum bicolor extract	SORGHUM	n/a	11/19/12	Designated			N/A	N/A	"Invenux, LLC"	Windsor	Colorado	80550	USA	EXACT	0711079AA	sorghum	CUL9PN8ELJ						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
extract of sorghum bicolor extract	Treatment of sickle cell disease	extract of sorghum bicolor extract	SORGHUM	n/a	11/19/12	Designated			N/A	N/A	"Invenux, LLC"	Windsor	Colorado	80550	USA	EXACT	0711079AA	sorghum	CUL9PN8ELJ						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
ezogabine	Treatment of KCNQ2 epileptic encephalopathy	ezogabine	EZOGABINE	Potiga	6/21/18	Designated			N/A	N/A	"Xenon Pharmaceuticals, Inc."	200-3650 Gilmore Way	British Columbia		Canada	EXACT	0222231AA	ezogabine	12G01I6BBU						Early Infantile Epileptic Encephalopathy	9255	done	
fecal microbiota	Treatment of recurrent Clostridium difficile infection (Clostridium difficile gastrointestinal disease)	fecal microbiota	FECAL MICROBIOTA	n/a	3/10/14	Designated			N/A	N/A	"Rebiotx, Inc."	Roseville	Minnesota	55113	USA	EXACT	0934338AA	fecal microbiota	Q805XO2F7C						Clostridium septicum infection	11969	approximate	
fenretinide	Treatment of Ewing's sarcoma family of tumors.	fenretinide	FENRETINIDE	n/a	2/1/07	Designated			N/A	N/A	Cancer Research UK				United Kingdom	EXACT	0136061AA	fenretinide	187EJ7QEXL						Ewing's family of tumors	9323	done	
"ferric hexacyanoferrate (II) ""Prussian Blue"""	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	"ferric hexacyanoferrate (II) ""Prussian Blue"""	FERRIC FERROCYANIDE	n/a	6/26/03	Designated			N/A	N/A	Degussa AG	Frankfurt			Germany	EXACT	0055709AA	ferric hexacyanoferrate	TLE294X33A								MISSING	not a disease
ferumoxytol	For use in MR imaging for the mangement of brain tumors	ferumoxytol	FERUMOXYTOL	Feraheme	4/29/11	Designated			N/A	N/A	"Edward A. Neuwelt, MD"	Portland	Oregon	97239	USA	EXACT	0327753AA	ferumoxytol	CLH5FT6412								MISSING	"not a disease, a procedure"
ferumoxytol	For use in magnetic resonance imaging in brain metastases	ferumoxytol	FERUMOXYTOL	n/a	10/7/11	Designated			N/A	N/A	Oregon Health & Science University	Portland	Oregon	97239	USA	EXACT	0327753AA	ferumoxytol	CLH5FT6412								MISSING	"not a disease, a procedure"
ferumoxytol	"For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)"	ferumoxytol	FERUMOXYTOL	n/a	4/6/12	Designated			N/A	N/A	"ArsNova Partners, LLC"	Newton	Massachusetts	2460	USA	EXACT	0327753AA	ferumoxytol	CLH5FT6412								MISSING	"not a disease, a procedure"
fexinidazole	Treatment of human African trypanosomiasis (HAT) or sleeping sickness	fexinidazole	FEXINIDAZOLE	n/a	4/4/16	Designated			N/A	N/A	"Sanofi US Services, Inc."	Bridgewater	New Jersey	8807	USA	EXACT	0278400AA	fexinidazole	306ERL82IR						"Trypanosomiasis, Human West-African "	7826	done	
fexinidazole	Treatment of human African trypanosomiasis (HAT) or sleeping sickness	fexinidazole	FEXINIDAZOLE	n/a	4/4/16	Designated			N/A	N/A	"Sanofi US Services, Inc."	Bridgewater	New Jersey	8807	USA	EXACT	0278400AA	fexinidazole	306ERL82IR						" Trypanosomiasis, Human East-African"	8540	done	
fidaxomicin	Treatment of pediatric Clostridium difficile infection	fidaxomicin	FIDAXOMICIN	Dificid	12/13/10	Designated			N/A	N/A	"Optimer Pharmaceuticals, Inc."	San Diego	California	92121	USA	EXACT	0322510AA	fidaxomicin	Z5N076G8YQ								MISSING	
filgrastim	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	filgrastim	"FILGRASTIM, LICENSE HOLDER UNSPECIFIED"	Neupogen	11/20/13	Designated/Approved	Approved for Orphan Indication	To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).	3/30/15	3/30/22	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0174823AA	filgrastim	PVI5M0M1GW								MISSING	"not a disease, a process"
filociclovir	Treatment of active cytomegalovirus infections	filociclovir	FILOCICLOVIR	n/a	11/29/10	Designated			N/A	N/A	"Microbiotix, Inc."	Worcester	Massachusetts	1605	USA	EXACT	0737531AA	filociclovir	EAO0TD9B13						Congenital cytomegalovirus	1480	approximate	origin of cytomegalovirus is not specified
fixed dose combination of methimazole and liothyronine	Treatment of brain metastases in patients with primary lung cancer	fixed dose combination of methimazole and liothyronine	LIOTHYRONINE	n/a	3/6/17	Designated			N/A	N/A	Musli Thyropeutics Ltd.	Zur Moshe			Israel	EXACT	0046957AA	liothyronine	06LU7C9H1V								MISSING	Not a rare disease
flavin mononucleotide	Treatment of mitochondrial disorders	"cytochrome C, flavin mononucleotide and thiamin diphosphate"	FLAVIN MONONUCLEOTIDE	n/a	6/17/11	Designated			N/A	N/A	"NBI Pharmaceuticals, Inc."	Bozeman	Montana	59715	USA	EXACT	0022888AA	flavin mononucleotide	7N464URE7E								MISSING	mitchondrial disease not specified
fluasterone	"Treatment of Cushing syndrome (including hyperglycemia, nonalcoholic fatty liver disease, and nonalcoholic steatosis)"	fluasterone	FLUASTERONE	n/a	3/28/18	Designated			N/A	N/A	"Sterotherapeutics, LLC"	716 North Bethlehem Pike	Suite 203	19002	USA	EXACT	0183108AA	fluasterone	R7M5UGD04G						Cushing's syndrome	6224	done	
flubendazole	"Treatment of lymphatic filariasis caused by nematodes of the family Filariodidea, in children and adults."	flubendazole	FLUBENDAZOLE	n/a	1/23/14	Designated			N/A	N/A	"Janssen Research and Development, LLC"	Raritan	New Jersey	8869	USA	EXACT	0083896AA	flubendazole	R8M46911LR						Lymphatic filariasis	3321	done	
fluciclovine f-18	For the diagnosis of glioma	"fluciclovine (18F)(anti-1-amino-3-fluorocyclobutane-1-carboxylic acid, labelled with Fluorine-18)"	FLUCICLOVINE F-18	n/a	4/7/15	Designated			N/A	N/A	Blue Earth Diagnostics Ltd.				United Kingdom	EXACT	0257603AA	fluciclovine f-18	38R1Q0L1ZE						Glioma	6513	done	
fluticasone propionate	Treatment of eosinophilic esophagitis	fluticasone propionate	FLUTICASONE PROPIONATE	n/a	12/29/15	Designated			N/A	N/A	"Banner Life Sciences, LLC"	High Point	North Carolina	27265	USA	EXACT	0157551AA	fluticasone propionate	O2GMZ0LF5W						Eosinophilic enteropathy	9142	done	
fluticasone propionate	Treatment of pediatric and adult eosinophilic esophagitis	fluticasone propionate	FLUTICASONE PROPIONATE	n/a	1/19/11	Designated			N/A	N/A	"Adare Pharmaceuticals, Inc."	Vandalia	Ohio	45377	USA	EXACT	0157551AA	fluticasone propionate	O2GMZ0LF5W						Eosinophilic enteropathy	9142	done	
fluticasone propionate	Treatment of symptomatic exophthalmos associated with thyroid related eye disease	salmeterol xinafoate/fluticasone propionate	FLUTICASONE PROPIONATE	n/a	10/29/09	Designated			N/A	N/A	"Lithera, Inc."	San Diego	California	92122	USA	EXACT	0157551AA	fluticasone propionate	O2GMZ0LF5W								MISSING	
fmiso f-18	"As a diagnostic for clinical management of soft tissue sarcoma, including rhabdomyosarcoma."	1-(2-Nitro-imidazolyl)-3-[18F]fluoro-2-propanol;1H-1-(3-[18F]fluoro-2-hydroxypropyl)-2-nitroimidazole	FLUOROMISONIDAZOLE F-18	n/a	1/6/16	Designated			N/A	N/A	"Advanced Imaging Projects, LLC"	Lake Worth	Florida	33467	USA	EXACT	0168729AA	fmiso f-18	8MSY49469G						Soft tissue sarcoma	4898	done	
fostamatinib disodium	Treatment of immune thrombocytopenic purpura	fostamatinib disodium	FOSTAMATINIB DISODIUM	n/a	8/25/15	Designated			N/A	N/A	"Rigel Pharmaceuticals, INc."	South San Francisco	California	94080	USA	EXACT	0305486AA	fostamatinib disodium	86EEZ49YVB						Idiopathic thrombocytopenic purpura	5194	approximate	
fully human nicotine-specific monoclonal antibody	Treatment of thromboangiitis obliterans (Buerger’s disease)	fully human nicotine-specific monoclonal antibody	NICOTINE	n/a	8/22/18	Designated			N/A	N/A	"Antidote Therapeutics, Inc."	708 Quince Orchard Rd.	Maryland	20878	USA	LONGEST CONTAINS	0008560AA	nicotine	6M3C89ZY6R						Buerger disease	5969	done	
gabapentin	Management of postherpetic neuralgia	gabapentin	GABAPENTIN	Gralise	11/8/10	Designated/Approved	Approved for Orphan Indication	For the management of postherpetic neuralgia	1/28/11	1/28/18	"Depomed, Inc."	Menlo Park	California	94025	USA	EXACT	0157051AA	gabapentin	6CW7F3G59X						Herpes zoster oticus	7525	approximate	postherpetic neuralgia is a complication of varicella-zoster virus infection
gabapentin enacarbil	Treatment of postherpetic neuralgia	gabapentin enacarbil	GABAPENTIN ENACARBIL	Horizant	6/7/11	Designated/Approved	Approved for Orphan Indication	Management of postherpetic neuralgia in adults.	6/6/12	6/6/19	"Arbor Pharmaceuticals, LLC"	Atlanta	Georgia	30328	USA	EXACT	0256462AA	gabapentin enacarbil	75OCL1SPBQ								MISSING	Not a rare disease; symptom
ganaxolone	Treatment of Protocadherin 19 (PCDH19) female epilepsy.	ganaxolone	GANAXOLONE	n/a	3/24/15	Designated			N/A	N/A	"Marinus Pharmaceuticals, Inc."	Radnor	Pennsylvania	19087	USA	EXACT	0184587AA	ganaxolone	98WI44OHIQ						PCDH19-related female-limited epilepsy	10806	done	
ganaxolone	Treatment of cyclin-dependent kinase-like 5 (CDKL5) gene-related early-onset infantile epileptic encephalopathy	ganaxolone	GANAXOLONE	n/a	6/28/17	Designated			N/A	N/A	Marinus Pharmaceuticals	Radnor	Pennsylvania	19087	USA	EXACT	0184587AA	ganaxolone	98WI44OHIQ							9255	done	
ganciclovir	Treatment of acute herpetic keratitis (dendritic and geographic ulcers)	ganciclovir	GANCICLOVIR	Zirgan	3/22/07	Designated/Approved	Approved for Orphan Indication	Treatment of acute herpetic keratitis (dendritic ulcers)	9/15/09	9/15/16	"Sirion Therapeutics, Inc."	Tampa	Florida	33619	USA	EXACT	0138738AA	ganciclovir	P9G3CKZ4P5						Vernal keratitis	10531	approximate	
ganitumab	Treatment of pancreatic cancer.	ganitumab	GANITUMAB	n/a	11/23/10	Designated			N/A	N/A	Nantcell	Culver City	California	90232	USA	EXACT	0432542AA	ganitumab	CK1441RCZ8						Pancreatic cancer	9364	done	Not a rare disease
gefitinib	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer	gefitinib	GEFITINIB	Iressa	8/26/14	Designated/Approved	Approved for Orphan Indication	For the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test	7/13/15	7/13/22	AstraZeneca Pharmaceuticals LP	Wilmington	Delaware	19803	USA	EXACT	0224022AA	gefitinib	S65743JHBS						"Non-small cell lung cancer, childhood"	9343	approximate	
gemcabene	Treatment of homozygous familial hypercholesterolemia	gemcabene	GEMCABENE	n/a	2/6/14	Designated			N/A	N/A	"Gemphire Therapeutics, Inc."	Northville	Michigan	48167	USA	EXACT	0299945AA	gemcabene	B96UX1DDKS						Familial hypercholesterolemia	10416	done	Not a rare disease
gemcitabine intra-arterial infusion via the RenovoCath™ RC120 catheter	Treatment of pancreatic cancer	gemcitabine intra-arterial infusion via the RenovoCath™ RC120 catheter	GEMCITABINE	n/a	4/24/18	Designated			N/A	N/A	RenovoRx	4546 El Camino Real	Suite 203	94022	USA	EXACT	0282086AA	gemcitabine	B76N6SBZ8R						Pancreatic cancer	9364	done	Not a rare disease
gemcitabine ready-to-use	Treatment of pancreatic cancer	gemcitabine ready-to-use	GEMCITABINE	n/a	6/24/15	Designated			N/A	N/A	Sun Pharmaceutical Industries Ltd.				India	EXACT	0282086AA	gemcitabine	B76N6SBZ8R						Pancreatic cancer	9364	done	Not a rare disease
gemfibrozil	Treatment of neuronal ceroid lipofuscinoses	gemfibrozil	GEMFIBROZIL	n/a	8/2/17	Designated			N/A	N/A	"Polaryx Therapeutics, Inc."	Paramus	New Jersey	7652	USA	EXACT	0063230AA	gemfibrozil	Q8X02027X3						Neuronal ceroid lipofuscinosis	10739	done	
gemfibrozil and vitamin A	Treatment of neuronal ceroid lipofuscinoses	gemfibrozil and vitamin A	GEMFIBROZIL	n/a	12/6/17	Designated			N/A	N/A	"Polaryx Therapeutics, Inc."	140 East Ridgewood Avenue	Paramus	7652	USA	EXACT	0063230AA	gemfibrozil	Q8X02027X3						Neuronal ceroid lipofuscinosis	10739	done	
"generation 4 hydroxyl-terminated polyamidoamine dendrimer containing an ethylene diamine (EDA) core, amidoamine repate units, and 64 hydroxyl end groups"	Treatment of x-linked adrenoleukodystrophy	"generation 4 hydroxyl-terminated polyamidoamine dendrimer containing an ethylene diamine (EDA) core, amidoamine repate units, and 64 hydroxyl end groups"	ETHYLENEDIAMINE	n/a	3/22/17	Designated			N/A	N/A	"Orpheris, Inc."	Redwood City	California	94065	USA	LONGEST CONTAINS	0017378AA	ethylene diamine	60V9STC53F						X-linked adrenoleukodystrophy	5758	done	
gevokizumab	Treatment of Behcet's disease	gevokizumab	GEVOKIZUMAB	n/a	7/27/10	Designated			N/A	N/A	XOMA (US) LLC	Berkeley	California	94710	USA	EXACT	0574107AA	gevokizumab	QX3JU54GYQ						Behçet disease	848	done	
gevokizumab	"Treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis"	gevokizumab	GEVOKIZUMAB	n/a	8/20/12	Designated			N/A	N/A	XOMA (US) LLC	Berkeley	California	94710	USA	EXACT	0574107AA	gevokizumab	QX3JU54GYQ						Panuveitis 	8577	approximate	
gevokizumab	"Treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis"	gevokizumab	GEVOKIZUMAB	n/a	8/20/12	Designated			N/A	N/A	XOMA (US) LLC	Berkeley	California	94710	USA	EXACT	0574107AA	gevokizumab	QX3JU54GYQ						 Anterior uveitis 	10941	approximate	
gevokizumab	"Treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis"	gevokizumab	GEVOKIZUMAB	n/a	8/20/12	Designated			N/A	N/A	XOMA (US) LLC	Berkeley	California	94710	USA	EXACT	0574107AA	gevokizumab	QX3JU54GYQ						 Posterior uveitis	4457	approximate	
gimeracil	Treatment of gastric cancer	Tegafur/gimeracil/oteracil	GIMERACIL	n/a	7/20/06	Designated			N/A	N/A	"Taiho Pharma USA, Inc."	Princeton	New Jersey	8540	USA	EXACT	0299901AA	gimeracil	UA8SE1325T						Stomach cancer	7704	done	
glecapreviR	Treatment of pediatric patients with chronic hepatitis C virus infection	glecaprevir and pibrentasvir	GLECAPREVIR	n/a	1/9/17	Designated			N/A	N/A	"AbbVie, Inc."	North Chicago	Illinois	60044	USA	EXACT	0850157AA	glecapreviR	K6BUU8J72P								MISSING	Not a rare disease
glecaprevir and pibrentasvir	Treatment of pediatric patients with chronic hepatitis C virus infection	glecaprevir and pibrentasvir	PIBRENTASVIR	n/a	1/9/17	Designated			N/A	N/A	"AbbVie, Inc."	North Chicago	Illinois	60044	USA	EXACT	0866911AA	pibrentasvir	2WU922TK3L								MISSING	Not a rare disease
gliadin	Treatment of amyotrophic lateral sclerosis	"superoxide dismutase, gliadin"	GLIADIN	Etr019	4/30/10	Designated			N/A	N/A	Verius Limited				United Kingdom	EXACT	1189668AA	gliadin	GR9478B3Q3						Amyotrophic lateral sclerosis	5786	done	
glibentek (glibenclamide oral suspension)	Treatment of neonatal diabetes (monogenic forms of diabetes that present in infancy)	glibentek (glibenclamide oral suspension)	GLYBURIDE	n/a	6/8/16	Designated			N/A	N/A	AMMTeK	Paris			France	EXACT	0053601AA	glibenclamide	SX6K58TVWC						Monogenic diabetes	10257	done	
glucagon (ready-to-use)	Treatment of hyperinsulinemic hypoglycemia (HH)	glucagon (ready-to-use)	GLUCAGON	n/a	1/24/18	Designated			N/A	N/A	"Xeris Pharmaceuticals, Inc."	3208 Red River Street	Austin	78705	USA	EXACT	0007114AA	glucagon	76LA80IG2G						Exercise-induced hyperinsulinemic hypoglycemia 	9932	approximate	
glucagon (ready-to-use)	Treatment of hyperinsulinemic hypoglycemia (HH)	glucagon (ready-to-use)	GLUCAGON	n/a	1/24/18	Designated			N/A	N/A	"Xeris Pharmaceuticals, Inc."	3208 Red River Street	Austin	78705	USA	EXACT	0007114AA	glucagon	76LA80IG2G						 Congenital hyperinsulinism	3947	approximate	
glucagon infusion	"Prevention of chronic, severe hypoglycemia related to congential hyperinsulinism"	glucagon infusion	GLUCAGON	G-Pump (Tm)	9/25/14	Designated			N/A	N/A	"Xeris Pharmaceuticals, Inc."	Austin	Texas	78705	USA	EXACT	0007114AA	glucagon	76LA80IG2G						Congenital hyperinsulinism	3947	done	
glucarpidase	Treatment of patients at risk of methotrexate toxicity	glucarpidase	GLUCARPIDASE	Voraxaze	8/19/03	Designated/Approved	Approved for Orphan Indication	Treatment of toxic (>1 micromole/liter) plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function.	1/17/12	1/17/19	BTG International Inc.	Brentwood	Tennessee	37027	USA	EXACT	0267130AA	glucarpidase	2GFP9BJD79								MISSING	not a disease
glucono-delta-lactone	Treatment of renal and bladder calculi of the apatite or struvite variety.	"Citric acid, glucono-delta-lactone and magnesium carbonate"	GLUCONOLACTONE	Renacidin Irrigation	8/28/89	Designated/Approved	Approved for Orphan Indication		10/2/90	10/2/97	"United-Guardian, Inc."	Smithtown	New York	11787	USA	EXACT	0015349AA	glucono-delta-lactone	WQ29KQ9POT								MISSING	
glufosfamide	For treatment of pancreatic cancer.	glufosfamide	GLUFOSFAMIDE	n/a	9/18/06	Designated			N/A	N/A	Eleison Pharmaceuticals LLC	St. Petersburg	Florida	33701	USA	EXACT	0254535AA	glufosfamide	1W5N8SZD9A						Pancreatic cancer	9364	done	Not a rare disease
glutathione	Treatment of lung dysfunction following lung transplant	glutathione	GLUTATHIONE	Arina-1	12/12/16	Designated			N/A	N/A	"Renovion, Inc."	Chapel Hill	North Carolina	27516	USA	EXACT	0012135AA	glutathione	GAN16C9B8O								MISSING	not a disease
glyburide	Treatment of acute spinal cord injury	glyburide	GLYBURIDE	n/a	9/29/15	Designated			N/A	N/A	"Remedy Pharmaceuticals, Inc."	New York	New York	10001	USA	EXACT	0053601AA	glyburide	SX6K58TVWC								MISSING	
glyburide	Treatment of acute subarachnoid hemorrhage	glyburide	GLYBURIDE	n/a	2/8/16	Designated			N/A	N/A	"Remedy Pharmaceuticals, Inc."	New York	New York	10001	USA	EXACT	0053601AA	glyburide	SX6K58TVWC								MISSING	
glycerin	To decrease intracranial hypertension and/or alleviate cerebral edema in patients who may benefit from osmotherapy.	Glyceol	GLYCERIN	n/a	2/22/90	Designated/Withdrawn			N/A	N/A	"Chugai Pharmaceutical Co., Ltd."					EXACT	0009143AA	glycerin	PDC6A3C0OX								MISSING	symptom; procedure
glycerol phenylbutyrate	Maintenance treatment of patients with deficiencies in enzymes of the urea cycle	glycerol phenylbutyrate	GLYCEROL PHENYLBUTYRATE	Ravicti	4/27/09	Designated/Approved	Approved for Orphan Indication	"Use as a nitrogen-binding adjunctive therapy for chronic management of adult and pediatric patients at least 2 years of age with urea cycle disorders (UCDs) that cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (eg, essential amino acids, arginine, citrulline, protein-free calorie supplements)."	2/1/13	2/1/20	"Horizon Pharma, Inc."	Lake Forest	Illinois	60045	USA	EXACT	0682848AA	glycerol phenylbutyrate	ZH6F1VCV7B								MISSING	
glycopyrrolate	Treatment of pathologic (chronic moderate to severe) drooling in pediatric patients	glycopyrrolate	GLYCOPYRROLATE	Cuvposa	6/9/06	Designated/Approved	Approved for Orphan Indication	To reduce chronic drooling in patients aged 3 - 16 with neurologic conditions associated with problem drooling (e.g. cerebral palsy)	7/28/10	7/28/17	"Shionogi, Inc."	Florham	New Jersey	7932	USA	EXACT	0029732AA	glycopyrrolate	V92SO9WP2I								MISSING	not a disease
golimumab	Treatment of chronic sarcoidosis	golimumab	GOLIMUMAB	n/a	11/2/04	Designated/Withdrawn			N/A	N/A	"Centocor, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	0265463AA	golimumab	91X1KLU43E						Sarcoidosis	7607	done	
golimumab	Treatment of polyarticular juvenile idiopathic arthritis in patients 0 through 18 years of age.	golimumab	GOLIMUMAB	Simponi Aria	4/2/15	Designated			N/A	N/A	"Janssen Research & Development, LLC"	Spring House	Pennsylvania	19477	USA	EXACT	0265463AA	golimumab	91X1KLU43E						Polyarticular onset juvenile idiopathic arthritis	10967	done	
golimumab	Treatment of sarcoidosis	golimumab	GOLIMUMAB	Simponi Aria	5/21/12	Designated/Withdrawn			N/A	N/A	"Janssen Biotech, Inc."	Spring House	Pennsylvania	19477	USA	EXACT	0265463AA	golimumab	91X1KLU43E						Sarcoidosis	7607	done	
golnerminogene pradenovec	Treatment of pancreatic cancer.	golnerminogene pradenovec		Tnferade(Tm) Biologic	10/28/09	Designated			N/A	N/A	"GenVec, Inc."	Gaithersburg	Maryland	20878	USA					golnerminogene pradenovec	NA	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/golnerminogene-pradenovec	done		Pancreatic cancer	9364	done	Not a rare disease
"granulocyte-macrophage colony stimulating factor-coding oncolytic adenovirus, Ad5/3-D24-GMCSF"	Treatment of soft tissue sarcoma	"granulocyte-macrophage colony stimulating factor-coding oncolytic adenovirus, Ad5/3-D24-GMCSF"		n/a	7/24/13	Designated			N/A	N/A	Oncos Therapeutics	Helsinki			Finland								PROBLEM	can't find	Soft tissue sarcoma	4898	done	
"growth hormone releasing hormone, 1-44 human amide"	Treatment of growth hormone deficiency	"growth hormone releasing hormone, 1-44 human amide"	SOMATORELIN	n/a	2/23/16	Designated			N/A	N/A	"Hollenbeck Pharmaceuticals, Inc."	Falls Village	Connecticut	6031	USA	EXACT	0127797AA	somatorelin	4UR7N9Z9MM						Growth hormone deficiency	6552	done	
guanfacine	Treatment of pediatric patients with Tourette's syndrome (0 through 16 years of age)	guanfacine and amphetamine	GUANFACINE	n/a	3/17/16	Designated			N/A	N/A	"Genco Sciences, LLC"	Willmette	Illinois	60091	USA	EXACT	0160112AA	guanfacine	30OMY4G3MK						Tourette syndrome	7783	done	
guanfacine and amphetamine	Treatment of pediatric patients with Tourette's syndrome (0 through 16 years of age)	guanfacine and amphetamine	AMPHETAMINE	n/a	3/17/16	Designated			N/A	N/A	"Genco Sciences, LLC"	Willmette	Illinois	60091	USA	EXACT	0010344AA	amphetamine	CK833KGX7E						Tourette syndrome	7783	done	
heat killed mycobacterium w immunomodulator	Adjuvant to multi-drug therapy in the management of multibacillary leprosy	heat killed mycobacterium w immunomodulator		Cadi Mw	11/21/02	Designated			N/A	N/A	"CPL, Inc."	Chesterfield	Missouri	63017	USA					Cadi 05	NA	https://adisinsight.springer.com/drugs/800026303	PROBLEM	absent from GINAS	Hansen's disease	6886	approximate	
heat killed mycobacterium w immunomodulator	Treatment of non-small cell lung cancers that express desmocollin-3	heat killed mycobacterium w immunomodulator		Cadi-Mw	7/31/12	Designated			N/A	N/A	Cadila Pharmaceuticals Limited	Gujarat			India					Cadi 05	NA	https://adisinsight.springer.com/drugs/800026303	PROBLEM	absent from GINAS	"Non-small cell lung cancer, childhood"	9343	approximate	
hematopoietic stem cells modified with a lentiviral vector containing the CD18 (Integrin Beta 2) gene	Treatment of leukocyte adhesion deficiency Type I	hematopoietic stem cells modified with a lentiviral vector containing the CD18 (Integrin Beta 2) gene	STEM CELLS	Ladilen	11/9/16	Designated			N/A	N/A	Centro de Investigacion Biomedica en Red (CIBER)	Madrid			Spain	LONGEST CONTAINS	0264620AA	stem cells	NW5JLT8E3A | FMN4CGB1C8 | TIW6JAG30P | INTEGRIN BETA-2	"HUMAN PERIPHERAL BLOOD HEMATOPOIETIC PROGENITOR CELL | HUMAN HEMATOPOIETIC PROGENITOR CELL, MARROW DERIVED"	NW5JLT8E3A | FMN4CGB1C8 | TIW6JAG30P | INTEGRIN BETA-2	https://ginas.ncats.nih.gov/ginas/app/substance/ddc1096a | https://ginas.ncats.nih.gov/ginas/app/substance/25d69951 | https://ginas.ncats.nih.gov/ginas/app/substance/d7f6b3f1	approximate	GINAS  has entry only for Integrin Beta 2 protein	Leukocyte adhesion deficiency type 1	6893	done	
heparan sulfate mimetic	Treatment of pancreatic cancer	heparan sulfate mimetic	HEPARAN SULFATE (PORCINE5500 MW)	n/a	5/29/14	Designated			N/A	N/A	"Momenta Pharmaceuticals, Inc."	Cambridge	Massachusetts	2142	USA	LONGEST CONTAINS	0565195AA	heparan sulfate	47959853R5						Pancreatic cancer	9364	done	Not a rare disease
heparin activated recombinant human fibroblast growth factor 1 (FGF1)in combination with a surgically implanted biodegradable device	Treatment of patients with a confirmed traumatic complete spinal cord injury where no motor or sensory function is preserved below the injury(Scale A)	heparin activated recombinant human fibroblast growth factor 1 (FGF1)in combination with a surgically implanted biodegradable device	FIBROBLAST GROWTH FACTOR-1	n/a	10/24/11	Designated			N/A	N/A	BioArctic Neuroscience AB	Stockholm			Sweden	LONGEST CONTAINS	0264960AA	human fibroblast growth factor 1	G53298VN9Y								MISSING	
hepatitis B immune globulin (human)	Prevention of hepatitis B recurrence following orthotopic liver transplant	hepatitis B immune globulin (human)	HEPATITIS B IMMUNE GLOBULIN (HUMAN)	Hepagam	3/24/08	Designated/Approved	Approved for Orphan Indication	Prevention of hepatitis B recurrence following liver transplantation in HBsAG-positive liver transplant patients	4/6/07	4/6/14	Cangene Corporation				Canada	EXACT	0324641AA	hepatitis B immune globulin (human)	XII270YC6M								MISSING	Not a rare disease
herpes simplex type 1 virus containing cellular B-myb gene as tumor-specific promoter	Treatment of pancreatic cancer	herpes simplex type 1 virus containing cellular B-myb gene as tumor-specific promoter	HERPES	n/a	12/23/14	Designated			N/A	N/A	Karcinolys S.A.S.				France	LONGEST CONTAINS	0354825AA	herpes					PROBLEM	can't find	Pancreatic cancer	9364	done	Not a rare disease
heterologous human liver derived progenitor cells	Treatment of Crigler-Najjar syndrome	heterologous human liver derived progenitor cells	HUMAN LIVER	n/a	3/9/12	Designated			N/A	N/A	Promethera Biosciences				Belgium	LONGEST CONTAINS	1309279AA	human liver	JFENOMOVE6						Crigler-Najjar syndrome type 2 	8683	done	
heterologous human liver derived progenitor cells	Treatment of Crigler-Najjar syndrome	heterologous human liver derived progenitor cells	HUMAN LIVER	n/a	3/9/12	Designated			N/A	N/A	Promethera Biosciences				Belgium	LONGEST CONTAINS	1309279AA	human liver	JFENOMOVE6						" Crigler Najjar syndrome, type 1"	47	done	
"high molecular weight multimer of E3-Fc, an endostatin C-terminus and IgG1-Fc fusion protein"	Treatment of systemic sclerosis	"high molecular weight multimer of E3-Fc, an endostatin C-terminus and IgG1-Fc fusion protein"	ENDOSTATIN	n/a	6/27/16	Designated			N/A	N/A	"iBio, Inc."	New York	New York	10022	USA	LONGEST CONTAINS	0265703AA	endostatin	67RHC0R671						Systemic scleroderma	9748	done	
homoharringtonine	Treatment for chronic myelogenous leukemia	homoharringtonine	OMACETAXINE MEPESUCCINATE	n/a	2/8/02	Designated			N/A	N/A	"American BioScience, Inc."	Santa Monica	California	90403	USA	EXACT	0313439AA	homoharringtonine	6FG8041S5B						Chronic myeloid leukemia	6105	done	
human Hepatocarcinoma-Intestine-pancreas/pancreatitis associated protein	Treatment of acute liver failure	human Hepatocarcinoma-Intestine-pancreas/pancreatitis associated protein	PROTEIN	n/a	5/11/11	Designated			N/A	N/A	Alfact Innovation SAS				France	LONGEST CONTAINS	0087274AA	protein					PROBLEM	can't find	Transient infantile liver failure	10593	approximate	
human IgG2 monoclonal antibody directed against the mucosal addressin cell adhesion molecule	Treatment of Crohn’s Disease (CD) in the pediatric population	human IgG2 monoclonal antibody directed against the mucosal addressin cell adhesion molecule		n/a	2/7/18	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc. (Shire)"	300 Shire Way	Lexington		USA				6LGI7RV4PB	ONTAMALIMAB | SHP 647	6LGI7RV4PB	https://fdasis.nlm.nih.gov/srs/auto/startswith/pf-00547659 | https://adisinsight.springer.com/drugs/800025580	done		Crohn's disease	10232	done	Not a rare disease
human allogeneic bone marrow derived osteoblastic cells	Treatment of osteonecrosis	human allogeneic bone marrow derived osteoblastic cells	"BONE MARROW, ALLOGENEIC"	Allob	1/10/14	Designated			N/A	N/A	Bone Therapeutics SA				Belgium	LONGEST CONTAINS	0260935AA	allogeneic bone marrow					PROBLEM	can't find			MISSING	
human donor hematopoietic stem and progenitor cells (HSPC) that have been treated ex vivo with TBX-4000	Enhancement of cell engraftment in patients receiving hematopoietic stem cell transplant.	human donor hematopoietic stem and progenitor cells (HSPC) that have been treated ex vivo with TBX-4000		n/a	6/2/16	Designated			N/A	N/A	"Taiga Biotechnologies, Inc."	Aurora	Colorado	80045	USA				FMN4CGB1C8	"HUMAN HEMATOPOIETIC PROGENITOR CELL, MARROW DERIVED | autologous human peripheral blood mononuclear cells incubated ex vivo with protein TBX-4000 (Tat-MYC) | TBX-3400"	FMN4CGB1C8	https://ginas.ncats.nih.gov/ginas/app/substance/25d69951 | https://adisinsight.springer.com/drugs/800051035	approximate				MISSING	"not a disease, a procedure"
"human fibrinogen concentrate, pasteurized"	Treatment of fibrinogen deficient patients.	"human fibrinogen concentrate, pasteurized"	FIBRINOGEN HUMAN	Riastap	3/13/08	Designated/Approved	Approved for Orphan Indication	Treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia)	1/16/09	1/16/16	"CSL Behring, LLC"	King of Prussia	Pennsylvania	19406	USA	EXACT	0323977AA	human fibrinogen	N94833051K						"Fibrinogen deficiency, congenital"	2320	done	
human gammaglobulin	Treatment for juvenile rheumatoid arthritis	human gammaglobulin	HUMAN IMMUNOGLOBULIN G	Oralgam	5/25/01	Designated			N/A	N/A	"Latona Life Sciences, Inc."	Mills	Massachusetts	2054	USA	EXACT	0201570AA	human gammaglobulin	66Y330CJHS						Juvenile idiopathic arthritis	3067	done	
human gammaglobulin	"Treatment of gastrointestinal disturbances (to include constipation, diarrhea, and abdominal pain) associated with regression-onset autism in pediatric patients."	human gammaglobulin	HUMAN IMMUNOGLOBULIN G	Oralgam	9/16/02	Designated			N/A	N/A	"Latona Life Sciences, Inc."	Mills	Massachusetts	2054	USA	EXACT	0201570AA	human gammaglobulin	66Y330CJHS								MISSING	not a disease
human gammaglobulin	Treatment of idiopathic inflammatory myopathies	human gammaglobulin	HUMAN IMMUNOGLOBULIN G	Oralgam	11/14/03	Designated			N/A	N/A	"Latona Life Sciences, Inc."	Mills	Massachusetts	2054	USA	EXACT	0201570AA	human gammaglobulin	66Y330CJHS						Idiopathic inflammatory myopathy	9128	done	
human glial restricted progenitor cells and their progeny	Treatment of transverse myelitis	human glial restricted progenitor cells and their progeny		Q-Cells®	4/11/18	Designated			N/A	N/A	"Q Therapeutics, Inc."	417 Wakara Way	Ste. 3510	84108	USA					glial restricted progenitor cell therapy	NA	https://adisinsight.springer.com/drugs/800051882	PROBLEM	absent from GINAS	Transverse myelitis	7796	done	
human haptoglobin	Treatment of sickle cell disease	human haptoglobin		n/a	11/19/13	Designated			N/A	N/A	BioProducts Laboratory Limited				United Kingdom								PROBLEM	can't find	Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
human haptoglobin	Treatment of sickle cell disease	human haptoglobin		n/a	11/19/13	Designated			N/A	N/A	BioProducts Laboratory Limited				United Kingdom								PROBLEM	can't find	 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
human haptoglobin	Treatment of sickle cell disease	human haptoglobin		n/a	11/19/13	Designated			N/A	N/A	BioProducts Laboratory Limited				United Kingdom								PROBLEM	can't find	 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
human haptoglobin	Treatment of sickle cell disease	human haptoglobin		n/a	11/19/13	Designated			N/A	N/A	BioProducts Laboratory Limited				United Kingdom								PROBLEM	can't find	 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
human haptoglobin	Treatment of sickle cell disease	human haptoglobin		n/a	11/19/13	Designated			N/A	N/A	BioProducts Laboratory Limited				United Kingdom								PROBLEM	can't find	 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
human haptoglobin	Treatment of sickle cell disease	human haptoglobin		n/a	11/19/13	Designated			N/A	N/A	BioProducts Laboratory Limited				United Kingdom								PROBLEM	can't find	 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
human insulin beta chain peptide with incomplete Freund's adjuvant vaccine	Treatment of Type 1 diabetes patients with residual beta cell function	human insulin beta chain peptide with incomplete Freund's adjuvant vaccine	INCOMPLETE FREUND'S ADJUVANT	n/a	2/11/13	Designated			N/A	N/A	"Orban Biotech, LLC"	Brookline	Massachusetts	2446	USA	LONGEST CONTAINS	0261096AA	incomplete Freund's adjuvant					PROBLEM	can't find	Diabetes mellitus type 1	10268	done	
human monoclonal antibody inhibitor of mannan binding lectin-associated serine protease-2 (MASP-2)	Treatment of Hematopoietic Stem-Cell Transplant-Associated Thrombotic Microangiopathy	human monoclonal antibody inhibitor of mannan binding lectin-associated serine protease-2 (MASP-2)	TRYPSIN-2	n/a	10/22/18	Designated			N/A	N/A	Omeros Corporation	201 Elliott Avenue West	Washington	98119	USA	LONGEST CONTAINS	1315408AA	serine protease 2	KYX76U3WJ4						Congenital thrombotic thrombocytopenic purpura	9430	approximate	
human plasma	Treatment of alopecia areata in pediatric patients	trafermin in combination with plasma and platelet rich plasma	HUMAN PLASMA	Fiblast	12/21/17	Designated			N/A	N/A	"HCell, Inc."	314 East Highland Mall Boulevard	Austin	78752	USA	EXACT	0233772AA	human plasma	T74K1VTI2X						Alopecia areata	5782	done	Not a rare disease
human tumor necrosis factor coupled to the C terminus of CNGRCG peptide	Treatment of liver cancer	human tumor necrosis factor coupled to the C terminus of CNGRCG peptide		n/a	10/1/09	Designated			N/A	N/A	Molecular Medicine S.p.A. (Molmed)				Italy								PROBLEM	can't find	Primary liver cancer	6608	approximate	
"humanized anti-CD40LG IgG1, kappa monoclonal antibody with heavy chain C220S/C226S/C229S/P238S substitutions to attenuate effector function"	Treatment of Amyotrophic Lateral Sclerosis (ALS)	"humanized anti-CD40LG IgG1, kappa monoclonal antibody with heavy chain C220S/C226S/C229S/P238S substitutions to attenuate effector function"	AT-1501	n/a	4/4/18	Designated			N/A	N/A	Anelixis Therapeutics	300 Technology Square		2139	USA	EXACT	0115353AB	"humanized anti-CD40LG IgG1, kappa monoclonal antibody with heavy chain C220S/C226S/C229S/P238S substitutions to attenuate effector function"	KX44A9HM0B	AT-1501 | TORALIZUMAB	KX44A9HM0B	https://www.als.net/at-1501/ | https://adisinsight.springer.com/drugs/800053445 | https://ginas.ncats.nih.gov/ginas/app/substance/fadba3e7	approximate	AT-1501 absent from GINAS; there is entry for TORALIZUMAB (ANTI-CD40L)	Amyotrophic lateral sclerosis	5786	done	
humanized immunoglobulin G1 (IgG1) T-cell bispecific (TCB) antibody targeting carcinoembryonic antigen (CEA)	"Treatment of gastric cancer, including gastroesophageal junction cancer"	humanized immunoglobulin G1 (IgG1) T-cell bispecific (TCB) antibody targeting carcinoembryonic antigen (CEA)	CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE 5	n/a	1/22/18	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way	South San Francisco	94080	USA	LONGEST CONTAINS	0113060AB	carcinoembryonic antigen	UHE660O07W						Stomach cancer	7704	done	
humanized monoclonal antibodies hu1B7 and hu11E6	Treatment of Bordetella pertussis	humanized monoclonal antibodies hu1B7 and hu11E6		n/a	9/11/14	Designated			N/A	N/A	"Synthetic Biologics, Inc."	Rockville	Maryland	20850	USA								PROBLEM	can't find	Whooping cough	8692	done	Not a rare disease
humanized monoclonal antibody targeting interleukin-15	Treatment of eosinophilic esophagitis	humanized monoclonal antibody targeting interleukin-15		n/a	10/25/18	Designated			N/A	N/A	CALYPSO BIOTECH BV	Gustav Mahlerplein 102			Netherlands				EJ48MR05C3	AMG-714 | CALY-002	EJ48MR05C3	https://fdasis.nlm.nih.gov/srs/auto/startswith/amg%20714 | https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3161681 | https://adisinsight.springer.com/drugs/800038466	approximate		Eosinophilic enteropathy	9142	done	
hyaluronic acid	Treatment of emphysema due to alpha1-antitrypsin deficiency.	hyaluronic acid	HYALURONIC ACID	n/a	1/18/17	Designated			N/A	N/A	"Gerard M. Turino, MD"	New York	New York	10019	USA	EXACT	0151804AA	hyaluronic acid	S270N0TRQY						Alpha-1 antitrypsin deficiency	5784	done	
hydrochloric acid	Treatment of patulous eustachian tube	chlorobutanol/propylene glycol/hydrochloric acid	HYDROCHLORIC ACID	Patul-End	2/18/97	Designated			N/A	N/A	Ear Foundation	Santa Barbara	California	93105	USA	EXACT	0049843AA	hydrochloric acid	QTT17582CB								MISSING	not a disease
hydrocortisone modified release capsules	Treatment of adrenal insufficiency.	hydrocortisone modified release capsules	HYDROCORTISONE	Chronocort(R)	9/3/15	Designated			N/A	N/A	Diurnal Ltd.				United Kingdom	EXACT	0007330AA	hydrocortisone	WI4X0X7BPJ						Secondary adrenal insufficiency	12735	approximate	not only secondary insufficiency
hydrocortisone modified release capsules	Treatment of congenital adrenal hyperpasia	hydrocortisone modified release capsules	HYDROCORTISONE	Chronocort	3/18/15	Designated			N/A	N/A	Diurnal Limited				United Kingdom	EXACT	0007330AA	hydrocortisone	WI4X0X7BPJ						Congenital adrenal hyperplasia	1467	done	
hydrocortisone modified release tabs	Treatment of adrenal insufficiency	hydrocortisone modified release tabs	HYDROCORTISONE	Duocort	6/18/08	Designated			N/A	N/A	"Shire ViroPharma, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0007330AA	hydrocortisone	WI4X0X7BPJ						Secondary adrenal insufficiency	12735	approximate	not only secondary insufficiency
hydrocortisone oral granules	Treatment of pediatric adrenal insufficiency (0 through 16 years of age).	hydrocortisone oral granules	HYDROCORTISONE	Infacort(R)	5/13/15	Designated			N/A	N/A	Diurnal Limited				United Kingdom	EXACT	0007330AA	hydrocortisone	WI4X0X7BPJ								MISSING	not a disease
hydroxycarbamide (hydroxyurea)	Treatment of sickle cell disease in patients under 18 years of age	hydroxycarbamide (hydroxyurea)	HYDROXYUREA	Siklos	7/24/13	Designated			N/A	N/A	addmedica Laboratories	Paris			France	EXACT	0020268AA	hydroxycarbamide	X6Q56QN5QC						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
hydroxycarbamide (hydroxyurea)	Treatment of sickle cell disease in patients under 18 years of age	hydroxycarbamide (hydroxyurea)	HYDROXYUREA	Siklos	7/24/13	Designated			N/A	N/A	addmedica Laboratories	Paris			France	EXACT	0020268AA	hydroxycarbamide	X6Q56QN5QC						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
hydroxycarbamide (hydroxyurea)	Treatment of sickle cell disease in patients under 18 years of age	hydroxycarbamide (hydroxyurea)	HYDROXYUREA	Siklos	7/24/13	Designated			N/A	N/A	addmedica Laboratories	Paris			France	EXACT	0020268AA	hydroxycarbamide	X6Q56QN5QC						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
hydroxycarbamide (hydroxyurea)	Treatment of sickle cell disease in patients under 18 years of age	hydroxycarbamide (hydroxyurea)	HYDROXYUREA	Siklos	7/24/13	Designated			N/A	N/A	addmedica Laboratories	Paris			France	EXACT	0020268AA	hydroxycarbamide	X6Q56QN5QC						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
hydroxycarbamide (hydroxyurea)	Treatment of sickle cell disease in patients under 18 years of age	hydroxycarbamide (hydroxyurea)	HYDROXYUREA	Siklos	7/24/13	Designated			N/A	N/A	addmedica Laboratories	Paris			France	EXACT	0020268AA	hydroxycarbamide	X6Q56QN5QC						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
hydroxycarbamide (hydroxyurea)	Treatment of sickle cell disease in patients under 18 years of age	hydroxycarbamide (hydroxyurea)	HYDROXYUREA	Siklos	7/24/13	Designated			N/A	N/A	addmedica Laboratories	Paris			France	EXACT	0020268AA	hydroxycarbamide	X6Q56QN5QC						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
hydroxyprogesterone caproate	Prevention of preterm birth in singleton pregnancies	hydroxyprogesterone caproate	HYDROXYPROGESTERONE CAPROATE	Makena	1/25/07	Designated/Approved	Approved for Orphan Indication	To reduce the risk of preterm birth in women with singleton pregnancy who have a history of singleton spontaneous preterm birth	2/3/11	2/3/18	KV Pharmaceutical Company	Bridgeton	Missouri	63044	USA	EXACT	0030160AA	hydroxyprogesterone caproate	276F2O42F5								MISSING	
hydroxyurea	"Treatment of symptomatic sickle cell disease in pediatric patients, less than 17 years of age."	hydroxyurea	HYDROXYUREA	Pedroxa	3/16/15	Designated			N/A	N/A	Ebelle D'Ebelle Pharmaceuticals LLC	Hamburg	New Jersey	7419	USA	EXACT	0020268AA	hydroxyurea	X6Q56QN5QC						Hemoglobinopathy	12455	approximate	
ibalizumab	Treatment of HIV-1 infection in treatment experienced adult patients with documented multi-antiretroviral class resistance and evidence of HIV-1 replication despite ongoing antiretroviral therapy	ibalizumab	IBALIZUMAB	n/a	10/20/14	Designated			N/A	N/A	"TaiMed Biologics, Inc."	Irvine	California	92612	USA	EXACT	0304938AA	ibalizumab	LT369U66CE								MISSING	Not a rare disease
ibritumomab tiuxetan	Treatment of B-cell non-Hodgkin's lymphoma.	ibritumomab tiuxetan	IBRITUMOMAB TIUXETAN	Zevalin	9/6/94	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan?) refractory follicular non-Hodgkin?s lymphoma"	2/19/02	2/19/09	"Spectrum Pharmaceuticals, Inc."	Irvine	California	92618	USA	EXACT	0243492AA	ibritumomab tiuxetan	4Q52C550XK						B-cell lymphoma	5877	done	
ibrutinib	"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma"	ibrutinib	IBRUTINIB	Imbruvica	2/1/18	Designated			N/A	N/A	"Pharmacyclics, LLC"	995 East Arques Avenue	Sunnyvale	94085	USA	EXACT	0625092AA	ibrutinib	1X70OSD4VX						Stomach cancer	7704	done	
ibrutinib	Treatment of pancreatic cancer	ibrutinib	IBRUTINIB	n/a	6/12/17	Designated			N/A	N/A	"Pharmacyclics, LLC"	Sunnyvale	California	94085	USA	EXACT	0625092AA	ibrutinib	1X70OSD4VX						Pancreatic cancer	9364	done	Not a rare disease
ibrutinib	Treatment of small lymphocytic lymphoma	ibrutinib	IBRUTINIB	Imbruvica	5/30/13	Designated/Approved	Approved for Orphan Indication	For treatment of patients with small lymphocytic lymphoma (SLL)	5/6/16	5/6/23	"Pharmacyclics, LLC"	Sunnyvale	California	94085	USA	EXACT	0625092AA	ibrutinib	1X70OSD4VX						B-cell lymphoma	5877	approximate	
icatibant	Treatment of angioedema	icatibant	ICATIBANT	Firazyr	11/25/03	Designated/Approved	Approved for Orphan Indication	Treatment of acute attacks of hereditary angioedema in adults 18 years of age and older	8/25/11	8/25/18	Shire Orphan Therapies	Lexington	Massachusetts	2421	USA	EXACT	0464302AA	icatibant	7PG89G35Q7						Hereditary angioedema	5979	done	
icatibant	Treatment of angioedema	icatibant	ICATIBANT	Firazyr	11/25/03	Designated/Approved	Approved for Orphan Indication	Treatment of acute attacks of hereditary angioedema in adults 18 years of age and older	8/25/11	8/25/18	Shire Orphan Therapies	Lexington	Massachusetts	2421	USA	EXACT	0464302AA	icatibant	7PG89G35Q7						Acquired angioedema	8605	done	
icatibant	Treatment of burn patients hospitalized with burn-induced edema	icatibant	ICATIBANT	n/a	5/5/04	Designated/Withdrawn			N/A	N/A	Shire Human Genetic Therapies	Cambridge	Massachusetts	2139	USA	EXACT	0464302AA	icatibant	7PG89G35Q7								MISSING	Not a rare disease
idarucizumab	To reverse the anticoagulant effect of dabigatran due to uncontrolled life-threatening bleeding requiring urgent intervention or a need to undergo an emergency surgery/urgent invasive procedure	idarucizumab	IDARUCIZUMAB	n/a	5/28/15	Designated/Approved	Approved for Orphan Indication	For use in patients treated with Pradaxa® when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding	10/16/15	10/16/22	"Boehringer Ingelheim Pharmaceuticals, Inc."	Ridgefield	Connecticut	6877	USA	EXACT	0872264AA	idarucizumab	97RWB5S1U6								MISSING	treatment of drug-induced side-effects
idebenone	Treatment of Leber's hereditary optic neuropathy.	idebenone	IDEBENONE	n/a	10/31/06	Designated			N/A	N/A	Santhera Pharmaceuticals Limited				Switzerland	EXACT	0167260AA	idebenone	HB6PN45W4J						Leber hereditary optic neuropathy	6870	done	
idebenone	"Treatment of mitochondrial myopathy, encephalopathy, lactic acidosis with stroke-like episodes syndrome (MELAS)"	idebenone	IDEBENONE	n/a	5/22/09	Designated			N/A	N/A	Santhera Pharmaceuticals Limited				Switzerland	EXACT	0167260AA	idebenone	HB6PN45W4J						Mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes	7009	done	
idursulfase IT	For treatment of neurocognitive symptoms associated with Hunter Syndrome	idursulfase IT	IDURSULFASE	n/a	9/3/09	Designated			N/A	N/A	Shire Human Genetic Therapies	Lexington	Massachusetts	2421	USA	EXACT	0264175AA	idursulfase	5W8JGG2651						Mucopolysaccharidosis type II	6675	done	
idursulfase beta	Treatment of Hunter Syndrome (mucopolysaccharidoses)	idursulfase beta	IDURSULFASE BETA	n/a	2/11/13	Designated			N/A	N/A	Green Cross Corp.				"Korea, Republic of"	EXACT	1088682AA	idursulfase beta	5GCF8EPY6R						Mucopolysaccharidosis type II	6675	done	
ifosfamide	Treatment of soft tissue and bone sarcomas	ifosfamide	IFOSFAMIDE	n/a	8/7/85	Designated			N/A	N/A	Bristol-Myers Squibb Company	Princeton	New Jersey	8543	USA	EXACT	0041770AA	ifosfamide	UM20QQM95Y						Soft tissue sarcoma 	4898	done	
ifosfamide	Treatment of soft tissue and bone sarcomas	ifosfamide	IFOSFAMIDE	n/a	8/7/85	Designated			N/A	N/A	Bristol-Myers Squibb Company	Princeton	New Jersey	8543	USA	EXACT	0041770AA	ifosfamide	UM20QQM95Y						 Osteosarcoma	7284	done	
iloprost	Treatment of purpura fulminans	eptifibatide and iloprost	ILOPROST	n/a	4/20/12	Designated			N/A	N/A	Thrombologic				Denmark	EXACT	0128096AA	iloprost	JED5K35YGL						Protein C deficiency	4521	done	
imatinib mesylate	Treatment of progressive multifocal leukencephalopathy	imatinib mesylate	IMATINIB MESYLATE	n/a	5/6/14	Designated			N/A	N/A	"Inhibikase Therapeutics, Inc."	Atlanta	Georgia	30339	USA	EXACT	0227065AA	imatinib mesylate	8A1O1M485B						Progressive multifocal leukoencephalopathy	7468	done	
imlifidase	Treatment of Guillain-Barré Syndrome (GBS)	imlifidase	IMLIFIDASE	n/a	2/14/18	Designated			N/A	N/A	Hansa Medical AB	P. O. Box 785			Sweden	EXACT	1269201AA	imlifidase	UVJ7NL8S2P						Guillain-Barre syndrom	6554	done	
immune globulin subcutaneous (Human)	Treatment of Dermatomyositis	immune globulin subcutaneous (Human)	IMMUNE GLOBULIN SUBCUTANEOUS (HUMAN)	Hizentra®	9/12/18	Designated			N/A	N/A	CSL Behring	1020 First Avenue	Pennsylvania	19406	USA	EXACT	0259290AA	immune globulin subcutaneous (Human)	66Y330CJHS						Dermatomyositis	6263	done	
inBreath airway transplant system	"To restore the structure and/or function of the trachea subsequent to tracheal damage due to cancer, injury or infection"	inBreath airway transplant system		n/a	9/4/14	Designated			N/A	N/A	"Biostage, Inc."	Holliston	Massachusetts	1746	USA								PROBLEM	can't find			MISSING	secondary condition
inclisiran	Treatment of homozygous familial hypercholesterolemia (HoFH)	inclisiran	INCLISIRAN	n/a	1/22/18	Designated			N/A	N/A	The Medicines Company	8 Sylvan Way	Parsippany-Troy Hills	7054	USA	EXACT	1254417AA	inclisiran	UOW2C71PG5						Familial hypercholesterolemia	10416	done	Not a rare disease
inebilizumab	Treatment of scleroderma	"humanized, afucosylated IgG1 kappa monoclonal antibody"	INEBILIZUMAB	n/a	12/3/09	Designated			N/A	N/A	MedImmune	Gaithersburg	Maryland	20878	USA	EXACT	0810173AA	inebilizumab	74T7185BMM						Scleroderma	10308	done	
infliximab	Treatment of Crohn's disease	infliximab	"INFLIXIMAB, LICENSE HOLDER UNSPECIFIED"	Remicade	11/14/95	Designated/Approved	Approved for Orphan Indication	"Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s)."	8/24/98	8/24/05	"Centocor, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	0233716AA	infliximab	B72HH48FLU						Crohn's disease	10232	done	Not a rare disease
infliximab	Treatment of juvenile rheumatoid arthritis	infliximab	"INFLIXIMAB, LICENSE HOLDER UNSPECIFIED"	Remicade	10/23/02	Designated			N/A	N/A	"Centocor, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	0233716AA	infliximab	B72HH48FLU						Juvenile idiopathic arthritis	3067	done	Not a rare disease
infliximab	Treatment of pediatric (0 to 16 years of age) ulcerative colitis	infliximab	"INFLIXIMAB, LICENSE HOLDER UNSPECIFIED"	Remicade	11/12/03	Designated/Approved	Approved for Orphan Indication	For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy	9/23/11	9/23/18	Janssen Biotech Inc.	Malvern	Pennsylvania	19355	USA	EXACT	0233716AA	infliximab	B72HH48FLU						Pediatric ulcerative colitis	9857	done	not a rare disease
inhaled carbon monoxide gas	Prevention of delayed graft function in renal transplant recipients	inhaled carbon monoxide gas	CARBON MONOXIDE	n/a	8/1/18	Designated			N/A	N/A	"Proterris, Inc."	197 West Springfield Street	Massachusetts	2118	USA	EXACT	0084899AA	carbon monoxide	7U1EE4V452								MISSING	
inolimomab	Treatment of graft versus host disease	inolimomab	INOLIMOMAB	Leukotac	10/23/02	Designated			N/A	N/A	Jazz Pharmaceuticals	Palo Alto	California	94304	USA	EXACT	0341877AA	inolimomab	GO90DFK14U						Chronic graft versus host disease 	10964	approximate	
inolimomab	Treatment of graft versus host disease	inolimomab	INOLIMOMAB	Leukotac	10/23/02	Designated			N/A	N/A	Jazz Pharmaceuticals	Palo Alto	California	94304	USA	EXACT	0341877AA	inolimomab	GO90DFK14U						 Acute graft versus host disease	6544	approximate	
interferon Beta-1a	Treatment of juvenile rheumatoid arthritis.	interferon Beta-1a	INTERFERON BETA-1A	Avonex	10/14/98	Designated/Withdrawn			N/A	N/A	"Biogen, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0215689AA	interferon Beta-1a	XRO4566Q4R						Juvenile idiopathic arthritis	3067	done	Not a rare disease
interferon-alpha secreting autologous micro-organ tissue converting into a biopump	Treatment of chronic hepatitis D	interferon-alpha secreting autologous micro-organ tissue converting into a biopump	"INTERFERON ALFA, ORAL"	Infradure Biopump	6/14/12	Designated			N/A	N/A	"Medgenics, Inc."	San Francisco	California	94104	USA	LONGEST CONTAINS	0259530AA	interferon alpha	43K1W2T1M6|VW75A46X0K|47RRR83SK7	INTERFERON ALFA-2B|INTERFERON ALFA-2C|INTERFERON ALFA-2A	43K1W2T1M6|VW75A46X0K|47RRR83SK7	"https://ginas.ncats.nih.gov/ginas/app/substances?q=root_names_name:""interferon%20alpha""&facet=Substance%20Class%2Fprotein&page=1"	done		Hepatitis D	13659	done	
"interleukin-1 receptor antagonist (IL-1Ra, sequence-homologous anakinra)"	Treatment of Bronchiolitis Obliterans	"interleukin-1 receptor antagonist (IL-1Ra, sequence-homologous anakinra)"	ANAKINRA	n/a	8/7/18	Designated			N/A	N/A	"Onspira Therapeutics, Inc."	101 Lindenwood Drive	Pennsylvania	19355	USA	LONGEST CONTAINS	0242524AA	anakinra	9013DUQ28K						Bronchiolitis obliterans	9551	done	
intravenous carbamazepine	Treatment of epilepsy patients who cannot take anything by mouth (NPO)	intravenous carbamazepine	CARBAMAZEPINE	Carnexiv	6/27/13	Designated/Approved	Approved for Orphan Indication	"• Indication: replacement therapy for oral carbamazepine formulations, when oral administration is temporarily not feasible, in adults with the following seizure types: (1) ¿ Partial seizures with complex symptomology; (2) ¿ Generalized clonic-tonic seizures; and ¿ Mixed seizure patterns which include the above or other partial or generalized seizures(3)"	10/7/16	TBD	Lundbeck LLC	Deerfield	Illinois	60015	USA	EXACT	0023803AA	carbamazepine	33CM23913M						Status epilepticus	10191	done	
intraventricular nimodipine	Treatment of subarachnoid hemorrhage	intraventricular nimodipine	NIMODIPINE	n/a	5/28/15	Designated			N/A	N/A	"Edge Therapeutics, Inc."	Newark	New Jersey	7103	USA	EXACT	0067243AA	nimodipine	57WA9QZ5WH								MISSING	
iobenguane sulfate I-123	"For the detection, localization, and staging of pheochromocytomas."	iobenguane sulfate I-123	IOBENGUANE SULFATE I-123	Omaclear	10/21/05	Designated			N/A	N/A	"Brogan Pharmaceuticals, Inc."	Crown Point	Indiana	46307	USA	EXACT	0094202AA	iobenguane sulfate I-123	23X1185WBO						Pheochromocytoma	7385	done	
ipilimumab	"Treatment of high risk Stage II, Stage III, and Stage IV melanoma"	ipilimumab	IPILIMUMAB	Yervoy	6/3/04	Designated/Approved	Approved for Orphan Indication	"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy."	10/28/15	10/28/22	Bristol-Myers Squibb Company	Princeton	New Jersey	8543	USA	EXACT	0265452AA	ipilimumab	6T8C155666								MISSING	too general term
ipilimumab	"Treatment of high risk Stage II, Stage III, and Stage IV melanoma"	ipilimumab	IPILIMUMAB	Yervoy	6/3/04	Designated/Approved	Approved for Orphan Indication	Treatment of unresectable or metastatic melanoma	3/25/11	3/25/18	Bristol-Myers Squibb Company	Princeton	New Jersey	8543	USA	EXACT	0265452AA	ipilimumab	6T8C155666								MISSING	too general term
ipilimumab	Treatment of mesothelioma	nivolumab and ipilimumab	IPILIMUMAB	n/a	8/16/17	Designated			N/A	N/A	Bristol-Myers Squibb Company	Wallingford	Connecticut	6492	USA	EXACT	0265452AA	ipilimumab	6T8C155666						Malignant mesothelioma	7026	done	
iratumumab	Treatment of CD30+ T-cell lymphoma	Human immunoglobin anti-CD30 monoclonal antibody	IRATUMUMAB	n/a	1/10/06	Designated			N/A	N/A	Bristol-Myers Squibb	Bloombury	New Jersey	8804	USA	EXACT	0256199AA	iratumumab	AYH22O1B1U						Adult T-cell leukemia/lymphoma	13103	done	
irinotecan	Treatment of pancreatic cancer	liposomal irinotecan	IRINOTECAN	n/a	7/21/11	Designated/Approved	Approved for Orphan Indication	"For use in combination with 5-fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas that has progressed following gemcitabine-based therapy"	10/22/15	10/22/22	"Merrimack Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0269705AA	irinotecan	7673326042						Pancreatic cancer	9364	done	Not a rare disease
irinotecan liposome injection	Treatment of small cell lung cancer	irinotecan liposome injection	IRINOTECAN	Onivyde	5/24/17	Designated			N/A	N/A	"Merrimack Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0269705AA	irinotecan	7673326042						Small cell lung cancer	9344	done	
isoniazid	For the short-course treatment of tuberculosis.	"Rifampin, isoniazid, pyrazinamide"	ISONIAZID	Rifater	9/12/85	Designated/Approved	Approved for Orphan Indication	Short-course treatment of tuberculosis.	5/31/94	5/31/01	Hoechst Marion Roussel	Kansas City	Missouri	64134	USA	EXACT	0008742AA	isoniazid	V83O1VOZ8L						Tuberculosis	7827	done	
isotretinoin	Treatment of congenital ichthyosis	isotretinoin	ISOTRETINOIN	n/a	4/10/14	Designated			N/A	N/A	"Patagonia Pharmaceuticals, LLC"	Woodcliff Lake	New Jersey	7677	USA	EXACT	0042944AA	isotretinoin	EH28UP18IF						CHILD syndrome 	6039	approximate	
isotretinoin	Treatment of congenital ichthyosis	isotretinoin	ISOTRETINOIN	n/a	4/10/14	Designated			N/A	N/A	"Patagonia Pharmaceuticals, LLC"	Woodcliff Lake	New Jersey	7677	USA	EXACT	0042944AA	isotretinoin	EH28UP18IF						 X-linked ichthyosis 	7904	approximate	
isotretinoin	Treatment of congenital ichthyosis	isotretinoin	ISOTRETINOIN	n/a	4/10/14	Designated			N/A	N/A	"Patagonia Pharmaceuticals, LLC"	Woodcliff Lake	New Jersey	7677	USA	EXACT	0042944AA	isotretinoin	EH28UP18IF						 KID syndrome 	3113	approximate	
isotretinoin	Treatment of congenital ichthyosis	isotretinoin	ISOTRETINOIN	n/a	4/10/14	Designated			N/A	N/A	"Patagonia Pharmaceuticals, LLC"	Woodcliff Lake	New Jersey	7677	USA	EXACT	0042944AA	isotretinoin	EH28UP18IF						 Harlequin ichthyosis 	6568	approximate	
isotretinoin	Treatment of congenital ichthyosis	isotretinoin	ISOTRETINOIN	n/a	4/10/14	Designated			N/A	N/A	"Patagonia Pharmaceuticals, LLC"	Woodcliff Lake	New Jersey	7677	USA	EXACT	0042944AA	isotretinoin	EH28UP18IF						 Lamellar ichthyosis 	10803	approximate	
isotretinoin	Treatment of congenital ichthyosis	isotretinoin	ISOTRETINOIN	n/a	4/10/14	Designated			N/A	N/A	"Patagonia Pharmaceuticals, LLC"	Woodcliff Lake	New Jersey	7677	USA	EXACT	0042944AA	isotretinoin	EH28UP18IF						 Netherton syndrome 	7182	approximate	
isotretinoin	Treatment of congenital ichthyosis	isotretinoin	ISOTRETINOIN	n/a	4/10/14	Designated			N/A	N/A	"Patagonia Pharmaceuticals, LLC"	Woodcliff Lake	New Jersey	7677	USA	EXACT	0042944AA	isotretinoin	EH28UP18IF						 Sjogren-Larsson syndrome 	7654	approximate	
isotretinoin	Treatment of congenital ichthyosis	isotretinoin	ISOTRETINOIN	n/a	4/10/14	Designated			N/A	N/A	"Patagonia Pharmaceuticals, LLC"	Woodcliff Lake	New Jersey	7677	USA	EXACT	0042944AA	isotretinoin	EH28UP18IF						 Trichothiodystrophy 	12109	approximate	
isotretinoin	Treatment of congenital ichthyosis	isotretinoin	ISOTRETINOIN	n/a	4/10/14	Designated			N/A	N/A	"Patagonia Pharmaceuticals, LLC"	Woodcliff Lake	New Jersey	7677	USA	EXACT	0042944AA	isotretinoin	EH28UP18IF						 Chanarin-Dorfman syndrome	3979	approximate	
itacitinib	Treatment of graft versus host disease	itacitinib	ITACITINIB	n/a	4/17/17	Designated			N/A	N/A	Incyte Corporation	Wilmington	Delaware	19803	USA	EXACT	0571540AA	itacitinib	19J3781LPM						Chronic graft versus host disease 	10964	approximate	
itacitinib	Treatment of graft versus host disease	itacitinib	ITACITINIB	n/a	4/17/17	Designated			N/A	N/A	Incyte Corporation	Wilmington	Delaware	19803	USA	EXACT	0571540AA	itacitinib	19J3781LPM						 Acute graft versus host disease	6544	approximate	
ivabradine	Treatment of post-cardiac transplant heart dysfunction	ivabradine	IVABRADINE	Corlanor	7/9/18	Designated			N/A	N/A	"Amgen, Inc.,"	1 Amgen Center Drive	California	91320	USA	EXACT	0276722AA	ivabradine	3H48L0LPZQ								MISSING	surgery complication
ivacaftor	Treatment of Cystic Fibrosis	"N-(1,3-dimethyl-1H-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide/tezacaftor/ivacaftor"	IVACAFTOR	n/a	8/29/18	Designated			N/A	N/A	Vertex Pharmaceuticals Inc.	50 Northern Avenue	Massachusetts	2210	USA	EXACT	0297132AA	ivacaftor	1Y740ILL1Z						Cystic fibrosis	6233	done	
ivacaftor	Treatment of Cystic Fibrosis	"potassium (benzenesulfonyl)({[6-(3-{2-[1-(trifluoromethyl)cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridin-3-yl]carbonyl})azanide/tezacaftor/ivacaftor"	IVACAFTOR	n/a	5/23/18	Designated			N/A	N/A	Vertex Pharmaceuticals Inc.	50 Northern Avenue		2210	USA	EXACT	0297132AA	ivacaftor	1Y740ILL1Z						Cystic fibrosis	6233	done	
ixazomib citrate	Treatment of systemic light chain (AL) amyloidosis.	"2,2'-{2-[1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid (ixazomib citrate)"	IXAZOMIB CITRATE	n/a	3/9/12	Designated			N/A	N/A	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0681276AA	ixazomib citrate	46CWK97Z3K						AL amyloidosis	5797	done	
k-777	Treatment of Chagas disease.	4-methylpiperazine-1-carboxylic acid [1-(3-benzenesufonyl-1-phenethylallyl-carbamoyl)-2-phenylethyl] amide	APC-3316	n/a	1/11/17	Designated			N/A	N/A	Center for Discovery & Innovation in Parasitic Diseases	LaJolla	California	92093	USA	EXACT	0855629AA	k-777	320A4L58IZ						Chagas disease	6030	done	Not a rare disease
ketamine	Treatment of postherpetic neuralgia	amitriptyline and ketamine	KETAMINE	Amiket(Tm)	1/19/10	Designated			N/A	N/A	"Immune Pharmaceuicals, Inc."	New York	New York	10016	USA	EXACT	0046822AA	ketamine	690G0D6V8H								MISSING	Not a rare disease; symptom
krn-5500	Treatment of multiple myeloma	"6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glycero-B-L-manno-heptopyranosyl]amino-9H-purine"	KRN-5500	n/a	6/12/14	Designated			N/A	N/A	"DARA BioSciences, Inc."	Raleigh	North Carolina	27615	USA	EXACT	0217243AA	krn-5500	8VH13L5K20						Multiple myeloma	7108	done	
"lactic acid bacteria (Lactobacilli, Bifidobacteria, and Steptococci)"	Treatment of active chronic pouchitis	"lactic acid bacteria (Lactobacilli, Bifidobacteria, and Steptococci)"	BIFIDOBACTERIUM SPP.	n/a	1/15/02	Designated			N/A	N/A	"VSL Pharmaceuticals, Inc."	Gaithersburg	Maryland	20877	USA	EXACT	0158316AA	Bifidobacteria	IO1WP3918D								MISSING	
"lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococcus species)"	Prevention of disease relapse in patients with chronic pouchitis	"lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococcus species)"	BIFIDOBACTERIUM SPP.	n/a	1/15/02	Designated			N/A	N/A	"VSL Pharmaceuticals, Inc."	Gaithersburg	Maryland	20877	USA	LONGEST CONTAINS	0158316AA	Bifidobacteria	IO1WP3918D								MISSING	
lactobacillus brevis CD2	Treatment Behcet's disease	lactobacillus brevis CD2	LACTOBACILLUS BREVIS	n/a	10/4/11	Designated			N/A	N/A	"VSL Pharmaceuticals, Inc."	Towson	Maryland	21204	USA	EXACT	1122607AA	lactobacillus brevis	268IL53Q7O						Behçet disease	848	done	
lapatinib	Treatment of ErbB2 positive gastric cancer	lapatinib	LAPATINIB	Tykerb	5/29/09	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0270268AA	lapatinib	0VUA21238F						Stomach cancer	7704	done	
laromustine	Treatment of acute myelogenous leukemia	laromustine	LAROMUSTINE	Onrigin	10/21/04	Designated			N/A	N/A	"Vion Pharmaceuticals, Inc."	New Haven	Connecticut	6511	USA	EXACT	0252620AA	laromustine	14J2G0U3NQ						Acute myeloid leukemia	12757	done	
larotrectinib	Treatment of solid tumors with NTRK-fusion proteins	larotrectinib	LAROTRECTINIB	n/a	5/9/17	Designated			N/A	N/A	"Loxo Oncology, Inc."	Stamford	Connecticut	6901	USA	EXACT	0934601AA	larotrectinib	PF9462I9HX								MISSING	tumor types not specified
ledipasvir	Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients	ledipasvir/sofosbuvir	LEDIPASVIR	Harvoni	10/12/16	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0740534AA	ledipasvir	013TE6E4WV								MISSING	Not a rare disease
leniolisib	"Activated P13Kdelta Syndrome/p110delta-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency"	leniolisib	LENIOLISIB	n/a	1/30/18	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	1 Health Plaza Drive	East Hanover	7936	USA	EXACT	0808902AA	leniolisib	L22772Z9CP						PASLI disease	11983	done	
lenvatinib	"Treatment of follicullar, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer"	lenvatinib	LENVATINIB	Lenvima	12/27/12	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine refractory differentiated thyroid cancer"	2/13/15	2/13/22	"Eisai, Inc."	Woodcliff Lake	New Jersey	7677	USA	EXACT	0255481AA	lenvatinib	EE083865G2						"Thyroid cancer, follicular "	5206	done	
lenvatinib	"Treatment of follicullar, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer"	lenvatinib	LENVATINIB	Lenvima	12/27/12	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine refractory differentiated thyroid cancer"	2/13/15	2/13/22	"Eisai, Inc."	Woodcliff Lake	New Jersey	7677	USA	EXACT	0255481AA	lenvatinib	EE083865G2						" Thyroid cancer, medullary "	7004	done	
lenvatinib	"Treatment of follicullar, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer"	lenvatinib	LENVATINIB	Lenvima	12/27/12	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine refractory differentiated thyroid cancer"	2/13/15	2/13/22	"Eisai, Inc."	Woodcliff Lake	New Jersey	7677	USA	EXACT	0255481AA	lenvatinib	EE083865G2						 Anaplastic thyroid cancer 	664	done	
lenvatinib	"Treatment of follicullar, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer"	lenvatinib	LENVATINIB	Lenvima	12/27/12	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine refractory differentiated thyroid cancer"	2/13/15	2/13/22	"Eisai, Inc."	Woodcliff Lake	New Jersey	7677	USA	EXACT	0255481AA	lenvatinib	EE083865G2						 Papillary thyroid carcinoma	12027	done	
lestaurtinib	Treatment of Philadelphia-negative classic myeloproliferative disorders	lestaurtinib	LESTAURTINIB	n/a	9/3/09	Designated			N/A	N/A	"Teva Branded Pharmaceutical Products R&D, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0224680AA	lestaurtinib	DO989GC5D1						Polycythemia vera 	7422	done	"The classical Philadelphia (Ph)-negative myeloproliferative neoplasms (MPNs) encompass three main myeloid malignancies: polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF)"
lestaurtinib	Treatment of Philadelphia-negative classic myeloproliferative disorders	lestaurtinib	LESTAURTINIB	n/a	9/3/09	Designated			N/A	N/A	"Teva Branded Pharmaceutical Products R&D, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0224680AA	lestaurtinib	DO989GC5D1						 Essential thrombocythemia 	6594	done	"The classical Philadelphia (Ph)-negative myeloproliferative neoplasms (MPNs) encompass three main myeloid malignancies: polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF)"
lestaurtinib	Treatment of Philadelphia-negative classic myeloproliferative disorders	lestaurtinib	LESTAURTINIB	n/a	9/3/09	Designated			N/A	N/A	"Teva Branded Pharmaceutical Products R&D, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0224680AA	lestaurtinib	DO989GC5D1						 Myelofibrosis	8618	done	"The classical Philadelphia (Ph)-negative myeloproliferative neoplasms (MPNs) encompass three main myeloid malignancies: polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF)"
letermovir	Prevention of human cytomegalovirus viremia and disease in at risk populations	letermovir	LETERMOVIR	n/a	12/12/11	Designated			N/A	N/A	Merck Sharpe & Dhome Corporation	North Wales	Pennsylvania	19454	USA	EXACT	0568912AA	letermovir	1H09Y5WO1F								MISSING	
leucine	Treatment of hyperphenylalaninemia	"Valine, isoleucine and leucine"	LEUCINE	Vil	1/5/96	Designated			N/A	N/A	Leas Research Products	North Haven	Connecticut	6473	USA	EXACT	0010811AA	leucine	GMW67QNF9C						Maternal hyperphenylalaninemia 	3413	approximate	
leucine	Treatment of hyperphenylalaninemia	"Valine, isoleucine and leucine"	LEUCINE	Vil	1/5/96	Designated			N/A	N/A	Leas Research Products	North Haven	Connecticut	6473	USA	EXACT	0010811AA	leucine	GMW67QNF9C						 6-pyruvoyl-tetrahydropterin synthase deficiency 	5682	approximate	
leucine	Treatment of hyperphenylalaninemia	"Valine, isoleucine and leucine"	LEUCINE	Vil	1/5/96	Designated			N/A	N/A	Leas Research Products	North Haven	Connecticut	6473	USA	EXACT	0010811AA	leucine	GMW67QNF9C						 GTP cyclohydrolase I deficiency 	2844	approximate	
leucine	Treatment of hyperphenylalaninemia	"Valine, isoleucine and leucine"	LEUCINE	Vil	1/5/96	Designated			N/A	N/A	Leas Research Products	North Haven	Connecticut	6473	USA	EXACT	0010811AA	leucine	GMW67QNF9C						 Dihydropteridine reductase deficiency 	4319	approximate	
leucine	Treatment of hyperphenylalaninemia	"Valine, isoleucine and leucine"	LEUCINE	Vil	1/5/96	Designated			N/A	N/A	Leas Research Products	North Haven	Connecticut	6473	USA	EXACT	0010811AA	leucine	GMW67QNF9C						 Hyperphenylalaninemia due to dehydratase deficiency	2843	approximate	
levetiracetam	Treatment of neonatal seizures	levetiracetam	LEVETIRACETAM	Keppra	4/30/10	Designated			N/A	N/A	University of California	La Jolla	California	92093	USA	EXACT	0165231AA	levetiracetam	44YRR34555						Seizures benign familial neonatal recessive form	4789	approximate	
levocarnitine	1. Prevention of secondary carnitine deficiency in valproic acid toxicity 2. Treatment of secondary carnitine deficiency in valproic acid toxicity	levocarnitine	LEVOCARNITINE	Carnitor	11/15/89	Designated			N/A	N/A	"Sigma-Tau Pharmaceuticals, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0086908AA	levocarnitine	0G389FZZ9M						Primary carnitine deficiency	5104	approximate	
levomefolate calcium	Treatment of megaloblastic anemia caused by folate deficiency	levomefolate calcium	LEVOMEFOLATE CALCIUM	n/a	2/10/15	Designated			N/A	N/A	Cox Biosciences LLC	New York	New York	10023	USA	EXACT	0092568AA	levomefolate calcium	A9R10K3F2F						Hereditary folate malabsorption	12983	done	
levothyroxine sodium	The preservation of organ function in brain-dead organ donors.	levothyroxine sodium	LEVOTHYROXINE SODIUM	n/a	4/26/11	Designated			N/A	N/A	"Fera Pharmaceuticals, LLC"	Locust Valley	New York	11560	USA	EXACT	0008800AA	levothyroxine sodium	9J765S329G								MISSING	procedure
liarozole	Treatment of congenital ichthyosis	liarozole	LIAROZOLE	n/a	6/18/04	Designated/Withdrawn			N/A	N/A	"Stiefel Laboratories, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0325053AA	liarozole	K0Q29TGV9Y						CHILD syndrome 	6039	approximate	
liarozole	Treatment of congenital ichthyosis	liarozole	LIAROZOLE	n/a	6/18/04	Designated/Withdrawn			N/A	N/A	"Stiefel Laboratories, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0325053AA	liarozole	K0Q29TGV9Y						 X-linked ichthyosis 	7904	approximate	
liarozole	Treatment of congenital ichthyosis	liarozole	LIAROZOLE	n/a	6/18/04	Designated/Withdrawn			N/A	N/A	"Stiefel Laboratories, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0325053AA	liarozole	K0Q29TGV9Y						 KID syndrome 	3113	approximate	
liarozole	Treatment of congenital ichthyosis	liarozole	LIAROZOLE	n/a	6/18/04	Designated/Withdrawn			N/A	N/A	"Stiefel Laboratories, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0325053AA	liarozole	K0Q29TGV9Y						 Harlequin ichthyosis 	6568	approximate	
liarozole	Treatment of congenital ichthyosis	liarozole	LIAROZOLE	n/a	6/18/04	Designated/Withdrawn			N/A	N/A	"Stiefel Laboratories, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0325053AA	liarozole	K0Q29TGV9Y						 Lamellar ichthyosis 	10803	approximate	
liarozole	Treatment of congenital ichthyosis	liarozole	LIAROZOLE	n/a	6/18/04	Designated/Withdrawn			N/A	N/A	"Stiefel Laboratories, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0325053AA	liarozole	K0Q29TGV9Y						 Netherton syndrome 	7182	approximate	
liarozole	Treatment of congenital ichthyosis	liarozole	LIAROZOLE	n/a	6/18/04	Designated/Withdrawn			N/A	N/A	"Stiefel Laboratories, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0325053AA	liarozole	K0Q29TGV9Y						 Sjogren-Larsson syndrome 	7654	approximate	
liarozole	Treatment of congenital ichthyosis	liarozole	LIAROZOLE	n/a	6/18/04	Designated/Withdrawn			N/A	N/A	"Stiefel Laboratories, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0325053AA	liarozole	K0Q29TGV9Y						 Trichothiodystrophy 	12109	approximate	
liarozole	Treatment of congenital ichthyosis	liarozole	LIAROZOLE	n/a	6/18/04	Designated/Withdrawn			N/A	N/A	"Stiefel Laboratories, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0325053AA	liarozole	K0Q29TGV9Y						 Chanarin-Dorfman syndrome	3979	approximate	
lintuzumab	Treatment of acute myelogenous leukemia	lintuzumab	LINTUZUMAB	Zamyl	9/9/02	Designated/Withdrawn			N/A	N/A	"Protein Design Labs, Inc."	Fremont	California	94555	USA	EXACT	0298033AA	lintuzumab	V00Y10W60W						Acute myeloid leukemia	12757	done	
liposomal amikacin	Treatment infections caused by non-tuberculous mycobacteria	liposomal amikacin	AMIKACIN	Arikace	3/25/13	Designated			N/A	N/A	"Insmed, Inc."	Bridgewater	New Jersey	8817	USA	EXACT	0122203AA	amikacin	84319SGC3C						Nontuberculous mycobacterial lung disease	12829	approximate	
liposomal amikacin	Treatment of bronchiectasis in patients with Pseudomonas aeruginosa or other susceptible microbial pathogens	liposomal amikacin	AMIKACIN	Arikace	8/25/09	Designated			N/A	N/A	"Insmed, Inc."	Monmouth Junction	New Jersey	8852	USA	EXACT	0122203AA	amikacin	84319SGC3C						Pneumonia caused by Pseudomonas aeruginosa infection	13613	approximate	
liposomal busulfan	For use as a conditioning regimen for patients with malignancies undergoing autologous or allogenic hematopoietic stem cell transplantation	liposomal busulfan	BUSULFAN	Busulipo	6/24/13	Designated			N/A	N/A	Pharmalink AB				Sweden	EXACT	0008946AA	busulfan	G1LN9045DK						Plasmablastic lymphoma	12125	approximate	
liposomal glutathione	Treatment of Dengue Virus infection.	liposomal glutathione	GLUTATHIONE	n/a	5/18/16	Designated			N/A	N/A	"Your Energy Systems, LLC"	Palo Alto	California	94301	USA	EXACT	0012135AA	glutathione	GAN16C9B8O						Dengue fever	6254	done	
liposomal p-ethoxy growth receptor bound protein-2 antisense product	Treatment of chronic myelogenous leukemia	liposomal p-ethoxy growth receptor bound protein-2 antisense product	PROTEIN	n/a	12/5/03	Designated			N/A	N/A	"Bio-Path, Inc."	Ogden	Utah	84403	USA	LONGEST CONTAINS	0087274AA	protein	8W1O4Y961B	PREXIGEBERSEN	8W1O4Y961B	https://ginas.ncats.nih.gov/ginas/app/substances?q=PREXIGEBERSEN	done		Chronic myeloid leukemia	6105	done	
liposome encapsulated paclitaxel	Treatment of gastric cancer	liposome encapsulated paclitaxel	PACLITAXEL	n/a	12/3/14	Designated			N/A	N/A	"Insys Development Company, Inc."	Chandler	Arizona	85286	USA	EXACT	0132127AA	paclitaxel	P88XT4IS4D						Stomach cancer	7704	done	
liraglutide	Treatment of Type I Diabetes Mellitus with residual beta cell function.	anti-interleukin 21 (NNC0114-0006) in combination with liraglutide	LIRAGLUTIDE	n/a	1/12/17	Designated			N/A	N/A	"Novo Nordisk, Inc."		New Jersey	8536	USA	EXACT	0358714AA	liraglutide	839I73S42A						Diabetes mellitus type 1	10268	done	
lisinopril oral solution	Treatment of hypertension in pediatric patients 0 through 16 years of age.	lisinopril oral solution	LISINOPRIL	n/a	10/14/15	Designated/Withdrawn by OPD			N/A	N/A	"Silvergate Pharmaceuticals, Inc."	Greenwood Village	Colorado	80111	USA	EXACT	0118014AA	lisinopril	E7199S1YWR						Pediatric hypertension	11921	done	
lisinopril oral solution	Treatment of primary hypertension with complications and secondary hypertension in pediatric patients (ages 0 through 16 years of age)	lisinopril oral solution	LISINOPRIL	n/a	1/27/15	Designated/Withdrawn by OPD			N/A	N/A	"BioRamo, LLC"	Ft. Lauderdale	Florida	33309	USA	EXACT	0118014AA	lisinopril	E7199S1YWR								MISSING	Not a rare disease
listeria monocytogenes	Treatment of pancreatic cancer	listeria monocytogenes	LISTERIA MONOCYTOGENES	n/a	9/5/13	Designated			N/A	N/A	"Aduro BioTech, Inc."	Berkeley	California	94710	USA	EXACT	0623063AA	listeria monocytogenes	3O44K14A86						Pancreatic cancer	9364	done	Not a rare disease
live attenuated bioengineered Listeria monocytogenes immunotherapy	Treatment of human papilloma virus-associated head and neck cancer	live attenuated bioengineered Listeria monocytogenes immunotherapy	LISTERIA MONOCYTOGENES	n/a	11/4/13	Designated			N/A	N/A	"Advaxis, Inc."	Princeton	New Jersey	8540	USA	LONGEST CONTAINS	0623063AA	Listeria monocytogenes	3O44K14A86						Squamous cell carcinoma of the head and neck	8503	done	Not a rare disease
live bacterial product consisting of defined consortia of Clostridium clusters live bacterial product consisting of defined consortia of Clostridium clusters	Prevention of recurrent Clostridium difficile infection in individuals with prior recurrent Clostridium difficile infection	live bacterial product consisting of defined consortia of Clostridium clusters live bacterial product consisting of defined consortia of Clostridium clusters		n/a	11/2/17	Designated			N/A	N/A	"Vedanta Biosciences, Inc."	19 Blackstone Street	Massachusetts	2139	USA				PJX89V9R6N	CLOSTRIDIUM DIFFICILE | VE 303	PJX89V9R6N	https://ginas.ncats.nih.gov/ginas/app/substance/3c73e521 | https://adisinsight.springer.com/drugs/800050854	done				MISSING	
lixivaptan	Treatment of autosomal dominant polycystic kidney disease (ADPKD)	lixivaptan	LIXIVAPTAN	n/a	9/18/17	Designated			N/A	N/A	"Palladio Biosciences, Inc."	Newtown	Pennsylvania	18940	USA	EXACT	0192814AA	lixivaptan	8F5X4B082E						Autosomal dominant polycystic kidney disease	10413	done	
lomitapide	Treatment of Familial Chylomicronemia	lomitapide	LOMITAPIDE	n/a	3/3/11	Designated			N/A	N/A	"Aegerion Pharmaceuticals, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0330030AA	lomitapide	82KUB0583F								MISSING	
lomitapide	Treatment of homozygous familial hypercholesterolemia	lomitapide	LOMITAPIDE	Juxtapid	10/23/07	Designated/Approved	Approved for Orphan Indication	"Adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH)."	12/21/12	12/21/19	"Aegerion Pharmaceuticals, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0330030AA	lomitapide	82KUB0583F						Familial hypercholesterolemia	10416	done	Not a rare disease
low molecular weight dextran sulfate	Prevention of graft rejection during pancreatic islet transplantation	low molecular weight dextran sulfate	DEXTRAN SULFATE SODIUM (MW 5000)	Ibsolvmir	10/20/09	Designated			N/A	N/A	TikoMed AB				Sweden	EXACT	1804304AA	low molecular weight dextran sulfate					PROBLEM	can't find	Chronic graft versus host disease	10964	approximate	type of GVHD (acute or chronic) is not specified
low molecular weight dextran sulfate	Prevention of graft rejection during pancreatic islet transplantation	low molecular weight dextran sulfate	DEXTRAN SULFATE SODIUM (MW 5000)	Ibsolvmir	10/20/09	Designated			N/A	N/A	TikoMed AB				Sweden	EXACT	1804304AA	low molecular weight dextran sulfate					PROBLEM	can't find	Acute graft versus host disease	6544	approximate	type of GVHD (acute or chronic) is not specified
low molecular weight dextran sulfate	Treatment to mobilze progenitor cells prior to stem cell transplantation	low molecular weight dextran sulfate	DEXTRAN SULFATE SODIUM (MW 5000)	Ibsolvmir(R)	7/6/11	Designated			N/A	N/A	TikoMed AB				Sweden	EXACT	1804304AA	low molecular weight dextran sulfate					PROBLEM	can't find			MISSING	procedure
lpt-99	Prevention of platinum-induced ototoxicity in pediatric patients	"2-(4-(2,4-dichlorophenethyl)-3,6-dioxo-1-(2-(thiophen-2-yl)ethyl)piperazin-2-yl)-N-(2-(5-methoxy-1H-indol-3-yl)ethyl) acetamide"	LPT-99	n/a	12/14/17	Designated			N/A	N/A	Spiral Therapeutics	1467 Dolores Street	San Francisco	94110	USA	EXACT	0113541AB	lpt-99	A2Y8E9P363								MISSING	prevention of drug-induced side-effects
lumefantrine	For the treatment of infections due to Plasmodium falciparum or mixed infections including P. falciparum.	artemether/lumefantrine	LUMEFANTRINE	Coartem	8/31/07	Designated/Approved	Approved for Orphan Indication	"Treatment of malaria in patients of 5 kg bodyweight or above with acute, uncomplicated malaria due to Plasmodium falciparum or mixed infections including P. falciparum"	4/7/09	4/7/16	Novartis Pharmaceuticals	East Hanover	New Jersey	7936	USA	EXACT	0319857AA	lumefantrine	F38R0JR742						Malaria	6961	done	
lurbinectedin	Treatment of small cell lung cancer (SCLC)	lurbinectedin	LURBINECTEDIN	Zepsyre	8/1/18	Designated			N/A	N/A	"PharmaMar USA, Inc."	205 East 42nd St.	New York	10017	USA	EXACT	0700583AA	lurbinectedin	2CN60TN6ZS						Small cell lung cancer	9344	done	
macromolecular conjugate of heparin sodium on a polymer backbone	Prevention of ischemia-reperfusion injury associated with solid organ tranplantation	macromolecular conjugate of heparin sodium on a polymer backbone	HEPARIN SODIUM	n/a	5/2/17	Designated			N/A	N/A	Corline Biomedical AB	Uppsala			Sweden	LONGEST CONTAINS	0006177AA	heparin sodium	ZZ45AB24CA								MISSING	Not a rare disease
magnesium sulfate	For cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in children and adolescents	"sodium sulfate, potassium sulfate, and magnesium sulfate"	"MAGNESIUM SULFATE, UNSPECIFIED FORM"	Suprep	10/31/12	Designated			N/A	N/A	"Braintree Laboratories, Inc."	Braintree	Massachusetts	2185	USA	EXACT	0052744AA	magnesium sulfate	DE08037SAB								MISSING	"not a disease, a procedure"
magnesium sulfate	For the cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in pediatric patients	"sodium sulfate, magnesium sulfate, potassium chloride"	"MAGNESIUM SULFATE, UNSPECIFIED FORM"	n/a	12/19/17	Designated			N/A	N/A	"Braintree Laboratories, Inc."	60 Columbian Street West	Braintree	2185	USA	EXACT	0052744AA	magnesium sulfate	DE08037SAB								MISSING	not a disease
magnesium sulfate	For use in cleansing of the colon in preparation for colonoscopy in children and adolescents	"sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride"	"MAGNESIUM SULFATE, UNSPECIFIED FORM"	Suclear	9/4/13	Designated			N/A	N/A	"Braintree Laboratories, Inc."	Braintree	Massachusetts	2185	USA	EXACT	0052744AA	magnesium sulfate	DE08037SAB								MISSING	"not a disease, a procedure"
maralixibat	Treatment of progressive familial intrahepatic cholestasis	maralixibat	MARALIXIBAT	n/a	9/4/13	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0862646AA	maralixibat	UYB6UOF69L						Progressive familial intrahepatic cholestasis 1 	9802	done	
maralixibat	Treatment of progressive familial intrahepatic cholestasis	maralixibat	MARALIXIBAT	n/a	9/4/13	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0862646AA	maralixibat	UYB6UOF69L						 Progressive familial intrahepatic cholestasis 2 	1288	done	
maralixibat	Treatment of progressive familial intrahepatic cholestasis	maralixibat	MARALIXIBAT	n/a	9/4/13	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0862646AA	maralixibat	UYB6UOF69L						 Progressive familial intrahepatic cholestasis 3 	1289	done	
maralixibat	Treatment of progressive familial intrahepatic cholestasis	maralixibat	MARALIXIBAT	n/a	9/4/13	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0862646AA	maralixibat	UYB6UOF69L						" Cholestasis, progressive familial intrahepatic 4"	9803	done	
maribavir	Prevention of cytomegalovirus viremia and disease in the populations at risk.	maribavir	MARIBAVIR	n/a	2/1/07	Designated			N/A	N/A	"Shire ViroPharma, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0215167AA	maribavir	PTB4X93HE1								MISSING	
maribavir	Treatment of clinically significant cytomegalovirus viremia and disease in at-risk patients.	maribavir	MARIBAVIR	n/a	6/7/11	Designated			N/A	N/A	"Shire ViroPharma, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0215167AA	maribavir	PTB4X93HE1								MISSING	
masitinib	Treatment of patients with pancreatic cancer	masitinib	MASITINIB	n/a	7/21/09	Designated			N/A	N/A	AB Science				France	EXACT	0302783AA	masitinib	M59NC4E26P						Pancreatic cancer	9364	done	Not a rare disease
masitinib mesylate	Treatment of gastric cancer including cancer of the gastroesophageal junction	masitinib mesylate	MASITINIB MESYLATE	n/a	9/14/15	Designated			N/A	N/A	AB Science	Paris			France	EXACT	0302772AA	masitinib mesylate	ZK89EG3A18						Stomach cancer	7704	done	
mebendazole	"Treatment of single or mixed gastrointestinal infestations by Trichuris trichiura (whipworm), Ascaris lumbricoides (large roundworm), and Ancylostoma duodenale and Nectar americanus (hookworm)."	mebendazole	MEBENDAZOLE	Vermox 500 Mg Chewable Tablets	9/3/14	Designated/Approved	Approved for Orphan Indication	treatment of patients one year of age and older withgastrointestinal infections caused by Ascaris lumbricoides (roundworm) and Trichuris trichiura (whipworm)	10/19/16	TBD	"Janssen Pharmaceutical Research & Development, LLC"	Raritan	New Jersey	8869	USA	EXACT	0063989AA	mebendazole	81G6I5V05I						Trichuriasis 	10720	done	
mebendazole	"Treatment of single or mixed gastrointestinal infestations by Trichuris trichiura (whipworm), Ascaris lumbricoides (large roundworm), and Ancylostoma duodenale and Nectar americanus (hookworm)."	mebendazole	MEBENDAZOLE	Vermox 500 Mg Chewable Tablets	9/3/14	Designated/Approved	Approved for Orphan Indication	treatment of patients one year of age and older withgastrointestinal infections caused by Ascaris lumbricoides (roundworm) and Trichuris trichiura (whipworm)	10/19/16	TBD	"Janssen Pharmaceutical Research & Development, LLC"	Raritan	New Jersey	8869	USA	EXACT	0063989AA	mebendazole	81G6I5V05I						 Ancylostomiasis	9742	done	
mecasermin	Treatment of Rett Syndrome.	"mecasermin, recombinant human insulin-like growth factor-1"	MECASERMIN	Increlex	9/21/15	Designated			N/A	N/A	Keck Graduate Institute of Applied Life Sciences	Claremont	California	91711	USA	EXACT	0167215AA	mecasermin	7GR9I2683O						Rett syndrome	5696	done	
mecasermin	Treatment of growth hormone receptor deficiency.	Recombinant human insulin-like growth factor 1	MECASERMIN	Igf-1	6/7/95	Designated/Withdrawn			N/A	N/A	Pharmacia & Upjohn	Kalamazoo	Michigan	49001	USA	EXACT	0167215AA	mecasermin	7GR9I2683O						Laron syndrome	6859	done	
mecasermin rinfabate	Treatment of amyotropic lateral sclerosis	mecasermin rinfabate	MECASERMIN RINFABATE	Iplex	7/23/12	Designated			N/A	N/A	"PCUT BioPartners, Inc."	San Jose	California	95124	USA	EXACT	0212953AA	mecasermin rinfabate	NZ8M50KKRG						Amyotrophic lateral sclerosis	5786	done	
mecasermin rinfabate	Treatment of major burns that require hospitalization.	Recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3	MECASERMIN RINFABATE	n/a	6/15/99	Designated			N/A	N/A	"Insmed, Inc."	Monmouth Junction	New Jersey	8852	USA	EXACT	0212953AA	mecasermin rinfabate	NZ8M50KKRG								MISSING	
mefloquine HCL	"For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs"	mefloquine HCL	MEFLOQUINE HYDROCHLORIDE	Lariam	4/13/88	Designated/Approved	Approved for Orphan Indication	Treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax	5/2/89	5/2/96	"Hoffmann-La Roche, Inc."	Nutley	New Jersey	7110	USA	EXACT	0130052AA	mefloquine HCL	5Y9L3636O3						Malaria	6961	done	Not a rare disease
mefloquine HCL	"For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs"	mefloquine HCL	MEFLOQUINE HYDROCHLORIDE	Lariam	4/13/88	Designated/Approved	Approved for Orphan Indication	Prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs	5/3/89	5/3/96	"Hoffmann-La Roche, Inc."	Nutley	New Jersey	7110	USA	EXACT	0130052AA	mefloquine HCL	5Y9L3636O3						Malaria	6961	done	Not a rare disease
melarsoprol-hydroxypropylbetadex	Treatment of human African trypanosomiasis (sleeping sickness)	melarsoprol-hydroxypropylbetadex	MELARSOPROL	n/a	9/13/13	Designated			N/A	N/A	"Peter Kennedy, CBE, MD, PhD, DSc, FRCP FMedSci,"	Glasgow			United Kingdom	EXACT	0026631AA	melarsoprol	ZF3786Q2E8						"Trypanosomiasis, Human West-African "	7826	done	
melarsoprol-hydroxypropylbetadex	Treatment of human African trypanosomiasis (sleeping sickness)	melarsoprol-hydroxypropylbetadex	MELARSOPROL	n/a	9/13/13	Designated			N/A	N/A	"Peter Kennedy, CBE, MD, PhD, DSc, FRCP FMedSci,"	Glasgow			United Kingdom	EXACT	0026631AA	melarsoprol	ZF3786Q2E8						" Trypanosomiasis, Human East-African"	8540	done	
melatonin	Treatment of Acute Radiation Syndrome	melatonin	MELATONIN	Survivis®	10/22/18	Designated			N/A	N/A	WORPHMED Srl	"Via Malachia Marchesi de Taddei, 21"			Italy	EXACT	0012657AA	melatonin	JL5DK93RCL								MISSING	
melatonin	Treatment of acute acetaminophen overdose	melatonin	MELATONIN	n/a	3/2/17	Designated			N/A	N/A	Therapicon SrL	Milano			Italy	EXACT	0012657AA	melatonin	JL5DK93RCL								MISSING	
melatonin	Treatment of neonatal hypoxic ischemic encephalopathy	melatonin	MELATONIN	n/a	4/12/13	Designated			N/A	N/A	Scharper S.p.A.	Milan			Italy	EXACT	0012657AA	melatonin	JL5DK93RCL								MISSING	Not a rare disease
melatonin	Treatment of perinatal asphyxia	melatonin	MELATONIN	Survivis 100®	3/8/18	Designated			N/A	N/A	Therapicon SrL	21 Via Malachia Marchesi de Taddei	Milano		Italy	EXACT	0012657AA	melatonin	JL5DK93RCL								MISSING	Not a disease
melatonin	Treatment of perinatal asphyxia	melatonin	MELATONIN	Survivis 100®	3/8/18	Designated			N/A	N/A	Therapicon SrL	21 Via Malachia Marchesi de Taddei			Italy	EXACT	0012657AA	melatonin	JL5DK93RCL								MISSING	Not a disease
melatonin	Treatment of subarachnoid hemorrhage	melatonin	MELATONIN	Survivis®	3/28/18	Designated			N/A	N/A	Therapicon SrL	21 Via Malachia Marchesi de Taddei			Italy	EXACT	0012657AA	melatonin	JL5DK93RCL								MISSING	
meloxicam	Treatment of juvenile rheumatoid arthritis	meloxicam	MELOXICAM	Mobic	11/22/02	Designated/Approved	Approved for Orphan Indication	For relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients 2 years of age or older	8/11/05	8/11/12	"Boehringer Ingelheim Pharmaceuticals, Inc."	Ridgefield	Connecticut	6877	USA	EXACT	0216182AA	meloxicam	VG2QF83CGL						Juvenile idiopathic arthritis	3067	done	Not a rare disease
melphalan	High dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation	melphalan	MELPHALAN	Evomela	11/24/08	Designated/Approved	Approved for Orphan Indication	for high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma	3/10/16	3/10/23	"Spectrum Pharmaceuticals, INc."	Irvine	California	92618	USA	EXACT	0023176AA	melphalan	Q41OR9510P								MISSING	not a disease
melphalan flufenamide hydrochloride	"Treatment of plasma cell myeloma, also referred to as multiple myeloma"	melphalan flufenamide hydrochloride	MELPHALAN FLUFENAMIDE HYDROCHLORIDE	n/a	3/16/15	Designated			N/A	N/A	Oncopeptides AB				Sweden	EXACT	1577113AA	melphalan flufenamide hydrochloride	3412470A0V						Multiple myeloma	7108	done	
mepivacaine	Treatment of painful HIV-associated neuropathy	mepivacaine	MEPIVACAINE	n/a	10/18/06	Designated			N/A	N/A	"Relmada Therapeutics, Inc."	New York	New York	10036	USA	EXACT	0016206AA	mepivacaine	B6E06QE59J								MISSING	
mepivacaine	Treatment of postherpetic neuralgia	mepivacaine	MEPIVACAINE	n/a	1/8/07	Designated			N/A	N/A	"Relmada Therapeutics, Inc."	New York	New York	10036	USA	EXACT	0016206AA	mepivacaine	B6E06QE59J								MISSING	Not a rare disease; symptom
mepolizumab	Treatment of Churg-Strauss Syndrome.	mepolizumab	MEPOLIZUMAB	n/a	7/14/11	Designated			N/A	N/A	GlaxoSmithKline LLC	Wilmington	Delaware	19808	USA	EXACT	0298077AA	mepolizumab	90Z2UF0E52						Granulomatosis eosinofílica con poliangitis	13452	done	
mesalamine	Treatment of ulcerative colitis in pediatric patients (revised indication 10/21/2010).	mesalamine; 5-aminosalicylic acid	MESALAMINE	Lialda	2/27/08	Designated			N/A	N/A	Shire	Wayne	Pennsylvania	19087	USA	EXACT	0127719AA	mesalamine	4Q81I59GXC						Pediatric ulcerative colitis	9857	done	
mesalamine and N-acetycysteine	Treatment of pediatric patients with ulcerative colitis (inclusive through age 16 years)	mesalamine and N-acetycysteine	MESALAMINE	n/a	9/10/09	Designated			N/A	N/A	"Altheus Therapeutics, Inc."	Oklahoma City	Oklahoma	73104	USA	EXACT	0127719AA	mesalamine	4Q81I59GXC						Pediatric ulcerative colitis	9857	done	
messanger ribonucleic acid (mRNA)-based therapeutic agent encoding human methylmalonyl-coenzyme A mutase	Treatment of isolated methylmalonic academia (MMA) due to methylmalonyl-Coenzyme A mutase (MUT) deficiency	messanger ribonucleic acid (mRNA)-based therapeutic agent encoding human methylmalonyl-coenzyme A mutase	METHYLMALONYL COENZYME A	n/a	3/7/18	Designated			N/A	N/A	"Moderna Therapeutics, Inc."	320 Bent Street		2141	USA	LONGEST CONTAINS	1047263AA	methylmalonyl coenzyme A					PROBLEM	can't find	Methylmalonic acidemia	7033	done	
metavert	Treatment of pancreatic cancer	"metavert, N-hydroxy-4-(5-((4-methoxyphenyl)amino)-1,3,4-oxadiazol-2-yl)benzamide"	ALB-185357	n/a	7/6/16	Designated			N/A	N/A	"Avenzoar Pharmaceuticals, Inc."	Encinitas	California	92024	USA	EXACT	1570894AA	metavert	IZB8PZ86FH						Pancreatic cancer	9364	done	Not a rare disease
metformin	Treatment of pediatric polycystic ovary syndrome	metformin	METFORMIN	n/a	5/29/14	Designated			N/A	N/A	EffRx Pharmaceuticals SA				Switzerland	EXACT	0030557AA	metformin	9100L32L2N						Polycystic ovarian syndrome	7421	done	
methimazole	Treatment of brain metastases in patients with primary lung cancer	fixed dose combination of methimazole and liothyronine	METHIMAZOLE	n/a	3/6/17	Designated			N/A	N/A	Musli Thyropeutics Ltd.	Zur Moshe			Israel	EXACT	0010526AA	methimazole	554Z48XN5E								MISSING	Not a rare disease
methotrexate	Prevention of proliferative vitreoretinopathy (PVR)	methotrexate	METHOTREXATE	n/a	4/11/18	Designated			N/A	N/A	"Helio Vision, Inc."	"1000 Winter Street, 4th Floor"		2451	USA	EXACT	0010059AA	methotrexate	YL5FZ2Y5U1								MISSING	prevention of surgical complications
methotrexate	Treatment of juvenile rheumatoid arthritis.	methotrexate	METHOTREXATE	Rheumatrex	8/23/93	Designated/Withdrawn			N/A	N/A	Wyeth-Ayerst Laboratories	Philadelphia	Pennsylvania	19101	USA	EXACT	0010059AA	methotrexate	YL5FZ2Y5U1						Juvenile idiopathic arthritis	3067	done	Not a rare disease
methotrexate oral solution	"Treatment of oligoarticular juvenile idiopathic arthritis (persistent oligoarthritis, psoriatic juvenile idiopathic arthritis, enthesitis-related arthritis, or undifferentiated arthritis) and polyarticular juvenile idiopathic arthritis in children 0 through 16 years of age"	methotrexate oral solution	METHOTREXATE	n/a	8/27/15	Designated			N/A	N/A	"Silvergate Pharmaeuticals, Inc."	Greenwood Village	Colorado	80111	USA	EXACT	0010059AA	methotrexate	YL5FZ2Y5U1						Polyarticular onset juvenile idiopathic arthritis 	10967	done	
methotrexate oral solution	"Treatment of oligoarticular juvenile idiopathic arthritis (persistent oligoarthritis, psoriatic juvenile idiopathic arthritis, enthesitis-related arthritis, or undifferentiated arthritis) and polyarticular juvenile idiopathic arthritis in children 0 through 16 years of age"	methotrexate oral solution	METHOTREXATE	n/a	8/27/15	Designated			N/A	N/A	"Silvergate Pharmaeuticals, Inc."	Greenwood Village	Colorado	80111	USA	EXACT	0010059AA	methotrexate	YL5FZ2Y5U1						 Enthesitis-related juvenile idiopathic arthritis 	10969	done	
methotrexate oral solution	"Treatment of oligoarticular juvenile idiopathic arthritis (persistent oligoarthritis, psoriatic juvenile idiopathic arthritis, enthesitis-related arthritis, or undifferentiated arthritis) and polyarticular juvenile idiopathic arthritis in children 0 through 16 years of age"	methotrexate oral solution	METHOTREXATE	n/a	8/27/15	Designated			N/A	N/A	"Silvergate Pharmaeuticals, Inc."	Greenwood Village	Colorado	80111	USA	EXACT	0010059AA	methotrexate	YL5FZ2Y5U1						 Psoriatic juvenile idiopathic arthritis	10970	done	
methoxsalen	For the prevention of acute rejection of cardiac allografts	methoxsalen	METHOXSALEN	Uvadex	5/12/94	Designated			N/A	N/A	"Therakos, Inc."	West Chester	Pennsylvania	19380	USA	EXACT	0023836AA	methoxsalen	U4VJ29L7BQ						Acute graft versus host disease	6544	approximate	
methyldopa	Treatment of type 1 diabetes in DQ8 positive patients with residual beta cell function	methyldopa	METHYLDOPA	n/a	1/12/17	Designated			N/A	N/A	IM Therapeutics LLC	Broomfield	Colorado	80021	USA	EXACT	0028911AA	methyldopa	56LH93261Y						Diabetes mellitus type 1	10268	done	not a rare disease
methylprednisolone oral suspension	Treatment of adrenal insufficiency in pediatric patients	methylprednisolone oral suspension	METHYLPREDNISOLONE	n/a	9/19/16	Designated			N/A	N/A	Generic Specialty Pharma	Stamullin			Ireland	EXACT	0014335AA	methylprednisolone	X4W7ZR7023						Secondary adrenal insufficiency	12735	approximate	not only secondary insufficiency
metronidazole	Treatment of clostridium difficile infection in pediatric patients (0 through 16 years of age).	metronidazole	METRONIDAZOLE	n/a	4/5/16	Designated			N/A	N/A	"Appili Therapeutics, Inc."	Halifax	Nova Scotia		Canada	EXACT	0025810AA	metronidazole	140QMO216E						Clostridium septicum infection	11969	done	
metronidazole	Treatment of pouchitis	metronidazole	METRONIDAZOLE	n/a	9/17/08	Designated			N/A	N/A	Avivia Project BV				Netherlands	EXACT	0025810AA	metronidazole	140QMO216E								MISSING	surgery complication
metronidazole	Treatment of pouchitis.	metronidazole	METRONIDAZOLE	n/a	4/26/11	Designated			N/A	N/A	S.L.A. Pharma Limited (UK)				United Kingdom	EXACT	0025810AA	metronidazole	140QMO216E								MISSING	surgery complication
metyrosine	Treatment of velocardiofacial syndrome associated psychosis.	metyrosine	METIROSINE	Demser	7/25/08	Designated			N/A	N/A	"Cerberus Princeton, LLC"	New York	New York	10022	USA	EXACT	0090153AA	metyrosine	DOQ0J0TPF7						22q11.2 deletion syndrome	10299	done	
mibefradil	Treatment of pancreatic cancer.	mibefradil	MIBEFRADIL	n/a	10/16/08	Designated			N/A	N/A	"Cavion, LLC"	Charlottesville	Virginia	22902	USA	EXACT	0339753AA	mibefradil	27B90X776A						Pancreatic cancer	9364	done	Not a rare disease
miconazole	Treatment of fungal otitis externa (otomycosis)	miconazole	MICONAZOLE	n/a	5/22/14	Designated			N/A	N/A	"Hill Dermaceuticals, Inc."	Sanford	Florida	32773	USA	EXACT	0061018AA	miconazole	7NNO0D7S5M								MISSING	Not a rare disease
midazolam	"Rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity (e.g. acute repetitive seizures, seizure clusters)"	midazolam	MIDAZOLAM	n/a	10/20/09	Designated			N/A	N/A	"Upsher-Smith Laboratories, Inc."	Maple Grove	Minnesota	55369	USA	EXACT	0127526AA	midazolam	R60L0SM5BC						Status epilepticus	10191	approximate	
midazolam	Treatment of bouts of increased seizure activity in selected refractory patients with epilepsy who are on stable regimens of anti-epileptic drugs and who require intermittent use of midazolam	midazolam	MIDAZOLAM	n/a	5/8/06	Designated			N/A	N/A	"UCB, Inc"	Smyrna	Georgia	30080	USA	EXACT	0127526AA	midazolam	R60L0SM5BC						Status epilepticus	10191	done	
midazolam	Treatment of nerve agent-induced seizures	midazolam	MIDAZOLAM	n/a	7/24/12	Designated			N/A	N/A	"Meridian Medical Technologies, Inc."	Columbia	Maryland	21046	USA	EXACT	0127526AA	midazolam	R60L0SM5BC						Neuroleptic malignant syndrome	7195	done	
midazolam	Treatment of seizures induced by organophosporous insecticide poisoning.	midazolam	MIDAZOLAM	n/a	2/8/16	Designated			N/A	N/A	"Meridian Medical Technologies, Inc."	Columbia	Maryland	21046	USA	EXACT	0127526AA	midazolam	R60L0SM5BC						Status epilepticus	10191	done	
midazolam	Treatment of status epilepticus	midazolam	MIDAZOLAM	Zeneo®-Midazolam	1/30/18	Designated			N/A	N/A	Crossject SA	6 Rue Pauline Kergomard	Dijon		France	EXACT	0127526AA	midazolam	R60L0SM5BC						Status epilepticus	10191	done	
mifepristone	Treatment of the clinical manifestations of endogenous Cushing's syndrone	mifepristone	MIFEPRISTONE	Korlym	7/5/07	Designated/Approved	Approved for Orphan Indication	for the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.	2/17/12	2/17/19	"Corcept Therapeutics, Inc."	Menlo Park	California	94025	USA	EXACT	0129613AA	mifepristone	320T6RNW1F						Cushing's syndrome	6224	done	
miglustat	Treatment of Pompe disease	recombinant human acid a-glucosidase co-administered with N-butyl-deoxynojirimycin (reconbinant human acid a-glucosidase/miglustat)	MIGLUSTAT	n/a	9/13/17	Designated			N/A	N/A	"Amicus Therapeutics, Inc."	Cranbury Township	New Jersey	8512	USA	EXACT	0169288AA	miglustat	ADN3S497AZ						Glycogen storage disease type 2	5714	done	
miglustat	"Treatment of the neurological manifestations of Niemann-Pick disease,type C."	miglustat	MIGLUSTAT	Zavesca (R)	11/12/08	Designated			N/A	N/A	Actelion Pharmaceuticals Ltd				Switzerland	EXACT	0169288AA	miglustat	ADN3S497AZ						Niemann-Pick disease type C1 	7207	approximate	
miglustat	"Treatment of the neurological manifestations of Niemann-Pick disease,type C."	miglustat	MIGLUSTAT	Zavesca (R)	11/12/08	Designated			N/A	N/A	Actelion Pharmaceuticals Ltd				Switzerland	EXACT	0169288AA	miglustat	ADN3S497AZ						 Niemann-Pick disease type C2	3992	approximate	
milrinone	Treatment of right heart failure (RHF) in left ventricular assist device (LVAD) patients	milrinone	MILRINONE	n/a	1/8/18	Designated			N/A	N/A	Cardiora Pty Ltd	"Level 9, 278 Collins Street"	Melbourne		Australia	EXACT	0121120AA	milrinone	JU9YAX04C7								MISSING	
miltefosine	Treatment of primary amebic encephalitis (PAM)	miltefosine	MILTEFOSINE	Impavido	12/6/16	Designated			N/A	N/A	"Profounda, Inc."	Orlando	Florida	32822	USA	EXACT	0273734AA	miltefosine	53EY29W7EC						Primary amebic meningoencephalitis	9554	done	
mipomersen	Treatment of homozygous familial hypercholesterolemia	mipomersen	MIPOMERSEN	Kynamro	5/23/06	Designated/Approved	Approved for Orphan Indication	"Adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH)."	1/29/13	1/29/20	"Kastle Therapeutics, LLC"	Chicago	Illinois	60602	USA	EXACT	0384065AA	mipomersen	9GJ8S4GU0M						Familial hypercholesterolemia	10416	done	Not a rare disease
misoprostol	Treatment of intrauterine fetal death not accompanied by complete expulsion of the products of conception in the second and third trimesters of pregnancy.	misoprostol	MISOPROSTOL	Gymiso	1/10/05	Designated			N/A	N/A	"Gynuity Health Projects, LLC"	New York	New York	10010	USA	EXACT	0118036AA	misoprostol	0E43V0BB57								MISSING	
mitomycin	Prevention of corneal sub-epithelial haze formation following surface ablation laser keratectomy	mitomycin	MITOMYCIN	n/a	6/1/11	Designated			N/A	N/A	"Mobius Therapeutics, LLC"	St. Louis	Missouri	63104	USA	EXACT	0132865AA	mitomycin	50SG953SK6								MISSING	
mitomycin	Prevention of recurrence of pterygium after its surgical excision.	mitomycin	MITOMYCIN	n/a	1/13/11	Designated			N/A	N/A	"Mobius Therapeutics, LLC"	St. Louis	Missouri	63108	USA	EXACT	0132865AA	mitomycin	50SG953SK6						Pterygium of the conjunctiva and cornea	4569	done	
mitomycin-C	Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.	mitomycin-C	MITOMYCIN	Mitosol	1/8/08	Designated/Approved	Approved for Orphan Indication	An adjunct to ab externo glaucoma surgery.	2/7/12	2/7/19	"Mobius Therapeutics, LLC"	St. Louis	Missouri	63104	USA	EXACT	0132865AA	mitomycin-C	50SG953SK6								MISSING	
mobilized perioheral blood cells that have undergone ex-vivo negative functionial selection of GvHD-causing T-cells by short term incubation with Fas-ligand	Prevention of graft versus host disease (GvHD)	mobilized perioheral blood cells that have undergone ex-vivo negative functionial selection of GvHD-causing T-cells by short term incubation with Fas-ligand	TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 6	n/a	8/15/17	Designated			N/A	N/A	Cellect Biotherapeutics	Kfar Saba			Israel	LONGEST CONTAINS	1803163AA	Fas ligand	LR39I7PC1F | J56RKY13OV	HUMAN PERIPHERAL BLOOD MONONUCLEAR CELL | HUMAN THYMOCYTE	LR39I7PC1F | J56RKY13OV	https://ginas.ncats.nih.gov/ginas/app/substance/20715f41 | https://ginas.ncats.nih.gov/ginas/app/substance/9784a943	approximate		Chronic graft versus host disease	10964	approximate	type of GVHD (acute or chronic) is not specified
mobilized perioheral blood cells that have undergone ex-vivo negative functionial selection of GvHD-causing T-cells by short term incubation with Fas-ligand	Prevention of graft versus host disease (GvHD)	mobilized perioheral blood cells that have undergone ex-vivo negative functionial selection of GvHD-causing T-cells by short term incubation with Fas-ligand	TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 6	n/a	8/15/17	Designated			N/A	N/A	Cellect Biotherapeutics	Kfar Saba			Israel	LONGEST CONTAINS	1803163AA	Fas ligand	LR39I7PC1F | J56RKY13OV	HUMAN PERIPHERAL BLOOD MONONUCLEAR CELL | HUMAN THYMOCYTE	LR39I7PC1F | J56RKY13OV	https://ginas.ncats.nih.gov/ginas/app/substance/20715f41 | https://ginas.ncats.nih.gov/ginas/app/substance/9784a943	approximate		Acute graft versus host disease	6544	approximate	type of GVHD (acute or chronic) is not specified
"modified mRNA encoding UGT1A1 protein, formulated in lipid nanoparticles"	Treatment of Crigler-Najjar syndrome	"modified mRNA encoding UGT1A1 protein, formulated in lipid nanoparticles"	PROTEIN	n/a	7/5/16	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	New Haven	Connecticut	6510	USA	LONGEST CONTAINS	0087274AA	protein		"modified mRNA encoding UGT1A1 protein, formulated in lipid nanoparticles"	NA	https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=526616	PROBLEM	absent from GINAS	Crigler-Najjar syndrome type 2 	8683	done	
"modified mRNA encoding UGT1A1 protein, formulated in lipid nanoparticles"	Treatment of Crigler-Najjar syndrome	"modified mRNA encoding UGT1A1 protein, formulated in lipid nanoparticles"	PROTEIN	n/a	7/5/16	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	New Haven	Connecticut	6510	USA	LONGEST CONTAINS	0087274AA	protein		"modified mRNA encoding UGT1A1 protein, formulated in lipid nanoparticles"	NA	https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=526616	PROBLEM	absent from GINAS	" Crigler Najjar syndrome, type 1"	47	done	
modified recombinant mitochondrial transcription factor A (TFAM) containing the mitochondrial transduction domain	Treatment of inherited mitochondrial respiratory chain disease	modified recombinant mitochondrial transcription factor A (TFAM) containing the mitochondrial transduction domain		n/a	8/20/12	Designated			N/A	N/A	Gencia Corporation	Charlottesville	Virginia	22902	USA								PROBLEM	can't find	Mitochondrial complex I deficiency 	3908	approximate	
modified recombinant mitochondrial transcription factor A (TFAM) containing the mitochondrial transduction domain	Treatment of inherited mitochondrial respiratory chain disease	modified recombinant mitochondrial transcription factor A (TFAM) containing the mitochondrial transduction domain		n/a	8/20/12	Designated			N/A	N/A	Gencia Corporation	Charlottesville	Virginia	22902	USA								PROBLEM	can't find	 Mitochondrial complex II deficiency 	5053	approximate	
modified recombinant mitochondrial transcription factor A (TFAM) containing the mitochondrial transduction domain	Treatment of inherited mitochondrial respiratory chain disease	modified recombinant mitochondrial transcription factor A (TFAM) containing the mitochondrial transduction domain		n/a	8/20/12	Designated			N/A	N/A	Gencia Corporation	Charlottesville	Virginia	22902	USA								PROBLEM	can't find	 Mitochondrial complex III deficiency 	8295	approximate	
modified recombinant mitochondrial transcription factor A (TFAM) containing the mitochondrial transduction domain	Treatment of inherited mitochondrial respiratory chain disease	modified recombinant mitochondrial transcription factor A (TFAM) containing the mitochondrial transduction domain		n/a	8/20/12	Designated			N/A	N/A	Gencia Corporation	Charlottesville	Virginia	22902	USA								PROBLEM	can't find	 Cytochrome c oxidase deficiency 	48	approximate	
modified recombinant mitochondrial transcription factor A (TFAM) containing the mitochondrial transduction domain	Treatment of inherited mitochondrial respiratory chain disease	modified recombinant mitochondrial transcription factor A (TFAM) containing the mitochondrial transduction domain		n/a	8/20/12	Designated			N/A	N/A	Gencia Corporation	Charlottesville	Virginia	22902	USA								PROBLEM	can't find	 Mitochondrial complex V deficiency	1459	approximate	
"monoclonal antibody consisting of three mouse/human chimeric IgG1 monoclonal antibodies (c2G4, c4G7, and c13C6) that target Ebola virus"	Treatment of Ebola virus infection	"monoclonal antibody consisting of three mouse/human chimeric IgG1 monoclonal antibodies (c2G4, c4G7, and c13C6) that target Ebola virus"	PORGAVIXIMAB	n/a	8/25/14	Designated			N/A	N/A	"LeafBio, Inc."	San Diego	California	90121	USA	LONGEST CONTAINS	1201349AA	c2G4	07EY0HWO2M						Ebola virus disease	2035	done	
monosialotetrahexosylganglioside	Treatment of Huntington’s Disease	monosialotetrahexosylganglioside	MONOSIALOTETRAHEXOSYLGANGLIOSIDE	Shenjie®	8/7/18	Designated			N/A	N/A	"Qilu Pharmaceutical Co., Ltd."	243 Gong Ye Bei Road Jinan			China	EXACT	0128416AA	monosialotetrahexosylganglioside	562413257Z	GANGLIOSIDE GM1	562413257Z	https://ginas.ncats.nih.gov/ginas/app/substance/01d4e7df	done		Huntington disease	6677	done	
motexafin gadolinium	For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors	motexafin gadolinium	MOTEXAFIN GADOLINIUM	Xcytrin	1/27/03	Designated			N/A	N/A	"Pharmacyclics, LLC"	Sunnyvale	California	94085	USA	EXACT	0188910AA	motexafin gadolinium	6433A42F4F								MISSING	not a disease
mul-1867	"Treatment of pulmonary infections in patients with cystic fibrosis including infections due to pseudomonas aeruginosa,Burkholderia cepacia and other bacteria"	"poly-N,N'-hexamethyleneguanidine-poly-N1,N4-hexamethyleneaminoguanidine"	MUL-1867	n/a	4/5/16	Designated			N/A	N/A	"TGV-Inhalonix, Inc."	New York	New York	10016	USA	EXACT	1802502AA	mul-1867	KYU75D2TUQ								MISSING	Not a rare disease
multi-vitamin infusion without vitamin K	Prevention of vitamin deficiency and thromboembolic complications in people receiving home parenteral nutrition and warfarin-type anticoagulant therapy	multi-vitamin infusion without vitamin K	PHYTONADIONE	M.V.I.-12	3/8/04	Designated/Approved	Approved for Orphan Indication	Prevention of vitamin deficiency and thrombormbolic complications in people receiving home parenteral nutrition who also receive warfarin-type anticoagulant therapy	9/9/04	9/9/11	Mayne Pharma (USA) Inc.	Paramus	New Jersey	7652	USA	LONGEST CONTAINS	0014620AA	vitamin K	A034SE7857								MISSING	prevention of drug-induced side-effects
mycobacterium vaccae	Treatment of pancreatic cancer	mycobacterium vaccae	MYCOBACTERIUM VACCAE	n/a	8/6/10	Designated/Withdrawn			N/A	N/A	Immodulon Therapeutics Ltd.				United Kingdom	EXACT	0787177AA	mycobacterium vaccae	I639ME27W5						Pancreatic cancer	9364	done	Not a rare disease
myristoylated recombinant SCR1-3 of human complement reseptor type I	Prevention of delayed graft function in solid organ transplant	myristoylated recombinant SCR1-3 of human complement reseptor type I	CDX-1135	Apt070	5/21/03	Designated/Withdrawn			N/A	N/A	Orexo AB				Sweden	LONGEST CONTAINS	0260719AA	SCR1	2RF4H67MOG								MISSING	
nabumetone	Treatment of pediatric juvenile rheumatoid arthritis	nabumetone	NABUMETONE	n/a	5/5/08	Designated			N/A	N/A	Cook Pharma	Chapel Hill	North Carolina	27516	USA	EXACT	0125871AA	nabumetone	LW0TIW155Z								MISSING	
naloxone	Treatment of opiate addiction in opiate users	buprenorphine in combination with naloxone	NALOXONE	Suboxone	10/27/94	Designated/Approved	Approved for Orphan Indication	Treatment of opioid dependence in patients 16 years of age or older	10/8/02	10/8/09	"Reckitt Benckiser Pharmaceuticals, Inc."	Richmond	Virginia	23235	USA	EXACT	0025989AA	naloxone	36B82AMQ7N								MISSING	
naltrexone	Treatment of Crohn's disease in pediatric patients	naltrexone	NALTREXONE	n/a	1/19/10	Designated			N/A	N/A	"TNI BioTech, Inc."	Bethesda	Maryland	20817	USA	EXACT	0057249AA	naltrexone	5S6W795CQM						Crohn's disease	10232	done	Not a rare disease
naltrexone	Treatment of postherpetic neuralgia	naltrexone	NALTREXONE	n/a	2/23/15	Designated			N/A	N/A	Allodynic Therapeutics LLC	North Miami	Florida	33181	USA	EXACT	0057249AA	naltrexone	5S6W795CQM								MISSING	Not a rare disease; symptom
naltrexone	Treatment of postherpetic neuralgia	naltrexone/clonidine combination	NALTREXONE	n/a	4/14/14	Designated			N/A	N/A	Allodynic Therapeutics LLC	North Miami	Florida	33181	USA	EXACT	0057249AA	naltrexone	5S6W795CQM								MISSING	Not a rare disease; symptom
nano-diamino-tetraiodothyroacetic acid	Treatment of pancreatic cancer	nano-diamino-tetraiodothyroacetic acid	"3,3',5,5'-TETRAIODOTHYROACETIC ACID"	n/a	10/28/15	Designated			N/A	N/A	"NanoPharmaceuticals, LLC"	Rensselaer	New York	12144	USA	LONGEST CONTAINS	0497176AA	tetraiodothyroacetic acid	PA7UX1FFYQ						Pancreatic cancer	9364	done	Not a rare disease
napabucasin	Treatment of gastric cancer including gastroesophageal junction cancer.	napabucasin	NAPABUCASIN	n/a	6/20/16	Designated			N/A	N/A	"Boston Biomedical, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0660093AA	napabucasin	Z1HHM49K7O						Stomach cancer	7704	done	
napabucasin	Treatment of pancreatic cancer.	napabucasin	NAPABUCASIN	n/a	10/25/16	Designated			N/A	N/A	"Boston Biomedical, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0660093AA	napabucasin	Z1HHM49K7O						Pancreatic cancer	9364	done	Not a rare disease
necitumumab	Treatment of squamous non-small cell lung cancer	necitumumab	NECITUMUMAB	n/a	11/20/15	Designated/Approved	Approved for Orphan Indication	"Use in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic, squamous, non-small cell lung cancer. PORTRAZZA is not indicated for treatment of non-squamous, non-small cell lung cancer"	11/24/15	11/24/22	Eli Lilly and Company	Branchburg	New Jersey	8876	USA	EXACT	0432495AA	necitumumab	2BT4C47RUI						"Non-small cell lung cancer, childhood"	9343	approximate	
neihulizumab	Treatment of acute graft-versus-host disease (aGvHD)	neihulizumab	NEIHULIZUMAB	n/a	1/25/18	Designated			N/A	N/A	"AbGenomics International, Inc."	5050 El Camino Real	Los Altos	94022	USA	EXACT	0341946AA	neihulizumab	615637S5PE						Acute graft versus host disease	6544	done	
nelatimotide and adegramotide (DSP-7888 dosing emulsion)	Treatment of brain cancer	nelatimotide and adegramotide (DSP-7888 dosing emulsion)	NELATIMOTIDE	n/a	9/18/17	Designated			N/A	N/A	"Boston Biomedical, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	1336294AA	nelatimotide	38184303XR						Anaplastic oligoastrocytoma	10637	approximate	brain cancer not specified
neostigmine	Treatment of acute colonic pseudo-obstruction	neostigmine	NEOSTIGMINE	n/a	3/18/13	Designated			N/A	N/A	"Luitpold Pharmaceuticals, Inc."	Shirley	New York	11967	USA	EXACT	0010297AA	neostigmine	3982TWQ96G						Ogilvie syndrome	7248	done	
neridronate	"Treatment of complex regional pain syndrome (CRPS-1, CRPS-II, CRPS-NOS)"	neridronate	NERIDRONIC ACID	n/a	3/25/13	Designated			N/A	N/A	"Grunenthal USA, Inc."	Bedminster	New Jersey	7921	USA	EXACT	0282519AA	neridronate	8U27U3RIN4						Complex regional pain syndrome	4647	done	
nevirapine	Prevention of HIV infection in pediatric patients under the age of 16 years	nevirapine	NEVIRAPINE	n/a	11/25/09	Designated			N/A	N/A	Auritec Pharmaceuticals	Santa Monica	California	90401	USA	EXACT	0174174AA	nevirapine	99DK7FVK1H								MISSING	Not a rare disease
nicotinamide riboside	"Treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome (MELAS)"	nicotinamide riboside	NICOTINAMIDE RIBOSIDE	Niasun	1/25/17	Designated			N/A	N/A	Rejuvenation Therapeutics	Incline Village	Nevada	89451	USA	EXACT	1800960AA	nicotinamide riboside	0I8H2M0L7N						Mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes	7009	done	
nifurtimox	Treatment of Chagas disease	nifurtimox	NIFURTIMOX	n/a	12/31/13	Designated			N/A	N/A	"MetronomX Therapeutics, LLC"	Houston	Texas	77030	USA	EXACT	0061585AA	nifurtimox	M84I3K7C2O						Chagas disease	6030	done	Not a rare disease
nifurtimox	Treatment of Chagas disease (American Typanosomiasis)caused by T. cruzi	nifurtimox	NIFURTIMOX	Lampit	8/5/10	Designated			N/A	N/A	"Bayer HealthCare Pharmaceuticals, Inc."	Montville	New Jersey	7045	USA	EXACT	0061585AA	nifurtimox	M84I3K7C2O						Chagas disease	6030	done	Not a rare disease
nilotinib	Treatment of chronic myelogenous leukemia	nilotinib	NILOTINIB	Tasigna	4/27/06	Designated/Approved	Approved for Orphan Indication	For the use for chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior therapy that included imatinib.	10/29/07	10/29/14	Novartis Pharmaceutical Corporation	East Hanover	New Jersey	7936	USA	EXACT	0297723AA	nilotinib	F41401512X						Chronic myeloid leukemia	6105	done	
nimodipine	Treatment of subarachnoid hemorrhage.	nimodipine	NIMODIPINE	Nymalize	9/16/11	Designated/Approved	Approved for Orphan Indication	"Improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V)."	5/10/13	5/10/20	"Arbor Pharmaceuticals, Inc."	Atlanta	Georgia	30328	USA	EXACT	0067243AA	nimodipine	57WA9QZ5WH								MISSING	
nimodipine intravenous	Treatment of subarachnoid hemorrhage	nimodipine intravenous	NIMODIPINE	n/a	8/10/17	Designated			N/A	N/A	"Grace Therapeutics, LLC"	North Brunswick Township	New Jersey	8902	USA	EXACT	0067243AA	nimodipine	57WA9QZ5WH								MISSING	
nimotuzumab	Treatment of pancreatic cancer.	nimotuzumab	NIMOTUZUMAB	n/a	9/8/15	Designated			N/A	N/A	InnoCIMab Pte Ltd				Singapore	EXACT	0298088AA	nimotuzumab	6NS400BXKH						Pancreatic cancer	9364	done	Not a rare disease
niprisan	Treatment of sickle cell disease	niprisan		Hemoxin	8/15/03	Designated			N/A	N/A	"Xechem International, Inc."	Edison	New Jersey	8837	USA					Niprisan	NA	https://adisinsight.springer.com/drugs/800017835	PROBLEM	absent from GINAS	Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
niprisan	Treatment of sickle cell disease	niprisan		Hemoxin	8/15/03	Designated			N/A	N/A	"Xechem International, Inc."	Edison	New Jersey	8837	USA					Niprisan	NA	https://adisinsight.springer.com/drugs/800017835	PROBLEM	absent from GINAS	 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
niprisan	Treatment of sickle cell disease	niprisan		Hemoxin	8/15/03	Designated			N/A	N/A	"Xechem International, Inc."	Edison	New Jersey	8837	USA					Niprisan	NA	https://adisinsight.springer.com/drugs/800017835	PROBLEM	absent from GINAS	 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
niprisan	Treatment of sickle cell disease	niprisan		Hemoxin	8/15/03	Designated			N/A	N/A	"Xechem International, Inc."	Edison	New Jersey	8837	USA					Niprisan	NA	https://adisinsight.springer.com/drugs/800017835	PROBLEM	absent from GINAS	 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
niprisan	Treatment of sickle cell disease	niprisan		Hemoxin	8/15/03	Designated			N/A	N/A	"Xechem International, Inc."	Edison	New Jersey	8837	USA					Niprisan	NA	https://adisinsight.springer.com/drugs/800017835	PROBLEM	absent from GINAS	 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
niprisan	Treatment of sickle cell disease	niprisan		Hemoxin	8/15/03	Designated			N/A	N/A	"Xechem International, Inc."	Edison	New Jersey	8837	USA					Niprisan	NA	https://adisinsight.springer.com/drugs/800017835	PROBLEM	absent from GINAS	 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
nitazoxanide	Treatment of intestinal giardiasis	nitazoxanide	NITAZOXANIDE	Alinia	2/14/02	Designated/Approved	Approved for Orphan Indication	Treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia	11/22/02	11/22/09	"Romark Laboratories, L.C."	Tampa	Florida	33607	USA	EXACT	0208855AA	nitazoxanide	SOA12P041N								MISSING	
nitric oxide	Treatment of non-tuberculous mycobacterial lung disease	nitric oxide	NITRIC OXIDE	Thiolanox	6/5/18	Designated			N/A	N/A	"Novoteris, LLC"	7245 Garden Grove Blvd.	Suite C	92841	USA	EXACT	0176341AA	nitric oxide	31C4KY9ESH						Nontuberculous mycobacterial lung disease	12829	done	
nitric oxide	Treatment of persistent pulmonary hypertension in newborns	nitric oxide	NITRIC OXIDE	n/a	6/18/12	Designated			N/A	N/A	"GeNO, LLC"	Cocoa	Florida	32926	USA	EXACT	0176341AA	nitric oxide	31C4KY9ESH						Pulmonary arterial hypertension	7501	approximate	
nitric oxide	Use in combination with a drug delivery device for acute treatment of sickle cell vaso-occlusive crisis (pain crises)	nitric oxide	NITRIC OXIDE	Inomax (R)	9/5/08	Designated			N/A	N/A	INO Therapeutics	Hampton	New Jersey	8827	USA	EXACT	0176341AA	nitric oxide	31C4KY9ESH						Sickle cell anemia	8614	approximate	Type of sickle cell disease is not specified
nivolumab	Treatment of gastric cancer (GC) and gastro-esophageal junction cancer (GEJ).	Fixed dose combination of relatlimab and nivolumab	NIVOLUMAB	n/a	6/18/18	Designated			N/A	N/A	Bristol-Myers Squibb Co.	P.O. Box 4000	New Jersey	8543	USA	EXACT	0761411AA	nivolumab	31YO63LBSN						Stomach cancer	7704	done	
nivolumab	Treatment of gastric cancer and gastro-esophageal junction cancer.	nivolumab	NIVOLUMAB	Opdivo	12/20/16	Designated			N/A	N/A	Bristol-Myers Squibb Co.	Wallingford	Connecticut	6492	USA	EXACT	0761411AA	nivolumab	31YO63LBSN						Stomach cancer	7704	done	
nivolumab	Treatment of mesothelioma	nivolumab and ipilimumab	NIVOLUMAB	n/a	8/16/17	Designated			N/A	N/A	Bristol-Myers Squibb Company	Wallingford	Connecticut	6492	USA	EXACT	0761411AA	nivolumab	31YO63LBSN						Malignant mesothelioma	7026	done	
nivolumab	Treatment of small cell lung cancer.	nivolumab	NIVOLUMAB	n/a	9/15/15	Designated			N/A	N/A	Bristol-Myers Squibb Company	Princeton	New Jersey	8543	USA	EXACT	0761411AA	nivolumab	31YO63LBSN						Small cell lung cancer	9344	done	
nktt-120	Treatment of sickle cell disease	recombinant humanized IgG1k monoclonal antibody to human invariant T cell receptor (iTCR)	NKTT-120	n/a	4/12/13	Designated			N/A	N/A	"NKT Therapeutics, Inc."	Waltham	Massachusetts	2451	USA	EXACT	0113910AB	nktt-120					PROBLEM	can't find	Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
nktt-120	Treatment of sickle cell disease	recombinant humanized IgG1k monoclonal antibody to human invariant T cell receptor (iTCR)	NKTT-120	n/a	4/12/13	Designated			N/A	N/A	"NKT Therapeutics, Inc."	Waltham	Massachusetts	2451	USA	EXACT	0113910AB	nktt-120					PROBLEM	can't find	 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
nktt-120	Treatment of sickle cell disease	recombinant humanized IgG1k monoclonal antibody to human invariant T cell receptor (iTCR)	NKTT-120	n/a	4/12/13	Designated			N/A	N/A	"NKT Therapeutics, Inc."	Waltham	Massachusetts	2451	USA	EXACT	0113910AB	nktt-120					PROBLEM	can't find	 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
nktt-120	Treatment of sickle cell disease	recombinant humanized IgG1k monoclonal antibody to human invariant T cell receptor (iTCR)	NKTT-120	n/a	4/12/13	Designated			N/A	N/A	"NKT Therapeutics, Inc."	Waltham	Massachusetts	2451	USA	EXACT	0113910AB	nktt-120					PROBLEM	can't find	 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
nktt-120	Treatment of sickle cell disease	recombinant humanized IgG1k monoclonal antibody to human invariant T cell receptor (iTCR)	NKTT-120	n/a	4/12/13	Designated			N/A	N/A	"NKT Therapeutics, Inc."	Waltham	Massachusetts	2451	USA	EXACT	0113910AB	nktt-120					PROBLEM	can't find	 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
nktt-120	Treatment of sickle cell disease	recombinant humanized IgG1k monoclonal antibody to human invariant T cell receptor (iTCR)	NKTT-120	n/a	4/12/13	Designated			N/A	N/A	"NKT Therapeutics, Inc."	Waltham	Massachusetts	2451	USA	EXACT	0113910AB	nktt-120					PROBLEM	can't find	 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
"non-replicating adeno-associated viral vector, serotype 8, expressing human myotubularin gene"	Treatment of x-linked myotubular myopathy	"non-replicating adeno-associated viral vector, serotype 8, expressing human myotubularin gene"		At001	12/3/14	Designated			N/A	N/A	"Audentes Therapeutics, Inc."	San Francisco	California	94104	USA								PROBLEM	can't find	X-linked myotubular myopathy	11925	done	
"non-replicating recombinant adeno-associated viral vector, serotype 8, expressing the 1A1 isoform of the bilirubin-uridine diphosphate glucuronosyltransferase gene"	Treatment of Crigler Najjar syndrome.	"non-replicating recombinant adeno-associated viral vector, serotype 8, expressing the 1A1 isoform of the bilirubin-uridine diphosphate glucuronosyltransferase gene"	PYROPHOSPHATE	n/a	5/24/16	Designated			N/A	N/A	"Audentes Therapeutics, Inc."	San Francisco	California	94109	USA	LONGEST CONTAINS	1206515AA	diphosphate	X3SSV2V6L3						Crigler-Najjar syndrome type 2 	8683	done	
"non-replicating recombinant adeno-associated viral vector, serotype 8, expressing the 1A1 isoform of the bilirubin-uridine diphosphate glucuronosyltransferase gene"	Treatment of Crigler Najjar syndrome.	"non-replicating recombinant adeno-associated viral vector, serotype 8, expressing the 1A1 isoform of the bilirubin-uridine diphosphate glucuronosyltransferase gene"	PYROPHOSPHATE	n/a	5/24/16	Designated			N/A	N/A	"Audentes Therapeutics, Inc."	San Francisco	California	94109	USA	LONGEST CONTAINS	1206515AA	diphosphate	X3SSV2V6L3						" Crigler Najjar syndrome, type 1"	47	done	
"non-replicating, recombinant adeno-associated virus (AAV) serotype 9 (AAV9) vector containing an hCLN2 expression cassette encoding for the soluble lysosomal enzyme tripeptidyl peptidase I (TPP1)"	Treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease.	"non-replicating, recombinant adeno-associated virus (AAV) serotype 9 (AAV9) vector containing an hCLN2 expression cassette encoding for the soluble lysosomal enzyme tripeptidyl peptidase I (TPP1)"		n/a	10/25/18	Designated			N/A	N/A	REGENXBIO Inc. (REGENXBIO)	9600 Medical Center Drive	Maryland	20850	USA					RGX-181	NA	https://regenxbio.gcs-web.com/news-releases/news-release-details/fda-grants-orphan-drug-designation-rgx-181-gene-therapy | https://adisinsight.springer.com/drugs/800052865	PROBLEM	absent from GINAS	Neuronal ceroid lipofuscinosis 2	3045	done	
obeticholic acid	Treatment of primary biliary cirrhosis	obeticholic acid	OBETICHOLIC ACID	Ocaliva	4/9/08	Designated/Approved	Approved for Orphan Indication	"Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA"	5/27/16	5/27/23	"Intercept Pharmaceuticals, Inc."	San Diego	California	92122	USA	EXACT	0322543AA	obeticholic acid	0462Z4S4OZ						Primary biliary cholangitis	7459	done	
obiltoxaximab	Treatment of exposure to B. anthracis spores	obiltoxaximab	OBILTOXAXIMAB	Anthim	6/9/06	Designated/Approved	Approved for Orphan Indication	Treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.	3/18/16	3/18/23	"Elusys Therapeutics, Inc."	Pine Brook	New Jersey	7058	USA	EXACT	1096566AA	obiltoxaximab	29Z5DNL48C						Anthrax	8157	done	
obinutuzumab	Treatment of diffuse large B cell lymphoma	obinutuzumab	OBINUTUZUMAB	n/a	2/17/12	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0322532AA	obinutuzumab	O43472U9X8						Diffuse Large B-Cell Lymphoma	3178	done	
oblimersen	"Treatment of advanced malignant melanoma (Stages II,III, IV)."	oblimersen	OBLIMERSEN	Genasense	7/31/00	Designated			N/A	N/A	"Genta, Inc."	Berkeley Heights	New Jersey	7922	USA	EXACT	0258731AA	oblimersen	85J5ZP6YSL						Nodular melanoma	9961	approximate	
olaparib	Treatment of pancreatic cancer	olaparib	OLAPARIB	n/a	10/11/18	Designated			N/A	N/A	AstraZeneca Pharmaceuticals LP	1800 Concord Pike	Delaware	19803	USA	EXACT	0298464AA	olaparib	WOH1JD9AR8						Pancreatic cancer	9364	done	Not a rare disease
olaparib	Treatment of primary peritoneal cancer	olaparib	OLAPARIB	n/a	5/15/18	Designated			N/A	N/A	AstraZeneca Pharmaceuticals LP	1800 Concord Pike	P. O. Box 8355	19803	USA	EXACT	0298464AA	olaparib	WOH1JD9AR8								MISSING	peritoneal cancer type not specified
oligodendrocyte progenitor cells	Treatment of acute spinal cord injury	oligodendrocyte progenitor cells		n/a	2/2/16	Designated			N/A	N/A	Asterias Biotherapeutics	Fremont	California	94555	USA								PROBLEM	can't find			MISSING	
olinciguat	Treatment of Sickle Cell Disease	olinciguat	OLINCIGUAT	n/a	6/4/18	Designated			N/A	N/A	"Ironwood Pharmaceuticals, Inc."	301 Binney Street		2142	USA	EXACT	1198318AA	olinciguat	PD5F4ZXD21						Sickle cell anemia 	8614	done	Type of sickle cell disease is unspecified
olinciguat	Treatment of Sickle Cell Disease	olinciguat	OLINCIGUAT	n/a	6/4/18	Designated			N/A	N/A	"Ironwood Pharmaceuticals, Inc."	301 Binney Street		2142	USA	EXACT	1198318AA	olinciguat	PD5F4ZXD21						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is unspecified
olinciguat	Treatment of Sickle Cell Disease	olinciguat	OLINCIGUAT	n/a	6/4/18	Designated			N/A	N/A	"Ironwood Pharmaceuticals, Inc."	301 Binney Street		2142	USA	EXACT	1198318AA	olinciguat	PD5F4ZXD21						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is unspecified
olinciguat	Treatment of Sickle Cell Disease	olinciguat	OLINCIGUAT	n/a	6/4/18	Designated			N/A	N/A	"Ironwood Pharmaceuticals, Inc."	301 Binney Street		2142	USA	EXACT	1198318AA	olinciguat	PD5F4ZXD21						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is unspecified
olinciguat	Treatment of Sickle Cell Disease	olinciguat	OLINCIGUAT	n/a	6/4/18	Designated			N/A	N/A	"Ironwood Pharmaceuticals, Inc."	301 Binney Street		2142	USA	EXACT	1198318AA	olinciguat	PD5F4ZXD21						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is unspecified
olinciguat	Treatment of Sickle Cell Disease	olinciguat	OLINCIGUAT	n/a	6/4/18	Designated			N/A	N/A	"Ironwood Pharmaceuticals, Inc."	301 Binney Street		2142	USA	EXACT	1198318AA	olinciguat	PD5F4ZXD21						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is unspecified
omacetaxine mepesuccinate	Treatment of chronic myelogenous leukemia	omacetaxine mepesuccinate	OMACETAXINE MEPESUCCINATE	Synribo	3/10/06	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI)	10/26/12	10/26/19	IVAX International GmbH	Frazer			Switzerland	EXACT	0313439AA	omacetaxine mepesuccinate	6FG8041S5B						Chronic myeloid leukemia	6105	done	
ombitasvir	Treatment of pediatric patients with hepatitis C virus infection (0 through 16 years of age)	ombitasvir/paritaprevir/ritonavir and dasabuvir	OMBITASVIR	Viekira Pak	7/16/15	Designated			N/A	N/A	"Abbvie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0871250AA	ombitasvir	2302768XJ8								MISSING	Not a rare disease
ombitasvir/paritaprevir/ritonavir and dasabuvir	Treatment of pediatric patients with hepatitis C virus infection (0 through 16 years of age)	ombitasvir/paritaprevir/ritonavir and dasabuvir	DASABUVIR	Viekira Pak	7/16/15	Designated			N/A	N/A	"Abbvie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0721448AA	dasabuvir	DE54EQW8T1								MISSING	Not a rare disease
ombrabulin	Treatment of soft tissue sarcoma	"ombrabulin; N-{2-methoxy-5-[(Z)-2-(3,4,5-trimethozyphenyl)vinyl]phenyl}-L-serinamide hydrochloride"	OMBRABULIN	n/a	3/3/11	Designated			N/A	N/A	"Sanofi-Aventis U.S., Inc."	Bridgewater	New Jersey	8807	USA	EXACT	0702794AA	ombrabulin	82JB1524Q6						Soft tissue sarcoma	4898	done	
omeprazole	Treatment of esophageal ulcers	omeprazole-lansoprazole with buffer	OMEPRAZOLE	n/a	2/10/15	Designated			N/A	N/A	"Effexus Pharmaceuticals, LLC"	Leawood	Kansas	66211	USA	EXACT	0128596AA	omeprazole	KG60484QX9								MISSING	Not a rare disease
omeprazole-lansoprazole with buffer	Treatment of esophageal ulcers	omeprazole-lansoprazole with buffer	LANSOPRAZOLE	n/a	2/10/15	Designated			N/A	N/A	"Effexus Pharmaceuticals, LLC"	Leawood	Kansas	66211	USA	EXACT	0163199AA	lansoprazole	0K5C5T2QPG								MISSING	Not a rare disease
ondansetron inhalation powder	Prevention of chemotherapy-induced nausea and vomiting due to highly emetogenic chemotherapy in pediatric patients (0 through 16 years of age) .	ondansetron inhalation powder	ONDANSETRON	n/a	10/14/15	Designated			N/A	N/A	"Luxena Pharmaceuticals, Inc."	Santa Clara	California	95050	USA	EXACT	0185068AA	ondansetron	4AF302ESOS								MISSING	
onl-1204	Treatment of retinal detachment	His-His-Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr	ONL-1204	n/a	3/11/13	Designated			N/A	N/A	"ONL Therapeutics, Inc"	Ann Arbor	Michigan	48109	USA	EXACT	1571740AA	onl-1204	XNA75YDV3F						Knobloch syndrome	380	approximate	
oral testosterone	Treatment of constitutional delay of growth and puberty in adolescent boys 14 to 17 years of age.	oral testosterone	TESTOSTERONE	n/a	6/2/16	Designated			N/A	N/A	"TesoRx Pharma, LLC"	Pomona	California	91768	USA	EXACT	0009734AA	testosterone	3XMK78S47O								MISSING	
oral unfractionated heparin	Treatment of sickle cell disease	oral unfractionated heparin	HEPARIN	n/a	1/29/04	Designated			N/A	N/A	"TRF Technologies, Inc."	Burlingame	California	94010	USA	EXACT	0118230AA	heparin	T2410KM04A						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
oral unfractionated heparin	Treatment of sickle cell disease	oral unfractionated heparin	HEPARIN	n/a	1/29/04	Designated			N/A	N/A	"TRF Technologies, Inc."	Burlingame	California	94010	USA	EXACT	0118230AA	heparin	T2410KM04A						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
oral unfractionated heparin	Treatment of sickle cell disease	oral unfractionated heparin	HEPARIN	n/a	1/29/04	Designated			N/A	N/A	"TRF Technologies, Inc."	Burlingame	California	94010	USA	EXACT	0118230AA	heparin	T2410KM04A						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
oral unfractionated heparin	Treatment of sickle cell disease	oral unfractionated heparin	HEPARIN	n/a	1/29/04	Designated			N/A	N/A	"TRF Technologies, Inc."	Burlingame	California	94010	USA	EXACT	0118230AA	heparin	T2410KM04A						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
oral unfractionated heparin	Treatment of sickle cell disease	oral unfractionated heparin	HEPARIN	n/a	1/29/04	Designated			N/A	N/A	"TRF Technologies, Inc."	Burlingame	California	94010	USA	EXACT	0118230AA	heparin	T2410KM04A						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
oral unfractionated heparin	Treatment of sickle cell disease	oral unfractionated heparin	HEPARIN	n/a	1/29/04	Designated			N/A	N/A	"TRF Technologies, Inc."	Burlingame	California	94010	USA	EXACT	0118230AA	heparin	T2410KM04A						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
osilodrostat	Treatment of Cushing's disease	osilodrostat	OSILODROSTAT	n/a	9/13/13	Designated			N/A	N/A	Novartis Pharmaceuticals corporation	East Hanover	New Jersey	7936	USA	EXACT	0761966AA	osilodrostat	5YL4IQ1078						Cushing's syndrome	6224	done	
osimertinib	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer	osimertinib	OSIMERTINIB	Tagrisso	9/4/14	Designated/Approved	Approved for Orphan Indication	"For treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy"	11/13/15	11/13/22	AstraZeneca Pharmaceuticals LP	Wilmington	Delaware	19803	USA	EXACT	0933415AA	osimertinib	3C06JJ0Z2O						"Non-small cell lung cancer, childhood"	9343	approximate	
otelixizumab	Treatment of new-onset type I diabetes mellitus	otelixizumab	OTELIXIZUMAB	n/a	2/6/06	Designated			N/A	N/A	GlaxoSmithKline	King of Prussia	Pennsylvania	19406	USA	EXACT	0266717AA	otelixizumab	I5HF2X04PB						Diabetes mellitus type 1	10268	done	Not a rare disease
oteracil	Treatment of gastric cancer	Tegafur/gimeracil/oteracil	OTERACIL	n/a	7/20/06	Designated			N/A	N/A	"Taiho Pharma USA, Inc."	Princeton	New Jersey	8540	USA	EXACT	0284015AA	oteracil	5VT6420TIG						Stomach cancer	7704	done	
oxitriptan	Treatment of postanoxic intention myoclonus.	L-5 Hydroxytrytophan	OXITRIPTAN	n/a	11/1/84	Designated			N/A	N/A	"Watson Laboratories, Inc."	Copiaque	New York	11726	USA	EXACT	0009110AA	oxitriptan	C1LJO185Q9						Myoclonus epilepsy	7142	approximate	
ozanimod	Treatment of pediatric (0 through 16 years of age) ulcerative colitis	ozanimod	OZANIMOD	n/a	12/29/15	Designated			N/A	N/A	"Receptos Services, LLC"	San Diego	California	92121	USA	EXACT	1121477AA	ozanimod	Z80293URPV						Pediatric ulcerative colitis	9857	done	not a rare disease
ozanimod	Treatment of pediatric Crohn’s disease	ozanimod	OZANIMOD	n/a	11/1/17	Designated			N/A	N/A	Celgene International II Sarl	4 Rue des Moulins			Switzerland	EXACT	1121477AA	ozanimod	Z80293URPV						Pediatric Crohn's disease	9856	done	
pVGI.1(VEGF2)	Treatment of thromboangiitis obliterans.	pVGI.1(VEGF2)		n/a	11/9/99	Designated/Withdrawn			N/A	N/A	"Corautus Genetics, Inc."	Atlanta	Georgia	30308	USA					pVGI.1(VEGF2)	NA	https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=124599	PROBLEM	absent from GINAS	Buerger disease	5969	done	
paclitaxel	Treatment of hormone-refractory prostate cancer.	docosahexanoic acid-paclitaxel	PACLITAXEL	Taxoprexin	3/5/01	Designated/Withdrawn			N/A	N/A	"Luitpold Pharmaceuticals, Inc."	Shirley	New York	11976	USA	EXACT	0132127AA	paclitaxel	P88XT4IS4D						Familial prostate cancer	4520	approximate	
paclitaxel	Treatment of non-superficial urothelial cancer	paclitaxel	PACLITAXEL	Tocosol	12/22/04	Designated/Withdrawn			N/A	N/A	"Sonus Pharmaceuticals, Inc."	Bothell	Washington	98021	USA	EXACT	0132127AA	paclitaxel	P88XT4IS4D						Transitional cell carcinoma	7794	approximate	
paclitaxel	Treatment of pancreatic cancer	paclitaxel	PACLITAXEL	n/a	5/1/09	Designated			N/A	N/A	"SynCore Biotechnology Co., Ltd."				Taiwan	EXACT	0132127AA	paclitaxel	P88XT4IS4D						Pancreatic cancer	9364	done	Not a rare disease
paclitaxel aqueous gel	Treatment of brain cancer.	paclitaxel aqueous gel	PACLITAXEL	Oncogel (Tm)	12/23/08	Designated			N/A	N/A	BTG International Inc.	Brentwood	Tennessee	37027	USA	EXACT	0132127AA	paclitaxel	P88XT4IS4D						Anaplastic oligoastrocytoma	10637	approximate	brain cancer not specified
paclitaxel nanoparticles	Treatment of pancreatic cancer	paclitaxel nanoparticles	PACLITAXEL	n/a	1/2/13	Designated			N/A	N/A	"CIRJ Co., Ltd."	Pasadena	California	91104	USA	EXACT	0132127AA	paclitaxel	P88XT4IS4D						Pancreatic cancer	9364	done	Not a rare disease
paclitaxel protein-bound particles	Treatment of pancreatic cancer.	paclitaxel protein-bound particles	PACLITAXEL	Abraxane	9/3/09	Designated/Approved	Approved for Orphan Indication	"Treatment of metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine."	9/6/13	9/6/20	"Abraxis BioScience, LLC"	Overland Park	Kansas	66210	USA	EXACT	0132127AA	paclitaxel	P88XT4IS4D						Pancreatic cancer	9364	done	Not a rare disease
"paclitaxel, micellar"	Treatment of ovarian cancer	"paclitaxel, micellar"	PACLITAXEL	Paclical	4/3/09	Designated			N/A	N/A	Oasmia Pharmaceutical AB				Sweden	EXACT	0132127AA	paclitaxel	P88XT4IS4D						Ovarian cancer	7295	done	
paclitaxel-coated buttress	For use as local administration at the time of curative surgery in the treatment of stage 0 to III non-small cell lung cancer.	paclitaxel-coated buttress	PACLITAXEL	n/a	7/15/14	Designated			N/A	N/A	"AcuityBio, Inc."	Newton	Massachusetts	2460	USA	EXACT	0132127AA	paclitaxel	P88XT4IS4D						"Non-small cell lung cancer, childhood"	9343	done	
pacritinib	"Treatment of primary myelofibrosis (MF), post-polycythemia vera MF, and post-essential thrombocythemia MF"	pacritinib	PACRITINIB	n/a	3/13/08	Designated			N/A	N/A	CTI BioPharma Corporation	Seattle	Washington	98121	USA	EXACT	0568956AA	pacritinib	G22N65IL3O						Myelofibrosis	8618	done	
pafuramidine maleate	Treatment of pneumocystis jiroveci pneumonia	pafuramidine maleate	PAFURAMIDINE MALEATE	n/a	11/17/06	Designated			N/A	N/A	"Immtech Pharmaceuticals, Inc."	Vernon Hills	Illinois	60061	USA	EXACT	0251650AA	pafuramidine maleate	K27F04K3A9						Pneumocystosis	4386	approximate	
pagibaximab	Prophylaxis of Staphylococcus epidermidis sepsis in low birth weight (1500 grams or less) infants.	"Chimeric, humanized monoclonal antibody to staphylococcus"	PAGIBAXIMAB	n/a	8/3/00	Designated			N/A	N/A	"Biosynexus, Inc."	Rockville	Maryland	20877	USA	EXACT	0298884AA	pagibaximab					PROBLEM	can't find			MISSING	Not a rare disease
palifermin	Reducing the incidence and severity of radiation-induced xerostomia.	Recombinant human keratinocyte growth factor	PALIFERMIN	n/a	12/20/99	Designated			N/A	N/A	Swedish Orphan Biovitrum AB (publ) (SOBI)	Stockholm			Sweden	EXACT	0252119AA	palifermin	QMS40680K6								MISSING	"prevention of drug-induced side-effects; Xerostomia is not a disease, but it may be a symptom of various medical conditions"
panobinostat	Treatment of Hodgkin's lymphoma	panobinostat	PANOBINOSTAT	Faridak	9/18/09	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0456257AA	panobinostat	9647FM7Y3Z						Hodgkin lymphoma	2714	done	
papaverine	Treatment of mesenteric ischemia	papaverine	PAPAVERINE	n/a	8/3/17	Designated			N/A	N/A	"Nir Barak, MD"	Tenafly	New Jersey	7670	USA	EXACT	0009916AA	papaverine	DAA13NKG2Q								MISSING	Not a rare disease
paquinimod	Treatment of systemic sclerosis	paquinimod	PAQUINIMOD	n/a	1/17/14	Designated			N/A	N/A	Active Biotech AB	LUND			Sweden	EXACT	0337280AA	paquinimod	HB76GLG27V						Systemic scleroderma	9748	done	
paricalcitol	Treatment of pediatric hyperparathyroidism	paricalcitol	PARICALCITOL	Zemplar	10/27/15	Designated/Approved	Approved for Orphan Indication	Indicated in pediatric patients 10 years and older for the prevention and treatment of secondary hyperparathyroidism associated with Chronic kidney disease (CKD) Stages 3 and 4 and CKD Stage 5 in patients on hemodialysis or peritoneal dialysis	10/18/16	TBD	"Abbvie, inc."	North Chicago	Illinois	60064	USA	EXACT	0192029AA	paricalcitol	6702D36OG5								MISSING	
paritaprevir	Treatment of pediatric patients with hepatitis C virus infection (0 through 16 years of age)	ombitasvir/paritaprevir/ritonavir and dasabuvir	PARITAPREVIR	Viekira Pak	7/16/15	Designated			N/A	N/A	"Abbvie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0343259AA	paritaprevir	OU2YM37K86								MISSING	Not a rare disease
pasireotide	Treatment of Cushing's disease	pasireotide	PASIREOTIDE	Signifor	7/24/09	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative	12/14/12	12/14/19	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0269534AA	pasireotide	98H1T17066						Cushing's syndrome	6224	done	
patupilone	Treatment of primary pertitoneal cancer.	patupilone	PATUPILONE	n/a	2/2/10	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0232393AA	patupilone	UEC0H0URSE								MISSING	peritoneal cancer type not specified
pb-1046	"Treatment of pulmonary arterial hypertension, WHO Group 1"	vasoactive intestinal peptide (VIP)-elastin-like peptide (ELP) fusion protein	PB-1046	n/a	5/13/14	Designated			N/A	N/A	"PhaseBio Pharmaceuticals, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	1267045AA	pb-1046	200AW54D93						Autoimmune pulmonary alveolar proteinosis	7499	done	
pegargiminase	Treatment of mesothelioma.	pegargiminase	PEGARGIMINASE	n/a	7/21/14	Designated			N/A	N/A	Polaris Group	San Diego	California	92121	USA	EXACT	0935046AA	pegargiminase	0B7PYQ9YRT						Malignant mesothelioma	7026	done	
pegloticase	To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.	pegloticase	PEGLOTICASE	Krystexxa	2/21/01	Designated/Approved	Approved for Orphan Indication	Treatment of chronic gout in adult patients refractory to conventional treatment	9/14/10	9/14/17	"Horizon Pharma Rheumatology, LLC"	Lake Forest	Illinois	60045	USA	EXACT	0432699AA	pegloticase	R581OT55EA								MISSING	secondary condition
pegvorhyaluronidase alfa	Treatment of pancreatic cancer	PEGylated recombinant human hyaluronidase PH20	PEGVORHYALURONIDASE ALFA	n/a	10/1/14	Designated			N/A	N/A	"Halozyme Therapeutics, Inc."	San Diego	California	92121	USA	EXACT	1336352AA	pegvorhyaluronidase alfa	P01I4980ZS						Pancreatic cancer	9364	done	Not a rare disease
pegylated carboxyhemoglobin	Treatment of acute painful sickling crises in patients with sickle cell disease	pegylated carboxyhemoglobin		n/a	10/21/10	Designated			N/A	N/A	"Sangart, Inc."	San Diego	California	92121	USA					SANGUINATE	NA	https://www.ncbi.nlm.nih.gov/pubmed/28397407	approximate		Sickle cell anemia	8614	done	
pegylated carboxyhemoglobin bovine	Treatment of the comorbidities associated with Sickle Cell Disease	pegylated carboxyhemoglobin bovine		Sanguinate	1/15/15	Designated			N/A	N/A	"Prolong Pharmaceuticals, LLC"	South Plainfield	New Jersey	7080	USA								PROBLEM	can't find	Hemoglobinopathy	12455	approximate	
pegylated granulocyte colony stimulating factor	Treatment of patients at risk of developing myelosuppression following a radiological or nuclear incident	pegylated granulocyte colony stimulating factor		n/a	4/30/14	Designated			N/A	N/A	PharmaEssentia				Taiwan				3A58010674	PEGFILGRASTIM	3A58010674	https://ginas.ncats.nih.gov/ginas/app/substance/cefb41f5	done				MISSING	not a disease
pelareorep	Treatment of gastric cancer	pelareorep	PELAREOREP	Reolysin	5/4/15	Designated			N/A	N/A	"Oncolytics Biotech, Inc."				Canada	EXACT	0809154AA	pelareorep	S9J80L3D1U						Stomach cancer	7704	done	
pelareorep	Treatment of pancreatic cancer	pelareorep	PELAREOREP	Reolysin(R)	2/11/15	Designated			N/A	N/A	"Oncolytics Biotech, Inc."				Canada	EXACT	0809154AA	pelareorep	S9J80L3D1U						Pancreatic cancer	9364	done	Not a rare disease
pelareorep	Treatment of primary peritoneal cancer	pelareorep	PELAREOREP	Reolysin(R)	2/24/15	Designated			N/A	N/A	"Oncolytics Biotech, Inc."				Canada	EXACT	0809154AA	pelareorep	S9J80L3D1U								MISSING	peritoneal cancer type not specified
pembrolizumab	"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma"	pembrolizumab	PEMBROLIZUMAB	Keytruda	6/16/15	Designated			N/A	N/A	"Merck, Sharp & Dohme"	Whitehouse Station	New Jersey	8889	USA	EXACT	0809245AA	pembrolizumab	DPT0O3T46P						Stomach cancer	7704	done	
pembrolizumab	Treatment of primary mediastinal B cell lymphoma.	pembrolizumab	PEMBROLIZUMAB	Ketruda	1/14/16	Designated			N/A	N/A	"Merck, Sharp & Dohme Corp."	Whitehouse Station	New Jersey	8889	USA	EXACT	0809245AA	pembrolizumab	DPT0O3T46P						B-cell lymphoma	5877	approximate	
pemetrexed disodium	Treatment of malignant pleural mesothelioma	pemetrexed disodium	PEMETREXED DISODIUM	Alimta	8/28/01	Designated/Approved	Approved for Orphan Indication	Treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery	2/4/04	2/4/11	Eli Lilly and Company	Indianapolis	Indiana	46285	USA	EXACT	0180916AA	pemetrexed disodium	2PKU919BA9						Malignant mesothelioma	7026	approximate	
pentamidine	Treatment of pancreatic cancer.	pentamidine	PENTAMIDINE	n/a	9/13/10	Designated/Withdrawn			N/A	N/A	"Oncozyme Pharma, Inc."				Canada	EXACT	0016637AA	pentamidine	673LC5J4LQ						Pancreatic cancer	9364	done	Not a rare disease
pentetate trisodium	"Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium."	pentetate trisodium	PENTETATE TRISODIUM	Diethylenetriaminepentaacetate	4/12/04	Designated			N/A	N/A	Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co. KG				Germany	EXACT	1801963AA	pentetate trisodium	79FZD535SC								MISSING	not a disease
pentosan polysulfate sodium	Treatment of sickle cell disease.	pentosan polysulfate sodium	PENTOSAN POLYSULFATE SODIUM	n/a	11/21/08	Designated			N/A	N/A	"TRF Pharma, Inc."	Burlingame	California	94010	USA	EXACT	0033545AA	pentosan polysulfate sodium	914032762Y						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
pentosan polysulfate sodium	Treatment of sickle cell disease.	pentosan polysulfate sodium	PENTOSAN POLYSULFATE SODIUM	n/a	11/21/08	Designated			N/A	N/A	"TRF Pharma, Inc."	Burlingame	California	94010	USA	EXACT	0033545AA	pentosan polysulfate sodium	914032762Y						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
pentosan polysulfate sodium	Treatment of sickle cell disease.	pentosan polysulfate sodium	PENTOSAN POLYSULFATE SODIUM	n/a	11/21/08	Designated			N/A	N/A	"TRF Pharma, Inc."	Burlingame	California	94010	USA	EXACT	0033545AA	pentosan polysulfate sodium	914032762Y						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
pentosan polysulfate sodium	Treatment of sickle cell disease.	pentosan polysulfate sodium	PENTOSAN POLYSULFATE SODIUM	n/a	11/21/08	Designated			N/A	N/A	"TRF Pharma, Inc."	Burlingame	California	94010	USA	EXACT	0033545AA	pentosan polysulfate sodium	914032762Y						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
pentosan polysulfate sodium	Treatment of sickle cell disease.	pentosan polysulfate sodium	PENTOSAN POLYSULFATE SODIUM	n/a	11/21/08	Designated			N/A	N/A	"TRF Pharma, Inc."	Burlingame	California	94010	USA	EXACT	0033545AA	pentosan polysulfate sodium	914032762Y						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
pentosan polysulfate sodium	Treatment of sickle cell disease.	pentosan polysulfate sodium	PENTOSAN POLYSULFATE SODIUM	n/a	11/21/08	Designated			N/A	N/A	"TRF Pharma, Inc."	Burlingame	California	94010	USA	EXACT	0033545AA	pentosan polysulfate sodium	914032762Y						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
pentosan polysulfate sodium	Treatment of sickle cell disease.	pentosan polysulfate sodium	PENTOSAN POLYSULFATE SODIUM	n/a	9/16/11	Designated			N/A	N/A	"Vanguard Therapeutics, Inc."	Half Moon Bay	California	94019	USA	EXACT	0033545AA	pentosan polysulfate sodium	914032762Y						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
pentosan polysulfate sodium	Treatment of sickle cell disease.	pentosan polysulfate sodium	PENTOSAN POLYSULFATE SODIUM	n/a	9/16/11	Designated			N/A	N/A	"Vanguard Therapeutics, Inc."	Half Moon Bay	California	94019	USA	EXACT	0033545AA	pentosan polysulfate sodium	914032762Y						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
pentosan polysulfate sodium	Treatment of sickle cell disease.	pentosan polysulfate sodium	PENTOSAN POLYSULFATE SODIUM	n/a	9/16/11	Designated			N/A	N/A	"Vanguard Therapeutics, Inc."	Half Moon Bay	California	94019	USA	EXACT	0033545AA	pentosan polysulfate sodium	914032762Y						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
pentosan polysulfate sodium	Treatment of sickle cell disease.	pentosan polysulfate sodium	PENTOSAN POLYSULFATE SODIUM	n/a	9/16/11	Designated			N/A	N/A	"Vanguard Therapeutics, Inc."	Half Moon Bay	California	94019	USA	EXACT	0033545AA	pentosan polysulfate sodium	914032762Y						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
pentosan polysulfate sodium	Treatment of sickle cell disease.	pentosan polysulfate sodium	PENTOSAN POLYSULFATE SODIUM	n/a	9/16/11	Designated			N/A	N/A	"Vanguard Therapeutics, Inc."	Half Moon Bay	California	94019	USA	EXACT	0033545AA	pentosan polysulfate sodium	914032762Y						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
pentosan polysulfate sodium	Treatment of sickle cell disease.	pentosan polysulfate sodium	PENTOSAN POLYSULFATE SODIUM	n/a	9/16/11	Designated			N/A	N/A	"Vanguard Therapeutics, Inc."	Half Moon Bay	California	94019	USA	EXACT	0033545AA	pentosan polysulfate sodium	914032762Y						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
pentoxifylline	Treatment of Behcet's disease	pentoxifylline	PENTOXIFYLLINE	n/a	6/14/12	Designated			N/A	N/A	Keck Graduate Institute of Applied Life Sciences	Claremont	California	91711	USA	EXACT	0046582AA	pentoxifylline	SD6QCT3TSU						Behçet disease	848	done	
peptide-based vaccine targeting telomerase reverse transcriptase	Treatment of telomerase reverse transcriptase (TERT) positive non-small cell lung cancer in HLA-A*0201 positive patients	peptide-based vaccine targeting telomerase reverse transcriptase		n/a	2/20/09	Designated			N/A	N/A	VAXON-Biotech				France								PROBLEM	can't find	"Non-small cell lung cancer, childhood"	9343	approximate	
peptide-conjugated phosporodiamidate morpholino oligomer (PPMO)	"Treatment of Duchenne muscular dystrophy in patients with a deletion, duplication or frame shift mutation correctable by skipping of exon 50 of the dystrophin gene to allow restoration of the reading frame (including mutations within exons 51, 51-53, or 51-55)."	peptide-conjugated phosporodiamidate morpholino oligomer (PPMO)	MORPHOLINO SUGAR FRAGMENT	n/a	9/3/09	Designated			N/A	N/A	"Sarepta Therapeutics, Inc."	Cambridge	Massachusetts	2142	USA	LONGEST CONTAINS	1797166AA	morpholino					PROBLEM	can't find	Duchenne muscular dystrophy	6291	done	
perhexiline maleate	Treatment of moderate to severe symptomatic hypertrophic cardiomyopathy	perhexiline maleate	PERHEXILINE MALEATE	n/a	6/14/12	Designated			N/A	N/A	"Heart Metabolics, Limited."				Ireland	EXACT	0046811AA	perhexiline maleate	K7V8Y90G0H						Familial hypertrophic cardiomyopathy	7229	approximate	
pertuzumab	"Treatment of gastric cancer, including gastroesophageal junction cancer"	pertuzumab	PERTUZUMAB	n/a	7/12/13	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0297938AA	pertuzumab	K16AIQ8CTM						Stomach cancer	7704	done	
phenobarbital	Treatment of neonatal seizures	phenobarbital	PHENOBARBITAL	n/a	10/25/17	Designated			N/A	N/A	"Renaissance SSA, LLC"	Newtown	Pennsylvania	18940	USA	EXACT	0007227AA	phenobarbital	YQE403BP4D						Seizures benign familial neonatal recessive form	4789	approximate	
phenobarbitol sodium injection	Treatment of hypoxic-ischemic encephalopathy to prevent siezures in neonates	phenobarbitol sodium injection	SODIUM	n/a	10/23/13	Designated			N/A	N/A	"Fera Pharmaceuticals, LLC"	Locust Valley	New York	11560	USA	EXACT	0048113AA	sodium	9NEZ333N27								MISSING	
phenylacetate	"For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency."	Benzoate and phenylacetate	PHENYL ACETATE	Ucephan	1/21/86	Designated/Approved	Approved for Orphan Indication		12/23/87	12/23/94	ImmunexImmunex	Irvine	California	92623	USA	EXACT	0019512AA	phenylacetate	355G9R500Y						Carbamoyl phosphate synthetase 1 deficiency 	7269	done	
phenylacetate	"For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency."	Benzoate and phenylacetate	PHENYL ACETATE	Ucephan	1/21/86	Designated/Approved	Approved for Orphan Indication		12/23/87	12/23/94	ImmunexImmunex	Irvine	California	92623	USA	EXACT	0019512AA	phenylacetate	355G9R500Y						 Ornithine transcarbamylase deficiency 	8391	done	
phenylacetate	"For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency."	Benzoate and phenylacetate	PHENYL ACETATE	Ucephan	1/21/86	Designated/Approved	Approved for Orphan Indication		12/23/87	12/23/94	ImmunexImmunex	Irvine	California	92623	USA	EXACT	0019512AA	phenylacetate	355G9R500Y						 Citrullinemia type I	6114	done	
phenylacetic acid	Treatment of gliomas	"antineoplaston A10, antineoplaston AS2-1"	PHENYLACETIC ACID	n/a	11/21/08	Designated			N/A	N/A	"Burzynski Research Institute, Inc."	Houston	Texas	77055	USA	EXACT	0017027AA	phenylacetic acid	ER5I1W795A						Glioma	6513	done	
phenylephrine	Treatment of ileal pouch anal anastomosis related fecal incontinence	phenylephrine	PHENYLEPHRINE	n/a	2/14/02	Designated			N/A	N/A	S.L.A. Pharma				United Kingdom	EXACT	0010139AA	phenylephrine	1WS297W6MV								MISSING	
phosphorothioate antisense olignucleotide against EWS-Fli-1	Treatment of Ewing's sarcoma	phosphorothioate antisense olignucleotide against EWS-Fli-1		n/a	9/22/08	Designated			N/A	N/A	The Cure Our Children Foundation	Pacific Palisades	California	90272	USA								PROBLEM	can't find	Ewing's family of tumors	9323	approximate	
phoxilium	For use as a replacement solution in patients undergoing continuous renal replacement therapy	phoxilium		n/a	2/14/14	Designated/Approved	Approved for Orphan Indication	As a replacement solution in Continuous Renal Replacement Therapy (CRRT) and in case of drug poisoning when CRRT is used to remove dialzable substances	1/13/15	1/13/22	"Gambro Renal Products, Inc."	Daytona Beach	Florida	32117	USA				M4I0D6VV5M|02F3473H9O|451W47IQ8X|660YQ98I10|8MDF5V39QO|IY9XDZ35W2|3B8D35Y7S4|GR686LBA74	"CALCIUM CHLORIDE|MAGNESIUM CHLORIDE|SODIUM CHLORIDE|POTASSIUM CHLORIDE|SODIUM BICARBONATE|DEXTROSE, UNSPECIFIED FORM|LACTIC ACID, DL-|SODIUM PHOSPHATE, DIBASIC, UNSPECIFIED FORM"	M4I0D6VV5M|02F3473H9O|451W47IQ8X|660YQ98I10|8MDF5V39QO|IY9XDZ35W2|3B8D35Y7S4|GR686LBA74	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021703s016-207026s001lbl.pdf	done				MISSING	not a disease
physostigmine salicylate	Treatment of Friedreich's and other inherited ataxias.	physostigmine salicylatephysostigmine salicylate	PHYSOSTIGMINE SALICYLATE	n/a	1/16/85	Designated/Withdrawn			N/A	N/A	Forest Pharmaceuticals.3-.3-.30 6	New York	New York	10155	USA	EXACT	0009518AA	physostigmine salicylate	2046ZRO9VU						Friedreich ataxia	6468	done	
piperaquine	"Treatment of uncomplicated malaria caused by ""Plasmodium falciparum,"" Plasmodium vivax,"" Plasmodium malariae,"" or ""Plasmodium ovale."""	dihydroartemisinin and piperaquine	PIPERAQUINE	Eurartesim	1/8/07	Designated			N/A	N/A	"Sigma-Tau Pharmaceuticals, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0337122AA	piperaquine	A0HV2Q956Y						Malaria	6961	done	
plasmin (human)	Treatment of acute peripheral arterial occlusion	plasmin (human)	FIBRINOLYSIN HUMAN	n/a	3/30/09	Designated			N/A	N/A	"Grifols Therapeutics, Inc."	Clayton	North Carolina	27520	USA	EXACT	0005050AA	plasmin (human)	D60E3WIF5Y								MISSING	
plasminogen (Human)	Treatment of idiopathic pulmonary fibrosis (IPF)	plasminogen (Human)	PLASMINOGEN	Ryplazim™ Plasminogen (Human)	12/14/17	Designated			N/A	N/A	"ProMetic BioTherapeutics, Inc"	1330 Piccard Drive	Rockville	20850	USA	LONGEST CONTAINS	0005061AA	plasminogen	1RXS4UE564 | U5NH2JV64T | T36L245S3T	AMEDIPLASE | SARUPLASE | DESMOTEPLASE	1RXS4UE564 | U5NH2JV64T | T36L245S3T	https://ginas.ncats.nih.gov/ginas/app/substances?q=PLASMINOGEN	done		Idiopathic pulmonary fibrosis	8609	done	
plasminogen (human)	"Treatment of hypoplasminogenemia, or type I plasminogen deficiency"	plasminogen (human)	PLASMINOGEN	n/a	3/5/13	Designated			N/A	N/A	"ProMetic BioTherapeutics, Inc"	Rockville	Maryland	20850	USA	EXACT	0005061AA	plasminogen	1RXS4UE564 | U5NH2JV64T | T36L245S3T	AMEDIPLASE | SARUPLASE | DESMOTEPLASE	1RXS4UE564 | U5NH2JV64T | T36L245S3T	https://ginas.ncats.nih.gov/ginas/app/substances?q=PLASMINOGEN	done		Type 1 plasminogen deficiency	4380	done	
pleconaril	Treatment of symptomatic enteroviral infection in the neonate	pleconaril	PLECONARIL	n/a	12/22/14	Designated			N/A	N/A	"AntiVirus Therapeutics, Inc."	Princeton	New Jersey	8550	USA	EXACT	0183368AA	pleconaril	9H4570Q89D								MISSING	
plerixafor	For use to improve the yield of progentor cells in the apheresis product for subsequest stem cell transplantation following myelosuppressive or myeloablative chemotherapy	plerixafor	PLERIXAFOR	Mozobil (R)	7/10/03	Designated/Approved	Approved for Orphan Indication	To enhance mobilization of hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma	12/15/08	12/15/15	Genzyme Corporation	Cambridge	Massachusetts	2142	USA	EXACT	0236373AA	plerixafor	S915P5499N								MISSING	"not a disease, a procedure"
polidocanol	Treatment of congenital venous malformations	polidocanol	POLIDOCANOL	n/a	2/19/15	Designated			N/A	N/A	Provensis Ltd				United Kingdom	EXACT	0005469AA	polidocanol	0AWH8BFG9A						CLOVES syndrome	10939	done	
poloxamer 188	Treatment of Acute Limb Ischemia	poloxamer 188	POLOXAMER 188	n/a	11/8/13	Designated			N/A	N/A	Mast Therapeutics Inc.	San Diego	California	92130	USA	EXACT	0006826AA	poloxamer 188	LQA7B6G8JG								MISSING	Not a rare disease
poloxamer-188	Treatment of sickle cell disease (this includes the treatment and prevention of complications of sickle cell disease)	poloxamer 188 (purified)	POLOXAMER 188	n/a	6/27/89	Designated			N/A	N/A	Mast Therapeutics Inc.	San Diego	California	92130	USA	EXACT	0006826AA	poloxamer 188	LQA7B6G8JG						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
poloxamer-188	Treatment of sickle cell disease (this includes the treatment and prevention of complications of sickle cell disease)	poloxamer 188 (purified)	POLOXAMER 188	n/a	6/27/89	Designated			N/A	N/A	Mast Therapeutics Inc.	San Diego	California	92130	USA	EXACT	0006826AA	poloxamer 188	LQA7B6G8JG						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
poloxamer-188	Treatment of sickle cell disease (this includes the treatment and prevention of complications of sickle cell disease)	poloxamer 188 (purified)	POLOXAMER 188	n/a	6/27/89	Designated			N/A	N/A	Mast Therapeutics Inc.	San Diego	California	92130	USA	EXACT	0006826AA	poloxamer 188	LQA7B6G8JG						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
poloxamer-188	Treatment of sickle cell disease (this includes the treatment and prevention of complications of sickle cell disease)	poloxamer 188 (purified)	POLOXAMER 188	n/a	6/27/89	Designated			N/A	N/A	Mast Therapeutics Inc.	San Diego	California	92130	USA	EXACT	0006826AA	poloxamer 188	LQA7B6G8JG						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
poloxamer-188	Treatment of sickle cell disease (this includes the treatment and prevention of complications of sickle cell disease)	poloxamer 188 (purified)	POLOXAMER 188	n/a	6/27/89	Designated			N/A	N/A	Mast Therapeutics Inc.	San Diego	California	92130	USA	EXACT	0006826AA	poloxamer 188	LQA7B6G8JG						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
poloxamer-188	Treatment of sickle cell disease (this includes the treatment and prevention of complications of sickle cell disease)	poloxamer 188 (purified)	POLOXAMER 188	n/a	6/27/89	Designated			N/A	N/A	Mast Therapeutics Inc.	San Diego	California	92130	USA	EXACT	0006826AA	poloxamer 188	LQA7B6G8JG						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
"poly (acetyl, arginyl) glucosamine"	Treatment of cystic fibrosis.	"poly (acetyl, arginyl) glucosamine"	GLUCOSAMINE	n/a	10/2/18	Designated			N/A	N/A	"Synedgen, Inc."	1420 North Claremont Boulevard	California	91711	USA	LONGEST CONTAINS	0040700AA	glucosamine	N08U5BOQ1K						Cystic fibrosis	6233	done	
poly(lactide-co-glycolide) carboxylated microparticle	Treatment of acute encephalitis syndrome	poly(lactide-co-glycolide) carboxylated microparticle	GLYCOLIDE	n/a	10/25/13	Designated			N/A	N/A	"Cour Pharmaceutical Development Company, Inc."	Elmhurst	Illinois	60126	USA	LONGEST CONTAINS	0528223AA	glycolide	YRZ676PGU6						Febrile infection-related epilepsy syndrome	11005	done	
pomalidomide	Treatment of Kaposi sarcoma	pomalidomide	POMALIDOMIDE	Pomalyst®	4/4/18	Designated			N/A	N/A	Celgene Corporation	86 Morris Ave.		7901	USA	EXACT	0244122AA	pomalidomide	D2UX06XLB5						Kaposi sarcoma	6814	done	
pomalidomide	Treatment of systemic sclerosis	pomalidomide	POMALIDOMIDE	n/a	8/22/13	Designated/Withdrawn			N/A	N/A	Celgene Corporation	Summit	New Jersey	7901	USA	EXACT	0244122AA	pomalidomide	D2UX06XLB5						Systemic scleroderma	9748	done	
porcine GM1 ganglioside	Treatment of acute spinal cord injury	porcine GM1 ganglioside		n/a	12/3/12	Designated			N/A	N/A	TRB Chemedica International S.A.	Geneva 12			Switzerland				562413257Z	GANGLIOSIDE GM1	562413257Z	https://ginas.ncats.nih.gov/ginas/app/substance/01d4e7df	done				MISSING	
porfimer	For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy	porfimer	PORFIMER	Photofrin	10/19/01	Designated/Approved	Approved for Orphan Indication	For the ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy	8/1/03	8/1/10	Axcan Scandipharm Inc.	Birmingham	Alabama	35242	USA	EXACT	0323331AA	porfimer	M15H03K69B						Barrett esophagus	20	done	Not a rare disease
potassium chloride	For use in cleansing of the colon in preparation for colonoscopy in children and adolescents	"sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride"	POTASSIUM CHLORIDE	Suclear	9/4/13	Designated			N/A	N/A	"Braintree Laboratories, Inc."	Braintree	Massachusetts	2185	USA	EXACT	0048395AA	potassium chloride	660YQ98I10								MISSING	"not a disease, a procedure"
potassium sodium aluminosilicate	For treatment of poisoning by or exposure to cesium.	potassium sodium aluminosilicate	SODIUM ALUMINOSILICATE	n/a	1/8/07	Designated			N/A	N/A	"Castle Creek Pharmaceuticals, LLC"	Northbrook	Illinois	60062	USA	LONGEST CONTAINS	0035405AA	sodium aluminosilicate	058TS43PSM								MISSING	not a disease
potassium sulfate	For use in cleansing of the colon in preparation for colonoscopy in children and adolescents	"sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride"	POTASSIUM SULFATE	Suclear	9/4/13	Designated			N/A	N/A	"Braintree Laboratories, Inc."	Braintree	Massachusetts	2185	USA	EXACT	0051194AA	potassium sulfate	1K573LC5TV								MISSING	"not a disease, a procedure"
povidone iodine	Treatment of endophthalmitis	povidone iodine	POVIDONE-IODINE	n/a	11/27/17	Designated			N/A	N/A	Veloce BioPharma LLC	7008 Lafayette Avenue	Fort Washington	19034	USA	EXACT	0006359AA	povidone iodine	85H0HZU99M								MISSING	"Endophthalmitis is an inflammatory condition of the intraocular cavities, usually caused by infection. Noninfectious (sterile) endophthalmitis may result from various causes such as retained native lens material after an operation or from toxic agents."
pracinostat	Treatment of acute myeloid leulemia	pracinostat	PRACINOSTAT	n/a	2/27/14	Designated			N/A	N/A	MEI Pharma Inc.	San Diego	California	92130	USA	EXACT	0383426AA	pracinostat	GPO2JN4UON						Acute myeloid leukemia	12757	done	
pralatrexate	Treatment of T-cell lymphoma	pralatrexate	PRALATREXATE	Folotyn	7/20/06	Designated/Approved	Approved for Orphan Indication	Treatment of patients with relapsed or refractory peripheral T-cell lymphoma	9/25/09	9/25/16	"Allos Therapeutics, Inc."	Westminister	Colorado	80020	USA	EXACT	0219034AA	pralatrexate	A8Q8I19Q20						Adult T-cell leukemia/lymphoma	13103	approximate	T-cell lymphoma not specified
pramipexole	Treatment of Tourette's syndrome in pediatric patients	pramipexole	PRAMIPEXOLE	Mirapex	1/31/08	Designated			N/A	N/A	"Boehringer-Ingelheim Pharmaceuticals, Inc."	Ridgefield	Connecticut	6877	USA	EXACT	0271943AA	pramipexole	83619PEU5T						Tourette syndrome	7783	done	
prasugrel hydrochloride	Treatment of sickle cell disease	prasugrel hydrochloride	PRASUGREL HYDROCHLORIDE	Effient	5/26/15	Designated			N/A	N/A	Eli Lilly	Indianapolis	Indiana	46285	USA	EXACT	0308327AA	prasugrel hydrochloride	G89JQ59I13						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
prasugrel hydrochloride	Treatment of sickle cell disease	prasugrel hydrochloride	PRASUGREL HYDROCHLORIDE	Effient	5/26/15	Designated			N/A	N/A	Eli Lilly	Indianapolis	Indiana	46285	USA	EXACT	0308327AA	prasugrel hydrochloride	G89JQ59I13						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
prasugrel hydrochloride	Treatment of sickle cell disease	prasugrel hydrochloride	PRASUGREL HYDROCHLORIDE	Effient	5/26/15	Designated			N/A	N/A	Eli Lilly	Indianapolis	Indiana	46285	USA	EXACT	0308327AA	prasugrel hydrochloride	G89JQ59I13						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
prasugrel hydrochloride	Treatment of sickle cell disease	prasugrel hydrochloride	PRASUGREL HYDROCHLORIDE	Effient	5/26/15	Designated			N/A	N/A	Eli Lilly	Indianapolis	Indiana	46285	USA	EXACT	0308327AA	prasugrel hydrochloride	G89JQ59I13						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
prasugrel hydrochloride	Treatment of sickle cell disease	prasugrel hydrochloride	PRASUGREL HYDROCHLORIDE	Effient	5/26/15	Designated			N/A	N/A	Eli Lilly	Indianapolis	Indiana	46285	USA	EXACT	0308327AA	prasugrel hydrochloride	G89JQ59I13						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
prasugrel hydrochloride	Treatment of sickle cell disease	prasugrel hydrochloride	PRASUGREL HYDROCHLORIDE	Effient	5/26/15	Designated			N/A	N/A	Eli Lilly	Indianapolis	Indiana	46285	USA	EXACT	0308327AA	prasugrel hydrochloride	G89JQ59I13						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
pritumumab	Treatment of pancreatic cancer.	pritumumab	PRITUMUMAB	n/a	4/6/16	Designated			N/A	N/A	"Nascent Biotech, Inc."	San Diego	California	92126	USA	EXACT	1079727AA	pritumumab	Z6Q90D1G53						Pancreatic cancer	9364	done	Not a rare disease
progesterone	Establishment and maintenance of pregnancy in women undergoing in vitro fertilization or embryo transfer procedures.	progesterone	PROGESTERONE	n/a	12/22/94	Designated			N/A	N/A	"Watson Laboratories, Inc."	Corona	California	91720	USA	EXACT	0009574AA	progesterone	4G7DS2Q64Y								MISSING	Not a rare disease
progesterone	For early intervention in the treatment of moderate to severe closed-head traumatic brain injury	progesterone	PROGESTERONE	n/a	9/3/09	Designated/Withdrawn			N/A	N/A	"BHR Pharma, LLC"	Herndon	Virginia	20170	USA	EXACT	0009574AA	progesterone	4G7DS2Q64Y								MISSING	
propofol hemisuccinate	Treatment of acute repetitive seizures	propofol hemisuccinate	PROPOFOL HEMISUCCINATE	n/a	8/19/16	Designated			N/A	N/A	EpaleX Corporation	Palo Alto	California	94301	USA	EXACT	1576756AA	propofol hemisuccinate	OIC0UYZ1W6						Status epilepticus	10191	approximate	
propranolol	Treatment of proliferating infantile hemangiomas requiring systemic therapy	propranolol	PROPRANOLOL	Hemangeol	9/5/08	Designated/Approved	Approved for Orphan Indication	Treatment of proliferating infantile hemangioma requiring systemic therapy.	3/14/14	3/14/21	Pierre Fabre Dermatologie	Parsippany	New Jersey	7054	USA	EXACT	0027587AA	propranolol	9Y8NXQ24VQ								MISSING	
propranolol and etodolac	Treatment of pancreatic cancer.	propranolol and etodolac	PROPRANOLOL	n/a	4/27/15	Designated			N/A	N/A	"Vicus Therapeutics, LLC"	Morristown	New Jersey	7960	USA	EXACT	0027587AA	propranolol	9Y8NXQ24VQ						Pancreatic cancer	9364	done	Not a rare disease
"protoplasmic protein matrix, omega-3 fatty oils, vitamins, minerals and trace elements, cell membrane matrix phospholipid, entracellular matrix, lipids, medium chain triglycerides, longer chain triglycerides, carbohydrates, probiotic, and phytonutrients"	Treatment of juvenile rheumatoid arthritis.	"protoplasmic protein matrix, omega-3 fatty oils, vitamins, minerals and trace elements, cell membrane matrix phospholipid, entracellular matrix, lipids, medium chain triglycerides, longer chain triglycerides, carbohydrates, probiotic, and phytonutrients"	"TRIGLYCERIDES,UNSPECIFIED LENGTH"	n/a	1/11/17	Designated			N/A	N/A	"Leonard S. Girsh, MD"	Naples	Florida	34107	USA	LONGEST CONTAINS	0083205AA	triglycerides	C9H2L21V7U | 71M78END5S	MEDIUM-CHAIN TRIGLYCERIDES | OMEGA-3 FATTY ACIDS	C9H2L21V7U | 71M78END5S	https://ginas.ncats.nih.gov/ginas/app/substance/5d795444 | https://ginas.ncats.nih.gov/ginas/app/substance/73cdfe17	approximate		Juvenile idiopathic arthritis	3067	done	Not a rare disease
pt-112	Treatment of multiple myeloma	"(1R,2R)-1,2-cyclohexane-diaminepyrophosphato-platinum(II)"	"CYCLOHEXANEDIAMINE PYROPHOSPHATOPLATINUM(II), (1R,2R)-"	n/a	11/22/17	Designated			N/A	N/A	Phosplatin Therapeutics LLC	1350 6th Avenue	New York	10019	USA	EXACT	0811541AA	pt-112	F5I3T42BXC						Multiple myeloma	7108	done	
purified autologous type 1 regulatory T lymphocytes specific for human type II collagen	Treatment of chronic non-infectious uveitis	purified autologous type 1 regulatory T lymphocytes specific for human type II collagen	LYMPHOCYTES	n/a	9/1/15	Designated			N/A	N/A	TxCell SA				France	LONGEST CONTAINS	0263092AA	lymphocytes					PROBLEM	can't find	Panuveitis	8577	done	
pyridoxine; vitamin B6	Treatment of pyridoxine dependent seizures.	pyridoxine; vitamin B6	PYRIDOXINE	n/a	3/3/11	Designated			N/A	N/A	"NBI Pharmaceuticals, Inc."	Bozeman	Montana	59715	USA	EXACT	0011369AA	vitamin B6	KV2JZ1BI6Z						Pyridoxine-dependent epilepsy	9298	done	
pyronaridine tetraphosphate	Treatment of malaria	fixed dose combination of pyronaridine tetraphosphate and artesunate	PYRONARIDINE TETRAPHOSPHATE	Pyramax®	9/27/18	Designated			N/A	N/A	"Shin Poong Pharmaceutical Co., Ltd."	"161 Yoksam-Ro, Gangnam-Gu"			"Korea, Republic of"	EXACT	0716314AA	pyronaridine tetraphosphate	2T289F9ACO						Malaria	6961	done	
quizartinib dihydrochloride	Treatment of acute myeloid leukemia	"N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy) imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt"	QUIZARTINIB DIHYDROCHLORIDE	n/a	3/18/09	Designated			N/A	N/A	Daiichi Sankyo Pharma Development	Edison	New Jersey	8837	USA	EXACT	0569266AA	quizartinib dihydrochloride	WK7Q6ZIZ10						Acute myeloid leukemia	12757	done	
rSP-C lung surfactant	Treatment of adult respiratory distress syndrome.	rSP-C lung surfactant	LUNG	Venticute	4/3/00	Designated			N/A	N/A	Byk Gulden Pharmaceuticals				Germany	LONGEST CONTAINS	0141979AA	lung	6MCT347Y2B	LUSUPULTIDE	6MCT347Y2B	https://ginas.ncats.nih.gov/ginas/app/substances?q=RSP-C%20SURFACTANT	done		Acute respiratory distress syndrome	5698	done	
rSP-C surfactant	"For use in patients with pneumonia or aspiration of gastric contents leading to intubation, mechanical ventilation, and severe oxygen impairment"	rSP-C surfactant	LUSUPULTIDE	Venticute	9/18/06	Designated			N/A	N/A	Altana Pharma	Florham Park	New Jersey	7932	USA	EXACT	0224475AA	rSP-C surfactant	6MCT347Y2B								MISSING	not a disease
raloxifene	Reduction of the risk of breast cancer in postmenopausal women	raloxifene	RALOXIFENE	Evista	7/14/05	Designated/Approved	Approved for Orphan Indication	Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer	9/13/07	9/13/14	Eli Lilly and Company	Indianapolis	Indiana	46285	USA	EXACT	0271965AA	raloxifene	YX9162EO3I						Familial breast cancer	10415	approximate	
ramucirumab	Treatment of gastric cancer	ramucirumab	RAMUCIRUMAB	Cyramza	2/16/12	Designated/Approved	Approved for Orphan Indication	"Treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, as a single agent or in combination with paclitaxel, after prior fluoropyrimidine- or platinium-containing chemotherapy."	11/5/14	11/5/21	Eli Lilly and Company	Branchburg	New Jersey	8876	USA	EXACT	0266911AA	ramucirumab	D99YVK4L0X						Stomach cancer	7704	done	
ramucirumab	Treatment of gastric cancer	ramucirumab	RAMUCIRUMAB	Cyramza	2/16/12	Designated/Approved	Approved for Orphan Indication	"Treatment of advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single-agent after prior fluoropyrimidine-or platinum-containing therapy."	4/21/14	4/21/21	Eli Lilly and Company	Branchburg	New Jersey	8876	USA	EXACT	0266911AA	ramucirumab	D99YVK4L0X						Stomach cancer	7704	done	
ranagengliotucel-L	Treatment of astrocytic tumors	ranagengliotucel-L		Glionix(Tm)	5/29/09	Designated			N/A	N/A	NovaRx Corporation	San Diego	California	92121	USA					Glionix	NA	https://drugprofiles.informa.com/drug_profiles/12724-glionix	PROBLEM		Anaplastic astrocytoma	5860	approximate	
rapamycin	Treatment of perivascular epithelioid cell tumors (PEComa)	rapamycin	SIROLIMUS	n/a	12/21/17	Designated			N/A	N/A	"Aadi Bioscience, Inc."	1343 Luna Vista Drive	Los Angeles	90272	USA	EXACT	0175177AA	rapamycin	W36ZG6FT64								MISSING	
rapamycin	Treatment of pulmonary arterial hypertention	rapamycin	SIROLIMUS	n/a	10/20/16	Designated			N/A	N/A	Lam Therapeutics	Guilford	Connecticut	6437	USA	EXACT	0175177AA	rapamycin	W36ZG6FT64						Autoimmune pulmonary alveolar proteinosis	7499	done	
rasburicase	Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.	rasburicase	RASBURICASE	Elitek	10/11/00	Designated/Approved	Approved for Orphan Indication	"Initial management of plasma uric acid levels in pediatric patients with leukemia,lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid."	7/12/02	7/12/09	Sanofi-Synthelabo Research	Malvern	Pennsylvania	19355	USA	EXACT	0178278AA	rasburicase	08GY9K1EUO								MISSING	
recombinant DNA plasmid	"Treatment of stage IIb, IIc, III and IV melanoma."	recombinant DNA plasmid		n/a	1/31/14	Designated			N/A	N/A	Scancell Ltd.	Nottingham			United Kingdom								PROBLEM	can't find	"Melanoma, familial"	3460	approximate	
recombinant IgA protease of bacterium Heamophilus influenzae	"Treatment of immunoglobulin A nephropathy (IgAN, Berger's disease)."	recombinant IgA protease of bacterium Heamophilus influenzae	PROTEASE	n/a	4/18/11	Designated			N/A	N/A	Shire Human Genetics Therapies	Lexington	Massachusetts	2421	USA	LONGEST CONTAINS	0005083AA	protease					PROBLEM	can't find	IgA nephropathy	863	done	
recombinant adeno-associated viral vector serotype HSC expressing human phenylalanine hydroxylase	Treatment of phenylalanine hydroxylase deficiency	recombinant adeno-associated viral vector serotype HSC expressing human phenylalanine hydroxylase	PHENYLALANINE	n/a	7/19/17	Designated			N/A	N/A	"Homology Medicines, Inc."	Bedford	Massachusetts	1730	USA	LONGEST CONTAINS	0011132AA	phenylalanine	47E5O17Y3R						Phenylketonuria	7383	done	
recombinant adeno-associated virus alpha 1-antitrypsin vector	Treatment of alpha1-antitrypsin deficiency	recombinant adeno-associated virus alpha 1-antitrypsin vector		Raav-Aat	1/27/03	Designated			N/A	N/A	Applied Genetic Technologies Corp.	Alachua	Florida	32615	USA					AGTC-0106	NA	https://adisinsight.springer.com/drugs/800017779	PROBLEM	absent from GINAS	Alpha-1 antitrypsin deficiency	5784	done	
recombinant adeno-associated virus serotype 8 vector encoding human glucose-6-phosphatase-alpha (G6Pase or G6PC)	Treatment of glycogen storage disease type Ia (von Gierke Disease)	recombinant adeno-associated virus serotype 8 vector encoding human glucose-6-phosphatase-alpha (G6Pase or G6PC)	ANHYDROUS DEXTROSE	n/a	9/28/16	Designated			N/A	N/A	Dimension Therapeutics	Cambridge	Massachusetts	2139	USA	LONGEST CONTAINS	0126692AA	glucose	5SL0G7R0OK						Glycogen storage disease type 1A	7864	done	
"recombinant adeno-associated virus serotype rhesus 74 (rh74) expressing the human CT GalNac transferase (GALGT2) gene, also called the Sda or Cad GAlNac transferase or b4Galnt2, under control of the muscle creatine kinase (MCK) promoter"	Treatment of Duchenne muscular dystrophy	"recombinant adeno-associated virus serotype rhesus 74 (rh74) expressing the human CT GalNac transferase (GALGT2) gene, also called the Sda or Cad GAlNac transferase or b4Galnt2, under control of the muscle creatine kinase (MCK) promoter"	CREATINE	n/a	6/16/15	Designated			N/A	N/A	Nationwide Children's Hospital	Columbus	Ohio	43205	USA	LONGEST CONTAINS	0009245AA	creatine	MU72812GK0						Duchenne muscular dystrophy	6291	done	
recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel alpha subunit (CNGA3)	Treatment of achromatopsia caused by mutations in the CNGA3 gene	recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel alpha subunit (CNGA3)		n/a	11/16/15	Designated			N/A	N/A	Applied Genetic Technologies Corp.	Alachua	Florida	32615	USA								PROBLEM	can't find	Achromatopsia 2	9649	done	
recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel beta subunit (rAAV-CNGB3)	Treatment of achromatopsia caused by mutations in the CNGB3 gene.	recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel beta subunit (rAAV-CNGB3)		n/a	2/4/11	Designated			N/A	N/A	Applied Genetic Technologies Corporation	Alachua	Florida	32615	USA								PROBLEM	can't find	Achromatopsia 3	9650	done	
recombinant adeno-associated virus vector serotype 9 expressing human N-Sulfoglucosamine Sulfohydrolase	"Treatment of mucopolysaccharidosis type III A, also called Sanfilippo syndrome A"	recombinant adeno-associated virus vector serotype 9 expressing human N-Sulfoglucosamine Sulfohydrolase		n/a	9/1/16	Designated			N/A	N/A	Research Institute at Nationwide Children's Hospital	Columbus	Ohio	43205	USA				B769I4XPY3 | X0MD128U01	ADENO-ASSOCIATED VIRUS | N-SULFOGLUCOSAMINE SULFOHYDROLASE RECOMBINANT	B769I4XPY3 | X0MD128U01	https://ginas.ncats.nih.gov/ginas/app/substance/1b238f0c | https://ginas.ncats.nih.gov/ginas/app/substance/a2c5f344	approximate	GINAS  has entry only for N-Sulfoglucosamine Sulfohydrolase protein	Mucopolysaccharidosis type IIIA	7071	done	
recombinant adeno-associated virus vector serotype 9 expressing human iduronate-2-sulfatase	"Treatment of mucopolysaccharidosis II, also called Hunter syndrome A."	recombinant adeno-associated virus vector serotype 9 expressing human iduronate-2-sulfatase		n/a	9/1/16	Designated			N/A	N/A	Research Institute at Nationwide Children's Hospital	Columbus	Ohio	43205	USA				B769I4XPY3 | 5GCF8EPY6R	ADENO-ASSOCIATED VIRUS | IDURSULFASE BETA | RGX-121	B769I4XPY3 | 5GCF8EPY6R	https://ginas.ncats.nih.gov/ginas/app/substance/1b238f0c | https://ginas.ncats.nih.gov/ginas/app/substance/71f3837c | https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3171943	approximate	GINAS  has entry only for iduronate-2-sulfatase protein	Mucopolysaccharidosis type II	6675	done	
recombinant human CD24FcIg (humanized fusion protein consisting of the extracellular domain of CD24 linked to IgG1 Fc domain	Prevention of graft-versus-host disease	recombinant human CD24FcIg (humanized fusion protein consisting of the extracellular domain of CD24 linked to IgG1 Fc domain	PROTEIN	n/a	6/9/15	Designated			N/A	N/A	"OncoImmune, Inc."	Washington	District of Columbia	20002	USA	LONGEST CONTAINS	0087274AA	protein					PROBLEM	can't find	Chronic graft versus host disease	10964	approximate	type of GVHD (acute or chronic) is not specified
recombinant human CD24FcIg (humanized fusion protein consisting of the extracellular domain of CD24 linked to IgG1 Fc domain	Prevention of graft-versus-host disease	recombinant human CD24FcIg (humanized fusion protein consisting of the extracellular domain of CD24 linked to IgG1 Fc domain	PROTEIN	n/a	6/9/15	Designated			N/A	N/A	"OncoImmune, Inc."	Washington	District of Columbia	20002	USA	LONGEST CONTAINS	0087274AA	protein					PROBLEM	can't find	Acute graft versus host disease	6544	approximate	type of GVHD (acute or chronic) is not specified
"recombinant human GM-CSF, molgramostim"	Treatment of pulmonary alveolar proteinosis	"recombinant human GM-CSF, molgramostim"	MOLGRAMOSTIM	n/a	10/31/12	Designated			N/A	N/A	Savara Inc.	Austin	Texas	78746	USA	EXACT	0259541AA	molgramostim	B321AL142J						Autoimmune pulmonary alveolar proteinosis	7499	done	
recombinant human alpha-1 antitrypsin (rAAT)	To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis	recombinant human alpha-1 antitrypsin (rAAT)	.ALPHA.1-PROTEINASE INHIBITOR (HUMAN)	n/a	8/28/01	Designated			N/A	N/A	AiroMedica LLC	Alameda	California	94611	USA	EXACT	0334770AA	.ALPHA.1-PROTEINASE INHIBITOR (HUMAN)	F43I396OIS						Alpha-1 antitrypsin deficiency	5784	done	
recombinant human alpha-glucosidase conjugated with synthetic bis-mannose-6-phosphate-Man6 glycan	Treatment of Pompe Disease	recombinant human alpha-glucosidase conjugated with synthetic bis-mannose-6-phosphate-Man6 glycan	PHOSPHATE ION	n/a	11/19/13	Designated			N/A	N/A	"Genzyme, a Sanofi Company"	Cambridge	Massachusetts	2142	USA	LONGEST CONTAINS	0055890AA	phosphate	NK08V8K8HR						Glycogen storage disease type 2	5714	done	
"recombinant human anti-human Sortilin (SORT1) monoclonal IgG1 G1m17,1 [or G1m (z,a)] kappa monoclonal antibody"	Treatment of Frontotemporal Dementia	"recombinant human anti-human Sortilin (SORT1) monoclonal IgG1 G1m17,1 [or G1m (z,a)] kappa monoclonal antibody"	SORTILIN	n/a	6/18/18	Designated			N/A	N/A	Alector	151 Oyster Point Boulevard	California	94080	USA	LONGEST CONTAINS	0112915AB	Sortilin	Z020Y8WIJ4						Frontotemporal dementia	8436	done	
recombinant human erythropoietin (rHuEPO)	Treatment of mutliple myeloma	recombinant human erythropoietin (rHuEPO)	ERYTHROPOIETIN	n/a	5/26/11	Designated			N/A	N/A	"XTL Biopharmaceuticals, Ltd"	Herzliya Pituach 46766			Israel	EXACT	0115195AA	erythropoietin	64FS3BFH5W						Multiple myeloma	7108	done	
recombinant human minibody against complement component C5 fused with RGD-motif	Prevention of ischemia/reperfusion injury associated with solid organ transplantation.	recombinant human minibody against complement component C5 fused with -motif		n/a	2/4/09	Designated			N/A	N/A	Adienne S.A.				Switzerland							https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=168119	PROBLEM	can't find			MISSING	Not a rare disease
recombinant human monoclonal antibody of the IgG1 kappa class against prostate stem cell antigen	Treatment of pancreatic cancer	recombinant human monoclonal antibody of the IgG1 kappa class against prostate stem cell antigen	PROSTATE	n/a	12/3/12	Designated/Withdrawn			N/A	N/A	"Astellas Pharma Global Development, Inc."	Northbrook	Illinois	60062	USA	LONGEST CONTAINS	0141957AA	prostate					PROBLEM	can't find	Pancreatic cancer	9364	done	Not a rare disease
recombinant human nerve growth factor	Treatment of neurotrophic keratitis	recombinant human nerve growth factor	RHNGF	n/a	6/23/14	Designated			N/A	N/A	Dompe s.p.a.	Milan			Italy	EXACT	1106214AA	recombinant human nerve growth factor	Y8JXJ39EE9						"Keratitis, hereditary"	3089	approximate	
recombinant human palmitoyl-protein thioesterase-1 (rhPPT1)	Treatment of PPT1-deficient neuronal ceroid lipofuscinoses	recombinant human palmitoyl-protein thioeserase-1 (rhPPT1)	PROTEIN	n/a	6/5/17	Designated			N/A	N/A	"Collaborations Pharmaceuticals, Inc."	Raleigh	North Carolina	27606	USA	LONGEST CONTAINS	0087274AA	protein		Recombinant palmitoyl-protein thioesterase-1	NA	https://adisinsight.springer.com/drugs/800052911	PROBLEM	absent from GINAS	Neuronal ceroid lipofuscinosis	10739	done	
"recombinant human porphobilinogen deaminase, erythropoetic form"	Treatment of acute intermittent porphyria preventing attacks	"recombinant human porphobilinogen deaminase, erythropoetic form"	"PORPHOBILINOGEN DEAMINASE, RECOMBINANT HUMAN ERYTHROID ISOFORM"	n/a	7/11/02	Designated			N/A	N/A	Zymenex A/S				Denmark	LONGEST CONTAINS	0265509AA	recombinant human porphobilinogen deaminase		"Recombinant human porphobilinogen deaminase, erythropoetic form"	NA	https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=157302	PROBLEM	absent from GINAS	Porphyria	10353	done	
recombinant human type I pancreatic elastase	Prevention of arteriovenous fistula and arteriovenous graft failure in patients with chronic kidney disease (CKD) who are receiving hemodialysis or preparing for hemodialysis	recombinant human type I pancreatic elastase	VONAPANITASE	n/a	4/3/09	Designated			N/A	N/A	"Proteon Therapeutics, Inc."	Waltham	Massachusetts	2451	USA	EXACT	0895807AA	recombinant human type I pancreatic elastase	3LWJ2H14I9								MISSING	
recombinant humanized IgG4 monoclonal antibody against pHERV-W Envelope protein	Treatment of chronic inflammatory demyelinating polyradiculoneuropathy/polyneuropathy (CIDP)	recombinant humanized IgG4 monoclonal antibody against pHERV-W Envelope protein	PROTEIN	n/a	2/14/18	Designated			N/A	N/A	GeNeuro S.A.	3 Chemin du Pré-Fleuri	Plan-les-Ouates		Switzerland	LONGEST CONTAINS	0087274AA	protein	T32CR1A69R	TEMELIMAB	T32CR1A69R	https://fdasis.nlm.nih.gov/srs/auto/startswith/temelimab | https://adisinsight.springer.com/drugs/800027319	done		Chronic inflammatory demyelinating polyneuropathy	6102	done	
recombinant humanized anti-HER2 monoclonal antibody-monomethyl auristatin E (MMAE) antibody-drug conjugate	Treatment of Gastric Cancer	recombinant humanized anti-HER2 monoclonal antibody-monomethyl auristatin E (MMAE) antibody-drug conjugate	MONOMETHYL AURISTATIN E	n/a	9/10/18	Designated			N/A	N/A	"RemeGen, Ltd."	58 Middle Beijing Road			China	LONGEST CONTAINS	0297756AA	monomethyl auristatin E	V7I58RC5EJ						Stomach cancer	7704	done	
recombinant humanized monoclonal antibody targeting the anti-müllerian hormone receptor II	Treatment of Anti -Mullerian Hormone Receptor II (AMHRII)-expressing ovarian cancer	recombinant humanized monoclonal antibody targeting the anti-müllerian hormone receptor II		n/a	1/30/18	Designated			N/A	N/A	GamaMabs Pharma SA	"Centre Pierre Potier, 1 place Pierre Potier"			France					GM 102	NA	https://adisinsight.springer.com/drugs/800047584	PROBLEM	absent from GINAS			MISSING	
recombinant interleukin-2	Treatment of brain and CNS tumors.	Liposome encapsulated recombinant interleukin-2		n/a	11/25/91	Designated			N/A	N/A	"Oncothyreon Canada, Inc."				Canada				M89N0Q7EQR	RECOMBINANT INTERLEUKIN-2 HUMAN	M89N0Q7EQR	https://ginas.ncats.nih.gov/ginas/app/substances?q=root_Display%5C%20Name:%22recombinant%20interleukin%202%22	done		Anaplastic oligoastrocytoma	10637	approximate	brain and CNS tumors not specified
recombinant neuroglobin (rNgb) containing mutations H64Q/C46G/C55S/C120S	Treatment of patients with carbon monoxide poisoning	recombinant neuroglobin (rNgb) containing mutations H64Q/C46G/C55S/C120S		n/a	11/17/14	Designated			N/A	N/A	University of Pittsburgh	Pittsburgh	Pennsylvania	15260	USA								PROBLEM	can't find			MISSING	
"recombinant, adeno-associated virus serotype 2 vector carrying linear single-stranded AADC mRNA cDNA"	Treatment of aromatic L-amino acid decarboxylase deficiency.	"recombinant, adeno-associated virus serotype 2 vector carrying linear single-stranded AADC mRNA cDNA"	AROMATIC-L-AMINO-ACID DECARBOXYLASE	n/a	6/8/16	Designated			N/A	N/A	"Agilis Biotherapeutics, LLC"	Cambridge	Massachusetts	2142	USA	LONGEST CONTAINS	1316718AA	AADC	BY6OQ7Q6TP						Aromatic L-amino acid decarboxylase deficiency	770	done	
"recombinant, adeno-associated virus serotype 5 vector, containing the transgene, which encodes for the human protein, frataxin"	Treatment of Friedreich's Ataxia	"recombinant, adeno-associated virus serotype 5 vector, containing the transgene, which encodes for the human protein, frataxin"	PROTEIN	n/a	7/25/16	Designated			N/A	N/A	"Agilis Biotherapeuties, LLC"	Cambridge	Massachusetts	2142	USA	LONGEST CONTAINS	0087274AA	protein	B769I4XPY3	ADENO-ASSOCIATED VIRUS | AGIL-FA | GT-FA	B769I4XPY3	https://ginas.ncats.nih.gov/ginas/app/substance/1b238f0c | https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3171906 | https://adisinsight.springer.com/drugs/800039620	approximate		Friedreich ataxia	6468	done	
"recombinant, non-pathogenic poliovirus:rhinovirus chimera that consists of the genome of the live attenuated poliovirus serotype 1 vaccine with its cognate IRES element replaced with that of HRV2"	Treatment of glioma	"recombinant, non-pathogenic poliovirus:rhinovirus chimera that consists of the genome of the live attenuated poliovirus serotype 1 vaccine with its cognate IRES element replaced with that of HRV2"	POLIOVIRUS	n/a	5/26/16	Designated			N/A	N/A	"Darell D. Bigner, MD, PhD"	Durham	North Carolina	27710	USA	LONGEST CONTAINS	0313962AA	poliovirus	FZJ641678T						Glioma	6513	done	
relacorilant	Treatment of Pancreatic Cancer	relacorilant	RELACORILANT	n/a	9/27/18	Designated			N/A	N/A	"Corcept Therapeutics, Inc."	149 Commonwealth Drive	California	94025	USA	EXACT	1254666AA	relacorilant	2158753C7E						Pancreatic cancer	9364	done	
relacorilant	Treatment of endogenous Cushing syndrome	relacorilant	RELACORILANT	n/a	10/15/18	Designated			N/A	N/A	"Corcept Therapeutics, Inc."	149 Commonwealth Drive	California	94025	USA	EXACT	1254666AA	relacorilant	2158753C7E						Cushing's syndrome	6224	done	
relatlimab	Treatment of gastric cancer (GC) and gastro-esophageal junction cancer (GEJ).	Fixed dose combination of relatlimab and nivolumab	RELATLIMAB	n/a	6/18/18	Designated			N/A	N/A	Bristol-Myers Squibb Co.	P.O. Box 4000	New Jersey	8543	USA	EXACT	0112569AB	relatlimab	AF75XOF6W3						Stomach cancer	7704	done	
reparixin	Prevention of delayed graft function in solid organ transplant	reparixin	REPARIXIN	n/a	1/27/03	Designated			N/A	N/A	Dompe S.p.A.				Italy	EXACT	0269103AA	reparixin	U604E1NB3K								MISSING	
reparixin	Prevention of graft loss in pancreatic islet transplantation	reparixin	REPARIXIN	n/a	9/25/12	Designated			N/A	N/A	Dompe S.p.A.	L'Aquila			Italy	EXACT	0269103AA	reparixin	U604E1NB3K								MISSING	
replication-deficient recombinant serotype 2 adeno-associated viral vector containing hAQP1 cDNA	Treatment of symptoms of Grade 2 and Grade 3 late xerostomia from parotid gland hypofunction caused by radiotherapy for cancer of the oral cavity.	replication-deficient recombinant serotype 2 adeno-associated viral vector containing hAQP1 cDNA		n/a	5/3/13	Designated			N/A	N/A	"MeiraGTx, LLC"	New York	New York	10016	USA								PROBLEM	can't find			MISSING	not a disease
resatorvid	Treatment of acute-on-chronic liver failure	resatorvid	RESATORVID	n/a	1/2/18	Designated			N/A	N/A	"Takeda Development Center Americas, Inc."	One Takeda Parkway	Deerfield	60015	USA	EXACT	0337268AA	resatorvid	H2MZ648C31						Transient infantile liver failure	10593	approximate	
resiniferatoxin	Treatment of intractable pain at end-stage disease	resiniferatoxin	RESINIFERATOXIN	n/a	5/13/03	Designated			N/A	N/A	"Sorrento Theraeputics, Inc."	San Diego	California	92121	USA	EXACT	0222128AA	resiniferatoxin	A5O6P1UL4I								MISSING	not a disease
reslizumab	Treatment of children with eosinophilic esophagitis	reslizumab	RESLIZUMAB	n/a	12/19/07	Designated			N/A	N/A	"Teva Respiratory, LLC"	Frazer	Pennsylvania	19335	USA	EXACT	0263843AA	reslizumab	35A26E427H						Eosinophilic enteropathy	9142	done	
resminostat	Treatment of Hodgkin's lymphoma.	resminostat	RESMINOSTAT	n/a	9/16/11	Designated			N/A	N/A	4SC AG				Germany	EXACT	0362061AA	resminostat	1578EUB98L						Hodgkin lymphoma	2714	done	
retroviral gamma-c cDNA containing vector	Treatment of X linked severe combined immune deficiency disease	retroviral gamma-c cDNA containing vector		n/a	4/29/02	Designated			N/A	N/A	"AVAX technologies, Inc."	Overland Park	Kansas	66210	USA					Retroviral gamma-c cDNA containing vector	NA	http://ec.europa.eu/health/documents/community-register/html/o038.htm	PROBLEM	absent from GINAS	X-linked severe combined immunodeficiency	5618	done	
revusiran	Treatment of transthyretin amyloidosis	revusiran	REVUSIRAN	n/a	5/18/15	Designated			N/A	N/A	"Alnylam Pharmaceuticals, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	1132996AA	revusiran	ZE6EHM8Z3A						Familial transthyretin amyloidosis	656	done	
"rh-microplasmin, ocriplasmin"	Adjunct to surgery in cases of pediatric vitrectomy	"rh-microplasmin, ocriplasmin"	OCRIPLASMIN	Jetrea	3/16/04	Designated			N/A	N/A	ThromboGenics Inc.	Dublin 12			Ireland	EXACT	0345562AA	microplasmin	7V6HE3DM5A								MISSING	
rhIGF-I/rhIGFBP-3	"Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)"	rhIGF-I/rhIGFBP-3	MECASERMIN RINFABATE	Somatokine	12/9/03	Designated			N/A	N/A	"Insmed, Inc."	Monmouth Junction	New Jersey	8852	USA	EXACT	0212953AA	rhIGF-I/rhIGFBP-3	NZ8M50KKRG						"Insulin-resistant acanthosis nigricans, type A "	3008	done	
rhIGF-I/rhIGFBP-3	"Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)"	rhIGF-I/rhIGFBP-3	MECASERMIN RINFABATE	Somatokine	12/9/03	Designated			N/A	N/A	"Insmed, Inc."	Monmouth Junction	New Jersey	8852	USA	EXACT	0212953AA	rhIGF-I/rhIGFBP-3	NZ8M50KKRG						 Rabson-Mendenhall syndrome 	226	done	
rhIGF-I/rhIGFBP-3	"Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)"	rhIGF-I/rhIGFBP-3	MECASERMIN RINFABATE	Somatokine	12/9/03	Designated			N/A	N/A	"Insmed, Inc."	Monmouth Junction	New Jersey	8852	USA	EXACT	0212953AA	rhIGF-I/rhIGFBP-3	NZ8M50KKRG						 Leprechaunism 	6885	done	
rhIGF-I/rhIGFBP-3	"Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)"	rhIGF-I/rhIGFBP-3	MECASERMIN RINFABATE	Somatokine	12/9/03	Designated			N/A	N/A	"Insmed, Inc."	Monmouth Junction	New Jersey	8852	USA	EXACT	0212953AA	rhIGF-I/rhIGFBP-3	NZ8M50KKRG						 Insulin-resistance type B	3009	done	
ribavirin	Treatment of chronic hepatitis C in pediatric patients	ribavirin	RIBAVIRIN	Rebetol	4/4/03	Designated/Approved	Approved for Orphan Indication	Treatment of chronic hepatitis C among previously untreated pediatric patients at least three years of age or older.	7/29/03	7/29/10	Schering Corporation	Kenilworth	New Jersey	7033	USA	EXACT	0064824AA	ribavirin	49717AWG6K								MISSING	Not a rare disease
ribavirin elaidate	"Treatment of follicular, medullary, and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer"	ribavirin elaidate	RIBAVIRIN ELAIDATE	n/a	9/2/11	Designated			N/A	N/A	"Translational Therapeutics, Inc."	Arlington	Massachusetts	2476	USA	EXACT	0740465AA	ribavirin elaidate	4LU13X0I13						"Thyroid cancer, follicular "	5206	done	
ribavirin elaidate	"Treatment of follicular, medullary, and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer"	ribavirin elaidate	RIBAVIRIN ELAIDATE	n/a	9/2/11	Designated			N/A	N/A	"Translational Therapeutics, Inc."	Arlington	Massachusetts	2476	USA	EXACT	0740465AA	ribavirin elaidate	4LU13X0I13						" Thyroid cancer, medullary "	7004	done	
ribavirin elaidate	"Treatment of follicular, medullary, and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer"	ribavirin elaidate	RIBAVIRIN ELAIDATE	n/a	9/2/11	Designated			N/A	N/A	"Translational Therapeutics, Inc."	Arlington	Massachusetts	2476	USA	EXACT	0740465AA	ribavirin elaidate	4LU13X0I13						 Anaplastic thyroid cancer 	664	done	
ribavirin elaidate	"Treatment of follicular, medullary, and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer"	ribavirin elaidate	RIBAVIRIN ELAIDATE	n/a	9/2/11	Designated			N/A	N/A	"Translational Therapeutics, Inc."	Arlington	Massachusetts	2476	USA	EXACT	0740465AA	ribavirin elaidate	4LU13X0I13						 Papillary thyroid carcinoma	12027	done	
riboflavin ophthalmic solution ultraviolet-A (UVA) irradiation	Treatment of corneal ectasia following refractive surgery	riboflavin ophthalmic solution ultraviolet-A (UVA) irradiation	RIBOFLAVIN	Photrexa Viscous	12/2/11	Designated/Approved	Approved for Orphan Indication	Treatment of corneal ectasia following refractive surgery	7/15/16	7/15/23	"Avedro, Inc."	Waltham	Massachusetts	2451	USA	EXACT	0014460AA	riboflavin	TLM2976OFR								MISSING	
ricin vaccine	Prevention of ricin intoxication.	ricin vaccine	RICIN	Rivax(R)	1/7/11	Designated			N/A	N/A	"Soligenix, Inc."	Princeton	New Jersey	8540	USA	LONGEST CONTAINS	0811450AA	ricin	U6E7R9OE4R								MISSING	
ridaforolimus	Treatment of bone sarcoma.	Rapamycin (mTOR) inhibitor	RIDAFOROLIMUS	n/a	8/9/05	Designated/Withdrawn			N/A	N/A	Merck Sharp & Dohme Corp.	North Wales	Pennsylvania	19454	USA	EXACT	0257125AA	ridaforolimus	48Z35KB15K						Osteosarcoma	7284	done	
rifabutin	Treatment of pediatric Crohn's disease.	"clarithromycin, rifabutin, clofazimine"	RIFABUTIN	n/a	4/26/11	Designated			N/A	N/A	RedHill Biopharma Ltd.				Israel	EXACT	0121153AA	rifabutin	1W306TDA6S						Pediatric Crohn's disease	9856	done	
rigosertib	Treatment of pancreatic cancer.	rigosertib	RIGOSERTIB	n/a	3/18/11	Designated			N/A	N/A	"Onconova Therapeutics, Inc"	Newtown	Pennsylvania	18940	USA	EXACT	0700016AA	rigosertib	67DOW7F9GL						Pancreatic cancer	9364	done	Not a rare disease
riluzole	Treatment of spinocereballar ataxia.	riluzole	RILUZOLE	n/a	2/23/16	Designated			N/A	N/A	"Biohaven Pharmaceutical Holding Company, Ltd."	New Haven	Connecticut	6511	USA	EXACT	0182978AA	riluzole	7LJ087RS6F						Spinocerebellar ataxia	10748	done	
riluzole oral soluble film (ROSF)	Treatment of amytrophic lateral sclerosis (ALS)	riluzole oral soluble film (ROSF)	RILUZOLE	n/a	1/23/18	Designated			N/A	N/A	Aquestive Therapeutics	30 Technology Drive South	Warren	7059	USA	EXACT	0182978AA	riluzole	7LJ087RS6F						Amyotrophic lateral sclerosis	5786	done	
riociguat	Treatment of systemic sclerosis	riociguat	RIOCIGUAT	Adempas	7/24/14	Designated			N/A	N/A	Bayer HealthCare Pharmaceuticals	Whippany	New Jersey	7981	USA	EXACT	0457852AA	riociguat	RU3FE2Y4XI						Systemic scleroderma	9748	done	
risperidone	Treatment of pediatric patients with schizophrenia	calcium benzoate and risperidone	RISPERIDONE	n/a	12/20/10	Designated			N/A	N/A	"University of California, Los Angeles"	Torrance	California	90509	USA	EXACT	0167908AA	risperidone	L6UH7ZF8HC						Childhood-Onset Schizophrenia	4766	done	
ritonavir	Treatment of pediatric patients with hepatitis C virus infection (0 through 16 years of age)	ombitasvir/paritaprevir/ritonavir and dasabuvir	RITONAVIR	Viekira Pak	7/16/15	Designated			N/A	N/A	"Abbvie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0184929AA	ritonavir	O3J8G9O825								MISSING	Not a rare disease
rituximab	Treatment of Rasmussen's encephalitis	rituximab	RITUXIMAB	n/a	11/9/16	Designated			N/A	N/A	Keck Graduate Institute of Applied Life Sciences	Claremont	California	91711	USA	EXACT	0225149AA	rituximab	4F4X42SYQ6						Rasmussen encephalitis	7527	done	
rituximab	Treatment of immune thrombocytopenic purpura	rituximab	RITUXIMAB	Rituxan	3/12/02	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0225149AA	rituximab	4F4X42SYQ6						Idiopathic thrombocytopenic purpura	5194	approximate	
rituximab	"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)"	rituximab	RITUXIMAB	Rituxan	2/14/06	Designated/Approved	Approved for Orphan Indication	For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). )	4/19/11	4/19/18	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0225149AA	rituximab	4F4X42SYQ6						Granulomatosis with polyangiitis 	7880	done	
rituximab	"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)"	rituximab	RITUXIMAB	Rituxan	2/14/06	Designated/Approved	Approved for Orphan Indication	For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). )	4/19/11	4/19/18	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0225149AA	rituximab	4F4X42SYQ6						 Microscopic polyangiitis 	3652	done	
rituximab	"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)"	rituximab	RITUXIMAB	Rituxan	2/14/06	Designated/Approved	Approved for Orphan Indication	For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). )	4/19/11	4/19/18	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0225149AA	rituximab	4F4X42SYQ6						 Eosinophilic granulomatosis with polyangiitis	6111	done	
rociletinib	Treatment of non-small cell lung cancer and mutations in the epidermal growth factor receptor	rociletinib	ROCILETINIB	n/a	5/14/13	Designated			N/A	N/A	"Clovis Oncology, Inc."	Boulder	Colorado	80301	USA	EXACT	0707380AA	rociletinib	72AH61702G						"Non-small cell lung cancer, childhood"	9343	approximate	
rofecoxib	Treatment of juvenile rheumatoid arthritis	rofecoxib	ROFECOXIB	Vioxx	3/16/04	Designated			N/A	N/A	"MERCK & Co., Inc."	Rahway	New Jersey	7065	USA	EXACT	0190089AA	rofecoxib	0QTW8Z7MCR						Juvenile idiopathic arthritis	3067	done	Not a rare disease
romidepsin	Treatment of non-Hodgkin T-cell lymphomas	romidepsin	ROMIDEPSIN	Istodax	9/30/04	Designated/Approved	Approved for Orphan Indication	Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy	6/16/11	6/16/18	Celgene Corporation	Cambridge	Massachusetts	2142	USA	EXACT	0218688AA	romidepsin	CX3T89XQBK						B-cell lymphoma	5877	approximate	
romidepsin	Treatment of non-Hodgkin T-cell lymphomas	romidepsin	ROMIDEPSIN	Istodax	9/30/04	Designated/Approved	Approved for Orphan Indication	Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy	11/5/09	11/5/16	Celgene Corporation	Cambridge	Massachusetts	2142	USA	EXACT	0218688AA	romidepsin	CX3T89XQBK						B-cell lymphoma	5877	approximate	
romiplostim	Treatment of immune thrombocytopenic purpura	romiplostim	ROMIPLOSTIM	Nplate	3/27/03	Designated/Approved	Approved for Orphan Indication	"Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy"	8/22/08	8/22/15	"Amgen, Inc."	Thousand Oaks				EXACT	0267958AA	romiplostim	GN5XU2DXKV						Idiopathic thrombocytopenic purpura	5194	approximate	
romiplostim	Treatment of patients acutely exposed to myelosuppressive doses of radiation following radiological/nuclear incident	romiplostim	ROMIPLOSTIM	Nplate	5/24/18	Designated			N/A	N/A	Amgen Inc.	1 Amgen Center Drive		91320	USA	EXACT	0267958AA	romiplostim	GN5XU2DXKV								MISSING	
romiplostim	Treatment of thrombocytopenia associated with myelodysplasia syndrome	romiplostim	ROMIPLOSTIM	n/a	10/31/07	Designated			N/A	N/A	Amgen Inc.	Thousand Oaks	California	91320	USA	EXACT	0267958AA	romiplostim	GN5XU2DXKV								MISSING	
rosuvastatin	For the treatment of pediatric homozygous familial hypercholesterolemia	rosuvastatin	ROSUVASTATIN	Crestor	2/14/14	Designated/Approved	Approved for Orphan Indication	"An adjunct to diet to reduce LDL-C, Total-C, nonHDL-C and ApoB in children and adolescents 7 to 17 years of age with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments (e.g., LDL apheresis)."	5/27/16	5/27/23	"iPR Pharmaceuticals, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0299230AA	rosuvastatin	413KH5ZJ73						Familial hypercholesterolemia	10416	done	Not a rare disease
rovalpituzumab tesirine	Treatment of small cell lung cancer	rovalpituzumab tesirine	ROVALPITUZUMAB TESIRINE	n/a	12/22/15	Designated			N/A	N/A	AbbVie Inc.	Lake Bluff	Illinois	60044	USA	EXACT	1180489AA	rovalpituzumab tesirine	P256HB60FF						Small cell lung cancer	9344	done	
rt-PA	Treatment of plastic bronchitis	rt-PA	ALTEPLASE	Activase	10/20/14	Designated			N/A	N/A	"Kathleen A Stringer, PharmD, FCCP - Professor"	Ann Arbor	Michigan	48109	USA	EXACT	0162447AA	rt-PA	1RXS4UE564								MISSING	
rubitecan	Treatment of pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndrome	rubitecan	RUBITECAN	n/a	7/17/02	Designated			N/A	N/A	"SuperGen, Inc."	Dublin	California	94568	USA	EXACT	0187597AA	rubitecan	H19C446XXB						Congenital human immunodeficiency virus	10328	approximate	
ruxolitinib	Treatment of graft versus host disease	ruxolitinib	RUXOLITINIB	Jakafi	11/3/16	Designated			N/A	N/A	Incyte Corporation	Wilmington	Delaware	19803	USA	EXACT	0557119AA	ruxolitinib	82S8X8XX8H						Chronic graft versus host disease 	10964	approximate	
ruxolitinib	Treatment of graft versus host disease	ruxolitinib	RUXOLITINIB	Jakafi	11/3/16	Designated			N/A	N/A	Incyte Corporation	Wilmington	Delaware	19803	USA	EXACT	0557119AA	ruxolitinib	82S8X8XX8H						 Acute graft versus host disease	6544	approximate	
ruxolitinib	Treatment of pancreatic cancer	ruxolitinib	RUXOLITINIB	Jakafi	8/16/13	Designated			N/A	N/A	Incyte Corporation	Wilmington	Delaware	19880	USA	EXACT	0557119AA	ruxolitinib	82S8X8XX8H						Pancreatic cancer	9364	done	Not a rare disease
sacituzumab govitecan	Treatment of pancreatic cancer.	sacituzumab govitecan	SACITUZUMAB GOVITECAN	n/a	5/29/14	Designated			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA	EXACT	1121035AA	sacituzumab govitecan	M9BYU8XDQ6						Pancreatic cancer	9364	done	Not a rare disease
sacituzumab govitecan	Treatment of small cell lung cancer	sacituzumab govitecan	SACITUZUMAB GOVITECAN	n/a	11/27/13	Designated			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA	EXACT	1121035AA	sacituzumab govitecan	M9BYU8XDQ6						Small cell lung cancer	9344	done	
salicylic acid 6%	Treatment of rare congenital ichthyoses.	salicylic acid 6%	SALICYLIC ACID	n/a	2/17/12	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0012044AA	salicylic acid	O414PZ4LPZ						CHILD syndrome 	6039	approximate	
salicylic acid 6%	Treatment of rare congenital ichthyoses.	salicylic acid 6%	SALICYLIC ACID	n/a	2/17/12	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0012044AA	salicylic acid	O414PZ4LPZ						 X-linked ichthyosis 	7904	approximate	
salicylic acid 6%	Treatment of rare congenital ichthyoses.	salicylic acid 6%	SALICYLIC ACID	n/a	2/17/12	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0012044AA	salicylic acid	O414PZ4LPZ						 KID syndrome 	3113	approximate	
salicylic acid 6%	Treatment of rare congenital ichthyoses.	salicylic acid 6%	SALICYLIC ACID	n/a	2/17/12	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0012044AA	salicylic acid	O414PZ4LPZ						 Harlequin ichthyosis 	6568	approximate	
salicylic acid 6%	Treatment of rare congenital ichthyoses.	salicylic acid 6%	SALICYLIC ACID	n/a	2/17/12	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0012044AA	salicylic acid	O414PZ4LPZ						 Lamellar ichthyosis 	10803	approximate	
salicylic acid 6%	Treatment of rare congenital ichthyoses.	salicylic acid 6%	SALICYLIC ACID	n/a	2/17/12	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0012044AA	salicylic acid	O414PZ4LPZ						 Netherton syndrome 	7182	approximate	
salicylic acid 6%	Treatment of rare congenital ichthyoses.	salicylic acid 6%	SALICYLIC ACID	n/a	2/17/12	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0012044AA	salicylic acid	O414PZ4LPZ						 Sjogren-Larsson syndrome 	7654	approximate	
salicylic acid 6%	Treatment of rare congenital ichthyoses.	salicylic acid 6%	SALICYLIC ACID	n/a	2/17/12	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0012044AA	salicylic acid	O414PZ4LPZ						 Trichothiodystrophy 	12109	approximate	
salicylic acid 6%	Treatment of rare congenital ichthyoses.	salicylic acid 6%	SALICYLIC ACID	n/a	2/17/12	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0012044AA	salicylic acid	O414PZ4LPZ						 Chanarin-Dorfman syndrome	3979	approximate	
salirasib	Treatment of pancreatic cancer.	salirasib	SALIRASIB	n/a	12/18/06	Designated			N/A	N/A	"Kadmon Corporation, LLC"	New York	New York	10016	USA	EXACT	0258559AA	salirasib	MZH0OM550M						Pancreatic cancer	9364	done	Not a rare disease
salmeterol xinafoate	Treatment of symptomatic exophthalmos associated with thyroid related eye disease	salmeterol xinafoate/fluticasone propionate	SALMETEROL XINAFOATE	n/a	10/29/09	Designated			N/A	N/A	"Lithera, Inc."	San Diego	California	92122	USA	EXACT	0163417AA	salmeterol xinafoate	6EW8Q962A5								MISSING	
sapacitabine	Treatment of acute myelogenous leukemia	1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine	SAPACITABINE	Sapacitabine	6/24/10	Designated			N/A	N/A	Cyclacel Limited				United Kingdom	EXACT	0222195AA	sapacitabine	W335P73C3L						Acute myeloid leukemia	12757	done	
sapropterin	Treatment of hyperphenylalaninemia	sapropterin	SAPROPTERIN	Kuvan	1/29/04	Designated/Approved	Approved for Orphan Indication	Indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet.	12/13/07	12/13/14	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA	EXACT	0118207AA	sapropterin	EGX657432I						Maternal hyperphenylalaninemia 	3413	approximate	
sapropterin	Treatment of hyperphenylalaninemia	sapropterin	SAPROPTERIN	Kuvan	1/29/04	Designated/Approved	Approved for Orphan Indication	Indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet.	12/13/07	12/13/14	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA	EXACT	0118207AA	sapropterin	EGX657432I						 6-pyruvoyl-tetrahydropterin synthase deficiency 	5682	approximate	
sapropterin	Treatment of hyperphenylalaninemia	sapropterin	SAPROPTERIN	Kuvan	1/29/04	Designated/Approved	Approved for Orphan Indication	Indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet.	12/13/07	12/13/14	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA	EXACT	0118207AA	sapropterin	EGX657432I						 GTP cyclohydrolase I deficiency 	2844	approximate	
sapropterin	Treatment of hyperphenylalaninemia	sapropterin	SAPROPTERIN	Kuvan	1/29/04	Designated/Approved	Approved for Orphan Indication	Indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet.	12/13/07	12/13/14	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA	EXACT	0118207AA	sapropterin	EGX657432I						 Dihydropteridine reductase deficiency 	4319	approximate	
sapropterin	Treatment of hyperphenylalaninemia	sapropterin	SAPROPTERIN	Kuvan	1/29/04	Designated/Approved	Approved for Orphan Indication	Indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet.	12/13/07	12/13/14	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA	EXACT	0118207AA	sapropterin	EGX657432I						 Hyperphenylalaninemia due to dehydratase deficiency	2843	approximate	
sarcosine	Treatment of obsessive compulsive disorder in pediatric patients (0 to 16 years of age)	sarcosine	SARCOSINE	n/a	10/12/11	Designated			N/A	N/A	"Guochuan Emil Tsai, MD, PhD"	Torrance	California	90502	USA	EXACT	0017447AA	sarcosine	Z711V88R5F								MISSING	
sargramostim	Treatment of pulmonary alveolar proteinosis (PAP).	sargramostim	SARGRAMOSTIM	Leukine®	10/22/18	Designated			N/A	N/A	"Partner Therapeutics, Inc."	19 Muzzey Street	Massachusetts	2421	USA	EXACT	0168536AA	sargramostim	5TAA004E22						Autoimmune pulmonary alveolar proteinosis	7499	done	
"scAAV9.MeCP2.hCLN3, a self-complementary AAV serotype 9 expressing human CLN3 (hCLN3)"	Treatment of neuronal ceroid lipofuscinosis Type 3 (CLN3)	"scAAV9.MeCP2.hCLN3, a self-complementary AAV serotype 9 expressing human CLN3 (hCLN3)"		n/a	6/27/17	Designated			N/A	N/A	Abeona Therapeutics	Cleveland	Ohio	44103	USA				B769I4XPY3	"ADENO-ASSOCIATED VIRUS | scAAV9.MeCP2.hCLN3, a self-complementary AAV serotype 9 expressing human CLN3 (hCLN3)"	B769I4XPY3	https://ginas.ncats.nih.gov/ginas/app/substance/1b238f0c | https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=570016	PROBLEM	absent from GINAS	Neuronal ceroid lipofuscinosis 3	5897	done	
scy-078	Treatment of invasive Aspergillus infections	"(1,3)-ß-D-glucan synthesis inhibitor"	MK-3118	n/a	8/22/16	Designated			N/A	N/A	"SCYNEXIS, Inc."	Jersey City	New Jersey	7302	USA	EXACT	0823574AA	scy-078	A92JFM5XNU								MISSING	not a disease
sebelipase alfa	"Treatment of lipase deficiencies, including Wolman Disease and cholesteryl ester storage disease"	Recombinant human lysosomal acid lipase or cholesteryl ester hydrolase	SEBELIPASE ALFA	Cholestrase	7/14/05	Designated			N/A	N/A	"Lysosomal Acid Lipase, LLC"	Owensboro	Kentucky	42301	USA	EXACT	0755544AA	sebelipase alfa	K4YTU42T8G						Wolman disease 	7899	done	
sebelipase alfa	"Treatment of lipase deficiencies, including Wolman Disease and cholesteryl ester storage disease"	Recombinant human lysosomal acid lipase or cholesteryl ester hydrolase	SEBELIPASE ALFA	Cholestrase	7/14/05	Designated			N/A	N/A	"Lysosomal Acid Lipase, LLC"	Owensboro	Kentucky	42301	USA	EXACT	0755544AA	sebelipase alfa	K4YTU42T8G						 Cholesteryl ester storage disease	12099	done	
secukinumab	Adjunctive treatment of chronic non-infectious uveitis requiring systemic immunosuppression	secukinumab	SECUKINUMAB	n/a	3/26/10	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceutical Corporation	East Hanover	New Jersey	7936	USA	EXACT	0695874AA	secukinumab	DLG4EML025						Panuveitis	8577	done	
seletalisib	Treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)	seletalisib	SELETALISIB	n/a	8/3/17	Designated			N/A	N/A	"UCB, Inc."	Smyrna	Georgia	30080	USA	EXACT	1120383AA	seletalisib	64CW205BDD						PASLI disease	11983	done	
"self-complementary non-replicating, recombinant adeno-associated virus serotype rhesus 74 (rh 74) expressing the human beta-sarcoglycan gene under the control of the muscle creatine kinase (MHCK7) promoter"	Treatment of Limb Girdle Muscular Dystrophy Type 2E (LGMD2E)	"self-complementary non-replicating, recombinant adeno-associated virus serotype rhesus 74 (rh 74) expressing the human beta-sarcoglycan gene under the control of the muscle creatine kinase (MHCK7) promoter"	CREATINE	n/a	2/15/18	Designated			N/A	N/A	Nationwide Children's Hospital	700 Children's Drive	Columbus		USA	LONGEST CONTAINS	0009245AA	creatine	MU72812GK0						Limb-girdle muscular dystrophy type 2E	3851	done	
"self-complimentary adeno-associated virus vector, serotype 9, packaging the full lenght GAN gene in the viral capsid"	Treatment of Giant Axonal Neuropathy	"self-complimentary adeno-associated virus vector, serotype 9, packaging the full lenght GAN gene in the viral capsid"		n/a	9/27/13	Designated			N/A	N/A	Hannah's Hope Fund	Rexford	New York	12148	USA								PROBLEM	can't find	Giant axonal neuropathy	6500	done	
selumetinib	Adjuvant treatment of patients with stage III or stage IV differentiated thyroid cancer.	selumetinib	SELUMETINIB	n/a	5/10/16	Designated			N/A	N/A	AstraZeneca Pharmaceuticals LP	Wilmington	Delaware	19803	USA	EXACT	0297176AA	selumetinib	6UH91I579U						Papillary thyroid carcinoma 	12027	approximate	
selumetinib	Adjuvant treatment of patients with stage III or stage IV differentiated thyroid cancer.	selumetinib	SELUMETINIB	n/a	5/10/16	Designated			N/A	N/A	AstraZeneca Pharmaceuticals LP	Wilmington	Delaware	19803	USA	EXACT	0297176AA	selumetinib	6UH91I579U						" Thyroid cancer, follicular"	5206	approximate	
semaxanib	Treatment of von Hippel-Lindau disease.	"3-(3,5-Dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one"	SEMAXANIB	n/a	3/23/00	Designated			N/A	N/A	"Sugen, Inc."	South San Francisco	California	94080	USA	EXACT	0221807AA	semaxanib	71IA9S35AJ						Von Hippel-Lindau disease	7855	done	
seribantumab	Treatment of heregulin-positive non-small cell lung cancer	seribantumab	SERIBANTUMAB	n/a	10/25/17	Designated			N/A	N/A	"Merrimack Pharmaceuticals, Inc."	Cambridge	Massachusetts		USA	EXACT	0777333AA	seribantumab	1N3L70MDFX						"Non-small cell lung cancer, childhood"	9343	approximate	
setmelanotide	Treatment of leptin receptor deficiency	setmelanotide	SETMELANOTIDE	n/a	11/27/17	Designated			N/A	N/A	"Rhythm Pharmaceuticals, Inc."	500 Boylston Street	Boston	2116	USA	EXACT	1074686AA	setmelanotide	N7T15V1FUY						Obesity due to congenital leptin deficiency	13015	done	
setmelanotide	Treatment of pro-opiomelanocortin (POMC) deficiency due to mutations in the POMC gene	setmelanotide	SETMELANOTIDE	n/a	4/4/16	Designated			N/A	N/A	"Rhythm Pharmaceuticals, Inc."	Boston	Massachusetts	2116	USA	EXACT	1074686AA	setmelanotide	N7T15V1FUY						Proopiomelanocortin deficiency	10823	done	
sevuparin	Treatment of sickle cell disease	sevuparin	SEVUPARIN	n/a	3/17/15	Designated			N/A	N/A	Dilaforette AB				Sweden	EXACT	0775768AA	sevuparin	7C17NQF03M						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
sevuparin	Treatment of sickle cell disease	sevuparin	SEVUPARIN	n/a	3/17/15	Designated			N/A	N/A	Dilaforette AB				Sweden	EXACT	0775768AA	sevuparin	7C17NQF03M						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
sevuparin	Treatment of sickle cell disease	sevuparin	SEVUPARIN	n/a	3/17/15	Designated			N/A	N/A	Dilaforette AB				Sweden	EXACT	0775768AA	sevuparin	7C17NQF03M						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
sevuparin	Treatment of sickle cell disease	sevuparin	SEVUPARIN	n/a	3/17/15	Designated			N/A	N/A	Dilaforette AB				Sweden	EXACT	0775768AA	sevuparin	7C17NQF03M						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
sevuparin	Treatment of sickle cell disease	sevuparin	SEVUPARIN	n/a	3/17/15	Designated			N/A	N/A	Dilaforette AB				Sweden	EXACT	0775768AA	sevuparin	7C17NQF03M						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
sevuparin	Treatment of sickle cell disease	sevuparin	SEVUPARIN	n/a	3/17/15	Designated			N/A	N/A	Dilaforette AB				Sweden	EXACT	0775768AA	sevuparin	7C17NQF03M						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
sgn-30	Treatment of Hodgkin's disease	Chimeric monoclonal antibody to CD30 (anti-CD30 antibody)	BRENTUXIMAB	n/a	7/18/03	Designated/Withdrawn			N/A	N/A	"Seattle Genetics, Inc"	Bothell	Washington	98021	USA	EXACT	0267685AA	sgn-30	C67ORA155P						Hodgkin lymphoma	2714	done	
siltuximab	Treatment of Castleman's disease	siltuximab	SILTUXIMAB	Sylvant	5/26/06	Designated/Approved	Approved for Orphan Indication	Treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.	4/23/14	4/23/21	"Janssen Biotech, Inc."	Raritan	New Jersey	8869	USA	EXACT	0432462AA	siltuximab	T4H8FMA7IM						Castleman disease	12656	done	
"single stranded, chemically modified oligonucleotide that binds to and inhibits the function of micro RNA-21"	Treatment of Alport syndrome	"single stranded, chemically modified oligonucleotide that binds to and inhibits the function of micro RNA-21"		n/a	7/17/14	Designated			N/A	N/A	"Regulus Therapeutics, Inc."	San Diego		92121	USA								PROBLEM	can't find	Alport syndrome	5785	done	
siplizumab	Treatment of T-cell lymphomas	siplizumab	SIPLIZUMAB	n/a	7/15/03	Designated/Withdrawn			N/A	N/A	"MedImmune, LLC"	Gaithersburg		20878	USA	EXACT	0298124AA	siplizumab	KUW1QG1ZM3						Adult T-cell leukemia/lymphoma	13103	approximate	T-cell lymphoma not specified
sirolimus	"Prevention of arteriovenous(AV) fistula or AV graft failure in patients with end stage renal disease, receiving hemodialysis or preparing for hemodialysis"	sirolimus in an implantable collagen matrix	SIROLIMUS	"Coll-R, Sirogen"	5/10/12	Designated			N/A	N/A	"Vascular Therapies, LLC"	Cresskill	New Jersey	7626	USA	EXACT	0175177AA	sirolimus	W36ZG6FT64								MISSING	
sirolimus	"Treatment of chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, noninfectious panuveitis and non-infectious, uveitis affecting the posterior of the eye (NICUPS)."	sirolimus	SIROLIMUS	n/a	11/4/11	Designated			N/A	N/A	Santen Inc.	Emeryville	California	94608	USA	EXACT	0175177AA	sirolimus	W36ZG6FT64						Posterior uveitis 	4457	approximate	
sirolimus	"Treatment of chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, noninfectious panuveitis and non-infectious, uveitis affecting the posterior of the eye (NICUPS)."	sirolimus	SIROLIMUS	n/a	11/4/11	Designated			N/A	N/A	Santen Inc.	Emeryville	California	94608	USA	EXACT	0175177AA	sirolimus	W36ZG6FT64						 Pars planitis 	7339	approximate	
sirolimus	"Treatment of chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, noninfectious panuveitis and non-infectious, uveitis affecting the posterior of the eye (NICUPS)."	sirolimus	SIROLIMUS	n/a	11/4/11	Designated			N/A	N/A	Santen Inc.	Emeryville	California	94608	USA	EXACT	0175177AA	sirolimus	W36ZG6FT64						  Panuveitis	8577	approximate	
sirolimus	Treatment of sickle cell disease	sirolimus	SIROLIMUS	n/a	3/13/18	Designated			N/A	N/A	Rare Partners srl Impresa Sociale	31 Corso Magenta			Italy	EXACT	0175177AA	sirolimus	W36ZG6FT64						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
sirolimus	Treatment of sickle cell disease	sirolimus	SIROLIMUS	n/a	3/13/18	Designated			N/A	N/A	Rare Partners srl Impresa Sociale	31 Corso Magenta			Italy	EXACT	0175177AA	sirolimus	W36ZG6FT64						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
sirolimus	Treatment of sickle cell disease	sirolimus	SIROLIMUS	n/a	3/13/18	Designated			N/A	N/A	Rare Partners srl Impresa Sociale	31 Corso Magenta			Italy	EXACT	0175177AA	sirolimus	W36ZG6FT64						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
sirolimus	Treatment of sickle cell disease	sirolimus	SIROLIMUS	n/a	3/13/18	Designated			N/A	N/A	Rare Partners srl Impresa Sociale	31 Corso Magenta			Italy	EXACT	0175177AA	sirolimus	W36ZG6FT64						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
sirolimus	Treatment of sickle cell disease	sirolimus	SIROLIMUS	n/a	3/13/18	Designated			N/A	N/A	Rare Partners srl Impresa Sociale	31 Corso Magenta			Italy	EXACT	0175177AA	sirolimus	W36ZG6FT64						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
sirolimus	Treatment of sickle cell disease	sirolimus	SIROLIMUS	n/a	3/13/18	Designated			N/A	N/A	Rare Partners srl Impresa Sociale	31 Corso Magenta			Italy	EXACT	0175177AA	sirolimus	W36ZG6FT64						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
sirukumab	Treatment of juvenile idiopathic arthritis (JIA) in pediatric patients	sirukumab	SIRUKUMAB	Plivensia™	7/3/17	Designated			N/A	N/A	"Janssen Research & Development, LLC"	Spring House	Pennsylvania	19477	USA	EXACT	0581395AA	sirukumab	640443FU93						Juvenile idiopathic arthritis	3067	done	Not a rare disease
"sodium 2,2-dimethylbutyrate"	Treatment of sickle cell disease.	"sodium 2, 2 dimethylbutyrate"	"SODIUM 2,2-DIMETHYLBUTYRATE"	n/a	7/25/08	Designated			N/A	N/A	"HemaQuest Pharmaceuticals, Inc."	Seattle	Washington	98154	USA	EXACT	0313622AA	"sodium 2,2-dimethylbutyrate"	XKM99SPB5I						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
"sodium 2,2-dimethylbutyrate"	Treatment of sickle cell disease.	"sodium 2, 2 dimethylbutyrate"	"SODIUM 2,2-DIMETHYLBUTYRATE"	n/a	7/25/08	Designated			N/A	N/A	"HemaQuest Pharmaceuticals, Inc."	Seattle	Washington	98154	USA	EXACT	0313622AA	"sodium 2,2-dimethylbutyrate"	XKM99SPB5I						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
"sodium 2,2-dimethylbutyrate"	Treatment of sickle cell disease.	"sodium 2, 2 dimethylbutyrate"	"SODIUM 2,2-DIMETHYLBUTYRATE"	n/a	7/25/08	Designated			N/A	N/A	"HemaQuest Pharmaceuticals, Inc."	Seattle	Washington	98154	USA	EXACT	0313622AA	"sodium 2,2-dimethylbutyrate"	XKM99SPB5I						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
"sodium 2,2-dimethylbutyrate"	Treatment of sickle cell disease.	"sodium 2, 2 dimethylbutyrate"	"SODIUM 2,2-DIMETHYLBUTYRATE"	n/a	7/25/08	Designated			N/A	N/A	"HemaQuest Pharmaceuticals, Inc."	Seattle	Washington	98154	USA	EXACT	0313622AA	"sodium 2,2-dimethylbutyrate"	XKM99SPB5I						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
"sodium 2,2-dimethylbutyrate"	Treatment of sickle cell disease.	"sodium 2, 2 dimethylbutyrate"	"SODIUM 2,2-DIMETHYLBUTYRATE"	n/a	7/25/08	Designated			N/A	N/A	"HemaQuest Pharmaceuticals, Inc."	Seattle	Washington	98154	USA	EXACT	0313622AA	"sodium 2,2-dimethylbutyrate"	XKM99SPB5I						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
"sodium 2,2-dimethylbutyrate"	Treatment of sickle cell disease.	"sodium 2, 2 dimethylbutyrate"	"SODIUM 2,2-DIMETHYLBUTYRATE"	n/a	7/25/08	Designated			N/A	N/A	"HemaQuest Pharmaceuticals, Inc."	Seattle	Washington	98154	USA	EXACT	0313622AA	"sodium 2,2-dimethylbutyrate"	XKM99SPB5I						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
sodium 2-hydroxylinoleate	Treatment of pancreatic cancer.	sodium 2-hydroxylinoleate	ABTL-0812 SODIUM	n/a	11/23/16	Designated			N/A	N/A	"Ability Pharmaceuticals, SL"	Bellaterra			Spain	EXACT	1718190AA	sodium 2-hydroxylinoleate	X1840C8161						Pancreatic cancer	9364	done	Not a rare disease
sodium ascorbate and menadione sodium bisulfite	Treatment of autosomal dominant polycystic kidney disease	sodium ascorbate and menadione sodium bisulfite	MENADIONE SODIUM BISULFITE	Apatone	4/15/13	Designated			N/A	N/A	IC-MedTech Corporation	El Cajon	California	92021	USA	EXACT	0020815AA	menadione sodium bisulfite	6XF3C2HK77						Autosomal dominant polycystic kidney disease	10413	done	
sodium ascorbate and menadione sodium bisulfite	Treatment of noninfected painful total joint without mechanical complication	sodium ascorbate and menadione sodium bisulfite	MENADIONE SODIUM BISULFITE	Apatone	4/9/15	Designated			N/A	N/A	IC-MedTech Corporation	El Cajon	California	92021	USA	EXACT	0020815AA	menadione sodium bisulfite	6XF3C2HK77								MISSING	
sodium chloride	For use in cleansing of the colon in preparation for colonoscopy in children and adolescents	"sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride"	SODIUM CHLORIDE	Suclear	9/4/13	Designated			N/A	N/A	"Braintree Laboratories, Inc."	Braintree	Massachusetts	2185	USA	EXACT	0049854AA	sodium chloride	451W47IQ8X								MISSING	"not a disease, a procedure"
sodium dichloroacetate	Use as an antidote in the management of systemic monochloroacetic acid poisoning	sodium dichloroacetate	SODIUM DICHLOROACETATE	n/a	7/3/03	Designated			N/A	N/A	EBD Group	Carlsbad	California	92011	USA	EXACT	0079492AA	sodium dichloroacetate	42932X67B5								MISSING	
sodium nitrite	Prevention of ischemia reperfusion injury to donor organ tissue associated with solid organ transplantation	sodium nitrite	SODIUM NITRITE	n/a	9/3/09	Designated			N/A	N/A	Hope Pharmaceuticals	Scottsdale	Arizona	85260	USA	EXACT	0049581AA	sodium nitrite	M0KG633D4F								MISSING	Not a rare disease
sodium nitrite	Treatment of chlorine gas poisoning	sodium nitrite	SODIUM NITRITE	n/a	1/9/12	Designated			N/A	N/A	Hope Pharmaceuticals	Scottsdale	Arizona	85260	USA	EXACT	0049581AA	sodium nitrite	M0KG633D4F								MISSING	Not a rare disease
sodium nitrite	Treatment of cyanide poisoning	"Amyl nitrite, sodium nitrite, sodium thiosulfate"	SODIUM NITRITE	Cyanide Antidote Kit	12/18/06	Designated			N/A	N/A	"Akorn, Inc."	Buffalo Grove	Illinois	60089	USA	EXACT	0049581AA	sodium nitrite	M0KG633D4F								MISSING	Not a disease
sodium nitrite	Treatment of cyanide poisoning	Sodium thiosulfate and sodium nitrite	SODIUM NITRITE	n/a	12/18/06	Designated			N/A	N/A	"Akorn, Inc."	Buffalo Grove	Illinois	60089	USA	EXACT	0049581AA	sodium nitrite	M0KG633D4F								MISSING	Not a disease
sodium nitrite	Treatment of cyanide poisoning	"Sodium thiosulfate, sodium nitrite, amyl nitrite"	SODIUM NITRITE	Cyanide Antidote Package	6/16/06	Designated			N/A	N/A	"Keystone Pharmaceuticals, Inc."	Laguna Hills	California	92653	USA	EXACT	0049581AA	sodium nitrite	M0KG633D4F								MISSING	Not a disease
sodium nitrite and sodium thiosulfate	Treatment of known or suspected cyanide poisoning	sodium nitrite and sodium thiosulfate	SODIUM NITRITE	Nithiodote	4/9/08	Designated/Approved	Approved for Orphan Indication	For sequential use for the treatment of cyanide poisoning that is judged to be life-threatening	1/14/11	1/14/18	Hope Pharmaceuticals	Scottsdale	Arizona	85260	USA	EXACT	0049581AA	Sodium nitrite	M0KG633D4F								MISSING	not a disease
sodium nitrite and sodium thiosulfate	Treatment of known or suspected cyanide poisoning	sodium nitrite and sodium thiosulfate	SODIUM THIOSULFATE	Nithiodote	4/9/08	Designated/Approved	Approved for Orphan Indication	For sequential use for the treatment of cyanide poisoning that is judged to be life-threatening	1/14/11	1/14/18	Hope Pharmaceuticals	Scottsdale	Arizona	85260	USA	EXACT	0053225AA	sodium thiosulfate	HX1032V43M								MISSING	not a disease
sodium phenylbutyrate	"Treatment for sickling disorders, which include S-S hemoglobinopathy, S-C hemoglobinopathy, and S-thalassemia hemoglobinopathy."	sodium phenylbutyrate	SODIUM PHENYLBUTYRATE	n/a	7/2/92	Designated			N/A	N/A	Medicis Pharmaceutical Corp.	Scottsdale	Arizona	85258	USA	EXACT	0180767AA	sodium phenylbutyrate	NT6K61736T						Sickle cell anemia 	8614	done	
sodium phenylbutyrate	"Treatment for sickling disorders, which include S-S hemoglobinopathy, S-C hemoglobinopathy, and S-thalassemia hemoglobinopathy."	sodium phenylbutyrate	SODIUM PHENYLBUTYRATE	n/a	7/2/92	Designated			N/A	N/A	Medicis Pharmaceutical Corp.	Scottsdale	Arizona	85258	USA	EXACT	0180767AA	sodium phenylbutyrate	NT6K61736T						 Hemoglobin SC disease 	6584	done	
sodium phenylbutyrate	"Treatment for sickling disorders, which include S-S hemoglobinopathy, S-C hemoglobinopathy, and S-thalassemia hemoglobinopathy."	sodium phenylbutyrate	SODIUM PHENYLBUTYRATE	n/a	7/2/92	Designated			N/A	N/A	Medicis Pharmaceutical Corp.	Scottsdale	Arizona	85258	USA	EXACT	0180767AA	sodium phenylbutyrate	NT6K61736T						 Sickle beta thalassemia	10333	done	
sodium phenylbutyrate	Treatment of urea cycle disorder.	sodium phenylbutyrate	SODIUM PHENYLBUTYRATE	n/a	1/19/10	Designated			N/A	N/A	Navinta LLC	Ewing	New Jersey	8618	USA	EXACT	0180767AA	sodium phenylbutyrate	NT6K61736T						Urea cycle disorders	7837	done	
sodium phenylbutyrate	"Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency."	sodium phenylbutyrate	SODIUM PHENYLBUTYRATE	Buphenyl	11/22/93	Designated/Approved	Approved for Orphan Indication	"Adjunctive therapy in the chronic managment of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase."	4/30/96	4/30/03	Medicis Pharmaceutical Corp.	Scottsdale	Arizona	85258	USA	EXACT	0180767AA	sodium phenylbutyrate	NT6K61736T						Urea cycle disorders	7837	done	
sodium sulfate	For cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in children and adolescents	"sodium sulfate, potassium sulfate, and magnesium sulfate"	SODIUM SULFATE	Suprep	10/31/12	Designated			N/A	N/A	"Braintree Laboratories, Inc."	Braintree	Massachusetts	2185	USA	EXACT	0050566AA	sodium sulfate	0YPR65R21J								MISSING	"not a disease, a procedure"
sodium sulfate	For the cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in pediatric patients	"sodium sulfate, magnesium sulfate, potassium chloride"	SODIUM SULFATE	n/a	12/19/17	Designated			N/A	N/A	"Braintree Laboratories, Inc."	60 Columbian Street West	Braintree	2185	USA	EXACT	0050566AA	sodium sulfate	0YPR65R21J								MISSING	not a disease
sodium sulfate	For use in cleansing of the colon in preparation for colonoscopy in children and adolescents	"sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride"	SODIUM SULFATE	Suclear	9/4/13	Designated			N/A	N/A	"Braintree Laboratories, Inc."	Braintree	Massachusetts	2185	USA	EXACT	0050566AA	sodium sulfate	0YPR65R21J								MISSING	"not a disease, a procedure"
"sodium sulfate, magnesium sulfate, potassium chloride"	For the cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in pediatric patients	"sodium sulfate, magnesium sulfate, potassium chloride"	POTASSIUM CHLORIDE	n/a	12/19/17	Designated			N/A	N/A	"Braintree Laboratories, Inc."	60 Columbian Street West	Braintree	2185	USA	EXACT	0048395AA	potassium chloride	660YQ98I10								MISSING	not a disease
"sodium sulfate, potassium sulfate, and magnesium sulfate"	For cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in children and adolescents	"sodium sulfate, potassium sulfate, and magnesium sulfate"	POTASSIUM SULFATE	Suprep	10/31/12	Designated			N/A	N/A	"Braintree Laboratories, Inc."	Braintree	Massachusetts	2185	USA	EXACT	0051194AA	potassium sulfate	1K573LC5TV								MISSING	"not a disease, a procedure"
"sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride"	For use in cleansing of the colon in preparation for colonoscopy in children and adolescents	"sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride"	SODIUM BICARBONATE	Suclear	9/4/13	Designated			N/A	N/A	"Braintree Laboratories, Inc."	Braintree	Massachusetts	2185	USA	EXACT	0022753AA	sodium bicarbonate	8MDF5V39QO								MISSING	"not a disease, a procedure"
sodium thiosulfate	Prevention of platinum-induced ototoxicity in pediatric patients	sodium thiosulfate	SODIUM THIOSULFATE	n/a	10/13/11	Designated			N/A	N/A	Hope Pharmaceuticals	Scottsdale	Arizona	85260	USA	EXACT	0053225AA	sodium thiosulfate	HX1032V43M								MISSING	prevention of drug-induced side-effects
sodium thiosulfate	Treatment of extravasation of meclorethamine hydrochloride into subcutaneous tissues.	sodium thiosulfate	SODIUM THIOSULFATE	n/a	12/2/10	Designated			N/A	N/A	Hope Pharmaceuticals	Scottsdale	Arizona	85260	USA	EXACT	0053225AA	sodium thiosulfate	HX1032V43M								MISSING	treatment of drug-induced side-effects
sodium thiosulfate	Treatment of severe acute cyanide poisoning.	Hydroxycobalamin/sodium thiosulfate	SODIUM THIOSULFATE	n/a	10/4/85	Designated/Withdrawn			N/A	N/A	"Hall, Alan H., M.D."	Elk Mountain	Wyoming	82324	USA	EXACT	0053225AA	sodium thiosulfate	HX1032V43M								MISSING	Not a disease
sodium thiosulfate	Treatment of sulfur mustard poisoning	sodium thiosulfate	SODIUM THIOSULFATE	n/a	3/3/11	Designated			N/A	N/A	Hope Pharmaceuticals	Scottsdale	Arizona	85260	USA	EXACT	0053225AA	sodium thiosulfate	HX1032V43M								MISSING	not a disease
sofosbuvir	Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients	ledipasvir/sofosbuvir	SOFOSBUVIR	Harvoni	10/12/16	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0755624AA	sofosbuvir	WJ6CA3ZU8B								MISSING	Not a rare disease
sofosbuvir	Treatment of pediatric chronic hepatitis C virus (HCV) infection	sofosbuvir/velpatasvir	SOFOSBUVIR	Epclusa	2/22/17	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0755624AA	sofosbuvir	WJ6CA3ZU8B								MISSING	
sofosbuvir	Treatment of pediatric chronic hepatitis C virus infection	sofosbuvir	SOFOSBUVIR	Sovaldi	10/25/16	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0755624AA	sofosbuvir	WJ6CA3ZU8B								MISSING	
solnatide	Treatment of primary graft dysfunction following lung transplantation	solnatide	SOLNATIDE	n/a	2/4/16	Designated			N/A	N/A	Apeptico Forschung und Entwicklung GmbH	Vienna			Austria	EXACT	0766778AA	solnatide	17ZS80333G								MISSING	surgery complication
solvent/detergent treated non-blood-group specific human coagulation active plasma	Treatment of thrombotic thrombocytopenic purpura	solvent/detergent treated non-blood-group specific human coagulation active plasma	HUMAN PLASMA	Uniplas	12/12/05	Designated			N/A	N/A	"Octapharma USA, Inc."	Hoboken	New Jersey	7030	USA	LONGEST CONTAINS	0233772AA	plasma	T74K1VTI2X						"Thrombotic thrombocytopenic purpura, acquired "	4607	approximate	
solvent/detergent treated non-blood-group specific human coagulation active plasma	Treatment of thrombotic thrombocytopenic purpura	solvent/detergent treated non-blood-group specific human coagulation active plasma	HUMAN PLASMA	Uniplas	12/12/05	Designated			N/A	N/A	"Octapharma USA, Inc."	Hoboken	New Jersey	7030	USA	LONGEST CONTAINS	0233772AA	plasma	T74K1VTI2X						 Congenital thrombotic thrombocytopenic purpura	9430	approximate	
"somatic cell therapy product containing hematopoietic progenitor cells (HPC), Facilitating Cells (FC), and alpha beta T cells."	Prevention of organ rejection in living donor kidney transplant recipients	"somatic cell therapy product containing hematopoietic progenitor cells (HPC), Facilitating Cells (FC), and alpha beta T cells."		n/a	2/4/16	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA				XU53VK93MC|NW5JLT8E3A|FMN4CGB1C8	"HUMAN CORD BLOOD HEMATOPOIETIC PROGENITOR CELL|HUMAN PERIPHERAL BLOOD HEMATOPOIETIC PROGENITOR CELL|HUMAN HEMATOPOIETIC PROGENITOR CELL, MARROW DERIVED"	XU53VK93MC|NW5JLT8E3A|FMN4CGB1C8	https://ginas.ncats.nih.gov/ginas/app/substances?q=progenitor&facet=Substance%20Class%2FstructurallyDiverse&page=1	done	mapping is approximate; the origin is not specified			MISSING	
somatorelin	Diagnostic measure of the capacity of the pituitary gland to release growth hormone.	somatorelin	SOMATORELIN	Somatrel	8/8/89	Designated			N/A	N/A	"Ferring Laboratories, Inc."	Suffern	New York	10901	USA	EXACT	0127797AA	somatorelin	4UR7N9Z9MM								MISSING	"not a disease, a procedure"
somatorelin	For the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Growth hormone releasing factor	SOMATORELIN	n/a	8/7/89	Designated			N/A	N/A	Valeant Pharmaceuticals North America	Bridgewater	New Jersey	8807	USA	EXACT	0127797AA	somatorelin	4UR7N9Z9MM						Growth hormone deficiency	6552	done	
somatropin (rDNA)	Treatment of growth failure in children who were born small for gestational age.	somatropin [rDNA]	SOMATROPIN	Genotropin	12/27/00	Designated/Approved	Approved for Orphan Indication	For long-term treatment of growth failure in children born small for gestational age who fail to manifest catch-up growth by two years of age.	7/25/01	7/25/08	Pharmacia and Upjohn Company	Kalamazoo	Michigan	49001	USA	EXACT	0054682AA	somatropin	NQX9KB6PCL								MISSING	not a disease
sorafenib	"Treatment of medullary thyroid cancer, anaplastic thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer"	sorafenib	SORAFENIB	Nexavar	12/12/11	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DCT) that is refractory to radioactive iodine treatment."	11/22/13	11/22/20	"Bayer HealthCare Pharmaceuticals, Inc."	Whippany	New Jersey	7981	USA	EXACT	0258582AA	sorafenib	9ZOQ3TZI87						"Thyroid cancer, medullary "	7004	done	
sorafenib	"Treatment of medullary thyroid cancer, anaplastic thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer"	sorafenib	SORAFENIB	Nexavar	12/12/11	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DCT) that is refractory to radioactive iodine treatment."	11/22/13	11/22/20	"Bayer HealthCare Pharmaceuticals, Inc."	Whippany	New Jersey	7981	USA	EXACT	0258582AA	sorafenib	9ZOQ3TZI87						 Anaplastic thyroid cancer 	664	done	
sorafenib	"Treatment of medullary thyroid cancer, anaplastic thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer"	sorafenib	SORAFENIB	Nexavar	12/12/11	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DCT) that is refractory to radioactive iodine treatment."	11/22/13	11/22/20	"Bayer HealthCare Pharmaceuticals, Inc."	Whippany	New Jersey	7981	USA	EXACT	0258582AA	sorafenib	9ZOQ3TZI87						" Thyroid cancer, follicular "	5206	done	
sorafenib	"Treatment of medullary thyroid cancer, anaplastic thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer"	sorafenib	SORAFENIB	Nexavar	12/12/11	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DCT) that is refractory to radioactive iodine treatment."	11/22/13	11/22/20	"Bayer HealthCare Pharmaceuticals, Inc."	Whippany	New Jersey	7981	USA	EXACT	0258582AA	sorafenib	9ZOQ3TZI87						 Papillary thyroid carcinoma	12027	done	
soraprazan	Treatment of Stargardt Disease (StD)		SORAPRAZAN	n/a	12/22/17	Designated			N/A	N/A	Katairo GmbH	21 Lederstraße	Kusterdingen		Germany	EXACT	0243390AA	soraprazan	5XB3671655						Stargardt disease	181	done	
sotalol (IV)	"For ventricular tachycardia, ventricular fibrillation, or the maintenance of sinus rhythm in patients converted from atrial fibrillation or atrial flutter when oral administration is not possible."	sotalol (IV)	SOTALOL	So-Aqueous	7/25/08	Designated/Approved	Approved for Orphan Indication	"For use as a substitute for oral sotalol in patients who are unable to take sotalol orally [oral sotalol is indicated for maintenance of normal sinus rhythm in patients with history of highly symptomatic atrial fibrillation /flutter, and for treatment of documented life-threatening ventricular arrhythmias]"	7/2/09	7/2/16	Academic Pharmaceuticals	Lake Bluff	Illinois	60044	USA	EXACT	0042068AA	sotalol	A6D97U294I								MISSING	not a disease
sotalol hydrochloride	Treatment of life-threatening ventricular arrhythmias in pediatric patients	sotalol hydrochloride	SOTALOL HYDROCHLORIDE	Sotylize	2/10/14	Designated			N/A	N/A	"Arbor Pharmaceuticals, LLC"	Atlanta	Georgia	30328	USA	EXACT	0032042AA	sotalol hydrochloride	HEC37C70XX								MISSING	
spherical carbon adsorbent	Treatment of chronic pouchitis	spherical carbon adsorbent	CARBON	n/a	12/19/07	Designated			N/A	N/A	"Ocera Therapeutics, Inc."	San Diego	California	92130	USA	LONGEST CONTAINS	0048204AA	carbon	2P3VWU3H10								MISSING	
spironolactone	Use in pediatric patients with primary hyperaldosteronism	spironolactone	SPIRONOLACTONE	Aldactone	5/22/14	Designated			N/A	N/A	"CMP Pharma, Inc."	Farmville	North Carolina	27828	USA	EXACT	0008117AA	spironolactone	27O7W4T232						Primary hyperaldosteronism	7456	done	
stabilized sulforaphane	Treatment of subarachnoid hemorrhage	stabilized sulforaphane	"SULFORAPHANE, (R)-"	n/a	8/22/16	Designated			N/A	N/A	Evgen Pharma PLC	Liverpool			United Kingdom	EXACT	0423063AA	sulforaphane	GA49J4310U								MISSING	
staphylococcal aureus protein A	Treatment of immune thrombocytopenic purpura	staphylococcal aureus protein A	IMMUNOGLOBULIN G-BINDING PROTEIN A	n/a	6/10/15	Designated			N/A	N/A	"Protalex, Inc."	Florham Park	New Jersey	7932	USA	EXACT	0817196AA	protein A					PROBLEM	BIRTAMIMAB is antibody to staphylococcal aureus protein A	Idiopathic thrombocytopenic purpura	5194	approximate	
substituted benzaldehyde that binds to the oxy-conformation of Hb between amino terminal residues of the alpha-subunits	Treatment of sickle cell disease.	substituted benzaldehyde that binds to the oxy-conformation of Hb between amino terminal residues of the alpha-subunits	BENZALDEHYDE	n/a	10/23/87	Designated/Withdrawn			N/A	N/A	Burroughs Wellcome Company	Research Triangle Pk	North Carolina	27709	USA	LONGEST CONTAINS	0016682AA	benzaldehyde	TA269SD04T						Sickle cell anemia 	8614	done	Type of sickle cell disease is not specified
substituted benzaldehyde that binds to the oxy-conformation of Hb between amino terminal residues of the alpha-subunits	Treatment of sickle cell disease.	substituted benzaldehyde that binds to the oxy-conformation of Hb between amino terminal residues of the alpha-subunits	BENZALDEHYDE	n/a	10/23/87	Designated/Withdrawn			N/A	N/A	Burroughs Wellcome Company	Research Triangle Pk	North Carolina	27709	USA	LONGEST CONTAINS	0016682AA	benzaldehyde	TA269SD04T						 Hemoglobin SE disease 	12088	done	Type of sickle cell disease is not specified
substituted benzaldehyde that binds to the oxy-conformation of Hb between amino terminal residues of the alpha-subunits	Treatment of sickle cell disease.	substituted benzaldehyde that binds to the oxy-conformation of Hb between amino terminal residues of the alpha-subunits	BENZALDEHYDE	n/a	10/23/87	Designated/Withdrawn			N/A	N/A	Burroughs Wellcome Company	Research Triangle Pk	North Carolina	27709	USA	LONGEST CONTAINS	0016682AA	benzaldehyde	TA269SD04T						 Sickle delta beta thalassemia 	10819	done	Type of sickle cell disease is not specified
substituted benzaldehyde that binds to the oxy-conformation of Hb between amino terminal residues of the alpha-subunits	Treatment of sickle cell disease.	substituted benzaldehyde that binds to the oxy-conformation of Hb between amino terminal residues of the alpha-subunits	BENZALDEHYDE	n/a	10/23/87	Designated/Withdrawn			N/A	N/A	Burroughs Wellcome Company	Research Triangle Pk	North Carolina	27709	USA	LONGEST CONTAINS	0016682AA	benzaldehyde	TA269SD04T						 Sickle cell - hemoglobin D disease 	12458	done	Type of sickle cell disease is not specified
substituted benzaldehyde that binds to the oxy-conformation of Hb between amino terminal residues of the alpha-subunits	Treatment of sickle cell disease.	substituted benzaldehyde that binds to the oxy-conformation of Hb between amino terminal residues of the alpha-subunits	BENZALDEHYDE	n/a	10/23/87	Designated/Withdrawn			N/A	N/A	Burroughs Wellcome Company	Research Triangle Pk	North Carolina	27709	USA	LONGEST CONTAINS	0016682AA	benzaldehyde	TA269SD04T						 Sickle beta thalassemia 	10333	done	Type of sickle cell disease is not specified
substituted benzaldehyde that binds to the oxy-conformation of Hb between amino terminal residues of the alpha-subunits	Treatment of sickle cell disease.	substituted benzaldehyde that binds to the oxy-conformation of Hb between amino terminal residues of the alpha-subunits	BENZALDEHYDE	n/a	10/23/87	Designated/Withdrawn			N/A	N/A	Burroughs Wellcome Company	Research Triangle Pk	North Carolina	27709	USA	LONGEST CONTAINS	0016682AA	benzaldehyde	TA269SD04T						 Hemoglobin SC disease	6584	done	Type of sickle cell disease is not specified
sulindac	Treatment of pancreatic cancer	eflornithine + sulindac	SULINDAC	n/a	1/8/18	Designated			N/A	N/A	"Cancer Prevention Pharmaceutical, Inc."	1760 East River Road	Tucson	85718	USA	EXACT	0064971AA	sulindac	184SNS8VUH						Pancreatic cancer	9364	done	Not a rare disease
sulthiame	Treatment of patients with benign epilepsy of childhood with centrotemporal spikes (BECTS) also known as rolandic epilepsy	sulthiame	SULTHIAME	n/a	7/25/13	Designated			N/A	N/A	"Marathon Pharmaceuticals, LLC"	Northbrook	Illinois	60062	USA	EXACT	0010695AA	sulthiame	I00Q766CZ2						Benign rolandic epilepsy (BRE)	10287	done	
synthetic 14-mer phosphorothioate antisense oligonucleotide directed against TGF-beta2 mRNA	Prevention of scarring post glaucoma filtration surgery	synthetic 14-mer phosphorothioate antisense oligonucleotide directed against TGF-beta2 mRNA		n/a	6/4/14	Designated			N/A	N/A	Isarna Therapeutics GmbH				Germany								PROBLEM	can't find			MISSING	prevention of surgical complications
synthetic double-stranded RNA oligonucleotide conjugated to N-acetyl-D-galactosamine aminosugar residues	Treatment of primary hyperoxaluria	synthetic double-stranded RNA oligonucleotide conjugated to N-acetyl-D-galactosamine aminosugar residues	GALACTOSAMINE	n/a	5/15/18	Designated			N/A	N/A	"Dicerna Pharmaceuticals, Inc."	87 Cambridge Park Drive		2140	USA	LONGEST CONTAINS	1114110AA	galactosamine	4Y6R29688W						Primary hyperoxaluria type 1 	2835	done	
synthetic double-stranded RNA oligonucleotide conjugated to N-acetyl-D-galactosamine aminosugar residues	Treatment of primary hyperoxaluria	synthetic double-stranded RNA oligonucleotide conjugated to N-acetyl-D-galactosamine aminosugar residues	GALACTOSAMINE	n/a	5/15/18	Designated			N/A	N/A	"Dicerna Pharmaceuticals, Inc."	87 Cambridge Park Drive		2140	USA	LONGEST CONTAINS	1114110AA	galactosamine	4Y6R29688W						 Primary hyperoxaluria type 2 	2836	done	
synthetic double-stranded RNA oligonucleotide conjugated to N-acetyl-D-galactosamine aminosugar residues	Treatment of primary hyperoxaluria	synthetic double-stranded RNA oligonucleotide conjugated to N-acetyl-D-galactosamine aminosugar residues	GALACTOSAMINE	n/a	5/15/18	Designated			N/A	N/A	"Dicerna Pharmaceuticals, Inc."	87 Cambridge Park Drive		2140	USA	LONGEST CONTAINS	1114110AA	galactosamine	4Y6R29688W						 Primary hyperoxaluria type 3	10738	done	
synthetic double-stranded siRNA oligonucleotide against p53 mRNA	Prophylaxis of delayed graft function in renal transplant patients	synthetic double-stranded siRNA oligonucleotide against p53 mRNA		n/a	12/23/09	Designated			N/A	N/A	"Quark Pharmaceuticals, Inc."	Fremont	California	94555	USA								PROBLEM	can't find			MISSING	
synthetic double-stranded siRNA oligonucleotide against transthyretin (TTR) mRNA	Treatment of familial amyloidotic polyneuropathy	synthetic double-stranded siRNA oligonucleotide against transthyretin (TTR) mRNA	TRANSTHYRETIN	n/a	6/14/12	Designated			N/A	N/A	"Alnylam Pharmaceuticals, Inc."	Cambridge	Maryland	2142	USA	LONGEST CONTAINS	0113161AB	transthyretin	2COU0B578R						Familial transthyretin amyloidosis	656	done	
synthetic double-stranded siRNA oligonucleotide that is covalently linked to a ligand containing three N-acetylgalactosamine residues and that is targeted against transthryetin mRNA	Treatment of transthyretin-mediated amyloidosis (ATTR amyloidosis)	synthetic double-stranded siRNA oligonucleotide that is covalently linked to a ligand containing three N-acetylgalactosamine residues and that is targeted against transthryetin mRNA		n/a	5/25/18	Designated			N/A	N/A	"Alnylam Pharmaceuticals, Inc."	300 Third Street		2142	USA					Vutrisiran (ALN-TTRSC02)	NA	https://adisinsight.springer.com/drugs/800045568 | https://www.ema.europa.eu/documents/orphan-designation/eu/3/18/2026-public-summary-opinion-orphan-designation-synthetic-double-stranded-sirna-oligonucleotide_en.pdf	PROBLEM	absent from GINAS	Familial transthyretin amyloidosis	656	done	
"synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue"	Treatment of preterm neonatal respiratory distress syndrome	"synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue"	"DIPALMITOYLPHOSPHATIDYLCHOLINE, DL-"	n/a	3/16/12	Designated			N/A	N/A	"Chiesi USA, Inc."	Cary	North Carolina	27518	USA	LONGEST CONTAINS	0039769AA	DPPC	2W15RT5V7V						"Respiratory distress syndrome, infant"	112	done	
"synthetic, single stranded, fully phosphorothioated 2’-OMethyl-RNA and DNA mixmer oligonucleotide-based compound targeted against natural antisense transcripts (NATs)"	Treatment of Dravet Syndrome	"synthetic, single stranded, fully phosphorothioated 2’-OMethyl-RNA and DNA mixmer oligonucleotide-based compound targeted against natural antisense transcripts (NATs)"		n/a	3/16/17	Designated			N/A	N/A	OPKO Ireland Global Holdings Ltd.	Camana Bay			Cayman Islands					CUR-1916	NA	https://www.ema.europa.eu/documents/orphan-designation/eu/3/17/1829-public-summary-opinion-orphan-designation-26-base-synthetic-single-stranded-fully_en.pdf	PROBLEM	absent from GINAS	Dravet syndrome	10430	done	
taberminogene vadenovec	Prevention of complications due to neointimal hyperplasia disease in certain vascular anastomoses.	taberminogene vadenovec		Trinam	10/24/00	Designated			N/A	N/A	"Finvector Vision Therapies, Ltd."				United Kingdom					Taberminogene vadenovec	NA	https://adisinsight.springer.com/drugs/800013649	PROBLEM	absent from GINAS			MISSING	
tacrolimus	Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant	tacrolimus	TACROLIMUS	Envarsus Xr	12/20/13	Designated/Approved	Approved for Orphan Indication	Prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants	7/10/15	7/10/22	"Veloxis Pharmaceuticals, Inc."	Edison	New Jersey	8837	USA	EXACT	0168956AA	tacrolimus	WM0HAQ4WNM								MISSING	
tacrolimus	Treatment of hemorrhagic cystitis	tacrolimus	TACROLIMUS	n/a	7/6/12	Designated			N/A	N/A	Lipella Pharmaceuticals Inc.	Pittsburgh	Pennsylvania	15208	USA	EXACT	0168956AA	tacrolimus	WM0HAQ4WNM								MISSING	
tadekinig alfa	"Treatment of Still's disease, including adult-onset Still's disease (AoSD) and systemic juvenile idiopathic arthritis (sJIA)"	tadekinig alfa	TADEKINIG ALFA	n/a	7/3/17	Designated			N/A	N/A	AB2 Bio Ltd	Lausanne			Switzerland	EXACT	1090422AA	tadekinig alfa	3G6834I4PF						Adult-onset Still's disease 	436	done	
tadekinig alfa	"Treatment of Still's disease, including adult-onset Still's disease (AoSD) and systemic juvenile idiopathic arthritis (sJIA)"	tadekinig alfa	TADEKINIG ALFA	n/a	7/3/17	Designated			N/A	N/A	AB2 Bio Ltd	Lausanne			Switzerland	EXACT	1090422AA	tadekinig alfa	3G6834I4PF						 Juvenile idiopathic arthritis	3067	done	
tafamidis	Treatment of familial amyloid polyneuropathy	tafamidis	TAFAMIDIS	n/a	5/23/06	Designated			N/A	N/A	"Pfizer, Inc."	Philadelphia	Pennsylvania	19101	USA	EXACT	0330278AA	tafamidis	8FG9H9D31J						Familial transthyretin amyloidosis	656	done	
tafamidis meglumine	Treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy.	tafamidis meglumine	TAFAMIDIS MEGLUMINE	n/a	2/17/12	Designated			N/A	N/A	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	0331453AA	tafamidis meglumine	ZU7CF08A1A						Familial transthyretin amyloidosis	656	done	
tak-418	Treatment of Kabuki Syndrome	"5-{(1R,2R)-2-[(Cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride"	TAK-418 FREE BASE	n/a	4/26/18	Designated			N/A	N/A	"Takeda Development Center Americas, Inc."	Takeda Parkway		60015	USA	EXACT	0111951AB	tak-418 free base	N9N6RK0CBN						Kabuki syndrome	6810	done	
talactoferrin alfa	For the prevention of graft-versus-host disease	talactoferrin alfa	TALACTOFERRIN ALFA	n/a	8/20/03	Designated			N/A	N/A	"Agennix, Inc."	Houston	Texas	77046	USA	EXACT	0314363AA	talactoferrin alfa	7A055A9QRR						Acute graft versus host disease 	6552	done	
talactoferrin alfa	For the prevention of graft-versus-host disease	talactoferrin alfa	TALACTOFERRIN ALFA	n/a	8/20/03	Designated			N/A	N/A	"Agennix, Inc."	Houston	Texas	77046	USA	EXACT	0314363AA	talactoferrin alfa	7A055A9QRR						 Chronic graft versus host disease	10964	done	
talactoferrin alfa	For the treatment of graft versus host disease	talactoferrin alfa	TALACTOFERRIN ALFA	n/a	8/20/03	Designated			N/A	N/A	"Agennix, Inc."	Houston	Texas	77046	USA	EXACT	0314363AA	talactoferrin alfa	7A055A9QRR						Acute graft versus host disease 	6552	done	
talactoferrin alfa	For the treatment of graft versus host disease	talactoferrin alfa	TALACTOFERRIN ALFA	n/a	8/20/03	Designated			N/A	N/A	"Agennix, Inc."	Houston	Texas	77046	USA	EXACT	0314363AA	talactoferrin alfa	7A055A9QRR						 Chronic graft versus host disease	10964	done	
talarozole	Treatment of congenital ichthyosis	talarazole	TALAROZOLE	n/a	3/16/12	Designated/Withdrawn			N/A	N/A	"Stiefel Laboratories, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0315060AA	talarozole	XKD9N5CJ6W						CHILD syndrome 	6039	approximate	
talarozole	Treatment of congenital ichthyosis	talarazole	TALAROZOLE	n/a	3/16/12	Designated/Withdrawn			N/A	N/A	"Stiefel Laboratories, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0315060AA	talarozole	XKD9N5CJ6W						 X-linked ichthyosis 	7904	approximate	
talarozole	Treatment of congenital ichthyosis	talarazole	TALAROZOLE	n/a	3/16/12	Designated/Withdrawn			N/A	N/A	"Stiefel Laboratories, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0315060AA	talarozole	XKD9N5CJ6W						 KID syndrome 	3113	approximate	
talarozole	Treatment of congenital ichthyosis	talarazole	TALAROZOLE	n/a	3/16/12	Designated/Withdrawn			N/A	N/A	"Stiefel Laboratories, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0315060AA	talarozole	XKD9N5CJ6W						 Harlequin ichthyosis 	6568	approximate	
talarozole	Treatment of congenital ichthyosis	talarazole	TALAROZOLE	n/a	3/16/12	Designated/Withdrawn			N/A	N/A	"Stiefel Laboratories, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0315060AA	talarozole	XKD9N5CJ6W						 Lamellar ichthyosis 	10803	approximate	
talarozole	Treatment of congenital ichthyosis	talarazole	TALAROZOLE	n/a	3/16/12	Designated/Withdrawn			N/A	N/A	"Stiefel Laboratories, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0315060AA	talarozole	XKD9N5CJ6W						 Netherton syndrome 	7182	approximate	
talarozole	Treatment of congenital ichthyosis	talarazole	TALAROZOLE	n/a	3/16/12	Designated/Withdrawn			N/A	N/A	"Stiefel Laboratories, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0315060AA	talarozole	XKD9N5CJ6W						 Sjogren-Larsson syndrome 	7654	approximate	
talarozole	Treatment of congenital ichthyosis	talarazole	TALAROZOLE	n/a	3/16/12	Designated/Withdrawn			N/A	N/A	"Stiefel Laboratories, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0315060AA	talarozole	XKD9N5CJ6W						 Trichothiodystrophy 	12109	approximate	
talarozole	Treatment of congenital ichthyosis	talarazole	TALAROZOLE	n/a	3/16/12	Designated/Withdrawn			N/A	N/A	"Stiefel Laboratories, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0315060AA	talarozole	XKD9N5CJ6W						 Chanarin-Dorfman syndrome	3979	approximate	
tarextumab	Treatment of pancreatic cancer	tarextumab	TAREXTUMAB	n/a	1/26/15	Designated			N/A	N/A	"OncoMed Pharmaceuticals, Inc."	Redwood City	California	94063	USA	EXACT	0872253AA	tarextumab	333YMY788E						Pancreatic cancer	9364	done	Not a rare disease
tarextumab	Treatment of small cell lung cancer	tarextumab	TAREXTUMAB	n/a	1/26/15	Designated			N/A	N/A	"OncoMed Pharmaceuticals, Inc."	Redwood City	California	94063	USA	EXACT	0872253AA	tarextumab	333YMY788E						Small cell lung cancer	9344	done	
tasimelteon	Non-24-hour sleepwake disorder in blind individuals without light perception	tasimelteon	TASIMELTEON	Hetlioz	1/19/10	Designated/Approved	Approved for Orphan Indication	Treatment of non-24-hour sleep-wake disorder	1/31/14	1/31/21	"Vanda Pharmaceuticals, Inc."	Washington	District of Columbia	20037	USA	EXACT	0224066AA	tasimelteon	SHS4PU80D9						Non 24 hour sleep wake disorder	10949	done	
taurolidine	Treatment of pancreatic cancer.	taurolidine	TAUROLIDINE	n/a	5/16/16	Designated			N/A	N/A	"Geistlich Pharma NA, Inc."	Princeton	New Jersey	8540	USA	EXACT	0177968AA	taurolidine	8OBZ1M4V3V						Pancreatic cancer	9364	done	Not a rare disease
tbo-filgrastim	For the mobilization of peripheral blood progenitor cells (PBPCs) in healthy donors prior to allogeneic PBPC transplantation	tbo-filgrastim	TBO-FILGRASTIM	n/a	7/10/17	Designated			N/A	N/A	Sicor Biotech UAB	Vilnius			Lithuania	EXACT	0778096AA	tbo-filgrastim	PVI5M0M1GW								MISSING	not a disease
tcn-202	Prevention of congential cytomegalovirus (CMV)infection following primary CMV infection in pregnant women.	monoclonal antibody		n/a	1/21/11	Designated/Withdrawn			N/A	N/A	Theraclone Sciences	Seattle	Washington	98104	USA					TCN-202		https://adisinsight.springer.com/drugs/800036257	PROBLEM		Congenital cytomegalovirus	1480	done	
technetium Tc 99m tilmanocept	"Use in sentinel lymph node detection (SLN) with a hand-held gamma-counter, with scintigraphic imaging, in patients with cancer of the head and neck"	technetium Tc 99m tilmanocept	TECHNETIUM TC-99M TILMANOCEPT	Lymphoseek	9/17/14	Designated/Approved	Approved for Orphan Indication	"Guiding sentinel lymph node biopsy, using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity."	6/13/14	6/13/21	Navidea Biopharmaceuticals	Dublin	Ohio	43017	USA	EXACT	0803543AA	technetium Tc 99m tilmanocept	8IHI69PQTC						Head and neck cancer	12425	done	
tecovirimat	Treatment of orthopoxvirus infections.	tecovirimat	TECOVIRIMAT	n/a	9/29/10	Designated			N/A	N/A	"SIGA Technologies, Inc."	Corvallis	Oregon	97333	USA	EXACT	0314487AA	tecovirimat	F925RR824R								MISSING	
telatinib	Treatment of gastric cancer	telatinib	TELATINIB	n/a	5/17/10	Designated			N/A	N/A	ACT Biotech Inc.	San Francisco	California	94103	USA	EXACT	0304632AA	telatinib	18P7197Q7J						Stomach cancer	7704	done	
temocillin sodium	Treatment of pulmonary infections caused by Burkholderia cepacia	temocillin sodium	TEMOCILLIN SODIUM	Negaban	4/21/04	Designated			N/A	N/A	Belpharma S.A.	Luxembourg			Germany	EXACT	0121051AA	temocillin sodium	96IIP39ODH								MISSING	
tenecteplase	Restore function to hemodialysis catheters	tenecteplase	TENECTEPLASE	n/a	5/15/09	Designated/Withdrawn			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0236715AA	tenecteplase	WGD229O42W								MISSING	procedure
tenofovir	Treatment of pediatric HIV infection.	tenofovir	TENOFOVIR	Viread	3/17/09	Designated/Approved	Approved for Orphan Indication	Treatment of HIV infection in combination with other antiretroviral agents in patients 12 to less than 18 years of age	3/24/10	3/24/17	"Gilead Sciences, Inc."	Foster city	California	94404	USA	EXACT	0215907AA	tenofovir	99YXE507IL						Congenital human immunodeficiency virus	10328	approximate	
tenofovir alafenamide	Treatment of HIV-1 infection in pediatric patients under 12 years of age	emtricitabine and tenofovir alafenamide combination	TENOFOVIR ALAFENAMIDE	Descovy(R)	6/6/17	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0763655AA	tenofovir alafenamide	EL9943AG5J								MISSING	Not a rare disease
tenofovir disoproxil fumarate	Prevention of mother to child transmission of hepatitis B virus	tenofovir disoproxil fumarate	TENOFOVIR DISOPROXIL FUMARATE	Viread	9/27/16	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0242886AA	tenofovir disoproxil fumarate	OTT9J7900I								MISSING	Not a rare disease
tenofovir disoproxil fumarate	Treatment of Human Immunodeficiency Virus type 1 infection in pediatric patients	bictegravir/emtricitabine/tenofovir disoproxil fumarate	TENOFOVIR DISOPROXIL FUMARATE	n/a	5/17/17	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0242886AA	tenofovir disoproxil fumarate	OTT9J7900I								MISSING	
tenofovir exalidex	Treatment of pediatric chronic hepatitis B infection (age 0 through 11 years of age)	tenofovir exalidex	TENOFOVIR EXALIDEX	n/a	2/20/18	Designated			N/A	N/A	"ContraVir Pharmaceuticals, Inc."	399 Thornall Street	Edison		USA	EXACT	0553639AA	tenofovir exalidex	K7J545MEMA								MISSING	
teplizumab	Treatment of recent-onset Type I diabetes	Humanized anti-CD3 monoclonal antibody	TEPLIZUMAB	n/a	9/29/06	Designated			N/A	N/A	"MacroGenics, Inc."	Rockville	Maryland	20850	USA	EXACT	0310623AA	teplizumab	S4M959U2IJ						Diabetes mellitus type 1	10268	done	
teprotumumab	Treatment of active (dynamic) phase Grave's orbitopathy	teprotumumab	TEPROTUMUMAB	n/a	5/6/13	Designated			N/A	N/A	"River Vision, Inc."	New York	New York	10020	USA	EXACT	0432939AA	teprotumumab	Y64GQ0KC0A						Graves' disease	6549	done	
terguride	Treatment of systemic sclerosis	terguride	TERGURIDE	"Mysalfon, Teluron"	5/17/13	Designated			N/A	N/A	Medac GmbH	Wedel			Germany	EXACT	0154869AA	terguride	21OJT43Q88						Systemic scleroderma	9748	done	
terlipressin	Treatment of ascites due to all etiologies except cancer	terlipressin	TERLIPRESSIN	n/a	9/8/16	Designated			N/A	N/A	Bio Vie Inc.	Beverly	Massachusetts	1915	USA	EXACT	0056111AA	terlipressin	7Z5X49W53P								MISSING	
tesetaxel	Treatment of gastric cancer	tesetaxel	TESETAXEL	n/a	12/22/08	Designated			N/A	N/A	Genta Inc.	Berkeley Heights	New Jersey	7922	USA	EXACT	0240233AA	tesetaxel	UG97LO5M8Y						Stomach cancer	7704	done	
tesetaxel	"Treatment of stages IIB, IIC, III, and stage IV melanoma"	tesetaxel	TESETAXEL	n/a	11/21/08	Designated			N/A	N/A	"Genta, Inc."	Berkley Heights	New Jersey	7922	USA	EXACT	0240233AA	tesetaxel	UG97LO5M8Y						"Melanoma, familial"	3460	approximate	
tesevatinib	Treatment of non-small cell lung cancer with epithelial growth factor receptor-activating mutations	tesevatinib	TESEVATINIB	n/a	8/3/17	Designated			N/A	N/A	"Kadmon Corporation, LLC"	New York	New York	10016	USA	EXACT	0733653AA	tesevatinib	F6XM2TN5A1						"Non-small cell lung cancer, childhood"	9343	approximate	
testosterone undecanoate (oral)	Treatment of constitutional delay in growth and puberty in adolescent boys (14-17 yrs of age)	testosterone undecanoate (oral)	TESTOSTERONE UNDECANOATE	n/a	2/13/13	Designated			N/A	N/A	"SOV Therapeutics, Inc."	Morrisville	North Carolina	27560	USA	EXACT	0084377AA	testosterone undecanoate	H16A5VCT9C								MISSING	
tetrabenazine	"Treatment of Tourette's Syndrome in school-age children, ages 5-16"	tetrabenazine	TETRABENAZINE	n/a	7/1/09	Designated			N/A	N/A	Valeant International (Barbados) SRL				Barbados	EXACT	0009825AA	tetrabenazine	Z9O08YRN8O						Tourette syndrome	7783	done	
tetracosactide hexaacetate (beta 1-24-corticotrophin)	Treatment of infantile spasms	tetracosactide hexaacetate (beta 1-24-corticotrophin)	COSYNTROPIN HEXAACETATE	"Synacthen Depot, S. Retard"	10/31/12	Designated			N/A	N/A	"Cerium Pharmaceuticals, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0787940AA	tetracosactide hexaacetate	H86HJ92K8Y						West syndrome	7887	done	
tezacaftor	Treatment of Cystic Fibrosis	"N-(1,3-dimethyl-1H-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide/tezacaftor/ivacaftor"	TEZACAFTOR	n/a	8/29/18	Designated			N/A	N/A	Vertex Pharmaceuticals Inc.	50 Northern Avenue	Massachusetts	2210	USA	EXACT	1139328AA	tezacaftor	8RW88Y506K						Cystic fibrosis	6233	done	
tezacaftor	Treatment of Cystic Fibrosis	"potassium (benzenesulfonyl)({[6-(3-{2-[1-(trifluoromethyl)cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridin-3-yl]carbonyl})azanide/tezacaftor/ivacaftor"	TEZACAFTOR	n/a	5/23/18	Designated			N/A	N/A	Vertex Pharmaceuticals Inc.	50 Northern Avenue		2210	USA	EXACT	1139328AA	tezacaftor	8RW88Y506K						Cystic fibrosis	6233	done	
thalidomide	1. Treatment of graft versus host disease in patients receiving bone marrow transplantation 2. Prevention of graft versus host disease in patients receiving bone marrow transplantation	thalidomide	THALIDOMIDE	n/a	9/19/88	Designated			N/A	N/A	"Pediatric Pharmaceuticals, Inc."	Westfield	New Jersey	7090	USA	EXACT	0007409AA	thalidomide	4Z8R6ORS6L						Chronic graft versus host disease 	10964	done	
thalidomide	1. Treatment of graft versus host disease in patients receiving bone marrow transplantation 2. Prevention of graft versus host disease in patients receiving bone marrow transplantation	thalidomide	THALIDOMIDE	n/a	9/19/88	Designated			N/A	N/A	"Pediatric Pharmaceuticals, Inc."	Westfield	New Jersey	7090	USA	EXACT	0007409AA	thalidomide	4Z8R6ORS6L						 Acute graft versus host disease	6544	done	
thiaminE diphosphate	Treatment of mitochondrial disorders	"cytochrome C, flavin mononucleotide and thiamin diphosphate"	COCARBOXYLASE	n/a	6/17/11	Designated			N/A	N/A	"NBI Pharmaceuticals, Inc."	Bozeman	Montana	59715	USA	EXACT	0139797AA	thiaminE diphosphate	Q57971654Y								MISSING	mitchondrial disease not specified
thioureidobutyronitrile	Treatment of pancreatic cancer.	thioureidobutyronitrile	4-ISOTHIOUREIDOBUTYRONITRILE	Kevetrin	1/20/16	Designated			N/A	N/A	Cellceutix Corporation	Beverly	Massachusetts	1915	USA	EXACT	0832633AA	thioureidobutyronitrile	C3059TG1KN						Pancreatic cancer	9364	done	Not a rare disease
thymopentin	Treatment of sarcoidosis.	thymopentin	THYMOPENTIN	n/a	2/4/11	Designated			N/A	N/A	Mondobiotech Laboratories AG				Switzerland	EXACT	0092284AA	thymopentin	O3Y80ZF13F						Sarcoidosis	7607	done	
thymosin beta 4	Treatment of patients with neurotrophic keratopathy	thymosin beta 4	THYMOSIN .BETA.-4	n/a	12/31/13	Designated			N/A	N/A	"ReGenTree, LLC"	Princeton	New Jersey	8540	USA	EXACT	0802891AA	thymosin beta 4	549LM7U24W								MISSING	
tilorone dihydrochloride	Treatment of Ebola infection	tilorone dihydrochloride	TILORONE HYDROCHLORIDE	n/a	2/7/18	Designated			N/A	N/A	"Collaborations Pharmaceuticals, Inc."	840 Main Campus Drive	Raleigh		USA	EXACT	0063581AA	tilorone dihydrochloride	BJ507J4LKY						Ebola virus disease	2035	done	
timolumab	Treatment of primary sclerosing cholangitis.	"recombinant, fully-human, IgG4 immunoglobulin with antigen-binding specificity for human vascular adhesion protein-1 (VAP-1)"	TIMOLUMAB	n/a	8/25/16	Designated			N/A	N/A	"Acorda Therapeutics, Inc."	Ardsley	New York	10502	USA	EXACT	1252875AA	timolumab	UJO03RO3K6						Primary sclerosing cholangitis	1280	done	
tin ethyl etiopurpurin	Prevention of access graft disease in hemodialysis patients	tin ethyl etiopurpurin	ROSTAPORFIN	n/a	11/4/03	Designated			N/A	N/A	Miravant Medical Technologies	Goleta	California	93117	USA	EXACT	0180790AA	tin ethyl etiopurpurin	466G63QE7G								MISSING	
tinidazole	Treatment of giardiasis	tinidazole	TINIDAZOLE	Tindamax	4/18/02	Designated/Approved	Approved for Orphan Indication	Treatment of giardiasis caused by G. duodenalis (also termed G. lamblia) in both adults and pediatric patients older than three years of age	5/17/04	5/17/11	"Presutti Laboratories, Inc."	Arlington Heights	Illinois	60004	USA	EXACT	0063161AA	tinidazole	033KF7V46H								MISSING	
tipiracil	Treatment of gastric cancer including cancer of the gastroesophageal junction	trifluridine/tipiracil	TIPIRACIL	n/a	4/17/17	Designated			N/A	N/A	"Taiho Oncology, Inc."	Princeton	New Jersey	8540	USA	EXACT	0700152AA	tipiracil	NGO10K751P						Stomach cancer	7704	done	
tirapazamine	Treatment of head and neck cancer	tirapazamine	TIRAPAZAMINE	n/a	10/23/02	Designated			N/A	N/A	"Sanofi-Aventis US, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	0176056AA	tirapazamine	1UD32YR59G						Head and neck cancer	12425	done	not a rare disease
titanium dioxide	For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy	"Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide"	TITANIUM DIOXIDE	Total Block Vl Spf 75	8/13/01	Designated			N/A	N/A	Fallien Cosmeceuticals Ltd.	King of Prussia	Pennsylvania	19406	USA	EXACT	0033807AA	titanium dioxide	15FIX9V2JP								MISSING	
tocilizumab	Treatment of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome	tocilizumab	TOCILIZUMAB	Actemra	8/1/17	Designated/Approved	Approved for Orphan Indication	Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older	8/30/17	8/30/24	"Genentech Inc., a member of the Roche Group"	South San Francisco	California	94080	USA	EXACT	0298146AA	tocilizumab	I031V2H011								MISSING	
tocilizumab	Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis	tocilizumab	TOCILIZUMAB	Actemra	7/31/12	Designated/Approved	Approved for Orphan Indication	Treatment of active polyarticular juvenile idiopathic arthritis in patients 2 through 16 years of age.	4/29/13	4/29/20	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0298146AA	tocilizumab	I031V2H011						Juvenile idiopathic arthritis	3067	done	
tocilizumab	Treatment of systemic sclerosis	tocilizumab	TOCILIZUMAB	Actemra	4/17/13	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0298146AA	tocilizumab	I031V2H011						Systemic scleroderma	9748	done	
tolvaptan	Treatment of autosomal dominant polycystic kidney disease	tolvaptan	TOLVAPTAN	Samsca	4/6/12	Designated			N/A	N/A	"Otsuka Pharmaceuticals Co., Ltd."	Tokyo			Japan	EXACT	0213923AA	tolvaptan	21G72T1950						Autosomal dominant polycystic kidney disease	10413	done	
topiramate injection	Treatment of partial onset or primary generalized tonic-clonic seizures for hospitalized epilepsy patients or epilepsy patients being treated in an emergency care setting who are unable to take oral topiramate	topiramate injection	TOPIRAMATE	n/a	7/24/13	Designated			N/A	N/A	"CURx Pharmaceuticals, Inc."	San Diego	California	92121	USA	EXACT	0157233AA	topiramate	0H73WJJ391								MISSING	
toralizumab	Treatment of immune thrombocytopenic purpura	toralizumab	TORALIZUMAB	n/a	3/14/02	Designated/Withdrawn			N/A	N/A	Biogen IDEC Inc.	San Diego	California	92121	USA	EXACT	0255016AA	toralizumab	KX44A9HM0B						Idiopathic thrombocytopenic purpura	5194	approximate	
tpi-287	Treatment of progressive supranuclear palsy	"(2'R,3'S)-2'-hydroxy-N-carboxy-3'-amino-5'-methyl-hexanoic,N-tert-butyl ester, 13 ester 5B-20-epoxy-1B,2a,4a,7B,9a,10a,13a-heptahydroxy-4,10-diacetate-2-benzoate-(1""S)-7,9-acrolein acetal-11(15-1)-abeotaxane"	TPI-287	n/a	6/23/14	Designated			N/A	N/A	"Cortice Biosciences, Inc."	New York	New York	10019	USA	EXACT	0271249AA	tpi-287	A2VM2V569A						Progressive supranuclear palsy	7471	done	
trabedersen	Treatment of pancreatic cancer.	trabedersen	TRABEDERSEN	n/a	7/21/09	Designated			N/A	N/A	"Oncotelic, Inc."	Agoura Hills	California	91301	USA	EXACT	1092633AA	trabedersen	98OYR854NY						Pancreatic cancer	9364	done	Not a rare disease
trafermin	Treatment of alopecia areata in pediatric patients	trafermin in combination with plasma and platelet rich plasma	TRAFERMIN	Fiblast	12/21/17	Designated			N/A	N/A	"HCell, Inc."	314 East Highland Mall Boulevard	Austin	78752	USA	EXACT	0776589AA	trafermin	333OX80X87						Alopecia areata	5782	done	Not a rare disease
trafermin in combination with plasma and platelet rich plasma	Treatment of alopecia areata in pediatric patients	trafermin in combination with plasma and platelet rich plasma	PLATELET RICH PLASMA HUMAN	Fiblast	12/21/17	Designated			N/A	N/A	"HCell, Inc."	314 East Highland Mall Boulevard	Austin	78752	USA	EXACT	0137553AA	platelet rich plasma	ZW1U5HYZ1A						Alopecia areata	5782	done	Not a rare disease
trametinib	Treatment of patients with BRAF mutation positive non-small cell lung cancer.	dabrafenib and trametinib	TRAMETINIB	n/a	10/29/15	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0631323AA	trametinib	33E86K87QN						"Non-small cell lung cancer, childhood"	9343	approximate	
tranexamic acid	Treatment of hereditary angioneurotic edema	tranexamic acid	TRANEXAMIC ACID	Cyklokapron	9/9/85	Designated/Approved/Withdrawn		Treatment of patients with hemophilia for short term use (2 to 8 days) before and after tooth extraction to reduce or prevent hemorrhage abd reduce the need for replacement therapy	N/A	12/30/93	Pharmacia Inc.	Columbus	Ohio	43216	USA	EXACT	0033089AA	tranexamic acid	6T84R30KC1						Hereditary angioedema	5979	done	
tranilast	Prevention of scarring following glaucoma filtration surgery	tranilast	TRANILAST	Rizaben	12/23/10	Designated			N/A	N/A	Altacor Ltd	Cambridge CB4 0WS			United Kingdom	EXACT	0130609AA	tranilast	HVF50SMY6E								MISSING	prevention of surgical complications
trans-resveratrol	Treatment of Friedreich’s Ataxia (FRDA)	trans-resveratrol	RESVERATROL	Jotrol	8/16/17	Designated			N/A	N/A	Jupiter Orphan Therapeutics	Jupiter	Florida	33458	USA	EXACT	0237978AA	trans-resveratrol	Q369O8926L						Friedreich ataxia	6468	done	
trastuzumab	"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction"	trastuzumab	TRASTUZUMAB	Herceptin	10/13/09	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease"	10/20/10	10/20/17	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0233954AA	trastuzumab	P188ANX8CK						Stomach cancer	7704	approximate	
trastuzumab	Treatment of patients with pancreatic cancer that overexpress p185HER2.	trastuzumab	TRASTUZUMAB	Herceptin	12/14/99	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0233954AA	trastuzumab	P188ANX8CK						Pancreatic cancer	9364	done	Not a rare disease
trastuzumab emtansine	For the treatment of gastric cancer including gastroesophageal junction cancer.	trastuzumab emtansine	ADO-TRASTUZUMAB EMTANSINE	Kadcyla Ã¿Æ¿Ã¿Â¿¿Ã¿Â¢Ã¢Â¿¿Â¬Ã¿Â¡Ã¿Æ¿Ã¢Â¿¬Å¡Ã¿Â¿¿Ã¿Â®	10/25/13	Designated/Withdrawn			N/A	N/A	"Genethech, Inc."	south San Francisco	California	94080	USA	EXACT	0271512AA	trastuzumab emtansine	SE2KH7T06F						Stomach cancer	7704	done	
treosulfan	Conditioning treatment prior to hematopoietic stem cell transplantation (HSCT) in malignant and non-malignant diseases in adults and pediatric patients.	treosulfan	TREOSULFAN	n/a	4/8/15	Designated			N/A	N/A	Medac GmbH				Germany	EXACT	0069998AA	treosulfan	CO61ER3EPI								MISSING	
"treprostinil sodium solution enclosed within a pre-filled, pre-programmed, single-use, electronically-controlled infusion pump"	Treatment of pulmonary arterial hypertension	"treprostinil sodium solution enclosed within a pre-filled, pre-programmed, single-use, electronically-controlled infusion pump"	TREPROSTINIL SODIUM	n/a	12/29/15	Designated			N/A	N/A	SteadyMed Therapeutics	San Ramon	California	94583	USA	EXACT	0244597AA	treprostinil sodium	7JZ75N2NT6						Autoimmune pulmonary alveolar proteinosis	7499	done	
trientine hydrochloride	Treatment of manganism.	trientine hydrochloride	TRIENTINE HYDROCHLORIDE	Syprine(R)	11/2/10	Designated			N/A	N/A	"Cerberus Princeton, LLC"	New York	New York	10022	USA	EXACT	0064993AA	trientine hydrochloride	HC3NX54582								MISSING	not a disease
trientine tetrahydrochloride	treatment of Wilson’s disease	trientine tetrahydrochloride	TRIENTINE TETRAHYDROCHLORIDE	n/a	3/10/16	Designated			N/A	N/A	GMP-Orphan SAS	Cambridge	Massachusetts	2142	USA	EXACT	1134210AA	trientine tetrahydrochloride	7360URE56Q						Wilson disease	7893	done	
trifarotene	Treatment of congenital ichthyosis	trifarotene	TRIFAROTENE	n/a	6/6/14	Designated			N/A	N/A	"Galderma R&D, LLC"	Cranbury	New Jersey	8512	USA	EXACT	0707653AA	trifarotene	0J8RN2W0HK						CHILD syndrome 	6039	approximate	
trifarotene	Treatment of congenital ichthyosis	trifarotene	TRIFAROTENE	n/a	6/6/14	Designated			N/A	N/A	"Galderma R&D, LLC"	Cranbury	New Jersey	8512	USA	EXACT	0707653AA	trifarotene	0J8RN2W0HK						 X-linked ichthyosis 	7904	approximate	
trifarotene	Treatment of congenital ichthyosis	trifarotene	TRIFAROTENE	n/a	6/6/14	Designated			N/A	N/A	"Galderma R&D, LLC"	Cranbury	New Jersey	8512	USA	EXACT	0707653AA	trifarotene	0J8RN2W0HK						 KID syndrome 	3113	approximate	
trifarotene	Treatment of congenital ichthyosis	trifarotene	TRIFAROTENE	n/a	6/6/14	Designated			N/A	N/A	"Galderma R&D, LLC"	Cranbury	New Jersey	8512	USA	EXACT	0707653AA	trifarotene	0J8RN2W0HK						 Harlequin ichthyosis 	6568	approximate	
trifarotene	Treatment of congenital ichthyosis	trifarotene	TRIFAROTENE	n/a	6/6/14	Designated			N/A	N/A	"Galderma R&D, LLC"	Cranbury	New Jersey	8512	USA	EXACT	0707653AA	trifarotene	0J8RN2W0HK						 Lamellar ichthyosis 	10803	approximate	
trifarotene	Treatment of congenital ichthyosis	trifarotene	TRIFAROTENE	n/a	6/6/14	Designated			N/A	N/A	"Galderma R&D, LLC"	Cranbury	New Jersey	8512	USA	EXACT	0707653AA	trifarotene	0J8RN2W0HK						 Netherton syndrome 	7182	approximate	
trifarotene	Treatment of congenital ichthyosis	trifarotene	TRIFAROTENE	n/a	6/6/14	Designated			N/A	N/A	"Galderma R&D, LLC"	Cranbury	New Jersey	8512	USA	EXACT	0707653AA	trifarotene	0J8RN2W0HK						 Sjogren-Larsson syndrome 	7654	approximate	
trifarotene	Treatment of congenital ichthyosis	trifarotene	TRIFAROTENE	n/a	6/6/14	Designated			N/A	N/A	"Galderma R&D, LLC"	Cranbury	New Jersey	8512	USA	EXACT	0707653AA	trifarotene	0J8RN2W0HK						 Trichothiodystrophy 	12109	approximate	
trifarotene	Treatment of congenital ichthyosis	trifarotene	TRIFAROTENE	n/a	6/6/14	Designated			N/A	N/A	"Galderma R&D, LLC"	Cranbury	New Jersey	8512	USA	EXACT	0707653AA	trifarotene	0J8RN2W0HK						 Chanarin-Dorfman syndrome	3979	approximate	
trifluridine	Treatment of gastric cancer including cancer of the gastroesophageal junction	trifluridine/tipiracil	TRIFLURIDINE	n/a	4/17/17	Designated			N/A	N/A	"Taiho Oncology, Inc."	Princeton	New Jersey	8540	USA	EXACT	0012102AA	trifluridine	RMW9V5RW38						Stomach cancer	7704	done	
triheptanoin	Treatment of fatty acid oxidation disorders	triheptanoin	TRIHEPTANOIN	n/a	4/15/15	Designated			N/A	N/A	"Ultragenyx Pharmaceutical, Inc."	Novato	California	94949	USA	EXACT	0236011AA	triheptanoin	2P6O7CFW5K								MISSING	fatty acid disorders not specified
triheptanoin	Treatment of glucose transporter type-1 deficiency syndrome	triheptanoin	TRIHEPTANOIN	n/a	10/21/14	Designated			N/A	N/A	"Ultragenyx Pharmaceutical, Inc."	Novato	California	94949	USA	EXACT	0236011AA	triheptanoin	2P6O7CFW5K						Glucose transporter type 1 deficiency syndrome	9265	done	
trypsin	Treatment of multiple myeloma.	"Papain, trypsin, and chymotrypsin"	"TRYPSIN, UNSPECIFIED FORM"	Wobe-Mugos	12/21/98	Designated			N/A	N/A	"Marlyn Nutraceuticals, Inc."	Scottsdale	Arizona	85254	USA	EXACT	0005174AA	trypsin	GV54A213NN						Multiple myeloma	7108	done	
tucatinib	Treatment of HER2+ colorectal cancer	tucatinib	TUCATINIB	n/a	9/18/17	Designated			N/A	N/A	"Cascadian Therapeutics, Inc."	Seattle	Washington	98121	USA	EXACT	1078393AA	tucatinib	234248D0HH						"Colorectal cancer, childhood "	9320	approximate	
tucatinib	Treatment of HER2+ colorectal cancer	tucatinib	TUCATINIB	n/a	9/18/17	Designated			N/A	N/A	"Cascadian Therapeutics, Inc."	Seattle	Washington	98121	USA	EXACT	1078393AA	tucatinib	234248D0HH						 Familial colorectal cancer	8533	approximate	
tucatinib	Treatment of breast cancer patients with brain metastases.	tucatinib	TUCATINIB	n/a	6/5/17	Designated			N/A	N/A	"Cascadian Therapeutics, Inc."	Seattle	Washington	98121	USA	EXACT	1078393AA	tucatinib	234248D0HH						Familial breast cancer	10415	approximate	
tyloxapol	"1. Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less 2. prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32 weeks gestation or less and in the treatment of established HMO at all gestational ages."	"Colfosceril palmitate, cetyl alcohol, tyloxapol"	TYLOXAPOL	Exosurf Neonatal For Intratracheal Suspension	10/20/89	Designated/Approved	Approved for Orphan Indication	"Prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32 weeks gestation or less and in the treatment of established HMO at all gestational ages"	8/2/90	8/2/97	Glaxo Wellcome Inc.	Research Triangle Park	North Carolina	27709	USA	EXACT	0063003AA	tyloxapol	Y27PUL9H56						"Respiratory distress syndrome, infant"	112	done	
tyloxapol	Treatment of adult respiratory distress syndrome.	"Colfosceril palmitate, cetyl alcohol, tyloxapol"	TYLOXAPOL	Exosurf	1/11/93	Designated/Withdrawn			N/A	N/A	GlaxoSmithKline	Research Triangle Park	North Carolina	27709	USA	EXACT	0063003AA	tyloxapol	Y27PUL9H56						Acute respiratory distress syndrome	5698	done	
ubidecarenone	Treatment of pancreatic cancer	ubidecarenone	UBIDECARENONE	n/a	11/8/17	Designated			N/A	N/A	"Berg, LLC"	500 Old Connecticut Path	Massachusetts	1701	USA	EXACT	0024282AA	ubidecarenone	EJ27X76M46						Pancreatic cancer	9364	done	Not a rare disease
ubiquinol	Treatment of Huntington's Disease	ubiquinol	UBIQUINOL	"Ubi-Q-Nol, Li-Q-Nol"	4/12/04	Designated			N/A	N/A	"Gel-Tec, Division of Tishcon Corp."	Westbury	New York	11590	USA	EXACT	0727435AA	ubiquinol	M9NL0C577Y						Huntington disease	6677	done	
ublituximab	"Treatment of Extranodal marginal zone lymphoma (mucosa-associated lymphatic tissue, MALT)"	ublituximab	UBLITUXIMAB	n/a	9/5/13	Designated			N/A	N/A	"TG Therapeutics, Inc."	New York	New York	10019	USA	EXACT	0574607AA	ublituximab	U59UGK3IPC						Marginal zone lymphoma	13237	done	
udenafil	Treatment of single ventricle congenital heart disease with Fontan physiology	udenafil	UDENAFIL	n/a	8/31/15	Designated			N/A	N/A	Mezzion Pharma Co. Ltd.	Seoul			"Korea, Republic of"	EXACT	0333528AA	udenafil	L5IB4XLY36						Single ventricular heart	4878	approximate	
upadacitinib	Treatment of pediatric systemic juvenile idiopathic arthritis	upadacitinib	UPADACITINIB	n/a	8/16/17	Designated			N/A	N/A	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0847847AA	upadacitinib	4RA0KN46E0						Systemic onset juvenile idiopathic arthritis	10966	done	
upamostat	Treatment of pancreatic cancer	upamostat	UPAMOSTAT	n/a	10/16/17	Designated			N/A	N/A	RedHill Biopharma Ltd.	Tel Aviv-Yafo			Israel	EXACT	0633205AA	upamostat	S5M7KW6U17						Pancreatic cancer	9364	done	Not a rare disease
urea	"Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis)."	urea	UREA	n/a	11/7/11	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0009290AA	urea	8W8T17847W						CHILD syndrome 	6039	approximate	
urea	"Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis)."	urea	UREA	n/a	11/7/11	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0009290AA	urea	8W8T17847W						 X-linked ichthyosis 	7904	approximate	
urea	"Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis)."	urea	UREA	n/a	11/7/11	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0009290AA	urea	8W8T17847W						 KID syndrome 	3113	approximate	
urea	"Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis)."	urea	UREA	n/a	11/7/11	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0009290AA	urea	8W8T17847W						 Harlequin ichthyosis 	6568	approximate	
urea	"Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis)."	urea	UREA	n/a	11/7/11	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0009290AA	urea	8W8T17847W						 Lamellar ichthyosis 	10803	approximate	
urea	"Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis)."	urea	UREA	n/a	11/7/11	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0009290AA	urea	8W8T17847W						 Netherton syndrome 	7182	approximate	
urea	"Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis)."	urea	UREA	n/a	11/7/11	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0009290AA	urea	8W8T17847W						 Sjogren-Larsson syndrome 	7654	approximate	
urea	"Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis)."	urea	UREA	n/a	11/7/11	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0009290AA	urea	8W8T17847W						 Trichothiodystrophy 	12109	approximate	
urea	"Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis)."	urea	UREA	n/a	11/7/11	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0009290AA	urea	8W8T17847W						 Chanarin-Dorfman syndrome	3979	approximate	
uridine triacetate	An antidote in the treatment of 5-fluorouracil or capecitabine poisoning	uridine triacetate	URIDINE TRIACETATE	n/a	5/1/09	Designated/Approved	Approved for Orphan Indication	"For the emergency treatment of adult and pediatric patients following a fluorouracil or capecitabine overdose regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration"	12/11/15	12/11/22	Wellstat Therapeutics Corp.	Gaithersburg	Maryland	20878	USA	EXACT	0179760AA	uridine triacetate	2WP61F175M								MISSING	
uridine triacetate	Treatment of hereditary orotic aciduria	uridine triacetate	URIDINE TRIACETATE	n/a	8/9/13	Designated/Approved	Approved for Orphan Indication	Treatment of hereditary orotic aciduria	9/4/15	9/4/22	"Wellstat Therapeutics, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0179760AA	uridine triacetate	2WP61F175M						Orotic aciduria type 1	5429	done	
uridine triacetate	Treatment of mitchondrial disease	uridine triacetate	URIDINE TRIACETATE	n/a	9/3/09	Designated			N/A	N/A	Wellstat Therapeutics Corporation	Gaithersburg	Maryland	20878	USA	EXACT	0179760AA	uridine triacetate	2WP61F175M								MISSING	mitchondrial disease not specified
ustekinumab	Treatment of chronic sarcoidosis	ustekinumab	USTEKINUMAB	Stelara	12/28/11	Designated/Withdrawn			N/A	N/A	"Janssen Biotech, Inc."	Horsham	Pennsylvania	19044	USA	EXACT	0266762AA	ustekinumab	FU77B4U5Z0						Sarcoidosis	7607	done	
ustekinumab	Treatment of pediatric systemic lupus erythematosus	ustekinumab	USTEKINUMAB	Stelara	7/18/17	Designated			N/A	N/A	"Janssen Biotech, Inc."	Horsham	Pennsylvania	19044	USA	EXACT	0266762AA	ustekinumab	FU77B4U5Z0						Lupus	10253	done	
ustekinumab	Treatment of primary biliary cirrhosis	ustekinumab; human monocloncal antibody to interkeukin 12p40	USTEKINUMAB	Stelara	12/22/11	Designated/Withdrawn			N/A	N/A	"Janssen Biotech, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	0266762AA	ustekinumab	FU77B4U5Z0						Primary biliary cholangitis	7459	done	
ustekinumab	Treatment of type 1 diabetes mellitus patients with residual beta-cell function.	ustekinumab	USTEKINUMAB	Stelara	11/29/10	Designated			N/A	N/A	Johnson & Johnson Pharmaceutical & Development LLC	Raritan	New Jersey	8869	USA	EXACT	0266762AA	ustekinumab	FU77B4U5Z0						Diabetes mellitus type 1	10268	done	not a rare disease
uv-4b	"Treatment of acute dengue illness (inclusive of acute dengue illness, dengue fever, dengue hemorrhagic fever, and dengue shock syndrome)"	N-(9-methoxynonyl)-1-deoxynojirimycin hydrochloride	N-9-METHOXYNONYLDEOXYNOJIRIMYCIN HYDROCHLORIDE	n/a	11/17/14	Designated			N/A	N/A	"Emergent Virology, LLC"	Gaithersburg	Maryland	20879	USA	EXACT	0925019AA	uv-4b	R3Y2198MRP						Dengue fever	6254	done	
valbenazine	Treatment of pediatric patients with Tourette syndrome (TS).	valbenazine	VALBENAZINE	Ingrezza®	10/19/17	Designated			N/A	N/A	"Neurocrine Biosciences, Inc."	San Diego	California	92130	USA	EXACT	0707700AA	valbenazine	54K37P50KH						Tourette syndrome	7783	done	
valsartan oral solution	Treatment of hypertension in pediatric patients 0 through 16 years of age	valsartan oral solution	VALSARTAN	n/a	10/28/15	Designated/Withdrawn by OPD			N/A	N/A	Carmel Biosciences	Atlanta	Georgia	30342	USA	EXACT	0181408AA	valsartan	80M03YXJ7I						Pediatric hypertension	11921	done	
vamorolone	Treatment of Duchenne muscular dystrophy	"delta-1,4,9(11)-pregnatriene-17-alpha,21-dihydroxy-16-alpha-methyl-3,20-dione"	VAMOROLONE	n/a	12/2/11	Designated			N/A	N/A	ReveraGen Biopharma	Rockville	Maryland	20850	USA	EXACT	0739719AA	vamorolone	8XP29XMB43						Duchenne muscular dystrophy	6291	done	
vancomycin	Treatment of endophthalmitis	vancomycin	VANCOMYCIN	n/a	12/27/12	Designated			N/A	N/A	"Fera Pharmaceuticals, LLC"	Locust Valley	New York	11560	USA	EXACT	0036180AA	vancomycin	6Q205EH1VU								MISSING	"Endophthalmitis is an inflammatory condition of the intraocular cavities, usually caused by infection. Noninfectious (sterile) endophthalmitis may result from various causes such as retained native lens material after an operation or from toxic agents."
vandetanib	"Treatment of patients with follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, and locally advanced and metastatic papillary thyroid carcinoma"	vandetanib	VANDETANIB	Caprelsa(R)	10/21/05	Designated/Approved	Approved for Orphan Indication	Treatment of asymptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease	4/6/11	4/6/18	Genzyme Corporation	Cambridge	Massachusetts	2142	USA	EXACT	0235789AA	vandetanib	YO460OQ37K						"Thyroid cancer, follicular "	5206	done	
vandetanib	"Treatment of patients with follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, and locally advanced and metastatic papillary thyroid carcinoma"	vandetanib	VANDETANIB	Caprelsa(R)	10/21/05	Designated/Approved	Approved for Orphan Indication	Treatment of asymptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease	4/6/11	4/6/18	Genzyme Corporation	Cambridge	Massachusetts	2142	USA	EXACT	0235789AA	vandetanib	YO460OQ37K						" Thyroid cancer, medullary "	7004	done	
vandetanib	"Treatment of patients with follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, and locally advanced and metastatic papillary thyroid carcinoma"	vandetanib	VANDETANIB	Caprelsa(R)	10/21/05	Designated/Approved	Approved for Orphan Indication	Treatment of asymptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease	4/6/11	4/6/18	Genzyme Corporation	Cambridge	Massachusetts	2142	USA	EXACT	0235789AA	vandetanib	YO460OQ37K						 Anaplastic thyroid cancer 	664	done	
vandetanib	"Treatment of patients with follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, and locally advanced and metastatic papillary thyroid carcinoma"	vandetanib	VANDETANIB	Caprelsa(R)	10/21/05	Designated/Approved	Approved for Orphan Indication	Treatment of asymptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease	4/6/11	4/6/18	Genzyme Corporation	Cambridge	Massachusetts	2142	USA	EXACT	0235789AA	vandetanib	YO460OQ37K						 Papillary thyroid carcinoma	12027	done	
vapreotide	Prevention of early postoperative complications following pancreatic resection.	vapreotide	VAPREOTIDE	Octastatin	3/6/00	Designated			N/A	N/A	Debiopharm S.A.				Switzerland	EXACT	0182183AA	vapreotide	2PK59M9GFF								MISSING	
vapreotide	Treatment of esophageal variceal hemorrhage patients with portal hypertension.	vapreotide	VAPREOTIDE	Sanvar	1/10/00	Designated			N/A	N/A	"Debiovision, Inc."	"Montreal, Quebec H3A 1E7"			Canada	EXACT	0182183AA	vapreotide	2PK59M9GFF								MISSING	Not a rare disease
vapreotide	Treatment of gastrointestinal and pancreatic fistulas.	vapreotide	VAPREOTIDE	Octastatin	1/10/00	Designated			N/A	N/A	Debiopharm S.A.				Switzerland	EXACT	0182183AA	vapreotide	2PK59M9GFF								MISSING	not a disease
varespladib sodium	Prevention of acute chest syndrome in at-risk patients with sickle cell disease	varespladib sodium	VARESPLADIB SODIUM	n/a	11/19/07	Designated/Withdrawn			N/A	N/A	"Anthera Pharmaceuticals, Inc."	Hayward	California	94545	USA	EXACT	0212668AA	varespladib sodium	F6M52CDT0W						Sickle cell anemia	8614	approximate	the exact type of sickle cell disease is not specified
varlitinib	Treatment of gastric cancer.	varlitinib	VARLITINIB	n/a	6/20/16	Designated			N/A	N/A	ASLAN Pharmaceuticals				Singapore	EXACT	0257692AA	varlitinib	846Y8197W1						Stomach cancer	7704	done	
vedolizumab	Prevention of graft versus host disease.	vedolizumab	VEDOLIZUMAB	n/a	8/4/16	Designated			N/A	N/A	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0263741AA	vedolizumab	9RV78Q2002						Chronic graft versus host disease	10964	approximate	type of GVHD (acute or chronic) is not specified
vedolizumab	Prevention of graft versus host disease.	vedolizumab	VEDOLIZUMAB	n/a	8/4/16	Designated			N/A	N/A	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0263741AA	vedolizumab	9RV78Q2002						Acute graft versus host disease	6544	approximate	type of GVHD (acute or chronic) is not specified
veliparib	Treatment of brain metastases when used in combination with DNA-damaging agents	veliparib	VELIPARIB	n/a	12/17/14	Designated			N/A	N/A	AbbVie Inc.	North Chicago	Illinois	60064	USA	EXACT	0338192AA	veliparib	01O4K0631N								MISSING	Not a rare disease; symptom of many types of cancer
veliparib	Treatment of squamous non-small cell lung cancer	veliparib	VELIPARIB	n/a	11/3/16	Designated			N/A	N/A	AbbVie Inc.	North Chicago	Illinois	60064	USA	EXACT	0338192AA	veliparib	01O4K0631N						"Non-small cell lung cancer, childhood"	9343	approximate	
velpatasvir	Treatment of pediatric chronic hepatitis C virus (HCV) infection	sofosbuvir/velpatasvir	VELPATASVIR	Epclusa	2/22/17	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	1078633AA	velpatasvir	KCU0C7RS7Z								MISSING	
veltuzumab	Treatment of immune thrombocytopenic purpura.	veltuzumab	VELTUZUMAB	n/a	7/28/15	Designated			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA	EXACT	0265894AA	veltuzumab	BPD4DGQ314						Idiopathic thrombocytopenic purpura	5194	approximate	
vemurafenib	Treatment of patients with non-small cell lung cancer (NSCLC) with BRAF V600 mutation	vemurafenib	VEMURAFENIB	Zelboraf	9/8/14	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0507620AA	vemurafenib	207SMY3FQT						"Non-small cell lung cancer, childhood"	9343	approximate	
venglustat	Treatment of Autosomal Dominant Polycystic Kidney Disease	venglustat	VENGLUSTAT	n/a	5/1/18	Designated			N/A	N/A	"Genzyme Corporation, a SANOFI COMPANY"	50 Binney Street		2142	USA	EXACT	1120270AA	venglustat	BLP1XA3FZA						Autosomal dominant polycystic kidney disease	10413	done	Not a rare disease
vitamin A	Treatment of neuronal ceroid lipofuscinoses	gemfibrozil and vitamin A	VITAMIN A	n/a	12/6/17	Designated			N/A	N/A	"Polaryx Therapeutics, Inc."	140 East Ridgewood Avenue	Paramus	7652	USA	EXACT	0011814AA	vitamin A	81G40H8B0T						Neuronal ceroid lipofuscinosis	10739	done	
vitamin D3	Use as a targeted contrast agent for diagnostic MRI for the detection and localization of focal liver lesions in patients where use of gadolinium based contrast agents may be medically inadvisable or where gadolinium based contrast agents cannot be administered	manganese (II) chloride tetrahydrate (with L-alanine and vitamin D3 as promoters of absorption)	CHOLECALCIFEROL	n/a	9/26/13	Designated			N/A	N/A	CMC Contrast AB				Denmark	EXACT	0011756AA	vitamin D3	1C6V77QF41								MISSING	
"volanesorsen sodium, apolipotrotein C-III antisense oligonucleotide"	treatment of familial chylomicronemia syndrome	"volanesorsen sodium, apolipotrotein C-III antisense oligonucleotide"	VOLANESORSEN SODIUM	n/a	6/23/15	Designated			N/A	N/A	"Ionis Pharmaceuticals, Inc."	Carlsbad	California	92010	USA	EXACT	1123111AA	volanesorsen sodium	6JON30SLDT								MISSING	"The term familial chylomicronemia is sometimes used synonymously with familial lipoprotein lipase deficiency. However, there are different causes of familial chylomicronemia."
von Willebrand Factor Human Concentrate	Treatment of Von Willebrand Disease	von Willebrand Factor Human Concentrate	VON WILLEBRAND FACTOR HUMAN	Wilfactin	5/29/14	Designated			N/A	N/A	"rEVO Biologics, Inc."	Framingham	Massachusetts	1702	USA	EXACT	0323342AA	von Willebrand Factor Human	ZE22NE22F1						Von Willebrand disease	7867	done	
vorinostat	Treatment of T-cell non-Hodgkin's lymphoma	vorinostat	VORINOSTAT	Zolinza	3/16/04	Designated/Approved	Approved for Orphan Indication	"Treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistant or recurrent disease on or following two systemic therapies."	10/6/06	10/6/13	"Merck & Co., Inc."	Rahway	New Jersey	7065	USA	EXACT	0233089AA	vorinostat	58IFB293JI						Adult T-cell leukemia/lymphoma	13103	approximate	
vorinostat	"Treatment of advanced melanoma (stages IIb, IIc, III, and IV)"	vorinostat	VORINOSTAT	n/a	10/13/16	Designated			N/A	N/A	Qameleon Therapeutics	Kudelstaart			Netherlands	EXACT	0233089AA	vorinostat	58IFB293JI						Nodular melanoma	9961	approximate	
vorinostat	Treatment of mesothelioma	vorinostat	VORINOSTAT	n/a	3/17/04	Designated/Withdrawn			N/A	N/A	"Merck & Co., Inc."	Rahway	New Jersey	7065	USA	EXACT	0233089AA	vorinostat	58IFB293JI						Malignant mesothelioma	7026	done	
xenon gas	To improve neurological outcome in hospitalized cardiac arrest patients.	xenon gas	XENON	n/a	5/18/15	Designated			N/A	N/A	Neuroprotexeon				United Kingdom	EXACT	0048260AA	xenon	3H3U766W84								MISSING	Not a rare disease
xenon gas	Treatment of hypoxic ischemic encephalopathy	xenon gas	XENON	n/a	12/3/14	Designated			N/A	N/A	Neuroprotexeon				United Kingdom	EXACT	0048260AA	xenon	3H3U766W84								MISSING	
zidovudine	Treatment of AIDS	zidovudine	ZIDOVUDINE	Retrovir	7/17/85	Designated/Approved	Approved for Orphan Indication	Management of certain adult patients with symptomatic HIV infection (AIDS and advanced ARC) who have a history of cytologically confirmed Pneumocytis carinii pneumonia (PCP) or an absolute CD4 (T4 helper/induccer) lymphocyte count of less than 200/mm in the peripheral blood before therapy is begun	3/19/87	3/19/94	Glaxo Wellcome Inc.	Research Triangle Park	North Carolina	27709	USA	EXACT	0148163AA	zidovudine	4B9XT59T7S						Congenital human immunodeficiency virus	10328	approximate	
zinc oxide	For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy	"Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide"	ZINC OXIDE	Total Block Vl Spf 75	8/13/01	Designated			N/A	N/A	Fallien Cosmeceuticals Ltd.	King of Prussia	Pennsylvania	19406	USA	EXACT	0033954AA	zinc oxide	SOI2LOH54Z								MISSING	
zoledronic acid	Treatment of complex regional pain syndrome (CRPS).	zoledronic acid	ZOLEDRONIC ACID	"Zometa, Reclast, Aclasta"	5/6/13	Designated			N/A	N/A	"Axsome Therapeutics, Inc."	New York	New York	10111	USA	EXACT	0183755AA	zoledronic acid	6XC1PAD3KF						Complex regional pain syndrome	4647	done	
zw-25	"Treatment of gastric cancer, including cancer of the gastroesophageal junction"	Anti-HER2 bispecific antibody	ZW-25	n/a	2/6/17	Designated			N/A	N/A	Zymeworks Inc.	Seattle	Washington	98119	USA	EXACT	0110929AB	zw-25	Z20OC92TDI						Stomach cancer	7704	done	
NZ-1001	"For enzyme replacement therapy in patients with all subtypes of glycogen storage disease type II (GSDII, Pompe Disease)"	Recombinant human highly phosphorylated acid alpha-glucosidase		Tbd	9/20/00	Designated			N/A	N/A	"Novazyme Pharmaceuticals, Inc."	Oklahoma City	Oklahoma	73104	USA	EXACT			DTI67O9503	.ALPHA.-GLUCOSIDASE	DTI67O9503	https://ginas.ncats.nih.gov/ginas/app/substance/4c336317	approximate		Glycogen storage disease type 2	5714	done	
flunarizine	Treatment of alternating hemiplegia.	flunarizine		Sibelium	1/6/86	Designated			N/A	N/A	Janssen Research Foundation	Titusville	New Jersey	8560	USA	EXACT	0330198AA	flunarizine	R7PLA2DM0J						Alternating hemiplegia	11		
flunarizine	Treatment of alternating hemiplegia	flunarizine		n/a	6/24/13	Designated			N/A	N/A	"Marathon Pharmaceuticals, LLC"	Northbrook	Illinois	60062	USA	EXACT	0330198AA	flunarizine	R7PLA2DM0J						Alternating hemiplegia	11		
Fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1	Treatment of X-linked hypohidrotic ectodermal dysplasia	EDI-200		n/a	1/11/06	Designated			N/A	N/A	"Edimer Pharmaceuticals, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0113808AB	EDI-200	AF6GZK1UMB						Hypohidrotic ectodermal dysplasia	76		
"non-replicating adeno-associated viral vector, serotype 8, expressing human myotubularin gene"	Treatment of x-linked myotubular myopathy	"non-replicating adeno-associated viral vector, serotype 8, expressing human myotubularin gene"		At001	12/3/14	Designated			N/A	N/A	"Audentes Therapeutics, Inc."	San Francisco	California	94104	USA										Myotubular myopathy	101		
modified vitamin D binding protein	Treatment of recurrent respiratory papillomatosis.	EF-022		n/a	4/17/17	Designated			N/A	N/A	"Efranat, Ltd."	Rehovot			Israel	EXACT									Recurrent respiratory papillomatosis	111		
Recombinant fusion protein of Mycobacterium bovis BCG Hsp65 and HPV16 E7	Treatment of recurrent respiratory papillomatosis (RRP)	Recombinant fusion protein of Mycobacterium bovis BCG Hsp65 and HPV16 E7		n/a	3/19/01	Designated			N/A	N/A	"StressGen Biotechnologies, Inc. is now Nventa"	San Diego	California	19426	USA	LONGEST CONTAINS	0935739AA	Mycobacterium bovis BCG	D3GOY6203T						Recurrent respiratory papillomatosis	111		
emixustat	Treatment of Stargardt disease (STGD)	emixustat		n/a	1/4/17	Designated			N/A	N/A	Acucela Inc.	Seattle	Washington	98101	USA	EXACT	0707120AA	emixustat	02DZ1HBF0M						Stargardt disease	181		
`	Treatment of Stargardt Disease (StD)	soraprazan		n/a	12/22/17	Designated			N/A	N/A	Katairo GmbH	21 Lederstraße	Kusterdingen		Germany	EXACT	0243390AA	soraprazan	5XB3671655						Stargardt disease	181		
"1-(3-{4-[3,4-difluoro-2-(trifluoromethyl)phenyl]piperidine-1-carbonyl}-1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridin-6-yl)ethan-1-one"	Treatment of Stargardt disease	LBS-008		n/a	9/19/17	Designated			N/A	N/A	"Lin BioScience, LLC"	San Diego	California	92121	USA	EXACT	0112622AB	LBS-008	63WI9S8P1M						Stargardt disease	181		
Lentiviral vector containing the human ABCA4 gene	Treatment of Stargardt disease	Lentiviral vector containing the human ABCA4 gene		Stargen (Tm)	4/30/10	Designated			N/A	N/A	"Sanofi US Services, Inc."	Bridgewater	New Jersey	8807	USA										Stargardt disease	181		
verteporfin	Treatment of chronic or recurrent central serous chorioretinopathy	verteporfin		Visudyne(R)	3/9/12	Designated			N/A	N/A	Valeant Pharmaceuticals North America LLC	Bridgewater	New Jersey	8807	USA	EXACT	0232280AA	verteporfin	0X9PA28K43						Central serous chorioretinopathy	200		
Albendazole	Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).	Albendazole		Albenza	1/17/96	Designated/Approved	Approved for Orphan Indication	"Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus."	6/11/96	6/11/03	Amedra Pharmaceuticals LLC	Horsham	Pennsylvania	19044	USA	EXACT	0121142AA	Albendazole	F4216019LN						Alveolar echinococcosis	207		
ivabradine	Treatment of pediatric patients (0 through 16 years of age) with dilated cardiomyopathy.	ivabradine		n/a	3/23/16	Designated			N/A	N/A	"Amgen, Inc.,"	Thousand Oaks	California	91320	USA	EXACT	0276722AA	ivabradine	3H48L0LPZQ						Dilated cardiomyopathy	221		
p38 mitogen-activated kinase inhibitor	"Treatment of dilated cardiomyopathy, including dilated cardiomyopathy secondary to lamin A/C gene mutations"	ARRY-797 		n/a	5/27/14	Designated			N/A	N/A	"Array BioPharma, Inc."	Boulder	Colorado	80301	USA	EXACT	0304358AA	ARRY-797	4JG61K4659						Dilated cardiomyopathy	221		
Vasomera	"Treatment of cardiomyopathy associated with dystrophinopathies; Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy BMD), and X-linked dilated cardiomyopathy (XL-dCMP)."	Vasomera		n/a	11/19/15	Designated			N/A	N/A	"PhaseBio Pharmaceuticals, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	1267045AA	Vasomera	200AW54D93						Dilated cardiomyopathy	221		
Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system	Treatment of dilated cardiomyopathy	Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system		n/a	1/25/07	Designated			N/A	N/A	Vericel Corporation.	Ann Arbor	Michigan	48105	USA	LONGEST CONTAINS	0260924AA	autologous bone marrow							Dilated cardiomyopathy	221		
trimetazidine	Treatment of idiopathic dilated cardiomyopathy	trimetazidine		n/a	10/30/18	Designated			N/A	N/A	"Martin Pharmaceuticals, Inc."	233 Broadway	New York	10279	USA	EXACT	0043196AA	trimetazidine	N9A0A0R9S8						Dilated cardiomyopathy	221		
rhIGF-I/rhIGFBP-3	"Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)"	rhIGF-I/rhIGFBP-3		Somatokine	12/9/03	Designated			N/A	N/A	"Insmed, Inc."	Monmouth Junction	New Jersey	8852	USA	EXACT	0212953AA	rhIGF-I/rhIGFBP-3	NZ8M50KKRG						Rabson-Mendenhall syndrome	226		
rhIGF-I/rhIGFBP-3	"Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)"	rhIGF-I/rhIGFBP-3		Somatokine	12/9/03	Designated			N/A	N/A	"Insmed, Inc."	Monmouth Junction	New Jersey	8852	USA	EXACT	0212953AA	rhIGF-I/rhIGFBP-3	NZ8M50KKRG						Mendenhall syndrome	226		
cethromycin	Prophylactic treatment of tularemia due to Francisella tularensis.	cethromycin		Restanza(Tm)	9/9/09	Designated			N/A	N/A	"Advanced Life Sciences, Inc."	Woodridge	Illinois	60517	USA	EXACT	0230580AA	cethromycin	J0086219X6						Tularemia	396		
canakinumab	Treatment of adult-onset Still's Disease	canakinumab		n/a	7/31/17	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0323159AA	canakinumab	37CQ2C7X93						Adult-onset Still's disease	436		
tadekinig alfa	"Treatment of Still's disease, including adult-onset Still's disease (AoSD) and systemic juvenile idiopathic arthritis (sJIA)"	tadekinig alfa		n/a	7/3/17	Designated			N/A	N/A	AB2 Bio Ltd	Lausanne			Switzerland	EXACT	1090422AA	tadekinig alfa	3G6834I4PF						Adult-onset Still's disease	436		
Interleukin-1 Trap	Treatment of Still's disease including juvenile rheumatoid arthritis and adult-onset Still's disease	Interleukin-1 Trap		n/a	4/4/05	Designated			N/A	N/A	"Regeneron Pharmaceuticals, Inc."	Tarrytown	New York	10591	USA	EXACT	0264119AA	Interleukin-1 Trap	8K80YB5GMG						Adult-onset Still's disease	436		
interleukin-1 receptor antagonist anakinra	Treatment of Still's disease including systemic juvenile idiopathic arithritis and adult-onset Still's disease.	Kineret		Kineret	9/15/15	Designated			N/A	N/A	Swedish Orphan Biovitrum AB				Sweden	EXACT	0242524AA	Kineret	9013DUQ28K						Adult-onset Still's disease	436		
moxetumomab pasudotox	Treatment of acute lymphoblastic leukemia	moxetumomab pasudotox		n/a	6/28/13	Designated			N/A	N/A	"MedImmune, LLC"	Gaithersburg	Maryland	20878	USA	EXACT	0432520AA	moxetumomab pasudotox	2NDX4B6N8F						Acute lymphoblastic leukemia	522		
epratuzumab	Treatment of acute lymphoblastic leukemia	epratuzumab		n/a	9/30/08	Designated			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA	EXACT	0281049AA	epratuzumab	3062P60MH9						Acute lymphoblastic leukemia	522		
ponatinib	Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)	ponatinib		Iclusig	11/20/09	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.	12/14/12	12/14/19	ARIAD Pharmaceuticals Inc.	Cambridge	Massachusetts	2139	USA	EXACT	0460162AA	ponatinib	4340891KFS						Acute lymphoblastic leukemia	522		
Idarubicin HCl for injection	Treatment of acute lymphoblastic leukemia in pediatric patients.	Idarubicin HCl for injection		Idamycin	2/12/91	Designated/Withdrawn			N/A	N/A	"Pfizer, Inc."	New York	New York	10017	USA	EXACT	0116574AA	Idarubicin HCl	5VV3MDU5IE						Acute lymphoblastic leukemia	522		
nelarabine	Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma	nelarabine		Arranon	8/10/04	Designated/Approved	Approved for Orphan Indication	Treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens	10/28/05	10/28/12	Novartis Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0183302AA	nelarabine	60158CV180						Acute lymphoblastic leukemia	522		
bortezomib	Treatment of acute lymphoblastic leukemia	bortezomib		Velcade	2/3/15	Designated			N/A	N/A	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0228319AA	bortezomib	69G8BD63PP						Acute lymphoblastic leukemia	522		
"(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride"	Treatment of acute lymphoblastic leukemia	FORODESINE HYDROCHLORIDE		n/a	8/13/04	Designated			N/A	N/A	Mundipharma Research Limited	England			United Kingdom	EXACT	0241736AA	FORODESINE HYDROCHLORIDE	6SN82Y9U73						Acute lymphoblastic leukemia	522		
clofarabine	Treatment of acute lymphoblastic leukemia	clofarabine		Clolar	2/7/02	Designated/Approved	Approved for Orphan Indication	Treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens	12/28/04	12/28/11	Genzyme Corporation	San Antonio	Texas	78229	USA	EXACT	0183813AA	clofarabine	762RDY0Y2H						Acute lymphoblastic leukemia	522		
Ruxolitinib	Treatment of acute lymphoblastic leukemia.	Ruxolitinib		n/a	7/18/16	Designated			N/A	N/A	Incyte Corporation	Wilmington	Delaware	19803	USA	EXACT	0557119AA	Ruxolitinib	82S8X8XX8H						Acute lymphoblastic leukemia	522		
small molecule inhibitor of histone methyltransferase DOT1L	Treatment of acute lymphoblastic leukemia (ALL)	EPZ-5676		n/a	8/8/13	Designated			N/A	N/A	Epizyme Inc.	Cambridge	Massachusetts	2139	USA	EXACT	0835916AA	EPZ-5676	8V9YR09EF3						Acute lymphoblastic leukemia	522		
Talotrexin	Treatment of acute lymphoblastic leukemia	Talotrexin		n/a	5/8/06	Designated/Withdrawn			N/A	N/A	"Hana Biosciences, Inc."	South San Francisco	California	94080	USA	EXACT	0307584AA	Talotrexin	A8E516A20K						Acute lymphoblastic leukemia	522		
imatinib	Treatment of Philadelphia-positive acute lymphoblastic leukemia	imatinib		Gleevec	10/11/05	Designated/Approved	Approved for Orphan Indication	"Treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy, approved under NDA #21588/S-037"	1/25/13	1/25/20	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0240153AA	imatinib	BKJ8M8G5HI						Acute lymphoblastic leukemia	522		
imatinib	Treatment of Philadelphia-positive acute lymphoblastic leukemia	imatinib		Gleevec	10/11/05	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL)	10/19/06	10/19/13	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0240153AA	imatinib	BKJ8M8G5HI						Acute lymphoblastic leukemia	522		
Erwinia L-asparaginase	For use as an alternative to E. coli asparaginase in those situations where repeat courses of asparaginase therapy for acute lymphoblastic leukemia are required or where allergic reactions force the discontinuance of the E. coli preparation.	Erwinase		n/a	1/25/85	Designated/Withdrawn			N/A	N/A	"Lyphomed, Inc."					EXACT	0260322AA	Erwinase	D733ET3F9O						Acute lymphoblastic leukemia	522		
mercaptopurine oral solution	Treatment of acute lymphoblastic leukemia in pediatric patients	mercaptopurine oral solution		Purixan	8/20/12	Designated/Approved	Approved for Orphan Indication	Treatment of patients with acute lymphoblastic leukemia as part of a combination regimen.	4/28/14	4/28/21	Nova Laboratories Limited	England			United Kingdom	EXACT	0007454AA	mercaptopurine	E7WED276I5						Acute lymphoblastic leukemia	522		
L-asparaginase encapsulated in red blood cells	Treatment of acute lymphoblastic leukemia	L-asparaginase 		Graspa	1/6/10	Designated			N/A	N/A	Erytech Pharma	LYON			France	EXACT	0099467AA	L-asparaginase	G4FQ3CKY5R						Acute lymphoblastic leukemia	522		
Granaticin B	Treatment of Acute Lymphoblastic Leukemia (ALL)	Granaticin B		n/a	3/7/18	Designated			N/A	N/A	"Lin BioScience, LLC"	3210 Merryfield Row		92121	USA	EXACT	0696720AA	Granaticin B	JS606MEA30						Acute lymphoblastic leukemia	522		
inotuzumab ozogamicin	Treatment of B-cell acute lymphoblastic leukemia	inotuzumab ozogamicin		n/a	3/25/13	Designated			N/A	N/A	"Pfizer, Inc."	Groton	Connecticut	6340	USA	EXACT	0301882AA	inotuzumab ozogamicin	P93RUU11P7						Acute lymphoblastic leukemia	522		
6-mercaptopurine oral liquid	Treatment of acute lymphoblastic leukemia in the pediatric population	6-mercaptopurine		n/a	12/7/09	Designated			N/A	N/A	Orbona Pharma Ltd	Surrey			United Kingdom	EXACT	0045852AA	6-mercaptopurine	PKK6MUZ20G						Acute lymphoblastic leukemia	522		
Dasatinib	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Dasatinib		Sprycel	11/18/05	Designated/Approved	Approved for Orphan Indication	Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy	6/28/06	6/28/13	Bristol-Myers Squibb Company	Wallingford	Connecticut	6492	USA	EXACT	0258560AA	Dasatinib	RBZ1571X5H						Acute lymphoblastic leukemia	522		
Liposomal annamycin	Treatment of acute lymphoblastic leukemia	Liposomal annamycin		n/a	6/17/05	Designated			N/A	N/A	"Callisto Pharmaceuticals, Inc."	New York	New York	10170	USA	EXACT	0191015AA	annamycin	SNU299M83Q						Acute lymphoblastic leukemia	522		
vinCRIStine sulfate LIPOSOME injection	Treatment of acute lymphoblastic leukemia	vinCRIStine sulfate LIPOSOME injection		Marqibo	1/8/07	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.	8/9/12	8/9/19	"Talon Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	0901202AA	vinCRIStine sulfate LIPOSOME	T5IRO3534A						Acute lymphoblastic leukemia	522		
Plitidepsin	Treatment of acute lymphoblastic leukemia	Plitidepsin		Aplidin	6/18/04	Designated/Withdrawn			N/A	N/A	"PharmaMar USA, Inc"	Cambridge	Massachusetts	2139	USA	EXACT	0252642AA	Plitidepsin	Y76ID234HW						Acute lymphoblastic leukemia	522		
mPEG-r-crisantaspase	Treatment of acute lymphoblastic leukemia.	Pegcrisantaspase 		Asparec(Tm)	2/1/10	Designated			N/A	N/A	"Jazz Pharmaceuticals, Inc."	Palo Alto	California	94304	USA	EXACT	1079589AA	Pegcrisantaspase	Y8KTZ6Y35U						Acute lymphoblastic leukemia	522		
methotrexate	Treatment of acute lymphoblastic leukemia	methotrexate		n/a	8/20/09	Designated			N/A	N/A	Orbona Pharma Ltd	England			United Kingdom	EXACT	0010059AA	methotrexate	YL5FZ2Y5U1						Acute lymphoblastic leukemia	522		
methotrexate oral liquid formulation	Treatment of acute lymphoblastic leukemia in pediatric patients aged 0 through 16 years.	methotrexate oral liquid formulation		n/a	3/18/15	Designated			N/A	N/A	Chesapeake Therapeutics	Pikesville	Maryland	21208	USA	EXACT	0010059AA	methotrexate	YL5FZ2Y5U1						Acute lymphoblastic leukemia	522		
methotrexate oral solution	Treatment of acute lymphoblastic leukemia in pediatric patients (0 through 16 years of age)	methotrexate oral solution		n/a	5/28/15	Designated			N/A	N/A	"Silvergate Pharmaceuticals, Inc."	Greenwood Village	Colorado	80111	USA	EXACT	0010059AA	methotrexate	YL5FZ2Y5U1						Acute lymphoblastic leukemia	522		
stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells	Treatment of acute lymphoblastic leukemia.	UMBILICAL CORD MESENCHYMAL STROMAL CELLS		Nicord(R)	11/13/14	Designated			N/A	N/A	Gamida Cell Ltd.	Jerusalem			Israel	EXACT	1794565AA	UMBILICAL CORD MESENCHYMAL STROMAL CELLS	3FXW1IW7WT						Acute lymphoblastic leukemia	522		
Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19	For the treatment of Acute Lymphoblastic Leukemia	Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19		n/a	1/31/14	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	LONGEST CONTAINS	1722709AA	CD19	IYZ9TI08W3						Acute lymphoblastic leukemia	522		
hematopoietic stem and progenitor cells expanded ex-vivo with a low molecular weight aryl hydrocarbon receptor (AHR) antagonist	Hematopoietic support in patients with acute lymphoblastic leukemia (ALL)	hematopoietic stem and progenitor cells expanded ex-vivo with a low molecular weight aryl hydrocarbon receptor (AHR) antagonist		n/a	8/27/14	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	LONGEST CONTAINS	0216671AA	hydrocarbon							Acute lymphoblastic leukemia	522		
autologous CD4+/CD8+ T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19	Treatment of acute lymphoblastic leukemia (inclusive of B-cell acute lymphoblastic leukemia)	autologous CD4+/CD8+ T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19		n/a	11/6/14	Designated			N/A	N/A	"Juno Therapeutics, Inc."	Seattle	Washington	98109	USA	LONGEST CONTAINS	1722709AA	CD19	IYZ9TI08W3						Acute lymphoblastic leukemia	522		
Autologous CD3+ T cells transduced with retroviral vector containing a chimeric antigen receptor directed against CD19 (Autologous CD3+ T cells containing CD19 chimeric antigen receptor)	Treatment of acute lymphoblastic leukemia (ALL)	Autologous CD3+ T cells transduced with retroviral vector containing a chimeric antigen receptor directed against CD19 (Autologous CD3+ T cells containing CD19 chimeric antigen receptor)		n/a	11/13/14	Designated			N/A	N/A	"Juno Therapeutics, Inc."	Seattle	Washington	98109	USA	LONGEST CONTAINS	1722709AA	CD19	IYZ9TI08W3						Acute lymphoblastic leukemia	522		
Autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor	Treatment of acute lymphoblastic leukemia. (ALL).	Autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor		n/a	4/20/16	Designated			N/A	N/A	"Kite Pharma, Inc."	Santa Monica	California	90404	USA	LONGEST CONTAINS	1722709AA	CD19	IYZ9TI08W3						Acute lymphoblastic leukemia	522		
autologous CD4+/CD8+ T cells expressing a CD19 chimeric antigen receptor and a truncated epidermal growth factor receptor	Treatment of acute lymphoblastic leukemia	autologous CD4+/CD8+ T cells expressing a CD19 chimeric antigen receptor and a truncated epidermal growth factor receptor		n/a	9/7/16	Designated			N/A	N/A	"Juno Therapeutics, Inc."	Seattle	Washington	98109	USA	LONGEST CONTAINS	1309962AA	epidermal growth factor receptor	RO03J093CP						Acute lymphoblastic leukemia	522		
chimeric Antigen Receptor (CAR) directed against the target protein CD5	Treatment of acute lymphoblastic leukemia	chimeric Antigen Receptor (CAR) directed against the target protein CD5		n/a	10/16/17	Designated			N/A	N/A	iCell Gene Therapeutics	Stony Brook	New York	11793	USA	LONGEST CONTAINS	0087274AA	protein							Acute lymphoblastic leukemia	522		
`	Treatment of acute lymphoblastic leukemia	"ICG140:CD19-CD123 cCAR T-cells, a chimeric antigen receptor (CAR) on the surface of T-cells directed against the target proteins CD19 and CD 123"		n/a	12/26/17	Designated			N/A	N/A	iCell Gene Therapeutics	25 Health Sciences Drive	Stony Brook	11793	USA	LONGEST CONTAINS	0634640AA	proteins							Acute lymphoblastic leukemia	522		
allogeneic anti-CD19 chimeric antigen receptor (CAR)-T cells	Treatment of acute lymphoblastic leukemia (ALL)	allogeneic anti-CD19 chimeric antigen receptor (CAR)-T cells		n/a	7/2/18	Designated			N/A	N/A	"Precision BioSciences, Inc."	302 East Pettigrew Street	North Carolina	27701	USA	LONGEST CONTAINS	1722709AA	CD19	IYZ9TI08W3						Acute lymphoblastic leukemia	522		
"3-[5-[(1R)-1-[bis(aziridin-1-yl(phosphoryloxy]ethyl]-2-nitrophenoxy]-N,N-dimethylbenzamide"	Treatment of Acute Lymphoblastic Leukemia	OBI-3424		n/a	9/17/18	Designated			N/A	N/A	"OBI Pharma USA, Inc."	"6020 Cornerstone Court W, Suite 200"	California	92121	USA	EXACT	0116369AB	OBI-3424	X6SH5T8H76						Acute lymphoblastic leukemia	522		
Tamibarotene	Treatment of acute promyelocytic leukemia (APL).	Tamibarotene		n/a	10/11/07	Designated			N/A	N/A	CytRx Corporation	San Diego	California	92109	USA	EXACT	0288891AA	Tamibarotene	08V52GZ3H9						Acute promyelocytic leukemia	538		
Alitretinoin	Treatment of acute promyelocytic leukemia	Alitretinoin		Panretin	4/10/92	Designated			N/A	N/A	"Ligand Pharmaceuticals, Inc."	San Diego	California	92121	USA	EXACT	0184576AA	Alitretinoin	1UA8E65KDZ						Acute promyelocytic leukemia	538		
menatetrenone	Treatment of acute promyelocytic leukemia.	menatetrenone		Mk4(R)	11/2/10	Designated			N/A	N/A	"NBI Pharmaceuticals, Inc."	Bozeman	Montana	59715	USA	EXACT	0274500AA	menatetrenone	27Y876D139						Acute promyelocytic leukemia	538		
Tretinoin	Treatment of acute promyelocytic leukemia.	Tretinoin		Vesanoid	10/24/90	Designated/Approved	Approved for Orphan Indication	Induction of remission in patients with acute promyelocytic leukemia who are refractory to or unable to tolerate anthracycline based cytotoxic chemotherapeutic regimens.	11/22/95	11/22/02	"Hoffmann-La Roche, Inc."	Nutley	New Jersey	7110	USA	EXACT	0024180AA	Tretinoin	5688UTC01R						Acute promyelocytic leukemia	538		
Phenylbutyrate	Treatment of acute promyelocytic leukemia.	Phenylbutyrate		n/a	1/19/00	Designated			N/A	N/A	"Elan Drug Delivery, Inc."	Gainesville	Georgia	30504	USA	EXACT	0300061AA	Phenylbutyrate	7WY7YBI87E						Acute promyelocytic leukemia	538		
Arsenic trioxide	Treatment of acute promyelocytic leukemia.	Arsenic trioxide		Trisenox	3/3/98	Designated/Approved	Approved for Orphan Indication	"For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation of PML/RAR-alpha gene expression."	9/25/00	9/25/07	Cephalon	Frazer	Pennsylvania	19355	USA	EXACT	0034720AA	Arsenic trioxide	S7V92P67HO						Acute promyelocytic leukemia	538		
arsenic trioxide capsule (oral)	Treatment of acute promyelocytic leukemia.	arsenic trioxide capsule (oral)		n/a	11/2/15	Designated			N/A	N/A	Orsenix Holdings BV	Wilmington	Delaware	19801	USA	EXACT	0034720AA	arsenic trioxide	S7V92P67HO						Acute promyelocytic leukemia	538		
linsitinib	Treatment of adrenocortical carcinoma	linsitinib		n/a	3/9/12	Designated/Withdrawn			N/A	N/A	"Astellas Pharma Global Development, Inc."	Northbrook	Illinois	60062	USA	EXACT	0460231AA	linsitinib	15A52GPT8T						Adrenocortical carcinoma	558		
"(N-[2,6-bis(1-methylethyl)-pheyl-N'-[[1-4-dimethyl-amino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt"	Treatment of adrenocortical carcinoma	ATR-101 HYDROCHLORIDE		n/a	3/9/12	Designated			N/A	N/A	"Atterocor, Inc."	Ann Arbor	Michigan	48104	USA	EXACT	0740421AA	atr-101	TK694ZFS57						Adrenocortical carcinoma	558		
diphenylcyclopenone	Treatment of chronic severe forms of alopecia areata (Alopecia Totalis [AT]/Alopecia Universalis [AU])	diphenylcyclopenone		n/a	6/13/03	Designated			N/A	N/A	"Lloyd E. King, Jr."	Nashville	Tennessee	37203	USA	EXACT	0128063AA	diphenylcyclopenone	I7G14NW5EC						Alopecia universalis	614		
deferasirox	Treatment of chronic iron overload in alpha-thalassemia	deferasirox		Exjade	2/24/15	Designated/Approved	Approved for Orphan Indication	Treatment of chronic iron overload in patients 10 years of age and older with non-transfusion dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and serum ferritin greater than 300 mcg/L.	1/23/13	1/23/20	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0232860AA	deferasirox	V8G4MOF2V9						Alpha-thalassemia	621		
Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2	Treatment of Leber congenital amaurosis due to RPE65 mutations.	Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2		n/a	6/24/08	Designated			N/A	N/A	"Spark Therapeutics, Inc."	Philadelphia	Pennsylvania	19104	USA	LONGEST CONTAINS	0018746AA	retinal	RR725D715M						Leber congenital amaurosis	634		
adenovirus associated viral vector serotype 5 containing the human RPE65 gene	Treatment of Leber congenital amaurosis	adenovirus associated viral vector serotype 5 containing the human RPE65 gene		n/a	3/10/16	Designated			N/A	N/A	MeiraGTx Limited	New York	New York	10016	USA	LONGEST CONTAINS	0116711AB	RPE65	CH2LY7Q64L						Leber congenital amaurosis	634		
adenovirus associated viral vector serotype 8 containing the human AIPL1 gene	"Treatment of inherited retinal dystrophy due to defects in AIPL1 gene, including Leber congenital amaurosis, retinitis pigmentosa, and cone-rod dystrophy"	adenovirus associated viral vector serotype 8 containing the human AIPL1 gene		n/a	2/1/18	Designated			N/A	N/A	MeiraGTx UK II Ltd	92 Britannia Walk	London		United Kingdom										Leber congenital amaurosis	634		
Tinidazole	Treatment of amebiasis	Tinidazole		Tindamax	8/20/03	Designated/Approved	Approved for Orphan Indication	Treatment of intestinal amebiasis and amebic liver abcess caused by E. histolytica in both adults and pediatric patients older than three years of age. It is not indicated for the treatment of asymptomatic cyst passage.	5/17/04	5/17/11	"Presutti Laboratories, Inc."	Arlington Heights	Illinois	60004	USA	EXACT	0063161AA	Tinidazole	033KF7V46H						Amebiasis	652		
auranofin	Treatment of amebiasis	auranofin		Ridaura	4/30/10	Designated			N/A	N/A	Ctr for Discovery & Innovation in Parasitic Diseas	San Francisco	California	94158	USA	EXACT	0064357AA	auranofin	3H04W2810V						Amebiasis	652		
miltefosine	Treatment of disseminated amebiasis	miltefosine		Impavido	6/19/17	Designated			N/A	N/A	"Profounda, Inc."	Orlando	Florida	32822	USA	EXACT	0273734AA	miltefosine	53EY29W7EC						Amebiasis	652		
nitazoxanide	Treatment for intestinal amebiasis	nitazoxanide		Cryptaz	10/23/01	Designated			N/A	N/A	"Romark Laboratories, L.C."	Tampa	Florida	33607	USA	EXACT	0208855AA	nitazoxanide	SOA12P041N						Amebiasis	652		
dabrafenib and trametinib	Treatment of patients with anaplastic thyroid cancer and locally advanced or metastatic papillary thyroid cancer whose tumors harbor a BRAF V600 mutation.	trametinib		Tafinlar(R) Capsules A Nd Mekinist(R) Tablets	9/1/16	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0631323AA	trametinib	33E86K87QN						Anaplastic thyroid cancer	664		
sorafenib	"Treatment of medullary thyroid cancer, anaplastic thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer"	sorafenib		Nexavar	12/12/11	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DCT) that is refractory to radioactive iodine treatment."	11/22/13	11/22/20	"Bayer HealthCare Pharmaceuticals, Inc."	Whippany	New Jersey	7981	USA	EXACT	0258582AA	sorafenib	9ZOQ3TZI87						Anaplastic thyroid cancer	664		
Combretastatin A4 Phosphate	"Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer"	Combretastatin A-4 Phosphate		n/a	7/23/03	Designated			N/A	N/A	"Mateon Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	0322623AA	Combretastatin A-4 Phosphate	I5590ES2QZ						Anaplastic thyroid cancer	664		
dabrafenib and trametinib	Treatment of patients with anaplastic thyroid cancer and locally advanced or metastatic papillary thyroid cancer whose tumors harbor a BRAF V600 mutation.	dabrafenib		Tafinlar(R) Capsules A Nd Mekinist(R) Tablets	9/1/16	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0632984AA	dabrafenib	QGP4HA4G1B						Anaplastic thyroid cancer	664		
"L-3,4-Dihydroxy-6-[18F]fluorophenylalanine"	Diagnostic agent for the management of patients with aromatic L-amino acid decarboxylase deficiency (AADC).	FLUORODOPA F-18		n/a	5/31/17	Designated			N/A	N/A	"Advanced Imaging Projects, LLC"	Lake Worth	Florida	33467	USA	EXACT	0173568AA	FLUORODOPA F-18	2C598205QX						Aromatic L-amino acid decarboxylase deficiency	770		
"recombinant, adeno-associated virus serotype 2 vector carrying linear single-stranded AADC mRNA cDNA"	Treatment of aromatic L-amino acid decarboxylase deficiency.	"recombinant, adeno-associated virus serotype 2 vector carrying linear single-stranded AADC mRNA cDNA"		n/a	6/8/16	Designated			N/A	N/A	"Agilis Biotherapeutics, LLC"	Cambridge	Massachusetts	2142	USA	LONGEST CONTAINS	1316718AA	AADC	BY6OQ7Q6TP						Aromatic L-amino acid decarboxylase deficiency	770		
adeno-associated virus type 2 encoding human aromatic L-amino acid decarboxylase	Treatment of aromatic L-amino acid decarboxylase deficiency	adeno-associated virus type 2 encoding human aromatic L-amino acid decarboxylase		n/a	11/14/17	Designated			N/A	N/A	University of California San Francisco	Department of Neurosurgery	California	94103	USA										Aromatic L-amino acid decarboxylase deficiency	770		
Buffered Ursodeoxycholic Acid	Treatment of pruritus in patients with Alagille Syndrome	Buffered Ursodeoxycholic Acid		Ursocarb	9/3/04	Designated			N/A	N/A	"Digestive Care, Inc."	Bethlehem	Pennsylvania	18017	USA	EXACT	0020519AA	Ursodeoxycholic Acid	724L30Y2QR						Alagille syndrome	804		
"(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride"	Treatment of alagille syndrome	MARALIXIBAT CHLORIDE		n/a	9/4/13	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0232326AA	MARALIXIBAT CHLORIDE	V78M04F0XC						Alagille syndrome	804		
"(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid"	Treatment of Alagille syndrome	Odevixibat		n/a	10/15/18	Designated			N/A	N/A	"Albireo AB c/o Albireo Pharma, Inc."	10 Post Office Square	Massachusetts	2109	USA	EXACT	1301333AA	Odevixibat	2W150K0UUC						Alagille syndrome	804		
Omega-3 (n-3) polyunsaturated fatty acids	Treatment of IgA nephropathy.	Omacor		Omacor	5/4/00	Designated			N/A	N/A	"Pronova Biocare, AS"				Norway	EXACT	0168058AA	Omacor	D87YGH4Z0Q						IgA nephropathy	863		
Human monoclonal antibody against platelet-derived growth factor D	To slow the progression of IgA nephropathy and delay kidney failure in patients affected by the disease.	CR-002		n/a	11/2/04	Designated			N/A	N/A	CuraGen Corporation	Branford	Connecticut	6405	USA	EXACT									IgA nephropathy	863		
alpha melanotropin	Treatment of chronic beryllium disease	alpha melanotropin		n/a	9/2/10	Designated			N/A	N/A	mondoBIOTECH Laboratories AG				Germany	EXACT	0052186AA	melanotropin	OVF025LA77						Beryllium disease	867		
alpha melanotropin	Treatment of chronic beryllium disease	alpha melanotropin		n/a	9/2/10	Designated			N/A	N/A	mondoBIOTECH Laboratories AG				Germany	EXACT	0052186AA	melanotropin	OVF025LA77						BERYLLIUM DIS	867		
sotatercept	Treatment of beta-thalassemia intermedia and major	sotatercept		n/a	12/5/13	Designated			N/A	N/A	Celgene Corporation	Summit	New Jersey	7901	USA	EXACT	0343931AA	sotatercept	0QI90BTJ37						Beta-thalassemia	871		
Isobutyramide	Treatment of beta-hemoglobinopathies and beta-thalassemia syndromes.	Isobutyramide		Isobutyramide Oral Solution	12/18/92	Designated			N/A	N/A	"Perrine, Susan P., M.D."	Boston	Massachusetts	2118	USA	EXACT	0180734AA	Isobutyramide	82UOE7B38Z						Beta-thalassemia	871		
Arginine butyrate	Treatment of beta-hemoglobinopathies and beta-thalassemia.	Arginine butyrate		n/a	4/7/92	Designated			N/A	N/A	"Perrine, Susan P., M.D."	Boston	Massachusetts	2118	USA	EXACT	0179828AA	Arginine butyrate	IK8S1P79MU						Beta-thalassemia	871		
sirolimus	Treatment of beta-thalassemia.	sirolimus		n/a	6/21/16	Designated			N/A	N/A	Rare Partners srl Impresa Sociale	Milano			Italy	EXACT	0175177AA	sirolimus	W36ZG6FT64						Beta-thalassemia	871		
deferoxamine starch conjugate	Treatment of chronic iron overload resulting from conventional transfusional treatment of beta-thalassemia major and sickle cell anemia.	deferoxamine starch conjugate		n/a	12/21/98	Designated			N/A	N/A	"Biomedical Frontiers, Inc."	Minneapolis	Minnesota	55414	USA	LONGEST CONTAINS	0012204AA	deferoxamine	J06Y7MXW4D						Beta-thalassemia	871		
Lentiviral vector encoded with a human beta-globin gene plasmid	Treatment of beta-thalassemia major and beta-thalassemia intermedia	Lentiviral vector encoded with a human beta-globin gene plasmid		Thalagen	1/11/06	Designated			N/A	N/A	Memorial Sloan-Kettering Cancer Center	New York	New York	10065	USA										Beta-thalassemia	871		
Botulism immune globulin	Treatment of infant botulism.	Babybig		Babybig	1/31/89	Designated/Approved	Approved for Orphan Indication	Indicated for treatment of infant botulism caused by type A or type B Clostridium botulinum.	10/23/03	10/23/10	California Department of Health Services	Berkeley	California	94704	USA	EXACT	0249354AA	Babybig	X641Y30OA7						Botulism	943		
"botulism antitoxin heptavalent (A, B, C, D, E, F, G) (Equine)"	Treatment of botulism.	"botulism antitoxin heptavalent (A, B, C, D, E, F, G) (Equine)"		n/a	6/29/11	Designated/Approved	Approved for Orphan Indication	"Treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients"	3/22/13	3/22/20	Cangene Corporation				Canada	LONGEST CONTAINS	0099025AA	botulism antitoxin							Botulism	943		
human monoclonal antibody targeting human sclerostin	Treatment of osteogenesis imperfecta.	BPS-804 		n/a	2/29/16	Designated			N/A	N/A	Mereo Biopharma 3 Limited	London			United Kingdom	EXACT	1806673AA	BPS-804	FPW3780T3E						Osteogenesis imperfecta	1017		
risedronate sodium	Treatment of patients with osteogenesis imperfecta.	risedronate sodium		Actonel	12/18/06	Designated/Withdrawn			N/A	N/A	Warner Chilcott Pharmaceuticals	Roakaway	New Jersey	7866	USA	EXACT	0163633AA	risedronate sodium	OFG5EXG60L						Osteogenesis imperfecta	1017		
alendronate	Treatment of osteogenesis imperfecta in pediatric patients 4 years of age and older	alendronate		Fosamax	3/31/03	Designated/Withdrawn			N/A	N/A	"Merck, Sharpe & Dohme Corp."	Rahway	New Jersey	7065	USA	EXACT	0214186AA	alendronate	X1J18R4W8P						Osteogenesis imperfecta	1017		
human allogeneic bone marrow derived osteoblastic cells	Treatment of osteogenesis imperfecta.	human allogeneic bone marrow derived osteoblastic cells		n/a	11/9/15	Designated			N/A	N/A	Bone Therapeutics SA	Gosselies			Belgium	LONGEST CONTAINS	0260935AA	allogeneic bone marrow							Osteogenesis imperfecta	1017		
peptide fraction derived from porcine brain protein	Treatment of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)	peptide fraction derived from porcine brain protein		Cerebrolysin	5/8/18	Designated			N/A	N/A	EVER Neuro Pharma GmbH	3 Oberburgau	4866 Unterach		Austria	LONGEST CONTAINS	0087274AA	protein							CADASIL	1049		
palm tocotrienol complex	Treatment of cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)	palm tocotrienol complex		n/a	6/13/17	Designated			N/A	N/A	Hovid Berhad	Ipoh			Malaysia	LONGEST CONTAINS	1015265AA	tocotrienol	0867I0N41V						CADASIL	1049		
"One, two, three, or four antisense oligonucleotides of Phosphorodiamidate morpholino oligomer combination that skips exons 4, 5, 6, and 7 of the gamma sarcoglycan (SGCG) gene"	"Treatment of limb-girdle muscular dystrophy type 2C that have mutations or deletions in exons 4, 5, 6, or 7of gamma sarcoglycan gene"	"One, two, three, or four antisense oligonucleotides of Phosphorodiamidate morpholino oligomer combination that skips exons 4, 5, 6, and 7 of the gamma sarcoglycan (SGCG) gene"		n/a	7/18/17	Designated			N/A	N/A	Kurt+Peter Foundation	Menlo Park	California	94025	USA	LONGEST CONTAINS	1797166AA	morpholino							Limb-girdle muscular dystrophy type 2	1057		
2-amino-3-[3-[[4-(2-pyridyloxymethyl)phenyl]methyl]isoxazol-5-yl]pyridin-1-ium-1-yl]methyl hydrogen phosphate	Treatment of invasive candidiasis	2-amino-3-(3-((4-(2-pyridyloxymethyl)phenyl)methyl)isoxazol-5-yl)pyridin-1-ium-1-yl)methyl hydrogen phosphate		n/a	10/19/16	Designated			N/A	N/A	"Amplyx Pharmaceuticals, Inc."	San Diego	California	92130	USA	EXACT	1718429AA	2-amino-3-(3-((4-(2-pyridyloxymethyl)phenyl)methyl)isoxazol-5-yl)pyridin-1-ium-1-yl)methyl hydrogen phosphate	1XQ871489P						Invasive candidiasis	1076		
isavuconazonium sulfate	Treatment of invasive candidiasis/candidemia	isavuconazonium sulfate		n/a	10/20/14	Designated			N/A	N/A	"Astellas Pharma Global Development, Inc."	Northbrook	Illinois	60062	USA	EXACT	0914921AA	isavuconazonium sulfate	31Q44514JV						Invasive candidiasis	1076		
Amphotericin B lipid complex	Treatment of invasive candidiasis.	Amphotericin B lipid complex		Abelcet	6/27/96	Designated/Withdrawn			N/A	N/A	"The Liposome Company, Inc."	Princeton	New Jersey	8540	USA	EXACT	0035881AA	Amphotericin B lipid complex	7XU7A7DROE						Invasive candidiasis	1076		
recombinant human monoclonal antibody to hsp90	Treatment of invasive candidiasis	EFUNGUMAB		Mycograb	9/16/02	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	East Hanover	New Jersey		United Kingdom	EXACT	0265850AA	EFUNGUMAB	BM86P708HW						Invasive candidiasis	1076		
"Echinocandin B,1-[(4R,5R)-4-hydroxy-N2-[[4’’-(pentyloxy)[1,1’:4’,1’’-terphenyl]-4-yl]carbonyl]-5-[2-(trimethylammonio)ethoxy]-L-ornithine]-4-[(4S)-4-hydroxy-4-(4-hydroxyphenyl)-L-allothreonine]"	Treatment of candidemia and invasive candidiasis infections caused by susceptible Candida spp.	"Echinocandin B,1-((4R,5R)-4-hydroxy-N2-((4’’-(pentyloxy)(1,1’:4’,1’’-terphenyl)-4-yl)carbonyl)-5-(2-(trimethylammonio)ethoxy)-L-ornithine)-4-((4S)-4-hydroxy-4-(4-hydroxyphenyl)-L-allothreonine)"		n/a	2/8/16	Designated			N/A	N/A	"Cidara Therapeutics, Inc."	San Diego	California	92121	USA	EXACT	0850635AA	Echinocandin B	CNW0ZW8ZTQ						Invasive candidiasis	1076		
vatiquinone	Treatment of pontocerebellar hypoplasia	vatiquinone		Vincerinone	10/18/17	Designated			N/A	N/A	BioElectron Technology Corporation	Mountain View	California	94043	USA	EXACT	0739468AA	vatiquinone	6O85FK9I0X						Cerebellar hypoplasia	1194		
"(RS)-baclofen, naltrexone and D-sorbitol"	Treatment of Charcot-Marie-Tooth disease type 1A	 D-sorbitol		n/a	3/17/14	Designated			N/A	N/A	Pharnext SA				France	EXACT	0007614AA	D-sorbitol	506T60A25R						Charcot-Marie-Tooth disease type 1A	1245		
"(RS)-baclofen, naltrexone and D-sorbitol"	Treatment of Charcot-Marie-Tooth disease type 1A	"(RS)-baclofen, naltrexone and D-sorbitol"		n/a	3/17/14	Designated			N/A	N/A	Pharnext SA				France	exact	0057249AA	naltrexone	5S6W795CQM						Charcot-Marie-Tooth disease type 1A	1245		
"(RS)-baclofen, naltrexone and D-sorbitol"	Treatment of Charcot-Marie-Tooth disease type 1A	BACLOFEN		n/a	3/17/14	Designated			N/A	N/A	Pharnext SA				France	EXACT	0032804AA	BACLOFEN	H789N3FKE8						Charcot-Marie-Tooth disease type 1A	1245		
ascorbic acid	Treatment of Charcot-Marie-Tooth disease type 1A.	ascorbic acid		n/a	5/11/09	Designated			N/A	N/A	Murigenetics SAS				France	EXACT	0007658AA	ascorbic acid	PQ6CK8PD0R						Charcot-Marie-Tooth disease type 1A	1245		
6-alpha-ethylchenodeoxycholic acid	Treatment of primary sclerosing cholangitis	OBETICHOLIC ACID		n/a	4/9/08	Designated			N/A	N/A	"Intercept Pharmaceuticals, Inc."	New York	New York	10013	USA	EXACT	0322543AA	OBETICHOLIC ACID	0462Z4S4OZ						Primary sclerosing cholangitis	1280		
simtuzumab	Treatment of primary sclerosing cholangitis	simtuzumab		n/a	1/5/15	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0762403AA	simtuzumab	11Z5AIU653						Primary sclerosing cholangitis	1280		
"5-cholesten-3ß, 25-diol 3-sulfate sodium salt (25HC3S)"	Treatment of primary sclerosing cholangitis (PSC)	DUR-928 SODIUM		n/a	7/6/17	Designated			N/A	N/A	DURECT Corporation	Cupertino	California	95014	USA	EXACT	1800562AA	DUR-928 SODIUM	71A5JOPBE8						Primary sclerosing cholangitis	1280		
"recombinant, fully-human, IgG4 immunoglobulin with antigen-binding specificity for human vascular adhesion protein-1 (VAP-1)"	Treatment of primary sclerosing cholangitis.	timolumab		n/a	8/25/16	Designated			N/A	N/A	"Acorda Therapeutics, Inc."	Ardsley	New York	10502	USA	EXACT	1252875AA	timolumab	UJO03RO3K6						Primary sclerosing cholangitis	1280		
"(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride"	Treatment of primary sclerosing cholangitis	MARALIXIBAT CHLORIDE		n/a	9/4/13	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	Lexington	California	2421	USA	EXACT	0232326AA	MARALIXIBAT CHLORIDE	V78M04F0XC						Primary sclerosing cholangitis	1280		
"docosahexaenoic acid, DHA"	Treatment of primary sclerosing cholangitis	"docosahexaenoic acid, DHA"		n/a	12/17/14	Designated			N/A	N/A	"Sancilio and Company, Inc."	Riviera Beach	Florida	33404	USA	EXACT	0145960AA	docosahexaenoic acid	ZAD9OKH9JC						Primary sclerosing cholangitis	1280		
"9,10-dimethoxy-5,6-dihydro-[1,3] dioxolo[4,5-g]isoquinolino[3,2-alpha]isoquinolin-7-ium(R)-4-((3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyhexadecahydro-1H-cyclopentane"	Treatment of primary sclerosing cholangitis	HTD-1801 		n/a	8/29/16	Designated			N/A	N/A	HighTide Biopharma Pty. Ltd.	Mount Waverley			Australia	EXACT	0117117AB	HTD-1801							Primary sclerosing cholangitis	1280		
Cotsiranib	Treatment of primary sclerosing cholangitis	STP-705		n/a	6/15/17	Designated			N/A	N/A	"Sirnaomics, Inc."	Gaithersburg	Maryland	20879	USA	EXACT									Primary sclerosing cholangitis	1280		
"(S)-3-((S)-2-(2,6-difluorophenyl)amino)-2-oxoacetamido)propanamido-4-oxo-5-(2,3,4,6-tetrafluorophenoxy)pentanoic acid"	Treatment of primary sclerosing cholangitis (PSC)	IDN-7314		n/a	6/21/17	Designated			N/A	N/A	Conatus Pharmaceuticals	San Diego	California	92127	USA	EXACT	0111923AB	IDN-7314	WLA1SUY9N8						Primary sclerosing cholangitis	1280		
Monoclonal antibody targeting CCL24	Treatment of primary sclerosing cholangitis	CM-101		n/a	10/11/18	Designated			N/A	N/A	"ChemomAb, Ltd."	6 Hanehoset St.			Israel	EXACT	0110872AB	CM-101							Primary sclerosing cholangitis	1280		
"2-[3-(2-chloro-4-{[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy}phenyl)-3-hydroxyazetidin-1-yl]pyridine-4-carboxylic acid—2-amino-2-(hydroxymethyl)propane-1,3-diol (1/1)"	Treatment of Primary Sclerosing Cholangitis (PSC)	CILOFEXOR TROMETHAMINE		n/a	10/25/18	Designated			N/A	N/A	"Gilead Sciences, Inc."	333 Lakeside Drive	California	94404	USA	EXACT	1240115AA	CILOFEXOR TROMETHAMINE	Z7AR0KNS4A						Primary sclerosing cholangitis	1280		
tazemetostat	Treatment of chordoma	tazemetostat		n/a	5/23/18	Designated			N/A	N/A	"Epizyme, Inc."	400 Technology Square	4th Floor	2139	USA	EXACT	1120394AA	tazemetostat	Q40W93WPE1						Chordoma	1303		
BN-Brachyury; a heterologous prime/boost therapeutic cancer vaccine composed of MVA-BN-Brachyury (prime) and FPV-Brachyury (boost)	Treatment of chordoma	BN-Brachyury; a heterologous prime/boost therapeutic cancer vaccine composed of MVA-BN-Brachyury (prime) and FPV-Brachyury (boost)		n/a	4/30/18	Designated			N/A	N/A	Bavarian Nordic A/S	3025 Carrington Mill Boulevard	Suite 100	27560	USA										Chordoma	1303		
alpha melanotropin	Treatment of chronic beryllium disease	alpha melanotropin		n/a	9/2/10	Designated			N/A	N/A	mondoBIOTECH Laboratories AG				Germany	EXACT	0052186AA	melanotropin	OVF025LA77						Chronic beryllium disease	1351		
corticotropin-releasing factor receptor-1 antagonist containing an unfused thiazole ring	Treatment of congenital adrenal hyperplasia	SPR-001		n/a	11/8/17	Designated			N/A	N/A	Spruce Biosciences	548 Market Street	California	94104	USA	EXACT	1803812AA	SPR-001	09QCEV5481						Congenital adrenal hyperplasia	1467		
"N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt"	Treatment of congenital adrenal hyperplasia	ATR-101		n/a	8/17/17	Designated			N/A	N/A	"Millendo Therapeutics, Inc."	Ann Arbor	Michigan	48104	USA	EXACT	0740410AA	ATR-101	VK9OS8R205						Congenital adrenal hyperplasia	1467		
"2,5-dimethyl-3-[2-methyl-4-(methyloxy)phenyl]-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-"	Treatment of congenital adrenal hyperplasia (CAH)	VERUCERFONT		n/a	1/15/15	Designated			N/A	N/A	"Neurocrine Biosciences, Inc."	San Diego	California	92130	USA	EXACT	0304610AA	VERUCERFONT	X60608B091						Congenital adrenal hyperplasia	1467		
adeno-associated virus vector expressing human 21-hydroxylase	Treatment of congenital adrenal hyperplasia 21-hydroxylase deficiency	adeno-associated virus vector expressing human 21-hydroxylase		n/a	8/30/18	Designated			N/A	N/A	Adrenas Therapeutics Inc	421 Kipling St	California	94301	USA										Congenital adrenal hyperplasia	1467		
human IgG1 anti-human cytomegalovirus monoclonal antibodies LJP538 and LJP539	Prevention of congenital cytomegalovirus (CMV) infection following primary CMV infection in pregnant women	LJP-539		n/a	10/18/17	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	Basel			Switzerland	EXACT	0113776AB	LJP-539							Congenital cytomegalovirus	1480		
Human cytomegalovirus immunoglobulin	Prevention of congenital cytomegalovirus (CMV) infection following primary CMV infection in pregnant women	Human cytomegalovirus immunoglobulin		n/a	12/20/06	Designated			N/A	N/A	Biotest Pharmaceuticals Corporation	Boca Raton	Florida	33487	USA	LONGEST CONTAINS	0354529AA	Human cytomegalovirus	7COI029E6K						Congenital cytomegalovirus	1480		
Glutamine	For use with human growth hormone in the treatment of short bowel syndrome (nutrient malabsorption from the gastrointestinal tract resulting from an inadequate absorptive surface).	Glutamine		Nutrestore	3/6/95	Designated/Approved	Approved for Orphan Indication	Treatment of short bowel syndrome in patients receiving specialized nutritional support when used in conjunction with a recombinant human growth hormone that is approved for this indication.	6/10/04	6/10/11	"Emmaus Medical, Inc."	Torrence	California	90501	USA	EXACT	0009165AA	Glutamine	0RH81L854J						Short bowel syndrome	1502		
human insulin (rDNA)	Treatment of short bowel syndrome (SBS).	human insulin (rDNA)		n/a	4/6/15	Designated			N/A	N/A	"Nutrinia, Ltd."				Israel	EXACT	0114738AA	human insulin	1Y17CTI5SR						Short bowel syndrome	1502		
opium tincture	Treatment of chronic diarrhea in short bowel syndrome patients with an inadequate response to anti-diarrheal treatment	opium tincture		n/a	12/2/11	Designated			N/A	N/A	"Valeant Pharmaceuticals International, Inc."	Bridgewater	New Jersey	8807	USA	EXACT	0001752AA	opium tincture	37M3MZ001L						Short bowel syndrome	1502		
glepaglutide	Treatment of short bowel syndrome	glepaglutide		n/a	10/20/17	Designated			N/A	N/A	Zealand Pharma A/S	Glostrup			Denmark	EXACT	0629572AA	glepaglutide	4M3C1913N6						Short bowel syndrome	1502		
teduglutide [rDNA origin]	Treatment of short bowel syndrome.	teduglutide (rDNA origin)		Gattex	6/29/00	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support	12/21/12	12/21/19	"NPS Pharmaceuticals, Inc."	Bedminster	New Jersey	7921	USA	EXACT	0232451AA	teduglutide (rDNA origin)	7M19191IKG						Short bowel syndrome	1502		
melatonin	Treatment of short bowel syndrome	melatonin		n/a	2/14/17	Designated			N/A	N/A	Therapicon SrL	Milano			Italy	EXACT	0012657AA	melatonin	JL5DK93RCL						Short bowel syndrome	1502		
Somatropin (r-DNA)	For use alone or in combination with glutamine in the treatment of short bowel syndrome.	Somatropin (r-DNA)		Zorbtive	3/6/95	Designated/Approved	Approved for Orphan Indication	Treatment of short bowel syndrome in patients receiving specialized nutritional support	12/1/03	12/1/10	"EMD Serono, Inc."	Roackland	Massachusetts	2370	USA	EXACT	0054682AA	Somatropin	NQX9KB6PCL						Short bowel syndrome	1502		
crofelemer	Treatment of short bowel syndrome	crofelemer		Mytesi	8/2/17	Designated			N/A	N/A	"Napo Pharmaceuticals, Inc."	San Francisco	California	94105	USA	EXACT	0175906AA	crofelemer	PY79D6C8RX						Short bowel syndrome	1502		
docosahexaenoic acid	Treatment of short bowel syndrome	docosahexaenoic acid		n/a	6/1/15	Designated			N/A	N/A	"Sancilio and Company, Inc."	Riviera Beach	Florida	33404	USA	EXACT	0145960AA	docosahexaenoic acid	ZAD9OKH9JC						Short bowel syndrome	1502		
conjugated bile acids	Treatment of steatorrhea in patients with short bowel syndrome	conjugated bile acids		Cobartin	7/18/03	Designated			N/A	N/A	"Jarrow Formulas, Inc."	Los Angeles	California	90035	USA	LONGEST CONTAINS	0148925AA	bile acids							Short bowel syndrome	1502		
recombinant fusion protein comprising exenatide and XTEN	Treatment of short bowel syndrome.	recombinant fusion protein comprising exenatide and XTEN		n/a	10/7/15	Designated			N/A	N/A	"NAIA Pharmaceuticals, Inc."	Kentfield	California	94904	USA	LONGEST CONTAINS	0232826AA	exenatide	9P1872D4OL						Short bowel syndrome	1502		
Glucagon-Like Peptide 2 fused to hyFc	Treatment of short bowel syndrome	Glucagon-Like Peptide 2 fused to hyFc		n/a	10/11/18	Designated			N/A	N/A	Genexine	700 Daewangpangyo-ro			"Korea, Republic of"	LONGEST CONTAINS	0007114AA	Glucagon	76LA80IG2G						Short bowel syndrome	1502		
copper histidine	Treatment of Menkes disease	copper histidine		n/a	5/14/12	Designated			N/A	N/A	"Stephen G. Kaler, M.D."	Bethesda	Maryland	20892	USA	EXACT	0905500AA	copper histidine	9078K3MO9U						Menkes disease	1521		
rsATP7A cDNA	Treatment of Menkes disease	rsATP7A cDNA		n/a	1/10/14	Designated			N/A	N/A	"Stephen G. Kaler, MD"	Bethesda	Maryland	20892	USA										Menkes disease	1521		
tegavivint	Treatment of Desmoid Tumors	tegavivint		n/a	4/11/18	Designated			N/A	N/A	Beta Cat Pharmaceuticals	"2450 Holcombe Blvd, Suite J606"		77021	USA	EXACT	0114190AB	tegavivint	18AP231HUP						Desmoid tumor	1820		
Toremifene	Treatment of desmoid tumors.	Toremifene		n/a	8/17/93	Designated			N/A	N/A	Orion Corporation				Finland	EXACT	0235745AA	Toremifene	7NFE54O27T						Desmoid tumor	1820		
nirogacestat	Treatment of desmoid tumor (aggressive fibromatosis)	nirogacestat		n/a	6/7/18	Designated			N/A	N/A	"SpringWorks Subsidiary 2, PBC"	575 5th Avenue		10017	USA	EXACT	0805970AA	nirogacestat	QZ62892OFJ						Desmoid tumor	1820		
Sulfapyridine	Treatment of dermatitis herpetiformis.	Sulfapyridine		n/a	9/10/90	Designated			N/A	N/A	Jacobus Pharmaceutical Company	Princeton	New Jersey	8540	USA	EXACT	0022811AA	Sulfapyridine	Y5V2N1KE8U						Dermatitis Herpetiformis	1917		
"2-Ethylbutyl (2S)-2-{[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate"	Treatment of Ebola virus disease	GS-5734		n/a	9/18/15	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	1180592AA	GS-5734	3QKI37EEHE						Ebola virus disease	2035		
Ranpirnase	Treatment of Ebola virus disease (EVD)	Ranpirnase		n/a	7/14/17	Designated			N/A	N/A	"Tamir Biotechnology, Inc."	Short Hills	New Jersey	7078	USA	EXACT	0167931AA	Ranpirnase	ZE15FIT23E						Ebola virus disease	2035		
"Monovalent replication-incompetent adenovirus serotype 26 (Ad26) vaccine, AD26.ZEBOV in combination with multivalent replication-defective Modified Vaccinia Ankara (MVA)-Bavarian Nordic (BN) vaccine, MVA-mBN226B"	Pre-exposure prophylaxis of Ebola virus disease	"Monovalent replication-incompetent adenovirus serotype 26 (Ad26) vaccine, AD26.ZEBOV in combination with multivalent replication-defective Modified Vaccinia Ankara (MVA)-Bavarian Nordic (BN) vaccine, MVA-mBN226B"		n/a	1/11/17	Designated			N/A	N/A	Crucell Holland B.V.	Leiden			Netherlands	LONGEST CONTAINS	0862602AA	Modified Vaccinia Ankara	TU8J357395						Ebola virus disease	2035		
Angiotensin (1-7)	Treatment of recessive dystrophic epidermolysis bullosa (RDEB).	Angiotensin (1-7)		n/a	9/1/16	Designated			N/A	N/A	"Tarix Orphan, LLC"	Cambridge	Massachusetts	2138	USA	EXACT	0232428AA	Angiotensin 1-7	IJ3FUK8MOF						Dystrophic epidermolysis bullosa	2150		
recombinant human type VII collagen	Treatment of hereditary dystrophic epidermolysis bullosa (DEB)	recombinant human type VII collagen		n/a	6/18/08	Designated			N/A	N/A	"David T. Woodley, MD and Mei Chen, MD"	Los Angeles	California	90033	USA	LONGEST CONTAINS	0006462AA	collagen							Dystrophic epidermolysis bullosa	2150		
expanded allogeneic human dermal fibroblasts in hypothermosol(r)-FRS	Treatment of Dystrophic Epidermolysis Bullosa.	expanded allogeneic human dermal fibroblasts in hypothermosol(r)-FRS		n/a	8/20/09	Designated			N/A	N/A	Intercytex Ltd.				United Kingdom										Dystrophic epidermolysis bullosa	2150		
recombinant human collagen alpha-1 (VII) chain homo-trimer (rC7)	Treatment of dystrophic epidermolysis bullosa	recombinant human collagen alpha-1 (VII) chain homo-trimer (rC7)		n/a	3/17/14	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	Lexington	Massachusetts	2421	USA	LONGEST CONTAINS	0006462AA	collagen							Dystrophic epidermolysis bullosa	2150		
autologous genetically modified human dermal fibroblasts	Treatment of dystrophic epidermolysis bullosa.	autologous genetically modified human dermal fibroblasts		n/a	6/10/14	Designated			N/A	N/A	"Fibrocell Technologies, Inc."	Exton	Pennsylvania	19341	USA										Dystrophic epidermolysis bullosa	2150		
ex-vivo-expanded autologous keratinocytes transduced with retroviral vector containing the human COL7A1 gene.	Treatment of dystrophic Epidermolysis Bullosa	ex-vivo-expanded autologous keratinocytes transduced with retroviral vector containing the human COL7A1 gene.		n/a	5/24/17	Designated			N/A	N/A	Abeona Therapeutics	Cleveland	Ohio	44103	USA	LONGEST CONTAINS	0112364AB	COL7A1							Dystrophic epidermolysis bullosa	2150		
antisense oligonucleotide targeting exon 73 in the COL7A1 gene	Treatment of dystrophic epidermolysis bullosa	antisense oligonucleotide targeting exon 73 in the COL7A1 gene		n/a	9/13/17	Designated			N/A	N/A	ProQR Therapeutics IV B.V.	Leiden			Netherlands	LONGEST CONTAINS	0112364AB	COL7A1							Dystrophic epidermolysis bullosa	2150		
replication defective herpes simplex type 1 virus (HSV-1) vector expressing human COL7 protein	Treatment of dystrophic epidermolysis bullosa	replication defective herpes simplex type 1 virus (HSV-1) vector expressing human COL7 protein		n/a	11/2/17	Designated			N/A	N/A	"Krystal Biotech, LLC"	2100 Wharton Street	Pennsylvania	15203	USA	LONGEST CONTAINS	0087274AA	protein							Dystrophic epidermolysis bullosa	2150		
Coagulation factor VIIa (recombinant)	Treatment of bleeding episodes in patients with congenital factor VII deficiency	Coagulation factor VIIa (recombinant)		Novoseven	9/10/04	Designated/Approved	Approved for Orphan Indication	Treatment of bleeding episodes in patients with Factor VII Deficiency	7/11/05	7/11/12	"Novo Nordisk, Inc."	Princeton	New Jersey	8540	USA	EXACT	0324765AA	Coagulation factor VIIa (recombinant)	AC71R787OV						Factor VII deficiency	2238		
Coagulation factor VIIa (recombinant)	Prevention of bleeding episodes in patients with congenital Factor VII deficiency	Coagulation factor VIIa (recombinant)		Novoseven	9/10/04	Designated/Approved	Approved for Orphan Indication	Prevention of bleeding in surgical interventions or invasive procedures in patients with congenital F VII deficiency	7/11/05	7/11/12	"Novo Nordisk, Inc."	Princeton	New Jersey	8540	USA	EXACT	0324765AA	Coagulation factor VIIa (recombinant)	AC71R787OV						Factor VII deficiency	2238		
recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)	Treatment of congenital factor VII deficiency which includes treatment and prophylaxis of bleeding episodes in patients with congenital factor VII deficiency	CSL-689		n/a	5/6/13	Designated			N/A	N/A	CSL Behring	King of Prussia	Pennsylvania	19406	USA	EXACT	0113916AB	CSL-689							Factor VII deficiency	2238		
phenylephrine	Treatment of Tetralogy of Fallot	phenylephrine		n/a	1/31/12	Designated			N/A	N/A	"Luitpold Pharmaceuticals, Inc."	Shirley	New York	11967	USA	EXACT	0010139AA	phenylephrine	1WS297W6MV						Tetralogy of Fallot	2245		
human platelet antigen-1a immunoglobulin (anti-HPA-1a)	Prevention of fetal and neonatal alloimmune thrombocytopenia	human platelet antigen-1a immunoglobulin (anti-HPA-1a)		Tromplate	6/27/13	Designated			N/A	N/A	Prophylix Pharma AS	Tromso			Norway										Fetal and neonatal alloimmune thrombocytopenia	2295		
imatinib mesylate	Treatment of dermatofibrosarcoma protuberans	imatinib mesylate		Gleevec	12/19/05	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP)"	10/19/06	10/19/13	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0227065AA	imatinib mesylate	8A1O1M485B						Fibrosarcoma	2327		
ibrutinib	Treatment of follicular lymphoma	ibrutinib		n/a	9/8/14	Designated			N/A	N/A	"Pharmacyclics, LLC"	Sunnyvale	California	94085	USA	EXACT	0625092AA	ibrutinib	1X70OSD4VX						Follicular lymphoma	2356		
rituximab and recombinant human hyaluronidase	Treatment of follicular lymphoma	rituximab		n/a	8/22/16	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0225149AA	rituximab	4F4X42SYQ6						Follicular lymphoma	2356		
daratumumab	Treatment of follicular lymphoma	daratumumab		n/a	8/6/15	Designated			N/A	N/A	"Janssen Research & Development, LLC"	Spring House	Pennsylvania	19477	USA	EXACT	0432519AA	daratumumab	4Z63YK6E0E						Follicular lymphoma	2356		
(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one	Treatment of follicular lymphoma	DUVELISIB		n/a	8/1/13	Designated			N/A	N/A	"Infinity Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0707493AA	DUVELISIB	610V23S0JI						Follicular lymphoma	2356		
"3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl) piperidine-2,6-dione hydrochloride"	Treatment of follicular lymphoma	AVADOMIDE HYDROCHLORIDE		n/a	3/12/18	Designated			N/A	N/A	Celgene Corporation	86 Morris Avenue		7901	USA	EXACT	0926830AA	AVADOMIDE HYDROCHLORIDE	6CX4AEX3KR						Follicular lymphoma	2356		
rituximab and recombinant human hyaluronidase	Treatment of follicular lymphoma	recombinant human hyaluronidase		n/a	8/22/16	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0257670AA	human hyaluronidase	743QUY4VD8						Follicular lymphoma	2356		
bendamustine for 50ml admixture	"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)"	bendamustine for 50ml admixture		Bendeka	7/2/14	Designated/Approved	Approved for Orphan Indication	Treatment of patients with CLL and treatment of patients with indolent B-cell NHL	12/7/15	N/A	"Eagle Pharmaceuticals, Inc."	Woodcliff Lake	New Jersey	7677	USA	EXACT	0304245AA	bendamustine	9266D9P3PQ						Follicular lymphoma	2356		
"4, 5 dibromorhodamine methyl ester"	Treatment of follicular lymphoma	TH-9402 FREE BASE		Theralux Photodynamic Therapy	10/30/08	Designated			N/A	N/A	"Kiadis Pharma Canada, Inc."				Canada	EXACT	0807454AA	TH-9402 FREE BASE	934QHK1OOK						Follicular lymphoma	2356		
bendamustine hydrochloride	"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)"	bendamustine hydrochloride		Treanda	11/26/13	Designated/Approved	Approved for Orphan Indication	Treatment of Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.	10/31/08	10/31/15	"Cephalon, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0249241AA	bendamustine hydrochloride	981Y8SX18M						Follicular lymphoma	2356		
pralatrexate	Treatment of follicular lymphoma	pralatrexate		n/a	10/20/08	Designated			N/A	N/A	"Allos Therapeutics, Inc."	Westminister	Colorado	80020	USA	EXACT	0219034AA	pralatrexate	A8Q8I19Q20						Follicular lymphoma	2356		
177Lu-tetraxetan-tetulomab	Treatment of Follicular Lymphoma	177Lu-tetraxetan-tetulomab		Betalutin	5/14/14	Designated			N/A	N/A	Nordic Nanovector AS	Oslo			Norway	EXACT	0931191AA	177Lu-tetraxetan-tetulomab	CPW7BR9UY7						Follicular lymphoma	2356		
pembrolizumab	Treatment of follicular lymphoma.	pembrolizumab		Keytruda(Tm)	6/6/17	Designated			N/A	N/A	"Merck, Sharp & Dohme Corp"	Whitehouse Station	New Jersey	8889	USA	EXACT	0809245AA	pembrolizumab	DPT0O3T46P						Follicular lymphoma	2356		
lenalidomide	Treatment of follicular lymphoma	lenalidomide		Revlimid	9/17/13	Designated			N/A	N/A	Celgene Corporation	Berkeley Heights	New Jersey	7922	USA	EXACT	0236099AA	lenalidomide	F0P408N6V4						Follicular lymphoma	2356		
humanized IgG1 monoclonal anti-CD20 antibody	Treatment of follicular lymphoma	Ocaratuzumab		n/a	5/26/11	Designated			N/A	N/A	"MENTRIK Biotech, LLC"	Dallas	Texas	75251	USA	EXACT	0761591AA	Ocaratuzumab	NTY9893GD0						Follicular lymphoma	2356		
obinutuzumab	Treatment of follicular lymphoma	obinutuzumab		Gazyva	4/15/15	Designated/Approved	Approved for Orphan Indication	"Indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen"	2/26/16	2/26/23	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0322532AA	obinutuzumab	O43472U9X8						Follicular lymphoma	2356		
tazemetostat	Treatment of follicular lymphoma (FL)	tazemetostat		n/a	11/14/17	Designated			N/A	N/A	"Epizyme, Inc."	400 Technology Square	Massachusetts	2139	USA	EXACT	1120394AA	tazemetostat	Q40W93WPE1						Follicular lymphoma	2356		
copanlisib	Treatment of follicular lymphoma	copanlisib		n/a	2/5/15	Designated			N/A	N/A	"Bayer HealthCare Pharmaceuticals, Inc."	Whippany	New Jersey	7981	USA	EXACT	0337111AA	copanlisib	WI6V529FZ9						Follicular lymphoma	2356		
idelalisib	Treatment of follicular lymphoma	idelalisib		Zydelig	9/26/13	Designated/Approved	Approved for Orphan Indication	Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies.	7/23/14	7/23/21	"Gilead Sciences, Inc."	Seattle	Washington	98102	USA	EXACT	0711308AA	idelalisib	YG57I8T5M0						Follicular lymphoma	2356		
dasiprotimut-T	Treatment of follicular lymphoma	dasiprotimut-T		Biovaxid	10/28/09	Designated			N/A	N/A	"Biovest International, Inc."	Tampa	Florida	33606	USA	EXACT	1347075AA	dasiprotimut-T							Follicular lymphoma	2356		
Glucopyranosyl lipid A stable emulsion	Treatment of follicular lymphoma	Glucopyranosyl lipid A		n/a	2/14/17	Designated			N/A	N/A	Immune Design Corp.	Seattle	Washington	98102	USA	EXACT	1802637AA	Glucopyranosyl lipid A	A1O9D5VN5D						Follicular lymphoma	2356		
autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor	Treatment of follicular lymphoma.	autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor		n/a	4/25/16	Designated			N/A	N/A	"Kite Pharma, Inc."	Santa Monica	California	90404	USA	LONGEST CONTAINS	1722709AA	CD19	IYZ9TI08W3						Follicular lymphoma	2356		
autologous CD4+/CD8+ T cells transduced with lentiviral vector that expresses CD19 chimeric antigen receptor	Treatment of follicular lymphoma (FL)	autologous CD4+/CD8+ T cells transduced with lentiviral vector that expresses CD19 chimeric antigen receptor		n/a	9/7/17	Designated			N/A	N/A	"Juno Therapeutics, Inc."	Seattle	Washington	98109	USA	LONGEST CONTAINS	1722709AA	CD19	IYZ9TI08W3						Follicular lymphoma	2356		
humanized IgG4-based anti-CD20 x anti-CD3 bispecific monoclonal antibody	Treatment of follicular lymphoma (FL)	humanized IgG4-based anti-CD20 x anti-CD3 bispecific monoclonal antibody		n/a	1/25/18	Designated			N/A	N/A	"Regeneron Pharmaceuticals, Inc."	777 Old Saw Mill River Road	Tarrytown	10591	USA	LONGEST CONTAINS	1722630AA	CD20	TB2Q79LBS0						Follicular lymphoma	2356		
N-[5-(6-fluoro-8-{[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl}-2-morpholinoquinazolin-4-yl)-2-methoxypyridin-3-yl]methanesulfonamide	Treatment Follicular Lymphoma	N-[5-(6-fluoro-8-{[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl}-2-morpholinoquinazolin-4-yl)-2-methoxypyridin-3-yl]methanesulfonamide		n/a	10/10/18	Designated			N/A	N/A	"Shanghai Yingli Pharmaceutical Co., Ltd."	"No.1 Building, 998 Halei Road"			China	EXACT	0117208AB								Follicular lymphoma	2356		
"68Ga-OPS202, small somatostatin analog labeled with 68Gallium"	Management of gastroenteropancreatic neuroendocrine tumors.	SATOREOTIDE TRIZOXETAN GALLIUM GA-68		n/a	9/24/14	Designated			N/A	N/A	"Ipsen Biosciences, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0113078AB	SATOREOTIDE TRIZOXETAN GALLIUM GA-68	ZP2ODR0UR3						Gastroenteropancreatic neuroendocrine tumor	2437		
veliparib	Treatment of glioblastoma multiforme when used in combination with DNA-damaging agents	veliparib		n/a	5/9/08	Designated			N/A	N/A	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0338192AA	veliparib	01O4K0631N						Glioblastoma	2491		
Ritanserin	Treatment of glioblastoma	Ritanserin		n/a	5/11/17	Designated			N/A	N/A	The University of Virginia/Benjamin Purow	Charlottesville	Virginia	22908	USA	EXACT	0143975AA	Ritanserin	145TFV465S						Glioblastoma	2491		
Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B)	Treatment of glioblastoma multiforme and anaplastic astrocytoma.	IODINE I-131 DERLOTUXIMAB BIOTIN		131ichtnt-1	2/12/99	Designated			N/A	N/A	"Peregrine Pharmaceuticals, Inc."	Tustin	California	92780	USA	EXACT	1114289AA	IODINE I-131 DERLOTUXIMAB BIOTIN	1724UJB90B						Glioblastoma	2491		
cannabidiol	Treatment of glioblastoma multiforme	cannabidiol		n/a	8/20/14	Designated			N/A	N/A	"Insys Development Company, Inc."	Chandler	Arizona	85286	USA	EXACT	0027441AA	cannabidiol	19GBJ60SN5						Glioblastoma	2491		
cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC)	Treatment of glioblastoma multiforme	cannabidiol		n/a	1/8/18	Designated			N/A	N/A	"AXIUM Pharmaceuticals, Inc."	265 Eastchester Drive	High Point	27262	USA	EXACT	0027441AA	cannabidiol	19GBJ60SN5						Glioblastoma	2491		
mibefradil	Treatment of glioblastoma multiforme.	mibefradil		n/a	8/25/09	Designated			N/A	N/A	"Cavion, LLC"	Charlottesville	Virginia	22902	USA	EXACT	0339753AA	mibefradil	27B90X776A						Glioblastoma	2491		
"6-{4-[l-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide"	Treatment of glioblastoma multiforme (GBM).	USL-311		n/a	2/11/16	Designated			N/A	N/A	"Upsher-Smith Laboratories, Inc."	Maple Grove	Minnesota	55369	USA	EXACT	1251123AA	USL-311	2BTG5MX2Q2						Glioblastoma	2491		
nivolumab	Treatment of glioblastoma	nivolumab		n/a	8/27/15	Designated			N/A	N/A	Bristol-Myers Squibb Co	Princeton	New Jersey	8543	USA	EXACT	0761411AA	nivolumab	31YO63LBSN						Glioblastoma	2491		
Varbulin	Treatment of glioblastoma multiforme.	VERUBULIN HYDROCHLORIDE		Azixa	11/5/09	Designated			N/A	N/A	"Myrexis, Inc."	Salt Lake City	Utah	84108	USA	EXACT	0252211AA	VERUBULIN HYDROCHLORIDE	33380QZ0QW						Glioblastoma	2491		
ropidoxuridine (5-iodo-2-pyrimidinone-2'-deoxyribose)	Radiosensitizer to be used during radiation treatment of glioblastoma multiforme.	ropidoxuridine (5-iodo-2-pyrimidinone-2'-deoxyribose)		n/a	5/19/16	Designated			N/A	N/A	"EMEK, Inc."	Warwick	Rhode Island	2889	USA	EXACT	0303173AA	ropidoxuridine	3HX21A3SQF						Glioblastoma	2491		
(20S)-7-tert-butyldimethysilyl-10-hydroxycamptothecin	Treatment of glioblastoma multiforme (GBM)	(20S)-7-tert-butyldimethysilyl-10-hydroxycamptothecin		n/a	7/13/17	Designated			N/A	N/A	"Vivacitas Oncology, Inc."	Walnut Creek	California	94596	USA	EXACT	0581500AA	(20S)-7-tert-butyldimethysilyl-10-hydroxycamptothecin	3YEA04NV6H						Glioblastoma	2491		
dodecafluoropentane emulsion (DDFPe)	Radiosensitizer to be used during radiation treatment of glioblastoma multiforme (GBM).	dodecafluoropentane emulsion (DDFPe)		n/a	12/2/15	Designated			N/A	N/A	NuvOx Pharma	Tucson	Arizona	85719	USA	EXACT	0183915AA	dodecafluoropentane	483AU1Y5CZ						Glioblastoma	2491		
20-mer oligonucleotide complementary to Akt mRNA	Treatment of glioblastoma	ARCHEXIN		n/a	12/8/04	Designated			N/A	N/A	Rexahn Corporation	Rockville	Maryland	20850	USA	EXACT	0252631AA	ARCHEXIN	4TEW51C830						Glioblastoma	2491		
"7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one*2HCl"	Treatment of glioblastoma.	ONC-201 DIHYDROCHLORIDE		n/a	6/23/16	Designated			N/A	N/A	"Oncoceutics, Inc."	Philadelphia	Pennsylvania	19104	USA	EXACT	0928052AA	ONC-201 DIHYDROCHLORIDE	53VG71J90J						Glioblastoma	2491		
methimazole and liothyronine sodium	Treatment of glioblastoma multiforme.	methimazole		n/a	6/2/16	Designated			N/A	N/A	Musli Thyropeutics Ltd	zur Moshe			Israel	EXACT	0010526AA	methimazole	554Z48XN5E						Glioblastoma	2491		
2-methoxyestradiol	Treatment of multiforme glioblastoma	2-methoxyestradiol		Panzem	6/16/06	Designated/Withdrawn			N/A	N/A	"EntreMed, Inc."	Durham	North Carolina	27703	USA	EXACT	0235176AA	2-methoxyestradiol	6I2QW73SR5						Glioblastoma	2491		
cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC)	Treatment of glioblastoma multiforme	cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC)		n/a	1/8/18	Designated			N/A	N/A	"AXIUM Pharmaceuticals, Inc."	265 Eastchester Drive	High Point	27262	USA	EXACT	0045169AA	tetrahydrocannabinol	7J8897W37S						Glioblastoma	2491		
Disufenton sodium	Treatment of glioblastoma multiforme.	Disufenton sodium		n/a	8/22/16	Designated			N/A	N/A	"Oblato, Inc."	Princeton	New Jersey	8540	USA	EXACT	0238426AA	Disufenton sodium	7M1J3HN9VO						Glioblastoma	2491		
Hypericin	Treatment of glioblastoma multiforme.	Hypericin		n/a	8/3/00	Designated			N/A	N/A	"HyBiopharma, Inc."	Jamison	Pennsylvania	18929	USA	EXACT	0028466AA	Hypericin	7V2F1075HD						Glioblastoma	2491		
EnGeneIC delivery vehicles loaded with doxorubicin and targeted to tumor with sequences from Vectibix and mouse monoclonal antibody	Treatment glioblastoma multiforme	DOXORUBICIN		n/a	2/14/17	Designated			N/A	N/A	EnGeneIC Ltd	Lane Cove West			Australia	EXACT	0061074AA	DOXORUBICIN	80168379AG						Glioblastoma	2491		
chloroquine	Treatment of glioblastoma multiforme.	chloroquine		n/a	5/20/15	Designated			N/A	N/A	"DualTpharma B.,V."				Netherlands	EXACT	0008559AA	chloroquine	886U3H6UFF						Glioblastoma	2491		
[a-N-(2'succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr	Treatment of glioblastoma multiforme	ANG-1005		n/a	5/14/14	Designated			N/A	N/A	"Angiochem, Inc."				Canada	EXACT	0632133AA	ANG-1005	8P77G99D3P						Glioblastoma	2491		
KIT and PDGFR inhibitor	Treatment of glioblastoma multiforme and anaplastic astrocytomas	DCC-2618		n/a	8/7/17	Designated			N/A	N/A	"Deciphera Pharmaceuticals, LLC"	Waltham	Massachusetts	2451	USA	EXACT	1177113AA	DCC-2618	9XW757O13D						Glioblastoma	2491		
autologous ex vivo expanded CD4+-enriched leukocytes treated with the de-methylating agent 5-aza-deoxycytidine	Treatment of glioblastoma multiforme	autologous ex vivo expanded CD4+-enriched leukocytes treated with the de-methylating agent 5-aza-deoxycytidine		Alecsat	9/13/13	Designated			N/A	N/A	CytoVac A/S	Horsholm			Denmark	EXACT	1803265AA	autologous ex vivo expanded CD4+-enriched leukocytes treated with the de-methylating agent 5-aza-deoxycytidine	B2NUS89036						Glioblastoma	2491		
aldoxorubicin	Treatment of glioblastoma multiforme	aldoxorubicin		n/a	9/24/14	Designated			N/A	N/A	CytRx Corporation	Los Angeles	California	90049	USA	EXACT	0738294AA	aldoxorubicin	C28MV4IM0B						Glioblastoma	2491		
[AC3-yCD2(V)] and Flucytosine (5-FC XR)	Treatment of glioblastoma multiforme	(AC3-yCD2(V)) and Flucytosine (5-FC XR)		n/a	1/12/11	Designated			N/A	N/A	"Tocagen, Inc."	San Diego	California	92109	USA	EXACT	0038175AA	Flucytosine	D83282DT06						Glioblastoma	2491		
[AC3-yCD2(V)] and Flucytosine (5-FC XR)	Treatment of glioblastoma multiforme	vocimagene amiretrorepvec		n/a	1/12/11	Designated			N/A	N/A	"Tocagen, Inc."	San Diego	California	92109	USA	EXACT	0908974AA	vocimagene amiretrorepvec	DC4WO3WA4Q						Glioblastoma	2491		
Human Monoclonal Antibody against Epidermal Growth Factor Receptor Linked to Monomethylauristatin F	Treatment of glioblastoma multiforme	Depatuxizumab mafodotin		n/a	5/29/14	Designated			N/A	N/A	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	1188950AA	Depatuxizumab mafodotin	F3R7A4P04N						Glioblastoma	2491		
methimazole and liothyronine sodium	Treatment of glioblastoma multiforme.	methimazole and liothyronine sodium		n/a	6/2/16	Designated			N/A	N/A	Musli Thyropeutics Ltd	zur Moshe			Israel	EXACT	0008811AA	liothyronine sodium	GCA9VV7D2N						Glioblastoma	2491		
rindopepimut	Treatment of EGFRvIII-expressing glioblastoma multiforme	rindopepimut		n/a	11/19/07	Designated			N/A	N/A	"Celldex Therapeutics, Inc."	Needham	Massachusetts	2494	USA	EXACT	0343920AA	rindopepimut	K3L4X0501F						Glioblastoma	2491		
saposin C	Treatment of glioblastoma multiforme	"1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHO-L-SERINE"		n/a	2/3/15	Designated			N/A	N/A	"Bexion Pharmaceuticals, LLC"	Covington	Kentucky	41011	USA	EXACT	0379997AA	"1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHO-L-SERINE"	KJ401H4834						Glioblastoma	2491		
olaptesed pegol	Treatment of glioblastoma in conjunction with radiotherapy.	olaptesed pegol		n/a	8/19/14	Designated			N/A	N/A	Noxxon Pharma AG	Berlin			Germany	EXACT	1090488AA	olaptesed pegol	MTM792B442						Glioblastoma	2491		
"3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-pyrrole-2,5-dione"	Treatment of glioblastoma	9-ING-41		n/a	3/29/16	Designated			N/A	N/A	Actuate Therapeutics	Fort Worth	Texas	76107	USA	EXACT	1576369AA	9-ING-41	ND1SOF0DLU						Glioblastoma	2491		
cediranib	Treatment of glioblastoma	cediranib		n/a	12/13/10	Designated			N/A	N/A	National Institutes of Health	Bethesda	Maryland	20892	USA	EXACT	0258913AA	cediranib	NQU9IPY4K9						Glioblastoma	2491		
"5-(6,6-dimethyl-4-morpholino-8,9-dihydro-6H-[1,4]oxazino[3,4-e]purin-2-yl)pyrimidin-2-amine"	Treatment of glioblastoma multiforme (GBM)	GDC-0084		n/a	2/21/18	Designated			N/A	N/A	Kazia Therapeutics Limited	20 George Street	Hornsby		Australia	EXACT	0706514AA	GDC-0084	P5DKZ70636						Glioblastoma	2491		
nano-diamino-tetraiodothyroacetic acid	Treatment of glioblastoma multiforme (GBM)	nano-diamino-tetraiodothyroacetic acid		n/a	7/9/15	Designated			N/A	N/A	"NanoPharmaceuticals, LLC"	Rensselaer	New York	12144	USA	EXACT	0497176AA	tetraiodothyroacetic acid	PA7UX1FFYQ						Glioblastoma	2491		
"2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid"	Treatment of glioblastoma multiforme.	RGX-104		n/a	6/16/15	Designated			N/A	N/A	"Rgenix, Inc."	New York	New York	10065	USA	EXACT	1576778AA	RGX-104	Q26B92650V						Glioblastoma	2491		
combination of disulfiram and copper gluconate	Treatment of glioblastoma multiforme.	combination of disulfiram and copper gluconate		n/a	5/18/16	Designated			N/A	N/A	"Cantex Pharmaceuticals, Inc."	Weston	Florida	33326	USA	EXACT	0027689AA	copper gluconate	RV823G6G67						Glioblastoma	2491		
"4-[1]benzofuro[3,2-d]pyrimidin-4-yl-N-(1,3-benzodioxol-5-ylmethyl)piperazine-1-carbothioamide"	"Treatment, in combination with radiotherapy and temozolomide chemotherapy, of patients with glioblastoma multiforme."	AMUVATINIB		n/a	7/30/08	Designated			N/A	N/A	"SuperGen, Inc."	Dublin	California	94568	USA	EXACT	0304392AA	AMUVATINIB	SO9S6QZB4R						Glioblastoma	2491		
altiratinib	Treatment of glioblastoma multiforme.	altiratinib		n/a	8/19/14	Designated			N/A	N/A	"Deciphera Pharmaceuticals, LLC"	Lawrence	Kansas	66044	USA	EXACT	1113491AA	altiratinib	T678746713						Glioblastoma	2491		
paclitaxel poliglumex	Treatment of glioblastoma multiforme	paclitaxel poliglumex		Opaxio	9/20/12	Designated			N/A	N/A	CTI BioPharma Corporation	Seattle	Washington	98119	USA	EXACT	0238335AA	paclitaxel poliglumex	TQ64FZ98ZN						Glioblastoma	2491		
combination of disulfiram and copper gluconate	Treatment of glioblastoma multiforme.	 disulfiram		n/a	5/18/16	Designated			N/A	N/A	"Cantex Pharmaceuticals, Inc."	Weston	Florida	33326	USA	EXACT	0016353AA	disulfiram	TR3MLJ1UAI						Glioblastoma	2491		
Fluorouracil	Treatment of glioblastoma multiforme.	Fluorouracil		n/a	6/29/00	Designated			N/A	N/A	Ethypharm SA				USA	EXACT	0007772AA	Fluorouracil	U3P01618RT						Glioblastoma	2491		
Enzastaurin	Treatment of glioblastoma multiforme	Enzastaurin		n/a	9/19/05	Designated			N/A	N/A	Denovo Biopharma LLC	San Diego	California	92121	USA	EXACT	0309955AA	Enzastaurin	UC96G28EQF						Glioblastoma	2491		
Recombinant humanized monoclonal antibody directed against an epidermal growth factor receptor	Treatment of glioblastoma multiforme	Depatuxizumab		n/a	2/17/12	Designated/Withdrawn			N/A	N/A	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0800953AA	Depatuxizumab	W984C353CG						Glioblastoma	2491		
8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo[c]chromen-6-one	Treatment of glioblastoma multiforme	8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo(c)chromen-6-one		n/a	1/21/15	Designated			N/A	N/A	"Diffusion Pharmaceuticals, Inc."	Charlottesville	Virginia	22902	USA	EXACT	0550663AA	8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo(c)chromen-6-one	XV9409EWG4						Glioblastoma	2491		
temozolomide	Treatment glioblastoma multiforme in pediatric patients	temozolomide		n/a	11/25/15	Designated			N/A	N/A	"AmpliPharm Pharmaceuticals, LLC"	Suwanee	Georgia	30024	USA	EXACT	0182990AA	temozolomide	YF1K15M17Y						Glioblastoma	2491		
trans sodium crocetinate	Treatment of glioblastoma in conjunction with radiotherapy	TRANSCROCETINATE SODIUM		n/a	7/21/11	Designated			N/A	N/A	"Diffusion Pharmaceuticals, LLC"	Charlottesville	Virginia	22902	USA	EXACT	0931737AA	TRANSCROCETINATE SODIUM	YP57637WMX						Glioblastoma	2491		
Anti-Beta1 integrin monoclonal antibody	Treatment of glioblastoma	 OS-2966		n/a	8/7/14	Designated			N/A	N/A	"OncoSynergy, Inc."	San Francisco	California	94158	USA	EXACT									Glioblastoma	2491		
saposin C	Treatment of glioblastoma multiforme	SAPOSIN C (RECOMBINANT HIS TAGGED)		n/a	2/3/15	Designated			N/A	N/A	"Bexion Pharmaceuticals, LLC"	Covington	Kentucky	41011	USA	EXACT	1804859AA	SAPOSIN C (RECOMBINANT HIS TAGGED)	QT2JK7C5U6						Glioblastoma	2491		
human recombinant bone morphogenetic protein 4	Treatment of glioblastoma multiforme.	human recombinant bone morphogenetic protein 4		n/a	5/4/16	Designated			N/A	N/A	"HyperStem Therapeutics, Inc."	San Diego	California	92129	USA	EXACT	0113890AB	human recombinant bone morphogenetic protein 4	08RQ4CQ601						Glioblastoma	2491		
"(3R,3aS,9R,9aS,9bS)-3-((dimethylamino)methyl)-9-hydroxy-6,9-dimethyl-3,3a,4,5,7,8,9,9a-octahydroazuleno[4,5-b]furan-2(9bH)-one fumarate"	Treatment of glioblastoma multiforme	ACT-001 FUMARATE		n/a	11/8/17	Designated			N/A	N/A	Accendatech USA Incorporated	3730 Kirby Drive	Texas	77098	USA	EXACT	0113583AB	ACT-001 FUMARATE	KM6239D2QV						Glioblastoma	2491		
Recombinant Human Monoclonal Antibody To Vascular Endothelial Growth Factor Receptor-2	Treatment of Glioblastoma	Recombinant Human Monoclonal Antibody To Vascular Endothelial Growth Factor Receptor-2		n/a	3/8/18	Designated			N/A	N/A	PharmAbcine Inc.	"#307, Daedeok Tech-Biz Center"	"593, Daedeok-daero"		"Korea, Republic of"	LONGEST CONTAINS	1340927AA	Vascular Endothelial Growth Factor Receptor 2	798536Z7S0						Glioblastoma	2491		
Recombinant fusion protein-extracellular portion of CD95 fused to the Fc part of human IgG1	Treatment of glioblastoma multiforme	Recombinant fusion protein-extracellular portion of CD95 fused to the Fc part of human IgG1		n/a	10/13/09	Designated			N/A	N/A	Apogenix GmbH				Germany	LONGEST CONTAINS	0087274AA	protein							Glioblastoma	2491		
"dendritic cells pulsed with synthetic peptides derived from antigens MAGE1, HER-2, AIM-2,TRP-2, gp100 and interleukin-13 receptor alpha"	Treatment of glioblastoma or brain stem glioma	"dendritic cells pulsed with synthetic peptides derived from antigens MAGE1, HER-2, AIM-2,TRP-2, gp100 and interleukin-13 receptor alpha"		n/a	6/7/10	Designated			N/A	N/A	ImmunoCellular Therapeutics Ltd.	Woodland Hills	California	91367	USA	LONGEST CONTAINS	0123397AA	antigens							Glioblastoma	2491		
P140K MGMT transduced human CD34 cells	For bone marrow protection in the treatment of glioblastoma multiforme	P140K MGMT transduced human CD34 cells		n/a	1/9/13	Designated			N/A	N/A	Lentigen Corporation	Gaithersburg	Maryland	20878	USA	LONGEST CONTAINS	1797735AA	CD34	ZWL6BH0E0S						Glioblastoma	2491		
"autologous tumor cells fused with polyethylene glycol to human allogeneic FO-1, DNA plasmid transfected tumor cell line"	Treatment of glioblastoma	"autologous tumor cells fused with polyethylene glycol to human allogeneic FO-1, DNA plasmid transfected tumor cell line"		n/a	5/6/15	Designated			N/A	N/A	"Sebastiano Gattoni-Celli, MD"	Charleston	South Carolina	29403	USA	LONGEST CONTAINS	0137031AA	polyethylene glycol	3WJQ0SDW1A						Glioblastoma	2491		
Autologous dendritic cell/tumor antigens	Treatment of glioblastoma multiforme (GBM)	Autologous dendritic cell/tumor antigens		n/a	9/27/16	Designated			N/A	N/A	China Medical University Hospital				Taiwan	LONGEST CONTAINS	0123397AA	antigens							Glioblastoma	2491		
synthetic survivin peptide SVN53-67/M57-keyhole limpet hemocyanin	Treatment of glioblastoma	synthetic survivin peptide SVN53-67/M57-keyhole limpet hemocyanin		n/a	8/2/17	Designated			N/A	N/A	"MimiVax, LLC"	Buffalo	New York	14263	USA	LONGEST CONTAINS	0222220AA	keyhole limpet hemocyanin	FV4Y0JO2CX						Glioblastoma	2491		
anti-EGFRvIII x anti-CD3 bispecific T cell engager antibody construct	Treatment of glioblastoma	anti-EGFRvIII x anti-CD3 bispecific T cell engager antibody construct		n/a	4/2/18	Designated			N/A	N/A	Amgen Inc.	One Amgen Center Drive	Mail Stop: 27-3-A	91320	USA										Glioblastoma	2491		
Autologous Cytokine-Induced Killer Cells (Cytokine-Induced Killer Cells Plus Cytotoxic T Lymphocytes)	Treatment of glioblastoma	Autologous Cytokine-Induced Killer Cells (Cytokine-Induced Killer Cells Plus Cytotoxic T Lymphocytes)		n/a	8/1/18	Designated			N/A	N/A	Green Cross Cell Corporation	"4, 6th floor, SJ Technovile 278"			"Korea, Republic of"	LONGEST CONTAINS	0263092AA	Lymphocytes							Glioblastoma	2491		
(1-hydroxy-2-oxopiperidin-3-yl)phosphonic acid	Treatment of Glioblastoma	(1-hydroxy-2-oxopiperidin-3-yl)phosphonic acid		n/a	8/9/18	Designated			N/A	N/A	The University of Texas MD Anderson Cancer Center	1515 Holcombe Blvd #2	Texas	77030	USA	EXACT	0117182AB								Glioblastoma	2491		
Ibudilast	Treatment of Glioblastoma	Ibudilast		n/a	10/2/18	Designated			N/A	N/A	"MediciNova, Inc."	4275 Executive Square	California	92037	USA	EXACT	0297905AA	Ibudilast	M0TTH61XC5						Glioblastoma	2491		
Multi-ligand somatostatin analog	"Treatment of patients with functional gastroenteropancreatic (GEP) neuroendocrine tumors (specifically, carcinoid, insulinoma, gastrinoma, somastatinoma, GRFoma, VIPoma and glucagonoma."	Pasireotide		n/a	7/27/04	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0269534AA	Pasireotide	98H1T17066						Glucagonoma	2496		
bivalirudin	For use as an anticoagulant in patients with or at risk of heparin-induced thrombocytopenia/heparin-induced thrombocytopenia thrombosis syndrome	bivalirudin		Angiomax	11/2/05	Designated			N/A	N/A	The Medicines Company	Parsippany	New Jersey	7054	USA	EXACT	0173795AA	bivalirudin	TN9BEX005G						Heparin-induced thrombocytopenia	2650		
Iodine I 131 murine monoclonal antibody to alpha-fetoprotein	1. Treatment of hepatocellular carcinoma and hepatoblastoma 2. Treatment of alpha-fetoprotein producing germ cell tumors	IMMU-31 I-131		n/a	9/30/88	Designated/Withdrawn			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA	EXACT	0113782AB	IMMU-31 I-131							Hepatoblastoma	2657		
Iodine I 123 murine monoclonal antibody to alpha-fetoprotein	1. Detection of hepatocellular carcinoma and hepatoblastoma 2. Detection of alpha-fetoprotein producing germ cell tumors	IMMU-31 I-123		n/a	9/30/88	Designated/Withdrawn			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA	EXACT	0113783AB	IMMU-31 I-123							Hepatoblastoma	2657		
Technetium Tc99m murine monoclonal antibody to human alpha-fetoprotein	Detection of hepatocellular carcinoma and hepatoblastoma.	Technetium Tc99m murine monoclonal antibody to human alpha-fetoprotein		"Immuraid, Afp-Scan"	8/1/89	Designated/Withdrawn			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA										Hepatoblastoma	2657		
Nitisinone	Treatment of tyrosinemia type 1.	Nitisinone		Orfadin	5/16/95	Designated/Approved	Approved for Orphan Indication	Adjunctive therapy to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1	1/18/02	1/18/09	Swedish Orphan Biovitrum AB	Waltham	Massachusetts	2451	USA	EXACT	0182581AA	Nitisinone	K5BN214699						Tyrosinemia type 1	2658		
Nitisinone	Treatment of tyrosinemia type 1.	Nitisinone		Orfadin	5/16/95	Designated/Approved	Approved for Orphan Indication	Treatment of hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.	4/22/16	4/22/23	Swedish Orphan Biovitrum AB	Waltham	Massachusetts	2451	USA	EXACT	0182581AA	Nitisinone	K5BN214699						Tyrosinemia type 1	2658		
"(S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one"	Treatment of Hodgkin lymphoma	Dezapelisib		n/a	4/29/15	Designated			N/A	N/A	Incyte Corporation	Wilmington	Delaware	19803	USA	EXACT	0897121AA	Dezapelisib	2K59L7G59M						Hodgkin lymphoma	2714		
nivolumab	Treatment of Hodgkin lymphoma	nivolumab		Opdivo	8/7/14	Designated/Approved	Approved for Orphan Indication	Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation brentuximab vedotin	5/17/16	5/17/23	Bristol-Myers Squibb Co.	Princeton	New Jersey	8543	USA	EXACT	0761411AA	nivolumab	31YO63LBSN						Hodgkin lymphoma	2714		
bortezomib	Treatment of follicular non-Hodgkin lymphoma	bortezomib		Velcade	1/4/11	Designated			N/A	N/A	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0228319AA	bortezomib	69G8BD63PP						Hodgkin lymphoma	2714		
pembrolizumab	Treatment of Hodgkin lymphoma.	pembrolizumab		Keytruda	12/30/15	Designated			N/A	N/A	"Merck, Sharp & Dohme Corp."	Whitehouse Station	New Jersey	8889	USA	EXACT	0809245AA	pembrolizumab	DPT0O3T46P						Hodgkin lymphoma	2714		
anti-CD30 Fc engineered humanized monoclonal antibody	Treatment of Hodgkin lymphoma	XmAb-2513		n/a	12/2/08	Designated			N/A	N/A	"Xencor, Inc."	Monrovia	California	91016	USA	EXACT	0117236AB								Hodgkin lymphoma	2714		
stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells	Treatment of Hodgkin lymphoma.	UMBILICAL CORD MESENCHYMAL STROMAL CELLS		Nicord(R)	11/13/14	Designated			N/A	N/A	Gamida Cell Ltd.	Jerusalem			Israel	EXACT	1794565AA	UMBILICAL CORD MESENCHYMAL STROMAL CELLS	3FXW1IW7WT						Hodgkin lymphoma	2714		
Recombinant antibody construct against human CD30 and CD16A	Treatment of Hodgkin lymphoma	AFM-13		n/a	8/20/09	Designated			N/A	N/A	Affimed GmbH				Germany	EXACT	0117154AB	AFM-13							Hodgkin lymphoma	2714		
autologous Epstein-Barr virus specific T-cells	Treatment of Epstein-Barr virus positive non-Hodgkin lymphomas.	autologous Epstein-Barr virus specific T-cells		n/a	3/9/15	Designated			N/A	N/A	"Cell Medica, Inc."	Houston	Texas	77054	USA										Hodgkin lymphoma	2714		
reslizumab	Treatment of hypereosinophilic syndrome	reslizumab		Cinquil	1/12/11	Designated			N/A	N/A	"Teva Pharmaceuticals, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0263843AA	reslizumab	35A26E427H						Hypereosinophilic syndrome	2804		
Imatinib mesylate	Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia	Imatinib mesylate		Gleevec	8/25/05	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with hypereosinophic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRÃ¿}Ã¿Â± fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRÃ¿}Ã¿Â± fusion kinase negative or unknown	10/19/06	10/19/13	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0227065AA	Imatinib mesylate	8A1O1M485B						Hypereosinophilic syndrome	2804		
mepolizumab	For first-line treatment in patients with hypereosinophilic syndrome	mepolizumab		n/a	5/28/04	Designated			N/A	N/A	GlaxoSmithKline LLC	Wilmington	Delaware	19808	USA	EXACT	0298077AA	mepolizumab	90Z2UF0E52						Hypereosinophilic syndrome	2804		
synthetic double-stranded (hybridized duplex) ribonucleic acid oligonucleotide specific to hydroxyacid oxidase 1 gene	Treatment of primary hyperoxaluria type 1	synthetic double-stranded (hybridized duplex) ribonucleic acid oligonucleotide specific to hydroxyacid oxidase 1 gene		n/a	4/22/15	Designated			N/A	N/A	"Dicerna Pharmaceuticals, Inc."	Cambridge	Massachusetts	2140	USA	LONGEST CONTAINS	0006724AA	ribonucleic acid							Primary hyperoxaluria type 1	2835		
synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 (HAO1) mRNA	Treatment of primary hyperoxaluria type 1	synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 (HAO1) mRNA		n/a	2/8/16	Designated			N/A	N/A	"Alnylam Pharmaceuticals, Inc."	Cambridge	Massachusetts	2142	USA										Primary hyperoxaluria type 1	2835		
solnatide	Treatment of generalized systemic pseudohypoaldosteronism type 1 (also known as autosomal recessive PHA-I or PHA-IB)	solnatide		n/a	2/8/16	Designated			N/A	N/A	Apeptico Forschung und Entwicklung GmbH	Vienna			Austria	EXACT	0766778AA	solnatide	17ZS80333G						Hypoaldosteronism	2874		
urea	"Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis)."	urea		n/a	11/7/11	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0009290AA	urea	8W8T17847W						Netherton syndrome	2967		
"6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-bensoxazin-4-one"	Treatment of Netherton syndrome	"6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-bensoxazin-4-one"		n/a	6/18/15	Designated			N/A	N/A	Sixera Pharma AB				Sweden	EXACT	1576950AA	"6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-bensoxazin-4-one"	BDQ30W2KTS						Netherton syndrome	2967		
recombinant kallikrein inhibitor	Treatment of Netherton Syndrome.	recombinant kallikrein inhibitor		n/a	11/23/10	Designated			N/A	N/A	Dermadis SA				France	LONGEST CONTAINS	0004808AA	kallikrein							Netherton syndrome	2967		
Multi-ligand somatostatin analog	"Treatment of patients with functional gastroenteropancreatic (GEP) neuroendocrine tumors (specifically, carcinoid, insulinoma, gastrinoma, somastatinoma, GRFoma, VIPoma and glucagonoma."	Pasireotide		n/a	7/27/04	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0269534AA	Pasireotide	98H1T17066						Insulinoma	3010		
crizotinib	Treatment of anaplastic large cell lymphoma	crizotinib		Xalkori	9/28/12	Designated			N/A	N/A	"Pfizer, Inc."	San Diego	California	92121	USA	EXACT	0274862AA	crizotinib	53AH36668S						Anaplastic large cell lymphoma	3112		
brentuximab vedotin	Treatment of anaplastic large cell lymphoma	brentuximab vedotin		Adcetris	10/23/08	Designated/Approved	Approved for Orphan Indication	The treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen	8/19/11	8/19/18	"Seattle Genetics, Inc."	Bothell	Washington	98021	USA	EXACT	0297767AA	brentuximab vedotin	7XL5ISS668						Anaplastic large cell lymphoma	3112		
urea	"Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis)."	urea		n/a	11/7/11	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0009290AA	urea	8W8T17847W						KID syndrome	3113		
5'-CTATCTGUC*G1TTCTCTGU-3'.17 Na+	Treatment of diffuse large B-cell lymphoma.	BAZLITORAN SODIUM		n/a	3/31/15	Designated			N/A	N/A	"Idera Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	1153317AA	BAZLITORAN SODIUM	1NLR4WAG4U						Diffuse Large B-Cell Lymphoma	3178		
ibrutinib	Treatment of diffuse large B-cell lymphoma	ibrutinib		n/a	10/23/13	Designated			N/A	N/A	"Pharmacyclics, LLC"	Sunnyvale	California	94085	USA	EXACT	0625092AA	ibrutinib	1X70OSD4VX						Diffuse Large B-Cell Lymphoma	3178		
Rosomidnar	Treatment of diffuse large B-cell lymphoma.	Rosomidnar		n/a	3/10/16	Designated/Withdrawn			N/A	N/A	"ProNAi Therapeutics, Inc."	Plymouth	Michigan	48170	USA	EXACT	1257643AA	Rosomidnar	2X4LQG2T5U						Diffuse Large B-Cell Lymphoma	3178		
"(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide"	Treatment of diffuse large B-cell lymphoma	Selinexor		n/a	5/14/14	Designated			N/A	N/A	"Karyopharm Therapeutics, Inc."	Natick	Massachusetts	1760	USA	EXACT	0899718AA	Selinexor	31TZ62FO8F						Diffuse Large B-Cell Lymphoma	3178		
C24H28N8O7S2	Treatment of diffuse large B-cell lymphoma (DLBCL).	CUDC-907		n/a	4/2/15	Designated			N/A	N/A	"Curis, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0836146AA	CUDC-907	3S9RX35S5X						Diffuse Large B-Cell Lymphoma	3178		
Rituximab/hyaluronidase	Treatment of diffuse large B-cell lymphoma	Rituximab 		Rituxan	9/7/16	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0225149AA	Rituximab	4F4X42SYQ6						Diffuse Large B-Cell Lymphoma	3178		
daratumumab	Treatment of diffuse large B-cell lymphoma.	daratumumab		Humax (R) - Cd38	11/9/15	Designated			N/A	N/A	"Janssen Research and Development, LLC"	Spring hOuse	Pennsylvania	19477	USA	EXACT	0432519AA	daratumumab	4Z63YK6E0E						Diffuse Large B-Cell Lymphoma	3178		
Valproic acid	Treatment of diffuse large B-cell lymphoma	Valproic acid		n/a	3/30/17	Designated			N/A	N/A	Valcuria AB	Lund			Sweden	EXACT	0016546AA	Valproic acid	614OI1Z5WI						Diffuse Large B-Cell Lymphoma	3178		
"3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride"	Treatment of diffuse large B-cell lymphoma	CC-122 HYDROCHLORIDE		n/a	9/19/16	Designated			N/A	N/A	Celgene Corporation	Berkeley Heights	New Jersey	7922	USA	EXACT	0926830AA	CC-122 HYDROCHLORIDE	6CX4AEX3KR						Diffuse Large B-Cell Lymphoma	3178		
"6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridine-3-one monocitrate"	Treatment of diffuse large B-cell lymphoma	TAK-659		n/a	2/14/17	Designated			N/A	N/A	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0893072AA	TAK-659	6ZJ8V3Q0H1						Diffuse Large B-Cell Lymphoma	3178		
Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through a protease cleavable valine-alanine linker	Treatment of diffuse large B-cell lymphoma	ADCT-402		n/a	6/8/17	Designated			N/A	N/A	ADC Therapeutics SA	Epalinges			Switzerland	EXACT	0112432AB	ADCT-402	7K5O7P6QIU						Diffuse Large B-Cell Lymphoma	3178		
brentuximab vedotin	Treatment of patients with diffuse large B-cell lymphoma.	brentuximab vedotin		Adcetris(R)	1/31/14	Designated			N/A	N/A	"Seattle Genetics, Inc."	Bothell	Washington	98021	USA	EXACT	0297767AA	brentuximab vedotin	7XL5ISS668						Diffuse Large B-Cell Lymphoma	3178		
Rituximab/hyaluronidase	Treatment of diffuse large B-cell lymphoma	hyaluronidase		Rituxan	9/7/16	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0004944AA	hyaluronidase	8KOG53Z5EM						Diffuse Large B-Cell Lymphoma	3178		
"4, 5 dibromorhodamine methyl ester"	Treatment of diffuse large B-cell lymphoma	TH-9402 FREE BASE		Theralux Photodynamic Therapy	10/30/08	Designated			N/A	N/A	"Kiadis Pharma Canada, Inc."				Canada	EXACT	0807454AA	TH-9402 FREE BASE	934QHK1OOK						Diffuse Large B-Cell Lymphoma	3178		
everolimus	Treatment of diffuse large B-cell lymphoma	everolimus		n/a	6/2/14	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0218031AA	everolimus	9HW64Q8G6G						Diffuse Large B-Cell Lymphoma	3178		
mocetinostat	Treatment of diffuse large B-cell lymphoma	mocetinostat		n/a	8/7/14	Designated			N/A	N/A	"Mirati Therapeutics, Inc."	San Diego	California	92121	USA	EXACT	0323115AA	mocetinostat	A6GWB8T96J						Diffuse Large B-Cell Lymphoma	3178		
pralatrexate	Treatment of diffuse large B-cell lymphoma	pralatrexate		n/a	10/20/08	Designated			N/A	N/A	"Allos Therapeutics, Inc."	Westminister	Colorado	80020	USA	EXACT	0219034AA	pralatrexate	A8Q8I19Q20						Diffuse Large B-Cell Lymphoma	3178		
lenalidomide	Treatment of diffuse large B-cell lymphoma	lenalidomide		Revlimid	3/28/11	Designated			N/A	N/A	Celgene Corporation	Summit	New Jersey	7901	USA	EXACT	0236099AA	lenalidomide	F0P408N6V4						Diffuse Large B-Cell Lymphoma	3178		
Ublituximab in combination with phosphoinositide-3-kinase (PI3K) delta inhibitor	Treatment of diffuse large B-cell lymphoma	TGR-1202		n/a	1/19/17	Designated			N/A	N/A	"TG Therapeutics, Inc."	New York	New York	10014	USA	EXACT	1085047AA	TGR-1202	FU8XW5V3FS						Diffuse Large B-Cell Lymphoma	3178		
Polatuzumab vedotin	Treatment of diffuse large B-cell lymphoma	Polatuzumab vedotin		n/a	12/12/16	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0804046AA	Polatuzumab vedotin	KG6VO684Z6						Diffuse Large B-Cell Lymphoma	3178		
"4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide"	Treatment of diffuse large B-cell lymphoma.	VENETOCLAX		n/a	3/27/14	Designated			N/A	N/A	AbbVie	North Chicago	Illinois	60064	USA	EXACT	0790283AA	VENETOCLAX	N54AIC43PW						Diffuse Large B-Cell Lymphoma	3178		
tisagenlecleucel-T	Treatment of diffuse large B-cell lymphoma	tisagenlecleucel-T		n/a	2/3/15	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	1058760AA	tisagenlecleucel-T	Q6C9WHR03O						Diffuse Large B-Cell Lymphoma	3178		
"6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-2'H-spiro[cyclohexane-1,3'-imidazo[1,5a]pyridine]-1',5'-dione hydrochloride"	Treatment of diffuse large B-cell lymphoma	eft-508		n/a	2/23/17	Designated			N/A	N/A	eFFECTOR Therapeutics	San Diego	California	92121	USA	EXACT	1200891AA	eft-508	U2H19X4WBV						Diffuse Large B-Cell Lymphoma	3178		
Ublituximab in combination with phosphoinositide-3-kinase (PI3K) delta inhibitor	Treatment of diffuse large B-cell lymphoma	Ublituximab		n/a	1/19/17	Designated			N/A	N/A	"TG Therapeutics, Inc."	New York	New York	10014	USA	EXACT	0574607AA	Ublituximab	U59UGK3IPC						Diffuse Large B-Cell Lymphoma	3178		
enzastaurin	Treatment of diffuse large B-cell lymphoma	enzastaurin		n/a	3/4/09	Designated			N/A	N/A	Denovo Biopharma LLC	San Diego	California	92121	USA	EXACT	0309955AA	enzastaurin	UC96G28EQF						Diffuse Large B-Cell Lymphoma	3178		
maytansinoid-conjugated humanized monoclonal antibody against CD37	Treatment of diffuse large B-cell lymphoma	NARATUXIMAB EMTANSINE		n/a	5/12/16	Designated			N/A	N/A	"ImmunoGen, Inc."	Waltham	Massachusetts	2451	USA	EXACT	1250993AA	NARATUXIMAB EMTANSINE	WE1X5A83B9						Diffuse Large B-Cell Lymphoma	3178		
humanized Fc engineered monoclonal antibody against CD19	Treatment of diffuse large B-cell lymphoma.	MOR-208		n/a	12/1/14	Designated			N/A	N/A	MorphoSys AG				Germany	EXACT	1804597AA	MOR-208	QQA9MLH692						Diffuse Large B-Cell Lymphoma	3178		
human IgG4-based anti-CD20 x anti-CD3 bispecific monoclonal antibody	Treatment of diffuse large b-cell lymphoma.	REGN-1979		n/a	6/6/17	Designated			N/A	N/A	"Regeneron Pharmaceuticals, Inc."	Tarrytown	New York	10591	USA	EXACT	0112214AB	REGN-1979							Diffuse Large B-Cell Lymphoma	3178		
autologous peripheral blood T lymphocytes transduced with retroviral vector containing anti CD19 CD28/CD3 zeta chimeric antigen receptor	Treatment of diffuse large B-cell lymphoma.	autologous peripheral blood T lymphocytes transduced with retroviral vector containing anti CD19 CD28/CD3 zeta chimeric antigen receptor		n/a	3/27/14	Designated			N/A	N/A	"Kite Pharma, Inc."	Santa Monica	California	90404	USA	LONGEST CONTAINS	0263092AA	lymphocytes							Diffuse Large B-Cell Lymphoma	3178		
autologous CD4+/CD8+ T cells expressing a CD19 chimeric antigen receptor and truncated epidermal growth factor receptor	Treatment of diffuse large B-cell lymphoma	autologous CD4+/CD8+ T cells expressing a CD19 chimeric antigen receptor and truncated epidermal growth factor receptor		n/a	4/27/16	Designated			N/A	N/A	"Juno Therapeutics, Inc."	Seattle	Washington	98109	USA	LONGEST CONTAINS	1309962AA	epidermal growth factor receptor	RO03J093CP						Diffuse Large B-Cell Lymphoma	3178		
sodium phenylbutyrate	Treatment of maple syrup urine disease	sodium phenylbutyrate		n/a	8/19/14	Designated			N/A	N/A	"Acer Therapeutics, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0180767AA	sodium phenylbutyrate	NT6K61736T						Maple syrup urine disease	3228		
arylsulfatase A (rhASA)	Treatment of metachromatic leukodystrophy	arylsulfatase A (rhASA)		n/a	2/27/08	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	Lexington	Massachusetts	2421	USA	EXACT	1805943AA	rhASA							Metachromatic leukodystrophy	3230		
recombinant human arylsulphatase A	Treatment of metachromatic leukodystrophy (MLD).	HGT-1111		n/a	4/11/08	Designated/Withdrawn			N/A	N/A	Shire Human Genetic Therapies	Lexington	Massachusetts	2421	USA	EXACT	1805943AA	HGT-1111							Metachromatic leukodystrophy	3230		
autologous CD34+ cells transduced with lentiviral vector which encodes for the aryl Sulfatase A complimentary deoxyribonucleic acid sequence	Treatment of the Metachromatic Leukodystrophy (including pre-symptomatic metachromatic leukodystrophy)	autologous CD34+ cells transduced with lentiviral vector which encodes for the aryl Sulfatase A complimentary deoxyribonucleic acid sequence		n/a	3/8/18	Designated			N/A	N/A	"GlaxoSmithKline Intellectual Property Development Limited, England"	980 Great West Road			United Kingdom	LONGEST CONTAINS	0006484AA	deoxyribonucleic acid							Metachromatic leukodystrophy	3230		
everolimus	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	everolimus		Afinitor	6/8/09	Designated/Approved	Approved for Orphan Indication	Treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical resection	10/29/10	10/29/17	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0218031AA	everolimus	9HW64Q8G6G						Lymphangioleiomyomatosis	3319		
everolimus	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	everolimus		Afinitor	6/8/09	Designated/Approved	Approved for Orphan Indication	Treatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery.	4/26/12	4/26/19	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0218031AA	everolimus	9HW64Q8G6G						Lymphangioleiomyomatosis	3319		
sirolimus	Treatment of lymphangioleiomyomatosis	sirolimus		Rapamune	10/31/12	Designated/Approved	Approved for Orphan Indication	Treatment of lymphangioleiomyomatosis (LAM)	5/28/15	5/28/22	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	0175177AA	sirolimus	W36ZG6FT64						Lymphangioleiomyomatosis	3319		
sirolimus	Treatment of lymphangioleiomyomatosis	sirolimus		n/a	6/25/14	Designated			N/A	N/A	"LAM Therapeutics, Inc."	Guilford	Connecticut		USA	EXACT	0175177AA	sirolimus	W36ZG6FT64						Lymphangioleiomyomatosis	3319		
sirolimus	Treatment of lymphangioleiomyomatosis	sirolimus		n/a	11/17/11	Designated			N/A	N/A	"Cote Orphan Consulting, LLC"	Silver Spring	Maryland	20910	USA	EXACT	0175177AA	sirolimus	W36ZG6FT64						Lymphangioleiomyomatosis	3319		
flubendazole	"Treatment of lymphatic filariasis caused by nematodes of the family Filariodidea, in children and adults."	flubendazole		n/a	1/23/14	Designated			N/A	N/A	"Janssen Research and Development, LLC"	Raritan	New Jersey	8869	USA	EXACT	0083896AA	flubendazole	R8M46911LR						Lymphatic filariasis	3321		
4”-(p-fluorobenzyl)tylosin A	Treatment of lymphatic filariasis	4”-(p-fluorobenzyl)tylosin A		n/a	6/6/17	Designated			N/A	N/A	AbbVie Inc.	North Chicago	Illinois	60044	USA	EXACT	 0111826AB	tylosin A	YEF4JXN031						Lymphatic filariasis	3321		
nelarabine	Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma	nelarabine		Arranon	8/10/04	Designated/Approved	Approved for Orphan Indication	Treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens	10/28/05	10/28/12	Novartis Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0183302AA	nelarabine	60158CV180						Lymphoblastic lymphoma	3329		
Protein C concentrate	For use in the prevention and treatment of purpura fulminans in meningococcemia.	Protein C concentrate		"Protein C Concentrate (Human) Vapor Heated, Immuno"	4/22/93	Designated/Withdrawn			N/A	N/A	Immuno Clinical Research Corp.	New York	New York	10022	USA	EXACT	0340501AA	Protein C	3Z6S89TXPW						Meningococcemia	3472		
rituximab	"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)"	rituximab		Rituxan	2/14/06	Designated/Approved	Approved for Orphan Indication	For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). )	4/19/11	4/19/18	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0225149AA	rituximab	4F4X42SYQ6						Microscopic polyangiitis	3652		
antagonist of the complement 5a receptor	"Treatment of anti-neutrophil cytoplasmic autoantibodies associated vasculitides (granulomatosis with polyangiitis or Wegener's granulomatosis), microscopic polyangiitis, and Churg-Strauss syndrome."	CCX-168		n/a	6/2/14	Designated			N/A	N/A	"ChemoCentryx, Inc."	Mountain View	California	94043	USA	EXACT	1083336AA	CCX-168	O880NM097T						Microscopic polyangiitis	3652		
recombinant thymidine phosphorylase encapsulated with autologous erythrocytes	Treatment of mitochondrial neurogastrointestinal encephalomyopathydue to thymidine phosphorylase deficiency.	recombinant thymidine phosphorylase encapsulated with autologous erythrocytes		n/a	12/13/10	Designated			N/A	N/A	St. George's University of London				United Kingdom	LONGEST CONTAINS	0007669AA	thymidine	VC2W18DGKR						Encephalomyopathy	3681		
Adenoassociated virus vector (AAV) carrying a modified AAV serotype 2 backbone and coding sequence of human thymidine phosphorylase preceded by a human thyroxin-binding globulin promoter	For the treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)	Adenoassociated virus vector (AAV) carrying a modified AAV serotype 2 backbone and coding sequence of human thymidine phosphorylase preceded by a human thyroxin-binding globulin promoter		n/a	9/4/14	Designated			N/A	N/A	Columbia University Medical Center	New York	New York	10032	USA	LONGEST CONTAINS	0007669AA	thymidine	VC2W18DGKR						Encephalomyopathy	3681		
cyclic pyranopterin monophosphate (cPMP)	Treatment of molybdenum cofactor deficiency type A (MoCD)	cyclic pyranopterin monophosphate (cPMP)		n/a	11/5/09	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	New Haven	Connecticut	6510	USA	EXACT	0790761AA	cyclic pyranopterin monophosphate	4X7K2681Y7						Molybdenum cofactor deficiency	3705		
lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase	Treatment of mucopolysaccharidosis Type IVA (Morquio Syndrome)	lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase		n/a	9/10/08	Designated			N/A	N/A	Vivendy Therapeutics LTD				Switzerland	LONGEST CONTAINS	0319062AA	sulfate	7IS9N8KPMG						Mucopolysaccharidosis type IVA	3785		
recombinant human Naglu- insulin-like growth factor II	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B)	TRALESINIDASE ALFA		n/a	3/5/13	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0112449AB	TRALESINIDASE ALFA	AA60A4ST8X						Mucopolysaccharidosis type III	3807		
chemically modified recombinant sulfamidase	Treatment of mucopolysaccharidosis type IIIA (MPS IIIA)	SOBI-003		n/a	6/28/17	Designated			N/A	N/A	Swedish Orphan Biovitrum AB (publ)	Linköping SV			Sweden	EXACT	0112128AB	SOBI-003	ZS87P77DQC						Mucopolysaccharidosis type III	3807		
adeno-associated virus vector serotype 9 expressing human sulfamidase	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A Syndrome).	adeno-associated virus vector serotype 9 expressing human sulfamidase		n/a	6/1/11	Designated			N/A	N/A	"Laboratorios del Dr. Esteve, S.A."	Barcelona			Spain										Mucopolysaccharidosis type III	3807		
adeno-associated viral vector serotype 9 containing human N-acetylglucosaminidase alpha gene	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome)	adeno-associated viral vector serotype 9 containing human N-acetylglucosaminidase alpha gene		n/a	12/27/12	Designated			N/A	N/A	"Laboratorios del Dr. Esteve, S.A."	Barcelona			Spain										Mucopolysaccharidosis type III	3807		
adeno associated viral vector serotype rh.10 carrying the human SGSH and SUMF1 cDNAs	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo type A syndrome)	adeno associated viral vector serotype rh.10 carrying the human SGSH and SUMF1 cDNAs		n/a	5/6/13	Designated			N/A	N/A	Lysogene	Paris			France										Mucopolysaccharidosis type III	3807		
recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase	Treatment of mucopolysaccharidosis type III-A (Sanfilippo Syndrome Type A)	recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase		n/a	4/29/14	Designated			N/A	N/A	Abeona Therapeutics	Cleveland	Ohio	44106	USA										Mucopolysaccharidosis type III	3807		
adeno-associated viral (AAV) vector serotype rh. 10 encoding the human N-sulfoglycosamine sulphohydrolase cDNA (SGSH)	Treatment of mucopolysaccharidosis type IIIA or Sanfilippo type A syndrome	adeno-associated viral (AAV) vector serotype rh. 10 encoding the human N-sulfoglycosamine sulphohydrolase cDNA (SGSH)		n/a	11/18/15	Designated			N/A	N/A	LYSOGENE	Neuilly-sur-Seine			France										Mucopolysaccharidosis type III	3807		
recombinant adeno-associated virus vector serotype 9 expressing human N-Sulfoglucosamine Sulfohydrolase	"Treatment of mucopolysaccharidosis type III A, also called Sanfilippo syndrome A"	recombinant adeno-associated virus vector serotype 9 expressing human N-Sulfoglucosamine Sulfohydrolase		n/a	9/1/16	Designated			N/A	N/A	Research Institute at Nationwide Children's Hospital	Columbus	Ohio	43205	USA										Mucopolysaccharidosis type III	3807		
Recombinant human insulin receptor monoclonal antibody-N-heparan sulfamidase fusion protein	"Treatment of Mucopolysaccharidosis Type IIIA, Sanfilippo A Syndrome"	Recombinant human insulin receptor monoclonal antibody-N-heparan sulfamidase fusion protein		n/a	7/12/18	Designated			N/A	N/A	"ArmaGen, Inc."	"26679 Agoura Road, Suite #100"	California	91302	USA	LONGEST CONTAINS	1337275AA	insulin receptor	4CH8636GFF						Mucopolysaccharidosis type III	3807		
Methotrexate with laurocapram	Topical treatment of mycosis fungoides.	 laurocapram		Methotrexate/Azone	10/15/90	Designated			N/A	N/A	"Echo Therapeutics, Ltd."	Philadelphia	Pennsylvania	19103	USA	EXACT	0126034AA	laurocapram	1F3X9DRV9X						Mycosis fungoides	3863		
naloxone	Topical treatment of pruritus associated with mycosis fungoides	naloxone		n/a	11/23/10	Designated			N/A	N/A	"Elorac, Inc."	Vernon Hills	Illinois	60061	USA	EXACT	0025989AA	naloxone	36B82AMQ7N						Mycosis fungoides	3863		
meclorethamine	Treatment of mycosis fungoides	mechlorethamine		Valchlor	8/17/04	Designated/Approved	Approved for Orphan Indication	Topical treatment of Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.	8/23/13	8/23/20	Actelion Pharmaceuticals Ltd.				Switzerland	EXACT	0008060AA	mechlorethamine	50D9XSG0VR						Mycosis fungoides	3863		
brentuximab vedotin	Treatment of mycosis fungoides	brentuximab vedotin		Adcetris	11/19/12	Designated			N/A	N/A	"Seattle Genetics, Inc."	Bothell	Washington	98021	USA	EXACT	0297767AA	brentuximab vedotin	7XL5ISS668						Mycosis fungoides	3863		
human anti-CD4 monoclonal antibody	Treatment of mycosis fungoides	zanolimumab		Humax-Cd4	8/13/04	Designated			N/A	N/A	"Emergent Product Development Seattle, LLC"	Seattle	Washington	98121	USA	EXACT	0298099AA	zanolimumab	HG3L8885M0						Mycosis fungoides	3863		
Methotrexate with laurocapram	Topical treatment of mycosis fungoides.	Methotrexate with laurocapram		Methotrexate/Azone	10/15/90	Designated			N/A	N/A	"Echo Therapeutics, Ltd."	Philadelphia	Pennsylvania	19103	USA	EXACT	0010059AA	Methotrexate	YL5FZ2Y5U1						Mycosis fungoides	3863		
priliximab	Treatment of mycosis fungoides (MF)	priliximab		n/a	9/18/17	Designated			N/A	N/A	"Onco Therapies, Inc."	Pasadena	California	91107	USA	EXACT	1093170AA	priliximab							Mycosis fungoides	3863		
MRG-106 oligonucleotide inhibitor of microRNA miR-155-5p	Treatment of mycosis fungoides	MRG-106 oligonucleotide inhibitor of microRNA miR-155-5p		n/a	3/30/17	Designated			N/A	N/A	"miRagen Therapeutics, Inc."	Boulder	Colorado	80301	USA										Mycosis fungoides	3863		
arimoclomol	Treatment of inclusion body myositis	arimoclomol		n/a	11/2/17	Designated			N/A	N/A	Orphazyme ApS	Ole Maaloes Vej 3			Denmark	EXACT	0320365AA	arimoclomol	EUT3557RT5						Inclusion body myositis	3896		
recombinant human monoclonal antibody against activin receptors type II	Treatment of inclusion body myositis	Bimagrumab 		n/a	6/18/12	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0793657AA	Bimagrumab	N15SW1DIV8						Inclusion body myositis	3896		
Adeno-associated virus delivered transgene of follistatin	Treatment of inclusion body myositis	Adeno-associated virus delivered transgene of follistatin		n/a	9/19/16	Designated			N/A	N/A	Milo Biotechnology	Cleveland Heights	Ohio	44106	USA										Inclusion body myositis	3896		
dihydroxyphenylalanine F 18/Fluorodopa (F18)	Diagnostic for the management of congenital hyperinsulinism	Fluorodopa F-18		n/a	1/22/18	Designated			N/A	N/A	Society of Nuclear Medicine and Molecular Imaging	1850 Samuel Morse Drive	Reston	20190	USA	EXACT	0173568AA	Fluorodopa F-18	2C598205QX						Congenital hyperinsulinism	3947		
glucagon	Prevention of hypoglycemia in the congenital hyperinsulinism population	glucagon		n/a	12/5/12	Designated			N/A	N/A	"Biodel, Inc."	Danbury	Connecticut	6810	USA	EXACT	0007114AA	glucagon	76LA80IG2G						Congenital hyperinsulinism	3947		
dasiglucagon	Treatment of hypoglycemia in patients with congenital hyperinsulinism (CH)	dasiglucagon		n/a	8/10/17	Designated			N/A	N/A	Zealand Pharma A/S	Glostrup			Denmark	EXACT	1578796AA	dasiglucagon	AD4J2O47FQ						Congenital hyperinsulinism	3947		
fully human IgG2 monoclonal antibody that binds insulin receptors	Treatment of congenital hyperinsulinism	XOMA-358		n/a	6/9/15	Designated			N/A	N/A	XOMA (US) LLC	Berkeley	California	94710	USA	EXACT	0114498AB	XOMA-358	QD87BSP58N						Congenital hyperinsulinism	3947		
glucagon analog conjugated with human immunoglobulin G4 fragment	Treatment of congenital hyperinsulinism (CHI)	glucagon analog conjugated with human immunoglobulin G4 fragment		n/a	2/1/18	Designated			N/A	N/A	"Hanmi Pharmaceutical Company, Ltd."	"14, Wiryeseong-daero"	Seoul		"Korea, Republic of"	LONGEST CONTAINS	0007114AA	glucagon	76LA80IG2G						Congenital hyperinsulinism	3947		
"9-cis,12-cis-11,11-D2-linoleic acid ethyl ester"	Treatment of PLA2G6-associated neurodegeneration	"9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER"		n/a	10/24/17	Designated			N/A	N/A	"Retrotope, Inc."	Los Altos	California	94022	USA	EXACT	1149173AA	"9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER"	24B102R86P						PLA2G6-Associated Neurodegeneration	3957		
Interferon gamma-1b	"Delaying time to disease progression in patients with severe, malignant osteopetrosis."	Interferon gamma-1b		Actimmune	9/30/96	Designated/Approved	Approved for Orphan Indication	"Delaying time to disease progression in patients with severe, malignant osteopetrosis."	2/10/00	2/10/07	Horizon Pharma Ireland Limited	Dublin 4			Ireland	EXACT	0174812AA	Interferon gamma-1b	21K6M2I7AG						Osteopetrosis	4155		
adeno-associated viral vector serotype 9 containing the human cardiac calsequestrin gene	Treatment of catecholaminergic polymorphic ventricular tachycardia	adeno-associated viral vector serotype 9 containing the human cardiac calsequestrin gene		Calmarythm	10/2/14	Designated			N/A	N/A	"Audentes Therapeutics, Inc."	San Francisco	California	94104	USA										Catecholaminergic polymorphic ventricular tachycardia	4421		
Ciclopirox	Treatment of congenital erythropoietic porphyria	Ciclopirox		n/a	4/17/18	Designated			N/A	N/A	Atlas Molecular Pharma S.L.	Parque Tecnológico de Bizkaia	Building 800		Spain	EXACT	0167271AA	Ciclopirox	19W019ZDRJ						Congenital erythropoietic porphyria	4446		
Uridine 5'-triphosphate	To facilitate the removal of lung secretions in the treatment of patients with primary ciliary dyskinesia.	Uridine 5'-triphosphate		n/a	6/26/96	Designated/Withdrawn			N/A	N/A	"Inspire Pharmaceuticals, Inc."	Durham	North Carolina	27703	USA	EXACT	0011052AA	Uridine 5'-triphosphate	UT0S826Z60						Primary ciliary dyskinesia	4484		
L-cysteine	For the prevention and lessening of photosensitivity in erythropoietic protoporphyria.	L-cysteine		n/a	5/16/94	Designated			N/A	N/A	Brigham and Women's Hospital	Boston	Massachusetts	2115	USA	EXACT	0008322AA	L-cysteine	K848JZ4886						Erythropoietic protoporphyria	4527		
exenatide	Treatment of idiopathic intracranial hypertension	exenatide		n/a	5/16/17	Designated			N/A	N/A	Alan Boyd Consultants Limited	Crewe			United Kingdom	EXACT	0232826AA	exenatide	9P1872D4OL						Idiopathic intracranial hypertension	4561		
delta-9-tetrahydrocannabinol and cannabidiol	Treatment of complex regional pain syndrome	cannabidiol		n/a	3/7/18	Designated			N/A	N/A	PhytoPain Pharma Inc.	9315-4466 Quebec Inc	1230 Boise Street		Canada	EXACT	0027441AA	cannabidiol	19GBJ60SN5						Complex regional pain syndrome	4647		
zoledronic acid	Treatment of complex regional pain syndrome (CRPS).	zoledronic acid		"Zometa, Reclast, Aclasta"	5/6/13	Designated			N/A	N/A	"Axsome Therapeutics, Inc."	New York	New York	10111	USA	EXACT	0183755AA	zoledronic acid	6XC1PAD3KF						Complex regional pain syndrome	4647		
delta-9-tetrahydrocannabinol and cannabidiol	Treatment of complex regional pain syndrome	delta-9-tetrahydrocannabinol		n/a	3/7/18	Designated			N/A	N/A	PhytoPain Pharma Inc.	9315-4466 Quebec Inc	1230 Boise Street		Canada	EXACT	0045169AA	delta-9-tetrahydrocannabinol	7J8897W37S						Complex regional pain syndrome	4647		
neridronate	"Treatment of complex regional pain syndrome (CRPS-1, CRPS-II, CRPS-NOS)"	neridronate		n/a	3/25/13	Designated			N/A	N/A	"Grunenthal USA, Inc."	Bedminster	New Jersey	7921	USA	EXACT	0282519AA	neridronate	8U27U3RIN4						Complex regional pain syndrome	4647		
baclofen	Treatment of complex regional pain syndrome.	baclofen		Gablofen	10/28/15	Designated			N/A	N/A	"Mallinckrodt, Inc."	St. Louis	Missouri	63134	USA	EXACT	0032804AA	baclofen	H789N3FKE8						Complex regional pain syndrome	4647		
hydromorphone hydrochloride (intrathecal infusion)	Treatment of complex regional pain syndrome	hydromorphone hydrochloride (intrathecal infusion)		n/a	6/16/16	Designated			N/A	N/A	Mallinckrodt Inc.	Hazelwood	Missouri	63042	USA	EXACT	0012373AA	hydromorphone hydrochloride	L960UP2KRW						Complex regional pain syndrome	4647		
"zoledronate D,L-lysine monohydrate (ZLM)"	Treatment of complex regional pain syndrome (CRPS)	"ZOLEDRONATE D,L-LYSINE MONOHYDRATE"		n/a	4/15/15	Designated			N/A	N/A	Thar Pharmaceuticals	Pittsburgh	Pennsylvania	15238	USA	EXACT	1577099AA	"ZOLEDRONATE D,L-LYSINE MONOHYDRATE"	IL1N7FSO1U						Complex regional pain syndrome	4647		
adeno-associated viral vector expressing human retinoschisin-1 gene	Treatment of X-linked juvenile retinoschisis (XLRS).	adeno-associated viral vector expressing human retinoschisin-1 gene		n/a	5/21/07	Designated			N/A	N/A	Applied Genetic Technologies Corporation	Alachua	Florida	32615	USA										Juvenile retinoschisis	4690		
N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide	Treatment of Schwannoma of the central nervous system	N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide		n/a	1/13/12	Designated			N/A	N/A	"Arno Therapeutics, Inc."	Flemington	New Jersey	8822	USA	EXACT	0740432AA	N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide	E0GG29V0AQ						Schwannoma	4767		
urea	"Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis)."	urea		n/a	11/7/11	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0009290AA	urea	8W8T17847W						KID syndrome	4800		
Humanized monoclonal antibody to TumorEndothelial Marker-1	Treatment of soft tissue sarcoma	Ontuxizumab		n/a	4/29/11	Designated			N/A	N/A	Morphotek	Exton	Pennsylvania	19341	USA	EXACT	0869692AA	Ontuxizumab	0M2XT000YC						Soft tissue sarcoma	4898		
selinexor	Treatment of soft tissue sarcoma	selinexor		n/a	7/7/16	Designated			N/A	N/A	"Karyopharm Therapeutics, Inc."	Newton	Maryland	2459	USA	EXACT	0899718AA	selinexor	31TZ62FO8F						Soft tissue sarcoma	4898		
epirubicin-conjugated polymer micelles	Treatment of soft tissue sarcoma	epirubicin-conjugated polymer micelles		n/a	7/13/17	Designated			N/A	N/A	"NanoCarrier Co., Ltd"	Kashiwa			Japan	EXACT	0147615AA	epirubicin	3Z8479ZZ5X						Soft tissue sarcoma	4898		
ridaforolimus	Treatment of soft tissue sarcoma	ridaforolimus		n/a	8/12/05	Designated/Withdrawn			N/A	N/A	Merck Sharp & Dohme Corp.	North Wales	Oregon	19454	USA	EXACT	0257125AA	ridaforolimus	48Z35KB15K						Soft tissue sarcoma	4898		
Palifosfamide	Treatment of soft tissue sarcomas	Palifosfamide		n/a	5/5/08	Designated/Withdrawn			N/A	N/A	"ZIOPHARM Oncology, Inc."	Boston	Massachusetts	2129	USA	EXACT	0315117AA	Palifosfamide	6A4U6NN813						Soft tissue sarcoma	4898		
CT-2584 Mesylate	Treatment of adult soft tissue sarcoma.	CT-2584 Mesylate		n/a	4/16/99	Designated/Withdrawn			N/A	N/A	"Cell Therapeutics, Inc."	Seattle	Washington	98119	USA	EXACT	0211803AA	CT-2584 Mesylate	6YX1G1VY8K						Soft tissue sarcoma	4898		
pazopanib	Treatment of soft tissue sarcomas	pazopanib		Votrient	10/20/09	Designated/Approved	Approved for Orphan Indication	Advanced soft tissue sarcoma (STS) who have received prior chemotherapy	4/26/12	4/26/19	Novartis Pharmaceuticals Corp	East Hanover	New Jersey	7936	USA	EXACT	0307299AA	pazopanib	7RN5DR86CK						Soft tissue sarcoma	4898		
Liposomal doxorubicin hydrochloride	Treatment of soft tissue sarcomas	Liposomal doxorubicin hydrochloride		Sarcodoxome	12/27/06	Designated			N/A	N/A	GP-Pharm SA	Barcelona			Spain	EXACT	0063014AA	doxorubicin hydrochloride	82F2G7BL4E						Soft tissue sarcoma	4898		
"ombrabulin; N-{2-methoxy-5-[(Z)-2-(3,4,5-trimethozyphenyl)vinyl]phenyl}-L-serinamide hydrochloride"	Treatment of soft tissue sarcoma	ombrabulin		n/a	3/3/11	Designated			N/A	N/A	"Sanofi-Aventis U.S., Inc."	Bridgewater	New Jersey	8807	USA	EXACT	0702794AA	ombrabulin	82JB1524Q6						Soft tissue sarcoma	4898		
"(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate"	Treatment of soft tissue sarcoma	"(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate"		n/a	3/9/12	Designated			N/A	N/A	"Threshold Pharmaceuticals, Inc."	South San Francisco	California	94080	USA	EXACT	0310474AA	"(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate"	8A9RZ3HN8W						Soft tissue sarcoma	4898		
1-(2-Nitro-imidazolyl)-3-[18F]fluoro-2-propanol;1H-1-(3-[18F]fluoro-2-hydroxypropyl)-2-nitroimidazole	"As a diagnostic for clinical management of soft tissue sarcoma, including rhabdomyosarcoma."	fmiso f-18		n/a	1/6/16	Designated			N/A	N/A	"Advanced Imaging Projects, LLC"	Lake Worth	Florida	33467	USA	EXACT	0168729AA	fmiso f-18	8MSY49469G						Soft tissue sarcoma	4898		
eribulin mesylate	Treatment of soft tissue sarcoma	eribulin mesylate		Halaven	5/14/12	Designated/Approved	Approved for Orphan Indication	Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen	1/28/16	1/28/23	Eisai Inc.	Woodcliff Lake	New Jersey	7677	USA	EXACT	0245272AA	eribulin mesylate	AV9U0660CW						Soft tissue sarcoma	4898		
(6-maleimidocaproyl)hydrazone of doxorubicin	Treatment of soft tissue sarcoma	(6-maleimidocaproyl)hydrazone of doxorubicin		n/a	6/29/11	Designated			N/A	N/A	CytRx Corporation	Los Angeles	California	90049	USA	EXACT	0738294AA	(6-maleimidocaproyl)hydrazone of doxorubicin	C28MV4IM0B						Soft tissue sarcoma	4898		
digitoxin	Treatment of soft tissue sarcomas	digitoxin		n/a	10/18/01	Designated			N/A	N/A	SimRx Advisors LLC	New York	New York	10024	USA	EXACT	0012351AA	digitoxin	E90NZP2L9U						Soft tissue sarcoma	4898		
Anlotinib	Treatment of soft tissue sarcoma	Anlotinib		n/a	6/19/17	Designated			N/A	N/A	"Advenchen Laboratories, LLC"	Moorpark	California	93021	USA	EXACT	1273149AA	Anlotinib	GKF8S4C432						Soft tissue sarcoma	4898		
trabectedin	Treatment of soft tissue sarcoma	trabectedin		Yondelis	9/30/04	Designated/Approved	Approved for Orphan Indication	For the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen	10/23/15	10/23/22	"Janssen Research & Development, LLC"	Raritan	New Jersey	8869	USA	EXACT	0213070AA	trabectedin	ID0YZQ2TCP						Soft tissue sarcoma	4898		
crenolanib	Treatment of soft tissue sarcoma	crenolanib		n/a	3/18/11	Designated			N/A	N/A	"AROG Pharmaceuticals, LLC"	Dallas	Texas	75251	USA	EXACT	0632973AA	crenolanib	LQF7I567TQ						Soft tissue sarcoma	4898		
tazemetostat	Treatment of soft tissue sarcoma	tazemetostat		n/a	6/15/17	Designated			N/A	N/A	"Epizyme, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	1120394AA	tazemetostat	Q40W93WPE1						Soft tissue sarcoma	4898		
18-(p-[131I]-iodophenyl)octadecyl phosphocholine	Treatment of soft tissue sarcomas including rhabdomyosarcoma	NM-404 I-131		n/a	5/8/18	Designated			N/A	N/A	"Cellectar Biosciences, Inc."	3301 Agriculture Drive		53716	USA	EXACT	1079705AA	NM-404 I-131	R048696O9L						Soft tissue sarcoma	4898		
"(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate"	Treatment of soft tissue sarcoma.	LAROTRECTINIB SULFATE		n/a	8/31/15	Designated			N/A	N/A	"Loxo Oncology, Inc."	Stamford	Connecticut	6901	USA	EXACT	0934634AA	LAROTRECTINIB SULFATE	RDF76R62ID						Soft tissue sarcoma	4898		
olaratumab	Treatment of soft tissue sarcoma	olaratumab		Lartruvo	10/9/14	Designated/Approved	Approved for Orphan Indication	"In combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery."	10/19/16	TBD	Eli Lilly and Company	Indianapolis	Indiana	46285	USA	EXACT	0907299AA	olaratumab	TT6HN20MVF						Soft tissue sarcoma	4898		
N-acetyl-sarcosyl-glycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl_L-prolylethylaminde acetate	Treatment of soft tissue sarcoma	ABT-510 ACETATE		n/a	12/9/03	Designated/Withdrawn			N/A	N/A	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	1801463AA	ABT-510 ACETATE	X1616TFEWT						Soft tissue sarcoma	4898		
Human/Murine Chimeric Monoclonal antibody to Endoglin	Treatment of soft tissue sarcoma.	trc-105		n/a	1/20/16	Designated			N/A	N/A	"Tracon Pharmaceuticals, Inc."	San Diego	California	92122	USA	EXACT	0812408AA	trc-105	YB2EWE6139						Soft tissue sarcoma	4898		
5-imino-13-deoxydoxorubicin HCl	Treatment of soft tissue sarcoma	GPX-150 HYDROCHLORIDE		n/a	12/31/15	Designated			N/A	N/A	"Gem Pharmaceuticals, LLC"	Birmingham	Alabama	35244	USA	EXACT	1721988AA	GPX-150 HYDROCHLORIDE	QFO4NOX87K						Soft tissue sarcoma	4898		
recombinant NY-ESO-1 protein mixed with glucopyranosyl lipid A	Treatment of soft tissue sarcoma.	RECOMBINANT NY-ESO-1 PROTEIN		n/a	1/6/16	Designated			N/A	N/A	Immune Design Corp.	Seattle	Washington	98102	USA	EXACT	1802524AA	RECOMBINANT NY-ESO-1 PROTEIN	9T6PW6J6MA						Soft tissue sarcoma	4898		
recombinant NY-ESO-1 protein mixed with glucopyranosyl lipid A	Treatment of soft tissue sarcoma.	glucopyranosyl lipid A		n/a	1/6/16	Designated			N/A	N/A	Immune Design Corp.	Seattle	Washington	98102	USA	EXACT	1802637AA	glucopyranosyl lipid A	A1O9D5VN5D						Soft tissue sarcoma	4898		
Mx-dnG1	Treatment of soft tissue sarcoma	Mx-dnG1		Rexin-G(R)	6/24/08	Designated			N/A	N/A	Epeius Biotechnologies Corporation	San Marino	California	91108	USA										Soft tissue sarcoma	4898		
Yttrium(90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10	Treatment of soft tissue sarcoma	Yttrium(90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10		n/a	12/3/12	Designated			N/A	N/A	"OncoTherapy Science, Inc."				Japan	LONGEST CONTAINS	0514954AA	Yttrium	58784XQC3Y						Soft tissue sarcoma	4898		
"granulocyte-macrophage colony stimulating factor-coding oncolytic adenovirus, Ad5/3-D24-GMCSF"	Treatment of soft tissue sarcoma	"granulocyte-macrophage colony stimulating factor-coding oncolytic adenovirus, Ad5/3-D24-GMCSF"		n/a	7/24/13	Designated			N/A	N/A	Oncos Therapeutics	Helsinki			Finland										Soft tissue sarcoma	4898		
"dendritic-cell targeting, lentiviral vector encoding the NY-ESO-1 gene"	Treatment of soft tissue sarcoma.	"dendritic-cell targeting, lentiviral vector encoding the NY-ESO-1 gene"		n/a	1/6/16	Designated			N/A	N/A	Immune Design Corp.	Seattle	Washington	98102	USA										Soft tissue sarcoma	4898		
Autologous CD4+/CD8+ T cells transduced with lentiviral vector directed against the NY-ESO-1 protein	Treatment of soft tissue sarcoma.	Autologous CD4+/CD8+ T cells transduced with lentiviral vector directed against the NY-ESO-1 protein		n/a	3/28/16	Designated			N/A	N/A	"Adaptimmune, LLC"	Philadelphia	Pennsylvania	19103	USA	LONGEST CONTAINS	0087274AA	protein							Soft tissue sarcoma	4898		
combinatorial regimen of LV305 (lentiviral vector encoding NY-ESO-1 gene) and G305 (NY-ESO-1 recombinant protein plus GLA-SE)	Treatment of soft tissue sarcoma	combinatorial regimen of LV305 (lentiviral vector encoding NY-ESO-1 gene) and G305 (NY-ESO-1 recombinant protein plus GLA-SE)		n/a	5/2/16	Designated			N/A	N/A	Immune Design Corp.	Seattle	Washington	98102	USA	LONGEST CONTAINS	0087274AA	protein							Soft tissue sarcoma	4898		
L-threonine	Treatment of spasticity associated with familial spastic paraparesis.	L-threonine		n/a	7/24/92	Designated/Withdrawn			N/A	N/A	"Interneuron Pharmaceuticals, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0012475AA	L-threonine	2ZD004190S						Spastic paraparesis	4912		
immune globulin intraveous (human)	Treatment of idiopathic thrombocytopenic purpura (also known as primary immune thrombocytopenia)	IVIG		Gammaplex	4/29/11	Designated/Approved	Approved for Orphan Indication	Idiopathic thrombocytopenic purpura	3/8/13	N/A	Bio Products Laboratory	England			United Kingdom	EXACT	0201570AA	IVIG	66Y330CJHS						Idiopathic thrombocytopenic purpura	5194		
Recombinant Human soluble Fc-gamma Receptor IIb	Treatment of idiopathic thrombocytopenic purpura	VALZIFLOCEPT		n/a	3/22/10	Designated			N/A	N/A	SuppreMol GmbH				Germany	EXACT	0112439AB	VALZIFLOCEPT	EA2075XV4Y						Idiopathic thrombocytopenic purpura	5194		
"1-(3-chloro-5-{[4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-l-yl)-1,3-thiazol-2-yl]carbamoyl}- 2-pyridyl) piperidine-4-caboxylic acid Monomaleate"	Treatment of idiopathic thrombocytopenic purpura	Avatrombopag maleate		n/a	9/1/11	Designated			N/A	N/A	"Eisai, Inc."	Woodcliff Lake	New Jersey	7677	USA	EXACT	0268520AA	Avatrombopag maleate	GDW7M2P1IS						Idiopathic thrombocytopenic purpura	5194		
humanized anti-human CD16 monoclonal antibody	Treatment of adult idiopathic thrombocytopenic purpura	GMA-161		n/a	3/21/05	Designated/Withdrawn			N/A	N/A	Genzyme Corporation	Cambridge	Massachusetts	2142	USA	EXACT	0267970AA	GMA-161	I0TG4Z02RN						Idiopathic thrombocytopenic purpura	5194		
PG2 (Astragalus polysaccharides extracted and purified from the dry root of Astragalus membranaceus)	Treatment of idiopathic thrombocytopenic purpura	PG2 (Astragalus polysaccharides extracted and purified from the dry root of Astragalus membranaceus)		n/a	7/5/12	Designated			N/A	N/A	PhytoHealth Corporation	Taipei ROC			Taiwan	LONGEST CONTAINS	0844597AA	Astragalus polysaccharides	71WW2LNL50						Idiopathic thrombocytopenic purpura	5194		
milciclib maleate	Treatment of thymic epithelial tumors.	milciclib maleate		n/a	9/20/12	Designated			N/A	N/A	Tiziana Life Sciences PLC	London			United Kingdom	EXACT	0281447AA	milciclib maleate	82W826FL6S						Thymic epithelial tumor	5201		
Multi-ligand somatostatin analog	"Treatment of patients with functional gastroenteropancreatic (GEP) neuroendocrine tumors (specifically, carcinoid, insulinoma, gastrinoma, somastatinoma, GRFoma, VIPoma and glucagonoma."	Pasireotide		n/a	7/27/04	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0269534AA	Pasireotide	98H1T17066						VIPoma	5493		
Octreotide	Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).	Octreotide		Sandostatin Lar	8/24/98	Designated/Approved	Approved for Orphan Indication	Treatment of profuse watery diarrhea associated with VIPoma.	11/25/98	11/25/05	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0169915AA	Octreotide	RWM8CCW8GP						VIPoma	5493		
recombinant nematode anticoagulant protein c2 (rNAPc2)	Treatment of viral hemorrhagic fever post-exposure to Ebola virus (treatment of Ebola)	recombinant nematode anticoagulant protein c2 (rNAPc2)		n/a	12/8/14	Designated			N/A	N/A	"ARCA Biopharma, Inc."	Westminster	Colorado	80020	USA	EXACT	0262362AA	recombinant nematode anticoagulant protein c2 (rNAPc2)	3TTT9ZD93F						Viral hemorrhagic fever	5494		
Oleoylethanolamide	Treatment of Prader-Willi syndrome	OLEIC MONOETHANOLAMIDE		n/a	6/8/17	Designated			N/A	N/A	"NutriForward, LLC"	Bedford	Texas	76022	USA	EXACT	0381157AA	OLEIC MONOETHANOLAMIDE	1HI5J9N8E6						Prader-Willi syndrome	5575		
oxytocin	Treatment of Prader-Willi syndrome	oxytocin		n/a	11/24/14	Designated			N/A	N/A	Pr Maithe Tauber	Toulouse			France	EXACT	0007545AA	oxytocin	1JQS135EYN						Prader-Willi syndrome	5575		
oxytocin	Treatment of Prader-Willi syndrome	oxytocin		n/a	6/15/17	Designated			N/A	N/A	"Eric Hollander, MD"	Bronx	New York	10467	USA	EXACT	0007545AA	oxytocin	1JQS135EYN						Prader-Willi syndrome	5575		
Etiocholanedione	Treatment of Prader-Willi syndrome.	Etiocholanedione		n/a	5/7/96	Designated			N/A	N/A	"SuperGen, Inc."	Dublin	California	94568	USA	EXACT	0164932AA	Etiocholanedione	213MVW2TZD						Prader-Willi syndrome	5575		
diazoxide choline	Treatment of Prader-Willi Syndrome	diazoxide choline		n/a	5/13/14	Designated			N/A	N/A	"Essentialis, Inc."	Carlsbad	California	92009	USA	EXACT	0720741AA	diazoxide choline	2U8NRZ7P8L						Prader-Willi syndrome	5575		
synthetic cyclic 8 amino acid analog of human unacylated ghrelin	Treatment of Prader-Willi syndrome (PWS)	AZP-531		n/a	10/12/17	Designated			N/A	N/A	Alizé Pharma	Écully			France	EXACT	1336136AA	AZP-531	9VHD7J6363						Prader-Willi syndrome	5575		
beloranib	Treatment of Prader-Willi syndrome	beloranib		n/a	1/15/13	Designated			N/A	N/A	"Zafgen, Inc."	Boston	Massachusetts	2114	USA	EXACT	0338523AA	beloranib	FI471K8BU6						Prader-Willi syndrome	5575		
setmelanotide	Treatment of Prader-Willi Syndrome.	setmelanotide		n/a	9/21/15	Designated			N/A	N/A	"Rhythm Metabolics, Inc."	Boston	Massachusetts	2116	USA	EXACT	1074686AA	setmelanotide	N7T15V1FUY						Prader-Willi syndrome	5575		
Somatropin [rDNA]	Treatment of short stature in patients with Prader-Willi syndrome.	Somatropin (rDNA)		Genotropin	7/6/99	Designated/Approved	Approved for Orphan Indication	Long-term treatment of pediatric patients who have growth failure due to Prader-Willi syndrome (PWS).	6/20/00	6/20/07	Pharmacia & Upjohn	Kalamazoo	Michigan	49001	USA	EXACT	0054682AA	Somatropin	NQX9KB6PCL						Prader-Willi syndrome	5575		
D-tagatose	Treatment of Prader-Willi Syndrome	D-tagatose		n/a	1/19/17	Designated			N/A	N/A	Biospherics.net LLC	Nicholasville	Kentucky	40356	USA	EXACT	0136152AA	D-tagatose	T7A20Y888Y						Prader-Willi syndrome	5575		
Betahistine dihydrochloride	Treatment of obesity associated with Prader Willi syndrome	Betahistine dihydrochloride		n/a	11/8/07	Designated			N/A	N/A	"Floyd R. Sallee, M.D., Ph.D."	Cincinnati	Ohio	45267	USA	EXACT	0043903AA	Betahistine dihydrochloride	49K58SMZ7U						Prader Willi Syndrome	5575		
carbetocin (nasal spray)	Treatment of Prader Willi syndrome	carbetocin (nasal spray)		n/a	4/11/14	Designated			N/A	N/A	"Ferring Pharmaceuticals, Inc."	Parsippany	New Jersey	7054	USA	EXACT	0175008AA	carbetocin	88TWF8015Y						Prader Willi Syndrome	5575		
diazoxide	Treatment of Prader Willi Syndrome	diazoxide		n/a	12/3/12	Designated			N/A	N/A	"Sedogen, LLC"	Glenview	Illinois	60025	USA	EXACT	0025274AA	diazoxide	O5CB12L4FN						Prader Willi Syndrome	5575		
"3,5-diiodothyropropionic acid"	Treatment of Allan-Herndon-Dudley syndrome	"3,5-diiodothyropropionic acid"		n/a	5/14/13	Designated			N/A	N/A	Zarion Pharmaceuticals P/L	Victoria			Australia	EXACT	0256859AA	"3,5-diiodothyropropionic acid"	1HTO2X0SJ9						Allan-Herndon-Dudley syndrome	5617		
Chenodeoxycholic acid	Treatment of cerebrotendinous xanthomatosis	Chenodeoxycholic acid		Chenofalk	1/29/04	Designated			N/A	N/A	Dr. Falk Pharma GmbH				Germany	EXACT	0026175AA	Chenodeoxycholic acid	0GEI24LG0J						Cerebrotendinous xanthomatosis	5622		
chenodeoxycholic acid	Treatment of cerebrotendinous xanthomatosis	chenodeoxycholic acid		n/a	2/12/07	Designated			N/A	N/A	"Baxalta US, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0026175AA	chenodeoxycholic acid	0GEI24LG0J						Cerebrotendinous xanthomatosis	5622		
chenodiol	Treatment of cerebrotendinous xanthomatosis	chenodiol		Chenadal	3/22/10	Designated			N/A	N/A	"Retrophin, Inc."	New York	New York	10017	USA	EXACT	0026175AA	chenodiol	0GEI24LG0J						Cerebrotendinous xanthomatosis	5622		
"(2E, 4E, 6Z, 8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-l-yl) nona-2,4,6,8-tetraen-l-yl acetate"	Treatment of retinitis pigmentosa	ZURETINOL ACETATE		n/a	12/2/10	Designated			N/A	N/A	QLT Inc.				Canada	EXACT	0728303AA	ZURETINOL ACETATE	2K3YP54BYU						Retinitis pigmentosa	5694		
Human umbilical tissue-derived cells	Treatment of retinitis pigmentosa	Human umbilical tissue-derived cells		n/a	3/13/06	Designated/Withdrawn			N/A	N/A	"Janssen Research and Development, LLC"	Spring House	Pennsylvania	19477	USA	EXACT	0741855AA	Human umbilical tissue-derived cells	3T0UGR2M5Q						Retinitis pigmentosa	5694		
N-acetyl cysteine amide	Treatment of retinitis pigmentosa	N-acetyl cysteine amide		n/a	12/31/13	Designated			N/A	N/A	"Brighton Biotech, Inc."	Ft. Worth	Texas	76102	USA	EXACT	0339991AA	N-acetyl cysteine amide	4N69717RKW						Retinitis pigmentosa	5694		
unoprostone isopropyl	Treatment of retinitis pigmentosa	unoprostone isopropyl		Rescula	9/16/10	Designated/Withdrawn			N/A	N/A	"R-Tech Ueno, Ltd."				Japan	EXACT	0214824AA	unoprostone isopropyl	5M161S5O5P						Retinitis pigmentosa	5694		
Urea for intravitreal injection	Treatment of retinitis pigmentosa	Urea for intravitreal injection		Neurosolve	12/14/05	Designated			N/A	N/A	"Vitreo Retinal Techologies, Inc"	Irvine	California	92618	USA	EXACT	0009290AA	Urea	8W8T17847W						Retinitis pigmentosa	5694		
"4-[(2E)-1-Oxo-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-propen-1-yl]-1-piperazinecarboxamide"	Treatment of retinitis pigmentosa	"4-((2E)-1-Oxo-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-propen-1-yl)-1-piperazinecarboxamide"		n/a	2/8/16	Designated			N/A	N/A	"Shire HGT, Inc."	Lexington	Massachusetts	2421	USA	EXACT	1576347AA	"4-((2E)-1-Oxo-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-propen-1-yl)-1-piperazinecarboxamide"	BC9KBY85WY						Retinitis pigmentosa	5694		
Epitalon	Treatment of retinitis pigmentosa	Epitalon		n/a	9/2/10	Designated/Withdrawn			N/A	N/A	BioDiem Ltd	Melbourne			Australia	EXACT	0737655AA	Epitalon	O65P17785G						Retinitis pigmentosa	5694		
recombinant human nerve growth factor	Treatment of retinitis pigmentosa	recombinant human nerve growth factor		n/a	8/8/13	Designated			N/A	N/A	Dompe s.p.a.	Milan			Italy	EXACT	1106214AA	recombinant human nerve growth factor	Y8JXJ39EE9						Retinitis pigmentosa	5694		
"all-cis-docosa-4,7,10,13,16,19-hexaenoic acid"	Treatment of retinitis pigmentosa	DOCONEXENT		Retriacyl	5/21/14	Designated			N/A	N/A	"Natac Pharma, S.L."	Madrid			Spain	EXACT	0145960AA	DOCONEXENT	ZAD9OKH9JC						Retinitis pigmentosa	5694		
recombinant human proinsulin (Including rhPI-Methionine)	Treatment of retinitis pigmentosa	PRO-001		n/a	12/10/08	Designated			N/A	N/A	"ProRetina Therapeutics, S.L."				Spain	EXACT	1803572AA	PRO-001	9XUI8JO6EH						Retinitis pigmentosa	5694		
recombinant lens epithelium derived growth factor 1-326	Treatment of retinitis pigmentosa	OCU-100		n/a	5/19/14	Designated			N/A	N/A	"Ocugen, Inc."	Aurora	Colorado	80045	USA	EXACT	1803016AA	OCU-100	I460W8FA7S						Retinitis pigmentosa	5694		
"human recombinant mesencephalic, astrocyte derived neurotrophic factor"	Treatment of retinitis pigmentosa	MANF		n/a	12/22/14	Designated			N/A	N/A	"Amarantus BioScience Holdings, Inc."	San Francisco	California	94111	USA	EXACT	0110776AB	MANF	5R3OV3AM5M						Retinitis pigmentosa	5694		
Gangliosides as sodium salts	Treatment of retinitis pigmentosa.	Gangliosides as sodium salts		Cronassial	11/17/88	Designated/Withdrawn			N/A	N/A	Fidia Pharmaceutical Corp.	Washington	District of Columbia	20005	USA	LONGEST CONTAINS	0121119AA	Gangliosides							Retinitis pigmentosa	5694		
Allogeneic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor	Treatment of retinitis pigmentosa	Allogeneic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor		n/a	9/1/04	Designated			N/A	N/A	"Neurotech USA, Inc."	Lincoln	Rhode Island	2865	USA	LONGEST CONTAINS	0018746AA	retinal	RR725D715M						Retinitis pigmentosa	5694		
recombinant human rod-derived cone viability factor	Treatment of retinitis pigmentosa	recombinant human rod-derived cone viability factor		n/a	1/7/08	Designated/Withdrawn			N/A	N/A	Fovea Pharmaceuticals	Paris			France										Retinitis pigmentosa	5694		
Lentiviral vector containing the human MY07A gene	Treatment of retinitis pigmentosa associated with Usher syndrome 1B gene defect.	Lentiviral vector containing the human MY07A gene		Ushstat(Tm)	5/17/10	Designated			N/A	N/A	"Sanofi US Services, Inc."	Bridgewater	New Jersey	8807	USA										Retinitis pigmentosa	5694		
human retinal progenitor cells	Treatment of retinitis pigmentosa	human retinal progenitor cells		n/a	7/23/12	Designated			N/A	N/A	"jCyte, Inc."	Irvine	California	92617	USA	LONGEST CONTAINS	0018746AA	retinal	RR725D715M						Retinitis pigmentosa	5694		
adeno-associated viral vector containing DNA encoding an RNAi targeting rhodopsin in combination with an adeno-associated viral vector containing DNA encoding a rhodopsin gene	treatment of retinitis pigmentosa	adeno-associated viral vector containing DNA encoding an RNAi targeting rhodopsin in combination with an adeno-associated viral vector containing DNA encoding a rhodopsin gene		n/a	12/13/12	Designated			N/A	N/A	Genable Technologies Limited	Dublin 2			Ireland										Retinitis pigmentosa	5694		
expanded human allogeneic neural retinal progenitor cells extracted from neural retina	Treatment of retinitis pigmentosa	expanded human allogeneic neural retinal progenitor cells extracted from neural retina		n/a	8/22/13	Designated			N/A	N/A	ReNeuron Ltd				United Kingdom	LONGEST CONTAINS	0018746AA	retinal	RR725D715M						Retinitis pigmentosa	5694		
non-replicating recombinant adeno-associated virus vector containing a fragment of the gene encoding channelrhodopsin-2 protein	Treatment of retinitis pigmentosa	non-replicating recombinant adeno-associated virus vector containing a fragment of the gene encoding channelrhodopsin-2 protein		n/a	10/20/14	Designated			N/A	N/A	"RetroSense Therapeutics, LLC"	Ann Arbor	Michigan	48104	USA	LONGEST CONTAINS	0087274AA	protein							Retinitis pigmentosa	5694		
adeno-associated viral vector type 2 expressing human recombinant retinal pigment epithelial 65KDa protein gene	Treatment of Retinitis Pigmentosa due to autosomal recessive RPE65 gene mutations	adeno-associated viral vector type 2 expressing human recombinant retinal pigment epithelial 65KDa protein gene		n/a	3/18/15	Designated			N/A	N/A	"Spark Therapeutics, Inc."	Philadelphia	Pennsylvania	19104	USA	LONGEST CONTAINS	0018746AA	retinal	RR725D715M						Retinitis pigmentosa	5694		
adenovirus-associated viral vector serotype 5 containing the human pde6B gene	Treatment of retinitis pigmentosa due to pde6B gene mutations	adenovirus-associated viral vector serotype 5 containing the human pde6B gene		n/a	7/5/16	Designated			N/A	N/A	"HORAMA, SAS"	Paris			France										Retinitis pigmentosa	5694		
adenovirus associated viral vector serotype 5 containing the RPGR gene	Treatment of retinitis pigmentosa	adenovirus associated viral vector serotype 5 containing the RPGR gene		n/a	11/29/16	Designated			N/A	N/A	MeiraGTx Limited	New York	New York	10016	USA										Retinitis pigmentosa	5694		
adeno-associated viral vector serotype 2.7m8 containing the chrimsonR-tdTomato gene	Treatment of retinitis pigmentosa	adeno-associated viral vector serotype 2.7m8 containing the chrimsonR-tdTomato gene		n/a	1/25/17	Designated			N/A	N/A	GenSight Biologics	Paris			France										Retinitis pigmentosa	5694		
antisense oligonucleotide targeting the c.7595-2144A>G mutation in intron 40 of the USH2A gene	Treatment of retinitis pigmentosa	antisense oligonucleotide targeting the c.7595-2144A>G mutation in intron 40 of the USH2A gene		n/a	6/28/17	Designated			N/A	N/A	ProQR Therapeutics IV B.V.	Leiden			Netherlands										Retinitis pigmentosa	5694		
antisense oligonucleotide targeting exon 13 of the USH2A gene	Treatment of retinitis pigmentosa	antisense oligonucleotide targeting exon 13 of the USH2A gene		n/a	7/27/17	Designated			N/A	N/A	ProQR Therapeutics IV B.V.	Leiden			Netherlands										Retinitis pigmentosa	5694		
recombinant adeno-associated virus vector expressing the retinitis pigmentosa GTPase regulator	Treatment of retinitis pigmentosa	recombinant adeno-associated virus vector expressing the retinitis pigmentosa GTPase regulator		n/a	7/31/17	Designated			N/A	N/A	Applied Genetic Technologies Corporation	Alachua	Florida	32615	USA										Retinitis pigmentosa	5694		
Adeno Associated Virus carried Multi Characteristic Opsin	Treatment of retinitis pigmentosa	Adeno Associated Virus carried Multi Characteristic Opsin		n/a	10/3/17	Designated			N/A	N/A	NanoScope Technologies	Bedford	Texas	76022	USA										Retinitis pigmentosa	5694		
2’-O-(2-methoxyethyl) modified antisense oligonucleotide targeting exon 13 in the USH2A gene	Treatment of retinitis pigmentosa	2’-O-(2-methoxyethyl) modified antisense oligonucleotide targeting exon 13 in the USH2A gene		n/a	11/20/17	Designated			N/A	N/A	ProQR Therapeutics IV B.V.	9 Zernikedreef			Netherlands										Retinitis pigmentosa	5694		
adenovirus associated viral vector serotype 8 containing the human AIPL1 gene	"Treatment of inherited retinal dystrophy due to defects in AIPL1 gene, including Leber congenital amaurosis, retinitis pigmentosa, and cone-rod dystrophy"	adenovirus associated viral vector serotype 8 containing the human AIPL1 gene		n/a	2/1/18	Designated			N/A	N/A	MeiraGTx UK II Ltd	92 Britannia Walk	London		United Kingdom										Retinitis pigmentosa	5694		
retinol palmitate (vitamin A palmitate)	Prevention of retinopathy of prematurity (ROP)	retinol palmitate (vitamin A palmitate)		n/a	6/28/17	Designated			N/A	N/A	orphanix GmbH	Ried im Innkreis			Austria	exact	0013901AA	vitamin A palmitate	1D1K0N0VVC						Retinopathy of prematurity	5695		
myo-inositol	Prevention of retinopathy of prematurity in preterm infants at risk for developing retinopathy of prematurity	myo-inositol		n/a	4/7/05	Designated			N/A	N/A	Abbott Nutrition	Columbus	Ohio	43215	USA	EXACT	0015076AA	myo-inositol	4L6452S749						Retinopathy of prematurity	5695		
mecasermin rinfabate	Prevention of retinopathy of prematurity in premature infants born at risk for the disease	mecasermin rinfabate		n/a	9/20/12	Designated			N/A	N/A	Premacure AB	Uppsala			Sweden	EXACT	0212953AA	mecasermin rinfabate	NZ8M50KKRG						Retinopathy of prematurity	5695		
3-[3-(6-guanidino-1-oxoisoindolin-2yl) propanamido]-3-(pyridine-3yl) propanoic acid dihydrochloride	Treatment of retinopathy of prematurity	3-(3-(6-GUANIDINO-1-OXOISOINDOLIN-2YL)PROPANAMIDO)-3-(PYRIDINE-3YL)PROPANOIC ACID DIHYDROCHLORIDE		Ocurin	1/17/17	Designated			N/A	N/A	"Advanced Imaging Projects, LLC"	Lake Worth	Florida	33467	USA	EXACT	1800993AA	3-(3-(6-GUANIDINO-1-OXOISOINDOLIN-2YL)PROPANAMIDO)-3-(PYRIDINE-3YL)PROPANOIC ACID DIHYDROCHLORIDE	BJM92K3NGH						Retinopathy of prematurity	5695		
tianeptine	Treatment of Rett syndrome (RTT)	tianeptine		n/a	3/8/18	Designated			N/A	N/A	AMO Pharma Ltd.	Throwsters	The Street		United Kingdom	EXACT	0289883AA	tianeptine	0T493YFU8O						Rett syndrome	5696		
"(2,2-diphenyl-tetrahydro-furan-3-yl-methyl)-dimethylamine hydrochloride"	Treatment of Rett Syndrome.	ANAVEX-2-73		n/a	5/18/16	Designated			N/A	N/A	Anavex Life Sciences Corporation	New York	New York	10019	USA	EXACT	0918718AA	ANAVEX-2-73	1M49V1PBPL						Rett syndrome	5696		
sarizotan	Treatment of Rett syndrome.	sarizotan		n/a	7/7/15	Designated			N/A	N/A	"Newron Pharmaceuticals US, Inc."	Morristown	New Jersey	7960	USA	EXACT	0307539AA	sarizotan	467LU0UCUW						Rett syndrome	5696		
acetyl-l-carnitine (ALC)	Treatment of Rett syndrome	acetyl-l-carnitine (ALC)		n/a	3/18/11	Designated			N/A	N/A	"Sigma-Tau Pharmaceuticals, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0156649AA	acetyl-l-carnitine	6DH1W9VH8Q						Rett syndrome	5696		
vatiquinone	Treatment of Rett syndrome	vatiquinone		Vincerinone	11/17/14	Designated			N/A	N/A	"Edison pharmaceuticals, Inc."	Mountain View	California	94043	USA	EXACT	0739468AA	vatiquinone	6O85FK9I0X						Rett syndrome	5696		
[(S)-1-(L-valyl)-N_((S)-1-phenyl-2-(pyridin-2-yl)ethyl)pyrrolidine-2-carboxamide fumarate]	Treatment of Rett Syndrome	AZD8108 FUMARATE		n/a	6/22/17	Designated			N/A	N/A	"Biohaven Pharmaceutics, Inc."	New Haven	Connecticut	6510	USA	EXACT	1098857AA	AZD8108 FUMARATE	6P4560AP4D						Rett syndrome	5696		
"mecasermin, recombinant human insulin-like growth factor-1"	Treatment of Rett Syndrome.	mecasermin		Increlex	9/21/15	Designated			N/A	N/A	Keck Graduate Institute of Applied Life Sciences	Claremont	California	91711	USA	EXACT	0167215AA	mecasermin	7GR9I2683O						Rett syndrome	5696		
3-chloro-4-fluorophenyl-[4-fluoro-4-[[(5-methylpyrimidin-2-ylmethyl)amino]methyl]piperidin-1yl]methanone	Treatment of Rett syndrome	F-15599		n/a	10/25/13	Designated			N/A	N/A	"Neurolixis, Inc."	San Diego	California	92121	USA	EXACT	0862306AA	F-15599	83481Y1YCX						Rett syndrome	5696		
"6'-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)- paromamine sulfate"	Treatment of Rett syndrome	NB-124 SULFATE		n/a	11/3/16	Designated			N/A	N/A	"Eloxx Pharmaceuticals, Ltd."	Ness Ziona			Israel	EXACT	1801145AA	NB-124 SULFATE	DZ671709NT						Rett syndrome	5696		
glycyl-L-2-methylpropyl-L-glutamic acid	Treatment of Rett syndrome	Trofinetide		n/a	2/11/15	Designated			N/A	N/A	"Neuren Pharmaceuticals, Ltd."				New Zealand	EXACT	0341640AA	Trofinetide	Z2ME8F52QL						Rett syndrome	5696		
cannabidivarin	Treatment of Rett syndrome	cannabidivarin		n/a	11/30/16	Designated			N/A	N/A	GW Research Ltd.	Cambridge			United Kingdom	EXACT	1064853AA	cannabidivarin	I198VBV98I						Rett syndrome	5696		
Nitric oxide	Treatment of acute respiratory distress syndrome in adults.	Nitric oxide		n/a	7/10/95	Designated			N/A	N/A	"INO Therapeutics, Inc."	Hampton	New Jersey	8827	USA	EXACT	0176341AA	Nitric oxide	31C4KY9ESH						Acute respiratory distress syndrome	5698		
Vasoactive intestinal peptide	Treatment of Acute Respiratory Distress Syndrome.	Vasoactive intestinal peptide		n/a	3/9/01	Designated			N/A	N/A	mondoBIOTECH				USA	EXACT	0094735AA	Vasoactive intestinal peptide	6J2WVD66KR						Acute respiratory distress syndrome	5698		
Liposomal prostaglandin E1 injection	Treatment of acute respiratory distress syndrome.	Liposomal prostaglandin E1 injection		n/a	4/25/96	Designated/Withdrawn			N/A	N/A	"Liposome Company, Inc."	Princeton	New Jersey	8540	USA	EXACT	0030864AA	prostaglandin E1	F5TD010360						Acute respiratory distress syndrome	5698		
calfactant	Treatment of acute respiratory distress syndrome (ARDS)	calfactant		Infasurf	9/5/00	Designated			N/A	N/A	"ONY, Inc."	Amherst	New York	14228	USA	EXACT	0153071AA	calfactant	Q4K217VGA9						Acute respiratory distress syndrome	5698		
Lucinactant	Treatment of acute respiratory distress syndrome in adults.	Lucinactant		Surfaxin	7/17/95	Designated			N/A	N/A	"Windtree Therapeutics, Inc."	Warrington	Pennsylvania	18976	USA	EXACT	0727402AA	Lucinactant							Acute respiratory distress syndrome	5698		
Secalciferol	Treatment of familial hypophosphatemic rickets.	Secalciferol		Osteo-D	7/26/93	Designated			N/A	N/A	Teva Pharmaceuticals USA	North Wales	Pennsylvania	19454	USA	EXACT	0066342AA	Secalciferol	460029IUDA						Rickets	5700		
recombinant human IgG1 monoclonal antibody	Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets)	KRN-23		n/a	12/14/09	Designated			N/A	N/A	"Ultragenyx Pharmaceutical, Inc."	Novato	California	94949	USA	EXACT	1257621AA	KRN-23	G9WJT6RD29						Rickets	5700		
extracellular domain of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 fused to the Fc region of human IgG1	Treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency (generalized arterial calcification of infancy and autosomal recessive hypophosphatemic rickets type 2)	extracellular domain of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 fused to the Fc region of human IgG1		n/a	6/11/18	Designated			N/A	N/A	Inozyme Pharma Inc.	700 Technology Square		2139	USA										Rickets	5700		
vapreotide	Treatment of acromegaly	vapreotide		Sanvar	11/4/03	Designated			N/A	N/A	"H3 Pharma, Inc."				USA	EXACT	0182183AA	vapreotide	2PK59M9GFF						Acromegaly	5725		
octreotide acetate subcutaneous implant	Treatment of acromegaly	octreotide acetate subcutaneous implant		n/a	12/7/09	Designated			N/A	N/A	"Endo Pharmaceuticals Solutions, Inc."	Chadds Ford	Pennsylvania	19317	USA	EXACT	0133891AA	octreotide acetate	75R0U2568I						Acromegaly	5725		
octreotide acetate (intranasal)	Treatment of acromegaly	octreotide acetate (intranasal)		n/a	1/23/18	Designated			N/A	N/A	"Dauntless Pharmaceuticals, Inc."	12390 El Camino Real	San Diego	92130	USA	EXACT	0133891AA	octreotide acetate	75R0U2568I						Acromegaly	5725		
pasireotide	Treatment of acromegaly	pasireotide		n/a	8/25/09	Designated/Approved	Approved for Orphan Indication	Treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option	12/15/14	12/15/21	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0269534AA	pasireotide	98H1T17066						Acromegaly	5725		
"cyclo(-y-aminobutyryl-L-phenylalanyl-L-tryptophanyl-D-tryptophanyl-L-lysyl-L-threonly-L-phenylalanyl-N-3-carboxypropyl)-glycine amide, acetate salt"	Treatment of acromegaly	VELDOREOTIDE ACETATE		n/a	6/24/13	Designated			N/A	N/A	Aspireo Pharmaceuticals Limited	Ra'annana			Israel	EXACT	1803027AA	VELDOREOTIDE ACETATE	9F2286627L						Acromegaly	5725		
H-(4-amino-3-iodo)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2	Treatment of acromegaly	ap-102		n/a	11/3/16	Designated			N/A	N/A	Amryt Research Ltd.	Dublin			Ireland	EXACT	1802193AA	ap-102	EW91FWW4HC						Acromegaly	5725		
2'-O-(2-methoxyethyl)phosphorothioate antisense oligonucleotide	Treatment of acromegaly	ATL-1103		n/a	5/10/16	Designated			N/A	N/A	Antisense Therapeutics Limited	Trevose			Australia	EXACT	1336205AA	ATL-1103	F3H59ON671						Acromegaly	5725		
Pegvisomant	Treatment of acromegaly.	Pegvisomant		Somavert	6/24/97	Designated/Approved	Approved for Orphan Indication	"Treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate"	3/25/03	3/25/10	Sensus Corporation	Austin	Texas	78701	USA	EXACT	0222264AA	Pegvisomant	N824AOU5XV						Acromegaly	5725		
Octreotide	Treatment of acromegaly.	Octreotide		Sandostatin Lar	8/24/98	Designated/Approved	Approved for Orphan Indication	Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly.	11/25/98	11/25/05	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0169915AA	Octreotide	RWM8CCW8GP						Acromegaly	5725		
octreotide (oral)	For the oral treatment of acromegaly	octreotide (oral)		Octreolin(Tm)	6/17/10	Designated			N/A	N/A	"Chiasma, Inc."	Newton Centre	Massachusetts	2459	USA	EXACT	0169915AA	octreotide	RWM8CCW8GP						Acromegaly	5725		
Hemin	"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria."	Hemin		Panhematin	3/16/84	Designated/Approved	Approved for Orphan Indication		7/20/83	7/20/90	Abbott Laboratories	Abbott Park	Illinois	60064	USA	EXACT	0135171AA	Hemin	743LRP9S7N						Acute intermittent porphyria	5732		
Histrelin	"Treatment of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria."	Histrelin		n/a	5/3/91	Designated			N/A	N/A	"Anderson, Karl E., M.D."	Galveston	Texas	77550	USA	EXACT	0135864AA	Histrelin	H50H3S3W74						Acute intermittent porphyria	5732		
recombinant human porphobilinogen deaminase	Treatment of acute intermittent porphyria attacks	recombinant human porphobilinogen deaminase		Porphozyme	9/9/02	Designated			N/A	N/A	Zymenex A/S				Denmark	EXACT	0265509AA	recombinant human porphobilinogen deaminase							Acute intermittent porphyria	5732		
"recombinant human porphobilinogen deaminase, erythropoetic form"	Treatment of acute intermittent porphyria preventing attacks	"recombinant human porphobilinogen deaminase, erythropoetic form"		n/a	7/11/02	Designated			N/A	N/A	Zymenex A/S				Denmark	LONGEST CONTAINS	0265509AA	recombinant human porphobilinogen deaminase							Acute intermittent porphyria	5732		
oblimersen	Treatment of acute myelocytic leukemia	oblimersen		Genasense	8/28/01	Designated			N/A	N/A	"Genta, Inc."	Berkeley Heights	New Jersey	7922	USA	EXACT	0258731AA	oblimersen	85J5ZP6YSL						Acute myelocytic leukemia	5734		
arsenic	"Treatment of acute myelocytic leukemia subtypes M0, M1, M2, M4, M5, M6 and M7"	arsenic		Trisenox	11/2/01	Designated			N/A	N/A	"Teva Branded Pharmaceutical Products R&D, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0048180AA	arsenic	N712M78A8G						Acute myelocytic leukemia	5734		
"(7S,13R)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one"	Treatment of non-small cell lung adenocarcinomas with adenocarcinoma histology	TPX-0005		n/a	6/22/17	Designated			N/A	N/A	"TP Therapeutics, Inc."	San Diego	California	92121	USA	EXACT	1574261AA	TPX-0005	08O3FQ4UNP						Lung adenocarcinoma	5742		
dovitinib	Treatment of adenoid cystic carcinoma	dovitinib		n/a	9/26/13	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0309342AA	dovitinib	I35H55G906						Adenoid cystic carcinoma	5743		
Para-toluenesulfonamide	Treatment of adenoid cystic carcinoma	P-toluenesulfonamide		n/a	1/30/17	Designated			N/A	N/A	PTS International Inc.	San Antonio	Texas	78230	USA	EXACT	0174447AA	P-toluenesulfonamide	I8266RI90M						Adenoid cystic carcinoma	5743		
(monomethoxypolyethylene glycol) recombinant adenosine deaminase	Treatment of adenosine deaminase deficiency in patients with severe combined immunodeficiency	EZN-2279 		n/a	3/19/15	Designated			N/A	N/A	"Sigma-Tau Pharmaceuticals, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	1311246AA	EZN-2279	9R3D3Y0UHS						Adenosine deaminase deficiency	5748		
autologus CD34+ cells transfected with retroviral vector containing adenosine deaminase gene	Treatment of severe combined immunodeficiency due to adenosine deaminase deficiency.	autologus CD34+ cells transfected with retroviral vector containing adenosine deaminase gene		n/a	8/26/09	Designated			N/A	N/A	Glaxo Group Limited				United Kingdom	LONGEST CONTAINS	1315157AA	adenosine deaminase	XPQ5L1L4WO						Adenosine deaminase deficiency	5748		
Pegademase bovine	For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.	Pegademase bovine		Adagen	5/29/84	Designated/Approved	Approved for Orphan Indication		3/21/90	3/21/97	"Sigma-tau Pharmaceuticals, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0152465AA	Pegademase bovine	HW3H7D91F6						ADA deficiency	5748		
adeno-associated virus vector expressing human 21-hydroxylase	Treatment of congenital adrenal hyperplasia 21-hydroxylase deficiency	adeno-associated virus vector expressing human 21-hydroxylase		n/a	8/30/18	Designated			N/A	N/A	Adrenas Therapeutics Inc	421 Kipling St	California	94301	USA										21-hydroxylase deficiency	5757		
Nitisinone	Treatment of alkaptonuria	Nitisinone		Orfadin	10/19/01	Designated			N/A	N/A	Swedish Orphan AB				Sweden	EXACT	0182581AA	Nitisinone	K5BN214699						Alkaptonuria	5775		
Recombinant secretory leucocyte protease inhibitor	Treatment of congenital alpha-1 antitrypsin deficiency.	SECRETORY LEUKOCYTE PROTEASE INHIBITOR		n/a	3/29/91	Designated/Withdrawn			N/A	N/A	Amgen Inc.	Boulder	Colorado	80301	USA	EXACT	0259972AA	SECRETORY LEUKOCYTE PROTEASE INHIBITOR	909E17P4ZW						Alpha-1 antitrypsin deficiency	5784		
hyaluronic acid	Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency	hyaluronic acid		n/a	3/19/02	Designated			N/A	N/A	CoTherix	South San Francisco	California	94080	USA	EXACT	0151804AA	hyaluronic acid	S270N0TRQY						Alpha-1 antitrypsin deficiency	5784		
double stranded oligomer AD00370 RNA interference-based liver targeted therapeutic	Treatment of Alpha-1 Antitrypsin deficiency	double stranded oligomer AD00370 RNA interference-based liver targeted therapeutic		n/a	6/9/15	Designated			N/A	N/A	Arrowhead Research Corporation	Pasadena	California	91101	USA	LONGEST CONTAINS	0152749AA	liver							Alpha-1 antitrypsin deficiency	5784		
three-dimensional bioprinted therapeutic liver tissue	Treatment of alpha-1 antitrypsin deficiency	three-dimensional bioprinted therapeutic liver tissue		n/a	12/21/17	Designated			N/A	N/A	Organovo Inc.	6275 Nancy Ridge Drive	San Diego	92121	USA	LONGEST CONTAINS	0152749AA	liver							Alpha-1 antitrypsin deficiency	5784		
double stranded oligomer ADS-001 RNA interference-based liver targeted therapeutic	Treatment of alpha-1 antitrypsin deficiency	double stranded oligomer ADS-001 RNA interference-based liver targeted therapeutic		n/a	2/14/18	Designated			N/A	N/A	Arrowhead Research Corporation	225 South Lake Avenue	Pasadena		USA	LONGEST CONTAINS	0152749AA	liver							Alpha-1 antitrypsin deficiency	5784		
bardoxolone methyl	Treatment of Alport Syndrome	bardoxolone methyl		n/a	7/3/17	Designated			N/A	N/A	"Reata Pharmaceuticals, Inc."	Irving	Texas	75063	USA	EXACT	0275354AA	bardoxolone methyl	CEG1Q6OGU1						Alport syndrome	5785		
"single stranded, chemically modified oligonucleotide that binds to and inhibits the function of micro RNA-21"	Treatment of Alport syndrome	"single stranded, chemically modified oligonucleotide that binds to and inhibits the function of micro RNA-21"		n/a	7/17/14	Designated			N/A	N/A	"Regulus Therapeutics, Inc."	San Diego		92121	USA										Alport syndrome	5785		
Ceftriaxone sodium	Treatment of amyotrophic lateral sclerosis	Ceftriaxone sodium		Rocephin	3/28/06	Designated			N/A	N/A	Mass General Hospital	Charlestown	Massachusetts	2129	USA	EXACT	0129919AA	Ceftriaxone sodium	023Z5BR09K						Amyotrophic lateral sclerosis	5786		
Branched chain amino acids	Treatment of amyotrophic lateral sclerosis.	ISOLEUCINE		n/a	12/23/88	Designated			N/A	N/A	Mount Sinai Medical Center	New York	New York	10029	USA	EXACT	0012668AA	ISOLEUCINE	04Y7590D77						Amyotrophic lateral sclerosis	5786		
nicotinamide riboside and pterostilbene	Treatment of Amyotrophic Lateral Sclerosis	nicotinamide riboside and pterostilbene		n/a	3/19/18	Designated			N/A	N/A	Elysium Health Inc.	434 Broadway	Floor 2	10013	USA	EXACT	1800960AA	nicotinamide riboside	0I8H2M0L7N						Amyotrophic lateral sclerosis	5786		
diacetyl(N(4)-methylthiosemicarbazonato) copper (II)	Treatment of amyotrophic lateral sclerosis (ALS)	CU-ASTM		n/a	12/18/17	Designated			N/A	N/A	Collaborative Medicinal Development Pty. Ltd. (CMD)	c/o Shaw Downie	Sydney		Australia	EXACT	1722652AA	CU-ASTM	0YDK1H9L3A						Amyotrophic lateral sclerosis	5786		
anti-nogo-A monoclonal antibody	Treatment of amyotrophic lateral sclerosis	ozanezumab		n/a	7/7/09	Designated/Withdrawn			N/A	N/A	GlaxoSmithKline				United Kingdom	EXACT	0762618AA	ozanezumab	123I05210W						Amyotrophic lateral sclerosis	5786		
Cannabidiol and delta-9-tetrahydrocannabinol	Treatment of amyotrophic lateral sclerosis	Cannabidiol 		n/a	3/15/18	Designated			N/A	N/A	"AXIUM Pharmaceuticals, Inc."	265 Eastchester Drive	"Suite 133, #201"	27262	USA	EXACT	0027441AA	Cannabidiol	19GBJ60SN5						Amyotrophic lateral sclerosis	5786		
recombinant human vascular endothelial growth factor	Treatment of amyotrophic lateral sclerosis	Telbermin		n/a	6/7/10	Designated			N/A	N/A	NeuroNova AB				Sweden	EXACT	0777208AA	Telbermin	22G76ZW50X						Amyotrophic lateral sclerosis	5786		
nicotinamide riboside and pterostilbene	Treatment of Amyotrophic Lateral Sclerosis	 pterostilbene		n/a	3/19/18	Designated			N/A	N/A	Elysium Health Inc.	434 Broadway	Floor 2	10013	USA	EXACT	0838506AA	pterostilbene	26R60S6A5I						Amyotrophic lateral sclerosis	5786		
Oxaloacetic acid	Treatment of amyotrophic lateral sclerosis	Oxaloacetic acid		n/a	11/18/15	Designated			N/A	N/A	Terra Biological LLC	San Diego	California	92130	USA	EXACT	0423290AA	Oxaloacetic acid	2F399MM81J						Amyotrophic lateral sclerosis	5786		
L-threonine	Treatment of amyotrophic lateral sclerosis.	L-threonine		Threostat	2/6/89	Designated/Withdrawn			N/A	N/A	Tyson And Associates	Hawthorne	California	90250	USA	EXACT	0012475AA	L-threonine	2ZD004190S						Amyotrophic lateral sclerosis	5786		
glatiramer acetate	Treatment of amyotrophic lateral sclerosis (ALS).	glatiramer acetate		Copaxone	11/14/07	Designated			N/A	N/A	"Teva Neurosciences, Inc."	Horsham	Pennsylvania	19044	USA	EXACT	0218484AA	glatiramer acetate	5M691HL4BO						Amyotrophic lateral sclerosis	5786		
Protirelin injection	Treatment of amyotrophic lateral sclerosis.	Protirelin injection		n/a	1/10/85	Designated/Withdrawn			N/A	N/A	Abbott Laboratories	Abbott Park	Illinois		USA	EXACT	0062486AA	Protirelin	5Y5F15120W						Amyotrophic lateral sclerosis	5786		
oligopeptide containing 6 amino acids (H-Phe-Ser-Arg-Tyr-Ala-Arg-OH)	Treatment of amyotrophic lateral sclerosis	GM-603		n/a	2/27/14	Designated			N/A	N/A	"Genervon Biopharmaceuticals, LLC"	Pasadena	California	91106	USA	EXACT	0567919AA	GM-603	6BK9OEG8CC						Amyotrophic lateral sclerosis	5786		
gabapentin	Treatment of amyotrophic lateral sclerosis	gabapentin		Neurontin	7/5/95	Designated			N/A	N/A	Warner-Lambert Company	Ann Arbor	Michigan	48105	USA	EXACT	0157051AA	gabapentin	6CW7F3G59X						Amyotrophic lateral sclerosis	5786		
Mecasermin	Treatment of amyotrophic lateral sclerosis.	Mecasermin		Myotrophin	8/5/91	Designated/Withdrawn			N/A	N/A	"Teva Branded Pharmaceutical Products R&D, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0167215AA	Mecasermin	7GR9I2683O						Amyotrophic lateral sclerosis	5786		
Cannabidiol and delta-9-tetrahydrocannabinol	Treatment of amyotrophic lateral sclerosis	delta-9-tetrahydrocannabinol		n/a	3/15/18	Designated			N/A	N/A	"AXIUM Pharmaceuticals, Inc."	265 Eastchester Drive	"Suite 133, #201"	27262	USA	EXACT	0045169AA	delta-9-tetrahydrocannabinol	7J8897W37S						Amyotrophic lateral sclerosis	5786		
Riluzole	Treatment of amyotrophic lateral sclerosis.	Riluzole		Rilutek	3/16/93	Designated/Approved	Approved for Orphan Indication	Treatment of patients with amyotrophic lateral sclerosis. Riluzole extends survival and/or time to tracheostomy.	12/12/95	12/12/02	"Rhone-Poulenc Rorer Pharmaceuticals, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	0182978AA	Riluzole	7LJ087RS6F						Amyotrophic lateral sclerosis	5786		
riluzole oral suspension	Treatment of amyotrophic lateral sclerosis (ALS).	riluzole oral suspension		Teglutik	9/15/16	Designated			N/A	N/A	Italfarmaco SpA	Cinisello Balsamo			Italy	EXACT	0182978AA	riluzole	7LJ087RS6F						Amyotrophic lateral sclerosis	5786		
riluzole orally disolving tablet	Treatment of amyotrophic lateral sclerosis (ALS)	riluzole orally disolving tablet		n/a	11/30/16	Designated			N/A	N/A	"Biohaven Pharmaceutical Holding Company, Ltd"	New Haven	Connecticut	6511	USA	EXACT	0182978AA	riluzole	7LJ087RS6F						Amyotrophic lateral sclerosis	5786		
hydrocinnamate-[Orn-Pro-dCha-Trp-Arg](CH3COO)	Treatment of amyotrophic lateral sclerosis	PMX-205 ACETATE		n/a	3/9/15	Designated			N/A	N/A	Alsonex Pty Ltd	Brisbane			Australia	EXACT	1805965AA	PMX-205 ACETATE	7P258240O5						Amyotrophic lateral sclerosis	5786		
DL-3-n-butylphthalide	Treatment of amyotrophic lateral sclerosis (ALS)	DL-3-n-butylphthalide		n/a	2/28/18	Designated			N/A	N/A	"CSPC NBP Pharmaceutical Co, Ltd, subsidiary of CSPC Pharma Group"	No. 88 Yangzi Road	Shijiazhuang Shi		China	EXACT	0510327AA	DL-3-n-butylphthalide	822Q956KGM						Amyotrophic lateral sclerosis	5786		
Cyclosporin A	Treatment of amyotrophic lateral sclerosis and its variants	Cyclosporin A		Mitogard	10/29/04	Designated			N/A	N/A	"Maas Biolab,LLC"	Albuquerque	New Mexico	87106	USA	EXACT	0066808AA	Cyclosporin A	83HN0GTJ6D						Amyotrophic lateral sclerosis	5786		
noscapine	Treatment of amyotrophic lateral sclerosis.	noscapine		n/a	12/29/15	Designated			N/A	N/A	KineMed Inc.	Emeryville	California	94608	USA	EXACT	0020575AA	noscapine	8V32U4AOQU						Amyotrophic lateral sclerosis	5786		
dextromethorphan hydrobromide/quinidine sulfate	Treatment of amyotrophic lateral sclerosis (ALS)	dextromethorphan hydrobromide		Nuedexta	2/14/17	Designated			N/A	N/A	Avanir Pharmaceuticals	Aliso Viejo	California	92656	USA	EXACT	0020064AA	dextromethorphan hydrobromide	9D2RTI9KYH						Amyotrophic lateral sclerosis	5786		
"4-cholest-en-3-one, oxime"	Treatment of amyotrophic lateral sclerosis	"4-cholest-en-3-one, oxime"		n/a	12/1/05	Designated/Withdrawn			N/A	N/A	Trophos SA				France	EXACT	0340045AA	"4-cholest-en-3-one, oxime"	A6778U5IFY						Amyotrophic lateral sclerosis	5786		
levosimendan	Treatment of amyotrophic lateral sclerosis	levosimendan		n/a	4/10/17	Designated			N/A	N/A	Orion Corporation				Finland	EXACT	0190658AA	levosimendan	C6T4514L4E						Amyotrophic lateral sclerosis	5786		
sarsasapogenin	Treatment of amyotrophic lateral sclerosis (ALS)	sarsasapogenin		n/a	6/18/04	Designated/Withdrawn			N/A	N/A	Phytopharm plc				United Kingdom	EXACT	0246559AA	sarsasapogenin	CFS802C28F						Amyotrophic lateral sclerosis	5786		
Ciliary neurotrophic factor	Treatment of amyotrophic lateral sclerosis.	Ciliary neurotrophic factor		n/a	1/30/92	Designated			N/A	N/A	Regeneron Pharmaceuticals Inc	Tarrytown	New York	10591	USA	EXACT	0259734AA	Ciliary neurotrophic factor	CR102F038W						Amyotrophic lateral sclerosis	5786		
talampanel	Treatment of amyotrophic lateral sclerosis	talampanel		n/a	3/24/08	Designated/Withdrawn			N/A	N/A	TEVA Neuroscience	Horsham	Pennsylvania	19044	USA	EXACT	0216773AA	talampanel	CVS43XG1L5						Amyotrophic lateral sclerosis	5786		
2'-O-methyl phosphorothioate 5'-GCUAGGUUUACGGGACCUCU-3'	Treatment of amyotrophic lateral sclerosis	LSP-GR3		n/a	10/31/12	Designated			N/A	N/A	LifeSplice Pharma LLC	Malvern	Pennsylvania	19355	USA	EXACT	1803129AA	LSP-GR3	DAGM66PSEW						Amyotrophic lateral sclerosis	5786		
arimoclomol	Treatment of amyotrophic lateral sclerosis	arimoclomol		n/a	3/29/05	Designated			N/A	N/A	CytRx Corporation	San Diego	California	92109	USA	EXACT	0320365AA	arimoclomol	EUT3557RT5						Amyotrophic lateral sclerosis	5786		
bis-choline tetrathiomolybdate	Treatment of Amyotrophic Lateral Sclerosis (ALS)	bis-choline tetrathiomolybdate		n/a	6/5/17	Designated			N/A	N/A	Wilson Therapeutics AB				USA	EXACT	0251763AA	choline tetrathiomolybdate	FD57A79R4P						Amyotrophic lateral sclerosis	5786		
sodium chlorite	For slowing the progression of amyotrophic lateral sclerosis.	sodium chlorite		n/a	8/22/11	Designated			N/A	N/A	"Neuraltus Pharmaceuticals, Inc."	Palo Alto	California	94303	USA	EXACT	0050884AA	sodium chlorite	G538EBV4VF						Amyotrophic lateral sclerosis	5786		
tirasemtiv	Treatment of amyotrophic lateral sclerosis (ALS)	tirasemtiv		n/a	3/2/10	Designated			N/A	N/A	Cytokinetics Inc.	South San Francisco	California	94080	USA	EXACT	0698646AA	tirasemtiv	G8WSM7R635						Amyotrophic lateral sclerosis	5786		
Branched chain amino acids	Treatment of amyotrophic lateral sclerosis.	LEUCINE		n/a	12/23/88	Designated			N/A	N/A	Mount Sinai Medical Center	New York	New York	10029	USA	EXACT	0010811AA	LEUCINE	GMW67QNF9C						Amyotrophic lateral sclerosis	5786		
smilagenin	Treatment of amyotrophic lateral sclerosis	smilagenin		Cogane	7/21/11	Designated			N/A	N/A	"Junaxo, Inc."				Canada	EXACT	0246560AA	smilagenin	GQE3Q7YMVZ						Amyotrophic lateral sclerosis	5786		
"superoxide dismutase, gliadin"	Treatment of amyotrophic lateral sclerosis	gliadin		Etr019	4/30/10	Designated			N/A	N/A	Verius Limited				United Kingdom	EXACT	1189668AA	gliadin	GR9478B3Q3						Amyotrophic lateral sclerosis	5786		
Branched chain amino acids	Treatment of amyotrophic lateral sclerosis.	VALINE		n/a	12/23/88	Designated			N/A	N/A	Mount Sinai Medical Center	New York	New York	10029	USA	EXACT	0012464AA	VALINE	HG18B9YRS7						Amyotrophic lateral sclerosis	5786		
"(R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl) butanamide"	Treatment of amyotrophic lateral sclerosis	EPI-589		n/a	7/27/17	Designated			N/A	N/A	BioElectron Technology Corporation	Mountain View	California	94043	USA	EXACT	1144270AA	EPI-589	I4ZSB1Q2DU						Amyotrophic lateral sclerosis	5786		
dextromethorphan hydrobromide/quinidine sulfate	Treatment of amyotrophic lateral sclerosis (ALS)	quinidine sulfate		Nuedexta	2/14/17	Designated			N/A	N/A	Avanir Pharmaceuticals	Aliso Viejo	California	92656	USA	EXACT	0007523AA	quinidine sulfate	J13S2394HE						Amyotrophic lateral sclerosis	5786		
repository corticortropin injection	Treatment of amyotrophic lateral sclerosis	ACTH		H.P. Acthar Gel	6/28/13	Designated			N/A	N/A	"Questor Pharmaceuticals, Inc."	Hayward	California	94545	USA	EXACT	0052175AA	ACTH	K0U68Q2TXA						Amyotrophic lateral sclerosis	5786		
ibudilast	Treatment of amyotrophic lateral sclerosis	ibudilast		n/a	10/6/16	Designated			N/A	N/A	"MediciNova, Inc."	La Jolla	California	92037	USA	EXACT	0297905AA	ibudilast	M0TTH61XC5						Amyotrophic lateral sclerosis	5786		
creatine	Treatment of amyotrophic lateral sclerosis	creatine		Creapure	2/12/02	Designated			N/A	N/A	"Avicena Group, Inc."	San Francisco	California	94104	USA	EXACT	0009245AA	creatine	MU72812GK0						Amyotrophic lateral sclerosis	5786		
combination of sodium phenylbutyrate and tauroursodeoxycholic acid dihydrate	Treatment of amyotrophic lateral sclerosis (ALS)	 sodium phenylbutyrate		n/a	7/27/17	Designated			N/A	N/A	Amylyx Pharmaceuticals Inc.	Cambridge	Massachusetts	2139	USA	EXACT	0180767AA	sodium phenylbutyrate	NT6K61736T						Amyotrophic lateral sclerosis	5786		
Orgotein for injection	"Treatment of familial amyotrophic lateral sclerosis associated with a mutation of the gene (on chromosome 21q) for copper, zinc superoxide dismutase."	Orgotein for injection		n/a	12/22/94	Designated/Withdrawn			N/A	N/A	"Oxis International, Inc."	Portland	Oregon	97217	USA	EXACT	0052379AA	Orgotein	PKE82W49V1						Amyotrophic lateral sclerosis	5786		
filgrastim	Treatment of amyotrophic lateral sclerosis (ALS)	filgrastim		n/a	1/27/15	Designated			N/A	N/A	Neurovision Pharma GmbH	Grunwald			Germany	EXACT	0174823AA	filgrastim	PVI5M0M1GW						Amyotrophic lateral sclerosis	5786		
lactobacillus plantarum	Treatment of amyotrophic lateral sclerosis (ALS)	lactobacillus plantarum		n/a	11/30/16	Designated			N/A	N/A	"New Biotic, LLC"	Rowland Heights	California	91748	USA	EXACT	0234731AA	lactobacillus plantarum	QFC21096ON						Amyotrophic lateral sclerosis	5786		
edaravone	Treatment of amyotrophic lateral sclerosis	edaravone		n/a	3/12/15	Designated			N/A	N/A	Treeway B.V.				Netherlands	EXACT	0307379AA	edaravone	S798V6YJRP						Amyotrophic lateral sclerosis	5786		
edaravone	Treatment of amyotrophic lateral sclerosis	edaravone		n/a	5/12/15	Designated			N/A	N/A	Mitsubishi Tanabe Pharma Corporation				Japan	EXACT	0307379AA	edaravone	S798V6YJRP						Amyotrophic lateral sclerosis	5786		
dexpramipexole	Treatment of amyotrophic lateral sclerosis	dexpramipexole		n/a	10/11/07	Designated			N/A	N/A	Knopp Biosciences LLC	Pittsburgh	Pennsylvania	15203	USA	EXACT	0457987AA	dexpramipexole	WI638GUS96						Amyotrophic lateral sclerosis	5786		
L-2-oxothiazolidine-4-carboxylic acid	Treatment of amyotrophic lateral sclerosis.	L-2-oxothiazolidine-4-carboxylic acid		Procysteine	7/30/96	Designated			N/A	N/A	"Transcend Therapeutics, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0694417AA	L-2-oxothiazolidine-4-carboxylic acid	X7063P804E						Amyotrophic lateral sclerosis	5786		
masitinib mesylate	Treatment of amyotrophic lateral sclerosis.	masitinib mesylate		n/a	3/18/15	Designated			N/A	N/A	AB Science				France	EXACT	0302772AA	masitinib mesylate	ZK89EG3A18						Amyotrophic lateral sclerosis	5786		
"[5,10,15,20-tetrakis(1,3-diethylimidazolium-2-yl)porphyrinato] manganese(III)pentachloride"	Treatment of Amyotrophic Lateral Sclerosis	AEOL-10150		n/a	11/4/03	Designated			N/A	N/A	"Aeolus Pharmaceuticals, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0251489AA	AEOL-10150	KPKO7W46E8						Amyotrophic lateral sclerosis	5786		
recombinant human cerebral dopamine neurotrophic factor	Treatment of amyotrophic lateral sclerosis	HER-902 		n/a	6/8/16	Designated			N/A	N/A	Herantis Pharma Plc	Helsinki			Finland	EXACT	1804268AA	HER-902	BA99H4C2PR						Amyotrophic lateral sclerosis	5786		
combination of sodium phenylbutyrate and tauroursodeoxycholic acid dihydrate	Treatment of amyotrophic lateral sclerosis (ALS)	 tauroursodeoxycholic acid dihydrate		n/a	7/27/17	Designated			N/A	N/A	Amylyx Pharmaceuticals Inc.	Cambridge	Massachusetts	2139	USA	EXACT	0112693AB	tauroursodeoxycholic acid dihydrate	U7XRV7RZ1I						Amyotrophic lateral sclerosis	5786		
Recombinant human antibody directed against human misfolded superoxide dismutase 1	Treatment of amyotrophic lateral sclerosis (ALS)	NI-204		n/a	8/10/17	Designated			N/A	N/A	AL-S Pharma SA	Schlieren			Switzerland	EXACT									Amyotrophic lateral sclerosis	5786		
"Ciliary neurotrophic factor, recombinant human"	"Treatment of motor neuron disease (including amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and primary lateral sclerosis)."	"Ciliary neurotrophic factor, recombinant human"		n/a	5/8/92	Designated/Withdrawn			N/A	N/A	Syntex-Synergen Neuroscience	Boulder	Colorado	80301	USA	EXACT	0113784AB	"Ciliary neurotrophic factor, recombinant human"							Amyotrophic lateral sclerosis	5786		
Neurotrophin-1	Treatment of motor neuron disease/amyotrophic lateral sclerosis.	Neurotrophin-1		n/a	9/13/94	Designated			N/A	N/A	"Ericsson, Arthur Dale, M.D."	Houston	Texas	77030	USA										Amyotrophic lateral sclerosis	5786		
Recombinant methionyl brain-derived neurotrophic factor	Treatment of amyotrophic lateral sclerosis.	Recombinant methionyl brain-derived neurotrophic factor		n/a	11/28/94	Designated			N/A	N/A	"Amgen, Inc."	Thousand Oaks	California	91320	USA										Amyotrophic lateral sclerosis	5786		
phosphorothioate oligonucleotide	Treatment of amyotrophic lateral sclerosis	phosphorothioate oligonucleotide		n/a	11/9/07	Designated/Withdrawn			N/A	N/A	"Isis Pharmaceuticals, Inc."	Carlsbad	California	92010	USA										Amyotrophic lateral sclerosis	5786		
autologous olfactory neural progenitors	Treatment of amyotrophic lateral sclerosis	autologous olfactory neural progenitors		Rhinocytes	12/31/08	Designated			N/A	N/A	"RhinoCyte, Inc."	Louisville	Kentucky	40202	USA										Amyotrophic lateral sclerosis	5786		
caprine hyperimmune serum against HIV lysate	Treatment of amyotrophic lateral sclerosis	caprine hyperimmune serum against HIV lysate		n/a	10/28/09	Designated			N/A	N/A	Daval International Limited				United Kingdom										Amyotrophic lateral sclerosis	5786		
NDX-peptides	Treatment of amyotrophic lateral sclerosis	NDX-peptides		n/a	12/14/10	Designated			N/A	N/A	NeoDiagnostic Research Ltd	Herts WD3 5LH			United Kingdom										Amyotrophic lateral sclerosis	5786		
ex-vivo expanded autologous bone marrow-derived mesenchymal stem cells	Treatment of Amyotrophic Lateral Sclerosis	ex-vivo expanded autologous bone marrow-derived mesenchymal stem cells		n/a	12/20/10	Designated			N/A	N/A	"TCA Cellular Therapy, LLC"	Covington	Louisiana	70433	USA	LONGEST CONTAINS	0260924AA	autologous bone marrow							Amyotrophic lateral sclerosis	5786		
human spinal cord derived neural stem cells	Treatment of amyotrophic lateral sclerosis	human spinal cord derived neural stem cells		n/a	2/4/11	Designated			N/A	N/A	"Neuralstem, Inc."	Germantown	Maryland	20876	USA	LONGEST CONTAINS	0141980AA	spinal cord							Amyotrophic lateral sclerosis	5786		
mesenchymal stromal cells secreting neurotrophic factors	Treatment of Amyotrophic Lateral Sclerosis	mesenchymal stromal cells secreting neurotrophic factors		Nurown	2/4/11	Designated			N/A	N/A	BrainStorm Cell Therapeutics Ltd.				Israel										Amyotrophic lateral sclerosis	5786		
Heat Shock Protein 70	Treatment of amyotrophic lateral sclerosis	Heat Shock Protein 70		n/a	3/18/11	Designated			N/A	N/A	ALS 	Doylestown	Pennsylvania	18902	USA	LONGEST CONTAINS	0087274AA	Protein							Amyotrophic lateral sclerosis	5786		
human umbilical tissue derived cells (hUTC)	Treatment of amyotrophic lateral sclerosis	human umbilical tissue derived cells (hUTC)		n/a	5/10/11	Designated/Withdrawn			N/A	N/A	"Janssen Research & Development, LLC"	Spring House	Pennsylvania	19477	USA										Amyotrophic lateral sclerosis	5786		
human glial restricted progenitor cells and their progeny	Treatment of amyotrophic lateral sclerosis	human glial restricted progenitor cells and their progeny		Q-Cells	9/11/13	Designated			N/A	N/A	"Q Therapeutics, Inc."	Salt Lake City	Utah	84108	USA										Amyotrophic lateral sclerosis	5786		
Allogeneic motor neuron progenitor cells derived from human embryonic stem cells	Treatment of Amyotrophic Lateral Sclerosis	Allogeneic motor neuron progenitor cells derived from human embryonic stem cells		Motorgraft (Tm)	1/17/14	Designated			N/A	N/A	California Stem Cell Inc.	Irvine	California	92612	USA	LONGEST CONTAINS	0264620AA	stem cells							Amyotrophic lateral sclerosis	5786		
DNA plasmid vector (pCK-HGFX7) expressing human hepatocyte growth factor	Treatment of amyotrophic lateral sclerosis	DNA plasmid vector (pCK-HGFX7) expressing human hepatocyte growth factor		n/a	2/6/14	Designated			N/A	N/A	"ViroMed Co., Ltd."	Atlanta	Georgia	30309	USA	LONGEST CONTAINS	0112288AB	human hepatocyte growth factor	BEI7G52Q8Z						Amyotrophic lateral sclerosis	5786		
autologous adipose derived mesenchymal stromal cells	Treatment of amyotrophic lateral sclerosis	autologous adipose derived mesenchymal stromal cells		n/a	10/22/14	Designated			N/A	N/A	Mayo Clinic	Rochester	Minnesota	55905	USA	EXACT	0116968AB	autologous adipose derived mesenchymal stromal cells							Amyotrophic lateral sclerosis	5786		
Mononuclear enriched fraction of human umbilical cord blood	Treatment of amyotrophic lateral sclerosis (ALS).	Mononuclear enriched fraction of human umbilical cord blood		U-Cord-Cell(R)	9/15/15	Designated			N/A	N/A	"Saneron CCEL Therapeutics, Inc."	Tampa	Florida	33618	USA	LONGEST CONTAINS	0854240AA	human umbilical cord blood	PVH8394DLN						Amyotrophic lateral sclerosis	5786		
antisense oligonucleotide inhibitor of the expression of superoxide dismutase 1 gene	Treatment of amyotrophic lateral sclerosis	antisense oligonucleotide inhibitor of the expression of superoxide dismutase 1 gene		n/a	9/19/16	Designated			N/A	N/A	Biogen	Cambridge	Massachusetts	2142	USA	LONGEST CONTAINS	1103588AA	superoxide dismutase	W2T4YRA9AD						Amyotrophic lateral sclerosis	5786		
electrokinetically altered saline solution with an elevated dissolved oxygen concentration	Treatment of amyotrophic lateral sclerosis (ALS)	electrokinetically altered saline solution with an elevated dissolved oxygen concentration		n/a	7/10/17	Designated			N/A	N/A	Revalesio Corporation	Tacoma	Washington	98421	USA	LONGEST CONTAINS	0002722AA	saline solution	451W47IQ8X						Amyotrophic lateral sclerosis	5786		
"humanized anti-CD40LG IgG1, kappa monoclonal antibody with heavy chain C220S/C226S/C229S/P238S substitutions to attenuate effector function"	Treatment of Amyotrophic Lateral Sclerosis (ALS)	"humanized anti-CD40LG IgG1, kappa monoclonal antibody with heavy chain C220S/C226S/C229S/P238S substitutions to attenuate effector function"		n/a	4/4/18	Designated			N/A	N/A	Anelixis Therapeutics	300 Technology Square		2139	USA	EXACT	0115353AB	"humanized anti-CD40LG IgG1, kappa monoclonal antibody with heavy chain C220S/C226S/C229S/P238S substitutions to attenuate effector function"							Amyotrophic lateral sclerosis	5786		
lenzumestrocel	Treatment of amyotrophic lateral sclerosis	lenzumestrocel		n/a	8/1/18	Designated			N/A	N/A	"Corestem, Inc."	"2F, 24, Pangyo-ro 255 beon-gil"			"Korea, Republic of"										Amyotrophic lateral sclerosis	5786		
S-[+]-apomorphine	Treatment of amyotrophic lateral sclerosis (ALS).	S-[+]-apomorphine		n/a	10/2/18	Designated			N/A	N/A	Aclipse One Inc	170 North Radnor Chester Road	Pennsylvania	19087	USA	EXACT	0117191AB	S-(+)-APOMORPHINE	LH812IV7LI						Amyotrophic lateral sclerosis	5786		
clenbuterol	Treatment of amyotrophic lateral sclerosis	clenbuterol		Spiropent	10/2/18	Designated			N/A	N/A	Duke University Medical Center	Department of Pediatrics	North Carolina	27710	USA	EXACT	0074497AA	clenbuterol	XTZ6AXU7KN						Amyotrophic lateral sclerosis	5786		
humanized IgG1 anti-serum amyloid A monoclonal antibody	Treatment of AA amyloidosis and AL amyloidosis	NEOD001		n/a	2/17/12	Designated			N/A	N/A	Prothena Therapeutics Limited	Dublin 2			Ireland	EXACT	0112523AB	NEOD001	VXQ2SK8I3P						AL amyloidosis	5797		
carboxy pyrrolidine hexanoyl pyrrolidine carboxylate	Treatment of AL amyloidosis	MIRIDESAP		n/a	2/10/15	Designated			N/A	N/A	"Glaxo Group Limited, England d/b/a GlaxoSmithKline"				United Kingdom	EXACT	0804353AA	MIRIDESAP	WO97N24A47						AL amyloidosis	5797		
"N-(3,4-dihydroxyphenyl)-3,4-dihydroxybenzamide"	Treatment of AL Amyloidosis	PTI-110		n/a	10/15/14	Designated			N/A	N/A	"ProteoTech, Inc."	Kirkland	Washington	98034	USA	EXACT	1577146AA	PTI-110	YI3H6V056C						AL amyloidosis	5797		
monoclonal antibody 11-1F4	For use as a therapeutic agent for patients AL amyloidosis.	CAEL-101		n/a	12/11/09	Designated			N/A	N/A	"Alan Solomon, M.D."	Knoxville	Tennessee	37920	USA										AL amyloidosis	5797		
"4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol"	Treatment of Angelman syndrome.	GABOXADOL		n/a	9/6/16	Designated			N/A	N/A	Ovid Therapeutics	New York	New York	10036	USA	EXACT	0306876AA	GABOXADOL	K1M5RVL18S						Angelman syndrome	5810		
recombinant adeno-associated virus serotype 9 vector containing the transgene UBE3A encoding for ubiquitin protein ligase E3A/E6-AP	Treatment of Angelman Syndrome.	recombinant adeno-associated virus serotype 9 vector containing the transgene UBE3A encoding for ubiquitin protein ligase E3A/E6-AP		n/a	10/29/15	Designated			N/A	N/A	"Agilis Biotherapeutics, LLC"	Cambridge	Massachusetts	2142	USA	LONGEST CONTAINS	0087274AA	protein							Angelman syndrome	5810		
antisense oligonucleotide specific to the antisense transcript of UBE3A	Treatment of Angelman Syndrome	antisense oligonucleotide specific to the antisense transcript of UBE3A		n/a	3/15/18	Designated			N/A	N/A	"GeneTx Biotherapeutics, LLC"	1918 Sweetbriar Lane		60561	USA										Angelman syndrome	5810		
[(4-benzylpiperazin-1-yl)(2-(isopentylamino)pyridin-3-yl)methanone]-phosphate	Treatment of Angelman Syndrome	NSI-189 PHOSPHATE		n/a	8/7/18	Designated			N/A	N/A	"Neuralstem, Inc."	20271 Goldenrod Lane	Maryland	20876	USA	EXACT	0894724AA	NSI-189 PHOSPHATE	HX0VO60T62						Angelman syndrome	5810		
ataluren	Treatment of aniridia	ataluren		n/a	9/1/15	Designated			N/A	N/A	"PTC Therapeutics, Inc."	South Plainfield	New Jersey	7080	USA	EXACT	0317259AA	ataluren	K16AME9I3V						Aniridia	5816		
Lactic acid	"Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients."	Lactic acid		Aphthaid	6/29/99	Designated			N/A	N/A	"Frontier Pharmaceutical, Inc."	Farmingdale	New York	11735	USA	EXACT	0001536AA	Lactic acid	33X04XA5AT						Aphthous stomatitis	5834		
Thalidomide	"Treatment of severe recurrent aphthous stomatitis in severely, terminally immunocompromised patients."	Thalidomide		n/a	5/1/95	Designated			N/A	N/A	Celgene Corporation	Warren				EXACT	0007409AA	Thalidomide	4Z8R6ORS6L						Aphthous stomatitis	5834		
Etiocholanedione	Treatment of aplastic anemia.	Etiocholanedione		n/a	11/3/95	Designated			N/A	N/A	"SuperGen, Inc."	Dublin	California	94568	USA	EXACT	0164932AA	Etiocholanedione	213MVW2TZD						Aplastic anemia	5836		
"Interleukin-1 alpha, human recombinant"	For hematopoietic potentiation in aplastic anemia.	INTERLEUKIN-1.ALPHA.		n/a	6/17/91	Designated/Withdrawn			N/A	N/A	Immunex Corporation	Seattle	Washington	98101	USA	EXACT	0260639AA	INTERLEUKIN-1.ALPHA.	8666ZWZ3E1						Aplastic anemia	5836		
Molgramostim	Treatment of aplastic anemia.	Molgramostim		Leucomax	9/25/89	Designated/Withdrawn			N/A	N/A	Schering Corporation	Kenilworth	New Jersey	7033	USA	EXACT	0259541AA	Molgramostim	B321AL142J						Aplastic anemia	5836		
eltrombopag	Treatment of aplastic anemia	eltrombopag		Promacta	11/8/13	Designated/Approved	Approved for Orphan Indication	Treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.	8/26/14	8/26/21	Novartis Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0305511AA	eltrombopag	S56D65XJ9G						Aplastic anemia	5836		
allogeneic ex-vivo expanded placental adherent stromal cells	Treatment of Aplastic Anemia	allogeneic ex-vivo expanded placental adherent stromal cells		n/a	2/18/13	Designated			N/A	N/A	"Pluristem Therapeutics, Inc."	Haifa			Israel										Aplastic anemia	5836		
adult hemogenic endothelial cells	Treatment of aplastic anemia	adult hemogenic endothelial cells		n/a	5/27/15	Designated			N/A	N/A	HemoGenyx LLC	Buffalo	New York	14203	USA										Aplastic anemia	5836		
mRNA encoding human argininosuccinate lyase	Treatment of argininosuccinate lyase deficiency	mRNA encoding human argininosuccinate lyase		n/a	9/18/17	Designated			N/A	N/A	"PhaseRx, Inc."	Seattle	Washington	98119	USA	EXACT	0182525AA	oxaliplatin	04ZR38536J						Argininosuccinate lyase deficiency	5843		
2-amino-3-[3-[[4-(2-pyridyloxymethyl)phenyl]methyl]isoxazol-5-yl]pyridin-1-ium-1-yl]methyl hydrogen phosphate	Treatment of invasive aspergillosis	APX-001		n/a	10/26/16	Designated			N/A	N/A	"Amplyx Pharmaceuticals, Inc."	San Diego	California	92130	USA	EXACT	1718429AA	APX-001	1XQ871489P						Aspergillosis	5856		
isavuconazonium sulfate	Treatment of invasive aspergillosis	isavuconazonium sulfate		Cresemba	5/6/13	Designated/Approved	Approved for Orphan Indication	Treatment of invasive aspergillosis in patienst 18 years of age and older	3/6/15	3/6/22	Astellas Pharma Global Development Inc.	Northbrook	Illinois	60062	USA	EXACT	0914921AA	isavuconazonium sulfate	31Q44514JV						Aspergillosis	5856		
Posaconazole	Treatment of invasive aspergillosis	Posaconazole		Noxafil	10/4/16	Designated			N/A	N/A	"Merck, Sharp & Dohme Corp."	Whitehouse Station	New Jersey	8889	USA	EXACT	0216080AA	Posaconazole	6TK1G07BHZ						Aspergillosis	5856		
Amphotericin B inhalation powder	"Prevention of pulmonary fungal infections in patients at risk for aspergillosis due to immunosuppressive therapy including those receiving organ or stem cell transplants, or treated with chemotherapy or radiation for hematologic malignancies"	Amphotericin B inhalation powder		n/a	12/15/05	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	San Carlos	California	94070	USA	EXACT	0035881AA	Amphotericin B	7XU7A7DROE						Aspergillosis	5856		
Cyclo{-Asn-Leu-d-Phe-Al[(N5-acetyl-N5-hydroxy-Orn)-(N5-acetyl-N5-hydroxy-Orn)-(N5-hydroxy-Orn)]-} . Al(III)	Treatment of invasive aspergillosis.	VL-2397		n/a	12/29/15	Designated			N/A	N/A	Vical Incorporated	San Diego	California	92121	USA	EXACT	1247843AA	VL-2397	E39B3691TD						Aspergillosis	5856		
Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B)	Treatment of glioblastoma multiforme and anaplastic astrocytoma.	IODINE I-131 DERLOTUXIMAB BIOTIN		131ichtnt-1	2/12/99	Designated			N/A	N/A	"Peregrine Pharmaceuticals, Inc."	Tustin	California	92780	USA	EXACT	1114289AA	IODINE I-131 DERLOTUXIMAB BIOTIN	1724UJB90B						Anaplastic astrocytoma	5860		
KIT and PDGFR inhibitor	Treatment of glioblastoma multiforme and anaplastic astrocytomas	DCC-2618		n/a	8/7/17	Designated			N/A	N/A	"Deciphera Pharmaceuticals, LLC"	Waltham	Massachusetts	2451	USA	EXACT	1177113AA	DCC-2618	9XW757O13D						Anaplastic astrocytoma	5860		
betamethasone	Treatment of Ataxia Telangiectasia.	betamethasone		n/a	10/7/15	Designated			N/A	N/A	"Grace Therapeutics, LLC"	North Brunswick Township	New Jersey	8902	USA	EXACT	0025365AA	betamethasone	9842X06Q6M						Ataxia telangiectasia	5862		
N-Acetyl-Leucine	Treatment of Ataxia Telangiectasia	ACETYLLEUCINE		n/a	10/2/18	Designated			N/A	N/A	IntraBio Inc.	270 Devon Road	New Jersey	7670	USA	EXACT	0301019AA	ACETYLLEUCINE	K76S41V71X						Ataxia telangiectasia	5862		
Revimmune	Treatment of autoimmune hemolytic anemia.	Revimmune		n/a	2/18/11	Designated			N/A	N/A	Accentia Biopharmaceuticals	Tampa	Florida	33606	USA	EXACT	0045692AA	Revimmune	8N3DW7272P						Autoimmune hemolytic anemia	5870		
fostamatinib	Treatment of autoimmune hemolytic anemia (AIHA)	fostamatinib		n/a	1/31/18	Designated			N/A	N/A	"Rigel Pharmaceuticals, INc."	1180 Veterans Blvd	South San Francisco	94080	USA	EXACT	0309933AA	fostamatinib	SQ8A3S5101						Autoimmune hemolytic anemia	5870		
"humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s (C1s)"	Treatment of autoimmune hemolytic anemia (AIHA)	TNT-009		n/a	7/27/16	Designated			N/A	N/A	"True North Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	1799617AA	TNT-009	GNWE7KJ995						Autoimmune hemolytic anemia	5870		
naltrexone	Treatment of autoimmune hepatitis	naltrexone		n/a	1/13/15	Designated			N/A	N/A	"TaiwanJ Pharmaceuticals Co., Ltd."	"Chutung, Hsinchu"			Taiwan	EXACT	0057249AA	naltrexone	5S6W795CQM						Autoimmune hepatitis	5871		
Synthetic PreImplantation Factor (H-Met-Val-Arg-Ile-Lys-Pro-Gly-Ser-Ala-Asn-Lys-Pro-Ser-Asp-Asp-OH	Treatment of autoimmune hepatitis (AIH)	Synthetic PreImplantation Factor (H-Met-Val-Arg-Ile-Lys-Pro-Gly-Ser-Ala-Asn-Lys-Pro-Ser-Asp-Asp-OH		Spif	11/22/17	Designated			N/A	N/A	"BioIncept, LLC"	140 East 40th Street	New York	10016	USA	LONGEST CONTAINS	1305255AA	Synthetic PreImplantation Factor	3K6A6FJ98O						Autoimmune hepatitis	5871		
cannabidiol	Treatment of autoimmune hepatitis	cannabidiol		n/a	6/25/18	Designated			N/A	N/A	Revive Therapeutics Ltd.	5 Director Court	Ontario		Canada	EXACT	0027441AA	cannabidiol	19GBJ60SN5						Autoimmune hepatitis	5871		
Tositumomab and iodine I 131 tositumomab	Treatment of non-Hodgkin's B-cell lymphoma.	Tositumomab		Bexxar	5/16/94	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy"	6/27/03	6/27/10	GlaxoSmithKline LLC	Wilmington	Delaware	19808	USA	EXACT	0248862AA	Tositumomab	0343IGH41U						B-cell lymphoma	5877		
5'-CTATCTGUC*G1TTCTCTGU-3'.17 Na+	Treatment of diffuse large B-cell lymphoma.	BAZLITORAN SODIUM		n/a	3/31/15	Designated			N/A	N/A	"Idera Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	1153317AA	BAZLITORAN SODIUM	1NLR4WAG4U						B-cell lymphoma	5877		
ibrutinib	Treatment of diffuse large B-cell lymphoma	ibrutinib		n/a	10/23/13	Designated			N/A	N/A	"Pharmacyclics, LLC"	Sunnyvale	California	94085	USA	EXACT	0625092AA	ibrutinib	1X70OSD4VX						B-cell lymphoma	5877		
Rosomidnar	Treatment of diffuse large B-cell lymphoma.	Rosomidnar		n/a	3/10/16	Designated/Withdrawn			N/A	N/A	"ProNAi Therapeutics, Inc."	Plymouth	Michigan	48170	USA	EXACT	1257643AA	Rosomidnar	2X4LQG2T5U						B-cell lymphoma	5877		
"(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide"	Treatment of diffuse large B-cell lymphoma	Selinexor		n/a	5/14/14	Designated			N/A	N/A	"Karyopharm Therapeutics, Inc."	Natick	Massachusetts	1760	USA	EXACT	0899718AA	Selinexor	31TZ62FO8F						B-cell lymphoma	5877		
C24H28N8O7S2	Treatment of diffuse large B-cell lymphoma (DLBCL).	CUDC-907		n/a	4/2/15	Designated			N/A	N/A	"Curis, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0836146AA	CUDC-907	3S9RX35S5X						B-cell lymphoma	5877		
rituximab	Treatment of non-Hodgkin's B-cell lymphoma	rituximab		Rituxan	6/13/94	Designated/Approved	Approved for Orphan Indication		11/26/97	11/26/04	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0225149AA	rituximab	4F4X42SYQ6						B-cell lymphoma	5877		
Rituximab/hyaluronidase	Treatment of diffuse large B-cell lymphoma	Rituximab 		Rituxan	9/7/16	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0225149AA	Rituximab	4F4X42SYQ6						B-cell lymphoma	5877		
blinatumomab	"Treatment of indolent B-cell lymphoma, excluding CLL and NHL with CNS involvement"	blinatumomab		n/a	2/6/06	Designated			N/A	N/A	"Amgen, Inc."	Thousand Oaks	California			EXACT	0322758AA	blinatumomab	4FR53SIF3A						B-cell lymphoma	5877		
daratumumab	Treatment of diffuse large B-cell lymphoma.	daratumumab		Humax (R) - Cd38	11/9/15	Designated			N/A	N/A	"Janssen Research and Development, LLC"	Spring hOuse	Pennsylvania	19477	USA	EXACT	0432519AA	daratumumab	4Z63YK6E0E						B-cell lymphoma	5877		
miltefosine	Topical treatment of cutaneous lymphoma encompassing cutaneous manifestations of T-cell lymphoma and B-cell lymphoma	miltefosine		Miltex/Impavido	3/18/09	Designated			N/A	N/A	ExperGen Drug Development GmbH				Austria	EXACT	0273734AA	miltefosine	53EY29W7EC						B-cell lymphoma	5877		
Valproic acid	Treatment of diffuse large B-cell lymphoma	Valproic acid		n/a	3/30/17	Designated			N/A	N/A	Valcuria AB	Lund			Sweden	EXACT	0016546AA	Valproic acid	614OI1Z5WI						B-cell lymphoma	5877		
"3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride"	Treatment of diffuse large B-cell lymphoma	CC-122 HYDROCHLORIDE		n/a	9/19/16	Designated			N/A	N/A	Celgene Corporation	Berkeley Heights	New Jersey	7922	USA	EXACT	0926830AA	CC-122 HYDROCHLORIDE	6CX4AEX3KR						B-cell lymphoma	5877		
"6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridine-3-one monocitrate"	Treatment of diffuse large B-cell lymphoma	TAK-659		n/a	2/14/17	Designated			N/A	N/A	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0893072AA	TAK-659	6ZJ8V3Q0H1						B-cell lymphoma	5877		
Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through a protease cleavable valine-alanine linker	Treatment of diffuse large B-cell lymphoma	ADCT-402		n/a	6/8/17	Designated			N/A	N/A	ADC Therapeutics SA	Epalinges			Switzerland	EXACT	0112432AB	ADCT-402	7K5O7P6QIU						B-cell lymphoma	5877		
brentuximab vedotin	Treatment of patients with diffuse large B-cell lymphoma.	brentuximab vedotin		Adcetris(R)	1/31/14	Designated			N/A	N/A	"Seattle Genetics, Inc."	Bothell	Washington	98021	USA	EXACT	0297767AA	brentuximab vedotin	7XL5ISS668						B-cell lymphoma	5877		
Rituximab/hyaluronidase	Treatment of diffuse large B-cell lymphoma	hyaluronidase		Rituxan	9/7/16	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0004944AA	hyaluronidase	8KOG53Z5EM						B-cell lymphoma	5877		
bendamustine for 50ml admixture	"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)"	bendamustine for 50ml admixture		Bendeka	7/2/14	Designated/Approved	Approved for Orphan Indication	Treatment of patients with CLL and treatment of patients with indolent B-cell NHL	12/7/15	N/A	"Eagle Pharmaceuticals, Inc."	Woodcliff Lake	New Jersey	7677	USA	EXACT	0304245AA	bendamustine	9266D9P3PQ						B-cell lymphoma	5877		
"4, 5 dibromorhodamine methyl ester"	Treatment of diffuse large B-cell lymphoma	TH-9402 FREE BASE		Theralux Photodynamic Therapy	10/30/08	Designated			N/A	N/A	"Kiadis Pharma Canada, Inc."				Canada	EXACT	0807454AA	TH-9402 FREE BASE	934QHK1OOK						B-cell lymphoma	5877		
bendamustine hydrochloride	"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)"	bendamustine hydrochloride		Treanda	11/26/13	Designated/Approved	Approved for Orphan Indication	Treatment of Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.	10/31/08	10/31/15	"Cephalon, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0249241AA	bendamustine hydrochloride	981Y8SX18M						B-cell lymphoma	5877		
everolimus	Treatment of diffuse large B-cell lymphoma	everolimus		n/a	6/2/14	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0218031AA	everolimus	9HW64Q8G6G						B-cell lymphoma	5877		
mocetinostat	Treatment of diffuse large B-cell lymphoma	mocetinostat		n/a	8/7/14	Designated			N/A	N/A	"Mirati Therapeutics, Inc."	San Diego	California	92121	USA	EXACT	0323115AA	mocetinostat	A6GWB8T96J						B-cell lymphoma	5877		
pralatrexate	Treatment of diffuse large B-cell lymphoma	pralatrexate		n/a	10/20/08	Designated			N/A	N/A	"Allos Therapeutics, Inc."	Westminister	Colorado	80020	USA	EXACT	0219034AA	pralatrexate	A8Q8I19Q20						B-cell lymphoma	5877		
lenalidomide	Treatment of diffuse large B-cell lymphoma	lenalidomide		Revlimid	3/28/11	Designated			N/A	N/A	Celgene Corporation	Summit	New Jersey	7901	USA	EXACT	0236099AA	lenalidomide	F0P408N6V4						B-cell lymphoma	5877		
Ublituximab in combination with phosphoinositide-3-kinase (PI3K) delta inhibitor	Treatment of diffuse large B-cell lymphoma	TGR-1202		n/a	1/19/17	Designated			N/A	N/A	"TG Therapeutics, Inc."	New York	New York	10014	USA	EXACT	1085047AA	TGR-1202	FU8XW5V3FS						B-cell lymphoma	5877		
Tositumomab and iodine I 131 tositumomab	Treatment of non-Hodgkin's B-cell lymphoma.	Tositumomab and iodine I 131 tositumomab		Bexxar	5/16/94	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy"	6/27/03	6/27/10	GlaxoSmithKline LLC	Wilmington	Delaware	19808	USA	EXACT	0248873AA	iodine I 131 tositumomab	K1KT5M40JC						B-cell lymphoma	5877		
Polatuzumab vedotin	Treatment of diffuse large B-cell lymphoma	Polatuzumab vedotin		n/a	12/12/16	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0804046AA	Polatuzumab vedotin	KG6VO684Z6						B-cell lymphoma	5877		
"4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide"	Treatment of diffuse large B-cell lymphoma.	VENETOCLAX		n/a	3/27/14	Designated			N/A	N/A	AbbVie	North Chicago	Illinois	60064	USA	EXACT	0790283AA	VENETOCLAX	N54AIC43PW						B-cell lymphoma	5877		
tisagenlecleucel-T	Treatment of diffuse large B-cell lymphoma	tisagenlecleucel-T		n/a	2/3/15	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	1058760AA	tisagenlecleucel-T	Q6C9WHR03O						B-cell lymphoma	5877		
"6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-2'H-spiro[cyclohexane-1,3'-imidazo[1,5a]pyridine]-1',5'-dione hydrochloride"	Treatment of diffuse large B-cell lymphoma	eft-508		n/a	2/23/17	Designated			N/A	N/A	eFFECTOR Therapeutics	San Diego	California	92121	USA	EXACT	1200891AA	eft-508	U2H19X4WBV						B-cell lymphoma	5877		
Ublituximab in combination with phosphoinositide-3-kinase (PI3K) delta inhibitor	Treatment of diffuse large B-cell lymphoma	Ublituximab		n/a	1/19/17	Designated			N/A	N/A	"TG Therapeutics, Inc."	New York	New York	10014	USA	EXACT	0574607AA	Ublituximab	U59UGK3IPC						B-cell lymphoma	5877		
enzastaurin	Treatment of diffuse large B-cell lymphoma	enzastaurin		n/a	3/4/09	Designated			N/A	N/A	Denovo Biopharma LLC	San Diego	California	92121	USA	EXACT	0309955AA	enzastaurin	UC96G28EQF						B-cell lymphoma	5877		
maytansinoid-conjugated humanized monoclonal antibody against CD37	Treatment of diffuse large B-cell lymphoma	NARATUXIMAB EMTANSINE		n/a	5/12/16	Designated			N/A	N/A	"ImmunoGen, Inc."	Waltham	Massachusetts	2451	USA	EXACT	1250993AA	NARATUXIMAB EMTANSINE	WE1X5A83B9						B-cell lymphoma	5877		
humanized Fc engineered monoclonal antibody against CD19	Treatment of diffuse large B-cell lymphoma.	MOR-208		n/a	12/1/14	Designated			N/A	N/A	MorphoSys AG				Germany	EXACT	1804597AA	MOR-208	QQA9MLH692						B-cell lymphoma	5877		
human IgG4-based anti-CD20 x anti-CD3 bispecific monoclonal antibody	Treatment of diffuse large b-cell lymphoma.	REGN-1979		n/a	6/6/17	Designated			N/A	N/A	"Regeneron Pharmaceuticals, Inc."	Tarrytown	New York	10591	USA	EXACT	0112214AB	REGN-1979							B-cell lymphoma	5877		
Monoclonal antibodies (murine or human) to B-cell lymphoma	Treatment of B-cell lymphoma.	Monoclonal antibodies (murine or human) to B-cell lymphoma		n/a	5/6/86	Designated/Withdrawn			N/A	N/A	IDEC Pharmaceuticals Corporation	San Diego	California	92121	USA										B-cell lymphoma	5877		
Iodine I 131 Lym-1 Monoclonal Antibody	Treatment of B-cell lymphoma.	Iodine I 131 Lym-1 Monoclonal Antibody		n/a	11/2/87	Designated/Withdrawn			N/A	N/A	Lederle Laboratories Division	Pearl River	New York	10965	USA	LONGEST CONTAINS	0049183AA	Iodine	9679TC07X4						B-cell lymphoma	5877		
Ricin (blocked) conjugated murine MCA (anti-B4)	Treatment of B-cell leukemia and B-cell lymphoma.	Ricin (blocked) conjugated murine MCA (anti-B4)		n/a	11/17/88	Designated/Withdrawn			N/A	N/A	"ImmunoGen, Inc."	Cambridge	Massachusetts	2139	USA	LONGEST CONTAINS	0811450AA	Ricin	U6E7R9OE4R						B-cell lymphoma	5877		
Iodine I 131 murine monoclonal antibody IgG2a to B cell	Treatment of B-cell leukemia and B-cell lymphoma.	Iodine I 131 murine monoclonal antibody IgG2a to B cell		"Immurait, Ll-2-I-131"	9/18/89	Designated/Withdrawn			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA	LONGEST CONTAINS	0049183AA	Iodine	9679TC07X4						B-cell lymphoma	5877		
Technetium Tc99m murine monoclonal antibody (IgG2a) to B cell	"Diagnostic imaging in the evaluation of the extent of disease in patients with histologically confirmed diagnosis of non-Hodgkin's B-cell lymphoma, acute B-cell lymphoblastic leukemia (in children and adults), and chronic B-cell lymphocytic leukemia."	Technetium Tc99m murine monoclonal antibody (IgG2a) to B cell		Lymphoscan	4/7/92	Designated			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA										B-cell lymphoma	5877		
autologous peripheral blood T lymphocytes transduced with retroviral vector containing anti CD19 CD28/CD3 zeta chimeric antigen receptor	Treatment of diffuse large B-cell lymphoma.	autologous peripheral blood T lymphocytes transduced with retroviral vector containing anti CD19 CD28/CD3 zeta chimeric antigen receptor		n/a	3/27/14	Designated			N/A	N/A	"Kite Pharma, Inc."	Santa Monica	California	90404	USA	LONGEST CONTAINS	0263092AA	lymphocytes							B-cell lymphoma	5877		
autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor	Treatment of primary mediastinal B-cell lymphoma.	autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor		n/a	4/20/16	Designated			N/A	N/A	"Kite Pharma, Inc."	Santa Monica	California	90404	USA	LONGEST CONTAINS	1722709AA	CD19	IYZ9TI08W3						B-cell lymphoma	5877		
autologous CD4+/CD8+ T cells expressing a CD19 chimeric antigen receptor and truncated epidermal growth factor receptor	Treatment of diffuse large B-cell lymphoma	autologous CD4+/CD8+ T cells expressing a CD19 chimeric antigen receptor and truncated epidermal growth factor receptor		n/a	4/27/16	Designated			N/A	N/A	"Juno Therapeutics, Inc."	Seattle	Washington	98109	USA	LONGEST CONTAINS	1309962AA	epidermal growth factor receptor	RO03J093CP						B-cell lymphoma	5877		
lisocabtagene maraleucel	Treatment of primary mediastinal large B-cell lymphoma	lisocabtagene maraleucel		n/a	7/12/18	Designated			N/A	N/A	"Juno Therapeutics, Inc."	a Celegne Company	Washington	98109	USA	EXACT	0114154AB	lisocabtagene maraleucel	7K2YOJ14X0						B-cell lymphoma	5877		
elamipretide	Treatment of Barth syndrome	elamipretide		Bendavia™	3/22/18	Designated			N/A	N/A	Stealth BioTherapeutics	275 Grove Street	Suite 3-107	2466	USA	EXACT	1115146AA	elamipretide	87GWG91S09						Barth syndrome	5890		
bezafibrate	For therapeutic treatment of Barth syndrome	bezafibrate		Bezalip	7/24/13	Designated			N/A	N/A	"Barth Sydrome Foundation, Inc."	Larchmont	New York	10538	USA	EXACT	0065394AA	bezafibrate	Y9449Q51XH						Barth syndrome	5890		
givinostat	Treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy	givinostat		n/a	4/12/13	Designated			N/A	N/A	Italfarmaco SpA				Italy	EXACT	0338341AA	givinostat	5P60F84FBH						Becker muscular dystrophy	5900		
L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal	Treatment of Duchenne and Becker muscular dystrophy	L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal		n/a	1/18/06	Designated			N/A	N/A	CepTor Corporation	Hunt Valley	Maryland	21030	USA	EXACT	0736856AA	L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal	BK727F83NO						Becker muscular dystrophy	5900		
Vasomera	"Treatment of cardiomyopathy associated with dystrophinopathies; Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy BMD), and X-linked dilated cardiomyopathy (XL-dCMP)."	Vasomera		n/a	11/19/15	Designated			N/A	N/A	"PhaseBio Pharmaceuticals, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	1267045AA	Vasomera	200AW54D93						Becker muscular dystrophy	5900		
Botulinum toxin type A	Treatment of essential blepharospasm.	Botulinum toxin type A		Dysport	3/23/89	Designated			N/A	N/A	"Porton International, Inc."	Washington	District of Columbia	20005	USA	EXACT	0171595AA	Botulinum toxin type A	E211KPY694						Essential Blepharospasm	5909		
	Treatment of essential blepharospasm.	DYSPORT		Dysport(R)	12/5/91	Designated			N/A	N/A	"Ipsen Biopharmaceuticals, Inc."	Basking Ridge	New Jersey	7920	USA	EXACT	0265690AA	DYSPORT	E211KPY694						Essential Blepharospasm	5909		
merestinib	Treatment of biliary tract cancer	merestinib		n/a	4/10/17	Designated			N/A	N/A	Eli Lilly and Company	Indianapolis	Indiana	46285	USA	EXACT	0342201AA	merestinib	5OGS5K699E						Biliary tract cancer	5924		
sodium 2-hydroxylinoleate	Treatment of biliary tract cancer	sodium 2-hydroxylinoleate		n/a	9/27/18	Designated			N/A	N/A	"Ability Pharmaceuticals, SL"	Edifici Eureka			Spain	EXACT	1718190AA	sodium 2-hydroxylinoleate	X1840C8161						Biliary tract cancer	5924		
Recombinant human superoxide dismutase	Prevention of bronchopulmonary dysplasia in premature neonates weighing less than 1500 grams.	ledismase		Oxsodrol	4/18/91	Designated/Withdrawn			N/A	N/A	"Savient Pharmaceuticals, Inc."	East Brunswick	New Jersey	8816	USA	EXACT	0156467AA	ledismase	0786H5RV0T						Bronchopulmonary dysplasia	5962		
Water-miscible vitamin A palmitate	Prevention of bronchopulmonary dysplasia.	Water-miscible vitamin A palmitate		Aquasol A Parenteral	3/26/10	Designated			N/A	N/A	"Fox Pharma, Inc."	Doylestown	Pennsylvania	18902	USA	EXACT	0013901AA	vitamin A palmitate	1D1K0N0VVC						Bronchopulmonary dysplasia	5962		
vitamin A palmitate	Prevention of bronchopulmonary dysplasia.	vitamin A palmitate		n/a	7/14/15	Designated			N/A	N/A	"Advent Therapeutics, Inc."	Lumberville	Pennsylvania	18933	USA	EXACT	0013901AA	vitamin A palmitate	1D1K0N0VVC						Bronchopulmonary dysplasia	5962		
Retinol palmitate	Prevention of bronchopulmonary dysplasia.	Retinol palmitate		n/a	8/8/16	Designated			N/A	N/A	"Phillipp Heinrich Novak, DVM, MSc"	Ried im Innkreis			Austria	EXACT	0013901AA	Retinol palmitate	1D1K0N0VVC						Bronchopulmonary dysplasia	5962		
Secretory leukocyte protease inhibitor	Treatment of bronchopulmonary dysplasia.	Secretory leukocyte protease inhibitor		n/a	6/30/92	Designated			N/A	N/A	"Synergen, Inc."	Boulder	Colorado	80301	USA	EXACT	0259972AA	Secretory leukocyte protease inhibitor	909E17P4ZW						Bronchopulmonary dysplasia	5962		
Recombinant human alpha 1-antitrypsin	Prevention of bronchopulmonary dysplasia	.ALPHA.1-PROTEINASE INHIBITOR (HUMAN)		n/a	4/28/05	Designated			N/A	N/A	"Arriva Pharmaceuticals, Inc."	Alameda	California	94501	USA	EXACT	0334770AA	.ALPHA.1-PROTEINASE INHIBITOR (HUMAN)	F43I396OIS						Bronchopulmonary dysplasia	5962		
Recombinant human Clara Cell 10kDa protein	Prevention of neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome.	UTEROGLOBIN		n/a	7/13/98	Designated			N/A	N/A	"Therabron Therapeutics, Inc."	Rockville	Maryland	20850	USA	EXACT	0112021AB	UTEROGLOBIN	95O4MMG4LJ						Bronchopulmonary dysplasia	5962		
Lucinactant	Treatment of bronchopulmonary dysplasia in premature infants.	Lucinactant		Surfaxin	10/21/05	Designated			N/A	N/A	"Windtree Therapeutics, Inc."	Warrington	Pennsylvania	18976	USA	EXACT	0727402AA	Lucinactant							Bronchopulmonary dysplasia	5962		
Lucinactant	Prevention of bronchopulmonary dysplasia in premature infants	Lucinactant		Surfaxin	5/23/06	Designated			N/A	N/A	"Windtree Therapeutics, Inc."	Warrington	Pennsylvania	18976	USA	EXACT	0727402AA	Lucinactant							Bronchopulmonary dysplasia	5962		
recombinant human surfactant protein D	Prevention of bronchopulmonary dysplasia	AT-100		n/a	6/23/14	Designated			N/A	N/A	Airway Therapeutics LLC	Cincinnati	Ohio	45219	USA	EXACT									Bronchopulmonary dysplasia	5962		
recombinant fragment human surfactant protein-D	Prevention of bronchopulmonary dysplasia	recombinant fragment human surfactant protein-D		n/a	11/1/17	Designated			N/A	N/A	Trimunocor Ltd.	2 Victoria Road			United Kingdom	LONGEST CONTAINS	0087274AA	protein							Bronchopulmonary dysplasia	5962		
human umbilical cord blood-derived mesenchymal stem cells	Prevention of bronchopulmonary dysplasia	human umbilical cord blood-derived mesenchymal stem cells		Pneumostem	11/26/13	Designated			N/A	N/A	"MEDIPOST America, Inc."	Rockville		20850	USA	LONGEST CONTAINS	0854240AA	human umbilical cord blood	PVH8394DLN						Bronchopulmonary dysplasia	5962		
canakinumab	Treatment of familial mediterranean fever	canakinumab		Ilaris	12/5/13	Designated/Approved	Approved for Orphan Indication	Indicated for Familial Mediterranean Fever (FMF) in adult and pediatric patients	9/23/16	9/23/23	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0323159AA	canakinumab	37CQ2C7X93						Mediterranean fever	5966		
rilonacept	Treatment of familial Mediterranean fever	rilonacept		Arcalyst	1/9/13	Designated			N/A	N/A	"Philip J Hashkes, MD, MSc."	Cleveland	Ohio	44195	USA	EXACT	0264119AA	rilonacept	8K80YB5GMG						Mediterranean fever	5966		
colchicine	Treatment of familial Mediterranean fever	colchicine		Colcrys	9/25/07	Designated/Approved	Approved for Orphan Indication	Treatment of familial Mediterranean fever	7/29/09	7/29/16	"AR Holding Company, Inc."	Philadelphia	Pennsylvania	19124	USA	EXACT	0011314AA	colchicine	SML2Y3J35T						Mediterranean fever	5966		
"humanized IgG4 Monoclonal Antibody against total complement component 1, subcomponent s (C1s)"	Treatment of bullous pemphigoid (BP).	TNT-009		n/a	8/17/17	Designated			N/A	N/A	"True North Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	1799617AA	TNT-009	GNWE7KJ995						Bullous pemphigoid	5972		
bertilimumab	Treatment of bullous pemphigoid	bertilimumab		n/a	8/17/18	Designated			N/A	N/A	"Immune Pharmaceuticals, Inc."	430 East 29th Street	New York	10016	USA	EXACT	1200868AA	bertilimumab	60879E4NED						Bullous pemphigoid	5972		
human monoclonal antibody directed against active plasma kallikrein	Treatment of hereditary angioedema (HAE)	Lanadelumab		n/a	11/26/13	Designated			N/A	N/A	Dyax Corporation	Burlington	Massachusetts	1803	USA	EXACT	1141964AA	Lanadelumab	2372V1TKXK						Hereditary angioedema	5979		
"C1-esterase-inhibitor, human, pasteurized"	Prevention and/or treatment of acute attacks of hereditary angioedema.	HUMAN C1-ESTERASE INHIBITOR		Berinert	10/16/92	Designated/Approved	Approved for Orphan Indication	Treatment of acute attacks of hereditary angioedema.	10/8/09	10/8/16	CSL Behring LLC	King of Prussia	Pennsylvania	19406	USA	EXACT	0322941AA	HUMAN C1-ESTERASE INHIBITOR	6KIC4BB60G						Hereditary angioedema	5979		
3-[2-(4-carbamimidoyl-phenylcarbamoyl)-5-methoxy-4-vinyl-phenyl]-6-(cyclopropylmethyl-carbamoyl)-pyridine-2-carboxylic acid	Prevention of acute attacks of angioedema in individuals with hereditary angioedema	AVORALSTAT		n/a	12/23/14	Designated			N/A	N/A	"BioCryst Pharmaceuticals, Inc."	Durham	North Carolina	27703	USA	EXACT	1120214AA	AVORALSTAT	UX17773O15						Hereditary angioedema	5979		
menaquinone	Treatment of calciphylaxis	menaquinone		Menaquinonegold	9/4/12	Designated			N/A	N/A	"Nu Science Trading, LLC"	Phoenix	Arizona	85022	USA	EXACT	1194758AA	menaquinone	12V8PA4WCH						Calciphylaxis	5980		
sodium thiosulfate	Treatment of uremic and non-uremic calciphylaxis	sodium thiosulfate		n/a	11/9/11	Designated			N/A	N/A	Hope Pharmaceuticals	Scottsdale	Arizona	85260	USA	EXACT	0053225AA	sodium thiosulfate	HX1032V43M						Calciphylaxis	5980		
Sodium Thiosulfate	Treatment of uremic and non-uremic calciphylaxis	Sodium Thiosulfate		n/a	2/16/12	Designated			N/A	N/A	"Luitpold Pharmaceuticals, Inc."	Norristown	Pennsylvania	19403	USA	EXACT	0053225AA	Sodium Thiosulfate	HX1032V43M						Calciphylaxis	5980		
sodium thiosulfate	Treatment of calciphylaxis	sodium thiosulfate		n/a	11/19/12	Designated			N/A	N/A	Edinburg BioQuarter	Edinburgh			United Kingdom	EXACT	0053225AA	sodium thiosulfate	HX1032V43M						Calciphylaxis	5980		
hexasodium phytate	Treatment of calciphylaxis	hexasodium phytate		n/a	12/2/12	Designated			N/A	N/A	"Laboratoris Sanifit, S.L."				Spain	EXACT	1120827AA	hexasodium phytate	ZBX50UG81V						Calciphylaxis	5980		
telotristat etiprate	Treatment of carcinoid syndrome in patients with neuroendocrine tumors	telotristat etiprate		n/a	3/9/12	Designated			N/A	N/A	"Lexicon Pharmaceuticals, Inc."	The Woodlands	Texas	77381	USA	EXACT	0569368AA	telotristat etiprate	3T25U84H4U						Carcinoid syndrome	5994		
lanreotide acetate	Treatment of symptoms associated with carcinoid syndrome	lanreotide acetate		n/a	9/8/11	Designated			N/A	N/A	"Ipsen Biopharmaceuticals, Inc."	Basking Ridge	New Jersey	7920	USA	EXACT	0169517AA	lanreotide acetate	IEU56G3J9C						Carcinoid syndrome	5994		
"(RS)-baclofen, naltrexone and D-sorbitol"	Treatment of Charcot-Marie-Tooth disease type 1A	 D-sorbitol		n/a	3/17/14	Designated			N/A	N/A	Pharnext SA				France	EXACT	0007614AA	D-sorbitol	506T60A25R						Charcot-Marie-Tooth disease	6034		
"(RS)-baclofen, naltrexone and D-sorbitol"	Treatment of Charcot-Marie-Tooth disease type 1A	"(RS)-baclofen, naltrexone and D-sorbitol"		n/a	3/17/14	Designated			N/A	N/A	Pharnext SA				France	exact	0057249AA	naltrexone	5S6W795CQM						Charcot-Marie-Tooth disease	6034		
"(RS)-baclofen, naltrexone and D-sorbitol"	Treatment of Charcot-Marie-Tooth disease type 1A	BACLOFEN		n/a	3/17/14	Designated			N/A	N/A	Pharnext SA				France	EXACT	0032804AA	BACLOFEN	H789N3FKE8						Charcot-Marie-Tooth disease	6034		
ascorbic acid	Treatment of Charcot-Marie-Tooth disease type 1A.	ascorbic acid		n/a	5/11/09	Designated			N/A	N/A	Murigenetics SAS				France	EXACT	0007658AA	ascorbic acid	PQ6CK8PD0R						Charcot-Marie-Tooth disease	6034		
Dynamine	Treatment of hereditary motor and sensory neuropathy type I (Charcot-Marie-Tooth disease).	Dynamine		n/a	10/16/91	Designated			N/A	N/A	Mayo Foundation	Rochester	Minnesota	55905	USA	EXACT	0144445AA	Dynamine	RU4S6E2G0J						Charcot-Marie-Tooth disease	6034		
urea	"Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis)."	urea		n/a	11/7/11	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0009290AA	urea	8W8T17847W						CHILD syndrome	6039		
oral potent and selective antagonist	Treatment of patients with chondrosarcoma.	Saridegib		n/a	2/18/11	Designated/Withdrawn			N/A	N/A	"Infinity Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0566449AA	Saridegib	JT96FPU35X						Chondrosarcoma	6055		
"aadeno-associated viral vector, serotype 2, containing the human choroideremia gene encoding human Rab escort protein 1"	Treatment of choroideremia due to mutations in the human choroideremia gene (CHM)	"aadeno-associated viral vector, serotype 2, containing the human choroideremia gene encoding human Rab escort protein 1"		n/a	9/12/13	Designated			N/A	N/A	"Sparks Therapeutics, Inc."	Philadelphia	Pennsylvania	19104	USA	LONGEST CONTAINS	0087274AA	protein							Choroideremia	6061		
adeno-associated viral vector serotype 2 containing the human Rab escort protein 1 gene	Treatment of choroideremia	adeno-associated viral vector serotype 2 containing the human Rab escort protein 1 gene		n/a	11/5/14	Designated			N/A	N/A	NightstaRx Ltd.	London			United Kingdom	LONGEST CONTAINS	0087274AA	protein							Choroideremia	6061		
adeno-associated virus (AAV2) capsid variant carrying a transgene encoding a codon-optimized human choroideremia (CHM) gene	Treatment of choroideremia (CHM)	adeno-associated virus (AAV2) capsid variant carrying a transgene encoding a codon-optimized human choroideremia (CHM) gene		n/a	10/12/17	Designated			N/A	N/A	"4D Molecular Therapeutics, Inc."	Emeryville	California	94608	USA	LONGEST CONTAINS	0112841AB	AAV2	YA02LE18L3						Choroideremia	6061		
Interferon gamma 1-b	Treatment of chronic granulomatous disease.	Interferon gamma-1b		Actimmune	9/30/88	Designated/Approved	Approved for Orphan Indication		12/20/90	12/20/97	Horizon Pharma Ireland Limited				Ireland	EXACT	0174812AA	Interferon gamma-1b	21K6M2I7AG						Chronic granulomatous disease	6100		
T-cell depleted stem cell enriched cellular product from peripheal b lood stem cells	Treatment of chronic granulomatous disease	T-cell depleted stem cell enriched cellular product from peripheal b lood stem cells		n/a	11/1/01	Designated			N/A	N/A	Nexell Therapeutics Inc.	Irvine	California	92618	USA	LONGEST CONTAINS	0264620AA	stem cells							Chronic granulomatous disease	6100		
fingolimod	Treatment of chronic inflammatory demyelinating polyneuropathy	fingolimod		n/a	4/30/10	Designated			N/A	N/A	Novartis Pharmaceutical Corporation	East Hanover	New Jersey	7936	USA	EXACT	0301757AA	fingolimod	3QN8BYN5QF						Chronic inflammatory demyelinating polyneuropathy	6102		
Immune Globulin (Human)	Treatment of chronic inflammatory demyelinating polyneuropathy	Immune Globulin (Human)		Gamunex(R)-C	7/27/04	Designated/Approved	Approved for Orphan Indication	Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse	9/12/08	9/12/15	"Grifols Therapeutics, Inc."	Clayton	North Carolina	27520	USA	EXACT	0232586AA	Immune Globulin (Human)	66Y330CJHS						Chronic inflammatory demyelinating polyneuropathy	6102		
"Immune Globulin Subcutaneous (Human), 20% Liquid"	Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)	HUMAN IMMUNOGLOBULIN G		Hizentra	8/18/14	Designated			N/A	N/A	CSL Behring	King of Prussia	Pennsylvania	19406	USA	EXACT	0201570AA	HUMAN IMMUNOGLOBULIN G	66Y330CJHS						Chronic inflammatory demyelinating polyneuropathy	6102		
immune globulin infusion 10% (human) with recombinant human hyaluronidase)	Treatment of chronic inflammatory demyelinating polyneuropathy	IVIG		n/a	3/31/16	Designated			N/A	N/A	"Baxalta US, Inc."	Westlake Village	California	91362	USA	EXACT	0201570AA	IVIG	66Y330CJHS						Chronic inflammatory demyelinating polyneuropathy	6102		
immune globulin infusion 10% (human) with recombinant human hyaluronidase)	Treatment of chronic inflammatory demyelinating polyneuropathy	HYALURONIDASE (HUMAN RECOMBINANT)		n/a	3/31/16	Designated			N/A	N/A	"Baxalta US, Inc."	Westlake Village	California	91362	USA	EXACT	0257670AA	HYALURONIDASE (HUMAN RECOMBINANT)	743QUY4VD8						Chronic inflammatory demyelinating polyneuropathy	6102		
recombinant multimerized human IgG1 Fc	Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).	GL-2045		n/a	7/14/15	Designated			N/A	N/A	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT									Chronic inflammatory demyelinating polyneuropathy	6102		
Inecalcitol	Treatment of chronic lymphocytic leukemia	Inecalcitol		n/a	5/14/14	Designated			N/A	N/A	"Hybrigenics, S.A."	Paris			France	EXACT	0220859AA	Inecalcitol	05FZV98342						Chronic lymphocytic leukemia	6104		
ibrutinib	Treatment of chronic lymphocytic leukemia (CLL).	ibrutinib		n/a	3/27/12	Designated/Withdrawn			N/A	N/A	"Pharmacyclics, LLC"	Sunnyvale	California	94085	USA	EXACT	0625092AA	ibrutinib	1X70OSD4VX						Chronic lymphocytic leukemia	6104		
ibrutinib	Treatment of chronic lymphocytic leukemia (CLL)	ibrutinib		Imbruvica	4/6/12	Designated/Approved	Approved for Orphan Indication	Indicated for the treatment of patients with chronic lymphocytic leukemia without 17p deletion who have not received at least one prior therapy (first line therapy).	3/4/16	3/4/23	"Pharmacyclics, LLC"	Sunnyvale	California	94085	USA	EXACT	0625092AA	ibrutinib	1X70OSD4VX						Chronic lymphocytic leukemia	6104		
ibrutinib	Treatment of chronic lymphocytic leukemia (CLL)	ibrutinib		Imbruvica	4/6/12	Designated/Approved	Approved for Orphan Indication	Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy	2/12/14	2/12/21	"Pharmacyclics, LLC"	Sunnyvale	California	94085	USA	EXACT	0625092AA	ibrutinib	1X70OSD4VX						Chronic lymphocytic leukemia	6104		
ibrutinib	Treatment of chronic lymphocytic leukemia (CLL)	ibrutinib		Imbruvica	4/6/12	Designated/Approved	Approved for Orphan Indication	Treatment of patients with chronic lymphocytic leukemia with 17p deletion who have not received at least one prior therapy	7/28/14	7/28/21	"Pharmacyclics, LLC"	Sunnyvale	California	94085	USA	EXACT	0625092AA	ibrutinib	1X70OSD4VX						Chronic lymphocytic leukemia	6104		
Fludarabine phosphate	"Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL."	Fludarabine phosphate		Fludara	4/18/89	Designated/Approved	Approved for Orphan Indication		4/18/91	4/18/98	"Berlex Laboratories, Inc."	Richmond	California	94804	USA	EXACT	0127479AA	Fludarabine phosphate	1X9VK9O1SC						Chronic lymphocytic leukemia	6104		
Fludarabine phosphate oral tablets	Treatment of B-cell chronic lymphocytic leukemia	Fludarabine phosphate oral tablets		n/a	12/18/07	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not responded to or has progressed during or after treatment with at least one standard alkylating-agent containing regimen	12/18/08	12/18/15	"Sanofi-Aventis U.S., Inc."	Bridgewater	New Jersey	8807	USA	EXACT	0127479AA	Fludarabine phosphate	1X9VK9O1SC						Chronic lymphocytic leukemia	6104		
humanized single chain monoclonal antibody(scFV: IgG1 hinge: IgG1 CH2 and CH3 domains)	Treatment of chronic lymphocytic leukemia	tru-016		n/a	11/17/11	Designated			N/A	N/A	"Emergent Product Development Seattle, LLC"	Seattle	Washington	98121	USA	EXACT	0907277AA	tru-016	2MZ3L2664T						Chronic lymphocytic leukemia	6104		
moxetumomab pasudotox	Treatment of CD22-positive chronic lymphocytic leukemia	moxetumomab pasudotox		n/a	11/15/07	Designated			N/A	N/A	"MedImmune, LLC"	Gaithersburg	Maryland	20878	USA	EXACT	0432520AA	moxetumomab pasudotox	2NDX4B6N8F						Chronic lymphocytic leukemia	6104		
milatuzumab	Treatment of chronic lymphocytic leukemia.	milatuzumab		n/a	6/24/08	Designated			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA	EXACT	0313213AA	milatuzumab	2OP4E0GC6V						Chronic lymphocytic leukemia	6104		
bendamustine hydrochloride with betadex sulfobutyl ether sodium	Treatment of chronic lymphocytic leukemia	bendamustine hydrochloride with betadex sulfobutyl ether sodium		n/a	9/10/13	Designated			N/A	N/A	"Supratek Pharma, Inc."	Quebec			Canada	EXACT	0209676AA	betadex sulfobutyl ether sodium	2PP9364507						Chronic lymphocytic leukemia	6104		
obatoclax mesylate	Treatment of chronic lymphocytic leukemia	obatoclax mesylate		n/a	10/8/04	Designated/Withdrawn			N/A	N/A	"Teva Branded Pharmaceutical Products R&D, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0252926AA	obatoclax mesylate	39200FJ43J						Chronic lymphocytic leukemia	6104		
Pentostatin	Treatment of patients with chronic lymphocytic leukemia.	Pentostatin		Nipent	1/29/91	Designated			N/A	N/A	"SuperGen, Inc."	San Ramon	California	94583	USA	EXACT	0067130AA	Pentostatin	395575MZO7						Chronic lymphocytic leukemia	6104		
alemtuzumab	Treatment of chronic lymphocytic leukemia.	alemtuzumab		Campath	10/20/97	Designated/Approved	Approved for Orphan Indication	The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy.	5/7/01	5/7/08	Genzyme Corporation	San Antonio	Texas	78229	USA	EXACT	0240302AA	alemtuzumab	3A189DH42V						Chronic lymphocytic leukemia	6104		
Alvocidib	Teatment of B-cell chronic lymphocytic leukemia (B-CLL) or prolymphocytic leukemia arising from CLL.	Alvocidib		n/a	4/13/07	Designated			N/A	N/A	"Tolero Pharmaceuticals, Inc."	Lehi	Utah	84043	USA	EXACT	0307846AA	Alvocidib	45AD6X575G						Chronic lymphocytic leukemia	6104		
cladribine	Treatment of chronic lymphocytic leukemia	cladribine		n/a	12/31/90	Designated/Withdrawn			N/A	N/A	"Janssen Research & Development, LLC"	Raritan	New Jersey	8869	USA	EXACT	0092944AA	cladribine	47M74X9YT5						Chronic lymphocytic leukemia	6104		
rituximab	Treatment of chronic lymphocytic leukemia	rituximab		Rituxan	1/29/04	Designated/Approved	Approved for Orphan Indication	Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide	2/18/10	2/18/17	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0225149AA	rituximab	4F4X42SYQ6						Chronic lymphocytic leukemia	6104		
rituximab and recombinant human hyaluronidase	Treatment of chronic lymphocytic leukemia (CLL)	rituximab 		Rituxin Sc	8/22/16	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0225149AA	rituximab	4F4X42SYQ6						Chronic lymphocytic leukemia	6104		
Blinatumomab	Treatment of chronic lymphocytic leukemia	Blinatumomab		n/a	5/16/08	Designated			N/A	N/A	"Amgen, Inc."	Thousand Oaks	California			EXACT	0322758AA	Blinatumomab	4FR53SIF3A						Chronic lymphocytic leukemia	6104		
dinaciclib	Treatment of chronic lymphocytic leukemia.	dinaciclib		n/a	8/25/11	Designated			N/A	N/A	Merck Sharp & Dohme Ltd.				United Kingdom	EXACT	0335637AA	dinaciclib	4V8ECV0NBQ						Chronic lymphocytic leukemia	6104		
acadesine	Treatment of chronic lymphocytic leukemia	acadesine		n/a	3/3/11	Designated			N/A	N/A	"Avanced In Vitro Cell Technologies, S.L."				Spain	EXACT	0171528AA	acadesine	53IEF47846						Chronic lymphocytic leukemia	6104		
nelarabine	Treatment of chronic lymphocytic leukemia.	nelarabine		n/a	9/2/99	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0183302AA	nelarabine	60158CV180						Chronic lymphocytic leukemia	6104		
duvelisib	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	duvelisib		n/a	4/15/13	Designated			N/A	N/A	Infinity Pharmaceuticals	Cambridge	Massachusetts	2139	USA	EXACT	0707493AA	duvelisib	610V23S0JI						Chronic lymphocytic leukemia	6104		
"Phosphatidylinositol 3-Kinase ""PI3K"" Inhibitor"	Treatment of chronic lymphocytic leukemia (CLL)	SF1126		n/a	11/2/10	Designated			N/A	N/A	Semafore Pharmaceuticals	Westfield	Indiana	46074	USA	EXACT	0310714AA	SF1126	63WQ37Y7BL						Chronic lymphocytic leukemia	6104		
"(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride"	"Treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia"	FORODESINE HYDROCHLORIDE		n/a	8/10/04	Designated			N/A	N/A	Mundipharma Research Ltd.				United Kingdom	EXACT	0241736AA	FORODESINE HYDROCHLORIDE	6SN82Y9U73						Chronic lymphocytic leukemia	6104		
rituximab and recombinant human hyaluronidase	Treatment of chronic lymphocytic leukemia (CLL)	rituximab and recombinant human hyaluronidase		Rituxin Sc	8/22/16	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0257670AA	human hyaluronidase	743QUY4VD8						Chronic lymphocytic leukemia	6104		
oblimersen	Treatment of chronic lymphocytic leukemia	oblimersen		Genasense	8/28/01	Designated			N/A	N/A	"Genta, Inc."	Berkeley Heights	New Jersey	7922	USA	EXACT	0258731AA	oblimersen	85J5ZP6YSL						Chronic lymphocytic leukemia	6104		
R-(-)-gossypol	Treatment of chronic lymphocytic leukemia.	R-(-)-gossypol		n/a	10/24/06	Designated			N/A	N/A	"Ascenta Therapeutics, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	0256440AA	R-(-)-gossypol	8DY2X8LXW4						Chronic lymphocytic leukemia	6104		
"anti-CD23 IgG1, kappa monoclonal antibody"	Treatment of chronic lymphocytic leukemia	Lumiliximab		n/a	2/12/03	Designated/Withdrawn			N/A	N/A	"Biogen IDEC, Inc."	San Diego	California	92122	USA	EXACT	0298102AA	Lumiliximab	8Z13S29R5A						Chronic lymphocytic leukemia	6104		
bendamustine for 50 ml admixture	Treatment of chronic lymphocytic leukemia	bendamustine for 50 ml admixture		Bendeka	7/2/14	Designated/Approved	Approved for Orphan Indication	Treatment of patients with CLL and treatment of patients with indolent B-cell NHL	12/7/15	N/A	"Eagle Pharmaceuticals, INc."	Woodcliff Lake	New Jersey	7677	USA	EXACT	0304245AA	bendamustine	9266D9P3PQ						Chronic lymphocytic leukemia	6104		
Bendamustine oral doseage formulation	Treatment of chronic lymphocytic leukemia	Bendamustine oral doseage formulation		n/a	11/5/15	Designated			N/A	N/A	Exinda Theapeutics LLC	Sacramento	California	95828	USA	EXACT	0304245AA	Bendamustine	9266D9P3PQ						Chronic lymphocytic leukemia	6104		
Bendamustine hydrochloride	Treatment of chronic lymphocytic leukemia	Bendamustine hydrochloride		Treanda	8/17/07	Designated/Approved	Approved for Orphan Indication	Treatment of patients with chronic lymphocytic leukemia	3/20/08	3/20/15	"Cephalon, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0249241AA	Bendamustine hydrochloride	981Y8SX18M						Chronic lymphocytic leukemia	6104		
bendamustine hydrochloride with betadex sulfobutyl ether sodium	Treatment of chronic lymphocytic leukemia	bendamustine hydrochloride		n/a	9/10/13	Designated			N/A	N/A	"Supratek Pharma, Inc."	Quebec			Canada	EXACT	0249241AA	bendamustine hydrochloride	981Y8SX18M						Chronic lymphocytic leukemia	6104		
"(S)-7-(1acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide"	Treatment of chronic lymphocytic leukemia.	BGB-3111		n/a	7/20/16	Designated			N/A	N/A	"BeiGene USA, Inc."	Fort Lee	New Jersey	7024	USA	EXACT	1143619AA	BGB-3111	AG9MHG098Z						Chronic lymphocytic leukemia	6104		
Granulocyte macrophage-colony stimulating factor	Treatment of chronic lymphocytic leukemia to increase granulocyte count.	Granulocyte macrophage-colony stimulating factor		Leucomax	5/4/90	Designated/Withdrawn			N/A	N/A	Schering Corporation	Kenilworth	New Jersey	7033	USA	EXACT	0259541AA	Granulocyte macrophage-colony stimulating factor	B321AL142J						Chronic lymphocytic leukemia	6104		
veltuzumab	Treatment of chronic lymphocytic leukemia	veltuzumab		n/a	8/28/08	Designated			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA	EXACT	0265894AA	veltuzumab	BPD4DGQ314						Chronic lymphocytic leukemia	6104		
Bruton's tyrosine kinase inhibitor	Treatment of chronic lymphocytic leukemia	Spebrutinib		n/a	2/10/14	Designated/Withdrawn			N/A	N/A	Celgene Corporation	Berkeley Heights	New Jersey	7922	USA	EXACT	0542096AA	Spebrutinib	DRU6NG543J						Chronic lymphocytic leukemia	6104		
lenalidomide	Treatment of chronic lymphocytic leukemia	lenalidomide		Revlimid	1/17/07	Designated			N/A	N/A	Celgene Corporation	Summit	New Jersey	7901	USA	EXACT	0236099AA	lenalidomide	F0P408N6V4						Chronic lymphocytic leukemia	6104		
phosphoinositide-3-kinase delta inhibitor	Treatment of chronic lymphocytic leukemia	TGR-1202		n/a	8/23/16	Designated			N/A	N/A	"TG Therapeutics, Inc."	New York	New York	10019	USA	EXACT	1085047AA	TGR-1202	FU8XW5V3FS						Chronic lymphocytic leukemia	6104		
Ublituximab and phosphoinositide-3-kinase delta inhibitor	Treatment of chronic lymphocytic leukemia	TGR-1202		n/a	1/5/17	Designated			N/A	N/A	"TG Therapeutics, Inc."	New York	New York	10014	USA	EXACT	1085047AA	TGR-1202	FU8XW5V3FS						Chronic lymphocytic leukemia	6104		
Bruton's Tyrosine Kinase (Btk) Inhibitor	Treatment of chronic lymphocytic leukemia (CLL).	ACP-196		n/a	5/13/15	Designated			N/A	N/A	Acerta Pharma BV				Netherlands	EXACT	1102961AA	ACP-196	I42748ELQW						Chronic lymphocytic leukemia	6104		
cenersen	Treatment of chronic lymphocytic leukemia	cenersen		Aezea	2/27/08	Designated			N/A	N/A	"Eleos, Inc."	Wayzata	Minnesota	55391	USA	EXACT	0781373AA	cenersen	K6KJ8AZ05F						Chronic lymphocytic leukemia	6104		
ofatumumab	Treatment of chronic lymphocytic leukemia	ofatumumab		Arzerra	3/10/09	Designated/Approved	Approved for Orphan Indication	Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine	10/26/09	10/26/16	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0329997AA	ofatumumab	M95KG522R0						Chronic lymphocytic leukemia	6104		
ofatumumab	Treatment of chronic lymphocytic leukemia	ofatumumab		Arzerra	3/10/09	Designated/Approved	Approved for Orphan Indication	"Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate."	4/17/14	4/17/21	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0329997AA	ofatumumab	M95KG522R0						Chronic lymphocytic leukemia	6104		
ofatumumab	Treatment of chronic lymphocytic leukemia	ofatumumab		Arzerra	3/10/09	Designated/Approved	Approved for Orphan Indication	Arzerra in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL).	8/30/16	8/30/23	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0329997AA	ofatumumab	M95KG522R0						Chronic lymphocytic leukemia	6104		
ofatumumab	Treatment of chronic lymphocytic leukemia	ofatumumab		Arzerra	3/10/09	Designated/Approved	Approved for Orphan Indication	For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.	1/19/16	1/19/23	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0329997AA	ofatumumab	M95KG522R0						Chronic lymphocytic leukemia	6104		
venetoclax	Treatment of chronic lymphocytic leukemia	venetoclax		Venclexta	9/20/12	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy"	4/11/16	4/11/23	"AbbVie, Inc"	North Chicago	Illinois	60064	USA	EXACT	0790283AA	venetoclax	N54AIC43PW						Chronic lymphocytic leukemia	6104		
obinutuzumab	Treatment of chronic lymphocytic leukemia	obinutuzumab		Gazyva	2/17/12	Designated/Approved	Approved for Orphan Indication	Treatment of patients with previously untreated chronic lymphocytic leukemia in combination with chlorambucil.	11/1/13	11/1/20	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0322532AA	obinutuzumab	O43472U9X8						Chronic lymphocytic leukemia	6104		
Recombinant anti-CD40 monoclonal antibody	Treatment of chronic lymphocytic leukemia	Lucatumumab		n/a	8/12/05	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceutical Corporation	East Hanover	New Jersey	7936	USA	EXACT	0304961AA	Lucatumumab	P0EP9VFC4R						Chronic lymphocytic leukemia	6104		
Arsenic trioxide	Treatment of chronic lymphocytic leukemia	Arsenic trioxide		Trisenox	5/13/03	Designated			N/A	N/A	"Teva Branded Pharmaceutical Products R&D, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0034720AA	Arsenic trioxide	S7V92P67HO						Chronic lymphocytic leukemia	6104		
polyphenon E	Treatment of chronic lymphocytic leukemia	polyphenon E		n/a	7/17/08	Designated			N/A	N/A	"Mitsui Norin Co., Ltd"				Japan	EXACT	0221158AA	polyphenon E	T432289GYZ						Chronic lymphocytic leukemia	6104		
"6-Amino-9-[(3R)-1-(but-2-ynoyl)pyrrolidin-3-yl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one monohydrochloride"	Treatment of chronic lymphocytic leukemia.	TIRABRUTINIB HYDROCHLORIDE		n/a	6/5/17	Designated			N/A	N/A	"Gilead Sciences, Inc."	Seattle	Washington	98102	USA	EXACT	1136692AA	TIRABRUTINIB HYDROCHLORIDE	U374135N48						Chronic lymphocytic leukemia	6104		
ublituximab	Treatment of chronic lymphocytic leukemia	ublituximab		n/a	8/6/10	Designated			N/A	N/A	"TG Therapeutics, Inc."	New York	New York	10019	USA	EXACT	0574607AA	ublituximab	U59UGK3IPC						Chronic lymphocytic leukemia	6104		
Ublituximab and phosphoinositide-3-kinase delta inhibitor	Treatment of chronic lymphocytic leukemia	Ublituximab and phosphoinositide-3-kinase delta inhibitor		n/a	1/5/17	Designated			N/A	N/A	"TG Therapeutics, Inc."	New York	New York	10014	USA	EXACT	0574607AA	Ublituximab	U59UGK3IPC						Chronic lymphocytic leukemia	6104		
dacetuzumab	Treatment of chronic lymphocytic leukemia	dacetuzumab		n/a	10/6/05	Designated			N/A	N/A	"Seattle Genetics, Inc."	Bothell	Washington	98021	USA	EXACT	0266295AA	dacetuzumab	UT59FF4T5X						Chronic lymphocytic leukemia	6104		
"(R)-4-(3-morpholin-4-yl-l-phenylsulfanylmenthyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-enylmethyl]-piperazin-l-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride"	Treatment of chronic lymphocytic leukemia	NAVITOCLAX DIHYDROCHLORIDE		n/a	12/19/07	Designated/Withdrawn			N/A	N/A	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0555895AA	NAVITOCLAX DIHYDROCHLORIDE	W8FZ00AY2S						Chronic lymphocytic leukemia	6104		
R-etodolac	Treatment of chronic lymphocytic leukemia	R-etodolac		n/a	12/9/02	Designated/Withdrawn			N/A	N/A	"Cephalon, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0244473AA	R-etodolac	Y1RAH31T6K						Chronic lymphocytic leukemia	6104		
idelalisib	Treatment of chronic lymphocytic leukemia	idelalisib		n/a	8/25/11	Designated			N/A	N/A	"Gilead Sciences, Inc."	Seattle	Washington	98102	USA	EXACT	0711308AA	idelalisib	YG57I8T5M0						Chronic lymphocytic leukemia	6104		
idelalisib	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	idelalisib		Zydelig	10/15/13	Designated/Approved	Approved for Orphan Indication	"(1) Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; and (2) Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies."	7/23/14	7/23/21	"Gilead Sciences, Inc."	Seattle	Washington	98102	USA	EXACT	0711308AA	idelalisib	YG57I8T5M0						Chronic lymphocytic leukemia	6104		
"6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo-[1,2-alpha]pyrazin-8-amine bis-methanesulfonate"	Treatment of chronic lymphocytic leukemia	ENTOSPLETINIB DIMESYLATE		n/a	4/14/14	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	1137173AA	ENTOSPLETINIB DIMESYLATE	4N0Q3I064C						Chronic lymphocytic leukemia	6104		
humanized Fc engineered monoclonal antibody against CD19	Treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma	MOR-208		n/a	4/29/14	Designated			N/A	N/A	MorphoSys AG				Germany	EXACT	1804597AA	MOR-208	QQA9MLH692						Chronic lymphocytic leukemia	6104		
"mouse-human chimeric antibody of the IgG1 isotype, directed against human CD37"	Treatment of chronic lymphocytic leukemia (CLL).	BI-836826		n/a	3/24/15	Designated			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc."	Ridgefield	Connecticut	6877	USA	EXACT	0110874AB	BI-836826	LB090AB8DB						Chronic lymphocytic leukemia	6104		
ST1-RTA immunotoxin (SR 44163)	1. Prevention of acute graft versus host disease in allogenic bone marrow transplantation 2. Treatment of patients with B-chronic lymphocytic leukemia	SR-44163		n/a	8/12/87	Designated/Withdrawn			N/A	N/A	"Sanofi Winthrop, Inc."	Malvern	Pennsylvania	19355	USA										Chronic lymphocytic leukemia	6104		
gene encoding chimeric CD40 ligand	Treatment of chronic lymphocytic leukemia	gene encoding chimeric CD40 ligand		n/a	2/4/09	Designated			N/A	N/A	"Memgen, LLC"	San Diego	California	92101	USA	LONGEST CONTAINS	0262113AA	CD40 ligand	T169OM1T8L						Chronic lymphocytic leukemia	6104		
autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19	Treatment of chronic lymphocytic leukemia	autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19		n/a	3/14/14	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	LONGEST CONTAINS	1722709AA	CD19	IYZ9TI08W3						Chronic lymphocytic leukemia	6104		
autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor	Treatment of chronic lymphocytic leukemia.	autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor		n/a	4/20/16	Designated			N/A	N/A	"Kite Pharma, Inc."	Santa Monica	California	90404	USA	LONGEST CONTAINS	1722709AA	CD19	IYZ9TI08W3						Chronic lymphocytic leukemia	6104		
autologous CD4+/CD8+ T cells expressing a CD19 chimeric antigen receptor (CAR) and a truncated epidermal growth factor receptor.	Treatment of chronic lymphocytic leukemia	autologous CD4+/CD8+ T cells expressing a CD19 chimeric antigen receptor (CAR) and a truncated epidermal growth factor receptor.		n/a	10/4/16	Designated			N/A	N/A	"Juno Therapeutics, Inc."	Seattle	Washington	98109	USA	LONGEST CONTAINS	0006804AA	epidermal growth factor	TZK30RF92W						Chronic lymphocytic leukemia	6104		
N-[5-(6-fluoro-8-{[4-(2-hydroxypropan-2-yl) piperidin-1-yl]methyl}-2-morpholinoquinazolin-4-yl)-2-methoxypyridin-3-]methanesulfonamide	Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	N-[5-(6-fluoro-8-{[4-(2-hydroxypropan-2-yl) piperidin-1-yl]methyl}-2-morpholinoquinazolin-4-yl)-2-methoxypyridin-3-]methanesulfonamide		n/a	10/11/18	Designated			N/A	N/A	"Shanghai Yingli Pharmaceutical Co., Ltd."	"No.1 Building, 998 Halei Road"			China	EXACT	0117208AB	methanesulfonamide							Chronic lymphocytic leukemia	6104		
"4-[4-[[[[3-(1,1-dimethylethyl)-1-(6-quinolinyl)-1H-pyrazol-5-yl]amino]carbonyl]-amino]-3-fluorophenoxyl]-N-methyl-2-pyridinecarboxamide, p-toluenesulfonate salt"	Treatment of Philadelphia chromosome positive chronic myeloid leukemia	"4-(4-((((3-(1,1-dimethylethyl)-1-(6-quinolinyl)-1H-pyrazol-5-yl)amino)carbonyl)-amino)-3-fluorophenoxyl)-N-methyl-2-pyridinecarboxamide, p-toluenesulfonate salt"		n/a	9/3/09	Designated			N/A	N/A	"Deciphera Pharmaceuticals, LLC"	Lawrence	Kansas	66044	USA	EXACT	0711137AA	"4-(4-((((3-(1,1-dimethylethyl)-1-(6-quinolinyl)-1H-pyrazol-5-yl)amino)carbonyl)-amino)-3-fluorophenoxyl)-N-methyl-2-pyridinecarboxamide, p-toluenesulfonate salt"	042A5NJE6B						Chronic myeloid leukemia	6105		
tetrandrine	Treatment of chronic myeloid leukemia.	tetrandrine		n/a	5/19/16	Designated			N/A	N/A	"Escend Pharmaceuticals, Inc."	Menlo Park	California	94025	USA	EXACT	0074260AA	tetrandrine	29EX23D5AJ						Chronic myeloid leukemia	6105		
ponatinib	Treatment of chronic myeloid leukemia	ponatinib		Iclusig	11/20/09	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy."	12/14/12	12/14/19	ARIAD Pharmaceuticals Inc.	Cambridge	Massachusetts	2139	USA	EXACT	0460162AA	ponatinib	4340891KFS						Chronic myeloid leukemia	6105		
arsenic trioxide	Treatment of chronic myeloid leukemia	arsenic trioxide		Trisenox	10/18/01	Designated			N/A	N/A	"Teva Branded Pharmaceutical Products R*D, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0034720AA	arsenic trioxide	S7V92P67HO						Chronic myeloid leukemia	6105		
"4-[2-(3-Propyl-[1,2,4]0xadiazol-5-yl)-vinyl]-benzene-1,2-diol"	Treatment of chronic myeloid leukemia	P-2745		n/a	10/4/11	Designated			N/A	N/A	Piramal Enterprises Limited	Mumbai			India	EXACT	0740476AA	P-2745	ZGL5E40F57						Chronic myeloid leukemia	6105		
oral tyrosine kinase inhibitor	Treatment of chronic myeloid leukemia	PF-114		n/a	6/28/17	Designated			N/A	N/A	"Fusion Pharma, LLC"				Russian Federation	EXACT	0112107AB	PF-114	I8C3R768IZ						Chronic myeloid leukemia	6105		
allogeneic ex vivo expanded umbilical cord blood cells	For use as hematopoietic support in patients with chronic myeloid leukemia	allogeneic ex vivo expanded umbilical cord blood cells		Stemex	2/1/10	Designated/Withdrawn			N/A	N/A	Gamida Cell - Teva Joint Venture				Israel	LONGEST CONTAINS	0854240AA	umbilical cord blood	PVH8394DLN						Chronic myeloid leukemia	6105		
Replication-incompetent GM-CSF-expressing gene-modified allogeneic chronic myeloid leukemia cancer cell lines	Treatment of chronic myeloid leukemia	Replication-incompetent GM-CSF-expressing gene-modified allogeneic chronic myeloid leukemia cancer cell lines		Gvax Chronic Myeloid Leukemia	4/30/10	Designated			N/A	N/A	"Aduro BioTech, Inc."	Berkeley	California	94710	USA										Chronic myeloid leukemia	6105		
Methanesulfonate-1-sec-butoxycarbonyloxymethyl-1-methyl-4-{4-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-benzyl}-piperazin-1-ium	Treatment of chronic myeloid leukemia	IKT-001PRO		n/a	9/13/18	Designated			N/A	N/A	"Inhibikase Therapeutics, Inc."	3350 Riverwood Parkway	Georgia	30339	USA	EXACT	 0117200AB								Chronic myeloid leukemia	6105		
D-mannitol and L-proline	Treatment of Cockayne syndrome	D-mannitol		Prodarsan	4/20/09	Designated			N/A	N/A	DNage B.V.				Netherlands	EXACT	0012033AA	D-mannitol	3OWL53L36A						Cockayne syndrome	6122		
D-mannitol and L-proline	Treatment of Cockayne syndrome	 L-proline		Prodarsan	4/20/09	Designated			N/A	N/A	DNage B.V.				Netherlands	EXACT	0023041AA	L-proline	9DLQ4CIU6V						Cockayne syndrome	6122		
B Lymphocyte Stimulator	Treatment of common variable immunodeficiency (CVID)	BLyS		Blys	2/21/01	Designated/Withdrawn			N/A	N/A	"Human Genome Sciences, Inc."	Rockville	Maryland	20850	USA	EXACT	0645692AA	BLyS	2IL2N4764F						Common variable immunodeficiency	6140		
Loxoribine	Treatment of common variable immunodeficiency.	Loxoribine		n/a	2/24/92	Designated/Withdrawn			N/A	N/A	R. W. Johnson Pharmaceutical Research Institute	Raritan	New Jersey	8869	USA	EXACT	0172123AA	Loxoribine	9CAS0V66OI						Common variable immunodeficiency	6140		
human plasminogen	Treatment of ligneous conjunctivitis	human plasminogen		n/a	6/7/10	Designated			N/A	N/A	"Kedrion, S.p.A."				Italy	EXACT	0005061AA	plasminogen							Ligneous conjunctivitis	6187		
Spiramycin	For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.	Spiramycin		Rovamycine	10/17/84	Designated/Withdrawn			N/A	N/A	Rhone-Poulenc Rorer Pharmaceuticals	Collegeville	Pennsylvania	19426	USA	EXACT	0002448AA	Spiramycin	71ODY0V87H						Cryptosporidiosis	6219		
Bovine whey protein concentrate	Treatment of cryptosporidiosis caused by the presence of Cryptosporidium parvum in the gastrointestinal tract of patients who are immunodeficient/immunocompromised or immunocompetent.	Bovine whey protein concentrate		Immuno-C	9/30/93	Designated			N/A	N/A	"Biomune Systems, Inc."	Salt Lake City	Utah	84108	USA	EXACT	0251569AA	whey protein concentrate	8617Z5FMF6						Cryptosporidiosis	6219		
Nitazoxanide	Treatment of cryptosporidiosis.	Nitazoxanide		Alinia	12/12/96	Designated/Approved	Approved for Orphan Indication	Treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia	11/22/02	11/22/09	"Romark Laboratories, L.C."	Tampa	Florida	33607	USA	EXACT	0208855AA	Nitazoxanide	SOA12P041N						Cryptosporidiosis	6219		
"2S,4R ketoconazole"	Treatment of endogenous Cushing's syndrome	"2S,4R ketoconazole"		n/a	3/9/12	Designated			N/A	N/A	Cortendo AB (HQ address)				Sweden	EXACT	0740454AA	"2S,4R ketoconazole"	2DJ8R0NT7K						Cushing's syndrome	6224		
Mifepristone	Treatment of Cushing's syndrome secondary to ectopic ACTH secretion	Mifepristone		n/a	2/7/05	Designated			N/A	N/A	HRA Pharma				France	EXACT	0129613AA	Mifepristone	320T6RNW1F						Cushing's syndrome	6224		
"N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt"	For the treatment of Cushing's Syndrome	PD-132301 HYDROCHLORIDE		n/a	1/7/15	Designated			N/A	N/A	"Millendo Therapeutics, Inc."	"Ann Arbor,"	Michigan	48104	USA	EXACT	0740421AA	PD-132301 HYDROCHLORIDE	TK694ZFS57						Cushing's syndrome	6224		
metyrapone	Treatment of Cushing's syndrome	metyrapone		n/a	9/25/12	Designated			N/A	N/A	Laboratoire HRA Pharma	Paris			France	EXACT	0008651AA	metyrapone	ZS9KD92H6V						Cushing's syndrome	6224		
fenretinide	Treatment of cutaneous T-cell lymphoma	fenretinide		n/a	9/4/13	Designated			N/A	N/A	"CerRx, Inc."	Lubbock	Texas	79416	USA	EXACT	0136061AA	fenretinide	187EJ7QEXL						Cutaneous T-cell lymphoma	6226		
fenretinide	Treatment of cutaneous T-cell lymphoma	fenretinide		n/a	12/19/17	Designated			N/A	N/A	"SciTech Development, LLC"	281 Kercheval Avenue	Grosse Pointe Farms	48236	USA	EXACT	0136061AA	fenretinide	187EJ7QEXL						Cutaneous T-cell lymphoma	6226		
tenalisib	Treatment of Cutaneous T-Cell Lymphoma	tenalisib		n/a	4/4/18	Designated			N/A	N/A	Rhizen Pharmaceuticals SA	40 Rue Fritz-Courvoisier			Switzerland	EXACT	1120952AA	tenalisib	2261HH611H						Cutaneous T-cell lymphoma	6226		
denileukin diftitox	Treatment of patients with cutaneous T-cell lymphoma	denileukin diftitox		Ontak	8/21/96	Designated/Approved	Approved for Orphan Indication	Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.	2/5/99	2/5/06	"Eisai, Inc."	Woodcliff Lake	New Jersey	7677	USA	EXACT	0233465AA	denileukin diftitox	25E79B5CTM						Cutaneous T-cell lymphoma	6226		
denileukin diftitox	Treatment of cutaneous T-cell lymphoma	denileukin diftitox		n/a	7/12/13	Designated			N/A	N/A	Eisai Inc.	Woodcliff Lake	New Jersey	7677	USA	EXACT	0233465AA	denileukin diftitox	25E79B5CTM						Cutaneous T-cell lymphoma	6226		
methylparaben suberohydroxamic acid phenyl ester	Treatment of cutaneous T-cell lymphoma	methylparaben suberohydroxamic acid phenyl ester		n/a	4/15/13	Designated			N/A	N/A	TetraLogic Pharmaceuticals	Malvern	Pennsylvania	19355	USA	EXACT	1071847AA	methylparaben suberohydroxamic acid phenyl ester	37NT056AT4						Cutaneous T-cell lymphoma	6226		
Pentostatin	Treatment of cutaneous T-cell lymphoma.	Pentostatin		Nipent	3/27/98	Designated			N/A	N/A	"SuperGen, Inc."	Dublin	California	94568	USA	EXACT	0067130AA	Pentostatin	395575MZO7						Cutaneous T-cell lymphoma	6226		
"N-[4-(4-amino-2-ethyl-lH-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide"	Treatment of cutaneous T-cell lymphoma	"N-(4-(4-amino-2-ethyl-lH-imidazo(4,5-c)quinolin-1-yl)butyl)methanesulfonamide"		n/a	3/24/06	Designated/Withdrawn			N/A	N/A	"Pfizer, Inc."	New London	Connecticut	6320	USA	EXACT	0249309AA	CPG-52852	6PJC3KPK6S						Cutaneous T-cell lymphoma	6226		
Peldesine	Treatment of cutaneous T-cell lymphoma.	Peldesine		n/a	10/5/93	Designated			N/A	N/A	"BioCryst Pharmaceuticals, Inc."	Birmingham	Alabama	35244	USA	EXACT	0181544AA	Peldesine	7B646RJ70F						Cutaneous T-cell lymphoma	6226		
Hypericin	Treatment of cutaneous T-cell lymphoma.	Hypericin		n/a	2/7/00	Designated			N/A	N/A	"Soligenix, Inc."	Princeton	New Jersey	8540	USA	EXACT	0028466AA	Hypericin	7V2F1075HD						Cutaneous T-cell lymphoma	6226		
Brentuximab vedotin	Treatment of cutaneous T-cell lymphoma	Brentuximab vedotin		n/a	2/6/17	Designated			N/A	N/A	"Seattle Genetics, Inc."	Bothell	Washington	98021	USA	EXACT	0297767AA	Brentuximab vedotin	7XL5ISS668						Cutaneous T-cell lymphoma	6226		
doxorubicin	Treatment of cutaneous T-cell lymphoma	doxorubicin		n/a	4/6/15	Designated			N/A	N/A	"Louis D. Falo, Jr."	Pittsburgh	Pennsylvania	15213	USA	EXACT	0061074AA	doxorubicin	80168379AG						Cutaneous T-cell lymphoma	6226		
Panobinostat	Treatment of cutaneous T-cell lymphoma	Panobinostat		Faridak	9/26/07	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0456257AA	Panobinostat	9647FM7Y3Z						Cutaneous T-cell lymphoma	6226		
Bexarotene	Treatment of cutaneous T-cell lymphoma.	Bexarotene		Targretin	6/18/99	Designated/Approved	Approved for Orphan Indication	Treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.	12/29/99	12/29/06	"Eisai, Inc."	Woodcliff Lake	New Jersey	7677	USA	EXACT	0184827AA	Bexarotene	A61RXM4375						Cutaneous T-cell lymphoma	6226		
hydralazine - magnesium valproate	Treatment of cutaneous T-cell lymphoma.	hydralazine - magnesium valproate		Transkrip(R)	3/17/11	Designated			N/A	N/A	Neolpharma S.A.DE C.V.	Mexico City			Mexico	EXACT	0086920AA	magnesium valproate	Q400352CM2						Cutaneous T-cell lymphoma	6226		
liposomal vinorelbine	Treatment of cutaneous t-cell lymphoma (CTCL)	liposomal vinorelbine		n/a	10/12/16	Designated			N/A	N/A	"Taiwan Liposome Company, Ltd."	Taipei City			Taiwan	EXACT	0201547AA	vinorelbine	Q6C979R91Y						Cutaneous T-cell lymphoma	6226		
resiquimod	Treatment of cutaneous T-cell lymphoma	resiquimod		n/a	5/24/17	Designated			N/A	N/A	"Galderma Research and Development, LLC"	Fort Worth	Texas	76177	USA	EXACT	0212055AA	resiquimod	V3DMU7PVXF						Cutaneous T-cell lymphoma	6226		
mogamulizumab	Treatment of patients with cutaneous T-cell lymphoma.	mogamulizumab		n/a	11/2/10	Designated			N/A	N/A	Kyowa Kirin Pharmaceutical Development Inc.	Princeton	New Jersey	8540	USA	EXACT	0574594AA	mogamulizumab	YI437801BE						Cutaneous T-cell lymphoma	6226		
Interferon beta (recombinant)	For the systemic treatment of cutaneous T-cell lymphoma.	Interferon beta (recombinant)		R-Huifn-Beta	4/18/91	Designated/Withdrawn			N/A	N/A	"Biogen, Inc."	Cambridge	Massachusetts	2142	USA	LONGEST CONTAINS	0297927AA	Interferon beta	V9GU1EM8SF						Cutaneous T-cell lymphoma	6226		
A-dmDT390-bisFv(UCHT1)	Treatment of cutaneous T-cell lymphoma	Resimmune		Resimmune	10/9/14	Designated			N/A	N/A	"Angimmune, LLC"	Rockville	Maryland	20855	USA	EXACT									Cutaneous T-cell lymphoma	6226		
humanized IgG1 monoclonal antibody targeting KIR3DL2	Treatment of cutaneous T-cell lymphoma.	IPH-4102		n/a	6/14/17	Designated			N/A	N/A	Innate Pharma	Marseille			France	EXACT	0111022AB	IPH-4102	N8O7MY0VNS						Cutaneous T-cell lymphoma	6226		
"1-118-signal regulatory protein alpha (human) fusion protein with immunoglobulin G1 (human Fc fragment), dimer"	Treatment of Cutaneous T-Cell Lymphoma	"1-118-signal regulatory protein alpha (human) fusion protein with immunoglobulin G1 (human Fc fragment), dimer"		n/a	3/8/18	Designated			N/A	N/A	Trillium Therapeutics Inc.	2488 Dunwin Drive			Canada	LONGEST CONTAINS	0087274AA	protein							Cutaneous T-cell lymphoma	6226		
Ricin (blocked) conjugated murine monoclonal antibody (CD6)	"Treatment of cutaneous T-cell lymphomas, acute T-cell leukemia-lymphoma, and related mature T-cell malignancies."	Ricin (blocked) conjugated murine monoclonal antibody (CD6)		n/a	9/6/94	Designated/Withdrawn			N/A	N/A	"ImmunoGen, Inc."	Waltham	Massachusetts	2451	USA	LONGEST CONTAINS	0811450AA	Ricin	U6E7R9OE4R						Cutaneous T-cell lymphoma	6226		
Fenretinide	Treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis patients	Fenretinide		n/a	4/7/10	Designated			N/A	N/A	McGill University				Canada	EXACT	0136061AA	Fenretinide	187EJ7QEXL						Cystic fibrosis	6233		
ivacaftor	Treatment of patients with cystic fibrosis	ivacaftor		Kalydeco	12/20/06	Designated/Approved	Approved for Orphan Indication	Treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene.	1/31/12	1/31/19	"Vertex Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0297132AA	ivacaftor	1Y740ILL1Z						Cystic fibrosis	6233		
lumacaftor/ivacaftor	Treatment of cystic fibrosis	ivacaftor		Orkambi	6/30/14	Designated/Approved	Approved for Orphan Indication	Treatment of cystic fibrosis in patients age 12 years and older who are homozygous for F508del mutation in the CFTR gene	7/2/15	7/2/22	Vertex Pharmaceuticals Inc.	Boston	Massachusetts	2210	USA	EXACT	0297132AA	ivacaftor	1Y740ILL1Z						Cystic fibrosis	6233		
Tezacaftor and Ivacaftor combination therapy	Treatment of cystic fibrosis (CF)	Ivacaftor		n/a	6/15/17	Designated			N/A	N/A	Vertex Pharmaceuticals Inc.	Boston	Massachusetts	2210	USA	EXACT	0297132AA	Ivacaftor	1Y740ILL1Z						Cystic fibrosis	6233		
"potassium (benzenesulfonyl)({[6-(3-{2-[1-(trifluoromethyl)cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridin-3-yl]carbonyl})azanide/tezacaftor/ivacaftor"	Treatment of Cystic Fibrosis	ivacaftor		n/a	5/23/18	Designated			N/A	N/A	Vertex Pharmaceuticals Inc.	50 Northern Avenue		2210	USA	EXACT	0297132AA	ivacaftor	1Y740ILL1Z						Cystic fibrosis	6233		
recombinant human neutrophil inhibitor (hNE)	Treatment of cystic fibrosis	recombinant human neutrophil inhibitor (hNE)		n/a	12/9/03	Designated			N/A	N/A	Dyax Corporation	Cambridge	Massachusetts	2139	USA	EXACT	0313804AA	recombinant human neutrophil inhibitor (hNE)	2M3V3B8OEA						Cystic fibrosis	6233		
fosfomycin/tobramycin	Treatment of pulmonary infections associated with cystic fibrosis	fosfomycin		n/a	11/28/08	Designated			N/A	N/A	"CURx Pharmaceuticals, Inc."	San Diego	California	92121	USA	EXACT	0061063AA	fosfomycin	2N81MY12TE						Cystic fibrosis	6233		
itraconazole inhalation powder	Treatment of pulmonary fungal infections in patients with cystic fibrosis	itraconazole inhalation powder		n/a	8/16/16	Designated			N/A	N/A	"Pulmatrix, Inc"	Lexington	Massachusetts	2421	USA	EXACT	0130278AA	itraconazole	304NUG5GF4						Cystic fibrosis	6233		
Nitric oxide	Treatment of cystic fibrosis	Nitric oxide		n/a	9/11/13	Designated			N/A	N/A	"Novoteris, LLC"	Garden Grove	California	92841	USA	EXACT	0176341AA	Nitric oxide	31C4KY9ESH						Cystic fibrosis	6233		
nitric oxide	Treatment of cystic fibrosis	nitric oxide		n/a	9/23/14	Designated			N/A	N/A	Advanced Inhalation Therapies Ltd.				Israel	EXACT	0176341AA	nitric oxide	31C4KY9ESH						Cystic fibrosis	6233		
"2-0-Butyryl-1-0-octyl-myo-inositol 3,4,5,6-tetrakisphosphate"	Treatment of cystic fibrosis	INO-4995		n/a	8/15/03	Designated			N/A	N/A	"Inologic, Inc."	Seattle	Washington	98119	USA	EXACT	0759411AA	INO-4995	3LM5SX2N4X						Cystic fibrosis	6233		
Mannitol	For use to facilitate clearance of mucus in patients with bronchiectasis and in patients with cystic fibrosis at risk for bronchiectasis	Mannitol		Bronchitol	2/11/05	Designated			N/A	N/A	Pharmaxis Ltd.	NSW 2086			Australia	EXACT	0012033AA	Mannitol	3OWL53L36A						Cystic fibrosis	6233		
gentamicin C2 congener	Treatment of cystic fibrosis	gentamicin C2 congener		n/a	3/29/16	Designated			N/A	N/A	La Jolla Pharmaceuticals Company	San Diego	California	92121	USA	EXACT	0270633AA	gentamicin C2	3P99H114B8						Cystic fibrosis	6233		
Selective inhibitor of polymorphonuclear leukocyte (PMN) elastase	Therapeutic management of patients with lung disease attributable to cystic fibrosis.	DMP-777		n/a	6/4/96	Designated			N/A	N/A	DuPont Pharmaceuticals Company	Wilmington	Delaware	19805	USA	EXACT	0213627AA	DMP-777	3Q0469283P						Cystic fibrosis	6233		
iclaprim	Treatment of Staphylococus aureus lung infections in patients with cystic fibrosis	iclaprim		n/a	9/14/17	Designated			N/A	N/A	Motif Bio PLC	New York	New York	10017	USA	EXACT	0297892AA	iclaprim	42445HUU0O						Cystic fibrosis	6233		
teicoplanin	Treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis	teicoplanin		n/a	5/24/18	Designated			N/A	N/A	Neupharma srl	8 Piazza del Duomo			Italy	EXACT	0139253AA	teicoplanin	4U3D3YY81M						Cystic fibrosis	6233		
D-peptide of the sequence AKRHHGYKRKFH - NH2	Treatment of cystic fibrosis	D-peptide of the sequence AKRHHGYKRKFH - NH2		Pulmadex	10/23/02	Designated			N/A	N/A	"Demegen, Inc."	Pittsburgh	Pennsylvania	15219	USA	EXACT	0760087AA	D-peptide of the sequence AKRHHGYKRKFH - NH2	513P3772TA						Cystic fibrosis	6233		
Liposomal ciprofloxacin for inhalation	Management of cystic fibrosis	Liposomal ciprofloxacin for inhalation		n/a	4/19/06	Designated			N/A	N/A	Aradigm Corporation	Hayward	California	94545	USA	EXACT	0140727AA	ciprofloxacin	5E8K9I0O4U						Cystic fibrosis	6233		
ciprofloxacin DPI	Management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis patients	ciprofloxacin DPI		Ciprofloxacin Pulmosphere(R)	2/2/10	Designated			N/A	N/A	"Bayer HealthCare Pharmaceuticals, Inc."	Whippany	New Jersey	7981	USA	EXACT	0140727AA	ciprofloxacin	5E8K9I0O4U						Cystic fibrosis	6233		
liposomal ciprofloxacin plus ciprofloxacin	For the management of cystic fibrosis	liposomal ciprofloxacin plus ciprofloxacin		n/a	6/1/12	Designated			N/A	N/A	Aradigm Corporation	Hayward	California	94545	USA	EXACT	0140727AA	ciprofloxacin	5E8K9I0O4U						Cystic fibrosis	6233		
ciprofloxacin dry powder inhaler	Treatment of non-cystic fibrosis bronchiectasis	ciprofloxacin dry powder inhaler		n/a	4/17/14	Designated			N/A	N/A	"Bayer HealthCare Pharmaceuticals, Inc."	Montville	New Jersey	7045	USA	EXACT	0140727AA	ciprofloxacin	5E8K9I0O4U						Cystic fibrosis	6233		
Cysteamine	Treatment of cystic fibrosis	Cysteamine		Lynovex	9/11/14	Designated			N/A	N/A	NovaBiotics Ltd.	Aberdeen AB21 9TR			United Kingdom	EXACT	0010377AA	Cysteamine	5UX2SD1KE2						Cystic fibrosis	6233		
Levofloxacin	Treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis patients	Levofloxacin		n/a	2/27/08	Designated			N/A	N/A	"Raptor Pharmaceuticals, Inc."	Novato	California	94949	USA	EXACT	0173580AA	Levofloxacin	6GNT3Y5LMF						Cystic fibrosis	6233		
vancomycin hydrochloride (inhalational)	Treatment of persistent methicillin-resistant S. aureus lung infection in patients with cystic fibrosis	vancomycin hydrochloride (inhalational)		n/a	9/20/12	Designated			N/A	N/A	"Savara Pharmaceuticals, Inc."	Austin	Texas	78730	USA	EXACT	0036191AA	vancomycin hydrochloride	71WO621TJD						Cystic fibrosis	6233		
ursodiol	Treatment of cystic fibrosis liver disease	ursodiol		Ursofalk Suspension	10/23/07	Designated			N/A	N/A	"Asklepion Pharmaceuticals, LLC"	Brentwood	Tennessee	37027	USA	EXACT	0020519AA	ursodiol	724L30Y2QR						Cystic fibrosis	6233		
S-nitrosoglutathione	Management of cystic fibrosis patients to improve airway clearance and to improve or stabilize pulmonary function	S-nitrosoglutathione		n/a	5/12/09	Designated			N/A	N/A	"N30 PHARMAceuticals, LLC"	Boulder	Colorado	80301	USA	EXACT	0231890AA	S-nitrosoglutathione	78RRI89ZTO						Cystic fibrosis	6233		
"p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium salt"	For the treatment of cystic fibrosis	DENUFOSOL TETRASODIUM		n/a	3/7/01	Designated/Withdrawn			N/A	N/A	"Inspire Pharmaceuticals, Inc."	Durham	North Carolina	27703	USA	EXACT	0238846AA	DENUFOSOL TETRASODIUM	82M942WZ4A						Cystic fibrosis	6233		
liposomal amikacin	Treatment of bronchopulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients	liposomal amikacin		Arikace	3/9/06	Designated			N/A	N/A	"Insmed, Inc."	Monmouth Junction	New Jersey	8852	USA	EXACT	0122203AA	amikacin	84319SGC3C						Cystic fibrosis	6233		
N-acetylcysteinate Lysine	For the management of cystic fibrosis	N-acetylcysteinate Lysine		Nacystelyn Dry Powder Inhaler	12/27/00	Designated			N/A	N/A	"Galephar Pharmaceutical Research, Inc."	Juncos			Puerto Rico	EXACT	0181431AA	N-acetylcysteinate Lysine	8G1KV0RT1P						Cystic fibrosis	6233		
"(R)-1-(2,2-difluorobenzo [d][1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide"	Treatment of cystic fibrosis	TEZACAFTOR		n/a	4/24/14	Designated			N/A	N/A	Vertex Pharmaceuticals Inc.	Boston	Massachusetts	2210	USA	EXACT	1139328AA	TEZACAFTOR	8RW88Y506K						Cystic fibrosis	6233		
Tezacaftor and Ivacaftor combination therapy	Treatment of cystic fibrosis (CF)	Tezacaftor and Ivacaftor combination therapy		n/a	6/15/17	Designated			N/A	N/A	Vertex Pharmaceuticals Inc.	Boston	Massachusetts	2210	USA	EXACT	1139328AA	Tezacaftor	8RW88Y506K						Cystic fibrosis	6233		
"potassium (benzenesulfonyl)({[6-(3-{2-[1-(trifluoromethyl)cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridin-3-yl]carbonyl})azanide/tezacaftor/ivacaftor"	Treatment of Cystic Fibrosis	tezacaftor		n/a	5/23/18	Designated			N/A	N/A	Vertex Pharmaceuticals Inc.	50 Northern Avenue		2210	USA	EXACT	1139328AA	tezacaftor	8RW88Y506K						Cystic fibrosis	6233		
Recombinant secretory leucocyte protease inhibitor	Treatment of cystic fibrosis.	SECRETORY LEUKOCYTE PROTEASE INHIBITOR		n/a	3/29/91	Designated			N/A	N/A	"Amgen, Inc."	Boulder	Colorado	80301	USA	EXACT	0259972AA	SECRETORY LEUKOCYTE PROTEASE INHIBITOR	909E17P4ZW						Cystic fibrosis	6233		
Dornase alfa	To reduce mucous viscosity and enable the clearance of airway secretions in patients with cystic fibrosis.	Dornase alfa		Pulmozyme	1/16/91	Designated/Approved	Approved for Orphan Indication	In conjunction with standard therapies in the management of cystic fibrosis patients to reduce the frequency of respiratory infections requiring parenteral antibiotics and to improve pulmonary function.	12/30/93	12/30/00	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0226175AA	Dornase alfa	953A26OA1Y						Cystic fibrosis	6233		
"(E, Z)-4,5,9-trithiadodeca-1, 6, 11-triene 9-oxide (Ajoene)"	Treatment of Pseudomonas aeruginosa pulmonary infections in cystic fibrosis patients	AJOENE		n/a	4/21/16	Designated			N/A	N/A	Neem Biotech Ltd.	Blaenau Gwent			United Kingdom	EXACT	0420508AA	AJOENE	99A0041VG8						Cystic fibrosis	6233		
sodium nitrite and EDTA	Treatment of Pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis	EDTA		n/a	11/10/15	Designated			N/A	N/A	"Arch Biopartners, Inc."	Toronto	Ontario		Canada	EXACT	0010300AA	EDTA	9G34HU7RV0						Cystic fibrosis	6233		
"8 Cyclopentyl 1,3-dipropylxanthine"	Treatment of cystic fibrosis.	"8-CYCLOPENTYL-1,3-DIPROPYLXANTHINE"		n/a	3/24/97	Designated/Withdrawn			N/A	N/A	"SciClone Pharmaceuticals, Inc."	San Mateo	California	94404	USA	EXACT	0183142AA	"8-CYCLOPENTYL-1,3-DIPROPYLXANTHINE"	9PTP4FOI9E						Cystic fibrosis	6233		
granulocyte macrophage colony stimuling factor	Treatment of cystic fibrosis	granulocyte macrophage colony stimuling factor		n/a	8/27/08	Designated			N/A	N/A	Savara Inc.	Austin	Texas	78746	USA	EXACT	0259541AA	Granulocyte macrophage-colony stimulating factor	B321AL142J						Cystic fibrosis	6233		
Doripenem	Treatment of bronchopulmonary infection in patients with cystic fibrosis who are colonized with Pseudomonas aeruginosa or Burkholderia cepacia.	Doripenem		n/a	7/16/04	Designated			N/A	N/A	"Shionogi, Inc."	Florham Park	New Jersey	7932	USA	EXACT	0296242AA	Doripenem	BHV525JOBH						Cystic fibrosis	6233		
Duramycin	Treatment of cystic fibrosis.	Duramycin		n/a	12/11/97	Designated			N/A	N/A	"Lantibio, Inc."	Chapel Hill	North Carolina	27517	USA	EXACT	0221749AA	Duramycin	BPR0F3X56H						Cystic fibrosis	6233		
"carbamic acid, [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methyl-ethyl]phenoxy]methyl]phenyl]methoxy]-phenyl]iminomethyl]-,ethyl ester"	Management of cystic fibrosis	amelubant		n/a	1/15/02	Designated/Withdrawn			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc"	Ridgefield	Connecticut	6877	USA	EXACT	0232064AA	amelubant	E0018IF0K4						Cystic fibrosis	6233		
digitoxin	Treatment of cystic fibrosis	digitoxin		n/a	5/27/05	Designated			N/A	N/A	Silver Pharmaceuticals	Rockville	Maryland	20854	USA	EXACT	0012351AA	digitoxin	E90NZP2L9U						Cystic fibrosis	6233		
"3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxyl-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid"	Treatment of cystic fibrosis	Lumacaftor		n/a	3/2/10	Designated			N/A	N/A	Vertex Pharmaceuticals Inc.	Cambridge	Massachusetts	2139	USA	EXACT	0633114AA	Lumacaftor	EGP8L81APK						Cystic fibrosis	6233		
lumacaftor/ivacaftor	Treatment of cystic fibrosis	lumacaftor		Orkambi	6/30/14	Designated/Approved	Approved for Orphan Indication	Treatment of cystic fibrosis in patients age 12 years and older who are homozygous for F508del mutation in the CFTR gene	7/2/15	7/2/22	Vertex Pharmaceuticals Inc.	Boston	Massachusetts	2210	USA	EXACT	0633114AA	lumacaftor	EGP8L81APK						Cystic fibrosis	6233		
recombinant human alpha-1 antitrypsin	Treatment of cystic fibrosis.	recombinant human alpha-1 antitrypsin		n/a	3/6/98	Designated			N/A	N/A	PPL Therapeutics (Scotland) Limited				United Kingdom	EXACT	0334770AA	.ALPHA.1-PROTEINASE INHIBITOR (HUMAN)	F43I396OIS						Cystic fibrosis	6233		
recombinant human alpha 1-antitrypsin (rAAT)	Treatment of cystic fibrosis	recombinant human alpha 1-antitrypsin (rAAT)		n/a	11/20/01	Designated			N/A	N/A	AiroMedica LLC	Alameda	California	94611	USA	EXACT	0334770AA	.ALPHA.1-PROTEINASE INHIBITOR (HUMAN)	F43I396OIS						Cystic fibrosis	6233		
Alpha1-Proteinase Inhibitor (Human)	Treatment of cystic fibrosis	Alpha1-Proteinase Inhibitor (Human)		Arc-Api	9/1/04	Designated			N/A	N/A	Kamada Ltd.	Ness Ziona			Israel	EXACT	0334770AA	Alpha1-Proteinase Inhibitor (Human)	F43I396OIS						Cystic fibrosis	6233		
alpha1-proteinase inhibitor (human)	Treatment of cystic fibrosis	alpha1-proteinase inhibitor (human)		n/a	2/20/09	Designated			N/A	N/A	CSL Behring LLC	King of Prussia	Pennsylvania	19406	USA	EXACT	0334770AA	alpha1-proteinase inhibitor (human)	F43I396OIS						Cystic fibrosis	6233		
alpha1-proteinase inhibitor (human)	Treatment of cystic fibrosis	alpha1-proteinase inhibitor (human)		n/a	4/6/12	Designated			N/A	N/A	"Grifols Therapeutics, Inc."	Clayton	North Carolina	27520	USA	EXACT	0334770AA	alpha1-proteinase inhibitor (human)	F43I396OIS						Cystic fibrosis	6233		
Meropenem	"Management of acute pulmonary exacerbations, in cystic fibrosis patients, due to respiratory tract infection with susceptible organisms."	Meropenem		Merrem Iv	4/27/00	Designated/Withdrawn			N/A	N/A	AstraZeneca Pharmaceuticals	Wilmington	Delaware	19850	USA	EXACT	0183562AA	Meropenem	FV9J3JU8B1						Cystic fibrosis	6233		
Amiloride HCl solution for inhalation	Treatment of cystic fibrosis.	Amiloride HCl solution for inhalation		n/a	7/18/90	Designated/Withdrawn			N/A	N/A	Glaxo Wellcome Research and Development	Research Triangle Park	North Carolina	27709	USA	EXACT	0038153AA	Amiloride HCl	FZJ37245UC						Cystic fibrosis	6233		
aztreonam	Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis	aztreonam		Cayston	3/12/02	Designated/Approved	Approved for Orphan Indication	To improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa	2/22/10	2/22/17	Gilead Sciences (formerly Corus Pharma)	Seattle	Washington	98102	USA	EXACT	0116723AA	aztreonam	G2B4VE5GH8						Cystic fibrosis	6233		
dextran 1	Treatment of cystic fibrosis	dextran 1		n/a	3/21/03	Designated			N/A	N/A	BCY LifeSciences Inc.	"Toronto, Ontario M4P 3B"			Canada	EXACT	0156387AA	dextran 1	I8LHQ0D645						Cystic fibrosis	6233		
cobiprostone	Treatment of cystic fibrosis	cobiprostone		n/a	11/14/02	Designated/Withdrawn			N/A	N/A	"Sucampo Pharma Americas, LLC."	Bethesda	Maryland	20814	USA	EXACT	0244462AA	cobiprostone	IL870Q3Z8I						Cystic fibrosis	6233		
diferuloylmethane	Treatment of cystic fibrosis	diferuloylmethane		n/a	6/13/03	Designated			N/A	N/A	"Allertein Therapeutics, LLC"	Fairfield	Connecticut	6824	USA	EXACT	0025901AA	diferuloylmethane	IT942ZTH98						Cystic fibrosis	6233		
leukotriene A4 hydrolase inhibitor	Treatment of cystic fibrosis	Acebilustat		n/a	1/26/15	Designated			N/A	N/A	"Celtaxsys, Inc."	Atlanta	Georgia	30363	USA	EXACT	1149208AA	Acebilustat	J64RI4D29U						Cystic fibrosis	6233		
Recombinant human gelsolin	Treatment of the respiratory symptoms of cystic fibrosis.	Recombinant human gelsolin		n/a	1/12/94	Designated			N/A	N/A	"BioAegis Therapeutics, Inc."	Morristown	New Jersey	7960	USA	EXACT	1577442AA	Recombinant human gelsolin	JBT6SFF5BV						Cystic fibrosis	6233		
ataluren	For use in the treatment of cystic fibrosis resulting fron a nonsense (premature stopcodon) mutation in the cystic bibrosis transmembrane conductance regulatory gene	ataluren		n/a	9/1/04	Designated			N/A	N/A	"PTC Therapeutics, Inc."	South Plainfield	New Jersey	7080	USA	EXACT	0317259AA	ataluren	K16AME9I3V						Cystic fibrosis	6233		
sodium nitrite and EDTA	Treatment of Pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis	sodium nitrite and EDTA		n/a	11/10/15	Designated			N/A	N/A	"Arch Biopartners, Inc."	Toronto	Ontario		Canada	EXACT	0049581AA	sodium nitrite	M0KG633D4F						Cystic fibrosis	6233		
amikacin sulfate	Management of cystic fibrosis patients with Pseudomonas aeruginosa lung infections	amikacin sulfate		n/a	1/5/15	Designated			N/A	N/A	PlumeStars s.r.l.				Italy	EXACT	0065178AA	amikacin sulfate	N6M33094FD						Cystic fibrosis	6233		
S-nitrosoglutathione reductase inhibitor	Treatment of cystic fibrosis	CAVOSONSTAT		n/a	1/13/16	Designated			N/A	N/A	"Nivalis Therapeutics, Inc."	Boulder	Colorado	80301	USA	EXACT	0925100AA	CAVOSONSTAT	O2Z8Q22ZE4						Cystic fibrosis	6233		
"(6aR, 10aR)-3-(1’,1’-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid"	Treatment of cystic fibrosis.	JBT-101		n/a	10/13/15	Designated			N/A	N/A	"Corbus Pharmaceuticals, Inc."	Norwood	Massachusetts	2062	USA	EXACT	0856735AA	JBT-101	OGN7X90BT8						Cystic fibrosis	6233		
Recombinant truncated SPINT2 protease inhibitor	Treatment of cystic fibrosis	Bikunin		n/a	6/24/05	Designated			N/A	N/A	"Aerovance, Inc."	Berkeley	California	94710	USA	EXACT	0549451AA	Bikunin	OR3S9IF86U						Cystic fibrosis	6233		
Sodium pyruvate	Treatment of cystic fibrosis	Sodium pyruvate		n/a	3/31/03	Designated			N/A	N/A	"Cellular Sciences, Inc"	Flemington	New Jersey	8822	USA	EXACT	0018235AA	Sodium pyruvate	POD38AIF08						Cystic fibrosis	6233		
"(R)-2-(5-cyano-2-(6-(methoxycarbonyl)-7-methyl-3-oxo-8-(3-(trifluoromethyl)phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidin-5-yl)phenyl)-N,N,N-trimethylethanaminium methanesulfonate dehydrate"	Treatment of cystic fibrosis	"(R)-2-(5-CYANO-2-(6-(METHOXYCARBONYL)-7-METHYL-3-OXO-8-(3-(TRIFLUOROMETHYL)PHENYL)-2,3,5,8-TETRAHYDRO-(1,2,4)TRIAZOLO(4,3-A)PYRIMIDIN-5-YL)PHENYL)-N,N,N-TRIMETHYLETHANAMINIUM METHANESULFONATE"		n/a	1/25/17	Designated			N/A	N/A	Chiesi Farmaceutici S.p.A.	Parma			Italy	EXACT	1801010AA	"(R)-2-(5-CYANO-2-(6-(METHOXYCARBONYL)-7-METHYL-3-OXO-8-(3-(TRIFLUOROMETHYL)PHENYL)-2,3,5,8-TETRAHYDRO-(1,2,4)TRIAZOLO(4,3-A)PYRIMIDIN-5-YL)PHENYL)-N,N,N-TRIMETHYLETHANAMINIUM METHANESULFONATE"	Q0656F336Y						Cystic fibrosis	6233		
D9-ivacaftor	Treatment of cystic fibrosis (CF)	CTP-656		n/a	1/18/17	Designated			N/A	N/A	"Concert Pharmaceuticals, Inc."	Lexington	Massachusetts	2421	USA	EXACT	1794510AA	CTP-656	SHA6U5FJZL						Cystic fibrosis	6233		
Heparin	Treatment of cystic fibrosis	Heparin		n/a	11/3/05	Designated/Withdrawn			N/A	N/A	"Vectura Group, Inc."				United Kingdom	EXACT	0118230AA	Heparin	T2410KM04A						Cystic fibrosis	6233		
Uridine 5'-triphosphate	Treatment of cystic fibrosis.	Uridine 5'-triphosphate		n/a	12/4/95	Designated/Withdrawn			N/A	N/A	"Inspire Pharmaceuticals, Inc."	Durham	North Carolina	27703	USA	EXACT	0011052AA	Uridine 5'-triphosphate	UT0S826Z60						Cystic fibrosis	6233		
"potassium (benzenesulfonyl)({[6-(3-{2-[1-(trifluoromethyl)cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridin-3-yl]carbonyl})azanide/tezacaftor/ivacaftor"	Treatment of Cystic Fibrosis	VX-659 POTASSIUM		n/a	5/23/18	Designated			N/A	N/A	Vertex Pharmaceuticals Inc.	50 Northern Avenue		2210	USA	EXACT	0115469AB	VX-659 POTASSIUM	VY7D8MTV72						Cystic fibrosis	6233		
Tobramycin for inhalation	Treatment of bronchopulmonary infections of Pseudomonas aeruginosa in cystic fibrosis patients.	Tobramycin for inhalation		Tobi	10/13/94	Designated/Approved	Approved for Orphan Indication	Management of cystic fibrosis patients with P.aeruginosa.	12/22/97	12/22/04	Novartis Pharmaceuticals Corp	East Hanover	New Jersey	7936	USA	EXACT	0064233AA	Tobramycin	VZ8RRZ51VK						Cystic fibrosis	6233		
fosfomycin/tobramycin	Treatment of pulmonary infections associated with cystic fibrosis	tobramycin		n/a	11/28/08	Designated			N/A	N/A	"CURx Pharmaceuticals, Inc."	San Diego	California	92121	USA	EXACT	0064233AA	tobramycin	VZ8RRZ51VK						Cystic fibrosis	6233		
tobramycin liposomal for inhalation	Treatment of chronic pulmonary infection due to P. aeruginosa in cystic fibrosis patients	tobramycin liposomal for inhalation		Fluidosomes	4/14/09	Designated/Withdrawn			N/A	N/A	Axentis Pharma AG	Zurich			Switzerland	EXACT	0064233AA	tobramycin	VZ8RRZ51VK						Cystic fibrosis	6233		
tobramycin liposomal	Treatment of pulmonary infection due to Burkholderia cepacia complex pathogens in cystic fibrosis patients	tobramycin liposomal		Fluidosoes(Tm)-Tobramycin	5/11/09	Designated/Withdrawn			N/A	N/A	Axentis Pharma AG				Switzerland	EXACT	0064233AA	tobramycin	VZ8RRZ51VK						Cystic fibrosis	6233		
"P1, P4-Di(uridine 5'-tetraphosphate), tetrasodium salt"	Treatment of cystic fibrosis.	DIQUAFOSOL TETRASODIUM		n/a	10/27/98	Designated/Withdrawn			N/A	N/A	"Inspire Pharmaceuticals, Inc."	Durham	North Carolina	27703	USA	EXACT	0296708AA	DIQUAFOSOL TETRASODIUM	X8T9SBH9LL						Cystic fibrosis	6233		
Tiotropium bromide	To improve pulmonary function in conjunction with standard therapy in the management of patients with cystic fibrosis	Tiotropium bromide		Spiriva	1/8/08	Designated			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc."	Ridgefield	Connecticut	6877	USA	EXACT	0189560AA	Tiotropium bromide	XX112XZP0J						Cystic fibrosis	6233		
Tyloxapol	Treatment of cystic fibrosis.	Tyloxapol		Supervent	3/8/95	Designated			N/A	N/A	"Kennedy & Hoidal, M.D.'s"	Salt Lake City	Utah	84132	USA	EXACT	0063003AA	Tyloxapol	Y27PUL9H56						Cystic fibrosis	6233		
Heparin sodium	Treatment of cystic fibrosis	Heparin sodium		n/a	6/29/06	Designated			N/A	N/A	Ockham Biotech Limited				United Kingdom	EXACT	0006177AA	Heparin sodium	ZZ45AB24CA						Cystic fibrosis	6233		
Cystic fibrosis transmembrane conductance regulator	For cystic fibrosis transmembrane conductance regulator protein replacement therapy in cystic fibrosis patients.	Cystic fibrosis transmembrane conductance regulator		n/a	1/14/92	Designated/Withdrawn			N/A	N/A	Genzyme Corporation	Framingham	Massachusetts	1701	USA	EXACT	1337559AA	Cystic fibrosis transmembrane conductance regulator	PW7453NX3R						Cystic fibrosis	6233		
Hypothiocyanite and lactoferrin	Treatment of cystic fibrosis	Hypothiocyanite and lactoferrin		Meveol	11/5/09	Designated			N/A	N/A	Alaxia Biotechnologies Sante				France	EXACT	1804393AA	Hypothiocyanite and lactoferrin	2BP92KEU27						Cystic fibrosis	6233		
Hypothiocyanite and lactoferrin	Treatment of cystic fibrosis	HYPOTHIOCYANITE ION		Meveol	11/5/09	Designated			N/A	N/A	Alaxia Biotechnologies Sante				France	EXACT	0547922AA	HYPOTHIOCYANITE ION	N84CZ7T0OY						Cystic fibrosis	6233		
Lucinactant	Treatment of cystic fibrosis.	Lucinactant		"Surfaxin(R), Aerosurf(R)"	10/21/10	Designated			N/A	N/A	"Windtree Therapeutics, Inc."	Warrington	Pennsylvania	18976	USA	EXACT	0727402AA	Lucinactant							Cystic fibrosis	6233		
2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl)acetamide	Treatment of cystic fibrosis	FDL-169		n/a	5/13/15	Designated			N/A	N/A	Flatley Discovery Lab	Charlestown	Massachusetts	2129	USA	EXACT	1309702AA	FDL-169	49PN4S4FDH						Cystic fibrosis	6233		
"poly-N,N'-hexamethyleneguanidine-poly-N1,N4-hexamethyleneaminoguanidine"	"Treatment of pulmonary infections in patients with cystic fibrosis including infections due to pseudomonas aeruginosa,Burkholderia cepacia and other bacteria"	mul-1867		n/a	4/5/16	Designated			N/A	N/A	"TGV-Inhalonix, Inc."	New York	New York	10016	USA	EXACT	1802502AA	mul-1867	KYU75D2TUQ						Cystic fibrosis	6233		
"N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)cyclobutyl)-3-phenylisoxazole-5-carboxamide"	Treatment of cystic fibrosis	PTI-428		n/a	3/7/18	Designated			N/A	N/A	"Proteostasis Therapeutics, Inc."	200 Technology Square		Massachusetts	USA	EXACT	0115043AB	PTI-428	T2U4ZA62U4						Cystic fibrosis	6233		
Brevenal	Treatment of cystic fibrosis	Brevenal		n/a	4/2/18	Designated			N/A	N/A	"Silurian Pharmaceuticals, Inc."	6490 Doyle Street		94608	USA	EXACT	0115044AB	Brevenal	ECX1L89MFR						Cystic fibrosis	6233		
"Dextran sulfate (inhaled, aerosolized)"	For use as an adjunct to the treatment of cystic fibrosis.	"Dextran sulfate (inhaled, aerosolized)"		Uendex	10/5/90	Designated			N/A	N/A	"Kennedy & Hoidal, M.D.'s"	Salt Lake City	Utah	84132	USA	LONGEST CONTAINS	0005856AA	Dextran							Cystic fibrosis	6233		
Mucoid exopolysaccharide Pseudomonas hyperimmune globulin	Prevention of pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.	Mucoid exopolysaccharide Pseudomonas hyperimmune globulin		Mep Igiv	11/7/90	Designated/Withdrawn			N/A	N/A	"North American Biologicals, Inc."	Rockville	Maryland	20852	USA										Cystic fibrosis	6233		
Mucoid exopolysaccharide Pseudomonas hyperimmune globulin	Treatment of pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.	Mucoid exopolysaccharide Pseudomonas hyperimmune globulin		Mep Igiv	1/9/91	Designated/Withdrawn			N/A	N/A	"North American Biologicals, Inc."	Rockville	Maryland	20852	USA										Cystic fibrosis	6233		
Cystic fibrosis gene therapy	Treatment of cystic fibrosis.	Cystic fibrosis gene therapy		n/a	6/30/92	Designated/Withdrawn			N/A	N/A	Genzyme Corporation	Framingham	Massachusetts	1701	USA										Cystic fibrosis	6233		
Cystic fibrosis transmembrane conductance regulator gene	Treatment of cystic fibrosis.	Cystic fibrosis transmembrane conductance regulator gene		n/a	1/8/93	Designated			N/A	N/A	"Genetic Therapy, Inc."	Gaithersburg	Maryland	20878	USA	LONGEST CONTAINS	1337559AA	Cystic fibrosis transmembrane conductance regulator	PW7453NX3R						Cystic fibrosis	6233		
2-0-desulfated heparin	Treatment of cystic fibrosis.	2-0-desulfated heparin		Aeropin	9/17/93	Designated			N/A	N/A	"Kennedy & Hoidal, M.D.'s"	Salt Lake City	Utah	84132	USA	LONGEST CONTAINS	0118230AA	heparin	T2410KM04A						Cystic fibrosis	6233		
Adeno-associated viral-based vector cystic fibrosis gene therapy	Treatment of cystic fibrosis.	Adeno-associated viral-based vector cystic fibrosis gene therapy		n/a	2/15/95	Designated/Withdrawn			N/A	N/A	Targeted Genetics Corporation	Seattle	Washington	98101	USA										Cystic fibrosis	6233		
Cystic fibrosis Tr gene therapy (recombinant adenovirus)	Treatment of cystic fibrosis.	Cystic fibrosis Tr gene therapy (recombinant adenovirus)		Adgvcftr.10	3/9/95	Designated			N/A	N/A	"GenVec, Inc."	Rockville	Maryland	20852	USA										Cystic fibrosis	6233		
Lipid/DNA human cystic fibrosis gene	Treatment of cystic fibrosis.	Lipid/DNA human cystic fibrosis gene		n/a	4/8/96	Designated/Withdrawn			N/A	N/A	Genzyme Corporation	Framingham	Massachusetts	1701	USA										Cystic fibrosis	6233		
octavalent Psuedomonas aeruginosa O-polysaccaharide-toxin A conjugate	Prevention of Psuedomonas aeruginosa infections in patients with cystic fibrosis	octavalent Psuedomonas aeruginosa O-polysaccaharide-toxin A conjugate		Aerugen	5/16/02	Designated/Withdrawn			N/A	N/A	Berna Biotech Ltd.	Berna			Switzerland										Cystic fibrosis	6233		
Plasmid DNA vector expressing cystic fibrosis transmembrane gene	Treatment of cystic fibrosis	Plasmid DNA vector expressing cystic fibrosis transmembrane gene		n/a	3/29/05	Designated			N/A	N/A	"Copernicus Therapeutics, Inc."	Cleveland	Ohio	44106	USA										Cystic fibrosis	6233		
anti-sense oligonucleotide consisting of 2Ã¿Æ¿Ã¿â¿¿Ã¿â¿¿Ã¿Â¢Ã¿Æ¿Ã¿Â¢Ã¿Â¢Ã¢â¿¿Â¬Ã¿Â¡Ã¿â¿¿Ã¿Â¬Ã¿Æ¿Ã¿Â¢Ã¿Â¢Ã¢â¿¿Â¬Ã¿Â¾Ã¿â¿¿Ã¿Â¢0-Me RNA with a phosphorothioate backbone	Treatment of cystic fibrosis	anti-sense oligonucleotide consisting of 2Ã¿Æ¿Ã¿â¿¿Ã¿â¿¿Ã¿Â¢Ã¿Æ¿Ã¿Â¢Ã¿Â¢Ã¢â¿¿Â¬Ã¿Â¡Ã¿â¿¿Ã¿Â¬Ã¿Æ¿Ã¿Â¢Ã¿Â¢Ã¢â¿¿Â¬Ã¿Â¾Ã¿â¿¿Ã¿Â¢0-Me RNA with a phosphorothioate backbone		n/a	9/23/13	Designated			N/A	N/A	ProQR Therapeutics III B.V.				Netherlands										Cystic fibrosis	6233		
PEGylated recombinant anti-Pseudomonas aeruginosa PcrV Fab' antibody	Treatment of cystic fibrosis patients with Pseudomonas aeruginosa lung infections	PEGylated recombinant anti-Pseudomonas aeruginosa PcrV Fab' antibody		n/a	10/25/13	Designated			N/A	N/A	"KaloBios Pharmaceuticals, Inc."	South San Francisco	California	94080	USA	LONGEST CONTAINS	0340727AA	Pseudomonas aeruginosa	Y793W5V55N						Cystic fibrosis	6233		
plasmid DNA encoding the human cystic fibrosis transmembrane conductance regulator gene complexed with a nonviral cationic lipid based gene transfer agent	Treatment of cystic fibrosis	plasmid DNA encoding the human cystic fibrosis transmembrane conductance regulator gene complexed with a nonviral cationic lipid based gene transfer agent		n/a	6/30/14	Designated			N/A	N/A	Imperial Innovations Limited				United Kingdom	LONGEST CONTAINS	1337559AA	cystic fibrosis transmembrane conductance regulator	PW7453NX3R						Cystic fibrosis	6233		
human cystic fibrosis transmembrane conductance regulator (hCFTR) messenger RNA (mRNA) complexed with branched polyethyleneimine (bPEI)	Treatment of patients with cystic fibrosis.	human cystic fibrosis transmembrane conductance regulator (hCFTR) messenger RNA (mRNA) complexed with branched polyethyleneimine (bPEI)		n/a	11/3/15	Designated			N/A	N/A	Shire	Lexington	Massachusetts	2421	USA	LONGEST CONTAINS	1337559AA	cystic fibrosis transmembrane conductance regulator	PW7453NX3R						Cystic fibrosis	6233		
sodium alginate oligosaccharide	Treatment of cystic fibrosis.	sodium alginate oligosaccharide		n/a	2/24/16	Designated			N/A	N/A	AlgiPharma AS	Sandvika			Norway	LONGEST CONTAINS	0006144AA	sodium alginate	C269C4G2ZQ						Cystic fibrosis	6233		
ascorbic acid	Treatment of cystic fibrosis	ascorbic acid		n/a	7/30/18	Designated			N/A	N/A	"Renovion, Inc."	112 South Duke Street	North Carolina	27701	USA	EXACT	0007658AA	ascorbic acid	PQ6CK8PD0R						Cystic fibrosis	6233		
"N-(1,3-dimethyl-1H-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide/tezacaftor/ivacaftor"	Treatment of Cystic Fibrosis	ivacaftor		n/a	8/29/18	Designated			N/A	N/A	Vertex Pharmaceuticals Inc.	50 Northern Avenue	Massachusetts	2210	USA	EXACT	0297132AA	ivacaftor	1Y740ILL1Z						Cystic fibrosis	6233		
"N-(1,3-dimethyl-1H-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide/tezacaftor/ivacaftor"	Treatment of Cystic Fibrosis	tezacaftor		n/a	8/29/18	Designated			N/A	N/A	Vertex Pharmaceuticals Inc.	50 Northern Avenue	Massachusetts	2210	USA	EXACT	1139328AA	tezacaftor	8RW88Y506K						Cystic fibrosis	6233		
"N-(1,3-dimethyl-1H-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide/tezacaftor/ivacaftor"	Treatment of Cystic Fibrosis	VX-445		n/a	8/29/18	Designated			N/A	N/A	Vertex Pharmaceuticals Inc.	50 Northern Avenue	Massachusetts	2210	USA	EXACT	1797279AA	VX-445	RRN67GMB0V						Cystic fibrosis	6233		
"poly (acetyl, arginyl) glucosamine"	Treatment of cystic fibrosis.	"poly (acetyl, arginyl) glucosamine"		n/a	10/2/18	Designated			N/A	N/A	"Synedgen, Inc."	1420 North Claremont Boulevard	California	91711	USA	LONGEST CONTAINS	0040700AA	glucosamine	N08U5BOQ1K						Cystic fibrosis	6233		
Cysteamine	Treatment of nephropathic cystinosis.	Cysteamine		n/a	5/1/86	Designated			N/A	N/A	"Thoene, Jess G., M.D."	Ann Arbor	Michigan	48109	USA	EXACT	0010377AA	Cysteamine	5UX2SD1KE2						Cystinosis	6236		
Cysteamine	Treatment of nephropathic cystinosis.	Cysteamine		Cystagon	1/25/91	Designated/Approved	Approved for Orphan Indication	Treatment of nephropathic cystinosis in adults and children.	8/15/94	8/15/01	"Mylan Laboratories, Inc."	Morgantown	West Virginia	26504	USA	EXACT	0010377AA	Cysteamine	5UX2SD1KE2						Cystinosis	6236		
cysteamine enteric coated	Treatment of cystinosis	cysteamine enteric coated		Procysbi	10/24/06	Designated/Approved	Approved for Orphan Indication	For management of nephropathic cystinosis in adults and children ages 6 years and older	4/30/13	4/30/20	"Raptor Therapeutics, Inc."	Novato	California	94949	USA	EXACT	0010377AA	cysteamine	5UX2SD1KE2						Cystinosis	6236		
cysteamine enteric coated	Treatment of cystinosis	cysteamine enteric coated		Procysbi	10/24/06	Designated/Approved	Approved for Orphan Indication	To expand the indication to pediatric patients 2-6 years of age with nephropathic cystinosis	8/14/15	8/14/22	"Raptor Therapeutics, Inc."	Novato	California	94949	USA	EXACT	0010377AA	cysteamine	5UX2SD1KE2						Cystinosis	6236		
"6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate"	Treatment of Cystinosis	NB-124 sulfate		n/a	4/26/18	Designated			N/A	N/A	"ELOXX Pharmaceuticals, Inc."	"950 Winter Street, North"		2451	USA	EXACT	1801145AA	NB-124 sulfate	DZ671709NT						Cystinosis	6236		
Cysteamine hydrochloride	Treatment of corneal cystine crystal accumulation in cystinosis patients.	Cysteamine hydrochloride		Cystaran	8/19/97	Designated/Approved	Approved for Orphan Indication	Treatment of corneal cystine crystal accumulation in patients with cystinosis	10/2/12	10/2/19	"Sigma-Tau Pharmaceuticals, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0023654AA	Cysteamine hydrochloride	IF1B771SVB						Cystinosis	6236		
Phosphocysteamine	Treatment of cystinosis.	Phosphocysteamine		n/a	9/12/88	Designated/Withdrawn			N/A	N/A	Medea Research Laboratories	Port Jefferson	New York	11776	USA	EXACT	0739093AA	Phosphocysteamine	WFH6A9S0V4						Cystinosis	6236		
taurine	Treatment of cystathionine beta-synthase deficient homocystinuria	taurine		n/a	3/22/10	Designated			N/A	N/A	"Johan L. Van Hove, MD, PhD"	Aurora	Colorado	80045	USA	EXACT	0017390AA	taurine	1EQV5MLY3D						Cystinuria	6237		
Betaine	Treatment of homocystinuria.	Betaine		Cystadane	5/16/94	Designated/Approved	Approved for Orphan Indication	Treatment of homocystinuria to decrease elevated homocysteine blood levels.	10/25/96	10/25/03	Jazz Pharmaceuticals	Palo Alto	California	94304	USA	EXACT	0017414AA	Betaine	3SCV180C9W						Cystinuria	6237		
Tiopronin	Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.	Tiopronin		Thiola	1/17/86	Designated/Approved	Approved for Orphan Indication		8/11/88	8/11/95	"Pak, Charles Y.C. M.D."	Dallas	Texas	75235	USA	EXACT	0037934AA	Tiopronin	C5W04GO61S						Cystinuria	6237		
Succimer	Prevention of cystine kidney stone formation in patients with homozygous cystinuria who are prone to stone development.	Succimer		Chemet	11/5/90	Designated			N/A	N/A	"Sanofi Winthrop, Inc."	New York	New York	10016	USA	EXACT	0068928AA	Succimer	DX1U2629QE						Cystinuria	6237		
Bucillamine	Treatment of cystinuria	Bucillamine		n/a	10/22/15	Designated			N/A	N/A	"Revive Therapeutics, Ltd."	Vaughan	Ontario		Canada	EXACT	0180245AA	Bucillamine	R80LRA5WTF						Cystinuria	6237		
L-cystine bis(N'-methylpiperazide)	Treatment of cystinuria.	LH-708		n/a	6/4/18	Designated			N/A	N/A	PharmaKrysto Ltd	Rmt Accountants & Business Advisors Ltd.	Gosforth Park Avenue		United Kingdom	EXACT	0115472AB	LH-708							Cystinuria	6237		
polyethylene glycol modified recombinant C-terminal truncate of human cystathionine beta-synthase	Treatment of homocystinuria	polyethylene glycol modified recombinant C-terminal truncate of human cystathionine beta-synthase		n/a	3/17/15	Designated			N/A	N/A	Orphan Technologies Limited					LONGEST CONTAINS	0137031AA	polyethylene glycol	3WJQ0SDW1A						Cystinuria	6237		
N-(9-methoxynonyl)-1-deoxynojirimycin hydrochloride	"Treatment of acute dengue illness (inclusive of acute dengue illness, dengue fever, dengue hemorrhagic fever, and dengue shock syndrome)"	uv-4b		n/a	11/17/14	Designated			N/A	N/A	"Emergent Virology, LLC"	Gaithersburg	Maryland	20879	USA	EXACT	0925019AA	uv-4b	R3Y2198MRP						Dengue fever	6254		
Conjugate of a dengue virus specific small chemical ligand and an amphiphilic PEG based polymer	Treatment of dengue fever (includes dengue hemorrhagic fever and dengue shock syndrome)	Conjugate of a dengue virus specific small chemical ligand and an amphiphilic PEG based polymer		n/a	8/6/13	Designated			N/A	N/A	NanoViricides Incorporated	West Haven	Connecticut	6516	USA										Dengue fever	6254		
Immune globulin intravenous (human)	Treatment of polymyositis/dermatomyositis.	IVIG		"Iveegam, Immuno"	10/13/92	Designated/Withdrawn			N/A	N/A	Immuno Clinical Research Corp.	New York	New York	10022	USA	EXACT	0233705AA	Immune globulin intravenous (human)	66Y330CJHS						Dermatomyositis	6263		
Immune globulin intravenous (human) octagam 10%	Treatment of dermatomyositis	IVIG		n/a	4/19/17	Designated			N/A	N/A	"OCTAPHARMA USA, Inc."	Hoboken	New Jersey	7030	USA	EXACT	0201570AA	IVIG	66Y330CJHS						Dermatomyositis	6263		
Eculizumab	Treatment of dermatomyositis	Eculizumab		n/a	9/21/00	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	Cheshire	Connecticut	6410	USA	EXACT	0298000AA	Eculizumab	A3ULP0F556						Dermatomyositis	6263		
sodium thiosulfate	Treatment of dermatomyositis	sodium thiosulfate		n/a	10/28/14	Designated			N/A	N/A	Hope Pharmaceuticals	Scottsdale	Arizona	85260	USA	EXACT	0053225AA	sodium thiosulfate	HX1032V43M						Dermatomyositis	6263		
siponimod	Treatment of dermatomyositis	siponimod		n/a	7/10/14	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0682360AA	siponimod	RR6P8L282I						Dermatomyositis	6263		
lenabasum	Treatment of dermatomyositis	lenabasum		n/a	7/18/18	Designated			N/A	N/A	"Corbus Pharmaceuticals, Inc."	100 River Ridge Drive	Massachusetts	2062	USA	EXACT	0856735AA	lenabasum	OGN7X90BT8						Dermatomyositis	6263		
immune globulin subcutaneous (Human)	Treatment of Dermatomyositis	immune globulin subcutaneous (Human)		Hizentra®	9/12/18	Designated			N/A	N/A	CSL Behring	1020 First Avenue	Pennsylvania	19406	USA	EXACT	0259290AA	immune globulin subcutaneous (Human)	66Y330CJHS						Dermatomyositis	6263		
cladribine	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	cladribine		n/a	3/19/15	Designated			N/A	N/A	Chord Therapeutics S.a.r.l.				Switzerland	EXACT	0092944AA	cladribine	47M74X9YT5						Neuromyelitis optica	6267		
"humanized affinity-optimized, afucosylated immunoglobulin G1 kappa monoclonal antibody against CD19"	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders	MEDI-551		n/a	2/10/16	Designated			N/A	N/A	"MedImmune, LLC"	Gaithersburg	Maryland	20878	USA	EXACT	0810173AA	MEDI-551	74T7185BMM						Neuromyelitis optica	6267		
eculizumab	Treatment of neuromyelitis optica	eculizumab		Soliris	6/24/13	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	Cheshire	Connecticut	6410	USA	EXACT	0298000AA	eculizumab	A3ULP0F556						Neuromyelitis optica	6267		
humanized anti-IL-6R receptor neutralizing IgG2 monoclonal antibody	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	Tocilizumab		n/a	6/30/14	Designated			N/A	N/A	"Chugai Pharma USA, LLC"	Berkeley Heights	New Jersey	7922	USA	EXACT	0298146AA	Tocilizumab	I031V2H011						Neuromyelitis optica	6267		
ublituximab	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	ublituximab		n/a	8/25/16	Designated			N/A	N/A	"TG Therapeutics, Inc."	New York	New York	10019	USA	EXACT	0574607AA	ublituximab	U59UGK3IPC						Neuromyelitis optica	6267		
Interleukin-3 human (recombinant)	Promotion of erythropoiesis in Diamond-Blackfan anemia (congenital pure red cell aplasia).	HUMAN INTERLEUKIN-3 (NONGLYCOSYLATED)		n/a	5/20/91	Designated/Withdrawn			N/A	N/A	Immunex Corporation	Seattle	Washington	98101	USA	EXACT	0259836AA	HUMAN INTERLEUKIN-3 (NONGLYCOSYLATED)	A802907MI4						Diamond-Blackfan anemia	6274		
golodirsen	Treatment of Duchenne muscular dystrophy (DMD)	golodirsen		n/a	5/22/18	Designated			N/A	N/A	"Sarepta Therapeutics, Inc."	215 First Street		2142	USA	EXACT	1336272AA	golodirsen	033072U4MZ						Duchenne muscular dystrophy	6291		
non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon 2 in the human DMD gene under the control of U7 small nuclear non-coding RNA	Treatment of Duchenne muscular dystrophy	non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon 2 in the human DMD gene under the control of U7 small nuclear non-coding RNA		n/a	9/19/17	Designated			N/A	N/A	Nationwide Children's Hospital	Columbus	Ohio	43205	USA	EXACT	1078393AA	tucatinib	234248D0HH						Duchenne muscular dystrophy	6291		
recombinant human anti-GDF-8 monoclonal antibody	Treatment of Duchenne Muscular Dystrophy.	Domagrozumab		n/a	7/24/12	Designated			N/A	N/A	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	1141953AA	Domagrozumab	516MD5WQ24						Duchenne muscular dystrophy	6291		
givinostat	Treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy	givinostat		n/a	4/12/13	Designated			N/A	N/A	Italfarmaco SpA				Italy	EXACT	0338341AA	givinostat	5P60F84FBH						Duchenne muscular dystrophy	6291		
5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzp[d]oxazole	Treatment of Duchenne Muscular Dystrophy	EZUTROMID		n/a	11/22/11	Designated			N/A	N/A	Summit Corporation plc				United Kingdom	EXACT	0740443AA	EZUTROMID	645R07LF0D						Duchenne muscular dystrophy	6291		
cosyntropin	Treatment of Duchenne muscular dystrophy.	cosyntropin		n/a	7/6/17	Designated			N/A	N/A	Mallinckrodt ARD Inc.	Hazelwood	Missouri	63042	USA	EXACT	0057410AA	cosyntropin	72YY86EA29						Duchenne muscular dystrophy	6291		
tadalafil	Treatment of Duchenne Muscular Dystrophy (DMD)	tadalafil		Cialis(R); Adcirca(R)	5/4/15	Designated			N/A	N/A	Eli Lilly and Company	Indianapolis	Indiana	46285	USA	EXACT	0223563AA	tadalafil	742SXX0ICT						Duchenne muscular dystrophy	6291		
20-hydroxyecdysone	Treatment of Duchenne Muscular Dystrophy	20-hydroxyecdysone		n/a	5/10/18	Designated			N/A	N/A	Biophytis SA	14 Avenue de l’Opera			France	EXACT	0842535AA	20-hydroxyecdysone	779A7KPL0Y						Duchenne muscular dystrophy	6291		
"delta-1,4,9(11)-pregnatriene-17-alpha,21-dihydroxy-16-alpha-methyl-3,20-dione"	Treatment of Duchenne muscular dystrophy	vamorolone		n/a	12/2/11	Designated			N/A	N/A	ReveraGen Biopharma	Rockville	Maryland	20850	USA	EXACT	0739719AA	vamorolone	8XP29XMB43						Duchenne muscular dystrophy	6291		
"N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)ethyl)-2-hydroxybenzamide"	Treatment of Duchenne muscular dystrophy	EDASALONEXENT		n/a	11/17/14	Designated			N/A	N/A	"Catabasis Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0709104AA	EDASALONEXENT	AF3Z6434KS						Duchenne muscular dystrophy	6291		
eteplirsen	Treatment of Duchenne Muscular Dystrophy.	eteplirsen		Exondys 51	10/23/07	Designated/Approved	Approved for Orphan Indication	Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping	9/19/16	9/19/23	"Sarepta Therapeutics, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0813503AA	eteplirsen	AIW6036FAS						Duchenne muscular dystrophy	6291		
Mazindol	Treatment of Duchenne muscular dystrophy.	Mazindol		Sanorex	12/8/86	Designated			N/A	N/A	"Collipp, Platon J. M.D."	Jesup	Georgia	31545	USA	EXACT	0060639AA	Mazindol	C56709M5NH						Duchenne muscular dystrophy	6291		
idebenone	Treatment of Duchenne muscular dystrophy	idebenone		n/a	2/16/07	Designated			N/A	N/A	Santhera Pharaceuticals Limited				Switzerland	EXACT	0167260AA	idebenone	HB6PN45W4J						Duchenne muscular dystrophy	6291		
angiotensin (1-7)[A(1-7)]	Treatment of Duchenne muscular dystrophy	angiotensin (1-7)(A(1-7))		n/a	7/25/13	Designated			N/A	N/A	"US Biotest, Inc."	San Luis Obispo	California	93401	USA	EXACT	0232428AA	Angiotensin 1-7	IJ3FUK8MOF						Duchenne muscular dystrophy	6291		
deflazacort	Treatment of Duchenne muscular dystrophy	deflazacort		Calcort	9/16/10	Designated			N/A	N/A	University of Rochester Medical Center	Rochester	New York	14620	USA	EXACT	0084537AA	deflazacort	KR5YZ6AE4B						Duchenne muscular dystrophy	6291		
deflazacort	Treatment of Duchenne muscular dystrophy	deflazacort		n/a	8/16/13	Designated			N/A	N/A	"Marathon Pharmaceuticals, LLC"	Northbrook	Illinois	60062	USA	EXACT	0084537AA	deflazacort	KR5YZ6AE4B						Duchenne muscular dystrophy	6291		
poloxamer-188 NF	Treatment of Duchenne muscular dystrophy	poloxamer-188		n/a	1/19/10	Designated			N/A	N/A	"Phrixus Pharmaceuticals, Inc."	Ann Arbor	Michigan	48104	USA	EXACT	0006826AA	poloxamer 188	LQA7B6G8JG						Duchenne muscular dystrophy	6291		
(3R)-3-Methyl-6-[2-({5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-1-yl}methyl)phenoxy]hexanoic acid hemisulfate	Treatment of Duchenne muscular dystrophy	MA-0211 HEMISULFATE		n/a	3/28/18	Designated			N/A	N/A	"Astellas Pharma Global Development, Inc."	1 Astellas Way		60062	USA	EXACT	0112276AB	MA-0211 HEMISULFATE	LWF2PR5DHD						Duchenne muscular dystrophy	6291		
halofuginone hydrobromide	Treatment of Duchenne Muscular Dystrophy	halofuginone hydrobromide		n/a	10/13/11	Designated			N/A	N/A	"Halo Theraeputics, LLC"	Newton	Massachusetts	2466	USA	EXACT	0247198AA	halofuginone hydrobromide	PTC2969MV1						Duchenne muscular dystrophy	6291		
rimeporide	Treatment of Duchenne muscular dystrophy	rimeporide		n/a	9/19/17	Designated			N/A	N/A	EspeRare Foundation	Plan-les-Ouates			Switzerland	EXACT	0336721AA	rimeporide	QH6B4V5743						Duchenne muscular dystrophy	6291		
laminin-111 (human)	Treatment of Duchenne Muscular Dystrophy	laminin-111 (human)		n/a	7/21/11	Designated			N/A	N/A	"Prothelia, Inc."	Milford	Massachusetts	1757	USA	EXACT	0761433AA	laminin-111 (human)	QJK0WC9NHE						Duchenne muscular dystrophy	6291		
O-(3-piperidino-2-hydroxyl-1-propyl)-nicotinic acid amidoxime hydrochloride	Treatment of Duchenne Muscular Dystrophy	bgp-15		n/a	1/15/13	Designated			N/A	N/A	Vudbenk Life Sciences				Hungary	EXACT	0828239AA	bgp-15	RLN2GTG4YS						Duchenne muscular dystrophy	6291		
naproxcinod	Treatment of Duchenne muscular dystrophy.	naproxcinod		n/a	3/16/15	Designated			N/A	N/A	Nicox SA	Valbonne			France	EXACT	0243732AA	naproxcinod	V24GR4LI3I						Duchenne muscular dystrophy	6291		
Peptide that inhibits mechanosensitive ion channel (MSC) activity	Treatment of Duchenne Muscular Dystrophy (DMD.)	AT-300		n/a	9/15/10	Designated			N/A	N/A	Rose Pharmaceuticals	Williamsville	New York	14221	USA	EXACT	1805409AA	AT-300							Duchenne muscular dystrophy	6291		
"4-[(7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl]benzoic acid, hemifumarate"	Treatment of patients with Duchenne Muscular Dystrophy.	ARM-210 HEMIFUMARATE		n/a	11/18/15	Designated			N/A	N/A	"ARMGO Pharma, Inc."	Tarrytown	New York	10591	USA	EXACT	1674802AA	ARM-210 HEMIFUMARATE	ZHR6WM1ADJ						Duchenne muscular dystrophy	6291		
Vasomera	"Treatment of cardiomyopathy associated with dystrophinopathies; Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy BMD), and X-linked dilated cardiomyopathy (XL-dCMP)."	Vasomera		n/a	11/19/15	Designated			N/A	N/A	"PhaseBio Pharmaceuticals, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	1267045AA	Vasomera	200AW54D93						Duchenne muscular dystrophy	6291		
recombinant human biglycan	Treatment of Duchenne Muscular Dystrophy	TVN-102		n/a	7/13/16	Designated			N/A	N/A	"Tivorsan Pharmaceuticals, Inc."	Providence	Rhode Island	2903	USA	EXACT	1802217AA	TVN-102	20ZC7Q59K8						Duchenne muscular dystrophy	6291		
Exon 46 specific phosphorothioate oligonucleotide	Treatment of Duchenne muscular dystrophy	Exon 46 specific phosphorothioate oligonucleotide		n/a	11/18/05	Designated/Withdrawn			N/A	N/A	Prosensa Therapuetics BV	Leiden			Netherlands										Duchenne muscular dystrophy	6291		
Exon 51 specific phosphorothioate oligonucleotide	Treatment of Duchenne Muscular Dystrophy.	Exon 51 specific phosphorothioate oligonucleotide		n/a	8/25/09	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA										Duchenne muscular dystrophy	6291		
peptide-conjugated phosporodiamidate morpholino oligomer (PPMO)	"Treatment of Duchenne muscular dystrophy in patients with a deletion, duplication or frame shift mutation correctable by skipping of exon 50 of the dystrophin gene to allow restoration of the reading frame (including mutations within exons 51, 51-53, or 51-55)."	peptide-conjugated phosporodiamidate morpholino oligomer (PPMO)		n/a	9/3/09	Designated			N/A	N/A	"Sarepta Therapeutics, Inc."	Cambridge	Massachusetts	2142	USA	LONGEST CONTAINS	1797166AA	morpholino							Duchenne muscular dystrophy	6291		
Exon 44 specific phosphorothioate oligonucleotide	Treatment of Duchenne Muscular Dystrophy in patients who have a mutation correctable by skipping of exon 44of the dystrophin gene.	Exon 44 specific phosphorothioate oligonucleotide		n/a	11/5/09	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA										Duchenne muscular dystrophy	6291		
ActRIIB-IgG1)	Treatment of Duchenne muscular dystrophy	ActRIIB-IgG1)		n/a	8/16/10	Designated			N/A	N/A	"Acceleron Pharma, Inc."	Cambridge	Massachusetts	2139	USA										Duchenne muscular dystrophy	6291		
adeno-associated viral vector containing modified U11 snRNA	Treatment of Duchenne muscular dystrophy.	adeno-associated viral vector containing modified U11 snRNA		n/a	9/15/10	Designated			N/A	N/A	uniQure B.V.	Amsterdam			Netherlands										Duchenne muscular dystrophy	6291		
Exon 55 specific phosphorothioate oligonucleotide	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 55	Exon 55 specific phosphorothioate oligonucleotide		n/a	1/23/13	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA										Duchenne muscular dystrophy	6291		
Exon 52 specific phosphorothiate oligonucleotide	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 52	Exon 52 specific phosphorothiate oligonucleotide		n/a	1/23/13	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA										Duchenne muscular dystrophy	6291		
Exon 45 specific phosphorothioate oligonucleotide	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 45	Exon 45 specific phosphorothioate oligonucleotide		n/a	1/23/13	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA										Duchenne muscular dystrophy	6291		
exon 53 specific phosphorothioate oligonucleotide	treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 53	exon 53 specific phosphorothioate oligonucleotide		n/a	1/23/13	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA										Duchenne muscular dystrophy	6291		
bivalent anti-human myostatin adnectin-IgG1	Treatment of duchenne muscular dystrophy	bivalent anti-human myostatin adnectin-IgG1		n/a	2/10/15	Designated			N/A	N/A	Bristol-Myers Squibb Co.	Wallingford	Connecticut	6492	USA	LONGEST CONTAINS	0803203AA	myostatin	6O86C0ZH33						Duchenne muscular dystrophy	6291		
allogeneic cardiosphere-derived cells	Treatment of Duchenne Muscular Dystrophy	allogeneic cardiosphere-derived cells		n/a	4/21/15	Designated			N/A	N/A	"Capricor, Inc."	Beverly HIlls	California	90211	USA										Duchenne muscular dystrophy	6291		
"recombinant adeno-associated virus serotype rhesus 74 (rh74) expressing the human CT GalNac transferase (GALGT2) gene, also called the Sda or Cad GAlNac transferase or b4Galnt2, under control of the muscle creatine kinase (MCK) promoter"	Treatment of Duchenne muscular dystrophy	"recombinant adeno-associated virus serotype rhesus 74 (rh74) expressing the human CT GalNac transferase (GALGT2) gene, also called the Sda or Cad GAlNac transferase or b4Galnt2, under control of the muscle creatine kinase (MCK) promoter"		n/a	6/16/15	Designated			N/A	N/A	Nationwide Children's Hospital	Columbus	Ohio	43205	USA	LONGEST CONTAINS	0009245AA	creatine	MU72812GK0						Duchenne muscular dystrophy	6291		
Adeno-associated viral vector differentially expressing microdystrophin 5 gene via the muscle-specific promoter CK8.	Treatment of Duchenne muscular dystrophy.	Adeno-associated viral vector differentially expressing microdystrophin 5 gene via the muscle-specific promoter CK8.		n/a	8/31/16	Designated			N/A	N/A	"Solid GT, LLC"	Cambridge	Massachusetts	2142	USA	LONGEST CONTAINS	0220666AA	muscle							Duchenne muscular dystrophy	6291		
small molecule Mas receptor agonist	Treatment of Duchenne muscular dystrophy	MMX-1902		n/a	4/25/17	Designated			N/A	N/A	"RASRx, LLC"	San Luis Obispo	California	93401	USA										Duchenne muscular dystrophy	6291		
Recombinant adeno-associated virus serotype 9 vector expressing codon-optimized miniaturized version of DMD gene	Treatment of Duchenne Muscular Dystrophy (DMD)	Recombinant adeno-associated virus serotype 9 vector expressing codon-optimized miniaturized version of DMD gene		n/a	5/22/17	Designated			N/A	N/A	"Bamboo Therapeutics, w wholly owned subsidiary of Pfizer"	Groton	Connecticut	6340	USA										Duchenne muscular dystrophy	6291		
partial myostatin antigen displayed on the surface of Lactobacillus casei	Treatment of Duchenne Muscular Dystrophy (DMD)	partial myostatin antigen displayed on the surface of Lactobacillus casei		n/a	12/28/17	Designated			N/A	N/A	BioLeaders Corporation	"7F, U-Tower, 767, Sinsu-ro, Suji-gu"	Yongin-si		"Korea, Republic of"	LONGEST CONTAINS	0234720AA	Lactobacillus casei	SA940P2U00						Duchenne muscular dystrophy	6291		
Recombinant adeno-associated virus serotype rh74 vector expressing the micro-dystrophin gene	Treatment of Duchenne Muscular Dystrophy	Recombinant adeno-associated virus serotype rh74 vector expressing the micro-dystrophin gene		n/a	6/21/18	Designated			N/A	N/A	Nationwide Children's Hospital	700 Children's Drive	Ohio	43205	USA										Duchenne muscular dystrophy	6291		
Synthetic stereopure antisense oligonucleotide specific for human dystrophin pre-messenger ribonucleic acid (mRNA)	Treatment of Duchenne muscular dystrophy	Synthetic stereopure antisense oligonucleotide specific for human dystrophin pre-messenger ribonucleic acid (mRNA)		n/a	8/7/18	Designated			N/A	N/A	Wave Life Sciences Ltd.	733 Concord Avenue	Massachusetts	2138	USA	LONGEST CONTAINS	0006724AA	ribonucleic acid							Duchenne muscular dystrophy	6291		
Hydralazine	Treatment of severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure greater than or equal to 160) associated with severe preeclampsia/eclampsia of pregnancy	Hydralazine		n/a	4/9/04	Designated			N/A	N/A	Bioniche Pharma USA LLC	Lake Forest	Illinois	60045	USA	EXACT	0014857AA	Hydralazine	26NAK24LS8						Eclampsia	6316		
S-nitrosoglutathione	Treatment of severe preeclampsia	S-nitrosoglutathione		n/a	12/28/12	Designated			N/A	N/A	Salupont Consulting Ltd	Bedfordshire SG19 2DD			United Kingdom	EXACT	0231890AA	S-nitrosoglutathione	78RRI89ZTO						Eclampsia	6316		
digoxin immune fab (ovine)	Treatment of severe preeclampsia and eclampsia	digoxin immune fab (ovine)		n/a	2/3/12	Designated			N/A	N/A	"Velo Bio, LLC"	Morrisville	North Carolina	27560	USA	EXACT	0324629AA	digoxin immune fab (ovine)	YB12NQZ1YN						Eclampsia	6316		
Recombinant human placental growth factor	Treatment of severe preeclampsia	RECOMBINANT HUMAN PLACENTAL GROWTH FACTOR (PLGF-131)		n/a	3/16/17	Designated			N/A	N/A	"Aggamin, LLC"	New York	New York	10032	USA	EXACT	0110873AB	RECOMBINANT HUMAN PLACENTAL GROWTH FACTOR (PLGF-131)	NOV5VI05MF						Eclampsia	6316		
allogeneic ex-vivo expanded placental adherent stromal cells	For the treatment of severe preeclampsia	allogeneic ex-vivo expanded placental adherent stromal cells		n/a	12/29/15	Designated			N/A	N/A	"Pluristem Therapeutics, Inc"	Haifa			Israel										Eclampsia	6316		
Fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1	Treatment of X-linked hypohidrotic ectodermal dysplasia	EDI-200		n/a	1/11/06	Designated			N/A	N/A	"Edimer Pharmaceuticals, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0113808AB	EDI-200	AF6GZK1UMB						Ectodermal dysplasia	6317		
"(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile"	Treatment of epidermolysis bullosa acquisita	LAS-191954		n/a	1/5/17	Designated			N/A	N/A	"Almirall, S.A."	Barcelona			Spain	EXACT	1793813AA	LAS-191954	1MK0TQ597B						Epidermolysis bullosa	6359		
allantoin	Treatment of skin blistering and erosions associated with inherited epidermolysis bullosa	allantoin		Alwextin	11/21/02	Designated			N/A	N/A	"Scioderm, Inc."	Durham	North Carolina	27703	USA	EXACT	0016319AA	allantoin	344S277G0Z						Epidermolysis bullosa	6359		
dry extract from Betulae Cortex (birch bark)	Treatment of epidermolysis bullosa	dry extract from Betulae Cortex (birch bark)		n/a	8/7/14	Designated			N/A	N/A	Birken AG	Niefern-Oeschelbronn			Germany	EXACT	0184098AA	birch bark	3R504894L9						Epidermolysis bullosa	6359		
diacerein	Treatment of epidermolysis bullosa	diacerein		n/a	10/15/14	Designated			N/A	N/A	Castle Creek Pharmaceuticals	Northbrook	Illinois	60062	USA	EXACT	0240733AA	diacerein	4HU6J11EL5						Epidermolysis bullosa	6359		
Thymosin beta 4	Treatment of epidermolysis bullosa.	Thymosin beta 4		n/a	5/28/04	Designated			N/A	N/A	"GtreeBNT Co., Ltd"	Gyeonggi-do			"Korea, Republic of"	EXACT	0802891AA	Thymosin beta 4	549LM7U24W						Epidermolysis bullosa	6359		
ubidecarenone	Treatment of Epidermolysis Bullosa	ubidecarenone		n/a	4/16/18	Designated			N/A	N/A	"Berg, LLC (BERG)"	500 Old Connecticut Path	Building B	1701	USA	EXACT	0024282AA	ubidecarenone	EJ27X76M46						Epidermolysis bullosa	6359		
Angiotensin (1-7)	Treatment of recessive dystrophic epidermolysis bullosa (RDEB).	Angiotensin (1-7)		n/a	9/1/16	Designated			N/A	N/A	"Tarix Orphan, LLC"	Cambridge	Massachusetts	2138	USA	EXACT	0232428AA	Angiotensin 1-7	IJ3FUK8MOF						Epidermolysis bullosa	6359		
Sucralfate suspension	Treatment of oral ulcerations and dysphagia in patients with epidermolysis bullosa.	Sucralfate suspension		n/a	3/4/91	Designated			N/A	N/A	"Darby Pharmaceuticals, Inc."	Rockville Centre	New York	11570	USA	EXACT	0066580AA	Sucralfate	XX73205DH5						Epidermolysis bullosa	6359		
recombinant human type VII collagen	Treatment of hereditary dystrophic epidermolysis bullosa (DEB)	recombinant human type VII collagen		n/a	6/18/08	Designated			N/A	N/A	"David T. Woodley, MD and Mei Chen, MD"	Los Angeles	California	90033	USA	LONGEST CONTAINS	0006462AA	collagen							Epidermolysis bullosa	6359		
expanded allogeneic human dermal fibroblasts in hypothermosol(r)-FRS	Treatment of Dystrophic Epidermolysis Bullosa.	expanded allogeneic human dermal fibroblasts in hypothermosol(r)-FRS		n/a	8/20/09	Designated			N/A	N/A	Intercytex Ltd.				United Kingdom										Epidermolysis bullosa	6359		
Dermagraft	Treatment of epidermolysis bullosa	Dermagraft		n/a	12/13/10	Designated			N/A	N/A	"Shire Regenerative Medicine, Inc."	San Diego	California	92121	USA										Epidermolysis bullosa	6359		
recombinant human collagen alpha-1 (VII) chain homo-trimer (rC7)	Treatment of dystrophic epidermolysis bullosa	recombinant human collagen alpha-1 (VII) chain homo-trimer (rC7)		n/a	3/17/14	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	Lexington	Massachusetts	2421	USA	LONGEST CONTAINS	0006462AA	collagen							Epidermolysis bullosa	6359		
autologous genetically modified human dermal fibroblasts	Treatment of dystrophic epidermolysis bullosa.	autologous genetically modified human dermal fibroblasts		n/a	6/10/14	Designated			N/A	N/A	"Fibrocell Technologies, Inc."	Exton	Pennsylvania	19341	USA										Epidermolysis bullosa	6359		
ex-vivo-expanded autologous keratinocytes transduced with retroviral vector containing the human COL7A1 gene.	Treatment of dystrophic Epidermolysis Bullosa	ex-vivo-expanded autologous keratinocytes transduced with retroviral vector containing the human COL7A1 gene.		n/a	5/24/17	Designated			N/A	N/A	Abeona Therapeutics	Cleveland	Ohio	44103	USA	LONGEST CONTAINS	0112364AB	COL7A1							Epidermolysis bullosa	6359		
antisense oligonucleotide targeting exon 73 in the COL7A1 gene	Treatment of dystrophic epidermolysis bullosa	antisense oligonucleotide targeting exon 73 in the COL7A1 gene		n/a	9/13/17	Designated			N/A	N/A	ProQR Therapeutics IV B.V.	Leiden			Netherlands	LONGEST CONTAINS	0112364AB	COL7A1							Epidermolysis bullosa	6359		
replication defective herpes simplex type 1 virus (HSV-1) vector expressing human COL7 protein	Treatment of dystrophic epidermolysis bullosa	replication defective herpes simplex type 1 virus (HSV-1) vector expressing human COL7 protein		n/a	11/2/17	Designated			N/A	N/A	"Krystal Biotech, LLC"	2100 Wharton Street	Pennsylvania	15203	USA	LONGEST CONTAINS	0087274AA	protein							Epidermolysis bullosa	6359		
adipose-derived mesenchymal stem cells in a hydrogel sheet	Treatment of Epidermolysis Bullosa	adipose-derived mesenchymal stem cells in a hydrogel sheet		n/a	10/25/18	Designated			N/A	N/A	"Anterogen Co., Ltd."	"405, Namsung Plaza"			"Korea, Republic of"	LONGEST CONTAINS	1339839AA	mesenchymal stem cells							Epidermolysis bullosa	6359		
"(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile"	Treatment of epidermolysis bullosa acquisita	LAS-191954		n/a	1/5/17	Designated			N/A	N/A	"Almirall, S.A."	Barcelona			Spain	EXACT	1793813AA	LAS-191954	1MK0TQ597B						Epidermolysis bullosa acquisita	6360		
vemurafenib	Treatment of Erdheim-Chester Disease	vemurafenib		Zelboral	8/2/16	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0507620AA	vemurafenib	207SMY3FQT						Erdheim-Chester disease	6369		
"(5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, hydrochloride"	Treatment of erythromelalgia	RAXATRIGINE HYDROCHLORIDE		n/a	1/30/17	Designated			N/A	N/A	Convergence Pharmaceuticals (Biogen Subsidiary)	Cambridge	Massachusetts	2142	USA	EXACT	0565708AA	RAXATRIGINE HYDROCHLORIDE	7L3OLR4M8T						Erythromelalgia	6377		
"1'-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3-f][1,3]benzodioxole-7,3'-indol]-2'(1'H)-one"	Treatment of erythromelalgia	FUNAPIDE		n/a	11/19/12	Designated			N/A	N/A	Teva Pharmaceuticals	Frazer	Pennsylvania	19355	USA	EXACT	0340012AA	FUNAPIDE	A5595LHJ2L						Erythromelalgia	6377		
capsaicin	Treatment of erythromelalgia	capsaicin		n/a	10/23/02	Designated			N/A	N/A	"Acorda Therapeutics, Inc."	Ardsley	New York	10502	USA	EXACT	0025490AA	capsaicin	S07O44R1ZM						Erythromelalgia	6377		
nivolumab	Treatment of esophageal cancer	nivolumab		Opdivo	8/22/16	Designated			N/A	N/A	Bristol-Myers Squibb Co.	Wallingford	Connecticut	6492	USA	EXACT	0761411AA	nivolumab	31YO63LBSN						Esophageal cancer	6383		
bryostatin-1	For use in combination with paclitaxel in the treatment of esophageal cancer	bryostatin-1		n/a	12/3/01	Designated			N/A	N/A	"GPC Biotech, Inc."	Waltham	Massachusetts	2451	USA	EXACT	0183233AA	bryostatin-1	37O2X55Y9E						Esophageal cancer	6383		
lapatinib ditosylate hydrochloride	Treatment of ErbB2 positive esophageal cancer	LAPATINIB DITOSYLATE		Tykerb	5/29/09	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceuticals Corp.	East Hanover	New Hampshire	7936	USA	EXACT	0245614AA	LAPATINIB DITOSYLATE	G873GX646R						Esophageal cancer	6383		
onartuzumab	Treatment of gastric cancer including gastroesophageal cancer	onartuzumab		n/a	1/23/13	Designated/Withdrawn			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0574209AA	onartuzumab	MS1J9720WC						Esophageal cancer	6383		
paclitaxel aqueous gel	Treatment of esophageal cancer	paclitaxel aqueous gel		Oncogel(Tm)	2/1/08	Designated			N/A	N/A	"BTG International, Inc."	Brentwood	Tennessee	37027	USA	EXACT	0132127AA	paclitaxel	P88XT4IS4D						Esophageal cancer	6383		
photochlor	Treatment of Esophageal Cancer	photochlor			5/24/18	Designated			N/A	N/A	"Ami Onco-Theranostics, LLC"	701 Ellicott Street	Center of Excellence	14203	USA	EXACT	0217061AA	photochlor	DOB7Y3RSX0						Esophageal cancer	6383		
ethanolamine	Prophylactic use in pediatric patients (age 0 through 16 years) with esophageal varices that are at risk of bleeding to obliterate varices and to prevent bleeding	ethanolamine		Ethamolin	1/17/14	Designated			N/A	N/A	"QOL Medical, LLC"	Vero Beach	Florida	32963	USA	EXACT	0022311AA	ethanolamine	5KV86114PT						Esophageal varices	6384		
Somatostatin	Treatment of bleeding esophageal varices.	Somatostatin		n/a	12/22/94	Designated			N/A	N/A	Eumedica Pharmaceuticals A.G. (Schweiz)	BASEL			Switzerland	EXACT	0078740AA	Somatostatin	6E20216Q0L						Esophageal varices	6384		
Terlipressin	Treatment of bleeding esophageal varices.	Terlipressin		Glypressin	3/6/86	Designated			N/A	N/A	"Ferring Laboratories, Inc."	Suffern	New York	10901	USA	EXACT	0056111AA	Terlipressin	7Z5X49W53P						Esophageal varices	6384		
Sodium tetradecyl sulfate	Treatment of bleeding esophageal varices.	Sodium tetradecyl sulfate		Sotradecol	6/10/86	Designated			N/A	N/A	"Elkins-Sinn, Inc."	Cherry Hill	New Jersey	8003	USA	EXACT	0022082AA	Sodium tetradecyl sulfate	Q1SUG5KBD6						Esophageal varices	6384		
Ethanolamine oleate	"Treatment of patients with esophageal varices that have recently bled, to prevent rebleeding."	Ethanolamine oleate		Ethamolin	3/22/84	Designated/Approved	Approved for Orphan Indication		12/22/88	12/22/95	QOL Medical	Vero Beach	Florida	32963	USA	EXACT	0123342AA	Ethanolamine oleate	U4RY8MRX7C						Esophageal varices	6384		
ganitumab	Treatment of Ewing sarcoma.	ganitumab		n/a	3/21/17	Designated			N/A	N/A	"NantCell, Inc."	Culver City	California	90232	USA	EXACT	0432542AA	ganitumab	CK1441RCZ8						Ewing sarcoma	6390		
Small molecule Ewing Sarcoma breakpoint region 1/Friend leukemia virus integration 1 fusion protein inhibitor	Treatment of Ewing sarcoma	TK-216 		n/a	6/30/16	Designated			N/A	N/A	"Tokalas, Inc."	Rancho Santa Fe	California	92067	USA	EXACT	1214784AA	TK-216	ELD8646UF9						Ewing sarcoma	6390		
ANA-conjugated dactunomycin nanoemulsion	Treatment of Ewing sarcoma	ANA-conjugated dactunomycin nanoemulsion		n/a	7/7/15	Designated			N/A	N/A	"NanoSmart Pharmaceuticals, Inc."	Laguna Hills	California	92653	USA										Ewing sarcoma	6390		
urea	"Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis)."	urea		n/a	11/7/11	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0009290AA	urea	8W8T17847W						Erythroderma	6393		
Alpha-galactosidase A	Long-term enzyme replacement therapy for the treatment of Fabry disease	Alpha-galactosidase A		Replagal	6/22/98	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0302125AA	Alpha-galactosidase A	2HLC17MX9G						Fabry disease	6400		
migalastat hydrochloride	Treatment of Fabry Disease	migalastat hydrochloride		n/a	2/25/04	Designated			N/A	N/A	"Amicus Therapeutics, Inc."	Cranbury	New Jersey	8512	USA	EXACT	0307142AA	migalastat hydrochloride	CLY7M0XD20						Fabry disease	6400		
lucerastat	Treatment of Fabry Disease.	lucerastat		n/a	10/29/15	Designated			N/A	N/A	Actelion Pharmaceuticals Ltd	Allschwil			Switzerland	EXACT	0699070AA	lucerastat	GVS3YDM418						Fabry disease	6400		
Human factor X	Treatment of hereditary factor X deficiency	Human factor X		Coagadex	11/8/07	Designated/Approved	Approved for Orphan Indication	Treatment of patients with hereditary Factor X Deficiency	10/20/15	10/20/22	Bio Products Laboratory				United Kingdom	exaCT	0324947AA	factor X	0P94UQE6SY						Factor X deficiency	6404		
eflornithine plus sulindac	Treatment of familial adenomatous polyposis	sulindac		n/a	1/22/13	Designated			N/A	N/A	"Cancer Prevention Pharmaceuticals, Inc."	Tucson	Arizona	85718	USA	EXACT	0064971AA	sulindac	184SNS8VUH						Familial adenomatous polyposis	6408		
"Valproic acid, sodium"	Treatment of familial adenomatous polyposis	"Valproic acid, sodium"		Peac(R)	6/24/05	Designated/Withdrawn			N/A	N/A	Topotarget A/S	Copenhagen			Denmark	EXACT	0032542AA	"Valproic acid, sodium"	5VOM6GYJ0D						Familial adenomatous polyposis	6408		
pyrvinium	Treatment of familial adenomatous polyposis	pyrvinium		n/a	1/5/15	Designated			N/A	N/A	"StemSynergy Therapeutics, Inc."	Miami	Florida	33136	USA	EXACT	0047483AA	pyrvinium	6B9991FLU3						Familial adenomatous polyposis	6408		
eicosapentaenoic acid	Treatment of familial adenomatous polyposis	eicosapentaenoic acid		n/a	3/8/11	Designated			N/A	N/A	S.L.A. Pharma Ltd. (UK)				United Kingdom	EXACT	0145959AA	eicosapentaenoic acid	AAN7QOV9EA						Familial adenomatous polyposis	6408		
eflornithine	Treatment of Familial Adenomatous Polyposis	eflornithine		n/a	2/4/11	Designated			N/A	N/A	Cancer Prevention Pharmaceuticals	Tucson	Arizona	85718	USA	EXACT	0311422AA	eflornithine	ZQN1G5V6SR						Familial adenomatous polyposis	6408		
eflornithine plus sulindac	Treatment of familial adenomatous polyposis	eflornithine plus sulindac		n/a	1/22/13	Designated			N/A	N/A	"Cancer Prevention Pharmaceuticals, Inc."	Tucson	Arizona	85718	USA	EXACT	0311422AA	eflornithine	ZQN1G5V6SR						Familial adenomatous polyposis	6408		
magnesium lysinate bis eicosapentaenoate	Treatment of familial adenomatous polyposis.	TP-252		n/a	12/23/15	Designated			N/A	N/A	Thetis Pharmaceuticals	Southport	Connecticut	6890	USA	EXACT	1802648AA	TP-252	QDG62BO0C2						Familial adenomatous polyposis	6408		
live attenuated E. Coli expressing Beta catenin shRNA	Treatment of Familial Adenomatous Polyposis	live attenuated E. Coli expressing Beta catenin shRNA		n/a	12/20/10	Designated			N/A	N/A	Marina Biotech	Cambridge	Massachusetts	2139	USA										Familial adenomatous polyposis	6408		
canakinumab	Treatment of familial mediterranean fever	canakinumab		Ilaris	12/5/13	Designated/Approved	Approved for Orphan Indication	Indicated for Familial Mediterranean Fever (FMF) in adult and pediatric patients	9/23/16	9/23/23	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0323159AA	canakinumab	37CQ2C7X93						Familial Mediterranean fever	6421		
rilonacept	Treatment of familial Mediterranean fever	rilonacept		Arcalyst	1/9/13	Designated			N/A	N/A	"Philip J Hashkes, MD, MSc."	Cleveland	Ohio	44195	USA	EXACT	0264119AA	rilonacept	8K80YB5GMG						Familial Mediterranean fever	6421		
colchicine	Treatment of familial Mediterranean fever	colchicine		Colcrys	9/25/07	Designated/Approved	Approved for Orphan Indication	Treatment of familial Mediterranean fever	7/29/09	7/29/16	"AR Holding Company, Inc."	Philadelphia	Pennsylvania	19124	USA	EXACT	0011314AA	colchicine	SML2Y3J35T						Familial Mediterranean fever	6421		
Fancalen (lentiviral vector containing the Fanconi anemia-A (FANCA) gene	Treatment of Fanconi anemia type A patients.	Fancalen (lentiviral vector containing the Fanconi anemia-A (FANCA) gene		n/a	5/2/16	Designated			N/A	N/A	Centro de Investigacion Biomedica en Red (CIBER)	Madrid			Spain										Fanconi anemia	6425		
triclabendazole	Treatment of fascioliasis.	triclabendazole		Triclathera(Tm)	6/27/16	Designated			N/A	N/A	"Tropicalis Pharmaceuticals, LLC"	Excelsior	Minnesota	55331	USA	EXACT	0238711AA	triclabendazole	4784C8E03O						Fascioliasis	6428		
Triclabendazole	Treatment of fascioliasis	Triclabendazole		Egaten	4/17/17	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0238711AA	Triclabendazole	4784C8E03O						Fascioliasis	6428		
palovarotene	Treatment of fibrodysplasia ossificans progressiva	palovarotene		n/a	7/21/14	Designated			N/A	N/A	"Clementia Pharmaceuticals, Inc."				Canada	EXACT	0322634AA	palovarotene	28K6I5M16G						Fibrodysplasia ossificans progressiva	6445		
Human monoclonal antibody directed against human Activin A	Treatment of fibrodysplasia ossificans progressiva	REGN-2477		n/a	1/19/17	Designated			N/A	N/A	"Regeneron Pharmaceuticals, Inc."	Tarrytown	New York	10591	USA	EXACT	0110822AB	REGN-2477	KR9ZSKO5QE						Fibrodysplasia ossificans progressiva	6445		
"4-(6-(4-(piperazin-1-yl)phenyl-pyrazolo[1,5-a]pyrimidin-3-yl)quinoline hydrochloride"	Treatment of fibrodysplasia ossificans progressiva	LDN-193189 MONOHYDROCHLORIDE		n/a	4/15/13	Designated			N/A	N/A	"La Jolla Pharmaceutical Company, Inc."	San Diego	California	92121	USA	EXACT	0822037AA	LDN-193189 MONOHYDROCHLORIDE	PLH51K438W						Fibrodysplasia ossificans progressiva	6445		
"3-(4-(1,5-NAPTHRYDINE)IMIDAZOLE(1,2-A)PYRIDINE-7-(1-PHENYL-4-(1-(4-METHYL PIPERAZINE)))"	Treatment of fibrodysplasia ossificans progressiva.	"3-(4-(1,5-NAPTHRYDINE)IMIDAZOLE(1,2-A)PYRIDINE-7-(1-PHENYL-4-(1-(4-METHYL PIPERAZINE)))"		EXACT	1802660AA	Designated	1G7DB33DC7		N/A	N/A	"La Jolla Pharmaceutical Company, Inc."	San Diego	California	92121	USA	EXACT	1802660AA	"3-(4-(1,5-NAPTHRYDINE)IMIDAZOLE(1,2-A)PYRIDINE-7-(1-PHENYL-4-(1-(4-METHYL PIPERAZINE)))"	1G7DB33DC7						Fibrodysplasia ossificans progressiva	6445		
"3-(4-(8-fluoroquinoline)-Imidazole[1,2-a]pyridine-7-(1-phenyl-4-(1-(4-methyl piperazine)"	Treatment of fibrodysplasia ossificans progressiva.	"3-(4-(8-FLUOROQUINOLINE)IMIDAZOLE(1,2-A)PYRIDINE-7-(1-PHENYL-4-(1-(4-METHYL PIPERAZINE)"		n/a	7/14/15	Designated			N/A	N/A	"La Jolla Pharmaceutical Company, Inc."	San Diego	California	92121	USA	EXACT	1802659AA	"3-(4-(8-FLUOROQUINOLINE)IMIDAZOLE(1,2-A)PYRIDINE-7-(1-PHENYL-4-(1-(4-METHYL PIPERAZINE)"	0PD95Q5DD1						Fibrodysplasia ossificans progressiva	6445		
Fenobam hydrochloride	Treatment of fragile X syndrome	Fenobam hydrochloride		n/a	11/20/06	Designated			N/A	N/A	"Neuropharm, Ltd."				United Kingdom	EXACT	0760101AA	Fenobam hydrochloride	18X2C0C12Z						Fragile X syndrome	6464		
cannabidiol	Treatment of Fragile X syndrome	cannabidiol		n/a	2/23/16	Designated			N/A	N/A	"Zynerba Pharmaceuticals, Inc."	Devon	Pennsylvania	19333	USA	EXACT	0027441AA	cannabidiol	19GBJ60SN5						Fragile X syndrome	6464		
guanfacine	Treatment of fragile X syndrome.	guanfacine		Tenex	8/5/99	Designated			N/A	N/A	"Watson Laboratories, Inc."	Corona	California	91718	USA	EXACT	0160112AA	guanfacine	30OMY4G3MK						Fragile X syndrome	6464		
basimglurant	Treatment of Fragile X Syndrome	basimglurant		n/a	3/9/12	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	Nutley	New Jersey	7110	USA	EXACT	0354110AA	basimglurant	3110E3AO8S						Fragile X syndrome	6464		
bryostatin 1	Treatment of Fragile X Syndrome.	bryostatin 1		n/a	3/31/15	Designated			N/A	N/A	"Neurotrope BioScience, Inc."	Newark	New Jersey	7102	USA	EXACT	0183233AA	bryostatin 1	37O2X55Y9E						Fragile X syndrome	6464		
Valproate	Treatment of fragile X syndrome	Valproate		n/a	5/5/08	Designated			N/A	N/A	"Neuropharm Ltd,"				United Kingdom	EXACT	0016546AA	Valproate	614OI1Z5WI						Fragile X syndrome	6464		
acetyl-l-carnitine	Treatment of Fragile X syndrome	acetyl-l-carnitine		n/a	7/24/12	Designated			N/A	N/A	"Sigma-Tau Pharmaceuticals, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0156649AA	acetyl-l-carnitine	6DH1W9VH8Q						Fragile X syndrome	6464		
3-fluoro-5-[5-(2-menthyl-thiazol-4-ylethylnyl)-pyridin-2-yl]-benzonitrile dihydrochloride	Treatment of behavioral abnormalities associated with fragile X syndrome.	STX-107 DIHYDROCHLORIDE		n/a	7/28/08	Designated			N/A	N/A	Seaside Therapeutics	Cambridge	Massachusetts	2139	USA	EXACT	0698000AA	STX-107 DIHYDROCHLORIDE	70QU352PWM						Fragile X syndrome	6464		
ganaxolone	Treatment of Fragile X Syndrome	ganaxolone		n/a	12/28/16	Designated			N/A	N/A	Marinus Pharmaceuticals	Radnor	Pennsylvania	19087	USA	EXACT	0184587AA	ganaxolone	98WI44OHIQ						Fragile X syndrome	6464		
metadoxine	Treatment of Fragile X Syndrome	metadoxine		n/a	12/16/13	Designated			N/A	N/A	"Alcobra, Inc."	Tel-Aviv			Israel	EXACT	0555475AA	metadoxine	EJQ7M98H5J						Fragile X syndrome	6464		
"(-)-(3aR,4S,7aR)-4-Hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester"	Treatment of Fragile X syndrome	MAVOGLURANT		n/a	10/12/11	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0568354AA	MAVOGLURANT	GT0I9SV4F6						Fragile X syndrome	6464		
Cannabidivarin	Treatment of Fragile X syndrome	Cannabidivarin		n/a	6/6/17	Designated			N/A	N/A	GW Research Ltd.	Cambridge			United Kingdom	EXACT	1064853AA	Cannabidivarin	I198VBV98I						Fragile X syndrome	6464		
"(3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one"	Treatment of Fragile X Syndrome.	FLINDOKALNER		n/a	12/9/15	Designated			N/A	N/A	Centre National de la Recherche Scientifique (CNRS)	Paris			France	EXACT	0221396AA	FLINDOKALNER	J57O328W4W						Fragile X syndrome	6464		
Gaboxadol	Treatment of Fragile X syndrome	Gaboxadol		n/a	10/3/17	Designated			N/A	N/A	Ovid Therapeutics	New York	New York	10036	USA	EXACT	0306876AA	Gaboxadol	K1M5RVL18S						Fragile X syndrome	6464		
acamprosate	Treatment of fragile X syndrome	acamprosate		n/a	3/25/13	Designated			N/A	N/A	"Confluence Pharmaceuticals, LLC"	Indianapolis	Indiana	46202	USA	EXACT	0310407AA	acamprosate	N4K14YGM3J						Fragile X syndrome	6464		
R-4-amino-3-(4-chlorophenyl)butanoic acid	Treatment of the behavorial abnormalities associated with fragile X syndrome	ARBACLOFEN		n/a	11/28/08	Designated			N/A	N/A	"Seaside Therapeutics, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0343044AA	ARBACLOFEN	NYU6UTW25B						Fragile X syndrome	6464		
glycyl-L-2-methylprolyl-L-glutamic Acid	Treatment of Fragile X Syndrome	Trofinetide		n/a	10/23/13	Designated			N/A	N/A	"Neuren Pharmaceuticals, Ltd."				New Zealand	EXACT	0341640AA	Trofinetide	Z2ME8F52QL						Fragile X syndrome	6464		
"5,5-dimethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione"	Treatment of fragile X syndrome	AUT-00206		n/a	6/12/17	Designated			N/A	N/A	Autifony Therapeutics Limited				United Kingdom	EXACT	0111874AB	AUT-00206	46P8AHZ243						Fragile X syndrome	6464		
Small molecule allosteric inhibitor of the phosphodiesterase-4D enzyme	Treatment of Fragile X Syndrome	BPN-14770		n/a	3/26/18	Designated			N/A	N/A	"Tetra Discovery Partners, Inc."	38 Fulton Street West	Suite 303	49503	USA	EXACT	0115048AB	BPN-14770	3XKI17C2E2						Fragile X syndrome	6464		
glycopyrrolate 2%	Treatment of Frey's syndrome	glycopyrrolate 2%		n/a	6/17/10	Designated			N/A	N/A	"Wellesley Therapeutics, Inc."				Canada	EXACT	0029732AA	glycopyrrolate	V92SO9WP2I						Frey's syndrome	6467		
N-(6-2-aminophenylamino)-6-oxohexyl)-4-methylbenzamide	Treatment of Friedreich's ataxia.	RG-2833		n/a	5/17/10	Designated/Withdrawn			N/A	N/A	Repligen Corporation	Waltham	Massachusetts	2453	USA	EXACT	0737348AA	RG-2833	17V14R89EU						Friedreich's ataxia	6468		
interferon gamma-1b	Treatment of Friedreich's Ataxia	interferon gamma-1b		Actimmune	10/1/14	Designated			N/A	N/A	Horizon Pharma Ireland Limited	Dublin 4			Ireland	EXACT	0174812AA	interferon gamma-1b	21K6M2I7AG						Friedreich's ataxia	6468		
"9-cis, 12-cis-11,11-d2-linoleic acid ethyl ester"	Treatment of Friedreich's Ataxia	RT-001		n/a	5/23/16	Designated			N/A	N/A	"Retroitope, Inc."	Los Altos	California	94022	USA	EXACT	1149173AA	RT-001	24B102R86P						Friedreich's ataxia	6468		
deferiprone	Treatment of Friedreich's ataxia	deferiprone		n/a	7/31/08	Designated			N/A	N/A	"ApoPharma, Inc."				Canada	EXACT	0179680AA	deferiprone	2BTY8KH53L						Friedreich's ataxia	6468		
vatiquinone	Treatment of Friedreich's ataxia	vatiquinone		Vincerinone	1/31/14	Designated			N/A	N/A	"Edison pharmaceuticals, Inc."	Mountain View	California	94043	USA	EXACT	0739468AA	vatiquinone	6O85FK9I0X						Friedreich's ataxia	6468		
D-amino acid oxidase inhibitor	Treatment of Friedreich's ataxia (FRDA)	TAK-831		n/a	12/6/17	Designated			N/A	N/A	"Takeda Development Center Americas, Inc."	Takeda Parkway	Deerfield	60015	USA	EXACT	1804075AA	TAK-831	76IC00YRVR						Friedreich's ataxia	6468		
coenzyme Q10 and d-alpha-tocopherol	Treatment of Friedreich's Ataxia.	coenzyme Q10		n/a	3/14/11	Designated			N/A	N/A	"NBI Pharmaceuticals, Inc."	Bozeman	Montana	59715	USA	EXACT	0024282AA	coenzyme Q10	EJ27X76M46						Friedreich's ataxia	6468		
dimethyl fumarate	Treatment of Friedreich's Ataxia	dimethyl fumarate		n/a	9/11/13	Designated			N/A	N/A	Gino Cortopassi	Davis	California	95616	USA	EXACT	0306796AA	dimethyl fumarate	FO2303MNI2						Friedreich's ataxia	6468		
omaveloxolone	Treatment of Friedreich's Ataxia	omaveloxolone		n/a	6/19/17	Designated			N/A	N/A	"Reata Pharmaceuticals, Inc."	Irving	Texas	75063	USA	EXACT	1148625AA	omaveloxolone	G69Z98951Q						Friedreich's ataxia	6468		
coenzyme Q10 and d-alpha-tocopherol	Treatment of Friedreich's Ataxia.	coenzyme Q10 and d-alpha-tocopherol		n/a	3/14/11	Designated			N/A	N/A	"NBI Pharmaceuticals, Inc."	Bozeman	Montana	59715	USA	EXACT	0025252AA	alpha tocopherol	H4N855PNZ1						Friedreich's ataxia	6468		
idebenone	Treatment of Friedreich's ataxia	idebenone		n/a	3/25/04	Designated			N/A	N/A	Santhera Pharmaceuticals LLC				Switzerland	EXACT	0167260AA	idebenone	HB6PN45W4J						Friedreich's ataxia	6468		
interferon gamma	Treatment of Friedreich's ataxia	interferon gamma		n/a	11/4/11	Designated			N/A	N/A	"Roberto Testi, MD"	Rome			Italy	EXACT	0214573AA	interferon gamma	P050J5FWC5						Friedreich's ataxia	6468		
Fusion protein linking human frataxin to a cell-penetrant peptide	Treatment of Friedreich's ataxia	CTI-1601		n/a	7/19/17	Designated			N/A	N/A	"Chondrial Therapeutics, Inc."	Bala Cynwyd	Pennsylvania	19004	USA	EXACT									Friedreich's ataxia	6468		
"recombinant, adeno-associated virus serotype 5 vector, containing the transgene, which encodes for the human protein, frataxin"	Treatment of Friedreich's Ataxia	"recombinant, adeno-associated virus serotype 5 vector, containing the transgene, which encodes for the human protein, frataxin"		n/a	7/25/16	Designated			N/A	N/A	"Agilis Biotherapeuties, LLC"	Cambridge	Massachusetts	2142	USA	LONGEST CONTAINS	0087274AA	protein							Friedreich's ataxia	6468		
"self-complimentary adeno-associated virus vector, serotype 9, packaging the full lenght GAN gene in the viral capsid"	Treatment of Giant Axonal Neuropathy	"self-complimentary adeno-associated virus vector, serotype 9, packaging the full lenght GAN gene in the viral capsid"		n/a	9/27/13	Designated			N/A	N/A	Hannah's Hope Fund	Rexford	New York	12148	USA										Giant axonal neuropathy	6500		
Dendritic cell/tumor cell fusion vaccine + recombinant human interleukin 12	Treatment of malignant glioma	Dendritic cell/tumor cell fusion vaccine + recombinant human interleukin 12		n/a	1/25/17	Designated			N/A	N/A	CyTIX Inc.	Minato-ku			Japan	EXACT	0343975AA	recombinant human interleukin 12	02FXP10O2U						Glioma	6513		
cytarabine liposome	Treatment of gliomas	cytarabine liposome		Depocyt	1/30/07	Designated			N/A	N/A	"Bruce Frankel, MD"	Charleston	South Carolina	29425	USA	EXACT	0023052AA	cytarabine liposome	04079A1RDZ						Glioma	6513		
Chlorotoxin	Treatment of malignant glioma	Chlorotoxin		n/a	12/18/07	Designated			N/A	N/A	"Morphotek, Inc."	Exon	Pennsylvania	19341	USA	EXACT	0736732AA	Chlorotoxin	06UV5RFW57						Glioma	6513		
18-(p-[124I]-iodophenyl)octadecyl phosphocholine	Diagnostic for the management of glioma	NM-404 I-124		n/a	4/30/14	Designated			N/A	N/A	"Cellectar Biosciences, Inc."	Madison	Wisconsin	53716	USA	EXACT	1079716AA	NM-404 I-124	08W354EC17						Glioma	6513		
Picropodophyllin	Treatment of glioma	Picropodophyllin		n/a	7/27/17	Designated			N/A	N/A	Axelar AB	Solna			Sweden	EXACT	0026266AA	Picropodophyllin	0F35AOI227						Glioma	6513		
A10 & AS2-1 Antineoplaston	Treatment for patients with brain stem glioma	A10 & AS2-1 Antineoplaston		n/a	9/3/04	Designated			N/A	N/A	"Burzynski Research Institute, Inc."	Houston	Texas	77055	USA	EXACT	0129599AA	antineoplaston A10	16VY3TM7ZO						Glioma	6513		
"antineoplaston A10, antineoplaston AS2-1"	Treatment of gliomas	antineoplaston A10		n/a	11/21/08	Designated			N/A	N/A	"Burzynski Research Institute, Inc."	Houston	Texas	77055	USA	EXACT	0129599AA	antineoplaston A10	16VY3TM7ZO						Glioma	6513		
cannabidiol	Treatment of glioma	cannabidiol		n/a	9/24/14	Designated			N/A	N/A	"Insys Development Company, Inc."	Chandler	Arizona	85286	USA	EXACT	0027441AA	cannabidiol	19GBJ60SN5						Glioma	6513		
delta-9-tetrahydrocannibinol and cannabidiol	Treatment of glioma.	tetrahydrocannibinol		n/a	12/3/15	Designated			N/A	N/A	GW Research Ltd.	Histon			United Kingdom	EXACT	0027441AA	cannabidiol	19GBJ60SN5						Glioma	6513		
oxaloacetate	Treatment of gliomas	OXALOACETIC ACID		n/a	7/24/12	Designated			N/A	N/A	Terra Biological LLC	San Diego	California	92130	USA	EXACT	0423290AA	OXALOACETIC ACID	2F399MM81J						Glioma	6513		
propranolol and etodolac	Treatment of malignant glioma.	etodolac		n/a	7/8/15	Designated			N/A	N/A	"Vicus Therapeutics, LLC"	Morristown	New Jersey	7960	USA	EXACT	0065327AA	etodolac	2M36281008						Glioma	6513		
bevacizumab	Treatment of malignant glioma	bevacizumab		Avastin	5/26/06	Designated/Approved	Approved for Orphan Indication	Treatment of glioblastoma with progressive disease following prior therapy	5/5/09	5/5/16	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0244257AA	bevacizumab	2S9ZZM9Q9V						Glioma	6513		
perillyl alcohol	Treatment of glioma	perillyl alcohol		n/a	4/18/11	Designated			N/A	N/A	"NeOnc Technologies, Inc."	Inglewood	California	90304	USA	EXACT	0191968AA	perillyl alcohol	319R5C7293						Glioma	6513		
Phenylacetate	"For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma."	Phenylacetate		n/a	3/6/98	Designated			N/A	N/A	"Elan Drug Delivery, Inc."	Gainesville	Georgia	30504	USA	EXACT	0019512AA	Phenylacetate	355G9R500Y						Glioma	6513		
"fluciclovine (18F)(anti-1-amino-3-fluorocyclobutane-1-carboxylic acid, labelled with Fluorine-18)"	For the diagnosis of glioma	fluciclovine f-18		n/a	4/7/15	Designated			N/A	N/A	Blue Earth Diagnostics Ltd.				United Kingdom	EXACT	0257603AA	fluciclovine f-18	38R1Q0L1ZE						Glioma	6513		
5-iodo-2-pytimidinone-2'-deoxyribose	Treatment of malginant glioma	ROPIDOXURIDINE		n/a	5/26/06	Designated			N/A	N/A	"Hana Biosciences, Inc."	South San Francisco	California	94080	USA	EXACT	0303173AA	ROPIDOXURIDINE	3HX21A3SQF						Glioma	6513		
transforming growth factor-beta receptor 1 kinase inhibitor	Treatment of glioma	galunisertib		n/a	3/11/13	Designated			N/A	N/A	Eli Lilly and Company	Indianapolis	Indiana	46285	USA	EXACT	0257001AA	galunisertib	3OKH1W5LZE						Glioma	6513		
(S)-perillyl alcohol temozolomide	Treatment of glioma	(S)-perillyl alcohol		n/a	11/12/14	Designated			N/A	N/A	"NeOnc Technologies, Inc."	Los Angeles	California	90069	USA	EXACT	1085558AA	(S)-perillyl alcohol	3UL4QIY642						Glioma	6513		
cilengitide	Treatment of malignant glioma	cilengitide		n/a	5/27/05	Designated/Withdrawn			N/A	N/A	"EMD Serono, Inc."	Rockland	Massachusetts	2370	USA	EXACT	0233294AA	cilengitide	4EDF46E4GI						Glioma	6513		
"1,2:5,6-Dianhdrogalactitol, NSC-132313"	Treatment of malignant gliomas	DIANHYDROGALACTITOL		n/a	1/31/12	Designated			N/A	N/A	"DelMar Pharmaceuticals, Inc."	Menlo Park	California	94025	USA	EXACT	0061712AA	DIANHYDROGALACTITOL	4S465RYF7M						Glioma	6513		
I(131)-TM-601 (chlorotoxin)	Treatment of malignant glioma	CHLOROTOXIN I-131		n/a	2/14/02	Designated			N/A	N/A	"Morphotek, Inc."	Exon	Pennsylvania	19341	USA	EXACT	0243630AA	CHLOROTOXIN I-131	544WOQ7W6W						Glioma	6513		
4-[131I]iodo-L-phenylalanine	Treatment of glioma.	4-(131I)iodo-L-phenylalanine		n/a	1/4/11	Designated			N/A	N/A	Therapeia GmbH & Co KG				Germany	EXACT	0738216AA	4-(131I)iodo-L-phenylalanine	606VTF676Y						Glioma	6513		
Nimotuzumab	Treatment of glioma	Nimotuzumab		n/a	11/17/04	Designated			N/A	N/A	InnoKeys PTE Ltd.				Singapore	EXACT	0298088AA	Nimotuzumab	6NS400BXKH						Glioma	6513		
nanoparticles containing Zoledronic acid	Treatment of Glioma	 Zoledronic acid		Edroma	11/29/16	Designated			N/A	N/A	Laboratorio Italiano Biochimico Farmaceutico Lisapharma SpA	Erba (CO)			Italy	EXACT	0183755AA	Zoledronic acid	6XC1PAD3KF						Glioma	6513		
marizomib	Treatment of malignant glioma.	marizomib		n/a	9/21/15	Designated			N/A	N/A	Triphase Research & Development I Corp.	San Diego	California	92121	USA	EXACT	0276028AA	marizomib	703P9YDP7F						Glioma	6513		
carboxyamidotriazole orotate	Treatment of malignant glioma	carboxyamidotriazole orotate		Pravitinib™	5/10/18	Designated			N/A	N/A	"Tactical Therapeutics, Inc."	"48 Wall Street, 12th Floor"		10005	USA	EXACT	0698077AA	carboxyamidotriazole orotate	776C212QQH						Glioma	6513		
"5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(phenylmethyl)-a-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S,10S)- (9CI)"	Treatment of malignant gliomas	BERUBICIN HYDROCHLORIDE		n/a	10/11/06	Designated/Withdrawn			N/A	N/A	"Reata Pharmaceuticals, Inc."	Dallas	Texas	75207	USA	EXACT	0252982AA	BERUBICIN HYDROCHLORIDE	7BA3X03948						Glioma	6513		
delta-9-tetrahydrocannibinol and cannabidiol	Treatment of glioma.	delta-9-tetrahydrocannabinol		n/a	12/3/15	Designated			N/A	N/A	GW Research Ltd.	Histon			United Kingdom	EXACT	0045169AA	delta-9-tetrahydrocannabinol	7J8897W37S						Glioma	6513		
Glutathione pegylated liposomal doxorubicin hydrochloride	Treatment of glioma	Glutathione pegylated liposomal doxorubicin hydrochloride		n/a	8/16/10	Designated			N/A	N/A	to-BBB technologies BV				Netherlands	EXACT	0063014AA	doxorubicin hydrochloride	82F2G7BL4E						Glioma	6513		
liposomal gadodiamide	Treatment of glioma.	liposomal gadodiamide		n/a	11/12/08	Designated			N/A	N/A	"MedGenesis Therapeutix, Inc."				Canada	EXACT	0168456AA	gadodiamide	84F6U3J2R6						Glioma	6513		
5-aminolevulinic acid	Visualization of malignant tissue during surgery for malignant glioma (WHO garde III and IV)	5-aminolevulinic acid		Gliolan	1/15/13	Designated			N/A	N/A	NX Development Corporation	Miami	Florida	33133	USA	EXACT	0300094AA	5-aminolevulinic acid	88755TAZ87						Glioma	6513		
1-(2-Nitro-imidazolyl)-3-[18F]fluoro-2-propanol; 1H-1-(3-[18F]fluoro-2-hydroxypropyl0-2-nitroimidazole (18F-Misonidazole)	Diagnostic for management of glioma.	FLUOROMISONIDAZOLE F-18		n/a	4/6/16	Designated			N/A	N/A	"Advanced Imaging Projects, LLC"	Lake Worth	Florida	33467	USA	EXACT	0168729AA	FLUOROMISONIDAZOLE F-18	8MSY49469G						Glioma	6513		
florilglutamic acid	Diagnostic for the management of glioma	florilglutamic acid		n/a	5/11/16	Designated			N/A	N/A	Piramal Imaging S.A.	Matran			Switzerland	EXACT	0698771AA	florilglutamic acid	954ZFH0S16						Glioma	6513		
liposomal topotecan hydrochloride	Treatment of gliomas	liposomal topotecan hydrochloride		n/a	10/30/08	Designated			N/A	N/A	"MedGenesis Therapeutix, Inc."				Canada	EXACT	0169415AA	topotecan hydrochloride	956S425ZCY						Glioma	6513		
trabedersen	Treatment of malignant glioma	trabedersen		Oncomun	6/5/02	Designated			N/A	N/A	Oncotelic Inc.	Agoura Hills	California	91301	USA	EXACT	1092633AA	trabedersen	98OYR854NY						Glioma	6513		
procaspase-activating compound 1	Treatment of malignant glioma	PAC-1		n/a	7/23/15	Designated			N/A	N/A	"Vanquish Oncology, Inc."	Champaign	Illinois	61820	USA	EXACT	0507653AA	PAC-1	9LIS8N0B2C						Glioma	6513		
"7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one"	Treatment of malignant glioma	ONC-201		n/a	6/4/18	Designated			N/A	N/A	"Oncoceutics, Inc."	3624 Market Street	Suite 5E	19104	USA	EXACT	0928041AA	ONC-201	9U35A31JAI						Glioma	6513		
propranolol and etodolac	Treatment of malignant glioma.	propranolol and etodolac		n/a	7/8/15	Designated			N/A	N/A	"Vicus Therapeutics, LLC"	Morristown	New Jersey	7960	USA	EXACT	0027587AA	propranolol	9Y8NXQ24VQ						Glioma	6513		
abeotaxane inhibitor of microtubules	Treatment of gliomas	TPI-287		n/a	10/7/11	Designated			N/A	N/A	Cortice Biosciences	New York	New York	10019	USA	EXACT	0271249AA	TPI-287	A2VM2V569A						Glioma	6513		
7-B-Hydroxy Cholesteryl-3-B-Oleate-Ester	Treatment of gliomas.	7.BETA.-HYDROXYCHOLESTERYL 3-OLEATE		n/a	6/15/11	Designated			N/A	N/A	Intsel Chimos SA				France	EXACT	0790921AA	7.BETA.-HYDROXYCHOLESTERYL 3-OLEATE	A59FMD985O						Glioma	6513		
N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl) pyridin-2-yl) Acetamide Besylate	Treatment of gliomas	KX2-361 BESYLATE		n/a	11/26/13	Designated			N/A	N/A	"Kinex Pharmaceuticals, Inc."	Buffalo	New York	14203	USA	EXACT	1304183AA	KX2-361 BESYLATE	A718CYC1N0						Glioma	6513		
2-chloroethyl-3-sarcosinamide-1-nitrosourea	Treatment for malignant gliomas	2-chloroethyl-3-sarcosinamide-1-nitrosourea		n/a	8/3/01	Designated			N/A	N/A	"Lawrence Panasci, MD"				USA	EXACT	0230228AA	2-chloroethyl-3-sarcosinamide-1-nitrosourea	BHB013S3MO						Glioma	6513		
2-chloroethyl-3-sarcosinamide-1-nitrosourea	Treatment for malignant glioma	2-chloroethyl-3-sarcosinamide-1-nitrosourea		Sarmustine	11/15/01	Designated			N/A	N/A	Pangene Corporation	Fremont	California	94538	USA	EXACT	0230228AA	2-chloroethyl-3-sarcosinamide-1-nitrosourea	BHB013S3MO						Glioma	6513		
talampanel	Treatment of glioma	talampanel		n/a	2/17/09	Designated/Withdrawn			N/A	N/A	"TEVA Neuroscience, Inc."	Horsham	Pennsylvania	19044	USA	EXACT	0216773AA	talampanel	CVS43XG1L5						Glioma	6513		
Erlotinib Hydrochloride	Treatment of malignant gliomas	Erlotinib Hydrochloride		Tarceva	7/18/03	Designated			N/A	N/A	"Genentech, Inc"	South San Francisco	California	94080	USA	EXACT	0222162AA	Erlotinib Hydrochloride	DA87705X9K						Glioma	6513		
A10 & AS2-1 Antineoplaston	Treatment for patients with brain stem glioma	A10 & AS2-1 Antineoplaston		n/a	9/3/04	Designated			N/A	N/A	"Burzynski Research Institute, Inc."	Houston	Texas	77055	USA	EXACT	0017027AA	phenylacetic acid	ER5I1W795A						Glioma	6513		
"antineoplaston A10, antineoplaston AS2-1"	Treatment of gliomas	phenylacetic acid		n/a	11/21/08	Designated			N/A	N/A	"Burzynski Research Institute, Inc."	Houston	Texas	77055	USA	EXACT	0017027AA	phenylacetic acid	ER5I1W795A						Glioma	6513		
"1-{2-[3-(3,4-Dichlorophenyl)ureido]-6-methyl-pyrimidin-4-yl}-amino-3(dimethylamino)propane Di methansulfonate"	Treatment of glioma	CT-179 DIMESYLATE		n/a	8/2/17	Designated			N/A	N/A	"Curtana Pharmaceuticals, Inc."	Austin	Texas	78754	USA	EXACT	0112689AB	CT-179 DIMESYLATE	FG4454219O						Glioma	6513		
N-[4-(trifluoromethyl)phenyl] 5 methylisoxazole-4-carboxamide	Treatment of malignant glioma.	LEFLUNOMIDE		n/a	5/25/95	Designated			N/A	N/A	"Sugen, Inc."	South San Francisco	California	94080	USA	EXACT	0170683AA	LEFLUNOMIDE	G162GK9U4W						Glioma	6513		
"(4S)-4-ethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1-H-pyrano[3?,4?:6,7]-indolizino-[1,2-b]-quinoline-11-carbaldehyde O-(tert-butyl)-(E)-oxime"	Treatment malignant glioma	GIMATECAN		Gimatecan	11/29/02	Designated/Withdrawn			N/A	N/A	"Sigma-Tau Research, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0241894AA	GIMATECAN	G1LN9045DK						Glioma	6513		
Glutathione pegylated liposomal doxorubicin hydrochloride	Treatment of glioma	Glutathione		n/a	8/16/10	Designated			N/A	N/A	to-BBB technologies BV				Netherlands	EXACT	0012135AA	Glutathione	GAN16C9B8O						Glioma	6513		
fosbretabulin tromethamine	Treatment of glioma	fosbretabulin tromethamine		n/a	6/8/16	Designated			N/A	N/A	"Mateon Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	0327219AA	fosbretabulin tromethamine	GBW044919E						Glioma	6513		
oncophage	Treatment of glioma	oncophage		n/a	4/14/09	Designated			N/A	N/A	"Agenus, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0310656AA	oncophage	H3598Y1TLJ						Glioma	6513		
Tranilast	For the treatment of maligant glioma	Tranilast		Rizaben	12/2/03	Designated			N/A	N/A	"Angiogen Pharmaceuticals, Pty. Ltd."				Australia	EXACT	0130609AA	Tranilast	HVF50SMY6E						Glioma	6513		
"(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamideNRC-AN-019"	Treatment of Glioma	NRC-AN-019		n/a	3/18/11	Designated			N/A	N/A	NATCO Pharma Limited	Hyderbad 500033			India	EXACT	0710883AA	NRC-AN-019	K6W49JL148						Glioma	6513		
crenolanib besylate	Treatment of malignant glioma	crenolanib besylate		n/a	12/20/10	Designated			N/A	N/A	"AROG Pharmaceuticals, LLC"	Dallas	Texas	75240	USA	EXACT	0251785AA	crenolanib besylate	MC4B01024K						Glioma	6513		
Sodium phenylbutyrate	"For use as an adjuct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma."	Sodium phenylbutyrate		n/a	4/24/98	Designated			N/A	N/A	"Elan Drug Delivery, Inc."	Gainesville	Georgia	30504	USA	EXACT	0180767AA	Sodium phenylbutyrate	NT6K61736T						Glioma	6513		
ivosidenib	Treatment of glioma.	ivosidenib		n/a	5/1/18	Designated			N/A	N/A	"Agios Pharmaceuticals, Inc."	88 Sidney Street		2139	USA	EXACT	1143879AA	ivosidenib	Q2PCN8MAM6						Glioma	6513		
dabrafenib	Treatment of malignant glioma with BRAF V600 mutation	dabrafenib		Tafinlar	2/8/16	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0632984AA	dabrafenib	QGP4HA4G1B						Glioma	6513		
polifeprosan 20 with carmustine	Treatment of malignant glioma.	polifeprosan 20 with carmustine		Gliadel	12/13/89	Designated/Approved	Approved for Orphan Indication	As an adjunct to surgery to prolong survival in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated	9/23/96	9/23/03	"Guilford Pharmaceuticals, Inc."	Baltimore	Maryland	21224	USA	EXACT	0353322AA	polifeprosan 20	S40C40DA21						Glioma	6513		
Arsenic trioxide	Treatment of malignant glioma	Arsenic trioxide		Trisenox	3/4/05	Designated			N/A	N/A	"Teva Branded Pharmaceutical Products R&D, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0034720AA	Arsenic trioxide	S7V92P67HO						Glioma	6513		
butylidenephthalide	Treatment of Malignant Glioma	butylidenephthalide		n/a	8/5/15	Designated			N/A	N/A	"Everfront Biotech, Inc."				Taiwan	EXACT	0350618AA	butylidenephthalide	S9178G4B3F						Glioma	6513		
polifeprosan 20 with carmustine	Treatment of malignant glioma.	carmustine		Gliadel	12/13/89	Designated/Approved	Approved for Orphan Indication	Expanding the indication to include patients with malignant glioma undergoing primary surgical resection.	2/25/03	2/25/10	"Guilford Pharmaceuticals, Inc."	Baltimore	Maryland	21224	USA	EXACT	0023596AA	carmustine	U68WG3173Y						Glioma	6513		
Procarbazine HCl	Treatment of malignant glioma	Procarbazine HCl		Matulane	8/8/06	Designated			N/A	N/A	"Sigma-Tau Pharmaceuticals, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0025296AA	Procarbazine HCl	XH0NPH5ZX8						Glioma	6513		
temozolomide	Treatment of recurrent malignant glioma.	temozolomide		Temodar	10/5/98	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with refractory anaplastic astrocytoma, i.e., patients at first relapse who have experienced disease progression on a drug regimen containing a nitrosourea and procarbazine"	8/11/99	8/11/06	Schering-Plough Research Institute	Kenilworth	New Jersey	7033	USA	EXACT	0182990AA	temozolomide	YF1K15M17Y						Glioma	6513		
temozolomide	Treatment of recurrent malignant glioma.	temozolomide		Temodar	10/5/98	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with newly diagnosed glioblastoma multiforme concomitatly with radiotherapy and then as maintenance treatment	3/15/05	3/15/12	Schering-Plough Research Institute	Kenilworth	New Jersey	7033	USA	EXACT	0182990AA	temozolomide	YF1K15M17Y						Glioma	6513		
Temozolomide	Treatment of newly diagnosed high grade glioma	Temozolomide		Temodal	10/18/04	Designated			N/A	N/A	Schering-Plough Research Institute	Kenilworth	New Jersey	7033	USA	EXACT	0182990AA	Temozolomide	YF1K15M17Y						Glioma	6513		
(S)-perillyl alcohol temozolomide	Treatment of glioma	 temozolomide		n/a	11/12/14	Designated			N/A	N/A	"NeOnc Technologies, Inc."	Los Angeles	California	90069	USA	EXACT	0182990AA	temozolomide	YF1K15M17Y						Glioma	6513		
"4,6,8-trihydroxy-10-(3,7,11-trimethyldodeca-2,6,10-trienyl)-5,10-dihydrodibenzo b,e][1,4]diazepin-11-one"	Treatment of malignant glioma.	DIAZEPINOMICIN		n/a	4/27/09	Designated/Withdrawn			N/A	N/A	"Thallion Pharmaceuticals, Inc."				Canada	EXACT	0736889AA	DIAZEPINOMICIN	YPH994Y0RF						Glioma	6513		
pritumumab	Treatment of glioma	pritumumab		n/a	10/28/14	Designated			N/A	N/A	"Nascent Biotech, Inc."	San Diego	California	92126	USA	EXACT	1079727AA	pritumumab	Z6Q90D1G53						Glioma	6513		
IL13-PE38QQR	Treatment of malignant glioma	cintredekin besudotox		n/a	11/2/01	Designated/Withdrawn			N/A	N/A	"Insys Development Company, Inc."	Chandler	Arizona	85286	USA	EXACT	0262986AA	IL13-PE38QQR	ZL04JX89M7						Glioma	6513		
Eflornithine	Treatment of anaplastic glioma	Eflornithine		n/a	9/29/06	Designated			N/A	N/A	"Orbus Therapeutics, Inc."	Aptos	California	95003	USA	EXACT	0311422AA	Eflornithine	ZQN1G5V6SR						Glioma	6513		
sitimagene ceradenovec	Use with gancyclovir in the treatment of malignant glioma	sitimagene ceradenovec		Cerepro	7/31/01	Designated			N/A	N/A	"Gliotherapy, Ltd."	London			United Kingdom	EXACT	1091630AA	sitimagene ceradenovec							Glioma	6513		
A10 & AS2-1 Antineoplaston	Treatment for patients with brain stem glioma	A10 & AS2-1 Antineoplaston		n/a	9/3/04	Designated			N/A	N/A	"Burzynski Research Institute, Inc."	Houston	Texas	77055	USA	EXACT	0478579AA	NSC-203800							Glioma	6513		
"antineoplaston A10, antineoplaston AS2-1"	Treatment of gliomas	NSC-203800		n/a	11/21/08	Designated			N/A	N/A	"Burzynski Research Institute, Inc."	Houston	Texas	77055	USA	EXACT	0478579AA	NSC-203800	92358I79RG						Glioma	6513		
pelareorep	Treatment of malignant glioma	pelareorep		Reolysin	4/15/15	Designated			N/A	N/A	"Oncolytics Biotech, Inc."				Canada	EXACT	0809154AA	pelareorep	S9J80L3D1U						Glioma	6513		
Azurin-p28	Treatment of glioma	Azurin-p28		n/a	12/2/15	Designated			N/A	N/A	"CDG Therapeutics, Inc."	Chicago	Illinois	60612	USA	EXACT	1313219AA	Azurin-p28	H4QZU9L323						Glioma	6513		
"N-(4-Methoxyphenyl)-N,2,6-trimethylfuro[2,3-d] pyrimidin-4-amine"	Treatment of glioma.	aag-1		n/a	2/18/16	Designated			N/A	N/A	"Flag Therapeutics, Inc."	Raleigh	North Carolina	27617	USA	EXACT	1577168AA	aag-1	LB2951OCS5						Glioma	6513		
Cell-penetrating dominant-negative activating transcription factor 5	Treatment of glioma	ST-36		n/a	3/20/17	Designated			N/A	N/A	"Sapience Therapeutics, Inc"	Scarsdale	New York	10583	USA	EXACT									Glioma	6513		
3-(1’-butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-N-butylimide methyl ester	Treatment of glioma	PHOTOBAC		Photobac	12/6/17	Designated			N/A	N/A	"Photolitec, LLC"	6220 Creekhaven Drive	East Amherst	14051	USA	EXACT	0113754AB	PHOTOBAC							Glioma	6513		
IL-4 Pseudomonas Toxin Fusion Protein (IL-4(38-37)-PE38KDEL)	Treatment of astrocytic glioma.	IL-4 Pseudomonas Toxin Fusion Protein (IL-4(38-37)-PE38KDEL)		n/a	4/6/00	Designated			N/A	N/A	"Medicenna Therapeutics, Inc."				Canada	LONGEST CONTAINS	0087274AA	Protein							Glioma	6513		
genetically engineered herpes simplex virus (G207)	Treatment of malignant glioma	genetically engineered herpes simplex virus (G207)		n/a	4/29/02	Designated			N/A	N/A	"Aettis, Inc."	Bala Cynwyd	Pennsylvania	19004	USA	LONGEST CONTAINS	0354825AA	herpes							Glioma	6513		
"dendritic cells pulsed with synthetic peptides derived from antigens MAGE1, HER-2, AIM-2,TRP-2, gp100 and interleukin-13 receptor alpha"	Treatment of glioblastoma or brain stem glioma	"dendritic cells pulsed with synthetic peptides derived from antigens MAGE1, HER-2, AIM-2,TRP-2, gp100 and interleukin-13 receptor alpha"		n/a	6/7/10	Designated			N/A	N/A	ImmunoCellular Therapeutics Ltd.	Woodland Hills	California	91367	USA	LONGEST CONTAINS	0123397AA	antigens							Glioma	6513		
glioma derived cell lysates and irradiated cells	Treatment of glioma.	glioma derived cell lysates and irradiated cells		n/a	1/12/11	Designated			N/A	N/A	Epitopoietic Research Corp.	Pasadena	California	91160	USA										Glioma	6513		
adenovirus containing a human FAS-c gene	Treatment of malignant glioma	adenovirus containing a human FAS-c gene		n/a	4/2/12	Designated			N/A	N/A	Vascular Biogenics Ltd	Or Yehuda			Israel										Glioma	6513		
IL-12 secreting dendritic cells loaded with autologous tumor lysate	Treatment of malignant glioma	IL-12 secreting dendritic cells loaded with autologous tumor lysate		n/a	6/24/13	Designated			N/A	N/A	Activartis Biotech GmbH				Austria										Glioma	6513		
"adenovirus delta 24-RGD, an oncolytic adenovirus genetically modified for treatment of glioma"	Treatment of glioma	"adenovirus delta 24-RGD, an oncolytic adenovirus genetically modified for treatment of glioma"		n/a	10/1/14	Designated			N/A	N/A	"DNAtrix, Inc."	San Diego	California	92121	USA										Glioma	6513		
human leukocyte antigen-A2 restricted peptides	Treatment of glioma.	human leukocyte antigen-A2 restricted peptides		n/a	1/26/15	Designated			N/A	N/A	"Stemline Therapeutics, Inc."	New York	New York	10022	USA	LONGEST CONTAINS	1806253AA	human leukocyte							Glioma	6513		
Adenoviral vector-RheoSwitch Therapeutic System-human interleukin 12 + veledimex	Treatment of malignant glioma.	Adenoviral vector-RheoSwitch Therapeutic System-human interleukin 12 + veledimex		n/a	7/23/15	Designated			N/A	N/A	"Ziopharm Oncology, Inc."	Boston	Maryland	2129	USA	LONGEST CONTAINS	0343986AA	human interleukin 12	7B590791ER						Glioma	6513		
"recombinant, non-pathogenic poliovirus:rhinovirus chimera that consists of the genome of the live attenuated poliovirus serotype 1 vaccine with its cognate IRES element replaced with that of HRV2"	Treatment of glioma	"recombinant, non-pathogenic poliovirus:rhinovirus chimera that consists of the genome of the live attenuated poliovirus serotype 1 vaccine with its cognate IRES element replaced with that of HRV2"		n/a	5/26/16	Designated			N/A	N/A	"Darell D. Bigner, MD, PhD"	Durham	North Carolina	27710	USA	LONGEST CONTAINS	0313962AA	poliovirus	FZJ641678T						Glioma	6513		
"disulfide-stabilized single-chain variable region fragment of the anti-EGFR wild type/EGFRvIII dual specificity monoclonal antibody with variable fragments fused to a truncated version of the Pseudomonas exotoxin A, PE38, and KDEL"	Treatment of glioma.	"disulfide-stabilized single-chain variable region fragment of the anti-EGFR wild type/EGFRvIII dual specificity monoclonal antibody with variable fragments fused to a truncated version of the Pseudomonas exotoxin A, PE38, and KDEL"		n/a	9/19/16	Designated			N/A	N/A	"Darell D. Bigner, MD, PhD"	Durham	North Carolina	27710	USA	LONGEST CONTAINS	0524969AA	disulfide	KD33TF3UJR						Glioma	6513		
Salmonella Typhi strain Ty21a transfected with a plasmid vector encoding for the human vascular endothelial growth factor receptor 2	Treatment of malignant glioma	Salmonella Typhi strain Ty21a transfected with a plasmid vector encoding for the human vascular endothelial growth factor receptor 2		n/a	8/31/17	Designated			N/A	N/A	Vaximm GmbH	Mannheim			Germany	LONGEST CONTAINS	1340927AA	vascular endothelial growth factor receptor 2	798536Z7S0						Glioma	6513		
autologous glioma tumor cells treated with 18-mer oligodeoxynucleotide sequence complementary to insulin-like growth factor type 1 receptor (IGF-1R) codons 2-7 in the IG-1R gene	Treatment of malignant glioma	autologous glioma tumor cells treated with 18-mer oligodeoxynucleotide sequence complementary to insulin-like growth factor type 1 receptor (IGF-1R) codons 2-7 in the IG-1R gene		n/a	10/11/17	Designated			N/A	N/A	Thomas Jefferson University	Philadelphia	Pennsylvania	19107	USA	LONGEST CONTAINS	0145299AA	insulin							Glioma	6513		
vorasidenib	Treatment of glioma	vorasidenib		n/a	9/10/18	Designated			N/A	N/A	"Agios Pharmaceuticals, Inc."	88 Sidney Street	Massachusetts	2139	USA	EXACT	1137117AA	vorasidenib	789Q85GA8P						Glioma	6513		
cytarabine liposome	Treatment of gliomas	cytarabine liposome		Depocyt	1/30/07	Designated			N/A	N/A	"Bruce Frankel, MD"	Charleston	South Carolina	29425	USA	EXACT	0023052AA	cytarabine liposome	04079A1RDZ						Gliomas	6513		
"antineoplaston A10, antineoplaston AS2-1"	Treatment of gliomas	antineoplaston A10		n/a	11/21/08	Designated			N/A	N/A	"Burzynski Research Institute, Inc."	Houston	Texas	77055	USA	EXACT	0129599AA	antineoplaston A10	16VY3TM7ZO						Gliomas	6513		
oxaloacetate	Treatment of gliomas	OXALOACETIC ACID		n/a	7/24/12	Designated			N/A	N/A	Terra Biological LLC	San Diego	California	92130	USA	EXACT	0423290AA	OXALOACETIC ACID	2F399MM81J						Gliomas	6513		
"1,2:5,6-Dianhdrogalactitol, NSC-132313"	Treatment of malignant gliomas	DIANHYDROGALACTITOL		n/a	1/31/12	Designated			N/A	N/A	"DelMar Pharmaceuticals, Inc."	Menlo Park	California	94025	USA	EXACT	0061712AA	DIANHYDROGALACTITOL	4S465RYF7M						Gliomas	6513		
"5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(phenylmethyl)-a-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S,10S)- (9CI)"	Treatment of malignant gliomas	BERUBICIN HYDROCHLORIDE		n/a	10/11/06	Designated/Withdrawn			N/A	N/A	"Reata Pharmaceuticals, Inc."	Dallas	Texas	75207	USA	EXACT	0252982AA	BERUBICIN HYDROCHLORIDE	7BA3X03948						Gliomas	6513		
liposomal topotecan hydrochloride	Treatment of gliomas	liposomal topotecan hydrochloride		n/a	10/30/08	Designated			N/A	N/A	"MedGenesis Therapeutix, Inc."				Canada	EXACT	0169415AA	topotecan hydrochloride	956S425ZCY						Gliomas	6513		
abeotaxane inhibitor of microtubules	Treatment of gliomas	TPI-287		n/a	10/7/11	Designated			N/A	N/A	Cortice Biosciences	New York	New York	10019	USA	EXACT	0271249AA	TPI-287	A2VM2V569A						Gliomas	6513		
7-B-Hydroxy Cholesteryl-3-B-Oleate-Ester	Treatment of gliomas.	7.BETA.-HYDROXYCHOLESTERYL 3-OLEATE		n/a	6/15/11	Designated			N/A	N/A	Intsel Chimos SA				France	EXACT	0790921AA	7.BETA.-HYDROXYCHOLESTERYL 3-OLEATE	A59FMD985O						Gliomas	6513		
N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl) pyridin-2-yl) Acetamide Besylate	Treatment of gliomas	KX2-361 BESYLATE		n/a	11/26/13	Designated			N/A	N/A	"Kinex Pharmaceuticals, Inc."	Buffalo	New York	14203	USA	EXACT	1304183AA	KX2-361 BESYLATE	A718CYC1N0						Gliomas	6513		
2-chloroethyl-3-sarcosinamide-1-nitrosourea	Treatment for malignant gliomas	2-chloroethyl-3-sarcosinamide-1-nitrosourea		n/a	8/3/01	Designated			N/A	N/A	"Lawrence Panasci, MD"				USA	EXACT	0230228AA	2-chloroethyl-3-sarcosinamide-1-nitrosourea	BHB013S3MO						Gliomas	6513		
Erlotinib Hydrochloride	Treatment of malignant gliomas	Erlotinib Hydrochloride		Tarceva	7/18/03	Designated			N/A	N/A	"Genentech, Inc"	South San Francisco	California	94080	USA	EXACT	0222162AA	Erlotinib Hydrochloride	DA87705X9K						Gliomas	6513		
"antineoplaston A10, antineoplaston AS2-1"	Treatment of gliomas	phenylacetic acid		n/a	11/21/08	Designated			N/A	N/A	"Burzynski Research Institute, Inc."	Houston	Texas	77055	USA	EXACT	0017027AA	phenylacetic acid	ER5I1W795A						Gliomas	6513		
"antineoplaston A10, antineoplaston AS2-1"	Treatment of gliomas	NSC-203800		n/a	11/21/08	Designated			N/A	N/A	"Burzynski Research Institute, Inc."	Houston	Texas	77055	USA	EXACT	0478579AA	NSC-203800	92358I79RG						Gliomas	6513		
recombinant human minibody against complement component C5	Treatment of primary membranoproliferative glomerulonephritis	recombinant human minibody against complement component C5		Mubodina	2/4/09	Designated			N/A	N/A	Adienne S.A.				Switzerland										Glomerulonephritis	6516		
propagermanium and irbesartan	Treatment of focal segmental glomerulosclerosis.	propagermanium		n/a	12/9/15	Designated			N/A	N/A	Dimerix Bioscience Ltd.	Melbourne			Australia	EXACT	0169324AA	propagermanium	1Q2P9TO9Q7						Focal segmental glomerulosclerosis	6517		
fresolimumab	Treatment of primary focal segmental glomerulosclerosis	fresolimumab		n/a	10/21/10	Designated/Withdrawn			N/A	N/A	"Genzyme, a Sanofi Company"	Framingham	Massachusetts	1702	USA	EXACT	0266319AA	fresolimumab	375142VBIA						Focal segmental glomerulosclerosis	6517		
sparsentan	Treatment of Focal Segmental Glomerulosclerosis	sparsentan		n/a	1/5/15	Designated			N/A	N/A	"Retrophin, LLC"	New York	New York	10031	USA	EXACT	0770536AA	sparsentan	9242RO5URM						Focal segmental glomerulosclerosis	6517		
propagermanium and irbesartan	Treatment of focal segmental glomerulosclerosis.	irbesartan		n/a	12/9/15	Designated			N/A	N/A	Dimerix Bioscience Ltd.	Melbourne			Australia	EXACT	0182809AA	irbesartan	J0E2756Z7N						Focal segmental glomerulosclerosis	6517		
"4-Chloro-N-[5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidin-4-ylcarbonyl)-3-pyridinyl]-3-(trifluoromethyl)benzenesulfonamide, sodium salt"	Treatment of focal segmental glomerulosclerosis	CCX-140B		n/a	9/12/18	Designated			N/A	N/A	"ChemoCentryx, Inc."	850 Maude Avenue	California	94043	USA	EXACT	0812793AA	CCX-140 SODIUM SALT	X39CM70JTQ						Focal segmental glomerulosclerosis	6517		
Recombinant human monoclonal antibody against human complement component C5a	Treatment of acute graft versus host disease	eculizumab		n/a	10/6/16	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	New Haven	Connecticut	6510	USA	EXACT	0298000AA	eculizumab	A3ULP0F556						Acute graft versus host disease	6544		
Allogeneic mesenchymoangioblast-derived mesenchymal stem cells	Treatment of acute graft versus host disease	Allogeneic mesenchymoangioblast-derived mesenchymal stem cells		n/a	3/26/18	Designated			N/A	N/A	Cynata Therapeutics Limited	"Level 3, 62 Lygon Street"			Australia	LONGEST CONTAINS	1339839AA	mesenchymal stem cells							Acute graft versus host disease	6544		
ST1-RTA immunotoxin (SR 44163)	1. Prevention of acute graft versus host disease in allogenic bone marrow transplantation 2. Treatment of patients with B-chronic lymphocytic leukemia	SR-44163		n/a	8/12/87	Designated/Withdrawn			N/A	N/A	"Sanofi Winthrop, Inc."	Malvern	Pennsylvania	19355	USA										Acute graft versus host disease	6544		
Ex vivo cultured adult human mesenchymal stem cells	Treatment of acute graft versus host disease	Ex vivo cultured adult human mesenchymal stem cells		Prochymal(R)	12/14/05	Designated			N/A	N/A	"Mesoblast, Inc."	New York	New York	10017	USA	LONGEST CONTAINS	1339839AA	mesenchymal stem cells							Acute graft versus host disease	6544		
Human alpha-1-antitrypsin	Treatment of acute graft versus host disease	Human alpha-1-antitrypsin		n/a	6/12/17	Designated			N/A	N/A	"Paul Maher, MD"	Bethesda	Maryland	20814	USA										Acute graft versus host disease	6544		
Sermorelin acetate	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	Sermorelin acetate		Geref	9/14/88	Designated/Approved	Approved for Orphan Indication		9/26/97	9/26/04	"EMD Serono, Inc."	Roackland	Massachusetts	2370	USA	EXACT	0165253AA	Sermorelin acetate	00IBG87IQW						Growth hormone deficiency	6552		
"growth hormone releasing hormone, 1-44 human amide"	Treatment of growth hormone deficiency	"growth hormone releasing hormone, 1-44 human amide"		n/a	2/23/16	Designated			N/A	N/A	"Hollenbeck Pharmaceuticals, Inc."	Falls Village	Connecticut	6031	USA	EXACT	0127797AA	somatorelin	4UR7N9Z9MM						Growth hormone deficiency	6552		
fusion protein analog with recombinant human growth hormone (rhGH) at once-a-month dosing	Treatment of growth hormone deficiency	VRS-317		n/a	10/16/13	Designated			N/A	N/A	"Versartis, Inc."	Redwood City		94065	USA	EXACT	0928176AA	VRS-317	4Y05SI704S						Growth hormone deficiency	6552		
Recombinant human insulin-like growth factor 1	Treatment of antibody-mediated growth hormone resistance in patients with isolated growth hormone deficiency Ia.	mecasermin		Igf-1	6/7/95	Designated/Withdrawn			N/A	N/A	Pharmacia & Upjohn	Kalamazoo	Michigan	49001	USA	EXACT	0167215AA	mecasermin	7GR9I2683O						Growth hormone deficiency	6552		
recombinant human serum albumin human growth hormone	Treatment of growth hormone deficiency	TV-1106 		n/a	1/13/16	Designated			N/A	N/A	"TEVA Branded Pharmaceutical Products R&D, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	1210679AA	TV-1106	88C1D8R8JW						Growth hormone deficiency	6552		
Peptidomimetic analog of hexarelin	Diagnosis of growth hormone deficiency	Macimorelin ACETATE		n/a	5/14/07	Designated			N/A	N/A	Aeterna Zentaris GmbH				Germany	EXACT	0891634AA	Macimorelin ACETATE	AQZ1003RMG						Growth hormone deficiency	6552		
Somatropin (rDNA origin)	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	Somatropin (rDNA origin)		Saizen	3/6/87	Designated/Approved	Approved for Orphan Indication	Long term treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.	10/8/96	N/A	"EMD Serono, Inc."	Roackland	Massachusetts	2370	USA	EXACT	0054682AA	Somatropin (rDNA origin)	NQX9KB6PCL						Growth hormone deficiency	6552		
Somatropin	Treatment of adults with growth hormone deficiency.	Somatropin		Genotropin	9/6/94	Designated/Approved	Approved for Orphan Indication		10/31/97	10/31/04	Pharmacia & Upjohn	Kalamazoo	Michigan	49001	USA	EXACT	0054682AA	Somatropin	NQX9KB6PCL						Growth hormone deficiency	6552		
Somatropin for injection	As replacement therapy for growth hormone deficiency in adults after epiphyseal closure.	Somatropin for injection		Nutropin	11/18/96	Designated/Approved	Approved for Orphan Indication		12/15/97	12/15/04	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0054682AA	Somatropin for injection	NQX9KB6PCL						Growth hormone deficiency	6552		
pralmorelin hydrochloride	As a diagnostic agent for the detection of growth hormone deficiency	pralmorelin hydrochloride		n/a	10/18/12	Designated			N/A	N/A	"Sella Pharmaceuticals, Inc."	Wynnewood	Pennsylvania	19096	USA	EXACT	0284537AA	pralmorelin hydrochloride	R4AVR27MM8						Growth hormone deficiency	6552		
ibutamoren mesylate	Treatment of growth hormone deficiency	ibutamoren mesylate		n/a	6/15/17	Designated			N/A	N/A	"Ammonett Pharma, LLC"	Midlothian	Virginia	23113	USA	EXACT	0184963AA	ibutamoren mesylate	R90JB6QJ2B						Growth hormone deficiency	6552		
MOD-423 hGH analogue	Treatment of growth hormone deficiency	MOD-423 hGH analogue		n/a	9/29/10	Designated			N/A	N/A	OPKO Biologics Ltd.	Nes-Ziona			Israel										Growth hormone deficiency	6552		
recombinant growth hormone fused to hyFc	Treatment of growth hormone deficiency.	recombinant growth hormone fused to hyFc		n/a	11/9/16	Designated			N/A	N/A	"Genexine, Inc."	Gyeonggi-do			"Korea, Republic of"	LONGEST CONTAINS	0054682AA	growth hormone	NQX9KB6PCL						Growth hormone deficiency	6552		
immune globulin (human)	Treatment of Guillain-Barre syndrome	immune globulin (human)		n/a	3/2/10	Designated			N/A	N/A	"Octapharma USA, Inc."	Hoboken	New Jersey	7030	USA	EXACT	0232586AA	immune globulin (human)	66Y330CJHS						Guillain-Barre syndrome	6554		
Recombinant protein inhibitor of complement factor 5	Treatment of Guillain-Barre Syndrome.	Coversin		n/a	5/10/16	Designated			N/A	N/A	Akari Therapeutics Plc	New York	New York	10018	USA	EXACT	1794985AA	Coversin	79V7Q9VIWQ						Guillain-Barre syndrome	6554		
4-Aminopyridine	Treatment chronic functional motor and sensory deficits from Guillain-Barre syndrome	4-Aminopyridine		n/a	12/14/05	Designated			N/A	N/A	"Acorda Therapeutics, Inc."	Ardsley	New York	10502	USA	EXACT	0121335AA	4-Aminopyridine	BH3B64OKL9						Guillain-Barre syndrome	6554		
humanized IgG4 monoclonal antibody binding to human C1q	Treatment of Guillain-Barre Syndrome	ANX-005		n/a	1/19/17	Designated			N/A	N/A	Annexon Biosciences	South San Francisco	California	94080	USA	EXACT	0114449AB	ANX-005	N5WBB45U8L						Guillain-Barre syndrome	6554		
afamelanotide	Treatment of familial benign chronic pemphigus (Hailey-Hailey disease)	afamelanotide		n/a	5/14/14	Designated			N/A	N/A	"Clinuvel, Inc."	New York	New York	10013	USA	EXACT	0253281AA	afamelanotide	QW68W3J66U						Hailey-Hailey disease	6559		
vemurafenib	Treatment of hairy cell leukemia (HCL).	vemurafenib		Zelboraf	8/26/14	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0507620AA	vemurafenib	207SMY3FQT						Hairy cell leukemia	6560		
moxetumomab pasudotox	Treatment of hairy cell leukemia	moxetumomab pasudotox		n/a	11/15/07	Designated			N/A	N/A	"MedImmune, LLC"	Gaithersburg	Maryland	20878	USA	EXACT	0432520AA	moxetumomab pasudotox	2NDX4B6N8F						Hairy cell leukemia	6560		
Pentostatin for injection	Treatment of hairy cell leukemia.	Pentostatin for injection		Nipent	9/10/87	Designated/Approved	Approved for Orphan Indication	Single agent treatment for adult patients with alpha-interferon-refractory hairy cell leukemia.	10/11/91	10/11/98	"SuperGen, Inc."	San Ramon	California	94583	USA	EXACT	0067130AA	Pentostatin	395575MZO7						Hairy cell leukemia	6560		
Cladribine	Treatment of hairy cell leukemia.	Cladribine		Leustatin Injection	11/15/90	Designated/Approved	Approved for Orphan Indication		2/26/93	2/26/00	R. W. Johnson Pharmaceutical Research Institute	Raritan	New Jersey	8869	USA	EXACT	0092944AA	Cladribine	47M74X9YT5						Hairy cell leukemia	6560		
blinatumomab	Treatment for hairy cell leukemia.	blinatumomab		n/a	5/16/08	Designated			N/A	N/A	"Amgen, Inc."	Thousand Oaks	California			EXACT	0322758AA	blinatumomab	4FR53SIF3A						Hairy cell leukemia	6560		
"(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride"	"Treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia"	FORODESINE HYDROCHLORIDE		n/a	8/10/04	Designated			N/A	N/A	Mundipharma Research Ltd.				United Kingdom	EXACT	0241736AA	FORODESINE HYDROCHLORIDE	6SN82Y9U73						Hairy cell leukemia	6560		
Granulocyte macrophage-colony stimulating factor	Treatment of neutropenia due to hairy cell leukemia.	Leucomax		Leucomax	5/3/90	Designated/Withdrawn			N/A	N/A	Schering Corporation	Kenilworth	New Jersey	7033	USA	EXACT	0259541AA	Leucomax	B321AL142J						Hairy cell leukemia	6560		
urea	"Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis)."	urea		n/a	11/7/11	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0009290AA	urea	8W8T17847W						Harlequin ichthyosis	6568		
insecticidal toxin derived from Bacillus thuringiensis	Treatment of soil transmitted helminth infection strongyloidiasis	insecticidal toxin derived from Bacillus thuringiensis		n/a	9/5/08	Designated			N/A	N/A	"University of California, San Diego"	LaJolla	California	92093	USA	LONGEST CONTAINS	1108118AA	Bacillus thuringiensis	3TK3LQP1N7						Helminth infection	6578		
flunarizine	Treatment of alternating hemiplegia.	flunarizine		Sibelium	1/6/86	Designated			N/A	N/A	Janssen Research Foundation	Titusville	New Jersey	8560	USA	EXACT	0330198AA	flunarizine	R7PLA2DM0J						Hemiplegia	6583		
flunarizine	Treatment of alternating hemiplegia	flunarizine		n/a	6/24/13	Designated			N/A	N/A	"Marathon Pharmaceuticals, LLC"	Northbrook	Illinois	60062	USA	EXACT	0330198AA	flunarizine	R7PLA2DM0J						Hemiplegia	6583		
humanized monoclonal antibody against Shiga-like toxin II	To prevent the development of or to decrease the incidence and severity of hemolytic uremic syndrome and associated sequelae of Shiga-like toxin-producing E. coli.	Urtoxazumab		n/a	9/12/01	Designated/Withdrawn			N/A	N/A	"Teijin America, Inc."	Princeton	New Jersey	8540	USA	EXACT	0727322AA	Urtoxazumab	232D35B3NT						Hemolytic uremic syndrome	6588		
eculizumab	Treatment of atypical hemolytic uremic syndrome	eculizumab		Soliris	4/29/09	Designated/Approved	Approved for Orphan Indication	For the treatment of atypical Hemolytic Uremic Syndrome (aHUS)	9/23/11	9/23/18	"Alexion Pharmaceuticals, Inc."	Cheshire	Connecticut	6410	USA	EXACT	0298000AA	eculizumab	A3ULP0F556						Hemolytic uremic syndrome	6588		
eculizumab	Treatment of Shiga-Toxin producing escherichia coli hemolytic uremic syndrome	eculizumab		Soliris	10/18/11	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	Cheshire	Connecticut	6410	USA	EXACT	0298000AA	eculizumab	A3ULP0F556						Hemolytic uremic syndrome	6588		
ravulizumab subcutaneous	Treatment of atypical hemolytic uremic syndrome (aHUS)	ravulizumab subcutaneous		n/a	10/27/17	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	New Haven	Connecticut		USA	EXACT	1800164AA	ravulizumab	C3VX249T6L						Hemolytic uremic syndrome	6588		
antagonist of the complement 5a receptor	Treatment of atypical hemolytic uremic syndrome	CCX-168		n/a	11/17/14	Designated			N/A	N/A	"ChemoCentryx, Inc."	Mountain View	California	94043	USA	EXACT	1083336AA	CCX-168	O880NM097T						Hemolytic uremic syndrome	6588		
complement factor H	Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system	complement factor H		n/a	12/7/09	Designated/Withdrawn			N/A	N/A	LFB Biotechnologies S.A.				France										Hemolytic uremic syndrome	6588		
recombinant human minibody against complement component	Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system.	recombinant human minibody against complement component		Mubodina(R)	6/7/11	Designated			N/A	N/A	Adienne S.A				Switzerland										Hemolytic uremic syndrome	6588		
tadekinig alfa	Treatment of hemophagocytic lymphohistiocytosis.	tadekinig alfa		n/a	1/12/17	Designated			N/A	N/A	AB2 Bio Ltd	Lausanne			Switzerland	EXACT	1090422AA	tadekinig alfa	3G6834I4PF						Hemophagocytic lymphohistiocytosis	6589		
Fully human anti-interferon gamma monoclonal antibody	Treatment of hemophagocytic lymphohistiocytosis	Ni-0501		Ni-0501	3/26/10	Designated			N/A	N/A	NovImmune S.A.				Switzerland	EXACT	1311291AA	Ni-0501	3S252O2Z4X						Hemophagocytic lymphohistiocytosis	6589		
Inhibitor of Tissue Factor Pathway Inhibitor (TFPI)	Treatment of hemophilia A and hemophilia B.	BAX-499		n/a	1/29/10	Designated			N/A	N/A	"Baxter Healthcare Corporation, Baxter BioScience"	Westlake Village	California	91362	USA	EXACT	1295494AA	BAX-499	0493WH50VT						Hemophilia A	6591		
human monoclonal antibody directed against tissue factor pathway inhibitor	"Treatment of hemophilia A and hemophilia B patients with or without inhibitors, which includes routine prophylaxis to prevent or reduce the frequency of bleeding in hemophilia A and hemophilia B patients."	PF-06741086		n/a	5/18/16	Designated			N/A	N/A	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	0112525AB	PF-06741086	0UB3OA67O7						Hemophilia A	6591		
Recombinant humanized MAb 5c8	Prevention and treatment of Factor VIII/Factor IX inhibitors in patients with hemophilia A or B.	Ruplizumab		n/a	10/14/98	Designated			N/A	N/A	"Biogen, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	1090342AA	Ruplizumab	562JQF15GN						Hemophilia A	6591		
human coagulation factor VIII	Immune tolerance induction in hemophilia A patients with inhibitors	HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX		Octanate	12/3/12	Designated			N/A	N/A	"OCTAPHARMA USA, Inc."	Hoboken	New Jersey	7030	USA	EXACT	0323353AA	HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX	5T6B772R4Q						Hemophilia A	6591		
factor VIII mimetic bispecific antibody	Treatment of hemophilia A	emicizumab		n/a	1/10/14	Designated			N/A	N/A	Genentech	South San Francisco	California	94080	USA	EXACT	1150205AA	emicizumab	7NL2E3F6K3						Hemophilia A	6591		
"antihemophilic factor (recombinant), Fc fusion protein"	Treatment of hemophilia A	Eloctate		Eloctate	11/23/10	Designated/Approved	Approved for Orphan Indication	"Treatment of adults and children with Hemophilia A (congenital Factor VIII deficiency) for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes."	6/6/14	6/6/21	Biogen Idec Inc.	Cambridge	Massachusetts	2142	USA	EXACT	0791979AA	Eloctate	7PCM518YLR						Hemophilia A	6591		
Coagulation factor VIIa (recombinant)	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Coagulation factor VIIa (recombinant)		Novoseven	6/6/88	Designated/Approved	Approved for Orphan Indication	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	3/25/99	3/25/06	"Novo Nordisk, Inc."	Princeton	New Jersey	8540	USA	EXACT	0324765AA	Coagulation factor VIIa (recombinant)	AC71R787OV						Hemophilia A	6591		
Coagulation factor VIIa (recombinant)	"Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors"	Coagulation factor VIIa (recombinant)		Novoseven	6/18/04	Designated/Approved	Approved for Orphan Indication	Prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX	8/12/05	8/12/12	"Novo Nordisk, Inc."	Princeton	New Jersey	8540	USA	EXACT	0324765AA	Coagulation factor VIIa (recombinant)	AC71R787OV						Hemophilia A	6591		
anti-inhibitor coagulant complex	Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors	anti-inhibitor coagulant complex		Feiba	4/12/13	Designated/Approved	Approved for Orphan Indication	Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors	12/16/13	12/16/20	"Baxalta US, Inc."	West Lake Village	California	91362	USA	EXACT	0345175AA	anti-inhibitor coagulant complex	CS849DUN3M						Hemophilia A	6591		
Recombinant Human Factor VIIa Variant	Routine prophylaxis to prevent bleeding episodes in patients with hemophilia A and B patients with inhibitors	MARZEPTACOG ALFA (ACTIVATED)		n/a	11/30/12	Designated			N/A	N/A	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	1198341AA	MARZEPTACOG ALFA (ACTIVATED)	J5LT149M79						Hemophilia A	6591		
Antihemophilic factor (recombinant)	Prophylaxis and treatment of bleeding in individuals with hemophilia A or for prophylaxis when surgery is required in individuals with hemophilia A.	Antihemophilic factor (recombinant)		Kogenate	9/25/89	Designated/Approved	Approved for Orphan Indication	Treatment and prophylaxis of bleeding in patients with hemophilia A (not von Willebrand's disease)	2/25/93	2/25/00	Bayer Corporation	Elkhart	Indiana	46515	USA	EXACT	0182832AA	Antihemophilic factor (recombinant)	P89DR4NY54						Hemophilia A	6591		
Antihemophilic factor (recombinant)	For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).	Antihemophilic factor (recombinant)		"Refacto, Xyntha"	2/8/96	Designated/Approved	Approved for Orphan Indication		3/6/00	N/A	"Wyeth Pharmaceuticals, Inc."	Philadelphia	Pennsylvania	19101	USA	EXACT	0182832AA	Antihemophilic factor (recombinant)	P89DR4NY54						Hemophilia A	6591		
Antihemophilic factor (recombinant) formulated with sucrose reconstituted with liposome diluent	Treatment of hemophilia A	Kogenate 		Kogenate Fs/Liposomal Diluent	4/29/09	Designated/Withdrawn			N/A	N/A	Bayer HealthCare LLC	Tarrytown	New York	10591	USA	EXACT	0182832AA	Kogenate	P89DR4NY54						Hemophilia A	6591		
Desmopressin acetate	Treatment of mild hemophilia A and von Willebrand's disease.	Desmopressin acetate		n/a	1/22/91	Designated/Approved	Approved for Orphan Indication	Treatment of patients with hemophilia A or von Willebrand's disease (type I) whose factor VIII coagulant activity level is greater than 5%.	3/7/94	3/7/01	Aventis Behring L.L.C.	King of Prussia	Pennsylvania	19406	USA	EXACT	0067027AA	Desmopressin acetate	XB13HYU18U						Hemophilia A	6591		
rVIIa-FP	Treatment and prophyllaxis of bleeding episodes in patients with congenital hemophilia and inhibitors to coagulation factor VIII or IX	rVIIa-FP		n/a	12/22/11	Designated			N/A	N/A	CSL Behring	King of Prussia	Pennsylvania	19406	USA	EXACT	0113916AB	rVIIa-FP							Hemophilia A	6591		
recombinant B-domain deleted human coagulation factor VIII Fc-von Willebrand factor-XTEN fusion protein	Treatment of hemophilia A	BIVV001		n/a	8/3/17	Designated			N/A	N/A	"Bioverativ Therapeutics, Inc."	Waltham	Massachusetts	2451	USA	EXACT									Hemophilia A	6591		
Adenovirus-based vector Factor VIII complementary DNA to somatic cells	Treatment of hemophilia A.	Adenovirus-based vector Factor VIII complementary DNA to somatic cells		Miniadfviii	12/15/99	Designated			N/A	N/A	GenStar Therapeutics Corporation	San Diego	California	92121	USA	LONGEST CONTAINS	0101768AA	Factor VIII							Hemophilia A	6591		
MaxAdFVIII	Treatment of Hemophilia A	MaxAdFVIII		n/a	3/3/03	Designated			N/A	N/A	GenStar Therapeutics Corporation	San Diego	California	92121	USA										Hemophilia A	6591		
modified recombinant human Factor VIIa (rFVIIa) molecule	Treatment of bleeding episodes in hemophilia A or B subjects with inhibitors	modified recombinant human Factor VIIa (rFVIIa) molecule		n/a	5/30/13	Designated/Withdrawn			N/A	N/A	"Bayer Healthcare Pharmaceuticals, Inc."	Whippany	New Jersey	7981	USA	LONGEST CONTAINS	0345153AA	human Factor VIIa	15FH07392N						Hemophilia A	6591		
synthetic double-stranded siRNA oligonucleotide against antithrombin (AT) mRNA	Treatment of hemophilia A	synthetic double-stranded siRNA oligonucleotide against antithrombin (AT) mRNA		n/a	8/16/13	Designated			N/A	N/A	Alnylam Pharmaceuticals	Cambridge	Massachusetts	2142	USA	LONGEST CONTAINS	0172032AA	antithrombin	T0LTO7L82X						Hemophilia A	6591		
long acting recombinantFactor VIIa-CTP3	Treatment and prophylaxis of bleeding episodes in patients with hemophilia A or B with inhibitors to factor VIII or factor IX	long acting recombinantFactor VIIa-CTP3		n/a	2/27/14	Designated			N/A	N/A	"PROLOR Biotech, Ltd"	Nes Ziona			Israel										Hemophilia A	6591		
immunologically active synthetic peptides	Treatment of Hemophilia A	immunologically active synthetic peptides		n/a	6/1/15	Designated			N/A	N/A	Apitope International NV				Belgium										Hemophilia A	6591		
adeno-associated virus vector encoding the SQ variant of human blood clotting factor VIII	Treatment of Hemophilia A.	adeno-associated virus vector encoding the SQ variant of human blood clotting factor VIII		n/a	2/29/16	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA	LONGEST CONTAINS	0101768AA	factor VIII							Hemophilia A	6591		
"Recombinant adeno-associated viral vector, AAV2 serotype 6 (rAAv2/6), expressing human factor 8 (hf8) cDNA"	Treatment of hemophilia A	"Recombinant adeno-associated viral vector, AAV2 serotype 6 (rAAv2/6), expressing human factor 8 (hf8) cDNA"		n/a	5/3/17	Designated			N/A	N/A	"Sangamo Therapeutics, Inc."	Richmond	California	94804	USA	LONGEST CONTAINS	0112841AB	AAV2	YA02LE18L3						Hemophilia A	6591		
Adeno-associated virus serotype 8 vector expressing B domain deleted codon optimized factor VIII	Treatment of hemophilia A	Adeno-associated virus serotype 8 vector expressing B domain deleted codon optimized factor VIII		n/a	9/18/17	Designated			N/A	N/A	Baxalta US Inc.	Westlake Village	California	91362	USA	LONGEST CONTAINS	0101768AA	factor VIII							Hemophilia A	6591		
recombinant adeno-associated viral (AAV) vector that contains a bioengineered capsid (AAV-Spark200) and a codon-optimized expression cassette to drive expression of the SQ form of a B-domain deleted human coagulation factor VIII (hFVIII)	Treatment of hemophilia A	recombinant adeno-associated viral (AAV) vector that contains a bioengineered capsid (AAV-Spark200) and a codon-optimized expression cassette to drive expression of the SQ form of a B-domain deleted human coagulation factor VIII (hFVIII)		n/a	1/16/18	Designated			N/A	N/A	"Spark Therapeutics, Inc."	3737 Market Street	Philadelphia	19104	USA	LONGEST CONTAINS	0101688AA	human coagulation factor VIII	839MOZ74GK						Hemophilia A	6591		
concizumab	Treatment of hemophilia A	concizumab		n/a	10/22/18	Designated			N/A	N/A	"Novo Nordisk, Inc."	P.O Box 846	New Jersey	8536	USA	EXACT	0804035AA	concizumab	68603V9EAF						Hemophilia A	6591		
rofecoxib	Treatment of hemophilic arthropathy (HA)	rofecoxib		n/a	9/26/17	Designated			N/A	N/A	"Tremeau Pharmaceuticals, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0190089AA	rofecoxib	0QTW8Z7MCR						Hemophilic arthropathy	6592		
ribavirin	Treatment of hemorrhagic fever with renal syndrome	ribavirin		Virazole	4/12/91	Designated			N/A	N/A	Valeant Pharmaceuticals International	Costa Mesa	California	92626	USA	EXACT	0064824AA	ribavirin	49717AWG6K						Hemorrhagic fever	6593		
N-(9-methoxynonyl)-1-deoxynojirimycin hydrochloride	"Treatment of acute dengue illness (inclusive of acute dengue illness, dengue fever, dengue hemorrhagic fever, and dengue shock syndrome)"	uv-4b		n/a	11/17/14	Designated			N/A	N/A	"Emergent Virology, LLC"	Gaithersburg	Maryland	20879	USA	EXACT	0925019AA	uv-4b	R3Y2198MRP						Hemorrhagic fever	6593		
recombinant nematode anticoagulant protein c2 (rNAPc2)	Treatment of viral hemorrhagic fever post-exposure to Ebola virus (treatment of Ebola)	recombinant nematode anticoagulant protein c2 (rNAPc2)		n/a	12/8/14	Designated			N/A	N/A	"ARCA Biopharma, Inc."	Westminster	Colorado	80020	USA	EXACT	0262362AA	recombinant nematode anticoagulant protein c2 (rNAPc2)	3TTT9ZD93F						Hemorrhagic fever	6593		
Hantaan virus and Puumala virus DNA vaccines	Prevention of hemorrhagic fever with renal syndrome caused by Hantaan virus and Puumala virus.	Hantaan virus and Puumala virus DNA vaccines		n/a	11/13/12	Designated			N/A	N/A	Surgeon General of the U. S. Army	Fort Detrick	Maryland	21702	USA										Hemorrhagic fever	6593		
Conjugate of a dengue virus specific small chemical ligand and an amphiphilic PEG based polymer	Treatment of dengue fever (includes dengue hemorrhagic fever and dengue shock syndrome)	Conjugate of a dengue virus specific small chemical ligand and an amphiphilic PEG based polymer		n/a	8/6/13	Designated			N/A	N/A	NanoViricides Incorporated	West Haven	Connecticut	6516	USA										Hemorrhagic fever	6593		
ruxolitinib phosphate	Treatment of essential thrombocythemia	ruxolitinib phosphate		Jakafi	3/22/10	Designated			N/A	N/A	Incyte Corporation	Wilmington	Delaware	19803	USA	EXACT	0557120AA	ruxolitinib phosphate	436LRU32H5						Essential thrombocythemia	6594		
pacritinib	"Treatment of primary myelofibrosis (MF), post-polycythemia vera MF, and post-essential thrombocythemia MF"	pacritinib		n/a	3/13/08	Designated			N/A	N/A	CTI BioPharma Corporation	Seattle	Washington	98121	USA	EXACT	0568956AA	pacritinib	G22N65IL3O						Essential thrombocythemia	6594		
Anagrelide	Treatment of essential thrombocythemia.	Anagrelide		Agrylin	1/27/88	Designated/Approved	Approved for Orphan Indication	Treatment of patients with essential thrombocythemia to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms.	3/14/97	3/14/04	Roberts Pharmaceutical Corp.	Eatontown	New Jersey	7724	USA	EXACT	0225956AA	Anagrelide	K9X45X0051						Essential thrombocythemia	6594		
pegylated proline interferon alpha-2b	Treatment of essential thrombocythemia	pegylated proline interferon alpha-2b		n/a	4/11/14	Designated			N/A	N/A	"PharmaEssentia, Corporation"				Taiwan	LONGEST CONTAINS	0160601AA	interferon alpha 2b	43K1W2T1M6						Essential thrombocythemia	6594		
terlipressin	Treatment of Hepatorenal Syndrome	terlipressin		n/a	10/29/04	Designated			N/A	N/A	Ikaria (INO Therapeutics)	Hampton	New Jersey	8827	USA	EXACT	0056111AA	terlipressin	7Z5X49W53P						Hepatorenal syndrome	6610		
Hemin	"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria."	Hemin		Panhematin	3/16/84	Designated/Approved	Approved for Orphan Indication		7/20/83	7/20/90	Abbott Laboratories	Abbott Park	Illinois	60064	USA	EXACT	0135171AA	Hemin	743LRP9S7N						Hereditary coproporphyria	6619		
Histrelin	"Treatment of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria."	Histrelin		n/a	5/3/91	Designated			N/A	N/A	"Anderson, Karl E., M.D."	Galveston	Texas	77550	USA	EXACT	0135864AA	Histrelin	H50H3S3W74						Hereditary coproporphyria	6619		
bevacizumab	Treatment of hereditary hemorrhagic telangiectasia	bevacizumab		n/a	10/21/10	Designated			N/A	N/A	"Terence M. Davidson, MD"	San Diego	California	92103	USA	EXACT	0244257AA	bevacizumab	2S9ZZM9Q9V						Hereditary hemorrhagic telangiectasia	6626		
raloxifene hydrochloride	Treatment of hereditary hemorrhagic telangiectasia	raloxifene hydrochloride		Evista	8/20/10	Designated			N/A	N/A	Consejo Superior de Investigaciones Cientificas	Madrid				EXACT	0125371AA	raloxifene hydrochloride	4F86W47BR6						Hereditary hemorrhagic telangiectasia	6626		
thalidomide	Treatment of hereditary hemorrhagic telangiectasia	thalidomide		Taldo	7/19/17	Designated			N/A	N/A	PlumeStars s.r.l.				Italy	EXACT	0007409AA	thalidomide	4Z8R6ORS6L						Hereditary hemorrhagic telangiectasia	6626		
PR-225 (redox-acyclovir)	Treatment of herpes simplex encephalitis in individuals afflicted with AIDS.	PR-225 (redox-acyclovir)		n/a	5/29/90	Designated/Withdrawn			N/A	N/A	Pharmos	Alachua	Florida	32615	USA	EXACT	0066773AA	acyclovir	X4HES1O11F						Herpes simplex encephalitis	6649		
recombinant human Naglu- insulin-like growth factor II	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B)	TRALESINIDASE ALFA		n/a	3/5/13	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0112449AB	TRALESINIDASE ALFA	AA60A4ST8X						Mucopolysaccharidosis type II	6675		
chemically modified recombinant sulfamidase	Treatment of mucopolysaccharidosis type IIIA (MPS IIIA)	SOBI-003		n/a	6/28/17	Designated			N/A	N/A	Swedish Orphan Biovitrum AB (publ)	Linköping SV			Sweden	EXACT	0112128AB	SOBI-003	ZS87P77DQC						Mucopolysaccharidosis type II	6675		
adeno-associated virus vector serotype 9 expressing human sulfamidase	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A Syndrome).	adeno-associated virus vector serotype 9 expressing human sulfamidase		n/a	6/1/11	Designated			N/A	N/A	"Laboratorios del Dr. Esteve, S.A."	Barcelona			Spain										Mucopolysaccharidosis type II	6675		
adeno-associated viral vector serotype 9 containing human N-acetylglucosaminidase alpha gene	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome)	adeno-associated viral vector serotype 9 containing human N-acetylglucosaminidase alpha gene		n/a	12/27/12	Designated			N/A	N/A	"Laboratorios del Dr. Esteve, S.A."	Barcelona			Spain										Mucopolysaccharidosis type II	6675		
adeno associated viral vector serotype rh.10 carrying the human SGSH and SUMF1 cDNAs	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo type A syndrome)	adeno associated viral vector serotype rh.10 carrying the human SGSH and SUMF1 cDNAs		n/a	5/6/13	Designated			N/A	N/A	Lysogene	Paris			France										Mucopolysaccharidosis type II	6675		
HIRMAb-IDS	Treatment of mucopolysaccharidosis Type II (Hunter Syndrome)	HIRMAb-IDS		n/a	5/15/13	Designated			N/A	N/A	"ArmaGen Technologies, Inc."	Santa Monica	California	90401	USA										Mucopolysaccharidosis type II	6675		
recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase	Treatment of mucopolysaccharidosis type III-A (Sanfilippo Syndrome Type A)	recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase		n/a	4/29/14	Designated			N/A	N/A	Abeona Therapeutics	Cleveland	Ohio	44106	USA										Mucopolysaccharidosis type II	6675		
adeno-associated virus serotype 9 vector containing human Iduronate-2-sulfatase transgene	Treatment of mucopolysaccharidosis type II (Hunter syndrome).	adeno-associated virus serotype 9 vector containing human Iduronate-2-sulfatase transgene		n/a	7/16/15	Designated			N/A	N/A	"Laboratorios del Dr. Esteve, S.A."	Barcelona			Spain										Mucopolysaccharidosis type II	6675		
adeno-associated viral (AAV) vector serotype rh. 10 encoding the human N-sulfoglycosamine sulphohydrolase cDNA (SGSH)	Treatment of mucopolysaccharidosis type IIIA or Sanfilippo type A syndrome	adeno-associated viral (AAV) vector serotype rh. 10 encoding the human N-sulfoglycosamine sulphohydrolase cDNA (SGSH)		n/a	11/18/15	Designated			N/A	N/A	LYSOGENE	Neuilly-sur-Seine			France										Mucopolysaccharidosis type II	6675		
non-replicating recombinant adeno-associated virus (AAV) vector of serotype 9 expressing human iduronate-2-sulfatase	Treatment of Mucopolysaccharidosis Type II	non-replicating recombinant adeno-associated virus (AAV) vector of serotype 9 expressing human iduronate-2-sulfatase		n/a	12/8/15	Designated			N/A	N/A	"REGENXBIO, Inc."	Rockville	Maryland	20850	USA										Mucopolysaccharidosis type II	6675		
recombinant adeno-associated virus vector serotype 9 expressing human N-Sulfoglucosamine Sulfohydrolase	"Treatment of mucopolysaccharidosis type III A, also called Sanfilippo syndrome A"	recombinant adeno-associated virus vector serotype 9 expressing human N-Sulfoglucosamine Sulfohydrolase		n/a	9/1/16	Designated			N/A	N/A	Research Institute at Nationwide Children's Hospital	Columbus	Ohio	43205	USA										Mucopolysaccharidosis type II	6675		
Adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and the human iduronate 2-sulfatase (hIDS) gene	Treatment of mucopolysaccharidosis type II	Adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and the human iduronate 2-sulfatase (hIDS) gene		n/a	2/27/17	Designated			N/A	N/A	"Sangamo Therapeutics, Inc."	Richmond	California	94804	USA	LONGEST CONTAINS	0048271AA	zinc	J41CSQ7QDS						Mucopolysaccharidosis type II	6675		
Recombinant human insulin receptor monoclonal antibody-N-heparan sulfamidase fusion protein	"Treatment of Mucopolysaccharidosis Type IIIA, Sanfilippo A Syndrome"	Recombinant human insulin receptor monoclonal antibody-N-heparan sulfamidase fusion protein		n/a	7/12/18	Designated			N/A	N/A	"ArmaGen, Inc."	"26679 Agoura Road, Suite #100"	California	91302	USA	LONGEST CONTAINS	1337275AA	insulin receptor	4CH8636GFF						Mucopolysaccharidosis type II	6675		
Humanized IgG-1 antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase	Treatment of Mucopolysaccharidosis Type II (MPS II) or Hunter Syndrome	Humanized IgG-1 antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase		n/a	10/15/18	Designated			N/A	N/A	"JCR Pharmaceuticals Co., Ltd."	2-4 Kasuga-cho			Japan	LONGEST CONTAINS	0158667AA	transferrin							Mucopolysaccharidosis type II	6675		
"5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline hydrochloride"	Treatment of Huntington's disease	PBT-1033 HYDROCHLORIDE		n/a	9/4/14	Designated			N/A	N/A	Prana Biotechnology Limited	Victoria 3052			Australia	EXACT	1656048AA	PBT-1033 HYDROCHLORIDE	24Z79C941B						Huntington's disease	6677		
laquinimod sodium	Treatment of Huntington's Disease	laquinimod sodium		n/a	1/31/17	Designated			N/A	N/A	Teva Branded Pharmaceutical Products R&D	Frazer	Pennsylvania	19355	USA	EXACT	0310678AA	laquinimod sodium	4H914M0CSP						Huntington's disease	6677		
"phenol, 4-[2-(aminomethyl)-4-thiazolyl]-2,6-bis (1,1-dimethyethyl) monohydrochloride"	Treatment of Huntington's disease.	BN-82451		n/a	3/16/15	Designated			N/A	N/A	"Ipsen Biopharmaceuticals, Inc."	Basking Ridge	New Jersey	7920	USA	EXACT	0832053AA	BN-82451	531B661QBY						Huntington's disease	6677		
small molecule inhibitor of phosphodiesterase 10	Treatment of Huntington's disease	OMS-824		n/a	9/26/13	Designated			N/A	N/A	Omeros Corporation	Seattle	Washington	98119	USA	EXACT	1704456AA	OMS-824	5I3920IR5F						Huntington's disease	6677		
cysteamine	Treatment of Huntington's disease	cysteamine		n/a	5/9/08	Designated			N/A	N/A	Raptor Therapeutics	Novato	California	94949	USA	EXACT	0010377AA	cysteamine	5UX2SD1KE2						Huntington's disease	6677		
lithium citrate tetrahydrate (in reverse micelle formulation)	Treatment of Huntington's disease.	lithium citrate tetrahydrate (in reverse micelle formulation)		n/a	12/13/10	Designated			N/A	N/A	Medesis Pharma				France	EXACT	0031812AA	lithium citrate tetrahydrate	5Z6E9K79YV						Huntington's disease	6677		
Ethyl eicosapentaenoate	Treatment of Huntington's disease.	Ethyl eicosapentaenoate		n/a	4/6/00	Designated			N/A	N/A	Laxdale Ltd.				United Kingdom	EXACT	0280284AA	Ethyl eicosapentaenoate	6GC8A4PAYH						Huntington's disease	6677		
Riluzole	Treatment of Huntington's disease.	Riluzole		Rilutek	10/15/96	Designated			N/A	N/A	"Rhone-Poulenc Rorer Pharmaceuticals, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	0182978AA	Riluzole	7LJ087RS6F						Huntington's disease	6677		
Remacemide	Treatment of Huntington's disease.	Remacemide		Ecovia	3/6/00	Designated/Withdrawn			N/A	N/A	AstraZeneca LP	Wayne	Pennsylvania	19087	USA	EXACT	0456882AA	Remacemide	EH6763C1IC						Huntington's disease	6677		
Coenzyme Q10	Treatment of Huntington's disease	Coenzyme Q10		n/a	3/5/01	Designated			N/A	N/A	"Integrative Therapeutics, Inc."	Green Bay	Wisconsin	54311	USA	EXACT	0024282AA	Coenzyme Q10	EJ27X76M46						Huntington's disease	6677		
Clotrimazole	Treatment of Huntington's disease	Clotrimazole		n/a	3/13/06	Designated			N/A	N/A	"EnVivo Pharmaceuticals, Inc."	Watertown	Massachusetts	2472	USA	EXACT	0062373AA	Clotrimazole	G07GZ97H65						Huntington's disease	6677		
selisistat	Treatment of Huntington's disease	selisistat		n/a	12/7/09	Designated			N/A	N/A	Siena Biotech SpA				Italy	EXACT	0700049AA	selisistat	L19ECD5014						Huntington's disease	6677		
ubiquinol	Treatment of Huntington's Disease	ubiquinol		"Ubi-Q-Nol, Li-Q-Nol"	4/12/04	Designated			N/A	N/A	"Gel-Tec, Division of Tishcon Corp."	Westbury	New York	11590	USA	EXACT	0727435AA	ubiquinol	M9NL0C577Y						Huntington's disease	6677		
carbenoxolone	Treatment of Huntington's Disease	carbenoxolone		n/a	7/2/14	Designated			N/A	N/A	"Oxalys Pharmaceuticals, Inc."	"Toronto, ON M1S 2L4"			Canada	EXACT	0147637AA	carbenoxolone	MM6384NG73						Huntington's disease	6677		
Creatine	Treatment of Huntington's disease	Creatine		Creapure	10/11/05	Designated			N/A	N/A	"Marathon Pharmaceuticals, LLC"	Northbrook	Illinois	60062	USA	EXACT	0009245AA	Creatine	MU72812GK0						Huntington's disease	6677		
dimebon	Treatment of Huntington's Disease.	dimebon		n/a	5/12/09	Designated			N/A	N/A	"Medivation, Inc."	San Francisco	California	94105	USA	EXACT	0313531AA	dimebon	OD9237K1Z6						Huntington's disease	6677		
"d6-tetrabenazine, deutetrabenazine"	Treatment of Huntington's Disease	"d6-tetrabenazine, deutetrabenazine"		n/a	11/5/14	Designated			N/A	N/A	"Teva Pharmaceuticals, Inc."	La Jolla	California	92037	USA	EXACT	0934827AA	deutetrabenazine	P341G6W9NB						Huntington's disease	6677		
4-(3-Methanesulfonyl-phenyl)-1-propylpiperidine HCl	Treatment of Huntington's disease.	PRIDOPIDINE HYDROCHLORIDE		n/a	12/12/05	Designated			N/A	N/A	Teva Branded Pharmaceutical Products R&D	Frazer	Pennsylvania	19355	USA	EXACT	0300130AA	PRIDOPIDINE HYDROCHLORIDE	QH6KD74EGF						Huntington's disease	6677		
2-[4-(1-Methyl-4-pyridin-4-yl-lH-pyrazol-3-yl)-phenoxymethyl]-quinoline succinic acid	Treatment of Huntington's disease.	MARDEPODECT SUCCINATE		n/a	6/2/14	Designated			N/A	N/A	Pfizer Inc.	Groton	Connecticut	6340	USA	EXACT	0271147AA	MARDEPODECT SUCCINATE	TJ5KAZ8T5G						Huntington's disease	6677		
Tetrabenazine	Treatment of Huntington's disease	Tetrabenazine		Xenazine	12/11/97	Designated/Approved	Approved for Orphan Indication	Treatment of chorea associated with Huntington's disease	8/15/08	8/15/15	"Prestwick Pharmaceuticals, Inc"	Washington	District of Columbia	20006	USA	EXACT	0009825AA	Tetrabenazine	Z9O08YRN8O						Huntington's disease	6677		
humanized IgG4 monoclonal antibody that binds to the SEMA4D antigen	Treatment of Huntington's disease	VX-15		n/a	8/16/16	Designated			N/A	N/A	"Vaccinex, Inc."	Rochester	New York	14620	USA	EXACT	0114280AB	VX-15	BPZ4A29SYE						Huntington's disease	6677		
Porcine fetal neural gabaergic cells and/or precursors aseptically prepared for intracerebral implantation for Huntington's disease.	Treatment of Huntington's disease.	Porcine fetal neural gabaergic cells and/or precursors aseptically prepared for intracerebral implantation for Huntington's disease.		Neurocell-Hd	12/10/96	Designated			N/A	N/A	Diacrin/Genzyme LLC	Cambridge	Massachusetts	2139	USA										Huntington's disease	6677		
Porcine fetal neural gabaergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation	Treatment of Huntington's disease.	Porcine fetal neural gabaergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation		Neurocell-Hd	12/10/96	Designated			N/A	N/A	Diacrin/Genzyme LLC	Cambridge	Massachusetts	2129	USA										Huntington's disease	6677		
recombinant adeno-associated virus encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP)	Treatment of Huntington's disease.	recombinant adeno-associated virus encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP)		n/a	8/25/09	Designated			N/A	N/A	"Neurologix, Inc."	Fort Lee	New Jersey	7024	USA	LONGEST CONTAINS	0087274AA	protein							Huntington's disease	6677		
Antisense oligonucleotide targeted to the huntingtin protein	Treatment of Huntington's disease	Antisense oligonucleotide targeted to the huntingtin protein		n/a	12/29/15	Designated			N/A	N/A	"Isis Pharmaceuticals, Inc."	Carlsbad	California	92010	USA	LONGEST CONTAINS	0087274AA	protein							Huntington's disease	6677		
antisense oligonucleotide targeting the U isoform of SNP rs362307	Treatment of Huntington's disease (prodromal stage Huntington's disease and diagnosed Huntington's disease)	antisense oligonucleotide targeting the U isoform of SNP rs362307		n/a	6/16/16	Designated			N/A	N/A	Wave LIfe Sciences	Cambridge	Massachusetts	2138	USA										Huntington's disease	6677		
synthetic stereopure antisense oligonucleotide specific to the mutant huntingtin mRNA transcript at the U variant of single nucleotide polymorphism rs326331	Treatment of Huntington's disease	synthetic stereopure antisense oligonucleotide specific to the mutant huntingtin mRNA transcript at the U variant of single nucleotide polymorphism rs326331		n/a	9/5/17	Designated			N/A	N/A	Wave Life Sciences Ltd.	Cambridge	Massachusetts	2138	USA										Huntington's disease	6677		
adeno-associated viral vector serotype 5 encoding a microRNA targeted to human huntingtin gene	Treatment of Huntington's disease.	adeno-associated viral vector serotype 5 encoding a microRNA targeted to human huntingtin gene		n/a	9/27/17	Designated			N/A	N/A	uniQure Biopharma B.V.	Lexington	Massachusetts	2421	USA										Huntington's disease	6677		
Teriparatide	Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism.	Teriparatide		Parathar	1/9/87	Designated/Approved	Approved for Orphan Indication		12/23/87	12/23/94	"Rhone-Poulenc Rorer Pharmaceuticals, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	0249503AA	Teriparatide	10T9CSU89I						Hypoparathyroidism	6733		
Synthetic Human Parathyroid Hormone 1-34	Treatment of hypoparathyroidism	Synthetic Human Parathyroid Hormone 1-34		n/a	1/26/01	Designated/Withdrawn			N/A	N/A	"Rare Disease Therapeutics, Inc."	Nashville	Tennessee	37217	USA	EXACT	0249503AA	Synthetic Human Parathyroid Hormone 1-34	10T9CSU89I						Hypoparathyroidism	6733		
teriparatide	Treatment of hypoparathyroidism	teriparatide		Forteo	4/18/14	Designated			N/A	N/A	"Entera Bio, Ltd."	Jeusalem			Israel	EXACT	0249503AA	teriparatide	10T9CSU89I						Hypoparathyroidism	6733		
parathyroid hormone	Treatment of hypoparathyroidism	parathyroid hormone		Natpara	8/31/07	Designated/Approved	Approved for Orphan Indication	An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism	1/23/15	1/23/22	"Shire-NPS Pharmaceuticals, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0005312AA	parathyroid hormone	N19A0T0E5J						Hypoparathyroidism	6733		
non-peptide small molecule orally available agonist of the parathyroid hormone receptor type I	Treatment of hypoparathyroidism	PC-0371		n/a	12/15/14	Designated			N/A	N/A	"Chugai Pharma USA, LLC"	Berkeley Heights	New Jersey	7922	USA	EXACT	1126121AA	PC-0371	TE53TU0WSQ						Hypoparathyroidism	6733		
TransCon Parathyroid Hormone (mPEG conjugated parathyroid hormone 1-34)	Treatment of hypoparathyroidism	TransCon Parathyroid Hormone (mPEG conjugated parathyroid hormone 1-34)		n/a	6/4/18	Designated			N/A	N/A	Ascendis Pharma Bone Diseases A/S	Tuborg Boulevard 5	DK-2900		Denmark	LONGEST CONTAINS	0005312AA	Parathyroid Hormone	N19A0T0E5J						Hypoparathyroidism	6733		
Asfotase alfa	Treatment of hypophosphatasia	Asfotase alfa		Strensiq	9/12/08	Designated/Approved	Approved for Orphan Indication	For the treatment of patients with perinatal/infantile-and juvenile-onset hypophosphatasia (HPP)	10/23/15	10/23/22	"Alexion Pharmaceuticals, Inc."	Cheshire	Connecticut	6410	USA	EXACT	0569506AA	Asfotase alfa	Z633861EIM						Hypophosphatasia	6734		
recombinant human alkaline phosphatase	Treatment of hypophosphatasia.	recombinant human alkaline phosphatase		n/a	5/13/15	Designated			N/A	N/A	AM-Pharma BV				Netherlands	EXACT	1802671AA	recombinant human alkaline phosphatase							Hypophosphatasia	6734		
Secalciferol	Treatment of familial hypophosphatemic rickets.	Secalciferol		Osteo-D	7/26/93	Designated			N/A	N/A	Teva Pharmaceuticals USA	North Wales	Pennsylvania	19454	USA	EXACT	0066342AA	Secalciferol	460029IUDA						Hypophosphatemic rickets	6735		
extracellular domain of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 fused to the Fc region of human IgG1	Treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency (generalized arterial calcification of infancy and autosomal recessive hypophosphatemic rickets type 2)	extracellular domain of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 fused to the Fc region of human IgG1		n/a	6/11/18	Designated			N/A	N/A	Inozyme Pharma Inc.	700 Technology Square		2139	USA										Hypophosphatemic rickets	6735		
immune globulin intraveous (human)	Treatment of idiopathic thrombocytopenic purpura (also known as primary immune thrombocytopenia)	IVIG		Gammaplex	4/29/11	Designated/Approved	Approved for Orphan Indication	Idiopathic thrombocytopenic purpura	3/8/13	N/A	Bio Products Laboratory	England			United Kingdom	EXACT	0201570AA	IVIG	66Y330CJHS						Immune thrombocytopenia	6768		
rozrolimupab	Treatment of primary immune thrombocytopenia.	rozrolimupab		n/a	9/13/10	Designated			N/A	N/A	Symphogen A/S				Denmark	EXACT	0324254AA	rozrolimupab	S134V96RPQ						Immune thrombocytopenia	6768		
Purified extract of Pseudomonas aeruginosa	Treatment of immune thrombocytopenia purpura where it is required to increase platelet counts.	Purified extract of Pseudomonas aeruginosa		Immudyn	9/22/97	Designated			N/A	N/A	"Able Laboratories, Inc."	Needham	Massachusetts	2494	USA	LONGEST CONTAINS	0340727AA	Pseudomonas aeruginosa	Y793W5V55N						Immune thrombocytopenia	6768		
human platelet antigen-1a immunoglobulin (anti-HPA-1a)	Prevention of fetal and neonatal alloimmune thrombocytopenia	human platelet antigen-1a immunoglobulin (anti-HPA-1a)		Tromplate	6/27/13	Designated			N/A	N/A	Prophylix Pharma AS	Tromso			Norway										Immune thrombocytopenia	6768		
"Humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s"	Treatment of immune thrombocytopenia	"Humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s"		n/a	3/28/18	Designated			N/A	N/A	Bioverativ USA Inc.	225 2nd Avenue		2451	USA										Immune thrombocytopenia	6768		
polyinosinic-polycytidilic acid	"Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses"	Poly-Iclc		Poly-Iclc	3/3/03	Designated			N/A	N/A	Oncovir	Washington	District of Columbia	20008	USA	EXACT	0777651AA	Poly-Iclc							Japanese encephalitis	6797		
"Japanese encephalitis vaccine (live, attenuated)"	Prevention of Japanese encephalitis.	"Japanese encephalitis vaccine (live, attenuated)"		n/a	5/19/99	Designated			N/A	N/A	"Glovax Co., Ltd."														Japanese encephalitis	6797		
"Japanese encephalitis vaccine, inactivated, adsorbed"	Prevention of Japanese encephalitis virus in pediatric patients.	"Japanese encephalitis vaccine, inactivated, adsorbed"		Ixiaro	9/25/12	Designated/Approved	Approved for Orphan Indication	"To extend the age range to include infants, children, and adolescents 2 months to less than 17 years of age for active immunization for the prevention of disease caused by Japanese encephalitis virus."	5/17/13	5/17/20	Intercell AG	Vienna			Austria										Japanese encephalitis	6797		
"5-{(1R,2R)-2-[(Cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride"	Treatment of Kabuki Syndrome	tak-418 		n/a	4/26/18	Designated			N/A	N/A	"Takeda Development Center Americas, Inc."	Takeda Parkway		60015	USA	EXACT	0111951AB	tak-418 free base	N9N6RK0CBN						Kabuki syndrome	6810		
pomalidomide	Treatment of Kaposi sarcoma	pomalidomide		Pomalyst®	4/4/18	Designated			N/A	N/A	Celgene Corporation	86 Morris Ave.		7901	USA	EXACT	0244122AA	pomalidomide	D2UX06XLB5						Kaposi sarcoma	6814		
H-Leu-Pro-Pro-Ser-Arg-OH	Treatment of Kaposi sarcoma	H-Leu-Pro-Pro-Ser-Arg-OH		n/a	9/20/12	Designated			N/A	N/A	"Immuno Tech, Inc."	Arlington	Washington	98223	USA	EXACT	1576472AA	H-Leu-Pro-Pro-Ser-Arg-OH	HFL33E395I						Kaposi sarcoma	6814		
Alitretinoin	Treatment of AIDS-related Kaposi's sarcoma.	Alitretinoin		Panretin	3/24/98	Designated/Approved	Approved for Orphan Indication	Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.	2/2/99	2/2/06	"Eisai, Inc"	Woodcliff Lake	New Jersey	7677	USA	EXACT	0184576AA	Alitretinoin	1UA8E65KDZ						Kaposi's Sarcoma	6814		
Interferon alfa-nl	Treatment of AIDS related Kaposi's sarcoma.	Wellferon		Wellferon	8/25/86	Designated/Withdrawn			N/A	N/A	Burroughs Wellcome Company	Research Triangle Pk	North Carolina	27709	USA	EXACT	0233727AA	Wellferon	41697D4Z5C						Kaposi's Sarcoma	6814		
Interferon alfa-2b (recombinant)	Treatment of AIDS-related Kaposi's sarcoma.	Interferon alfa-2b (recombinant)		Intron A	6/24/87	Designated/Approved	Approved for Orphan Indication	Treatment of selected patients with AIDS-related Kaposi's sarcoma.	11/21/88	11/21/95	Schering Corporation	Kenilworth	New Jersey	7033	USA	EXACT	0160601AA	Interferon alfa-2b (recombinant)	43K1W2T1M6						Kaposi's Sarcoma	6814		
Interferon alfa-2a (recombinant)	Treatment of AIDS related Kaposi's sarcoma.	Interferon alfa-2a (recombinant)		Roferon-A	12/14/87	Designated/Approved	Approved for Orphan Indication		11/21/88	11/21/95	"Hoffmann-La Roche, Inc."	Nutley	New Jersey	7110	USA	EXACT	0158269AA	Interferon alfa-2a (recombinant)	47RRR83SK7						Kaposi's Sarcoma	6814		
L-glutamyl-L-tryptophan	Treatment of AIDS-related Kaposi's sarcoma.	OGLUFANIDE		n/a	10/20/99	Designated			N/A	N/A	Implicit Bioscience Pty Ltd				Australia	EXACT	0308167AA	OGLUFANIDE	4RHY598T5U						Kaposi's Sarcoma	6814		
Thalidomide	Treatment of Kaposi's sarcoma.	Thalidomide		n/a	7/29/98	Designated			N/A	N/A	Celgene Corporation	Warren				EXACT	0007409AA	Thalidomide	4Z8R6ORS6L						Kaposi's Sarcoma	6814		
Daunorubicin citrate liposome injection	Treatment of patients with advanced HIV-associated Kaposi's sarcoma.	Daunorubicin citrate		Daunoxome	5/14/93	Designated/Approved	Approved for Orphan Indication	"First line cytotoxic therapy for advanced, HIV related Kaposi's sarcoma."	4/8/96	4/8/03	"NeXstar Pharmaceuticals, Inc."	San Dimas	California	91773	USA	EXACT	0203952AA	Daunorubicin citrate	5L84T2Z6NP						Kaposi's Sarcoma	6814		
"3-(3,5-dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one"	Treatment of Kaposi's sarcoma.	Save3D Zoom		n/a	9/11/98	Designated			N/A	N/A	"Sugen, Inc."	South San Francisco	California	94080	USA	EXACT	0221807AA	semaxanib	71IA9S35AJ						Kaposi's Sarcoma	6814		
Paclitaxel	Treatment of AIDS-related Kaposi's sarcoma.	Paclitaxel		Taxol	3/25/97	Designated/Approved	Approved for Orphan Indication	For the second line treatment of AIDS-related Kaposi's sarcoma.	8/4/97	8/4/04	Bristol-Myers Squibb Pharmaceutical Research Institute	Wallingford	Connecticut	6492	USA	EXACT	0132127AA	Paclitaxel	P88XT4IS4D						Kaposi's Sarcoma	6814		
Paclitaxel	Treatment of AIDS-related Kaposi's sarcoma.	Paclitaxel		Paxene	4/15/97	Designated			N/A	N/A	"Baker Norton Pharmaceuticals, Inc."	Miami	Florida	33137	USA	EXACT	0132127AA	Paclitaxel	P88XT4IS4D						Kaposi's Sarcoma	6814		
Interferon beta (recombinant)	For the intralesional and/or systemic treatment of AIDS-related Kaposi's sarcoma.	Interferon beta (recombinant)		R-Huifn-Beta	5/9/91	Designated/Withdrawn			N/A	N/A	"Biogen, Inc."	Cambridge	Massachusetts	2142	USA	LONGEST CONTAINS	0297927AA	Interferon beta	V9GU1EM8SF						Kaposi's Sarcoma	6814		
Uridine 5'-triphosphate	To facilitate the removal of lung secretions in the treatment of patients with primary ciliary dyskinesia.	Uridine 5'-triphosphate		n/a	6/26/96	Designated/Withdrawn			N/A	N/A	"Inspire Pharmaceuticals, Inc."	Durham	North Carolina	27703	USA	EXACT	0011052AA	Uridine 5'-triphosphate	UT0S826Z60						Primary Ciliary Dyskinesia	6815		
copper sulfate	Treatment of keratoconus	copper sulfate		n/a	10/26/17	Designated			N/A	N/A	"iVeena Drug Delivery Systems, Inc."	Salt Lake City	Utah		USA	EXACT	0050942AA	copper sulfate	LRX7AJ16DT						Keratoconus	6824		
riboflavin-vitamin E-TPGS topical solution	Treatment of keratoconus in patients undergoing crosslinking procedure	vitamin E TPGS		Ribocross	11/8/16	Designated			N/A	N/A	Institute of Refractive & Ophthalmic Surgery	Napoli			Italy	EXACT	0143511AA	vitamin E TPGS	O03S90U1F2						Keratoconus	6824		
riboflavin ophthalmic solution & ultraviolet A	Treatment of keratoconus	riboflavin ophthalmic solution & ultraviolet A		Photrexa Viscous	9/2/11	Designated/Approved	Approved for Orphan Indication	Treatment of progressive keratoconus	4/15/16	4/15/23	"Avedro, Inc."	Waltham	Massachusetts	2451	USA	EXACT	0014460AA	riboflavin	TLM2976OFR						Keratoconus	6824		
riboflavin-vitamin E-TPGS topical solution	Treatment of keratoconus in patients undergoing crosslinking procedure	riboflavin		Ribocross	11/8/16	Designated			N/A	N/A	Institute of Refractive & Ophthalmic Surgery	Napoli			Italy	EXACT	0014460AA	riboflavin	TLM2976OFR						Keratoconus	6824		
ibudilast	Treatment of Krabbe disease	ibudilast		n/a	6/1/15	Designated			N/A	N/A	"MediciNova, Inc."	La Jolla	California	92037	USA	EXACT	0297905AA	ibudilast	M0TTH61XC5						Krabbe disease	6844		
recombinant human galactocerebrosidase (rhGALC);	Treatment of globoid cell leukodystrophy (Krabbe Disease)	Galaczym		Galaczym	12/12/11	Designated			N/A	N/A	ACE BioSciences A/S				Denmark	exact									Krabbe disease	6844		
Dynamine	Treatment of Lambert Eaton myasthenic syndrome.	Dynamine		n/a	2/5/90	Designated			N/A	N/A	Mayo Foundation	Rochester	Minnesota	55905	USA	EXACT	0144445AA	Dynamine	RU4S6E2G0J						Lambert Eaton myasthenic syndrome	6851		
Mecasermin	Treatment of growth hormone insensitivity syndrome.	Mecasermin		Increlex	12/12/95	Designated/Approved	Approved for Orphan Indication	Long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone.	8/30/05	8/30/12	"Ipsen Biopharmaceuticals, Inc."	Basking Ridge	New Jersey	7920	USA	EXACT	0167215AA	Mecasermin	7GR9I2683O						Growth Hormone Insensitivity Syndrome	6859		
mecasermin rinfabate	Treatment of growth hormone insensitivity syndrome (GHIS)	mecasermin rinfabate		Iplex	5/17/02	Designated/Approved	Approved for Orphan Indication	Treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone	12/12/05	12/12/12	"Insmed, Inc."	Monmouth Junction	New Jersey	8852	USA	EXACT	0212953AA	mecasermin rinfabate	NZ8M50KKRG						Growth Hormone Insensitivity Syndrome	6859		
adeno-associated viral vector containing the human NADH Dehydrogenase 4 Gene	Treatment of Leber Hereditary Optic Neuropathy	adeno-associated viral vector containing the human NADH Dehydrogenase 4 Gene		n/a	11/20/13	Designated			N/A	N/A	Gen Sight Biologics					LONGEST CONTAINS	0693221AA	NADH	4J24DQ0916						Leber hereditary optic neuropathy	6870		
vatiquinone	Treatment of Leigh Syndrome	vatiquinone		Vincerinone	6/4/14	Designated			N/A	N/A	"Edison Pharmaceuticals, Inc."	Mountain View	California	94043	USA	EXACT	0739468AA	vatiquinone	6O85FK9I0X						Leigh syndrome	6877		
miltefosine	Treatment of leishmaniasis.	miltefosine		Impavido	10/10/06	Designated/Approved	Approved for Orphan Indication	"Treatment of visceral leishmaniasis due to Leishmania donovani; cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis; and mucosal leishmaniasis due to Leishmania braziliensis."	3/19/14	3/19/21	Knight Therapeutics (USA)	Wilmington	Delaware	19801	USA	EXACT	0273734AA	miltefosine	53EY29W7EC						Leishmaniasis	6881		
paromomycin	Treatment of cutaneous leishmaniasis (Old World and New World)	paromomycin		n/a	2/11/15	Designated			N/A	N/A	"The Surgeon General, Dept. of the Army"	Ft. Detrick	Maryland	21702	USA	EXACT	0010048AA	paromomycin	61JJC8N5ZK						Leishmaniasis	6881		
Liposomal amphotericin B	Treatment of visceral leishmaniasis.	Liposomal amphotericin B		Ambisome	12/6/96	Designated/Approved	Approved for Orphan Indication	Treatment of visceral leishmaniasis.	8/11/97	8/11/04	"Fujisawa USA, Inc."	Deerfield	Illinois	60015	USA	EXACT	0035881AA	amphotericin B	7XU7A7DROE						Leishmaniasis	6881		
amphotericin B	Treatment of visceral leishmaniasis.	amphotericin B		n/a	9/15/10	Designated			N/A	N/A	iCo Therapeutics Inc.	"Vancouver, BC V6Z 1S4"			Canada	EXACT	0035881AA	amphotericin B	7XU7A7DROE						Leishmaniasis	6881		
enchochleate amphotericin B	Treatment of visceral leishmaniasis	enchochleate amphotericin B		n/a	1/10/14	Designated			N/A	N/A	"Aquarius Biotechnologies, Inc."	Chicago	Illinois	60612	USA	EXACT	0035881AA	amphotericin B	7XU7A7DROE						Leishmaniasis	6881		
Aminosidine	Treatment of visceral leishmaniasis (kala-azar).	Aminosidine		Paromomycin	9/9/94	Designated			N/A	N/A	"Kanyok, Thomas P. Pharm.D."	Chicago	Illinois	60612	USA	EXACT	0033465AA	Aminosidine	845NU6GJPS						Leishmaniasis	6881		
aminosidine	Treatment of visceral leishmaniasis	aminosidine		Paromomycin	3/29/05	Designated			N/A	N/A	The Institute for One World Health	San Francisco	California	94111	USA	EXACT	0033465AA	aminosidine	845NU6GJPS						Leishmaniasis	6881		
paromomycin sulfate/gentamicin sulfate	Treatment of all uncomplicated cutaneous leishmaniasis (both New World and Old World)	paromomycin sulfate /gentamicin sulfate		n/a	1/18/08	Designated			N/A	N/A	Office of the Surgeon General	Ft. Detrick	Maryland	21702	USA	EXACT	0033465AA	paromomycin sulfate	845NU6GJPS						Leishmaniasis	6881		
paromomycin sulfate/gentamicin sulfate	Treatment of all uncomplicated cutaneous leishmaniasis (both New World and Old World)	paromomycin sulfate/ gentamicin sulfate		n/a	1/18/08	Designated			N/A	N/A	Office of the Surgeon General	Ft. Detrick	Maryland	21702	USA	EXACT	0036306AA	gentamicin sulfate	8X7386QRLV						Leishmaniasis	6881		
corifungin	Treatment of visceral leishmaniasis	corifungin		n/a	7/6/11	Designated			N/A	N/A	Sandler Center for Drug Discovery	San Francisco	California	94158	USA	EXACT	0807998AA	corifungin	L26BTK4791						Leishmaniasis	6881		
Sodium stibogluconate	Treatment of cutaneous leishmaniasis	Sodium stibogluconate		n/a	6/16/06	Designated			N/A	N/A	"VioQuest Pharmaceuticals, Inc."	Basking Ridge	New Jersey	7920	USA	EXACT	0056951AA	Sodium stibogluconate	V083S0159D						Leishmaniasis	6881		
sodium stibogluconate	Treatment of cutaneous leishmaniasis	sodium stibogluconate		n/a	10/28/09	Designated			N/A	N/A	Surgeon General of the US Army	Ft. Detrick	Maryland	21702	USA	EXACT	0056951AA	sodium stibogluconate	V083S0159D						Leishmaniasis	6881		
Allopurinol riboside	1. Treatment of Chagas' disease 2. Treatment of cutaneous and visceral leishmaniasis	Allopurinol riboside		n/a	12/4/85	Designated/Withdrawn			N/A	N/A	Burroughs Wellcome Company	Research Triangle Park	North Carolina	27709	USA	EXACT	0125473AA	Allopurinol riboside	WZS8452SEC						Leishmaniasis	6881		
oleylphosphocholine	Treatment of leishmaniasis	oleylphosphocholine		n/a	10/25/13	Designated			N/A	N/A	Dafra Pharma International nv				Belgium	EXACT	1577124AA	oleylphosphocholine	Z46GXL23LX						Leishmaniasis	6881		
rhIGF-I/rhIGFBP-3	"Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)"	rhIGF-I/rhIGFBP-3		Somatokine	12/9/03	Designated			N/A	N/A	"Insmed, Inc."	Monmouth Junction	New Jersey	8852	USA	EXACT	0212953AA	rhIGF-I/rhIGFBP-3	NZ8M50KKRG						Leprechaunism	6885		
Glyceryl trioleate and glyceryl trierucate	Treatment of adrenoleukodystrophy.	Glyceryl trioleate and glyceryl trierucate		n/a	2/14/95	Designated			N/A	N/A	"Moser, Hugo W. M.D."	Baltimore	Maryland	21205	USA	EXACT	0168683AA	glyceryl trierucate	I0IDQ0M20R						Leukodystrophy	6895		
Glyceryl trioleate and glyceryl trierucate	Treatment of adrenoleukodystrophy.	Glyceryl trioleate		n/a	2/14/95	Designated			N/A	N/A	"Moser, Hugo W. M.D."	Baltimore	Maryland	21205	USA	EXACT	0019421AA	Glyceryl trioleate	O05EC62663						Leukodystrophy	6895		
sobetirome	Treatment of X-linked adrenoleukodystrophy	sobetirome		n/a	4/29/11	Designated			N/A	N/A	"NeuroVia, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0322587AA	sobetirome	XQ31741E9Q						Leukodystrophy	6895		
arylsulfatase A (rhASA)	Treatment of metachromatic leukodystrophy	arylsulfatase A (rhASA)		n/a	2/27/08	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	Lexington	Massachusetts	2421	USA	EXACT	1805943AA	rhASA							Leukodystrophy	6895		
recombinant human arylsulphatase A	Treatment of metachromatic leukodystrophy (MLD).	HGT-1111		n/a	4/11/08	Designated/Withdrawn			N/A	N/A	Shire Human Genetic Therapies	Lexington	Massachusetts	2421	USA	EXACT	1805943AA	HGT-1111							Leukodystrophy	6895		
recombinant human galactocerebrosidase (rhGALC);	Treatment of globoid cell leukodystrophy (Krabbe Disease)	Galaczym		Galaczym	12/12/11	Designated			N/A	N/A	ACE BioSciences A/S				Denmark	exact									Leukodystrophy	6895		
"Propanoic acid, 2,2-dimethyl-,1,1'-[[[[4-[[4-hydroxy-3-(phenylmethyl)phenyl]methyl]-3,5-dimethylphenoxy]methyl]phosphinylidene]bis(oxymethylene)] ester"	Treatment of X-linked adrenoleukodystrophy.	VK-0214		n/a	12/5/16	Designated			N/A	N/A	"Viking Therapeutics, Inc."	San Diego	California	92130	USA	EXACT	1800324AA	VK-0214	BYT6883X9X						Leukodystrophy	6895		
hydroxypioglitazone	Treatment of X-linked adrenoleukodystrophy	hydroxypioglitazone		n/a	1/30/17	Designated			N/A	N/A	Minoryx Therapeutics S.L.	Mataró			Spain	EXACT	0869885AA	hydroxypioglitazone	K824X25AYA						Leukodystrophy	6895		
autologous CD34+ cells transduced with lentiviral vector which encodes for the aryl Sulfatase A complimentary deoxyribonucleic acid sequence	Treatment of the Metachromatic Leukodystrophy (including pre-symptomatic metachromatic leukodystrophy)	autologous CD34+ cells transduced with lentiviral vector which encodes for the aryl Sulfatase A complimentary deoxyribonucleic acid sequence		n/a	3/8/18	Designated			N/A	N/A	"GlaxoSmithKline Intellectual Property Development Limited, England"	980 Great West Road			United Kingdom	LONGEST CONTAINS	0006484AA	deoxyribonucleic acid							Leukodystrophy	6895		
autologous CD34+ hematopoietic stem cells tranduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA	Treatment of andrenoleukodystrophy	autologous CD34+ hematopoietic stem cells tranduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA		n/a	4/19/12	Designated			N/A	N/A	"bluebird bio, Inc."	Cambridge	Massachusetts	2139	USA	LONGEST CONTAINS	0264620AA	stem cells							Leukodystrophy	6895		
"generation 4 hydroxyl-terminated polyamidoamine dendrimer containing an ethylene diamine (EDA) core, amidoamine repate units, and 64 hydroxyl end groups"	Treatment of x-linked adrenoleukodystrophy	"generation 4 hydroxyl-terminated polyamidoamine dendrimer containing an ethylene diamine (EDA) core, amidoamine repate units, and 64 hydroxyl end groups"		n/a	3/22/17	Designated			N/A	N/A	"Orpheris, Inc."	Redwood City	California	94065	USA	LONGEST CONTAINS	0017378AA	ethylene diamine	60V9STC53F						Leukodystrophy	6895		
Angiotensin (1-7)	Treatment of limb-girdle muscular dystrophy	Angiotensin (1-7)		n/a	11/26/13	Designated			N/A	N/A	"US Biotest, Inc."	San Luis Obispo	California	93401	USA	EXACT	0232428AA	Angiotensin 1-7	IJ3FUK8MOF						Limb-girdle muscular dystrophy	6907		
"One, two, three, or four antisense oligonucleotides of Phosphorodiamidate morpholino oligomer combination that skips exons 4, 5, 6, and 7 of the gamma sarcoglycan (SGCG) gene"	"Treatment of limb-girdle muscular dystrophy type 2C that have mutations or deletions in exons 4, 5, 6, or 7of gamma sarcoglycan gene"	"One, two, three, or four antisense oligonucleotides of Phosphorodiamidate morpholino oligomer combination that skips exons 4, 5, 6, and 7 of the gamma sarcoglycan (SGCG) gene"		n/a	7/18/17	Designated			N/A	N/A	Kurt+Peter Foundation	Menlo Park	California	94025	USA	LONGEST CONTAINS	1797166AA	morpholino							Limb-girdle muscular dystrophy	6907		
metreleptin	Treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy	metreleptin		n/a	8/22/01	Designated			N/A	N/A	"Aegerion Pharnaceuticals, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0213069AA	metreleptin	TL60C27RLH						Lipodystrophy	6909		
metreleptin	Treatment of metabolic disorders secondary to lipodystrophy	metreleptin		Myalept	8/22/01	Designated/Approved	Approved for Orphan Indication	Adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.	2/24/14	2/24/21	"Aegerion Pharmaceuticals, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0213069AA	metreleptin	TL60C27RLH						Lipodystrophy	6909		
"(3'R,4'S,5'R)-N-[(3R,6S)-6-Carbamoyltetrahydro-2H-pyran-3-yl]-6''-chloro-4'-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2''-oxo-1'',2''-dihydrodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indole]-5'-carboxamide mono(4-methylbenzenesulfonate) monohydrate"	Treatment of liposarcoma	DS-3032 TOSYLATE MONOHYDRATE		n/a	2/13/17	Designated			N/A	N/A	"Daiichi Sankyo, Inc."	Edison	New Jersey	8837	USA	EXACT	1800971AA	DS-3032 TOSYLATE MONOHYDRATE	4Y0K58UFU2						Liposarcoma	6913		
"2-(1,1-difluoroethyl)-5-methyl-N-[4-(pentafluoro-¿{6}-sulfanyl)phenyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine"	Treatment of malaria	DSM-265		n/a	8/18/17	Designated			N/A	N/A	"Paul Maher, MD"	Bethesda	Maryland	20814	USA	EXACT	1210588AA	DSM-265	0Q42P4YI6B						Malaria	6961		
tafenoquine	Treatment of malaria	tafenoquine		n/a	1/15/13	Designated			N/A	N/A	"Glaxo Group Limited, England"				United Kingdom	EXACT	0288697AA	tafenoquine	262P8GS9L9						Malaria	6961		
Sodium dichloroacetate	Treatment of lactic acidosis in patients with severe malaria.	Sodium dichloroacetate		n/a	11/10/94	Designated			N/A	N/A	"Stacpoole, Peter W. M.D., Ph.D."	Gainesville	Florida	32610	USA	EXACT	0079492AA	Sodium dichloroacetate	42932X67B5						Malaria	6961		
"N'-(7-Chloroquinolin-4-yl)-N,N-diethyl-propane-1,3-diamine"	Treatment of malaria.	AQ-13 FREE BASE		n/a	10/29/15	Designated			N/A	N/A	"Donald J. Krogstad, MD"	New Orleans	Louisiana	70112	USA	EXACT	0807669AA	AQ-13 FREE BASE	4K7VT5621X						Malaria	6961		
Mefloquine HCl	Treatment and prevention of chloroquine-resistant Falciparummalaria	Mefloquine HCl		Mephaquin	7/22/87	Designated			N/A	N/A	Mepha AG				Switzerland	EXACT	0130052AA	Mefloquine HCl	5Y9L3636O3						Malaria	6961		
mefloquine HCL	"For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs"	mefloquine HCL		Lariam	4/13/88	Designated/Approved	Approved for Orphan Indication	Treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax	5/2/89	5/2/96	"Hoffmann-La Roche, Inc."	Nutley	New Jersey	7110	USA	EXACT	0130052AA	mefloquine HCL	5Y9L3636O3						Malaria	6961		
mefloquine HCL	"For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs"	mefloquine HCL		Lariam	4/13/88	Designated/Approved	Approved for Orphan Indication	Prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs	5/3/89	5/3/96	"Hoffmann-La Roche, Inc."	Nutley	New Jersey	7110	USA	EXACT	0130052AA	mefloquine HCL	5Y9L3636O3						Malaria	6961		
Artesunate	Treatment of malaria.	Artesunate		n/a	7/19/99	Designated			N/A	N/A	World Health Organization				Switzerland	EXACT	0237285AA	Artesunate	60W3249T9M						Malaria	6961		
Artesunate	Immediate treatment of malaria	Artesunate		n/a	3/28/06	Designated			N/A	N/A	US Army Medical Materiel Development Activity	Ft. Detrick	Maryland	21702	USA	EXACT	0237285AA	Artesunate	60W3249T9M						Malaria	6961		
Artesunate	Treatment of malaria	Artesunate		n/a	9/5/17	Designated			N/A	N/A	"Guilin Pharmaceutical Co., Ltd."	Guilin Guangxi			China	EXACT	0237285AA	Artesunate	60W3249T9M						Malaria	6961		
dihydroartemisinin and piperaquine	"Treatment of uncomplicated malaria caused by ""Plasmodium falciparum,"" Plasmodium vivax,"" Plasmodium malariae,"" or ""Plasmodium ovale."""	dihydroartemisinin and piperaquine		Eurartesim	1/8/07	Designated			N/A	N/A	"Sigma-Tau Pharmaceuticals, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0303333AA	dihydroartemisinin	6A9O50735X						Malaria	6961		
Reversal agent linked to chloroquine-like moiety	Treatment of malaria	DM-1157		n/a	3/26/10	Designated			N/A	N/A	DesignMedix	Portland	Oregon	97201	USA	EXACT	1805432AA	DM-1157	6X58GJ0RMS						Malaria	6961		
artemisone	Treatment of malaria	artemisone		n/a	7/19/17	Designated			N/A	N/A	"Artemis Therapeutics, Inc."	New York	New York	10003	USA	EXACT	0339015AA	artemisone	796LMW5BUZ						Malaria	6961		
dihydroartemisinin and piperaquine	"Treatment of uncomplicated malaria caused by ""Plasmodium falciparum,"" Plasmodium vivax,"" Plasmodium malariae,"" or ""Plasmodium ovale."""	piperaquine		Eurartesim	1/8/07	Designated			N/A	N/A	"Sigma-Tau Pharmaceuticals, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0337122AA	piperaquine	A0HV2Q956Y						Malaria	6961		
Pafuramidine maleate	Treatment of malaria	Pafuramidine maleate		n/a	5/14/07	Designated			N/A	N/A	"Immtech Pharmaceuticsl, Inc."	Vernon Hills	Illinois	60061	USA	EXACT	0251650AA	Pafuramidine maleate	K27F04K3A9						Malaria	6961		
quinine Sulfate	Treatment of malaria	quinine Sulfate		n/a	6/3/04	Designated/Approved	Approved for Orphan Indication	Treatment of uncomplicated Plasmodium falciparum malaria	8/12/05	8/12/12	"AR Holding Company, Inc."	Philadelphia	Pennsylvania	19124	USA	EXACT	0031083AA	quinine Sulfate	KF7Z0E0Q2B						Malaria	6961		
quinine sulfate	Treatment of malaria excluding Plasmodium faliparum	quinine sulfate		n/a	12/2/08	Designated			N/A	N/A	"Zydus Pharmaceuticals, Inc."	Princeton	New Jersey	8540	USA	EXACT	0031083AA	quinine sulfate	KF7Z0E0Q2B						Malaria	6961		
AQ-13 (4-aminoquinoline analog)	Treatment of malaria	AQ-13		n/a	9/12/08	Designated			N/A	N/A	"Immtech Pharmaceuticals, Inc."	Vernon Hills	Illinois	60061	USA	EXACT	0552976AA	AQ-13	PKT9732S5K						Malaria	6961		
"cis-adamantane-2-spiro-3'-8'-[4'-[2'-(4'-morpholinyl)ethoxy]phenyl]-1',2,'4'-trioxaspiro[4.5] decane mesylate"	"Treatment of malaria caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, or Plasmodium malariae"	OZ-439 mesylate		n/a	1/19/10	Designated			N/A	N/A	Medicines for Malaria Venture (MMV)	CH-1215 Geneva 15			Switzerland	EXACT	0739377AA	OZ-439 mesylate	PXW0Q9H3IJ						Malaria	6961		
Halofantrine	Treatment of mild to moderate acute malaria caused by susceptible strains of P. falciparum and P. vivax.	Halofantrine		Halfan	11/4/91	Designated/Approved	Approved for Orphan Indication	Treatment of adults who can tolerate oral medication and who have mild to moderate malaria caused by Plasmodium falciparum or Plasmodium vivax.	7/24/92	7/24/99	SmithKline Beecham Pharmaceuticals	Philadelphia	Pennsylvania	19101	USA	EXACT	0281118AA	Halofantrine	Q2OS4303HZ						Malaria	6961		
Cipargamin	Treatment of malaria	Cipargamin		n/a	7/27/17	Designated			N/A	N/A	"Paul Maher, MD"	Bethesda	Maryland	20814	USA	EXACT	0924618AA	Cipargamin	Z7Q4FWA04P						Malaria	6961		
"2-amino-1-[2-(4-fluoro-phenyl)-3-(4-fluoro-phenyl)amino)-8,8-dimethyl-5,6-dihydro-imidazo[1,2-a]pyrazin-7(8H)-yl)-ethanone diphosphate"	Treatment of malaria.	KAF-156 DIPHOSPHATE		n/a	5/11/17	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0111776AB	KAF-156 DIPHOSPHATE	R3ZA37PM4S						Malaria	6961		
poly(lactide-co-glycolide) carboxylated microparticle	Treatment of malaria	poly(lactide-co-glycolide) carboxylated microparticle		n/a	9/13/16	Designated			N/A	N/A	"Cour Pharmaceutical Development Company, Inc."	Elmhurst	Illinois	60126	USA	LONGEST CONTAINS	0528223AA	glycolide	YRZ676PGU6						Malaria	6961		
fixed dose combination of pyronaridine tetraphosphate and artesunate	Treatment of malaria	artesunate		Pyramax®	9/27/18	Designated			N/A	N/A	"Shin Poong Pharmaceutical Co., Ltd."	"161 Yoksam-Ro, Gangnam-Gu"			"Korea, Republic of"	EXACT	0237285AA	artesunate	60W3249T9M						Malaria	6961		
fixed dose combination of pyronaridine tetraphosphate and artesunate	Treatment of malaria	 pyronaridine tetraphosphate		Pyramax®	9/27/18	Designated			N/A	N/A	"Shin Poong Pharmaceutical Co., Ltd."	"161 Yoksam-Ro, Gangnam-Gu"			"Korea, Republic of"	EXACT	0716314AA	pyronaridine tetraphosphate	2T289F9ACO						Malaria	6961		
dantrolene sodium suspension for injection	Treatment of malignant hyperthermia syndrome	dantrolene sodium suspension for injection		Ryanodex	8/16/13	Designated/Approved	Approved for Orphan Indication	Treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk.	7/22/14	7/22/21	"Eagle Pharmaceuticals, Inc."	Woodcliff Lake	New Jersey	7677	USA	EXACT	0056122AA	dantrolene sodium	287M0347EV						Malignant hyperthermia	6964		
Recombinant human alpha-mannosidase	Treatment of alpha-mannosidosis	Recombinant human alpha-mannosidase		n/a	2/2/06	Designated			N/A	N/A	"Chiesi USA, Inc."	Cary	North Carolina	27518	USA	EXACT	0774301AA	Recombinant human alpha-mannosidase	M91TG242P2						Alpha-mannosidosis	6968		
adeno-associated virus serotype 6 containing human LAMAN cDNA	Treatment of alpha-mannosidosis	adeno-associated virus serotype 6 containing human LAMAN cDNA		n/a	2/15/18	Designated			N/A	N/A	"Stephen G. Kaler, MD"	Eunice Kennedy Shriver NICHD	Bethesda		USA										Alpha-mannosidosis	6968		
ibrutinib	Treatment of mantle cell lymphoma	ibrutinib		Imbruvica	12/3/12	Designated/Approved	Approved for Orphan Indication	Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy	11/13/13	11/13/20	"Pharmacyclics, LLC"	Sunnyvale	California	94085	USA	EXACT	0625092AA	ibrutinib	1X70OSD4VX						Mantle cell lymphoma	6969		
daratumumab	Treatment of mantle cell lymphoma.	daratumumab		n/a	8/20/15	Designated			N/A	N/A	"Janssen Research & Development, LLC"	Spring House	Pennsylvania	19477	USA	EXACT	0432519AA	daratumumab	4Z63YK6E0E						Mantle cell lymphoma	6969		
bortezomib	Treatment of mantle cell lymphoma.	bortezomib		Velcade	5/30/12	Designated/Approved	Approved for Orphan Indication	Treatment of patients with mantle cell lymphoma who have not received at least 1 prior therapy	10/8/14	10/8/21	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0228319AA	bortezomib	69G8BD63PP						Mantle cell lymphoma	6969		
bortezomib	Treatment of mantle cell lymphoma.	bortezomib		Velcade	5/30/12	Designated/Approved	Approved for Orphan Indication	Treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.	12/8/06	12/8/13	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0228319AA	bortezomib	69G8BD63PP						Mantle cell lymphoma	6969		
Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through a protease cleavable valine-alanine linker	Treatment of mantle cell lymphoma	ADCT-402		n/a	6/8/17	Designated			N/A	N/A	ADC Therapeutics SA	Epalinges			Switzerland	EXACT	0112432AB	ADCT-402	7K5O7P6QIU						Mantle cell lymphoma	6969		
"7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one-2HCL"	Treatment of mantle cell lymphoma (MCL)	ONC-201		n/a	2/7/17	Designated			N/A	N/A	"Oncoceutics, Inc."	Philadelphia	Pennsylvania	19104	USA	EXACT	0928041AA	ONC-201	9U35A31JAI						Mantle cell lymphoma	6969		
"(S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydroprazolo[1,5-a]pyrimidine-3-carboxamide"	Treatment of mantle cell lymphoma.	BGB-3111		n/a	6/23/16	Designated			N/A	N/A	"BeiGene USA, Inc."	Fort Lee	New Jersey	7024	USA	EXACT	1143619AA	BGB-3111	AG9MHG098Z						Mantle cell lymphoma	6969		
lenalidomide	Treatment of mantle cell lymphoma	lenalidomide		Revlimid	4/27/09	Designated/Approved	Approved for Orphan Indication	"Treatment of mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib."	6/5/13	6/5/20	Celgene Corporation	Berkeley Heights	New Jersey	7922	USA	EXACT	0236099AA	lenalidomide	F0P408N6V4						Mantle cell lymphoma	6969		
"(S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)-imidazo[1,5-a]pyrazine-1-yl)-N-(pyridine-2-yl)-benzamide"	Treatment of mantle cell lymphoma.	ACALABRUTINIB		n/a	9/21/15	Designated			N/A	N/A	Acerta Pharma BV				Netherlands	EXACT	1102961AA	ACALABRUTINIB	I42748ELQW						Mantle cell lymphoma	6969		
Venetoclax	Treatment of mantle cell lymphoma	Venetoclax		Venclexta	8/31/17	Designated			N/A	N/A	AbbVie Inc.	North Chicago	Illinois	60064	USA	EXACT	0790283AA	Venetoclax	N54AIC43PW						Mantle cell lymphoma	6969		
dasiprotimut-T	Treatment of mantle cell lymphoma	dasiprotimut-T		Biovax Id	6/17/10	Designated			N/A	N/A	"Biovest International, Inc."	Tampa	Florida	33606	USA	EXACT	1347075AA	dasiprotimut-T							Mantle cell lymphoma	6969		
triterpenoid saponin	Treatment of mantle cell lymphoma	triterpenoid saponin		n/a	7/23/14	Designated			N/A	N/A	"Avicin Therapeutics, Ltd."	Durham	North Carolina	27713	USA	LONGEST CONTAINS	0633896AA	saponin							Mantle cell lymphoma	6969		
"DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the native eIF5A mRNA, and PEI (polyethyleneimine)"	Treatment of mantle cell lymphoma	"DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the native eIF5A mRNA, and PEI (polyethyleneimine)"		n/a	7/24/12	Designated			N/A	N/A	"Senesco Technologies, Inc."	Bridgewater	New Jersey	8807	USA	LONGEST CONTAINS	0087274AA	protein							Mantle cell lymphoma	6969		
autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor	Treatment of mantle cell lymphoma.	autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor		n/a	4/28/16	Designated			N/A	N/A	"Kite Pharma, Inc."	Santa Monica	California	90404	USA	LONGEST CONTAINS	1722709AA	CD19	IYZ9TI08W3						Mantle cell lymphoma	6969		
losartan	Treatment of Marfan Syndrome	losartan		n/a	12/12/11	Designated			N/A	N/A	National Marfan Foundation	Port Washington	New York	11050	USA	EXACT	0298782AA	losartan	JMS50MPO89						Marfan syndrome	6975		
small molecule inhibitor of Exon 17 Mutant KIT	Treatment of mastocytosis	BLU-285		n/a	1/21/16	Designated			N/A	N/A	Blueprint Medicines Corporation	Cambridge	Massachusetts	2139	USA	EXACT	1152154AA	BLU-285	513P80B4YJ						Mastocytosis	6987		
Imatinib mesylate	Treatment of systemic mastocytosis without the D816V c-kit mutation	Imatinib mesylate		Gleevec	9/9/05	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with aggressive mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown	10/19/06	10/19/13	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0227065AA	Imatinib mesylate	8A1O1M485B						Mastocytosis	6987		
Midostaurin	Treatment of mastocytosis	Midostaurin		Rydapt	4/30/10	Designated			N/A	N/A	Novartis Oncology	East Hanover	New Jersey	7936	USA	EXACT	0230091AA	Midostaurin	ID912S5VON						Mastocytosis	6987		
masitinib	Treatment of mastocytosis	masitinib		n/a	9/14/05	Designated			N/A	N/A	AB Science				France	EXACT	0302783AA	masitinib	M59NC4E26P						Mastocytosis	6987		
Cromolyn sodium	Treatment of mastocytosis.	Cromolyn sodium		Gastrocrom	3/8/84	Designated/Approved	Approved for Orphan Indication		12/22/89	12/22/96	Fisons Corporation	Rochester	New York	14603	USA	EXACT	0056871AA	Cromolyn sodium	Q2WXR1I0PK						Mastocytosis	6987		
cromolyn sodium for inhalation	Treatment of mastocytosis.	cromolyn sodium for inhalation		n/a	12/9/15	Designated			N/A	N/A	"Patara Pharma, LLC"	San Diego	California	92130	USA	EXACT	0056871AA	cromolyn sodium	Q2WXR1I0PK						Mastocytosis	6987		
ketotifen	Treatment of mastocytosis	ketotifen		n/a	2/25/15	Designated			N/A	N/A	"Valcrest Pharmaceuticals, LLC"	Tarrytown	New York	10591	USA	EXACT	0064493AA	ketotifen	X49220T18G						Mastocytosis	6987		
humanized IgG1 low affinity allergic reactivity inhibiting (LARI) monoclonal antibody	Treatment for mastocytosis	humanized IgG1 low affinity allergic reactivity inhibiting (LARI) monoclonal antibody		n/a	2/15/18	Designated			N/A	N/A	Sixal Inc.	416 15th Street	Santa Monica		USA										Mastocytosis	6987		
sonidegib	Treatment of medulloblastoma	sonidegib		n/a	3/23/15	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0568978AA	sonidegib	0RLU3VTK5M						Medulloblastoma	7005		
"1,2:5,6-dianhydrogalactitol"	Treatment of medulloblastoma.	"1,2:5,6-dianhydrogalactitol"		n/a	3/10/16	Designated			N/A	N/A	"DelMar Pharmaceuticals, Inc."	Menlo Park	California	94025	USA	EXACT	0061712AA	"1,2:5,6-dianhydrogalactitol"	4S465RYF7M						Medulloblastoma	7005		
"2-Amino-4-[11C]methylsulfanyl-butanoic acid, l-[S methyl[11C]methionine"	Diagnostic agent for the Clinical Management of Medulloblastoma	METHIONINE C-11		n/a	1/17/17	Designated			N/A	N/A	"Advanced Imaging Projects, LLC"	Lake Worth	Florida	33467	USA	EXACT	0154803AA	METHIONINE C-11	ED857BWP29						Medulloblastoma	7005		
N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide	Treatment of meningioma	N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide		n/a	1/13/12	Designated			N/A	N/A	"Arno Therapeutics, Inc."	Flemington	New Jersey	8822	USA	EXACT	0740432AA	N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide	E0GG29V0AQ						Meningioma	7015		
"5,6-dihydro-5-azacytidine"	Treatment of malignant mesothelioma.	"5,6-dihydro-5-azacytidine"		n/a	5/11/92	Designated			N/A	N/A	"ILEX Oncology, Inc."	San Antonio	Texas	78229	USA	EXACT	0549939AA	"5,6-dihydro-5-azacytidine"	0627D8VG1C						Malignant mesothelioma	7026		
CT-2584 mesylate	Treatment of malignant mesothelioma.	CT-2584 mesylate		n/a	4/16/99	Designated/Withdrawn			N/A	N/A	"Cell Therapeutics, Inc."	Seattle	Washington	98119	USA	EXACT	0211803AA	CT-2584 mesylate	6YX1G1VY8K						Malignant mesothelioma	7026		
"Liposomal-cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane-Pt (II)"	Treatment of malignant mesothelioma.	AROPLATIN		Aroplatin	9/1/99	Designated/Withdrawn			N/A	N/A	Antigenics Incorporated	Lexington	Massachusetts	2421	USA	EXACT	0230808AA	AROPLATIN	J7M4Z2D183						Malignant mesothelioma	7026		
tremelimumab	Treatment of malignant mesothelioma	tremelimumab		n/a	3/18/15	Designated			N/A	N/A	"MedImmune, LLC"	Gaithersburg	Maryland	20878	USA	EXACT	0310634AA	tremelimumab	QEN1X95CIX						Malignant mesothelioma	7026		
5-[8-methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6yl]-2-pyrimidinamine	Treatment of malignant mesothelioma	VS-5584		n/a	2/10/15	Designated/Withdrawn			N/A	N/A	"Verastem, Inc."	Needham	Massachusetts	2494	USA	EXACT	1193084AA	VS-5584	W71J4X250V						Malignant mesothelioma	7026		
profimer sodium	Treatment of malignant mesothelioma	profimer sodium		Photofrin(R)	12/2/11	Designated			N/A	N/A	"Concordia Laboratories, Inc."					EXACT	0172452AA	profimer sodium	Y3834SIK5F						Malignant mesothelioma	7026		
ranprinase	Treatment of malignant mesothelioma	RANPIRNASE		Onconase	1/25/07	Designated			N/A	N/A	Alfacell Corporation	Bloomfield	New Jersey	7003	USA	EXACT	0167931AA	RANPIRNASE	ZE15FIT23E						Malignant mesothelioma	7026		
Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin	Treatment of malignant mesothelioma	Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin		n/a	2/11/02	Designated			N/A	N/A	National Institutes of Health	Rockville	Maryland	20852	USA	LONGEST CONTAINS	1805772AA	mesothelin	J27WDC343N						Malignant mesothelioma	7026		
autologous dendritic cells pulsed with allogeneic tumor cell lysate	Treatment of malignant mesothelioma	autologous dendritic cells pulsed with allogeneic tumor cell lysate		n/a	5/6/14	Designated			N/A	N/A	Amphera BV				Netherlands										Malignant mesothelioma	7026		
Oncolytic adenovirus coding for granulocyte macrophage colony stimulating factor (ONCOS-102)	Treatment of malignant mesothelioma	Oncolytic adenovirus coding for granulocyte macrophage colony stimulating factor (ONCOS-102)		n/a	12/22/14	Designated			N/A	N/A	Oncos Therapeutics	Helsinki			Finland										Malignant mesothelioma	7026		
Peptide 144 TGF beta-1-inhibitor	Treatment of localized scleroderma	Peptide 144 TGF beta-1-inhibitor		n/a	4/26/06	Designated			N/A	N/A	"Digna Biotech, S.L."				Spain	EXACT	0679798AA	DISITERTIDE	3N988KP8HD						Localized scleroderma	7058		
HDF-LV-RTS-MMP1 (human dermal fibroblasts genetically modified with LV-RTS-MMP1) and Veledimex	Treatment of localized scleroderma.	Veledimex		n/a	4/19/16	Designated			N/A	N/A	"Fibrocell Technologies, Inc."	Exton	Pennsylvania	19341	USA	EXACT	0801672AA	Veledimex	ASU841TV0X						Localized scleroderma	7058		
HDF-LV-RTS-MMP1 (human dermal fibroblasts genetically modified with LV-RTS-MMP1) and Veledimex	Treatment of localized scleroderma.	HDF-LV-RTS-MMP1 (human dermal fibroblasts genetically modified with LV-RTS-MMP1) and Veledimex		n/a	4/19/16	Designated			N/A	N/A	"Fibrocell Technologies, Inc."	Exton	Pennsylvania	19341	USA	LONGEST CONTAINS	0801672AA	Veledimex	ASU841TV0X						Localized scleroderma	7058		
Theranost 68 Ga RGD	A Diagnostic for the management of Moyamoya disease (MMD)	Theranost 68 Ga RGD		n/a	10/1/14	Designated			N/A	N/A	"Advanced Imaging Projects, LLC (AIP)"	Boca Raton	Florida	33467	USA	EXACT	1577533AA	Theranost 68 Ga RGD	5EKN6H63OA						Moyamoya disease	7064		
"N-acetylgalactosamine-4-sulfatase, recombinant human"	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	GALSULFASE		Naglazyme	2/17/99	Designated/Approved	Approved for Orphan Indication	For patients with mucopolysaccharidosis VI. Galsulfase has been shown to improve walking and stair-climbing capacity.	5/31/05	5/31/12	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA	EXACT	0263661AA	GALSULFASE	59UA429E5G						Mucopolysaccharidosis	7065		
idursulfase	Long term enzyme replacement therapy for patients with mucopolysaccharidosis II (Hunter Syndrome)	idursulfase		Elaprase	11/28/01	Designated/Approved	Approved for Orphan Indication	"Indicated for patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Idursulfase has been shown to improve walking capacity in these patients"	7/24/06	7/24/13	"Shire Human Genetic Therapies, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0264175AA	idursulfase	5W8JGG2651						Mucopolysaccharidosis	7065		
recombinant human alpha-N-acetylglucosaminidase	Treatment of mucopolysaccharidosis IIIB (Sanfilippo B syndrome)	SBC-103		n/a	4/15/13	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	Hew Haven	Connecticut	6510	USA	EXACT	1311871AA	SBC-103	61A4G0P3IB						Mucopolysaccharidosis	7065		
recombinant human beta-glucuronidase	"Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)"	VESTRONIDASE ALFA		n/a	2/16/12	Designated			N/A	N/A	"Ultragenyx Pharmaceutical, Inc."	Novato	California	94949	USA	EXACT	1217738AA	VESTRONIDASE ALFA	7XZ4062R17						Mucopolysaccharidosis	7065		
pentosan polysulfate sodium	Treatment of mucopolysaccharidosis (MPS) type VI	pentosan polysulfate sodium		Lysosan (Tm)	1/5/15	Designated			N/A	N/A	"Plexcera Therapeutics, LLC"	Vero Beach	Florida	32963	USA	EXACT	0033545AA	pentosan polysulfate sodium	914032762Y						Mucopolysaccharidosis	7065		
recombinant human Naglu- insulin-like growth factor II	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B)	TRALESINIDASE ALFA		n/a	3/5/13	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0112449AB	TRALESINIDASE ALFA	AA60A4ST8X						Mucopolysaccharidosis	7065		
chimeric fusion protein of recombinant human alpha-N-acetylglucosaminidase and human insulin-like growth factor 2	"Treatment of mucopolysaccharidosis III Type B (MPS IIIB, Sanfilippo Syndrome Type B)"	TRALESINIDASE ALFA		n/a	11/25/14	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA	EXACT	0112449AB	TRALESINIDASE ALFA	AA60A4ST8X						Mucopolysaccharidosis	7065		
odiparcil	Treatment of mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome)	odiparcil		n/a	8/3/17	Designated			N/A	N/A	Inventiva Pharma				France	EXACT	0235858AA	odiparcil	FIK1414ZI8						Mucopolysaccharidosis	7065		
ataluren	Treatment of mucopolysaccharidosis type I	ataluren		Translarna	12/10/14	Designated			N/A	N/A	"PTC Therapeutics, Inc."	South Plainfield	New Jersey	7080	USA	EXACT	0317259AA	ataluren	K16AME9I3V						Mucopolysaccharidosis	7065		
elosulfase alfa	Use in the treatment of mucopolysaccharidosis (MPS) Type IV A (Morquio A syndrome)	elosulfase alfa		Vimizim	5/15/09	Designated/Approved	Approved for Orphan Indication	Patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome)	2/14/14	2/14/21	BioMarin Pharmaceutical Inc.	Novato	California	94949	USA	EXACT	0786301AA	elosulfase alfa	ODJ69JZG85						Mucopolysaccharidosis	7065		
laronidase	Treatment of patients with mucopolysaccharidosis-I.	laronidase		Aldurazyme	9/24/97	Designated/Approved	Approved for Orphan Indication	Treatment for patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms	4/30/03	4/30/10	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA	EXACT	0248646AA	laronidase	WP58SVM6R4						Mucopolysaccharidosis	7065		
chemically modified recombinant sulfamidase	Treatment of mucopolysaccharidosis type IIIA (MPS IIIA)	SOBI-003		n/a	6/28/17	Designated			N/A	N/A	Swedish Orphan Biovitrum AB (publ)	Linköping SV			Sweden	EXACT	0112128AB	SOBI-003	ZS87P77DQC						Mucopolysaccharidosis	7065		
"6-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)- paromamine sulfate"	Treatment of mucopolysaccharidosis type 1 (MPS I)	NB-124 SULFATE		n/a	10/18/16	Designated			N/A	N/A	"Eloxx Pharmaceuticals, Ltd."	Ness Ziona			Israel	EXACT	1801145AA	NB-124 SULFATE	DZ671709NT						Mucopolysaccharidosis	7065		
Recombinant human highly phosphorylated alpha-L-iduronidase (rhHP-IDUA)	Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I.	Recombinant human highly phosphorylated alpha-L-iduronidase (rhHP-IDUA)		n/a	4/11/01	Designated			N/A	N/A	"Novazyme Pharmaceuticals, Inc."	Oklahoma City	Oklahoma	73104	USA										Mucopolysaccharidosis	7065		
IDUA-HIRMAb fusion protein	Treatment of mucopolysaccharidosis Type 1 (MPS)	IDUA-HIRMAb fusion protein		n/a	1/10/08	Designated			N/A	N/A	"ArmaGen Technologies, Inc."	Santa Monica	California	90401	USA	LONGEST CONTAINS	0087274AA	protein							Mucopolysaccharidosis	7065		
lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase	Treatment of mucopolysaccharidosis Type IVA (Morquio Syndrome)	lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase		n/a	9/10/08	Designated			N/A	N/A	Vivendy Therapeutics LTD				Switzerland	LONGEST CONTAINS	0319062AA	sulfate	7IS9N8KPMG						Mucopolysaccharidosis	7065		
iduvec	Treatment of Mucopolysaccharidosis Type I	iduvec		n/a	1/21/11	Designated			N/A	N/A	Zebraic Corporation	Brooklyn Park	Minnesota	55443	USA										Mucopolysaccharidosis	7065		
adeno associated viral vector containing human ARSB gene	Treatment of mucopolysaccharidosis type VI (MPS VI; Maroteaux-Lamy syndrome)	adeno associated viral vector containing human ARSB gene		n/a	3/17/11	Designated			N/A	N/A	Fondazione Telethon				Italy										Mucopolysaccharidosis	7065		
adeno-associated virus vector serotype 9 expressing human sulfamidase	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A Syndrome).	adeno-associated virus vector serotype 9 expressing human sulfamidase		n/a	6/1/11	Designated			N/A	N/A	"Laboratorios del Dr. Esteve, S.A."	Barcelona			Spain										Mucopolysaccharidosis	7065		
adeno-associated viral vector serotype 9 containing human N-acetylglucosaminidase alpha gene	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome)	adeno-associated viral vector serotype 9 containing human N-acetylglucosaminidase alpha gene		n/a	12/27/12	Designated			N/A	N/A	"Laboratorios del Dr. Esteve, S.A."	Barcelona			Spain										Mucopolysaccharidosis	7065		
adeno associated viral vector serotype rh.10 carrying the human SGSH and SUMF1 cDNAs	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo type A syndrome)	adeno associated viral vector serotype rh.10 carrying the human SGSH and SUMF1 cDNAs		n/a	5/6/13	Designated			N/A	N/A	Lysogene	Paris			France										Mucopolysaccharidosis	7065		
HIRMAb-IDS	Treatment of mucopolysaccharidosis Type II (Hunter Syndrome)	HIRMAb-IDS		n/a	5/15/13	Designated			N/A	N/A	"ArmaGen Technologies, Inc."	Santa Monica	California	90401	USA										Mucopolysaccharidosis	7065		
recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase	Treatment of mucopolysaccharidosis type III-A (Sanfilippo Syndrome Type A)	recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase		n/a	4/29/14	Designated			N/A	N/A	Abeona Therapeutics	Cleveland	Ohio	44106	USA										Mucopolysaccharidosis	7065		
Recombinant AAV9 expressing human alpha-N-acetylglucosaminidase	Mucopolysaccharidosis III-B (Sanfilippo Syndrome Type B)	Recombinant AAV9 expressing human alpha-N-acetylglucosaminidase		n/a	4/30/14	Designated			N/A	N/A	Abeona Therapeutics LLC	Cleveland	Ohio	44106	USA										Mucopolysaccharidosis	7065		
adeno-associated virus serotype 9 vector containing human Iduronate-2-sulfatase transgene	Treatment of mucopolysaccharidosis type II (Hunter syndrome).	adeno-associated virus serotype 9 vector containing human Iduronate-2-sulfatase transgene		n/a	7/16/15	Designated			N/A	N/A	"Laboratorios del Dr. Esteve, S.A."	Barcelona			Spain										Mucopolysaccharidosis	7065		
aden-associated virus vector serotype 9 expressing human a-L-iduronidase	Treatment of mucopolysaccharidosis Type I (MSP I).	aden-associated virus vector serotype 9 expressing human a-L-iduronidase		n/a	9/29/15	Designated			N/A	N/A	"REGENXBIO, Inc."	Rockville	Maryland	20850	USA										Mucopolysaccharidosis	7065		
adeno-associated viral (AAV) vector serotype rh. 10 encoding the human N-sulfoglycosamine sulphohydrolase cDNA (SGSH)	Treatment of mucopolysaccharidosis type IIIA or Sanfilippo type A syndrome	adeno-associated viral (AAV) vector serotype rh. 10 encoding the human N-sulfoglycosamine sulphohydrolase cDNA (SGSH)		n/a	11/18/15	Designated			N/A	N/A	LYSOGENE	Neuilly-sur-Seine			France										Mucopolysaccharidosis	7065		
non-replicating recombinant adeno-associated virus (AAV) vector of serotype 9 expressing human iduronate-2-sulfatase	Treatment of Mucopolysaccharidosis Type II	non-replicating recombinant adeno-associated virus (AAV) vector of serotype 9 expressing human iduronate-2-sulfatase		n/a	12/8/15	Designated			N/A	N/A	"REGENXBIO, Inc."	Rockville	Maryland	20850	USA										Mucopolysaccharidosis	7065		
recombinant adeno-associated virus vector serotype 9 expressing human iduronate-2-sulfatase	"Treatment of mucopolysaccharidosis II, also called Hunter syndrome A."	recombinant adeno-associated virus vector serotype 9 expressing human iduronate-2-sulfatase		n/a	9/1/16	Designated			N/A	N/A	Research Institute at Nationwide Children's Hospital	Columbus	Ohio	43205	USA										Mucopolysaccharidosis	7065		
recombinant adeno-associated virus vector serotype 9 expressing human N-Sulfoglucosamine Sulfohydrolase	"Treatment of mucopolysaccharidosis type III A, also called Sanfilippo syndrome A"	recombinant adeno-associated virus vector serotype 9 expressing human N-Sulfoglucosamine Sulfohydrolase		n/a	9/1/16	Designated			N/A	N/A	Research Institute at Nationwide Children's Hospital	Columbus	Ohio	43205	USA										Mucopolysaccharidosis	7065		
adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and the human alpha-L-iduronidase (hIDUA) gene	Treatment of mucopolysaccharidosis type I (MPS I)	adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and the human alpha-L-iduronidase (hIDUA) gene		n/a	1/9/17	Designated			N/A	N/A	"Sangamo Therapeutics, Inc."	Richmond	California	94804	USA	LONGEST CONTAINS	0048271AA	zinc	J41CSQ7QDS						Mucopolysaccharidosis	7065		
Adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and the human iduronate 2-sulfatase (hIDS) gene	Treatment of mucopolysaccharidosis type II	Adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and the human iduronate 2-sulfatase (hIDS) gene		n/a	2/27/17	Designated			N/A	N/A	"Sangamo Therapeutics, Inc."	Richmond	California	94804	USA	LONGEST CONTAINS	0048271AA	zinc	J41CSQ7QDS						Mucopolysaccharidosis	7065		
Autologous CD34+ hematopoietic stem cells transduced with an hCD11b lentiviral vector encoding for the human N-sulfoglucosamine sulfohydrolase (SGSH) gene	Treatment of mucopolysaccharidosis IIIA	Autologous CD34+ hematopoietic stem cells transduced with an hCD11b lentiviral vector encoding for the human N-sulfoglucosamine sulfohydrolase (SGSH) gene		n/a	5/3/17	Designated			N/A	N/A	Orchard Therapeutics North America	Foster City	California	94404	USA	LONGEST CONTAINS	0264620AA	stem cells							Mucopolysaccharidosis	7065		
Sleeping Beauty Transposon-Engineered Autologous Plasmablasts for Expression and Delivery of Alpha-L-Iduronidase	Treatment of mucopolysaccharidosis type I (MPS I)	Sleeping Beauty Transposon-Engineered Autologous Plasmablasts for Expression and Delivery of Alpha-L-Iduronidase		Iduronicrin Genleukocel-T (Iduroicel)	3/19/18	Designated			N/A	N/A	Immusoft Corporation	454 North 34th Street		98103	USA										Mucopolysaccharidosis	7065		
Recombinant human insulin receptor monoclonal antibody-N-heparan sulfamidase fusion protein	"Treatment of Mucopolysaccharidosis Type IIIA, Sanfilippo A Syndrome"	Recombinant human insulin receptor monoclonal antibody-N-heparan sulfamidase fusion protein		n/a	7/12/18	Designated			N/A	N/A	"ArmaGen, Inc."	"26679 Agoura Road, Suite #100"	California	91302	USA	LONGEST CONTAINS	1337275AA	insulin receptor	4CH8636GFF						Mucopolysaccharidosis	7065		
Humanized IgG-1 antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase	Treatment of Mucopolysaccharidosis Type II (MPS II) or Hunter Syndrome	Humanized IgG-1 antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase		n/a	10/15/18	Designated			N/A	N/A	"JCR Pharmaceuticals Co., Ltd."	2-4 Kasuga-cho			Japan	LONGEST CONTAINS	0158667AA	transferrin							Mucopolysaccharidosis	7065		
chemically modified recombinant sulfamidase	Treatment of mucopolysaccharidosis type IIIA (MPS IIIA)	SOBI-003		n/a	6/28/17	Designated			N/A	N/A	Swedish Orphan Biovitrum AB (publ)	Linköping SV			Sweden	EXACT	0112128AB	SOBI-003	ZS87P77DQC						Mucopolysaccharidosis type IIIA	7071		
adeno-associated virus vector serotype 9 expressing human sulfamidase	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A Syndrome).	adeno-associated virus vector serotype 9 expressing human sulfamidase		n/a	6/1/11	Designated			N/A	N/A	"Laboratorios del Dr. Esteve, S.A."	Barcelona			Spain										Mucopolysaccharidosis type IIIA	7071		
adeno associated viral vector serotype rh.10 carrying the human SGSH and SUMF1 cDNAs	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo type A syndrome)	adeno associated viral vector serotype rh.10 carrying the human SGSH and SUMF1 cDNAs		n/a	5/6/13	Designated			N/A	N/A	Lysogene	Paris			France										Mucopolysaccharidosis type IIIA	7071		
adeno-associated viral (AAV) vector serotype rh. 10 encoding the human N-sulfoglycosamine sulphohydrolase cDNA (SGSH)	Treatment of mucopolysaccharidosis type IIIA or Sanfilippo type A syndrome	adeno-associated viral (AAV) vector serotype rh. 10 encoding the human N-sulfoglycosamine sulphohydrolase cDNA (SGSH)		n/a	11/18/15	Designated			N/A	N/A	LYSOGENE	Neuilly-sur-Seine			France										Mucopolysaccharidosis type IIIA	7071		
Recombinant human insulin receptor monoclonal antibody-N-heparan sulfamidase fusion protein	"Treatment of Mucopolysaccharidosis Type IIIA, Sanfilippo A Syndrome"	Recombinant human insulin receptor monoclonal antibody-N-heparan sulfamidase fusion protein		n/a	7/12/18	Designated			N/A	N/A	"ArmaGen, Inc."	"26679 Agoura Road, Suite #100"	California	91302	USA	LONGEST CONTAINS	1337275AA	insulin receptor	4CH8636GFF						Mucopolysaccharidosis type IIIA	7071		
recombinant human Naglu- insulin-like growth factor II	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B)	TRALESINIDASE ALFA		n/a	3/5/13	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0112449AB	TRALESINIDASE ALFA	AA60A4ST8X						Mucopolysaccharidosis type IIIB	7072		
adeno-associated viral vector serotype 9 containing human N-acetylglucosaminidase alpha gene	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome)	adeno-associated viral vector serotype 9 containing human N-acetylglucosaminidase alpha gene		n/a	12/27/12	Designated			N/A	N/A	"Laboratorios del Dr. Esteve, S.A."	Barcelona			Spain										Mucopolysaccharidosis type IIIB	7072		
18Fluorine-N-3-Fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl) Nortropane	Diagnostic to be used in the management of multiple system atrophy (MSA)	18F-Ioflupane		n/a	1/26/15	Designated			N/A	N/A	"Advanced Imaging Projects, LLC"	Lake Worth	Florida	33467	USA	EXACT	1311655AA	18F-Ioflupane	NT4P0L3OCX						Multiple system atrophy	7079		
"N-acetylgalactosamine-4-sulfatase, recombinant human"	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	GALSULFASE		Naglazyme	2/17/99	Designated/Approved	Approved for Orphan Indication	For patients with mucopolysaccharidosis VI. Galsulfase has been shown to improve walking and stair-climbing capacity.	5/31/05	5/31/12	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA	EXACT	0263661AA	GALSULFASE	59UA429E5G						Mucopolysaccharidosis type VI	7095		
odiparcil	Treatment of mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome)	odiparcil		n/a	8/3/17	Designated			N/A	N/A	Inventiva Pharma				France	EXACT	0235858AA	odiparcil	FIK1414ZI8						Mucopolysaccharidosis type VI	7095		
adeno associated viral vector containing human ARSB gene	Treatment of mucopolysaccharidosis type VI (MPS VI; Maroteaux-Lamy syndrome)	adeno associated viral vector containing human ARSB gene		n/a	3/17/11	Designated			N/A	N/A	Fondazione Telethon				Italy										Mucopolysaccharidosis type VI	7095		
maytansinoid DM1-conjugated humanized monoclonal antibody N901	Treatment of multiple myeloma.	IMGN-901		n/a	11/29/10	Designated/Withdrawn			N/A	N/A	"ImmunoGen, Inc."	Waltham	Massachusetts	2451	USA	EXACT	0432575AA	IMGN-901	0IVD6ASY0W						Multiple myeloma	7108		
galinpepimut-S	Treatment of multiple myeloma	galinpepimut-S		n/a	5/8/18	Designated			N/A	N/A	"SELLAS Life Sciences Group, Inc."	315 Madison Avenue	4th floor	10017	USA	EXACT	1307057AA	galinpepimut-S	12R66419FZ						Multiple myeloma	7108		
elotuzumab	Treatment of multiple myeloma	elotuzumab		Empliciti	9/1/11	Designated/Approved	Approved for Orphan Indication	Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies	11/30/15	11/30/22	Bristol-Myers Squibb Co.	Princeton	New Jersey	8540	USA	EXACT	0322565AA	elotuzumab	1351PE5UGS						Multiple myeloma	7108		
roneparstat	Treatment of multiple myeloma	roneparstat		n/a	3/19/15	Designated			N/A	N/A	Sigma-Tau Research Switerland S.A.				Switzerland	EXACT	1120816AA	roneparstat	1J0593208B						Multiple myeloma	7108		
ibrutinib	Treatment of multiple myeloma	ibrutinib		n/a	5/16/13	Designated			N/A	N/A	"Pharmacyclics, LLC"	Sunnyvale	California	94085	USA	EXACT	0625092AA	ibrutinib	1X70OSD4VX						Multiple myeloma	7108		
triciribine	Treatment of multiple myeloma	triciribine		n/a	2/1/08	Designated			N/A	N/A	"VioQuest Pharmaceuticals, Inc."	Basking Ridge	New Jersey	7920	USA	EXACT	0377673AA	triciribine	2421HMY9N6						Multiple myeloma	7108		
perifosine	Treatment of multiple myeloma.	perifosine		n/a	9/3/09	Designated/Withdrawn			N/A	N/A	Aeterna Zentaris GmbH				Germany	EXACT	0232406AA	perifosine	2GWV496552						Multiple myeloma	7108		
milatuzumab	Treatment of multiple myeloma	milatuzumab		n/a	3/10/08	Designated			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA	EXACT	0313213AA	milatuzumab	2OP4E0GC6V						Multiple myeloma	7108		
selinexor	Treatment of multiple myeloma	selinexor		n/a	1/5/15	Designated			N/A	N/A	"Karyopharm Therapeutics, Inc."	Newton	Maryland	2459	USA	EXACT	0899718AA	selinexor	31TZ62FO8F						Multiple myeloma	7108		
melphalan flufenamide hydrochloride	"Treatment of plasma cell myeloma, also referred to as multiple myeloma"	melphalan flufenamide hydrochloride		n/a	3/16/15	Designated			N/A	N/A	Oncopeptides AB				Sweden	EXACT	1577113AA	melphalan flufenamide hydrochloride	3412470A0V						Multiple myeloma	7108		
(2-((2-chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide)	Treatment of multiple myeloma	CITARINOSTAT		n/a	11/29/16	Designated			N/A	N/A	"Acetylon Pharmaceuticals, Inc."	Summit	New Jersey	7901	USA	EXACT	1125617AA	CITARINOSTAT	441P620G3P						Multiple myeloma	7108		
ixazomib citrate	Treatment of multiple myeloma	ixazomib citrate		Ninlaro	2/18/11	Designated/Approved	Approved for Orphan Indication	Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy	11/20/15	11/20/22	Millennium Pharmaceuticals	Cambridge	Massachusetts	2139	USA	EXACT	0681276AA	ixazomib citrate	46CWK97Z3K						Multiple myeloma	7108		
Tanespimycin	Treatment of multiple myeloma	Tanespimycin		n/a	9/9/04	Designated			N/A	N/A	Bristol-Myers Squibb	Wallingford	Connecticut	6492	USA	EXACT	0230819AA	Tanespimycin	4GY0AVT3L4						Multiple myeloma	7108		
daratumumab	Treatment of multiple myeloma.	daratumumab		Darzalex	5/6/13	Designated/Approved	Approved for Orphan Indication	For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent	11/16/15	11/16/22	"Janssen Research & Development, LLC"	Raritan	New Jersey	8869	USA	EXACT	0432519AA	daratumumab	4Z63YK6E0E						Multiple myeloma	7108		
Thalidomide	Treatment of multiple myeloma	Thalidomide		Thalomid	10/14/98	Designated/Approved	Approved for Orphan Indication	Treatment of patients with newly diagnosed multiple myeloma	5/25/06	5/25/13	Celgene Corporation	Warren				EXACT	0007409AA	Thalidomide	4Z8R6ORS6L						Multiple myeloma	7108		
acadesine	Treatment of multiple myeloma	acadesine		n/a	5/4/11	Designated			N/A	N/A	Advancell-Advanced In Vitro Cell Technologies S.A.	Barcelona			Spain	EXACT	0171528AA	acadesine	53IEF47846						Multiple myeloma	7108		
vorinostat	Treatment of multiple myeloma	vorinostat		n/a	6/12/03	Designated/Withdrawn			N/A	N/A	Merck Research Laboratories	Rahway	New Jersey	7065	USA	EXACT	0233089AA	vorinostat	58IFB293JI						Multiple myeloma	7108		
"1-(4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide"	Treatment of multiple myeloma	CB-5083		n/a	7/8/15	Designated			N/A	N/A	"Cleave Biosciences, Inc."	Burlingame	California	94010	USA	EXACT	1069836AA	CB-5083	591IV6UL6J						Multiple myeloma	7108		
avicin d	Treatment of multiple myeloma	avicin d		n/a	3/24/15	Designated			N/A	N/A	Avicin Therapeutics Ltd.	Durham	North Carolina	27713	USA	EXACT	0377151AA	avicin d	69451KN1RO						Multiple myeloma	7108		
bortezomib	Treatment of multiple myeloma	bortezomib		Velcade	1/15/03	Designated/Approved	Approved for Orphan Indication	Treatment of multiple myeloma patients who have received at least one prior therapy	3/25/05	3/25/12	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0228319AA	bortezomib	69G8BD63PP						Multiple myeloma	7108		
bortezomib	Treatment of multiple myeloma	bortezomib		Velcade	1/15/03	Designated/Approved	Approved for Orphan Indication	Treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy	5/13/03	5/13/10	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0228319AA	bortezomib	69G8BD63PP						Multiple myeloma	7108		
bortezomib	Treatment of multiple myeloma	bortezomib		Velcade	1/15/03	Designated/Approved	Approved for Orphan Indication	First-line therapy of multiple myeloma.	6/20/08	6/20/15	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0228319AA	bortezomib	69G8BD63PP						Multiple myeloma	7108		
2-methoxyestradiol	Treatment of multiple myeloma	2-methoxyestradiol		Panzem	7/10/01	Designated/Withdrawn			N/A	N/A	"EntreMed, Inc."	Durham	North Carolina	27703	USA	EXACT	0235176AA	2-methoxyestradiol	6I2QW73SR5						Multiple myeloma	7108		
"(2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide"	Treatment of multiple myeloma	LCL-161		n/a	6/28/17	Designated			N/A	N/A	"Paul Maher, MD"	Bethesda	Maryland	20814	USA	EXACT	0922861AA	LCL-161	6TNS415Y3P						Multiple myeloma	7108		
Marizomib	Treatment of multiple myeloma	Marizomib		n/a	12/13/13	Designated			N/A	N/A	Triphase Research and Development I Corp.	San Diego	California	92121	USA	EXACT	0276028AA	Marizomib	703P9YDP7F						Multiple myeloma	7108		
carfilzomib	Treatment of multiple myeloma	carfilzomib		Kyprolis	1/18/08	Designated/Approved	Approved for Orphan Indication	Treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.	7/20/12	7/20/19	"Onyx Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	0256984AA	carfilzomib	72X6E3J5AR						Multiple myeloma	7108		
Tasquinimod	Treatment of multiple myeloma	Tasquinimod		n/a	4/10/17	Designated			N/A	N/A	Active Biotech AB	Lund			Sweden	EXACT	0322816AA	Tasquinimod	756U07KN1R						Multiple myeloma	7108		
Multi-peptide cancer vaccine	Treatment of multiple myeloma	PVX-401 COMPONENT XBP1 SP367-375 (YLFPQLISV)		n/a	6/23/13	Designated			N/A	N/A	"OncoPep, Inc."	North Andover	Massachusetts	1845	USA	EXACT	1803049AA	PVX-401 COMPONENT XBP1 SP367-375 (YLFPQLISV)	7AS3WP8FO8						Multiple myeloma	7108		
dexamethasone	Treatment of multiple myeloma (MM)	dexamethasone		n/a	3/26/18	Designated			N/A	N/A	Dexcel Pharma Technologies Ltd	Dexcel Street			Israel	EXACT	0007192AA	dexamethasone	7S5I7G3JQL						Multiple myeloma	7108		
"O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1yl]diazen-1-ium-1,2-diolate"	Treatment of multiple myeloma	JS-K		n/a	12/13/13	Designated			N/A	N/A	"JSK Therapeutics, Inc."	Salt Lake City	Utah	84158	USA	EXACT	0761193AA	JS-K	80P1Q21652						Multiple myeloma	7108		
doxorubicin HCL liposome injection	Treatment of multiple myeloma	doxorubicin HCL liposome injection		Doxil	12/29/04	Designated/Approved	Approved for Orphan Indication	For use in combination with bortezomib for the treatment of patients with multiple myeloma who have not previously received bortezomib and have at least one prior therapy.	5/17/07	5/17/14	Johnson & Johnson Pharmaceutical Research & Dev.	Raritan		8869	USA	exact	0063014AA	doxorubicin HCL	82F2G7BL4E						Multiple myeloma	7108		
oblimersen	Treatment of multiple myeloma	oblimersen		Genasense	8/28/01	Designated			N/A	N/A	"Genta, Inc."	Berkeley Heights	New Jersey	7922	USA	EXACT	0258731AA	oblimersen	85J5ZP6YSL						Multiple myeloma	7108		
filanesib	Treatment of multiple myeloma.	filanesib		n/a	5/6/14	Designated			N/A	N/A	"Array BioPharma, Inc."	Boulder	Colorado	80301	USA	EXACT	0299467AA	filanesib	8A49OSO368						Multiple myeloma	7108		
Imexon	Treatment of multiple myeloma.	Imexon		n/a	11/8/96	Designated			N/A	N/A	AmpliMed Corporation	Tucson	Arizona	85718	USA	EXACT	0297121AA	Imexon	8F63U28T2V						Multiple myeloma	7108		
"6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glycero-B-L-manno-heptopyranosyl]amino-9H-purine"	Treatment of multiple myeloma	krn-5500		n/a	6/12/14	Designated			N/A	N/A	"DARA BioSciences, Inc."	Raleigh	North Carolina	27615	USA	EXACT	0217243AA	krn-5500	8VH13L5K20						Multiple myeloma	7108		
bendamustine	Treatment of multiple myeloma	bendamustine		n/a	6/22/17	Designated			N/A	N/A	"Paul Maher, MD"	Bethesda	Maryland	20814	USA	EXACT	0304245AA	bendamustine	9266D9P3PQ						Multiple myeloma	7108		
panobinostat	Treatment of multiple myeloma	panobinostat		Farydak	8/20/12	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent"	2/23/15	2/23/22	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0456257AA	panobinostat	9647FM7Y3Z						Multiple myeloma	7108		
"Papain, trypsin, and chymotrypsin"	Treatment of multiple myeloma.	Papain		Wobe-Mugos	12/21/98	Designated			N/A	N/A	"Marlyn Nutraceuticals, Inc."	Scottsdale	Arizona	85254	USA	EXACT	0004999AA	Papain	A236A06Y32						Multiple myeloma	7108		
"Papain, trypsin, and chymotrypsin"	Treatment of multiple myeloma.	"Papain, trypsin, and chymotrypsin"		Wobe-Mugos	12/21/98	Designated			N/A	N/A	"Marlyn Nutraceuticals, Inc."	Scottsdale	Arizona	85254	USA	EXACT	0005743AA	chymotrypsin	BVS505O332						Multiple myeloma	7108		
pomalidomide	Treatment of multiple myeloma	pomalidomide		Pomalyst	1/15/03	Designated/Approved	Approved for Orphan Indication	Treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.	2/8/13	2/8/20	Celgene Corporation	Berkeley Heights	New Jersey	7922	USA	EXACT	0244122AA	pomalidomide	D2UX06XLB5						Multiple myeloma	7108		
Humanized anti-BCMA (B-cell maturation antigen) monoclonal antibody	Treatment of multiple myeloma	GSK-2857916		n/a	6/22/17	Designated			N/A	N/A	GlaxoSmithKline	Brentford-Middlesex			United Kingdom	EXACT	0928494AA	GSK-2857916	DB1041CXDG						Multiple myeloma	7108		
pembrolizumab	Treatment of multiple myeloma.	pembrolizumab		Keytruda	2/17/16	Designated			N/A	N/A	"Merck, Sharp & Dohme Corp."	Whitehouse Station	New Jersey	8889	USA	EXACT	0809245AA	pembrolizumab	DPT0O3T46P						Multiple myeloma	7108		
Multi-peptide cancer vaccine	Treatment of multiple myeloma	PVX-401 COMPONENT CS1 239-247(SLFVLGLFL)		n/a	6/23/13	Designated			N/A	N/A	"OncoPep, Inc."	North Andover	Massachusetts	1845	USA	EXACT	1803061AA	PVX-401 COMPONENT CS1 239-247(SLFVLGLFL)	EHT3VE7CI1						Multiple myeloma	7108		
lenalidomide	Treatment of multiple myeloma	lenalidomide		Revlimid	9/20/01	Designated/Approved	Approved for Orphan Indication	For use in combination with dexamethasone for the treatment of patients with multiple myeloma who have not received at least one prior therapy (first line treatment)	2/17/15	2/17/22	Celgene Corporation	Berkeley Heights	New Jersey	7922	USA	EXACT	0236099AA	lenalidomide	F0P408N6V4						Multiple myeloma	7108		
lenalidomide	Treatment of multiple myeloma	lenalidomide		Revlimid	9/20/01	Designated/Approved	Approved for Orphan Indication	"Treatment of multiple myeloma (MM), as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT)"	2/22/17	2/22/24	Celgene Corporation	Berkeley Heights	New Jersey	7922	USA	EXACT	0236099AA	lenalidomide	F0P408N6V4						Multiple myeloma	7108		
lenalidomide	Treatment of multiple myeloma	lenalidomide		Revlimid	9/20/01	Designated/Approved	Approved for Orphan Indication	For use in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy	6/29/06	6/29/13	Celgene Corporation	Berkeley Heights	New Jersey	7922	USA	EXACT	0236099AA	lenalidomide	F0P408N6V4						Multiple myeloma	7108		
"(1R,2R)-1,2-cyclohexane-diaminepyrophosphato-platinum(II)"	Treatment of multiple myeloma	pt-112		n/a	11/22/17	Designated			N/A	N/A	Phosplatin Therapeutics LLC	1350 6th Avenue	New York	10019	USA	EXACT	0811541AA	pt-112	F5I3T42BXC						Multiple myeloma	7108		
Interferon-alfa-1b	Treatment of multiple myeloma	Interferon-alfa-1b		n/a	4/17/01	Designated			N/A	N/A	Ernest C.Borden	Clevland	Ohio	44195	USA	EXACT	0263412AA	Interferon-alfa-1b	G7407IV2FS						Multiple myeloma	7108		
"Papain, trypsin, and chymotrypsin"	Treatment of multiple myeloma.	trypsin		Wobe-Mugos	12/21/98	Designated			N/A	N/A	"Marlyn Nutraceuticals, Inc."	Scottsdale	Arizona	85254	USA	EXACT	0005174AA	trypsin	GV54A213NN						Multiple myeloma	7108		
nelfinavir	Treatment of multiple myeloma	nelfinavir		Viracept	2/14/17	Designated			N/A	N/A	Swiss Group for Clinical Cancer Research (SAKK)	Bern			Switzerland	EXACT	0225558AA	nelfinavir	HO3OGH5D7I						Multiple myeloma	7108		
Dovitinib	Treatment of multiple myeloma	Dovitinib		n/a	10/3/06	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0309342AA	Dovitinib	I35H55G906						Multiple myeloma	7108		
"(3E,5E)-3,5-bis[(4-fluoro-3-nitrophenyl)methylidene]-1-(prop-2-enoyl)azepan-4-0ne"	Treatment of multiple myeloma	VLX-1570		n/a	4/30/14	Designated			N/A	N/A	VivoLux AB				Sweden	EXACT	1101059AA	VLX-1570	K6067N5M6N						Multiple myeloma	7108		
2-(2-phenylvinyl)-4-[4-methylpiperazin-l-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	Treatment of multiple myeloma.	ENMD-2076		n/a	12/22/08	Designated			N/A	N/A	"EntreMed, Inc."	Durham	North Carolina	27703	USA	EXACT	1129813AA	ENMD-2076	KXQ762CQTH						Multiple myeloma	7108		
Beta alethine	Treatment of multiple myeloma.	Beta alethine		Betathine	3/24/97	Designated			N/A	N/A	"Dovetail Technologies, Inc."	College Park	Maryland	20742	USA	EXACT	0422275AA	alethine	LY583605Y8						Multiple myeloma	7108		
N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole) mesylate	Treatment of multiple myeloma.	Masitinib		n/a	10/17/05	Designated			N/A	N/A	AB Science				France	EXACT	0302783AA	Masitinib	M59NC4E26P						Multiple myeloma	7108		
tipifarnib	Treatment of multiple myeloma	tipifarnib		n/a	6/22/17	Designated			N/A	N/A	"Paul Maher, MD"	Bethesda	Maryland	20814	USA	EXACT	0218622AA	tipifarnib	MAT637500A						Multiple myeloma	7108		
human anti-cellular adhesion molecule-1 monoclonal antibody	Treatment of multiple myeloma	BI-505		n/a	7/29/08	Designated			N/A	N/A	BioInvent International AB				Sweden	EXACT	0341742AA	BI-505	MP3N1L4OR6						Multiple myeloma	7108		
oprozomib	Treatment of multiple myeloma	oprozomib		n/a	10/28/14	Designated			N/A	N/A	"Onyx Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	0701406AA	oprozomib	MZ37792Y8J						Multiple myeloma	7108		
Venetoclax	Treatment of multiple myeloma	Venetoclax		n/a	8/29/16	Designated			N/A	N/A	AbbVie Inc.	North Chicago	Illinois	60064	USA	EXACT	0790283AA	Venetoclax	N54AIC43PW						Multiple myeloma	7108		
Recombinant anti-CD-40 monoclonal antibody	Treatment of multiple myeloma	Lucatumumab		n/a	1/25/06	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceutical Corporation	East Hanover	New Jersey	7936	USA	EXACT	0304961AA	Lucatumumab	P0EP9VFC4R						Multiple myeloma	7108		
tabalumab	Treatment of multiple myeloma	tabalumab		n/a	11/19/12	Designated/Withdrawn			N/A	N/A	Eli Lilly and Company	Indianapolis	Indiana	46285	USA	EXACT	0659063AA	tabalumab	PQP8VH3MJW						Multiple myeloma	7108		
Melphalan	Treatment of patients with multiple myeloma for whom oral therapy is inappropriate.	Melphalan		Alkeran For Injection	2/24/92	Designated/Approved	Approved for Orphan Indication	For the palliative treatment of patients with multiple myeloma for whom oral melphalan is not appropriate.	11/18/92	11/18/99	Glaxo Wellcome Inc.	Research Triangle Park	North Carolina	27709	USA	EXACT	0023176AA	Melphalan	Q41OR9510P						Multiple myeloma	7108		
1 8-(p[131I]-iodophenyl)octadecyl phosphocholine	Treatment of multiple myeloma	NM-404 I-131		n/a	12/3/14	Designated			N/A	N/A	"Cellectar Biosciences, Inc."	Madison	Wisconsin	53716	USA	EXACT	1079705AA	NM-404 I-131	R048696O9L						Multiple myeloma	7108		
humanized immunoglobulin monoclonal antibody against CD38	Treatment of multiple myeloma.	Isatuximab		n/a	5/22/14	Designated			N/A	N/A	"Sanofi U.S. Services, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	1094640AA	Isatuximab	R30772KCU0						Multiple myeloma	7108		
Arsenic trioxide	Treatment of multiple myeloma.	Arsenic trioxide		Trisenox	4/28/00	Designated			N/A	N/A	"TEVA Branded Pharmaceutical Products R & D, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0034720AA	Arsenic trioxide	S7V92P67HO						Multiple myeloma	7108		
siltuximab	Treatment of multiple myeloma	siltuximab		n/a	10/11/05	Designated/Withdrawn			N/A	N/A	"Janssen Research & Development, LLC"	Raritan	New Jersey	8869	USA	EXACT	0432462AA	siltuximab	T4H8FMA7IM						Multiple myeloma	7108		
S(-)-3-[3-amino-phthalimido]-glutaramide	Treatment of multiple myeloma	S(-)-3-(3-amino-phthalimido)-glutaramide		n/a	3/14/02	Designated			N/A	N/A	EntreMed Incorporated	Rockville	Maryland	20850	USA	EXACT	0736878AA	S(-)-3-(3-amino-phthalimido)-glutaramide	TG87FSR590						Multiple myeloma	7108		
dacetuzumab	Treatment of multiple myeloma.	dacetuzumab		n/a	8/13/04	Designated			N/A	N/A	"Seattle Genetics, Inc."	Bothell	Washington	98021	USA	EXACT	0266295AA	dacetuzumab	UT59FF4T5X						Multiple myeloma	7108		
Multi-peptide cancer vaccine	Treatment of multiple myeloma	PVX-401 COMPONENT CD138 260-268(GLVGLIFAV)		n/a	6/23/13	Designated			N/A	N/A	"OncoPep, Inc."	North Andover	Massachusetts	1845	USA	EXACT	1803050AA	PVX-401 COMPONENT CD138 260-268(GLVGLIFAV)	V1QJC0TIE6						Multiple myeloma	7108		
Multi-peptide cancer vaccine	Treatment of multiple myeloma	PVX-401 COMPONENT XBP1 US184-192(YISPWILAV)		n/a	6/23/13	Designated			N/A	N/A	"OncoPep, Inc."	North Andover	Massachusetts	1845	USA	EXACT	1803038AA	PVX-401 COMPONENT XBP1 US184-192(YISPWILAV)	W7QU8GP4UY						Multiple myeloma	7108		
"(R)-4-(3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enylmethyl]-piperazin-1-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride"	Treatment of multiple myeloma	NAVITOCLAX DIHYDROCHLORIDE		n/a	5/5/08	Designated/Withdrawn			N/A	N/A	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0555895AA	NAVITOCLAX DIHYDROCHLORIDE	W8FZ00AY2S						Multiple myeloma	7108		
N2'-Deacetyl-N2'-[4-methyl-4-(oxobuthyldithio)-1-oxopentyl]-maytansine-chimerized anti-CD138 IgG4 Monoclonal Antibody	Treatment of multiple myeloma	Indatuximab ravtansine		n/a	2/27/08	Designated			N/A	N/A	Biotest Pharmaceuticals Corporation	Boca Raton	Florida	33487	USA	EXACT	0659198AA	Indatuximab ravtansine	XGL4M23834						Multiple myeloma	7108		
Plitidepsin	Treatment of multiple myeloma	Plitidepsin		Aplidin	9/30/04	Designated			N/A	N/A	"PharmaMar USA, Inc."	New York	New York	10017	USA	EXACT	0252642AA	Plitidepsin	Y76ID234HW						Multiple myeloma	7108		
recombinant human monoclonal IgM antibody targeting glucose regulated protein 78	Treatment of multiple myeloma	PAT SM-6		n/a	10/25/13	Designated			N/A	N/A	Patrys Ltd.				Australia	EXACT									Multiple myeloma	7108		
synthetic signal peptide of human mucin-1 (amino acids 1-21)	Treatment of multiple myeloma.	IMMUCIN		n/a	6/16/15	Designated			N/A	N/A	Vaxil Bio Therapeutics Ltd.				Israel	EXACT	1310641AA	IMMUCIN	YRY1GG3QHU						Multiple myeloma	7108		
tinostamustine hydrochloride	Treatment of multiple myeloma	tinostamustine hydrochloride		n/a	4/2/18	Designated			N/A	N/A	Mundipharma EDO GmbH	74 Sankt Alban-Rheinweg			Switzerland	EXACT	0115045AB	tinostamustine hydrochloride	QK4ZBS4FPO						Multiple myeloma	7108		
Chelating agent delivering Holmium-166	Treatment of multiple myeloma.	Chelating agent delivering Holmium ho-166		n/a	2/10/99	Designated			N/A	N/A	NeoRx Corporation	Seattle	Washington	98119	USA	LONGEST CONTAINS	0446560AA	Holmium	W1XX32SQN1						Multiple myeloma	7108		
autologous antigen presenting cells pulsed with autologous tumor Ig idiotype	Treatment of multiple myeloma	autologous antigen presenting cells pulsed with autologous tumor Ig idiotype		Mylovenge	4/18/02	Designated/Withdrawn			N/A	N/A	Dendreon Corporation	Seattle	Washington	98121	USA										Multiple myeloma	7108		
DNA plasmid vector expressing eIF5Ak50	Treatment of multiple myeloma.	DNA plasmid vector expressing eIF5Ak50		n/a	12/13/10	Designated			N/A	N/A	"Senesco Technologies, Inc."	New Brunswick	New Jersey	8901	USA										Multiple myeloma	7108		
IgG1 chimeric monoclonal antibody	Treatment of multiple myeloma.	MDX-1097		n/a	6/22/11	Designated			N/A	N/A	Immune System Therapeutics Ltd				Australia										Multiple myeloma	7108		
"Extract of sea cucumber, sea sponge, shark fin, sea urchin, and sargassum grass"	Treatment of multiple myeloma	"Extract of sea cucumber, sea sponge, shark fin, sea urchin, and sargassum grass"		n/a	5/14/12	Designated			N/A	N/A	Unicorn Pacific Corporation	Port Vila			Vanuatu	LONGEST CONTAINS	0377457AA	sea cucumber	LUE8BK8H5Q						Multiple myeloma	7108		
autologous T-lymphocytes transduced with anti-BCMA02 CAR lentiviral vector encoding a chimeric antigen receptor (CAR) specific for the human B cell maturation antigen	Treatment of multiple myeloma	autologous T-lymphocytes transduced with anti-BCMA02 CAR lentiviral vector encoding a chimeric antigen receptor (CAR) specific for the human B cell maturation antigen		n/a	5/11/16	Designated			N/A	N/A	"bluebird bio, Inc."	Cambridge	Massachusetts	2141	USA	LONGEST CONTAINS	0263092AA	lymphocytes							Multiple myeloma	7108		
Human major histocompatibility complex (MHC) non-restricted T-cell line 104	Treatment of multiple myeloma	Human major histocompatibility complex (MHC) non-restricted T-cell line 104		n/a	4/17/17	Designated			N/A	N/A	Galileo Research srl	Pisa			Italy										Multiple myeloma	7108		
Autologous CD4+/CD8+ T cells expressing a BCMA-specific chimeric antigen receptor (CAR)	Treatment of Multiple Myeloma (MM)	Autologous CD4+/CD8+ T cells expressing a BCMA-specific chimeric antigen receptor (CAR)		n/a	9/28/17	Designated			N/A	N/A	"Juno Therapeutics, Inc."	Seattle	Washington	98109	USA	LONGEST CONTAINS	1321079AA	BCMA	PK6VHJAIBD						Multiple myeloma	7108		
autologous T lymphocyte enriched population cultured in the rpesence of phosphatidylinositol 3-kinase inhibitor (bb007) that contains cells transduced with an anti-human B cell maturation antigen (BCMA02) chimeric antigen receptor (CAR) lentiviral vector encoding a CAR that targets human BCMA	Treatment of multiple myeloma	autologous T lymphocyte enriched population cultured in the rpesence of phosphatidylinositol 3-kinase inhibitor (bb007) that contains cells transduced with an anti-human B cell maturation antigen (BCMA02) chimeric antigen receptor (CAR) lentiviral vector encoding a CAR that targets human BCMA		n/a	10/5/17	Designated			N/A	N/A	"bluebird bio, Inc."	Cambridge	Massachusetts	2142	USA	LONGEST CONTAINS	0144649AA	phosphatidylinositol							Multiple myeloma	7108		
lentiviral transfected chimeric antigen receptor T-cells modified to target B-cell maturation antigen and CS1	Treatment of multiple myeloma	lentiviral transfected chimeric antigen receptor T-cells modified to target B-cell maturation antigen and CS1		n/a	12/14/17	Designated			N/A	N/A	iCell Gene Therapeutics	25 Health Sciences Drive	Stony Brook	11793	USA	LONGEST CONTAINS	0116660AB	chimeric antigen receptor T cells							Multiple myeloma	7108		
anti-CD47 monoclonal antibody	Treatment of multiple myeloma	anti-CD47 monoclonal antibody		n/a	7/30/18	Designated			N/A	N/A	"Surface Oncology, Inc."	"50 Hampshire St, 8th Floor"	Massachusetts	1239	USA	LONGEST CONTAINS	1806015AA	CD47	90DHW5TM9S						Multiple myeloma	7108		
autologous engineered T-cell product that targets B-cell maturation antigen (BCMA)	Treatment of multiple myeloma	autologous engineered T-cell product that targets B-cell maturation antigen (BCMA)		n/a	9/10/18	Designated			N/A	N/A	"Kite Pharma, Inc."	2225 Colorado Avenue	California	90404	USA	LONGEST CONTAINS	1321079AA	BCMA	PK6VHJAIBD						Multiple myeloma	7108		
bispecific T-cell engager antibody with a single chain Fc moiety that binds to B cell maturation antigen surface receptor and CD3	Treatment of multiple myeloma	AMG-420		n/a	10/10/18	Designated			N/A	N/A	Amgen Inc.	One Amgen Center Drive	California	91320	USA	EXACT	0117064AB	AMG-420	102VUR9WQE						Multiple myeloma	7108		
antibody-drug conjugate comprised of a human aglycosylated anti-CD74 IgG1 antibody (SP7219) and two non-cleavable maytansinoid linker warheads	Treatment of multiple myeloma	STRO-001		n/a	10/10/18	Designated			N/A	N/A	"Sutro Biopharma, Inc."	310 Utah Avenue	California	94080	USA	EXACT									Multiple myeloma	7108		
melphalan flufenamide hydrochloride	"Treatment of plasma cell myeloma, also referred to as multiple myeloma"	melphalan flufenamide hydrochloride		n/a	3/16/15	Designated			N/A	N/A	Oncopeptides AB				Sweden	EXACT	1577113AA	melphalan flufenamide hydrochloride	3412470A0V						Plasma cell myeloma	7108		
monarsen	Treatment of myasthenia gravis	monarsen		n/a	11/14/03	Designated			N/A	N/A	"Bioline Rx, Ltd."	Jerusalem			Israel	EXACT	1798283AA	monarsen	4TT3V55XYT						Myasthenia gravis	7122		
immune globulin (human)	Treatment of Myasthenia Gravis	immune globulin (human)		Gamunex (R)-C	12/12/16	Designated			N/A	N/A	"Grifols Therapeutics, Inc."	Research Triangle Park	North Carolina	27709	USA	EXACT	0232586AA	immune globulin (human)	66Y330CJHS						Myasthenia gravis	7122		
amifampridine phosphate	Treatment of myasthenia gravis	amifampridine phosphate		n/a	8/31/16	Designated			N/A	N/A	"Catalyst Pharmaceuticals, Inc."	Coral Gables	Florida	33134	USA	EXACT	0736254AA	amifampridine phosphate	8HF8FIN815						Myasthenia gravis	7122		
Mycophenolate mofetil	Treatment of myasthenia gravis	Mycophenolate mofetil		Cellcept	12/19/05	Designated/Withdrawn			N/A	N/A	"Hoffman-LaRoche, Inc."	Nutley	New Jersey	7110	USA	EXACT	0167157AA	Mycophenolate mofetil	9242ECW6R0						Myasthenia gravis	7122		
human anti-neonatal Fc receptor IgG1 Fc fragment	Treatment of myasthenia gravis	EFGARTIGIMOD ALFA		n/a	9/20/17	Designated			N/A	N/A	argenx BVBA	Gent			Belgium	EXACT	1799311AA	EFGARTIGIMOD ALFA	961YV2O515						Myasthenia gravis	7122		
neostigmine methylsulfate	Treatment of Myasthenia Gravis	neostigmine methylsulfate		n/a	2/17/12	Designated			N/A	N/A	"Luitpold Pharmaceuticals, Inc."	Shirley	New York	11967	USA	EXACT	0007976AA	neostigmine methylsulfate	98IMH7M386						Myasthenia gravis	7122		
eculizumab	Treatment of Myasthenia Gravis.	eculizumab		n/a	6/12/14	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	New Haven	Connecticut	6510	USA	EXACT	0298000AA	eculizumab	A3ULP0F556						Myasthenia gravis	7122		
Methotrexate	Treatment of Myasthenia Gravis	Methotrexate		Amethopterin	8/28/14	Designated			N/A	N/A	The Universtiy of Kanasa Medical Center	Kanasa City	Kansas	66160	USA	EXACT	0010059AA	Methotrexate	YL5FZ2Y5U1						Myasthenia gravis	7122		
Recombinant Human Alpha-Fetoprotein (rhAFP)	Treatment of myasthenia gravis	Recombinant Human Alpha-Fetoprotein (rhAFP)		n/a	2/22/01	Designated			N/A	N/A	"Alpha Cancer Technologies, Inc."	Toronto	Ontario		Canada										Myasthenia gravis	7122		
peptides mimicking antigen receptors on autoimmune B cells and autoimmune T cells associated with myasthenia gravis	Treatment of myasthenia gravis	peptides mimicking antigen receptors on autoimmune B cells and autoimmune T cells associated with myasthenia gravis		n/a	2/4/11	Designated			N/A	N/A	CuraVac Europe SPRL				Belgium										Myasthenia gravis	7122		
DNA plasmid encoding the acetylcholine receptor	Treatment of myasthenia gravis.	DNA plasmid encoding the acetylcholine receptor		n/a	4/18/11	Designated/Withdrawn			N/A	N/A	Bayhill Therapeutics	Palo Alto	California	94303	USA	LONGEST CONTAINS	0300107AA	acetylcholine	N9YNS0M02X						Myasthenia gravis	7122		
tolerogen	Treatment of myasthenia gravis	tolerogen		n/a	2/5/15	Designated			N/A	N/A	Toleranzia AB				Sweden										Myasthenia gravis	7122		
Mutated form of human acetylcholine receptor a1 extracellular domain subunit	Treatment of myasthenia gravis	Mutated form of human acetylcholine receptor a1 extracellular domain subunit		n/a	3/16/17	Designated			N/A	N/A	Toleranzia AB	Gothenburg			Sweden	LONGEST CONTAINS	0300107AA	acetylcholine	N9YNS0M02X						Myasthenia gravis	7122		
Rifabutin	Treatment of disseminated Mycobacterium avium complex disease.	Rifabutin		n/a	12/18/89	Designated			N/A	N/A	Pfizer Inc.	New York	New York	10017	USA	EXACT	0121153AA	Rifabutin	1W306TDA6S						Mycobacterium Avium Complex	7123		
Rifabutin	Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.	Rifabutin		Mycobutin	12/18/89	Designated/Approved	Approved for Orphan Indication	Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections.	12/23/92	12/23/99	"Adria Laboratories, Inc."	Columbus	Ohio	43216	USA	EXACT	0121153AA	Rifabutin	1W306TDA6S						Mycobacterium Avium Complex	7123		
Aminosidine	Treatment of Mycobacterium avium complex.	Aminosidine		Gabbromicina	11/15/93	Designated			N/A	N/A	"Kanyok, Thomas P. Pharm.D."	Chicago	Illinois	60612	USA	EXACT	0033465AA	Aminosidine	845NU6GJPS						Mycobacterium Avium Complex	7123		
Rifapentine	Treatment of Mycobacterium avium complex in patients with AIDS.	Rifapentine		Priftin	6/9/95	Designated			N/A	N/A	"Hoechst Marion Roussel , Inc."	Kansas City	Missouri	64134	USA	EXACT	0185999AA	Rifapentine	XJM390A33U						Mycobacterium Avium Complex	7123		
Rifapentine	Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.	Rifapentine		Priftin	3/12/96	Designated			N/A	N/A	"Hoechst Marion Roussel, Inc."	Kansas City	Missouri	64134	USA	EXACT	0185999AA	Rifapentine	XJM390A33U						Mycobacterium Avium Complex	7123		
cladribine	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	cladribine		n/a	3/19/15	Designated			N/A	N/A	Chord Therapeutics S.a.r.l.				Switzerland	EXACT	0092944AA	cladribine	47M74X9YT5						Myelitis	7130		
"humanized affinity-optimized, afucosylated immunoglobulin G1 kappa monoclonal antibody against CD19"	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders	MEDI-551		n/a	2/10/16	Designated			N/A	N/A	"MedImmune, LLC"	Gaithersburg	Maryland	20878	USA	EXACT	0810173AA	MEDI-551	74T7185BMM						Myelitis	7130		
Recombinant human insulin-like growth factor-I	Treatment of post-poliomyelitis syndrome.	Mecasermin		n/a	10/13/95	Designated/Withdrawn			N/A	N/A	"Teva Branded Pharmaceutical Product R&D, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0167215AA	Mecasermin	7GR9I2683O						Myelitis	7130		
dalbavancin	Treatment of acute osteomyelitis in children (0 through 16 years of age)	dalbavancin		Dalvance	3/30/15	Designated			N/A	N/A	Durata Therapeutics International B.V.				Netherlands	EXACT	0237478AA	dalbavancin	808UI9MS5K						Myelitis	7130		
eculizumab	Treatment of neuromyelitis optica	eculizumab		Soliris	6/24/13	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	Cheshire	Connecticut	6410	USA	EXACT	0298000AA	eculizumab	A3ULP0F556						Myelitis	7130		
baclofen	"Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy)."	baclofen		Lioresal Intrathecal	11/10/87	Designated/Approved	Approved for Orphan Indication	Management of severe spasticity of spinal cord origin in patients who are unresponsive to oral baclofen therapy or experience intolerable CNS side effects at effective doses.	6/25/92	6/25/99	"Medtronic, Inc."	Minneapolis	Minnesota	55432	USA	EXACT	0032804AA	baclofen	H789N3FKE8						Myelitis	7130		
humanized anti-IL-6R receptor neutralizing IgG2 monoclonal antibody	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	Tocilizumab		n/a	6/30/14	Designated			N/A	N/A	"Chugai Pharma USA, LLC"	Berkeley Heights	New Jersey	7922	USA	EXACT	0298146AA	Tocilizumab	I031V2H011						Myelitis	7130		
Gentamicin impregnated PMMA beads on surgical wire	"Treatment of chronic osteomyelitis of post-traumatic, postoperative, or hematogenous origin."	Gentamicin impregnated PMMA beads on surgical wire		Septopal	1/31/91	Designated			N/A	N/A	"Lipha Pharmaceuticals, Inc."	New York	New York	10019	USA	EXACT	0036055AA	Gentamicin	T6Z9V48IKG						Myelitis	7130		
ublituximab	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	ublituximab		n/a	8/25/16	Designated			N/A	N/A	"TG Therapeutics, Inc."	New York	New York	10019	USA	EXACT	0574607AA	ublituximab	U59UGK3IPC						Myelitis	7130		
human glial restricted progenitor cells and their progeny	Treatment of transverse myelitis	human glial restricted progenitor cells and their progeny		Q-Cells®	4/11/18	Designated			N/A	N/A	"Q Therapeutics, Inc."	417 Wakara Way	Ste. 3510	84108	USA										Myelitis	7130		
RII retinamide	Treatment of myelodysplastic syndromes.	RII retinamide		n/a	5/6/93	Designated			N/A	N/A	"Sparta Pharmaceuticals, Inc."	Horsham	Pennsylvania	19044	USA	EXACT	0136061AA	RII retinamide	187EJ7QEXL						Myelodysplastic syndromes	7132		
rigosertib	Treatment of myelodysplastic syndromes	rigosertib		n/a	9/3/09	Designated			N/A	N/A	"Onconova Therapeutics, Inc."	Newtown	Pennsylvania	18940	USA	EXACT	0700016AA	rigosertib	67DOW7F9GL						Myelodysplastic syndromes	7132		
omacetaine mepesuccinate	Treatment of myelodysplastic syndromes	OMACETAXINE MEPESUCCINATE		n/a	1/12/09	Designated			N/A	N/A	IVAX International GmbH				Switzerland	EXACT	0313439AA	OMACETAXINE MEPESUCCINATE	6FG8041S5B						Myelodysplastic syndromes	7132		
decitabine	Treatment of myelodysplastic syndromes.	decitabine		Dacogen	3/8/99	Designated/Approved	Approved for Orphan Indication	"for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups"	5/2/06	5/2/13	Otsuka Pharmaceutical Development	Princeton	New Jersey	8540	USA	EXACT	0171244AA	decitabine	776B62CQ27						Myelodysplastic syndromes	7132		
Imatinib mesylate	Treatment of myeloproliferative disorders/myelodysplastic syndromes associated with platelet-derived growth factor gene re-arrangements	Imatinib mesylate		Gleevec	10/5/05	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements	10/19/06	10/19/13	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0227065AA	Imatinib mesylate	8A1O1M485B						Myelodysplastic syndromes	7132		
lenalidomide	Treatment of myelodysplastic syndromes	lenalidomide		Revlimid	1/29/04	Designated/Approved	Approved for Orphan Indication	Treatment of patients with transfusion dependant anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5 q cytogenetic abnormality with or without additional cytogenetic abnormalities	12/27/05	12/27/12	Celgene Corporation	Summit	New Jersey	7901	USA	EXACT	0236099AA	lenalidomide	F0P408N6V4						Myelodysplastic syndromes	7132		
Amifostine	Treatment of myelodysplastic syndromes.	Amifostine		Ethyol	10/4/99	Designated			N/A	N/A	Clinigen Group plc				United Kingdom	EXACT	0102409AA	Amifostine	M487QF2F4V						Myelodysplastic syndromes	7132		
azacitidine	Treatament of myelodysplastic syndromes	azacitidine		Vidaza	12/3/01	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia and requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia"	5/19/04	5/19/11	Celgene Corporation	Overland Park	Kansas	66210	USA	EXACT	0099478AA	azacitidine	M801H13NRU						Myelodysplastic syndromes	7132		
Heme arginate	Treatment of myelodysplastic syndromes.	Heme arginate		Normosang	3/1/94	Designated			N/A	N/A	Orphan Europe	92800 Puteaux			France	EXACT	0554778AA	Heme arginate	R1B526117P						Myelodysplastic syndromes	7132		
Idarubicin	Treatment of myelodysplastic syndromes.	Idarubicin		Idamycin	12/1/92	Designated/Withdrawn			N/A	N/A	Pharmacia & Upjohn	Kalamazoo	Michigan	49001	USA	EXACT	0270655AA	Idarubicin	ZRP63D75JW						Myelodysplastic syndromes	7132		
Nine amino acid polypeptide derived from proteinase 3	Treatment of myelodysplastic syndromes requiring therapy	PR-1		n/a	9/3/04	Designated			N/A	N/A	The Vaccine Company	Carmel	California	93921	USA	EXACT	1801894AA	PR-1	54XUF2TZ7G						Myelodysplastic syndromes	7132		
Fully human IgG1 antibody specific for CD33	Treatment of myelodysplastic syndromes (MDS)	BI-836858		n/a	2/27/17	Designated			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc."	Ridgefield	Connecticut	6877	USA	EXACT	0113084AB	BI-836858							Myelodysplastic syndromes	7132		
allogeneic ex vivo expanded unbilical cord blood cells	For use as hematopoietic support in patients with myelodysplastic syndromes	allogeneic ex vivo expanded unbilical cord blood cells		Stemex	2/1/10	Designated/Withdrawn			N/A	N/A	Gamida Cell - Teva Joint Venture				Israel	LONGEST CONTAINS	0854240AA	cord blood	PVH8394DLN						Myelodysplastic syndromes	7132		
Immune globulin intravenous (human)	Treatment of patients with acute myocarditis.	IVIG		"Immune Globulin Intravenous (Human) Immuno, Iveegam"	11/22/93	Designated/Withdrawn			N/A	N/A	Immuno Clinical Research Corp.	New York	New York	10022	USA	EXACT	0233705AA	Immune globulin intravenous (human)	66Y330CJHS						Myocarditis	7137		
Indium In 111 murine monoclonal antibody FAB to myosin	To aid in the diagnosis of myocarditis.	INDIUM IN-111 IMCIROMAB PENTETATE		Myoscint	8/7/89	Designated/Withdrawn			N/A	N/A	"Centocor, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	0260128AA	INDIUM IN-111 IMCIROMAB PENTETATE	77OCC8FTPV						Myocarditis	7137		
metformin	Treatment of progressive myoclonus epilepsy type 2 (Lafora disease)	metformin		n/a	12/14/17	Designated			N/A	N/A	"Consorcio Centro de Investigación Biomédica en Red, M.P. (CIBER)"	Monforte de Lemos	Madrid		Spain	EXACT	0030557AA	metformin	9100L32L2N						Myoclonus epilepsy	7142		
Gamma-hydroxybutyric acid	"Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations, and automatic behavior."	Gamma-hydroxybutyric acid		n/a	1/22/85	Designated/Withdrawn			N/A	N/A	Sigma Chemical Company					EXACT	0029663AA	Gamma-hydroxybutyric acid	30IW36W5B2						Narcolepsy	7162		
Gamma hydroxybutyrate	"Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations and automatic behavior."	Gamma hydroxybutyrate		n/a	12/3/87	Designated			N/A	N/A	"Biocraft Laboratories, Inc."	Fair Lawn	New Jersey	7410	USA	EXACT	0029663AA	Gamma hydroxybutyrate	30IW36W5B2						Narcolepsy	7162		
oxybate	Treatment of narcolepsy.	oxybate		Xyrem	11/7/94	Designated/Approved	Approved for Orphan Indication	Treatment of excessive daytime sleepiness in patients with narcolepsy	11/18/05	11/18/12	Jazz Pharmaceuticals	Palo Alto	California	94304	USA	EXACT	0029663AA	oxybate	30IW36W5B2						Narcolepsy	7162		
oxybate	Treatment of narcolepsy.	oxybate		Xyrem	11/7/94	Designated/Approved	Approved for Orphan Indication	Treatment of cataplexy associated with narcolepsy	7/17/02	7/17/09	Jazz Pharmaceuticals	Palo Alto	California	94304	USA	EXACT	0029663AA	oxybate	30IW36W5B2						Narcolepsy	7162		
BF2.649 (Pitolisant)	Treatment of narcolepsy	BF2.649 (Pitolisant)		n/a	5/17/10	Designated			N/A	N/A	Bioprojet Pharma	Paris			France	EXACT	0682724AA	Pitolisant	4BC83L4PIY						Narcolepsy	7162		
sodium oxybate extended-release oral suspension	Treatment of narcolepsy	sodium oxybate extended-release oral suspension		n/a	1/8/18	Designated			N/A	N/A	Flamel Ireland Limited	Block 10-1 Blanchardstown Corporate Park	Dublin		Ireland	EXACT	0026777AA	sodium oxybate	7G33012534						Narcolepsy	7162		
mazindol	Treatment of narcolepsy	mazindol		n/a	7/6/16	Designated			N/A	N/A	NLS-0 Pharma AG	Stans NW			Switzerland	EXACT	0060639AA	mazindol	C56709M5NH						Narcolepsy	7162		
optically pure phenylalanine derivative	Treatment of narcolepsy	JZP-110 HYDROCHLORIDE		n/a	8/20/12	Designated			N/A	N/A	Jazz Pharmaceuticals International III Limited	Palo Alto	California	94304	USA	EXACT	0218553AA	JZP-110 HYDROCHLORIDE	K7RO88SP7A						Narcolepsy	7162		
fixed dose combination of modafinil and flecainide	Treatment of narcolepsy	fixed dose combination of modafinil and flecainide		n/a	9/19/16	Designated			N/A	N/A	Theranexus S.A	Orsay			France	EXACT	0269249AA	flecainide	K94FTS1806						Narcolepsy	7162		
viloxazine HCL	Treatment of cataplexy and narcolepsy	viloxazine HCL		Catatrol	6/11/84	Designated/Withdrawn			N/A	N/A	Stuart Pharmaceuticals	Wilmington	Delaware	19897	USA	EXACT	0081710AA	viloxazine HCL	OQW30I1332						Narcolepsy	7162		
Modafinil	Treatment of excessive daytime sleepiness in narcolepsy.	Modafinil		Provigil	3/15/93	Designated/Approved	Approved for Orphan Indication	Improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy.	12/24/98	12/24/05	"Cephalon, Inc."	West Chester	Pennsylvania	19380	USA	EXACT	0183415AA	Modafinil	R3UK8X3U3D						Narcolepsy	7162		
fixed dose combination of modafinil and flecainide	Treatment of narcolepsy	fixed dose combination of modafinil 		n/a	9/19/16	Designated			N/A	N/A	Theranexus S.A	Orsay			France	EXACT	0183415AA	modafinil	R3UK8X3U3D						Narcolepsy	7162		
Pentetrazol	Treatment of narcolepsy	Pentetrazol		n/a	3/16/17	Designated			N/A	N/A	"Balance Therapeutics, Inc."	San Bruno	California	94066	USA	EXACT	0008797AA	Pentetrazol	WM5Z385K7T						Narcolepsy	7162		
"methyl (2R,3S)-3-[(methylsulfonyl)amino]-2-{[(cis-4-phenylcyclohexyl)oxy]methyl}piperidine-1-carboxylate"	Treatment of narcolepsy	TAK-925		n/a	12/19/17	Designated			N/A	N/A	"Takeda Development Center Americas, Inc."	Takeda Parkway	Deerfield	60015	USA	EXACT	0114122AB	TAK-925	1QMD83K4YN						Narcolepsy	7162		
reboxetine	Treatment of narcolepsy	reboxetine		Edronax; Davedax; Irenor; Narebox; Norebox; Prolift; Solvex; Vestra	10/15/18	Designated			N/A	N/A	"Axsome Therapeutics, Inc."	"25 Broadway, 9th Floor"	New York	10004	USA	EXACT	0285938AA	reboxetine	947S0YZ36I						Narcolepsy	7162		
pembrolizumab	Treatment of nasopharyngeal carcinoma	pembrolizumab		Keytruda	10/11/16	Designated			N/A	N/A	"Merck, Sharp & Dohme Corp., a subsidiary of Merck & Co."		New Jersey	8889	USA	EXACT	0809245AA	pembrolizumab	DPT0O3T46P						Nasopharyngeal carcinoma	7163		
(s)-perillyl alcohol temozolomide carbamate	Treatment of nasopharyngeal carcinoma	(s)-perillyl alcohol temozolomide carbamate		n/a	7/27/17	Designated			N/A	N/A	"NeOnc Technologies, Inc."	Los Angeles	California	90069	USA	EXACT	1802206AA	(s)-perillyl alcohol temozolomide carbamate	237TB781D9						Nasopharyngeal carcinoma	7163		
Epstein-Barr virus-specific autologous cytotoxic T lymphocytes	Treatment of Epstein-Barr virus positive head and neck cancers (which includes nasopharyngeal carcinoma)	Epstein-Barr virus-specific autologous cytotoxic T lymphocytes		n/a	6/12/14	Designated			N/A	N/A	FFCanVac Pte Ltd				Singapore	LONGEST CONTAINS	0263092AA	lymphocytes							Nasopharyngeal carcinoma	7163		
patidegib	Treatment of nevoid basal cell carcinoma syndrome (Gorlin syndrome)	patidegib		n/a	7/19/17	Designated			N/A	N/A	"PellePharm, Inc."	Menlo Park	California	94025	USA	EXACT	0566449AA	patidegib	JT96FPU35X						Nevoid basal cell carcinoma syndrome	7166		
N-Methanocarbathymidine	Treatment of neonatal herpes	N-Methanocarbathymidine		n/a	10/15/14	Designated			N/A	N/A	"N & N Pharmaceuticals, Inc."	Rockville	Maryland	20850	USA	EXACT	1218571AA	N-Methanocarbathymidine	LTM5S02010						Neonatal herpes	7173		
urea	"Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis)."	urea		n/a	11/7/11	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0009290AA	urea	8W8T17847W						Netherton syndrome	7182		
"6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-bensoxazin-4-one"	Treatment of Netherton syndrome	"6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-bensoxazin-4-one"		n/a	6/18/15	Designated			N/A	N/A	Sixera Pharma AB				Sweden	EXACT	1576950AA	"6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-bensoxazin-4-one"	BDQ30W2KTS						Netherton syndrome	7182		
recombinant kallikrein inhibitor	Treatment of Netherton Syndrome.	recombinant kallikrein inhibitor		n/a	11/23/10	Designated			N/A	N/A	Dermadis SA				France	LONGEST CONTAINS	0004808AA	kallikrein							Netherton syndrome	7182		
Fenretinide	Treatment of neuroblastoma	Fenretinide		n/a	10/5/05	Designated			N/A	N/A	USC-CHLA Institute for Pediatric Clinical Research	Los Angeles	California	90027	USA	EXACT	0136061AA	Fenretinide	187EJ7QEXL						Neuroblastoma	7185		
Iobenguane Sulfate I-123	"For scintigraphic detection, localization and staging of neuroblastoma."	Iobenguane Sulfate I-123		Omaclear	10/17/05	Designated			N/A	N/A	"Brogan Pharmaceuticals, LLC"	Schererville	Indiana	46375	USA	EXACT	0094202AA	Iobenguane Sulfate I-123	23X1185WBO						Neuroblastoma	7185		
perifosine	Treatment of neuroblastoma	perifosine		n/a	7/9/10	Designated			N/A	N/A	Aeterna Zentaris GmbH				Germany	EXACT	0232406AA	perifosine	2GWV496552						Neuroblastoma	7185		
monoclonal antibody 3F8	Treatment of neuroblastoma	monoclonal antibody 3F8		n/a	10/16/08	Designated			N/A	N/A	United Therapeutics Corporation	Research Triangle Park	North Carolina	27709	USA	EXACT	0263014AA	monoclonal antibody 3F8	3GFS72WN4M						Neuroblastoma	7185		
crizotinib	Treatment of neuroblastoma	crizotinib		Xalkori	10/31/12	Designated			N/A	N/A	"Pfizer, Inc."	San Diego	California	92121	USA	EXACT	0274862AA	crizotinib	53AH36668S						Neuroblastoma	7185		
dinutuximab	Treatment of neuroblastoma	dinutuximab		Unituxin	12/20/10	Designated/Approved	Approved for Orphan Indication	"For use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy"	3/10/15	3/10/22	United Therapeutics Corporation	Research Triangle Park	North Carolina	27709	USA	EXACT	0872457AA	dinutuximab	7SQY4ZUD30						Neuroblastoma	7185		
mouse-human chimeric monoclonal anti-GD2 IgG1 antibody	Treatment of neuroblastoma.	DINUTUXIMAB		n/a	9/20/12	Designated			N/A	N/A	APEIRON Biologics AG				Austria	EXACT	0872457AA	DINUTUXIMAB	7SQY4ZUD30						Neuroblastoma	7185		
taurolidine	Treatment of neuroblastoma	taurolidine		n/a	2/22/18	Designated			N/A	N/A	"CorMedix, Inc."	1430 U.S. 206	Bedminster Township		USA	EXACT	0177968AA	taurolidine	8OBZ1M4V3V						Neuroblastoma	7185		
Humanized 3F8-IgG1 monoclonal antibody	Treatment of neuroblastoma	Humanized 3F8-IgG1 monoclonal antibody		n/a	6/24/13	Designated			N/A	N/A	Memorial Sloan-Kettering Cancer Center	New York	New York	10065	USA	EXACT	0863138AA	Humanized 3F8	9K8GNJ2874						Neuroblastoma	7185		
abeotaxane inhibitor of microtubules	Treatment of pediatric neuroblastoma.	TPI-287		n/a	4/18/11	Designated			N/A	N/A	Cortice Biosciences	New York	New York	10019	USA	EXACT	0271249AA	TPI-287	A2VM2V569A						Neuroblastoma	7185		
131-I-8H9 monoclonal antibody	Treatment of neuroblastoma	131-I-8H9 monoclonal antibody		n/a	8/29/16	Designated			N/A	N/A	Memorial Sloan Kettering Cancer Center	New York	New York	10065	USA	EXACT	0113888AB	131-I-8H9 monoclonal antibody	B6PMV8U3C4						Neuroblastoma	7185		
"entrectinib;N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide"	Treatment of neuroblastoma	entrectinib		n/a	12/22/14	Designated			N/A	N/A	"Ignyta, Inc."	San Diego	California	92121	USA	EXACT	0933608AA	entrectinib	L5ORF0AN1I						Neuroblastoma	7185		
Buthionine sulfoxamine	For use in children as a modulator of chemotherapy for the treatment of pediatric patients with neuroblastoma	BUTHIONINE SULFOXIMINE		n/a	10/5/05	Designated			N/A	N/A	USC-CHLA Institute for Pediatric Clinical Research	Los Angeles	California	90027	USA	EXACT	0791208AA	BUTHIONINE SULFOXIMINE	LW4108Q0BV						Neuroblastoma	7185		
"3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5 f]indol-7-yl)-pyrrole-2,5-dione"	Treatment of Neuroblastoma	9-ING-41		n/a	8/18/17	Designated			N/A	N/A	Actuate Therapeutics	Fort Worth	Texas	76107	USA	EXACT	1576369AA	9-ING-41	ND1SOF0DLU						Neuroblastoma	7185		
Iobenguane I 123	For the diagnosis of neuroblastomas	Iobenguane I 123		Adreview	12/1/06	Designated/Approved	Approved for Orphan Indication	To be used in the detection of primary or metastatic pheochromocytomas or neuroblastomas as an adjunct to other diagnostic tests	9/19/08	9/19/15	"GE Healthcare, Inc."	Princeton	New Jersey	8540	USA	EXACT	0234708AA	Iobenguane I 123	P2TH1XYZ84						Neuroblastoma	7185		
18-(p-[131]-iodophenyl)octadecyl phosphocholine	Treatment of neuroblastoma	NM-404 I-131		n/a	3/15/18	Designated			N/A	N/A	"Cellectar Biosciences, Inc."	3301 Agriculture Drive		53716	USA	EXACT	1079705AA	NM-404 I-131	R048696O9L						Neuroblastoma	7185		
firtecan pegol	Treatment of neuroblastoma.	firtecan pegol		n/a	4/18/11	Designated			N/A	N/A	"Enzon Pharmaceuticals, Inc."	Piscataway	New Jersey	8854	USA	EXACT	0646366AA	firtecan pegol	WC4978T687						Neuroblastoma	7185		
N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide	Treatment of neuroblastoma	N-(2-((4-hydroxyphenyl)amino)-3-pyridinyl)-4-methoxybenzenesulfonamide		n/a	9/30/04	Designated/Withdrawn			N/A	N/A	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0240313AA	N-(2-((4-hydroxyphenyl)amino)-3-pyridinyl)-4-methoxybenzenesulfonamide	WDT5V5OB9F						Neuroblastoma	7185		
sodium 2-hydroxylinoleate	Treatment of neuroblastoma.	sodium 2-hydroxylinoleate		n/a	8/25/15	Designated			N/A	N/A	"Ability Pharmaceuticals, SL"	Bellaterra			Spain	EXACT	1718190AA	sodium 2-hydroxylinoleate	X1840C8161						Neuroblastoma	7185		
eflornithine	Treatment of neuroblastoma	eflornithine		n/a	11/23/10	Designated			N/A	N/A	"Cancer Prevention Pharmaceutical, Inc."	Tucson	Arizona	85718	USA	EXACT	0311422AA	eflornithine	ZQN1G5V6SR						Neuroblastoma	7185		
eflornithine	Treatment of neuroblastoma	eflornithine		n/a	11/22/17	Designated			N/A	N/A	"KC Pharma, LLC"	Towers Office Building	Florida	33408	USA	EXACT	0311422AA	eflornithine	ZQN1G5V6SR						Neuroblastoma	7185		
theranost 68Ga-RGD	Diagnostic for clinical management of patients with neuroblastoma	theranost 68Ga-RGD		n/a	12/8/14	Designated			N/A	N/A	"Advanced Imaging Projects, LLC"	Boca Raton	Florida	33431	USA	EXACT	1577533AA	theranost 68Ga RGD	5EKN6H63OA						Neuroblastoma	7185		
anisina	Treatment of neuroblastoma.	anisina		n/a	7/14/15	Designated			N/A	N/A	Novogen Ltd				Australia	EXACT	1803505AA	anisina							Neuroblastoma	7185		
dendritic hybrid cell vaccine	Treatment of neuroblastoma	dendritic hybrid cell vaccine		Neuroblaxin	9/23/11	Designated			N/A	N/A	"Orbis Health Solutions, LLC"	Greenville	South Carolina	29607	USA										Neuroblastoma	7185		
"MV-NB-02, its bivalent ganglioside vaccine consisting of GD2-lactone and GD3-lactone each covalently conjugated to keyhole hemocyanin"	Treatment of Neuroblastoma	"MV-NB-02, its bivalent ganglioside vaccine consisting of GD2-lactone and GD3-lactone each covalently conjugated to keyhole hemocyanin"		n/a	9/23/14	Designated			N/A	N/A	"MabVax Therapeutics, Inc."	San Diego	California	92121	USA										Neuroblastoma	7185		
16 base single stranded PNA oligonucleotide–7 aminoacids peptide	Treatment of neuroblastoma	16 base single stranded PNA oligonucleotide–7 aminoacids peptide		n/a	10/25/17	Designated			N/A	N/A	BIOGENERA SpA	46 Via Marconi		Porretta Terme (BO)											Neuroblastoma	7185		
"[4-(4-{1-[2-(2-{2-[2-(2-{2-[2-(4-guanidinomethyl-phenoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethyl]-1H-[1,2,3]triazol-4-ylmethoxy}-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]-acetic acid"	Treatment of neuroblastoma	"[4-(4-{1-[2-(2-{2-[2-(2-{2-[2-(4-guanidinomethyl-phenoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethyl]-1H-[1,2,3]triazol-4-ylmethoxy}-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]-acetic acid"		n/a	10/17/18	Designated			N/A	N/A	"NanoPharmaceuticals, LLC"	1 Discovery Place	New York	12144	USA	EXACT	0117194AB	"(4-(4-(1-(2-(2-(2-(2-(2-(2-(2-(4-GUANIDINOMETHYL-PHENOXY)-ETHOXY)-ETHOXY)-ETHOXY)-ETHOXY)-ETHOXY)-ETHOXY)-ETHYL)-1H-(1,2,3)TRIAZOL-4-YLMETHOXY)-3,5-DIIODO-PHENOXY)-3,5-DIIODO-PHENYL)-ACETIC ACID"							Neuroblastoma	7185		
bortezomib	Treatment of neurofibromatosis type 2 (NF2)	bortezomib		n/a	7/5/16	Designated			N/A	N/A	BioXcel Corporation	Branford	Connecticut	6405	USA	EXACT	0228319AA	bortezomib	69G8BD63PP						Neurofibroma	7191		
selumetinib	Treatment of Neurofibromatosis Type 1	selumetinib		n/a	2/14/18	Designated			N/A	N/A	AstraZeneca Pharmaceuticals LP	1800 Concord Pike	Wilmington		USA	EXACT	0297176AA	selumetinib	6UH91I579U						Neurofibroma	7191		
"N-[(2R)-2,3 dihydroxypropoxyl]-3,4 difluro-2 -[(2-fluoro-4-iodophenyl)amino] benzamide"	Treatment of Neurofibromatosis type I	PD-0325901		n/a	10/30/18	Designated			N/A	N/A	"SpringWorks Subsidiary 3, PBC (Spring Works)"	"575 5th Avenue, 16th Floor"	New York	10017	USA	EXACT	0743146AA	PD-0325901	86K0J5AK6M						Neurofibroma	7191		
bortezomib	Treatment of neurofibromatosis type 2 (NF2)	bortezomib		n/a	7/5/16	Designated			N/A	N/A	BioXcel Corporation	Branford	Connecticut	6405	USA	EXACT	0228319AA	bortezomib	69G8BD63PP						Neurofibromatosis type 2	7193		
Dantrolene sodium	Treatment of the neuroleptic malignant syndrome.	Dantrolene sodium		Dantrium	12/14/87	Designated/Withdrawn			N/A	N/A	Norwich Eaton Pharmaceuticals	Norwich	New York	13815	USA	EXACT	0056122AA	Dantrolene sodium	287M0347EV						Neuroleptic malignant syndrome	7195		
moxidectin	Treatment of onchocerciasis volvulus in children and adults.	moxidectin		n/a	9/29/10	Designated			N/A	N/A	Medicines Development Limited	Melbourne			Australia	EXACT	0307993AA	moxidectin	NGU5H31YO9						Onchocerciasis	7252		
flubendazole	Treatment of onchocerciasis caused by Onchocerca volvulus	flubendazole		n/a	10/25/13	Designated			N/A	N/A	"Janssen Research & Development, LLC"	Raritan	New Jersey	8869	USA	EXACT	0083896AA	flubendazole	R8M46911LR						Onchocerciasis	7252		
4”-(p-fluorobenzyl)tylosin A	Treatment of onchocerciasis	4''-(P-FLUOROBENZYL)TYLOSIN A		n/a	6/8/17	Designated			N/A	N/A	AbbVie Inc.	North Chicago	Illinois	60044	USA	EXACT	0111826AB	4''-(P-FLUOROBENZYL)TYLOSIN A	HXL1F57P8O						Onchocerciasis	7252		
palovarotene	Treatment of multiple osteochondromas	palovarotene		n/a	11/6/17	Designated			N/A	N/A	"Clementia Pharmaceuticals, Inc."	4150 Rue Sainte-Catherine West	Quebec		Canada	EXACT	0322634AA	palovarotene	28K6I5M16G						Osteochondroma	7281		
mifamuritide	Treatment of osteosarcoma	Mifamurtide		Junovan	6/5/01	Designated			N/A	N/A	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0178267AA	Mifamurtide	1LM890Q4FY						Osteosarcoma	7284		
Levoleucovorin	For use in conjunction with high-dose methotrexate in the treatment of osteosarcoma.	Levoleucovorin		Fusilev	8/1/91	Designated/Approved	Approved for Orphan Indication	Levoleucovorin rescue is indicated after high-dose methotrexate therapy in osteosarcoma. Levoleucovorin is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists	3/7/08	3/7/15	"Spectrum Pharmaceuticals, Inc."	Irvine	California	92618	USA	EXACT	0275490AA	Levoleucovorin	990S25980Y						Osteosarcoma	7284		
monoclonal antibody Hu3F8	Treatment of osteosarcoma	monoclonal antibody Hu3F8		n/a	1/10/14	Designated			N/A	N/A	Memorial Sloan-Kettering Cancer Center	New York	New York	10065	USA	exact	0863138AA	Hu3F8	9K8GNJ2874						Osteosarcoma	7284		
5(S)-(2'-hydroxy ethoxy)-20(S)-Camptothecin	Treatment of osteosarcoma (bone cancer)	5(S)-(2'-hydroxy ethoxy)-20(S)-Camptothecin		n/a	6/15/07	Designated			N/A	N/A	"Dr. Reddy's Laboratories, Inc."	Bridgewater	New Jersey	8807	USA	EXACT	0711239AA	5(S)-(2'-hydroxy ethoxy)-20(S)-Camptothecin	JY0ZTV10W1						Osteosarcoma	7284		
Cisplatin in liposomal formulation	Treatment of osteosarcoma	Cisplatin in liposomal formulation		Slit Cisplatin For Inhalation	3/20/07	Designated			N/A	N/A	Eleison Pharmaceuticals LLC	St. Petersburg	Florida	33701	USA	EXACT	0056633AA	Cisplatin	Q20Q21Q62J						Osteosarcoma	7284		
Leucovorin	For rescue use after high dose methotrexate therapy in the treatment of osteosarcoma.	Leucovorin		Leucovorin Calcium	8/17/88	Designated/Approved	Approved for Orphan Indication		8/31/88	8/31/95	Immunex Corporation	Seattle	Washington	98101	USA	EXACT	0009665AA	Leucovorin	Q573I9DVLP						Osteosarcoma	7284		
Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala -gylcerolidpalmitoyl	Treatment of osteosarcoma.	DIPALMITOYL N-ACETYL-B-D-GLUCOSAMINYL-(1-4)-N-ACETYLMURAMYL-ALANYL-D-ISOGLUTAMINYL-ALANYL-GLYCEROL		Immther	6/10/98	Designated			N/A	N/A	Endorex Corp.	Lake Bluff	Illinois	60044	USA	EXACT	0237070AA	DIPALMITOYL N-ACETYL-B-D-GLUCOSAMINYL-(1-4)-N-ACETYLMURAMYL-ALANYL-D-ISOGLUTAMINYL-ALANYL-GLYCEROL	6PHSP9EORV						Osteosarcoma	7284		
Anti-STAT3 B VHH13 single domain antibody	Treatment of osteosarcoma	SBT-100		n/a	9/27/17	Designated			N/A	N/A	"Singh Biotechnology, LLC"	Lutz	Florida	33558	USA	EXACT									Osteosarcoma	7284		
Mx-dnG1	Treatment of osteosarcoma.	Mx-dnG1		Rexin-G	6/24/08	Designated			N/A	N/A	Epeius Biotechnologies Corporation	San Marino	California	91108	USA										Osteosarcoma	7284		
live attenuated bioengineered Listeria monocytogenes immunotherapy	Treatment of osteosarcoma.	live attenuated bioengineered Listeria monocytogenes immunotherapy		n/a	5/21/14	Designated			N/A	N/A	"Advaxis, Inc."	Princeton	New Jersey	8540	USA	LONGEST CONTAINS	0623063AA	Listeria monocytogenes	3O44K14A86						Osteosarcoma	7284		
18-(p-[131I]-iodophenyl)octadecyl phosphocholine	Treatment of osteosarcoma	NM-404 I-131		n/a	9/24/18	Designated			N/A	N/A	"Cellectar Biosciences, Inc."	3301 Agriculture Drive	Wisconsin	53716	USA	EXACT	1079705AA	NM-404 I-131	R048696O9L						Osteosarcoma	7284		
Methotrexate sodium	Treatment of osteogenic sarcoma.	Methotrexate sodium		Methotrexate	10/21/85	Designated/Approved	Approved for Orphan Indication	For the use of high dose methotrexate with leucovorin rescue in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor.	4/7/88	4/7/95	Lederle Laboratories	Pearl River	New York	10965	USA	EXACT	0047881AA	Methotrexate sodium	3IG1E710ZN						Osteogenic sarcoma	7284		
SDF-1 (108) Lysine Dlmer	Treatment of osteogenic sarcoma	CTCE-9908		n/a	7/7/05	Designated			N/A	N/A	Chemokine Therapeutics Corporation	"Vancouver, BC V6T 1Z3"			Canada	EXACT	0646753AA	CTCE-9908	NF0BX95A31						Osteogenic sarcoma	7284		
Trimetrexate	Treatment of metastatic osteogenic sarcoma.	Trimetrexate		Neutrexin	8/10/00	Designated/Withdrawn			N/A	N/A	"Medimmune Oncology, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0182218AA	Trimetrexate	UPN4ITI8T4						Osteogenic sarcoma	7284		
burosumab	Treatment of tumor-induced osteomalacia (TIO) syndrome	burosumab		n/a	6/15/17	Designated			N/A	N/A	Ultragenyx Pharmaceutical Inc.	Novato	California	94949	USA	EXACT	1257621AA	burosumab	G9WJT6RD29						Osteomalacia	7285		
dalbavancin	Treatment of acute osteomyelitis in children (0 through 16 years of age)	dalbavancin		Dalvance	3/30/15	Designated			N/A	N/A	Durata Therapeutics International B.V.				Netherlands	EXACT	0237478AA	dalbavancin	808UI9MS5K						Osteomyelitis	7286		
Gentamicin impregnated PMMA beads on surgical wire	"Treatment of chronic osteomyelitis of post-traumatic, postoperative, or hematogenous origin."	Gentamicin impregnated PMMA beads on surgical wire		Septopal	1/31/91	Designated			N/A	N/A	"Lipha Pharmaceuticals, Inc."	New York	New York	10019	USA	EXACT	0036055AA	Gentamicin	T6Z9V48IKG						Osteomyelitis	7286		
veliparib	Treatment of epithelial ovarian cancer in combination with DNA-damaging agents	veliparib		n/a	9/3/09	Designated			N/A	N/A	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0338192AA	veliparib	01O4K0631N						Ovarian cancer	7295		
Oxaliplatin	Treatment of ovarian cancer.	Oxaliplatin		n/a	10/6/92	Designated			N/A	N/A	Debio Pharm S.A.				Switzerland	EXACT	0182525AA	Oxaliplatin	04ZR38536J						Ovarian cancer	7295		
Combretastatin A4 phosphate	Treatment of ovarian cancer	Combretastatin A4 phosphate		n/a	5/8/06	Designated			N/A	N/A	"Mateon Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	0424179AA	Combretastatin A4	16U6OP69RQ						Ovarian cancer	7295		
binimetinib	Treatment of ovarian cancer	binimetinib		n/a	7/31/14	Designated			N/A	N/A	"Array Biopharma, Inc."	Boulder	Colorado	80301	USA	EXACT	0273018AA	binimetinib	181R97MR71						Ovarian cancer	7295		
"sodium 4-{ [9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-d] [2] benzazepin-2-yl]-2-methoxybenzoate"	Treatment of ovarian cancer	ALISERTIB SODIUM ANHYDROUS		n/a	4/3/09	Designated/Withdrawn			N/A	N/A	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0702487AA	ALISERTIB SODIUM ANHYDROUS	23KN826MQ4						Ovarian cancer	7295		
mibefradil	Treatment of ovarian cancer	mibefradil		n/a	6/15/07	Designated			N/A	N/A	"Cavion, LLC"	Charlottesville	Virginia	22902	USA	EXACT	0339753AA	mibefradil	27B90X776A						Ovarian cancer	7295		
small molecule normalizing the p53 function	Treatment of ovarian cancer	coti-2		n/a	6/12/14	Designated			N/A	N/A	"Critical Outcome Technologies, Inc."	London			Canada	EXACT	1142194AA	coti-2	2BTA1O65BR						Ovarian cancer	7295		
lurbinectedin	Treatment of ovarian cancer	lurbinectedin		n/a	8/20/12	Designated			N/A	N/A	"PharmaMar USA, Inc."	New York	New York	10017	USA	EXACT	0700583AA	lurbinectedin	2CN60TN6ZS						Ovarian cancer	7295		
farletuzumab	Treatment of ovarian cancer	farletuzumab		n/a	6/16/06	Designated			N/A	N/A	"Morphotek, Inc."	Exton	Pennsylvania	19341	USA	EXACT	0267561AA	farletuzumab	2O09BG0OWA						Ovarian cancer	7295		
bevacizumab	Therapeutic treatment of patients with ovarian cancer	bevacizumab		Avastin	2/9/06	Designated/Approved	Approved for Orphan Indication	"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens"	11/14/14	11/14/21	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0244257AA	bevacizumab	2S9ZZM9Q9V						Ovarian cancer	7295		
mifepristone	Treatment of ovarian cancer.	mifepristone		Korlym	1/14/16	Designated			N/A	N/A	"Corcept Therapeutics, Inc."	Menlo Park	California	94025	USA	EXACT	0129613AA	mifepristone	320T6RNW1F						Ovarian cancer	7295		
vintafolide	Treatment of ovarian cancer	vintafolide		n/a	12/16/13	Designated			N/A	N/A	"Endocyte, Inc."	West Lafayette	Indiana	47906	USA	EXACT	0275887AA	vintafolide	36O410ZD4I						Ovarian cancer	7295		
abagovomab	Treatment of epithelial ovarian cancer	abagovomab		n/a	11/25/03	Designated/Withdrawn			N/A	N/A	Menarini Ricerche S.p.A.				Italy	EXACT	0459176AA	abagovomab	3YK0326U7X						Ovarian cancer	7295		
"8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naph-thyrin-3(2H)-one mono-hydrochloride"	Treatment of ovarian cancer.	MK-2206		n/a	9/3/09	Designated			N/A	N/A	Merck Sharp & Dohme Corp.	North Wales	Pennsylvania	19454	USA	EXACT	0540136AA	MK-2206	4HA45S22ZZ						Ovarian cancer	7295		
AEZS-108 (LHRH-agonist linked to doxorubicin)	Treatment of ovarian cancer	AEZS-108		n/a	4/30/10	Designated			N/A	N/A	Aeterna Zentaris	Basking Ridge	New Jersey	7920	USA	EXACT	1798409AA	AEZS-108	4IA03SIO30						Ovarian cancer	7295		
"1,2:5,6-dianhydrogalactitol"	Treatment of ovarian cancer.	"1,2:5,6-dianhydrogalactitol"		n/a	4/19/16	Designated			N/A	N/A	"DelMar Pharmaceuticals, Inc. (Clinical Operations)"	Menlo Park	California	94025	USA	EXACT	0061712AA	"1,2:5,6-dianhydrogalactitol"	4S465RYF7M						Ovarian cancer	7295		
20-mer oligonucleotide complementary to Akt mRNA	Treatment of ovarian cancer	ARCHEXIN		n/a	12/1/04	Designated			N/A	N/A	Rexahn Corporation	Rockville	Maryland	20850	USA	EXACT	0252631AA	ARCHEXIN	4TEW51C830						Ovarian cancer	7295		
squalamine lactate	Treatment of ovarian cancer refractory or resistant to standard chemotherapy	squalamine lactate		n/a	5/11/01	Designated			N/A	N/A	Genaera Corporation	Plymouth Meeting	Pennsylvania	19462	USA	EXACT	0222515AA	squalamine lactate	4WE915J1KX						Ovarian cancer	7295		
defactinib	Treatment of ovarian cancer	defactinib		n/a	2/12/15	Designated			N/A	N/A	"Verastem, Inc."	Needham	Massachusetts	2494	USA	EXACT	0705351AA	defactinib	53O87HA2QU						Ovarian cancer	7295		
cantrixil	Treatment of ovarian cancer	cantrixil		n/a	4/20/15	Designated			N/A	N/A	"CanTx, Inc."	New Haven	Connecticut	6511	USA	EXACT	1567039AA	cantrixil	5DVS457HEG						Ovarian cancer	7295		
pentamidine	Treatment of ovarian cancer	pentamidine		n/a	8/12/13	Designated/Withdrawn			N/A	N/A	"Oncozyme Pharma, Inc."				Canada	EXACT	0016637AA	pentamidine	673LC5J4LQ						Ovarian cancer	7295		
rigosertib	Treatment of ovarian cancer	rigosertib		n/a	3/16/12	Designated			N/A	N/A	"Onconova Therapeutics, Inc."	Newton	Pennsylvania	18940	USA	EXACT	0700016AA	rigosertib	67DOW7F9GL						Ovarian cancer	7295		
irofulven	Treatment of ovarian cancer.	irofulven		n/a	7/6/99	Designated/Withdrawn			N/A	N/A	"Eisai, Inc."	Woodcliff Lake	New Jersey	7677	USA	EXACT	0209234AA	irofulven	6B799IH05A						Ovarian cancer	7295		
2-methoxyestradiol	Treatment of ovarian cancer	2-methoxyestradiol		Panzem Ncd	4/4/05	Designated/Withdrawn			N/A	N/A	"EntreMed, Inc."	Durham	North Carolina	27703	USA	EXACT	0235176AA	2-methoxyestradiol	6I2QW73SR5						Ovarian cancer	7295		
ilorasertib	Treatment of ovarian cancer	ilorasertib		n/a	3/16/12	Designated/Withdrawn			N/A	N/A	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0700776AA	ilorasertib	6L5D03D975						Ovarian cancer	7295		
Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)	Treatment of ovarian cancer	CNTO-888		n/a	4/30/10	Designated			N/A	N/A	Ortho Biotech	Malvern	Pennsylvania	19355	USA	EXACT	0583222AA	CNTO-888	6TC1BB2EV9						Ovarian cancer	7295		
human soluble receptor-Fc fusion protein that targets human activin A	Treatment of ovarian cancer.	STM 434		n/a	10/14/15	Designated			N/A	N/A	Atara Biotherapeutics	Westlake Village	California	91361	USA	EXACT	1058942AA	STM 434	7G4D2B5AC8						Ovarian cancer	7295		
Antibody drug conjugate consisting of a humanized IgG1 anti-NaPi2b monoclonal antibody and monomethyl auristatin E	Treatment of ovarian cancer	Lifastuzumab Vedotin 		n/a	7/29/14	Designated/Withdrawn			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0925417AA	Lifastuzumab Vedotin	7IUT83FK6S						Ovarian cancer	7295		
pazopanib	Treatment of ovarian cancer.	pazopanib		n/a	5/6/13	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0307299AA	pazopanib	7RN5DR86CK						Ovarian cancer	7295		
Doxorubicin liposome	Treatment of ovarian cancer.	Doxorubicin liposome		Doxil	11/4/98	Designated/Approved	Approved for Orphan Indication	"Treatment of metastatic carcinoma of the ovary in patients with disease that is refractory to both paclitaxel- and platinium-based chemotherapy regimens. Refractory disease is defined as disease that has progressed while on treatment, or within 6 months of completing treatment."	6/28/99	6/28/06	Alza Corporation	Mountain View	California	94039	USA	EXACT	0061074AA	Doxorubicin	80168379AG						Ovarian cancer	7295		
rucaparib	Treatment of ovarian cancer	rucaparib		n/a	7/31/12	Designated			N/A	N/A	"Clovis Oncology, Inc."	Boulder	Colorado	80301	USA	EXACT	0647756AA	rucaparib	8237F3U7EH						Ovarian cancer	7295		
imexon	Treatment of ovarian cancer.	imexon		Amplimexon	8/12/05	Designated			N/A	N/A	AmpliMed Corporation	Tucson	Arizona	85718	USA	EXACT	0297121AA	imexon	8F63U28T2V						Ovarian cancer	7295		
maytansinoid conjugated humanized monoclonal antibody against FOLRI	Treatment of ovarian cancer	Mirvetuximab soravtansine		n/a	7/14/14	Designated			N/A	N/A	"ImmunoGen, Inc."	Waltham	Massachusetts	2451	USA	EXACT	1120894AA	Mirvetuximab soravtansine	98DE7VN88D						Ovarian cancer	7295		
anlotinib hydrochloride	Treatment of ovarian cancer	ANLOTINIB DIHYDROCHLORIDE		n/a	12/31/15	Designated			N/A	N/A	"Advenchen Laboratories, LLC"	Moorpark	California	93021	USA	EXACT	1338983AA	ANLOTINIB HYDROCHLORIDE	A3749M6582						Ovarian cancer	7295		
Protaxel	Treatment of ovarian cancer	Protaxel		n/a	5/21/03	Designated			N/A	N/A	"Biophysica, Inc."	La Jolla	California	92037	USA	EXACT	0457432AA	Protaxel	B3C86E80A0						Ovarian cancer	7295		
gemcitabine ready-to-use	Treatment of ovarian cancer	gemcitabine ready-to-use		n/a	6/24/15	Designated			N/A	N/A	Sun Pharmaceutical Industries Ltd.				India	EXACT	0282086AA	gemcitabine	B76N6SBZ8R						Ovarian cancer	7295		
aldoxorubicin	Treatment of ovarian cancer	aldoxorubicin		n/a	9/24/14	Designated			N/A	N/A	CytRx Corporation	Los Angeles	California	90049	USA	EXACT	0738294AA	aldoxorubicin	C28MV4IM0B						Ovarian cancer	7295		
thioureidobutyronitrile	Treatment of ovarian cancer	thioureidobutyronitrile		Kevetrin	7/14/15	Designated			N/A	N/A	Cellceutix Corporation	Beverly	Massachusetts	1915	USA	EXACT	0832633AA	thioureidobutyronitrile	C3059TG1KN						Ovarian cancer	7295		
Synthesized peptide of the L-amino acids with the sequence H-Lys-Glu-Phe-Leu-His-Pro-Ser-Lys-Val-Asp-Leu-Pro-Arg-OH	Treatment of ovarian cancer.	SOR-C13 		n/a	2/4/16	Designated			N/A	N/A	Soricimed Biopharma Inc.	Moncton	New Brunswick		Canada	EXACT	1311984AA	SOR-C13	C79B5A73C4						Ovarian cancer	7295		
Treosulfan	Treatment of ovarian cancer.	Treosulfan		Ovastat	5/16/94	Designated			N/A	N/A	Medac GmbH				Germany	EXACT	0069998AA	Treosulfan	CO61ER3EPI						Ovarian cancer	7295		
digitoxin	Treatment of ovarian cancer	digitoxin		n/a	11/2/01	Designated			N/A	N/A	SimRx Advisors LLC	New York	New York	10024	USA	EXACT	0012351AA	digitoxin	E90NZP2L9U						Ovarian cancer	7295		
OTL38; conjugate of pteroi acid and S0456 near infrared dye	Detecting folic receptor alpha positive lesions in ovarian cancer patients (diagnostic for the management of ovarian cancer)	OTL-38		n/a	12/23/14	Designated			N/A	N/A	"On Target Laboratories, LLC"	West Lafayette	Indiana	47906	USA	EXACT	1100772AA	OTL-38	F7BD3Z4X8L						Ovarian cancer	7295		
N-[4-(trifluoromethyl)phenyl]-5-methylisoxazole-4-carboxamide	Treatment of ovarian cancer.	LEFLUNOMIDE		n/a	3/12/96	Designated			N/A	N/A	"Sugen, Inc."	South San Francisco	California	94080	USA	EXACT	0170683AA	LEFLUNOMIDE	G162GK9U4W						Ovarian cancer	7295		
niraparib	Treatment of ovarian cancer	niraparib		n/a	4/30/10	Designated			N/A	N/A	"TESARO, Inc."	Waltham	Massachusetts	2451	USA	EXACT	0682757AA	niraparib	HMC2H89N35						Ovarian cancer	7295		
Monoclonal antibody-B43.13	Treatment of epithelial ovarian cancer.	Oregovomab		Ovarex Mab-B43.13	11/25/96	Designated			N/A	N/A	"Quest PharmaTech, Inc."				Canada	EXACT	0261745AA	Oregovomab	HX101E7L6S						Ovarian cancer	7295		
trabectedin	Treatment of patients with ovarian cancer	trabectedin		Yondelis	3/29/05	Designated			N/A	N/A	"Janssen Research & Development, LLC"	Raritan	New Jersey	8869	USA	EXACT	0213070AA	trabectedin	ID0YZQ2TCP						Ovarian cancer	7295		
pertuzumab	Treatment of ovarian cancer	pertuzumab		n/a	6/8/09	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0297938AA	pertuzumab	K16AIQ8CTM						Ovarian cancer	7295		
Plevitrexed	Treatment of ovarian cancer	Plevitrexed		Plevitrexed	5/14/07	Designated/Withdrawn			N/A	N/A	BTG International Ltd				United Kingdom	EXACT	0284402AA	Plevitrexed	L9P2881C3H						Ovarian cancer	7295		
etirinotecan pegol	Treatment of ovarian cancer.	etirinotecan pegol		n/a	4/18/11	Designated			N/A	N/A	Nektar Therapeutics	San Francisco	California	94158	USA	EXACT	0756069AA	etirinotecan pegol	LJ16641SFT						Ovarian cancer	7295		
Catumaxomab	Treatment of ovarian cancer	Catumaxomab		Removab	6/9/06	Designated			N/A	N/A	"Neoviibiotech North America, Inc."	Waltham	Massachusetts	2451	USA	EXACT	0268304AA	Catumaxomab	M2HPV837HO						Ovarian cancer	7295		
Ethiofos	Use as a chemoprotective agent for cisplatin and cyclophosphamide in the treatment of ovarian cancer.	Ethiofos		n/a	8/1/89	Designated/Withdrawn			N/A	N/A	U.S. Bioscience	West Conshohocken	Pennsylvania	19428	USA	EXACT	0102409AA	Ethiofos	M487QF2F4V						Ovarian cancer	7295		
"(5S,8S, 10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5] diazocine-8-carboxyamide"	Treatment of ovarian cancer	Debio-1143		n/a	4/14/16	Designated			N/A	N/A	DebioPharm International SA	Lausanne			Switzerland	EXACT	0793680AA	Debio-1143	N65WC8PXDD						Ovarian cancer	7295		
Taxol isolated from Taxus brevifolia	Treatment of ovarian cancer.	Taxol isolated from Taxus brevifolia		n/a	10/15/90	Designated/Withdrawn			N/A	N/A	Bristol-Myers Squibb	Wallingford	Connecticut	6492	USA	EXACT	0132127AA	Taxol	P88XT4IS4D						Ovarian cancer	7295		
"paclitaxel, micellar"	Treatment of ovarian cancer	"paclitaxel, micellar"		Paclical	4/3/09	Designated			N/A	N/A	Oasmia Pharmaceutical AB				Sweden	EXACT	0132127AA	paclitaxel	P88XT4IS4D						Ovarian cancer	7295		
liposomal encapsulated paclitaxel	Treatment of ovarian cancer	liposomal encapsulated paclitaxel		n/a	1/21/15	Designated			N/A	N/A	"Insys Development Company, Inc."	Chandler	Arizona	85286	USA	EXACT	0132127AA	paclitaxel	P88XT4IS4D						Ovarian cancer	7295		
nanoparticulate paclitaxel	Treatment of ovarian cancer	nanoparticulate paclitaxel		Nanotax	10/6/15	Designated			N/A	N/A	"NanOlogy, LLC"	San Luis Obispo	California	93401	USA	EXACT	0132127AA	paclitaxel	P88XT4IS4D						Ovarian cancer	7295		
Liposomal cisplatin	Treatment of ovarian cancer	Liposomal cisplatin		Lipova-Pt	5/23/06	Designated			N/A	N/A	Eleison Pharmaceuticals LLC	St. Petersburg	Florida	33701	USA	EXACT	0056633AA	cisplatin	Q20Q21Q62J						Ovarian cancer	7295		
"2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid"	Treatment of ovarian cancer.	RGX-104		n/a	6/16/15	Designated			N/A	N/A	"Rgenix, Inc."	New York	New York	10065	USA	EXACT	1576778AA	RGX-104	Q26B92650V						Ovarian cancer	7295		
oglufanide disodium	Treatment of ovarian cancer	oglufanide disodium		n/a	9/24/01	Designated			N/A	N/A	Implicit Bioscience Pty Ltd				Australia	EXACT	0211643AA	oglufanide disodium	Q60AU1LLNU						Ovarian cancer	7295		
Patupilone	Treatment of ovarian cancer.	Patupilone		n/a	10/4/05	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceutical Corporation	East Hanover	New Jersey	7936	USA	EXACT	0232393AA	Patupilone	UEC0H0URSE						Ovarian cancer	7295		
olaparib	Treatment of ovarian cancer	olaparib		Lynparza	10/16/13	Designated/Approved	Approved for Orphan Indication	Use of as monotherapy for patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy	12/19/14	12/19/21	AstraZeneca Pharmaceuticals LP	Wilmington	Delaware	19803	USA	EXACT	0298464AA	olaparib	WOH1JD9AR8						Ovarian cancer	7295		
"{2-amino-8-[4-(pyrrolidinylcarbonyl)phenyl](3H-benzo[f]azepin-4-yl)}-N,N-dipropycarboxamide"	Treatment of ovarian cancer	Motolimod		n/a	4/10/14	Designated			N/A	N/A	"VentiRx Pharmaceuticals, Inc."	Seattle	Washington	98101	USA	EXACT	0778074AA	Motolimod	WP6PY72ZH3						Ovarian cancer	7295		
trebananib	Treatment of ovarian cancer	trebananib		n/a	8/30/13	Designated			N/A	N/A	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0698260AA	trebananib	X8Y5U6NC7E						Ovarian cancer	7295		
prolactin receptor antagonist	Treatment of ovarian cancer	PROLACTIN G129R		Prolanta	4/15/13	Designated			N/A	N/A	"Oncolix, Inc."	Houston	Texas	77014	USA	EXACT	1276831AA	PROLACTIN G129R	Y88638Q24R						Ovarian cancer	7295		
anti-HER2 bispecific antibody	Treatment of ovarian cancer	ZW-25		n/a	5/18/16	Designated			N/A	N/A	Zymeworks Inc.	Seattle	Washington	98119	USA	EXACT	0110929AB	ZW-25	Z20OC92TDI						Ovarian cancer	7295		
anti-Lewis Y humanized monoclonal antibody	Treament of ovarian cancer	HU3S193		n/a	3/9/12	Designated			N/A	N/A	Recepta Biopharma S.A.				Brazil	EXACT	0263616AA	HU3S193							Ovarian cancer	7295		
chimeric monoclonal antibody against Claudin 6	Treatment of ovarian cancer	IMAB-027		n/a	3/18/13	Designated			N/A	N/A	Ganymed Pharmaceuticals AG				Germany	EXACT	0116824AB	IMAB-027							Ovarian cancer	7295		
N-(4-{3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxy}phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine bis-mesylate dihydrate	Treatment of ovarian cancer	AMG-900 BISMESYLATE DIHYDRATE		n/a	10/21/14	Designated			N/A	N/A	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	1577599AA	AMG-900 BISMESYLATE DIHYDRATE	E717YSV70L						Ovarian cancer	7295		
anti-Beta1 integrin monoclonal antibody	Treatment of ovarian cancer	OS-2966 		n/a	1/13/15	Designated			N/A	N/A	"OncoSynergy, Inc."	San Francisco	California	94158	USA	EXACT	1802126AA	OS-2966							Ovarian cancer	7295		
pelareorep	Treatment of ovarian cancer	pelareorep		Reolysin(R)	2/10/15	Designated			N/A	N/A	"Oncolytics Biotech, Inc."				Canada	EXACT	0809154AA	pelareorep	S9J80L3D1U						Ovarian cancer	7295		
folate binding protein peptide: Glu-Ile-Trp-Thr-His-Ser-Tyr-Lys-Val	Treatment (including prevention of recurrence) of ovarian cancer	GALE-302		n/a	6/8/16	Designated			N/A	N/A	"Galena Biopharma, Inc."	San Ramon	California	94583	USA	EXACT	 0114504AB	GALE-302							Ovarian cancer	7295		
Folate Binding Protein Peptide: Glu-Ile-Trp-Thr-Phe-Ser-Thr-Lys-Val	Treatment (including prevention of recurrence) of ovarian cancer	Folate Binding Protein Peptide: Glu-Ile-Trp-Thr-Phe-Ser-Thr-Lys-Val		n/a	6/8/16	Designated			N/A	N/A	"Galena Biopharma, Inc."	San Ramon	California	94583	USA	EXACT	1704218AA	Folate Binding Protein Peptide: Glu-Ile-Trp-Thr-Phe-Ser-Thr-Lys-Val	AYW9KM2EPO						Ovarian cancer	7295		
Sperm Protein-17 oral microparticle vaccine	Treatment of ovarian cancer	BSK01		n/a	6/21/16	Designated			N/A	N/A	"Kiromic, LLC"	Houston	Texas	77002	USA	EXACT									Ovarian cancer	7295		
anti-HER2 bispecific antibody drug conjugate	Treatment of ovarian cancer	zw-33		n/a	7/6/16	Designated			N/A	N/A	Zymeworks Inc.	Seattle	Washington	98119	USA	EXACT									Ovarian cancer	7295		
anti-angiogenic peptide	Treatment of ovarian cancer	ALM-201		n/a	6/21/17	Designated			N/A	N/A	Almac Group	Craigavon			United Kingdom	EXACT	1312158AA	ALM-201	8EUTMEPN0L						Ovarian cancer	7295		
chelmab-y or chelamusab-Y	Treatment of ovarian cancer.	chelmab-y or chelamusab-Y		Oncorad Ov103	4/24/90	Designated			N/A	N/A	Cytogen Corporation	Princeton	New Jersey	8540	USA										Ovarian cancer	7295		
Bispecific antibody 520c9x22	For in vivo serotherapy of patients with ovarian cancer.	Bispecific antibody 520c9x22		n/a	10/5/93	Designated/Withdrawn			N/A	N/A	"Medarex, Inc."	Bloomsbury	New Jersey	8804	USA										Ovarian cancer	7295		
"RGG0853, E1A lipid complex"	Treatment of ovarian cancer.	RGG-853		n/a	9/15/95	Designated/Withdrawn			N/A	N/A	Targeted Genetics Corporation	Seattle	Washington	98101	USA										Ovarian cancer	7295		
"Murine MAb to polymorphic epithelial mucin, human milk fat globule 1"	Adjuvant treatment of ovarian cancer.	"Murine MAb to polymorphic epithelial mucin, human milk fat globule 1"		Theragyn	3/22/99	Designated			N/A	N/A	Antisoma plc	London W5 3QR			United Kingdom	LONGEST CONTAINS	1804553AA	polymorphic epithelial mucin	I903D7RK7W						Ovarian cancer	7295		
Recombinant replication deficient adenovirus vector carrying human p53 gene	Treatment of primary ovarian cancer.	Recombinant replication deficient adenovirus vector carrying human p53 gene		n/a	4/12/99	Designated			N/A	N/A	Schering Corporation	Kenilworth	New Jersey	7033	USA										Ovarian cancer	7295		
DNP-Modified autologous tumor vaccine	Adjuvant therapy for the treatment of ovarian cancer	DNP-Modified autologous tumor vaccine		O-Vax	9/21/00	Designated			N/A	N/A	"AVAX Technologies, Inc."	Overland Park	Kansas	66210	USA										Ovarian cancer	7295		
Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin	Treatment of epithelial ovarian cancer	Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin		n/a	2/11/02	Designated			N/A	N/A	National Institutes of Health	Rockville	Maryland	20852	USA	LONGEST CONTAINS	1805772AA	mesothelin	J27WDC343N						Ovarian cancer	7295		
DNA plasmid vector expressing human IL-12 gene	Treatment of ovarian cancer.	DNA plasmid vector expressing human IL-12 gene		n/a	4/4/05	Designated			N/A	N/A	Celsion Corporation	Lawrenceville	New Jersey	8068	USA										Ovarian cancer	7295		
Anti-EphA1 monoclonal antibody conjugated to mcMMAF	Treatment of ovarian cancer	MEDI-547		n/a	7/27/09	Designated/Withdrawn			N/A	N/A	"MedImmune, LLC"	Gaithersburg	Maryland	20878	USA										Ovarian cancer	7295		
DNA plasmid expressing diphtheria toxin triggered by the presence of oncofetal gen H19	Treatment of ovarian cancer	DNA plasmid expressing diphtheria toxin triggered by the presence of oncofetal gen H19		n/a	8/20/09	Designated			N/A	N/A	BioCancell Therapeutics Ltd.				Israel	LONGEST CONTAINS	1183820AA	diphtheria toxin							Ovarian cancer	7295		
Autologous dendritic cells pulsed with recombinant human fusion protein (mucin1- glutathione S transferase) coupled to oxidized polymannose	Treatment of ovarian cancer.	Autologous dendritic cells pulsed with recombinant human fusion protein (mucin1- glutathione S transferase) coupled to oxidized polymannose		Cvac(Tm)	9/13/10	Designated			N/A	N/A	Prima Biomed Ltd.	"Armadale, Victoria 3143"			Australia	LONGEST CONTAINS	0012135AA	glutathione	GAN16C9B8O						Ovarian cancer	7295		
bi-shRNAfurin and granulocyte macrophage colony stimulating factor augmented autologus tumor cell vaccine	Treatment of ovarian cancer	bi-shRNAfurin and granulocyte macrophage colony stimulating factor augmented autologus tumor cell vaccine		Fang	4/18/11	Designated			N/A	N/A	"Gradalis, Inc."	Carrollton	Texas	75006	USA										Ovarian cancer	7295		
human MHC non-restricted cytotoxic T-cell line	Treatment of ovarian cancer	human MHC non-restricted cytotoxic T-cell line		n/a	7/6/12	Designated			N/A	N/A	Galileo Research srl	Pisa			Italy										Ovarian cancer	7295		
DCVAC OvCa	Treatment of ovarian cancer	DCVAC OvCa		n/a	5/14/13	Designated			N/A	N/A	SOTIOS a.s.				Czech Republic										Ovarian cancer	7295		
Ad5/3-D24-granulocyte-macrophage colony stimulating factor (GMCSF)-encoding oncolytic adenovirus	Treatment of ovarian cancer	Ad5/3-D24-granulocyte-macrophage colony stimulating factor (GMCSF)-encoding oncolytic adenovirus		n/a	3/17/14	Designated			N/A	N/A	Oncos Therapeutics	Helsinki			Finland										Ovarian cancer	7295		
poly-CD-PEG-camptothecin	Treatment of ovarian cancer.	poly-CD-PEG-camptothecin		n/a	5/21/15	Designated			N/A	N/A	"Cerulean Pharma, Inc."	Waltham	Massachusetts	2451	USA	LONGEST CONTAINS	0210300AA	camptothecin	XT3Z54Z28A						Ovarian cancer	7295		
DPX-Survivac	Treatment of ovarian cancer.	DPX-Survivac		n/a	7/14/15	Designated			N/A	N/A	"Immunovaccine Technologies, Inc."				Canada										Ovarian cancer	7295		
multi-epitope folate receptor alpha peptide vaccine with GM-CSF adjuvant (TPIV200)	Treatment of ovarian cancer.	multi-epitope folate receptor alpha peptide vaccine with GM-CSF adjuvant (TPIV200)		n/a	12/7/15	Designated			N/A	N/A	"Tapimmune, Inc."	Jacksonville	Florida	32202	USA	LONGEST CONTAINS	0113604AB	folate receptor alpha	I9G3JZ25IH						Ovarian cancer	7295		
Nanocomplex consisting of a small interfering RNA that targets the human EV11 oncogenic transcription factor and an elastin-like polypeptide drug carrier.	Treatment of ovarian cancer.	Nanocomplex consisting of a small interfering RNA that targets the human EV11 oncogenic transcription factor and an elastin-like polypeptide drug carrier.		n/a	5/23/16	Designated			N/A	N/A	PeptiMed	Madison	Wisconsin	53714	USA	LONGEST CONTAINS	0006508AA	elastin	VRC4754D50						Ovarian cancer	7295		
recombinant humanized monoclonal antibody targeting the anti-müllerian hormone receptor II	Treatment of Anti -Mullerian Hormone Receptor II (AMHRII)-expressing ovarian cancer	recombinant humanized monoclonal antibody targeting the anti-müllerian hormone receptor II		n/a	1/30/18	Designated			N/A	N/A	GamaMabs Pharma SA	"Centre Pierre Potier, 1 place Pierre Potier"			France										Ovarian cancer	7295		
N-(2-amino-2-oxoethyl)-2-(2-((4-fluorophenethyl)amino)-N-isobutylacetamido)-N-(3-(2-oxopyrrolidin-1-yl)propyl)acetamide N-({Carbamoylmethyl-[3-(2-oxo-pyrrolidin-1-yl)propyl}-carbamoyl}-methyl)-2-[2-(2-fluorophenyl)-ethylamino]-N-isobutyl-acetamide	Treatment of optic neuritis	BN-201		n/a	11/17/14	Designated			N/A	N/A	Bionure Farma SL	Barcelona			Spain	EXACT	1182485AA	BN-201	KCN37L7EIH						Optic neuritis	7320		
cinacalcet	Treatment of hypercalcemia in patients with parathyroid carcinoma	cinacalcet		Sensipar	5/12/03	Designated/Approved	Approved for Orphan Indication	Treatment of hypercalcemia in patients with parathyroid carcinoma	3/8/04	3/8/11	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0282031AA	cinacalcet	UAZ6V7728S						Parathyroid carcinoma	7329		
"S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)"	Treatment of paroxysmal nocturnal hemoglobinuria (PNH)	AMY-101		n/a	10/9/14	Designated			N/A	N/A	Amyndas Pharmaceuticals	Glyfada			Greece	EXACT	1802864AA	AMY-101	4Z4DFR9BX7						Paroxysmal nocturnal hemoglobinuria	7337		
coversin; rEV675	Treatment of paroxysmal nocturnal hemoglobinuria	coversin		n/a	9/8/16	Designated			N/A	N/A	Akari Therapeutics Plc	New York	New York	10018	USA	EXACT	1794985AA	coversin	79V7Q9VIWQ						Paroxysmal nocturnal hemoglobinuria	7337		
eculizumab	Treatment of paroxysmal nocturnal hemoglobinuria	eculizumab		Soliris	8/20/03	Designated/Approved	Approved for Orphan Indication	Treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis	3/16/07	3/16/14	"Alexion Pharmaceuticals, Inc."	Cheshire	Connecticut	6410	USA	EXACT	0298000AA	eculizumab	A3ULP0F556						Paroxysmal nocturnal hemoglobinuria	7337		
humanized monoclonal antibody that blocks activity of complement component C5	Treatment of paroxysmal nocturnal hemoglobinuria	ALXN-1210		n/a	1/4/17	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	1800164AA	ALXN-1210	C3VX249T6L						Paroxysmal nocturnal hemoglobinuria	7337		
"(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide"	Treatment of paroxysmal nocturnal hemoglobinuria	ACH-4471		n/a	11/2/17	Designated			N/A	N/A	"Achillion Pharmaceuticals, Inc"	300 George Street	Connecticut	6511	USA	EXACT	0113191AB	ACH-4471	JM8C1SFX0U						Paroxysmal nocturnal hemoglobinuria	7337		
Ac-Ile-Cys-Val-Trp(1-Me)-Gln-Asp-Trp-Gly-Ala-His-Arg-Cys-Thr-AEEA-Lys-PEG 40KDa-Lys-AEEA-Thr-Cys-Arg-His-ALa-Gly-Trp-Asp-Gln-(1-Me)Trp-Val-Cys-Ile-Ac	Treatment of paroxysmal nocturnal hemoglobinuria	apl-2		n/a	4/20/14	Designated			N/A	N/A	"Apellis Pharmaceuticals, Inc."	Crestwood	Kentucky	40014	USA	EXACT	0971233AA	apl-2	OB8P1NJZ9B						Paroxysmal nocturnal hemoglobinuria	7337		
Synthetic 15-amino-acid macrocyclic peptide acylated with a ethyleneglycol palmitoylated linker	Treatment of paroxysmal nocturnal hemoglobinuria (PNH)	RA-101495		n/a	7/19/17	Designated			N/A	N/A	"Ra Pharmaceuticals, Inc."	Cambridge	Massachusetts	2140	USA	EXACT	1797951AA	RA-101495	YG391PK0CC						Paroxysmal nocturnal hemoglobinuria	7337		
recombinant humanized anti-complement component 5 monoclonal antibody	Treatment of paroxysmal nocturnal hemoglobinuria (PNH)	RG-6107 		n/a	9/5/17	Designated			N/A	N/A	Hoffmann-La Roche Inc.	South San Francisco	California	94080	USA	EXACT	0113230AB	RG-6107 							Paroxysmal nocturnal hemoglobinuria	7337		
"S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)"	Treatment of paroxysmal nocturnal hemoglobinuria (PNH)	AMY-101		n/a	10/9/14	Designated			N/A	N/A	Amyndas Pharmaceuticals	Glyfada			Greece	EXACT	1802864AA	AMY-101	4Z4DFR9BX7						Paroxysmal nocturnal hemoglobinuria (PNH)	7337		
Synthetic 15-amino-acid macrocyclic peptide acylated with a ethyleneglycol palmitoylated linker	Treatment of paroxysmal nocturnal hemoglobinuria (PNH)	RA-101495		n/a	7/19/17	Designated			N/A	N/A	"Ra Pharmaceuticals, Inc."	Cambridge	Massachusetts	2140	USA	EXACT	1797951AA	RA-101495	YG391PK0CC						Paroxysmal nocturnal hemoglobinuria (PNH)	7337		
recombinant humanized anti-complement component 5 monoclonal antibody	Treatment of paroxysmal nocturnal hemoglobinuria (PNH)	RG-6107 		n/a	9/5/17	Designated			N/A	N/A	Hoffmann-La Roche Inc.	South San Francisco	California	94080	USA	EXACT	0113230AB	RG-6107 							Paroxysmal nocturnal hemoglobinuria (PNH)	7337		
Ibuprofen lysine	Treatment of patent ductus arteriosus	Ibuprofen lysine		Neoprofen	10/29/96	Designated/Approved	Approved for Orphan Indication	"For closure of a clinically significant patent ductus arteriosus in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective"	4/13/06	4/13/13	"Lundbeck, Inc."	Deerfield	Illinois	60015	USA	EXACT	0175520AA	Ibuprofen lysine	N01ORX9D6S						Patent ductus arteriosus	7342		
Ibuprofen i.v. solution	Prevention of patent ductus arteriosus.	Ibuprofen i.v. solution		Salprofen	10/29/96	Designated			N/A	N/A	"Farmacon-IL, LLC"	Westport	Connecticut	6880	USA	EXACT	0056779AA	Ibuprofen	WK2XYI10QM						Patent ductus arteriosus	7342		
"(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile"	Treatment of pemphigus vulgaris	LAS-191954		n/a	1/26/15	Designated			N/A	N/A	Almirall S.A.	Barcelona			Spain	EXACT	1793813AA	LAS-191954	1MK0TQ597B						Pemphigus	7352		
rituximab	Treatment of pemphigus vulgaris.	rituximab		Rituxan(R); Mabthera(R)	2/23/15	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California		United States Minor Outlying Islands	EXACT	0225149AA	rituximab	4F4X42SYQ6						Pemphigus	7352		
Mycophenolate mofetil	Treatment of pemphigus vulgaris	Mycophenolate mofetil		Cellcept	5/26/06	Designated/Withdrawn			N/A	N/A	"Hoffman-La Roche, Inc."	Nutley	New Jersey	7110	USA	EXACT	0167157AA	Mycophenolate mofetil	9242ECW6R0						Pemphigus	7352		
veltuzumab	Treatment of pemphigus	veltuzumab		n/a	11/17/14	Designated			N/A	N/A	"Immunomedics, Inc."	Morris Plains	New Jersey	7950	USA	EXACT	0265894AA	veltuzumab	BPD4DGQ314						Pemphigus	7352		
Small Molecule Bruton's Agammaglobulinemia Tyrosine Kinase (BKT) Inhibitor	Treatment of Pemphigus Vulgaris	PRN-1008		n/a	6/29/17	Designated			N/A	N/A	Principia Biopharma Inc.	South San Francisco	California	94080	USA	EXACT	1128070AA	PRN-1008	NWN58M4F5T						Pemphigus	7352		
afamelanotide	Treatment of familial benign chronic pemphigus (Hailey-Hailey disease)	afamelanotide		n/a	5/14/14	Designated			N/A	N/A	"Clinuvel, Inc."	New York	New York	10013	USA	EXACT	0253281AA	afamelanotide	QW68W3J66U						Pemphigus	7352		
Desmoglein 3 synthetic peptide (PI-0824)	Treatment of pemphigus vulgaris	PI-0824		n/a	10/26/04	Designated			N/A	N/A	"Peptimmune, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0265929AA	PI-0824	UG5KU6AQ0Z						Pemphigus	7352		
orilanolimab	Treatment of pemphigus	orilanolimab		n/a	9/10/18	Designated			N/A	N/A	"Syntimmune, Inc."	116 Huntington Avenue	Massachusetts	2116	USA	EXACT	0116310AB	orilanolimab	1LTT6HMX9N						Pemphigus	7352		
"(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile"	Treatment of pemphigus vulgaris	LAS-191954		n/a	1/26/15	Designated			N/A	N/A	Almirall S.A.	Barcelona			Spain	EXACT	1793813AA	LAS-191954	1MK0TQ597B						Pemphigus vulgaris	7355		
rituximab	Treatment of pemphigus vulgaris.	rituximab		Rituxan(R); Mabthera(R)	2/23/15	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California		United States Minor Outlying Islands	EXACT	0225149AA	rituximab	4F4X42SYQ6						Pemphigus vulgaris	7355		
Mycophenolate mofetil	Treatment of pemphigus vulgaris	Mycophenolate mofetil		Cellcept	5/26/06	Designated/Withdrawn			N/A	N/A	"Hoffman-La Roche, Inc."	Nutley	New Jersey	7110	USA	EXACT	0167157AA	Mycophenolate mofetil	9242ECW6R0						Pemphigus vulgaris	7355		
Small Molecule Bruton's Agammaglobulinemia Tyrosine Kinase (BKT) Inhibitor	Treatment of Pemphigus Vulgaris	PRN-1008		n/a	6/29/17	Designated			N/A	N/A	Principia Biopharma Inc.	South San Francisco	California	94080	USA	EXACT	1128070AA	PRN-1008	NWN58M4F5T						Pemphigus vulgaris	7355		
Desmoglein 3 synthetic peptide (PI-0824)	Treatment of pemphigus vulgaris	PI-0824		n/a	10/26/04	Designated			N/A	N/A	"Peptimmune, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0265929AA	PI-0824	UG5KU6AQ0Z						Pemphigus vulgaris	7355		
fenretinide	Treatment of peripheral T-cell lymphoma	fenretinide		n/a	9/4/13	Designated			N/A	N/A	"CerRx, Inc."	Lubbock	Texas	79416	USA	EXACT	0136061AA	fenretinide	187EJ7QEXL						Peripheral T-cell lymphoma	7368		
fenretinide	Treatment of peripheral T-cell lymphoma (including follicular T-cell lymphoma)	fenretinide		n/a	12/22/17	Designated			N/A	N/A	"SciTech Development, LLC"	281 Kercheval Avenue	Grosse Pointe Farms	48236	USA	EXACT	0136061AA	fenretinide	187EJ7QEXL						Peripheral T-cell lymphoma	7368		
(S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one)	Treatment of peripheral T-cell lymphoma	Tenalisib		n/a	12/18/17	Designated			N/A	N/A	Rhizen Pharmaceuticals SA	40 Rue Fritz-Courvoisier	La Chaux-de-Fonds		Switzerland	EXACT	1120952AA	Tenalisib	2261HH611H						Peripheral T-cell lymphoma	7368		
denileukin diftitox	Treatment of peripheral T-cell lymphoma	denileukin diftitox		Ontak	4/30/10	Designated			N/A	N/A	"Eisai, Inc."	Woodcliff Lake	New Jersey	7677	USA	EXACT	0233465AA	denileukin diftitox	25E79B5CTM						Peripheral T-cell lymphoma	7368		
denileukin diftitox	Treatment of peripheral T-cell lymphoma (PTCL)	denileukin diftitox		n/a	6/29/11	Designated			N/A	N/A	"Eisai, Inc."	Woodcliff Lake	New Jersey	5271	USA	EXACT	0233465AA	denileukin diftitox	25E79B5CTM						Peripheral T-cell lymphoma	7368		
Pentostatin	Treatment of peripheral T-cell lymphomas.	Pentostatin		Nipent	11/24/99	Designated			N/A	N/A	"SuperGen, Inc."	Dublin	California	94568	USA	EXACT	0067130AA	Pentostatin	395575MZO7						Peripheral T-cell lymphoma	7368		
brentuximab vedotin	"Treatment of patients with peripheral T-cell lymphoma, not otherwise specified"	brentuximab vedotin		Adcetris	4/15/13	Designated			N/A	N/A	"Seattle Genetics, Inc."	Bothell	Washington	98021	USA	EXACT	0297767AA	brentuximab vedotin	7XL5ISS668						Peripheral T-cell lymphoma	7368		
Darinaparsin	Treatment of peripheral T-cell lymphoma.	Darinaparsin		n/a	9/13/10	Designated			N/A	N/A	Solasia Pharma K.K.				Japan	EXACT	0255516AA	Darinaparsin	9XX54M675G						Peripheral T-cell lymphoma	7368		
"6,8-bis(benzylthio)octanoic acid"	Treatment of Peripheral T-cell Lymphoma (PTCL)	"6,8-bis(benzylthio)octanoic acid"		n/a	2/28/18	Designated			N/A	N/A	"Rafael Pharmaceuticals, Inc."	1 Duncan Drive	Cranbury Township	8512	USA	EXACT	0298840AA	"6,8-bis(benzylthio)octanoic acid"	E76113IR49						Peripheral T-cell lymphoma	7368		
Belinostat	Treatment of peripheral T-cell lymphoma (PTCL).	Belinostat		Beleodaq	9/3/09	Designated/Approved	Approved for Orphan Indication	Treatment of patients with relapsed or refractory peripheral T-cell lymphoma	7/3/14	7/3/21	"Spectrum Pharmaceuticals, Inc."	Irvine	California	92618	USA	EXACT	0252915AA	Belinostat	F4H96P17NZ						Peripheral T-cell lymphoma	7368		
alisertib	Treatment of peripheral T-cell lymphoma	alisertib		n/a	5/14/12	Designated/Withdrawn			N/A	N/A	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0383482AA	alisertib	T66ES73M18						Peripheral T-cell lymphoma	7368		
Mitoxantrone hydrochloride liposome	Treatment of peripheral T-cell lymphoma	Mitoxantrone hydrochloride liposome		n/a	9/20/17	Designated			N/A	N/A	"CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd."	Shijiazhuang Shi			China	EXACT	0092546AA	Mitoxantrone hydrochloride	U6USW86RD0						Peripheral T-cell lymphoma	7368		
mogamulizumab	Treatment of peripheral T-cell lymphoma.	mogamulizumab		n/a	11/2/10	Designated			N/A	N/A	"Kyowa Kirin Pharmaceutical Development, Inc."	Princeton	New Jersey	8540	USA	EXACT	0574594AA	mogamulizumab	YI437801BE						Peripheral T-cell lymphoma	7368		
chimeric antigen receptor directed against the target protein CD4 lentivirally transfected T cells	Treatment of peripheral T-cell lymphoma	chimeric antigen receptor directed against the target protein CD4 lentivirally transfected T cells		n/a	7/28/16	Designated			N/A	N/A	iCell Gene Therapeutics	Stony Brook	New York	11793	USA	LONGEST CONTAINS	0087274AA	protein							Peripheral T-cell lymphoma	7368		
cerdulatinib	Treatment of peripheral T-cell lymphoma (PTCL).	cerdulatinib		n/a	9/21/18	Designated			N/A	N/A	"Portola Pharmaceuticals, Inc."	270 East Grand Avenue	California	94080	USA	EXACT	1078008AA	cerdulatinib	D1LXQ45S1O						Peripheral T-cell lymphoma	7368		
Pentostatin	Treatment of peripheral T-cell lymphomas.	Pentostatin		Nipent	11/24/99	Designated			N/A	N/A	"SuperGen, Inc."	Dublin	California	94568	USA	EXACT	0067130AA	Pentostatin	395575MZO7						Peripheral T-Cell Lymphomas	7368		
a strain of modified live probiotic bacterium Escherichia coli (E.coli) Nissle 1917 that has been modified to treat phenylketonuria by consuming phenylalanine within the gastrointestinal tract	Treatment of phenylketonuria (PKU)	a strain of modified live probiotic bacterium Escherichia coli (E.coli) Nissle 1917 that has been modified to treat phenylketonuria by consuming phenylalanine within the gastrointestinal tract		n/a	10/18/17	Designated			N/A	N/A	"Synlogic, Inc."	Cambridge	Massachusetts	2139	USA	LONGEST CONTAINS	0140147AA	Escherichia coli	514B9K0L10						Phenylketonuria	7383		
recombinant lentivirus vector expressing the human phenylalanine hydroxylase (PAH) gene under control of a liver-specific promoter	Treatment of Phenylketonuria	recombinant lentivirus vector expressing the human phenylalanine hydroxylase (PAH) gene under control of a liver-specific promoter		n/a	10/15/18	Designated			N/A	N/A	American Gene Technologies International Inc.	9640 Medical Center Drive	Maryland	20850	USA	LONGEST CONTAINS	0011132AA	phenylalanine	47E5O17Y3R						Phenylketonuria	7383		
iobenguane sulfate I-123	"For the detection, localization, and staging of pheochromocytomas."	iobenguane sulfate I-123		Omaclear	10/21/05	Designated			N/A	N/A	"Brogan Pharmaceuticals, Inc."	Crown Point	Indiana	46307	USA	EXACT	0094202AA	iobenguane sulfate I-123	23X1185WBO						Pheochromocytoma	7385		
Iobenguane Sulfate I 131	For use as a diagnostic adjunct in patients with pheochromocytoma.	Iobenguane Sulfate I 131		n/a	11/14/84	Designated/Approved/Withdrawn		Adjunctive diagnostic agent in the localization of primary or metastatic pheochromocytomas.	N/A	3/25/01	University of Michigan	Ann Arbor	Michigan	48109	USA	EXACT	0094199AA	Iobenguane Sulfate I 131	M575VKV19N						Pheochromocytoma	7385		
Iobenguane I 123	For the diagnosis of pheochromocytomas	Iobenguane I 123		Adreview	12/1/06	Designated/Approved	Approved for Orphan Indication	To be used in the detection of primary or metastatic pheochromocytomas or neuroblastomas as an adjunct to other diagnostic tests	9/19/08	9/19/15	"GE Healthcare, Inc."	Princeton	New Jersey	8540	USA	EXACT	0234708AA	Iobenguane I 123	P2TH1XYZ84						Pheochromocytoma	7385		
recombinant humanized IgG4 monoclonal antibody that binds human colony stimulating factor 1 receptor	Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor	Cabiralizumab		n/a	1/11/16	Designated			N/A	N/A	"Five Prime Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	1132816AA	Cabiralizumab	5FJL6W0640						Pigmented villonodular synovitis	7396		
recombinant humanized monoclonal antibody of the immunoglobulin G1 subclass directed against colony stimulating factor-1 receptor expressed on macrophages	Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor	Emactuzumab		n/a	5/14/14	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0931204AA	Emactuzumab	6FY6EI1X8R						Pigmented villonodular synovitis	7396		
recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor	"Treatment of pigmented villonodular synovitis, including giant cell tumor of the tendon sheath"	OTILIMAB		n/a	8/19/14	Designated			N/A	N/A	Novartis Pharmaceuticals Corp	East Hanover	New Jersey	7936	USA	EXACT	0112972AB	OTILIMAB	Y8127R3VCH						Pigmented villonodular synovitis	7396		
"[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride salt"	Treatment of pigmented villonodular synovitis/giant cell tumor of the tendon sheath	PEXIDARTINIB HYDROCHLORIDE		n/a	2/14/14	Designated			N/A	N/A	"Daiichi Sankyo, Inc."	Edison	New Jersey	8837	USA	EXACT	0341048AA	PEXIDARTINIB HYDROCHLORIDE	YS6WAI3XN7						Pigmented villonodular synovitis	7396		
Recombinant human insulin-like growth factor-I	Treatment of post-poliomyelitis syndrome.	Mecasermin		n/a	10/13/95	Designated/Withdrawn			N/A	N/A	"Teva Branded Pharmaceutical Product R&D, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0167215AA	Mecasermin	7GR9I2683O						Poliomyelitis	7413		
Givinostat	Treatment of polycythemia vera (PV)	Givinostat		n/a	9/28/17	Designated			N/A	N/A	Italfarmaco SpA	Cinisello Balsamo			Italy	EXACT	0338341AA	Givinostat	5P60F84FBH						Polycythemia vera	7422		
ruxolitinib	Treatment of polycythemia vera	ruxolitinib		Jakafi	3/26/10	Designated/Approved	Approved for Orphan Indication	Treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.	12/4/14	12/4/21	Incyte Corporation	Wilmington	Delaware	19803	USA	EXACT	0557119AA	ruxolitinib	82S8X8XX8H						Polycythemia vera	7422		
Adenosine triphosphate type 1 competitive inhibitor of JAK2 V617F tyrosine kinase	"Treatment of myeloproliferative disorders (polycythemia vera, essential throbocythemia, and myelofibrosis)"	LY2784544		n/a	3/3/11	Designated			N/A	N/A	Eli Lilly and Company	Indianapolis	Indiana	46285	USA	EXACT	0763075AA	LY2784544	ANC71R916O						Polycythemia vera	7422		
pacritinib	"Treatment of primary myelofibrosis (MF), post-polycythemia vera MF, and post-essential thrombocythemia MF"	pacritinib		n/a	3/13/08	Designated			N/A	N/A	CTI BioPharma Corporation	Seattle	Washington	98121	USA	EXACT	0568956AA	pacritinib	G22N65IL3O						Polycythemia vera	7422		
Anagrelide	Treatment of polycythemia vera.	Anagrelide		Agrylin	6/11/85	Designated			N/A	N/A	Roberts Pharmaceutical Corp.	Eatontown	New Jersey	7724	USA	EXACT	0225956AA	Anagrelide	K9X45X0051						Polycythemia vera	7422		
idasanutlin	Treatment of polycythemia vera	idasanutlin		n/a	11/29/17	Designated			N/A	N/A	Hoffmann-La Roche Inc.	430 East 29th Street	New York	10016	USA	EXACT	0927402AA	idasanutlin	QSQ883V35U						Polycythemia vera	7422		
inhibitor of microRNA-451	Treatment of polycythemia vera	MGN-4893		n/a	2/4/11	Designated			N/A	N/A	"miRagen Therapeutics, Inc."	Boulder	Colorado	80301	USA	EXACT									Polycythemia vera	7422		
N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate	Treatment of polycythemia vera	N-tert-butyl-3-((5-methyl-2-((4-(2-pyrrolidin-1-ylethoxy)phenyl)amino)pyrimidin-4-yl)amino) benzenesulfonamide dihydrochloride monohydrate		n/a	3/21/13	Designated			N/A	N/A	sanofi-aventis U.S. LLC	Bridgewater	New Jersey	8807	USA	EXACT	1577577AA	N-tert-butyl-3-((5-methyl-2-((4-(2-pyrrolidin-1-ylethoxy)phenyl)amino)pyrimidin-4-yl)amino) benzenesulfonamide dihydrochloride monohydrate	UH9J2HBQWJ						Polycythemia vera	7422		
natural human lymphoblastoid interferon-alpha	Treatment of polycythemia vera	natural human lymphoblastoid interferon-alpha		n/a	11/18/02	Designated			N/A	N/A	"Amarillo Biosciences, Inc."	Amarillo	Texas	79110	USA	LONGEST CONTAINS	0259530AA	interferon alpha							Polycythemia vera	7422		
pegylated proline-interferon alpha-2b; PEG-P-IFNa-2b	Treatment of polycythemia vera	pegylated proline-interferon alpha-2b; PEG-P-IFNa-2b		n/a	4/2/12	Designated			N/A	N/A	PharmaEssentia Corporation	Taipei 115			Taiwan	LONGEST CONTAINS	0259530AA	interferon alpha							Polycythemia vera	7422		
Immune globulin intravenous (human)	Treatment of polymyositis/dermatomyositis.	IVIG		"Iveegam, Immuno"	10/13/92	Designated/Withdrawn			N/A	N/A	Immuno Clinical Research Corp.	New York	New York	10022	USA	EXACT	0233705AA	Immune globulin intravenous (human)	66Y330CJHS						Polymyositis	7425		
Siponimod	Treatment of polymyositis	Siponimod		n/a	11/26/13	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0682360AA	Siponimod	RR6P8L282I						Polymyositis	7425		
brincidofovir	Treatment of Smallpox	brincidofovir		n/a	6/5/18	Designated			N/A	N/A	"Chimerix, Inc."	2505 Meridian Parkway	Suite 100	27713	USA	EXACT	0645921AA	brincidofovir	6794O900AX						Smallpox	7444		
tecovirimat	post exposure prophylaxis against smallpox	tecovirimat		n/a	12/18/06	Designated			N/A	N/A	"SIGA Technologies, Inc."	Corvallis	Oregon	97333	USA	EXACT	0314487AA	tecovirimat	F925RR824R						Smallpox	7444		
tecovirimat	Treatment of smallpox.	tecovirimat		n/a	12/27/06	Designated			N/A	N/A	"SIGA Technologies, Inc."	Corvallis	Oregon	97333	USA	EXACT	0314487AA	tecovirimat	F925RR824R						Smallpox	7444		
polyinosinic-polycytidilic acid	As an adjuvant to smallpox vaccination	Poly-Iclc		Poly-Iclc	8/2/02	Designated			N/A	N/A	Oncovir	Washington	District of Columbia	20008	USA	EXACT	0777651AA	Poly-Iclc							Smallpox	7444		
Vaccinia Immune Globulin (Human) Intravenous	Treatment of severe complications from the smallpox vaccine	Vaccinia Immune Globulin (Human) Intravenous		n/a	6/18/04	Designated/Approved	Approved for Orphan Indication	"Treatment and modification of aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in cases of isolated keratitis), mouth, or other areas where vaccinia infection would constitute a special hazard; eczema vaccinatum; progressive vaccinia; severe generalized vaccinia, and vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions"	2/18/05	2/18/12	DynPort Vaccine Company LLC	Frederick	Maryland	21702	USA	LONGEST CONTAINS	0322907AA	Vaccinia Immune Globulin	7UB4J759TD						Smallpox	7444		
triptorelin pamoate	Treatment of central precocious puberty	triptorelin pamoate		n/a	8/20/12	Designated			N/A	N/A	"Arbor Pharmaceuticals, LLC"	Atlanta	Georgia	30328	USA	EXACT	0173955AA	triptorelin pamoate	08AN7WA2G0						Precocious puberty	7446		
Leuprolide acetate	Treatment of central precocious puberty	Leuprolide acetate		Lupron Injection	7/25/88	Designated/Approved	Approved for Orphan Indication	Treatment of children with central precocious puberty	4/16/93	4/16/00	"Tap Pharmaceuticals, Inc."	Deerfield	Illinois	60015	USA	EXACT	0141322AA	Leuprolide acetate	37JNS02E7V						Precocious puberty	7446		
Nafarelin acetate	Treatment of central precocious puberty.	Nafarelin acetate		Synarel Nasal Solution	7/20/88	Designated/Approved	Approved for Orphan Indication	Treatment of central precocious puberty (gonadotropin-dependent precocious puberty) in children of both sexes.	2/26/92	2/26/99	"Syntex (USA), Inc."	Palo Alto	California	94303	USA	EXACT	0129873AA	Nafarelin acetate	8ENZ0QJW4H						Precocious puberty	7446		
Histrelin	Treatment of central precocious puberty	Histrelin		Supprelin La	11/18/05	Designated/Approved	Approved for Orphan Indication	Treatment of central precocious puberty	5/3/07	5/3/14	"Endo Pharmaceuticals Solutions, Inc."	Chadds Ford	Pennsylvania	19317	USA	EXACT	0135864AA	Histrelin	H50H3S3W74						Precocious puberty	7446		
Histrelin acetate	Treatment of central precocious puberty.	Histrelin acetate		Supprelin Injection	8/10/88	Designated/Approved	Approved for Orphan Indication	Treatment of central precocious puberty.	12/24/91	12/24/98	Roberts Pharmaceutical Corp.	Eatontown	New Jersey	7724	USA	EXACT	0134269AA	Histrelin acetate	QMG7HLD1ZE						Precocious puberty	7446		
Deslorelin	Treatment of central precocious puberty.	Deslorelin		Somagard	11/5/87	Designated			N/A	N/A	Roberts Pharmaceutical Corp.	Eatontown	New Jersey	7724	USA	EXACT	0168354AA	Deslorelin	TKG3I66TVE						Precocious puberty	7446		
2-[4-[[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate	Treatment of primary biliary cholangitis	SELADELPAR LYSINE DIHYDRATE		n/a	11/7/16	Designated			N/A	N/A	CymaBay Therapeutics	Newark	California	94560	USA	EXACT	1194054AA	SELADELPAR LYSINE DIHYDRATE	N1429130KR						Primary biliary cholangitis	7459		
lonafarnib	Treatment of Hutchinson-Gilford progeria syndrome	lonafarnib		n/a	4/18/11	Designated			N/A	N/A	"The Progeria Research Foundation, Inc."	Peabody	Massachusetts	1961	USA	EXACT	0223494AA	lonafarnib	IOW153004F						Progeria	7467		
progerinin	Treatment of Hutchinson-Gilford progeria syndrome	progerinin		n/a	10/2/18	Designated			N/A	N/A	"PRG S&T Co., Ltd."	306 Hyowon Industry-Cooperation Bldg.			"Korea, Republic of"										Progeria	7467		
glycosylated recombinant human interleukin-7	Treatment of progressive multifocal leukoencephalopathy	cyt-107		n/a	9/27/12	Designated			N/A	N/A	"Cytheris, Inc."	Rockville	Maryland	20852	USA	EXACT	0265872AA	cyt-107	418XB47Y71						Progressive multifocal leukoencephalopathy	7468		
Anti-eTau Humanized IgG4 Monoclonal Antibody	Treatment of Progressive Supranuclear Palsy	BMS-986168		n/a	5/13/15	Designated			N/A	N/A	Britol-Myers Squibb Company	Princeton	New Jersey	8543	USA	EXACT	1154332AA	BMS-986168	09FZ7Q0PQZ						Progressive supranuclear palsy	7471		
tolfenamic acid	Treatment of progressive supranuclear palsy	tolfenamic acid		n/a	7/13/16	Designated			N/A	N/A	Nasser H. Zawia	Warwick	Rhode Island	2886	USA	EXACT	0290722AA	tolfenamic acid	3G943U18KM						Progressive supranuclear palsy	7471		
"1-(fluoro-18F)-3-((2-((1E,3E)-4-(6-(methylamino)pyridin-3-yl)buta-1,3-dien-1-yl)benzo[d]thiazol-6-yl)oxy)propan-2-ol"	A diagnostic for the management of progressive supranuclear palsy	MNI-958 F-18		n/a	11/1/17	Designated			N/A	N/A	Aprinoia Therapeutics	"17F, No. 3 Yuanqu Street"			Taiwan	EXACT	1576869AA	MNI-958 F-18	51M993JIQ4						Progressive supranuclear palsy	7471		
"5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride"	Treatment of progressive supranuclear palsy.	"5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride"		n/a	4/18/11	Designated			N/A	N/A	"Mithridion, Inc."	Madison	Wisconsin	53711	USA	EXACT	0645669AA	"5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride"	6P87MRR8OA						Progressive supranuclear palsy	7471		
"(2'R,3'S)-2'-hydroxy-N-carboxy-3'-amino-5'-methyl-hexanoic,N-tert-butyl ester, 13 ester 5B-20-epoxy-1B,2a,4a,7B,9a,10a,13a-heptahydroxy-4,10-diacetate-2-benzoate-(1""S)-7,9-acrolein acetal-11(15-1)-abeotaxane"	Treatment of progressive supranuclear palsy	tpi-287		n/a	6/23/14	Designated			N/A	N/A	"Cortice Biosciences, Inc."	New York	New York	10019	USA	EXACT	0271249AA	tpi-287	A2VM2V569A						Progressive supranuclear palsy	7471		
davunetide	Treatment of progressive supranuclear palsy.	davunetide		n/a	12/7/09	Designated			N/A	N/A	"Allon Therapeutics, Inc."				Canada	EXACT	0257647AA	davunetide	GF00K3IIWE						Progressive supranuclear palsy	7471		
"4-benzyl-2-(a-naphtyl)-1,2,4-thiadiazolidine-3,5-dione"	Treatment of progressive supranuclear palsy	TIDEGLUSIB		n/a	10/13/09	Designated/Withdrawn			N/A	N/A	"NOSCIRA, S.A."	Madrid			Spain	EXACT	0362094AA	TIDEGLUSIB	Q747Y6TT42						Progressive supranuclear palsy	7471		
recombinant humanized anti-tau antibody	Treatment of progressive supranuclear palsy	ABBV-8E12		n/a	1/22/15	Designated			N/A	N/A	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0935660AA	ABBV-8E12	MY9Z7GDJ8J						Progressive supranuclear palsy	7471		
competetive small molecule inhibitor of the enzyme O-GlcNAcase	Treatment of progressive supranuclear palsy.	MK-8719		n/a	3/10/16	Designated			N/A	N/A	"Merck & Company, Inc."	Rahway	New Jersey	7065	USA	EXACT	1577011AA	MK-8719	GPA3Z4E1UU						Progressive supranuclear palsy	7471		
N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine disulphate salt	Treatment of progressive supranuclear palsy	AZP-2006 DISULFATE		n/a	3/20/17	Designated			N/A	N/A	Alzprotect sas	Loos			France	EXACT	0111780AB	AZP-2006 DISULFATE							Progressive supranuclear palsy	7471		
recombinant humanized IgG4P monoclonal antibody with specificity for human tau	Treatment of progressive supranuclear palsy (PSP)	recombinant humanized IgG4P monoclonal antibody with specificity for human tau		n/a	9/5/17	Designated			N/A	N/A	"UCB, Inc."	Smyrna	Georgia	30080	USA										Progressive supranuclear palsy	7471		
competitive and reversible small molecule inhibitor of the O-linked-B-N-acetylglucosaminidase enzyme	Treatment of progressive supranuclear palsy	ASN120290		n/a	7/10/18	Designated			N/A	N/A	Asceneuron S.A.	EPFL Innovation Park			Switzerland	EXACT									Progressive supranuclear palsy	7471		
"3-{3-[4-(1-aminocyclobutyl)phenyl]-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl}cpyridin-2-amine bis-mesylate"	Treatment of Proteus Syndrome.	ARQ-092		n/a	11/9/15	Designated			N/A	N/A	"ArQule, Inc."	Burlington	Massachusetts	1803	USA	EXACT	0708770AA	ARQ-092	T1DQI1B52Y						Proteus syndrome	7475		
L-cysteine	For the prevention and lessening of photosensitivity in erythropoietic protoporphyria.	L-cysteine		n/a	5/16/94	Designated			N/A	N/A	Brigham and Women's Hospital	Boston	Massachusetts	2115	USA	EXACT	0008322AA	L-cysteine	K848JZ4886						Protoporphyria	7476		
2-{4-[(9R)-9-Hydroxy-2-(3-hydroxy-3-methylbutyloxy)-9-(trifluoromethyl)-9H-fluoren-4-yl]-1H-pyrazol-1-yl}-2-methylpropanamide monohydrate	Treatment of pulmonary arterial hypertension	JTT-251 MONOHYDRATE		n/a	1/23/18	Designated			N/A	N/A	Akros Pharma Inc.	302 Carnegie Center	Princeton	8540	USA	EXACT	0932321AA	JTT-251 MONOHYDRATE	0AQV15PQ6M						Pulmonary arterial hypertension	7501		
vasoactive intestinal peptide (VIP)-elastin-like peptide (ELP) fusion protein	"Treatment of pulmonary arterial hypertension, WHO Group 1"	pb-1046		n/a	5/13/14	Designated			N/A	N/A	"PhaseBio Pharmaceuticals, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	1267045AA	pb-1046	200AW54D93						Pulmonary arterial hypertension	7501		
terguride	Treatment of pulmonary arterial hypertension	terguride		n/a	5/2/08	Designated/Withdrawn			N/A	N/A	ErgoNex Pharma GmbH				Switzerland	EXACT	0154869AA	terguride	21OJT43Q88						Pulmonary arterial hypertension	7501		
nitric oxide	Treatment of pulmonary arterial hypertension	nitric oxide		Inomax	12/28/11	Designated			N/A	N/A	Bellerophon Therapeutics	Hampton	New Jersey	8827	USA	EXACT	0176341AA	nitric oxide	31C4KY9ESH						Pulmonary arterial hypertension	7501		
nitric oxide	Treatment of pulmonary arterial hypertension excluding persistent pulmonary hypertension of the newborn	nitric oxide		n/a	1/25/17	Designated			N/A	N/A	"GeNo, LLC"	Cocoa	Florida	32926	USA	EXACT	0176341AA	nitric oxide	31C4KY9ESH						Pulmonary arterial hypertension	7501		
Beraprost	"Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV)."	Beraprost		n/a	4/29/99	Designated			N/A	N/A	"LungRx, Inc."	Silver Spring	Maryland	20910	USA	EXACT	0304665AA	Beraprost	35E3NJJ4O6						Pulmonary arterial hypertension	7501		
sildenafil	Treatment of pediatric (defined as children less than 17 years of age) pulmonary arterial hypertension	sildenafil		Revatio	7/28/11	Designated			N/A	N/A	"Pfizer, Inc."	New York	New York	10017	USA	EXACT	0229618AA	sildenafil	3M7OB98Y7H						Pulmonary arterial hypertension	7501		
sodium dichloroacetate	For pulmonary arterial hypertension.	sodium dichloroacetate		n/a	11/29/10	Designated			N/A	N/A	"Peter W. Stackpoole, PhD, MD"	Gainesville	Florida	32611	USA	EXACT	0079492AA	sodium dichloroacetate	42932X67B5						Pulmonary arterial hypertension	7501		
"(S)-8-{2-Amino-6-[1-(5-chloro-biphenyl-2-yl)-(R)-2,2,2-trifluoro-ethoxy]-pyrimidin-4-yl}-2,8-diaza-spiro[4.5]decane-3-carboxylic acid ethyl ester"	Treatment of pulmonary arterial hypertension (PAH).	KAR-5585		n/a	10/6/15	Designated			N/A	N/A	"KAROS Pharmaceuticals, Inc."	New Haven	Connecticut	6511	USA	EXACT	1200460AA	KAR-5585	507FY6OL37						Pulmonary arterial hypertension	7501		
selexipag	Treatment of pulmonary arterial hypertension	selexipag		Uptravi	4/30/10	Designated/Approved	Approved for Orphan Indication	"For use of Uptravi (Selexipag) Tablets, 200, 400, 600, 800, 1000, 1200, 1400, and 1600 mcg for treatment of pulmonary arterial hypertension (PAH, WHO Group I) to reduce the risks of disease progression and hospitalization for PAH"	12/21/15	12/21/22	Actelion Ltd	Allschwil CH-4123			Switzerland	EXACT	0362083AA	selexipag	5EXC0E384L						Pulmonary arterial hypertension	7501		
beraprost sodium 314d	Treatment of pulmonary arterial hypertension	beraprost sodium 314d		n/a	12/22/11	Designated			N/A	N/A	"Lung Rx, Inc."	Silver Spring	Maryland	20910	USA	EXACT	0761126AA	beraprost sodium 314d	6C8TLD4Q9K						Pulmonary arterial hypertension	7501		
2-methoxyestradiol	Treatment of pulmonary arterial hypertension	2-methoxyestradiol		Pulmolar	4/11/05	Designated			N/A	N/A	"PR Pharmaceuticals, Inc."	Fort Collins	Colorado	80524	USA	EXACT	0235176AA	2-methoxyestradiol	6I2QW73SR5						Pulmonary arterial hypertension	7501		
Sitaxsentan Sodium	For the treatment of pulmonary arterial hypertension in the absence of chronic obstructive pulmonary disease or congestive heart failure.	Sitaxsentan Sodium		n/a	11/2/04	Designated			N/A	N/A	Pfizer Global Research and Development	New London	Connecticut	6320	USA	EXACT	0220188AA	Sitaxsentan Sodium	6V9JH46E20						Pulmonary arterial hypertension	7501		
tadalafil	Treatment of pulmonary arterial hypertension	tadalafil		Adcirca	12/18/06	Designated/Approved	Approved for Orphan Indication	Treatment of pulmonary arterial hypertension (WHO Group I) to improve exercise ability	5/22/09	5/22/16	Eli Lilly and Company	Indianapolis	Indiana	46285	USA	EXACT	0223563AA	tadalafil	742SXX0ICT						Pulmonary arterial hypertension	7501		
ambrisentan/tadalafil fixed combination	Treatment of pulmonary arterial hypertension	tadalafil		n/a	8/22/16	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0223563AA	tadalafil	742SXX0ICT						Pulmonary arterial hypertension	7501		
fixed dose combination formulation of macitentan and tadalafil	Treatment of pulmonary arterial hypertension	 tadalafil		n/a	10/19/16	Designated			N/A	N/A	"Actelion Clinical Research, Inc."	Cherry Hill	New Jersey	8002	USA	EXACT	0223563AA	tadalafil	742SXX0ICT						Pulmonary arterial hypertension	7501		
tiprelestat	Treatment of pulmonary arterial hypertension	tiprelestat		Elafin	12/28/12	Designated			N/A	N/A	Proteo Biotech AG				Germany	EXACT	0795799AA	tiprelestat	78I8295690						Pulmonary arterial hypertension	7501		
bardoxolone	Treatment of pulmonary arterial hypertension	bardoxolone		n/a	3/30/15	Designated			N/A	N/A	"Reata Pharmaceuticals, Inc."	Irving	Texas	75063	USA	EXACT	0268439AA	bardoxolone	7HT68L8941						Pulmonary arterial hypertension	7501		
"treprostinil sodium solution enclosed within a pre-filled, pre-programmed, single-use, electronically-controlled infusion pump"	Treatment of pulmonary arterial hypertension	"treprostinil sodium solution enclosed within a pre-filled, pre-programmed, single-use, electronically-controlled infusion pump"		n/a	12/29/15	Designated			N/A	N/A	SteadyMed Therapeutics	San Ramon	California	94583	USA	EXACT	0244597AA	treprostinil sodium	7JZ75N2NT6						Pulmonary arterial hypertension	7501		
"5-((4-(6-chlorothieno[2,3-d]pyrimidine-4-ylamino)piperidin-1-yl)methyl)-2-fluorobenzonitrile monofumurate"	Treatment of pulmonary arterial hypertension	"5-((4-(6-chlorothieno(2,3-d)pyrimidine-4-ylamino)piperidin-1-yl)methyl)-2-fluorobenzonitrile monofumurate"		n/a	10/21/10	Designated/Withdrawn			N/A	N/A	"Forest Laboratories, Inc."	Jersey City	New Jersey	7311	USA	EXACT	0737360AA	"5-((4-(6-chlorothieno(2,3-d)pyrimidine-4-ylamino)piperidin-1-yl)methyl)-2-fluorobenzonitrile monofumurate"	92E9B7675Y						Pulmonary arterial hypertension	7501		
aviptadil	Treatment of pulmonary arterial hypertension	aviptadil		n/a	2/22/05	Designated			N/A	N/A	Mondobiotech Laboratories AG				Switzerland	EXACT	0464313AA	aviptadil	A67JUW790C						Pulmonary arterial hypertension	7501		
imatinib	Treatment of pulmonary arterial hypertension	imatinib		n/a	4/7/10	Designated/Withdrawn			N/A	N/A	Novartis	East Hanover	New Jersey	7936	USA	EXACT	0240153AA	imatinib	BKJ8M8G5HI						Pulmonary arterial hypertension	7501		
"2-{[(1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexy]methoxy} acetic acid"	Treatment of pulmonary arterial hypertension	apd-811		n/a	8/28/14	Designated			N/A	N/A	"Arena Pharmaceuticals, Inc."	San Diego	California	92121	USA	EXACT	1076182AA	apd-811	CQY12ZJN6E						Pulmonary arterial hypertension	7501		
lisuride	Treatment of pulmonary arterial hypertension	lisuride		n/a	1/17/13	Designated			N/A	N/A	Sinoxa Pharma GmbH				Germany	EXACT	0120194AA	lisuride	E0QN3D755O						Pulmonary arterial hypertension	7501		
ambrisentan	Treatment of pulmonary arterial hypertension	ambrisentan		Letairis	7/16/04	Designated/Approved	Approved for Orphan Indication	Treatment of pulmonary arterial hypertension (WHO group I) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening	6/15/07	6/15/14	Gilead Colorado	Westminister	Colorado	80021	USA	EXACT	0243696AA	ambrisentan	HW6NV07QEC						Pulmonary arterial hypertension	7501		
ambrisentan/tadalafil fixed combination	Treatment of pulmonary arterial hypertension	ambrisentan		n/a	8/22/16	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0243696AA	ambrisentan	HW6NV07QEC						Pulmonary arterial hypertension	7501		
ubenimex	Treatment of pulmonary arterial hypertension.	ubenimex		n/a	11/19/15	Designated			N/A	N/A	"Eiger BioPharmaceuticals, Inc."	Palo Alto	California	94306	USA	EXACT	0092795AA	ubenimex	I0J33N5627						Pulmonary arterial hypertension	7501		
"6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo[b][1,4]oxazin-3(4H)-one hydrochloride"	Treatment of pulmonary arterial hypertension (WHO Group 1)	RP-5063 hydrochloride		n/a	11/9/16	Designated			N/A	N/A	"Reviva Pharmaceuticals, Inc."	Santa Clara	California	95054	USA	EXACT	1800357AA	RP-5063 hydrochloride	I440YY0HX0						Pulmonary arterial hypertension	7501		
Angiotensin-(1-7)	Treatment of pulmonary arterial hypertension.	Angiotensin-(1-7)		n/a	9/13/11	Designated			N/A	N/A	"US Biotest, Inc."	San Luis Obispo	California	93401	USA	EXACT	0232428AA	Angiotensin-(1-7)	IJ3FUK8MOF						Pulmonary arterial hypertension	7501		
Iloprost inhalation solution	Treatment of pulmonary arterial hypertension	Iloprost inhalation solution		Ventavis	8/17/04	Designated/Approved	Approved for Orphan Indication	Treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms	12/29/04	12/29/11	"CoTherix, Inc."	South San Francisco	California	94080	USA	EXACT	0128096AA	Iloprost	JED5K35YGL						Pulmonary arterial hypertension	7501		
iloprost	Treatment of pulmonary arterial hypertension	iloprost		n/a	4/6/12	Designated			N/A	N/A	"Algorithum Sciences, LLC"	Wilmington	Delaware	19801	USA	EXACT	0128096AA	iloprost	JED5K35YGL						Pulmonary arterial hypertension	7501		
sodium nitrite	Treatment of pulmonary arterial hypertension	sodium nitrite		n/a	7/8/08	Designated			N/A	N/A	"Airess Pharmaceuticals, Inc."	San Diego	California	92130	USA	EXACT	0049581AA	sodium nitrite	M0KG633D4F						Pulmonary arterial hypertension	7501		
"5-(4-Cyclopropyl-1H-imidazol-l-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide"	Treatment pulmonary arterial hypertension	Selonsertib		n/a	1/15/15	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	1077527AA	Selonsertib	NS3988A2TC						Pulmonary arterial hypertension	7501		
iferanserin (S-MPEC)	For use in pulmonary arterial hypertension.	iferanserin (S-MPEC)		n/a	12/13/10	Designated			N/A	N/A	"Sam Amer & Company, Inc."	Montecito	California	93150	USA	EXACT	0337575AA	iferanserin	NWR3BEB8PA						Pulmonary arterial hypertension	7501		
Bosentan	Treatment of pulmonary arterial hypertension.	Bosentan		Tracleer	10/6/00	Designated/Approved	Approved for Orphan Indication	Treatment of pulmonary arterial hypertension.	11/20/01	11/20/08	Actelion Life Sciences Ltd.	San Mateo	California	94404	USA	EXACT	0186663AA	Bosentan	Q326023R30						Pulmonary arterial hypertension	7501		
riociguat	Treatment of pulmonary arterial hypertension.	riociguat		Adempas	9/19/13	Designated/Approved	Approved for Orphan Indication	"Treatment of adults with pulmonary arterial hypertension (PAH) WHO Group 1, to improve exercise capacity, WHO functional class and to delay clinical worsening."	10/8/13	10/8/20	"Bayer HealthCare Pharmaceuticals, Inc."	Whippany	New Jersey	7981	USA	EXACT	0457852AA	riociguat	RU3FE2Y4XI						Pulmonary arterial hypertension	7501		
treprostinil	Treatment of pulmonary arterial hypertension.	treprostinil		Remodulin	6/4/97	Designated/Approved	Approved for Orphan Indication	Treatment of pulmonary arterial hypertension.	5/21/02	5/21/09	United Therapeutics Corp.	Research Triangle Park	North Carolina	27709	USA	EXACT	0175053AA	treprostinil	RUM6K67ESG						Pulmonary arterial hypertension	7501		
treprostinil (inhalational)	Treatment of pulmonary arterial hypertension	treprostinil (inhalational)		Tyvaso	6/17/10	Designated/Approved	Approved for Orphan Indication	"Treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III symptoms, to increase walk distance"	7/30/09	7/30/16	"LungRx, Inc."	Satellite Beach	Florida	32937	USA	EXACT	0175053AA	treprostinil	RUM6K67ESG						Pulmonary arterial hypertension	7501		
cicletanine hydrochloride	Treatment for pulmonary arterial hypertension.	cicletanine hydrochloride		n/a	6/24/08	Designated/Withdrawn			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0168558AA	cicletanine hydrochloride	T0SY6373OQ						Pulmonary arterial hypertension	7501		
Partial agonist at the opioid receptor-like 1 receptor with amino acid sequence Ac-Arg-Tyr-Tyr-Arg-Trp-Lys-Lys-Lys-Lys-Lys-Lys-Lys-NH2	Treatment of pulmonary arterial hypertension	SER-100		n/a	10/19/16	Designated			N/A	N/A	Serodus ASA	Oslo			Norway	EXACT	0248431AA	SER-100	VJ98TJ922K						Pulmonary arterial hypertension	7501		
tacrolimus	Treatment of pulmonary arterial hypertension.	tacrolimus		n/a	3/16/15	Designated			N/A	N/A	"Selten Pharma, Inc."	Saratoga	California	95070	USA	EXACT	0168956AA	tacrolimus	WM0HAQ4WNM						Pulmonary arterial hypertension	7501		
tacrolimus	Treatment of pulmonary arterial hypertension	tacrolimus		n/a	5/4/15	Designated			N/A	N/A	Stanford University School of Medicine	Stanford	California	94305	USA	EXACT	0168956AA	tacrolimus	WM0HAQ4WNM						Pulmonary arterial hypertension	7501		
macitentan	Treatment of pulmonary arterial hypertension	macitentan		Opsumit	9/3/09	Designated/Approved	Approved for Orphan Indication	"Treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). Opsumit also reduced hospitalization for PAH."	10/18/13	10/18/20	Actelion Pharmaceuticals Ltd	Allschwil			Switzerland	EXACT	0339333AA	macitentan	Z9K9Y9WMVL						Pulmonary arterial hypertension	7501		
fixed dose combination formulation of macitentan and tadalafil	Treatment of pulmonary arterial hypertension	fixed dose combination formulation of macitentan and tadalafil		n/a	10/19/16	Designated			N/A	N/A	"Actelion Clinical Research, Inc."	Cherry Hill	New Jersey	8002	USA	EXACT	0339333AA	macitentan	Z9K9Y9WMVL						Pulmonary arterial hypertension	7501		
"(S)-3-((3-(1-((6-((3,4-dimethoxyphenyl)pryazin-2-yl)amino)ethyl)phenyl)carbamoyl)-5-methylpridin-1-ium"	Treatment of pulmonary arterial hypertension	PK-10571		n/a	11/17/14	Designated			N/A	N/A	"Pulmokine, Inc."	Rensselaer	New York	12144	USA	EXACT	1793506AA	PK-10571	3P63ZTE3OY						Pulmonary arterial hypertension	7501		
Humanized IgG4 monoclonal antibody that antagonizes endothelin-1 receptor subtype A	Treatment of pulmonary arterial hypertension (PAH)	GMA-301		n/a	6/6/17	Designated			N/A	N/A	"GenThera, Inc."	Thousand Oaks	California	91362	USA	EXACT									Pulmonary arterial hypertension	7501		
Active calcium sensing receptor antagonist derived from tetrahydropyrazolopyrimidine	Treatment of pulmonary arterial hypertension	TAK-075		n/a	6/13/17	Designated			N/A	N/A	"Takeda Development Centre Europe, Ltd."	London			United Kingdom	EXACT	0114260AB	TAK-075	N9LP5QC07K						Pulmonary arterial hypertension	7501		
"N-(tert-butylcarbamoyl)-5-cyano-2-((4'-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)oxy)benzenesulfonamide"	Treatment of pulmonary arterial hypertension	NTP-42		n/a	3/1/18	Designated			N/A	N/A	ATXA Therapeutics Limited	75 Avoca Avenue	Blackrock		Ireland	EXACT	0114497AB	NTP-42	2057H3EG0S						Pulmonary arterial hypertension	7501		
trimetazidine	Treatment of pulmonary arterial hypertension	trimetazidine		n/a	8/7/18	Designated			N/A	N/A	"Martin Pharmaceuticals, Inc."	233 Broadway	New York	10279	USA	EXACT	0043196AA	trimetazidine	N9A0A0R9S8						Pulmonary arterial hypertension	7501		
Interleukin-3 human (recombinant)	Promotion of erythropoiesis in Diamond-Blackfan anemia (congenital pure red cell aplasia).	HUMAN INTERLEUKIN-3 (NONGLYCOSYLATED)		n/a	5/20/91	Designated/Withdrawn			N/A	N/A	Immunex Corporation	Seattle	Washington	98101	USA	EXACT	0259836AA	HUMAN INTERLEUKIN-3 (NONGLYCOSYLATED)	A802907MI4						Pure red cell aplasia	7504		
gevokizumab	Treatment of pyoderma gangrenosum	gevokizumab		n/a	2/21/14	Designated			N/A	N/A	XOMA (US) LLC	Berkeley	California	94710	USA	EXACT	0574107AA	gevokizumab	QX3JU54GYQ						Pyoderma gangrenosum	7510		
allosteric activator of the red blood cell-specific form of pyruvate kinase	Treatment of pyruvate kinase deficiency	AG-348		n/a	3/24/15	Designated			N/A	N/A	"Agios Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0933379AA	AG-348	N4JTA67V3O						Pyruvate kinase deficiency	7514		
lentiviral vector containing the human liver and erythroid pyruvate kinase gene	Treatment of pyruvate kinase deficiency.	lentiviral vector containing the human liver and erythroid pyruvate kinase gene		n/a	3/23/16	Designated			N/A	N/A	Centro de Investigacion Biomedica en RED (CIBER)	Madrid			Spain	LONGEST CONTAINS	1309279AA	human liver	JFENOMOVE6						Pyruvate kinase deficiency	7514		
PyNTTTTGT class of oligodeoxynucleotide with a 24-base single chain composed of nucleotide sequence 5'TCATCATTTTGTCATTTTGTCATT 3'	Treatment of rabies virus infections	IMT-504		Imt504	11/24/14	Designated			N/A	N/A	"Mid-Atlantic BioTherapeutics, Inc."	Doylestown	Pennsylvania	18902	USA	EXACT	1802831AA	IMT-504	8A805B1IH6						Rabies	7516		
Mixture of 2 anti-rabies humanized monoclonal immunoglobulin (Ig)G1k antibodies	Post-exposure prophylaxis against rabies virus infection	Mixture of 2 anti-rabies humanized monoclonal immunoglobulin (Ig)G1k antibodies		n/a	10/7/15	Designated			N/A	N/A	"Synermore Biologics Co., Ltd"				Taiwan										Rabies	7516		
"Inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium)"	Prevention of rabies virus infection including post-exposure prophylaxis (PEP) for rabies	"Inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium)"		n/a	12/29/16	Designated			N/A	N/A	"Yisheng US Biopharma, Inc."	Gaithersburg	Maryland	20878	USA	LONGEST CONTAINS	0317044AA	rabies virus	I0V66KI1LD						Rabies	7516		
thioureidobutyronitrile	Treatment of retinoblastoma.	thioureidobutyronitrile		Kevetrin	11/17/15	Designated			N/A	N/A	Cellceutix Corporation	Beverly	Massachusetts	1915	USA	EXACT	0832633AA	thioureidobutyronitrile	C3059TG1KN						Retinoblastoma	7563		
melphalan	Treatment of retinoblastoma	melphalan		n/a	11/19/12	Designated			N/A	N/A	"Icon Bioscience, Inc."	Sunnyvale	California	94089	USA	EXACT	0023176AA	melphalan	Q41OR9510P						Retinoblastoma	7563		
tazemetostat	Treatment of malignant rhabdoid tumors (MRTs)	tazemetostat		n/a	2/4/16	Designated			N/A	N/A	Epizyme Inc.	Cambridge	Massachusetts	2139	USA	EXACT	1120394AA	tazemetostat	Q40W93WPE1						Rhabdoid tumor	7572		
pyrimethamine	Treatment of GM-2 gangliosidoses (Tay-Sachs disease and Sandhoff disease).	pyrimethamine		n/a	8/16/11	Designated			N/A	N/A	ExSAR Corporation	Monmouth Junction	New Jersey	8852	USA	EXACT	0009687AA	pyrimethamine	Z3614QOX8W						Sandhoff disease	7604		
recombinant adeno- associated virus vector AAV2/rh8 expressing human B-hexosaminidase A and B subunits	For the treatment of Sandhoff disease	recombinant adeno- associated virus vector AAV2/rh8 expressing human B-hexosaminidase A and B subunits		n/a	3/25/13	Designated			N/A	N/A	Nat'l Tay-Sachs & Allied Diseases Association	Boston	Massachusetts	2135	USA	LONGEST CONTAINS	0081481AA	hexosaminidase A							Sandhoff disease	7604		
Recombinant adeno-associated virus serotype 2/1 vector encoding human beta-hexosaminidase alpha & beta subunits (rAAV2/1 Hex alpha & beta)	Treatment of GM2 gangliosidosis (Tay-Sachs & Sandhoff diseases)	Recombinant adeno-associated virus serotype 2/1 vector encoding human beta-hexosaminidase alpha & beta subunits (rAAV2/1 Hex alpha & beta)		n/a	11/14/17	Designated			N/A	N/A	University of Cambridge	Hills Road			United Kingdom										Sandhoff disease	7604		
(monomethoxypolyethylene glycol) recombinant adenosine deaminase	Treatment of adenosine deaminase deficiency in patients with severe combined immunodeficiency	EZN-2279 		n/a	3/19/15	Designated			N/A	N/A	"Sigma-Tau Pharmaceuticals, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	1311246AA	EZN-2279	9R3D3Y0UHS						Severe combined immunodeficiency	7628		
Pegademase bovine	For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.	Pegademase bovine		Adagen	5/29/84	Designated/Approved	Approved for Orphan Indication		3/21/90	3/21/97	"Sigma-tau Pharmaceuticals, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0152465AA	Pegademase bovine	HW3H7D91F6						Severe combined immunodeficiency	7628		
autologus CD34+ cells transfected with retroviral vector containing adenosine deaminase gene	Treatment of severe combined immunodeficiency due to adenosine deaminase deficiency.	autologus CD34+ cells transfected with retroviral vector containing adenosine deaminase gene		n/a	8/26/09	Designated			N/A	N/A	Glaxo Group Limited				United Kingdom	LONGEST CONTAINS	1315157AA	adenosine deaminase	XPQ5L1L4WO						Severe combined immunodeficiency	7628		
"autologous bone marrow CD34+ cells transduced ex vivo with a self activating HIV-1 -based lentiviral vector, EFS-ADA"	Treatment of adenosine deaminase deficient severe combined immunodeficiency	"autologous bone marrow CD34+ cells transduced ex vivo with a self activating HIV-1 -based lentiviral vector, EFS-ADA"		n/a	10/21/14	Designated			N/A	N/A	"Donald B. Kohn, MD - Professor, UC-UCLA"	Los Angeles	California	90095	USA	LONGEST CONTAINS	0260924AA	autologous bone marrow							Severe combined immunodeficiency	7628		
deferiprone	Treatment of superficial siderosis	deferiprone		n/a	9/1/11	Designated			N/A	N/A	"ApoPharma, Inc."				Canada	EXACT	0179680AA	deferiprone	2BTY8KH53L						Siderosis	7645		
nusinersen	Treatment of spinal muscular atrophy	nusinersen		n/a	4/18/11	Designated			N/A	N/A	"Biogen, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	1080166AA	nusinersen	5Z9SP3X666						Spinal muscular atrophy	7674		
"cholest-4-en-3-one, oxime"	Treatment of spinal muscular atrophy.	"cholest-4-en-3-one, oxime"		n/a	2/17/09	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0340045AA	"cholest-4-en-3-one, oxime"	A6778U5IFY						Spinal muscular atrophy	7674		
ataluren	Treatment of spinal muscular atrophy	ataluren		n/a	3/10/08	Designated			N/A	N/A	"PTC Therapeutics, Inc."	South Plainfield	New Jersey	7080	USA	EXACT	0317259AA	ataluren	K16AME9I3V						Spinal muscular atrophy	7674		
"5-[1-(2,6-Dichlorobenzyl)-piperidin-4-yl]methoxyquinazoline-2,4-diamine"	Treatment of spinal muscular atrophy	"5-(1-(2,6-Dichlorobenzyl)-piperidin-4-yl)methoxyquinazoline-2,4-diamine"		n/a	8/25/09	Designated			N/A	N/A	CureSMA	Elk Grove Village	Illinois	60007	USA	EXACT	0659858AA	"5-(1-(2,6-Dichlorobenzyl)-piperidin-4-yl)methoxyquinazoline-2,4-diamine"	KSV93L7URW						Spinal muscular atrophy	7674		
Sodium phenylbutyrate	Treatment of spinal muscular atrophy	Sodium phenylbutyrate		Buphenyl	1/25/07	Designated			N/A	N/A	"OrphaMed, Inc."	Scottsdale	Arizona	85256	USA	EXACT	0180767AA	Sodium phenylbutyrate	NT6K61736T						Spinal muscular atrophy	7674		
Sodium phenylbutyrate	Treatment of spinal muscular atrophy	Sodium phenylbutyrate		n/a	3/20/07	Designated			N/A	N/A	"Tikvah Therapeutics, Inc."	Atlanta	Georgia	30308	USA	EXACT	0180767AA	Sodium phenylbutyrate	NT6K61736T						Spinal muscular atrophy	7674		
sodium 4-phenylbutyrate	Treatment of spinal muscular atrophy	sodium 4-phenylbutyrate		n/a	10/18/11	Designated			N/A	N/A	GMP-Orphan SAS	Paris			France	EXACT	0180767AA	sodium 4-phenylbutyrate	NT6K61736T						Spinal muscular atrophy	7674		
branaplam	Treatment of spinal muscular atrophy (SMA)	branaplam		n/a	1/23/18	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	1 Health Plaza	East Hanover	7936	USA	EXACT	1115248AA	branaplam	P12R69543A						Spinal muscular atrophy	7674		
Glyceryl tri (4-phenylbutyrate)	Treatment of spinal muscular atrophy	Glyceryl tri (4-phenylbutyrate)		n/a	5/24/05	Designated			N/A	N/A	"Ucyclyd Pharma, Inc"	Scottsdale	Arizona	85256	USA	EXACT	0682848AA	Glyceryl tri (4-phenylbutyrate)	ZH6F1VCV7B						Spinal muscular atrophy	7674		
pyridopyrimidinone SMN2 splicing modifier	Treatment of spinal muscular atrophy	RO-7034067		n/a	1/4/17	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	South San Francisco	California	94080	USA	EXACT	1575902AA	RO-7034067	76RS4S2ET1						Spinal muscular atrophy	7674		
fast skeletal muscle troponin activator	Treatment of spinal muscular atrophy	CK-2127107		n/a	5/11/17	Designated			N/A	N/A	"Cytokinetics, Inc."	South San Francisco	California	94080	USA	EXACT	0111777AB	CK-2127107	4S0HBYW6QE						Spinal muscular atrophy	7674		
fully human anti-proMyostatin monoclonal antibody of the IgG4/lambda isotype that binds to human pro- and latent myostatin with high affinity	Treatment of spinal muscular atrophy	fully human anti-proMyostatin monoclonal antibody of the IgG4/lambda isotype that binds to human pro- and latent myostatin with high affinity		n/a	3/22/18	Designated			N/A	N/A	Scholar Rock	620 Memorial Drive	Suite E	2139	USA	LONGEST CONTAINS	0803203AA	myostatin	6O86C0ZH33						Spinal muscular atrophy	7674		
late stage human motor neutron progenitors	Treatment of spinal muscular atrophy	late stage human motor neutron progenitors		Motorgraft(Tm)	11/25/09	Designated			N/A	N/A	"California Stem Cell, Inc."	Irvine	California	92612	USA										Spinal muscular atrophy	7674		
adeno-associated virus serotype 9 expressing the human Survival Motor Neuron gene	Treatment of spinal muscular atrophy	adeno-associated virus serotype 9 expressing the human Survival Motor Neuron gene		n/a	9/30/14	Designated			N/A	N/A	"AveXis, Inc."	Dallas	Texas	75206	USA										Spinal muscular atrophy	7674		
recombinant adeno-associated viral vector containing a single-stranded transgene encoding a codon-optimized human SMN1 complementary deoxyribonucleic acid under the control of the chicken beta actin promoter	Treatment of Spinal Muscular Atrophy	recombinant adeno-associated viral vector containing a single-stranded transgene encoding a codon-optimized human SMN1 complementary deoxyribonucleic acid under the control of the chicken beta actin promoter		n/a	7/16/18	Designated			N/A	N/A	Biogen Inc.	225 Binney Street	Massachusetts	2142	USA	LONGEST CONTAINS	0006484AA	deoxyribonucleic acid							Spinal muscular atrophy	7674		
Amphotericin B lipid complex	Treatment of invasive sporotrichosis.	Amphotericin B lipid complex		Abelcet	9/23/96	Designated/Withdrawn			N/A	N/A	"The Liposome Company, Inc."	Princeton	New Jersey	8540	USA	EXACT	0035881AA	Amphotericin B lipid complex	7XU7A7DROE						Sporotrichosis	7692		
3-aminopropyl-butyl phosphinic acid	Treatment of succinic semialdehyde dehydrogenase deficiency.	SGS-742		n/a	12/13/16	Designated			N/A	N/A	"Speragen, Inc."	Austin	Texas	78750	USA	EXACT	0242740AA	SGS-742	GBZ5UC0RME						Succinic semialdehyde dehydrogenase deficiency	7695		
bevacizumab	In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.	bevacizumab		Avastin	11/20/09	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0244257AA	bevacizumab	2S9ZZM9Q9V						Stomach cancer	7704		
20-mer complementary to Akt mRNA	Treatment of stomach cancer	ARCHEXIN		n/a	12/10/04	Designated			N/A	N/A	Rexahn Corporation	Rockville	Maryland	20850	USA	EXACT	0252631AA	ARCHEXIN	4TEW51C830						Stomach cancer	7704		
Plevitrexed	Treatment of gastric (stomach cancer	Plevitrexed		Plevitrexed	5/29/07	Designated/Withdrawn			N/A	N/A	BTG International Ltd				United Kingdom	EXACT	0284402AA	Plevitrexed	L9P2881C3H						Stomach cancer	7704		
Inosine pranobex	Treatment of subacute sclerosing panencephalitis.	Inosine pranobex		Isoprinosine	9/20/88	Designated			N/A	N/A	Newport Pharmaceuticals	Newport Beach	California	92663	USA	EXACT	0105760AA	Inosine pranobex	W1SO0V223F						Subacute sclerosing panencephalitis	7708		
Sacrosidase	Treatment of congenital sucrase-isomaltase deficiency	Sacrosidase		Sucraid	12/10/93	Designated/Approved	Approved for Orphan Indication	"Oral replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrease-isomaltase deficiency."	4/9/98	4/9/05	"QOL Medical, LLC"	Vero Beach	Florida	32963	USA	EXACT	0227634AA	Sacrosidase	8A7F670F2Y						Congenital sucrase-isomaltase deficiency	7710		
recombinant humanized IgG4 monoclonal antibody that binds human colony stimulating factor 1 receptor	Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor	Cabiralizumab		n/a	1/11/16	Designated			N/A	N/A	"Five Prime Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	1132816AA	Cabiralizumab	5FJL6W0640						Synovitis	7722		
recombinant humanized monoclonal antibody of the immunoglobulin G1 subclass directed against colony stimulating factor-1 receptor expressed on macrophages	Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor	Emactuzumab		n/a	5/14/14	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0931204AA	Emactuzumab	6FY6EI1X8R						Synovitis	7722		
recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor	"Treatment of pigmented villonodular synovitis, including giant cell tumor of the tendon sheath"	OTILIMAB		n/a	8/19/14	Designated			N/A	N/A	Novartis Pharmaceuticals Corp	East Hanover	New Jersey	7936	USA	EXACT	0112972AB	OTILIMAB	Y8127R3VCH						Synovitis	7722		
"[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride salt"	Treatment of pigmented villonodular synovitis/giant cell tumor of the tendon sheath	PEXIDARTINIB HYDROCHLORIDE		n/a	2/14/14	Designated			N/A	N/A	"Daiichi Sankyo, Inc."	Edison	New Jersey	8837	USA	EXACT	0341048AA	PEXIDARTINIB HYDROCHLORIDE	YS6WAI3XN7						Synovitis	7722		
Recombinant human relaxin	Treatment of progressive systemic sclerosis.	Recombinant human relaxin		n/a	11/3/95	Designated/Withdrawn			N/A	N/A	Connetics Corporation	Palo Alto	California	94303	USA	EXACT	0171619AA	Recombinant human relaxin	W0122B976Y						Progressive systemic sclerosis	7727		
N-acetyl-glucosamine thiazoline	Treatment of adult Tay-Sachs disease	N-acetyl-glucosamine thiazoline		n/a	2/6/06	Designated			N/A	N/A	ExSAR Corporation	Monmouth Junction	New Jersey	8852	USA	EXACT	0760098AA	N-acetyl-glucosamine thiazoline	ML5FHL557A						Tay-Sachs disease	7737		
pyrimethamine	Treatment of GM-2 gangliosidoses (Tay-Sachs disease and Sandhoff disease).	pyrimethamine		n/a	8/16/11	Designated			N/A	N/A	ExSAR Corporation	Monmouth Junction	New Jersey	8852	USA	EXACT	0009687AA	pyrimethamine	Z3614QOX8W						Tay-Sachs disease	7737		
recombinant adenovirus vector AAV2/rh8 expressing human B-hexosaminidase A & B subunits	Treatment of Tay-Sachs disease	recombinant adenovirus vector AAV2/rh8 expressing human B-hexosaminidase A & B subunits		n/a	3/25/13	Designated			N/A	N/A	Na't Tay-Sachs & Allied Diseases Association	Boston	Massachusetts	2135	USA	LONGEST CONTAINS	0081481AA	hexosaminidase A							Tay-Sachs disease	7737		
Ifosfamide	Treatment of testicular cancer.	Ifosfamide		Ifex	1/20/87	Designated/Approved	Approved for Orphan Indication	"In combination with certain other approved antineoplastic agents, for third line chemotherapy in the treatment of germ cell testicular cancer."	12/30/88	12/30/95	Bristol-Myers Squibb Pharmaceutical Research Institute	Wallingford	Connecticut	6492	USA	EXACT	0041770AA	Ifosfamide	UM20QQM95Y						Testicular cancer	7746		
L-5-hydroxytryptophan	Treatment of tetrahydrobiopterin deficiency.	oxitriptan		n/a	1/20/99	Designated			N/A	N/A	"Watson Laboratories, Inc."	Corona	California	91718	USA	EXACT	0009110AA	oxitriptan	C1LJO185Q9						Tetrahydrobiopterin deficiency	7751		
"5-aza-2'-dexocytidine combined with 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one"	Treatment of thalassemia	TETRAHYDROURIDINE		n/a	2/16/17	Designated			N/A	N/A	EpiDestiny Inc.	Solon	Ohio	44139	USA	EXACT	0058957AA	TETRAHYDROURIDINE	0NIZ8H6OL8						Thalassemia	7756		
recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB (ActRIIB) linked to a human IgG1 Fc domain	Treatment of B-thalassemia	Sotatercept		n/a	3/11/13	Designated			N/A	N/A	Celgene Corporation	Overland Park	Kansas	66210	USA	EXACT	0343931AA	Sotatercept	0QI90BTJ37						Thalassemia	7756		
sotatercept	Treatment of beta-thalassemia intermedia and major	sotatercept		n/a	12/5/13	Designated			N/A	N/A	Celgene Corporation	Summit	New Jersey	7901	USA	EXACT	0343931AA	sotatercept	0QI90BTJ37						Thalassemia	7756		
"5-aza-2'-dexocytidine combined with 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one"	Treatment of thalassemia	5-aza-2'-deoxycytidine		n/a	2/16/17	Designated			N/A	N/A	EpiDestiny Inc.	Solon	Ohio	44139	USA	EXACT	0171244AA	5-aza-2'-deoxycytidine	776B62CQ27						Thalassemia	7756		
Isobutyramide	Treatment of beta-hemoglobinopathies and beta-thalassemia syndromes.	Isobutyramide		Isobutyramide Oral Solution	12/18/92	Designated			N/A	N/A	"Perrine, Susan P., M.D."	Boston	Massachusetts	2118	USA	EXACT	0180734AA	Isobutyramide	82UOE7B38Z						Thalassemia	7756		
Isobutyramide	Treatment of sickle cell disease and beta thalassemia.	Isobutyramide		n/a	5/25/94	Designated			N/A	N/A	Alpha Therapeutic Corporation	Los Angeles	California	90032	USA	EXACT	0180734AA	Isobutyramide	82UOE7B38Z						Thalassemia	7756		
Arginine butyrate	Treatment of beta-hemoglobinopathies and beta-thalassemia.	Arginine butyrate		n/a	4/7/92	Designated			N/A	N/A	"Perrine, Susan P., M.D."	Boston	Massachusetts	2118	USA	EXACT	0179828AA	Arginine butyrate	IK8S1P79MU						Thalassemia	7756		
Arginine butyrate	Treatment of sickle cell disease and beta thalassemia.	Arginine butyrate		n/a	5/25/94	Designated/Withdrawn			N/A	N/A	Vertex Pharmaceuticals Inc.	Cambridge	Massachusetts	2139	USA	EXACT	0179828AA	Arginine butyrate	IK8S1P79MU						Thalassemia	7756		
sodium phenylbutyrate	"Treatment for sickling disorders, which include S-S hemoglobinopathy, S-C hemoglobinopathy, and S-thalassemia hemoglobinopathy."	sodium phenylbutyrate		n/a	7/2/92	Designated			N/A	N/A	Medicis Pharmaceutical Corp.	Scottsdale	Arizona	85258	USA	EXACT	0180767AA	sodium phenylbutyrate	NT6K61736T						Thalassemia	7756		
bitopertin	Treatment of ß-thalassemia	bitopertin		n/a	8/16/17	Designated			N/A	N/A	Hoffmann-La Roche Inc.	South San Francisco	California	94080	USA	EXACT	0459825AA	bitopertin	Q8L6AN59YY						Thalassemia	7756		
deferasirox	Treatment of chronic iron overload in alpha-thalassemia	deferasirox		Exjade	2/24/15	Designated/Approved	Approved for Orphan Indication	Treatment of chronic iron overload in patients 10 years of age and older with non-transfusion dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and serum ferritin greater than 300 mcg/L.	1/23/13	1/23/20	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0232860AA	deferasirox	V8G4MOF2V9						Thalassemia	7756		
sirolimus	Treatment of beta-thalassemia.	sirolimus		n/a	6/21/16	Designated			N/A	N/A	Rare Partners srl Impresa Sociale	Milano			Italy	EXACT	0175177AA	sirolimus	W36ZG6FT64						Thalassemia	7756		
2 dimethylbutyrate	Treatment of beta thalassemia	"SODIUM 2,2-DIMETHYLBUTYRATE"		n/a	6/18/08	Designated			N/A	N/A	"HemaQuest Pharmaceuticals, Inc."	Seattle	Washington	98154	USA	EXACT	0313622AA	"SODIUM 2,2-DIMETHYLBUTYRATE"	XKM99SPB5I						Thalassemia	7756		
deferoxamine starch conjugate	Treatment of chronic iron overload resulting from conventional transfusional treatment of beta-thalassemia major and sickle cell anemia.	deferoxamine starch conjugate		n/a	12/21/98	Designated			N/A	N/A	"Biomedical Frontiers, Inc."	Minneapolis	Minnesota	55414	USA	LONGEST CONTAINS	0012204AA	deferoxamine	J06Y7MXW4D						Thalassemia	7756		
Lentiviral vector encoded with a human beta-globin gene plasmid	Treatment of beta-thalassemia major and beta-thalassemia intermedia	Lentiviral vector encoded with a human beta-globin gene plasmid		Thalagen	1/11/06	Designated			N/A	N/A	Memorial Sloan-Kettering Cancer Center	New York	New York	10065	USA										Thalassemia	7756		
autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene	Treatment of B-thalassemia major and intermedia	autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene		n/a	3/18/13	Designated			N/A	N/A	"bluebird bio, Inc."	Cambridge	Massachusetts	2141	USA	LONGEST CONTAINS	0264620AA	stem cells							Thalassemia	7756		
hepcidin mimetic peptide	Treatment of ß-thalassemia	PTG-300		n/a	3/1/18	Designated			N/A	N/A	Protagonist Therapeutics	521 Cottonwood Drive	Milpitas	95035	USA										Thalassemia	7756		
coagulation factor VIIa (recombinant)	Treatment of bleeding episodes in Glanzmann's thrombasthenia	coagulation factor VIIa (recombinant)		Novoseven Rt	6/18/04	Designated/Approved	Approved for Orphan Indication	"Treatment of bleeding episodes and peri-operative management in adults and children with Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets."	7/2/14	7/2/21	Novo Nordisk Inc.	Plainsboro	New Jersey	8536	USA	EXACT	0324765AA	coagulation factor VIIa (recombinant)	AC71R787OV						Thrombasthenia	7760		
Coagulation factor VIIa (recombinant)	Prevention of bleeding episodes in Glanzmann's thrombasthenia	Coagulation factor VIIa (recombinant)		Novoseven	6/18/04	Designated			N/A	N/A	"Novo Nordisk, Inc."	Princeton	New Jersey	8540	USA	EXACT	0324765AA	Coagulation factor VIIa (recombinant)	AC71R787OV						Thrombasthenia	7760		
mitomycin	Treatment of upper tract urothelial cell cancers (transitional cell carcinoma of the renal pelvis and ureter)	mitomycin		Mitogel	9/8/14	Designated			N/A	N/A	"TheraCoat, Ltd."				Israel	EXACT	0132865AA	mitomycin	50SG953SK6						Transitional cell carcinoma	7794		
Sodium ascorbate and menadione sodium bisulfite	Treatment of metastatic or locally advanced inoperable transitional cell carcinoma of the urothelium (stage III and IV bladder cancer)	Sodium ascorbate and menadione sodium bisulfite		Apatone	7/31/07	Designated			N/A	N/A	IC-MedTech Corporation	San Diego	California	92021	USA	EXACT	0020815AA	menadione sodium bisulfite	6XF3C2HK77						Transitional cell carcinoma	7794		
pralatrexate	Treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder	pralatrexate		n/a	5/3/10	Designated			N/A	N/A	"Allos Therapeutics, Inc."	Westminister	Colorado	80020	USA	EXACT	0219034AA	pralatrexate	A8Q8I19Q20						Transitional cell carcinoma	7794		
Sodium ascorbate and menadione sodium bisulfite	Treatment of metastatic or locally advanced inoperable transitional cell carcinoma of the urothelium (stage III and IV bladder cancer)	Sodium ascorbate		Apatone	7/31/07	Designated			N/A	N/A	IC-MedTech Corporation	San Diego	California	92021	USA	EXACT	0021363AA	Sodium ascorbate	S033EH8359						Transitional cell carcinoma	7794		
Porfimer sodium	For the photodynamic therapy of patients with transitional cell carcinoma in situ of the urinary bladder.	Porfimer sodium		Photofrin	11/15/89	Designated			N/A	N/A	"QLT Phototherapeutics, Inc."	Pearl River	New York	10965	USA	EXACT	0172452AA	Porfimer sodium	Y3834SIK5F						Transitional cell carcinoma	7794		
baclofen	"Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy)."	baclofen		Lioresal Intrathecal	11/10/87	Designated/Approved	Approved for Orphan Indication	Management of severe spasticity of spinal cord origin in patients who are unresponsive to oral baclofen therapy or experience intolerable CNS side effects at effective doses.	6/25/92	6/25/99	"Medtronic, Inc."	Minneapolis	Minnesota	55432	USA	EXACT	0032804AA	baclofen	H789N3FKE8						Transverse myelitis	7796		
human glial restricted progenitor cells and their progeny	Treatment of transverse myelitis	human glial restricted progenitor cells and their progeny		Q-Cells®	4/11/18	Designated			N/A	N/A	"Q Therapeutics, Inc."	417 Wakara Way	Ste. 3510	84108	USA										Transverse myelitis	7796		
carbon dioxide	Treatment of trigeminal neuralgia	carbon dioxide		n/a	12/17/15	Designated			N/A	N/A	"Capnia, Inc."	Redwood City	California	94065	USA	EXACT	0019772AA	carbon dioxide	142M471B3J						Trigeminal neuralgia	7805		
dehydrated alcohol	Treatment of trigeminal neuralgia	dehydrated alcohol		n/a	3/16/12	Designated			N/A	N/A	"Luitpold Pharmaceuticals, Inc."	Shirley	New York	11967	USA	EXACT	0011187AA	dehydrated alcohol	3K9958V90M						Trigeminal neuralgia	7805		
L-baclofen	Treatment of trigeminal neuralgia.	L-baclofen		n/a	7/13/90	Designated			N/A	N/A	"Fromm, Gerhard M.D."	Pittsburgh	Pennsylvania	15261	USA	EXACT	0133971AA	L-baclofen	3OHN4989XM						Trigeminal neuralgia	7805		
L-baclofen	Treatment of trigeminal neuralgia	L-baclofen		n/a	1/6/98	Designated			N/A	N/A	Osmotica Pharmaceutical Corp.	Wilmington	North Carolina	28405	USA	EXACT	0133971AA	L-baclofen	3OHN4989XM						Trigeminal neuralgia	7805		
"(5R)-5-(4-{[2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, hydrochloride"	Treatment of trigeminal neuralgia	RAXATRIGINE HYDROCHLORIDE		n/a	7/24/13	Designated			N/A	N/A	Convergence Pharmaceuticals Ltd.				United Kingdom	EXACT	0565708AA	RAXATRIGINE HYDROCHLORIDE	7L3OLR4M8T						Trigeminal neuralgia	7805		
"5-{[(3R,4R)-1-(4-chloro-2,6-difluorophenyl)-3,4-dihydroxypiperidin-4-yl]methoxy}-8-fluoro-3,4-dihydroquinolin-2(1H)-one"	Treatment of active tuberculosis	OPC-167832		n/a	12/5/16	Designated			N/A	N/A	"Otsuka Pharmaceutical Company, Ltd"	Rockville	Maryland	20850	USA	EXACT	1565044AA	OPC-167832	1PQN78P4S3						Tuberculosis	7827		
"Rifampin, isoniazid, pyrazinamide"	For the short-course treatment of tuberculosis.	"Rifampin , isoniazid, pyrazinamide"		Rifater	9/12/85	Designated/Approved	Approved for Orphan Indication	Short-course treatment of tuberculosis.	5/31/94	5/31/01	Hoechst Marion Roussel	Kansas City	Missouri	64134	USA	EXACT	0016499AA	pyrazinamide	2KNI5N06TI						Tuberculosis	7827		
"(3S)-3-(4-trifluoromethoxybenzyloxy)-6-nitro-2H-3,4-dihydroimidazo[2,1-b]oxazine"	Treatment of tuberculosis	"(3S)-3-(4-trifluoromethoxybenzyloxy)-6-nitro-2H-3,4-dihydroimidazo(2,1-b)oxazine"		n/a	7/5/07	Designated			N/A	N/A	Global Alliance for TB Drug Development	New York	New York	10005	USA	EXACT	0736743AA	"(3S)-3-(4-trifluoromethoxybenzyloxy)-6-nitro-2H-3,4-dihydroimidazo(2,1-b)oxazine"	2XOI31YC4N						Tuberculosis	7827		
Nitric oxide	Treatment of non-tuberculosis mycobacterial (NTM) infections	Nitric oxide		n/a	9/26/17	Designated			N/A	N/A	Advanced Inhalation Therapies Ltd.				Israel	EXACT	0176341AA	Nitric oxide	31C4KY9ESH						Tuberculosis	7827		
"N-{[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide"	Treatment of tuberculosis.	SUTEZOLID		n/a	2/4/11	Designated			N/A	N/A	"Sequella, Inc."	Rockville	Maryland	20820	USA	EXACT	0570752AA	SUTEZOLID	3A71182L8P						Tuberculosis	7827		
"(R)-3-[3-Fluoro-4-(1+A4263:A4292-methyl-1,4,5,6-tetrahydro-1,2,4-triazin-4-yl)phenyl]-5(R)-(hydroxymethyl)oxazolidin-2-one"	Treatment of tuberculosis	DELPAZOLID		n/a	7/19/17	Designated			N/A	N/A	"LegoChem Biosciences, Inc."	Daejeon			"Korea, Republic of"	EXACT	1123779AA	DELPAZOLID	43EP6XV33E						Tuberculosis	7827		
Thalidomide	Treatment of the clinical manifestations of mycobacterial infection caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria.	Thalidomide		n/a	1/12/93	Designated			N/A	N/A	Celgene Corporation	Warren				EXACT	0007409AA	Thalidomide	4Z8R6ORS6L						Tuberculosis	7827		
Substituted imidazopyridine amide	Treatment of active tuberculosis (TB).	q-203		n/a	12/22/15	Designated			N/A	N/A	"Qurient Co., Ltd."	Gyeonggi-do			"Korea, Republic of"	EXACT	1119499AA	q-203	55G92WGH3X						Tuberculosis	7827		
Aminosalicylic acid	Treatment of tuberculosis infections	Aminosalicylic acid		Paser Granules	2/19/92	Designated/Approved	Approved for Orphan Indication	Treatment of tuberculosis	6/30/94	6/30/01	Jacobus Pharmaceutical Company	Princeton	New Jersey	8540	USA	EXACT	0011438AA	Aminosalicylic acid	5B2658E0N2						Tuberculosis	7827		
"bedaquiline; (1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol"	Treatment of active tuberculosis	bedaquiline		Sirturo	1/10/05	Designated/Approved	Approved for Orphan Indication	Part of combination therapy in adults (greater than or equal to 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB).	12/28/12	12/28/19	"Janssen Research & Development, LLC"	Raritan	New Jersey	8869	USA	EXACT	0338421AA	bedaquiline	78846I289Y						Tuberculosis	7827		
Bedaquiline	Treatment of Nontuberculosis Mycobacteria infection	Bedaquiline		n/a	7/27/17	Designated			N/A	N/A	"Janssen Research & Development, LLC"	Titusville	New Jersey	8560	USA	EXACT	0338421AA	Bedaquiline	78846I289Y						Tuberculosis	7827		
Aminosidine	Treatment of tuberculosis.	Aminosidine		Gabbromicina	5/14/93	Designated			N/A	N/A	"Kanyok, Thomas P. Pharm.D."	Chicago	Illinois	60612	USA	EXACT	0033465AA	Aminosidine	845NU6GJPS						Tuberculosis	7827		
Aconiazide	Treatment of tuberculosis.	Aconiazide		n/a	6/20/88	Designated/Withdrawn			N/A	N/A	Lincoln Diagnostics	Decatur	Illinois	62525	USA	EXACT	0174470AA	Aconiazide	8OKQ9NS8MO						Tuberculosis	7827		
"(R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole"	Treatment of pulmonary tuberculosis.	Delamanid		n/a	7/12/07	Designated			N/A	N/A	"Otsuka Pharmaceutical Company, Ltd"	Rockville	Maryland	20850	USA	EXACT	0382809AA	Delamanid	8OOT6M1PC7						Tuberculosis	7827		
N-adamantanyl-N'-Geranyl-ethylenediamine	Treatment of tuberculosis.	SQ-109		n/a	10/16/07	Designated			N/A	N/A	"Sequella, Inc."	Rockville	Maryland	20850	USA	EXACT	0444246AA	SQ-109	9AU7XUV31A						Tuberculosis	7827		
moxifloxacin hydrochloride	Treatment of tuberculosis	moxifloxacin hydrochloride		n/a	4/30/14	Designated/Withdrawn			N/A	N/A	"Bayer HealthCare Pharmaceuticals, Inc."	Whippany	New Jersey	7981	USA	EXACT	0211347AA	moxifloxacin hydrochloride	C53598599T						Tuberculosis	7827		
clofazimine	Treatment of active tuberculosis	clofazimine		Lamprene	6/25/14	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0038186AA	clofazimine	D959AE5USF						Tuberculosis	7827		
"2-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-trifluoromethyl-4H-1,3-benzothiazin-4-one"	Treatment of Tuberculosis (TB)	BTZ-043		n/a	3/15/18	Designated			N/A	N/A	Klinikum der Universität München	15 Marchioninistr.			Germany	EXACT	0811847AA	BTZ-043	G55ZH52P57						Tuberculosis	7827		
mycobacterium vaccae	Treatment of tuberculosis	mycobacterium vaccae		n/a	8/20/10	Designated			N/A	N/A	Immodulon Therapeutics Ltd				United Kingdom	EXACT	0787177AA	mycobacterium vaccae	I639ME27W5						Tuberculosis	7827		
Rifalazil	Treatment of pulmonary tuberculosis.	Rifalazil		n/a	4/13/99	Designated			N/A	N/A	PathoGenesis Corporation	Seattle	Washington	98119	USA	EXACT	0191673AA	Rifalazil	S1976TE8QK						Tuberculosis	7827		
"Rifampin, isoniazid, pyrazinamide"	For the short-course treatment of tuberculosis.	isoniazid		Rifater	9/12/85	Designated/Approved	Approved for Orphan Indication	Short-course treatment of tuberculosis.	5/31/94	5/31/01	Hoechst Marion Roussel	Kansas City	Missouri	64134	USA	EXACT	0008742AA	isoniazid	V83O1VOZ8L						Tuberculosis	7827		
"Rifampin, isoniazid, pyrazinamide"	For the short-course treatment of tuberculosis.	Rifampin		Rifater	9/12/85	Designated/Approved	Approved for Orphan Indication	Short-course treatment of tuberculosis.	5/31/94	5/31/01	Hoechst Marion Roussel	Kansas City	Missouri	64134	USA	EXACT	0054966AA	Rifampin	VJT6J7R4TR						Tuberculosis	7827		
Rifampin	For antituberculosis treatment where use of the oral form of the drug is not feasible.	Rifampin		Rifadin I.V.	12/9/85	Designated/Approved	Approved for Orphan Indication		5/25/89	5/25/96	Hoechst Marion Roussel	Kansas City	Missouri	64134	USA	EXACT	0054966AA	Rifampin	VJT6J7R4TR						Tuberculosis	7827		
Rifapentine	Treatment of pulmonary tuberculosis.	Rifapentine		Priftin	6/9/95	Designated/Approved	Approved for Orphan Indication		6/22/98	6/22/05	Hoechst Marion Roussel	Kansas City	Missouri	64134	USA	EXACT	0185999AA	Rifapentine	XJM390A33U						Tuberculosis	7827		
dimethyl sulfoxide	For use in combination with antimicrobial drugs for the treatment of drug resistant tuberculosis	dimethyl sulfoxide		n/a	5/9/08	Designated			N/A	N/A	"Abela Pharmaceuticals, Inc."	Lake Forest	California	92630	USA	EXACT	0011676AA	dimethyl sulfoxide	YOW8V9698H						Tuberculosis	7827		
Theranost 68Ga RGD	Diagnostic for the clinical management of patients with tuberculosis	THERANOST 68 GA RGD		n/a	1/26/15	Designated			N/A	N/A	"Advanced Imaging Projects, LLC"	Boca Raton	Florida	33431	USA	EXACT	1577533AA	THERANOST 68 GA RGD	5EKN6H63OA						Tuberculosis	7827		
heat killed Mycobacterium w immunomodulator	Active tuberculosis	heat killed Mycobacterium w immunomodulator		Cadi Mw	9/3/04	Designated			N/A	N/A	"Cadila Pharmaceuticals Limited, Inc."	Gaithersburg	Maryland	20878	USA										Tuberculosis	7827		
tubimod	Treatment of active tuberculosis	tubimod		n/a	4/10/17	Designated			N/A	N/A	"Immunitor, Inc."				Canada										Tuberculosis	7827		
cannabidiol	Treatment of tuberous sclerosis complex.	cannabidiol		n/a	4/19/16	Designated			N/A	N/A	GW Pharma Ltd.	Research Triangle Park	North Carolina	27709	USA	EXACT	0027441AA	cannabidiol	19GBJ60SN5						Tuberous sclerosis	7830		
everolimus	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	everolimus		Afinitor	6/8/09	Designated/Approved	Approved for Orphan Indication	Treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical resection	10/29/10	10/29/17	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0218031AA	everolimus	9HW64Q8G6G						Tuberous sclerosis	7830		
everolimus	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	everolimus		Afinitor	6/8/09	Designated/Approved	Approved for Orphan Indication	Treatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery.	4/26/12	4/26/19	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0218031AA	everolimus	9HW64Q8G6G						Tuberous sclerosis	7830		
everolimus ointment	Topical treatment of Tuberous Sclerosis Complex-related skin lesions	everolimus		n/a	9/10/15	Designated			N/A	N/A	"Aucta Pharmaceuticals, LLC"	North Brunswick	New Jersey	8902	USA	EXACT	0218031AA	everolimus	9HW64Q8G6G						Tuberous sclerosis	7830		
Rapamycin	Treatment of tuberous sclerosis complex	Rapamycin		n/a	3/20/07	Designated			N/A	N/A	"OncoImmune, Inc."	Ann Arbor	Michigan	48103	USA	EXACT	0175177AA	Rapamycin	W36ZG6FT64						Tuberous sclerosis	7830		
rapamycin	Treatment of facial angiofibromas (FA) associated with tuberous sclerosis complex (TSC).	rapamycin		n/a	2/24/16	Designated			N/A	N/A	DSLP	Auckland			New Zealand	EXACT	0175177AA	rapamycin	W36ZG6FT64						Tuberous sclerosis	7830		
sirolimus	Treatment of tuberous sclerosis complex-related facial angiofibromas	sirolimus		n/a	2/13/17	Designated			N/A	N/A	"Aucta Pharmaceuticals, LLC"	North Brunswick	New Jersey	8902	USA	EXACT	0175177AA	sirolimus	W36ZG6FT64						Tuberous sclerosis	7830		
sirolimus	Treatment of angiofibroma associated with tuberous sclerosis	sirolimus		n/a	5/17/17	Designated			N/A	N/A	"NobelPharma Co., LTD"	Chuo-ku			Japan	EXACT	0175177AA	sirolimus	W36ZG6FT64						Tuberous sclerosis	7830		
estradiol Gel	Estrogen replacement therapy in females with Turner syndrome	estradiol Gel		n/a	10/31/06	Designated			N/A	N/A	"Ascend Therapeutics US, LLC"	Herndon	Virginia	21070	USA	EXACT	0007363AA	estradiol	4TI98Z838E						Turner syndrome	7831		
Somatropin	Treatment of short stature associated with Turner syndrome.	Somatropin		Humatrope	5/8/90	Designated/Approved	Approved for Orphan Indication	Treatment of short stature associated with Turner syndrome in patients whose epiphyses are not closed.	12/30/96	12/30/03	Eli Lilly and Company	Indianapolis	Indiana	46285	USA	EXACT	0054682AA	Somatropin	NQX9KB6PCL						Turner syndrome	7831		
sodium phenylbutyrate	"Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency."	sodium phenylbutyrate		Buphenyl	11/22/93	Designated/Approved	Approved for Orphan Indication	"Adjunctive therapy in the chronic managment of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase."	4/30/96	4/30/03	Medicis Pharmaceutical Corp.	Scottsdale	Arizona	85258	USA	EXACT	0180767AA	sodium phenylbutyrate	NT6K61736T						Urea cycle disorders	7837		
sodium phenylbutyrate	Treatment of urea cycle disorders	sodium phenylbutyrate		Pheburane	6/6/13	Designated			N/A	N/A	Lucane Pharma SA	Paris			France	EXACT	0180767AA	sodium phenylbutyrate	NT6K61736T						Urea cycle disorders	7837		
human heterologous liver cells	Treatment of urea cycle disorders	human heterologous liver cells		n/a	2/14/11	Designated			N/A	N/A	Promethera Biosciences S.A./N.V.				Belgium	LONGEST CONTAINS	0152749AA	liver							Urea cycle disorders	7837		
heterologous human adult liver derived progenitor cells (HHALPC)	Treatment of urea cycle disorders	heterologous human adult liver derived progenitor cells (HHALPC)		n/a	1/13/12	Designated			N/A	N/A	Promethera Biosciences				Belgium	LONGEST CONTAINS	0152749AA	liver							Urea cycle disorders	7837		
live E. coli Nissle bacterium modified to assimilate ammonia	Treatment of urea cycle disorders	live E. coli Nissle bacterium modified to assimilate ammonia		n/a	8/22/16	Designated			N/A	N/A	"Synlogic, Inc."	Cambridge	Massachusetts	2139	USA	LONGEST CONTAINS	0049978AA	ammonia	5138Q19F1X						Urea cycle disorders	7837		
Lentiviral vector containing the human MY07A gene	Treatment of retinitis pigmentosa associated with Usher syndrome 1B gene defect.	Lentiviral vector containing the human MY07A gene		Ushstat(Tm)	5/17/10	Designated			N/A	N/A	"Sanofi US Services, Inc."	Bridgewater	New Jersey	8807	USA										Usher syndrome	7843		
Histrelin	"Treatment of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria."	Histrelin		n/a	5/3/91	Designated			N/A	N/A	"Anderson, Karl E., M.D."	Galveston	Texas	77550	USA	EXACT	0135864AA	Histrelin	H50H3S3W74						Variegate porphyria	7848		
Hemin	"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria."	Hemin		Panhematin	3/16/84	Designated/Approved	Approved for Orphan Indication		7/20/83	7/20/90	Abbott Laboratories	Abbott Park	Illinois	60064	USA	EXACT	0135171AA	Hemin	743LRP9S7N						Variegate porphyria	7848		
Levocabastine HCl ophthalmic suspension 0.05%	Treatment of vernal keratoconjunctivitis.	Levocabastine HCl ophthalmic suspension 0.05%		n/a	2/29/88	Designated/Withdrawn			N/A	N/A	Iolab Pharmaceuticals	Claremont	California	94608	USA	EXACT	0156003AA	Levocabastine HCl	124XMA6YEI						Vernal keratoconjunctivitis	7854		
Lodoxamide tromethamine	Treatment of vernal keratoconjunctivitis.	Lodoxamide tromethamine		Alomide Ophthalmic Solution	10/16/91	Designated/Approved	Approved for Orphan Indication	"Treatment of ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, vernal keratitis."	9/23/93	9/23/00	"Alcon Laboratories, Inc."	Fort Worth	Texas	76134	USA	EXACT	0075843AA	Lodoxamide tromethamine	50LV9A548L						Vernal keratoconjunctivitis	7854		
Cyclosporine A	Treatment of vernal keratoconjunctivitis	Cyclosporine A		n/a	5/4/07	Designated			N/A	N/A	Santen SAS				France	EXACT	0066808AA	Cyclosporine A	83HN0GTJ6D						Vernal keratoconjunctivitis	7854		
Cromolyn sodium 4% ophthalmic solution	Treatment of vernal keratoconjunctivitis.	Cromolyn sodium 4% ophthalmic solution		Opticrom 4% Ophthalmic Solution	7/24/85	Designated/Approved	Approved for Orphan Indication		10/3/84	10/3/91	Fisons Corporation	Rochester	New York	14603	USA	EXACT	0056871AA	Cromolyn sodium	Q2WXR1I0PK						Vernal keratoconjunctivitis	7854		
"3-(3,5-Dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one"	Treatment of von Hippel-Lindau disease.	semaxanib		n/a	3/23/00	Designated			N/A	N/A	"Sugen, Inc."	South San Francisco	California	94080	USA	EXACT	0221807AA	semaxanib	71IA9S35AJ						Von Hippel-Lindau disease	7855		
Teriparatide	Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism.	Teriparatide		Parathar	1/9/87	Designated/Approved	Approved for Orphan Indication		12/23/87	12/23/94	"Rhone-Poulenc Rorer Pharmaceuticals, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	0249503AA	Teriparatide	10T9CSU89I						Pseudohypoparathyroidism	7860		
selumetinib	Treatment of Neurofibromatosis Type 1	selumetinib		n/a	2/14/18	Designated			N/A	N/A	AstraZeneca Pharmaceuticals LP	1800 Concord Pike	Wilmington		USA	EXACT	0297176AA	selumetinib	6UH91I579U						Neurofibromatosis type 1	7866		
everolimus	Treatment of Waldenstrom macroglobulinemia (also known as lymphoplasmacytic lymphoma)	everolimus		Afinitor	9/16/10	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0218031AA	everolimus	9HW64Q8G6G						Waldenstrom macroglobulinemia	7872		
"(S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)-imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)-benzamide"	Treatment of Waldenstrom macroglobulinemia.	"(S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)-imidazo(1,5-a)pyrazin-1-yl)-N-(pyridin-2-yl)-benzamide"		n/a	10/22/15	Designated			N/A	N/A	Acerta Pharma BV				Netherlands	EXACT	1102961AA	ACALABRUTINIB	I42748ELQW						Waldenstrom macroglobulinemia	7872		
ibrutinib	Treatment of Waldenstrom's macroglobulinemia	ibrutinib		Imbruvica	10/15/13	Designated/Approved	Approved for Orphan Indication	Treatment of patients with Waldenstrom's macroglobulinemia	1/29/15	1/29/22	"Pharmacyclics, LLC"	Sunnyvale	California	94085	USA	EXACT	0625092AA	ibrutinib	1X70OSD4VX						Waldenstrom macroglobulinemia	7872		
"antagonist of the endosomal Toll-like receptors (TLRs) 7, 8, and 9"	Treatment of Waldenstrom's macroglobulinemia	IMO-8400 		n/a	12/23/14	Designated			N/A	N/A	"Idera Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	1153271AA	IMO-8400	2U46M95B5M						Waldenstrom macroglobulinemia	7872		
"(S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide"	Treatment of Waldenstrom's macroglobulinemia	BGB-3111		n/a	6/29/16	Designated			N/A	N/A	"BeiGene USA, Inc."	Fort Lee	New Jersey	7024	USA	EXACT	1143619AA	BGB-3111	AG9MHG098Z						Waldenstrom macroglobulinemia	7872		
oprozomib	Treatment of Waldenstrom's macroglobulinemia	oprozomib		n/a	8/25/14	Designated			N/A	N/A	"Onyx Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	0701406AA	oprozomib	MZ37792Y8J						Waldenstrom macroglobulinemia	7872		
idelalisib	Treatment of lymphoplasmacytic lymphoma with or without Walenstrom's macroglobulinemia	idelalisib		n/a	9/26/13	Designated			N/A	N/A	"Gilead Sciences, Inc."	Seattle	Washington	98102	USA	EXACT	0711308AA	idelalisib	YG57I8T5M0						Waldenstrom macroglobulinemia	7872		
Autologous lymphoma-derived immunoglobulin idiotype antigen vaccine conjugated to keyhole limpet hemocyanin	Treatment of Waldenstrom's macroglobulinemia	Autologous lymphoma-derived immunoglobulin idiotype antigen vaccine conjugated to keyhole limpet hemocyanin		Biovaxid	10/18/11	Designated			N/A	N/A	"Biovest International, Inc."	Tampa	Florida	33606	USA	LONGEST CONTAINS	0222220AA	keyhole limpet hemocyanin	FV4Y0JO2CX						Waldenstrom macroglobulinemia	7872		
antagonist of the complement 5a receptor	"Treatment of anti-neutrophil cytoplasmic autoantibodies associated vasculitides (granulomatosis with polyangiitis or Wegener's granulomatosis), microscopic polyangiitis, and Churg-Strauss syndrome."	CCX-168		n/a	6/2/14	Designated			N/A	N/A	"ChemoCentryx, Inc."	Mountain View	California	94043	USA	EXACT	1083336AA	CCX-168	O880NM097T						Granulomatosis with polyangiitis	7880		
rituximab	"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)"	rituximab		Rituxan	2/14/06	Designated/Approved	Approved for Orphan Indication	For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). )	4/19/11	4/19/18	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0225149AA	rituximab	4F4X42SYQ6						Wegener's Granulomatosis	7880		
Etanercept	Treatment of Wegener's granulomatosis.	Etanercept		Enbrel	4/6/99	Designated/Withdrawn			N/A	N/A	Immunex Corporation	Seattle	Washington	98101	USA	EXACT	0233556AA	Etanercept	OP401G7OJC						Wegener's Granulomatosis	7880		
gusperimus trihydrochloride	Treatment of Wegener's granulomatosis	gusperimus trihydrochloride		n/a	6/29/11	Designated			N/A	N/A	Nordic Group B.V.				Netherlands	EXACT	0156194AA	gusperimus trihydrochloride	QZS4144IO0						Wegener's Granulomatosis	7880		
"(1S,3S)-3-amino-4-(difluoromethylene)cyclopentanecarboxylic acid hydrochloride, (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride"	Treatment of infantile spasms.	CPP-115		n/a	9/15/10	Designated			N/A	N/A	"Catalyst Pharmaceuticals, Inc."	Coral Gables	Florida	33134	USA	EXACT	0737337AA	CPP-115	0285I2MVUA						Infantile spasms	7887		
cannabidiol	Treatment of infantile spasms	cannabidiol		n/a	7/23/15	Designated			N/A	N/A	"Insys Development Company, Inc."	Chandler	Arizona	85286	USA	EXACT	0027441AA	cannabidiol	19GBJ60SN5						Infantile spasms	7887		
cannabidiol	Treatment of infantile spasms	cannabidiol		n/a	6/13/16	Designated			N/A	N/A	GW Research Ltd.	Histon			United Kingdom	EXACT	0027441AA	cannabidiol	19GBJ60SN5						Infantile spasms	7887		
"tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride"	Treatment of infantile spasms	ANAVEX-2-73		n/a	6/20/16	Designated			N/A	N/A	Anavex Life Sciences Corp.	New York	New York	10019	USA	EXACT	0918718AA	ANAVEX-2-73	1M49V1PBPL						Infantile spasms	7887		
cosyntropin	Treatment of infantile spasms.	cosyntropin		n/a	8/2/17	Designated			N/A	N/A	"West Therapeutic Development, LLC"	Grayslake	Illinois	60030	USA	EXACT	0057410AA	cosyntropin	72YY86EA29						Infantile spasms	7887		
vigabatrin and cosyntropin	Treatment of infantile spasms	vigabatrin and cosyntropin		n/a	11/1/17	Designated			N/A	N/A	"West Therapeutic Development, LLC"	540 Ziegler Drive	Illinois	60030	USA	EXACT	0057410AA	cosyntropin	72YY86EA29						Infantile spasms	7887		
Ganaxolone	Treatment of infantile spasms.	Ganaxolone		n/a	5/25/94	Designated			N/A	N/A	"Marinus Pharmaceuticals, Inc."	Branford	Connecticut	6405	USA	EXACT	0184587AA	Ganaxolone	98WI44OHIQ						Infantile spasms	7887		
1-(2-chlorophenyl)-1-(S)-hydroxy-2-(S)-carbamoyloxy-propane	Treatment of infantile spasms	1-(2-chlorophenyl)-1-(S)-hydroxy-2-(S)-carbamoyloxy-propane		n/a	3/20/17	Designated			N/A	N/A	"Bio-Pharm Solutions, Co., Ltd."	Suwon			"Korea, Republic of"	EXACT	1625292AA	1-(2-chlorophenyl)-1-(S)-hydroxy-2-(S)-carbamoyloxy-propane	D7NM51C3GU						Infantile spasms	7887		
vigabatrin	Treatment of infantile spasms.	vigabatrin		Sabril	6/12/00	Designated/Approved	Approved for Orphan Indication	For infantile spasms (IS) - 1 month to 2 years of age.	8/21/09	8/21/16	H. Lundbeck A/S	Deerfield	Illinois	60015	USA	EXACT	0125359AA	vigabatrin	GR120KRT6K						Infantile spasms	7887		
vigabatrin and cosyntropin	Treatment of infantile spasms	vigabatrin		n/a	11/1/17	Designated			N/A	N/A	"West Therapeutic Development, LLC"	540 Ziegler Drive	Illinois	60030	USA	EXACT	0125359AA	vigabatrin	GR120KRT6K						Infantile spasms	7887		
tetracosactide hexaacetate (beta 1-24-corticotrophin)	Treatment of infantile spasms	tetracosactide hexaacetate (beta 1-24-corticotrophin)		"Synacthen Depot, S. Retard"	10/31/12	Designated			N/A	N/A	"Cerium Pharmaceuticals, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0787940AA	tetracosactide hexaacetate	H86HJ92K8Y						Infantile spasms	7887		
repository corticotropin or adrenocorticotropic hormone	Treatment of infantile spasms	 Acthar		H.P. Acthar Gel	5/21/03	Designated/Approved	Approved for Orphan Indication	To treat infantile spasms	10/15/10	10/15/17	"Questcor Pharmaceuticals, Inc."	Hayward	California	94545	USA	EXACT	0052175AA	Acthar	K0U68Q2TXA						Infantile spasms	7887		
carisbamate	Management of patients with infantile spasms	carisbamate		n/a	3/16/12	Designated			N/A	N/A	"SK Life Science, Inc."	Fair Lawn	New Jersey	7410	USA	EXACT	0230002AA	carisbamate	P7725I9V3Z						Infantile spasms	7887		
Autologous CD34+ cells transfected with lentiviral vector containing the human WAS cDNA (Telethon 003)	Treatment of Wiskott Aldrich syndrome	Autologous CD34+ cells transfected with lentiviral vector containing the human WAS cDNA (Telethon 003)		n/a	4/30/10	Designated			N/A	N/A	GlaxoSmithKline Intellectual Property Development				United Kingdom										Wiskott Aldrich syndrome	7895		
dantrolene sodium	Treatment of Wolfram Syndrome	dantrolene sodium		n/a	2/17/16	Designated			N/A	N/A	Washington University in St. Louis	St. Louis	Missouri	63110	USA	EXACT	0056122AA	dantrolene sodium	287M0347EV						Wolfram syndrome	7898		
sodium valproate	Treatment of Wolfram syndrome	sodium valproate		n/a	8/5/15	Designated			N/A	N/A	The University of Birmingham				United Kingdom	EXACT	0032542AA	sodium valproate	5VOM6GYJ0D						Wolfram syndrome	7898		
Recombinant human lysosomal acid lipase or cholesteryl ester hydrolase	"Treatment of lipase deficiencies, including Wolman Disease and cholesteryl ester storage disease"	sebelipase alfa		Cholestrase	7/14/05	Designated			N/A	N/A	"Lysosomal Acid Lipase, LLC"	Owensboro	Kentucky	42301	USA	EXACT	0755544AA	sebelipase alfa	K4YTU42T8G						Wolman disease	7899		
urea	"Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis)."	urea		n/a	11/7/11	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0009290AA	urea	8W8T17847W						X-linked ichthyosis	7904		
Pro-Pro-Thr-Val-Pro-Thr-Arg	Treatment of xeroderma pigmentosum	Pro-Pro-Thr-Val-Pro-Thr-Arg		n/a	7/27/17	Designated			N/A	N/A	ProGeLife S.A.S	Marseille			France	EXACT	0112659AB	Pro-Pro-Thr-Val-Pro-Thr-Arg	CU50CY5QP5						Xeroderma pigmentosum	7910		
"T4 endonuclease V, liposome encapsulated"	To prevent cutaneous neoplasms and other skin abnormalities in xeroderma pigmentosum.	"T4 endonuclease V, liposome encapsulated"		n/a	6/27/89	Designated			N/A	N/A	AGI Dermatics	Freeport	New York	11520	USA	LONGEST CONTAINS	0266671AA	liposome							Xeroderma pigmentosum	7910		
polyinosinic-polycytidilic acid	"Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses"	Poly-Iclc		Poly-Iclc	3/3/03	Designated			N/A	N/A	Oncovir	Washington	District of Columbia	20008	USA	EXACT	0777651AA	Poly-Iclc							Yellow fever	7914		
Synthetic human secretin	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	Synthetic human secretin		Chirostim	6/16/99	Designated/Approved	Approved for Orphan Indication	"Stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction, stimulation of gastrin secretion to aid in the diagnosis of gastrinoma, and stimulation of pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography"	4/9/04	N/A	"ChiRhoClin, Inc."	Silver Spring	Maryland	20905	USA	EXACT	0234559AA	Synthetic human secretin	A0426J905J						Zollinger-Ellison syndrome	7918		
Synthetic porcine secretin	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	Synthetic porcine secretin		Secreflo	6/18/99	Designated/Approved	Approved for Orphan Indication	Use in secretin stimulation testing for stimulation of gastrin secretion to aid in the diagnosis of gastrinoma	4/4/02	4/4/09	"ChiRhoClin, Inc."	Silver Spring	Maryland	20905	USA	EXACT	0223132AA	Synthetic porcine secretin	D0L9J6I13I						Zollinger-Ellison syndrome	7918		
golodirsen	Treatment of Duchenne muscular dystrophy (DMD)	golodirsen		n/a	5/22/18	Designated			N/A	N/A	"Sarepta Therapeutics, Inc."	215 First Street		2142	USA	EXACT	1336272AA	golodirsen	033072U4MZ						Muscular dystrophy	7922		
non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon 2 in the human DMD gene under the control of U7 small nuclear non-coding RNA	Treatment of Duchenne muscular dystrophy	non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon 2 in the human DMD gene under the control of U7 small nuclear non-coding RNA		n/a	9/19/17	Designated			N/A	N/A	Nationwide Children's Hospital	Columbus	Ohio	43205	USA	EXACT	1078393AA	tucatinib	234248D0HH						Muscular dystrophy	7922		
recombinant human anti-GDF-8 monoclonal antibody	Treatment of Duchenne Muscular Dystrophy.	Domagrozumab		n/a	7/24/12	Designated			N/A	N/A	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	1141953AA	Domagrozumab	516MD5WQ24						Muscular dystrophy	7922		
givinostat	Treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy	givinostat		n/a	4/12/13	Designated			N/A	N/A	Italfarmaco SpA				Italy	EXACT	0338341AA	givinostat	5P60F84FBH						Muscular dystrophy	7922		
omigapil	Treatment of congenital muscular dystrophy.	omigapil		n/a	6/24/08	Designated			N/A	N/A	Santhera Pharmaceuticals Limited				Switzerland	EXACT	0283830AA	omigapil	5V14HD0N4Q						Muscular dystrophy	7922		
5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzp[d]oxazole	Treatment of Duchenne Muscular Dystrophy	EZUTROMID		n/a	11/22/11	Designated			N/A	N/A	Summit Corporation plc				United Kingdom	EXACT	0740443AA	EZUTROMID	645R07LF0D						Muscular dystrophy	7922		
cosyntropin	Treatment of Duchenne muscular dystrophy.	cosyntropin		n/a	7/6/17	Designated			N/A	N/A	Mallinckrodt ARD Inc.	Hazelwood	Missouri	63042	USA	EXACT	0057410AA	cosyntropin	72YY86EA29						Muscular dystrophy	7922		
tadalafil	Treatment of Duchenne Muscular Dystrophy (DMD)	tadalafil		Cialis(R); Adcirca(R)	5/4/15	Designated			N/A	N/A	Eli Lilly and Company	Indianapolis	Indiana	46285	USA	EXACT	0223563AA	tadalafil	742SXX0ICT						Muscular dystrophy	7922		
rebastinib	Treatment of Facioscapulohumeral Muscular Dystrophy	rebastinib		n/a	5/23/18	Designated			N/A	N/A	Genea Biocells US Inc.	11099 North Torrey Pines Road		92037	USA	EXACT	0711148AA	rebastinib	75017Q6I97						Muscular dystrophy	7922		
20-hydroxyecdysone	Treatment of Duchenne Muscular Dystrophy	20-hydroxyecdysone		n/a	5/10/18	Designated			N/A	N/A	Biophytis SA	14 Avenue de l’Opera			France	EXACT	0842535AA	20-hydroxyecdysone	779A7KPL0Y						Muscular dystrophy	7922		
Oxandrolone	Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.	Oxandrolone		Oxandrin	4/22/97	Designated			N/A	N/A	"Savient Pharmaceuticals, Inc."	East Brunswick	New Jersey	8816	USA	EXACT	0008435AA	Oxandrolone	7H6TM3CT4L						Muscular dystrophy	7922		
"delta-1,4,9(11)-pregnatriene-17-alpha,21-dihydroxy-16-alpha-methyl-3,20-dione"	Treatment of Duchenne muscular dystrophy	vamorolone		n/a	12/2/11	Designated			N/A	N/A	ReveraGen Biopharma	Rockville	Maryland	20850	USA	EXACT	0739719AA	vamorolone	8XP29XMB43						Muscular dystrophy	7922		
"N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)ethyl)-2-hydroxybenzamide"	Treatment of Duchenne muscular dystrophy	EDASALONEXENT		n/a	11/17/14	Designated			N/A	N/A	"Catabasis Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0709104AA	EDASALONEXENT	AF3Z6434KS						Muscular dystrophy	7922		
eteplirsen	Treatment of Duchenne Muscular Dystrophy.	eteplirsen		Exondys 51	10/23/07	Designated/Approved	Approved for Orphan Indication	Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping	9/19/16	9/19/23	"Sarepta Therapeutics, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0813503AA	eteplirsen	AIW6036FAS						Muscular dystrophy	7922		
trehalose	Treatment of occulopharyngeal muscular dystrophy	trehalose		Cabaletta	10/25/13	Designated			N/A	N/A	"BioBlast Pharma, Ltd."	New Haven	Connecticut	6510	USA	EXACT	0340954AA	trehalose	B8WCK70T7I						Muscular dystrophy	7922		
L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal	Treatment of Duchenne and Becker muscular dystrophy	L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal		n/a	1/18/06	Designated			N/A	N/A	CepTor Corporation	Hunt Valley	Maryland	21030	USA	EXACT	0736856AA	L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal	BK727F83NO						Muscular dystrophy	7922		
Mazindol	Treatment of Duchenne muscular dystrophy.	Mazindol		Sanorex	12/8/86	Designated			N/A	N/A	"Collipp, Platon J. M.D."	Jesup	Georgia	31545	USA	EXACT	0060639AA	Mazindol	C56709M5NH						Muscular dystrophy	7922		
nandrolone decanoate	Treatment of Duchenne's Muscular Dystrophy.	nandrolone decanoate		n/a	6/13/17	Designated			N/A	N/A	Sarcomed AB	Hägersten-Liljeholmen			Sweden	EXACT	0025150AA	nandrolone decanoate	H45187T098						Muscular dystrophy	7922		
idebenone	Treatment of Duchenne muscular dystrophy	idebenone		n/a	2/16/07	Designated			N/A	N/A	Santhera Pharaceuticals Limited				Switzerland	EXACT	0167260AA	idebenone	HB6PN45W4J						Muscular dystrophy	7922		
angiotensin (1-7)[A(1-7)]	Treatment of Duchenne muscular dystrophy	angiotensin (1-7)(A(1-7))		n/a	7/25/13	Designated			N/A	N/A	"US Biotest, Inc."	San Luis Obispo	California	93401	USA	EXACT	0232428AA	Angiotensin 1-7	IJ3FUK8MOF						Muscular dystrophy	7922		
Angiotensin (1-7)	Treatment of limb-girdle muscular dystrophy	Angiotensin (1-7)		n/a	11/26/13	Designated			N/A	N/A	"US Biotest, Inc."	San Luis Obispo	California	93401	USA	EXACT	0232428AA	Angiotensin 1-7	IJ3FUK8MOF						Muscular dystrophy	7922		
Angiotensin (1-7)	Treatment of LAMA2-related muscular dystrophy	Angiotensin (1-7)		n/a	2/8/16	Designated			N/A	N/A	"Tarix Orphan, LLC"	Cambridge	Massachusetts	2138	USA	EXACT	0232428AA	Angiotensin 1-7	IJ3FUK8MOF						Muscular dystrophy	7922		
ataluren	Treatment of Muscular Dystrophy resulting from premature stop mutations in the dystrohin gene	ataluren		n/a	1/10/05	Designated			N/A	N/A	"PTC Therapeutics, Inc."	South Plainfield	New Jersey	7080	USA	EXACT	0317259AA	ataluren	K16AME9I3V						Muscular dystrophy	7922		
deflazacort	Treatment of Duchenne muscular dystrophy	deflazacort		Calcort	9/16/10	Designated			N/A	N/A	University of Rochester Medical Center	Rochester	New York	14620	USA	EXACT	0084537AA	deflazacort	KR5YZ6AE4B						Muscular dystrophy	7922		
deflazacort	Treatment of Duchenne muscular dystrophy	deflazacort		n/a	8/16/13	Designated			N/A	N/A	"Marathon Pharmaceuticals, LLC"	Northbrook	Illinois	60062	USA	EXACT	0084537AA	deflazacort	KR5YZ6AE4B						Muscular dystrophy	7922		
poloxamer-188 NF	Treatment of Duchenne muscular dystrophy	poloxamer-188		n/a	1/19/10	Designated			N/A	N/A	"Phrixus Pharmaceuticals, Inc."	Ann Arbor	Michigan	48104	USA	EXACT	0006826AA	poloxamer 188	LQA7B6G8JG						Muscular dystrophy	7922		
(3R)-3-Methyl-6-[2-({5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-1-yl}methyl)phenoxy]hexanoic acid hemisulfate	Treatment of Duchenne muscular dystrophy	MA-0211 HEMISULFATE		n/a	3/28/18	Designated			N/A	N/A	"Astellas Pharma Global Development, Inc."	1 Astellas Way		60062	USA	EXACT	0112276AB	MA-0211 HEMISULFATE	LWF2PR5DHD						Muscular dystrophy	7922		
halofuginone hydrobromide	Treatment of Duchenne Muscular Dystrophy	halofuginone hydrobromide		n/a	10/13/11	Designated			N/A	N/A	"Halo Theraeputics, LLC"	Newton	Massachusetts	2466	USA	EXACT	0247198AA	halofuginone hydrobromide	PTC2969MV1						Muscular dystrophy	7922		
rimeporide	Treatment of Duchenne muscular dystrophy	rimeporide		n/a	9/19/17	Designated			N/A	N/A	EspeRare Foundation	Plan-les-Ouates			Switzerland	EXACT	0336721AA	rimeporide	QH6B4V5743						Muscular dystrophy	7922		
laminin-111 (human)	Treatment of Duchenne Muscular Dystrophy	laminin-111 (human)		n/a	7/21/11	Designated			N/A	N/A	"Prothelia, Inc."	Milford	Massachusetts	1757	USA	EXACT	0761433AA	laminin-111 (human)	QJK0WC9NHE						Muscular dystrophy	7922		
human laminin-111	Treatment of merosin (laminin-alpha2) deficient congential muscular dystrophy type 1A.	human laminin-111		n/a	9/23/11	Designated			N/A	N/A	"Prothelia, Inc."	Milford	Massachusetts	1757	USA	EXACT	0761433AA	human laminin-111	QJK0WC9NHE						Muscular dystrophy	7922		
O-(3-piperidino-2-hydroxyl-1-propyl)-nicotinic acid amidoxime hydrochloride	Treatment of Duchenne Muscular Dystrophy	bgp-15		n/a	1/15/13	Designated			N/A	N/A	Vudbenk Life Sciences				Hungary	EXACT	0828239AA	bgp-15	RLN2GTG4YS						Muscular dystrophy	7922		
naproxcinod	Treatment of Duchenne muscular dystrophy.	naproxcinod		n/a	3/16/15	Designated			N/A	N/A	Nicox SA	Valbonne			France	EXACT	0243732AA	naproxcinod	V24GR4LI3I						Muscular dystrophy	7922		
Recombinant human histidyl-tRNA synthetase	Treatment of patients with limb girdle muscular dystrophy	ATYR-1940		n/a	2/23/17	Designated			N/A	N/A	aTyr Pharma	San Diego	California	92121	USA	EXACT	1107024AA	ATYR-1940	WS7U5TQ7ZJ						Muscular dystrophy	7922		
Peptide that inhibits mechanosensitive ion channel (MSC) activity	Treatment of Duchenne Muscular Dystrophy (DMD.)	AT-300		n/a	9/15/10	Designated			N/A	N/A	Rose Pharmaceuticals	Williamsville	New York	14221	USA	EXACT	1805409AA	AT-300							Muscular dystrophy	7922		
"4-[(7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl]benzoic acid, hemifumarate"	Treatment of patients with Duchenne Muscular Dystrophy.	ARM-210 HEMIFUMARATE		n/a	11/18/15	Designated			N/A	N/A	"ARMGO Pharma, Inc."	Tarrytown	New York	10591	USA	EXACT	1674802AA	ARM-210 HEMIFUMARATE	ZHR6WM1ADJ						Muscular dystrophy	7922		
Vasomera	"Treatment of cardiomyopathy associated with dystrophinopathies; Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy BMD), and X-linked dilated cardiomyopathy (XL-dCMP)."	Vasomera		n/a	11/19/15	Designated			N/A	N/A	"PhaseBio Pharmaceuticals, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	1267045AA	Vasomera	200AW54D93						Muscular dystrophy	7922		
recombinant human biglycan	Treatment of Duchenne Muscular Dystrophy	TVN-102		n/a	7/13/16	Designated			N/A	N/A	"Tivorsan Pharmaceuticals, Inc."	Providence	Rhode Island	2903	USA	EXACT	1802217AA	TVN-102	20ZC7Q59K8						Muscular dystrophy	7922		
Exon 46 specific phosphorothioate oligonucleotide	Treatment of Duchenne muscular dystrophy	Exon 46 specific phosphorothioate oligonucleotide		n/a	11/18/05	Designated/Withdrawn			N/A	N/A	Prosensa Therapuetics BV	Leiden			Netherlands										Muscular dystrophy	7922		
Exon 51 specific phosphorothioate oligonucleotide	Treatment of Duchenne Muscular Dystrophy.	Exon 51 specific phosphorothioate oligonucleotide		n/a	8/25/09	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA										Muscular dystrophy	7922		
peptide-conjugated phosporodiamidate morpholino oligomer (PPMO)	"Treatment of Duchenne muscular dystrophy in patients with a deletion, duplication or frame shift mutation correctable by skipping of exon 50 of the dystrophin gene to allow restoration of the reading frame (including mutations within exons 51, 51-53, or 51-55)."	peptide-conjugated phosporodiamidate morpholino oligomer (PPMO)		n/a	9/3/09	Designated			N/A	N/A	"Sarepta Therapeutics, Inc."	Cambridge	Massachusetts	2142	USA	LONGEST CONTAINS	1797166AA	morpholino							Muscular dystrophy	7922		
Exon 44 specific phosphorothioate oligonucleotide	Treatment of Duchenne Muscular Dystrophy in patients who have a mutation correctable by skipping of exon 44of the dystrophin gene.	Exon 44 specific phosphorothioate oligonucleotide		n/a	11/5/09	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA										Muscular dystrophy	7922		
ActRIIB-IgG1)	Treatment of Duchenne muscular dystrophy	ActRIIB-IgG1)		n/a	8/16/10	Designated			N/A	N/A	"Acceleron Pharma, Inc."	Cambridge	Massachusetts	2139	USA										Muscular dystrophy	7922		
adeno-associated viral vector containing modified U11 snRNA	Treatment of Duchenne muscular dystrophy.	adeno-associated viral vector containing modified U11 snRNA		n/a	9/15/10	Designated			N/A	N/A	uniQure B.V.	Amsterdam			Netherlands										Muscular dystrophy	7922		
adeno-associated virus transgene of follistatin	Treatment of Duchennes and Becker's muscular dystrophy	adeno-associated virus transgene of follistatin		n/a	11/19/12	Designated			N/A	N/A	Milo Biotechnology	Cleveland Heights	Ohio	44106	USA										Muscular dystrophy	7922		
Exon 55 specific phosphorothioate oligonucleotide	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 55	Exon 55 specific phosphorothioate oligonucleotide		n/a	1/23/13	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA										Muscular dystrophy	7922		
Exon 52 specific phosphorothiate oligonucleotide	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 52	Exon 52 specific phosphorothiate oligonucleotide		n/a	1/23/13	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA										Muscular dystrophy	7922		
Exon 45 specific phosphorothioate oligonucleotide	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 45	Exon 45 specific phosphorothioate oligonucleotide		n/a	1/23/13	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA										Muscular dystrophy	7922		
exon 53 specific phosphorothioate oligonucleotide	treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 53	exon 53 specific phosphorothioate oligonucleotide		n/a	1/23/13	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA										Muscular dystrophy	7922		
bivalent anti-human myostatin adnectin-IgG1	Treatment of duchenne muscular dystrophy	bivalent anti-human myostatin adnectin-IgG1		n/a	2/10/15	Designated			N/A	N/A	Bristol-Myers Squibb Co.	Wallingford	Connecticut	6492	USA	LONGEST CONTAINS	0803203AA	myostatin	6O86C0ZH33						Muscular dystrophy	7922		
allogeneic cardiosphere-derived cells	Treatment of Duchenne Muscular Dystrophy	allogeneic cardiosphere-derived cells		n/a	4/21/15	Designated			N/A	N/A	"Capricor, Inc."	Beverly HIlls	California	90211	USA										Muscular dystrophy	7922		
recombinant human histidyl tRNA synthetase	Treatment of facioscapulohumeral muscular dystrophy	ATYR-1923		n/a	4/22/15	Designated			N/A	N/A	"aTyr Pharma, Inc."	San Diego	California	92121	USA	EXACT									Muscular dystrophy	7922		
"recombinant adeno-associated virus serotype rhesus 74 (rh74) expressing the human CT GalNac transferase (GALGT2) gene, also called the Sda or Cad GAlNac transferase or b4Galnt2, under control of the muscle creatine kinase (MCK) promoter"	Treatment of Duchenne muscular dystrophy	"recombinant adeno-associated virus serotype rhesus 74 (rh74) expressing the human CT GalNac transferase (GALGT2) gene, also called the Sda or Cad GAlNac transferase or b4Galnt2, under control of the muscle creatine kinase (MCK) promoter"		n/a	6/16/15	Designated			N/A	N/A	Nationwide Children's Hospital	Columbus	Ohio	43205	USA	LONGEST CONTAINS	0009245AA	creatine	MU72812GK0						Muscular dystrophy	7922		
Adeno-associated viral vector differentially expressing microdystrophin 5 gene via the muscle-specific promoter CK8.	Treatment of Duchenne muscular dystrophy.	Adeno-associated viral vector differentially expressing microdystrophin 5 gene via the muscle-specific promoter CK8.		n/a	8/31/16	Designated			N/A	N/A	"Solid GT, LLC"	Cambridge	Massachusetts	2142	USA	LONGEST CONTAINS	0220666AA	muscle							Muscular dystrophy	7922		
recombinant adeno-associated virus serotype rhesus 74 expressing the human dysferin gene (AAVrh74.MHCK7.DYSF.DV)	Treatment of Limb Girdle Muscular Dystrophy Type 2B	recombinant adeno-associated virus serotype rhesus 74 expressing the human dysferin gene (AAVrh74.MHCK7.DYSF.DV)		n/a	9/19/16	Designated			N/A	N/A	Nationwide Children's Hospital	Columbus	Ohio	43205	USA										Muscular dystrophy	7922		
small molecule Mas receptor agonist	Treatment of Duchenne muscular dystrophy	MMX-1902		n/a	4/25/17	Designated			N/A	N/A	"RASRx, LLC"	San Luis Obispo	California	93401	USA										Muscular dystrophy	7922		
Recombinant adeno-associated virus serotype 9 vector expressing codon-optimized miniaturized version of DMD gene	Treatment of Duchenne Muscular Dystrophy (DMD)	Recombinant adeno-associated virus serotype 9 vector expressing codon-optimized miniaturized version of DMD gene		n/a	5/22/17	Designated			N/A	N/A	"Bamboo Therapeutics, w wholly owned subsidiary of Pfizer"	Groton	Connecticut	6340	USA										Muscular dystrophy	7922		
"One, two, three, or four antisense oligonucleotides of Phosphorodiamidate morpholino oligomer combination that skips exons 4, 5, 6, and 7 of the gamma sarcoglycan (SGCG) gene"	"Treatment of limb-girdle muscular dystrophy type 2C that have mutations or deletions in exons 4, 5, 6, or 7of gamma sarcoglycan gene"	"One, two, three, or four antisense oligonucleotides of Phosphorodiamidate morpholino oligomer combination that skips exons 4, 5, 6, and 7 of the gamma sarcoglycan (SGCG) gene"		n/a	7/18/17	Designated			N/A	N/A	Kurt+Peter Foundation	Menlo Park	California	94025	USA	LONGEST CONTAINS	1797166AA	morpholino							Muscular dystrophy	7922		
partial myostatin antigen displayed on the surface of Lactobacillus casei	Treatment of Duchenne Muscular Dystrophy (DMD)	partial myostatin antigen displayed on the surface of Lactobacillus casei		n/a	12/28/17	Designated			N/A	N/A	BioLeaders Corporation	"7F, U-Tower, 767, Sinsu-ro, Suji-gu"	Yongin-si		"Korea, Republic of"	LONGEST CONTAINS	0234720AA	Lactobacillus casei	SA940P2U00						Muscular dystrophy	7922		
"self-complementary non-replicating, recombinant adeno-associated virus serotype rhesus 74 (rh 74) expressing the human beta-sarcoglycan gene under the control of the muscle creatine kinase (MHCK7) promoter"	Treatment of Limb Girdle Muscular Dystrophy Type 2E (LGMD2E)	"self-complementary non-replicating, recombinant adeno-associated virus serotype rhesus 74 (rh 74) expressing the human beta-sarcoglycan gene under the control of the muscle creatine kinase (MHCK7) promoter"		n/a	2/15/18	Designated			N/A	N/A	Nationwide Children's Hospital	700 Children's Drive	Columbus		USA	LONGEST CONTAINS	0009245AA	creatine	MU72812GK0						Muscular dystrophy	7922		
Recombinant adeno-associated virus serotype rh74 vector expressing the micro-dystrophin gene	Treatment of Duchenne Muscular Dystrophy	Recombinant adeno-associated virus serotype rh74 vector expressing the micro-dystrophin gene		n/a	6/21/18	Designated			N/A	N/A	Nationwide Children's Hospital	700 Children's Drive	Ohio	43205	USA										Muscular dystrophy	7922		
Follistatin291-IgG2 Fc fusion protein	Treatment of facioscapulohumeral muscular dystrophy	Follistatin291-IgG2 Fc fusion protein		n/a	7/3/18	Designated			N/A	N/A	Acceleron Pharma Inc.	128 Sidney Street	Massachusetts	2139	USA	LONGEST CONTAINS	0087274AA	protein							Muscular dystrophy	7922		
Synthetic stereopure antisense oligonucleotide specific for human dystrophin pre-messenger ribonucleic acid (mRNA)	Treatment of Duchenne muscular dystrophy	Synthetic stereopure antisense oligonucleotide specific for human dystrophin pre-messenger ribonucleic acid (mRNA)		n/a	8/7/18	Designated			N/A	N/A	Wave Life Sciences Ltd.	733 Concord Avenue	Massachusetts	2138	USA	LONGEST CONTAINS	0006724AA	ribonucleic acid							Muscular dystrophy	7922		
Recombinant human anti-GDF-8 (growth and differentiation factor-8) antibody	Treatment of Duchenne and Becker muscular dystrophies	Stamulumab		n/a	2/16/05	Designated/Withdrawn			N/A	N/A	"Wyeth Pharmaceuticals, Inc."	Philadelphia	Pennsylvania	19101	USA	EXACT	0267016AA	Stamulumab	V43X8G4797						Muscular Dystrophies	7922		
human monoclonal anti-PA antibody	For post-exposure prophylaxis and treatment of inhalation anthrax.	Yervoy		Yervoy	10/21/10	Designated/Approved	Approved for Orphan Indication			N/A	"Emergent Product Development Gaithersburg, Inc."	Gaithersburg	Maryland	20879	USA	EXACT	0265452AA	Yervoy	6T8C155666						Anthrax	8157		
raxibacumab	Treatment of anthrax	raxibacumab		Abthraxtm	11/12/03	Designated/Approved	Approved for Orphan Indication	"Treatment of inhalation anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs,"	12/14/12	12/14/19	"Human Genome Sciences, Inc."	Rockville	Maryland	20850	USA	EXACT	0267856AA	raxibacumab	794PGL549S						Anthrax	8157		
Recombinant fully human monoclonal antibody to anthrax protective antigen	Treatment of anthrax infection	Valortim		Valortim	2/16/06	Designated			N/A	N/A	"PharmAthene, Inc."	Annapolis	Maryland	21401	USA	EXACT	0772269AA	Valortim	7D0R3114J3						Anthrax	8157		
Anthrax Vaccine Adsorbed	For post-exposure prophylaxis of anthrax disease resulting from suspected or confirmed Bacillus anthracis exposure	Anthrax Vaccine Adsorbed		Biothrax	4/11/14	Designated		"For post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs."	N/A	11/23/22	Emergent BioDefense Operations Lansing LLC	Gaithersburg	Maryland	20879	USA	EXACT	0101257AA	Anthrax Vaccine Adsorbed	873OI62848						Anthrax	8157		
cethromycin	Prophylactic treatment of patients exposed to inhalation anthrax.	cethromycin		n/a	2/28/07	Designated			N/A	N/A	"Advanced LIfe Sciences, Inc."	Woodridge	Illinois	60517	USA	EXACT	0230580AA	cethromycin	J0086219X6						Anthrax	8157		
anthrax immune globulin (human)	Treatment of inhalational anthrax	anthrax immune globulin (human)		n/a	7/29/08	Designated/Approved	Approved for Orphan Indication	Treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs	3/24/15	3/24/22	Cangene Corp. - Emergent Biosolutions	"Winnipeg, MB"			Canada	LONGEST CONTAINS	0006531AA	immune globulin							Anthrax	8157		
anthrax immune globulin	Treatment of inhalation anthrax disease	anthrax immune globulin		n/a	9/3/09	Designated/Withdrawn			N/A	N/A	"Emergent Biosolutions, Inc."	Gaithersburg	Maryland	20879	USA	LONGEST CONTAINS	0006531AA	immune globulin							Anthrax	8157		
L-alanoyl-D-glutamate endopeptidase from Bacillus-infected bacteriophages	Treatment of inhalational anthrax	L-alanoyl-D-glutamate endopeptidase from Bacillus-infected bacteriophages		n/a	6/21/18	Designated			N/A	N/A	"iNtRON Biotechnology, Inc."	"137 Sagimakgol-ro, Seongnam-si"			"Korea, Republic of"	LONGEST CONTAINS	0005072AA	endopeptidase							Anthrax	8157		
vatiquinone	Treatment of pontocerebellar hypoplasia	vatiquinone		Vincerinone	10/18/17	Designated			N/A	N/A	BioElectron Technology Corporation	Mountain View	California	94043	USA	EXACT	0739468AA	vatiquinone	6O85FK9I0X						Pontocerebellar hypoplasia	8168		
Recombinant human fibroblast growth factor receptor 3	Treatment of achondroplasia.	TA-46		n/a	6/2/17	Designated			N/A	N/A	TherAchon AG	Basel			Switzerland	EXACT	0114452AB	TA-46	620C079F3I						Achondroplasia	8173		
modified recombinant human C-type natriuretic peptide (CNP)	Treatment of achondroplasia	Vosoritide		n/a	1/17/13	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA	EXACT	1124147AA	Vosoritide	7SE5582Q2P						Achondroplasia	8173		
Praziquantel	Treatment of neurocysticercosis.	Praziquantel		n/a	4/18/88	Designated/Withdrawn			N/A	N/A	"EM Pharmaceuticals, Inc."					EXACT	0120274AA	Praziquantel	6490C9U457						Cysticercosis	8194		
Albendazole	"Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis."	Albendazole		Albenza	1/18/96	Designated/Approved	Approved for Orphan Indication	"Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium."	6/11/96	6/11/03	Amedra Pharmaceuticals LLC	Horsham	Pennsylvania	19044	USA	EXACT	0121142AA	Albendazole	F4216019LN						Cysticercosis	8194		
oxfendazole	Treatment of cysticercosis (including neurocysticercosis)	oxfendazole		n/a	7/14/14	Designated			N/A	N/A	"Robert H. Gilman, MD, DTMH and"	Baltimore	Maryland	21205	USA	EXACT	0132503AA	oxfendazole	OMP2H17F9E						Cysticercosis	8194		
oxfendazole	Treatment of cysticercosis	oxfendazole		n/a	8/7/17	Designated			N/A	N/A	Oxfendazole Development Group	Blue Bell	Pennsylvania	19422	USA	EXACT	0132503AA	oxfendazole	OMP2H17F9E						Cysticercosis	8194		
insecticidal toxin derived from Bacillus thuringiensis	Treatment of soil transmitted helminth infection strongyloidiasis	insecticidal toxin derived from Bacillus thuringiensis		n/a	9/5/08	Designated			N/A	N/A	"University of California, San Diego"	LaJolla	California	92093	USA	LONGEST CONTAINS	1108118AA	Bacillus thuringiensis	3TK3LQP1N7						Strongyloidiasis	8195		
melatonin	Treatment of smith-magenis syndrome in combination with a beta-blocker	melatonin		n/a	11/3/16	Designated			N/A	N/A	Therapicon SrL	Milano			Italy	EXACT	0012657AA	melatonin	JL5DK93RCL						Smith-Magenis syndrome	8197		
tasimelteon	Treatment of sleep-wake disorder in Smith-Magenis syndrome associated with diurnal melatonin secretion	tasimelteon		n/a	4/30/10	Designated			N/A	N/A	"Vanda Pharmaceuticals, Inc."	Rockville	Maryland	20850	USA	EXACT	0224066AA	tasimelteon	SHS4PU80D9						Smith-Magenis syndrome	8197		
metformin	Treatment of progressive myoclonus epilepsy type 2 (Lafora disease)	metformin		n/a	12/14/17	Designated			N/A	N/A	"Consorcio Centro de Investigación Biomédica en Red, M.P. (CIBER)"	Monforte de Lemos	Madrid		Spain	EXACT	0030557AA	metformin	9100L32L2N						Lafora disease	8214		
"(2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl]oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate"	Treatment of chronic myelomonocytic leukemia (CMML)	H3B-8800		n/a	6/22/17	Designated			N/A	N/A	"H3 Biomedicine Inc. (US Research Subsidiary of Eisai Co., Ltd.)"	Cambridge	Massachusetts	2139	USA	EXACT	1297763AA	H3B-8800	90YLS47BRX						Chronic myelomonocytic leukemia	8225		
Cytarabine:daunorubicin liposome injection	Treatment of acute myeloid leukemia	Cytarabine		n/a	8/22/08	Designated			N/A	N/A	"Celator Pharmaceuticals, Inc."	Ewing	New Jersey	8628	USA	EXACT	0023052AA	Cytarabine	04079A1RDZ						Myeloid leukemia	8226		
"4-[4-[[[[3-(1,1-dimethylethyl)-1-(6-quinolinyl)-1H-pyrazol-5-yl]amino]carbonyl]-amino]-3-fluorophenoxyl]-N-methyl-2-pyridinecarboxamide, p-toluenesulfonate salt"	Treatment of Philadelphia chromosome positive chronic myeloid leukemia	"4-(4-((((3-(1,1-dimethylethyl)-1-(6-quinolinyl)-1H-pyrazol-5-yl)amino)carbonyl)-amino)-3-fluorophenoxyl)-N-methyl-2-pyridinecarboxamide, p-toluenesulfonate salt"		n/a	9/3/09	Designated			N/A	N/A	"Deciphera Pharmaceuticals, LLC"	Lawrence	Kansas	66044	USA	EXACT	0711137AA	"4-(4-((((3-(1,1-dimethylethyl)-1-(6-quinolinyl)-1H-pyrazol-5-yl)amino)carbonyl)-amino)-3-fluorophenoxyl)-N-methyl-2-pyridinecarboxamide, p-toluenesulfonate salt"	042A5NJE6B						Myeloid leukemia	8226		
inecalcitol	Treatment of acute myeloid leukemia.	inecalcitol		n/a	8/3/15	Designated			N/A	N/A	"Hybrigenics, S.A."	Paris			France	EXACT	0220859AA	inecalcitol	05FZV98342						Myeloid leukemia	8226		
tamibarotene	Treatment of acute myeloid leukemia (AML)	tamibarotene		n/a	8/16/17	Designated			N/A	N/A	"Syros Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0288891AA	tamibarotene	08V52GZ3H9						Myeloid leukemia	8226		
CD123 x CD3 dual affinity re-targeting (DART®) protein	Treatment of acute myeloid leukemia (AML)	MGd-006		n/a	12/22/16	Designated			N/A	N/A	"MacroGenics, Inc."	Rockville	Maryland	20850	USA	EXACT	0914705AA	MGd-006	0AHT0IC02G						Myeloid leukemia	8226		
Human Wilms tumor protein 1 peptides	Treatment of acute myeloid leukemia	GALINPEPIMUT-S		n/a	12/23/15	Designated			N/A	N/A	SELLAS Life Sciences Group	Zug			Switzerland	EXACT	1307057AA	GALINPEPIMUT-S	12R66419FZ						Myeloid leukemia	8226		
E-selectin antagonist	Treatment of acute myeloid leukemia (AML)	gmi-1271		n/a	5/13/15	Designated			N/A	N/A	"GlycoMimetics, Inc."	Gaithersburg	Maryland	20879	USA	EXACT	0933040AA	gmi-1271	17ZJN0Q4CJ						Myeloid leukemia	8226		
menatetrenone	Treatment of acute myeloid leukemia	menatetrenone		Mk4	3/17/11	Designated			N/A	N/A	"NBI Pharmaceuticals, Inc."	Bozeman	Montana	59718	USA	EXACT	0274500AA	menatetrenone	27Y876D139						Myeloid leukemia	8226		
tetrandrine	Treatment of chronic myeloid leukemia.	tetrandrine		n/a	5/19/16	Designated			N/A	N/A	"Escend Pharmaceuticals, Inc."	Menlo Park	California	94025	USA	EXACT	0074260AA	tetrandrine	29EX23D5AJ						Myeloid leukemia	8226		
tetrandrine	Treatment of acute myeloid leukemia.	tetrandrine		n/a	12/13/16	Designated			N/A	N/A	"Escend Pharmaceuticals, Inc."	Menlo Park	California	94025	USA	EXACT	0074260AA	tetrandrine	29EX23D5AJ						Myeloid leukemia	8226		
guadecitabine	Treatment of acute myeloid leukemia.	guadecitabine		n/a	9/29/15	Designated			N/A	N/A	"Astex Pharmaceuticals, Inc."	Pleasanton	California	94588	USA	EXACT	0540103AA	guadecitabine	2KT4YN1DP7						Myeloid leukemia	8226		
"N-[(2S)-5-{[(2S)-2-(4-fluorophenyl)cyclopropyl]amino}-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide bis-tosylate salt"	Treatment of acute myeloid leukemia (AML)	IMG-7289 DITOSYLATE		n/a	2/7/17	Designated			N/A	N/A	"Imago BioSciences, Inc."	San Carlos	California	94070	USA	EXACT	1801123AA	IMG-7289 DITOSYLATE	2PYF2U9JNF						Myeloid leukemia	8226		
"Selinexor; (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide"	Treatment of acute myeloid leukemia	Selinexor		n/a	5/14/14	Designated			N/A	N/A	"Karyopharm Therapeutics, Inc."	Natick	Massachusetts	1760	USA	EXACT	0899718AA	Selinexor	31TZ62FO8F						Myeloid leukemia	8226		
ponatinib	Treatment of chronic myeloid leukemia	ponatinib		Iclusig	11/20/09	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy."	12/14/12	12/14/19	ARIAD Pharmaceuticals Inc.	Cambridge	Massachusetts	2139	USA	EXACT	0460162AA	ponatinib	4340891KFS						Myeloid leukemia	8226		
alvocidib	Treatment of acute myeloid leukemia	alvocidib		n/a	4/21/14	Designated			N/A	N/A	"Tolero Pharmaceuticals, Inc."	Lehi	Utah	84043	USA	EXACT	0307846AA	alvocidib	45AD6X575G						Myeloid leukemia	8226		
Cladribine	Treatment of acute myeloid leukemia.	Cladribine		Leustatin	7/20/90	Designated/Withdrawn			N/A	N/A	"Janssen Research & Development, LLC"	Raritan	New Jersey	8869	USA	EXACT	0092944AA	Cladribine	47M74X9YT5						Myeloid leukemia	8226		
"2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thienol[3,2,-f]-[1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)-acetamide dihydrate"	Treatment of acute myeloid leukemia	BIRABRESIB DIHYDRATE		n/a	7/16/14	Designated			N/A	N/A	OncoEthix SA				Switzerland	EXACT	0796065AA	BIRABRESIB DIHYDRATE	4Q356KA5V2						Myeloid leukemia	8226		
N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide	Treatment of acute myeloid leukemia	N-(2-amino-phenyl)-4-((4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl) benzamide dihydrobromide		n/a	2/1/08	Designated			N/A	N/A	"Mirati Therapeutics, Inc."	San Diego	California	92121	USA	EXACT	0323104AA	MOCETINOSTAT DIHYDROBROMIDE	4V9P667Y2G						Myeloid leukemia	8226		
Triciribine phosphate	Treatment of acute myeloid leukemia	Triciribine phosphate		n/a	4/24/17	Designated			N/A	N/A	Prescient Therapeutics LTD	Palm Springs	California	92262	USA	EXACT	0118785AA	Triciribine phosphate	5L5GE3DV88						Myeloid leukemia	8226		
Daunorubicin liposomal	Treatment of acute myeloid leukemia	Daunorubicin liposomal		n/a	9/5/08	Designated			N/A	N/A	"Diatos USA, LLC"	Tampa	Florida	33647	USA	EXACT	0203952AA	Daunorubicin liposomal	5L84T2Z6NP						Myeloid leukemia	8226		
daunorubicin citrate liposome	Treatment of acute myeloid leukemia	daunorubicin citrate liposome		Daunoxome	4/15/13	Designated/Withdrawn			N/A	N/A	Galen Limited				United Kingdom	EXACT	0203952AA	daunorubicin citrate liposome	5L84T2Z6NP						Myeloid leukemia	8226		
acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-cysteinyl-D-glutaminyl-D-cystenyl-D-arginyl-D-arginyl-D-lysyl-D-asparaginylmaide disulfide	Treatment of acute myeloid leukemia.	GO-203-2c 		n/a	11/24/15	Designated			N/A	N/A	"Genus Oncology, LLC"	Chicago	Illinois	60614	USA	EXACT	0761739AA	GO-203-2c	5YSY733NA3						Myeloid leukemia	8226		
Troxacitabine	Treatment of acute myeloid leukemia	Troxacitabine		Troxatyl	4/4/05	Designated/Withdrawn			N/A	N/A	"Structural GenomiX, Inc. (SGX)"	San Diego	California	92121	USA	EXACT	0220382AA	Troxacitabine	60KQZ0388Y						Myeloid leukemia	8226		
Gilteritinib	Treatment of acute myeloid leukemia (AML)	Gilteritinib		n/a	7/13/17	Designated			N/A	N/A	"Astellas Pharma US, Inc."	Northbrook	Illinois	60062	USA	EXACT	0911762AA	Gilteritinib	66D92MGC8M						Myeloid leukemia	8226		
"1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy) phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide fumarate salt"	Treatment of Acute Myeloid Leukemia	NMS-P937		n/a	9/28/17	Designated			N/A	N/A	"Trovagene, Inc."	San Diego	California	92121	USA	EXACT	0341399AA	NMS-P937	67RM91WDHQ						Myeloid leukemia	8226		
Peptide inhibiting murine double minute 2 (MDM2) and murine double minute X (MDMX)	Treatment of acute myeloid leukemia	ALRN-6924		n/a	4/19/17	Designated			N/A	N/A	"Aileron Therapeutics, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	1086379AA	ALRN-6924	6BGF28R54M						Myeloid leukemia	8226		
volasertib	Treatment of acute myeloid leukemia	volasertib		n/a	4/14/14	Designated			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc."	Ridgefield	Connecticut	6877	USA	EXACT	0362118AA	volasertib	6EM57086EA						Myeloid leukemia	8226		
"N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino] isonicotinamide hydrochloride"	Treatment of acute myeloid leukemia (AML).	PIMASERTIB HYDROCHLORIDE		n/a	1/12/11	Designated			N/A	N/A	"EMD Serono, Inc."	Rockland	Massachusetts	2370	USA	EXACT	0736890AA	PIMASERTIB HYDROCHLORIDE	6GS1ULF5HV						Myeloid leukemia	8226		
entospletinib	Treatment of acute myeloid leukemia	entospletinib		n/a	6/15/17	Designated			N/A	N/A	Gilead Sciences (formerly Corus Pharma)	Seattle	Washington	98102	USA	EXACT	0928507AA	entospletinib	6I3O3W6O3B						Myeloid leukemia	8226		
"6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one monocitrate"	Treatment of acute myeloid leukemia (AML)	TAK-659		n/a	10/3/17	Designated			N/A	N/A	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0893072AA	TAK-659	6ZJ8V3Q0H1						Myeloid leukemia	8226		
tigecycline	Treatment of acute myeloid leukemia.	tigecycline		n/a	10/23/13	Designated			N/A	N/A	"Trillium Therapeutics, Inc."				Canada	EXACT	0228411AA	tigecycline	70JE2N95KR						Myeloid leukemia	8226		
bisantrene HCl	Treatment of acute myeloid leukemia	bisantrene HCl		n/a	2/14/14	Designated			N/A	N/A	"Update Pharma, Inc."	San Francisco	California	94109	USA	EXACT	0093516AA	bisantrene HCl	74GNV897RO						Myeloid leukemia	8226		
decitabine	Treatment of acute myeloid leukemia	decitabine		Dacogen	8/4/06	Designated/Withdrawn			N/A	N/A	Otsuka Pharmaceutical Development &	Princeton	New Jersey	8540	USA	EXACT	0171244AA	decitabine	776B62CQ27						Myeloid leukemia	8226		
ulocuplumab	Treatment of acute myeloid leukemia	ulocuplumab		n/a	1/12/15	Designated			N/A	N/A	Bristol-Myers Squibb Company	Wallingford	Connecticut	6492	USA	EXACT	0778541AA	ulocuplumab	7KNP87L4X4						Myeloid leukemia	8226		
Cell-penetrating activating transcription factor 5 mimetic	Treatment of Acute Myeloid Leukemia	ST-101		n/a	4/30/18	Designated			N/A	N/A	"Sapience Therapeutics, Inc"	500 Mamaroneck Avenue	Suite 320	10528	USA	EXACT	0924254AA	ST-101	7TTT61784C						Myeloid leukemia	8226		
"O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate"	Treatment of acute myeloid leukemia	"O2-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate"		n/a	3/16/12	Designated			N/A	N/A	"JSK Therapeutics, Inc."	Salt Lake City	Utah	84158	USA	EXACT	0761193AA	"O2-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate"	80P1Q21652						Myeloid leukemia	8226		
Zosuquidar trihydrochloride	Treatment of acute myeloid leukemia	Zosuquidar trihydrochloride		n/a	12/15/05	Designated			N/A	N/A	"Kanisa Pharmaceuticals, Inc."	San Diego	California	2130	USA	EXACT	0220951AA	Zosuquidar trihydrochloride	813AGY3126						Myeloid leukemia	8226		
Histamine	Adjunct to cytokine therapy in the treatment of acute myeloid leukemia.	Histamine		Ceplene	12/15/99	Designated			N/A	N/A	EpiCept Corporation	Tarrytown	New York	10591	USA	EXACT	0007909AA	Histamine	820484N8I3						Myeloid leukemia	8226		
Gemtuzumab ozogamicin	Treatment of acute myeloid leukemia	Gemtuzumab ozogamicin		Mylotarg	11/24/99	Designated/Approved	Approved for Orphan Indication	Treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy	5/17/00	5/17/07	"Wyeth Pharmaceuticals, Inc., a Pfizer Company"	San Diego	California	92121	USA	EXACT	0231038AA	Gemtuzumab ozogamicin	8GZG754X6M						Myeloid leukemia	8226		
small molecule inhibitor of histone methyltransferase DOT1L	Treatment of Acute Myeloid Leukemia	 EPZ-5676		n/a	8/15/13	Designated			N/A	N/A	Epizyme Inc.	Cambridge	Massachusetts	2139	USA	EXACT	0835916AA	EPZ-5677	8V9YR09EF4						Myeloid leukemia	8226		
"(2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl]oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate"	Treatment of acute myeloid leukemia (AML)	H3B-8800		n/a	6/21/17	Designated			N/A	N/A	"H3 Biomedicine Inc. (US Research Subsidiary of Eisai Co., Ltd.)"	Cambridge	Massachusetts	2139	USA	EXACT	1297763AA	H3B-8800	90YLS47BRX						Myeloid leukemia	8226		
4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide monohydrochloride	Treatment of acute myeloid leukemia	JNJ-28312141		n/a	7/20/06	Designated			N/A	N/A	"Johnson & Johnson Pharmaceutical Research & Dev,"	Raritan	New Jersey	8869	USA	EXACT	0736481AA	JNJ-28312141	9M5069B3F8						Myeloid leukemia	8226		
antroquinonol	Treatment of acute myeloid leukemia	antroquinonol		Hocena(R)	4/30/15	Designated			N/A	N/A	Golden Biotechnology Corporation				Taiwan	EXACT	1216428AA	antroquinonol	AX9P92T7JZ						Myeloid leukemia	8226		
selective antagonist of the chemokine receptor type 4	Treatment of acute myeloid leukemia	BL-8040		n/a	9/5/13	Designated			N/A	N/A	"BioLineRx, Ltd."	Modi'in			Israel	EXACT	1154194AA	BL-8040	DA9G065962						Myeloid leukemia	8226		
Lestaurtinib	Treatment of acute myeloid leukemia	Lestaurtinib		n/a	3/24/06	Designated			N/A	N/A	"Teva Branded Pharmaceutical Products R&D, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0224680AA	Lestaurtinib	DO989GC5D1						Myeloid leukemia	8226		
"6,8-bis-benzylsulfanyl-octanoic acid"	Treatment of acute myeloid leukemia.	"6,8-bis-benzylsulfanyl-octanoic acid"		n/a	8/22/11	Designated			N/A	N/A	"Cornerstone Pharmaceuticals, Inc."	Stony Brook	New Mexico	11790	USA	EXACT	0298840AA	CPI-613	E76113IR49						Myeloid leukemia	8226		
L-asparaginase	Treatment of acute myeloid leukemia	L-asparaginase		n/a	3/27/14	Designated			N/A	N/A	ERYTECH Pharma S.A.	Lyon			France	EXACT	0099467AA	L-asparaginase	G4FQ3CKY5R						Myeloid leukemia	8226		
Midostaurin	Treatment of acute myeloid leukemia	Midostaurin		n/a	7/7/09	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0230091AA	Midostaurin	ID912S5VON						Myeloid leukemia	8226		
Glasdegib	Treatment of acute myeloid leukemia (AML)	Glasdegib		n/a	6/28/17	Designated			N/A	N/A	"Pfizer, Inc."	Groton	Connecticut	6340	USA	EXACT	0705259AA	Glasdegib	K673DMO5H9						Myeloid leukemia	8226		
vosaroxin	Treatment of acute myeloid leukemia	vosaroxin		n/a	10/28/09	Designated			N/A	N/A	"Sunesis Pharmaceuticals, Inc."	South San Francisco	California	94080	USA	EXACT	0252653AA	vosaroxin	K6A90IIZ19						Myeloid leukemia	8226		
cenersen	Treatment of acute myeloid leukemia	cenersen		n/a	5/8/06	Designated			N/A	N/A	"Eleos, Inc."	Wayzata	Minnesota	55391	USA	EXACT	0781373AA	cenersen	K6KJ8AZ05F						Myeloid leukemia	8226		
2-(2-phenylvinyl)-4-[-methylpiperazin-l-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	Treatment of acute myeloid leukemia.	ENMD-2076		n/a	1/29/10	Designated			N/A	N/A	"EntreMed, Inc."	Durham	North Carolina	27703	USA	EXACT	1129813AA	ENMD-2076	KXQ762CQTH						Myeloid leukemia	8226		
Tosedostat	Treatment of acute myeloid leukemia	Tosedostat		n/a	12/10/08	Designated			N/A	N/A	CTI BioPharma Corporation	Seattle	Washington	98121	USA	EXACT	0682779AA	Tosedostat	KZK563J2UW						Myeloid leukemia	8226		
Lisofylline	Treatment of patients undergoing induction therapy for acute myeloid leukemia.	Lisofylline		n/a	6/10/99	Designated			N/A	N/A	"Cell Therapeutics, Inc."	Seattle	Washington	98119	USA	EXACT	0182785AA	Lisofylline	L1F2Q2X956						Myeloid leukemia	8226		
Amonafide L-malate	Treatment of acute myeloid leukemia	Amonafide L-malate		Xanafide	12/20/06	Designated/Withdrawn			N/A	N/A	"Xanthus Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0247518AA	Amonafide L-malate	LI06Q37TEG						Myeloid leukemia	8226		
Azacitidine	Treatment of acute myeloid leukemia	Azacitidine		Vidaza	6/18/08	Designated			N/A	N/A	Celgene Corporation	Overland Park	Kansas	66210	USA	EXACT	0099478AA	Azacitidine	M801H13NRU						Myeloid leukemia	8226		
Tipifarnib	Treatment of acute myeloid leukemia	Tipifarnib		Zarnestra	7/6/04	Designated			N/A	N/A	Johnson & Johnson Pharmaceutical Research & Dev.	Raritan	New Jersey	8869	USA	EXACT	0218622AA	Tipifarnib	MAT637500A						Myeloid leukemia	8226		
apomorphine palmitate	Treatment of Acute Myeloid Leukemia	apomorphine palmitate		n/a	6/4/18	Designated			N/A	N/A	Leukos Biotech	"Muntaner 383, 3°2°"			Spain	EXACT	0009654AA	apomorphine	N21FAR7B4S						Myeloid leukemia	8226		
venetoclax	Treatment of acute myeloid leukemia.	venetoclax		n/a	2/4/16	Designated			N/A	N/A	AbbVie Inc.	North Chicago	Illinois	60044	USA	EXACT	0790283AA	venetoclax	N54AIC43PW						Myeloid leukemia	8226		
bromodomain and Extra-Terminal (BET) Inhibitor	Treatment of acute myeloid leukemia	FT-1101		n/a	4/5/17	Designated			N/A	N/A	"FORMA Therapeutics, Inc."	Watertown	Massachusetts	2472	USA	EXACT	1155573AA	FT-1101	NV8C50O5WW						Myeloid leukemia	8226		
Filgrastim	"Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia."	Filgrastim		Neupogen	11/7/96	Designated/Approved	Approved for Orphan Indication	"Reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with acute myeloid leukemia."	4/2/98	4/2/05	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0174823AA	Filgrastim	PVI5M0M1GW						Myeloid leukemia	8226		
isocitrate dehydrogenase 1 (IDH1)-mutant inhibitor	Treatment of acute myeloid leukemia (AML)	Ivosidenib		n/a	6/9/15	Designated			N/A	N/A	"Agios Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	1143879AA	Ivosidenib	Q2PCN8MAM6						Myeloid leukemia	8226		
chrysoeriol	Treatment of acute myeloid leukemia	chrysoeriol		n/a	6/22/17	Designated			N/A	N/A	Flavocure Biotech	Baltimore	Maryland	21202	USA	EXACT	0963359AA	chrysoeriol	Q813145M20						Myeloid leukemia	8226		
"4-{[(2R,3S,4R,5S)-4-(4-Chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid"	Treatment of Acute Myeloid Leukemia	IDASANUTLIN		n/a	5/19/14	Designated			N/A	N/A	Roche Genentech	New York	New York	10016	USA	EXACT	0927402AA	IDASANUTLIN	QSQ883V35U						Myeloid leukemia	8226		
"(1S, 2S, 3R, 4R)-3-(5-Fluoro-2-(3-methyl-4-(4-methylpiperazin-1-yl)-phenylamino)-pyrimidin-4-ylamino)bicycle[2.2.1]hept-5-ene-2-carboxamide benzoate"	Treatment of acute myeloid leukemia	CENISERTIB BENZOATE		n/a	1/19/10	Designated/Withdrawn			N/A	N/A	"EMD Serono, Inc."	Rockland	Massachusetts	2370	USA	EXACT	0737315AA	CENISERTIB BENZOATE	S68QU67MAZ						Myeloid leukemia	8226		
arsenic trioxide	Treatment of chronic myeloid leukemia	arsenic trioxide		Trisenox	10/18/01	Designated			N/A	N/A	"Teva Branded Pharmaceutical Products R*D, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0034720AA	arsenic trioxide	S7V92P67HO						Myeloid leukemia	8226		
plerixafor	Treatment of acute myeloid leukemia	plerixafor		Mozobil (R)	7/28/11	Designated/Withdrawn			N/A	N/A	Genzyme Corporation	Cambridge	Massachusetts	2142	USA	EXACT	0236373AA	plerixafor	S915P5499N						Myeloid leukemia	8226		
Liposomal annamycin	Treatment of acute myeloid leukemia	Liposomal annamycin		n/a	6/17/05	Designated			N/A	N/A	"Callisto Pharmaceuticals, Inc."	New York	New York	10170	USA	EXACT	0191015AA	annamycin	SNU299M83Q						Myeloid leukemia	8226		
liposomal annamycin	Treatment of acute myeloid leukemia.	liposomal annamycin		n/a	3/20/17	Designated			N/A	N/A	"Moleculin Biotech, Inc."	Houston	Texas	77054	USA	EXACT	0191015AA	annamycin	SNU299M83Q						Myeloid leukemia	8226		
vadastuximab talirine	Treatment of acute myeloid leukemia.	vadastuximab talirine		n/a	11/10/15	Designated			N/A	N/A	"Seattle Genetics, Inc."	Bothell	Washington	98021	USA	EXACT	1185451AA	vadastuximab talirine	T13V17U431						Myeloid leukemia	8226		
elacytarabine	Treatment of acute myeloid leukemia (AML)	elacytarabine		n/a	6/18/08	Designated			N/A	N/A	Clavis Pharma ASA				Norway	EXACT	0256451AA	elacytarabine	TA7WJG93AR						Myeloid leukemia	8226		
echinomycin	Treatment of acute myeloid leukemia.	echinomycin		n/a	5/21/15	Designated			N/A	N/A	"OncoImmune, Inc."	Washington	District of Columbia	20002	USA	EXACT	0121448AA	echinomycin	TG824J6RQT						Myeloid leukemia	8226		
lintuzumab	Treatment of acute myeloid leukemia.	lintuzumab		n/a	1/30/07	Designated/Withdrawn			N/A	N/A	"Seattle Genetics, Inc."	Bothell	Washington	98021	USA	EXACT	0298033AA	lintuzumab	V00Y10W60W						Myeloid leukemia	8226		
Sodium Stibogluconate	Treatment of acute myeloid leukemia	Sodium Stibogluconate		n/a	6/5/17	Designated			N/A	N/A	BioXcel Corporation	Branford	Connecticut	6405	USA	EXACT	0056951AA	Sodium Stibogluconate	V083S0159D						Myeloid leukemia	8226		
"2-(5-fluoro-2-methyl-1H-indol-3-yl)-1H-imidazo[4,5-f][1,10] phenanthroline"	Treatment of acute myeloid leukemia	APTO-253		n/a	6/1/15	Designated			N/A	N/A	"Aptose Biosciences, Inc."	"Mississauga, Ontario L4V"			Canada	EXACT	0547717AA	APTO-253	WB59MRW00U						Myeloid leukemia	8226		
"N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy) imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt"	Treatment of acute myeloid leukemia	quizartinib dihydrochloride 		n/a	3/18/09	Designated			N/A	N/A	Daiichi Sankyo Pharma Development	Edison	New Jersey	8837	USA	EXACT	0569266AA	quizartinib dihydrochloride	WK7Q6ZIZ10						Myeloid leukemia	8226		
2-[[3-({4-[(5-{2-[(3-Fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}propyl](ethyl)amino]ethyl dihydrogen phosphate trihydrate	Treatment of acute myeloid leukemia	BARASERTIB TRIHYDRATE		n/a	1/19/10	Designated			N/A	N/A	AstraZeneca Pharmaceuticals LP	Wilmington	Delaware	19803	USA	EXACT	0269636AA	BARASERTIB TRIHYDRATE	WM1NC31680						Myeloid leukemia	8226		
humanized monoclonal antibody that targets the a-subunit of the human IL-3 receptor also known as the CD123 antigen; (JNJ-56022473)	Treatment of acute myeloid leukemia	Talacotuzumab 		n/a	5/5/15	Designated			N/A	N/A	"Janssen Research & Development, LLC"	Raritan	New Jersey	8869	USA	EXACT	0112443AB	Talacotuzumab	X8JR0I7JE1						Myeloid leukemia	8226		
1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea	Treatment of acute myeloid leukemia	1-Cyclopropyl-3-(3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl)-urea		n/a	11/12/09	Designated			N/A	N/A	Astex Therapeutics Ltd				United Kingdom	EXACT	0281403AA	1-Cyclopropyl-3-(3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl)-urea	XAV9KYN9WL						Myeloid leukemia	8226		
"4-[2-(3-Propyl-[1,2,4]0xadiazol-5-yl)-vinyl]-benzene-1,2-diol"	Treatment of chronic myeloid leukemia	P-2745		n/a	10/4/11	Designated			N/A	N/A	Piramal Enterprises Limited	Mumbai			India	EXACT	0740476AA	P-2745	ZGL5E40F57						Myeloid leukemia	8226		
Cytarabine:daunorubicin liposome injection	Treatment of acute myeloid leukemia	daunorubicin		n/a	8/22/08	Designated			N/A	N/A	"Celator Pharmaceuticals, Inc."	Ewing	New Jersey	8628	USA	EXACT	0059392AA	daunorubicin	ZS7284E0ZP						Myeloid leukemia	8226		
human interleukin-3 genetically conjugated to diphtheria toxin protein	Treatment of acute myeloid leukemia.	SL-401		n/a	2/18/11	Designated			N/A	N/A	"Stemline Therapeutics, Inc."	New York	New York	10128	USA	EXACT	1667250AA	SL-401	8ZHS5657EH						Myeloid leukemia	8226		
human fully IgG1 antibody specific for CD33	Treatment of acute myeloid leukemia	BI-836858		n/a	6/19/14	Designated			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc."	Ridgefield	Connecticut	6877	USA	EXACT	0113084AB	BI-836858							Myeloid leukemia	8226		
mutated isocitrate dehydrogenase 1 (IDH1) inhibitor	Treatment of acute myeloid leukemia	FT-2102		n/a	4/27/17	Designated			N/A	N/A	"FORMA Therapeutics, Inc."	Watertown	Massachusetts	2472	USA	EXACT	0111778AB	FT-2102	0T4IMT8S5Z						Myeloid leukemia	8226		
oral tyrosine kinase inhibitor	Treatment of chronic myeloid leukemia	PF-114		n/a	6/28/17	Designated			N/A	N/A	"Fusion Pharma, LLC"				Russian Federation	EXACT	0112107AB	PF-114	I8C3R768IZ						Myeloid leukemia	8226		
tetravalent tandem diabody binding both CD3 and CD33	Treatment of patients with acute myeloid leukemia (AML)	AMV-564		n/a	8/17/17	Designated			N/A	N/A	"Amphivena Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	0114018AB	AMV-564	56FUB33G5M						Myeloid leukemia	8226		
"1-{3-fluoro-4-[7-(5-methyl-lH-imidazol-2-yl)- 1-oxo-2,3-dihydro-lH-isoindo 1-4-yl]-phenyl}-3-(3-trifluoromethyl-phenyl)-urea"	Treatment of acute myeloid leukemia (AML)	CG-026806		n/a	12/22/17	Designated			N/A	N/A	"Aptose Biosciences, Inc."	12770 High Bluff Drive	San Diego	92130	USA	EXACT	0114040AB	CG-026806	7W3FGR71NN						Myeloid leukemia	8226		
"7-(4-fluoro-2-methoxyphenyl)-6-methyl-N-(1-(piperidin-4-yl)-1H-pyrazol-4-yl) thieno [3,2-d]pyrimidin-2-amine semi-fumarate"	Treatment of acute myeloid leukemia	MAX-40279 HEMIFUMARATE		n/a	3/26/18	Designated			N/A	N/A	"MaxiNovel Pharmaceutical Co.,Ltd"	Building A4-1005	181 Science Boulevard		China	EXACT	0115047AB	MAX-40279 HEMIFUMARATE	JU19P2M2KM						Myeloid leukemia	8226		
Indolino-benzodiazepine compound (sulfonated DGN462) conjugated to the humanized anti-CD33 monoclonal antibody (Z4681A) via the sulfo-SPDB linker	Treatment of acute myeloid leukemia	IMGN-779		n/a	5/2/18	Designated			N/A	N/A	"ImmunoGen, Inc."	830 Winter Street		2451	USA	LONGEST CONTAINS	0511740AA	benzodiazepine	M0Q7802G2B						Myeloid leukemia	8226		
Ricin (blocked) conjugated murine MCA (anti-my9)	"Treatment of myeloid leukemia, including AML, and blast crisis of CML."	Ricin (blocked) conjugated murine MCA (anti-my9)		n/a	8/3/89	Designated/Withdrawn			N/A	N/A	"ImmunoGen, Inc."	Waltham	Massachusetts	2451	USA	LONGEST CONTAINS	0811450AA	Ricin	U6E7R9OE4R						Myeloid leukemia	8226		
Antisense 20-mer oligonucleotide complementary to R2 component of ribonucleotide reductase mRNA	Treatment of acute myeloid leukemia	Antisense 20-mer oligonucleotide complementary to R2 component of ribonucleotide reductase mRNA		n/a	4/15/05	Designated			N/A	N/A	"Lorus Therapeutics, Inc."	M9W 4Z7			Canada	LONGEST CONTAINS	1577157AA	ribonucleotide reductase	W8C4AP9R9S						Myeloid leukemia	8226		
recombinant human histone H1.3; recombinant human N-bis-met-histone H1.3	Treatment of acute myeloid leukemia	recombinant human histone H1.3; recombinant human N-bis-met-histone H1.3		Oncohist	10/20/08	Designated			N/A	N/A	Xenetic Biosciences Plc	London			United Kingdom										Myeloid leukemia	8226		
chimeric murine/human IgG1 monoclonal antibody to human interleukin-3 receptor alpha chain	Treatment of acute myeloid leukemia	chimeric murine/human IgG1 monoclonal antibody to human interleukin-3 receptor alpha chain		n/a	4/3/09	Designated/Withdrawn			N/A	N/A	CSl Limited				Australia										Myeloid leukemia	8226		
Nucleic acid aptamer binding to tumor cell nucleolin	Treatment of acute myeloid leukemia	Nucleic acid aptamer binding to tumor cell nucleolin		n/a	9/10/09	Designated			N/A	N/A	"Antisoma, Inc."	Cambridge	Massachusetts	2139	USA										Myeloid leukemia	8226		
allogeneic ex vivo expanded umbilical cord blood cells	For use as hematopoietic support in patients with chronic myeloid leukemia	allogeneic ex vivo expanded umbilical cord blood cells		Stemex	2/1/10	Designated/Withdrawn			N/A	N/A	Gamida Cell - Teva Joint Venture				Israel	LONGEST CONTAINS	0854240AA	umbilical cord blood	PVH8394DLN						Myeloid leukemia	8226		
Replication-incompetent GM-CSF-expressing gene-modified allogeneic acute myeloid leukemia cancer cell lines	Treatment of acute myeloid leukemia	Replication-incompetent GM-CSF-expressing gene-modified allogeneic acute myeloid leukemia cancer cell lines		Gvax Acute Myeloid Leukemia	3/2/10	Designated			N/A	N/A	"Aduro BioTech, Inc."	Berkeley	California	94710	USA										Myeloid leukemia	8226		
Replication-incompetent GM-CSF-expressing gene-modified allogeneic chronic myeloid leukemia cancer cell lines	Treatment of chronic myeloid leukemia	Replication-incompetent GM-CSF-expressing gene-modified allogeneic chronic myeloid leukemia cancer cell lines		Gvax Chronic Myeloid Leukemia	4/30/10	Designated			N/A	N/A	"Aduro BioTech, Inc."	Berkeley	California	94710	USA										Myeloid leukemia	8226		
CNDO-109-activated allogeneic natural killer cells	Treatment of acute myeloid leukemia	CNDO-109-activated allogeneic natural killer cells		n/a	6/18/12	Designated			N/A	N/A	"Coronado Biosciences, Inc."	Burlington	Massachusetts	1803	USA	LONGEST CONTAINS	1313639AA	killer	H8QG06RS7R						Myeloid leukemia	8226		
	For the treatment of acute myeloid leukemia	Nicord		Nicord	4/28/14	Designated			N/A	N/A	Gamida Cell Ltd	Jerusalem			Israel										Myeloid leukemia	8226		
liposomal P-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide	Treatment of acute myeloid leukemia	liposomal P-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide		n/a	4/27/15	Designated			N/A	N/A	"Bio-Path Holdings, Inc."	Houston	Texas	77401	USA	LONGEST CONTAINS	0087274AA	protein							Myeloid leukemia	8226		
131I-BC8 monoclonal antibody (Anti-CD45 murine monoclonal antibody radiolabeled with 131I	Treatment of Acute Myeloid Leukemia (AML)	bc-8 i-131		n/a	3/28/16	Designated			N/A	N/A	"Actinium Pharmaceuticals, Inc."	Edison	New Jersey	8837	USA										Myeloid leukemia	8226		
allogeneic ex-vivo generated CD56+CD3-natural killer cells from CD34+ umbilical cord blood progenitor cells	Treatment of acute myeloid leukemia	allogeneic ex-vivo generated CD56+CD3-natural killer cells from CD34+ umbilical cord blood progenitor cells		n/a	4/20/16	Designated			N/A	N/A	IPD-Therapeutics BV				Netherlands	LONGEST CONTAINS	0854240AA	umbilical cord blood	PVH8394DLN						Myeloid leukemia	8226		
"THIOMAB antibody drug conjugate comprised of humanized IgG1 anti-C-type lectin-like molecule-1 monoclonal antibody and DNA alkylating cross-linking agent pyrrolo [2,1-c][1,4] benzodiazepine dimer"	Treatment of acute myeloid leukemia	"THIOMAB antibody drug conjugate comprised of humanized IgG1 anti-C-type lectin-like molecule-1 monoclonal antibody and DNA alkylating cross-linking agent pyrrolo [2,1-c][1,4] benzodiazepine dimer"		n/a	10/24/17	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	LONGEST CONTAINS	0511740AA	benzodiazepine	M0Q7802G2B						Myeloid leukemia	8226		
"2-O, 3-O, desulfated heparin"	Treatment of acute myeloid leukemia	"2-O, 3-O, desulfated heparin"		n/a	12/21/17	Designated			N/A	N/A	"Cantex Pharmaceuticals, Inc."	1792 Bell Tower Lane	Weston	33326	USA	LONGEST CONTAINS	0118230AA	heparin	T2410KM04A						Myeloid leukemia	8226		
"2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)nicotinic acid"	Treatment of acute myeloid leukemia	ASLAN-003		n/a	8/16/18	Designated			N/A	N/A	"ASLAN Pharmaceuticals Pte, Ltd."	83 Clemenceau Avenue			Singapore	EXACT	0117178AB	ASLAN-003							Myeloid leukemia	8226		
Methanesulfonate-1-sec-butoxycarbonyloxymethyl-1-methyl-4-{4-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-benzyl}-piperazin-1-ium	Treatment of chronic myeloid leukemia	IKT-001PRO		n/a	9/13/18	Designated			N/A	N/A	"Inhibikase Therapeutics, Inc."	3350 Riverwood Parkway	Georgia	30339	USA	EXACT	 0117200AB								Myeloid leukemia	8226		
Indolino-benzodiazepine compound (sulfonated DGN549-C) conjugated to the humanized anti-CD123 monoclonal antibody (G4723A)	Treatment of acute myeloid leukemia	Indolino-benzodiazepine compound (sulfonated DGN549-C) conjugated to the humanized anti-CD123 monoclonal antibody (G4723A)		n/a	10/10/18	Designated			N/A	N/A	"ImmunoGen, Inc."	830 Winter Street	Massachusetts	2451	USA	LONGEST CONTAINS	0511740AA	benzodiazepine	M0Q7802G2B						Myeloid leukemia	8226		
"5-Chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazine-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine·monohydrate"	Treatment of Acute Myeloid Leukemia	HM-43239 MONOHYDRATE		n/a	10/25/18	Designated			N/A	N/A	"Hanmi Pharmaceutical Company, Ltd."	"14, Wiryeseong-daero"			"Korea, Republic of"	EXACT	0115284AB	HM-43239 MONOHYDRATE	1YT25M37WR						Myeloid leukemia	8226		
arsenic	"Treatment of acute myelocytic leukemia subtypes M0, M1, M2, M4, M5, M6 and M7"	arsenic		Trisenox	11/2/01	Designated			N/A	N/A	"Teva Branded Pharmaceutical Products R&D, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0048180AA	arsenic	N712M78A8G						Myeloid leukemia	8226		
ambroxol	Treatment of Gaucher disease	ambroxol		n/a	6/29/11	Designated			N/A	N/A	"Belrose Pharma, Inc."	Princeton	New Jersey	8540	USA	EXACT	0302261AA	ambroxol	200168S0CL						Gaucher disease	8233		
velaglucerase-alfa	Treatment of Gaucher disease	velaglucerase-alfa		Vpriv	6/8/09	Designated/Approved	Approved for Orphan Indication	Treatment of Type I Gaucher Disease	2/26/10	N/A	"Shire Human Genetics Therapies, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0310565AA	velaglucerase alfa	23HYE36B0I						Gaucher disease	8233		
isofagomine tartrate	Treatment of Gaucher disease	isofagomine tartrate		n/a	1/10/06	Designated			N/A	N/A	"Amicus Therapeutics, Inc."	Cranbury	New Jersey	8512	USA	EXACT	0328938AA	isofagomine tartrate	285ZJJ9773						Gaucher disease	8233		
miglustat	Treatment of Gaucher disease.	miglustat		Zavesca	5/29/98	Designated/Approved	Approved for Orphan Indication	"Treatment of mild to moderate Type I Gaucher disease in adults for whom enzyme replacement therapy is not a therapeutic option (e.g., due to constraints such as allergy, hypersensitivity, or poor venous access)."	7/31/03	7/31/10	Actelion Pharmaceuticals Ltd				Switzerland	EXACT	0169288AA	miglustat	ADN3S497AZ						Gaucher disease	8233		
"(3S)-1-azabicyclo[2.2.2]oct-3-yl {2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate"	Treatment of Gaucher disease	VENGLUSTAT		n/a	9/11/14	Designated			N/A	N/A	Genzyme	Cambridge	Massachusetts	2142	USA	EXACT	1120270AA	VENGLUSTAT	BLP1XA3FZA						Gaucher disease	8233		
eliglustat	Treatment of Type I Gaucher disease	eliglustat		Cerdelga	9/17/08	Designated/Approved	Approved for Orphan Indication	"Long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test."	8/19/14	8/19/21	Genzyme Corporation	Cambridge	Massachusetts	2142	USA	EXACT	0459698AA	eliglustat	DR40J4WA67						Gaucher disease	8233		
Alendronate disodium	Treatment of the bone manifestations of Gaucher disease	Alendronate disodium		Fosamax	2/13/01	Designated			N/A	N/A	"Richard J. Wenstrup, M.D."	Cincinnati	Ohio	45229	USA	EXACT	1576632AA	Alendronate disodium	I2U0WCC042						Gaucher disease	8233		
Recombinant retroviral vector - glucocerebrosidase	"For use as enzyme replacement therapy for patients with types I, II, or III Gaucher disease."	Recombinant retroviral vector - glucocerebrosidase		n/a	11/15/93	Designated			N/A	N/A	"Genetic Therapy, Inc."	Gaithersburg	Maryland	20878	USA										Gaucher disease	8233		
"Retroviral vector, R-GC and GC gene 1750"	Treatment of Gaucher disease.	"Retroviral vector, R-GC and GC gene 1750"		n/a	5/6/97	Designated/Withdrawn			N/A	N/A	Genzyme Corporation	Cambridge	Massachusetts	1701	USA										Gaucher disease	8233		
Modified cholera toxin	Treatment of Gaucher disease	Modified cholera toxin		n/a	2/7/17	Designated			N/A	N/A	"ERAD Therapeutics, Inc."	Potomac	Maryland	20854	USA										Gaucher disease	8233		
Tideglusib	Treatment of myotonic dystrophy type 1 (DM1)	Tideglusib		n/a	6/19/17	Designated			N/A	N/A	AMO Pharma Ltd.	Wonersh			United Kingdom	EXACT	0362094AA	Tideglusib	Q747Y6TT42						Myotonic dystrophy type 1	8310		
Tesevatinib	Treatment of patients with autosomal recessive polycystic kidney disease (ARPKD)	Tesevatinib		n/a	3/1/16	Designated			N/A	N/A	"Kadmon Corporation, LLC"	New York	New York	10016	USA	EXACT	0733653AA	Tesevatinib	F6XM2TN5A1						Autosomal recessive polycystic kidney disease	8378		
extracellular domain of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 fused to the Fc region of human IgG1	Treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency (generalized arterial calcification of infancy and autosomal recessive hypophosphatemic rickets type 2)	extracellular domain of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 fused to the Fc region of human IgG1		n/a	6/11/18	Designated			N/A	N/A	Inozyme Pharma Inc.	700 Technology Square		2139	USA										Arterial calcification of infancy	8380		
sodium phenylbutyrate	"Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency."	sodium phenylbutyrate		Buphenyl	11/22/93	Designated/Approved	Approved for Orphan Indication	"Adjunctive therapy in the chronic managment of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase."	4/30/96	4/30/03	Medicis Pharmaceutical Corp.	Scottsdale	Arizona	85258	USA	EXACT	0180767AA	sodium phenylbutyrate	NT6K61736T						Ornithine transcarbamylase deficiency	8391		
recombinant adeno-associated virus serotype AAV8 vector encoding human ornithine transcarbamylase	Treatment of ornithine transcarbamylase deficiency	recombinant adeno-associated virus serotype AAV8 vector encoding human ornithine transcarbamylase		n/a	12/29/15	Designated			N/A	N/A	Dimension Therapeutics	Cambridge	Massachusetts	2139	USA	LONGEST CONTAINS	0012168AA	ornithine	E524N2IXA3						Ornithine transcarbamylase deficiency	8391		
mRNA encoding human ornithine transcarbamylase	Treatment of ornithine transcarbamylase deficiency	mRNA encoding human ornithine transcarbamylase		n/a	11/23/16	Designated			N/A	N/A	"PhaseRx, Inc."	Seattle	Washington	98119	USA	LONGEST CONTAINS	0012168AA	ornithine	E524N2IXA3						Ornithine transcarbamylase deficiency	8391		
cerebrolysin	"Treatment of frontotemporal dementia, including all subvariants"	cerebrolysin		n/a	4/5/16	Designated			N/A	N/A	EVER Neuro Pharma GmbH				Austria	EXACT	0227543AA	cerebrolysin	37KZM6S21G						Frontotemporal dementia	8436		
tolfenamic acid	Treatment of Frontotemporal Dementia	tolfenamic acid		n/a	7/13/16	Designated			N/A	N/A	Nasser H. Zawia	Warwick	Rhode Island	2886	USA	EXACT	0290722AA	tolfenamic acid	3G943U18KM						Frontotemporal dementia	8436		
"Isoindolin-1,3-Di Thione"	Treatment of Frontotemporal dementia	"Isoindolin-1,3-DiThione"		n/a	11/21/16	Designated			N/A	N/A	"P2D, Inc."	Cincinnati	Ohio	45242	USA	EXACT	1800391AA	"Isoindolin-1,3-DiThione"	7R978066MK						Frontotemporal dementia	8436		
"1-(2,8-Dimethyl-1-thia-3,8-diazaspiro[4.5]dec-3-yl)-3-(1H-indol-3-yl)propan-1-one"	Treatment of frontotemporal dementia.	"1-(2,8-Dimethyl-1-thia-3,8-diazaspiro(4.5)dec-3-yl)-3-(1H-indol-3-yl)propan-1-one"		n/a	4/6/16	Designated			N/A	N/A	Anavex Life Sciences Corp.	New York	New York	10019	USA	EXACT	1576610AA	"1-(2,8-Dimethyl-1-thia-3,8-diazaspiro(4.5)dec-3-yl)-3-(1H-indol-3-yl)propan-1-one"	AAE07Z061B						Frontotemporal dementia	8436		
"recombinant human anti-human Sortilin (SORT1) monoclonal IgG1 G1m17,1 [or G1m (z,a)] kappa monoclonal antibody"	Treatment of Frontotemporal Dementia	"recombinant human anti-human Sortilin (SORT1) monoclonal IgG1 G1m17,1 [or G1m (z,a)] kappa monoclonal antibody"		n/a	6/18/18	Designated			N/A	N/A	Alector	151 Oyster Point Boulevard	California	94080	USA	LONGEST CONTAINS	0112915AB	Sortilin	Z020Y8WIJ4						Frontotemporal dementia	8436		
dexamethasone intravitreal implant	"Treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate, posterior, and panuveitis"	dexamethasone intravitreal implant		Ozurdex	9/11/98	Designated/Approved	Approved for Orphan Indication	For treatment of non-infectious uveitis affecting the posterior segment of the eye	9/24/10	9/24/17	Allergan	Irvine	California	92623	USA	EXACT	0007192AA	dexamethasone	7S5I7G3JQL						Panuveitis	8577		
difluprednate	Treatment of endogenous and traumatic anterior uveitis and panuveitis.	difluprednate		Durezol	9/30/08	Designated/Approved	Approved for Orphan Indication	Treatment of endogenous anterior uveitis	6/13/12	6/13/19	Alcon Pharmaceuticals. Ltd.				Switzerland	EXACT	0062395AA	difluprednate	S8A06QG2QE						Panuveitis	8577		
sirolimus	"Treatment of chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, noninfectious panuveitis and non-infectious, uveitis affecting the posterior of the eye (NICUPS)."	sirolimus		n/a	11/4/11	Designated			N/A	N/A	Santen Inc.	Emeryville	California	94608	USA	EXACT	0175177AA	sirolimus	W36ZG6FT64						Panuveitis	8577		
regorafenib	Treatment gastrointestinal stromal tumors	regorafenib		Stivarga	1/12/11	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate."	2/25/13	2/25/20	"Bayer HealthCare Pharmaceuticals, Inc."	Whippany	New Jersey	7981	USA	EXACT	0338647AA	regorafenib	24T2A1DOYB						Gastrointestinal Stromal Tumors	8598		
ponatinib	Treatment of gastrointestinal stromal tumors (GIST).	ponatinib		Iclusig(R)	3/12/15	Designated			N/A	N/A	"ARIAD Pharmaceuticals, Inc."	Cambridge	Massachusetts	2339	USA	EXACT	0460162AA	ponatinib	4340891KFS						Gastrointestinal Stromal Tumors	8598		
Small Molecule Inhibitor of Exon 17 mutant KIT	Treatment of gastrointestinal stromal tumors (GIST).	BLU-285		n/a	1/6/16	Designated			N/A	N/A	Blueprint Medicines Corporation	Cambridge	Massachusetts	2139	USA	EXACT	1152154AA	BLU-285	513P80B4YJ						Gastrointestinal Stromal Tumors	8598		
imatinib mesylate	Treatment of gastrointestinal stromal tumors	imatinib mesylate		Gleevec	11/1/01	Designated/Approved	Approved for Orphan Indication	Adjuvant treatment of adult patients following complete resection Kit (CD 117) positive gastrointestinal stromal tumors (GIST).	12/19/08	12/19/15	Novartis Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0227065AA	imatinib mesylate	8A1O1M485B						Gastrointestinal Stromal Tumors	8598		
imatinib mesylate	Treatment of gastrointestinal stromal tumors	imatinib mesylate		Gleevec	11/1/01	Designated/Approved	Approved for Orphan Indication	Treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST)	2/1/02	2/1/09	Novartis Pharmaceuticals Corp.	East Hanover	New Jersey	7936	USA	EXACT	0227065AA	imatinib mesylate	8A1O1M485B						Gastrointestinal Stromal Tumors	8598		
Inhibitor of primary and secondary KIT and PDGFR alpha kinase mutants found in GIST	Treatment of gastrointestinal stromal tumors (GIST)	DCC-2618		n/a	10/2/14	Designated			N/A	N/A	"Deciphera Pharmaceuticals, LLC"	Lawrence	Kansas	66044	USA	EXACT	1177113AA	DCC-2618	9XW757O13D						Gastrointestinal Stromal Tumors	8598		
nilotinib	Treatment of gastrointestinal stromal tumors.	nilotinib		Tasigna	3/20/07	Designated/Withdrawn			N/A	N/A	Novartis Pharmaeuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0297723AA	nilotinib	F41401512X						Gastrointestinal Stromal Tumors	8598		
masitinib	Treatment of malignant gastrointestinal stromal tumors	masitinib		n/a	4/20/05	Designated			N/A	N/A	AB Science	Paris			France	EXACT	0302783AA	masitinib	M59NC4E26P						Gastrointestinal Stromal Tumors	8598		
"N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide, phosphate (1:2)"	Treatment of gastrointestinal stromal tumors	MOTESANIB DIPHOSPHATE		n/a	1/13/05	Designated/Withdrawn			N/A	N/A	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0302750AA	MOTESANIB DIPHOSPHATE	T6Q3060U91						Gastrointestinal Stromal Tumors	8598		
retaspimycin	Treatment for gastrointestinal stromal tumor	retaspimycin		n/a	8/31/07	Designated/Withdrawn			N/A	N/A	"Infinity Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0315128AA	retaspimycin	BZF2ZM0I5Z						Gastrointestinal Stromal Tumors	8598		
tipelukast	Treatment of idiopathic pulmonary fibrosis	tipelukast		n/a	10/20/14	Designated			N/A	N/A	"MediciNova, Inc."	La Jolla	California	92037	USA	EXACT	0257034AA	tipelukast	08379P260O						Idiopathic pulmonary fibrosis	8609		
Recombinant humanized anti-LOXL2 monoclonal antibody	Treatment of idiopathic pulmonary fibrosis	Simtuzumab		n/a	4/18/11	Designated/Withdrawn			N/A	N/A	"Gilead Sciences, Inc."	Seattle	Washington	98102	USA	EXACT	0762403AA	Simtuzumab	11Z5AIU653						Idiopathic pulmonary fibrosis	8609		
interferon gamma-1b	Treatment of idiopathic pulmonary fibrosis	interferon gamma-1b		Actimmune	9/12/02	Designated/Withdrawn			N/A	N/A	"InterMune, Inc."	Brisbane	California	94005	USA	EXACT	0174812AA	interferon gamma-1b	21K6M2I7AG						Idiopathic pulmonary fibrosis	8609		
nitric oxide	Treatment of idiopathic pulmonary fibrosis	nitric oxide		n/a	1/31/17	Designated			N/A	N/A	"GeNo, LLC"	Cocoa	Florida	32926	USA	EXACT	0176341AA	nitric oxide	31C4KY9ESH						Idiopathic pulmonary fibrosis	8609		
"human anti-transforming growth factor-B1,2,3"	Treatment of idiopathic pulmonary fibrosis	Fresolimumab		n/a	7/9/04	Designated/Withdrawn			N/A	N/A	Genzyme Corporation	Cambridge	Massachusetts	2142	USA	EXACT	0266319AA	Fresolimumab	375142VBIA						Idiopathic pulmonary fibrosis	8609		
(R)-1-phenylethyl-5-(4-biphenyl-4-cyclopropanecarboxylic acid)-3-methylisoxazole-4-yl carbamate sodium salt	Treatment of idiopathic pulmonary fibrosis	BMS-986020 		n/a	4/15/11	Designated			N/A	N/A	Bristol-Myers Squibb Company	Princeton	New Jersey	8543	USA	EXACT	1125833AA	BMS-986020	38CTP01B4L						Idiopathic pulmonary fibrosis	8609		
small molecule inhibitor of the Wnt pathway	Treatment of idiopathic pulmonary fibrosis (IPF).	SM-04690		n/a	6/6/17	Designated			N/A	N/A	"Samumed, LLC"	San Diego	California	92121	USA	EXACT	0111825AB	SM-04690	42EK42WHI5						Idiopathic pulmonary fibrosis	8609		
"2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione"	Treatment of idiopathic pulmonary fibrosis.	"2-(2-chlorophenyl)-4-(3-(dimethylamino)phenyl)-5-methyl-1H-pyrazolo(4,3-C)pyridine-3,6(2H,5H)-dione"		n/a	9/21/10	Designated			N/A	N/A	GenKyoTex S.A.	Geneva			Switzerland	EXACT	0711295AA	"2-(2-chlorophenyl)-4-(3-(dimethylamino)phenyl)-5-methyl-1H-pyrazolo(4,3-C)pyridine-3,6(2H,5H)-dione"	45II35329V						Idiopathic pulmonary fibrosis	8609		
ammonium tetrathiomolybdate	Treatment of idiopathic pulmonary fibrosis	ammonium tetrathiomolybdate		n/a	5/5/08	Designated			N/A	N/A	"Pipex Pharmaceuticals, Inc."	Ann Arbor	Michigan	48108	USA	EXACT	0161820AA	ammonium tetrathiomolybdate	4V6I63LW1E						Idiopathic pulmonary fibrosis	8609		
carlumab	Treatment of idiopathic pulmonary fibrosis	carlumab		n/a	11/8/07	Designated/Withdrawn			N/A	N/A	"Janssen Biotech, Inc."	Spring House	Pennsylvania	19477	USA	EXACT	0583222AA	carlumab	6TC1BB2EV9						Idiopathic pulmonary fibrosis	8609		
carbon monoxide	Treatment of idiopathic pulmonary fibrosis (IPF).	carbon monoxide		n/a	8/16/16	Designated			N/A	N/A	"Proterris, Inc."	Boston	Massachusetts	2118	USA	EXACT	0084899AA	carbon monoxide	7U1EE4V452						Idiopathic pulmonary fibrosis	8609		
"Sar9, Met(O2)11-Substance P"	Treatment of idiopathic pulmonary fibrosis	"Sar9, Met(O2)11-Substance P"		Homspera	3/16/11	Designated			N/A	N/A	"ImmuneRegen BioSciences, Inc."	Scottsdale	Arizona	85258	USA	EXACT	0803601AA	"Sar9, Met(O2)11-Substance P"	8V0QAFPRXV						Idiopathic pulmonary fibrosis	8609		
pirfenidone	Treatment of idiopathic pulmonary fibrosis	pirfenidone		Esbriet	3/5/04	Designated/Approved	Approved for Orphan Indication	Treatment of idiopathic pulmonary fibrosis	10/15/14	10/15/21	Genentech	South San Francisco	California	94080	USA	EXACT	0065996AA	pirfenidone	D7NLD2JX7U						Idiopathic pulmonary fibrosis	8609		
pirfenidone	Treatment of idiopathic pulmonary fibrosis	pirfenidone		n/a	7/31/14	Designated			N/A	N/A	"Genoa Pharmaceuticals, Inc."	San Diego	California	92130	USA	EXACT	0065996AA	pirfenidone	D7NLD2JX7U						Idiopathic pulmonary fibrosis	8609		
recombinant human Pentraxin-2; recombinant human Serum Amyloid P	Treatment of idiopathic pulmonary fibrosis.	PRM-151		n/a	2/17/12	Designated			N/A	N/A	"Promedior, Inc."	Lexington	Massachusetts	19355	USA	EXACT	1198001AA	PRM-151	F68WAH6N5E						Idiopathic pulmonary fibrosis	8609		
nintedanib	Treatment of patients with idiopathic pulmonary fibrosis.	nintedanib		Ofev	6/29/11	Designated/Approved	Approved for Orphan Indication	Treatment of idiopathic pulmonary fibrosis	10/15/14	10/15/21	"Boehringer Ingelheim Pharmaceuticals, Inc."	Ridgefield	Connecticut	6877	USA	EXACT	0359900AA	nintedanib	G6HRD2P839						Idiopathic pulmonary fibrosis	8609		
tralokinumab	Treatment of idiopathic pulmonary fibrosis	tralokinumab		n/a	7/24/12	Designated/Withdrawn			N/A	N/A	MedImmune Ltd.	Cambridge CB21 6GH			United Kingdom	EXACT	0742278AA	tralokinumab	GK1LYB375A						Idiopathic pulmonary fibrosis	8609		
ambrisentan	Treatment of idiopathic pulmonary fibrosis	ambrisentan		Letairis	12/23/09	Designated/Withdrawn			N/A	N/A	"Gilead Sciences, Inc."	Seattle	Washington	98102	USA	EXACT	0243696AA	ambrisentan	HW6NV07QEC						Idiopathic pulmonary fibrosis	8609		
"2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-piperazin-1-yl)-8-methylimidazo[1,2-a]pyridin-3-yl)-(methyl)amino)-4-(4-fluorophenyl)-thiazole-5-carbonitrile"	Treatment of idiopathic pulmonary fibrosis.	GLPG-1690		n/a	6/8/17	Designated			N/A	N/A	Galapagos NV	Mechelen			Belgium	EXACT	1569660AA	GLPG-1690	I02418V13W						Idiopathic pulmonary fibrosis	8609		
"6-(4-(4-(2,3-Dicholorophenyl) piperazin-1-yl) butoxy)-2H-benzo [b] [1,4] oxazin-3(4H)-one hydrochloride"	Treatment of Idiopathic Pulmonary Fibrosis	RP-5063 hydrochloride		n/a	4/4/18	Designated			N/A	N/A	"Reviva Pharmaceuticals, Inc."	"1250 Oakmead Parkway, Suite 210"		94085	USA	EXACT	1800357AA	RP-5063 hydrochloride	I440YY0HX0						Idiopathic pulmonary fibrosis	8609		
humanized monoclonal antibody against human integrin alphaVbeta6	Treatment of idiopathic pulmonary fibrosis	STX-100		n/a	8/5/10	Designated			N/A	N/A	"Biogen Idec, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0313677AA	STX-100	JD43Y6YF3N						Idiopathic pulmonary fibrosis	8609		
tetra-substituted porphyrin derivative containing manganese (III)	Treatment of idiopathic pulmonary fibrosis	AEOL-10150		n/a	3/16/15	Designated			N/A	N/A	Aeolus Pharmaceuticals	Mission Viejo	California	92691	USA	EXACT	0251489AA	AEOL-10150	KPKO7W46E8						Idiopathic pulmonary fibrosis	8609		
yinfenidone	Treatment of idiopathic pulmonary fibrosis	YIFENIDONE		n/a	8/10/17	Designated			N/A	N/A	"Sunshine Lake Pharma Co., Ltd"	Dongguan			China	EXACT	1801907AA	YIFENIDONE	KUCKUGJB6K						Idiopathic pulmonary fibrosis	8609		
"4-[[9-(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol"	Treatment of idiopathic pulmonary fibrosis	TANZISERTIB		n/a	9/23/11	Designated			N/A	N/A	Celgene Corporation	Warren	New Jersey	7059	USA	EXACT	0357608AA	TANZISERTIB	M5O06306UO						Idiopathic pulmonary fibrosis	8609		
bispecific antibody targeting interleukin 4 (IL-4) and interleukin 13 (IL-13)	Treatment of idiopathic pulmonary fibrosis.	SAR-156597		n/a	9/14/11	Designated			N/A	N/A	"Sanofi-Aventis US, Inc."	Bridgewater	New Jersey	8807	USA	EXACT	0114274AB	SAR-156597	O8HNJ174XS						Idiopathic pulmonary fibrosis	8609		
bosentan	Treatment of idiopathic pulmonary fibrosis	bosentan		Tracleer	9/30/08	Designated/Withdrawn			N/A	N/A	Actelion Pharmaceuticals Ltd				Switzerland	EXACT	0186663AA	bosentan	Q326023R30						Idiopathic pulmonary fibrosis	8609		
"human recombinant DNA-derived, IgG1 kappa monoclonal anti-body to connective growth factor"	Treatment of idiopathic pulmonary fibrosis	FG-3019		n/a	7/6/12	Designated			N/A	N/A	"FibroGen, Inc."	San Francisco	California	94158	USA	EXACT	0267458AA	FG-3019	QS5F6VTS0O						Idiopathic pulmonary fibrosis	8609		
3-pentylbenzenacetic acid sodium salt	Treatment of idiopathic pulmonary fibrosis.	3-pentylbenzenacetic acid sodium salt		n/a	2/11/15	Designated			N/A	N/A	"ProMetic Life Sciences, Inc."				Canada	EXACT	1576621AA	3-pentylbenzenacetic acid sodium salt	R05571KE07						Idiopathic pulmonary fibrosis	8609		
lebrikizumab	Treatment of idiopathic pulmonary fibrosis	lebrikizumab		n/a	3/9/15	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0331522AA	lebrikizumab	U9JLP7V031						Idiopathic pulmonary fibrosis	8609		
3-[4-(lH-imidazol-l-ylmethyl)phenyl]-5-(2-methylpropyl) thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt	Treatment of idiopathic pulmonary fibrosis	C-21 sodium		n/a	1/25/17	Designated			N/A	N/A	Vicore Pharma	Mölndal			Sweden	EXACT	1801156AA	C-21 sodium	Y151F1Q61I						Idiopathic pulmonary fibrosis	8609		
macitentan	Treatment of idiopathic pulmonary fibrosis.	macitentan		n/a	4/14/09	Designated/Withdrawn			N/A	N/A	Actelion Pharmaceuticals Ltd.				Switzerland	EXACT	0339333AA	macitentan	Z9K9Y9WMVL						Idiopathic pulmonary fibrosis	8609		
Cintredekin Besudotox	Treatment of idiopathic pulmonary fibrosis	Cintredekin Besudotox		n/a	4/30/10	Designated			N/A	N/A	"Insys Development Company, Inc."	Chandler	Arizona	85286	USA	EXACT	0262986AA	Cintredekin Besudotox	ZL04JX89M7						Idiopathic pulmonary fibrosis	8609		
Interferon gamma	Treatment of idiopathic pulmonary fibrosis	Interferon gamma		n/a	10/11/07	Designated			N/A	N/A	mondoBIOTECH Laboratories AG				Germany	EXACT	0214573AA	Interferon gamma	P050J5FWC5						Idiopathic pulmonary fibrosis	8609		
monoclonal antibody targeting eotaxin-2	Treatment of idiopathic pulmonary fibrosis.	cm-101		n/a	10/29/15	Designated			N/A	N/A	"ChemomAb, Ltd."	Tel Aviv			Israel	EXACT	0110872AB	cm-101							Idiopathic pulmonary fibrosis	8609		
human single domain antibody-like protein inhibitor of the chemokine receptor type 4	Treatment of idiopathic pulmonary fibrosis	AD-114 		n/a	1/11/17	Designated			N/A	N/A	AdAlta Limited	Bundoora			Australia	EXACT									Idiopathic pulmonary fibrosis	8609		
plasminogen (Human)	Treatment of idiopathic pulmonary fibrosis (IPF)	plasminogen (Human)		Ryplazim™ Plasminogen (Human)	12/14/17	Designated			N/A	N/A	"ProMetic BioTherapeutics, Inc"	1330 Piccard Drive	Rockville	20850	USA	LONGEST CONTAINS	0005061AA	plasminogen							Idiopathic pulmonary fibrosis	8609		
"N-(2-chloro-6-propoxypyridin-4-yl)-2-(2-hydroxyethyl)-2-(4-isopropyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)hydrazinecarboxamide"	Treatment of Idiopathic pulmonary fibrosis (IPF)	AB-​22		n/a	5/23/18	Designated			N/A	N/A	"Arroyo Biosciences, LLC"	1812 Pelling Court		20905	USA	EXACT									Idiopathic pulmonary fibrosis	8609		
purified bovine type collagen	Treatment of idiopathic pulmonary fibrosis	purified bovine type collagen		n/a	4/27/09	Designated			N/A	N/A	"ImmuneWorks, Inc."	Indianapolis	Indiana	46202	USA	LONGEST CONTAINS	0006462AA	collagen							Idiopathic pulmonary fibrosis	8609		
small molecule selective inhibitor of c-Jun N-terminal kinase	Treatment of idiopathic pulmonary fibrosis	CC-90001		n/a	6/27/18	Designated			N/A	N/A	Celgene Corporation	86 Morris Avenue	New Jersey	7901	USA	EXACT	1295121AA	CC-90001	JD5ZWE631K						Idiopathic pulmonary fibrosis	8609		
"soidum (5-(3-cyanopyrazolo[1,5-a]pyridin-5-yl)-2-methoxypyridin-3-yl)((2,4-difluorophenyl)sulfonyl)amide"	Treatment of idiopathic pulmonary fibrosis (IPF)	HEC-68498 SODIUM		n/a	7/9/18	Designated			N/A	N/A	"Sunshine Lake Pharma Co., Ltd"	Northern Industry Road #1			China	EXACT	0114833AB	HEC-68498 SODIUM	8PL809KPW4						Idiopathic pulmonary fibrosis	8609		
small molecule inhibitor of integrins avb6 and avb1	Treatment of Idiopathic Pulmonary Fibrosis	small molecule inhibitor of integrins avb6 and avb1		n/a	8/1/18	Designated			N/A	N/A	"Pliant Therapeutics, Inc."	260 Littlefield Avenue	California	94080	USA										Idiopathic pulmonary fibrosis	8609		
cinacalcet	"Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery"	cinacalcet		Sensipar	4/30/10	Designated/Approved	Approved for Orphan Indication	Treatment of severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy	2/25/11	2/25/18	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0282031AA	cinacalcet	UAZ6V7728S						Primary hyperparathyroidism	8612		
cinacalcet	"Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery"	cinacalcet		Sensipar	4/30/10	Designated/Approved	Approved for Orphan Indication	"Treatment of hypercalcemia in adult patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy."	11/21/14	11/21/21	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0282031AA	cinacalcet	UAZ6V7728S						Primary hyperparathyroidism	8612		
decitabine	Treatment of sickle cell anemia	decitabine		n/a	9/9/02	Designated/Withdrawn			N/A	N/A	Otsuka Pharmaceutical Development &	Princeton	New Jersey	8540	USA	EXACT	0171244AA	decitabine	776B62CQ27						Sickle cell anemia	8614		
Hydroxyurea	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Hydroxyurea		Droxia	10/1/90	Designated/Approved	Approved for Orphan Indication	To reduce the frequency of painful crises and to reduce the need for blood transfusions in adult patients with sickle cell anemia with recurrent moderate to severe painful crises (generally at least 3 during the preceding 12 months).	2/25/98	2/25/05	Bristol-Myers Squibb Pharmaceutical Research Institute	Princeton	New Jersey	8543	USA	EXACT	0020268AA	Hydroxyurea	X6Q56QN5QC						Sickle cell anemia	8614		
hydroxyurea	Treatment of pediatric patients with sickle cell anemia.	hydroxyurea		n/a	4/15/05	Designated			N/A	N/A	"UPM Pharmaceuticals, Inc."	Baltimore	Maryland	21224	USA	EXACT	0020268AA	hydroxyurea	X6Q56QN5QC						Sickle cell anemia	8614		
Hydroxyurea	Treatment of sickle cell anemia in pediatric patients	Hydroxyurea		n/a	3/2/17	Designated			N/A	N/A	Nova Laboratories Limited	Leicester			United Kingdom	EXACT	0020268AA	Hydroxyurea	X6Q56QN5QC						Sickle cell anemia	8614		
Polymeric oxygen	Treatment of sickle cell anemia.	Polymeric oxygen		n/a	3/25/92	Designated			N/A	N/A	Capmed USA	Bryn Mawr	Pennsylvania	19010	USA	LONGEST CONTAINS	0051230AA	oxygen	S88TT14065						Sickle cell anemia	8614		
deferoxamine starch conjugate	Treatment of chronic iron overload resulting from conventional transfusional treatment of beta-thalassemia major and sickle cell anemia.	deferoxamine starch conjugate		n/a	12/21/98	Designated			N/A	N/A	"Biomedical Frontiers, Inc."	Minneapolis	Minnesota	55414	USA	LONGEST CONTAINS	0012204AA	deferoxamine	J06Y7MXW4D						Sickle cell anemia	8614		
Parvovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine	Prevention of transient aplastic crisis in patients with sickle cell anemia.	Parvovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine		Medi-491	5/7/99	Designated			N/A	N/A	"MedImmune, Inc."	Gaithersburg	Maryland	20878	USA	LONGEST CONTAINS	0699354AA	Parvovirus B19	94N635564T						Sickle cell anemia	8614		
Imatinib mesylate	Treatment of systemic mastocytosis without the D816V c-kit mutation	Imatinib mesylate		Gleevec	9/9/05	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with aggressive mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown	10/19/06	10/19/13	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0227065AA	Imatinib mesylate	8A1O1M485B						Systemic mastocytosis	8616		
"8-(6-iodobenzo[1,3]dioxol-5-ylsufanyl)-9-(3-isopropylamino propyl)adenine dihydrochloride"	Treatment of Myelofibrosis	PU-H71		n/a	5/16/18	Designated			N/A	N/A	"Samus Therapeutics, Inc."	10 South Main Street		1983	USA	EXACT	0540341AA	PU-H71	06IVK87M04						Myelofibrosis	8618		
"Recombinant humanized anti-LOXL2 monoclonal antibody, IgG4(S241P)"	Treatment of myelofibrosis.	Simtuzumab		n/a	6/1/11	Designated/Withdrawn			N/A	N/A	"Gilead Sciences, Inc."	Seattle	Washington	98102	USA	EXACT	0762403AA	Simtuzumab	11Z5AIU653						Myelofibrosis	8618		
"N-[(2S)-5-{[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino}-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide, bis-tosylate salt"	Treatment of myelofibrosis	IMG-7289 DITOSYLATE		n/a	6/26/17	Designated			N/A	N/A	"Imago BioSciences, Inc."	San Carlos	California	94070	USA	EXACT	1801123AA	IMG-7289 DITOSYLATE	2PYF2U9JNF						Myelofibrosis	8618		
Obatoclax mesylate	Treatment of myelofibrosis	Obatoclax mesylate		n/a	12/1/06	Designated/Withdrawn			N/A	N/A	"Gemin X Pharmaceuticals US, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	0252926AA	Obatoclax mesylate	39200FJ43J						Myelofibrosis	8618		
ruxolitinib phosphate	Treatment of myelofibrosis	ruxolitinib phosphate		Jakafi	9/5/08	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis"	11/16/11	11/16/18	Incyte Corporation	Wilmington	Delaware	19803	USA	EXACT	0557120AA	ruxolitinib phosphate	436LRU32H5						Myelofibrosis	8618		
N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl(phenyl]amino}pyrimidin-4-yl)benzamide	Treatment of myelofibrosis	Momelotinib		n/a	8/5/10	Designated			N/A	N/A	"Gilead Sciences, Inc."	Foster City	California	94404	USA	EXACT	0347079AA	Momelotinib	6O01GMS00P						Myelofibrosis	8618		
Adenosine triphosphate type 1 competitive inhibitor of JAK2 V617F tyrosine kinase	"Treatment of myeloproliferative disorders (polycythemia vera, essential throbocythemia, and myelofibrosis)"	LY2784544		n/a	3/3/11	Designated			N/A	N/A	Eli Lilly and Company	Indianapolis	Indiana	46285	USA	EXACT	0763075AA	LY2784544	ANC71R916O						Myelofibrosis	8618		
pomalidomide	Treatment of persons with myeloproliferative neoplasm-associated myelofibrosis and anemia who are red blood cell tranfusion dependent.	pomalidomide		n/a	9/21/10	Designated			N/A	N/A	Celgene Corporation	Summit	New Jersey	7901	USA	EXACT	0244122AA	pomalidomide	D2UX06XLB5						Myelofibrosis	8618		
imetelstat	Treatment of myelofibrosis	imetelstat		n/a	6/11/15	Designated			N/A	N/A	"Janssen Research & Development, LLC"	Raritan	New Jersey	8869	USA	EXACT	0257396AA	imetelstat	F60NE4XB53						Myelofibrosis	8618		
recombinant human Pentraxin-2	Treatment of myelofibrosis	PRM-151		n/a	8/26/14	Designated			N/A	N/A	"Promedior, Inc."	Lexington	Massachusetts	2421	USA	EXACT	1198001AA	PRM-151	F68WAH6N5E						Myelofibrosis	8618		
pacritinib	"Treatment of primary myelofibrosis (MF), post-polycythemia vera MF, and post-essential thrombocythemia MF"	pacritinib		n/a	3/13/08	Designated			N/A	N/A	CTI BioPharma Corporation	Seattle	Washington	98121	USA	EXACT	0568956AA	pacritinib	G22N65IL3O						Myelofibrosis	8618		
N-tert-butyl-3-[5-methyl-2-{[4-(2-pryyolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl-amino] benzenesulfonamide dihydrochloride monohydrate	Treatment of secondary and primary myelofibrosis	FEDRATINIB DIHYDROCHLORIDE MONOHYDRATE		n/a	5/18/09	Designated			N/A	N/A	"Sanofi-Aventis US, LLC a Sanofi company"	Bridgewater	New Jersey	8807	USA	EXACT	1577577AA	FEDRATINIB DIHYDROCHLORIDE MONOHYDRATE	UH9J2HBQWJ						Myelofibrosis	8618		
pegylated proline interferon alpha-2b	Treatment of myelofibrosis	pegylated proline interferon alpha-2b		n/a	4/10/14	Designated			N/A	N/A	"PharmaEssentia, Corporation"				Taiwan	LONGEST CONTAINS	0160601AA	interferon alpha 2b	43K1W2T1M6						Myelofibrosis	8618		
eculizumab	Treatment of atypical hemolytic uremic syndrome	eculizumab		Soliris	4/29/09	Designated/Approved	Approved for Orphan Indication	For the treatment of atypical Hemolytic Uremic Syndrome (aHUS)	9/23/11	9/23/18	"Alexion Pharmaceuticals, Inc."	Cheshire	Connecticut	6410	USA	EXACT	0298000AA	eculizumab	A3ULP0F556						Atypical hemolytic uremic syndrome	8702		
ravulizumab subcutaneous	Treatment of atypical hemolytic uremic syndrome (aHUS)	ravulizumab subcutaneous		n/a	10/27/17	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	New Haven	Connecticut		USA	EXACT	1800164AA	ravulizumab	C3VX249T6L						Atypical hemolytic uremic syndrome	8702		
antagonist of the complement 5a receptor	Treatment of atypical hemolytic uremic syndrome	CCX-168		n/a	11/17/14	Designated			N/A	N/A	"ChemoCentryx, Inc."	Mountain View	California	94043	USA	EXACT	1083336AA	CCX-168	O880NM097T						Atypical hemolytic uremic syndrome	8702		
complement factor H	Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system	complement factor H		n/a	12/7/09	Designated/Withdrawn			N/A	N/A	LFB Biotechnologies S.A.				France										Atypical hemolytic uremic syndrome	8702		
recombinant human minibody against complement component	Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system.	recombinant human minibody against complement component		Mubodina(R)	6/7/11	Designated			N/A	N/A	Adienne S.A				Switzerland										Atypical hemolytic uremic syndrome	8702		
methylene blue	Treatment of methemoglobinemia	methylene blue		n/a	7/24/12	Designated			N/A	N/A	"Fera Pharmaceuticals, LLC"	Locust Valley	New York	11560	USA	EXACT	0010753AA	methylene blue	T42P99266K						Hemoglobinemia	8712		
methylene blue injection	Treatment of congenital and acquired methemoglobinemia	methylene blue injection		n/a	8/11/12	Designated			N/A	N/A	"Luitpold Pharmaceuticals, Inc."	Shirley	New York	11967	USA	EXACT	0010753AA	methylene blue	T42P99266K						Hemoglobinemia	8712		
methylene blue0.5%	Treatment of hereditary and acquired methemoglobinemia	methylene blue		Provayblue	12/18/12	Designated/Approved	Approved for Orphan Indication	For treatment of pediatric and adult patients with acquired methemoglobinemia.	4/8/16	4/8/23	Provepharm SAS				France	EXACT	0010753AA	methylene blue	T42P99266K						Hemoglobinemia	8712		
PR-239 (redox penicillin G)	Treatment of AIDS associated neurosyphilis.	PR-239 (redox penicillin G)		n/a	5/23/90	Designated/Withdrawn			N/A	N/A	Pharmos	Alachua	Florida	32615	USA	EXACT	0010662AA	penicillin G	Q42T66VG0C						Neurosyphilis	8729		
"Coagulation factor IX (recombinant), Fc fusion protein"	Control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease)	ALPROLIX		Alprolix	10/30/08	Designated/Approved	Approved for Orphan Indication	"Adults and children with Hemophilia B for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes."	3/28/14	3/28/21	Biogen Idec Inc.	Cambridge	Massachusetts	2142	USA	EXACT	0784349AA	ALPROLIX	02E00T2QDE						Hemophilia B	8732		
Inhibitor of Tissue Factor Pathway Inhibitor (TFPI)	Treatment of hemophilia A and hemophilia B.	BAX-499		n/a	1/29/10	Designated			N/A	N/A	"Baxter Healthcare Corporation, Baxter BioScience"	Westlake Village	California	91362	USA	EXACT	1295494AA	BAX-499	0493WH50VT						Hemophilia B	8732		
human monoclonal antibody directed against tissue factor pathway inhibitor	"Treatment of hemophilia A and hemophilia B patients with or without inhibitors, which includes routine prophylaxis to prevent or reduce the frequency of bleeding in hemophilia A and hemophilia B patients."	PF-06741086		n/a	5/18/16	Designated			N/A	N/A	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	0112525AB	PF-06741086	0UB3OA67O7						Hemophilia B	8732		
40K PEGylated recombinant factor IX	Routine prophylactic administration for prevention of bleeding in patients with hemophilia B (Christmas disease)	REBINYN		n/a	3/18/13	Designated			N/A	N/A	"Novo Nordisk, Inc."	Princeton		8540	USA	EXACT	0432600AA	REBINYN	27Y83O992Q						Hemophilia B	8732		
Coagulation Factor IX (recombinant)	Treatment of hemophilia B.	Coagulation Factor IX (recombinant)		Benefix	10/3/94	Designated/Approved	Approved for Orphan Indication	"For the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency and Christmas disease), including control and prevention of bleeding in surgical settings."	2/11/97	2/11/04	"Genetics Institute, Inc."	Cambridge	Massachusetts	2140	USA	EXACT	0222004AA	Coagulation Factor IX (recombinant)	382L14738L						Hemophilia B	8732		
coagulation factor IX (recombinant)	Prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (routine prophylaxis in patients where there is no evidence or suspicion of bleeding)	coagulation factor IX (recombinant)		Rixubis	10/31/12	Designated/Approved	Approved for Orphan Indication	Adults with Hemophilia B for routine prophylaxis to prevent or reduce the frequency of bleeding episodes.	6/26/13	6/26/20	"Baxalta US, Inc."	Westlake Village	California	91362	USA	EXACT	0222004AA	coagulation factor IX (recombinant)	382L14738L						Hemophilia B	8732		
Coagulation Factor IX (human)	"For use as replacement therapy in patients with hemophilia B for the prevention and control of bleeding episodes, and during surgery to correct defective hemostasis."	Coagulation Factor IX (human)		Alphanine	7/5/90	Designated/Approved	Approved for Orphan Indication		12/31/90	12/31/97	Alpha Therapeutic Corporation	Los Angeles	California	90032	USA	EXACT	0174834AA	Coagulation Factor IX (human)	6U90Y1795T						Hemophilia B	8732		
recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)	Treatment of patients with congenital factor IX deficiency (hemophilia B).	Idelvion		Idelvion	4/27/12	Designated/Approved	Approved for Orphan Indication	"Indicated for the (1) on-demand control and prevention of bleeding episodes, (2) perioperative management of bleeding, and (3) routine prophylaxis to prevent or reduce the frequency of bleeding episodes."	3/4/16	3/4/23	"CSL Behring, LLC"	King of Prussia	Pennsylvania	19406	USA	EXACT	1085127AA	Idelvion	A57KX1VL5P						Hemophilia B	8732		
Coagulation factor IX	Replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia B.	COAGULATION FACTOR IX (HUMAN)		Mononine	6/27/89	Designated/Approved	Approved for Orphan Indication	"Prevention and control of bleeding in factor IX deficiency, also known as hemophilia B or Christmas disease."	8/20/92	8/20/99	Armour Pharmaceutical Company	Collegeville	Pennsylvania	19426	USA	EXACT	0174834AA	COAGULATION FACTOR IX (HUMAN)	6U90Y1795T						Hemophilia B	8732		
an adeno-associated viral vector containing a codon-optimised human factor IX gene (AAV5-hFIXco)	Treatment of hemophilia B	an adeno-associated viral vector containing a codon-optimised human factor IX gene (AAV5-hFIXco)		n/a	12/22/11	Designated			N/A	N/A	"uniQure, B.V."	Amsterdam			Netherlands	LONGEST CONTAINS	0313315AA	factor IX							Hemophilia B	8732		
synthetic double-stranded siRNA oligonucleotide against antithrombin mRNA	Treatment of hemophilia B	synthetic double-stranded siRNA oligonucleotide against antithrombin mRNA		n/a	8/12/13	Designated			N/A	N/A	Alnylam Pharmaceuticals	Cambridge	Massachusetts	2142	USA	LONGEST CONTAINS	0172032AA	antithrombin	T0LTO7L82X						Hemophilia B	8732		
adeno associated virus with modified transthyretin and sequence encoding factor IX variant gene	Treatment of hemophilia B	adeno associated virus with modified transthyretin and sequence encoding factor IX variant gene		n/a	3/14/14	Designated			N/A	N/A	"Baxalta US, Inc."	Westlake Village	California	91362	USA	LONGEST CONTAINS	0113161AB	transthyretin	2COU0B578R						Hemophilia B	8732		
Adeno-associated virus serotype rh10 vector encoding the human factor IX gene	Treatment of hemophilia B.	Adeno-associated virus serotype rh10 vector encoding the human factor IX gene		n/a	8/25/15	Designated			N/A	N/A	Dimension Therapeutics	Cambridge	Massachusetts	2139	USA	LONGEST CONTAINS	0313315AA	factor IX							Hemophilia B	8732		
adeno-associated viral vector composed of a bioengineered AAV capsid and a codon-optimized expression cassette encoding a high-specific activity variant of human coagulation factor IX	Treatment of hemophilia B.	adeno-associated viral vector composed of a bioengineered AAV capsid and a codon-optimized expression cassette encoding a high-specific activity variant of human coagulation factor IX		n/a	9/21/15	Designated			N/A	N/A	"Spark Therapeutics, Inc."	Philadelphia	Pennsylvania	19104	USA	LONGEST CONTAINS	0324969AA	human coagulation factor IX	6U90Y1795T						Hemophilia B	8732		
Adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and human factor 9 gene (SB-FIX)	Treatment of hemophilia B	Adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and human factor 9 gene (SB-FIX)		n/a	9/1/16	Designated			N/A	N/A	"Sangamo BioSciences, Inc."	Richmond	California	94804	USA	LONGEST CONTAINS	0048271AA	zinc	J41CSQ7QDS						Hemophilia B	8732		
Subcutaneous recombinant human factor IX variant with three point mutations	Treatment for hemophilia B	Subcutaneous recombinant human factor IX variant with three point mutations		n/a	9/20/17	Designated			N/A	N/A	"Catalyst Biosciences, Inc."	South San Francisco	California	94080	USA	LONGEST CONTAINS	0313315AA	factor IX							Hemophilia B	8732		
pentetrazol	Treatment of idiopathic hypersomnia.	pentetrazol		n/a	9/9/15	Designated			N/A	N/A	"Balance Therapeutics, Inc."	San Bruno	California	94066	USA	EXACT	0008797AA	pentetrazol	WM5Z385K7T						Idiopathic hypersomnia	8737		
Cysteamine	Treatment of nephropathic cystinosis.	Cysteamine		n/a	5/1/86	Designated			N/A	N/A	"Thoene, Jess G., M.D."	Ann Arbor	Michigan	48109	USA	EXACT	0010377AA	Cysteamine	5UX2SD1KE2						Nephropathic cystinosis	9120		
Cysteamine	Treatment of nephropathic cystinosis.	Cysteamine		Cystagon	1/25/91	Designated/Approved	Approved for Orphan Indication	Treatment of nephropathic cystinosis in adults and children.	8/15/94	8/15/01	"Mylan Laboratories, Inc."	Morgantown	West Virginia	26504	USA	EXACT	0010377AA	Cysteamine	5UX2SD1KE2						Nephropathic cystinosis	9120		
abatacept	Treatment of idiopathic inflammatory myopathy (IIM)	abatacept		n/a	2/22/17	Designated			N/A	N/A	Bristol-Myers Squibb Research & Development	Princeton	New Jersey	8543	USA	EXACT	0258173AA	abatacept	7D0YB67S97						Idiopathic inflammatory myopathy	9128		
omigapil	Treatment of congenital muscular dystrophy.	omigapil		n/a	6/24/08	Designated			N/A	N/A	Santhera Pharmaceuticals Limited				Switzerland	EXACT	0283830AA	omigapil	5V14HD0N4Q						Congenital muscular dystrophy	9138		
patupilone	Treatment of primary fallopian tube cancer.	patupilone		n/a	2/2/10	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0232393AA	patupilone	UEC0H0URSE						Fallopian tube cancer	9162		
olaparib	Treatment of Fallopian Tube Cancer	olaparib		n/a	5/15/18	Designated			N/A	N/A	AstraZeneca Pharmaceuticals LP	1800 Concord Pike	P. O. Box 8355	19803	USA	EXACT	0298464AA	olaparib	WOH1JD9AR8						Fallopian tube cancer	9162		
pelareorep	Treatment of fallopian tube cancer	pelareorep		Reolysin	2/24/15	Designated			N/A	N/A	"Oncolytics Biotech, Inc."				Canada	EXACT	0809154AA	pelareorep	S9J80L3D1U						Fallopian tube cancer	9162		
Immune Globulin (Human) containing high titers of West Nile virus antibodies	Treatment of the West Nile virus infection	Immune Globulin (Human) containing high titers of West Nile virus antibodies		Omr-Igg-Am (Tm) 5% (Wnv)	3/17/04	Designated			N/A	N/A	"OMRIX Biopharmaceuticals, Ltd."				Israel	LONGEST CONTAINS	0006531AA	Immune Globulin							West nile virus	9238		
maytansinoid DM1-conjugated humanized monoclonal antibody N901	Treatment of Merkel cell carcinoma	IMGN-901		CD123	3/2/10	Designated/Withdrawn			N/A	N/A	"ImmunoGen, Inc."	Waltham	Massachusetts	2451	USA	EXACT	0432575AA	IMGN-901	0IVD6ASY0W						Merkel cell carcinoma	9266		
pembrolizumab	Treatment of Merkel cell carcinoma	pembrolizumab		Keytruda	12/28/16	Designated			N/A	N/A	"Merck, Sharp, and Dohme Corp."		New Jersey	8889	USA	EXACT	0809245AA	pembrolizumab	DPT0O3T46P						Merkel cell carcinoma	9266		
recombinant human monoclonal IgG1 antibody against programmed death ligand-1 (anti-PD-L1)	Treatment of merkel cell carcinoma.	Avelumab		n/a	9/21/15	Designated			N/A	N/A	"EMD Serono, Inc."	Billerica	Massachusetts	1821	USA	EXACT	0935433AA	Avelumab	KXG2PJ551I						Merkel cell carcinoma	9266		
activated natural killer[aNK])	Treatment of Merkel cell carcinoma	activated natural killer[aNK])		n/a	3/15/17	Designated			N/A	N/A	"NantKwest, Inc."	Culver City	California	90232	USA	LONGEST CONTAINS	1313639AA	killer	H8QG06RS7R						Merkel cell carcinoma	9266		
polyhexanide	Treatment of Acanthamoeba keratitis	polyhexanide		n/a	11/6/17	Designated			N/A	N/A	Società Industria Farmaceutica Italiana S.p.A.	36 Via Ercole Patti			Italy	EXACT	0377979AA	polyhexanide	322U039GMF						Acanthamoeba keratitis	9285		
miltefosine	Treatment of Acanthamoeba keratitis	miltefosine		Impavido	12/6/16	Designated			N/A	N/A	"Profounda, Inc."	Orlando	Florida	32822	USA	EXACT	0273734AA	miltefosine	53EY29W7EC						Acanthamoeba keratitis	9285		
Propamidine isethionate 0.1% ophthalmic solution	Treatment of acanthamoeba keratitis.	Propamidine isethionate		Brolene	3/10/88	Designated/Withdrawn			N/A	N/A	Bausch & Lomb	Tampa	Florida	33637	USA	EXACT	0153797AA	Propamidine isethionate	7T9IJ84C42						Acanthamoeba keratitis	9285		
povidone-iodine 0.5% (w/w) in dimethylsulfoxide 44% (w/w)	Treatment of microbial keratitis (which includes Acanthamoeba keratitis).	povidone-iodine		n/a	5/11/17	Designated			N/A	N/A	Veloce BioPharma LLC	Fort Washington	Pennsylvania	19034	USA	EXACT	0006359AA	povidone-iodine	85H0HZU99M						Acanthamoeba keratitis	9285		
"N1-(1H-benzimidazol-2-ylmethyl)-N1-((S)-5,6,7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine"	"Treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome"	MAVORIXAFOR		n/a	10/10/18	Designated			N/A	N/A	"X4 Pharmaceuticals, Inc."	1 Broadway	Massachusetts	2142	USA	EXACT	0248602AA	MAVORIXAFOR	0G9LGB5O2W						"Warts, hypogammaglobulinemia, infections, and myelokathexis"	9297		
nivolumab	Treatment of anal cancer	nivolumab		Opdivo	8/7/17	Designated			N/A	N/A	Bristol-Myers Squibb Co.	Wallingford	Connecticut	6492	USA	EXACT	0761411AA	nivolumab	31YO63LBSN						Anal cancer	9300		
Cisplatin	Treatment of anal cancer	Cisplatin		n/a	9/6/16	Designated			N/A	N/A	Privo Technologies	Cambridge	Massachusetts	2141	USA	EXACT	0056633AA	Cisplatin	Q20Q21Q62J						Anal cancer	9300		
"2-Pyrazinecarbonitrile, 5-[[5-2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino] monomesylate monohydrate"	Treatment of anal cancer	PREXASERTIB MESYLATE MONOHYDRATE		n/a	4/9/15	Designated			N/A	N/A	Eli Lilly and Company	Indianapolis	Indiana	46285	USA	EXACT	0898760AA	PREXASERTIB MESYLATE MONOHYDRATE	S4D3L195S4						Anal cancer	9300		
ADXS11-001	Treatment of HPV-positive associated anal cancer	ADXS-11		n/a	8/12/13	Designated			N/A	N/A	"Advaxis, Inc."	Princeton	New Jersey	8540	USA										Anal cancer	9300		
3-bromopyruvate	Treatment of liver and intrahepatic bile duct cancer	3-bromopyruvate		n/a	3/5/13	Designated			N/A	N/A	"Primocure Pharma, Inc."	New Castle	Delaware	19803	USA	EXACT	0548458AA	3-bromopyruvate	63JMV04GRK						Bile duct cancer	9304		
pentamidine	Treatment of liver and intrahepatic bile duct cancer	pentamidine		n/a	8/12/13	Designated/Withdrawn			N/A	N/A	"Verlyx Pharma, Inc."				Canada	EXACT	0016637AA	pentamidine	673LC5J4LQ						Bile duct cancer	9304		
opioid growth factor	Treatment of liver and intrahepatic bile duct cancer	opioid growth factor		n/a	4/16/13	Designated			N/A	N/A	"Primocure Pharma, Inc."	New Castle	Delaware	19803	USA	EXACT	0128574AA	opioid growth factor	9JEZ9OD3AS						Bile duct cancer	9304		
Vapreotide	Treatment of symptomatic carcinoid tumors	Vapreotide		Sanvar	4/6/04	Designated			N/A	N/A	"H3 Pharma, Inc."				Canada	EXACT	0182183AA	Vapreotide	2PK59M9GFF						Carcinoid tumor	9316		
Octreotide	Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.	Octreotide		Sandostatin Lar	8/24/98	Designated/Approved	Approved for Orphan Indication	Supression of severe diarrhea and flushing associated with malignant carcinoid syndrome.	11/25/98	11/25/05	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0169915AA	Octreotide	RWM8CCW8GP						Carcinoid tumor	9316		
"2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5] decane dimaleate"	Treatment of carcinoid tumors	ATIPRIMOD DIMALEATE		Atiprimod	9/18/06	Designated			N/A	N/A	"Callisto Pharmaceuticals, Inc."	New York	New York	10170	USA	EXACT	0216206AA	ATIPRIMOD DIMALEATE	YNU265SSR3						Carcinoid tumor	9316		
Vapreotide	Treatment of symptomatic carcinoid tumors	Vapreotide		Sanvar	4/6/04	Designated			N/A	N/A	"H3 Pharma, Inc."				Canada	EXACT	0182183AA	Vapreotide	2PK59M9GFF						Carcinoid	9316		
telotristat etiprate	Treatment of carcinoid syndrome in patients with neuroendocrine tumors	telotristat etiprate		n/a	3/9/12	Designated			N/A	N/A	"Lexicon Pharmaceuticals, Inc."	The Woodlands	Texas	77381	USA	EXACT	0569368AA	telotristat etiprate	3T25U84H4U						Carcinoid	9316		
Multi-ligand somatostatin analog	"Treatment of patients with functional gastroenteropancreatic (GEP) neuroendocrine tumors (specifically, carcinoid, insulinoma, gastrinoma, somastatinoma, GRFoma, VIPoma and glucagonoma."	Pasireotide		n/a	7/27/04	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0269534AA	Pasireotide	98H1T17066						Carcinoid	9316		
"R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1 H -1,4-benzodiazepine -3-yl]-3-(3-methylaminophenyl)urea"	Treatment of gastric carcinoids	Netazepide		n/a	9/10/09	Designated			N/A	N/A	Trio Medicines Ltd.				United Kingdom	EXACT	0338432AA	Netazepide	HOU4I0G29C						Carcinoid	9316		
lanreotide acetate	Treatment of symptoms associated with carcinoid syndrome	lanreotide acetate		n/a	9/8/11	Designated			N/A	N/A	"Ipsen Biopharmaceuticals, Inc."	Basking Ridge	New Jersey	7920	USA	EXACT	0169517AA	lanreotide acetate	IEU56G3J9C						Carcinoid	9316		
Octreotide	Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.	Octreotide		Sandostatin Lar	8/24/98	Designated/Approved	Approved for Orphan Indication	Supression of severe diarrhea and flushing associated with malignant carcinoid syndrome.	11/25/98	11/25/05	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0169915AA	Octreotide	RWM8CCW8GP						Carcinoid	9316		
"2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5] decane dimaleate"	Treatment of carcinoid tumors	ATIPRIMOD DIMALEATE		Atiprimod	9/18/06	Designated			N/A	N/A	"Callisto Pharmaceuticals, Inc."	New York	New York	10170	USA	EXACT	0216206AA	ATIPRIMOD DIMALEATE	YNU265SSR3						Carcinoid	9316		
"5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)-pyridin-2-amine"	Treatment of primary central nervous system lymphoma.	BIMIRALISIB		n/a	11/21/16	Designated			N/A	N/A	PIQUR Therapeutics AG				Switzerland	EXACT	1106225AA	BIMIRALISIB	6Z3QHB00LB						Primary central nervous system lymphoma	9318		
Cisplatin ChemoThin Wafer	"Treatment of anatomically accessible oral cancers (lip, tongue, gum, floor of mouth, salivary gland, and other oral cavity)"	Cisplatin ChemoThin Wafer		n/a	11/3/15	Designated			N/A	N/A	Privo Technologies	Cambridge	Massachusetts	2141	USA	EXACT	0056633AA	Cisplatin	Q20Q21Q62J						Oral cancer	9360		
cladribine	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	cladribine		n/a	3/19/15	Designated			N/A	N/A	Chord Therapeutics S.a.r.l.				Switzerland	EXACT	0092944AA	cladribine	47M74X9YT5						Neuromyelitis optica spectrum disorder	9414		
"humanized affinity-optimized, afucosylated immunoglobulin G1 kappa monoclonal antibody against CD19"	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders	MEDI-551		n/a	2/10/16	Designated			N/A	N/A	"MedImmune, LLC"	Gaithersburg	Maryland	20878	USA	EXACT	0810173AA	MEDI-551	74T7185BMM						Neuromyelitis optica spectrum disorder	9414		
humanized anti-IL-6R receptor neutralizing IgG2 monoclonal antibody	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	Tocilizumab		n/a	6/30/14	Designated			N/A	N/A	"Chugai Pharma USA, LLC"	Berkeley Heights	New Jersey	7922	USA	EXACT	0298146AA	Tocilizumab	I031V2H011						Neuromyelitis optica spectrum disorder	9414		
ublituximab	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	ublituximab		n/a	8/25/16	Designated			N/A	N/A	"TG Therapeutics, Inc."	New York	New York	10019	USA	EXACT	0574607AA	ublituximab	U59UGK3IPC						Neuromyelitis optica spectrum disorder	9414		
carglumic acid	Treatment of organic acidemias	carglumic acid		Carbaglu	6/17/14	Designated			N/A	N/A	Orphan Europe SARL	92800 Puteaux			France	EXACT	0311864AA	carglumic acid	5L0HB4V1EW						Organic acidemia	9433		
sodium ascorbate and menadione sodium bisulfite	Treatment of autosomal dominant polycystic liver disease	sodium ascorbate and menadione sodium bisulfite		Apatone	4/15/13	Designated			N/A	N/A	IC-Medtech Corporation	El Cajon	California	92021	USA	EXACT	0020815AA	menadione sodium bisulfite	6XF3C2HK77						Polycystic liver disease	9457		
menadione sodium bisulfite	Treatment of autosomal dominant polycystic liver disease	menadione sodium bisulfite		n/a	5/14/14	Designated			N/A	N/A	IC-MedTech Corporation	El Cajon	California	92021	USA	EXACT	0020815AA	menadione sodium bisulfite	6XF3C2HK77						Polycystic liver disease	9457		
sodium ascorbate and menadione sodium bisulfite	Treatment of autosomal dominant polycystic liver disease	sodium ascorbate		Apatone	4/15/13	Designated			N/A	N/A	IC-Medtech Corporation	El Cajon	California	92021	USA	EXACT	0021363AA	sodium ascorbate	S033EH8359						Polycystic liver disease	9457		
2-amino-3-[3-[[4-(2-pyridyloxymethyl)phenyl]methyl]isoxazol-5-yl]pyridin-1-ium-1-yl]methyl hydrogen phosphate	Treatment of coccidioidomycosis	APX-001		n/a	11/3/16	Designated			N/A	N/A	"Amplyx Pharmaceuticals, Inc."	San Diego	California	92130	USA	EXACT	1718429AA	APX-001	1XQ871489P						Coccidioidomycosis	9525		
Amphotericin B lipid complex	Treatment of invasive coccidioidomycosis.	Amphotericin B lipid complex		Abelcet	5/6/96	Designated/Withdrawn			N/A	N/A	"The Liposome Company, Inc."	Princeton	New Jersey	8540	USA	EXACT	0035881AA	Amphotericin B lipid complex	7XU7A7DROE						Coccidioidomycosis	9525		
Nikkomycin Z	Treatment of coccidioidomycosis	Nikkomycin Z		n/a	2/14/06	Designated			N/A	N/A	Valley Fever Center for Excellence (1-111 INF)	Tucson	Arizona	85723	USA	EXACT	0224726AA	Nikkomycin Z	9Z22C3QQCJ						Coccidioidomycosis	9525		
selective inhibitor of fungal CYP51	Treatment of coccidioidomycosis.	VT-1598		n/a	3/3/16	Designated			N/A	N/A	"Viamet Pharmaceuticals, Inc."	Durham	North Carolina	27703	USA	EXACT	0111752AB	VT-1598	AV9K9X720D						Coccidioidomycosis	9525		
coccidioidin SD Skin Test Antigen	For the diagnosis of Coccidioidomycosis	coccidioidin SD Skin Test Antigen		n/a	12/19/07	Designated/Approved	Approved for Orphan Indication	"For the detection of delayed type hypersensitivity to C. immitis in individuals, 18-64 years of age, with a history of pulmonary coccidioidomy-cosis"	7/29/11	N/A	"Allermed Labortories, Inc."	San Diego	California	92111	USA	LONGEST CONTAINS	0463105AA	coccidioidin	ZP77O7YY70						Coccidioidomycosis	9525		
Ganciclovir sodium	Treatment of cytomegalovirus retinitis in immunocompromised patients with AIDS.	Ganciclovir sodium		Cytovene	10/31/85	Designated/Approved/Withdrawn			N/A	6/23/96	"Syntex (USA), Inc."	Palo Alto	California	94304	USA	EXACT	0138772AA	Ganciclovir sodium	02L083W284						Cytomegalovirus retinitis	9531		
Ganciclovir intravitreal implant	Treatment of cytomegalovirus retinitis.	Ganciclovir intravitreal implant		Vitrasert Implant	6/7/95	Designated/Approved	Approved for Orphan Indication	Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome.	3/4/96	3/4/03	"Bausch & Lomb Surgical, Chiron Vision Products"	Irvine	California	92718	USA	EXACT	0138738AA	Ganciclovir	P9G3CKZ4P5						Cytomegalovirus retinitis	9531		
Filgrastim	"Treatment of patients with AIDS who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir"	Filgrastim		Neupogen	9/3/91	Designated/Withdrawn			N/A	N/A	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0174823AA	Filgrastim	PVI5M0M1GW						Cytomegalovirus retinitis	9531		
Monoclonal antibody to cytomegalovirus (human)	Treatment of cytomegalovirus retinitis in patients with AIDS.	Monoclonal antibody to cytomegalovirus (human)		n/a	11/15/91	Designated/Withdrawn			N/A	N/A	"Protein Design Labs, Inc."	Mountain View	California	94043	USA	LONGEST CONTAINS	0354529AA	cytomegalovirus	7COI029E6K						Cytomegalovirus retinitis	9531		
liposomal cyclosporine for inhalation	Prevention of bronchiolitis obliterans.	liposomal cyclosporine for inhalation		n/a	6/24/08	Designated			N/A	N/A	PARI Pharma GmbH				Germany	EXACT	0066808AA	cyclosporine	83HN0GTJ6D						Bronchiolitis obliterans	9551		
liposomal cyclosporine	Treatment of bronchiolitis obliterans	liposomal cyclosporine		n/a	5/11/09	Designated			N/A	N/A	PARI Pharma GmbH				Germany	EXACT	0066808AA	cyclosporine	83HN0GTJ6D						Bronchiolitis obliterans	9551		
recombinant human club cell protein	Treatment of bronchiolitis obliterans	UTEROGLOBIN		n/a	4/10/17	Designated			N/A	N/A	"Therabron Therapeutics, Inc."	Rockville	Maryland	20850	USA	EXACT	0112021AB	UTEROGLOBIN	95O4MMG4LJ						Bronchiolitis obliterans	9551		
"interleukin-1 receptor antagonist (IL-1Ra, sequence-homologous anakinra)"	Treatment of Bronchiolitis Obliterans	"interleukin-1 receptor antagonist (IL-1Ra, sequence-homologous anakinra)"		n/a	8/7/18	Designated			N/A	N/A	"Onspira Therapeutics, Inc."	101 Lindenwood Drive	Pennsylvania	19355	USA	LONGEST CONTAINS	0242524AA	anakinra	9013DUQ28K						Bronchiolitis obliterans	9551		
imatinib mesylate	Treatment of dermatofibrosarcoma protuberans	imatinib mesylate		Gleevec	12/19/05	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP)"	10/19/06	10/19/13	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0227065AA	imatinib mesylate	8A1O1M485B						Dermatofibrosarcoma protuberans	9569		
Abatacept	Treatment of giant cell arteritis	Abatacept		n/a	2/22/17	Designated			N/A	N/A	Bristol-Myers Squibb Research & Development	Princeton	New Jersey	8543	USA	EXACT	0258173AA	Abatacept	7D0YB67S97						Giant cell arteritis	9615		
infliximab	Treatment of giant cell arteritis	infliximab		Remicade	5/6/03	Designated/Withdrawn			N/A	N/A	"Centocor, Inc."	Malvern	Pennsylvania	19355	USA	EXACT	0233716AA	infliximab	B72HH48FLU						Giant cell arteritis	9615		
burosumab	Treatment of tumor-induced osteomalacia (TIO) syndrome	burosumab		n/a	6/15/17	Designated			N/A	N/A	Ultragenyx Pharmaceutical Inc.	Novato	California	94949	USA	EXACT	1257621AA	burosumab	G9WJT6RD29						Tumor-induced osteomalacia	9652		
Titanium dioxide and bisoctrizole	"For the secondary prevention (prevention of lesional induction) of disorders with UV-A and visible light-induced photosensitivity, specifically Actinic prurigo, Hydroa vacciniforme, Solar urticara (SU), Chronic Actinic Dermatitis (CAD), the cutaneous prophyrias, Smith-Lemli-Optiz Syndrome, and Hartnup's Disease."	Titanium dioxide and bisoctrizole		n/a	5/25/05	Designated/Withdrawn			N/A	N/A	Orfagen				France	EXACT	0033807AA	Titanium dioxide	15FIX9V2JP						Hydroa vacciniforme	9654		
Titanium dioxide and bisoctrizole	"For the secondary prevention (prevention of lesional induction) of disorders with UV-A and visible light-induced photosensitivity, specifically Actinic prurigo, Hydroa vacciniforme, Solar urticara (SU), Chronic Actinic Dermatitis (CAD), the cutaneous prophyrias, Smith-Lemli-Optiz Syndrome, and Hartnup's Disease."	 bisoctrizole		n/a	5/25/05	Designated/Withdrawn			N/A	N/A	Orfagen				France	EXACT	0254579AA	bisoctrizole	8NT850T0YS						Hydroa vacciniforme	9654		
human coagulation factor XI	Treatment of congenital factor XI deficiency	COAGULATION FACTOR XIA		n/a	2/15/18	Designated			N/A	N/A	Bio Products Laboratory	Dagger Lane			United Kingdom	EXACT	1205590AA	COAGULATION FACTOR XIA	Y42G5XID5M						Factor XI deficiency	9670		
human coagulation factor XI	Treatment of severe congential Factor XI deficiency.	Hemoleven		Hemoleven	11/8/07	Designated			N/A	N/A	Laboratoire francais du Fractionnement et des Biot				France	EXACT	1205590AA	Hemoleven	Y42G5XID5M						Factor XI deficiency	9670		
Human plasma derived conagulation protein-Factor XI	For the treatment of congenital Factor XI deficiency	Human plasma derived conagulation protein-Factor XI		n/a	4/30/14	Designated			N/A	N/A	Cambryn Biologics	Sarasota	Florida	34243	USA	LONGEST CONTAINS	0233772AA	Human plasma	T74K1VTI2X						Factor XI deficiency	9670		
miltefosine	Treatment of schistosomiasis	miltefosine		Impavido	8/2/17	Designated			N/A	N/A	"Profounda, Inc."	Orlando	Florida	32822	USA	EXACT	0273734AA	miltefosine	53EY29W7EC						Schistosomiasis	9687		
(R)-praziquantel	Treatment of schistosomiasis	(R)-praziquantel		n/a	6/27/17	Designated			N/A	N/A	"Tongli Biomedical Co., Ltd. (TLB)"	Zhangjiagang			China	EXACT	0872526AA	(R)-praziquantel	WF15T5925V						Schistosomiasis	9687		
cantharidin	"Treatment of perforating diseases, including Kyrle's disease, reactive perforating collangenosis, perforating folliculitis and elastosis perforans serpiginosa"	cantharidin		n/a	7/24/12	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0129293AA	cantharidin	IGL471WQ8P						Kyrle's disease	9738		
"(1'R,6'R)-3-(Benzylamine)-6-hydroxy-3'-methyl-4-pentyl-6'-(prop-1-en-2-yl)-[1,1'-bi(cyclohexane)]-2',3,6-triene-2,5-dione"	Treatment of systemic scleroderma (SSc)	EHP-101		n/a	7/6/17	Designated			N/A	N/A	Emerald Health Pharmaceuticals Inc.	San Diego	California	92121	USA	EXACT	 0112106AB	EHP-101	KTJCIKNF3F						Systemic scleroderma	9748		
Recombinant human relaxin	Treatment of progressive systemic sclerosis.	Recombinant human relaxin		n/a	11/3/95	Designated/Withdrawn			N/A	N/A	Connetics Corporation	Palo Alto	California	94303	USA	EXACT	0171619AA	Recombinant human relaxin	W0122B976Y						Progressive systemic sclerosis	9748		
Cysteamine	Treatment of nephropathic cystinosis.	Cysteamine		n/a	5/1/86	Designated			N/A	N/A	"Thoene, Jess G., M.D."	Ann Arbor	Michigan	48109	USA	EXACT	0010377AA	Cysteamine	5UX2SD1KE2						Nephropathic cystinosis	9755		
Cysteamine	Treatment of nephropathic cystinosis.	Cysteamine		Cystagon	1/25/91	Designated/Approved	Approved for Orphan Indication	Treatment of nephropathic cystinosis in adults and children.	8/15/94	8/15/01	"Mylan Laboratories, Inc."	Morgantown	West Virginia	26504	USA	EXACT	0010377AA	Cysteamine	5UX2SD1KE2						Nephropathic cystinosis	9755		
Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis	Prevention of necrotizing enterocolitis (NEC) in premature infants with very low birth weight less than or equal to 1500 grams	Lactobacillus acidophilus		n/a	3/24/15	Designated			N/A	N/A	"Sigma-Tau Pharmaceuticals, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0098453AA	Lactobacillus acidophilus	1PRR1V42V5						Necrotizing enterocolitis	9767		
Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis	Prevention of necrotizing enterocolitis (NEC) in premature infants with very low birth weight less than or equal to 1500 grams	Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis		n/a	3/24/15	Designated			N/A	N/A	"Sigma-Tau Pharmaceuticals, Inc."	Gaithersburg	Maryland	20878	USA	EXACT	0726943AA	Bifidobacterium animalis subsp. lactis	5307V7XW8I						Necrotizing enterocolitis	9767		
L. reuteri	"Prevention of necrotizing enterocolitis in preterm infants with birth weight less than or equal to 1,500 grams"	L. reuteri		n/a	8/1/13	Designated			N/A	N/A	Infant Bacterial Therapeutics	Stockholm			Sweden	EXACT	0734827AA	L. reuteri	9913I24QEE						Necrotizing enterocolitis	9767		
melatonin	Treatment of necrotizing enterocolitis	melatonin		n/a	1/25/17	Designated			N/A	N/A	Therapicon SrL	Milano			Italy	EXACT	0012657AA	melatonin	JL5DK93RCL						Necrotizing enterocolitis	9767		
bovine lactoferrin	Prevention of necrotizing enterocolitis in very low birth weight infants (birth weight less than or equal to 1500 grams)	bovine lactoferrin		n/a	2/23/15	Designated			N/A	N/A	"Metrodora Therapeutics, LLC"	Brooklyn	New York	11210	USA	EXACT	0187393AA	bovine lactoferrin	KG21X1090A						Necrotizing enterocolitis	9767		
Heparin-binding epidermal growth factor-like growth factor	"Prevention and treatment of necrotizing enterocolitis (NEC) in preterm infants with birth weight less than 1,500 grams"	Heparin-binding epidermal growth factor-like growth factor		n/a	9/18/06	Designated			N/A	N/A	"Trillium Therapeutics, Inc."				Canada	LONGEST CONTAINS	0006804AA	epidermal growth factor	TZK30RF92W						Necrotizing enterocolitis	9767		
inter-Alpha-Inhibitor-Proteins (IaIp) (Human)	Treatment of necrotizing enterocolitis (NEC)	inter-Alpha-Inhibitor-Proteins (IaIp) (Human)		n/a	2/13/18	Designated			N/A	N/A	"ProMetic BioTherapeutics, Inc"	1330 Piccard Drive	Rockville		USA	LONGEST CONTAINS	0634640AA	Proteins							Necrotizing enterocolitis	9767		
picibanil	Treatment of patients with lymphatic malformations	picibanil		n/a	5/15/09	Designated			N/A	N/A	"Royds Pharmaceuticals, Inc."	Princeton	New Jersey	8540	USA	EXACT	0172769AA	picibanil	2F42BH7X2L						Lymphatic malformations	9789		
picibanil	Treatment of lymphatic malformations	picibanil		n/a	3/17/11	Designated			N/A	N/A	"Richard Smith, M.D."	Iowa City	Iowa	52242	USA	EXACT	0172769AA	picibanil	2F42BH7X2L						Lymphatic malformations	9789		
Ethanol gel	Treatment of congenital lymphatic malformations	Ethanol gel		n/a	3/13/06	Designated/Withdrawn			N/A	N/A	Orfagen				France	EXACT	0098679AA	Ethanol	3K9958V90M						Lymphatic malformations	9789		
Brimonidine	Treatment of anterior ischemic optic neuropathy.	Brimonidine		Alphagan	2/7/00	Designated			N/A	N/A	"Allergan, Inc."	Irvine	California	92612	USA	EXACT	0277236AA	Brimonidine	E6GNX3HHTE						Anterior ischemic optic neuropathy	9790		
"3-[2-(1-methylpyrrolidin-2-yl) ethyl]-6-(2-pyrrolidin-1yl) ethyl-9-benzyloxycarbonyl-12-diethyl-4,7-dioxo-3,6,9,12-tetraazadodecancarboxamide"	Treatment of anterior ischemic optic neuropathy (AION)	"3-[2-(1-methylpyrrolidin-2-yl) ethyl]-6-(2-pyrrolidin-1yl) ethyl-9-benzyloxycarbonyl-12-diethyl-4,7-dioxo-3,6,9,12-tetraazadodecancarboxamide"		n/a	12/26/17	Designated			N/A	N/A	Neurizon Pharma	15 Paul-Ehrlich-Straße	Tübingen		Germany										Anterior ischemic optic neuropathy	9790		
brentuximab vedotin	Treatment of enteropathy-associated T-cell lymphoma.	brentuximab vedotin		Adcetris	7/7/16	Designated			N/A	N/A	"Seattle Genetics, Inc."	Bothell	Washington	98021	USA	EXACT	0297767AA	brentuximab vedotin	7XL5ISS668						Enteropathy-associated T-cell lymphoma	9809		
mexiletine	Treatment of nondystrophic myotonia	mexiletine		n/a	9/2/10	Designated			N/A	N/A	University of Rochester Medical Center	Rochester	New York	14620	USA	EXACT	0091429AA	mexiletine	1U511HHV4Z						Nondystrophic myotonia	9852		
"clarithromycin, rifabutin, clofazimine"	Treatment of pediatric Crohn's disease.	 rifabutin		n/a	4/26/11	Designated			N/A	N/A	RedHill Biopharma Ltd.				Israel	EXACT	0121153AA	rifabutin	1W306TDA6S						Pediatric Crohn's disease	9856		
"(3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate"	Treatment of Pediatric Crohn's disease	UPADACITINIB		n/a	6/15/17	Designated			N/A	N/A	AbbVie	North Chicago	Illinois	60044	USA	EXACT	0847847AA	UPADACITINIB	4RA0KN46E0						Pediatric Crohn's disease	9856		
risankizumab	Treatment of pediatric Crohn's disease	risankizumab		n/a	11/29/16	Designated			N/A	N/A	AbbVie Inc.	North Chicago	Illinois	60044	USA	EXACT	0812022AA	risankizumab	90ZX3Q3FR7						Pediatric Crohn's disease	9856		
"clarithromycin, rifabutin, clofazimine"	Treatment of pediatric Crohn's disease.	clofazimine		n/a	4/26/11	Designated			N/A	N/A	RedHill Biopharma Ltd.				Israel	EXACT	0038186AA	clofazimine	D959AE5USF						Pediatric Crohn's disease	9856		
ustekinumab	Treatment of pediatric Crohn's disease (0 through 16 years of age)	ustekinumab		Stelara	5/18/16	Designated			N/A	N/A	"Janssen Research & Development, LLC"	Spring House	Pennsylvania	19477	USA	EXACT	0266762AA	ustekinumab	FU77B4U5Z0						Pediatric Crohn's disease	9856		
adalimumab	Treatment of pediatric Crohn's disease.	adalimumab		Humira	10/19/06	Designated/Approved	Approved for Orphan Indication	"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate. (Orphan approval for patients from 6 through 16 years of age.)"	9/23/14	9/23/21	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0247176AA	adalimumab	FYS6T7F842						Pediatric Crohn's disease	9856		
"clarithromycin, rifabutin, clofazimine"	Treatment of pediatric Crohn's disease.	clarithromycin		n/a	4/26/11	Designated			N/A	N/A	RedHill Biopharma Ltd.				Israel	EXACT	0152090AA	clarithromycin	H1250JIK0A						Pediatric Crohn's disease	9856		
etrolizumab	Treatment of pediatric Crohn's disease.	etrolizumab		n/a	7/13/17	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0574094AA	etrolizumab	I2A72G2V3J						Pediatric Crohn's disease	9856		
filgotinib maleate	Treatment of pediatric Crohn's disease	filgotinib maleate		n/a	7/18/17	Designated			N/A	N/A	"Gilead Sciences, Inc."	Seattle	Washington	98102	USA	EXACT	0112235AB	filgotinib maleate	JG8OB4UL9Y						Pediatric Crohn's disease	9856		
mongersen	Treatment of pediatric Crohn's disease	mongersen		n/a	7/20/15	Designated			N/A	N/A	Celgene Corporation	Summit	New Jersey	7901	USA	EXACT	1123484AA	mongersen	O1VIU3R1NE						Pediatric Crohn's disease	9856		
humanized immunoglobulin G4-variant monoclonal antibody directed against the p19 subunit of interleukin (IL)-23	Treatment of pediatric Crohn's disease	MIRIKIZUMAB		n/a	7/6/17	Designated			N/A	N/A	Eli Lilly & Company	Indianapolis	Indiana	46285	USA	EXACT	1800186AA	MIRIKIZUMAB	Z7HVY03PHP						Pediatric Crohn's disease	9856		
bifidobacterium longum infantis 35624	Treatment of pediatric Crohn's disease	bifidobacterium longum infantis 35624		n/a	1/16/03	Designated			N/A	N/A	Alimentary Health Limited	County Cork			Ireland	EXACT	1803390AA	bifidobacterium longum infantis 35624	0Z1FKO93PO						Pediatric Crohn's disease	9856		
"L-amino acids, vitamins and minerals combined with omega-3 fatty acids"	Treatment of patients with pediatric Crohn's disease	"L-amino acids, vitamins and minerals combined with omega-3 fatty acids"		n/a	1/12/11	Designated			N/A	N/A	"Immunopath Profile, Inc."	Naples	Florida	34110	USA	LONGEST CONTAINS	0362765AA	omega 3 fatty acids	71M78END5S						Pediatric Crohn's disease	9856		
hydrocortisone acetate	Treatment of pediatric ulcerative colitis	hydrocortisone acetate		n/a	6/27/17	Designated			N/A	N/A	"Cristcot HCA, LLC"	Concord	Massachusetts	1742	USA	EXACT	0007205AA	hydrocortisone acetate	3X7931PO74						Pediatric ulcerative colitis	9857		
mesalamine	Treatment of pediatric ulcerative colitis	mesalamine		Canasa	1/19/10	Designated			N/A	N/A	"Aptalis Pharma US, Inc."	Bridgewater	New Jersey	8807	USA	EXACT	0127719AA	mesalamine	4Q81I59GXC						Pediatric ulcerative colitis	9857		
golimumab	Treatment of pediatric ulcerative colitis	golimumab		Simponi	3/16/12	Designated			N/A	N/A	"Janssen Biotech, Inc."	Horsham	Pennsylvania	19044	USA	EXACT	0265463AA	golimumab	91X1KLU43E						Pediatric ulcerative colitis	9857		
ustekinumab	Treatment of pediatric ulcerative colitis	ustekinumab		Stelara	2/22/17	Designated			N/A	N/A	"Janssen Biotech, Inc."	Spring House	Pennsylvania	19477	USA	EXACT	0266762AA	ustekinumab	FU77B4U5Z0						Pediatric ulcerative colitis	9857		
filgotinib maleate	Treatment of pediatric ulcerative colitis (UC)	filgotinib maleate		n/a	10/5/17	Designated			N/A	N/A	"Gilead Sciences, Inc."	Seattle	Washington	98102	USA	EXACT	0112235AB	filgotinib maleate	JG8OB4UL9Y						Pediatric ulcerative colitis	9857		
5-(4-carboxymethyl-phenylazo)-2-hydroxybenzoic acid disodium salt	Treatment of pediatric ulcerative colitis (UC)	INN-108 DISODIUM		n/a	8/31/17	Designated			N/A	N/A	"Innovate Biopharmaceuticals, Inc."	Raleigh	North Carolina	27615	USA	EXACT	0112692AB	INN-108 DISODIUM	QS757J8N0F						Pediatric ulcerative colitis	9857		
bifidobacterium infantis 35624	Treatment of pediatric ulcerative colitis	bifidobacterium infantis 35624		n/a	3/24/08	Designated			N/A	N/A	Alimentary Health Limited				Ireland	EXACT	1803390AA	bifidobacterium infantis 35624	0Z1FKO93PO						Pediatric ulcerative colitis	9857		
anti-tumor necrosis factor (TNF) polyclonal antibody (bovine)	Treatment of pediatric ulcerative colitis (0 through 16 years of age)	anti-tumor necrosis factor (TNF) polyclonal antibody (bovine)		n/a	11/17/14	Designated			N/A	N/A	"Avaxia Biologics, Incorporated"	Lexington	Massachusetts	2421	USA										Pediatric ulcerative colitis	9857		
"Eubacterial Spores, Purified Suspension, Encapsulated"	Treatment of pediatric ulcerative colitis	"Eubacterial Spores, Purified Suspension, Encapsulated"		n/a	11/27/17	Designated			N/A	N/A	"Seres Therapeutics, Inc."	200 Sidney Street	Cambridge	2139	USA										Pediatric ulcerative colitis	9857		
"(2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl]oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate"	Treatment of chronic myelomonocytic leukemia (CMML)	H3B-8800		n/a	6/22/17	Designated			N/A	N/A	"H3 Biomedicine Inc. (US Research Subsidiary of Eisai Co., Ltd.)"	Cambridge	Massachusetts	2139	USA	EXACT	1297763AA	H3B-8800	90YLS47BRX						Chronic Myelomonocytic Leukemia	9884		
Topiramate	Treatment of Lennox-Gastaut syndrome.	Topiramate		Topamax	11/25/92	Designated/Approved	Approved for Orphan Indication	As adjunctive therapy in patients two years and older with siezures associated with Lennox-Gastaut syndrome.	8/28/01	8/28/08	"Johnson & Johnson Pharmaceutical R & D, LLC"	Raritan	New Jersey	8869	USA	EXACT	0157233AA	Topiramate	0H73WJJ391						Lennox-Gastaut syndrome	9912		
cholesterol 24S-hydroxylase inhibitor	Treatment of Lennox-Gastaut syndrome	TAK-935		n/a	12/6/17	Designated			N/A	N/A	"Takeda Development Center Americas, Inc."	Takeda Parkway	Deerfield	60015	USA	EXACT	1066166AA	TAK-935	1766MU795L						Lennox-Gastaut syndrome	9912		
cannabidiol;	Treatment of Lennox-Gastaut syndrome	cannabidiol;		n/a	2/27/14	Designated			N/A	N/A	GW Pharma Ltd.				United Kingdom	EXACT	0027441AA	cannabidiol	19GBJ60SN5						Lennox-Gastaut syndrome	9912		
cannabidiol	Treatment of Lennox-Gastaut syndrome	cannabidiol		n/a	6/23/14	Designated			N/A	N/A	"Insys Development Company, Inc."	Chandler	Arizona	85286	USA	EXACT	0027441AA	cannabidiol	19GBJ60SN5						Lennox-Gastaut syndrome	9912		
cannabidiol (CBD)	Treatment of Lennox-Gastaut syndrome	cannabidiol (CBD)		n/a	10/24/17	Designated			N/A	N/A	"AXIUM Pharmaceuticals, Inc."	High Point	North Carolina	27262	USA	EXACT	0027441AA	cannabidiol	19GBJ60SN5						Lennox-Gastaut syndrome	9912		
Fenfluramine	Treatment of Lennox-Gastaut syndrome	Fenfluramine		n/a	6/19/17	Designated			N/A	N/A	Zogenix Inc.	Emeryville	California	94608	USA	EXACT	0025898AA	Fenfluramine	2DS058H2CF						Lennox-Gastaut syndrome	9912		
clobazam	Treatment of Lennox-Gastaut Syndrome	clobazam		Onfi	12/18/07	Designated/Approved	Approved for Orphan Indication	Adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome inpatients 2 years of age or older	10/21/11	10/21/18	"Lundbeck, Inc."	Deerfield	Illinois	60015	USA	EXACT	0060833AA	clobazam	2MRO291B4U						Lennox-Gastaut syndrome	9912		
perampanel	Treatment of Lennox-Gastaut Syndrome	perampanel		Fycompa	12/7/12	Designated			N/A	N/A	"Eisai, Inc."	Woodcliff	New Jersey	7677	USA	EXACT	0249456AA	perampanel	H821664NPK						Lennox-Gastaut syndrome	9912		
carisbamate	Treatment of Lennox-Gastaut syndrome	carisbamate		n/a	8/2/17	Designated			N/A	N/A	"SK Life Sciences, Inc."	Fair Lawn	New Jersey	7410	USA	EXACT	0230002AA	carisbamate	P7725I9V3Z						Lennox-Gastaut syndrome	9912		
Lamotrigine	Treatment of Lennox-Gastaut syndrome.	Lamotrigine		Lamictal	8/23/95	Designated/Approved	Approved for Orphan Indication	Adjunctive treatment of Lennox-Gastaut syndrome in pediatric and adult patients.	8/24/98	8/24/05	Glaxo Wellcome Research and Development	Research Triangle Park	North Carolina	27709	USA	EXACT	0135422AA	Lamotrigine	U3H27498KS						Lennox-Gastaut syndrome	9912		
rufinamide	Treatment of Lennox-Gastaut Syndrome.	rufinamide		Banzel	10/8/04	Designated/Approved	Approved for Orphan Indication	Adjunctive therapy of seizures associated with Lennox-Gastaut syndrome.	11/14/08	11/14/15	"Eisai, Inc."	Woodcliff Lake	New Jersey	7677	USA	EXACT	0173591AA	rufinamide	WFW942PR79						Lennox-Gastaut syndrome	9912		
Felbamate	Treatment of Lennox-Gastaut syndrome.	Felbamate		Felbatol	1/24/89	Designated/Approved	Approved for Orphan Indication	As adjunctive therapy in the treatment of partial and generalized seizures associated with the Lennox-Gastaut syndrome in children.	7/29/93	7/29/00	Wallace Laboratories	Princeton	New Jersey	8540	USA	EXACT	0125279AA	Felbamate	X72RBB02N8						Lennox-Gastaut syndrome	9912		
recombinant thymidine phosphorylase encapsulated with autologous erythrocytes	Treatment of mitochondrial neurogastrointestinal encephalomyopathydue to thymidine phosphorylase deficiency.	recombinant thymidine phosphorylase encapsulated with autologous erythrocytes		n/a	12/13/10	Designated			N/A	N/A	St. George's University of London				United Kingdom	LONGEST CONTAINS	0007669AA	thymidine	VC2W18DGKR						Thymidine Phosphorylase Deficiency	9920		
rebastinib	Treatment of Facioscapulohumeral Muscular Dystrophy	rebastinib		n/a	5/23/18	Designated			N/A	N/A	Genea Biocells US Inc.	11099 North Torrey Pines Road		92037	USA	EXACT	0711148AA	rebastinib	75017Q6I97						Facioscapulohumeral muscular dystrophy	9941		
recombinant human histidyl tRNA synthetase	Treatment of facioscapulohumeral muscular dystrophy	ATYR-1923		n/a	4/22/15	Designated			N/A	N/A	"aTyr Pharma, Inc."	San Diego	California	92121	USA	EXACT									Facioscapulohumeral muscular dystrophy	9941		
Follistatin291-IgG2 Fc fusion protein	Treatment of facioscapulohumeral muscular dystrophy	Follistatin291-IgG2 Fc fusion protein		n/a	7/3/18	Designated			N/A	N/A	Acceleron Pharma Inc.	128 Sidney Street	Massachusetts	2139	USA	LONGEST CONTAINS	0087274AA	protein							Facioscapulohumeral muscular dystrophy	9941		
recombinant adeno-associated virus vector encoding human CYP4V2 protein	Treatment of Bietti's crystalline dystrophy	recombinant adeno-associated virus vector encoding human CYP4V2 protein		n/a	6/21/18	Designated			N/A	N/A	Reflection Biotechnologies Limited	"Unit 308-313, 3/F, Enterprise Place"			Hong Kong	LONGEST CONTAINS	0087274AA	protein							Bietti's crystalline dystrophy	10050		
cantharidin	"Treatment of perforating diseases, including Kyrle's disease, reactive perforating collangenosis, perforating folliculitis and elastosis perforans serpiginosa"	cantharidin		n/a	7/24/12	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0129293AA	cantharidin	IGL471WQ8P						Elastosis perforans serpiginosa	10103		
Pr-320 (molecusol-carbamazepine)	"For the emergency rescue treatment of status epilepticus, grand mal type."	carbamazepine		n/a	7/20/90	Designated/Withdrawn			N/A	N/A	Pharmos	Alachua	Florida	32615	USA	EXACT	0023803AA	carbamazepine	33CM23913M						Status epilepticus	10191		
ganaxolone	Treatment of status epilepticus.	ganaxolone		n/a	4/14/16	Designated			N/A	N/A	"Marinus Pharmaceuticals, Inc."	Radnor	Pennsylvania	19087	USA	EXACT	0184587AA	ganaxolone	98WI44OHIQ						Status epilepticus	10191		
Fosphenytoin	For the acute treatment of patients with status epilepticus of the grand mal type.	Fosphenytoin		Cerebyx	6/4/91	Designated/Approved	Approved for Orphan Indication	For the control of generalized convulsive status epilepticus.	8/5/96	8/5/03	Warner-Lambert Company	Ann Arbor	Michigan	48106	USA	EXACT	0276426AA	Fosphenytoin	B4SF212641						Status epilepticus	10191		
midazolam	Treatment of status epilepticus	midazolam		n/a	2/4/16	Designated			N/A	N/A	"Meridian Medical Technologies, Inc."	Columbia	Maryland	21046	USA	EXACT	0127526AA	midazolam	R60L0SM5BC						Status epilepticus	10191		
midazolam	Treatment of status epilepticus	midazolam		n/a	2/18/16	Designated			N/A	N/A	Shire Development LLC	Lexington	Massachusetts	2421	USA	EXACT	0127526AA	midazolam	R60L0SM5BC						Status epilepticus	10191		
midazolam	Treatment of status epilepticus	midazolam		Zeneo®-Midazolam	1/30/18	Designated			N/A	N/A	Crossject SA	6 Rue Pauline Kergomard	Dijon		France	EXACT	0127526AA	midazolam	R60L0SM5BC						Status epilepticus	10191		
allopregnanolone	Treatment of status epilepticus	allopregnanolone		n/a	4/20/14	Designated			N/A	N/A	Sage Therapeutics	Cambridge	Massachusetts	2142	USA	EXACT	0920434AA	allopregnanolone	S39XZ5QV8Y						Status epilepticus	10191		
1-(2-chlorophenyl)-1-(S)-hydroxy-2-(S)-carbamoyloxy-propane	Treatment of status epilepticus	JBPOS-0101		n/a	7/7/16	Designated			N/A	N/A	"Bio-Pharm Solutions Co., Ltd."	Yeongtong Suwon			"Korea, Republic of"	EXACT	1625292AA	JBPOS-0101	D7NM51C3GU						Status epilepticus	10191		
Pr-122 (redox-phenytoin)	"For the emergency rescue treatment of status epilepticus, grand mal type."	Pr-122 (redox-phenytoin)		n/a	7/5/90	Designated/Withdrawn			N/A	N/A	Pharmos	Alachua	Florida	32615	USA	EXACT	0009381AA	phenytoin	6158TKW0C5						Status epilepticus	10191		
isavuconazonium sulfate	Treatment of zygomycosis	isavuconazonium sulfate		Cresemba	10/25/13	Designated/Approved	Approved for Orphan Indication	Treatment of invasive mucormycosis in patients 18 years of age and older	3/6/15	3/6/22	Astellas Pharma Global Development Inc.	Northbrook	Illinois	60062	USA	EXACT	0914921AA	isavuconazonium sulfate	31Q44514JV						Zygomycosis	10224		
Posaconazole	Treatment of zygomycosis	Posaconazole		Posoril	7/16/04	Designated			N/A	N/A	Schering-Plough Corporation	Kenilwortoh	New Jersey	7033	USA	EXACT	0216080AA	Posaconazole	6TK1G07BHZ						Zygomycosis	10224		
Amphotericin B lipid complex	Treatment of invasive zygomycosis.	Amphotericin B lipid complex		Abelcet	5/6/96	Designated/Withdrawn			N/A	N/A	"The Liposome Company, Inc."	Princeton	New Jersey	8540	USA	EXACT	0035881AA	Amphotericin B lipid complex	7XU7A7DROE						Zygomycosis	10224		
recombinant human Naglu- insulin-like growth factor II	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B)	TRALESINIDASE ALFA		n/a	3/5/13	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	Lexington	Massachusetts	2421	USA	EXACT	0112449AB	TRALESINIDASE ALFA	AA60A4ST8X						Mucopolysaccharidosis type I	10335		
ataluren	Treatment of mucopolysaccharidosis type I	ataluren		Translarna	12/10/14	Designated			N/A	N/A	"PTC Therapeutics, Inc."	South Plainfield	New Jersey	7080	USA	EXACT	0317259AA	ataluren	K16AME9I3V						Mucopolysaccharidosis type I	10335		
chemically modified recombinant sulfamidase	Treatment of mucopolysaccharidosis type IIIA (MPS IIIA)	SOBI-003		n/a	6/28/17	Designated			N/A	N/A	Swedish Orphan Biovitrum AB (publ)	Linköping SV			Sweden	EXACT	0112128AB	SOBI-003	ZS87P77DQC						Mucopolysaccharidosis type I	10335		
lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase	Treatment of mucopolysaccharidosis Type IVA (Morquio Syndrome)	lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase		n/a	9/10/08	Designated			N/A	N/A	Vivendy Therapeutics LTD				Switzerland	LONGEST CONTAINS	0319062AA	sulfate	7IS9N8KPMG						Mucopolysaccharidosis type I	10335		
iduvec	Treatment of Mucopolysaccharidosis Type I	iduvec		n/a	1/21/11	Designated			N/A	N/A	Zebraic Corporation	Brooklyn Park	Minnesota	55443	USA										Mucopolysaccharidosis type I	10335		
adeno-associated virus vector serotype 9 expressing human sulfamidase	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A Syndrome).	adeno-associated virus vector serotype 9 expressing human sulfamidase		n/a	6/1/11	Designated			N/A	N/A	"Laboratorios del Dr. Esteve, S.A."	Barcelona			Spain										Mucopolysaccharidosis type I	10335		
adeno-associated viral vector serotype 9 containing human N-acetylglucosaminidase alpha gene	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome)	adeno-associated viral vector serotype 9 containing human N-acetylglucosaminidase alpha gene		n/a	12/27/12	Designated			N/A	N/A	"Laboratorios del Dr. Esteve, S.A."	Barcelona			Spain										Mucopolysaccharidosis type I	10335		
adeno associated viral vector serotype rh.10 carrying the human SGSH and SUMF1 cDNAs	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo type A syndrome)	adeno associated viral vector serotype rh.10 carrying the human SGSH and SUMF1 cDNAs		n/a	5/6/13	Designated			N/A	N/A	Lysogene	Paris			France										Mucopolysaccharidosis type I	10335		
HIRMAb-IDS	Treatment of mucopolysaccharidosis Type II (Hunter Syndrome)	HIRMAb-IDS		n/a	5/15/13	Designated			N/A	N/A	"ArmaGen Technologies, Inc."	Santa Monica	California	90401	USA										Mucopolysaccharidosis type I	10335		
recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase	Treatment of mucopolysaccharidosis type III-A (Sanfilippo Syndrome Type A)	recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase		n/a	4/29/14	Designated			N/A	N/A	Abeona Therapeutics	Cleveland	Ohio	44106	USA										Mucopolysaccharidosis type I	10335		
adeno-associated virus serotype 9 vector containing human Iduronate-2-sulfatase transgene	Treatment of mucopolysaccharidosis type II (Hunter syndrome).	adeno-associated virus serotype 9 vector containing human Iduronate-2-sulfatase transgene		n/a	7/16/15	Designated			N/A	N/A	"Laboratorios del Dr. Esteve, S.A."	Barcelona			Spain										Mucopolysaccharidosis type I	10335		
aden-associated virus vector serotype 9 expressing human a-L-iduronidase	Treatment of mucopolysaccharidosis Type I (MSP I).	aden-associated virus vector serotype 9 expressing human a-L-iduronidase		n/a	9/29/15	Designated			N/A	N/A	"REGENXBIO, Inc."	Rockville	Maryland	20850	USA										Mucopolysaccharidosis type I	10335		
adeno-associated viral (AAV) vector serotype rh. 10 encoding the human N-sulfoglycosamine sulphohydrolase cDNA (SGSH)	Treatment of mucopolysaccharidosis type IIIA or Sanfilippo type A syndrome	adeno-associated viral (AAV) vector serotype rh. 10 encoding the human N-sulfoglycosamine sulphohydrolase cDNA (SGSH)		n/a	11/18/15	Designated			N/A	N/A	LYSOGENE	Neuilly-sur-Seine			France										Mucopolysaccharidosis type I	10335		
non-replicating recombinant adeno-associated virus (AAV) vector of serotype 9 expressing human iduronate-2-sulfatase	Treatment of Mucopolysaccharidosis Type II	non-replicating recombinant adeno-associated virus (AAV) vector of serotype 9 expressing human iduronate-2-sulfatase		n/a	12/8/15	Designated			N/A	N/A	"REGENXBIO, Inc."	Rockville	Maryland	20850	USA										Mucopolysaccharidosis type I	10335		
recombinant adeno-associated virus vector serotype 9 expressing human N-Sulfoglucosamine Sulfohydrolase	"Treatment of mucopolysaccharidosis type III A, also called Sanfilippo syndrome A"	recombinant adeno-associated virus vector serotype 9 expressing human N-Sulfoglucosamine Sulfohydrolase		n/a	9/1/16	Designated			N/A	N/A	Research Institute at Nationwide Children's Hospital	Columbus	Ohio	43205	USA										Mucopolysaccharidosis type I	10335		
adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and the human alpha-L-iduronidase (hIDUA) gene	Treatment of mucopolysaccharidosis type I (MPS I)	adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and the human alpha-L-iduronidase (hIDUA) gene		n/a	1/9/17	Designated			N/A	N/A	"Sangamo Therapeutics, Inc."	Richmond	California	94804	USA	LONGEST CONTAINS	0048271AA	zinc	J41CSQ7QDS						Mucopolysaccharidosis type I	10335		
Adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and the human iduronate 2-sulfatase (hIDS) gene	Treatment of mucopolysaccharidosis type II	Adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and the human iduronate 2-sulfatase (hIDS) gene		n/a	2/27/17	Designated			N/A	N/A	"Sangamo Therapeutics, Inc."	Richmond	California	94804	USA	LONGEST CONTAINS	0048271AA	zinc	J41CSQ7QDS						Mucopolysaccharidosis type I	10335		
Sleeping Beauty Transposon-Engineered Autologous Plasmablasts for Expression and Delivery of Alpha-L-Iduronidase	Treatment of mucopolysaccharidosis type I (MPS I)	Sleeping Beauty Transposon-Engineered Autologous Plasmablasts for Expression and Delivery of Alpha-L-Iduronidase		Iduronicrin Genleukocel-T (Iduroicel)	3/19/18	Designated			N/A	N/A	Immusoft Corporation	454 North 34th Street		98103	USA										Mucopolysaccharidosis type I	10335		
Recombinant human insulin receptor monoclonal antibody-N-heparan sulfamidase fusion protein	"Treatment of Mucopolysaccharidosis Type IIIA, Sanfilippo A Syndrome"	Recombinant human insulin receptor monoclonal antibody-N-heparan sulfamidase fusion protein		n/a	7/12/18	Designated			N/A	N/A	"ArmaGen, Inc."	"26679 Agoura Road, Suite #100"	California	91302	USA	LONGEST CONTAINS	1337275AA	insulin receptor	4CH8636GFF						Mucopolysaccharidosis type I	10335		
Humanized IgG-1 antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase	Treatment of Mucopolysaccharidosis Type II (MPS II) or Hunter Syndrome	Humanized IgG-1 antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase		n/a	10/15/18	Designated			N/A	N/A	"JCR Pharmaceuticals Co., Ltd."	2-4 Kasuga-cho			Japan	LONGEST CONTAINS	0158667AA	transferrin							Mucopolysaccharidosis type I	10335		
Ciclopirox	Treatment of congenital erythropoietic porphyria	Ciclopirox		n/a	4/17/18	Designated			N/A	N/A	Atlas Molecular Pharma S.L.	Parque Tecnológico de Bizkaia	Building 800		Spain	EXACT	0167271AA	Ciclopirox	19W019ZDRJ						Porphyria	10353		
Hemin	"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria."	Hemin		Panhematin	3/16/84	Designated/Approved	Approved for Orphan Indication		7/20/83	7/20/90	Abbott Laboratories	Abbott Park	Illinois	60064	USA	EXACT	0135171AA	Hemin	743LRP9S7N						Porphyria	10353		
Histrelin	"Treatment of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria."	Histrelin		n/a	5/3/91	Designated			N/A	N/A	"Anderson, Karl E., M.D."	Galveston	Texas	77550	USA	EXACT	0135864AA	Histrelin	H50H3S3W74						Porphyria	10353		
L-cysteine	For the prevention and lessening of photosensitivity in erythropoietic protoporphyria.	L-cysteine		n/a	5/16/94	Designated			N/A	N/A	Brigham and Women's Hospital	Boston	Massachusetts	2115	USA	EXACT	0008322AA	L-cysteine	K848JZ4886						Porphyria	10353		
afamelanotide	Treatment of erythropoietic porphyrias	afamelanotide		n/a	7/17/08	Designated			N/A	N/A	Clinuvel Inc.	New York	New York	10013	USA	EXACT	0253281AA	afamelanotide	QW68W3J66U						Porphyria	10353		
afamelanotide	Treatment of cutaneous variants of porphyria (which includes treatment and prevention of cutaneous manifestations of disease)	afamelanotide		n/a	2/4/16	Designated			N/A	N/A	Clinuvel Inc.	New York	New York	10013	USA	EXACT	0253281AA	afamelanotide	QW68W3J66U						Porphyria	10353		
Heme arginate	Treatment of symptomatic stage of acute porphyria.	Heme arginate		Normosang	3/10/88	Designated			N/A	N/A	Orphan Europe SARL	92800 Puteaux			France	EXACT	0554778AA	Heme arginate	R1B526117P						Porphyria	10353		
recombinant human porphobilinogen deaminase	Treatment of acute intermittent porphyria attacks	recombinant human porphobilinogen deaminase		Porphozyme	9/9/02	Designated			N/A	N/A	Zymenex A/S				Denmark	EXACT	0265509AA	recombinant human porphobilinogen deaminase							Porphyria	10353		
"recombinant human porphobilinogen deaminase, erythropoetic form"	Treatment of acute intermittent porphyria preventing attacks	"recombinant human porphobilinogen deaminase, erythropoetic form"		n/a	7/11/02	Designated			N/A	N/A	Zymenex A/S				Denmark	LONGEST CONTAINS	0265509AA	recombinant human porphobilinogen deaminase							Porphyria	10353		
Synthetic double-stranded small interfering RNA (siRNA) oligonucleotide targeting delta-aminoevulinic acid synthase 1	Treatment of acute hepatic porphyria	Synthetic double-stranded small interfering RNA (siRNA) oligonucleotide targeting delta-aminoevulinic acid synthase 1		n/a	8/29/16	Designated			N/A	N/A	Alnylam Pharmaceuticals	Cambridge	Massachusetts	2142	USA										Porphyria	10353		
Ascorbic acid	Treatment of scurvy	Ascorbic acid		Ascor L 500	8/31/07	Designated			N/A	N/A	McGuff Pharmaceuticals Inc.	Santa Ana	California	92704	USA	EXACT	0007658AA	Ascorbic acid	PQ6CK8PD0R						Scurvy	10406		
"Coagulation factor IX (recombinant), Fc fusion protein"	Control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease)	ALPROLIX		Alprolix	10/30/08	Designated/Approved	Approved for Orphan Indication	"Adults and children with Hemophilia B for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes."	3/28/14	3/28/21	Biogen Idec Inc.	Cambridge	Massachusetts	2142	USA	EXACT	0784349AA	ALPROLIX	02E00T2QDE						Hemophilia	10418		
Inhibitor of Tissue Factor Pathway Inhibitor (TFPI)	Treatment of hemophilia A and hemophilia B.	BAX-499		n/a	1/29/10	Designated			N/A	N/A	"Baxter Healthcare Corporation, Baxter BioScience"	Westlake Village	California	91362	USA	EXACT	1295494AA	BAX-499	0493WH50VT						Hemophilia	10418		
human monoclonal antibody directed against tissue factor pathway inhibitor	"Treatment of hemophilia A and hemophilia B patients with or without inhibitors, which includes routine prophylaxis to prevent or reduce the frequency of bleeding in hemophilia A and hemophilia B patients."	PF-06741086		n/a	5/18/16	Designated			N/A	N/A	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	0112525AB	PF-06741086	0UB3OA67O7						Hemophilia	10418		
40K PEGylated recombinant factor IX	Routine prophylactic administration for prevention of bleeding in patients with hemophilia B (Christmas disease)	REBINYN		n/a	3/18/13	Designated			N/A	N/A	"Novo Nordisk, Inc."	Princeton		8540	USA	EXACT	0432600AA	REBINYN	27Y83O992Q						Hemophilia	10418		
Coagulation Factor IX (recombinant)	Treatment of hemophilia B.	Coagulation Factor IX (recombinant)		Benefix	10/3/94	Designated/Approved	Approved for Orphan Indication	"For the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency and Christmas disease), including control and prevention of bleeding in surgical settings."	2/11/97	2/11/04	"Genetics Institute, Inc."	Cambridge	Massachusetts	2140	USA	EXACT	0222004AA	Coagulation Factor IX (recombinant)	382L14738L						Hemophilia	10418		
coagulation factor IX (recombinant)	Prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (routine prophylaxis in patients where there is no evidence or suspicion of bleeding)	coagulation factor IX (recombinant)		Rixubis	10/31/12	Designated/Approved	Approved for Orphan Indication	Adults with Hemophilia B for routine prophylaxis to prevent or reduce the frequency of bleeding episodes.	6/26/13	6/26/20	"Baxalta US, Inc."	Westlake Village	California	91362	USA	EXACT	0222004AA	coagulation factor IX (recombinant)	382L14738L						Hemophilia	10418		
Recombinant humanized MAb 5c8	Prevention and treatment of Factor VIII/Factor IX inhibitors in patients with hemophilia A or B.	Ruplizumab		n/a	10/14/98	Designated			N/A	N/A	"Biogen, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	1090342AA	Ruplizumab	562JQF15GN						Hemophilia	10418		
human coagulation factor VIII	Immune tolerance induction in hemophilia A patients with inhibitors	HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX		Octanate	12/3/12	Designated			N/A	N/A	"OCTAPHARMA USA, Inc."	Hoboken	New Jersey	7030	USA	EXACT	0323353AA	HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX	5T6B772R4Q						Hemophilia	10418		
Coagulation Factor IX (human)	"For use as replacement therapy in patients with hemophilia B for the prevention and control of bleeding episodes, and during surgery to correct defective hemostasis."	Coagulation Factor IX (human)		Alphanine	7/5/90	Designated/Approved	Approved for Orphan Indication		12/31/90	12/31/97	Alpha Therapeutic Corporation	Los Angeles	California	90032	USA	EXACT	0174834AA	Coagulation Factor IX (human)	6U90Y1795T						Hemophilia	10418		
factor VIII mimetic bispecific antibody	Treatment of hemophilia A	emicizumab		n/a	1/10/14	Designated			N/A	N/A	Genentech	South San Francisco	California	94080	USA	EXACT	1150205AA	emicizumab	7NL2E3F6K3						Hemophilia	10418		
"antihemophilic factor (recombinant), Fc fusion protein"	Treatment of hemophilia A	Eloctate		Eloctate	11/23/10	Designated/Approved	Approved for Orphan Indication	"Treatment of adults and children with Hemophilia A (congenital Factor VIII deficiency) for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes."	6/6/14	6/6/21	Biogen Idec Inc.	Cambridge	Massachusetts	2142	USA	EXACT	0791979AA	Eloctate	7PCM518YLR						Hemophilia	10418		
recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)	Treatment of patients with congenital factor IX deficiency (hemophilia B).	Idelvion		Idelvion	4/27/12	Designated/Approved	Approved for Orphan Indication	"Indicated for the (1) on-demand control and prevention of bleeding episodes, (2) perioperative management of bleeding, and (3) routine prophylaxis to prevent or reduce the frequency of bleeding episodes."	3/4/16	3/4/23	"CSL Behring, LLC"	King of Prussia	Pennsylvania	19406	USA	EXACT	1085127AA	Idelvion	A57KX1VL5P						Hemophilia	10418		
Coagulation factor VIIa (recombinant)	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Coagulation factor VIIa (recombinant)		Novoseven	6/6/88	Designated/Approved	Approved for Orphan Indication	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	3/25/99	3/25/06	"Novo Nordisk, Inc."	Princeton	New Jersey	8540	USA	EXACT	0324765AA	Coagulation factor VIIa (recombinant)	AC71R787OV						Hemophilia	10418		
Coagulation factor VIIa (recombinant)	"Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors"	Coagulation factor VIIa (recombinant)		Novoseven	6/18/04	Designated/Approved	Approved for Orphan Indication	Prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX	8/12/05	8/12/12	"Novo Nordisk, Inc."	Princeton	New Jersey	8540	USA	EXACT	0324765AA	Coagulation factor VIIa (recombinant)	AC71R787OV						Hemophilia	10418		
anti-inhibitor coagulant complex	Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors	anti-inhibitor coagulant complex		Feiba	4/12/13	Designated/Approved	Approved for Orphan Indication	Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors	12/16/13	12/16/20	"Baxalta US, Inc."	West Lake Village	California	91362	USA	EXACT	0345175AA	anti-inhibitor coagulant complex	CS849DUN3M						Hemophilia	10418		
Recombinant Human Factor VIIa Variant	Routine prophylaxis to prevent bleeding episodes in patients with hemophilia A and B patients with inhibitors	MARZEPTACOG ALFA (ACTIVATED)		n/a	11/30/12	Designated			N/A	N/A	"Pfizer, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	1198341AA	MARZEPTACOG ALFA (ACTIVATED)	J5LT149M79						Hemophilia	10418		
Antihemophilic factor (recombinant)	Prophylaxis and treatment of bleeding in individuals with hemophilia A or for prophylaxis when surgery is required in individuals with hemophilia A.	Antihemophilic factor (recombinant)		Kogenate	9/25/89	Designated/Approved	Approved for Orphan Indication	Treatment and prophylaxis of bleeding in patients with hemophilia A (not von Willebrand's disease)	2/25/93	2/25/00	Bayer Corporation	Elkhart	Indiana	46515	USA	EXACT	0182832AA	Antihemophilic factor (recombinant)	P89DR4NY54						Hemophilia	10418		
Antihemophilic factor (recombinant)	For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).	Antihemophilic factor (recombinant)		"Refacto, Xyntha"	2/8/96	Designated/Approved	Approved for Orphan Indication		3/6/00	N/A	"Wyeth Pharmaceuticals, Inc."	Philadelphia	Pennsylvania	19101	USA	EXACT	0182832AA	Antihemophilic factor (recombinant)	P89DR4NY54						Hemophilia	10418		
Antihemophilic factor (recombinant) formulated with sucrose reconstituted with liposome diluent	Treatment of hemophilia A	Kogenate 		Kogenate Fs/Liposomal Diluent	4/29/09	Designated/Withdrawn			N/A	N/A	Bayer HealthCare LLC	Tarrytown	New York	10591	USA	EXACT	0182832AA	Kogenate	P89DR4NY54						Hemophilia	10418		
Desmopressin acetate	Treatment of mild hemophilia A and von Willebrand's disease.	Desmopressin acetate		n/a	1/22/91	Designated/Approved	Approved for Orphan Indication	Treatment of patients with hemophilia A or von Willebrand's disease (type I) whose factor VIII coagulant activity level is greater than 5%.	3/7/94	3/7/01	Aventis Behring L.L.C.	King of Prussia	Pennsylvania	19406	USA	EXACT	0067027AA	Desmopressin acetate	XB13HYU18U						Hemophilia	10418		
Coagulation factor IX	Replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia B.	COAGULATION FACTOR IX (HUMAN)		Mononine	6/27/89	Designated/Approved	Approved for Orphan Indication	"Prevention and control of bleeding in factor IX deficiency, also known as hemophilia B or Christmas disease."	8/20/92	8/20/99	Armour Pharmaceutical Company	Collegeville	Pennsylvania	19426	USA	EXACT	0174834AA	COAGULATION FACTOR IX (HUMAN)	6U90Y1795T						Hemophilia	10418		
rVIIa-FP	Treatment and prophyllaxis of bleeding episodes in patients with congenital hemophilia and inhibitors to coagulation factor VIII or IX	rVIIa-FP		n/a	12/22/11	Designated			N/A	N/A	CSL Behring	King of Prussia	Pennsylvania	19406	USA	EXACT	0113916AB	rVIIa-FP							Hemophilia	10418		
recombinant B-domain deleted human coagulation factor VIII Fc-von Willebrand factor-XTEN fusion protein	Treatment of hemophilia A	BIVV001		n/a	8/3/17	Designated			N/A	N/A	"Bioverativ Therapeutics, Inc."	Waltham	Massachusetts	2451	USA	EXACT									Hemophilia	10418		
Adenovirus-based vector Factor VIII complementary DNA to somatic cells	Treatment of hemophilia A.	Adenovirus-based vector Factor VIII complementary DNA to somatic cells		Miniadfviii	12/15/99	Designated			N/A	N/A	GenStar Therapeutics Corporation	San Diego	California	92121	USA	LONGEST CONTAINS	0101768AA	Factor VIII							Hemophilia	10418		
Adeno-associated viral vector containing the gene for human coagulation factor IX	Intramuscular treatment of patients with moderate to severe hemophilia	Adeno-associated viral vector containing the gene for human coagulation factor IX		Coagulin-B	6/13/01	Designated			N/A	N/A	"Avigen, Inc."	Alameda	California	94502	USA	LONGEST CONTAINS	0324969AA	human coagulation factor IX	6U90Y1795T						Hemophilia	10418		
Adeno-associated viral vector containing the gene for human coagulation factor IX	Intrahepatic treatment of patients with moderate to severe hemophilia	Adeno-associated viral vector containing the gene for human coagulation factor IX		Coagulin-B	6/13/01	Designated			N/A	N/A	"Avigen, Inc."	Alameda	California	94502	USA	LONGEST CONTAINS	0324969AA	human coagulation factor IX	6U90Y1795T						Hemophilia	10418		
MaxAdFVIII	Treatment of Hemophilia A	MaxAdFVIII		n/a	3/3/03	Designated			N/A	N/A	GenStar Therapeutics Corporation	San Diego	California	92121	USA										Hemophilia	10418		
Microvesiculated modified glycosylated tissue factor	"Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in hemophiliac patients"	Microvesiculated modified glycosylated tissue factor		n/a	1/25/07	Designated			N/A	N/A	Thrombotargets Corp.	Durham	North Carolina	27713	USA	LONGEST CONTAINS	0005163AA	tissue factor	1U5PI2DLU1						Hemophilia	10418		
an adeno-associated viral vector containing a codon-optimised human factor IX gene (AAV5-hFIXco)	Treatment of hemophilia B	an adeno-associated viral vector containing a codon-optimised human factor IX gene (AAV5-hFIXco)		n/a	12/22/11	Designated			N/A	N/A	"uniQure, B.V."	Amsterdam			Netherlands	LONGEST CONTAINS	0313315AA	factor IX							Hemophilia	10418		
modified recombinant human Factor VIIa (rFVIIa) molecule	Treatment of bleeding episodes in hemophilia A or B subjects with inhibitors	modified recombinant human Factor VIIa (rFVIIa) molecule		n/a	5/30/13	Designated/Withdrawn			N/A	N/A	"Bayer Healthcare Pharmaceuticals, Inc."	Whippany	New Jersey	7981	USA	LONGEST CONTAINS	0345153AA	human Factor VIIa	15FH07392N						Hemophilia	10418		
synthetic double-stranded siRNA oligonucleotide against antithrombin mRNA	Treatment of hemophilia B	synthetic double-stranded siRNA oligonucleotide against antithrombin mRNA		n/a	8/12/13	Designated			N/A	N/A	Alnylam Pharmaceuticals	Cambridge	Massachusetts	2142	USA	LONGEST CONTAINS	0172032AA	antithrombin	T0LTO7L82X						Hemophilia	10418		
synthetic double-stranded siRNA oligonucleotide against antithrombin (AT) mRNA	Treatment of hemophilia A	synthetic double-stranded siRNA oligonucleotide against antithrombin (AT) mRNA		n/a	8/16/13	Designated			N/A	N/A	Alnylam Pharmaceuticals	Cambridge	Massachusetts	2142	USA	LONGEST CONTAINS	0172032AA	antithrombin	T0LTO7L82X						Hemophilia	10418		
long acting recombinantFactor VIIa-CTP3	Treatment and prophylaxis of bleeding episodes in patients with hemophilia A or B with inhibitors to factor VIII or factor IX	long acting recombinantFactor VIIa-CTP3		n/a	2/27/14	Designated			N/A	N/A	"PROLOR Biotech, Ltd"	Nes Ziona			Israel										Hemophilia	10418		
adeno associated virus with modified transthyretin and sequence encoding factor IX variant gene	Treatment of hemophilia B	adeno associated virus with modified transthyretin and sequence encoding factor IX variant gene		n/a	3/14/14	Designated			N/A	N/A	"Baxalta US, Inc."	Westlake Village	California	91362	USA	LONGEST CONTAINS	0113161AB	transthyretin	2COU0B578R						Hemophilia	10418		
immunologically active synthetic peptides	Treatment of Hemophilia A	immunologically active synthetic peptides		n/a	6/1/15	Designated			N/A	N/A	Apitope International NV				Belgium										Hemophilia	10418		
Adeno-associated virus serotype rh10 vector encoding the human factor IX gene	Treatment of hemophilia B.	Adeno-associated virus serotype rh10 vector encoding the human factor IX gene		n/a	8/25/15	Designated			N/A	N/A	Dimension Therapeutics	Cambridge	Massachusetts	2139	USA	LONGEST CONTAINS	0313315AA	factor IX							Hemophilia	10418		
adeno-associated viral vector composed of a bioengineered AAV capsid and a codon-optimized expression cassette encoding a high-specific activity variant of human coagulation factor IX	Treatment of hemophilia B.	adeno-associated viral vector composed of a bioengineered AAV capsid and a codon-optimized expression cassette encoding a high-specific activity variant of human coagulation factor IX		n/a	9/21/15	Designated			N/A	N/A	"Spark Therapeutics, Inc."	Philadelphia	Pennsylvania	19104	USA	LONGEST CONTAINS	0324969AA	human coagulation factor IX	6U90Y1795T						Hemophilia	10418		
adeno-associated virus vector encoding the SQ variant of human blood clotting factor VIII	Treatment of Hemophilia A.	adeno-associated virus vector encoding the SQ variant of human blood clotting factor VIII		n/a	2/29/16	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA	LONGEST CONTAINS	0101768AA	factor VIII							Hemophilia	10418		
Adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and human factor 9 gene (SB-FIX)	Treatment of hemophilia B	Adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and human factor 9 gene (SB-FIX)		n/a	9/1/16	Designated			N/A	N/A	"Sangamo BioSciences, Inc."	Richmond	California	94804	USA	LONGEST CONTAINS	0048271AA	zinc	J41CSQ7QDS						Hemophilia	10418		
"Recombinant adeno-associated viral vector, AAV2 serotype 6 (rAAv2/6), expressing human factor 8 (hf8) cDNA"	Treatment of hemophilia A	"Recombinant adeno-associated viral vector, AAV2 serotype 6 (rAAv2/6), expressing human factor 8 (hf8) cDNA"		n/a	5/3/17	Designated			N/A	N/A	"Sangamo Therapeutics, Inc."	Richmond	California	94804	USA	LONGEST CONTAINS	0112841AB	AAV2	YA02LE18L3						Hemophilia	10418		
Adeno-associated virus serotype 8 vector expressing B domain deleted codon optimized factor VIII	Treatment of hemophilia A	Adeno-associated virus serotype 8 vector expressing B domain deleted codon optimized factor VIII		n/a	9/18/17	Designated			N/A	N/A	Baxalta US Inc.	Westlake Village	California	91362	USA	LONGEST CONTAINS	0101768AA	factor VIII							Hemophilia	10418		
Subcutaneous recombinant human factor IX variant with three point mutations	Treatment for hemophilia B	Subcutaneous recombinant human factor IX variant with three point mutations		n/a	9/20/17	Designated			N/A	N/A	"Catalyst Biosciences, Inc."	South San Francisco	California	94080	USA	LONGEST CONTAINS	0313315AA	factor IX							Hemophilia	10418		
recombinant adeno-associated viral (AAV) vector that contains a bioengineered capsid (AAV-Spark200) and a codon-optimized expression cassette to drive expression of the SQ form of a B-domain deleted human coagulation factor VIII (hFVIII)	Treatment of hemophilia A	recombinant adeno-associated viral (AAV) vector that contains a bioengineered capsid (AAV-Spark200) and a codon-optimized expression cassette to drive expression of the SQ form of a B-domain deleted human coagulation factor VIII (hFVIII)		n/a	1/16/18	Designated			N/A	N/A	"Spark Therapeutics, Inc."	3737 Market Street	Philadelphia	19104	USA	LONGEST CONTAINS	0101688AA	human coagulation factor VIII	839MOZ74GK						Hemophilia	10418		
concizumab	Treatment of hemophilia A	concizumab		n/a	10/22/18	Designated			N/A	N/A	"Novo Nordisk, Inc."	P.O Box 846	New Jersey	8536	USA	EXACT	0804035AA	concizumab	68603V9EAF						Hemophilia	10418		
mecasermin	Treatment of myotonic dystrophy	mecasermin		Iplex	12/3/07	Designated			N/A	N/A	"Insmed, Inc."	Bridgewater	New Jersey	8817	USA	EXACT	0167215AA	mecasermin	7GR9I2683O						Myotonic dystrophy	10419		
synthetic oligomer of 16 nucleotides	Treatment of myotonic dystrophy Type I	BALIFORSEN		n/a	1/13/15	Designated			N/A	N/A	"Ionis Pharmaceuticals, Inc."	Carlsbad	California	92010	USA	EXACT	1312056AA	BALIFORSEN	DR9CF3915M						Myotonic dystrophy	10419		
Tideglusib	Treatment of myotonic dystrophy type 1 (DM1)	Tideglusib		n/a	6/19/17	Designated			N/A	N/A	AMO Pharma Ltd.	Wonersh			United Kingdom	EXACT	0362094AA	Tideglusib	Q747Y6TT42						Myotonic dystrophy	10419		
bortezomib	Treatment of neurofibromatosis type 2 (NF2)	bortezomib		n/a	7/5/16	Designated			N/A	N/A	BioXcel Corporation	Branford	Connecticut	6405	USA	EXACT	0228319AA	bortezomib	69G8BD63PP						Neurofibromatosis	10420		
selumetinib	Treatment of Neurofibromatosis Type 1	selumetinib		n/a	2/14/18	Designated			N/A	N/A	AstraZeneca Pharmaceuticals LP	1800 Concord Pike	Wilmington		USA	EXACT	0297176AA	selumetinib	6UH91I579U						Neurofibromatosis	10420		
"N-[(2R)-2,3 dihydroxypropoxyl]-3,4 difluro-2 -[(2-fluoro-4-iodophenyl)amino] benzamide"	Treatment of Neurofibromatosis type I	PD-0325901		n/a	10/30/18	Designated			N/A	N/A	"SpringWorks Subsidiary 3, PBC (Spring Works)"	"575 5th Avenue, 16th Floor"	New York	10017	USA	EXACT	0743146AA	PD-0325901	86K0J5AK6M						Neurofibromatosis	10420		
Fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1	Treatment of X-linked hypohidrotic ectodermal dysplasia	EDI-200		n/a	1/11/06	Designated			N/A	N/A	"Edimer Pharmaceuticals, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0113808AB	EDI-200	AF6GZK1UMB						X-linked hypohidrotic ectodermal dysplasia	10427		
droxidopa	"Treatment of neurogenic symptomatic orthostatic hypotension in patients with primary autonomic failure, dopamine-beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy."	droxidopa		Northera	1/17/07	Designated/Approved	Approved for Orphan Indication	"Treatment of orthostatic dizziness, lightheadedness, or the ""feeling that you are about to black out"" in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy."	2/18/14	2/18/21	Lundbeck LLC	Deerfield	Illinois	60015	USA	EXACT	0295921AA	droxidopa	J7A92W69L7						Autonomic failure	10428		
Huperzine A	Treatment of Dravet syndrome	Huperzine A		n/a	4/12/17	Designated			N/A	N/A	"Biscayne Neurotherapeutics, Inc."	Miami	Florida	33137	USA	EXACT	0242671AA	Huperzine A	0111871I23						Dravet syndrome	10430		
cholesterol 24S-hydroxylase inhibitor	Treatment of Dravet syndrome	TAK-935		n/a	11/29/17	Designated			N/A	N/A	"Takeda Development Center Americas, Inc."	Takeda Parkway	Deerfield	60015	USA	EXACT	1066166AA	TAK-935	1766MU795L						Dravet syndrome	10430		
cannabidiol	Treatment of Dravet syndrome.	cannabidiol		n/a	11/14/13	Designated			N/A	N/A	GW Pharma Ltd.				United Kingdom	EXACT	0027441AA	cannabidiol	19GBJ60SN5						Dravet syndrome	10430		
cannabidiol	Treatment of Dravet syndrome	cannabidiol		n/a	7/1/14	Designated			N/A	N/A	"Insys Development Company, Inc."	Chandler	Arizona	85286	USA	EXACT	0027441AA	cannabidiol	19GBJ60SN5						Dravet syndrome	10430		
cannabidiol	Treatment of Dravet syndrome	cannabidiol		n/a	12/21/17	Designated			N/A	N/A	"AXIUM Pharmaceuticals, Inc."	265 Eastchester Drive	High Point	27262	USA	EXACT	0027441AA	cannabidiol	19GBJ60SN5						Dravet syndrome	10430		
fenfluramine HCI	For the Treatment of Dravet Syndrome	fenfluramine hydrochloride		Brabafen	12/20/13	Designated			N/A	N/A	"Zogenix, Inc."	Emeryville	California		United Kingdom	EXACT	0025489AA	fenfluramine hydrochloride	3KC089243P						Dravet syndrome	10430		
lorcaserin	Treatment of Dravet syndrome	lorcaserin		Belviq	4/17/17	Designated			N/A	N/A	"Epygenix Therapeutics, Inc."	Paramus	New Jersey	7652	USA	EXACT	0307095AA	lorcaserin	637E494O0Z						Dravet syndrome	10430		
diazepam	Treatment of Dravet syndrome	diazepam		n/a	5/23/18	Designated			N/A	N/A	"Xeris Pharmaceutical, Inc."	180 North LaSalle Street	Suite 1800	60601	USA	EXACT	0025752AA	diazepam	Q3JTX2Q7TU						Dravet syndrome	10430		
stiripentol	Treatment of Dravet syndrome	stiripentol		Diacomit	10/30/08	Designated			N/A	N/A	Biocodex				France	EXACT	0157404AA	stiripentol	R02XOT8V8I						Dravet syndrome	10430		
clemizole	Treatment of Dravet syndrome	clemizole		n/a	4/19/17	Designated			N/A	N/A	"Epygenix Therapeutics, Inc."	Paramus	New Jersey	7652	USA	EXACT	0025809AA	clemizole	T97CB3796L						Dravet syndrome	10430		
trazodone	Treatment of Dravet syndrome	trazodone		n/a	8/18/17	Designated			N/A	N/A	"Epygenix Therapeutics, Inc."	Paramus	New Jersey	7652	USA	EXACT	0144401AA	trazodone	YBK48BXK30						Dravet syndrome	10430		
"synthetic, single stranded, fully phosphorothioated 2’-OMethyl-RNA and DNA mixmer oligonucleotide-based compound targeted against natural antisense transcripts (NATs)"	Treatment of Dravet Syndrome	"synthetic, single stranded, fully phosphorothioated 2’-OMethyl-RNA and DNA mixmer oligonucleotide-based compound targeted against natural antisense transcripts (NATs)"		n/a	3/16/17	Designated			N/A	N/A	OPKO Ireland Global Holdings Ltd.	Camana Bay			Cayman Islands										Dravet syndrome	10430		
"anti-TCR murine monoclonal antibody (MAB, type IgM)"	Treatment of pediatric multiple sclerosis in patients less than or equal to 16 years of age	TOL-101		n/a	1/12/11	Designated			N/A	N/A	"Tolera Therapeutics, Inc."	Kalamazoo	Michigan	49008	USA	EXACT	0113923AB	TOL-101	28X0AGG6P8						Pediatric multiple sclerosis	10443		
"T cell receptor (TCR) peptide (BV5S2, BV6S5, BV13S1) vaccine"	Treatment of Pediatric Multiple Sclerosis	HUMAN T-CELL RECEPTOR (BV5S2)PEPTIDE		Neurovax	2/6/14	Designated			N/A	N/A	"Immune Response BioPharma, Inc."	New York		10001	USA	EXACT	0264313AA	HUMAN T-CELL RECEPTOR (BV5S2)PEPTIDE	VS2A96444Q						Pediatric multiple sclerosis	10443		
"T cell receptor (TCR) peptide (BV5S2, BV6S5, BV13S1) vaccine"	Treatment of Pediatric Multiple Sclerosis	HUMAN T-CELL RECEPTOR (BV13S1)PEPTIDE		Neurovax	2/6/14	Designated			N/A	N/A	"Immune Response BioPharma, Inc."	New York		10001	USA	EXACT	0264335AA	HUMAN T-CELL RECEPTOR (BV13S1)PEPTIDE	VYD9GJM8HP						Pediatric multiple sclerosis	10443		
"T cell receptor (TCR) peptide (BV5S2, BV6S5, BV13S1) vaccine"	Treatment of Pediatric Multiple Sclerosis	IR-208		Neurovax	2/6/14	Designated			N/A	N/A	"Immune Response BioPharma, Inc."	New York		10001	USA	EXACT	1259387AA	IR-208	6532E45BS6						Pediatric multiple sclerosis	10443		
recombinant ovine interferon tau	Treatment of pediatric multiple sclerosis	Tauferon		Tauferon	1/25/05	Designated			N/A	N/A	PEPGEN Corporation	Alameda	California	94502	USA										Pediatric multiple sclerosis	10443		
Glyeraldehyde-3-phosphate dehydrogenase	Treatment of pediatric multiple sclerosis	Glyeraldehyde-3-phosphate dehydrogenase		Proenzy	4/30/10	Designated			N/A	N/A	"BPT Pharmaceuticals, Inc."	Los Angeles	California	90069	USA	LONGEST CONTAINS	0055890AA	phosphate	NK08V8K8HR						Pediatric multiple sclerosis	10443		
modified a-cobratoxin	Treatment of pediatric multiple sclerosis (0 through 16 years of age).	modified a-cobratoxin		n/a	9/1/15	Designated			N/A	N/A	Nutra Pharma Corporation	Coral Springs	Florida	33071	USA										Pediatric multiple sclerosis	10443		
Sodium aluminosilicate	Treatment of chronic hepatic encephalopathy	Sodium aluminosilicate		n/a	3/4/05	Designated			N/A	N/A	Castle Creek Pharmaceuticals LLC	Northbrook	Illinois	60062	USA	EXACT	0035405AA	Sodium aluminosilicate	058TS43PSM						Hepatic encephalopathy	10452		
Sodium phenylacetate/sodium benzoate 10%/10% Injection	Treatment of grade III and IV hepatic encephalopathy	Sodium phenylacetate		Ammonul(R)	6/3/05	Designated			N/A	N/A	"Ucyclyd Pharma, Inc."	Scottsdale	Arizona	85256	USA	EXACT	0093538AA	Sodium phenylacetate	48N6U1781G						Hepatic encephalopathy	10452		
L-ornithine phenylacetate	Treatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure or acute on chronic liver disase	L-ornithine phenylacetate		n/a	4/7/10	Designated			N/A	N/A	"Ocera Therapeutics, Inc."	Durham	North Carolina	27703	USA	EXACT	0460548AA	ornithine phenylacetate	9D6YZ105SN						Hepatic encephalopathy	10452		
rifaximin	Treatment of hepatic encephalopathy	rifaximin		Normix	2/10/98	Designated/Approved	Approved for Orphan Indication	Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age	3/24/10	3/24/17	"Salix Pharmaceuticals, Inc."	Somerset	New Jersey	8807	USA	EXACT	0211574AA	rifaximin	L36O5T016N						Hepatic encephalopathy	10452		
Sodium phenylacetate/sodium benzoate 10%/10% Injection	Treatment of grade III and IV hepatic encephalopathy	sodium benzoate 10%/10% Injection		Ammonul(R)	6/3/05	Designated			N/A	N/A	"Ucyclyd Pharma, Inc."	Scottsdale	Arizona	85256	USA	EXACT	0027849AA	sodium benzoate	OJ245FE5EU						Hepatic encephalopathy	10452		
gylceryl tri (4-pheynlybutyrate)	For intermittent or chronic treatment of patients with cirrhosis and any grade hepatic encephalopathy.	GLYCEROL PHENYLBUTYRATE		n/a	9/3/09	Designated			N/A	N/A	"Horizon Therapeutics, Inc."	Deerfield	Illinois	60015	USA	EXACT	0682848AA	GLYCEROL PHENYLBUTYRATE	ZH6F1VCV7B						Hepatic encephalopathy	10452		
Beractant	"Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis."	Beractant		Survanta Intratracheal Suspension	12/20/93	Designated			N/A	N/A	Ross Laboratories	Columbus	Ohio	43215	USA	EXACT	0171164AA	Beractant	S866O45PIG						Meconium aspiration syndrome	10494		
Lucinactant	Treatment of meconium aspiration syndrome in newborn infants	Lucinactant		Surfaxin	7/30/96	Designated/Withdrawn			N/A	N/A	"Windtree Therapeutics, Inc."	Warrington	Pennsylvania	18976	USA	EXACT	0727402AA	Lucinactant							Meconium aspiration syndrome	10494		
Rilonacept	Treatment of deficiency of interleukin-1 receptor antagonist (DIRA)	Rilonacept		n/a	5/9/17	Designated			N/A	N/A	"Regeneron Pharmaceuticals, Inc."	Tarrytown	New York	10591	USA	EXACT	0264119AA	Rilonacept	8K80YB5GMG						Deficiency of interleukin-1 receptor antagonist	10516		
human interleukin-3 genetically conjugated to diphtheria toxin protein	Treatment of blastic plasmacytoid dendritic cell neoplasm	sl-401		n/a	6/6/13	Designated			N/A	N/A	"Stemline Therapeutics, Inc."	New York	New York	10022	USA	EXACT	1667250AA	sl-401	8ZHS5657EH						Blastic plasmacytoid dendritic cell	10556		
everolimus	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	everolimus		Afinitor	6/8/09	Designated/Approved	Approved for Orphan Indication	Treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical resection	10/29/10	10/29/17	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0218031AA	everolimus	9HW64Q8G6G						Subependymal giant cell astrocytoma	10632		
everolimus	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	everolimus		Afinitor	6/8/09	Designated/Approved	Approved for Orphan Indication	Treatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery.	4/26/12	4/26/19	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0218031AA	everolimus	9HW64Q8G6G						Subependymal giant cell astrocytoma	10632		
Botulinum toxin type B	Treatment of cervical dystonia.	Botulinum toxin type B		Myobloc	1/16/92	Designated/Approved	Approved for Orphan Indication	Treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.	12/8/00	12/8/07	"Soltice Neurosciences, LLC"	Louisville	Kentucky	40207	USA	EXACT	0238619AA	Botulinum toxin type B	0Y70779M1F						Cervical dystonia	10668		
Botulinum toxin type A	Treatment of cervical dystonia.	Botulinum toxin type A		Botox	8/20/86	Designated/Approved	Approved for Orphan Indication	Treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia.	12/21/00	12/21/07	"Allergan, Inc."	Irvine	California	92623	USA	EXACT	0171595AA	Botulinum toxin type A	E211KPY694						Cervical dystonia	10668		
Botulinum toxin type A	Treatment of spasmodic torticollis (cervical dystonia).	Botulinum toxin type A		Dysport	8/12/98	Designated			N/A	N/A	Ipsen Biopharm Limited	"Berkshire, SL6 4UH"			United Kingdom	EXACT	0171595AA	Botulinum toxin type A	E211KPY694						Cervical dystonia	10668		
daxibotulinumtoxinA	Treatment of cervical dystonia	daxibotulinumtoxin A		n/a	11/16/17	Designated			N/A	N/A	"Revance Therapeutics, Inc."	7555 Gateway Boulevard	California	94560	USA	EXACT	1199388AA	daxibotulinumtoxin A	E211KPY694						Cervical dystonia	10668		
Botulinum toxin type F	Treatment of spasmodic torticollis (cervical dystonia).	Botulinum toxin type F		n/a	10/24/91	Designated			N/A	N/A	Ipsen Limited	Milford	Massachusetts	1757	USA	EXACT	0791162AA	Botulinum toxin type F	U1R2P71O7G						Cervical dystonia	10668		
"Ciliary neurotrophic factor, recombinant human"	"Treatment of motor neuron disease (including amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and primary lateral sclerosis)."	"Ciliary neurotrophic factor, recombinant human"		n/a	5/8/92	Designated/Withdrawn			N/A	N/A	Syntex-Synergen Neuroscience	Boulder	Colorado	80301	USA	EXACT	0113784AB	"Ciliary neurotrophic factor, recombinant human"							Primary lateral sclerosis	10684		
cerliponase alfa	Treatment of neuronal ceroid lipofuscinosis type 2	cerliponase alfa		n/a	4/1/13	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA	EXACT	0934667AA	cerliponase alfa	X8R2D92QP1						Neuronal ceroid lipofuscinosis	10739		
N-t-butylhydroxylamine	Treatment of infantile neuronal ceroid lipofuscinosis.	N-t-butylhydroxylamine		n/a	5/12/15	Designated			N/A	N/A	Andrew Lim	Pasadena	California	91125	USA	EXACT	1577135AA	N-t-butylhydroxylamine	BQ5JE2DA91						Neuronal ceroid lipofuscinosis	10739		
adeno-associated viral serotype 2 vector under the regulatory control of a CMV promoter encoding the human tripeptidyl peptidase-1 (hTPP1) cDNA	Treatment of CLN2 disease (neuronal ceroid lipofuscinosis (NCL)) caused by TPP1 deficiency.	adeno-associated viral serotype 2 vector under the regulatory control of a CMV promoter encoding the human tripeptidyl peptidase-1 (hTPP1) cDNA		n/a	3/16/16	Designated			N/A	N/A	"Spark Therapeutics, Inc."	Philadelphia	Pennsylvania	19104	USA	LONGEST CONTAINS	0110845AB	CMV promoter							Neuronal ceroid lipofuscinosis	10739		
"scAAV9.MeCP2.hCLN3, a self-complementary AAV serotype 9 expressing human CLN3 (hCLN3)"	Treatment of neuronal ceroid lipofuscinosis Type 3 (CLN3)	"scAAV9.MeCP2.hCLN3, a self-complementary AAV serotype 9 expressing human CLN3 (hCLN3)"		n/a	6/27/17	Designated			N/A	N/A	Abeona Therapeutics	Cleveland	Ohio	44103	USA										Neuronal ceroid lipofuscinosis	10739		
a self-complementary adeno-associated virus serotype 9 expressing human codon-optimized CLN1 under control of CBh	Treatment of neuronal ceroid lipofuscinosis type 1 (CLN1)	a self-complementary adeno-associated virus serotype 9 expressing human codon-optimized CLN1 under control of CBh		n/a	2/7/18	Designated			N/A	N/A	Abeona Therapeutics	6555 Carnegie Blvd	Cleveland		USA										Neuronal ceroid lipofuscinosis	10739		
"non-replicating, recombinant adeno-associated virus (AAV) serotype 9 (AAV9) vector containing an hCLN2 expression cassette encoding for the soluble lysosomal enzyme tripeptidyl peptidase I (TPP1)"	Treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease.	"non-replicating, recombinant adeno-associated virus (AAV) serotype 9 (AAV9) vector containing an hCLN2 expression cassette encoding for the soluble lysosomal enzyme tripeptidyl peptidase I (TPP1)"		n/a	10/25/18	Designated			N/A	N/A	REGENXBIO Inc. (REGENXBIO)	9600 Medical Center Drive	Maryland	20850	USA										Neuronal ceroid lipofuscinosis	10739		
Bindarit	Treatment of lupus nephritis.	Bindarit		n/a	2/3/98	Designated			N/A	N/A	"Angelini Pharmaceuticals, Inc."	River Edge	New Jersey	7661	USA	EXACT	0176421AA	Bindarit	JQ11LH711M						Lupus nephritis	10747		
Abetimus	Treatment of lupus nephritis.	Abetimus		n/a	7/28/00	Designated			N/A	N/A	La Jolla Pharmaceutical Co.	San Diego	California	92121	USA	EXACT	0766187AA	Abetimus	P3UVQ22SHK						Lupus nephritis	10747		
Monoclonal antibody for immunization against lupus nephritis	Treatment of lupus nephritis.	Monoclonal antibody for immunization against lupus nephritis		n/a	1/7/93	Designated			N/A	N/A	"VivoRx Autoimmune, Inc."	Santa Monica	California	90404	USA										Lupus nephritis	10747		
N-acetyl-DL-leucine	Treatment of Spinocerebellar Ataxia (SCA)	N-acetyl-DL-leucine		n/a	6/6/18	Designated			N/A	N/A	IntraBio Inc.	270 Devon Road		7670	USA	EXACT	0301019AA	N-acetyl-DL-leucine	K76S41V71X						Spinocerebellar ataxia	10748		
2-amino-N-({methyl-[(6-trifluoromethoxy-benzothiazol-2-ylcarbamoyl)-methyl]-carbamoyl}-methyl)-acetamide monohydrochloride	Treatment of spinocerebellar ataxia.	BHV-4157 HYDROCHLORIDE		n/a	5/18/16	Designated			N/A	N/A	"Biohaven Pharmaceuticals, Inc."	New Haven	Connecticut	6510	USA	EXACT	1718554AA	BHV-4157 HYDROCHLORIDE	BQ5F77DZS3						Spinocerebellar ataxia	10748		
stemchymal	Treatment of polyqlutamine spinocerebellar ataxia	stemchymal		n/a	12/16/15	Designated			N/A	N/A	"Steminent Biotherapeutics, Inc."				Taiwan										Spinocerebellar ataxia	10748		
sirolimus	Treatment of pachyonychia congenita	sirolimus		n/a	3/18/13	Designated			N/A	N/A	Palvella Therapeutics LLC	Wayne	Pennsylvania	19087	USA	EXACT	0175177AA	sirolimus	W36ZG6FT64						Pachyonychia congenita	10753		
TD-K6a.513a.12	Treatment of pachyonychia congenita	TD-K6a.513a.12		Reveker	6/15/06	Designated			N/A	N/A	"TransDerm, Inc."	Santa Cruz	California	95060	USA										Pachyonychia congenita	10753		
Teriparatide	Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism.	Teriparatide		Parathar	1/9/87	Designated/Approved	Approved for Orphan Indication		12/23/87	12/23/94	"Rhone-Poulenc Rorer Pharmaceuticals, Inc."	Collegeville	Pennsylvania	19426	USA	EXACT	0249503AA	Teriparatide	10T9CSU89I						Pseudohypoparathyroidism	10758		
factor XIII concentrate (human)	Treatment of congenital factor XIII deficiency	factor XIII concentrate (human)		Corifact	1/16/85	Designated/Approved	Approved for Orphan Indication	For the routine prophylactic treatment of congenital factor XIII deficiency	2/17/11	2/17/18	CSL Behring LLC	King of Prussia	Pennsylvania	19406	USA	EXACT	0360598AA	factor XIII concentrate (human)	F7R0FBC1XD						Factor XIII deficiency	10766		
factor XIII concentrate (human)	Treatment of congenital factor XIII deficiency	factor XIII concentrate (human)		Corifact	1/16/85	Designated/Approved	Approved for Orphan Indication	Peri-operative management of surgical bleeding in adult and pediatric patients with congenital Factor XIII deficiency.	1/24/13	1/24/20	CSL Behring LLC	King of Prussia	Pennsylvania	19406	USA	EXACT	0360598AA	factor XIII concentrate (human)	F7R0FBC1XD						Factor XIII deficiency	10766		
"Factor XIII, recombinant"	Treatment of congenital factor XIII deficiency.	CATRIDECACOG		n/a	4/22/93	Designated/Withdrawn			N/A	N/A	"Zymogenetics, Inc."	Seattle	Washington	98105	USA	EXACT	0679458AA	CATRIDECACOG	NU23Q531G1						Factor XIII deficiency	10766		
coagulation factor XIII A-subunit (recombinant)	Prophylaxis of bleeding associated with congential factor XIII deficiency	Catridecacog		Tretten	11/6/03	Designated/Approved	Approved for Orphan Indication	Routine prophylaxis of bleeding in patients with congenital Factor XIII A-subunit deficiency.	12/23/13	12/23/20	"Novo Nordisk, Inc."	Plainsboro	New Jersey	8536	USA	EXACT	0679458AA	Catridecacog	NU23Q531G1						Factor XIII deficiency	10766		
flunarizine	Treatment of hemiplegic migraine	flunarizine		n/a	7/20/16	Designated			N/A	N/A	"Xenon Pharmaceuticals, Inc."	Burnaby	British Columbia		Canada	EXACT	0330198AA	flunarizine	R7PLA2DM0J						Hemiplegic migraine	10768		
taurine	Treatment of cystathionine beta-synthase deficient homocystinuria	taurine		n/a	3/22/10	Designated			N/A	N/A	"Johan L. Van Hove, MD, PhD"	Aurora	Colorado	80045	USA	EXACT	0017390AA	taurine	1EQV5MLY3D						Homocystinuria	10770		
Betaine	Treatment of homocystinuria.	Betaine		Cystadane	5/16/94	Designated/Approved	Approved for Orphan Indication	Treatment of homocystinuria to decrease elevated homocysteine blood levels.	10/25/96	10/25/03	Jazz Pharmaceuticals	Palo Alto	California	94304	USA	EXACT	0017414AA	Betaine	3SCV180C9W						Homocystinuria	10770		
polyethylene glycol modified recombinant C-terminal truncate of human cystathionine beta-synthase	Treatment of homocystinuria	polyethylene glycol modified recombinant C-terminal truncate of human cystathionine beta-synthase		n/a	3/17/15	Designated			N/A	N/A	Orphan Technologies Limited					LONGEST CONTAINS	0137031AA	polyethylene glycol	3WJQ0SDW1A						Homocystinuria	10770		
adenovirus associated viral vector serotype 8 containing the human AIPL1 gene	"Treatment of inherited retinal dystrophy due to defects in AIPL1 gene, including Leber congenital amaurosis, retinitis pigmentosa, and cone-rod dystrophy"	adenovirus associated viral vector serotype 8 containing the human AIPL1 gene		n/a	2/1/18	Designated			N/A	N/A	MeiraGTx UK II Ltd	92 Britannia Walk	London		United Kingdom										Cone-rod dystrophy	10790		
urea	"Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis)."	urea		n/a	11/7/11	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0009290AA	urea	8W8T17847W						Lamellar ichthyosis	10803		
adeno-associated virus (AAV) serotype rh.10 expressing beta-galactosidase	Treatment of GM1 gangliosidosis	adeno-associated virus (AAV) serotype rh.10 expressing beta-galactosidase		n/a	1/30/17	Designated			N/A	N/A	"Lysogene, Inc."	Cambridge	Massachusetts	2142	USA										GM1 gangliosidosis	10891		
canakinumab	Treatment of cryopyrin-associated periodic syndromes	canakinumab		Ilaris	12/18/07	Designated/Approved	Approved for Orphan Indication	"Treatment of cryopyrin-associated periodic syndromes (CAPS), in adults and children 4 years of age and older."	6/17/09	6/17/16	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0323159AA	canakinumab	37CQ2C7X93						Cryopyrin-associated periodic syndrome	10927		
anakinra	Treatment of cryopyrin-associated periodic syndromes	anakinra		Kineret	8/19/10	Designated/Approved	Approved for Orphan Indication	Treatment of neonatal-onset multisystem inflammatory disease (NOMID)	12/21/12	12/21/19	Swedish Orphan Biovitrum AB (publ)	Stockholm			Sweden	EXACT	0242524AA	anakinra	9013DUQ28K						Cryopyrin-associated periodic syndrome	10927		
"Ciliary neurotrophic factor, recombinant human"	"Treatment of motor neuron disease (including amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and primary lateral sclerosis)."	"Ciliary neurotrophic factor, recombinant human"		n/a	5/8/92	Designated/Withdrawn			N/A	N/A	Syntex-Synergen Neuroscience	Boulder	Colorado	80301	USA	EXACT	0113784AB	"Ciliary neurotrophic factor, recombinant human"							Progressive bulbar palsy	10928		
adalimumab	"Treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis"	adalimumab		Humira	5/13/14	Designated/Approved	Approved for Orphan Indication	"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients"	6/30/16	6/30/23	"AbbVie, Inc."	North Chicago	Illinois	60064	USA	EXACT	0247176AA	adalimumab	FYS6T7F842						Anterior uveitis	10941		
gevokizumab	"Treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis"	gevokizumab		n/a	8/20/12	Designated			N/A	N/A	XOMA (US) LLC	Berkeley	California	94710	USA	EXACT	0574107AA	gevokizumab	QX3JU54GYQ						Anterior uveitis	10941		
difluprednate	Treatment of endogenous and traumatic anterior uveitis and panuveitis.	difluprednate		Durezol	9/30/08	Designated/Approved	Approved for Orphan Indication	Treatment of endogenous anterior uveitis	6/13/12	6/13/19	Alcon Pharmaceuticals. Ltd.				Switzerland	EXACT	0062395AA	difluprednate	S8A06QG2QE						Anterior uveitis	10941		
Somatropin	Treatment of short stature in patients with Noonan syndrome	Somatropin		Norditropin	8/9/06	Designated/Approved	Approved for Orphan Indication	Treatment of short stature in patients with Noonan syndrome	5/31/07	5/31/14	Novo Nordisk Inc.	Princeton	New Jersey	8540	USA	EXACT	0054682AA	Somatropin	NQX9KB6PCL						Noonan syndrome	10955		
ibrutinib	Treatment of chronic Graft versus Host disease.	ibrutinib		n/a	6/23/16	Designated			N/A	N/A	"Pharmacyclics, LLC"	Sunnyvale	California	94085	USA	EXACT	0625092AA	ibrutinib	1X70OSD4VX						Chronic graft versus host disease	10964		
"autologous lymphocytes depleted ex vivo of immunoreactive T cells using 4,5"	Treatment of chronic graft versus host disease	"autologous lymphocytes depleted ex vivo of immunoreactive T cells using 4,5"		Theralux Photodynamic Therapy	4/3/08	Designated			N/A	N/A	"Kiadis Pharma Canada, Inc."				Canada	LONGEST CONTAINS	0263092AA	lymphocytes							Chronic graft versus host disease	10964		
methotrexate oral solution	"Treatment of oligoarticular juvenile idiopathic arthritis (persistent oligoarthritis, psoriatic juvenile idiopathic arthritis, enthesitis-related arthritis, or undifferentiated arthritis) and polyarticular juvenile idiopathic arthritis in children 0 through 16 years of age"	methotrexate oral solution		n/a	8/27/15	Designated			N/A	N/A	"Silvergate Pharmaeuticals, Inc."	Greenwood Village	Colorado	80111	USA	EXACT	0010059AA	methotrexate	YL5FZ2Y5U1						Psoriatic juvenile idiopathic arthritis	10970		
cerliponase alfa	Treatment of neuronal ceroid lipofuscinosis type 2	cerliponase alfa		n/a	4/1/13	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	Novato	California	94949	USA	EXACT	0934667AA	cerliponase alfa	X8R2D92QP1						ceroid lipofuscinosis	10973		
N-t-butylhydroxylamine	Treatment of infantile neuronal ceroid lipofuscinosis.	N-t-butylhydroxylamine		n/a	5/12/15	Designated			N/A	N/A	Andrew Lim	Pasadena	California	91125	USA	EXACT	1577135AA	N-t-butylhydroxylamine	BQ5JE2DA91						ceroid lipofuscinosis	10973		
adeno-associated viral serotype 2 vector under the regulatory control of a CMV promoter encoding the human tripeptidyl peptidase-1 (hTPP1) cDNA	Treatment of CLN2 disease (neuronal ceroid lipofuscinosis (NCL)) caused by TPP1 deficiency.	adeno-associated viral serotype 2 vector under the regulatory control of a CMV promoter encoding the human tripeptidyl peptidase-1 (hTPP1) cDNA		n/a	3/16/16	Designated			N/A	N/A	"Spark Therapeutics, Inc."	Philadelphia	Pennsylvania	19104	USA	LONGEST CONTAINS	0110845AB	CMV promoter							ceroid lipofuscinosis	10973		
"scAAV9.MeCP2.hCLN3, a self-complementary AAV serotype 9 expressing human CLN3 (hCLN3)"	Treatment of neuronal ceroid lipofuscinosis Type 3 (CLN3)	"scAAV9.MeCP2.hCLN3, a self-complementary AAV serotype 9 expressing human CLN3 (hCLN3)"		n/a	6/27/17	Designated			N/A	N/A	Abeona Therapeutics	Cleveland	Ohio	44103	USA										ceroid lipofuscinosis	10973		
a self-complementary adeno-associated virus serotype 9 expressing human codon-optimized CLN1 under control of CBh	Treatment of neuronal ceroid lipofuscinosis type 1 (CLN1)	a self-complementary adeno-associated virus serotype 9 expressing human codon-optimized CLN1 under control of CBh		n/a	2/7/18	Designated			N/A	N/A	Abeona Therapeutics	6555 Carnegie Blvd	Cleveland		USA										ceroid lipofuscinosis	10973		
"non-replicating, recombinant adeno-associated virus (AAV) serotype 9 (AAV9) vector containing an hCLN2 expression cassette encoding for the soluble lysosomal enzyme tripeptidyl peptidase I (TPP1)"	Treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease.	"non-replicating, recombinant adeno-associated virus (AAV) serotype 9 (AAV9) vector containing an hCLN2 expression cassette encoding for the soluble lysosomal enzyme tripeptidyl peptidase I (TPP1)"		n/a	10/25/18	Designated			N/A	N/A	REGENXBIO Inc. (REGENXBIO)	9600 Medical Center Drive	Maryland	20850	USA										ceroid lipofuscinosis	10973		
vatiquinone	Treatment of pontocerebellar hypoplasia	vatiquinone		Vincerinone	10/18/17	Designated			N/A	N/A	BioElectron Technology Corporation	Mountain View	California	94043	USA	EXACT	0739468AA	vatiquinone	6O85FK9I0X						Pontocerebellar hypoplasia	10977		
immune globulin infusion (human)	Treatment of multifocal motor neuropathy	IVIG		Gammagard Liquid	7/20/06	Designated/Approved	Approved for Orphan Indication	Maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN).	6/22/12	6/22/19	"Baxalta US, Inc."	Westlake Village	California	91362	USA	EXACT	0201570AA	IVIG	66Y330CJHS						Multifocal motor neuropathy	11011		
deferiprone	Treatment of neurodegeneration with brain iron accumulation (NBIA)	deferiprone		n/a	6/15/17	Designated			N/A	N/A	"ApoPharma, Inc."				Canada	EXACT	0179680AA	deferiprone	2BTY8KH53L						Neurodegeneration with brain iron accumulation	11899		
amifampridine phosphate	Treatment of congenital myasthenic syndromes	amifampridine phosphate		n/a	3/3/15	Designated			N/A	N/A	Catalyst Pharmaceuticals	Coral Gables	Florida	33134	USA	EXACT	0736254AA	amifampridine phosphate	8HF8FIN815						Congenital myasthenic syndrome	11902		
"3,4-diaminopyridine"	Treatment of congenital myasthenic syndrome (CMS)	"3,4-diaminopyridine"		n/a	3/30/17	Designated			N/A	N/A	"Jacobus Pharmaceutical Co., Inc."	Princeton	New Jersey	8540	USA	EXACT	0144445AA	"3,4-diaminopyridine"	RU4S6E2G0J						Congenital myasthenic syndrome	11902		
"non-replicating adeno-associated viral vector, serotype 8, expressing human myotubularin gene"	Treatment of x-linked myotubular myopathy	"non-replicating adeno-associated viral vector, serotype 8, expressing human myotubularin gene"		At001	12/3/14	Designated			N/A	N/A	"Audentes Therapeutics, Inc."	San Francisco	California	94104	USA										X-linked myotubular myopathy	11925		
brentuximab vedotin	Treatment of patients with angioimmunoblastic T-cell lymphoma	brentuximab vedotin		Adcetris	9/13/13	Designated			N/A	N/A	"Seattle Genetics, Inc."	Bothell	Washington	98021	USA	EXACT	0297767AA	brentuximab vedotin	7XL5ISS668						Angioimmunoblastic T-cell lymphoma	11973		
Vancomycin HCL and Tobramycin sulfate multi-pack component of the Joint Purification Systems X7 Spacer	Treatment of periprosthetic joint infection	Vancomycin HCL		n/a	1/9/17	Designated			N/A	N/A	Joint Purification Systems LLC	Solana Beach	California	92075	USA	EXACT	0036191AA	Vancomycin HCL	71WO621TJD						Prosthetic joint infection	11977		
Vancomycin HCL and Tobramycin sulfate multi-pack component of the Joint Purification Systems X7 Spacer	Treatment of periprosthetic joint infection	Vancomycin HCL and Tobramycin sulfate multi-pack component of the Joint Purification Systems X7 Spacer		n/a	1/9/17	Designated			N/A	N/A	Joint Purification Systems LLC	Solana Beach	California	92075	USA	EXACT	0114261AA	Tobramycin sulfate	HJT0RXD7JK						Prosthetic joint infection	11977		
sodium fusidate	Treatment of patients with prosthetic joint infections	sodium fusidate		n/a	10/23/13	Designated			N/A	N/A	"Cempra Pharmaceuticals, Inc."	Chapel Hill	North Carolina	27517	USA	EXACT	0035847AA	sodium fusidate	J7P3696BCQ						Prosthetic joint infection	11977		
recombinant human minibody against complement component C5	Treatment of primary membranoproliferative glomerulonephritis	recombinant human minibody against complement component C5		Mubodina	2/4/09	Designated			N/A	N/A	Adienne S.A.				Switzerland										Membranoproliferative glomerulonephritis	11982		
vandetanib	"Treatment of patients with follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, and locally advanced and metastatic papillary thyroid carcinoma"	vandetanib		Caprelsa(R)	10/21/05	Designated/Approved	Approved for Orphan Indication	Treatment of asymptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease	4/6/11	4/6/18	Genzyme Corporation	Cambridge	Massachusetts	2142	USA	EXACT	0235789AA	vandetanib	YO460OQ37K						Papillary thyroid carcinoma	12027		
sebelipase alfa	Treatment of lysosomal acid lipase deficiency	sebelipase alfa		Kanuma	7/1/10	Designated/Approved	Approved for Orphan Indication	Indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency	12/8/15	12/8/22	Alexion Pharmaceuticals	New Haven	Connecticut	6510	USA	EXACT	0755544AA	sebelipase alfa	K4YTU42T8G						Lysosomal acid lipase deficiency	12097		
Recombinant human lysosomal acid lipase or cholesteryl ester hydrolase	"Treatment of lipase deficiencies, including Wolman Disease and cholesteryl ester storage disease"	sebelipase alfa		Cholestrase	7/14/05	Designated			N/A	N/A	"Lysosomal Acid Lipase, LLC"	Owensboro	Kentucky	42301	USA	EXACT	0755544AA	sebelipase alfa	K4YTU42T8G						Cholesteryl ester storage disease	12099		
dusquetide	Treatment of macrophage activation syndrome	dusquetide		n/a	8/10/16	Designated			N/A	N/A	"Soligenix, Inc."	Princeton	New Jersey	8540	USA	EXACT	1116116AA	dusquetide	IKX7W49NLN						Macrophage activation syndrome	12124		
heterodimeric fusion protein that binds to IL-1 beta consisting of human extracellular domain of IL1 receptor and a mutant Fc fragment of human IgG1 and part of human IL1 receptor accessory protein	Treatment of Schnitzler Syndrome	heterodimeric fusion protein that binds to IL-1 beta consisting of human extracellular domain of IL1 receptor and a mutant Fc fragment of human IgG1 and part of human IL1 receptor accessory protein		n/a	10/15/18	Designated			N/A	N/A	R-Pharm Overseas	505 Cost Boulevard South	California	92037	USA	LONGEST CONTAINS	0087274AA	protein							Schnitzler syndrome	12390		
pirfenidone	Treatment of systemic sclerosis (including the associated interstitial lung disease)	pirfenidone		n/a	11/19/13	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0065996AA	pirfenidone	D7NLD2JX7U						Systemic sclerosis 	12427		
nintedanib	Treatment of systemic sclerosis (including the associated interstitial lung disease).	nintedanib		n/a	7/6/16	Designated			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc."	Ridgefield	Connecticut	6877	USA	EXACT	0359900AA	nintedanib	G6HRD2P839						Systemic sclerosis 	12427		
"(RS)-baclofen, naltrexone and D-sorbitol"	Treatment of Charcot-Marie-Tooth disease type 1A	 D-sorbitol		n/a	3/17/14	Designated			N/A	N/A	Pharnext SA				France	EXACT	0007614AA	D-sorbitol	506T60A25R						Charcot-Marie-Tooth disease type 1	12433		
"(RS)-baclofen, naltrexone and D-sorbitol"	Treatment of Charcot-Marie-Tooth disease type 1A	"(RS)-baclofen, naltrexone and D-sorbitol"		n/a	3/17/14	Designated			N/A	N/A	Pharnext SA				France	exact	0057249AA	naltrexone	5S6W795CQM						Charcot-Marie-Tooth disease type 1	12433		
"(RS)-baclofen, naltrexone and D-sorbitol"	Treatment of Charcot-Marie-Tooth disease type 1A	BACLOFEN		n/a	3/17/14	Designated			N/A	N/A	Pharnext SA				France	EXACT	0032804AA	BACLOFEN	H789N3FKE8						Charcot-Marie-Tooth disease type 1	12433		
ascorbic acid	Treatment of Charcot-Marie-Tooth disease type 1A.	ascorbic acid		n/a	5/11/09	Designated			N/A	N/A	Murigenetics SAS				France	EXACT	0007658AA	ascorbic acid	PQ6CK8PD0R						Charcot-Marie-Tooth disease type 1	12433		
N-acetyl-DL-leucine	Treatment of GM2 Gangliosidosis	N-acetyl-DL-leucine		n/a	3/26/18	Designated			N/A	N/A	IntraBio Inc.	270 Devon Road		7670	USA	EXACT	0301019AA	N-acetyl-DL-leucine	K76S41V71X						Gangliosidosis	12510		
adeno-associated virus (AAV) serotype rh.10 expressing beta-galactosidase	Treatment of GM1 gangliosidosis	adeno-associated virus (AAV) serotype rh.10 expressing beta-galactosidase		n/a	1/30/17	Designated			N/A	N/A	"Lysogene, Inc."	Cambridge	Massachusetts	2142	USA										Gangliosidosis	12510		
Recombinant adeno-associated virus serotype 2/1 vector encoding human beta-hexosaminidase alpha & beta subunits (rAAV2/1 Hex alpha & beta)	Treatment of GM2 gangliosidosis (Tay-Sachs & Sandhoff diseases)	Recombinant adeno-associated virus serotype 2/1 vector encoding human beta-hexosaminidase alpha & beta subunits (rAAV2/1 Hex alpha & beta)		n/a	11/14/17	Designated			N/A	N/A	University of Cambridge	Hills Road			United Kingdom										Gangliosidosis	12510		
urea	"Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis)."	urea		n/a	11/7/11	Designated			N/A	N/A	"Orenova Group, LLC"	White Plains	New York	10604	USA	EXACT	0009290AA	urea	8W8T17847W						Lipid storage disease	12511		
Recombinant human insulin-like growth factor 1	Treatment of antibody-mediated growth hormone resistance in patients with isolated growth hormone deficiency Ia.	mecasermin		Igf-1	6/7/95	Designated/Withdrawn			N/A	N/A	Pharmacia & Upjohn	Kalamazoo	Michigan	49001	USA	EXACT	0167215AA	mecasermin	7GR9I2683O						Isolated growth hormone deficiency	12556		
adult adherent bone marrow-derived multipotent stem cells	"Treatment of MPS-1, including Hurler syndrome"	adult adherent bone marrow-derived multipotent stem cells		Multistem	7/6/12	Designated			N/A	N/A	"Athersys, Inc."	Cleveland	Ohio	44115	USA	LONGEST CONTAINS	0100072AA	bone marrow							Hurler syndrome	12559		
lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase	Treatment of mucopolysaccharidosis Type IVA (Morquio Syndrome)	lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase		n/a	9/10/08	Designated			N/A	N/A	Vivendy Therapeutics LTD				Switzerland	LONGEST CONTAINS	0319062AA	sulfate	7IS9N8KPMG						Mucopolysaccharidosis type IV	12562		
"9-cis,12-cis-11,11-D2-linoleic acid ethyl ester"	Treatment of PLA2G6-associated neurodegeneration	"9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER"		n/a	10/24/17	Designated			N/A	N/A	"Retrotope, Inc."	Los Altos	California	94022	USA	EXACT	1149173AA	"9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER"	24B102R86P						PLA2G6-associated neurodegeneration	12567		
miltefosine	Treatment of granulomatous amebic encephalitis (GAE)	miltefosine		Impavido	6/19/17	Designated			N/A	N/A	"Profounda, Inc."	Orlando	Florida	32822	USA	EXACT	0273734AA	miltefosine	53EY29W7EC						Granulomatous Amebic Encephalitis	12651		
miltefosine	Treatment of granulomatous amebic encephalitis (GAE)	miltefosine		Impavido	6/19/17	Designated			N/A	N/A	"Profounda, Inc."	Orlando	Florida	32822	USA	EXACT	0273734AA	miltefosine	53EY29W7EC						Granulomatous amebic encephal	12651		
Dynamine	Treatment of hereditary motor and sensory neuropathy type I (Charcot-Marie-Tooth disease).	Dynamine		n/a	10/16/91	Designated			N/A	N/A	Mayo Foundation	Rochester	Minnesota	55905	USA	EXACT	0144445AA	Dynamine	RU4S6E2G0J						Hereditary motor and sensory neuropathy	12685		
recombinant human antithrombin	"Treatment of congenital antithrombin deficiency to prevent the occurrence of serious, potentially life-threatening venous thromboembolisms which may develop as a result of surgical or obstetrical procedures"	Atryn		Atryn	12/7/07	Designated/Approved	Approved for Orphan Indication	"Prevention of peri-operative and peri-partum thromboembolic events, in hereditary antithrombin deficient patients."	2/6/09	2/6/16	"GTC Biotherapeutics, Inc."	Framingham	Massachusetts	1702	USA	EXACT	0310463AA	Atryn	AWV6I5L6H2						Antithrombin deficiency	12690		
recombinant human platelet derived growth factor-BB	Treatment of osteochondritis dissecans	REGRANEX		n/a	8/6/10	Designated/Withdrawn			N/A	N/A	"Biomimetic Therapeutics, Inc."	Franklin	Tennessee	37067	USA	EXACT	0226755AA	REGRANEX	1B56C968OA						Osteochondritis dissecans	12703		
tamibarotene	Treatment of acute myeloid leukemia (AML)	tamibarotene		n/a	8/16/17	Designated			N/A	N/A	"Syros Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0288891AA	tamibarotene	08V52GZ3H9						Acute myeloid leukemia 	12757		
CD123 x CD3 dual affinity re-targeting (DART®) protein	Treatment of acute myeloid leukemia (AML)	MGd-006		n/a	12/22/16	Designated			N/A	N/A	"MacroGenics, Inc."	Rockville	Maryland	20850	USA	EXACT	0914705AA	MGd-006	0AHT0IC02G						Acute myeloid leukemia 	12757		
E-selectin antagonist	Treatment of acute myeloid leukemia (AML)	gmi-1271		n/a	5/13/15	Designated			N/A	N/A	"GlycoMimetics, Inc."	Gaithersburg	Maryland	20879	USA	EXACT	0933040AA	gmi-1271	17ZJN0Q4CJ						Acute myeloid leukemia 	12757		
"N-[(2S)-5-{[(2S)-2-(4-fluorophenyl)cyclopropyl]amino}-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide bis-tosylate salt"	Treatment of acute myeloid leukemia (AML)	IMG-7289 DITOSYLATE		n/a	2/7/17	Designated			N/A	N/A	"Imago BioSciences, Inc."	San Carlos	California	94070	USA	EXACT	1801123AA	IMG-7289 DITOSYLATE	2PYF2U9JNF						Acute myeloid leukemia 	12757		
Gilteritinib	Treatment of acute myeloid leukemia (AML)	Gilteritinib		n/a	7/13/17	Designated			N/A	N/A	"Astellas Pharma US, Inc."	Northbrook	Illinois	60062	USA	EXACT	0911762AA	Gilteritinib	66D92MGC8M						Acute myeloid leukemia 	12757		
"N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino] isonicotinamide hydrochloride"	Treatment of acute myeloid leukemia (AML).	PIMASERTIB HYDROCHLORIDE		n/a	1/12/11	Designated			N/A	N/A	"EMD Serono, Inc."	Rockland	Massachusetts	2370	USA	EXACT	0736890AA	PIMASERTIB HYDROCHLORIDE	6GS1ULF5HV						Acute myeloid leukemia 	12757		
"6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one monocitrate"	Treatment of acute myeloid leukemia (AML)	TAK-659		n/a	10/3/17	Designated			N/A	N/A	"Millennium Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	0893072AA	TAK-659	6ZJ8V3Q0H1						Acute myeloid leukemia 	12757		
"(2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl]oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate"	Treatment of acute myeloid leukemia (AML)	H3B-8800		n/a	6/21/17	Designated			N/A	N/A	"H3 Biomedicine Inc. (US Research Subsidiary of Eisai Co., Ltd.)"	Cambridge	Massachusetts	2139	USA	EXACT	1297763AA	H3B-8800	90YLS47BRX						Acute myeloid leukemia 	12757		
Glasdegib	Treatment of acute myeloid leukemia (AML)	Glasdegib		n/a	6/28/17	Designated			N/A	N/A	"Pfizer, Inc."	Groton	Connecticut	6340	USA	EXACT	0705259AA	Glasdegib	K673DMO5H9						Acute myeloid leukemia 	12757		
isocitrate dehydrogenase 1 (IDH1)-mutant inhibitor	Treatment of acute myeloid leukemia (AML)	Ivosidenib		n/a	6/9/15	Designated			N/A	N/A	"Agios Pharmaceuticals, Inc."	Cambridge	Massachusetts	2139	USA	EXACT	1143879AA	Ivosidenib	Q2PCN8MAM6						Acute myeloid leukemia 	12757		
elacytarabine	Treatment of acute myeloid leukemia (AML)	elacytarabine		n/a	6/18/08	Designated			N/A	N/A	Clavis Pharma ASA				Norway	EXACT	0256451AA	elacytarabine	TA7WJG93AR						Acute myeloid leukemia 	12757		
tetravalent tandem diabody binding both CD3 and CD33	Treatment of patients with acute myeloid leukemia (AML)	AMV-564		n/a	8/17/17	Designated			N/A	N/A	"Amphivena Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	0114018AB	AMV-564	56FUB33G5M						Acute myeloid leukemia 	12757		
"1-{3-fluoro-4-[7-(5-methyl-lH-imidazol-2-yl)- 1-oxo-2,3-dihydro-lH-isoindo 1-4-yl]-phenyl}-3-(3-trifluoromethyl-phenyl)-urea"	Treatment of acute myeloid leukemia (AML)	CG-026806		n/a	12/22/17	Designated			N/A	N/A	"Aptose Biosciences, Inc."	12770 High Bluff Drive	San Diego	92130	USA	EXACT	0114040AB	CG-026806	7W3FGR71NN						Acute myeloid leukemia 	12757		
131I-BC8 monoclonal antibody (Anti-CD45 murine monoclonal antibody radiolabeled with 131I	Treatment of Acute Myeloid Leukemia (AML)	bc-8 i-131		n/a	3/28/16	Designated			N/A	N/A	"Actinium Pharmaceuticals, Inc."	Edison	New Jersey	8837	USA										Acute myeloid leukemia 	12757		
Angiotensin (1-7)	Treatment of recessive dystrophic epidermolysis bullosa (RDEB).	Angiotensin (1-7)		n/a	9/1/16	Designated			N/A	N/A	"Tarix Orphan, LLC"	Cambridge	Massachusetts	2138	USA	EXACT	0232428AA	Angiotensin 1-7	IJ3FUK8MOF						Recessive dystrophic epidermolysis bullosa 	12795		
humanized monoclonal IgG1 antibody (mAb) against human interleukin (IL)36R	Treatment of generalized pustular psoriasis	humanized monoclonal IgG1 antibody (mAb) against human interleukin (IL)36R		n/a	10/3/18	Designated			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc. (BI)"	900 Ridgebury Road	Connecticut	6877	USA										Pustular psoriasis	12813		
humanized monoclonal IgG1 antibody (mAb) against human interleukin (IL)36R	Treatment of generalized pustular psoriasis	humanized monoclonal IgG1 antibody (mAb) against human interleukin (IL)36R		n/a	10/3/18	Designated			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc. (BI)"	900 Ridgebury Road	Connecticut	6877	USA										Generalized pustular psoriasis	12819		
Hydralazine	Treatment of severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure greater than or equal to 160) associated with severe preeclampsia/eclampsia of pregnancy	Hydralazine		n/a	4/9/04	Designated			N/A	N/A	Bioniche Pharma USA LLC	Lake Forest	Illinois	60045	USA	EXACT	0014857AA	Hydralazine	26NAK24LS8						Preeclampsia	12924		
S-nitrosoglutathione	Treatment of severe preeclampsia	S-nitrosoglutathione		n/a	12/28/12	Designated			N/A	N/A	Salupont Consulting Ltd	Bedfordshire SG19 2DD			United Kingdom	EXACT	0231890AA	S-nitrosoglutathione	78RRI89ZTO						Preeclampsia	12924		
digoxin immune fab (ovine)	Treatment of severe preeclampsia and eclampsia	digoxin immune fab (ovine)		n/a	2/3/12	Designated			N/A	N/A	"Velo Bio, LLC"	Morrisville	North Carolina	27560	USA	EXACT	0324629AA	digoxin immune fab (ovine)	YB12NQZ1YN						Preeclampsia	12924		
Recombinant human placental growth factor	Treatment of severe preeclampsia	RECOMBINANT HUMAN PLACENTAL GROWTH FACTOR (PLGF-131)		n/a	3/16/17	Designated			N/A	N/A	"Aggamin, LLC"	New York	New York	10032	USA	EXACT	0110873AB	RECOMBINANT HUMAN PLACENTAL GROWTH FACTOR (PLGF-131)	NOV5VI05MF						Preeclampsia	12924		
allogeneic ex-vivo expanded placental adherent stromal cells	For the treatment of severe preeclampsia	allogeneic ex-vivo expanded placental adherent stromal cells		n/a	12/29/15	Designated			N/A	N/A	"Pluristem Therapeutics, Inc"	Haifa			Israel										Preeclampsia	12924		
Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B)	Treatment of glioblastoma multiforme and anaplastic astrocytoma.	IODINE I-131 DERLOTUXIMAB BIOTIN		131ichtnt-1	2/12/99	Designated			N/A	N/A	"Peregrine Pharmaceuticals, Inc."	Tustin	California	92780	USA	EXACT	1114289AA	IODINE I-131 DERLOTUXIMAB BIOTIN	1724UJB90B						Astrocytoma	12928		
everolimus	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	everolimus		Afinitor	6/8/09	Designated/Approved	Approved for Orphan Indication	Treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical resection	10/29/10	10/29/17	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0218031AA	everolimus	9HW64Q8G6G						Astrocytoma	12928		
everolimus	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	everolimus		Afinitor	6/8/09	Designated/Approved	Approved for Orphan Indication	Treatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery.	4/26/12	4/26/19	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0218031AA	everolimus	9HW64Q8G6G						Astrocytoma	12928		
KIT and PDGFR inhibitor	Treatment of glioblastoma multiforme and anaplastic astrocytomas	DCC-2618		n/a	8/7/17	Designated			N/A	N/A	"Deciphera Pharmaceuticals, LLC"	Waltham	Massachusetts	2451	USA	EXACT	1177113AA	DCC-2618	9XW757O13D						Astrocytoma	12928		
Diaziquone	Treatment of primary brain malignancies (grade III and IV astrocytomas).	Diaziquone		n/a	11/10/83	Designated/Withdrawn			N/A	N/A	Warner-Lambert Company	Ann Arbor	Michigan	48106	USA	EXACT	0094473AA	Diaziquone	FQL5EUP13W						Astrocytoma	12928		
IL-4 Pseudomonas Toxin Fusion Protein (IL-4(38-37)-PE38KDEL)	Treatment of astrocytic glioma.	IL-4 Pseudomonas Toxin Fusion Protein (IL-4(38-37)-PE38KDEL)		n/a	4/6/00	Designated			N/A	N/A	"Medicenna Therapeutics, Inc."				Canada	LONGEST CONTAINS	0087274AA	Protein							Astrocytic glioma	12928		
Secalciferol	Treatment of familial hypophosphatemic rickets.	Secalciferol		Osteo-D	7/26/93	Designated			N/A	N/A	Teva Pharmaceuticals USA	North Wales	Pennsylvania	19454	USA	EXACT	0066342AA	Secalciferol	460029IUDA						Hypophosphatemic	12942		
extracellular domain of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 fused to the Fc region of human IgG1	Treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency (generalized arterial calcification of infancy and autosomal recessive hypophosphatemic rickets type 2)	extracellular domain of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 fused to the Fc region of human IgG1		n/a	6/11/18	Designated			N/A	N/A	Inozyme Pharma Inc.	700 Technology Square		2139	USA										Hypophosphatemic	12942		
recombinant human IgG1 monoclonal antibody	Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets)	KRN-23		n/a	12/14/09	Designated			N/A	N/A	"Ultragenyx Pharmaceutical, Inc."	Novato	California	94949	USA	EXACT	1257621AA	KRN-23	G9WJT6RD29						X-linked hypophosphatemia	12943		
defibrotide	For the treatment of hepatic veno-occlusive disease	defibrotide		Defitelio	5/21/03	Designated/Approved	Approved for Orphan Indication	"For the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT)."	3/30/16	3/30/23	"Jazz Pharmaceuticals, Inc."	Palo Alto	California	94304	USA	EXACT	0645487AA	defibrotide	L7CHH2B2J0						Hepatic veno-occlusive disease	13004		
defibrotide	For the prevention of hepatic veno-occlusive disease.	defibrotide		n/a	1/8/07	Designated			N/A	N/A	"Jazz Pharmaceuticals, Inc."	Palo Alto	California	94304	USA	EXACT	0645487AA	defibrotide	L7CHH2B2J0						Hepatic veno-occlusive disease	13004		
[Lu-177]-DOTA-Tyr3-Octreotate	Treatment of gastro-entero-pancreatic neuroendocrine tumors	DOTATATE LUTENIUM LU-177		n/a	1/12/09	Designated			N/A	N/A	Advanced Accelerator Applications				France	EXACT	0807501AA	DOTATATE LUTENIUM LU-177	AE221IM3BB						Pancreatic neuroendocrine tumor	13034		
lutetium (177Lu)-edotreotide	Treatment of gastro-entero-pancreatic neuroendocrine tumors	EDOTREOTIDE LUTETIUM LU-177		n/a	5/21/15	Designated			N/A	N/A	ITG Isotope Technologies Garching GmbH				Germany	EXACT	1575548AA	EDOTREOTIDE LUTETIUM LU-177	RGO812Q0C8						Pancreatic neuroendocrine tumor	13034		
"68Ga-OPS202, small somatostatin analog labeled with 68Gallium"	Management of gastroenteropancreatic neuroendocrine tumors.	SATOREOTIDE TRIZOXETAN GALLIUM GA-68		n/a	9/24/14	Designated			N/A	N/A	"Ipsen Biosciences, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0113078AB	SATOREOTIDE TRIZOXETAN GALLIUM GA-68	ZP2ODR0UR3						Pancreatic neuroendocrine tumor	13034		
deuterated S-lisofylline	Treatment of Necrobiosis Lipoidica	CTP-499		n/a	6/18/18	Designated			N/A	N/A	Processa Pharmaceuticals Inc	7380 Coca Cola Drive	Maryland	21076	USA	EXACT	0864799AA	CTP-499	FLV771E8ZV						Necrobiosis lipoidica	13040		
denosumab	Treatment of patients with giant cell tumor of bone	denosumab		Xgeva	12/20/10	Designated/Approved	Approved for Orphan Indication	Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.	6/13/13	6/13/20	"Amgen, Inc."	Thousand Oaks	California	91320	USA	EXACT	0297949AA	denosumab	4EQZ6YO2HI						Giant cell tumor of bone	13046		
brentuximab vedotin	Treatment of adult T-cell leukemia/lymphoma	brentuximab vedotin		n/a	5/23/16	Designated			N/A	N/A	"Seattle Genetics, Inc."	Bothell	Washington	98021	USA	EXACT	0297767AA	brentuximab vedotin	7XL5ISS668						Adult T-cell leukemia/lymphoma	13103		
mogamulizumab	Treatment of adult T-cell leukemia/lymphoma (ATLL).	mogamulizumab		n/a	7/14/11	Designated			N/A	N/A	"Kyowa Kirin Pharmaceutical Development, Inc."	Princeton	New Jersey	8540	USA	EXACT	0574594AA	mogamulizumab	YI437801BE						Adult T-cell leukemia/lymphoma	13103		
riociguat	Treatment of chronic thromboembolic pulmonary hypertension	riociguat		Adempas	9/19/13	Designated/Approved	Approved for Orphan Indication	"Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) WHO Group 4, after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class"	10/8/13	10/8/20	"Bayer HealthCare Pharmaceuticals, Inc."	Whippany	New Jersey	7981	USA	EXACT	0457852AA	riociguat	RU3FE2Y4XI						Chronic thromboembolic pulmonary hypertension	13124		
Neutrophil-endothelial interaction inhibitor	Treatment of post-ischemic pulmonary reperfusion edema following surgical treatment for chronic thromboembolic pulmonary hypertension.	CYLEXIN		Cylexin	12/22/93	Designated			N/A	N/A	Cytel Corporation	San Diego	California	92121	USA	EXACT	0184930AA	CYLEXIN	WLZ3BA9R26						Chronic thromboembolic pulmonary hypertension	13124		
macitentan	Treatment of chronic thromboembolic pulmonary hypertension (CTEPH)	macitentan		n/a	6/15/17	Designated			N/A	N/A	"Actelion Clinical Research, Inc."	Cherry Hill	New Jersey	8002	USA	EXACT	0339333AA	macitentan	Z9K9Y9WMVL						Chronic thromboembolic pulmonary hypertension	13124		
selexipag	Treatment of Chronic Thromboembolic Pulmonary Hypertension	selexipag		Uptravi	10/2/18	Designated			N/A	N/A	"Actelion Pharmaceuticals, Ltd."	Gewerbestrasse 16			Switzerland	EXACT	0362083AA	selexipag	5EXC0E384L						Chronic thromboembolic pulmonary hypertension	13124		
riociguat	Treatment of chronic thromboembolic pulmonary hypertension	riociguat		Adempas	9/19/13	Designated/Approved	Approved for Orphan Indication	"Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) WHO Group 4, after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class"	10/8/13	10/8/20	"Bayer HealthCare Pharmaceuticals, Inc."	Whippany	New Jersey	7981	USA	EXACT	0457852AA	riociguat	RU3FE2Y4XI						Thromboembolic pulmonary hypertension	13124		
Neutrophil-endothelial interaction inhibitor	Treatment of post-ischemic pulmonary reperfusion edema following surgical treatment for chronic thromboembolic pulmonary hypertension.	CYLEXIN		Cylexin	12/22/93	Designated			N/A	N/A	Cytel Corporation	San Diego	California	92121	USA	EXACT	0184930AA	CYLEXIN	WLZ3BA9R26						Thromboembolic pulmonary hypertension	13124		
macitentan	Treatment of chronic thromboembolic pulmonary hypertension (CTEPH)	macitentan		n/a	6/15/17	Designated			N/A	N/A	"Actelion Clinical Research, Inc."	Cherry Hill	New Jersey	8002	USA	EXACT	0339333AA	macitentan	Z9K9Y9WMVL						Thromboembolic pulmonary hypertension	13124		
selexipag	Treatment of Chronic Thromboembolic Pulmonary Hypertension	selexipag		Uptravi	10/2/18	Designated			N/A	N/A	"Actelion Pharmaceuticals, Ltd."	Gewerbestrasse 16			Switzerland	EXACT	0362083AA	selexipag	5EXC0E384L						Thromboembolic pulmonary hypertension	13124		
Recombinant human interleukin-12	Treatment of renal cell carcinoma.	Recombinant human interleukin-12		n/a	10/20/97	Designated			N/A	N/A	"Genetics Institute, Inc."	Cambridge	Massachusetts	2140	USA	EXACT	0343975AA	Recombinant human interleukin-12	02FXP10O2U						Renal cell carcinoma	13215		
Interferon gamma-1b	Treatment of renal cell carcinoma.	Interferon gamma-1b		Actimmune	12/4/95	Designated			N/A	N/A	Horizon Pharma Ireland Limited	Dublin 4			Ireland	EXACT	0174812AA	Interferon gamma-1b	21K6M2I7AG						Renal cell carcinoma	13215		
bevacizumab	Treatment of renal cell carcinoma	bevacizumab		Avastin	11/6/03	Designated/Approved	Approved for Orphan Indication	Treatment of renal cell carcinoma in combination with interferon alfa	7/31/09	7/31/16	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0244257AA	bevacizumab	2S9ZZM9Q9V						Renal cell carcinoma	13215		
Interferon alfa-2b (recombinant)	Treatment of metastatic renal cell carcinoma.	Interferon alfa-2b (recombinant)		Intron A	6/22/87	Designated/Withdrawn			N/A	N/A	Schering Corporation	Kenilworth	New Jersey	7033	USA	EXACT	0160601AA	Interferon alfa-2b (recombinant)	43K1W2T1M6						Renal cell carcinoma	13215		
Interferon alfa-2a (recombinant)	Treatment of renal cell carcinoma.	Interferon alfa-2a (recombinant)		Roferon-A	4/18/88	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	Nutley	New Jersey	7110	USA	EXACT	0158269AA	Interferon alfa-2a (recombinant)	47RRR83SK7						Renal cell carcinoma	13215		
Interferon alfa-2a (recombinant)	For the concomitant administration with Teceleukin for the treatment of metastatic renal cell carcinoma.	Interferon alfa-2a (recombinant)		Roferon-A	5/2/90	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	Nutley	New Jersey	7119	USA	EXACT	0158269AA	Interferon alfa-2a (recombinant)	47RRR83SK7						Renal cell carcinoma	13215		
20-mer oligonucleotide complementary to Akt mRNA	Treatment of renal cell carcinoma	ARCHEXIN		n/a	12/1/04	Designated			N/A	N/A	Rexahn Corporation	Rockville	Maryland	20850	USA	EXACT	0252631AA	ARCHEXIN	4TEW51C830						Renal cell carcinoma	13215		
Chimeric (human-murine) G250 IgG monoclonal antibody	Treatment of renal cell carcinoma.	girentuximab		n/a	7/24/00	Designated/Withdrawn			N/A	N/A	Wilex Biotechnology GmbH				Germany	EXACT	0432917AA	girentuximab	539B57DFJF						Renal cell carcinoma	13215		
Girentuximab	Treatment of renal cell carcinoma.	Girentuximab		Rencarex	3/22/01	Designated			N/A	N/A	Wilex Biotechnology GmbH				Germany	EXACT	0432917AA	Girentuximab	539B57DFJF						Renal cell carcinoma	13215		
antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA]	Treatment for renal cell carcinoma	Gti-2040		Gti-2040	3/12/03	Designated			N/A	N/A	"Lorus Therapeutics, Inc"				Canada	EXACT	0234639AA	Gti-2040	5WY0FWR2CF						Renal cell carcinoma	13215		
Temsirolimus	Treatment of renal cell carcinoma	Temsirolimus		Torisel	12/16/04	Designated/Approved	Approved for Orphan Indication	Treatment of advanced renal cell carcinoma	5/30/07	5/30/14	"Wyeth Pharmaceuticals, Inc."	Philadelphia	Pennsylvania	19101	USA	EXACT	0228922AA	Temsirolimus	624KN6GM2T						Renal cell carcinoma	13215		
irofulven	Treatment of renal cell carcinoma.	irofulven		n/a	7/27/99	Designated/Withdrawn			N/A	N/A	"Eisai, Inc."	Woodcliff Lake	New Jersey	7677	USA	EXACT	0209234AA	irofulven	6B799IH05A						Renal cell carcinoma	13215		
talactoferrin alfa	Treatment of renal cell carcinoma	talactoferrin alfa		n/a	9/29/06	Designated/Withdrawn			N/A	N/A	"Agennix, Inc."	Houston	Texas	77046	USA	EXACT	0314363AA	talactoferrin alfa	7A055A9QRR						Renal cell carcinoma	13215		
Solasonine and solamargine	Treatment of renal cell carcinoma	Solasonine and solamargine		Coramsine	11/2/05	Designated			N/A	N/A	Solbec Pharmaceuticals Limited				Australia	EXACT	0791219AA	solamargine	8KG991E7BN						Renal cell carcinoma	13215		
Poly I: poly C12U	Treatment of renal cell carcinoma.	ampligen		Ampligen	5/20/91	Designated			N/A	N/A	"Hemispherx Biopharma, Inc."	Philadelphia	Pennsylvania	19103	USA	EXACT	0182025AA	ampligen	94325AJ25N						Renal cell carcinoma	13215		
Sorafenib	Treatment of renal cell carcinoma.	Sorafenib		Nexavar	10/8/04	Designated/Approved	Approved for Orphan Indication	Treatment of patients with advanced renal cell carcinoma	12/20/05	12/20/12	Bayer Pharmaceutical Corporation	West Haven	Connecticut	6516	USA	EXACT	0258582AA	Sorafenib	9ZOQ3TZI87						Renal cell carcinoma	13215		
Coumarin	Treatment of renal cell carcinoma.	Coumarin		Onkolox	12/22/94	Designated			N/A	N/A	Drossapharm LTD				Switzerland	EXACT	0015463AA	Coumarin	A4VZ22K1WT						Renal cell carcinoma	13215		
antiangiogenic components extracted from marine cartilage	Treatment of renal cell carcinoma	Ae-941		Neovastat (Ae-941)	10/16/02	Designated			N/A	N/A	"AEterna Zentaris, Inc."	"Quebec G1P 4P5, Canada"			Canada	EXACT	1200857AA	Ae-941	D2YCN1I522						Renal cell carcinoma	13215		
Interleukin-2	Treatment of metastatic renal cell carcinoma.	Teceleukin		Teceleukin	2/5/90	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	Nutley	New Jersey	7110	USA	EXACT	0323864AA	Teceleukin	H5ZRB188EI						Renal cell carcinoma	13215		
Interleukin-2	In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.	Teceleukin		Teceleukin	5/3/90	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	Nutley	New Jersey	7119	USA	EXACT	0323864AA	Teceleukin	H5ZRB188EI						Renal cell carcinoma	13215		
Aldesleukin	Treatment of metastatic renal cell carcinoma.	Aldesleukin		Proleukin	9/14/88	Designated/Approved	Approved for Orphan Indication	Treatment of adults (>18 years old) with metastatic renal cell carcinoma.	5/5/92	5/5/99	Chiron Corporation	Emeryville	California	94608	USA	EXACT	0181566AA	Aldesleukin	M89N0Q7EQR						Renal cell carcinoma	13215		
Peginterferon alfa-2a	Treatment of renal cell carcinoma.	Peginterferon alfa-2a		Pegasys	7/13/98	Designated			N/A	N/A	Hoffman-La Roche Inc.	Nutley	New Jersey	7110	USA	EXACT	0246593AA	Peginterferon alfa-2a	Q46947FE7K						Renal cell carcinoma	13215		
Solasonine and solamargine	Treatment of renal cell carcinoma	Solasonine		Coramsine	11/2/05	Designated			N/A	N/A	Solbec Pharmaceuticals Limited				Australia	EXACT	0789935AA	Solasonine	TR60638HXL						Renal cell carcinoma	13215		
Iboctadekin	Treatment of renal cell carcinoma	Iboctadekin		n/a	6/3/05	Designated/Withdrawn			N/A	N/A	GlaxoSmithKline LLC	Wilmington	Delaware	19808	USA	EXACT	0264777AA	Iboctadekin	X08H9UZ7TO						Renal cell carcinoma	13215		
Interferon beta (recombinant)	For the systemic treatment of metastatic renal cell carcinoma.	Interferon beta (recombinant)		R-Ifn-Beta	2/12/91	Designated/Withdrawn			N/A	N/A	"Biogen, Inc."	Cambridge	Massachusetts	2142	USA	LONGEST CONTAINS	0297927AA	Interferon beta	V9GU1EM8SF						Renal cell carcinoma	13215		
Autolymphocyte therapy	Treatment of renal cell carcinoma.	Autolymphocyte therapy		n/a	7/12/94	Designated			N/A	N/A	Cytogen Corporation	Princeton	New Jersey	8540	USA										Renal cell carcinoma	13215		
"DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2"	Treatment of renal cell carcinoma.	"DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2"		Leuvectin	4/28/00	Designated			N/A	N/A	Vical Incorporated	San Diego	California	92121	USA										Renal cell carcinoma	13215		
autologous tumor-derived gp96 heat shock protein-peptide complex	Treatment of renal cell carcinoma	autologous tumor-derived gp96 heat shock protein-peptide complex		Oncophage	5/10/02	Designated			N/A	N/A	"Agenus, Inc."	Lexington	Massachusetts	2421	USA	LONGEST CONTAINS	0087274AA	protein							Renal cell carcinoma	13215		
Nucleic acid aptamer binding to tumor cell nucleon	Treatment of renal cell carcinoma	Nucleic acid aptamer binding to tumor cell nucleon		n/a	7/28/05	Designated			N/A	N/A	Antisoma Inc.	Cambridge	Massachusetts		USA										Renal cell carcinoma	13215		
ADF-APO-CCN-GUC-K67-MET-MMP-MUC-RGS; HLA class I/II binding tumor associated peptides	Treatment of renal cell carcinoma in HLA-A*2 positive patients	ADF-APO-CCN-GUC-K67-MET-MMP-MUC-RGS; HLA class I/II binding tumor associated peptides		n/a	9/28/12	Designated/Withdrawn			N/A	N/A	Immatics Biotechnologies GmbH				Germany										Renal cell carcinoma	13215		
ibrutinib	Treatment of nodal marginal zone lymphoma	ibrutinib		Imbruvica	2/5/15	Designated			N/A	N/A	"Pharmacyclics, LLC"	Sunnyvale	California	94085	USA	EXACT	0625092AA	ibrutinib	1X70OSD4VX						Marginal zone lymphoma	13237		
ibrutinib	Treatment of splenic marginal zone lymphoma	ibrutinib		Imbruvica	2/5/15	Designated			N/A	N/A	"Pharmacyclics, LLC"	Sunnyvale	California	94085	USA	EXACT	0625092AA	ibrutinib	1X70OSD4VX						Marginal zone lymphoma	13237		
ibrutinib	Treatment of patients with extranodal marginal zone lymphoma (mucosa associated lymphoid tissue [MALT type] lymphoma)	ibrutinib		Imbruvica	2/2/16	Designated			N/A	N/A	"Pharmacyclics, LLC"	Sunnyvale	California	94085	USA	EXACT	0625092AA	ibrutinib	1X70OSD4VX						Marginal zone lymphoma	13237		
bendamustine for 50ml admixture	"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)"	bendamustine for 50ml admixture		Bendeka	7/2/14	Designated/Approved	Approved for Orphan Indication	Treatment of patients with CLL and treatment of patients with indolent B-cell NHL	12/7/15	N/A	"Eagle Pharmaceuticals, Inc."	Woodcliff Lake	New Jersey	7677	USA	EXACT	0304245AA	bendamustine	9266D9P3PQ						Marginal zone lymphoma	13237		
bendamustine hydrochloride	"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)"	bendamustine hydrochloride		Treanda	11/26/13	Designated/Approved	Approved for Orphan Indication	Treatment of Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.	10/31/08	10/31/15	"Cephalon, Inc."	Frazer	Pennsylvania	19355	USA	EXACT	0249241AA	bendamustine hydrochloride	981Y8SX18M						Marginal zone lymphoma	13237		
lenalidomide	Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue	lenalidomide		Revlimid	4/29/15	Designated			N/A	N/A	Celgene Corporation	Berkley Heights	New Jersey	7922	USA	EXACT	0236099AA	lenalidomide	F0P408N6V4						Marginal zone lymphoma	13237		
lenalidomide	Treatment of splenic marginal zone lymphoma	lenalidomide		n/a	1/4/17	Designated			N/A	N/A	Celgene Corporation	Berkley Heights	New Jersey	7922	USA	EXACT	0236099AA	lenalidomide	F0P408N6V4						Marginal zone lymphoma	13237		
lenalidomide	Treatment of nodal marginal zone lymphoma	lenalidomide		Revlimid	1/4/17	Designated			N/A	N/A	Celgene Corporation	Berkley Heights	New Jersey	7922	USA	EXACT	0236099AA	lenalidomide	F0P408N6V4						Marginal zone lymphoma	13237		
obinutuzumab	Treatment of splenic marginal zone lymphoma	obinutuzumab		Gazyva	6/11/15	Designated/Withdrawn			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0322532AA	obinutuzumab	O43472U9X8						Marginal zone lymphoma	13237		
obinutuzumab	Treatment of splenic marginal zone lymphoma	obinutuzumab		Gazyva	8/17/17	Designated			N/A	N/A	"Genentech, Inc."	South San Francisco	California	94080	USA	EXACT	0322532AA	obinutuzumab	O43472U9X8						Marginal zone lymphoma	13237		
ublituximab	"Treatment of Extranodal marginal zone lymphoma (mucosa-associated lymphatic tissue, MALT)"	ublituximab		n/a	9/5/13	Designated			N/A	N/A	"TG Therapeutics, Inc."	New York	New York	10019	USA	EXACT	0574607AA	ublituximab	U59UGK3IPC						Marginal zone lymphoma	13237		
ublituximab	Treatment of Nodal marginal zone lymphoma	ublituximab		n/a	9/5/13	Designated			N/A	N/A	"TG Therapeutics, Inc."	New York	New York	10019	USA	EXACT	0574607AA	ublituximab	U59UGK3IPC						Marginal zone lymphoma	13237		
copanlisib	Treatment of extranodal marginal zone lymphoma	copanlisib		n/a	2/7/17	Designated			N/A	N/A	"Bayer HealthCare Pharmaceuticals, Inc."	Hanover	New Jersey	7981	USA	EXACT	0337111AA	copanlisib	WI6V529FZ9						Marginal zone lymphoma	13237		
copanlisib	Treatment of nodal marginal zone lymphoma	copanlisib		n/a	2/7/17	Designated			N/A	N/A	"Bayer HealthCare Pharmaceuticals, Inc."	Hanover	New Jersey	7981	USA	EXACT	0337111AA	copanlisib	WI6V529FZ9						Marginal zone lymphoma	13237		
copanlisib	Treatment of splenic marginal zone lymphoma	copanlisib		n/a	2/7/17	Designated			N/A	N/A	"Bayer HealthCare Pharmaceuticals, Inc."	Hanover	New Jersey	7981	USA	EXACT	0337111AA	copanlisib	WI6V529FZ9						Marginal zone lymphoma	13237		
idelalisib	Treatment of extranodal marginal zone lymphoma	idelalisib		n/a	10/15/13	Designated			N/A	N/A	"Gilead Sciences, Inc."	Seattle	Washington	98102	USA	EXACT	0711308AA	idelalisib	YG57I8T5M0						Marginal zone lymphoma	13237		
idelalisib	Treatment of nodal marginal zone lymphoma.	idelalisib		n/a	10/15/13	Designated			N/A	N/A	"Gilead Sciences, Inc."	Seattle	Washington	98102	USA	EXACT	0711308AA	idelalisib	YG57I8T5M0						Marginal zone lymphoma	13237		
idelalisib	Treatment of splenic marginal zone lymphoma	idelalisib		n/a	10/15/13	Designated			N/A	N/A	"Gilead Sciences, Inc."	Seattle	Washington	98102	USA	EXACT	0711308AA	idelalisib	YG57I8T5M0						Marginal zone lymphoma	13237		
olipudase alfa	Treatment of acid sphingomyelinase deficiency (Niemann-Pick disease)	olipudase alfa		n/a	8/3/00	Designated			N/A	N/A	Genzyme Corporation	Cambridge	Massachusetts	2142	USA	EXACT	1079272AA	olipudase alfa	6D5766Q4OP						Niemann-Pick disease	13334		
Ursodeoxycholic acid	"Treatment of Niemann-Pick disease, type C"	Ursodeoxycholic acid		n/a	4/26/18	Designated			N/A	N/A	IntraBio Inc.	270 Devon Road		7670	USA	EXACT	0020519AA	Ursodeoxycholic acid	724L30Y2QR						Niemann-Pick disease	13334		
miglustat	"Treatment of the neurological manifestations of Niemann-Pick disease,type C."	miglustat		Zavesca (R)	11/12/08	Designated			N/A	N/A	Actelion Pharmaceuticals Ltd				Switzerland	EXACT	0169288AA	miglustat	ADN3S497AZ						Niemann-Pick disease	13334		
N-acetyl-DL-leucine	"Treatment of Niemann-Pick disease, type C"	N-acetyl-DL-leucine		n/a	2/22/18	Designated			N/A	N/A	IntraBio Inc.	270 Devon Road	Tenafly		USA	EXACT	0301019AA	N-acetyl-DL-leucine	K76S41V71X						Niemann-Pick disease	13334		
melphalan hydrochloride	Treatment of neuroendocrine tumors	melphalan hydrochloride		n/a	5/22/09	Designated			N/A	N/A	"Delcath Systems, Inc."	New York	New York	10019	USA	EXACT	0099401AA	melphalan hydrochloride	1VXP4V453T						Neuroendocrine tumor	13445		
telotristat etiprate	Treatment of carcinoid syndrome in patients with neuroendocrine tumors	telotristat etiprate		n/a	3/9/12	Designated			N/A	N/A	"Lexicon Pharmaceuticals, Inc."	The Woodlands	Texas	77381	USA	EXACT	0569368AA	telotristat etiprate	3T25U84H4U						Neuroendocrine tumor	13445		
"N-(bromoacetyl)-3,3-dinitroazetidine"	Treatment of neuroendocrine tumors	RRX-001		n/a	6/15/17	Designated			N/A	N/A	"EpicentRx, Inc."	San Diego	California	92121	USA	EXACT	0832199AA	RRX-001	7RPW6SU9SC						Neuroendocrine tumor	13445		
Multi-ligand somatostatin analog	"Treatment of patients with functional gastroenteropancreatic (GEP) neuroendocrine tumors (specifically, carcinoid, insulinoma, gastrinoma, somastatinoma, GRFoma, VIPoma and glucagonoma."	Pasireotide		n/a	7/27/04	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0269534AA	Pasireotide	98H1T17066						Neuroendocrine tumor	13445		
"(R)-1-[1-(4-Acetoxy-3,3-dimethyl-2-oxo-butyl)-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-(3-methylamino-phenyl)-urea"	Treatment of gastric neuroendocrine tumors (gastric NETs).	TR2-A		n/a	5/12/16	Designated			N/A	N/A	Trio Medicines Ltd.				United Kingdom	EXACT	1718623AA	TR2-A	99B5ZR9276						Neuroendocrine tumor	13445		
everolimus	Treatment of neuroendocrine tumors	everolimus		Afinitor	2/14/08	Designated/Approved	Approved for Orphan Indication	"Treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease"	5/5/11	5/5/18	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0218031AA	everolimus	9HW64Q8G6G						Neuroendocrine tumor	13445		
everolimus	Treatment of neuroendocrine tumors	everolimus		Afinitor	2/14/08	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with progressive, well-differentiated, non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin, (excluding pancreatic) with unresectable, locally advanced or metastatic disease."	2/26/16	2/26/23	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0218031AA	everolimus	9HW64Q8G6G						Neuroendocrine tumor	13445		
radiolabeled somastatin analog	Diagnostic for the management of neuroendocrine tumors	GALLIUM OXODOTREOTIDE GA-68		Galiomedix(Tm)	12/31/13	Designated			N/A	N/A	"RadioMedix, Inc."	Houston	Texas	77042	USA	EXACT	0707926AA	GALLIUM OXODOTREOTIDE GA-68	9L17Y0H71P						Neuroendocrine tumor	13445		
90Y-DOTA-tyr3-Octreotide	Treatment of neuroendocrine tumors	EDOTREOTIDE YTTRIUM Y-90		n/a	1/20/16	Designated			N/A	N/A	"M. Sue O'Dorisio, MD, PhD"	Iowa City	Iowa	52242	USA	EXACT	0221534AA	EDOTREOTIDE YTTRIUM Y-90	ABF7OG3FA3						Neuroendocrine tumor	13445		
[Lu-177]-DOTA-Tyr3-Octreotate	Treatment of gastro-entero-pancreatic neuroendocrine tumors	DOTATATE LUTENIUM LU-177		n/a	1/12/09	Designated			N/A	N/A	Advanced Accelerator Applications				France	EXACT	0807501AA	DOTATATE LUTENIUM LU-177	AE221IM3BB						Neuroendocrine tumor	13445		
fosbretabulin tromethamine	Treatment of neuroendocrine tumors	fosbretabulin tromethamine		n/a	12/29/15	Designated			N/A	N/A	"Mateon Therapeutics, Inc."	South San Francisco	California	94080	USA	EXACT	0327219AA	fosbretabulin tromethamine	GBW044919E						Neuroendocrine tumor	13445		
lanreotide acetate	Treatment of neuroendocrine tumors	lanreotide acetate		Somatuline Depot	8/25/11	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with unresectable,well- or moderately-differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival"	12/16/14	12/16/21	"Ipsen Biopharmaceuticals, Inc."	Basking Ridge	New Jersey	7920	USA	EXACT	0169517AA	lanreotide acetate	IEU56G3J9C						Neuroendocrine tumor	13445		
"trans-4-({2-(aminocarbonyl)-5-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]phenyl}amino)cyclohexyl glycinate mesylate"	Treatment of neuroendocrine tumors (NETs).	SNX-5422 MESYLATE		n/a	5/23/18	Designated			N/A	N/A	Esanex Inc.	115 West Washington Street	South Tower Suite 1680	46240	USA	EXACT	0709579AA	SNX-5422 MESYLATE	K3BO8V06RM						Neuroendocrine tumor	13445		
111Indium pentetreotide	Treatment of somatostatin receptor positive neuroendocrine tumors.	111Indium pentetreotide		Somatother	6/10/99	Designated			N/A	N/A	Louisiana State University Medical Center Foundation	New Orleans	Louisiana	70112	USA	EXACT	0181771AA	111Indium pentetreotide	M312JJ6Z32						Neuroendocrine tumor	13445		
Indium-111 pentetreotide	Treatment of neuroendocrine tumors	INDIUM IN-111 PENTETREOTIDE		Neuroendomedix	6/16/06	Designated			N/A	N/A	RadioIsotope Therapy of America (RITA) Foundation	Houston	Texas	77042	USA	EXACT	0257272AA	INDIUM IN-111 PENTETREOTIDE	M312JJ6Z32						Neuroendocrine tumor	13445		
Iobenguane I 131	Treatment of neuroendocrine tumors	Iobenguane I 131		Azedra Ultratrace	1/18/06	Designated			N/A	N/A	Molecular Insight Pharmaceuticals	Cambridge	Massachusetts	2142	USA	EXACT	0128392AA	Iobenguane I 131	Q461L7AK4R						Neuroendocrine tumor	13445		
iobenguane I 131	Treatment of neuroendocrine tumors	iobenguane I 131		n/a	7/5/07	Designated			N/A	N/A	"Jubilant DraxImage, Inc."				Canada	EXACT	0128392AA	iobenguane I 131	Q461L7AK4R						Neuroendocrine tumor	13445		
humanized monoclonal antibody against human PD-1	Treatment of neuroendocrine tumors	spartalizumab		n/a	6/8/17	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	1798067AA	spartalizumab	QOG25L6Z8Z						Neuroendocrine tumor	13445		
lutetium (177Lu)-edotreotide	Treatment of gastro-entero-pancreatic neuroendocrine tumors	EDOTREOTIDE LUTETIUM LU-177		n/a	5/21/15	Designated			N/A	N/A	ITG Isotope Technologies Garching GmbH				Germany	EXACT	1575548AA	EDOTREOTIDE LUTETIUM LU-177	RGO812Q0C8						Neuroendocrine tumor	13445		
octreotide	Treatment of neuroendocrine tumors	octreotide		Sandostatin Lar	8/5/10	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	East Hanover	New Jersey	7936	USA	EXACT	0169915AA	octreotide	RWM8CCW8GP						Neuroendocrine tumor	13445		
Gallium-68 (DOTA0-Phel-Tyr3)octreotide	The management of neuroendocrine tumors	EDOTREOTIDE GALLIUM GA-68		n/a	10/25/13	Designated			N/A	N/A	University of Iowa Hospital & Clinics	Iowa City	Iowa	52242	USA	EXACT	1117799AA	EDOTREOTIDE GALLIUM GA-68	Y68179SY2L						Neuroendocrine tumor	13445		
"Gallium [Ga-68]-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic(2-7)disulfide"	Diagnostic for the clinical management of neuroendocrine tumors	EDOTREOTIDE GALLIUM GA-68		Netspot	12/31/13	Designated/Approved	Approved for Orphan Indication	"For use after radiolabeling with Ga 68, with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients."	6/1/16	6/1/23	"Advanced Accelerator Applications, USA"	New York	New York	10118	USA	EXACT	1117799AA	EDOTREOTIDE GALLIUM GA-68	Y68179SY2L						Neuroendocrine tumor	13445		
Gallium (68Ga) edotreotide	Diagnostic for the clinical management of neuroendocrine tumors.	EDOTREOTIDE GALLIUM GA-68		Somakit Toc	7/1/15	Designated			N/A	N/A	"Advanced Accelerator Applications, USA"	New York	New York	10118	USA	EXACT	1117799AA	EDOTREOTIDE GALLIUM GA-68	Y68179SY2L						Neuroendocrine tumor	13445		
Copper 64-DOTA-TATE	Diagnostic for the management of neuroendocrine tumors.	Copper 64-DOTA-TATE		Netmedix (Tm)	5/18/16	Designated			N/A	N/A	"RadioMedix, Inc."	Houston	Texas	77042	USA	EXACT	1576927AA	Copper 64-DOTA-TATE	N3858377KC						Neuroendocrine tumor	13445		
"68Ga-OPS202, small somatostatin analog labeled with 68Gallium"	Management of gastroenteropancreatic neuroendocrine tumors.	SATOREOTIDE TRIZOXETAN GALLIUM GA-68		n/a	9/24/14	Designated			N/A	N/A	"Ipsen Biosciences, Inc."	Cambridge	Massachusetts	2142	USA	EXACT	0113078AB	SATOREOTIDE TRIZOXETAN GALLIUM GA-68	ZP2ODR0UR3						Neuroendocrine tumor	13445		
Recombinant human endostatin protein	Treatment of neuroendocrine tumors	Recombinant human endostatin protein		n/a	8/13/01	Designated			N/A	N/A	"EntreMed, Inc."	Rockville	Maryland	20850	USA	EXACT	0734214AA	Recombinant human endostatin protein	GVG18ZDN65						Neuroendocrine tumor	13445		
Seneca Valley virus	Treatment of neuroendocrine tumors	Seneca Valley virus		n/a	8/22/08	Designated			N/A	N/A	"Neotropix, Inc."	Malvern	Pennsylvania	19355	USA										Neuroendocrine tumor	13445		
Lead-212 DOTAMTATE	Treatment of neuroendocrine tumors	Lead-212 DOTAMTATE		Alphamedix™	10/11/18	Designated			N/A	N/A	"RadioMedix, Inc."	9701 Richmond Avenue	Texas	77042	USA	EXACT	0117207AB								Neuroendocrine tumor	13445		